
PMID- 29622466
OWN - NLM
STAT- Publisher
LR  - 20180406
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Apr 2
TI  - Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
LID - S1535-6108(18)30114-4 [pii]
LID - 10.1016/j.ccell.2018.03.010 [doi]
AB  - We analyzed 921 adenocarcinomas of the esophagus, stomach, colon, and rectum to
      examine shared and distinguishing molecular characteristics of gastrointestinal
      tract adenocarcinomas (GIACs). Hypermutated tumors were distinct regardless of
      cancer type and comprised those enriched for insertions/deletions, representing
      microsatellite instability cases with epigenetic silencing of MLH1 in the context
      of CpG island methylator phenotype, plus tumors with elevated single-nucleotide
      variants associated with mutations in POLE. Tumors with chromosomal instability
      were diverse, with gastroesophageal adenocarcinomas harboring fragmented genomes 
      associated with genomic doubling and distinct mutational signatures. We
      identified a group of tumors in the colon and rectum lacking hypermutation and
      aneuploidy termed genome stable and enriched in DNA hypermethylation and
      mutations in KRAS, SOX9, and PCBP1.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Liu, Yang
AU  - Liu Y
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Boston, MA 02115, USA.
FAU - Sethi, Nilay S
AU  - Sethi NS
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Boston, MA 02115, USA.
FAU - Hinoue, Toshinori
AU  - Hinoue T
AD  - Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503,
      USA.
FAU - Schneider, Barbara G
AU  - Schneider BG
AD  - Department of Medicine, Division of Gastroenterology, Vanderbilt University
      Medical Center, Nashville, TN 37232, USA.
FAU - Cherniack, Andrew D
AU  - Cherniack AD
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Boston, MA 02115, USA.
FAU - Sanchez-Vega, Francisco
AU  - Sanchez-Vega F
AD  - Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York,
      NY 10065, USA.
FAU - Seoane, Jose A
AU  - Seoane JA
AD  - Department of Medicine, and Department of Genetics, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Farshidfar, Farshad
AU  - Farshidfar F
AD  - Department of Oncology, Cumming School of Medicine, University of Calgary,
      Calgarry, Canada.
FAU - Bowlby, Reanne
AU  - Bowlby R
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Islam, Mirazul
AU  - Islam M
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Boston, MA 02115, USA.
FAU - Kim, Jaegil
AU  - Kim J
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Chatila, Walid
AU  - Chatila W
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kanchi, Rupa S
AU  - Kanchi RS
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Rabkin, Charles S
AU  - Rabkin CS
AD  - Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, 
      MD 20892, USA.
FAU - Willis, Joseph E
AU  - Willis JE
AD  - Department of Pathology, Case Western Reserve University, Cleveland, OH 44106,
      USA.
FAU - Wang, Kenneth K
AU  - Wang KK
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905,
      USA.
FAU - McCall, Shannon J
AU  - McCall SJ
AD  - Department of Pathology, Duke University, Durham, NC 27710, USA.
FAU - Mishra, Lopa
AU  - Mishra L
AD  - Center for Translational Research, Department of Surgery, George Washington
      University Cancer Center, Washington, DC 20052, USA.
FAU - Ojesina, Akinyemi I
AU  - Ojesina AI
AD  - Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
      35294, USA; HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
FAU - Bullman, Susan
AU  - Bullman S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115,
      USA.
FAU - Pedamallu, Chandra Sekhar
AU  - Pedamallu CS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115,
      USA.
FAU - Lazar, Alexander J
AU  - Lazar AJ
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Sakai, Ryo
AU  - Sakai R
AD  - PharmiWeb Solutions, Bracknell RG12 1QB, UK.
CN  - Cancer Genome Atlas Research Network
FAU - Thorsson, Vesteinn
AU  - Thorsson V
AD  - Institute for Systems Biology, Seattle, WA 98109, USA. Electronic address:
      vesteinn.thorsson@systemsbiology.org.
FAU - Bass, Adam J
AU  - Bass AJ
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Boston, MA 02115, USA; Center for Cancer Genome
      Discovery, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Electronic
      address: adam_bass@dfci.harvard.edu.
FAU - Laird, Peter W
AU  - Laird PW
AD  - Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503,
      USA. Electronic address: peter.laird@vai.org.
LA  - eng
PT  - Journal Article
DEP - 20180402
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - cancer
OT  - colon
OT  - colorectal
OT  - epigenetic
OT  - esophagus
OT  - genomic
OT  - methylation
OT  - rectum
OT  - stomach
OT  - tumor
IR  - Caesar-Johnson SJ
FIR - Caesar-Johnson, Samantha J
IR  - Demchok JA
FIR - Demchok, John A
IR  - Felau I
FIR - Felau, Ina
IR  - Kasapi M
FIR - Kasapi, Melpomeni
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Wang Z
FIR - Wang, Zhining
IR  - Yang L
FIR - Yang, Liming
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Pihl T
FIR - Pihl, Todd
IR  - Sun Q
FIR - Sun, Qiang
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wu Y
FIR - Wu, Ye
IR  - Cho J
FIR - Cho, Juok
IR  - DeFreitas T
FIR - DeFreitas, Timothy
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Getz G
FIR - Getz, Gad
IR  - Heiman DI
FIR - Heiman, David I
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lin P
FIR - Lin, Pei
IR  - Meier S
FIR - Meier, Sam
IR  - Noble MS
FIR - Noble, Michael S
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Voet D
FIR - Voet, Doug
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Bernard B
FIR - Bernard, Brady
IR  - Chambwe N
FIR - Chambwe, Nyasha
IR  - Dhankani V
FIR - Dhankani, Varsha
IR  - Knijnenburg T
FIR - Knijnenburg, Theo
IR  - Kramer R
FIR - Kramer, Roger
IR  - Leinonen K
FIR - Leinonen, Kalle
IR  - Liu Y
FIR - Liu, Yuexin
IR  - Miller M
FIR - Miller, Michael
IR  - Reynolds S
FIR - Reynolds, Sheila
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Thorsson V
FIR - Thorsson, Vesteinn
IR  - Zhang W
FIR - Zhang, Wei
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Broom BM
FIR - Broom, Bradley M
IR  - Hegde AM
FIR - Hegde, Apurva M
IR  - Ju Z
FIR - Ju, Zhenlin
IR  - Kanchi RS
FIR - Kanchi, Rupa S
IR  - Korkut A
FIR - Korkut, Anil
IR  - Li J
FIR - Li, Jun
IR  - Liang H
FIR - Liang, Han
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu W
FIR - Liu, Wenbin
IR  - Lu Y
FIR - Lu, Yiling
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Ng KS
FIR - Ng, Kwok-Shing
IR  - Rao A
FIR - Rao, Arvind
IR  - Ryan M
FIR - Ryan, Michael
IR  - Wang J
FIR - Wang, Jing
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Zhang J
FIR - Zhang, Jiexin
IR  - Abeshouse A
FIR - Abeshouse, Adam
IR  - Armenia J
FIR - Armenia, Joshua
IR  - Chakravarty D
FIR - Chakravarty, Debyani
IR  - Chatila WK
FIR - Chatila, Walid K
IR  - Bruijn I
FIR - Bruijn, Inode
IR  - Gao J
FIR - Gao, Jianjiong
IR  - Gross BE
FIR - Gross, Benjamin E
IR  - Heins ZJ
FIR - Heins, Zachary J
IR  - Kundra R
FIR - Kundra, Ritika
IR  - La K
FIR - La, Konnor
IR  - Ladanyi M
FIR - Ladanyi, Marc
IR  - Luna A
FIR - Luna, Augustin
IR  - Nissan MG
FIR - Nissan, Moriah G
IR  - Ochoa A
FIR - Ochoa, Angelica
IR  - Phillips SM
FIR - Phillips, Sarah M
IR  - Reznik E
FIR - Reznik, Ed
IR  - Sanchez-Vega F
FIR - Sanchez-Vega, Francisco
IR  - Sander C
FIR - Sander, Chris
IR  - Schultz N
FIR - Schultz, Nikolaus
IR  - Sheridan R
FIR - Sheridan, Robert
IR  - Sumer SO
FIR - Sumer, S Onur
IR  - Sun Y
FIR - Sun, Yichao
IR  - Taylor BS
FIR - Taylor, Barry S
IR  - Wang J
FIR - Wang, Jioajiao
IR  - Zhang H
FIR - Zhang, Hongxin
IR  - Anur P
FIR - Anur, Pavana
IR  - Peto M
FIR - Peto, Myron
IR  - Spellman P
FIR - Spellman, Paul
IR  - Benz C
FIR - Benz, Christopher
IR  - Stuart JM
FIR - Stuart, Joshua M
IR  - Wong CK
FIR - Wong, Christopher K
IR  - Yau C
FIR - Yau, Christina
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Parker JS
FIR - Parker, Joel S
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Ally A
FIR - Ally, Adrian
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Chuah E
FIR - Chuah, Eric
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Holt R
FIR - Holt, Robert
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Lee D
FIR - Lee, Darlene
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Tam A
FIR - Tam, Angela
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Tse K
FIR - Tse, Kane
IR  - Wong T
FIR - Wong, Tina
IR  - Berger AC
FIR - Berger, Ashton C
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gao GF
FIR - Gao, Galen F
IR  - Ha G
FIR - Ha, Gavin
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Shih J
FIR - Shih, Juliann
IR  - Kucherlapati MH
FIR - Kucherlapati, Melanie H
IR  - Kucherlapati RS
FIR - Kucherlapati, Raju S
IR  - Baylin S
FIR - Baylin, Stephen
IR  - Cope L
FIR - Cope, Leslie
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Auman JT
FIR - Auman, J Todd
IR  - Balu S
FIR - Balu, Saianand
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Fan C
FIR - Fan, Cheng
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Meng S
FIR - Meng, Shaowu
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Perou AH
FIR - Perou, Amy H
IR  - Perou CM
FIR - Perou, Charles M
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Shi Y
FIR - Shi, Yan
IR  - Simons JV
FIR - Simons, Janae V
IR  - Skelly T
FIR - Skelly, Tara
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Tan D
FIR - Tan, Donghui
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Fan H
FIR - Fan, Huihui
IR  - Hinoue T
FIR - Hinoue, Toshinori
IR  - Laird PW
FIR - Laird, Peter W
IR  - Shen H
FIR - Shen, Hui
IR  - Zhou W
FIR - Zhou, Wanding
IR  - Bellair M
FIR - Bellair, Michelle
IR  - Chang K
FIR - Chang, Kyle
IR  - Covington K
FIR - Covington, Kyle
IR  - Creighton CJ
FIR - Creighton, Chad J
IR  - Dinh H
FIR - Dinh, Huyen
IR  - Doddapaneni H
FIR - Doddapaneni, HarshaVardhan
IR  - Donehower LA
FIR - Donehower, Lawrence A
IR  - Drummond J
FIR - Drummond, Jennifer
IR  - Gibbs RA
FIR - Gibbs, Richard A
IR  - Glenn R
FIR - Glenn, Robert
IR  - Hale W
FIR - Hale, Walker
IR  - Han Y
FIR - Han, Yi
IR  - Hu J
FIR - Hu, Jianhong
IR  - Korchina V
FIR - Korchina, Viktoriya
IR  - Lee S
FIR - Lee, Sandra
IR  - Lewis L
FIR - Lewis, Lora
IR  - Li W
FIR - Li, Wei
IR  - Liu X
FIR - Liu, Xiuping
IR  - Morgan M
FIR - Morgan, Margaret
IR  - Morton D
FIR - Morton, Donna
IR  - Muzny D
FIR - Muzny, Donna
IR  - Santibanez J
FIR - Santibanez, Jireh
IR  - Sheth M
FIR - Sheth, Margi
IR  - Shinbrot E
FIR - Shinbrot, Eve
IR  - Wang L
FIR - Wang, Linghua
IR  - Wang M
FIR - Wang, Min
IR  - Wheeler DA
FIR - Wheeler, David A
IR  - Xi L
FIR - Xi, Liu
IR  - Zhao F
FIR - Zhao, Fengmei
IR  - Hess J
FIR - Hess, Julian
IR  - Appelbaum EL
FIR - Appelbaum, Elizabeth L
IR  - Bailey M
FIR - Bailey, Matthew
IR  - Cordes MG
FIR - Cordes, Matthew G
IR  - Ding L
FIR - Ding, Li
IR  - Fronick CC
FIR - Fronick, Catrina C
IR  - Fulton LA
FIR - Fulton, Lucinda A
IR  - Fulton RS
FIR - Fulton, Robert S
IR  - Kandoth C
FIR - Kandoth, Cyriac
IR  - Mardis ER
FIR - Mardis, Elaine R
IR  - McLellan MD
FIR - McLellan, Michael D
IR  - Miller CA
FIR - Miller, Christopher A
IR  - Schmidt HK
FIR - Schmidt, Heather K
IR  - Wilson RK
FIR - Wilson, Richard K
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Lau K
FIR - Lau, Kevin
IR  - Mallery D
FIR - Mallery, David
IR  - Morris S
FIR - Morris, Scott
IR  - Paulauskis J
FIR - Paulauskis, Joseph
IR  - Penny R
FIR - Penny, Robert
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Sherman M
FIR - Sherman, Mark
IR  - Thompson E
FIR - Thompson, Eric
IR  - Yena P
FIR - Yena, Peggy
IR  - Bowen J
FIR - Bowen, Jay
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gerken M
FIR - Gerken, Mark
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Wise L
FIR - Wise, Lisa
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Corcoran N
FIR - Corcoran, Niall
IR  - Costello T
FIR - Costello, Tony
IR  - Hovens C
FIR - Hovens, Christopher
IR  - Carvalho AL
FIR - Carvalho, Andre L
IR  - de Carvalho AC
FIR - de Carvalho, Ana C
IR  - Fregnani JH
FIR - Fregnani, Jose H
IR  - Longatto-Filho A
FIR - Longatto-Filho, Adhemar
IR  - Reis RM
FIR - Reis, Rui M
IR  - Scapulatempo-Neto C
FIR - Scapulatempo-Neto, Cristovam
IR  - Silveira HCS
FIR - Silveira, Henrique C S
IR  - Vidal DO
FIR - Vidal, Daniel O
IR  - Burnette A
FIR - Burnette, Andrew
IR  - Eschbacher J
FIR - Eschbacher, Jennifer
IR  - Hermes B
FIR - Hermes, Beth
IR  - Noss A
FIR - Noss, Ardene
IR  - Singh R
FIR - Singh, Rosy
IR  - Anderson ML
FIR - Anderson, Matthew L
IR  - Castro PD
FIR - Castro, Patricia D
IR  - Ittmann M
FIR - Ittmann, Michael
IR  - Huntsman D
FIR - Huntsman, David
IR  - Kohl B
FIR - Kohl, Bernard
IR  - Le X
FIR - Le, Xuan
IR  - Thorp R
FIR - Thorp, Richard
IR  - Andry C
FIR - Andry, Chris
IR  - Duffy ER
FIR - Duffy, Elizabeth R
IR  - Lyadov V
FIR - Lyadov, Vladimir
IR  - Paklina O
FIR - Paklina, Oxana
IR  - Setdikova G
FIR - Setdikova, Galiya
IR  - Shabunin A
FIR - Shabunin, Alexey
IR  - Tavobilov M
FIR - Tavobilov, Mikhail
IR  - McPherson C
FIR - McPherson, Christopher
IR  - Warnick R
FIR - Warnick, Ronald
IR  - Berkowitz R
FIR - Berkowitz, Ross
IR  - Cramer D
FIR - Cramer, Daniel
IR  - Feltmate C
FIR - Feltmate, Colleen
IR  - Horowitz N
FIR - Horowitz, Neil
IR  - Kibel A
FIR - Kibel, Adam
IR  - Muto M
FIR - Muto, Michael
IR  - Raut CP
FIR - Raut, Chandrajit P
IR  - Malykh A
FIR - Malykh, Andrei
IR  - Barnholtz-Sloan JS
FIR - Barnholtz-Sloan, Jill S
IR  - Barrett W
FIR - Barrett, Wendi
IR  - Devine K
FIR - Devine, Karen
IR  - Fulop J
FIR - Fulop, Jordonna
IR  - Ostrom QT
FIR - Ostrom, Quinn T
IR  - Shimmel K
FIR - Shimmel, Kristen
IR  - Wolinsky Y
FIR - Wolinsky, Yingli
IR  - Sloan AE
FIR - Sloan, Andrew E
IR  - De Rose A
FIR - De Rose, Agostino
IR  - Giuliante F
FIR - Giuliante, Felice
IR  - Goodman M
FIR - Goodman, Marc
IR  - Karlan BY
FIR - Karlan, Beth Y
IR  - Hagedorn CH
FIR - Hagedorn, Curt H
IR  - Eckman J
FIR - Eckman, John
IR  - Harr J
FIR - Harr, Jodi
IR  - Myers J
FIR - Myers, Jerome
IR  - Tucker K
FIR - Tucker, Kelinda
IR  - Zach LA
FIR - Zach, Leigh Anne
IR  - Deyarmin B
FIR - Deyarmin, Brenda
IR  - Hu H
FIR - Hu, Hai
IR  - Kvecher L
FIR - Kvecher, Leonid
IR  - Larson C
FIR - Larson, Caroline
IR  - Mural RJ
FIR - Mural, Richard J
IR  - Somiari S
FIR - Somiari, Stella
IR  - Vicha A
FIR - Vicha, Ales
IR  - Zelinka T
FIR - Zelinka, Tomas
IR  - Bennett J
FIR - Bennett, Joseph
IR  - Iacocca M
FIR - Iacocca, Mary
IR  - Rabeno B
FIR - Rabeno, Brenda
IR  - Swanson P
FIR - Swanson, Patricia
IR  - Latour M
FIR - Latour, Mathieu
IR  - Lacombe L
FIR - Lacombe, Louis
IR  - Tetu B
FIR - Tetu, Bernard
IR  - Bergeron A
FIR - Bergeron, Alain
IR  - McGraw M
FIR - McGraw, Mary
IR  - Staugaitis SM
FIR - Staugaitis, Susan M
IR  - Chabot J
FIR - Chabot, John
IR  - Hibshoosh H
FIR - Hibshoosh, Hanina
IR  - Sepulveda A
FIR - Sepulveda, Antonia
IR  - Su T
FIR - Su, Tao
IR  - Wang T
FIR - Wang, Timothy
IR  - Potapova O
FIR - Potapova, Olga
IR  - Voronina O
FIR - Voronina, Olga
IR  - Desjardins L
FIR - Desjardins, Laurence
IR  - Mariani O
FIR - Mariani, Odette
IR  - Roman-Roman S
FIR - Roman-Roman, Sergio
IR  - Sastre X
FIR - Sastre, Xavier
IR  - Stern MH
FIR - Stern, Marc-Henri
IR  - Cheng F
FIR - Cheng, Feixiong
IR  - Signoretti S
FIR - Signoretti, Sabina
IR  - Berchuck A
FIR - Berchuck, Andrew
IR  - Bigner D
FIR - Bigner, Darell
IR  - Lipp E
FIR - Lipp, Eric
IR  - Marks J
FIR - Marks, Jeffrey
IR  - McCall S
FIR - McCall, Shannon
IR  - McLendon R
FIR - McLendon, Roger
IR  - Secord A
FIR - Secord, Angeles
IR  - Sharp A
FIR - Sharp, Alexis
IR  - Behera M
FIR - Behera, Madhusmita
IR  - Brat DJ
FIR - Brat, Daniel J
IR  - Chen A
FIR - Chen, Amy
IR  - Delman K
FIR - Delman, Keith
IR  - Force S
FIR - Force, Seth
IR  - Khuri F
FIR - Khuri, Fadlo
IR  - Magliocca K
FIR - Magliocca, Kelly
IR  - Maithel S
FIR - Maithel, Shishir
IR  - Olson JJ
FIR - Olson, Jeffrey J
IR  - Owonikoko T
FIR - Owonikoko, Taofeek
IR  - Pickens A
FIR - Pickens, Alan
IR  - Ramalingam S
FIR - Ramalingam, Suresh
IR  - Shin DM
FIR - Shin, Dong M
IR  - Sica G
FIR - Sica, Gabriel
IR  - Van Meir EG
FIR - Van Meir, Erwin G
IR  - Zhang H
FIR - Zhang, Hongzheng
IR  - Eijckenboom W
FIR - Eijckenboom, Wil
IR  - Gillis A
FIR - Gillis, Ad
IR  - Korpershoek E
FIR - Korpershoek, Esther
IR  - Looijenga L
FIR - Looijenga, Leendert
IR  - Oosterhuis W
FIR - Oosterhuis, Wolter
IR  - Stoop H
FIR - Stoop, Hans
IR  - van Kessel KE
FIR - van Kessel, Kim E
IR  - Zwarthoff EC
FIR - Zwarthoff, Ellen C
IR  - Calatozzolo C
FIR - Calatozzolo, Chiara
IR  - Cuppini L
FIR - Cuppini, Lucia
IR  - Cuzzubbo S
FIR - Cuzzubbo, Stefania
IR  - DiMeco F
FIR - DiMeco, Francesco
IR  - Finocchiaro G
FIR - Finocchiaro, Gaetano
IR  - Mattei L
FIR - Mattei, Luca
IR  - Perin A
FIR - Perin, Alessandro
IR  - Pollo B
FIR - Pollo, Bianca
IR  - Chen C
FIR - Chen, Chu
IR  - Houck J
FIR - Houck, John
IR  - Lohavanichbutr P
FIR - Lohavanichbutr, Pawadee
IR  - Hartmann A
FIR - Hartmann, Arndt
IR  - Stoehr C
FIR - Stoehr, Christine
IR  - Stoehr R
FIR - Stoehr, Robert
IR  - Taubert H
FIR - Taubert, Helge
IR  - Wach S
FIR - Wach, Sven
IR  - Wullich B
FIR - Wullich, Bernd
IR  - Kycler W
FIR - Kycler, Witold
IR  - Murawa D
FIR - Murawa, Dawid
IR  - Wiznerowicz M
FIR - Wiznerowicz, Maciej
IR  - Chung K
FIR - Chung, Ki
IR  - Edenfield WJ
FIR - Edenfield, W Jeffrey
IR  - Martin J
FIR - Martin, Julie
IR  - Baudin E
FIR - Baudin, Eric
IR  - Bubley G
FIR - Bubley, Glenn
IR  - Bueno R
FIR - Bueno, Raphael
IR  - De Rienzo A
FIR - De Rienzo, Assunta
IR  - Richards WG
FIR - Richards, William G
IR  - Kalkanis S
FIR - Kalkanis, Steven
IR  - Mikkelsen T
FIR - Mikkelsen, Tom
IR  - Noushmehr H
FIR - Noushmehr, Houtan
IR  - Scarpace L
FIR - Scarpace, Lisa
IR  - Girard N
FIR - Girard, Nicolas
IR  - Aymerich M
FIR - Aymerich, Marta
IR  - Campo E
FIR - Campo, Elias
IR  - Gine E
FIR - Gine, Eva
IR  - Guillermo AL
FIR - Guillermo, Armando Lopez
IR  - Van Bang N
FIR - Van Bang, Nguyen
IR  - Hanh PT
FIR - Hanh, Phan Thi
IR  - Phu BD
FIR - Phu, Bui Duc
IR  - Tang Y
FIR - Tang, Yufang
IR  - Colman H
FIR - Colman, Howard
IR  - Evason K
FIR - Evason, Kimberley
IR  - Dottino PR
FIR - Dottino, Peter R
IR  - Martignetti JA
FIR - Martignetti, John A
IR  - Gabra H
FIR - Gabra, Hani
IR  - Juhl H
FIR - Juhl, Hartmut
IR  - Akeredolu T
FIR - Akeredolu, Teniola
IR  - Stepa S
FIR - Stepa, Serghei
IR  - Hoon D
FIR - Hoon, Dave
IR  - Ahn K
FIR - Ahn, Keunsoo
IR  - Kang KJ
FIR - Kang, Koo Jeong
IR  - Beuschlein F
FIR - Beuschlein, Felix
IR  - Breggia A
FIR - Breggia, Anne
IR  - Birrer M
FIR - Birrer, Michael
IR  - Bell D
FIR - Bell, Debra
IR  - Borad M
FIR - Borad, Mitesh
IR  - Bryce AH
FIR - Bryce, Alan H
IR  - Castle E
FIR - Castle, Erik
IR  - Chandan V
FIR - Chandan, Vishal
IR  - Cheville J
FIR - Cheville, John
IR  - Copland JA
FIR - Copland, John A
IR  - Farnell M
FIR - Farnell, Michael
IR  - Flotte T
FIR - Flotte, Thomas
IR  - Giama N
FIR - Giama, Nasra
IR  - Ho T
FIR - Ho, Thai
IR  - Kendrick M
FIR - Kendrick, Michael
IR  - Kocher JP
FIR - Kocher, Jean-Pierre
IR  - Kopp K
FIR - Kopp, Karla
IR  - Moser C
FIR - Moser, Catherine
IR  - Nagorney D
FIR - Nagorney, David
IR  - O'Brien D
FIR - O'Brien, Daniel
IR  - O'Neill BP
FIR - O'Neill, Brian Patrick
IR  - Patel T
FIR - Patel, Tushar
IR  - Petersen G
FIR - Petersen, Gloria
IR  - Que F
FIR - Que, Florencia
IR  - Rivera M
FIR - Rivera, Michael
IR  - Roberts L
FIR - Roberts, Lewis
IR  - Smallridge R
FIR - Smallridge, Robert
IR  - Smyrk T
FIR - Smyrk, Thomas
IR  - Stanton M
FIR - Stanton, Melissa
IR  - Thompson RH
FIR - Thompson, R Houston
IR  - Torbenson M
FIR - Torbenson, Michael
IR  - Yang JD
FIR - Yang, Ju Dong
IR  - Zhang L
FIR - Zhang, Lizhi
IR  - Brimo F
FIR - Brimo, Fadi
IR  - Ajani JA
FIR - Ajani, Jaffer A
IR  - Gonzalez AMA
FIR - Gonzalez, Ana Maria Angulo
IR  - Behrens C
FIR - Behrens, Carmen
IR  - Bondaruk J
FIR - Bondaruk, Jolanta
IR  - Broaddus R
FIR - Broaddus, Russell
IR  - Czerniak B
FIR - Czerniak, Bogdan
IR  - Esmaeli B
FIR - Esmaeli, Bita
IR  - Fujimoto J
FIR - Fujimoto, Junya
IR  - Gershenwald J
FIR - Gershenwald, Jeffrey
IR  - Guo C
FIR - Guo, Charles
IR  - Lazar AJ
FIR - Lazar, Alexander J
IR  - Logothetis C
FIR - Logothetis, Christopher
IR  - Meric-Bernstam F
FIR - Meric-Bernstam, Funda
IR  - Moran C
FIR - Moran, Cesar
IR  - Ramondetta L
FIR - Ramondetta, Lois
IR  - Rice D
FIR - Rice, David
IR  - Sood A
FIR - Sood, Anil
IR  - Tamboli P
FIR - Tamboli, Pheroze
IR  - Thompson T
FIR - Thompson, Timothy
IR  - Troncoso P
FIR - Troncoso, Patricia
IR  - Tsao A
FIR - Tsao, Anne
IR  - Wistuba I
FIR - Wistuba, Ignacio
IR  - Carter C
FIR - Carter, Candace
IR  - Haydu L
FIR - Haydu, Lauren
IR  - Hersey P
FIR - Hersey, Peter
IR  - Jakrot V
FIR - Jakrot, Valerie
IR  - Kakavand H
FIR - Kakavand, Hojabr
IR  - Kefford R
FIR - Kefford, Richard
IR  - Lee K
FIR - Lee, Kenneth
IR  - Long G
FIR - Long, Georgina
IR  - Mann G
FIR - Mann, Graham
IR  - Quinn M
FIR - Quinn, Michael
IR  - Saw R
FIR - Saw, Robyn
IR  - Scolyer R
FIR - Scolyer, Richard
IR  - Shannon K
FIR - Shannon, Kerwin
IR  - Spillane A
FIR - Spillane, Andrew
IR  - Stretch J
FIR - Stretch, Jonathan
IR  - Synott M
FIR - Synott, Maria
IR  - Thompson J
FIR - Thompson, John
IR  - Wilmott J
FIR - Wilmott, James
IR  - Al-Ahmadie H
FIR - Al-Ahmadie, Hikmat
IR  - Chan TA
FIR - Chan, Timothy A
IR  - Ghossein R
FIR - Ghossein, Ronald
IR  - Gopalan A
FIR - Gopalan, Anuradha
IR  - Levine DA
FIR - Levine, Douglas A
IR  - Reuter V
FIR - Reuter, Victor
IR  - Singer S
FIR - Singer, Samuel
IR  - Singh B
FIR - Singh, Bhuvanesh
IR  - Tien NV
FIR - Tien, Nguyen Viet
IR  - Broudy T
FIR - Broudy, Thomas
IR  - Mirsaidi C
FIR - Mirsaidi, Cyrus
IR  - Nair P
FIR - Nair, Praveen
IR  - Drwiega P
FIR - Drwiega, Paul
IR  - Miller J
FIR - Miller, Judy
IR  - Smith J
FIR - Smith, Jennifer
IR  - Zaren H
FIR - Zaren, Howard
IR  - Park JW
FIR - Park, Joong-Won
IR  - Hung NP
FIR - Hung, Nguyen Phi
IR  - Kebebew E
FIR - Kebebew, Electron
IR  - Linehan WM
FIR - Linehan, W Marston
IR  - Metwalli AR
FIR - Metwalli, Adam R
IR  - Pacak K
FIR - Pacak, Karel
IR  - Pinto PA
FIR - Pinto, Peter A
IR  - Schiffman M
FIR - Schiffman, Mark
IR  - Schmidt LS
FIR - Schmidt, Laura S
IR  - Vocke CD
FIR - Vocke, Cathy D
IR  - Wentzensen N
FIR - Wentzensen, Nicolas
IR  - Worrell R
FIR - Worrell, Robert
IR  - Yang H
FIR - Yang, Hannah
IR  - Moncrieff M
FIR - Moncrieff, Marc
IR  - Goparaju C
FIR - Goparaju, Chandra
IR  - Melamed J
FIR - Melamed, Jonathan
IR  - Pass H
FIR - Pass, Harvey
IR  - Botnariuc N
FIR - Botnariuc, Natalia
IR  - Caraman I
FIR - Caraman, Irina
IR  - Cernat M
FIR - Cernat, Mircea
IR  - Chemencedji I
FIR - Chemencedji, Inga
IR  - Clipca A
FIR - Clipca, Adrian
IR  - Doruc S
FIR - Doruc, Serghei
IR  - Gorincioi G
FIR - Gorincioi, Ghenadie
IR  - Mura S
FIR - Mura, Sergiu
IR  - Pirtac M
FIR - Pirtac, Maria
IR  - Stancul I
FIR - Stancul, Irina
IR  - Tcaciuc D
FIR - Tcaciuc, Diana
IR  - Albert M
FIR - Albert, Monique
IR  - Alexopoulou I
FIR - Alexopoulou, Iakovina
IR  - Arnaout A
FIR - Arnaout, Angel
IR  - Bartlett J
FIR - Bartlett, John
IR  - Engel J
FIR - Engel, Jay
IR  - Gilbert S
FIR - Gilbert, Sebastien
IR  - Parfitt J
FIR - Parfitt, Jeremy
IR  - Sekhon H
FIR - Sekhon, Harman
IR  - Thomas G
FIR - Thomas, George
IR  - Rassl DM
FIR - Rassl, Doris M
IR  - Rintoul RC
FIR - Rintoul, Robert C
IR  - Bifulco C
FIR - Bifulco, Carlo
IR  - Tamakawa R
FIR - Tamakawa, Raina
IR  - Urba W
FIR - Urba, Walter
IR  - Hayward N
FIR - Hayward, Nicholas
IR  - Timmers H
FIR - Timmers, Henri
IR  - Antenucci A
FIR - Antenucci, Anna
IR  - Facciolo F
FIR - Facciolo, Francesco
IR  - Grazi G
FIR - Grazi, Gianluca
IR  - Marino M
FIR - Marino, Mirella
IR  - Merola R
FIR - Merola, Roberta
IR  - de Krijger R
FIR - de Krijger, Ronald
IR  - Gimenez-Roqueplo AP
FIR - Gimenez-Roqueplo, Anne-Paule
IR  - Piche A
FIR - Piche, Alain
IR  - Chevalier S
FIR - Chevalier, Simone
IR  - McKercher G
FIR - McKercher, Ginette
IR  - Birsoy K
FIR - Birsoy, Kivanc
IR  - Barnett G
FIR - Barnett, Gene
IR  - Brewer C
FIR - Brewer, Cathy
IR  - Farver C
FIR - Farver, Carol
IR  - Naska T
FIR - Naska, Theresa
IR  - Pennell NA
FIR - Pennell, Nathan A
IR  - Raymond D
FIR - Raymond, Daniel
IR  - Schilero C
FIR - Schilero, Cathy
IR  - Smolenski K
FIR - Smolenski, Kathy
IR  - Williams F
FIR - Williams, Felicia
IR  - Morrison C
FIR - Morrison, Carl
IR  - Borgia JA
FIR - Borgia, Jeffrey A
IR  - Liptay MJ
FIR - Liptay, Michael J
IR  - Pool M
FIR - Pool, Mark
IR  - Seder CW
FIR - Seder, Christopher W
IR  - Junker K
FIR - Junker, Kerstin
IR  - Omberg L
FIR - Omberg, Larsson
IR  - Dinkin M
FIR - Dinkin, Mikhail
IR  - Manikhas G
FIR - Manikhas, George
IR  - Alvaro D
FIR - Alvaro, Domenico
IR  - Bragazzi MC
FIR - Bragazzi, Maria Consiglia
IR  - Cardinale V
FIR - Cardinale, Vincenzo
IR  - Carpino G
FIR - Carpino, Guido
IR  - Gaudio E
FIR - Gaudio, Eugenio
IR  - Chesla D
FIR - Chesla, David
IR  - Cottingham S
FIR - Cottingham, Sandra
IR  - Dubina M
FIR - Dubina, Michael
IR  - Moiseenko F
FIR - Moiseenko, Fedor
IR  - Dhanasekaran R
FIR - Dhanasekaran, Renumathy
IR  - Becker KF
FIR - Becker, Karl-Friedrich
IR  - Janssen KP
FIR - Janssen, Klaus-Peter
IR  - Slotta-Huspenina J
FIR - Slotta-Huspenina, Julia
IR  - Abdel-Rahman MH
FIR - Abdel-Rahman, Mohamed H
IR  - Aziz D
FIR - Aziz, Dina
IR  - Bell S
FIR - Bell, Sue
IR  - Cebulla CM
FIR - Cebulla, Colleen M
IR  - Davis A
FIR - Davis, Amy
IR  - Duell R
FIR - Duell, Rebecca
IR  - Elder JB
FIR - Elder, J Bradley
IR  - Hilty J
FIR - Hilty, Joe
IR  - Kumar B
FIR - Kumar, Bahavna
IR  - Lang J
FIR - Lang, James
IR  - Lehman NL
FIR - Lehman, Norman L
IR  - Mandt R
FIR - Mandt, Randy
IR  - Nguyen P
FIR - Nguyen, Phuong
IR  - Pilarski R
FIR - Pilarski, Robert
IR  - Rai K
FIR - Rai, Karan
IR  - Schoenfield L
FIR - Schoenfield, Lynn
IR  - Senecal K
FIR - Senecal, Kelly
IR  - Wakely P
FIR - Wakely, Paul
IR  - Hansen P
FIR - Hansen, Paul
IR  - Lechan R
FIR - Lechan, Ronald
IR  - Powers J
FIR - Powers, James
IR  - Tischler A
FIR - Tischler, Arthur
IR  - Grizzle WE
FIR - Grizzle, William E
IR  - Sexton KC
FIR - Sexton, Katherine C
IR  - Kastl A
FIR - Kastl, Alison
IR  - Henderson J
FIR - Henderson, Joel
IR  - Porten S
FIR - Porten, Sima
IR  - Waldmann J
FIR - Waldmann, Jens
IR  - Fassnacht M
FIR - Fassnacht, Martin
IR  - Asa SL
FIR - Asa, Sylvia L
IR  - Schadendorf D
FIR - Schadendorf, Dirk
IR  - Couce M
FIR - Couce, Marta
IR  - Graefen M
FIR - Graefen, Markus
IR  - Huland H
FIR - Huland, Hartwig
IR  - Sauter G
FIR - Sauter, Guido
IR  - Schlomm T
FIR - Schlomm, Thorsten
IR  - Simon R
FIR - Simon, Ronald
IR  - Tennstedt P
FIR - Tennstedt, Pierre
IR  - Olabode O
FIR - Olabode, Oluwole
IR  - Nelson M
FIR - Nelson, Mark
IR  - Bathe O
FIR - Bathe, Oliver
IR  - Carroll PR
FIR - Carroll, Peter R
IR  - Chan JM
FIR - Chan, June M
IR  - Disaia P
FIR - Disaia, Philip
IR  - Glenn P
FIR - Glenn, Pat
IR  - Kelley RK
FIR - Kelley, Robin K
IR  - Landen CN
FIR - Landen, Charles N
IR  - Phillips J
FIR - Phillips, Joanna
IR  - Prados M
FIR - Prados, Michael
IR  - Simko J
FIR - Simko, Jeffry
IR  - Smith-McCune K
FIR - Smith-McCune, Karen
IR  - VandenBerg S
FIR - VandenBerg, Scott
IR  - Roggin K
FIR - Roggin, Kevin
IR  - Fehrenbach A
FIR - Fehrenbach, Ashley
IR  - Kendler A
FIR - Kendler, Ady
IR  - Sifri S
FIR - Sifri, Suzanne
IR  - Steele R
FIR - Steele, Ruth
IR  - Jimeno A
FIR - Jimeno, Antonio
IR  - Carey F
FIR - Carey, Francis
IR  - Forgie I
FIR - Forgie, Ian
IR  - Mannelli M
FIR - Mannelli, Massimo
IR  - Carney M
FIR - Carney, Michael
IR  - Hernandez B
FIR - Hernandez, Brenda
IR  - Campos B
FIR - Campos, Benito
IR  - Herold-Mende C
FIR - Herold-Mende, Christel
IR  - Jungk C
FIR - Jungk, Christin
IR  - Unterberg A
FIR - Unterberg, Andreas
IR  - von Deimling A
FIR - von Deimling, Andreas
IR  - Bossler A
FIR - Bossler, Aaron
IR  - Galbraith J
FIR - Galbraith, Joseph
IR  - Jacobus L
FIR - Jacobus, Laura
IR  - Knudson M
FIR - Knudson, Michael
IR  - Knutson T
FIR - Knutson, Tina
IR  - Ma D
FIR - Ma, Deqin
IR  - Milhem M
FIR - Milhem, Mohammed
IR  - Sigmund R
FIR - Sigmund, Rita
IR  - Godwin AK
FIR - Godwin, Andrew K
IR  - Madan R
FIR - Madan, Rashna
IR  - Rosenthal HG
FIR - Rosenthal, Howard G
IR  - Adebamowo C
FIR - Adebamowo, Clement
IR  - Adebamowo SN
FIR - Adebamowo, Sally N
IR  - Boussioutas A
FIR - Boussioutas, Alex
IR  - Beer D
FIR - Beer, David
IR  - Giordano T
FIR - Giordano, Thomas
IR  - Mes-Masson AM
FIR - Mes-Masson, Anne-Marie
IR  - Saad F
FIR - Saad, Fred
IR  - Bocklage T
FIR - Bocklage, Therese
IR  - Landrum L
FIR - Landrum, Lisa
IR  - Mannel R
FIR - Mannel, Robert
IR  - Moore K
FIR - Moore, Kathleen
IR  - Moxley K
FIR - Moxley, Katherine
IR  - Postier R
FIR - Postier, Russel
IR  - Walker J
FIR - Walker, Joan
IR  - Zuna R
FIR - Zuna, Rosemary
IR  - Feldman M
FIR - Feldman, Michael
IR  - Valdivieso F
FIR - Valdivieso, Federico
IR  - Dhir R
FIR - Dhir, Rajiv
IR  - Luketich J
FIR - Luketich, James
IR  - Pinero EMM
FIR - Pinero, Edna M Mora
IR  - Quintero-Aguilo M
FIR - Quintero-Aguilo, Mario
IR  - Carlotti CG Jr.
FIR - Carlotti, Carlos Gilberto Jr.
IR  - Dos Santos JS
FIR - Dos Santos, Jose Sebastiao
IR  - Kemp R
FIR - Kemp, Rafael
IR  - Sankarankuty A
FIR - Sankarankuty, Ajith
IR  - Tirapelli D
FIR - Tirapelli, Daniela
IR  - Catto J
FIR - Catto, James
IR  - Agnew K
FIR - Agnew, Kathy
IR  - Swisher E
FIR - Swisher, Elizabeth
IR  - Creaney J
FIR - Creaney, Jenette
IR  - Robinson B
FIR - Robinson, Bruce
IR  - Shelley CS
FIR - Shelley, Carl Simon
IR  - Godwin EM
FIR - Godwin, Eryn M
IR  - Kendall S
FIR - Kendall, Sara
IR  - Shipman C
FIR - Shipman, Cassaundra
IR  - Bradford C
FIR - Bradford, Carol
IR  - Carey T
FIR - Carey, Thomas
IR  - Haddad A
FIR - Haddad, Andrea
IR  - Moyer J
FIR - Moyer, Jeffey
IR  - Peterson L
FIR - Peterson, Lisa
IR  - Prince M
FIR - Prince, Mark
IR  - Rozek L
FIR - Rozek, Laura
IR  - Wolf G
FIR - Wolf, Gregory
IR  - Bowman R
FIR - Bowman, Rayleen
IR  - Fong KM
FIR - Fong, Kwun M
IR  - Yang I
FIR - Yang, Ian
IR  - Korst R
FIR - Korst, Robert
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Fantacone-Campbell JL
FIR - Fantacone-Campbell, J Leigh
IR  - Hooke JA
FIR - Hooke, Jeffrey A
IR  - Kovatich AJ
FIR - Kovatich, Albert J
IR  - Shriver CD
FIR - Shriver, Craig D
IR  - DiPersio J
FIR - DiPersio, John
IR  - Drake B
FIR - Drake, Bettina
IR  - Govindan R
FIR - Govindan, Ramaswamy
IR  - Heath S
FIR - Heath, Sharon
IR  - Ley T
FIR - Ley, Timothy
IR  - Van Tine B
FIR - Van Tine, Brian
IR  - Westervelt P
FIR - Westervelt, Peter
IR  - Rubin MA
FIR - Rubin, Mark A
IR  - Lee JI
FIR - Lee, Jung Il
IR  - Aredes ND
FIR - Aredes, Natalia D
IR  - Mariamidze A
FIR - Mariamidze, Armaz
EDAT- 2018/04/07 06:00
MHDA- 2018/04/07 06:00
CRDT- 2018/04/07 06:00
PHST- 2017/07/21 00:00 [received]
PHST- 2018/01/25 00:00 [revised]
PHST- 2018/03/07 00:00 [accepted]
PHST- 2018/04/07 06:00 [entrez]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
AID - S1535-6108(18)30114-4 [pii]
AID - 10.1016/j.ccell.2018.03.010 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Apr 2. pii: S1535-6108(18)30114-4. doi:
      10.1016/j.ccell.2018.03.010.

PMID- 29622464
OWN - NLM
STAT- Publisher
LR  - 20180406
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Apr 1
TI  - A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
LID - S1535-6108(18)30119-3 [pii]
LID - 10.1016/j.ccell.2018.03.014 [doi]
AB  - We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of
      four gynecological types plus breast. Our aims were to identify shared and unique
      molecular features, clinically significant subtypes, and potential therapeutic
      targets. We found 61 somatic copy-number alterations (SCNAs) and 46 significantly
      mutated genes (SMGs). Eleven SCNAs and 11 SMGs had not been identified in
      previous TCGA studies of the individual tumor types. We found functionally
      significant estrogen receptor-regulated long non-coding RNAs (lncRNAs) and
      gene/lncRNA interaction networks. Pathway analysis identified subtypes with high 
      leukocyte infiltration, raising potential implications for immunotherapy. Using
      16 key molecular features, we identified five prognostic subtypes and developed a
      decision tree that classified patients into the subtypes based on just six
      features that are assessable in clinical laboratories.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Berger, Ashton C
AU  - Berger AC
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Korkut, Anil
AU  - Korkut A
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kanchi, Rupa S
AU  - Kanchi RS
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hegde, Apurva M
AU  - Hegde AM
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Lenoir, Walter
AU  - Lenoir W
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Liu, Wenbin
AU  - Liu W
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Liu, Yuexin
AU  - Liu Y
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Fan, Huihui
AU  - Fan H
AD  - Center for Epigenetics, Van Andel Research Institute, 333 Bostwick Avenue NE,
      Grand Rapids, MI 49503, USA.
FAU - Shen, Hui
AU  - Shen H
AD  - Center for Epigenetics, Van Andel Research Institute, 333 Bostwick Avenue NE,
      Grand Rapids, MI 49503, USA.
FAU - Ravikumar, Visweswaran
AU  - Ravikumar V
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Rao, Arvind
AU  - Rao A
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Schultz, Andre
AU  - Schultz A
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Li, Xubin
AU  - Li X
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Sumazin, Pavel
AU  - Sumazin P
AD  - Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030,
      USA.
FAU - Williams, Cecilia
AU  - Williams C
AD  - Department of Protein Sciences, CBH, KTH - Royal Institute of Technology, Science
      for Life Laboratory, Tomtebodavagen 23, 171 21 Solna, Sweden.
FAU - Mestdagh, Pieter
AU  - Mestdagh P
AD  - Department of Pediatrics and Medical Genetics, Ghent University, Ghent, Belgium.
FAU - Gunaratne, Preethi H
AU  - Gunaratne PH
AD  - Department of Biology & Biochemistry, UH-Sequencing Core, University of Houston, 
      Houston, TX 77204, USA; Human Genome Sequencing Center, Baylor College of
      Medicine, Houston, TX 77030, USA.
FAU - Yau, Christina
AU  - Yau C
AD  - Buck Institute of Research on Aging, Novato, CA 94945, USA; Department of
      Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
FAU - Bowlby, Reanne
AU  - Bowlby R
AD  - BC Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Robertson, A Gordon
AU  - Robertson AG
AD  - BC Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Tiezzi, Daniel G
AU  - Tiezzi DG
AD  - Breast Disease and Gynecologic Oncology Division - Department of Gynecology and
      Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, 3900
      Bandeirantes Avenue, Ribeirao Preto, SP 14048-900, Brazil.
FAU - Wang, Chen
AU  - Wang C
AD  - Department of Health Sciences Research, Mayo Clinic College of Medicine, 200
      First Street SW, Rochester, MN 55905, USA; Department of Obstetrics and
      Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN
      55905, USA.
FAU - Cherniack, Andrew D
AU  - Cherniack AD
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Godwin, Andrew K
AU  - Godwin AK
AD  - Department of Pathology and Laboratory Medicine, The University of Kansas Medical
      Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
FAU - Kuderer, Nicole M
AU  - Kuderer NM
AD  - Advanced Cancer Research Group, Seattle, Washington, and Center for Cancer
      Innovation, Department of Medicine, University of Washington, WA 98195, USA.
FAU - Rader, Janet S
AU  - Rader JS
AD  - Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee,
      WI 53226, USA.
FAU - Zuna, Rosemary E
AU  - Zuna RE
AD  - Pathology Department, University of Oklahoma Health Sciences Center, Oklahoma
      City, OK 73104, USA.
FAU - Sood, Anil K
AU  - Sood AK
AD  - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Lazar, Alexander J
AU  - Lazar AJ
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Translational
      Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, 
      TX 77030, USA.
FAU - Ojesina, Akinyemi I
AU  - Ojesina AI
AD  - Department of Epidemiology and Comprehensive Cancer Center, University of Alabama
      at Birmingham, Birmingham, AL 35294, USA.
FAU - Adebamowo, Clement
AU  - Adebamowo C
AD  - Department of Epidemiology and Public Health, Institute of Human Virology and
      Greenebaum Comprehensive Cancer Center, University of Maryland School of
      Medicine, Baltimore, MD 21201, USA; Institute of Human Virology, Abuja, Nigeria.
FAU - Adebamowo, Sally N
AU  - Adebamowo SN
AD  - Department of Epidemiology and Public Health, Institute of Human Virology and
      Greenebaum Comprehensive Cancer Center, University of Maryland School of
      Medicine, Baltimore, MD 21201, USA.
FAU - Baggerly, Keith A
AU  - Baggerly KA
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Chen, Ting-Wen
AU  - Chen TW
AD  - Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030,
      USA; Bioinformatics Center, Molecular Medicine Research Center, Chang Gung
      University, Taoyuan, Taiwan.
FAU - Chiu, Hua-Sheng
AU  - Chiu HS
AD  - Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030,
      USA.
FAU - Lefever, Steve
AU  - Lefever S
AD  - Department of Pediatrics and Medical Genetics, Ghent University, Ghent, Belgium.
FAU - Liu, Liang
AU  - Liu L
AD  - Department of Cancer Biology, Wake Forest Baptist Health Center, Winston Salem,
      NC 27157, USA.
FAU - MacKenzie, Karen
AU  - MacKenzie K
AD  - School of Women's and Children's Health, University of New South Wales, Sydney,
      Australia.
FAU - Orsulic, Sandra
AU  - Orsulic S
AD  - Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute,
      Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FAU - Roszik, Jason
AU  - Roszik J
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Melanoma Medical Oncology,
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Shelley, Carl Simon
AU  - Shelley CS
AD  - Leukemia Therapeutics, LLC, Hull, MA 02045, USA.
FAU - Song, Qianqian
AU  - Song Q
AD  - Department of Cancer Biology, Wake Forest Baptist Health Center, Winston Salem,
      NC 27157, USA.
FAU - Vellano, Christopher P
AU  - Vellano CP
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Wentzensen, Nicolas
AU  - Wentzensen N
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Bethesda, MD 20892, USA.
CN  - Cancer Genome Atlas Research Network
FAU - Weinstein, John N
AU  - Weinstein JN
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology,
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic
      address: jweinste@mdanderson.org.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA. Electronic address: gmills@mdanderson.org.
FAU - Levine, Douglas A
AU  - Levine DA
AD  - Gynecologic Oncology, Perlmutter Cancer Center, New York University Langone
      Health, New York, NY 10016, USA. Electronic address: douglas.levine@nyumc.org.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:
      rakbani@mdanderson.org.
LA  - eng
PT  - Journal Article
DEP - 20180401
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - TCGA
OT  - The Cancer Genome Atlas
OT  - breast cancer
OT  - cervical cancer
OT  - gynecologic cancer
OT  - omics
OT  - ovarian cancer
OT  - pan-gynecologic
OT  - uterine cancer
OT  - uterine carcinosarcoma
IR  - Caesar-Johnson SJ
FIR - Caesar-Johnson, Samantha J
IR  - Demchok JA
FIR - Demchok, John A
IR  - Felau I
FIR - Felau, Ina
IR  - Kasapi M
FIR - Kasapi, Melpomeni
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Wang Z
FIR - Wang, Zhining
IR  - Yang L
FIR - Yang, Liming
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Pihl T
FIR - Pihl, Todd
IR  - Sun Q
FIR - Sun, Qiang
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wu Y
FIR - Wu, Ye
IR  - Cho J
FIR - Cho, Juok
IR  - DeFreitas T
FIR - DeFreitas, Timothy
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Getz G
FIR - Getz, Gad
IR  - Heiman DI
FIR - Heiman, David I
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lin P
FIR - Lin, Pei
IR  - Meier S
FIR - Meier, Sam
IR  - Noble MS
FIR - Noble, Michael S
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Voet D
FIR - Voet, Doug
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Bernard B
FIR - Bernard, Brady
IR  - Chambwe N
FIR - Chambwe, Nyasha
IR  - Dhankani V
FIR - Dhankani, Varsha
IR  - Knijnenburg T
FIR - Knijnenburg, Theo
IR  - Kramer R
FIR - Kramer, Roger
IR  - Leinonen K
FIR - Leinonen, Kalle
IR  - Liu Y
FIR - Liu, Yuexin
IR  - Miller M
FIR - Miller, Michael
IR  - Reynolds S
FIR - Reynolds, Sheila
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Thorsson V
FIR - Thorsson, Vesteinn
IR  - Zhang W
FIR - Zhang, Wei
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Broom BM
FIR - Broom, Bradley M
IR  - Hegde AM
FIR - Hegde, Apurva M
IR  - Ju Z
FIR - Ju, Zhenlin
IR  - Kanchi RS
FIR - Kanchi, Rupa S
IR  - Korkut A
FIR - Korkut, Anil
IR  - Li J
FIR - Li, Jun
IR  - Liang H
FIR - Liang, Han
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu W
FIR - Liu, Wenbin
IR  - Lu Y
FIR - Lu, Yiling
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Ng KS
FIR - Ng, Kwok-Shing
IR  - Rao A
FIR - Rao, Arvind
IR  - Ryan M
FIR - Ryan, Michael
IR  - Wang J
FIR - Wang, Jing
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Zhang J
FIR - Zhang, Jiexin
IR  - Abeshouse A
FIR - Abeshouse, Adam
IR  - Armenia J
FIR - Armenia, Joshua
IR  - Chakravarty D
FIR - Chakravarty, Debyani
IR  - Chatila WK
FIR - Chatila, Walid K
IR  - de Bruijn I
FIR - de Bruijn, Ino
IR  - Gao J
FIR - Gao, Jianjiong
IR  - Gross BE
FIR - Gross, Benjamin E
IR  - Heins ZJ
FIR - Heins, Zachary J
IR  - Kundra R
FIR - Kundra, Ritika
IR  - La K
FIR - La, Konnor
IR  - Ladanyi M
FIR - Ladanyi, Marc
IR  - Luna A
FIR - Luna, Augustin
IR  - Nissan MG
FIR - Nissan, Moriah G
IR  - Ochoa A
FIR - Ochoa, Angelica
IR  - Phillips SM
FIR - Phillips, Sarah M
IR  - Reznik E
FIR - Reznik, Ed
IR  - Sanchez-Vega F
FIR - Sanchez-Vega, Francisco
IR  - Sander C
FIR - Sander, Chris
IR  - Schultz N
FIR - Schultz, Nikolaus
IR  - Sheridan R
FIR - Sheridan, Robert
IR  - Sumer SO
FIR - Sumer, S Onur
IR  - Sun Y
FIR - Sun, Yichao
IR  - Taylor BS
FIR - Taylor, Barry S
IR  - Wang J
FIR - Wang, Jioajiao
IR  - Zhang H
FIR - Zhang, Hongxin
IR  - Anur P
FIR - Anur, Pavana
IR  - Peto M
FIR - Peto, Myron
IR  - Spellman P
FIR - Spellman, Paul
IR  - Benz C
FIR - Benz, Christopher
IR  - Stuart JM
FIR - Stuart, Joshua M
IR  - Wong CK
FIR - Wong, Christopher K
IR  - Yau C
FIR - Yau, Christina
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Parker JS
FIR - Parker, Joel S
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Ally A
FIR - Ally, Adrian
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Chuah E
FIR - Chuah, Eric
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Holt R
FIR - Holt, Robert
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Lee D
FIR - Lee, Darlene
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Tam A
FIR - Tam, Angela
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Tse K
FIR - Tse, Kane
IR  - Wong T
FIR - Wong, Tina
IR  - Berger AC
FIR - Berger, Ashton C
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gao GF
FIR - Gao, Galen F
IR  - Ha G
FIR - Ha, Gavin
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Shih J
FIR - Shih, Juliann
IR  - Kucherlapati MH
FIR - Kucherlapati, Melanie H
IR  - Kucherlapati RS
FIR - Kucherlapati, Raju S
IR  - Baylin S
FIR - Baylin, Stephen
IR  - Cope L
FIR - Cope, Leslie
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Auman JT
FIR - Auman, J Todd
IR  - Balu S
FIR - Balu, Saianand
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Fan C
FIR - Fan, Cheng
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Meng S
FIR - Meng, Shaowu
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Perou AH
FIR - Perou, Amy H
IR  - Perou CM
FIR - Perou, Charles M
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Shi Y
FIR - Shi, Yan
IR  - Simons JV
FIR - Simons, Janae V
IR  - Skelly T
FIR - Skelly, Tara
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Tan D
FIR - Tan, Donghui
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Fan H
FIR - Fan, Huihui
IR  - Hinoue T
FIR - Hinoue, Toshinori
IR  - Laird PW
FIR - Laird, Peter W
IR  - Shen H
FIR - Shen, Hui
IR  - Zhou W
FIR - Zhou, Wanding
IR  - Bellair M
FIR - Bellair, Michelle
IR  - Chang K
FIR - Chang, Kyle
IR  - Covington K
FIR - Covington, Kyle
IR  - Creighton CJ
FIR - Creighton, Chad J
IR  - Dinh H
FIR - Dinh, Huyen
IR  - Doddapaneni H
FIR - Doddapaneni, HarshaVardhan
IR  - Donehower LA
FIR - Donehower, Lawrence A
IR  - Drummond J
FIR - Drummond, Jennifer
IR  - Gibbs RA
FIR - Gibbs, Richard A
IR  - Glenn R
FIR - Glenn, Robert
IR  - Hale W
FIR - Hale, Walker
IR  - Han Y
FIR - Han, Yi
IR  - Hu J
FIR - Hu, Jianhong
IR  - Korchina V
FIR - Korchina, Viktoriya
IR  - Lee S
FIR - Lee, Sandra
IR  - Lewis L
FIR - Lewis, Lora
IR  - Li W
FIR - Li, Wei
IR  - Liu X
FIR - Liu, Xiuping
IR  - Morgan M
FIR - Morgan, Margaret
IR  - Morton D
FIR - Morton, Donna
IR  - Muzny D
FIR - Muzny, Donna
IR  - Santibanez J
FIR - Santibanez, Jireh
IR  - Sheth M
FIR - Sheth, Margi
IR  - Shinbrot E
FIR - Shinbrot, Eve
IR  - Wang L
FIR - Wang, Linghua
IR  - Wang M
FIR - Wang, Min
IR  - Wheeler DA
FIR - Wheeler, David A
IR  - Xi L
FIR - Xi, Liu
IR  - Zhao F
FIR - Zhao, Fengmei
IR  - Hess J
FIR - Hess, Julian
IR  - Appelbaum EL
FIR - Appelbaum, Elizabeth L
IR  - Bailey M
FIR - Bailey, Matthew
IR  - Cordes MG
FIR - Cordes, Matthew G
IR  - Ding L
FIR - Ding, Li
IR  - Fronick CC
FIR - Fronick, Catrina C
IR  - Fulton LA
FIR - Fulton, Lucinda A
IR  - Fulton RS
FIR - Fulton, Robert S
IR  - Kandoth C
FIR - Kandoth, Cyriac
IR  - Mardis ER
FIR - Mardis, Elaine R
IR  - McLellan MD
FIR - McLellan, Michael D
IR  - Miller CA
FIR - Miller, Christopher A
IR  - Schmidt HK
FIR - Schmidt, Heather K
IR  - Wilson RK
FIR - Wilson, Richard K
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Lau K
FIR - Lau, Kevin
IR  - Mallery D
FIR - Mallery, David
IR  - Morris S
FIR - Morris, Scott
IR  - Paulauskis J
FIR - Paulauskis, Joseph
IR  - Penny R
FIR - Penny, Robert
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Sherman M
FIR - Sherman, Mark
IR  - Thompson E
FIR - Thompson, Eric
IR  - Yena P
FIR - Yena, Peggy
IR  - Bowen J
FIR - Bowen, Jay
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gerken M
FIR - Gerken, Mark
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Wise L
FIR - Wise, Lisa
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Corcoran N
FIR - Corcoran, Niall
IR  - Costello T
FIR - Costello, Tony
IR  - Hovens C
FIR - Hovens, Christopher
IR  - Carvalho AL
FIR - Carvalho, Andre L
IR  - de Carvalho AC
FIR - de Carvalho, Ana C
IR  - Fregnani JH
FIR - Fregnani, Jose H
IR  - Longatto-Filho A
FIR - Longatto-Filho, Adhemar
IR  - Reis RM
FIR - Reis, Rui M
IR  - Scapulatempo-Neto C
FIR - Scapulatempo-Neto, Cristovam
IR  - Silveira HCS
FIR - Silveira, Henrique C S
IR  - Vidal DO
FIR - Vidal, Daniel O
IR  - Burnette A
FIR - Burnette, Andrew
IR  - Eschbacher J
FIR - Eschbacher, Jennifer
IR  - Hermes B
FIR - Hermes, Beth
IR  - Noss A
FIR - Noss, Ardene
IR  - Singh R
FIR - Singh, Rosy
IR  - Anderson ML
FIR - Anderson, Matthew L
IR  - Castro PD
FIR - Castro, Patricia D
IR  - Ittmann M
FIR - Ittmann, Michael
IR  - Huntsman D
FIR - Huntsman, David
IR  - Kohl B
FIR - Kohl, Bernard
IR  - Le X
FIR - Le, Xuan
IR  - Thorp R
FIR - Thorp, Richard
IR  - Andry C
FIR - Andry, Chris
IR  - Duffy ER
FIR - Duffy, Elizabeth R
IR  - Lyadov V
FIR - Lyadov, Vladimir
IR  - Paklina O
FIR - Paklina, Oxana
IR  - Setdikova G
FIR - Setdikova, Galiya
IR  - Shabunin A
FIR - Shabunin, Alexey
IR  - Tavobilov M
FIR - Tavobilov, Mikhail
IR  - McPherson C
FIR - McPherson, Christopher
IR  - Warnick R
FIR - Warnick, Ronald
IR  - Berkowitz R
FIR - Berkowitz, Ross
IR  - Cramer D
FIR - Cramer, Daniel
IR  - Feltmate C
FIR - Feltmate, Colleen
IR  - Horowitz N
FIR - Horowitz, Neil
IR  - Kibel A
FIR - Kibel, Adam
IR  - Muto M
FIR - Muto, Michael
IR  - Raut CP
FIR - Raut, Chandrajit P
IR  - Malykh A
FIR - Malykh, Andrei
IR  - Barnholtz-Sloan JS
FIR - Barnholtz-Sloan, Jill S
IR  - Barrett W
FIR - Barrett, Wendi
IR  - Devine K
FIR - Devine, Karen
IR  - Fulop J
FIR - Fulop, Jordonna
IR  - Ostrom QT
FIR - Ostrom, Quinn T
IR  - Shimmel K
FIR - Shimmel, Kristen
IR  - Wolinsky Y
FIR - Wolinsky, Yingli
IR  - Sloan AE
FIR - Sloan, Andrew E
IR  - De Rose A
FIR - De Rose, Agostino
IR  - Giuliante F
FIR - Giuliante, Felice
IR  - Goodman M
FIR - Goodman, Marc
IR  - Karlan BY
FIR - Karlan, Beth Y
IR  - Hagedorn CH
FIR - Hagedorn, Curt H
IR  - Eckman J
FIR - Eckman, John
IR  - Harr J
FIR - Harr, Jodi
IR  - Myers J
FIR - Myers, Jerome
IR  - Tucker K
FIR - Tucker, Kelinda
IR  - Zach LA
FIR - Zach, Leigh Anne
IR  - Deyarmin B
FIR - Deyarmin, Brenda
IR  - Hu H
FIR - Hu, Hai
IR  - Kvecher L
FIR - Kvecher, Leonid
IR  - Larson C
FIR - Larson, Caroline
IR  - Mural RJ
FIR - Mural, Richard J
IR  - Somiari S
FIR - Somiari, Stella
IR  - Vicha A
FIR - Vicha, Ales
IR  - Zelinka T
FIR - Zelinka, Tomas
IR  - Bennett J
FIR - Bennett, Joseph
IR  - Iacocca M
FIR - Iacocca, Mary
IR  - Rabeno B
FIR - Rabeno, Brenda
IR  - Swanson P
FIR - Swanson, Patricia
IR  - Latour M
FIR - Latour, Mathieu
IR  - Lacombe L
FIR - Lacombe, Louis
IR  - Tetu B
FIR - Tetu, Bernard
IR  - Bergeron A
FIR - Bergeron, Alain
IR  - McGraw M
FIR - McGraw, Mary
IR  - Staugaitis SM
FIR - Staugaitis, Susan M
IR  - Chabot J
FIR - Chabot, John
IR  - Hibshoosh H
FIR - Hibshoosh, Hanina
IR  - Sepulveda A
FIR - Sepulveda, Antonia
IR  - Su T
FIR - Su, Tao
IR  - Wang T
FIR - Wang, Timothy
IR  - Potapova O
FIR - Potapova, Olga
IR  - Voronina O
FIR - Voronina, Olga
IR  - Desjardins L
FIR - Desjardins, Laurence
IR  - Mariani O
FIR - Mariani, Odette
IR  - Roman-Roman S
FIR - Roman-Roman, Sergio
IR  - Sastre X
FIR - Sastre, Xavier
IR  - Stern MH
FIR - Stern, Marc-Henri
IR  - Cheng F
FIR - Cheng, Feixiong
IR  - Signoretti S
FIR - Signoretti, Sabina
IR  - Berchuck A
FIR - Berchuck, Andrew
IR  - Bigner D
FIR - Bigner, Darell
IR  - Lipp E
FIR - Lipp, Eric
IR  - Marks J
FIR - Marks, Jeffrey
IR  - McCall S
FIR - McCall, Shannon
IR  - McLendon R
FIR - McLendon, Roger
IR  - Secord A
FIR - Secord, Angeles
IR  - Sharp A
FIR - Sharp, Alexis
IR  - Behera M
FIR - Behera, Madhusmita
IR  - Brat DJ
FIR - Brat, Daniel J
IR  - Chen A
FIR - Chen, Amy
IR  - Delman K
FIR - Delman, Keith
IR  - Force S
FIR - Force, Seth
IR  - Khuri F
FIR - Khuri, Fadlo
IR  - Magliocca K
FIR - Magliocca, Kelly
IR  - Maithel S
FIR - Maithel, Shishir
IR  - Olson JJ
FIR - Olson, Jeffrey J
IR  - Owonikoko T
FIR - Owonikoko, Taofeek
IR  - Pickens A
FIR - Pickens, Alan
IR  - Ramalingam S
FIR - Ramalingam, Suresh
IR  - Shin DM
FIR - Shin, Dong M
IR  - Sica G
FIR - Sica, Gabriel
IR  - Van Meir EG
FIR - Van Meir, Erwin G
IR  - Zhang H
FIR - Zhang, Hongzheng
IR  - Eijckenboom W
FIR - Eijckenboom, Wil
IR  - Gillis A
FIR - Gillis, Ad
IR  - Korpershoek E
FIR - Korpershoek, Esther
IR  - Looijenga L
FIR - Looijenga, Leendert
IR  - Oosterhuis W
FIR - Oosterhuis, Wolter
IR  - Stoop H
FIR - Stoop, Hans
IR  - van Kessel KE
FIR - van Kessel, Kim E
IR  - Zwarthoff EC
FIR - Zwarthoff, Ellen C
IR  - Calatozzolo C
FIR - Calatozzolo, Chiara
IR  - Cuppini L
FIR - Cuppini, Lucia
IR  - Cuzzubbo S
FIR - Cuzzubbo, Stefania
IR  - DiMeco F
FIR - DiMeco, Francesco
IR  - Finocchiaro G
FIR - Finocchiaro, Gaetano
IR  - Mattei L
FIR - Mattei, Luca
IR  - Perin A
FIR - Perin, Alessandro
IR  - Pollo B
FIR - Pollo, Bianca
IR  - Chen C
FIR - Chen, Chu
IR  - Houck J
FIR - Houck, John
IR  - Lohavanichbutr P
FIR - Lohavanichbutr, Pawadee
IR  - Hartmann A
FIR - Hartmann, Arndt
IR  - Stoehr C
FIR - Stoehr, Christine
IR  - Stoehr R
FIR - Stoehr, Robert
IR  - Taubert H
FIR - Taubert, Helge
IR  - Wach S
FIR - Wach, Sven
IR  - Wullich B
FIR - Wullich, Bernd
IR  - Kycler W
FIR - Kycler, Witold
IR  - Murawa D
FIR - Murawa, Dawid
IR  - Wiznerowicz M
FIR - Wiznerowicz, Maciej
IR  - Chung K
FIR - Chung, Ki
IR  - Edenfield WJ
FIR - Edenfield, W Jeffrey
IR  - Martin J
FIR - Martin, Julie
IR  - Baudin E
FIR - Baudin, Eric
IR  - Bubley G
FIR - Bubley, Glenn
IR  - Bueno R
FIR - Bueno, Raphael
IR  - De Rienzo A
FIR - De Rienzo, Assunta
IR  - Richards WG
FIR - Richards, William G
IR  - Kalkanis S
FIR - Kalkanis, Steven
IR  - Mikkelsen T
FIR - Mikkelsen, Tom
IR  - Noushmehr H
FIR - Noushmehr, Houtan
IR  - Scarpace L
FIR - Scarpace, Lisa
IR  - Girard N
FIR - Girard, Nicolas
IR  - Aymerich M
FIR - Aymerich, Marta
IR  - Campo E
FIR - Campo, Elias
IR  - Gine E
FIR - Gine, Eva
IR  - Guillermo AL
FIR - Guillermo, Armando Lopez
IR  - Van Bang N
FIR - Van Bang, Nguyen
IR  - Hanh PT
FIR - Hanh, Phan Thi
IR  - Phu BD
FIR - Phu, Bui Duc
IR  - Tang Y
FIR - Tang, Yufang
IR  - Colman H
FIR - Colman, Howard
IR  - Evason K
FIR - Evason, Kimberley
IR  - Dottino PR
FIR - Dottino, Peter R
IR  - Martignetti JA
FIR - Martignetti, John A
IR  - Gabra H
FIR - Gabra, Hani
IR  - Juhl H
FIR - Juhl, Hartmut
IR  - Akeredolu T
FIR - Akeredolu, Teniola
IR  - Stepa S
FIR - Stepa, Serghei
IR  - Hoon D
FIR - Hoon, Dave
IR  - Ahn K
FIR - Ahn, Keunsoo
IR  - Kang KJ
FIR - Kang, Koo Jeong
IR  - Beuschlein F
FIR - Beuschlein, Felix
IR  - Breggia A
FIR - Breggia, Anne
IR  - Birrer M
FIR - Birrer, Michael
IR  - Bell D
FIR - Bell, Debra
IR  - Borad M
FIR - Borad, Mitesh
IR  - Bryce AH
FIR - Bryce, Alan H
IR  - Castle E
FIR - Castle, Erik
IR  - Chandan V
FIR - Chandan, Vishal
IR  - Cheville J
FIR - Cheville, John
IR  - Copland JA
FIR - Copland, John A
IR  - Farnell M
FIR - Farnell, Michael
IR  - Flotte T
FIR - Flotte, Thomas
IR  - Giama N
FIR - Giama, Nasra
IR  - Ho T
FIR - Ho, Thai
IR  - Kendrick M
FIR - Kendrick, Michael
IR  - Kocher JP
FIR - Kocher, Jean-Pierre
IR  - Kopp K
FIR - Kopp, Karla
IR  - Moser C
FIR - Moser, Catherine
IR  - Nagorney D
FIR - Nagorney, David
IR  - O'Brien D
FIR - O'Brien, Daniel
IR  - O'Neill BP
FIR - O'Neill, Brian Patrick
IR  - Patel T
FIR - Patel, Tushar
IR  - Petersen G
FIR - Petersen, Gloria
IR  - Que F
FIR - Que, Florencia
IR  - Rivera M
FIR - Rivera, Michael
IR  - Roberts L
FIR - Roberts, Lewis
IR  - Smallridge R
FIR - Smallridge, Robert
IR  - Smyrk T
FIR - Smyrk, Thomas
IR  - Stanton M
FIR - Stanton, Melissa
IR  - Thompson RH
FIR - Thompson, R Houston
IR  - Torbenson M
FIR - Torbenson, Michael
IR  - Yang JD
FIR - Yang, Ju Dong
IR  - Zhang L
FIR - Zhang, Lizhi
IR  - Brimo F
FIR - Brimo, Fadi
IR  - Ajani JA
FIR - Ajani, Jaffer A
IR  - Angulo Gonzalez AM
FIR - Angulo Gonzalez, Ana Maria
IR  - Behrens C
FIR - Behrens, Carmen
IR  - Bondaruk J
FIR - Bondaruk, Jolanta
IR  - Broaddus R
FIR - Broaddus, Russell
IR  - Czerniak B
FIR - Czerniak, Bogdan
IR  - Esmaeli B
FIR - Esmaeli, Bita
IR  - Fujimoto J
FIR - Fujimoto, Junya
IR  - Gershenwald J
FIR - Gershenwald, Jeffrey
IR  - Guo C
FIR - Guo, Charles
IR  - Lazar AJ
FIR - Lazar, Alexander J
IR  - Logothetis C
FIR - Logothetis, Christopher
IR  - Meric-Bernstam F
FIR - Meric-Bernstam, Funda
IR  - Moran C
FIR - Moran, Cesar
IR  - Ramondetta L
FIR - Ramondetta, Lois
IR  - Rice D
FIR - Rice, David
IR  - Sood A
FIR - Sood, Anil
IR  - Tamboli P
FIR - Tamboli, Pheroze
IR  - Thompson T
FIR - Thompson, Timothy
IR  - Troncoso P
FIR - Troncoso, Patricia
IR  - Tsao A
FIR - Tsao, Anne
IR  - Wistuba I
FIR - Wistuba, Ignacio
IR  - Carter C
FIR - Carter, Candace
IR  - Haydu L
FIR - Haydu, Lauren
IR  - Hersey P
FIR - Hersey, Peter
IR  - Jakrot V
FIR - Jakrot, Valerie
IR  - Kakavand H
FIR - Kakavand, Hojabr
IR  - Kefford R
FIR - Kefford, Richard
IR  - Lee K
FIR - Lee, Kenneth
IR  - Long G
FIR - Long, Georgina
IR  - Mann G
FIR - Mann, Graham
IR  - Quinn M
FIR - Quinn, Michael
IR  - Saw R
FIR - Saw, Robyn
IR  - Scolyer R
FIR - Scolyer, Richard
IR  - Shannon K
FIR - Shannon, Kerwin
IR  - Spillane A
FIR - Spillane, Andrew
IR  - Stretch J
FIR - Stretch, Jonathan
IR  - Synott M
FIR - Synott, Maria
IR  - Thompson J
FIR - Thompson, John
IR  - Wilmott J
FIR - Wilmott, James
IR  - Al-Ahmadie H
FIR - Al-Ahmadie, Hikmat
IR  - Chan TA
FIR - Chan, Timothy A
IR  - Ghossein R
FIR - Ghossein, Ronald
IR  - Gopalan A
FIR - Gopalan, Anuradha
IR  - Levine DA
FIR - Levine, Douglas A
IR  - Reuter V
FIR - Reuter, Victor
IR  - Singer S
FIR - Singer, Samuel
IR  - Singh B
FIR - Singh, Bhuvanesh
IR  - Tien NV
FIR - Tien, Nguyen Viet
IR  - Broudy T
FIR - Broudy, Thomas
IR  - Mirsaidi C
FIR - Mirsaidi, Cyrus
IR  - Nair P
FIR - Nair, Praveen
IR  - Drwiega P
FIR - Drwiega, Paul
IR  - Miller J
FIR - Miller, Judy
IR  - Smith J
FIR - Smith, Jennifer
IR  - Zaren H
FIR - Zaren, Howard
IR  - Park JW
FIR - Park, Joong-Won
IR  - Hung NP
FIR - Hung, Nguyen Phi
IR  - Kebebew E
FIR - Kebebew, Electron
IR  - Linehan WM
FIR - Linehan, W Marston
IR  - Metwalli AR
FIR - Metwalli, Adam R
IR  - Pacak K
FIR - Pacak, Karel
IR  - Pinto PA
FIR - Pinto, Peter A
IR  - Schiffman M
FIR - Schiffman, Mark
IR  - Schmidt LS
FIR - Schmidt, Laura S
IR  - Vocke CD
FIR - Vocke, Cathy D
IR  - Wentzensen N
FIR - Wentzensen, Nicolas
IR  - Worrell R
FIR - Worrell, Robert
IR  - Yang H
FIR - Yang, Hannah
IR  - Moncrieff M
FIR - Moncrieff, Marc
IR  - Goparaju C
FIR - Goparaju, Chandra
IR  - Melamed J
FIR - Melamed, Jonathan
IR  - Pass H
FIR - Pass, Harvey
IR  - Botnariuc N
FIR - Botnariuc, Natalia
IR  - Caraman I
FIR - Caraman, Irina
IR  - Cernat M
FIR - Cernat, Mircea
IR  - Chemencedji I
FIR - Chemencedji, Inga
IR  - Clipca A
FIR - Clipca, Adrian
IR  - Doruc S
FIR - Doruc, Serghei
IR  - Gorincioi G
FIR - Gorincioi, Ghenadie
IR  - Mura S
FIR - Mura, Sergiu
IR  - Pirtac M
FIR - Pirtac, Maria
IR  - Stancul I
FIR - Stancul, Irina
IR  - Tcaciuc D
FIR - Tcaciuc, Diana
IR  - Albert M
FIR - Albert, Monique
IR  - Alexopoulou I
FIR - Alexopoulou, Iakovina
IR  - Arnaout A
FIR - Arnaout, Angel
IR  - Bartlett J
FIR - Bartlett, John
IR  - Engel J
FIR - Engel, Jay
IR  - Gilbert S
FIR - Gilbert, Sebastien
IR  - Parfitt J
FIR - Parfitt, Jeremy
IR  - Sekhon H
FIR - Sekhon, Harman
IR  - Thomas G
FIR - Thomas, George
IR  - Rassl DM
FIR - Rassl, Doris M
IR  - Rintoul RC
FIR - Rintoul, Robert C
IR  - Bifulco C
FIR - Bifulco, Carlo
IR  - Tamakawa R
FIR - Tamakawa, Raina
IR  - Urba W
FIR - Urba, Walter
IR  - Hayward N
FIR - Hayward, Nicholas
IR  - Timmers H
FIR - Timmers, Henri
IR  - Antenucci A
FIR - Antenucci, Anna
IR  - Facciolo F
FIR - Facciolo, Francesco
IR  - Grazi G
FIR - Grazi, Gianluca
IR  - Marino M
FIR - Marino, Mirella
IR  - Merola R
FIR - Merola, Roberta
IR  - de Krijger R
FIR - de Krijger, Ronald
IR  - Gimenez-Roqueplo AP
FIR - Gimenez-Roqueplo, Anne-Paule
IR  - Piche A
FIR - Piche, Alain
IR  - Chevalier S
FIR - Chevalier, Simone
IR  - McKercher G
FIR - McKercher, Ginette
IR  - Birsoy K
FIR - Birsoy, Kivanc
IR  - Barnett G
FIR - Barnett, Gene
IR  - Brewer C
FIR - Brewer, Cathy
IR  - Farver C
FIR - Farver, Carol
IR  - Naska T
FIR - Naska, Theresa
IR  - Pennell NA
FIR - Pennell, Nathan A
IR  - Raymond D
FIR - Raymond, Daniel
IR  - Schilero C
FIR - Schilero, Cathy
IR  - Smolenski K
FIR - Smolenski, Kathy
IR  - Williams F
FIR - Williams, Felicia
IR  - Morrison C
FIR - Morrison, Carl
IR  - Borgia JA
FIR - Borgia, Jeffrey A
IR  - Liptay MJ
FIR - Liptay, Michael J
IR  - Pool M
FIR - Pool, Mark
IR  - Seder CW
FIR - Seder, Christopher W
IR  - Junker K
FIR - Junker, Kerstin
IR  - Omberg L
FIR - Omberg, Larsson
IR  - Dinkin M
FIR - Dinkin, Mikhail
IR  - Manikhas G
FIR - Manikhas, George
IR  - Alvaro D
FIR - Alvaro, Domenico
IR  - Bragazzi MC
FIR - Bragazzi, Maria Consiglia
IR  - Cardinale V
FIR - Cardinale, Vincenzo
IR  - Carpino G
FIR - Carpino, Guido
IR  - Gaudio E
FIR - Gaudio, Eugenio
IR  - Chesla D
FIR - Chesla, David
IR  - Cottingham S
FIR - Cottingham, Sandra
IR  - Dubina M
FIR - Dubina, Michael
IR  - Moiseenko F
FIR - Moiseenko, Fedor
IR  - Dhanasekaran R
FIR - Dhanasekaran, Renumathy
IR  - Becker KF
FIR - Becker, Karl-Friedrich
IR  - Janssen KP
FIR - Janssen, Klaus-Peter
IR  - Slotta-Huspenina J
FIR - Slotta-Huspenina, Julia
IR  - Abdel-Rahman MH
FIR - Abdel-Rahman, Mohamed H
IR  - Aziz D
FIR - Aziz, Dina
IR  - Bell S
FIR - Bell, Sue
IR  - Cebulla CM
FIR - Cebulla, Colleen M
IR  - Davis A
FIR - Davis, Amy
IR  - Duell R
FIR - Duell, Rebecca
IR  - Elder JB
FIR - Elder, J Bradley
IR  - Hilty J
FIR - Hilty, Joe
IR  - Kumar B
FIR - Kumar, Bahavna
IR  - Lang J
FIR - Lang, James
IR  - Lehman NL
FIR - Lehman, Norman L
IR  - Mandt R
FIR - Mandt, Randy
IR  - Nguyen P
FIR - Nguyen, Phuong
IR  - Pilarski R
FIR - Pilarski, Robert
IR  - Rai K
FIR - Rai, Karan
IR  - Schoenfield L
FIR - Schoenfield, Lynn
IR  - Senecal K
FIR - Senecal, Kelly
IR  - Wakely P
FIR - Wakely, Paul
IR  - Hansen P
FIR - Hansen, Paul
IR  - Lechan R
FIR - Lechan, Ronald
IR  - Powers J
FIR - Powers, James
IR  - Tischler A
FIR - Tischler, Arthur
IR  - Grizzle WE
FIR - Grizzle, William E
IR  - Sexton KC
FIR - Sexton, Katherine C
IR  - Kastl A
FIR - Kastl, Alison
IR  - Henderson J
FIR - Henderson, Joel
IR  - Porten S
FIR - Porten, Sima
IR  - Waldmann J
FIR - Waldmann, Jens
IR  - Fassnacht M
FIR - Fassnacht, Martin
IR  - Asa SL
FIR - Asa, Sylvia L
IR  - Schadendorf D
FIR - Schadendorf, Dirk
IR  - Couce M
FIR - Couce, Marta
IR  - Graefen M
FIR - Graefen, Markus
IR  - Huland H
FIR - Huland, Hartwig
IR  - Sauter G
FIR - Sauter, Guido
IR  - Schlomm T
FIR - Schlomm, Thorsten
IR  - Simon R
FIR - Simon, Ronald
IR  - Tennstedt P
FIR - Tennstedt, Pierre
IR  - Olabode O
FIR - Olabode, Oluwole
IR  - Nelson M
FIR - Nelson, Mark
IR  - Bathe O
FIR - Bathe, Oliver
IR  - Carroll PR
FIR - Carroll, Peter R
IR  - Chan JM
FIR - Chan, June M
IR  - Disaia P
FIR - Disaia, Philip
IR  - Glenn P
FIR - Glenn, Pat
IR  - Kelley RK
FIR - Kelley, Robin K
IR  - Landen CN
FIR - Landen, Charles N
IR  - Phillips J
FIR - Phillips, Joanna
IR  - Prados M
FIR - Prados, Michael
IR  - Simko J
FIR - Simko, Jeffry
IR  - Smith-McCune K
FIR - Smith-McCune, Karen
IR  - VandenBerg S
FIR - VandenBerg, Scott
IR  - Roggin K
FIR - Roggin, Kevin
IR  - Fehrenbach A
FIR - Fehrenbach, Ashley
IR  - Kendler A
FIR - Kendler, Ady
IR  - Sifri S
FIR - Sifri, Suzanne
IR  - Steele R
FIR - Steele, Ruth
IR  - Jimeno A
FIR - Jimeno, Antonio
IR  - Carey F
FIR - Carey, Francis
IR  - Forgie I
FIR - Forgie, Ian
IR  - Mannelli M
FIR - Mannelli, Massimo
IR  - Carney M
FIR - Carney, Michael
IR  - Hernandez B
FIR - Hernandez, Brenda
IR  - Campos B
FIR - Campos, Benito
IR  - Herold-Mende C
FIR - Herold-Mende, Christel
IR  - Jungk C
FIR - Jungk, Christin
IR  - Unterberg A
FIR - Unterberg, Andreas
IR  - von Deimling A
FIR - von Deimling, Andreas
IR  - Bossler A
FIR - Bossler, Aaron
IR  - Galbraith J
FIR - Galbraith, Joseph
IR  - Jacobus L
FIR - Jacobus, Laura
IR  - Knudson M
FIR - Knudson, Michael
IR  - Knutson T
FIR - Knutson, Tina
IR  - Ma D
FIR - Ma, Deqin
IR  - Milhem M
FIR - Milhem, Mohammed
IR  - Sigmund R
FIR - Sigmund, Rita
IR  - Godwin AK
FIR - Godwin, Andrew K
IR  - Madan R
FIR - Madan, Rashna
IR  - Rosenthal HG
FIR - Rosenthal, Howard G
IR  - Adebamowo C
FIR - Adebamowo, Clement
IR  - Adebamowo SN
FIR - Adebamowo, Sally N
IR  - Boussioutas A
FIR - Boussioutas, Alex
IR  - Beer D
FIR - Beer, David
IR  - Giordano T
FIR - Giordano, Thomas
IR  - Mes-Masson AM
FIR - Mes-Masson, Anne-Marie
IR  - Saad F
FIR - Saad, Fred
IR  - Bocklage T
FIR - Bocklage, Therese
IR  - Landrum L
FIR - Landrum, Lisa
IR  - Mannel R
FIR - Mannel, Robert
IR  - Moore K
FIR - Moore, Kathleen
IR  - Moxley K
FIR - Moxley, Katherine
IR  - Postier R
FIR - Postier, Russel
IR  - Walker J
FIR - Walker, Joan
IR  - Zuna R
FIR - Zuna, Rosemary
IR  - Feldman M
FIR - Feldman, Michael
IR  - Valdivieso F
FIR - Valdivieso, Federico
IR  - Dhir R
FIR - Dhir, Rajiv
IR  - Luketich J
FIR - Luketich, James
IR  - Mora Pinero EM
FIR - Mora Pinero, Edna M
IR  - Quintero-Aguilo M
FIR - Quintero-Aguilo, Mario
IR  - Carlotti CG Jr.
FIR - Carlotti, Carlos Gilberto Jr.
IR  - Dos Santos JS
FIR - Dos Santos, Jose Sebastiao
IR  - Kemp R
FIR - Kemp, Rafael
IR  - Sankarankuty A
FIR - Sankarankuty, Ajith
IR  - Tirapelli D
FIR - Tirapelli, Daniela
IR  - Catto J
FIR - Catto, James
IR  - Agnew K
FIR - Agnew, Kathy
IR  - Swisher E
FIR - Swisher, Elizabeth
IR  - Creaney J
FIR - Creaney, Jenette
IR  - Robinson B
FIR - Robinson, Bruce
IR  - Shelley CS
FIR - Shelley, Carl Simon
IR  - Godwin EM
FIR - Godwin, Eryn M
IR  - Kendall S
FIR - Kendall, Sara
IR  - Shipman C
FIR - Shipman, Cassaundra
IR  - Bradford C
FIR - Bradford, Carol
IR  - Carey T
FIR - Carey, Thomas
IR  - Haddad A
FIR - Haddad, Andrea
IR  - Moyer J
FIR - Moyer, Jeffey
IR  - Peterson L
FIR - Peterson, Lisa
IR  - Prince M
FIR - Prince, Mark
IR  - Rozek L
FIR - Rozek, Laura
IR  - Wolf G
FIR - Wolf, Gregory
IR  - Bowman R
FIR - Bowman, Rayleen
IR  - Fong KM
FIR - Fong, Kwun M
IR  - Yang I
FIR - Yang, Ian
IR  - Korst R
FIR - Korst, Robert
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Fantacone-Campbell JL
FIR - Fantacone-Campbell, J Leigh
IR  - Hooke JA
FIR - Hooke, Jeffrey A
IR  - Kovatich AJ
FIR - Kovatich, Albert J
IR  - Shriver CD
FIR - Shriver, Craig D
IR  - DiPersio J
FIR - DiPersio, John
IR  - Drake B
FIR - Drake, Bettina
IR  - Govindan R
FIR - Govindan, Ramaswamy
IR  - Heath S
FIR - Heath, Sharon
IR  - Ley T
FIR - Ley, Timothy
IR  - Van Tine B
FIR - Van Tine, Brian
IR  - Westervelt P
FIR - Westervelt, Peter
IR  - Rubin MA
FIR - Rubin, Mark A
IR  - Lee JI
FIR - Lee, Jung Il
IR  - Aredes ND
FIR - Aredes, Natalia D
IR  - Mariamidze A
FIR - Mariamidze, Armaz
EDAT- 2018/04/07 06:00
MHDA- 2018/04/07 06:00
CRDT- 2018/04/07 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2018/02/22 00:00 [revised]
PHST- 2018/03/12 00:00 [accepted]
PHST- 2018/04/07 06:00 [entrez]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
AID - S1535-6108(18)30119-3 [pii]
AID - 10.1016/j.ccell.2018.03.014 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Apr 1. pii: S1535-6108(18)30119-3. doi:
      10.1016/j.ccell.2018.03.014.

PMID- 29622465
OWN - NLM
STAT- Publisher
LR  - 20180406
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Mar 31
TI  - lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that
      Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
LID - S1535-6108(18)30110-7 [pii]
LID - 10.1016/j.ccell.2018.03.006 [doi]
AB  - We characterized the epigenetic landscape of genes encoding long noncoding RNAs
      (lncRNAs) across 6,475 tumors and 455 cancer cell lines. In stark contrast to the
      CpG island hypermethylation phenotype in cancer, we observed a recurrent
      hypomethylation of 1,006 lncRNA genes in cancer, including EPIC1
      (epigenetically-induced lncRNA1). Overexpression of EPIC1 is associated with poor
      prognosis in luminal B breast cancer patients and enhances tumor growth in vitro 
      and in vivo. Mechanistically, EPIC1 promotes cell-cycle progression by
      interacting with MYC through EPIC1's 129-283 nt region. EPIC1 knockdown reduces
      the occupancy of MYC to its target genes (e.g., CDKN1A, CCNA2, CDC20, and CDC45).
      MYC depletion abolishes EPIC1's regulation of MYC target and luminal breast
      cancer tumorigenesis in vitro and in vivo.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Wang, Zehua
AU  - Wang Z
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Yang, Bo
AU  - Yang B
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Zhang, Min
AU  - Zhang M
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Guo, Weiwei
AU  - Guo W
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Wu, Zhiyuan
AU  - Wu Z
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Wang, Yue
AU  - Wang Y
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Jia, Lin
AU  - Jia L
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Li, Song
AU  - Li S
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
CN  - Cancer Genome Atlas Research Network
FAU - Xie, Wen
AU  - Xie W
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Yang, Da
AU  - Yang D
AD  - Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of
      Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute,
      University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Computational 
      and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
      Electronic address: dyang@pitt.edu.
LA  - eng
PT  - Journal Article
DEP - 20180331
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - CIMP
OT  - ENSG00000224271
OT  - EPIC1
OT  - LOC284930
OT  - MYC
OT  - P21
OT  - TCGA pan-cancer
OT  - breast cancer
OT  - long noncoding RNA
IR  - Caesar-Johnson SJ
FIR - Caesar-Johnson, Samantha J
IR  - Demchok JA
FIR - Demchok, John A
IR  - Felau I
FIR - Felau, Ina
IR  - Kasapi M
FIR - Kasapi, Melpomeni
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Wang Z
FIR - Wang, Zhining
IR  - Yang L
FIR - Yang, Liming
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Pihl T
FIR - Pihl, Todd
IR  - Sun Q
FIR - Sun, Qiang
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wu Y
FIR - Wu, Ye
IR  - Cho J
FIR - Cho, Juok
IR  - DeFreitas T
FIR - DeFreitas, Timothy
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Getz G
FIR - Getz, Gad
IR  - Heiman DI
FIR - Heiman, David I
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lin P
FIR - Lin, Pei
IR  - Meier S
FIR - Meier, Sam
IR  - Noble MS
FIR - Noble, Michael S
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Voet D
FIR - Voet, Doug
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Bernard B
FIR - Bernard, Brady
IR  - Chambwe N
FIR - Chambwe, Nyasha
IR  - Dhankani V
FIR - Dhankani, Varsha
IR  - Knijnenburg T
FIR - Knijnenburg, Theo
IR  - Kramer R
FIR - Kramer, Roger
IR  - Leinonen K
FIR - Leinonen, Kalle
IR  - Liu Y
FIR - Liu, Yuexin
IR  - Miller M
FIR - Miller, Michael
IR  - Reynolds S
FIR - Reynolds, Sheila
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Thorsson V
FIR - Thorsson, Vesteinn
IR  - Zhang W
FIR - Zhang, Wei
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Broom BM
FIR - Broom, Bradley M
IR  - Hegde AM
FIR - Hegde, Apurva M
IR  - Ju Z
FIR - Ju, Zhenlin
IR  - Kanchi RS
FIR - Kanchi, Rupa S
IR  - Korkut A
FIR - Korkut, Anil
IR  - Li J
FIR - Li, Jun
IR  - Liang H
FIR - Liang, Han
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu W
FIR - Liu, Wenbin
IR  - Lu Y
FIR - Lu, Yiling
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Ng KS
FIR - Ng, Kwok-Shing
IR  - Rao A
FIR - Rao, Arvind
IR  - Ryan M
FIR - Ryan, Michael
IR  - Wang J
FIR - Wang, Jing
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Zhang J
FIR - Zhang, Jiexin
IR  - Abeshouse A
FIR - Abeshouse, Adam
IR  - Armenia J
FIR - Armenia, Joshua
IR  - Chakravarty D
FIR - Chakravarty, Debyani
IR  - Chatila WK
FIR - Chatila, Walid K
IR  - Bruijn I
FIR - Bruijn, Inode
IR  - Gao J
FIR - Gao, Jianjiong
IR  - Gross BE
FIR - Gross, Benjamin E
IR  - Heins ZJ
FIR - Heins, Zachary J
IR  - Kundra R
FIR - Kundra, Ritika
IR  - La K
FIR - La, Konnor
IR  - Ladanyi M
FIR - Ladanyi, Marc
IR  - Luna A
FIR - Luna, Augustin
IR  - Nissan MG
FIR - Nissan, Moriah G
IR  - Ochoa A
FIR - Ochoa, Angelica
IR  - Phillips SM
FIR - Phillips, Sarah M
IR  - Reznik E
FIR - Reznik, Ed
IR  - Sanchez-Vega F
FIR - Sanchez-Vega, Francisco
IR  - Sander C
FIR - Sander, Chris
IR  - Schultz N
FIR - Schultz, Nikolaus
IR  - Sheridan R
FIR - Sheridan, Robert
IR  - Sumer SO
FIR - Sumer, S Onur
IR  - Sun Y
FIR - Sun, Yichao
IR  - Taylor BS
FIR - Taylor, Barry S
IR  - Wang J
FIR - Wang, Jioajiao
IR  - Zhang H
FIR - Zhang, Hongxin
IR  - Anur P
FIR - Anur, Pavana
IR  - Peto M
FIR - Peto, Myron
IR  - Spellman P
FIR - Spellman, Paul
IR  - Benz C
FIR - Benz, Christopher
IR  - Stuart JM
FIR - Stuart, Joshua M
IR  - Wong CK
FIR - Wong, Christopher K
IR  - Yau C
FIR - Yau, Christina
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Parker JS
FIR - Parker, Joel S
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Ally A
FIR - Ally, Adrian
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Chuah E
FIR - Chuah, Eric
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Holt R
FIR - Holt, Robert
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Lee D
FIR - Lee, Darlene
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Tam A
FIR - Tam, Angela
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Tse K
FIR - Tse, Kane
IR  - Wong T
FIR - Wong, Tina
IR  - Berger AC
FIR - Berger, Ashton C
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gao GF
FIR - Gao, Galen F
IR  - Ha G
FIR - Ha, Gavin
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Shih J
FIR - Shih, Juliann
IR  - Kucherlapati MH
FIR - Kucherlapati, Melanie H
IR  - Kucherlapati RS
FIR - Kucherlapati, Raju S
IR  - Baylin S
FIR - Baylin, Stephen
IR  - Cope L
FIR - Cope, Leslie
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Auman JT
FIR - Auman, J Todd
IR  - Balu S
FIR - Balu, Saianand
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Fan C
FIR - Fan, Cheng
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Meng S
FIR - Meng, Shaowu
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Perou AH
FIR - Perou, Amy H
IR  - Perou CM
FIR - Perou, Charles M
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Shi Y
FIR - Shi, Yan
IR  - Simons JV
FIR - Simons, Janae V
IR  - Skelly T
FIR - Skelly, Tara
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Tan D
FIR - Tan, Donghui
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Fan H
FIR - Fan, Huihui
IR  - Hinoue T
FIR - Hinoue, Toshinori
IR  - Laird PW
FIR - Laird, Peter W
IR  - Shen H
FIR - Shen, Hui
IR  - Zhou W
FIR - Zhou, Wanding
IR  - Bellair M
FIR - Bellair, Michelle
IR  - Chang K
FIR - Chang, Kyle
IR  - Covington K
FIR - Covington, Kyle
IR  - Creighton CJ
FIR - Creighton, Chad J
IR  - Dinh H
FIR - Dinh, Huyen
IR  - Doddapaneni H
FIR - Doddapaneni, HarshaVardhan
IR  - Donehower LA
FIR - Donehower, Lawrence A
IR  - Drummond J
FIR - Drummond, Jennifer
IR  - Gibbs RA
FIR - Gibbs, Richard A
IR  - Glenn R
FIR - Glenn, Robert
IR  - Hale W
FIR - Hale, Walker
IR  - Han Y
FIR - Han, Yi
IR  - Hu J
FIR - Hu, Jianhong
IR  - Korchina V
FIR - Korchina, Viktoriya
IR  - Lee S
FIR - Lee, Sandra
IR  - Lewis L
FIR - Lewis, Lora
IR  - Li W
FIR - Li, Wei
IR  - Liu X
FIR - Liu, Xiuping
IR  - Morgan M
FIR - Morgan, Margaret
IR  - Morton D
FIR - Morton, Donna
IR  - Muzny D
FIR - Muzny, Donna
IR  - Santibanez J
FIR - Santibanez, Jireh
IR  - Sheth M
FIR - Sheth, Margi
IR  - Shinbrot E
FIR - Shinbrot, Eve
IR  - Wang L
FIR - Wang, Linghua
IR  - Wang M
FIR - Wang, Min
IR  - Wheeler DA
FIR - Wheeler, David A
IR  - Xi L
FIR - Xi, Liu
IR  - Zhao F
FIR - Zhao, Fengmei
IR  - Hess J
FIR - Hess, Julian
IR  - Appelbaum EL
FIR - Appelbaum, Elizabeth L
IR  - Bailey M
FIR - Bailey, Matthew
IR  - Cordes MG
FIR - Cordes, Matthew G
IR  - Ding L
FIR - Ding, Li
IR  - Fronick CC
FIR - Fronick, Catrina C
IR  - Fulton LA
FIR - Fulton, Lucinda A
IR  - Fulton RS
FIR - Fulton, Robert S
IR  - Kandoth C
FIR - Kandoth, Cyriac
IR  - Mardis ER
FIR - Mardis, Elaine R
IR  - McLellan MD
FIR - McLellan, Michael D
IR  - Miller CA
FIR - Miller, Christopher A
IR  - Schmidt HK
FIR - Schmidt, Heather K
IR  - Wilson RK
FIR - Wilson, Richard K
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Lau K
FIR - Lau, Kevin
IR  - Mallery D
FIR - Mallery, David
IR  - Morris S
FIR - Morris, Scott
IR  - Paulauskis J
FIR - Paulauskis, Joseph
IR  - Penny R
FIR - Penny, Robert
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Sherman M
FIR - Sherman, Mark
IR  - Thompson E
FIR - Thompson, Eric
IR  - Yena P
FIR - Yena, Peggy
IR  - Bowen J
FIR - Bowen, Jay
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gerken M
FIR - Gerken, Mark
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Wise L
FIR - Wise, Lisa
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Corcoran N
FIR - Corcoran, Niall
IR  - Costello T
FIR - Costello, Tony
IR  - Hovens C
FIR - Hovens, Christopher
IR  - Carvalho AL
FIR - Carvalho, Andre L
IR  - de Carvalho AC
FIR - de Carvalho, Ana C
IR  - Fregnani JH
FIR - Fregnani, Jose H
IR  - Longatto-Filho A
FIR - Longatto-Filho, Adhemar
IR  - Reis RM
FIR - Reis, Rui M
IR  - Scapulatempo-Neto C
FIR - Scapulatempo-Neto, Cristovam
IR  - Silveira HCS
FIR - Silveira, Henrique C S
IR  - Vidal DO
FIR - Vidal, Daniel O
IR  - Burnette A
FIR - Burnette, Andrew
IR  - Eschbacher J
FIR - Eschbacher, Jennifer
IR  - Hermes B
FIR - Hermes, Beth
IR  - Noss A
FIR - Noss, Ardene
IR  - Singh R
FIR - Singh, Rosy
IR  - Anderson ML
FIR - Anderson, Matthew L
IR  - Castro PD
FIR - Castro, Patricia D
IR  - Ittmann M
FIR - Ittmann, Michael
IR  - Huntsman D
FIR - Huntsman, David
IR  - Kohl B
FIR - Kohl, Bernard
IR  - Le X
FIR - Le, Xuan
IR  - Thorp R
FIR - Thorp, Richard
IR  - Andry C
FIR - Andry, Chris
IR  - Duffy ER
FIR - Duffy, Elizabeth R
IR  - Lyadov V
FIR - Lyadov, Vladimir
IR  - Paklina O
FIR - Paklina, Oxana
IR  - Setdikova G
FIR - Setdikova, Galiya
IR  - Shabunin A
FIR - Shabunin, Alexey
IR  - Tavobilov M
FIR - Tavobilov, Mikhail
IR  - McPherson C
FIR - McPherson, Christopher
IR  - Warnick R
FIR - Warnick, Ronald
IR  - Berkowitz R
FIR - Berkowitz, Ross
IR  - Cramer D
FIR - Cramer, Daniel
IR  - Feltmate C
FIR - Feltmate, Colleen
IR  - Horowitz N
FIR - Horowitz, Neil
IR  - Kibel A
FIR - Kibel, Adam
IR  - Muto M
FIR - Muto, Michael
IR  - Raut CP
FIR - Raut, Chandrajit P
IR  - Malykh A
FIR - Malykh, Andrei
IR  - Barnholtz-Sloan JS
FIR - Barnholtz-Sloan, Jill S
IR  - Barrett W
FIR - Barrett, Wendi
IR  - Devine K
FIR - Devine, Karen
IR  - Fulop J
FIR - Fulop, Jordonna
IR  - Ostrom QT
FIR - Ostrom, Quinn T
IR  - Shimmel K
FIR - Shimmel, Kristen
IR  - Wolinsky Y
FIR - Wolinsky, Yingli
IR  - Sloan AE
FIR - Sloan, Andrew E
IR  - De Rose A
FIR - De Rose, Agostino
IR  - Giuliante F
FIR - Giuliante, Felice
IR  - Goodman M
FIR - Goodman, Marc
IR  - Karlan BY
FIR - Karlan, Beth Y
IR  - Hagedorn CH
FIR - Hagedorn, Curt H
IR  - Eckman J
FIR - Eckman, John
IR  - Harr J
FIR - Harr, Jodi
IR  - Myers J
FIR - Myers, Jerome
IR  - Tucker K
FIR - Tucker, Kelinda
IR  - Zach LA
FIR - Zach, Leigh Anne
IR  - Deyarmin B
FIR - Deyarmin, Brenda
IR  - Hu H
FIR - Hu, Hai
IR  - Kvecher L
FIR - Kvecher, Leonid
IR  - Larson C
FIR - Larson, Caroline
IR  - Mural RJ
FIR - Mural, Richard J
IR  - Somiari S
FIR - Somiari, Stella
IR  - Vicha A
FIR - Vicha, Ales
IR  - Zelinka T
FIR - Zelinka, Tomas
IR  - Bennett J
FIR - Bennett, Joseph
IR  - Iacocca M
FIR - Iacocca, Mary
IR  - Rabeno B
FIR - Rabeno, Brenda
IR  - Swanson P
FIR - Swanson, Patricia
IR  - Latour M
FIR - Latour, Mathieu
IR  - Lacombe L
FIR - Lacombe, Louis
IR  - Tetu B
FIR - Tetu, Bernard
IR  - Bergeron A
FIR - Bergeron, Alain
IR  - McGraw M
FIR - McGraw, Mary
IR  - Staugaitis SM
FIR - Staugaitis, Susan M
IR  - Chabot J
FIR - Chabot, John
IR  - Hibshoosh H
FIR - Hibshoosh, Hanina
IR  - Sepulveda A
FIR - Sepulveda, Antonia
IR  - Su T
FIR - Su, Tao
IR  - Wang T
FIR - Wang, Timothy
IR  - Potapova O
FIR - Potapova, Olga
IR  - Voronina O
FIR - Voronina, Olga
IR  - Desjardins L
FIR - Desjardins, Laurence
IR  - Mariani O
FIR - Mariani, Odette
IR  - Roman-Roman S
FIR - Roman-Roman, Sergio
IR  - Sastre X
FIR - Sastre, Xavier
IR  - Stern MH
FIR - Stern, Marc-Henri
IR  - Cheng F
FIR - Cheng, Feixiong
IR  - Signoretti S
FIR - Signoretti, Sabina
IR  - Berchuck A
FIR - Berchuck, Andrew
IR  - Bigner D
FIR - Bigner, Darell
IR  - Lipp E
FIR - Lipp, Eric
IR  - Marks J
FIR - Marks, Jeffrey
IR  - McCall S
FIR - McCall, Shannon
IR  - McLendon R
FIR - McLendon, Roger
IR  - Secord A
FIR - Secord, Angeles
IR  - Sharp A
FIR - Sharp, Alexis
IR  - Behera M
FIR - Behera, Madhusmita
IR  - Brat DJ
FIR - Brat, Daniel J
IR  - Chen A
FIR - Chen, Amy
IR  - Delman K
FIR - Delman, Keith
IR  - Force S
FIR - Force, Seth
IR  - Khuri F
FIR - Khuri, Fadlo
IR  - Magliocca K
FIR - Magliocca, Kelly
IR  - Maithel S
FIR - Maithel, Shishir
IR  - Olson JJ
FIR - Olson, Jeffrey J
IR  - Owonikoko T
FIR - Owonikoko, Taofeek
IR  - Pickens A
FIR - Pickens, Alan
IR  - Ramalingam S
FIR - Ramalingam, Suresh
IR  - Shin DM
FIR - Shin, Dong M
IR  - Sica G
FIR - Sica, Gabriel
IR  - Van Meir EG
FIR - Van Meir, Erwin G
IR  - Zhang H
FIR - Zhang, Hongzheng
IR  - Eijckenboom W
FIR - Eijckenboom, Wil
IR  - Gillis A
FIR - Gillis, Ad
IR  - Korpershoek E
FIR - Korpershoek, Esther
IR  - Looijenga L
FIR - Looijenga, Leendert
IR  - Oosterhuis W
FIR - Oosterhuis, Wolter
IR  - Stoop H
FIR - Stoop, Hans
IR  - van Kessel KE
FIR - van Kessel, Kim E
IR  - Zwarthoff EC
FIR - Zwarthoff, Ellen C
IR  - Calatozzolo C
FIR - Calatozzolo, Chiara
IR  - Cuppini L
FIR - Cuppini, Lucia
IR  - Cuzzubbo S
FIR - Cuzzubbo, Stefania
IR  - DiMeco F
FIR - DiMeco, Francesco
IR  - Finocchiaro G
FIR - Finocchiaro, Gaetano
IR  - Mattei L
FIR - Mattei, Luca
IR  - Perin A
FIR - Perin, Alessandro
IR  - Pollo B
FIR - Pollo, Bianca
IR  - Chen C
FIR - Chen, Chu
IR  - Houck J
FIR - Houck, John
IR  - Lohavanichbutr P
FIR - Lohavanichbutr, Pawadee
IR  - Hartmann A
FIR - Hartmann, Arndt
IR  - Stoehr C
FIR - Stoehr, Christine
IR  - Stoehr R
FIR - Stoehr, Robert
IR  - Taubert H
FIR - Taubert, Helge
IR  - Wach S
FIR - Wach, Sven
IR  - Wullich B
FIR - Wullich, Bernd
IR  - Kycler W
FIR - Kycler, Witold
IR  - Murawa D
FIR - Murawa, Dawid
IR  - Wiznerowicz M
FIR - Wiznerowicz, Maciej
IR  - Chung K
FIR - Chung, Ki
IR  - Edenfield WJ
FIR - Edenfield, W Jeffrey
IR  - Martin J
FIR - Martin, Julie
IR  - Baudin E
FIR - Baudin, Eric
IR  - Bubley G
FIR - Bubley, Glenn
IR  - Bueno R
FIR - Bueno, Raphael
IR  - De Rienzo A
FIR - De Rienzo, Assunta
IR  - Richards WG
FIR - Richards, William G
IR  - Kalkanis S
FIR - Kalkanis, Steven
IR  - Mikkelsen T
FIR - Mikkelsen, Tom
IR  - Noushmehr H
FIR - Noushmehr, Houtan
IR  - Scarpace L
FIR - Scarpace, Lisa
IR  - Girard N
FIR - Girard, Nicolas
IR  - Aymerich M
FIR - Aymerich, Marta
IR  - Campo E
FIR - Campo, Elias
IR  - Gine E
FIR - Gine, Eva
IR  - Guillermo AL
FIR - Guillermo, Armando Lopez
IR  - Van Bang N
FIR - Van Bang, Nguyen
IR  - Hanh PT
FIR - Hanh, Phan Thi
IR  - Phu BD
FIR - Phu, Bui Duc
IR  - Tang Y
FIR - Tang, Yufang
IR  - Colman H
FIR - Colman, Howard
IR  - Evason K
FIR - Evason, Kimberley
IR  - Dottino PR
FIR - Dottino, Peter R
IR  - Martignetti JA
FIR - Martignetti, John A
IR  - Gabra H
FIR - Gabra, Hani
IR  - Juhl H
FIR - Juhl, Hartmut
IR  - Akeredolu T
FIR - Akeredolu, Teniola
IR  - Stepa S
FIR - Stepa, Serghei
IR  - Hoon D
FIR - Hoon, Dave
IR  - Ahn K
FIR - Ahn, Keunsoo
IR  - Kang KJ
FIR - Kang, Koo Jeong
IR  - Beuschlein F
FIR - Beuschlein, Felix
IR  - Breggia A
FIR - Breggia, Anne
IR  - Birrer M
FIR - Birrer, Michael
IR  - Bell D
FIR - Bell, Debra
IR  - Borad M
FIR - Borad, Mitesh
IR  - Bryce AH
FIR - Bryce, Alan H
IR  - Castle E
FIR - Castle, Erik
IR  - Chandan V
FIR - Chandan, Vishal
IR  - Cheville J
FIR - Cheville, John
IR  - Copland JA
FIR - Copland, John A
IR  - Farnell M
FIR - Farnell, Michael
IR  - Flotte T
FIR - Flotte, Thomas
IR  - Giama N
FIR - Giama, Nasra
IR  - Ho T
FIR - Ho, Thai
IR  - Kendrick M
FIR - Kendrick, Michael
IR  - Kocher JP
FIR - Kocher, Jean-Pierre
IR  - Kopp K
FIR - Kopp, Karla
IR  - Moser C
FIR - Moser, Catherine
IR  - Nagorney D
FIR - Nagorney, David
IR  - O'Brien D
FIR - O'Brien, Daniel
IR  - O'Neill BP
FIR - O'Neill, Brian Patrick
IR  - Patel T
FIR - Patel, Tushar
IR  - Petersen G
FIR - Petersen, Gloria
IR  - Que F
FIR - Que, Florencia
IR  - Rivera M
FIR - Rivera, Michael
IR  - Roberts L
FIR - Roberts, Lewis
IR  - Smallridge R
FIR - Smallridge, Robert
IR  - Smyrk T
FIR - Smyrk, Thomas
IR  - Stanton M
FIR - Stanton, Melissa
IR  - Thompson RH
FIR - Thompson, R Houston
IR  - Torbenson M
FIR - Torbenson, Michael
IR  - Yang JD
FIR - Yang, Ju Dong
IR  - Zhang L
FIR - Zhang, Lizhi
IR  - Brimo F
FIR - Brimo, Fadi
IR  - Ajani JA
FIR - Ajani, Jaffer A
IR  - Gonzalez AMA
FIR - Gonzalez, Ana Maria Angulo
IR  - Behrens C
FIR - Behrens, Carmen
IR  - Bondaruk J
FIR - Bondaruk, Jolanta
IR  - Broaddus R
FIR - Broaddus, Russell
IR  - Czerniak B
FIR - Czerniak, Bogdan
IR  - Esmaeli B
FIR - Esmaeli, Bita
IR  - Fujimoto J
FIR - Fujimoto, Junya
IR  - Gershenwald J
FIR - Gershenwald, Jeffrey
IR  - Guo C
FIR - Guo, Charles
IR  - Lazar AJ
FIR - Lazar, Alexander J
IR  - Logothetis C
FIR - Logothetis, Christopher
IR  - Meric-Bernstam F
FIR - Meric-Bernstam, Funda
IR  - Moran C
FIR - Moran, Cesar
IR  - Ramondetta L
FIR - Ramondetta, Lois
IR  - Rice D
FIR - Rice, David
IR  - Sood A
FIR - Sood, Anil
IR  - Tamboli P
FIR - Tamboli, Pheroze
IR  - Thompson T
FIR - Thompson, Timothy
IR  - Troncoso P
FIR - Troncoso, Patricia
IR  - Tsao A
FIR - Tsao, Anne
IR  - Wistuba I
FIR - Wistuba, Ignacio
IR  - Carter C
FIR - Carter, Candace
IR  - Haydu L
FIR - Haydu, Lauren
IR  - Hersey P
FIR - Hersey, Peter
IR  - Jakrot V
FIR - Jakrot, Valerie
IR  - Kakavand H
FIR - Kakavand, Hojabr
IR  - Kefford R
FIR - Kefford, Richard
IR  - Lee K
FIR - Lee, Kenneth
IR  - Long G
FIR - Long, Georgina
IR  - Mann G
FIR - Mann, Graham
IR  - Quinn M
FIR - Quinn, Michael
IR  - Saw R
FIR - Saw, Robyn
IR  - Scolyer R
FIR - Scolyer, Richard
IR  - Shannon K
FIR - Shannon, Kerwin
IR  - Spillane A
FIR - Spillane, Andrew
IR  - Stretch J
FIR - Stretch, Jonathan
IR  - Synott M
FIR - Synott, Maria
IR  - Thompson J
FIR - Thompson, John
IR  - Wilmott J
FIR - Wilmott, James
IR  - Al-Ahmadie H
FIR - Al-Ahmadie, Hikmat
IR  - Chan TA
FIR - Chan, Timothy A
IR  - Ghossein R
FIR - Ghossein, Ronald
IR  - Gopalan A
FIR - Gopalan, Anuradha
IR  - Levine DA
FIR - Levine, Douglas A
IR  - Reuter V
FIR - Reuter, Victor
IR  - Singer S
FIR - Singer, Samuel
IR  - Singh B
FIR - Singh, Bhuvanesh
IR  - Tien NV
FIR - Tien, Nguyen Viet
IR  - Broudy T
FIR - Broudy, Thomas
IR  - Mirsaidi C
FIR - Mirsaidi, Cyrus
IR  - Nair P
FIR - Nair, Praveen
IR  - Drwiega P
FIR - Drwiega, Paul
IR  - Miller J
FIR - Miller, Judy
IR  - Smith J
FIR - Smith, Jennifer
IR  - Zaren H
FIR - Zaren, Howard
IR  - Park JW
FIR - Park, Joong-Won
IR  - Hung NP
FIR - Hung, Nguyen Phi
IR  - Kebebew E
FIR - Kebebew, Electron
IR  - Linehan WM
FIR - Linehan, W Marston
IR  - Metwalli AR
FIR - Metwalli, Adam R
IR  - Pacak K
FIR - Pacak, Karel
IR  - Pinto PA
FIR - Pinto, Peter A
IR  - Schiffman M
FIR - Schiffman, Mark
IR  - Schmidt LS
FIR - Schmidt, Laura S
IR  - Vocke CD
FIR - Vocke, Cathy D
IR  - Wentzensen N
FIR - Wentzensen, Nicolas
IR  - Worrell R
FIR - Worrell, Robert
IR  - Yang H
FIR - Yang, Hannah
IR  - Moncrieff M
FIR - Moncrieff, Marc
IR  - Goparaju C
FIR - Goparaju, Chandra
IR  - Melamed J
FIR - Melamed, Jonathan
IR  - Pass H
FIR - Pass, Harvey
IR  - Botnariuc N
FIR - Botnariuc, Natalia
IR  - Caraman I
FIR - Caraman, Irina
IR  - Cernat M
FIR - Cernat, Mircea
IR  - Chemencedji I
FIR - Chemencedji, Inga
IR  - Clipca A
FIR - Clipca, Adrian
IR  - Doruc S
FIR - Doruc, Serghei
IR  - Gorincioi G
FIR - Gorincioi, Ghenadie
IR  - Mura S
FIR - Mura, Sergiu
IR  - Pirtac M
FIR - Pirtac, Maria
IR  - Stancul I
FIR - Stancul, Irina
IR  - Tcaciuc D
FIR - Tcaciuc, Diana
IR  - Albert M
FIR - Albert, Monique
IR  - Alexopoulou I
FIR - Alexopoulou, Iakovina
IR  - Arnaout A
FIR - Arnaout, Angel
IR  - Bartlett J
FIR - Bartlett, John
IR  - Engel J
FIR - Engel, Jay
IR  - Gilbert S
FIR - Gilbert, Sebastien
IR  - Parfitt J
FIR - Parfitt, Jeremy
IR  - Sekhon H
FIR - Sekhon, Harman
IR  - Thomas G
FIR - Thomas, George
IR  - Rassl DM
FIR - Rassl, Doris M
IR  - Rintoul RC
FIR - Rintoul, Robert C
IR  - Bifulco C
FIR - Bifulco, Carlo
IR  - Tamakawa R
FIR - Tamakawa, Raina
IR  - Urba W
FIR - Urba, Walter
IR  - Hayward N
FIR - Hayward, Nicholas
IR  - Timmers H
FIR - Timmers, Henri
IR  - Antenucci A
FIR - Antenucci, Anna
IR  - Facciolo F
FIR - Facciolo, Francesco
IR  - Grazi G
FIR - Grazi, Gianluca
IR  - Marino M
FIR - Marino, Mirella
IR  - Merola R
FIR - Merola, Roberta
IR  - de Krijger R
FIR - de Krijger, Ronald
IR  - Gimenez-Roqueplo AP
FIR - Gimenez-Roqueplo, Anne-Paule
IR  - Piche A
FIR - Piche, Alain
IR  - Chevalier S
FIR - Chevalier, Simone
IR  - McKercher G
FIR - McKercher, Ginette
IR  - Birsoy K
FIR - Birsoy, Kivanc
IR  - Barnett G
FIR - Barnett, Gene
IR  - Brewer C
FIR - Brewer, Cathy
IR  - Farver C
FIR - Farver, Carol
IR  - Naska T
FIR - Naska, Theresa
IR  - Pennell NA
FIR - Pennell, Nathan A
IR  - Raymond D
FIR - Raymond, Daniel
IR  - Schilero C
FIR - Schilero, Cathy
IR  - Smolenski K
FIR - Smolenski, Kathy
IR  - Williams F
FIR - Williams, Felicia
IR  - Morrison C
FIR - Morrison, Carl
IR  - Borgia JA
FIR - Borgia, Jeffrey A
IR  - Liptay MJ
FIR - Liptay, Michael J
IR  - Pool M
FIR - Pool, Mark
IR  - Seder CW
FIR - Seder, Christopher W
IR  - Junker K
FIR - Junker, Kerstin
IR  - Omberg L
FIR - Omberg, Larsson
IR  - Dinkin M
FIR - Dinkin, Mikhail
IR  - Manikhas G
FIR - Manikhas, George
IR  - Alvaro D
FIR - Alvaro, Domenico
IR  - Bragazzi MC
FIR - Bragazzi, Maria Consiglia
IR  - Cardinale V
FIR - Cardinale, Vincenzo
IR  - Carpino G
FIR - Carpino, Guido
IR  - Gaudio E
FIR - Gaudio, Eugenio
IR  - Chesla D
FIR - Chesla, David
IR  - Cottingham S
FIR - Cottingham, Sandra
IR  - Dubina M
FIR - Dubina, Michael
IR  - Moiseenko F
FIR - Moiseenko, Fedor
IR  - Dhanasekaran R
FIR - Dhanasekaran, Renumathy
IR  - Becker KF
FIR - Becker, Karl-Friedrich
IR  - Janssen KP
FIR - Janssen, Klaus-Peter
IR  - Slotta-Huspenina J
FIR - Slotta-Huspenina, Julia
IR  - Abdel-Rahman MH
FIR - Abdel-Rahman, Mohamed H
IR  - Aziz D
FIR - Aziz, Dina
IR  - Bell S
FIR - Bell, Sue
IR  - Cebulla CM
FIR - Cebulla, Colleen M
IR  - Davis A
FIR - Davis, Amy
IR  - Duell R
FIR - Duell, Rebecca
IR  - Elder JB
FIR - Elder, J Bradley
IR  - Hilty J
FIR - Hilty, Joe
IR  - Kumar B
FIR - Kumar, Bahavna
IR  - Lang J
FIR - Lang, James
IR  - Lehman NL
FIR - Lehman, Norman L
IR  - Mandt R
FIR - Mandt, Randy
IR  - Nguyen P
FIR - Nguyen, Phuong
IR  - Pilarski R
FIR - Pilarski, Robert
IR  - Rai K
FIR - Rai, Karan
IR  - Schoenfield L
FIR - Schoenfield, Lynn
IR  - Senecal K
FIR - Senecal, Kelly
IR  - Wakely P
FIR - Wakely, Paul
IR  - Hansen P
FIR - Hansen, Paul
IR  - Lechan R
FIR - Lechan, Ronald
IR  - Powers J
FIR - Powers, James
IR  - Tischler A
FIR - Tischler, Arthur
IR  - Grizzle WE
FIR - Grizzle, William E
IR  - Sexton KC
FIR - Sexton, Katherine C
IR  - Kastl A
FIR - Kastl, Alison
IR  - Henderson J
FIR - Henderson, Joel
IR  - Porten S
FIR - Porten, Sima
IR  - Waldmann J
FIR - Waldmann, Jens
IR  - Fassnacht M
FIR - Fassnacht, Martin
IR  - Asa SL
FIR - Asa, Sylvia L
IR  - Schadendorf D
FIR - Schadendorf, Dirk
IR  - Couce M
FIR - Couce, Marta
IR  - Graefen M
FIR - Graefen, Markus
IR  - Huland H
FIR - Huland, Hartwig
IR  - Sauter G
FIR - Sauter, Guido
IR  - Schlomm T
FIR - Schlomm, Thorsten
IR  - Simon R
FIR - Simon, Ronald
IR  - Tennstedt P
FIR - Tennstedt, Pierre
IR  - Olabode O
FIR - Olabode, Oluwole
IR  - Nelson M
FIR - Nelson, Mark
IR  - Bathe O
FIR - Bathe, Oliver
IR  - Carroll PR
FIR - Carroll, Peter R
IR  - Chan JM
FIR - Chan, June M
IR  - Disaia P
FIR - Disaia, Philip
IR  - Glenn P
FIR - Glenn, Pat
IR  - Kelley RK
FIR - Kelley, Robin K
IR  - Landen CN
FIR - Landen, Charles N
IR  - Phillips J
FIR - Phillips, Joanna
IR  - Prados M
FIR - Prados, Michael
IR  - Simko J
FIR - Simko, Jeffry
IR  - Smith-McCune K
FIR - Smith-McCune, Karen
IR  - VandenBerg S
FIR - VandenBerg, Scott
IR  - Roggin K
FIR - Roggin, Kevin
IR  - Fehrenbach A
FIR - Fehrenbach, Ashley
IR  - Kendler A
FIR - Kendler, Ady
IR  - Sifri S
FIR - Sifri, Suzanne
IR  - Steele R
FIR - Steele, Ruth
IR  - Jimeno A
FIR - Jimeno, Antonio
IR  - Carey F
FIR - Carey, Francis
IR  - Forgie I
FIR - Forgie, Ian
IR  - Mannelli M
FIR - Mannelli, Massimo
IR  - Carney M
FIR - Carney, Michael
IR  - Hernandez B
FIR - Hernandez, Brenda
IR  - Campos B
FIR - Campos, Benito
IR  - Herold-Mende C
FIR - Herold-Mende, Christel
IR  - Jungk C
FIR - Jungk, Christin
IR  - Unterberg A
FIR - Unterberg, Andreas
IR  - von Deimling A
FIR - von Deimling, Andreas
IR  - Bossler A
FIR - Bossler, Aaron
IR  - Galbraith J
FIR - Galbraith, Joseph
IR  - Jacobus L
FIR - Jacobus, Laura
IR  - Knudson M
FIR - Knudson, Michael
IR  - Knutson T
FIR - Knutson, Tina
IR  - Ma D
FIR - Ma, Deqin
IR  - Milhem M
FIR - Milhem, Mohammed
IR  - Sigmund R
FIR - Sigmund, Rita
IR  - Godwin AK
FIR - Godwin, Andrew K
IR  - Madan R
FIR - Madan, Rashna
IR  - Rosenthal HG
FIR - Rosenthal, Howard G
IR  - Adebamowo C
FIR - Adebamowo, Clement
IR  - Adebamowo SN
FIR - Adebamowo, Sally N
IR  - Boussioutas A
FIR - Boussioutas, Alex
IR  - Beer D
FIR - Beer, David
IR  - Giordano T
FIR - Giordano, Thomas
IR  - Mes-Masson AM
FIR - Mes-Masson, Anne-Marie
IR  - Saad F
FIR - Saad, Fred
IR  - Bocklage T
FIR - Bocklage, Therese
IR  - Landrum L
FIR - Landrum, Lisa
IR  - Mannel R
FIR - Mannel, Robert
IR  - Moore K
FIR - Moore, Kathleen
IR  - Moxley K
FIR - Moxley, Katherine
IR  - Postier R
FIR - Postier, Russel
IR  - Walker J
FIR - Walker, Joan
IR  - Zuna R
FIR - Zuna, Rosemary
IR  - Feldman M
FIR - Feldman, Michael
IR  - Valdivieso F
FIR - Valdivieso, Federico
IR  - Dhir R
FIR - Dhir, Rajiv
IR  - Luketich J
FIR - Luketich, James
IR  - Pinero EMM
FIR - Pinero, Edna M Mora
IR  - Quintero-Aguilo M
FIR - Quintero-Aguilo, Mario
IR  - Carlotti CG Jr.
FIR - Carlotti, Carlos Gilberto Jr.
IR  - Dos Santos JS
FIR - Dos Santos, Jose Sebastiao
IR  - Kemp R
FIR - Kemp, Rafael
IR  - Sankarankuty A
FIR - Sankarankuty, Ajith
IR  - Tirapelli D
FIR - Tirapelli, Daniela
IR  - Catto J
FIR - Catto, James
IR  - Agnew K
FIR - Agnew, Kathy
IR  - Swisher E
FIR - Swisher, Elizabeth
IR  - Creaney J
FIR - Creaney, Jenette
IR  - Robinson B
FIR - Robinson, Bruce
IR  - Shelley CS
FIR - Shelley, Carl Simon
IR  - Godwin EM
FIR - Godwin, Eryn M
IR  - Kendall S
FIR - Kendall, Sara
IR  - Shipman C
FIR - Shipman, Cassaundra
IR  - Bradford C
FIR - Bradford, Carol
IR  - Carey T
FIR - Carey, Thomas
IR  - Haddad A
FIR - Haddad, Andrea
IR  - Moyer J
FIR - Moyer, Jeffey
IR  - Peterson L
FIR - Peterson, Lisa
IR  - Prince M
FIR - Prince, Mark
IR  - Rozek L
FIR - Rozek, Laura
IR  - Wolf G
FIR - Wolf, Gregory
IR  - Bowman R
FIR - Bowman, Rayleen
IR  - Fong KM
FIR - Fong, Kwun M
IR  - Yang I
FIR - Yang, Ian
IR  - Korst R
FIR - Korst, Robert
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Fantacone-Campbell JL
FIR - Fantacone-Campbell, J Leigh
IR  - Hooke JA
FIR - Hooke, Jeffrey A
IR  - Kovatich AJ
FIR - Kovatich, Albert J
IR  - Shriver CD
FIR - Shriver, Craig D
IR  - DiPersio J
FIR - DiPersio, John
IR  - Drake B
FIR - Drake, Bettina
IR  - Govindan R
FIR - Govindan, Ramaswamy
IR  - Heath S
FIR - Heath, Sharon
IR  - Ley T
FIR - Ley, Timothy
IR  - Van Tine B
FIR - Van Tine, Brian
IR  - Westervelt P
FIR - Westervelt, Peter
IR  - Rubin MA
FIR - Rubin, Mark A
IR  - Lee JI
FIR - Lee, Jung Il
IR  - Aredes ND
FIR - Aredes, Natalia D
IR  - Mariamidze A
FIR - Mariamidze, Armaz
EDAT- 2018/04/07 06:00
MHDA- 2018/04/07 06:00
CRDT- 2018/04/07 06:00
PHST- 2017/06/25 00:00 [received]
PHST- 2018/02/13 00:00 [revised]
PHST- 2018/03/05 00:00 [accepted]
PHST- 2018/04/07 06:00 [entrez]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
AID - S1535-6108(18)30110-7 [pii]
AID - 10.1016/j.ccell.2018.03.006 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Mar 31. pii: S1535-6108(18)30110-7. doi:
      10.1016/j.ccell.2018.03.006.

PMID- 29622463
OWN - NLM
STAT- Publisher
LR  - 20180406
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Mar 31
TI  - Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
LID - S1535-6108(18)30111-9 [pii]
LID - 10.1016/j.ccell.2018.03.007 [doi]
AB  - Aneuploidy, whole chromosome or chromosome arm imbalance, is a near-universal
      characteristic of human cancers. In 10,522 cancer genomes from The Cancer Genome 
      Atlas, aneuploidy was correlated with TP53 mutation, somatic mutation rate, and
      expression of proliferation genes. Aneuploidy was anti-correlated with expression
      of immune signaling genes, due to decreased leukocyte infiltrates in
      high-aneuploidy samples. Chromosome arm-level alterations show cancer-specific
      patterns, including loss of chromosome arm 3p in squamous cancers. We applied
      genome engineering to delete 3p in lung cells, causing decreased proliferation
      rescued in part by chromosome 3 duplication. This study defines genomic and
      phenotypic correlates of cancer aneuploidy and provides an experimental approach 
      to study chromosome arm aneuploidy.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Taylor, Alison M
AU  - Taylor AM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA; Cancer Program, Broad Institute, 415 Main Street, 
      Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, 25
      Shattuck Street, Boston, MA 02115, USA.
FAU - Shih, Juliann
AU  - Shih J
AD  - Cancer Program, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA.
FAU - Ha, Gavin
AU  - Ha G
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA; Cancer Program, Broad Institute, 415 Main Street, 
      Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, 25
      Shattuck Street, Boston, MA 02115, USA.
FAU - Gao, Galen F
AU  - Gao GF
AD  - Cancer Program, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA.
FAU - Zhang, Xiaoyang
AU  - Zhang X
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA; Cancer Program, Broad Institute, 415 Main Street, 
      Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, 25
      Shattuck Street, Boston, MA 02115, USA.
FAU - Berger, Ashton C
AU  - Berger AC
AD  - Cancer Program, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA.
FAU - Schumacher, Steven E
AU  - Schumacher SE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA; Cancer Program, Broad Institute, 415 Main Street, 
      Cambridge, MA 02142, USA.
FAU - Wang, Chen
AU  - Wang C
AD  - Department of Health Sciences Research, Mayo Clinic College of Medicine, 200
      First Street SW, Rochester, MN 55905, USA; Department of Obstetrics and
      Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN
      55905, USA.
FAU - Hu, Hai
AU  - Hu H
AD  - Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963,
      USA.
FAU - Liu, Jianfang
AU  - Liu J
AD  - Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963,
      USA.
FAU - Lazar, Alexander J
AU  - Lazar AJ
AD  - Departments of Pathology, Genomic Medicine, and Translational Molecular
      Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe
      Boulevard, Unit 85, Houston, TX, USA.
CN  - Cancer Genome Atlas Research Network
FAU - Cherniack, Andrew D
AU  - Cherniack AD
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA; Cancer Program, Broad Institute, 415 Main Street, 
      Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, 25
      Shattuck Street, Boston, MA 02115, USA.
FAU - Beroukhim, Rameen
AU  - Beroukhim R
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA; Cancer Program, Broad Institute, 415 Main Street, 
      Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, 25
      Shattuck Street, Boston, MA 02115, USA.
FAU - Meyerson, Matthew
AU  - Meyerson M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA; Cancer Program, Broad Institute, 415 Main Street, 
      Cambridge, MA 02142, USA; Department of Pathology, Harvard Medical School, 25
      Shattuck Street, Boston, MA 02115, USA. Electronic address:
      matthew_meyerson@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
DEP - 20180331
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - aneuploidy
OT  - cancer genomics
OT  - genome engineering
OT  - lung squamous cell carcinoma
IR  - Caesar-Johnson SJ
FIR - Caesar-Johnson, Samantha J
IR  - Demchok JA
FIR - Demchok, John A
IR  - Felau I
FIR - Felau, Ina
IR  - Kasapi M
FIR - Kasapi, Melpomeni
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Wang Z
FIR - Wang, Zhining
IR  - Yang L
FIR - Yang, Liming
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Pihl T
FIR - Pihl, Todd
IR  - Sun Q
FIR - Sun, Qiang
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wu Y
FIR - Wu, Ye
IR  - Cho J
FIR - Cho, Juok
IR  - DeFreitas T
FIR - DeFreitas, Timothy
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Getz G
FIR - Getz, Gad
IR  - Heiman DI
FIR - Heiman, David I
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lin P
FIR - Lin, Pei
IR  - Meier S
FIR - Meier, Sam
IR  - Noble MS
FIR - Noble, Michael S
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Voet D
FIR - Voet, Doug
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Bernard B
FIR - Bernard, Brady
IR  - Chambwe N
FIR - Chambwe, Nyasha
IR  - Dhankani V
FIR - Dhankani, Varsha
IR  - Knijnenburg T
FIR - Knijnenburg, Theo
IR  - Kramer R
FIR - Kramer, Roger
IR  - Leinonen K
FIR - Leinonen, Kalle
IR  - Liu Y
FIR - Liu, Yuexin
IR  - Miller M
FIR - Miller, Michael
IR  - Reynolds S
FIR - Reynolds, Sheila
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Thorsson V
FIR - Thorsson, Vesteinn
IR  - Zhang W
FIR - Zhang, Wei
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Broom BM
FIR - Broom, Bradley M
IR  - Hegde AM
FIR - Hegde, Apurva M
IR  - Ju Z
FIR - Ju, Zhenlin
IR  - Kanchi RS
FIR - Kanchi, Rupa S
IR  - Korkut A
FIR - Korkut, Anil
IR  - Li J
FIR - Li, Jun
IR  - Liang H
FIR - Liang, Han
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu W
FIR - Liu, Wenbin
IR  - Lu Y
FIR - Lu, Yiling
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Ng KS
FIR - Ng, Kwok-Shing
IR  - Rao A
FIR - Rao, Arvind
IR  - Ryan M
FIR - Ryan, Michael
IR  - Wang J
FIR - Wang, Jing
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Zhang J
FIR - Zhang, Jiexin
IR  - Abeshouse A
FIR - Abeshouse, Adam
IR  - Armenia J
FIR - Armenia, Joshua
IR  - Chakravarty D
FIR - Chakravarty, Debyani
IR  - Chatila WK
FIR - Chatila, Walid K
IR  - de Bruijn I
FIR - de Bruijn, Ino
IR  - Gao J
FIR - Gao, Jianjiong
IR  - Gross BE
FIR - Gross, Benjamin E
IR  - Heins ZJ
FIR - Heins, Zachary J
IR  - Kundra R
FIR - Kundra, Ritika
IR  - La K
FIR - La, Konnor
IR  - Ladanyi M
FIR - Ladanyi, Marc
IR  - Luna A
FIR - Luna, Augustin
IR  - Nissan MG
FIR - Nissan, Moriah G
IR  - Ochoa A
FIR - Ochoa, Angelica
IR  - Phillips SM
FIR - Phillips, Sarah M
IR  - Reznik E
FIR - Reznik, Ed
IR  - Sanchez-Vega F
FIR - Sanchez-Vega, Francisco
IR  - Sander C
FIR - Sander, Chris
IR  - Schultz N
FIR - Schultz, Nikolaus
IR  - Sheridan R
FIR - Sheridan, Robert
IR  - Sumer SO
FIR - Sumer, S Onur
IR  - Sun Y
FIR - Sun, Yichao
IR  - Taylor BS
FIR - Taylor, Barry S
IR  - Wang J
FIR - Wang, Jioajiao
IR  - Zhang H
FIR - Zhang, Hongxin
IR  - Anur P
FIR - Anur, Pavana
IR  - Peto M
FIR - Peto, Myron
IR  - Spellman P
FIR - Spellman, Paul
IR  - Benz C
FIR - Benz, Christopher
IR  - Stuart JM
FIR - Stuart, Joshua M
IR  - Wong CK
FIR - Wong, Christopher K
IR  - Yau C
FIR - Yau, Christina
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Parker JS
FIR - Parker, Joel S
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Ally A
FIR - Ally, Adrian
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Chuah E
FIR - Chuah, Eric
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Holt R
FIR - Holt, Robert
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Lee D
FIR - Lee, Darlene
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Tam A
FIR - Tam, Angela
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Tse K
FIR - Tse, Kane
IR  - Wong T
FIR - Wong, Tina
IR  - Berger AC
FIR - Berger, Ashton C
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gao GF
FIR - Gao, Galen F
IR  - Ha G
FIR - Ha, Gavin
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Shih J
FIR - Shih, Juliann
IR  - Kucherlapati MH
FIR - Kucherlapati, Melanie H
IR  - Kucherlapati RS
FIR - Kucherlapati, Raju S
IR  - Baylin S
FIR - Baylin, Stephen
IR  - Cope L
FIR - Cope, Leslie
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Auman JT
FIR - Auman, J Todd
IR  - Balu S
FIR - Balu, Saianand
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Fan C
FIR - Fan, Cheng
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Meng S
FIR - Meng, Shaowu
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Perou AH
FIR - Perou, Amy H
IR  - Perou CM
FIR - Perou, Charles M
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Shi Y
FIR - Shi, Yan
IR  - Simons JV
FIR - Simons, Janae V
IR  - Skelly T
FIR - Skelly, Tara
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Tan D
FIR - Tan, Donghui
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Fan H
FIR - Fan, Huihui
IR  - Hinoue T
FIR - Hinoue, Toshinori
IR  - Laird PW
FIR - Laird, Peter W
IR  - Shen H
FIR - Shen, Hui
IR  - Zhou W
FIR - Zhou, Wanding
IR  - Bellair M
FIR - Bellair, Michelle
IR  - Chang K
FIR - Chang, Kyle
IR  - Covington K
FIR - Covington, Kyle
IR  - Creighton CJ
FIR - Creighton, Chad J
IR  - Dinh H
FIR - Dinh, Huyen
IR  - Doddapaneni H
FIR - Doddapaneni, HarshaVardhan
IR  - Donehower LA
FIR - Donehower, Lawrence A
IR  - Drummond J
FIR - Drummond, Jennifer
IR  - Gibbs RA
FIR - Gibbs, Richard A
IR  - Glenn R
FIR - Glenn, Robert
IR  - Hale W
FIR - Hale, Walker
IR  - Han Y
FIR - Han, Yi
IR  - Hu J
FIR - Hu, Jianhong
IR  - Korchina V
FIR - Korchina, Viktoriya
IR  - Lee S
FIR - Lee, Sandra
IR  - Lewis L
FIR - Lewis, Lora
IR  - Li W
FIR - Li, Wei
IR  - Liu X
FIR - Liu, Xiuping
IR  - Morgan M
FIR - Morgan, Margaret
IR  - Morton D
FIR - Morton, Donna
IR  - Muzny D
FIR - Muzny, Donna
IR  - Santibanez J
FIR - Santibanez, Jireh
IR  - Sheth M
FIR - Sheth, Margi
IR  - Shinbrot E
FIR - Shinbrot, Eve
IR  - Wang L
FIR - Wang, Linghua
IR  - Wang M
FIR - Wang, Min
IR  - Wheeler DA
FIR - Wheeler, David A
IR  - Xi L
FIR - Xi, Liu
IR  - Zhao F
FIR - Zhao, Fengmei
IR  - Hess J
FIR - Hess, Julian
IR  - Appelbaum EL
FIR - Appelbaum, Elizabeth L
IR  - Bailey M
FIR - Bailey, Matthew
IR  - Cordes MG
FIR - Cordes, Matthew G
IR  - Ding L
FIR - Ding, Li
IR  - Fronick CC
FIR - Fronick, Catrina C
IR  - Fulton LA
FIR - Fulton, Lucinda A
IR  - Fulton RS
FIR - Fulton, Robert S
IR  - Kandoth C
FIR - Kandoth, Cyriac
IR  - Mardis ER
FIR - Mardis, Elaine R
IR  - McLellan MD
FIR - McLellan, Michael D
IR  - Miller CA
FIR - Miller, Christopher A
IR  - Schmidt HK
FIR - Schmidt, Heather K
IR  - Wilson RK
FIR - Wilson, Richard K
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Lau K
FIR - Lau, Kevin
IR  - Mallery D
FIR - Mallery, David
IR  - Morris S
FIR - Morris, Scott
IR  - Paulauskis J
FIR - Paulauskis, Joseph
IR  - Penny R
FIR - Penny, Robert
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Sherman M
FIR - Sherman, Mark
IR  - Thompson E
FIR - Thompson, Eric
IR  - Yena P
FIR - Yena, Peggy
IR  - Bowen J
FIR - Bowen, Jay
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gerken M
FIR - Gerken, Mark
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Wise L
FIR - Wise, Lisa
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Corcoran N
FIR - Corcoran, Niall
IR  - Costello T
FIR - Costello, Tony
IR  - Hovens C
FIR - Hovens, Christopher
IR  - Carvalho AL
FIR - Carvalho, Andre L
IR  - de Carvalho AC
FIR - de Carvalho, Ana C
IR  - Fregnani JH
FIR - Fregnani, Jose H
IR  - Longatto-Filho A
FIR - Longatto-Filho, Adhemar
IR  - Reis RM
FIR - Reis, Rui M
IR  - Scapulatempo-Neto C
FIR - Scapulatempo-Neto, Cristovam
IR  - Silveira HCS
FIR - Silveira, Henrique C S
IR  - Vidal DO
FIR - Vidal, Daniel O
IR  - Burnette A
FIR - Burnette, Andrew
IR  - Eschbacher J
FIR - Eschbacher, Jennifer
IR  - Hermes B
FIR - Hermes, Beth
IR  - Noss A
FIR - Noss, Ardene
IR  - Singh R
FIR - Singh, Rosy
IR  - Anderson ML
FIR - Anderson, Matthew L
IR  - Castro PD
FIR - Castro, Patricia D
IR  - Ittmann M
FIR - Ittmann, Michael
IR  - Huntsman D
FIR - Huntsman, David
IR  - Kohl B
FIR - Kohl, Bernard
IR  - Le X
FIR - Le, Xuan
IR  - Thorp R
FIR - Thorp, Richard
IR  - Andry C
FIR - Andry, Chris
IR  - Duffy ER
FIR - Duffy, Elizabeth R
IR  - Lyadov V
FIR - Lyadov, Vladimir
IR  - Paklina O
FIR - Paklina, Oxana
IR  - Setdikova G
FIR - Setdikova, Galiya
IR  - Shabunin A
FIR - Shabunin, Alexey
IR  - Tavobilov M
FIR - Tavobilov, Mikhail
IR  - McPherson C
FIR - McPherson, Christopher
IR  - Warnick R
FIR - Warnick, Ronald
IR  - Berkowitz R
FIR - Berkowitz, Ross
IR  - Cramer D
FIR - Cramer, Daniel
IR  - Feltmate C
FIR - Feltmate, Colleen
IR  - Horowitz N
FIR - Horowitz, Neil
IR  - Kibel A
FIR - Kibel, Adam
IR  - Muto M
FIR - Muto, Michael
IR  - Raut CP
FIR - Raut, Chandrajit P
IR  - Malykh A
FIR - Malykh, Andrei
IR  - Barnholtz-Sloan JS
FIR - Barnholtz-Sloan, Jill S
IR  - Barrett W
FIR - Barrett, Wendi
IR  - Devine K
FIR - Devine, Karen
IR  - Fulop J
FIR - Fulop, Jordonna
IR  - Ostrom QT
FIR - Ostrom, Quinn T
IR  - Shimmel K
FIR - Shimmel, Kristen
IR  - Wolinsky Y
FIR - Wolinsky, Yingli
IR  - Sloan AE
FIR - Sloan, Andrew E
IR  - De Rose A
FIR - De Rose, Agostino
IR  - Giuliante F
FIR - Giuliante, Felice
IR  - Goodman M
FIR - Goodman, Marc
IR  - Karlan BY
FIR - Karlan, Beth Y
IR  - Hagedorn CH
FIR - Hagedorn, Curt H
IR  - Eckman J
FIR - Eckman, John
IR  - Harr J
FIR - Harr, Jodi
IR  - Myers J
FIR - Myers, Jerome
IR  - Tucker K
FIR - Tucker, Kelinda
IR  - Zach LA
FIR - Zach, Leigh Anne
IR  - Deyarmin B
FIR - Deyarmin, Brenda
IR  - Hu H
FIR - Hu, Hai
IR  - Kvecher L
FIR - Kvecher, Leonid
IR  - Larson C
FIR - Larson, Caroline
IR  - Mural RJ
FIR - Mural, Richard J
IR  - Somiari S
FIR - Somiari, Stella
IR  - Vicha A
FIR - Vicha, Ales
IR  - Zelinka T
FIR - Zelinka, Tomas
IR  - Bennett J
FIR - Bennett, Joseph
IR  - Iacocca M
FIR - Iacocca, Mary
IR  - Rabeno B
FIR - Rabeno, Brenda
IR  - Swanson P
FIR - Swanson, Patricia
IR  - Latour M
FIR - Latour, Mathieu
IR  - Lacombe L
FIR - Lacombe, Louis
IR  - Tetu B
FIR - Tetu, Bernard
IR  - Bergeron A
FIR - Bergeron, Alain
IR  - McGraw M
FIR - McGraw, Mary
IR  - Staugaitis SM
FIR - Staugaitis, Susan M
IR  - Chabot J
FIR - Chabot, John
IR  - Hibshoosh H
FIR - Hibshoosh, Hanina
IR  - Sepulveda A
FIR - Sepulveda, Antonia
IR  - Su T
FIR - Su, Tao
IR  - Wang T
FIR - Wang, Timothy
IR  - Potapova O
FIR - Potapova, Olga
IR  - Voronina O
FIR - Voronina, Olga
IR  - Desjardins L
FIR - Desjardins, Laurence
IR  - Mariani O
FIR - Mariani, Odette
IR  - Roman-Roman S
FIR - Roman-Roman, Sergio
IR  - Sastre X
FIR - Sastre, Xavier
IR  - Stern MH
FIR - Stern, Marc-Henri
IR  - Cheng F
FIR - Cheng, Feixiong
IR  - Signoretti S
FIR - Signoretti, Sabina
IR  - Berchuck A
FIR - Berchuck, Andrew
IR  - Bigner D
FIR - Bigner, Darell
IR  - Lipp E
FIR - Lipp, Eric
IR  - Marks J
FIR - Marks, Jeffrey
IR  - McCall S
FIR - McCall, Shannon
IR  - McLendon R
FIR - McLendon, Roger
IR  - Secord A
FIR - Secord, Angeles
IR  - Sharp A
FIR - Sharp, Alexis
IR  - Behera M
FIR - Behera, Madhusmita
IR  - Brat DJ
FIR - Brat, Daniel J
IR  - Chen A
FIR - Chen, Amy
IR  - Delman K
FIR - Delman, Keith
IR  - Force S
FIR - Force, Seth
IR  - Khuri F
FIR - Khuri, Fadlo
IR  - Magliocca K
FIR - Magliocca, Kelly
IR  - Maithel S
FIR - Maithel, Shishir
IR  - Olson JJ
FIR - Olson, Jeffrey J
IR  - Owonikoko T
FIR - Owonikoko, Taofeek
IR  - Pickens A
FIR - Pickens, Alan
IR  - Ramalingam S
FIR - Ramalingam, Suresh
IR  - Shin DM
FIR - Shin, Dong M
IR  - Sica G
FIR - Sica, Gabriel
IR  - Van Meir EG
FIR - Van Meir, Erwin G
IR  - Zhang H
FIR - Zhang, Hongzheng
IR  - Eijckenboom W
FIR - Eijckenboom, Wil
IR  - Gillis A
FIR - Gillis, Ad
IR  - Korpershoek E
FIR - Korpershoek, Esther
IR  - Looijenga L
FIR - Looijenga, Leendert
IR  - Oosterhuis W
FIR - Oosterhuis, Wolter
IR  - Stoop H
FIR - Stoop, Hans
IR  - van Kessel KE
FIR - van Kessel, Kim E
IR  - Zwarthoff EC
FIR - Zwarthoff, Ellen C
IR  - Calatozzolo C
FIR - Calatozzolo, Chiara
IR  - Cuppini L
FIR - Cuppini, Lucia
IR  - Cuzzubbo S
FIR - Cuzzubbo, Stefania
IR  - DiMeco F
FIR - DiMeco, Francesco
IR  - Finocchiaro G
FIR - Finocchiaro, Gaetano
IR  - Mattei L
FIR - Mattei, Luca
IR  - Perin A
FIR - Perin, Alessandro
IR  - Pollo B
FIR - Pollo, Bianca
IR  - Chen C
FIR - Chen, Chu
IR  - Houck J
FIR - Houck, John
IR  - Lohavanichbutr P
FIR - Lohavanichbutr, Pawadee
IR  - Hartmann A
FIR - Hartmann, Arndt
IR  - Stoehr C
FIR - Stoehr, Christine
IR  - Stoehr R
FIR - Stoehr, Robert
IR  - Taubert H
FIR - Taubert, Helge
IR  - Wach S
FIR - Wach, Sven
IR  - Wullich B
FIR - Wullich, Bernd
IR  - Kycler W
FIR - Kycler, Witold
IR  - Murawa D
FIR - Murawa, Dawid
IR  - Wiznerowicz M
FIR - Wiznerowicz, Maciej
IR  - Chung K
FIR - Chung, Ki
IR  - Edenfield WJ
FIR - Edenfield, W Jeffrey
IR  - Martin J
FIR - Martin, Julie
IR  - Baudin E
FIR - Baudin, Eric
IR  - Bubley G
FIR - Bubley, Glenn
IR  - Bueno R
FIR - Bueno, Raphael
IR  - De Rienzo A
FIR - De Rienzo, Assunta
IR  - Richards WG
FIR - Richards, William G
IR  - Kalkanis S
FIR - Kalkanis, Steven
IR  - Mikkelsen T
FIR - Mikkelsen, Tom
IR  - Noushmehr H
FIR - Noushmehr, Houtan
IR  - Scarpace L
FIR - Scarpace, Lisa
IR  - Girard N
FIR - Girard, Nicolas
IR  - Aymerich M
FIR - Aymerich, Marta
IR  - Campo E
FIR - Campo, Elias
IR  - Gine E
FIR - Gine, Eva
IR  - Guillermo AL
FIR - Guillermo, Armando Lopez
IR  - Van Bang N
FIR - Van Bang, Nguyen
IR  - Hanh PT
FIR - Hanh, Phan Thi
IR  - Phu BD
FIR - Phu, Bui Duc
IR  - Tang Y
FIR - Tang, Yufang
IR  - Colman H
FIR - Colman, Howard
IR  - Evason K
FIR - Evason, Kimberley
IR  - Dottino PR
FIR - Dottino, Peter R
IR  - Martignetti JA
FIR - Martignetti, John A
IR  - Gabra H
FIR - Gabra, Hani
IR  - Juhl H
FIR - Juhl, Hartmut
IR  - Akeredolu T
FIR - Akeredolu, Teniola
IR  - Stepa S
FIR - Stepa, Serghei
IR  - Hoon D
FIR - Hoon, Dave
IR  - Ahn K
FIR - Ahn, Keunsoo
IR  - Kang KJ
FIR - Kang, Koo Jeong
IR  - Beuschlein F
FIR - Beuschlein, Felix
IR  - Breggia A
FIR - Breggia, Anne
IR  - Birrer M
FIR - Birrer, Michael
IR  - Bell D
FIR - Bell, Debra
IR  - Borad M
FIR - Borad, Mitesh
IR  - Bryce AH
FIR - Bryce, Alan H
IR  - Castle E
FIR - Castle, Erik
IR  - Chandan V
FIR - Chandan, Vishal
IR  - Cheville J
FIR - Cheville, John
IR  - Copland JA
FIR - Copland, John A
IR  - Farnell M
FIR - Farnell, Michael
IR  - Flotte T
FIR - Flotte, Thomas
IR  - Giama N
FIR - Giama, Nasra
IR  - Ho T
FIR - Ho, Thai
IR  - Kendrick M
FIR - Kendrick, Michael
IR  - Kocher JP
FIR - Kocher, Jean-Pierre
IR  - Kopp K
FIR - Kopp, Karla
IR  - Moser C
FIR - Moser, Catherine
IR  - Nagorney D
FIR - Nagorney, David
IR  - O'Brien D
FIR - O'Brien, Daniel
IR  - O'Neill BP
FIR - O'Neill, Brian Patrick
IR  - Patel T
FIR - Patel, Tushar
IR  - Petersen G
FIR - Petersen, Gloria
IR  - Que F
FIR - Que, Florencia
IR  - Rivera M
FIR - Rivera, Michael
IR  - Roberts L
FIR - Roberts, Lewis
IR  - Smallridge R
FIR - Smallridge, Robert
IR  - Smyrk T
FIR - Smyrk, Thomas
IR  - Stanton M
FIR - Stanton, Melissa
IR  - Thompson RH
FIR - Thompson, R Houston
IR  - Torbenson M
FIR - Torbenson, Michael
IR  - Yang JD
FIR - Yang, Ju Dong
IR  - Zhang L
FIR - Zhang, Lizhi
IR  - Brimo F
FIR - Brimo, Fadi
IR  - Ajani JA
FIR - Ajani, Jaffer A
IR  - Angulo Gonzalez AM
FIR - Angulo Gonzalez, Ana Maria
IR  - Behrens C
FIR - Behrens, Carmen
IR  - Bondaruk J
FIR - Bondaruk, Jolanta
IR  - Broaddus R
FIR - Broaddus, Russell
IR  - Czerniak B
FIR - Czerniak, Bogdan
IR  - Esmaeli B
FIR - Esmaeli, Bita
IR  - Fujimoto J
FIR - Fujimoto, Junya
IR  - Gershenwald J
FIR - Gershenwald, Jeffrey
IR  - Guo C
FIR - Guo, Charles
IR  - Lazar AJ
FIR - Lazar, Alexander J
IR  - Logothetis C
FIR - Logothetis, Christopher
IR  - Meric-Bernstam F
FIR - Meric-Bernstam, Funda
IR  - Moran C
FIR - Moran, Cesar
IR  - Ramondetta L
FIR - Ramondetta, Lois
IR  - Rice D
FIR - Rice, David
IR  - Sood A
FIR - Sood, Anil
IR  - Tamboli P
FIR - Tamboli, Pheroze
IR  - Thompson T
FIR - Thompson, Timothy
IR  - Troncoso P
FIR - Troncoso, Patricia
IR  - Tsao A
FIR - Tsao, Anne
IR  - Wistuba I
FIR - Wistuba, Ignacio
IR  - Carter C
FIR - Carter, Candace
IR  - Haydu L
FIR - Haydu, Lauren
IR  - Hersey P
FIR - Hersey, Peter
IR  - Jakrot V
FIR - Jakrot, Valerie
IR  - Kakavand H
FIR - Kakavand, Hojabr
IR  - Kefford R
FIR - Kefford, Richard
IR  - Lee K
FIR - Lee, Kenneth
IR  - Long G
FIR - Long, Georgina
IR  - Mann G
FIR - Mann, Graham
IR  - Quinn M
FIR - Quinn, Michael
IR  - Saw R
FIR - Saw, Robyn
IR  - Scolyer R
FIR - Scolyer, Richard
IR  - Shannon K
FIR - Shannon, Kerwin
IR  - Spillane A
FIR - Spillane, Andrew
IR  - Stretch J
FIR - Stretch, Jonathan
IR  - Synott M
FIR - Synott, Maria
IR  - Thompson J
FIR - Thompson, John
IR  - Wilmott J
FIR - Wilmott, James
IR  - Al-Ahmadie H
FIR - Al-Ahmadie, Hikmat
IR  - Chan TA
FIR - Chan, Timothy A
IR  - Ghossein R
FIR - Ghossein, Ronald
IR  - Gopalan A
FIR - Gopalan, Anuradha
IR  - Levine DA
FIR - Levine, Douglas A
IR  - Reuter V
FIR - Reuter, Victor
IR  - Singer S
FIR - Singer, Samuel
IR  - Singh B
FIR - Singh, Bhuvanesh
IR  - Tien NV
FIR - Tien, Nguyen Viet
IR  - Broudy T
FIR - Broudy, Thomas
IR  - Mirsaidi C
FIR - Mirsaidi, Cyrus
IR  - Nair P
FIR - Nair, Praveen
IR  - Drwiega P
FIR - Drwiega, Paul
IR  - Miller J
FIR - Miller, Judy
IR  - Smith J
FIR - Smith, Jennifer
IR  - Zaren H
FIR - Zaren, Howard
IR  - Park JW
FIR - Park, Joong-Won
IR  - Hung NP
FIR - Hung, Nguyen Phi
IR  - Kebebew E
FIR - Kebebew, Electron
IR  - Linehan WM
FIR - Linehan, W Marston
IR  - Metwalli AR
FIR - Metwalli, Adam R
IR  - Pacak K
FIR - Pacak, Karel
IR  - Pinto PA
FIR - Pinto, Peter A
IR  - Schiffman M
FIR - Schiffman, Mark
IR  - Schmidt LS
FIR - Schmidt, Laura S
IR  - Vocke CD
FIR - Vocke, Cathy D
IR  - Wentzensen N
FIR - Wentzensen, Nicolas
IR  - Worrell R
FIR - Worrell, Robert
IR  - Yang H
FIR - Yang, Hannah
IR  - Moncrieff M
FIR - Moncrieff, Marc
IR  - Goparaju C
FIR - Goparaju, Chandra
IR  - Melamed J
FIR - Melamed, Jonathan
IR  - Pass H
FIR - Pass, Harvey
IR  - Botnariuc N
FIR - Botnariuc, Natalia
IR  - Caraman I
FIR - Caraman, Irina
IR  - Cernat M
FIR - Cernat, Mircea
IR  - Chemencedji I
FIR - Chemencedji, Inga
IR  - Clipca A
FIR - Clipca, Adrian
IR  - Doruc S
FIR - Doruc, Serghei
IR  - Gorincioi G
FIR - Gorincioi, Ghenadie
IR  - Mura S
FIR - Mura, Sergiu
IR  - Pirtac M
FIR - Pirtac, Maria
IR  - Stancul I
FIR - Stancul, Irina
IR  - Tcaciuc D
FIR - Tcaciuc, Diana
IR  - Albert M
FIR - Albert, Monique
IR  - Alexopoulou I
FIR - Alexopoulou, Iakovina
IR  - Arnaout A
FIR - Arnaout, Angel
IR  - Bartlett J
FIR - Bartlett, John
IR  - Engel J
FIR - Engel, Jay
IR  - Gilbert S
FIR - Gilbert, Sebastien
IR  - Parfitt J
FIR - Parfitt, Jeremy
IR  - Sekhon H
FIR - Sekhon, Harman
IR  - Thomas G
FIR - Thomas, George
IR  - Rassl DM
FIR - Rassl, Doris M
IR  - Rintoul RC
FIR - Rintoul, Robert C
IR  - Bifulco C
FIR - Bifulco, Carlo
IR  - Tamakawa R
FIR - Tamakawa, Raina
IR  - Urba W
FIR - Urba, Walter
IR  - Hayward N
FIR - Hayward, Nicholas
IR  - Timmers H
FIR - Timmers, Henri
IR  - Antenucci A
FIR - Antenucci, Anna
IR  - Facciolo F
FIR - Facciolo, Francesco
IR  - Grazi G
FIR - Grazi, Gianluca
IR  - Marino M
FIR - Marino, Mirella
IR  - Merola R
FIR - Merola, Roberta
IR  - de Krijger R
FIR - de Krijger, Ronald
IR  - Gimenez-Roqueplo AP
FIR - Gimenez-Roqueplo, Anne-Paule
IR  - Piche A
FIR - Piche, Alain
IR  - Chevalier S
FIR - Chevalier, Simone
IR  - McKercher G
FIR - McKercher, Ginette
IR  - Birsoy K
FIR - Birsoy, Kivanc
IR  - Barnett G
FIR - Barnett, Gene
IR  - Brewer C
FIR - Brewer, Cathy
IR  - Farver C
FIR - Farver, Carol
IR  - Naska T
FIR - Naska, Theresa
IR  - Pennell NA
FIR - Pennell, Nathan A
IR  - Raymond D
FIR - Raymond, Daniel
IR  - Schilero C
FIR - Schilero, Cathy
IR  - Smolenski K
FIR - Smolenski, Kathy
IR  - Williams F
FIR - Williams, Felicia
IR  - Morrison C
FIR - Morrison, Carl
IR  - Borgia JA
FIR - Borgia, Jeffrey A
IR  - Liptay MJ
FIR - Liptay, Michael J
IR  - Pool M
FIR - Pool, Mark
IR  - Seder CW
FIR - Seder, Christopher W
IR  - Junker K
FIR - Junker, Kerstin
IR  - Omberg L
FIR - Omberg, Larsson
IR  - Dinkin M
FIR - Dinkin, Mikhail
IR  - Manikhas G
FIR - Manikhas, George
IR  - Alvaro D
FIR - Alvaro, Domenico
IR  - Bragazzi MC
FIR - Bragazzi, Maria Consiglia
IR  - Cardinale V
FIR - Cardinale, Vincenzo
IR  - Carpino G
FIR - Carpino, Guido
IR  - Gaudio E
FIR - Gaudio, Eugenio
IR  - Chesla D
FIR - Chesla, David
IR  - Cottingham S
FIR - Cottingham, Sandra
IR  - Dubina M
FIR - Dubina, Michael
IR  - Moiseenko F
FIR - Moiseenko, Fedor
IR  - Dhanasekaran R
FIR - Dhanasekaran, Renumathy
IR  - Becker KF
FIR - Becker, Karl-Friedrich
IR  - Janssen KP
FIR - Janssen, Klaus-Peter
IR  - Slotta-Huspenina J
FIR - Slotta-Huspenina, Julia
IR  - Abdel-Rahman MH
FIR - Abdel-Rahman, Mohamed H
IR  - Aziz D
FIR - Aziz, Dina
IR  - Bell S
FIR - Bell, Sue
IR  - Cebulla CM
FIR - Cebulla, Colleen M
IR  - Davis A
FIR - Davis, Amy
IR  - Duell R
FIR - Duell, Rebecca
IR  - Elder JB
FIR - Elder, J Bradley
IR  - Hilty J
FIR - Hilty, Joe
IR  - Kumar B
FIR - Kumar, Bahavna
IR  - Lang J
FIR - Lang, James
IR  - Lehman NL
FIR - Lehman, Norman L
IR  - Mandt R
FIR - Mandt, Randy
IR  - Nguyen P
FIR - Nguyen, Phuong
IR  - Pilarski R
FIR - Pilarski, Robert
IR  - Rai K
FIR - Rai, Karan
IR  - Schoenfield L
FIR - Schoenfield, Lynn
IR  - Senecal K
FIR - Senecal, Kelly
IR  - Wakely P
FIR - Wakely, Paul
IR  - Hansen P
FIR - Hansen, Paul
IR  - Lechan R
FIR - Lechan, Ronald
IR  - Powers J
FIR - Powers, James
IR  - Tischler A
FIR - Tischler, Arthur
IR  - Grizzle WE
FIR - Grizzle, William E
IR  - Sexton KC
FIR - Sexton, Katherine C
IR  - Kastl A
FIR - Kastl, Alison
IR  - Henderson J
FIR - Henderson, Joel
IR  - Porten S
FIR - Porten, Sima
IR  - Waldmann J
FIR - Waldmann, Jens
IR  - Fassnacht M
FIR - Fassnacht, Martin
IR  - Asa SL
FIR - Asa, Sylvia L
IR  - Schadendorf D
FIR - Schadendorf, Dirk
IR  - Couce M
FIR - Couce, Marta
IR  - Graefen M
FIR - Graefen, Markus
IR  - Huland H
FIR - Huland, Hartwig
IR  - Sauter G
FIR - Sauter, Guido
IR  - Schlomm T
FIR - Schlomm, Thorsten
IR  - Simon R
FIR - Simon, Ronald
IR  - Tennstedt P
FIR - Tennstedt, Pierre
IR  - Olabode O
FIR - Olabode, Oluwole
IR  - Nelson M
FIR - Nelson, Mark
IR  - Bathe O
FIR - Bathe, Oliver
IR  - Carroll PR
FIR - Carroll, Peter R
IR  - Chan JM
FIR - Chan, June M
IR  - Disaia P
FIR - Disaia, Philip
IR  - Glenn P
FIR - Glenn, Pat
IR  - Kelley RK
FIR - Kelley, Robin K
IR  - Landen CN
FIR - Landen, Charles N
IR  - Phillips J
FIR - Phillips, Joanna
IR  - Prados M
FIR - Prados, Michael
IR  - Simko J
FIR - Simko, Jeffry
IR  - Smith-McCune K
FIR - Smith-McCune, Karen
IR  - VandenBerg S
FIR - VandenBerg, Scott
IR  - Roggin K
FIR - Roggin, Kevin
IR  - Fehrenbach A
FIR - Fehrenbach, Ashley
IR  - Kendler A
FIR - Kendler, Ady
IR  - Sifri S
FIR - Sifri, Suzanne
IR  - Steele R
FIR - Steele, Ruth
IR  - Jimeno A
FIR - Jimeno, Antonio
IR  - Carey F
FIR - Carey, Francis
IR  - Forgie I
FIR - Forgie, Ian
IR  - Mannelli M
FIR - Mannelli, Massimo
IR  - Carney M
FIR - Carney, Michael
IR  - Hernandez B
FIR - Hernandez, Brenda
IR  - Campos B
FIR - Campos, Benito
IR  - Herold-Mende C
FIR - Herold-Mende, Christel
IR  - Jungk C
FIR - Jungk, Christin
IR  - Unterberg A
FIR - Unterberg, Andreas
IR  - von Deimling A
FIR - von Deimling, Andreas
IR  - Bossler A
FIR - Bossler, Aaron
IR  - Galbraith J
FIR - Galbraith, Joseph
IR  - Jacobus L
FIR - Jacobus, Laura
IR  - Knudson M
FIR - Knudson, Michael
IR  - Knutson T
FIR - Knutson, Tina
IR  - Ma D
FIR - Ma, Deqin
IR  - Milhem M
FIR - Milhem, Mohammed
IR  - Sigmund R
FIR - Sigmund, Rita
IR  - Godwin AK
FIR - Godwin, Andrew K
IR  - Madan R
FIR - Madan, Rashna
IR  - Rosenthal HG
FIR - Rosenthal, Howard G
IR  - Adebamowo C
FIR - Adebamowo, Clement
IR  - Adebamowo SN
FIR - Adebamowo, Sally N
IR  - Boussioutas A
FIR - Boussioutas, Alex
IR  - Beer D
FIR - Beer, David
IR  - Giordano T
FIR - Giordano, Thomas
IR  - Mes-Masson AM
FIR - Mes-Masson, Anne-Marie
IR  - Saad F
FIR - Saad, Fred
IR  - Bocklage T
FIR - Bocklage, Therese
IR  - Landrum L
FIR - Landrum, Lisa
IR  - Mannel R
FIR - Mannel, Robert
IR  - Moore K
FIR - Moore, Kathleen
IR  - Moxley K
FIR - Moxley, Katherine
IR  - Postier R
FIR - Postier, Russel
IR  - Walker J
FIR - Walker, Joan
IR  - Zuna R
FIR - Zuna, Rosemary
IR  - Feldman M
FIR - Feldman, Michael
IR  - Valdivieso F
FIR - Valdivieso, Federico
IR  - Dhir R
FIR - Dhir, Rajiv
IR  - Luketich J
FIR - Luketich, James
IR  - Mora Pinero EM
FIR - Mora Pinero, Edna M
IR  - Quintero-Aguilo M
FIR - Quintero-Aguilo, Mario
IR  - Carlotti CG Jr.
FIR - Carlotti, Carlos Gilberto Jr.
IR  - Dos Santos JS
FIR - Dos Santos, Jose Sebastiao
IR  - Kemp R
FIR - Kemp, Rafael
IR  - Sankarankuty A
FIR - Sankarankuty, Ajith
IR  - Tirapelli D
FIR - Tirapelli, Daniela
IR  - Catto J
FIR - Catto, James
IR  - Agnew K
FIR - Agnew, Kathy
IR  - Swisher E
FIR - Swisher, Elizabeth
IR  - Creaney J
FIR - Creaney, Jenette
IR  - Robinson B
FIR - Robinson, Bruce
IR  - Shelley CS
FIR - Shelley, Carl Simon
IR  - Godwin EM
FIR - Godwin, Eryn M
IR  - Kendall S
FIR - Kendall, Sara
IR  - Shipman C
FIR - Shipman, Cassaundra
IR  - Bradford C
FIR - Bradford, Carol
IR  - Carey T
FIR - Carey, Thomas
IR  - Haddad A
FIR - Haddad, Andrea
IR  - Moyer J
FIR - Moyer, Jeffey
IR  - Peterson L
FIR - Peterson, Lisa
IR  - Prince M
FIR - Prince, Mark
IR  - Rozek L
FIR - Rozek, Laura
IR  - Wolf G
FIR - Wolf, Gregory
IR  - Bowman R
FIR - Bowman, Rayleen
IR  - Fong KM
FIR - Fong, Kwun M
IR  - Yang I
FIR - Yang, Ian
IR  - Korst R
FIR - Korst, Robert
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Fantacone-Campbell JL
FIR - Fantacone-Campbell, J Leigh
IR  - Hooke JA
FIR - Hooke, Jeffrey A
IR  - Kovatich AJ
FIR - Kovatich, Albert J
IR  - Shriver CD
FIR - Shriver, Craig D
IR  - DiPersio J
FIR - DiPersio, John
IR  - Drake B
FIR - Drake, Bettina
IR  - Govindan R
FIR - Govindan, Ramaswamy
IR  - Heath S
FIR - Heath, Sharon
IR  - Ley T
FIR - Ley, Timothy
IR  - Van Tine B
FIR - Van Tine, Brian
IR  - Westervelt P
FIR - Westervelt, Peter
IR  - Rubin MA
FIR - Rubin, Mark A
IR  - Lee JI
FIR - Lee, Jung Il
IR  - Aredes ND
FIR - Aredes, Natalia D
IR  - Mariamidze A
FIR - Mariamidze, Armaz
EDAT- 2018/04/07 06:00
MHDA- 2018/04/07 06:00
CRDT- 2018/04/07 06:00
PHST- 2017/12/15 00:00 [received]
PHST- 2018/02/14 00:00 [revised]
PHST- 2018/03/06 00:00 [accepted]
PHST- 2018/04/07 06:00 [entrez]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
AID - S1535-6108(18)30111-9 [pii]
AID - 10.1016/j.ccell.2018.03.007 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Mar 31. pii: S1535-6108(18)30111-9. doi:
      10.1016/j.ccell.2018.03.007.

PMID- 29606349
OWN - NLM
STAT- Publisher
LR  - 20180407
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Mar 29
TI  - Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib
      Sensitivity in Pancreatic Cancer.
LID - S1535-6108(18)30065-5 [pii]
LID - 10.1016/j.ccell.2018.02.012 [doi]
AB  - Pancreatic ribonuclease (RNase) is a secreted enzyme critical for host defense.
      We discover an intrinsic RNase function, serving as a ligand for epidermal growth
      factor receptor (EGFR), a member of receptor tyrosine kinase (RTK), in pancreatic
      ductal adenocarcinoma (PDAC). The closely related bovine RNase A and human RNase 
      5 (angiogenin [ANG]) can trigger oncogenic transformation independently of their 
      catalytic activities via direct association with EGFR. Notably, high plasma ANG
      level in PDAC patients is positively associated with response to EGFR inhibitor
      erlotinib treatment. These results identify a role of ANG as a serum biomarker
      that may be used to stratify patients for EGFR-targeted therapies, and offer
      insights into the ligand-receptor relationship between RNase and RTK families.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Wang, Ying-Nai
AU  - Wang YN
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine,
      China Medical University, Taichung 404, Taiwan.
FAU - Lee, Heng-Huan
AU  - Lee HH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Chou, Chao-Kai
AU  - Chou CK
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine,
      China Medical University, Taichung 404, Taiwan.
FAU - Yang, Wen-Hao
AU  - Yang WH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Wei, Yongkun
AU  - Wei Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Chen, Chun-Te
AU  - Chen CT
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Yao, Jun
AU  - Yao J
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Hsu, Jennifer L
AU  - Hsu JL
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine,
      China Medical University, Taichung 404, Taiwan.
FAU - Zhu, Cihui
AU  - Zhu C
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Ying, Haoqiang
AU  - Ying H
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center, Houston, TX 77030, USA.
FAU - Ye, Yuanqing
AU  - Ye Y
AD  - Department of Epidemiology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Wang, Wei-Jan
AU  - Wang WJ
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Lim, Seung-Oe
AU  - Lim SO
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Xia, Weiya
AU  - Xia W
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Ko, How-Wen
AU  - Ko HW
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Liu, Xiuping
AU  - Liu X
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Liu, Chang-Gong
AU  - Liu CG
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Wu, Xifeng
AU  - Wu X
AD  - Department of Epidemiology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of
      Texas Health Science Center, Houston, TX 77030, USA.
FAU - Wang, Huamin
AU  - Wang H
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Li, Donghui
AU  - Li D
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical
      Sciences, The University of Texas Health Science Center, Houston, TX 77030, USA.
FAU - Prakash, Laura R
AU  - Prakash LR
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Katz, Matthew H
AU  - Katz MH
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Kang, Yaan
AU  - Kang Y
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Kim, Michael
AU  - Kim M
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Fleming, Jason B
AU  - Fleming JB
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Fogelman, David
AU  - Fogelman D
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Javle, Milind
AU  - Javle M
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Maitra, Anirban
AU  - Maitra A
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of
      Texas Health Science Center, Houston, TX 77030, USA.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences
      and Center for Molecular Medicine, China Medical University, Taichung 404,
      Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan.
      Electronic address: mhung@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA211615/CA/NCI NIH HHS/United States
GR  - T32 CA186892/CA/NCI NIH HHS/United States
GR  - U01 CA201777/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180329
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - EGFR inhibitor
OT  - EGFR ligand
OT  - PDAC
OT  - angiogenin
OT  - erlotinib
OT  - receptor tyrosine kinase
OT  - ribonuclease
OT  - serum biomarker
EDAT- 2018/04/03 06:00
MHDA- 2018/04/03 06:00
CRDT- 2018/04/03 06:00
PHST- 2017/03/23 00:00 [received]
PHST- 2017/10/20 00:00 [revised]
PHST- 2018/02/20 00:00 [accepted]
PHST- 2018/04/03 06:00 [entrez]
PHST- 2018/04/03 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
AID - S1535-6108(18)30065-5 [pii]
AID - 10.1016/j.ccell.2018.02.012 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Mar 29. pii: S1535-6108(18)30065-5. doi:
      10.1016/j.ccell.2018.02.012.

PMID- 29533787
OWN - NLM
STAT- In-Data-Review
LR  - 20180317
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like
      Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
PG  - 512-526.e8
LID - S1535-6108(18)30056-4 [pii]
LID - 10.1016/j.ccell.2018.02.003 [doi]
AB  - KDM6A, an X chromosome-encoded histone demethylase and member of the COMPASS-like
      complex, is frequently mutated in a broad spectrum of malignancies and
      contributes to oncogenesis with poorly characterized mechanisms. We found that
      KDM6A loss induced squamous-like, metastatic pancreatic cancer selectively in
      females through deregulation of the COMPASS-like complex and aberrant activation 
      of super-enhancers regulating DeltaNp63, MYC, and RUNX3 oncogenes. This subtype
      of tumor developed in males had concomitant loss of UTY and KDM6A, suggesting
      overlapping roles, and points to largely demethylase independent tumor suppressor
      functions. We also demonstrate that KDM6A-deficient pancreatic cancer is
      selectively sensitive to BET inhibitors, which reversed squamous differentiation 
      and restrained tumor growth in vivo, highlighting a therapeutic niche for patient
      tailored therapies.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Andricovich, Jaclyn
AU  - Andricovich J
AD  - Cancer Epigenetics Laboratory, Department of Anatomy and Regenerative Biology,
      George Washington University (GWU) School of Medicine and Health Sciences,
      Washington, DC 20052, USA; GWU Cancer Center, GWU School of Medicine and Health
      Sciences, Washington, DC 20052, USA.
FAU - Perkail, Stephanie
AU  - Perkail S
AD  - Cancer Epigenetics Laboratory, Department of Anatomy and Regenerative Biology,
      George Washington University (GWU) School of Medicine and Health Sciences,
      Washington, DC 20052, USA; GWU Cancer Center, GWU School of Medicine and Health
      Sciences, Washington, DC 20052, USA.
FAU - Kai, Yan
AU  - Kai Y
AD  - Cancer Epigenetics Laboratory, Department of Anatomy and Regenerative Biology,
      George Washington University (GWU) School of Medicine and Health Sciences,
      Washington, DC 20052, USA; GWU Cancer Center, GWU School of Medicine and Health
      Sciences, Washington, DC 20052, USA; Department of Physics, GWU, Washington, DC
      20052, USA.
FAU - Casasanta, Nicole
AU  - Casasanta N
AD  - Cancer Epigenetics Laboratory, Department of Anatomy and Regenerative Biology,
      George Washington University (GWU) School of Medicine and Health Sciences,
      Washington, DC 20052, USA.
FAU - Peng, Weiqun
AU  - Peng W
AD  - GWU Cancer Center, GWU School of Medicine and Health Sciences, Washington, DC
      20052, USA; Department of Physics, GWU, Washington, DC 20052, USA.
FAU - Tzatsos, Alexandros
AU  - Tzatsos A
AD  - Cancer Epigenetics Laboratory, Department of Anatomy and Regenerative Biology,
      George Washington University (GWU) School of Medicine and Health Sciences,
      Washington, DC 20052, USA; GWU Cancer Center, GWU School of Medicine and Health
      Sciences, Washington, DC 20052, USA. Electronic address: atzatsos@gwu.edu.
LA  - eng
GR  - R00 CA158582/CA/NCI NIH HHS/United States
GR  - R03 CA212068/CA/NCI NIH HHS/United States
GR  - R21 CA182662/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5854186
MID - NIHMS944417
OTO - NOTNLM
OT  - COMPASS-like complex
OT  - JQ1
OT  - KDM6A
OT  - KMT2D
OT  - MYC
OT  - UTY
OT  - p63
OT  - pancreatic cancer
OT  - squamous
OT  - super-enhancer
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PMCR- 2019/03/12 00:00
PHST- 2017/05/06 00:00 [received]
PHST- 2017/10/16 00:00 [revised]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2019/03/12 00:00 [pmc-release]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30056-4 [pii]
AID - 10.1016/j.ccell.2018.02.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):512-526.e8. doi: 10.1016/j.ccell.2018.02.003.

PMID- 29533786
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring
      Kynurenine and AhR Activation.
PG  - 480-494.e7
LID - S1535-6108(18)30058-8 [pii]
LID - 10.1016/j.ccell.2018.02.005 [doi]
AB  - Despite the clinical successes fostered by immune checkpoint inhibitors,
      mechanisms underlying PD-1 upregulation in tumor-infiltrating T cells remain an
      enigma. Here, we show that tumor-repopulating cells (TRCs) drive PD-1
      upregulation in CD8(+) T cells through a transcellular kynurenine (Kyn)-aryl
      hydrocarbon receptor (AhR) pathway. Interferon-gamma produced by CD8(+) T cells
      stimulates release of high levels of Kyn produced by TRCs, which is transferred
      into adjacent CD8(+) T cells via the transporters SLC7A8 and PAT4. Kyn induces
      and activates AhR and thereby upregulates PD-1 expression. This Kyn-AhR pathway
      is confirmed in both tumor-bearing mice and cancer patients and its blockade
      enhances antitumor adoptive T cell therapy efficacy. Thus, we uncovered a
      mechanism of PD-1 upregulation with potential tumor immunotherapeutic
      applications.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Liu, Yuying
AU  - Liu Y
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China; Clinical Immunology Center, 
      CAMS, Beijing 100005, China.
FAU - Liang, Xiaoyu
AU  - Liang X
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Dong, Wenqian
AU  - Dong W
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Fang, Yi
AU  - Fang Y
AD  - National Cancer Center/Cancer Hospital, CAMS, Beijing 100005, China.
FAU - Lv, Jiadi
AU  - Lv J
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Zhang, Tianzhen
AU  - Zhang T
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Fiskesund, Roland
AU  - Fiskesund R
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Xie, Jing
AU  - Xie J
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Liu, Jinyan
AU  - Liu J
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Yin, Xiaonan
AU  - Yin X
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Jin, Xun
AU  - Jin X
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Chen, Degao
AU  - Chen D
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Tang, Ke
AU  - Tang K
AD  - Department of Biochemistry & Molecular Biology, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan 430030, China.
FAU - Ma, Jingwei
AU  - Ma J
AD  - Department of Biochemistry & Molecular Biology, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan 430030, China.
FAU - Zhang, Huafeng
AU  - Zhang H
AD  - Department of Biochemistry & Molecular Biology, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan 430030, China.
FAU - Yu, Jing
AU  - Yu J
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Department 1,
      Institute of Surgery Research, Daping Hospital, Third Military Medical
      University, Chongqing 400042, China.
FAU - Yan, Jun
AU  - Yan J
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Department 1,
      Institute of Surgery Research, Daping Hospital, Third Military Medical
      University, Chongqing 400042, China.
FAU - Liang, Huaping
AU  - Liang H
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Department 1,
      Institute of Surgery Research, Daping Hospital, Third Military Medical
      University, Chongqing 400042, China.
FAU - Mo, Siqi
AU  - Mo S
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Cheng, Feiran
AU  - Cheng F
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Zhou, Yabo
AU  - Zhou Y
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Zhang, Haizeng
AU  - Zhang H
AD  - National Cancer Center/Cancer Hospital, CAMS, Beijing 100005, China.
FAU - Wang, Jing
AU  - Wang J
AD  - National Cancer Center/Cancer Hospital, CAMS, Beijing 100005, China.
FAU - Li, Jingnan
AU  - Li J
AD  - Department of Gastroenterology, Peking Union Medical College Hospital, CAMS,
      Beijing 100005, China.
FAU - Chen, Yang
AU  - Chen Y
AD  - Department of Gastroenterology, Peking Union Medical College Hospital, CAMS,
      Beijing 100005, China.
FAU - Cui, Bing
AU  - Cui B
AD  - Molecular Immunology and Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, CAMS,
      Beijing 100005, China.
FAU - Hu, Zhuo-Wei
AU  - Hu ZW
AD  - Molecular Immunology and Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, CAMS,
      Beijing 100005, China.
FAU - Cao, Xuetao
AU  - Cao X
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China.
FAU - Xiao-Feng Qin, F
AU  - Xiao-Feng Qin F
AD  - Center of Systems Medicine, Institute of Basic Medical Sciences, CAMS & Suzhou
      Institute of Systems Medicine, Suzhou 215123, China.
FAU - Huang, Bo
AU  - Huang B
AD  - Department of Immunology & National Key Laboratory of Medical Molecular Biology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) &
      Peking Union Medical College, Beijing 100005, China; Clinical Immunology Center, 
      CAMS, Beijing 100005, China; Department of Biochemistry & Molecular Biology,
      Tongji Medical College, Huazhong University of Science & Technology, Wuhan
      430030, China. Electronic address: tjhuangbo@hotmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - CD8(+) T cells
OT  - Kyn transporter
OT  - PD-1 upregulation
OT  - aryl hydrocarbon receptor
OT  - kynurenine
OT  - transcellular delivery
OT  - tumor-repopulating cells
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2017/07/06 00:00 [received]
PHST- 2017/11/30 00:00 [revised]
PHST- 2018/02/08 00:00 [accepted]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30058-8 [pii]
AID - 10.1016/j.ccell.2018.02.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):480-494.e7. doi: 10.1016/j.ccell.2018.02.005.

PMID- 29533785
OWN - NLM
STAT- In-Data-Review
LR  - 20180324
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Systematic Functional Annotation of Somatic Mutations in Cancer.
PG  - 450-462.e10
LID - S1535-6108(18)30021-7 [pii]
LID - 10.1016/j.ccell.2018.01.021 [doi]
AB  - The functional impact of the vast majority of cancer somatic mutations remains
      unknown, representing a critical knowledge gap for implementing precision
      oncology. Here, we report the development of a moderate-throughput functional
      genomic platform consisting of efficient mutant generation, sensitive viability
      assays using two growth factor-dependent cell models, and functional proteomic
      profiling of signaling effects for select aberrations. We apply the platform to
      annotate >1,000 genomic aberrations, including gene amplifications, point
      mutations, indels, and gene fusions, potentially doubling the number of driver
      mutations characterized in clinically actionable genes. Further, the platform is 
      sufficiently sensitive to identify weak drivers. Our data are accessible through 
      a user-friendly, public data portal. Our study will facilitate biomarker
      discovery, prediction algorithm improvement, and drug development.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Ng, Patrick Kwok-Shing
AU  - Ng PK
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Li, Jun
AU  - Li J
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Jeong, Kang Jin
AU  - Jeong KJ
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Shao, Shan
AU  - Shao S
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Chen, Hu
AU  - Chen H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Program in
      Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Tsang, Yiu Huen
AU  - Tsang YH
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Sengupta, Sohini
AU  - Sengupta S
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63108, USA.
FAU - Wang, Zixing
AU  - Wang Z
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Bhavana, Venkata Hemanjani
AU  - Bhavana VH
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Tran, Richard
AU  - Tran R
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Soewito, Stephanie
AU  - Soewito S
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Minussi, Darlan Conterno
AU  - Minussi DC
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Moreno, Daniela
AU  - Moreno D
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Kong, Kathleen
AU  - Kong K
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Dogruluk, Turgut
AU  - Dogruluk T
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Lu, Hengyu
AU  - Lu H
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Gao, Jianjiong
AU  - Gao J
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Tokheim, Collin
AU  - Tokheim C
AD  - Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD
      21218, USA; Institute for Computational Medicine, Johns Hopkins University,
      Baltimore, MD 21218, USA.
FAU - Zhou, Daniel Cui
AU  - Zhou DC
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63108, USA.
FAU - Johnson, Amber M
AU  - Johnson AM
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Zeng, Jia
AU  - Zeng J
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Ip, Carman Ka Man
AU  - Ip CKM
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ju, Zhenlin
AU  - Ju Z
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Wester, Matthew
AU  - Wester M
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Yu, Shuangxing
AU  - Yu S
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Li, Yongsheng
AU  - Li Y
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Vellano, Christopher P
AU  - Vellano CP
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Schultz, Nikolaus
AU  - Schultz N
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Karchin, Rachel
AU  - Karchin R
AD  - Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD
      21218, USA; Institute for Computational Medicine, Johns Hopkins University,
      Baltimore, MD 21218, USA; Department of Oncology, Johns Hopkins Medicine,
      Baltimore, MD 21287, USA.
FAU - Ding, Li
AU  - Ding L
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63108, USA; Siteman Cancer Center, Washington University, St. Louis, MO 63108,
      USA.
FAU - Lu, Yiling
AU  - Lu Y
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Cheung, Lydia Wai Ting
AU  - Cheung LWT
AD  - HKU Shenzhen Institute of Research and Innovation, Shenzhen, China; School of
      Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong,
      Pokfulam, Hong Kong SAR.
FAU - Chen, Ken
AU  - Chen K
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Shaw, Kenna R
AU  - Shaw KR
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Meric-Bernstam, Funda
AU  - Meric-Bernstam F
AD  - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA; Department of Breast Surgical Oncology,
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
      Department of Investigational Cancer Therapeutics, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Scott, Kenneth L
AU  - Scott KL
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Yi, Song
AU  - Yi S
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA. Electronic address: syi2@mdanderson.org.
FAU - Sahni, Nidhi
AU  - Sahni N
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Graduate Program in Quantitative and Computational
      Biosciences, Baylor College of Medicine, Houston, TX 77030, USA. Electronic
      address: nsahni@mdanderson.org.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology,
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
      Graduate Program in Quantitative and Computational Biosciences, Baylor College of
      Medicine, Houston, TX 77030, USA. Electronic address: hliang1@mdanderson.org.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - TCGA
OT  - cellular assay
OT  - clinical marker
OT  - driver mutation
OT  - drug sensitivity
OT  - functional genomics
OT  - functional proteomics
OT  - therapeutic target
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2017/09/14 00:00 [received]
PHST- 2017/12/07 00:00 [revised]
PHST- 2018/01/30 00:00 [accepted]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30021-7 [pii]
AID - 10.1016/j.ccell.2018.01.021 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):450-462.e10. doi: 10.1016/j.ccell.2018.01.021.

PMID- 29533784
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific
      Dependencies in Medulloblastoma.
PG  - 435-449.e6
LID - S1535-6108(18)30059-X [pii]
LID - 10.1016/j.ccell.2018.02.006 [doi]
AB  - Cancer cells often express differentiation programs unrelated to their tissue of 
      origin, although the contribution of these aberrant phenotypes to malignancy is
      poorly understood. An aggressive subgroup of medulloblastoma, a malignant
      pediatric brain tumor of the cerebellum, expresses a photoreceptor
      differentiation program normally expressed in the retina. We establish that two
      photoreceptor-specific transcription factors, NRL and CRX, are master regulators 
      of this program and are required for tumor maintenance in this subgroup. Beyond
      photoreceptor lineage genes, we identify BCL-XL as a key transcriptional target
      of NRL and provide evidence substantiating anti-BCL therapy as a rational
      treatment opportunity for select MB patients. Our results highlight the utility
      of studying aberrant differentiation programs in cancer and their potential as
      selective therapeutic vulnerabilities.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Garancher, Alexandra
AU  - Garancher A
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Lin, Charles Y
AU  - Lin CY
AD  - Baylor College of Medicine, Department of Molecular and Human Genetics, 1 Baylor 
      Plaza, Houston, TX 77030, USA.
FAU - Morabito, Morgane
AU  - Morabito M
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Richer, Wilfrid
AU  - Richer W
AD  - PSL Research University, Paris, France; Institut Curie, Paris 75248, France;
      INSERM U830, Paris 75248, France; Translational Research in Pediatric Oncology,
      Institut Curie SiRIC, Paris, France.
FAU - Rocques, Nathalie
AU  - Rocques N
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Larcher, Magalie
AU  - Larcher M
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Bihannic, Laure
AU  - Bihannic L
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France; Department of
      Developmental Neurobiology, St. Jude Children's Research Hospital, 262 Danny
      Thomas Place, MS325, Memphis, TN 38017, USA.
FAU - Smith, Kyle
AU  - Smith K
AD  - Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 
      262 Danny Thomas Place, MS325, Memphis, TN 38017, USA.
FAU - Miquel, Catherine
AU  - Miquel C
AD  - Departement de Neuropathologie, Hopital Sainte-Anne, INSERM UMR_S1165, Universite
      Paris Diderot, Sorbonne Paris Cite, Paris, France; Universite Paris Descartes,
      Sorbonne Paris Cite, Paris, France.
FAU - Leboucher, Sophie
AU  - Leboucher S
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France.
FAU - Herath, Nirmitha I
AU  - Herath NI
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Dupuy, Fanny
AU  - Dupuy F
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Varlet, Pascale
AU  - Varlet P
AD  - Universite Paris Descartes, Sorbonne Paris Cite, Paris, France; Departement de
      Neuropathologie, Hopital Sainte-Anne, INSERM U894, Universite Paris Diderot,
      Sorbonne Paris Cite, Paris, France.
FAU - Haberler, Christine
AU  - Haberler C
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria.
FAU - Walczak, Christine
AU  - Walczak C
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; Universite Paris Sud-11, 91405 Orsay, France; PSL Research
      University, Paris, France; INSERM U1196, CNRS UMR9187, Centre Universitaire,
      Orsay 91405, France.
FAU - El Tayara, Nadine
AU  - El Tayara N
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; Universite Paris Sud-11, 91405 Orsay, France; PSL Research
      University, Paris, France; INSERM U1196, CNRS UMR9187, Centre Universitaire,
      Orsay 91405, France.
FAU - Volk, Andreas
AU  - Volk A
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; Universite Paris Sud-11, 91405 Orsay, France; PSL Research
      University, Paris, France; INSERM U1196, CNRS UMR9187, Centre Universitaire,
      Orsay 91405, France.
FAU - Puget, Stephanie
AU  - Puget S
AD  - Universite Paris Descartes, Sorbonne Paris Cite, Paris, France; AP-HP, Hopital
      Necker-Enfants Malades, Departement Neurochirurgie pediatrique, Paris, France.
FAU - Doz, Francois
AU  - Doz F
AD  - Institut Curie, Paris 75248, France; Universite Paris Descartes, Sorbonne Paris
      Cite, Paris, France; SIREDO Center (Care, innovation, Research in pediatric,
      adolescent and young adult oncology), Institut Curie, Paris, France.
FAU - Delattre, Olivier
AU  - Delattre O
AD  - PSL Research University, Paris, France; Institut Curie, Paris 75248, France;
      INSERM U830, Paris 75248, France; SIREDO Center (Care, innovation, Research in
      pediatric, adolescent and young adult oncology), Institut Curie, Paris, France.
FAU - Druillennec, Sabine
AU  - Druillennec S
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Ayrault, Olivier
AU  - Ayrault O
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Wechsler-Reya, Robert J
AU  - Wechsler-Reya RJ
AD  - Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
FAU - Eychene, Alain
AU  - Eychene A
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France.
FAU - Bourdeaut, Franck
AU  - Bourdeaut F
AD  - PSL Research University, Paris, France; Institut Curie, Paris 75248, France;
      INSERM U830, Paris 75248, France; Translational Research in Pediatric Oncology,
      Institut Curie SiRIC, Paris, France; SIREDO Center (Care, innovation, Research in
      pediatric, adolescent and young adult oncology), Institut Curie, Paris, France.
FAU - Northcott, Paul A
AU  - Northcott PA
AD  - Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 
      262 Danny Thomas Place, MS325, Memphis, TN 38017, USA. Electronic address:
      paul.northcott@stjude.org.
FAU - Pouponnot, Celio
AU  - Pouponnot C
AD  - Institut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex
      91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 
      3347, Centre Universitaire, Orsay 91405, France; Universite Paris Sud-11, 91405
      Orsay, France; PSL Research University, Paris, France. Electronic address:
      celio.pouponnot@curie.fr.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - BCL2
OT  - CRX
OT  - MAF
OT  - NRL
OT  - apoptosis
OT  - medulloblastoma
OT  - photoreceptor
OT  - retina
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/11/01 00:00 [revised]
PHST- 2018/02/10 00:00 [accepted]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30059-X [pii]
AID - 10.1016/j.ccell.2018.02.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):435-449.e6. doi: 10.1016/j.ccell.2018.02.006.

PMID- 29533783
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma
      Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis.
PG  - 417-434.e7
LID - S1535-6108(18)30020-5 [pii]
LID - 10.1016/j.ccell.2018.01.020 [doi]
AB  - Trait-associated loci often map to genomic regions encoding long noncoding RNAs
      (lncRNAs), but the role of these lncRNAs in disease etiology is largely
      unexplored. We show that a pair of sense/antisense lncRNA (6p22lncRNAs) encoded
      by CASC15 and NBAT1 located at the neuroblastoma (NB) risk-associated 6p22.3
      locus are tumor suppressors and show reduced expression in high-risk NBs. Loss of
      functional synergy between 6p22lncRNAs results in an undifferentiated state that 
      is maintained by a gene-regulatory network, including SOX9 located on 17q, a
      region frequently gained in NB. 6p22lncRNAs regulate SOX9 expression by
      controlling CHD7 stability via modulating the cellular localization of USP36,
      encoded by another 17q gene. This regulatory nexus between 6p22.3 and 17q regions
      may lead to potential NB treatment strategies.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Mondal, Tanmoy
AU  - Mondal T
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Juvvuna, Prasanna Kumar
AU  - Juvvuna PK
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Kirkeby, Agnete
AU  - Kirkeby A
AD  - Wallenberg Neuroscience Center, Lund University, 22184 Lund, Sweden; Danish Stem 
      Cell Center (DanStem), University of Copenhagen, 2200 Copenhagen, Denmark.
FAU - Mitra, Sanhita
AU  - Mitra S
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Kosalai, Subazini Thankaswamy
AU  - Kosalai ST
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Traxler, Larissa
AU  - Traxler L
AD  - Wallenberg Neuroscience Center, Lund University, 22184 Lund, Sweden.
FAU - Hertwig, Falk
AU  - Hertwig F
AD  - Department of Experimental Pediatric Oncology, University Children's Hospital,
      and Center for Molecular Medicine (CMMC), Medical Faculty, University of Cologne,
      50937 Cologne, Germany; Department of Pediatric Oncology and Hematology, Charite 
      - Universitatsmedizin Berlin, 10117 Berlin, Germany.
FAU - Wernig-Zorc, Sara
AU  - Wernig-Zorc S
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Miranda, Caroline
AU  - Miranda C
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Deland, Lily
AU  - Deland L
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Volland, Ruth
AU  - Volland R
AD  - Department of Experimental Pediatric Oncology, University Children's Hospital,
      and Center for Molecular Medicine (CMMC), Medical Faculty, University of Cologne,
      50937 Cologne, Germany.
FAU - Bartenhagen, Christoph
AU  - Bartenhagen C
AD  - Department of Experimental Pediatric Oncology, University Children's Hospital,
      and Center for Molecular Medicine (CMMC), Medical Faculty, University of Cologne,
      50937 Cologne, Germany.
FAU - Bartsch, Deniz
AU  - Bartsch D
AD  - Center for Molecular Medicine Cologne, Institute for Neurophysiology, The Cologne
      Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases, 
      University of Cologne, Cologne, Germany.
FAU - Bandaru, Sashidhar
AU  - Bandaru S
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Engesser, Anne
AU  - Engesser A
AD  - Department of Experimental Pediatric Oncology, University Children's Hospital,
      and Center for Molecular Medicine (CMMC), Medical Faculty, University of Cologne,
      50937 Cologne, Germany.
FAU - Subhash, Santhilal
AU  - Subhash S
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Martinsson, Tommy
AU  - Martinsson T
AD  - Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska
      Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Caren, Helena
AU  - Caren H
AD  - Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of
      Biomedicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg,
      Sweden.
FAU - Akyurek, Levent M
AU  - Akyurek LM
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden;
      Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska
      Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
FAU - Kurian, Leo
AU  - Kurian L
AD  - Center for Molecular Medicine Cologne, Institute for Neurophysiology, The Cologne
      Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases, 
      University of Cologne, Cologne, Germany.
FAU - Kanduri, Meena
AU  - Kanduri M
AD  - Department of Clinical Chemistry and Transfusion Medicine, Institute of
      Biomedicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg,
      Sweden.
FAU - Huarte, Maite
AU  - Huarte M
AD  - Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 55,
      31008 Pamplona, Spain.
FAU - Kogner, Per
AU  - Kogner P
AD  - Childhood Cancer Research Unit, Astrid Lindgren Children's Hospital, Karolinska
      University Hospital, 17176 Stockholm, Sweden.
FAU - Fischer, Matthias
AU  - Fischer M
AD  - Department of Experimental Pediatric Oncology, University Children's Hospital,
      and Center for Molecular Medicine (CMMC), Medical Faculty, University of Cologne,
      50937 Cologne, Germany.
FAU - Kanduri, Chandrasekhar
AU  - Kanduri C
AD  - Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
      Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
      Electronic address: kanduri.chandrasekhar@gu.se.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - CASC15
OT  - CHD7
OT  - NBAT1
OT  - SOX9
OT  - USP36
OT  - lncRNA
OT  - long noncoding RNA
OT  - neuroblastoma
OT  - neuronal differentiation
OT  - ubiquitination
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2017/07/10 00:00 [received]
PHST- 2017/10/27 00:00 [revised]
PHST- 2018/01/27 00:00 [accepted]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30020-5 [pii]
AID - 10.1016/j.ccell.2018.01.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):417-434.e7. doi: 10.1016/j.ccell.2018.01.020.

PMID- 29533782
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of
      Homologous Recombination Deficiency.
PG  - 401-416.e8
LID - S1535-6108(18)30019-9 [pii]
LID - 10.1016/j.ccell.2018.01.019 [doi]
AB  - Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells
      with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1,
      BRCA2, and other pathway members. We sought small molecules that induce HRD in
      HR-competent cells to induce synthetic lethality with PARPi and extend the
      utility of PARPi. We demonstrated that inhibition of bromodomain containing 4
      (BRD4) induced HRD and sensitized cells across multiple tumor lineages to PARPi
      regardless of BRCA1/2, TP53, RAS, or BRAF mutation status through depletion of
      the DNA double-stand break resection protein CtIP (C-terminal binding protein
      interacting protein). Importantly, BRD4 inhibitor (BRD4i) treatment reversed
      multiple mechanisms of resistance to PARPi. Furthermore, PARPi and BRD4i are
      synergistic in multiple in vivo models.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Sun, Chaoyang
AU  - Sun C
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan 430030, China; Department of
      Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX
      77030, USA. Electronic address: suncydoctor@gmail.com.
FAU - Yin, Jun
AU  - Yin J
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Aurora Research Institute, Milwaukee, WI 53202, USA.
FAU - Fang, Yong
AU  - Fang Y
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan 430030, China; Department of
      Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX
      77030, USA.
FAU - Chen, Jian
AU  - Chen J
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Department of General Surgery, Second Affiliated
      Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province
      310000, China.
FAU - Jeong, Kang Jin
AU  - Jeong KJ
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Chen, Xiaohua
AU  - Chen X
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Vellano, Christopher P
AU  - Vellano CP
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ju, Zhenlin
AU  - Ju Z
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Zhang, Dong
AU  - Zhang D
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Lu, Yiling
AU  - Lu Y
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Meric-Bernstam, Funda
AU  - Meric-Bernstam F
AD  - Department of Investigational Cancer Therapeutics, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yap, Timothy A
AU  - Yap TA
AD  - Department of Investigational Cancer Therapeutics, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hattersley, Maureen
AU  - Hattersley M
AD  - IMED Oncology, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
FAU - O'Connor, Mark J
AU  - O'Connor MJ
AD  - AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2
      0RE, UK.
FAU - Chen, Huawei
AU  - Chen H
AD  - IMED Oncology, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
FAU - Fawell, Stephen
AU  - Fawell S
AD  - IMED Oncology, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
FAU - Lin, Shiaw-Yih
AU  - Lin SY
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Peng, Guang
AU  - Peng G
AD  - Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer 
      Center, Houston, TX 77030, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - BRD4 inhibitor
OT  - CtBP-interacting protein
OT  - CtIP
OT  - PARP inhibitor
OT  - homologous recombination
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2017/07/16 00:00 [received]
PHST- 2017/11/13 00:00 [revised]
PHST- 2018/01/27 00:00 [accepted]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30019-9 [pii]
AID - 10.1016/j.ccell.2018.01.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

PMID- 29533781
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth.
PG  - 355-367.e7
LID - S1535-6108(18)30057-6 [pii]
LID - 10.1016/j.ccell.2018.02.004 [doi]
AB  - Expression of PKM2, which diverts glucose-derived carbon from catabolic to
      biosynthetic pathways, is a hallmark of cancer. However, PKM2 function in
      tumorigenesis remains controversial. Here, we show that, when expressed rather
      than PKM2, the PKM isoform PKM1 exhibits a tumor-promoting function in
      KRAS(G12D)-induced or carcinogen-initiated mouse models or in some human cancers.
      Analysis of Pkm mutant mouse lines expressing specific PKM isoforms established
      that PKM1 boosts tumor growth cell intrinsically. PKM1 activated glucose
      catabolism and stimulated autophagy/mitophagy, favoring malignancy. Importantly, 
      we observed that pulmonary neuroendocrine tumors (NETs), including small-cell
      lung cancer (SCLC), express PKM1, and that PKM1 expression is required for SCLC
      cell proliferation. Our findings provide a rationale for targeting PKM1
      therapeutically in certain cancer subtypes, including pulmonary NETs.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Morita, Mami
AU  - Morita M
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan; Division of Respiratory Oncology, Tohoku University Graduate
      School of Medicine, Sendai 980-8575, Japan; Department of Respiratory Medicine,
      Miyagi Cancer Center Hospital, Natori 981-1293, Japan.
FAU - Sato, Taku
AU  - Sato T
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan; Department of Thoracic Surgery, Institute of Development, Aging 
      and Cancer, Tohoku University, Sendai 980-8575, Japan.
FAU - Nomura, Miyuki
AU  - Nomura M
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Sakamoto, Yoshimi
AU  - Sakamoto Y
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Inoue, Yui
AU  - Inoue Y
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Tanaka, Ryota
AU  - Tanaka R
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan; Department of Thoracic Surgery, Institute of Development, Aging 
      and Cancer, Tohoku University, Sendai 980-8575, Japan.
FAU - Ito, Shigemi
AU  - Ito S
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Kurosawa, Koreyuki
AU  - Kurosawa K
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Yamaguchi, Kazunori
AU  - Yamaguchi K
AD  - Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research
      Institute, Natori 981-1293, Japan.
FAU - Sugiura, Yuki
AU  - Sugiura Y
AD  - Department of Biochemistry, Keio University School of Medicine, Tokyo 160-8582,
      Japan.
FAU - Takizaki, Hiroshi
AU  - Takizaki H
AD  - Division of Cancer Molecular Biology, Tohoku University Graduate School of
      Medicine, Sendai 980-8575, Japan.
FAU - Yamashita, Yoji
AU  - Yamashita Y
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Katakura, Ryuichi
AU  - Katakura R
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Sato, Ikuro
AU  - Sato I
AD  - Tissue Bank, Miyagi Cancer Center Research Institute, Natori 981-1293, Japan.
FAU - Kawai, Masaaki
AU  - Kawai M
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan.
FAU - Okada, Yoshinori
AU  - Okada Y
AD  - Department of Thoracic Surgery, Institute of Development, Aging and Cancer,
      Tohoku University, Sendai 980-8575, Japan.
FAU - Watanabe, Hitomi
AU  - Watanabe H
AD  - Laboratory of Animal Experiments for Regeneration, Institute for Frontier Medical
      Sciences, Kyoto University, Kyoto 606-8507, Japan.
FAU - Kondoh, Gen
AU  - Kondoh G
AD  - Laboratory of Animal Experiments for Regeneration, Institute for Frontier Medical
      Sciences, Kyoto University, Kyoto 606-8507, Japan.
FAU - Matsumoto, Shoko
AU  - Matsumoto S
AD  - Department of Biological Science, Graduate School of Humanities and Sciences,
      Nara Women's University, Nara 630-8506, Japan.
FAU - Kishimoto, Ayako
AU  - Kishimoto A
AD  - Department of Biological Science, Graduate School of Humanities and Sciences,
      Nara Women's University, Nara 630-8506, Japan.
FAU - Obata, Miki
AU  - Obata M
AD  - Department of Biochemistry, Niigata University Graduate School of Medical and
      Dental Sciences, Niigata 951-8510, Japan.
FAU - Matsumoto, Masaki
AU  - Matsumoto M
AD  - Department of Molecular and Cellular Biology, Medical Institute of Bioregulation,
      Kyusyu University, Fukuoka 812-8582, Japan.
FAU - Fukuhara, Tatsuro
AU  - Fukuhara T
AD  - Department of Respiratory Medicine, Miyagi Cancer Center Hospital, Natori
      981-1293, Japan.
FAU - Motohashi, Hozumi
AU  - Motohashi H
AD  - Department of Gene Expression Regulation, Institute of Development, Aging and
      Cancer, Tohoku University, Sendai 980-8575, Japan.
FAU - Suematsu, Makoto
AU  - Suematsu M
AD  - Department of Biochemistry, Keio University School of Medicine, Tokyo 160-8582,
      Japan.
FAU - Komatsu, Masaaki
AU  - Komatsu M
AD  - Department of Biochemistry, Niigata University Graduate School of Medical and
      Dental Sciences, Niigata 951-8510, Japan.
FAU - Nakayama, Keiichi I
AU  - Nakayama KI
AD  - Department of Molecular and Cellular Biology, Medical Institute of Bioregulation,
      Kyusyu University, Fukuoka 812-8582, Japan.
FAU - Watanabe, Toshio
AU  - Watanabe T
AD  - Department of Biological Science, Graduate School of Humanities and Sciences,
      Nara Women's University, Nara 630-8506, Japan.
FAU - Soga, Tomoyoshi
AU  - Soga T
AD  - Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan.
FAU - Shima, Hiroshi
AU  - Shima H
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan; Division of Cancer Molecular Biology, Tohoku University Graduate
      School of Medicine, Sendai 980-8575, Japan.
FAU - Maemondo, Makoto
AU  - Maemondo M
AD  - Division of Respiratory Oncology, Tohoku University Graduate School of Medicine, 
      Sendai 980-8575, Japan; Department of Respiratory Medicine, Miyagi Cancer Center 
      Hospital, Natori 981-1293, Japan.
FAU - Tanuma, Nobuhiro
AU  - Tanuma N
AD  - Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori 
      981-1293, Japan; Division of Cancer Molecular Biology, Tohoku University Graduate
      School of Medicine, Sendai 980-8575, Japan. Electronic address:
      ntanuma@med.tohoku.ac.jp.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - PKM
OT  - PKM1
OT  - PKM2
OT  - autophagy
OT  - glucose metabolism
OT  - lung neuroendocrine tumor
OT  - mitophagy
OT  - small-cell lung cancer
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2017/09/06 00:00 [received]
PHST- 2017/12/28 00:00 [revised]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30057-6 [pii]
AID - 10.1016/j.ccell.2018.02.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):355-367.e7. doi: 10.1016/j.ccell.2018.02.004.

PMID- 29533780
OWN - NLM
STAT- In-Data-Review
LR  - 20180408
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic
      Colonization.
PG  - 347-354
LID - S1535-6108(18)30022-9 [pii]
LID - 10.1016/j.ccell.2018.02.001 [doi]
AB  - Metastases arising from tumors have the proclivity to colonize specific organs,
      suggesting that they must rewire their biology to meet the demands of the organ
      colonized, thus altering their primary properties. Each metastatic site presents 
      distinct metabolic challenges to a colonizing cancer cell, ranging from fuel and 
      oxygen availability to oxidative stress. Here, we discuss the organ-specific
      metabolic adaptations that cancer cells must undergo, which provide the ability
      to overcome the unique barriers to colonization in foreign tissues and establish 
      the metastatic tissue tropism phenotype.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Schild, Tanya
AU  - Schild T
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of
      Pharmacology, Weill Cornell Medicine, New York, NY, USA.
FAU - Low, Vivien
AU  - Low V
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of
      Pharmacology, Weill Cornell Medicine, New York, NY, USA.
FAU - Blenis, John
AU  - Blenis J
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of
      Pharmacology, Weill Cornell Medicine, New York, NY, USA. Electronic address:
      jblenis@med.cornell.edu.
FAU - Gomes, Ana P
AU  - Gomes AP
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of
      Pharmacology, Weill Cornell Medicine, New York, NY, USA. Electronic address:
      and2049@med.cornell.edu.
LA  - eng
GR  - F31 CA220750/CA/NCI NIH HHS/United States
GR  - R01 CA046595/CA/NCI NIH HHS/United States
GR  - R01 GM051405/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5889305
MID - NIHMS953766
OTO - NOTNLM
OT  - cancer
OT  - metabolism
OT  - metastasis
OT  - tissue tropism
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2017/08/28 00:00 [received]
PHST- 2017/11/17 00:00 [revised]
PHST- 2018/02/01 00:00 [accepted]
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30022-9 [pii]
AID - 10.1016/j.ccell.2018.02.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):347-354. doi: 10.1016/j.ccell.2018.02.001.

PMID- 29533779
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - A Non-canonical Polycomb Dependency in Synovial Sarcoma.
PG  - 344-346
LID - S1535-6108(18)30066-7 [pii]
LID - 10.1016/j.ccell.2018.02.013 [doi]
AB  - Disruptions in the antagonistic balance between the chromatin-modifying Polycomb 
      and Trithorax group proteins drive many malignancies. In this issue of Cancer
      Cell, Banito et al. describe how the SS18-SSX oncogenic fusion protein in
      synovial sarcoma directly co-opts these complexes to drive gene dysregulation and
      sustain the transformed state.
CI  - Published by Elsevier Inc.
FAU - Waterfall, Joshua J
AU  - Waterfall JJ
AD  - Institut Curie, PSL Research University, 75005 Paris, France; INSERM U830, 75005 
      Paris, France; Institut Curie, Translational Research Department, 75005 Paris,
      France.
FAU - Meltzer, Paul S
AU  - Meltzer PS
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda,
      MD 20892, USA. Electronic address: pmeltzer@mail.nih.gov.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30066-7 [pii]
AID - 10.1016/j.ccell.2018.02.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):344-346. doi: 10.1016/j.ccell.2018.02.013.

PMID- 29533778
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - ORY-1001: Overcoming the Differentiation Block in AML.
PG  - 342-343
LID - S1535-6108(18)30067-9 [pii]
LID - 10.1016/j.ccell.2018.02.014 [doi]
AB  - In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo
      findings with ORY-1001-an oral, highly potent and selective covalent
      small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)-in development
      for acute myeloid leukemia (AML), as well as correlative data from two AML
      patients receiving ORY-1001.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Bose, Prithviraj
AU  - Bose P
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Konopleva, Marina Y
AU  - Konopleva MY
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA. Electronic address: mkonople@mdanderson.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30067-9 [pii]
AID - 10.1016/j.ccell.2018.02.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):342-343. doi: 10.1016/j.ccell.2018.02.014.

PMID- 29533777
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Targeting mRNA Decapping in AML.
PG  - 339-341
LID - S1535-6108(18)30068-0 [pii]
LID - 10.1016/j.ccell.2018.02.015 [doi]
AB  - In this issue of Cancer Cell, Yamauchi et al. identify a dependency of acute
      myeloid leukemia (AML) on DCPS, which catalyzes the final step of 3'-to-5' mRNA
      decay and is implicated in numerous aspects of RNA metabolism. DCPS is targetable
      with a clinical inhibitor, underscoring the translational importance of this
      discovery.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Yoshimi, Akihide
AU  - Yoshimi A
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
      and Weill Cornell Medical College, New York, NY, USA.
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
      and Weill Cornell Medical College, New York, NY, USA; Leukemia Service,
      Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA. Electronic address: abdelwao@mskcc.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30068-0 [pii]
AID - 10.1016/j.ccell.2018.02.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):339-341. doi: 10.1016/j.ccell.2018.02.015.

PMID- 29533776
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Glucose Metabolism in Cancer: The Saga of Pyruvate Kinase Continues.
PG  - 337-339
LID - S1535-6108(18)30061-8 [pii]
LID - 10.1016/j.ccell.2018.02.008 [doi]
AB  - Altered glucose metabolism is common in cancer. In this issue of Cancer Cell,
      Morita et al. report new mouse models that express specific isoforms of pyruvate 
      kinase to study glycolysis in tumors. They report several unanticipated findings 
      that challenge current ideas in cancer metabolism.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Allen, Annamarie E
AU  - Allen AE
AD  - Department of Pharmacology and Cancer Biology, Duke University School of
      Medicine, Durham, NC 27710, USA.
FAU - Locasale, Jason W
AU  - Locasale JW
AD  - Department of Pharmacology and Cancer Biology, Duke University School of
      Medicine, Durham, NC 27710, USA. Electronic address: jason.locasale@duke.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2018/03/14 06:00 [entrez]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - S1535-6108(18)30061-8 [pii]
AID - 10.1016/j.ccell.2018.02.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):337-339. doi: 10.1016/j.ccell.2018.02.008.

PMID- 29502955
OWN - NLM
STAT- In-Data-Review
LR  - 20180404
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
PG  - 527-541.e8
LID - S1535-6108(18)30018-7 [pii]
LID - 10.1016/j.ccell.2018.01.018 [doi]
AB  - Synovial sarcoma is an aggressive cancer invariably associated with a chromosomal
      translocation involving genes encoding the SWI-SNF complex component SS18 and an 
      SSX (SSX1 or SSX2) transcriptional repressor. Using functional genomics, we
      identify KDM2B, a histone demethylase and component of a non-canonical polycomb
      repressive complex 1 (PRC1.1), as selectively required for sustaining synovial
      sarcoma cell transformation. SS18-SSX1 physically interacts with PRC1.1 and
      co-associates with SWI/SNF and KDM2B complexes on unmethylated CpG islands. Via
      KDM2B, SS18-SSX1 binds and aberrantly activates expression of developmentally
      regulated genes otherwise targets of polycomb-mediated repression, which is
      restored upon KDM2B depletion, leading to irreversible mesenchymal
      differentiation. Thus, SS18-SSX1 deregulates developmental programs to drive
      transformation by hijacking a transcriptional repressive complex to aberrantly
      activate gene expression.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Banito, Ana
AU  - Banito A
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Li, Xiang
AU  - Li X
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York,
      NY 10065, USA.
FAU - Laporte, Aimee N
AU  - Laporte AN
AD  - Department of Pathology and Laboratory Medicine, Vancouver Coastal Health
      Research Institute and Faculty of Medicine, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Roe, Jae-Seok
AU  - Roe JS
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
FAU - Sanchez-Vega, Francisco
AU  - Sanchez-Vega F
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Huang, Chun-Hao
AU  - Huang CH
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Dancsok, Amanda R
AU  - Dancsok AR
AD  - Department of Pathology and Laboratory Medicine, Vancouver Coastal Health
      Research Institute and Faculty of Medicine, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Hatzi, Katerina
AU  - Hatzi K
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Chen, Chi-Chao
AU  - Chen CC
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York,
      NY 10065, USA.
FAU - Tschaharganeh, Darjus F
AU  - Tschaharganeh DF
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Chandwani, Rohit
AU  - Chandwani R
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Tasdemir, Nilgun
AU  - Tasdemir N
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Jones, Kevin B
AU  - Jones KB
AD  - Department of Orthopedics and Oncological Sciences, Huntsman Cancer Institute,
      University of Utah School of Medicine, Salt Lake City, UT 84103, USA.
FAU - Capecchi, Mario R
AU  - Capecchi MR
AD  - Department of Human Genetics, University of Utah School of Medicine, Salt Lake
      City, UT 84112, USA.
FAU - Vakoc, Christopher R
AU  - Vakoc CR
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
FAU - Schultz, Nikolaus
AU  - Schultz N
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ladanyi, Marc
AU  - Ladanyi M
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Nielsen, Torsten O
AU  - Nielsen TO
AD  - Department of Pathology and Laboratory Medicine, Vancouver Coastal Health
      Research Institute and Faculty of Medicine, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Lowe, Scott W
AU  - Lowe SW
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New 
      York, NY 10065, USA; Howard Hughes Medical Institute, New York, NY 10065, USA.
      Electronic address: lowes@mskcc.org.
LA  - eng
GR  - P01 CA013106/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180301
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5881394
MID - NIHMS947383
OTO - NOTNLM
OT  - CRISPR/Cas9-mediated endogenous protein tagging
OT  - DNA methylation
OT  - SWI/SNF
OT  - epigenetics
OT  - non-canonical polycomb repressive complex
OT  - oncogenic gene fusion
OT  - sarcoma
EDAT- 2018/03/06 06:00
MHDA- 2018/03/06 06:00
CRDT- 2018/03/06 06:00
PMCR- 2019/03/12 00:00
PHST- 2017/07/06 00:00 [received]
PHST- 2017/11/14 00:00 [revised]
PHST- 2018/01/27 00:00 [accepted]
PHST- 2019/03/12 00:00 [pmc-release]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2018/03/06 06:00 [entrez]
AID - S1535-6108(18)30018-7 [pii]
AID - 10.1016/j.ccell.2018.01.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):527-541.e8. doi: 10.1016/j.ccell.2018.01.018. Epub
      2018 Mar 1.

PMID- 29502954
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of
      Acute Leukemia.
PG  - 495-511.e12
LID - S1535-6108(18)30023-0 [pii]
LID - 10.1016/j.ccell.2018.02.002 [doi]
AB  - The lysine-specific demethylase KDM1A is a key regulator of stem cell potential
      in acute myeloid leukemia (AML). ORY-1001 is a highly potent and selective KDM1A 
      inhibitor that induces H3K4me2 accumulation on KDM1A target genes, blast
      differentiation, and reduction of leukemic stem cell capacity in AML. ORY-1001
      exhibits potent synergy with standard-of-care drugs and selective epigenetic
      inhibitors, reduces growth of an AML xenograft model, and extends survival in a
      mouse PDX (patient-derived xenograft) model of T cell acute leukemia. Surrogate
      pharmacodynamic biomarkers developed based on expression changes in leukemia cell
      lines were translated to samples from patients treated with ORY-1001. ORY-1001 is
      a selective KDM1A inhibitor in clinical trials and is currently being evaluated
      in patients with leukemia and solid tumors.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Maes, Tamara
AU  - Maes T
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain. 
      Electronic address: tmaes@oryzon.com.
FAU - Mascaro, Cristina
AU  - Mascaro C
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Tirapu, Inigo
AU  - Tirapu I
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Estiarte, Angels
AU  - Estiarte A
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Ciceri, Filippo
AU  - Ciceri F
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Lunardi, Serena
AU  - Lunardi S
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Guibourt, Nathalie
AU  - Guibourt N
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Perdones, Alvaro
AU  - Perdones A
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Lufino, Michele M P
AU  - Lufino MMP
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Somervaille, Tim C P
AU  - Somervaille TCP
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Wiseman, Dan H
AU  - Wiseman DH
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Duy, Cihangir
AU  - Duy C
AD  - Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell 
      Medicine, New York, 10065 NY, USA.
FAU - Melnick, Ari
AU  - Melnick A
AD  - Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell 
      Medicine, New York, 10065 NY, USA; Department of Pharmacology, Weill Cornell
      Medicine, New York, 10065 NY, USA.
FAU - Willekens, Christophe
AU  - Willekens C
AD  - Drug Development Department (DITEP) and Hematology Department, Gustave Roussy,
      Universite Paris-Saclay, 94805 Villejuif, France.
FAU - Ortega, Alberto
AU  - Ortega A
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Martinell, Marc
AU  - Martinell M
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Valls, Nuria
AU  - Valls N
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Kurz, Guido
AU  - Kurz G
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Fyfe, Matthew
AU  - Fyfe M
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Castro-Palomino, Julio Cesar
AU  - Castro-Palomino JC
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
FAU - Buesa, Carlos
AU  - Buesa C
AD  - Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Spain.
LA  - eng
PT  - Journal Article
DEP - 20180301
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - KDM1A
OT  - LSD1
OT  - ORY-1001
OT  - acute myeloid leukemia
OT  - differentiation
OT  - epigenetic
OT  - histone methylation
EDAT- 2018/03/06 06:00
MHDA- 2018/03/06 06:00
CRDT- 2018/03/06 06:00
PHST- 2017/05/19 00:00 [received]
PHST- 2017/09/17 00:00 [revised]
PHST- 2018/02/01 00:00 [accepted]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2018/03/06 06:00 [entrez]
AID - S1535-6108(18)30023-0 [pii]
AID - 10.1016/j.ccell.2018.02.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002.
      Epub 2018 Mar 1.

PMID- 29478914
OWN - NLM
STAT- In-Data-Review
LR  - 20180316
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a
      Pre-mRNA Metabolic Pathway Regulated by DCPS.
PG  - 386-400.e5
LID - S1535-6108(18)30012-6 [pii]
LID - 10.1016/j.ccell.2018.01.012 [doi]
AB  - To identify novel targets for acute myeloid leukemia (AML) therapy, we performed 
      genome-wide CRISPR-Cas9 screening using AML cell lines, followed by a second
      screen in vivo. Here, we show that the mRNA decapping enzyme scavenger (DCPS)
      gene is essential for AML cell survival. The DCPS enzyme interacted with
      components of pre-mRNA metabolic pathways, including spliceosomes, as revealed by
      mass spectrometry. RG3039, a DCPS inhibitor originally developed to treat spinal 
      muscular atrophy, exhibited anti-leukemic activity via inducing pre-mRNA
      mis-splicing. Humans harboring germline biallelic DCPS loss-of-function mutations
      do not exhibit aberrant hematologic phenotypes, indicating that DCPS is
      dispensable for human hematopoiesis. Our findings shed light on a pre-mRNA
      metabolic pathway and identify DCPS as a target for AML therapy.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Yamauchi, Takuji
AU  - Yamauchi T
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA; Department of Medicine and
      Biosystemic Science, Kyushu University Graduate School of Medical Sciences,
      Fukuoka 812-8582, Japan; Department of Stem Cell Biology and Medicine, Kyushu
      University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
FAU - Masuda, Takeshi
AU  - Masuda T
AD  - Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto
      University, Kumamoto 862-0973, Japan.
FAU - Canver, Matthew C
AU  - Canver MC
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Department of
      Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute,
      Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Seiler, Michael
AU  - Seiler M
AD  - H3 Biomedicine, Inc., Cambridge, MA 02139, USA.
FAU - Semba, Yuichiro
AU  - Semba Y
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School
      of Medical Sciences, Fukuoka 812-8582, Japan.
FAU - Shboul, Mohammad
AU  - Shboul M
AD  - Institute of Medical Biology, A *STAR, 8A Biomedical Grove, Singapore 138648,
      Singapore.
FAU - Al-Raqad, Mohammed
AU  - Al-Raqad M
AD  - Institute of Medical Biology, A *STAR, 8A Biomedical Grove, Singapore 138648,
      Singapore; Al-Balqa Applied University, Faculty of Science, Al-Salt, Salt 19117, 
      Jordan.
FAU - Maeda, Manami
AU  - Maeda M
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Schoonenberg, Vivien A C
AU  - Schoonenberg VAC
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Department of
      Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute,
      Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Cole, Mitchel A
AU  - Cole MA
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Department of
      Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute,
      Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Macias-Trevino, Claudio
AU  - Macias-Trevino C
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Department of
      Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute,
      Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Ishikawa, Yuichi
AU  - Ishikawa Y
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Yao, Qiuming
AU  - Yao Q
AD  - Department of Pathology & Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA.
FAU - Nakano, Michitaka
AU  - Nakano M
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School
      of Medical Sciences, Fukuoka 812-8582, Japan.
FAU - Arai, Fumio
AU  - Arai F
AD  - Department of Stem Cell Biology and Medicine, Kyushu University Graduate School
      of Medical Sciences, Fukuoka 812-8582, Japan.
FAU - Orkin, Stuart H
AU  - Orkin SH
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Department of
      Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute,
      Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Reversade, Bruno
AU  - Reversade B
AD  - Institute of Medical Biology, A *STAR, 8A Biomedical Grove, Singapore 138648,
      Singapore.
FAU - Buonamici, Silvia
AU  - Buonamici S
AD  - H3 Biomedicine, Inc., Cambridge, MA 02139, USA.
FAU - Pinello, Luca
AU  - Pinello L
AD  - Department of Pathology & Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA.
FAU - Akashi, Koichi
AU  - Akashi K
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School
      of Medical Sciences, Fukuoka 812-8582, Japan; Center for Cellular and Molecular
      Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.
FAU - Bauer, Daniel E
AU  - Bauer DE
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Department of
      Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute,
      Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Maeda, Takahiro
AU  - Maeda T
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA; Center for Cellular and Molecular 
      Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan. Electronic
      address: t_maeda@cancer.med.kyushu-u.ac.jp.
LA  - eng
GR  - K08 DK093705/DK/NIDDK NIH HHS/United States
GR  - R03 DK109232/DK/NIDDK NIH HHS/United States
GR  - P30 DK049216/DK/NIDDK NIH HHS/United States
GR  - P01 HL032262/HL/NHLBI NIH HHS/United States
GR  - R00 HG008399/HG/NHGRI NIH HHS/United States
GR  - F30 DK103359/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20180222
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5849534
MID - NIHMS937033
OTO - NOTNLM
OT  - CRISPR-Cas9 saturation mutagenesis
OT  - acute myeloid leukemia
OT  - decapping enzyme
OT  - drug repurposing
OT  - genome-wide CRISPR-Cas9 screening
OT  - mRNA decay
OT  - pre-mRNA metabolism
OT  - pre-mRNA splicing
EDAT- 2018/02/27 06:00
MHDA- 2018/02/27 06:00
CRDT- 2018/02/27 06:00
PMCR- 2019/03/12 00:00
PHST- 2017/08/04 00:00 [received]
PHST- 2017/11/23 00:00 [revised]
PHST- 2018/01/19 00:00 [accepted]
PHST- 2019/03/12 00:00 [pmc-release]
PHST- 2018/02/27 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2018/02/27 06:00 [entrez]
AID - S1535-6108(18)30012-6 [pii]
AID - 10.1016/j.ccell.2018.01.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):386-400.e5. doi: 10.1016/j.ccell.2018.01.012. Epub
      2018 Feb 22.

PMID- 29455928
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Transcriptional Regulation of the Warburg Effect in Cancer by SIX1.
PG  - 368-385.e7
LID - S1535-6108(18)30010-2 [pii]
LID - 10.1016/j.ccell.2018.01.010 [doi]
AB  - Aerobic glycolysis (the Warburg effect) facilitates tumor growth, and drugs
      targeting aerobic glycolysis are being developed. However, how the Warburg effect
      is directly regulated is largely unknown. Here we show that transcription factor 
      SIX1 directly increases the expression of many glycolytic genes, promoting the
      Warburg effect and tumor growth in vitro and in vivo. SIX1 regulates glycolysis
      through HBO1 and AIB1 histone acetyltransferases. Cancer-related SIX1 mutation
      increases its ability to promote aerobic glycolysis and tumor growth. SIX1
      glycolytic function is directly repressed by microRNA-548a-3p, which is
      downregulated, inversely correlates with SIX1, and is a good predictor of
      prognosis in breast cancer patients. Thus, the microRNA-548a-3p/SIX1 axis
      strongly links aerobic glycolysis to carcinogenesis and may become a promising
      cancer therapeutic target.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Li, Ling
AU  - Li L
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
FAU - Liang, Yingchun
AU  - Liang Y
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
FAU - Kang, Lei
AU  - Kang L
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China;
      Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034,
      China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China;
      Department of Thoracic Surgery, PLA General Hospital, Beijing 100853, China.
FAU - Gao, Shan
AU  - Gao S
AD  - CAS Key Laboratory of Biomedical Diagnostics, Suzhou Institute of Biomedical
      Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China.
FAU - Chen, Siyu
AU  - Chen S
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China;
      Department of Thoracic Surgery, PLA General Hospital, Beijing 100853, China.
FAU - Li, Ying
AU  - Li Y
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China;
      Department of Oncology, PLA General Hospital, Beijing 100853, China.
FAU - You, Wenye
AU  - You W
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China;
      Department of Oncology, PLA General Hospital, Beijing 100853, China.
FAU - Dong, Qian
AU  - Dong Q
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
FAU - Hong, Tian
AU  - Hong T
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
FAU - Yan, Zhifeng
AU  - Yan Z
AD  - Department of Gynecology and Obstetrics, PLA General Hospital, Beijing 100853,
      China.
FAU - Jin, Shuai
AU  - Jin S
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China;
      Department of Thoracic Surgery, PLA General Hospital, Beijing 100853, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Oncology, 307 Hospital of People's Liberation Army, Beijing 100071,
      China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Oncology, General Hospital of the PLA Rocket Force, Beijing 100088,
      China.
FAU - Mai, Haixing
AU  - Mai H
AD  - Department of Urology, 307 Hospital of People's Liberation Army, Beijing 100071, 
      China.
FAU - Huang, Jun
AU  - Huang J
AD  - Department of Urology, 307 Hospital of People's Liberation Army, Beijing 100071, 
      China.
FAU - Han, Xiao
AU  - Han X
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
FAU - Ji, Quanbo
AU  - Ji Q
AD  - Department of Orthopedics, PLA General Hospital, Beijing 100853, China.
FAU - Song, Qi
AU  - Song Q
AD  - Department of Oncology, PLA General Hospital, Beijing 100853, China.
FAU - Yang, Chao
AU  - Yang C
AD  - Department of Oncology, General Hospital of the PLA Rocket Force, Beijing 100088,
      China.
FAU - Zhao, Shixin
AU  - Zhao S
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
FAU - Xu, Xiaojie
AU  - Xu X
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
      Electronic address: miraclexxj@126.com.
FAU - Ye, Qinong
AU  - Ye Q
AD  - Department of Medical Molecular Biology, Beijing Institute of Biotechnology,
      Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China.
      Electronic address: yeqn66@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20180215
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - SIX1
OT  - Warburg effect
OT  - aerobic glycolysis
OT  - cancer
OT  - microRNA
OT  - transcription factor
EDAT- 2018/02/20 06:00
MHDA- 2018/02/20 06:00
CRDT- 2018/02/20 06:00
PHST- 2017/07/14 00:00 [received]
PHST- 2017/10/26 00:00 [revised]
PHST- 2018/01/18 00:00 [accepted]
PHST- 2018/02/20 06:00 [pubmed]
PHST- 2018/02/20 06:00 [medline]
PHST- 2018/02/20 06:00 [entrez]
AID - S1535-6108(18)30010-2 [pii]
AID - 10.1016/j.ccell.2018.01.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):368-385.e7. doi: 10.1016/j.ccell.2018.01.010. Epub
      2018 Feb 15.

PMID- 29455927
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 3
DP  - 2018 Mar 12
TI  - Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast
      Cancer.
PG  - 463-479.e10
LID - S1535-6108(18)30011-4 [pii]
LID - 10.1016/j.ccell.2018.01.011 [doi]
AB  - Carcinoma-associated fibroblasts (CAF) are key players in the tumor
      microenvironment. Here, we characterize four CAF subsets in breast cancer with
      distinct properties and levels of activation. Two myofibroblastic subsets
      (CAF-S1, CAF-S4) accumulate differentially in triple-negative breast cancers
      (TNBC). CAF-S1 fibroblasts promote an immunosuppressive environment through a
      multi-step mechanism. By secreting CXCL12, CAF-S1 attracts CD4(+)CD25(+) T
      lymphocytes and retains them by OX40L, PD-L2, and JAM2. Moreover, CAF-S1
      increases T lymphocyte survival and promotes their differentiation into
      CD25(High)FOXP3(High), through B7H3, CD73, and DPP4. Finally, in contrast to
      CAF-S4, CAF-S1 enhances the regulatory T cell capacity to inhibit T effector
      proliferation. These data are consistent with FOXP3+ T lymphocyte accumulation in
      CAF-S1-enriched TNBC and show how a CAF subset contributes to immunosuppression.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Costa, Ana
AU  - Costa A
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Kieffer, Yann
AU  - Kieffer Y
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Scholer-Dahirel, Alix
AU  - Scholer-Dahirel A
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France; Institut Curie, Integrative Biology of Human
      Dendritic Cells and T Cells Laboratory, PSL Research University, Inserm, U932,
      26, rue d'Ulm, 75005 Paris, France.
FAU - Pelon, Floriane
AU  - Pelon F
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Bourachot, Brigitte
AU  - Bourachot B
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Cardon, Melissa
AU  - Cardon M
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Sirven, Philemon
AU  - Sirven P
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France; Institut Curie, Integrative Biology of Human
      Dendritic Cells and T Cells Laboratory, PSL Research University, Inserm, U932,
      26, rue d'Ulm, 75005 Paris, France.
FAU - Magagna, Ilaria
AU  - Magagna I
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Fuhrmann, Laetitia
AU  - Fuhrmann L
AD  - Department of Pathology, Institut Curie Hospital Group, 26, rue d'Ulm, 75248
      Paris, France.
FAU - Bernard, Charles
AU  - Bernard C
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Bonneau, Claire
AU  - Bonneau C
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Kondratova, Maria
AU  - Kondratova M
AD  - Institut Curie, PSL Research University, Inserm, U900, Mines Paris Tech, Paris
      75005, France.
FAU - Kuperstein, Inna
AU  - Kuperstein I
AD  - Institut Curie, PSL Research University, Inserm, U900, Mines Paris Tech, Paris
      75005, France.
FAU - Zinovyev, Andrei
AU  - Zinovyev A
AD  - Institut Curie, PSL Research University, Inserm, U900, Mines Paris Tech, Paris
      75005, France.
FAU - Givel, Anne-Marie
AU  - Givel AM
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France.
FAU - Parrini, Maria-Carla
AU  - Parrini MC
AD  - Analysis of Transduction Pathway, Institut Curie, Inserm, U830, PSL Research
      University, 26 rue d'Ulm, Paris 75005, France.
FAU - Soumelis, Vassili
AU  - Soumelis V
AD  - Institut Curie, Integrative Biology of Human Dendritic Cells and T Cells
      Laboratory, PSL Research University, Inserm, U932, 26, rue d'Ulm, 75005 Paris,
      France.
FAU - Vincent-Salomon, Anne
AU  - Vincent-Salomon A
AD  - Department of Pathology, Institut Curie Hospital Group, 26, rue d'Ulm, 75248
      Paris, France.
FAU - Mechta-Grigoriou, Fatima
AU  - Mechta-Grigoriou F
AD  - Institut Curie, Stress and Cancer Laboratory, Equipe labelisee Ligue Nationale
      Contre le Cancer, PSL Research University, 26, rue d'Ulm, 75005 Paris, France;
      Inserm, U830, Paris 75005, France. Electronic address:
      fatima.mechta-grigoriou@curie.fr.
LA  - eng
PT  - Journal Article
DEP - 20180215
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - CAF
OT  - FOXP3
OT  - T lymphocytes
OT  - Treg
OT  - breast cancers
OT  - fibroblasts
OT  - heterogeneity
OT  - regulatory T cell
OT  - stroma
OT  - triple-negative
EDAT- 2018/02/20 06:00
MHDA- 2018/02/20 06:00
CRDT- 2018/02/20 06:00
PHST- 2017/08/03 00:00 [received]
PHST- 2017/11/16 00:00 [revised]
PHST- 2018/01/18 00:00 [accepted]
PHST- 2018/02/20 06:00 [pubmed]
PHST- 2018/02/20 06:00 [medline]
PHST- 2018/02/20 06:00 [entrez]
AID - S1535-6108(18)30011-4 [pii]
AID - 10.1016/j.ccell.2018.01.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Mar 12;33(3):463-479.e10. doi: 10.1016/j.ccell.2018.01.011.
      Epub 2018 Feb 15.

PMID- 29606348
OWN - NLM
STAT- Publisher
LR  - 20180402
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Mar 9
TI  - GKAP Acts as a Genetic Modulator of NMDAR Signaling to Govern Invasive Tumor
      Growth.
LID - S1535-6108(18)30064-3 [pii]
LID - 10.1016/j.ccell.2018.02.011 [doi]
AB  - Genetic linkage analysis previously suggested that GKAP, a scaffold protein of
      the N-methyl-D-aspartate receptor (NMDAR), was a potential modifier of invasion
      in a mouse model of pancreatic neuroendocrine tumor (PanNET). Here, we establish 
      that GKAP governs invasive growth and treatment response to NMDAR inhibitors of
      PanNET via its pivotal role in regulating NMDAR pathway activity. Combining
      genetic knockdown of GKAP and pharmacological inhibition of NMDAR, we implicate
      as downstream effectors FMRP and HSF1, which along with GKAP demonstrably support
      invasiveness of PanNET and pancreatic ductal adenocarcinoma cancer cells.
      Furthermore, we distilled genome-wide expression profiles orchestrated by the
      NMDAR-GKAP signaling axis, identifying transcriptome signatures in tumors with
      low/inhibited NMDAR activity that significantly associate with favorable patient 
      prognosis in several cancer types.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Li, Leanne
AU  - Li L
AD  - Swiss Institute of Cancer Research, School of Life Sciences, Swiss Federal
      Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland.
FAU - Zeng, Qiqun
AU  - Zeng Q
AD  - Swiss Institute of Cancer Research, School of Life Sciences, Swiss Federal
      Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland.
FAU - Bhutkar, Arjun
AU  - Bhutkar A
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Galvan, Jose A
AU  - Galvan JA
AD  - Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern,
      Switzerland.
FAU - Karamitopoulou, Eva
AU  - Karamitopoulou E
AD  - Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern,
      Switzerland.
FAU - Noordermeer, Daan
AU  - Noordermeer D
AD  - Swiss Institute of Cancer Research, School of Life Sciences, Swiss Federal
      Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland.
FAU - Peng, Mei-Wen
AU  - Peng MW
AD  - Swiss Institute of Cancer Research, School of Life Sciences, Swiss Federal
      Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland.
FAU - Piersigilli, Alessandra
AU  - Piersigilli A
AD  - Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern,
      Switzerland; School of Life Science, Swiss Federal Institute of Technology
      Lausanne (EPFL), 1015 Lausanne, Switzerland.
FAU - Perren, Aurel
AU  - Perren A
AD  - Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern,
      Switzerland.
FAU - Zlobec, Inti
AU  - Zlobec I
AD  - Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern,
      Switzerland.
FAU - Robinson, Hugh
AU  - Robinson H
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK.
FAU - Iruela-Arispe, M Luisa
AU  - Iruela-Arispe ML
AD  - Department of Molecular, Cell and Developmental Biology, Jonsson Comprehensive
      Cancer Center and Molecular Biology Institute, University of California, Los
      Angeles, CA 90095, USA.
FAU - Hanahan, Douglas
AU  - Hanahan D
AD  - Swiss Institute of Cancer Research, School of Life Sciences, Swiss Federal
      Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland. Electronic
      address: douglas.hanahan@epfl.ch.
LA  - eng
PT  - Journal Article
DEP - 20180309
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - FMRP
OT  - GKAP/Dlgap1
OT  - GluN2b/NR2b/Grin2b
OT  - HSF1
OT  - MK801
OT  - NMDAR
OT  - RIP1Tag2
OT  - cancer modifier
OT  - glutamate receptor
OT  - memantine
OT  - pancreatic ductal adenocarcinoma (PDAC)
EDAT- 2018/04/03 06:00
MHDA- 2018/04/03 06:00
CRDT- 2018/04/03 06:00
PHST- 2017/08/13 00:00 [received]
PHST- 2017/12/05 00:00 [revised]
PHST- 2018/02/19 00:00 [accepted]
PHST- 2018/04/03 06:00 [entrez]
PHST- 2018/04/03 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
AID - S1535-6108(18)30064-3 [pii]
AID - 10.1016/j.ccell.2018.02.011 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Mar 9. pii: S1535-6108(18)30064-3. doi:
      10.1016/j.ccell.2018.02.011.

PMID- 29576375
OWN - NLM
STAT- Publisher
LR  - 20180326
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Mar 8
TI  - Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
LID - S1535-6108(18)30063-1 [pii]
LID - 10.1016/j.ccell.2018.02.010 [doi]
AB  - With the use of a mouse model expressing human Fc-gamma receptors (FcgammaRs), we
      demonstrated that antibodies with isotypes equivalent to ipilimumab and
      tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo,
      increasing the CD8(+) to Treg cell ratio and promoting tumor rejection.
      Antibodies with improved FcgammaR binding profiles drove superior anti-tumor
      responses and survival. In patients with advanced melanoma, response to
      ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such
      activity only appeared relevant in the context of inflamed tumors, explaining the
      modest response rates observed in the clinical setting. Our data suggest that the
      activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of
      FcgammaR binding, whereas poorly infiltrated tumors will likely require
      combination approaches.
CI  - Copyright (c) 2018 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Arce Vargas, Frederick
AU  - Arce Vargas F
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Furness, Andrew J S
AU  - Furness AJS
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK; The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Litchfield, Kevin
AU  - Litchfield K
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London
      NW1 1AT, UK.
FAU - Joshi, Kroopa
AU  - Joshi K
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK; The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Rosenthal, Rachel
AU  - Rosenthal R
AD  - Bill Lyons Informatics Centre, UCL Cancer Institute, London WC1E 6DD, UK; Cancer 
      Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E
      6DD, UK.
FAU - Ghorani, Ehsan
AU  - Ghorani E
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Solomon, Isabelle
AU  - Solomon I
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Lesko, Marta H
AU  - Lesko MH
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Ruef, Nora
AU  - Ruef N
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Roddie, Claire
AU  - Roddie C
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Henry, Jake Y
AU  - Henry JY
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Spain, Lavinia
AU  - Spain L
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Ben Aissa, Assma
AU  - Ben Aissa A
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Georgiou, Andrew
AU  - Georgiou A
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Wong, Yien Ning Sophia
AU  - Wong YNS
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK.
FAU - Smith, Myles
AU  - Smith M
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Strauss, Dirk
AU  - Strauss D
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Hayes, Andrew
AU  - Hayes A
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Nicol, David
AU  - Nicol D
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - O'Brien, Tim
AU  - O'Brien T
AD  - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK.
FAU - Martensson, Linda
AU  - Martensson L
AD  - BioInvent International AB, 223 70 Lund, Sweden.
FAU - Ljungars, Anne
AU  - Ljungars A
AD  - BioInvent International AB, 223 70 Lund, Sweden.
FAU - Teige, Ingrid
AU  - Teige I
AD  - BioInvent International AB, 223 70 Lund, Sweden.
FAU - Frendeus, Bjorn
AU  - Frendeus B
AD  - BioInvent International AB, 223 70 Lund, Sweden.
CN  - TRACERx Melanoma
CN  - TRACERx Renal
CN  - TRACERx Lung consortia
FAU - Pule, Martin
AU  - Pule M
AD  - Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
FAU - Marafioti, Teresa
AU  - Marafioti T
AD  - Department of Cellular Pathology, University College London Hospital, London NW1 
      2BU, UK.
FAU - Gore, Martin
AU  - Gore M
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Larkin, James
AU  - Larkin J
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Turajlic, Samra
AU  - Turajlic S
AD  - The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Translational Cancer 
      Therapeutics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
FAU - Swanton, Charles
AU  - Swanton C
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London
      NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer
      Institute, London WC1E 6DD, UK; Translational Cancer Therapeutics Laboratory, UCL
      Cancer Institute, London WC1E 6DD, UK.
FAU - Peggs, Karl S
AU  - Peggs KS
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK. Electronic address: k.peggs@ucl.ac.uk.
FAU - Quezada, Sergio A
AU  - Quezada SA
AD  - Cancer Immunology Unit, University College London (UCL) Cancer Institute, London 
      WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London
      WC1E 6DD, UK. Electronic address: s.quezada@ucl.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20180308
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - CTLA-4
OT  - Fc-gamma receptors
OT  - IgG subclass
OT  - antibody-dependent cell-mediated cytotoxicity
OT  - immune checkpoints
OT  - immune regulatory antibodies
OT  - ipilimumab
OT  - regulatory T cell depletion
OT  - tremelimumab
OT  - tumor immunotherapy
IR  - Harrington K
FIR - Harrington, Kevin
IR  - Melcher A
FIR - Melcher, Alan
IR  - Wotherspoon A
FIR - Wotherspoon, Andrew
IR  - Francis N
FIR - Francis, Nicholas
IR  - Challacombe B
FIR - Challacombe, Ben
IR  - Fernando A
FIR - Fernando, Archana
IR  - Hazell S
FIR - Hazell, Steve
IR  - Chandra A
FIR - Chandra, Ashish
IR  - Pickering L
FIR - Pickering, Lisa
IR  - Lynch J
FIR - Lynch, Joanna
IR  - Rudman S
FIR - Rudman, Sarah
IR  - Chowdhury S
FIR - Chowdhury, Simon
IR  - Harrison-Phipps K
FIR - Harrison-Phipps, Karen
IR  - Varia M
FIR - Varia, Mary
IR  - Horsfield C
FIR - Horsfield, Catherine
IR  - Polson A
FIR - Polson, Alexander
IR  - Stamp G
FIR - Stamp, Gordon
IR  - O'Donnell M
FIR - O'Donnell, Marie
IR  - Drake W
FIR - Drake, William
IR  - Hill P
FIR - Hill, Peter
IR  - Hrouda D
FIR - Hrouda, David
IR  - Mayer E
FIR - Mayer, Eric
IR  - Olsburgh J
FIR - Olsburgh, Jonathan
IR  - Kooiman G
FIR - Kooiman, Gordon
IR  - O'Connor K
FIR - O'Connor, Kevin
IR  - Stewart G
FIR - Stewart, Grant
IR  - Aitchison M
FIR - Aitchison, Michael
IR  - Tran M
FIR - Tran, Maxine
IR  - Fotiadis N
FIR - Fotiadis, Nicos
IR  - Verma H
FIR - Verma, Hema
IR  - Lopez J
FIR - Lopez, Jose
IR  - Lester J
FIR - Lester, Jason
IR  - Morgan F
FIR - Morgan, Fiona
IR  - Kornaszewska M
FIR - Kornaszewska, Malgorzata
IR  - Attanoos R
FIR - Attanoos, Richard
IR  - Adams H
FIR - Adams, Haydn
IR  - Davies H
FIR - Davies, Helen
IR  - Fennell D
FIR - Fennell, Dean
IR  - Shaw J
FIR - Shaw, Jacqui
IR  - Le Quesne J
FIR - Le Quesne, John
IR  - Nakas A
FIR - Nakas, Apostolos
IR  - Rathinam S
FIR - Rathinam, Sridhar
IR  - Monteiro W
FIR - Monteiro, William
IR  - Marshall H
FIR - Marshall, Hilary
IR  - Nelson L
FIR - Nelson, Louise
IR  - Bennett J
FIR - Bennett, Jonathan
IR  - Riley J
FIR - Riley, Joan
IR  - Primrose L
FIR - Primrose, Lindsay
IR  - Martinson L
FIR - Martinson, Luke
IR  - Anand G
FIR - Anand, Girija
IR  - Khan S
FIR - Khan, Sajid
IR  - Nicolson M
FIR - Nicolson, Marianne
IR  - Kerr K
FIR - Kerr, Keith
IR  - Palmer S
FIR - Palmer, Shirley
IR  - Remmen H
FIR - Remmen, Hardy
IR  - Miller J
FIR - Miller, Joy
IR  - Buchan K
FIR - Buchan, Keith
IR  - Chetty M
FIR - Chetty, Mahendran
IR  - Gomersall L
FIR - Gomersall, Lesley
IR  - Lock S
FIR - Lock, Sara
IR  - Naidu B
FIR - Naidu, Babu
IR  - Langman G
FIR - Langman, Gerald
IR  - Trotter S
FIR - Trotter, Simon
IR  - Bellamy M
FIR - Bellamy, Mary
IR  - Bancroft H
FIR - Bancroft, Hollie
IR  - Kerr A
FIR - Kerr, Amy
IR  - Kadiri S
FIR - Kadiri, Salma
IR  - Webb J
FIR - Webb, Joanne
IR  - Middleton G
FIR - Middleton, Gary
IR  - Djearaman M
FIR - Djearaman, Madava
IR  - Summers Y
FIR - Summers, Yvonne
IR  - Califano R
FIR - Califano, Raffaele
IR  - Taylor P
FIR - Taylor, Paul
IR  - Shah R
FIR - Shah, Rajesh
IR  - Krysiak P
FIR - Krysiak, Piotr
IR  - Rammohan K
FIR - Rammohan, Kendadai
IR  - Fontaine E
FIR - Fontaine, Eustace
IR  - Booton R
FIR - Booton, Richard
IR  - Evison M
FIR - Evison, Matthew
IR  - Crosbie P
FIR - Crosbie, Phil
IR  - Moss S
FIR - Moss, Stuart
IR  - Idries F
FIR - Idries, Faiza
IR  - Novasio J
FIR - Novasio, Juliette
IR  - Joseph L
FIR - Joseph, Leena
IR  - Bishop P
FIR - Bishop, Paul
IR  - Chaturvedi A
FIR - Chaturvedi, Anshuman
IR  - Marie Quinn A
FIR - Marie Quinn, Anne
IR  - Doran H
FIR - Doran, Helen
IR  - Leek A
FIR - Leek, Angela
IR  - Harrison P
FIR - Harrison, Phil
IR  - Moore K
FIR - Moore, Katrina
IR  - Waddington R
FIR - Waddington, Rachael
IR  - Blackhall F
FIR - Blackhall, Fiona
IR  - Rogan J
FIR - Rogan, Jane
IR  - Smith E
FIR - Smith, Elaine
IR  - Dive C
FIR - Dive, Caroline
IR  - Brady G
FIR - Brady, Ged
IR  - Rothwell D
FIR - Rothwell, Dominic
IR  - Gulati S
FIR - Gulati, Sakshi
IR  - Chemie F
FIR - Chemie, Francesca
IR  - Tugwood J
FIR - Tugwood, Jonathan
IR  - Pierce J
FIR - Pierce, Jackie
IR  - Lawrence D
FIR - Lawrence, David
IR  - Hayward M
FIR - Hayward, Martin
IR  - Panagiotopoulos N
FIR - Panagiotopoulos, Nikolaos
IR  - George R
FIR - George, Robert
IR  - Patrini D
FIR - Patrini, Davide
IR  - Falzon M
FIR - Falzon, Mary
IR  - Borg E
FIR - Borg, Elaine
IR  - Khiroya R
FIR - Khiroya, Reena
IR  - Jamal-Hanjani M
FIR - Jamal-Hanjani, Mariam
IR  - Wilson G
FIR - Wilson, Gareth
IR  - Juul Birkbak N
FIR - Juul Birkbak, Nicolai
IR  - Watkins T
FIR - Watkins, Thomas
IR  - McGranahan N
FIR - McGranahan, Nicholas
IR  - Abbosh C
FIR - Abbosh, Christopher
IR  - Horswell S
FIR - Horswell, Stuart
IR  - Mitter R
FIR - Mitter, Richard
IR  - Escudero M
FIR - Escudero, Mickael
IR  - Stewart A
FIR - Stewart, Aengus
IR  - Rowan A
FIR - Rowan, Andrew
IR  - Hiley C
FIR - Hiley, Crispin
IR  - Goldman J
FIR - Goldman, Jacki
IR  - Ahmed A
FIR - Ahmed, Asia
IR  - Taylor M
FIR - Taylor, Magali
IR  - Choudhary J
FIR - Choudhary, Junaid
IR  - Shaw P
FIR - Shaw, Penny
IR  - Veeriah R
FIR - Veeriah, Raju
IR  - Czyzewska-Khan J
FIR - Czyzewska-Khan, Justyna
IR  - Johnson D
FIR - Johnson, Diana
IR  - Laycock J
FIR - Laycock, Joanne
IR  - Hynds R
FIR - Hynds, Robert
IR  - Werner Sunderland M
FIR - Werner Sunderland, Mariana
IR  - Reading J
FIR - Reading, James
IR  - Novelli M
FIR - Novelli, Marco
IR  - Oukrif D
FIR - Oukrif, Dahmane
IR  - Janes S
FIR - Janes, Sam
IR  - Forster M
FIR - Forster, Martin
IR  - Ahmad T
FIR - Ahmad, Tanya
IR  - Ming Lee S
FIR - Ming Lee, Siow
IR  - van Loo P
FIR - van Loo, Peter
IR  - Herrero J
FIR - Herrero, Javier
IR  - Hartley J
FIR - Hartley, John
IR  - Kevin Stone R
FIR - Kevin Stone, Richard
IR  - Denner T
FIR - Denner, Tamara
IR  - Costa M
FIR - Costa, Marta
IR  - Begum S
FIR - Begum, Sharmin
IR  - Phillimore B
FIR - Phillimore, Ben
IR  - Chambers T
FIR - Chambers, Tim
IR  - Nye E
FIR - Nye, Emma
IR  - Ward S
FIR - Ward, Sophie
IR  - Elgar G
FIR - Elgar, Greg
IR  - Al-Bakir M
FIR - Al-Bakir, Maise
IR  - Carnell D
FIR - Carnell, Dawn
IR  - Mendes R
FIR - Mendes, Ruheena
IR  - George J
FIR - George, Jeremy
IR  - Navani N
FIR - Navani, Neal
IR  - Papadatos-Pastos D
FIR - Papadatos-Pastos, Dionysis
IR  - Scarci M
FIR - Scarci, Marco
IR  - Gorman P
FIR - Gorman, Pat
IR  - Lowe H
FIR - Lowe, Helen
IR  - Ensell L
FIR - Ensell, Leah
IR  - Moore D
FIR - Moore, David
IR  - MacKenzie M
FIR - MacKenzie, Mairead
IR  - Wilcox M
FIR - Wilcox, Maggie
IR  - Bell H
FIR - Bell, Harriet
IR  - Hackshaw A
FIR - Hackshaw, Allan
IR  - Ngai Y
FIR - Ngai, Yenting
IR  - Smith S
FIR - Smith, Sean
IR  - Gower N
FIR - Gower, Nicole
IR  - Ottensmeier C
FIR - Ottensmeier, Christian
IR  - Chee S
FIR - Chee, Serena
IR  - Johnson B
FIR - Johnson, Benjamin
IR  - Alzetani A
FIR - Alzetani, Aiman
IR  - Shaw E
FIR - Shaw, Emily
IR  - Lim E
FIR - Lim, Eric
IR  - De Sousa P
FIR - De Sousa, Paulo
IR  - Tavares Barbosa M
FIR - Tavares Barbosa, Monica
IR  - Nicholson A
FIR - Nicholson, Andrew
IR  - Bowman A
FIR - Bowman, Alex
IR  - Jordan S
FIR - Jordan, Simon
IR  - Rice A
FIR - Rice, Alexandra
IR  - Raubenheimer H
FIR - Raubenheimer, Hilgardt
IR  - Proli C
FIR - Proli, Chiara
IR  - Elena Cufari M
FIR - Elena Cufari, Maria
IR  - Carlo Ronquillo J
FIR - Carlo Ronquillo, John
IR  - Kwayie A
FIR - Kwayie, Angela
IR  - Bhayani H
FIR - Bhayani, Harshil
IR  - Hamilton M
FIR - Hamilton, Morag
IR  - Bakar Y
FIR - Bakar, Yusura
IR  - Mensah N
FIR - Mensah, Natalie
IR  - Ambrose L
FIR - Ambrose, Lyn
IR  - Devaraj A
FIR - Devaraj, Anand
IR  - Buderi S
FIR - Buderi, Silviu
IR  - Finch J
FIR - Finch, Jonathan
IR  - Azcarate L
FIR - Azcarate, Leire
IR  - Chavan H
FIR - Chavan, Hema
IR  - Green S
FIR - Green, Sophie
IR  - Mashinga H
FIR - Mashinga, Hillaria
IR  - Lau K
FIR - Lau, Kelvin
IR  - Sheaff M
FIR - Sheaff, Michael
IR  - Schmid P
FIR - Schmid, Peter
IR  - Conibear J
FIR - Conibear, John
IR  - Ezhil V
FIR - Ezhil, Veni
IR  - Prakash V
FIR - Prakash, Vineet
IR  - Danson S
FIR - Danson, Sarah
IR  - Bury J
FIR - Bury, Jonathan
IR  - Edwards J
FIR - Edwards, John
IR  - Hill J
FIR - Hill, Jennifer
IR  - Matthews S
FIR - Matthews, Sue
IR  - Kitsanta Y
FIR - Kitsanta, Yota
IR  - Suvarna K
FIR - Suvarna, Kim
IR  - Shackcloth M
FIR - Shackcloth, Michael
IR  - Gosney J
FIR - Gosney, John
IR  - Postmus P
FIR - Postmus, Pieter
IR  - Feeney S
FIR - Feeney, Sarah
IR  - Asante-Siaw J
FIR - Asante-Siaw, Julius
IR  - Russell P
FIR - Russell, Peter
IR  - Light T
FIR - Light, Teresa
IR  - Horey T
FIR - Horey, Tracey
IR  - Blyth K
FIR - Blyth, Kevin
IR  - Dick C
FIR - Dick, Craig
IR  - Kirk A
FIR - Kirk, Alan
EDAT- 2018/03/27 06:00
MHDA- 2018/03/27 06:00
CRDT- 2018/03/27 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/12/13 00:00 [revised]
PHST- 2018/02/15 00:00 [accepted]
PHST- 2018/03/27 06:00 [entrez]
PHST- 2018/03/27 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
AID - S1535-6108(18)30063-1 [pii]
AID - 10.1016/j.ccell.2018.02.010 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Mar 8. pii: S1535-6108(18)30063-1. doi:
      10.1016/j.ccell.2018.02.010.

PMID- 29576376
OWN - NLM
STAT- Publisher
LR  - 20180326
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Mar 3
TI  - Complex Interplay between Epitope Specificity and Isotype Dictates the Biological
      Activity of Anti-human CD40 Antibodies.
LID - S1535-6108(18)30062-X [pii]
LID - 10.1016/j.ccell.2018.02.009 [doi]
AB  - Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function 
      hold promise as therapeutics for cancer and autoimmunity. Rules governing their
      diverse range of functions, however, are lacking. Here we determined
      characteristics of nine hCD40 mAbs engaging epitopes throughout the CD40
      extracellular region expressed as varying isotypes. All mAb formats were strong
      agonists when hyper-crosslinked; however, only those binding the membrane-distal 
      cysteine-rich domain 1 (CRD1) retained agonistic activity with physiological Fc
      gamma receptor crosslinking or as human immunoglobulin G2 isotype; agonistic
      activity decreased as epitopes drew closer to the membrane. In addition, all
      CRD2-4 binding mAbs blocked CD40 ligand interaction and were potent antagonists. 
      Thus, the membrane distal CRD1 provides a region of choice for selecting CD40
      agonists while CRD2-4 provides antagonistic epitopes.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Yu, Xiaojie
AU  - Yu X
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Chan, H T Claude
AU  - Chan HTC
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Orr, Christian M
AU  - Orr CM
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Dadas, Osman
AU  - Dadas O
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Booth, Steven G
AU  - Booth SG
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Dahal, Lekh N
AU  - Dahal LN
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Penfold, Christine A
AU  - Penfold CA
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - O'Brien, Lyn
AU  - O'Brien L
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Mockridge, C Ian
AU  - Mockridge CI
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - French, Ruth R
AU  - French RR
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - Duriez, Patrick
AU  - Duriez P
AD  - Protein Core Facility, University of Southampton Faculty of Medicine, Southampton
      SO16 6YD, UK.
FAU - Douglas, Leon R
AU  - Douglas LR
AD  - Protein Core Facility, University of Southampton Faculty of Medicine, Southampton
      SO16 6YD, UK.
FAU - Pearson, Arwen R
AU  - Pearson AR
AD  - Hamburg Centre for Ultrafast Imaging & Institute for Nanostructure and Solid
      State Physics, University of Hamburg, 20146 Hamburg, Germany.
FAU - Cragg, Mark S
AU  - Cragg MS
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK; Institute for Life Sciences,
      University of Southampton, Southampton SO17 1BJ, UK.
FAU - Tews, Ivo
AU  - Tews I
AD  - Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK;
      Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.
FAU - Glennie, Martin J
AU  - Glennie MJ
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK.
FAU - White, Ann L
AU  - White AL
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton
      Faculty of Medicine, Southampton SO16 6YD, UK. Electronic address:
      ann.white@ucb.com.
LA  - eng
PT  - Journal Article
DEP - 20180303
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - CD40
OT  - Fc receptors
OT  - TNFR
OT  - agonist
OT  - antagonist
OT  - crystal structure
OT  - epitope
OT  - immunotherapy
OT  - isotype
OT  - monoclonal antibody
EDAT- 2018/03/27 06:00
MHDA- 2018/03/27 06:00
CRDT- 2018/03/27 06:00
PHST- 2017/10/24 00:00 [received]
PHST- 2017/12/20 00:00 [revised]
PHST- 2018/02/15 00:00 [accepted]
PHST- 2018/03/27 06:00 [entrez]
PHST- 2018/03/27 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
AID - S1535-6108(18)30062-X [pii]
AID - 10.1016/j.ccell.2018.02.009 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Mar 3. pii: S1535-6108(18)30062-X. doi:
      10.1016/j.ccell.2018.02.009.

PMID- 29551594
OWN - NLM
STAT- Publisher
LR  - 20180319
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
DP  - 2018 Mar 1
TI  - Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible
      Therapeutic Target in the Multiple Myeloma Microenvironment.
LID - S1535-6108(18)30060-6 [pii]
LID - 10.1016/j.ccell.2018.02.007 [doi]
AB  - Tumor-promoting inflammation and avoiding immune destruction are hallmarks of
      cancer. Here, we demonstrate that the pro-inflammatory cytokine interleukin
      (IL)-18 is critically involved in these hallmarks in multiple myeloma (MM). Mice 
      deficient for IL-18 were remarkably protected from Vk( *)MYC MM progression in a 
      CD8(+) T cell-dependent manner. The MM-niche-derived IL-18 drove generation of
      myeloid-derived suppressor cells (MDSCs), leading to accelerated disease
      progression. A global transcriptome analysis of the immune microenvironment in 73
      MM patients strongly supported the negative impact of IL-18-driven MDSCs on T
      cell responses. Strikingly, high levels of bone marrow plasma IL-18 were
      associated with poor overall survival in MM patients. Furthermore, our
      preclinical studies suggested that IL-18 could be a potential therapeutic target 
      in MM.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Nakamura, Kyohei
AU  - Nakamura K
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, 4006 QLD, Australia.
FAU - Kassem, Sahar
AU  - Kassem S
AD  - Cancer Research Center of Toulouse, INSERM UMR 1037, 2 av Hubert Curien, 31037
      Toulouse, France.
FAU - Cleynen, Alice
AU  - Cleynen A
AD  - Institut Montpellierain Alexander Grothendieck, CNRS, University Montpellier,
      34095 Montpellier, France.
FAU - Chretien, Marie-Lorraine
AU  - Chretien ML
AD  - Cancer Research Center of Toulouse, INSERM UMR 1037, 2 av Hubert Curien, 31037
      Toulouse, France; University Hospital, Dijon, 21000 Dijon, France.
FAU - Guillerey, Camille
AU  - Guillerey C
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, 4006 QLD, Australia; School of Medicine,
      University of Queensland, St Lucia 4006 QLD, Australia.
FAU - Putz, Eva Maria
AU  - Putz EM
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, 4006 QLD, Australia.
FAU - Bald, Tobias
AU  - Bald T
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, 4006 QLD, Australia.
FAU - Forster, Irmgard
AU  - Forster I
AD  - Immunology and Environment, LIMES Institute, University of Bonn, 53115 Bonn,
      Germany.
FAU - Vuckovic, Slavica
AU  - Vuckovic S
AD  - School of Medicine, University of Queensland, St Lucia 4006 QLD, Australia;
      Department of Bone Marrow Transplantation, QIMR Berghofer Medical Research
      Institute, Herston, 4006 QLD, Australia.
FAU - Hill, Geoffrey R
AU  - Hill GR
AD  - Department of Bone Marrow Transplantation, QIMR Berghofer Medical Research
      Institute, Herston, 4006 QLD, Australia.
FAU - Masters, Seth L
AU  - Masters SL
AD  - Division of Inflammation, The Walter and Eliza Hall Institute of Medical
      Research, Parkville 3052, Australia; Department of Medical Biology, The
      University of Melbourne, Parkville 3010, Australia.
FAU - Chesi, Marta
AU  - Chesi M
AD  - Mayo Clinic in Arizona, Phoenix, AZ 85054, USA.
FAU - Bergsagel, P Leif
AU  - Bergsagel PL
AD  - Mayo Clinic in Arizona, Phoenix, AZ 85054, USA.
FAU - Avet-Loiseau, Herve
AU  - Avet-Loiseau H
AD  - Cancer Research Center of Toulouse, INSERM UMR 1037, 2 av Hubert Curien, 31037
      Toulouse, France; Institut Universitaire du Cancer, Toulouse 31100, France.
FAU - Martinet, Ludovic
AU  - Martinet L
AD  - Cancer Research Center of Toulouse, INSERM UMR 1037, 2 av Hubert Curien, 31037
      Toulouse, France. Electronic address: ludovic.martinet@inserm.fr.
FAU - Smyth, Mark J
AU  - Smyth MJ
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, 4006 QLD, Australia; School of Medicine,
      University of Queensland, St Lucia 4006 QLD, Australia. Electronic address:
      mark.smyth@qimrberghofer.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20180301
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - IL-18
OT  - cancer
OT  - immunosuppression
OT  - immunotherapy
OT  - inflammasome
OT  - inflammation
OT  - myeloid-derived suppressor cells
OT  - myeloma
OT  - tumor microenvironment
EDAT- 2018/03/20 06:00
MHDA- 2018/03/20 06:00
CRDT- 2018/03/20 06:00
PHST- 2017/09/23 00:00 [received]
PHST- 2017/12/27 00:00 [revised]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/03/20 06:00 [entrez]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2018/03/20 06:00 [medline]
AID - S1535-6108(18)30060-6 [pii]
AID - 10.1016/j.ccell.2018.02.007 [doi]
PST - aheadofprint
SO  - Cancer Cell. 2018 Mar 1. pii: S1535-6108(18)30060-6. doi:
      10.1016/j.ccell.2018.02.007.

PMID- 29438700
OWN - NLM
STAT- In-Data-Review
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Targeting the Senescence-Overriding Cooperative Activity of Structurally
      Unrelated H3K9 Demethylases in Melanoma.
PG  - 322-336.e8
LID - S1535-6108(18)30002-3 [pii]
LID - 10.1016/j.ccell.2018.01.002 [doi]
AB  - Oncogene-induced senescence, e.g., in melanocytic nevi, terminates the expansion 
      of pre-malignant cells via transcriptional silencing of proliferation-related
      genes due to decoration of their promoters with repressive trimethylated histone 
      H3 lysine 9 (H3K9) marks. We show here that structurally distinct H3K9-active
      demethylases-the lysine-specific demethylase-1 (LSD1) and several Jumonji C
      domain-containing moieties (such as JMJD2C)-disable senescence and permit
      Ras/Braf-evoked transformation. In mouse and zebrafish models, enforced LSD1 or
      JMJD2C expression promoted Braf-V600E-driven melanomagenesis. A large subset of
      established melanoma cell lines and primary human melanoma samples presented with
      a collective upregulation of related and unrelated H3K9 demethylase activities,
      whose targeted inhibition restored senescence, even in Braf inhibitor-resistant
      melanomas, evoked secondary immune effects and controlled tumor growth in vivo.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Yu, Yong
AU  - Yu Y
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
FAU - Schleich, Kolja
AU  - Schleich K
AD  - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical
      Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and
      Molekulares Krebsforschungszentrum, 13353 Berlin, Germany.
FAU - Yue, Bin
AU  - Yue B
AD  - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical
      Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and
      Molekulares Krebsforschungszentrum, 13353 Berlin, Germany.
FAU - Ji, Sujuan
AU  - Ji S
AD  - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical
      Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and
      Molekulares Krebsforschungszentrum, 13353 Berlin, Germany.
FAU - Lohneis, Philipp
AU  - Lohneis P
AD  - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Institute
      of Pathology, 10117 Berlin, Germany.
FAU - Kemper, Kristel
AU  - Kemper K
AD  - Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 
      1066 CX Amsterdam, the Netherlands.
FAU - Silvis, Mark R
AU  - Silvis MR
AD  - Department of Surgery, University of Utah Health Sciences Center & Huntsman
      Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
FAU - Qutob, Nouar
AU  - Qutob N
AD  - Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot
      7610001, Israel.
FAU - van Rooijen, Ellen
AU  - van Rooijen E
AD  - Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric 
      Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute,
      Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and
      Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
FAU - Werner-Klein, Melanie
AU  - Werner-Klein M
AD  - Regensburg Center for Interventional Immunology (RCI) and University Medical
      Center of Regensburg, 93053 Regensburg, Germany; Experimental Medicine and
      Therapy Research, University of Regensburg, 93053 Regensburg, Germany.
FAU - Li, Lianjie
AU  - Li L
AD  - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical
      Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and
      Molekulares Krebsforschungszentrum, 13353 Berlin, Germany.
FAU - Dhawan, Dhriti
AU  - Dhawan D
AD  - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical
      Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and
      Molekulares Krebsforschungszentrum, 13353 Berlin, Germany.
FAU - Meierjohann, Svenja
AU  - Meierjohann S
AD  - University of Wurzburg, Physiological Chemistry, Biocenter, 97074 Wurzburg,
      Germany.
FAU - Reimann, Maurice
AU  - Reimann M
AD  - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical
      Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and
      Molekulares Krebsforschungszentrum, 13353 Berlin, Germany.
FAU - Elkahloun, Abdel
AU  - Elkahloun A
AD  - National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
FAU - Treitschke, Steffi
AU  - Treitschke S
AD  - Fraunhofer-Institute for Toxicology and Experimental Medicine, 93053 Regensburg, 
      Germany.
FAU - Dorken, Bernd
AU  - Dorken B
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie 
      Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow 
      Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, Germany; Deutsches 
      Konsortium fur Translationale Krebsforschung (German Cancer Consortium), Partner 
      Site Berlin, Germany.
FAU - Speck, Christian
AU  - Speck C
AD  - Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College
      London, and MRC London Institute of Medical Sciences (LMS), London W12 0NN, UK.
FAU - Mallette, Frederick A
AU  - Mallette FA
AD  - Department of Medicine, Universite de Montreal, Maisonneuve-Rosemont Hospital
      Research Centre, Montreal, QC H1T 2M4, Canada.
FAU - Zon, Leonard I
AU  - Zon LI
AD  - Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric 
      Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute,
      Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and
      Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
FAU - Holmen, Sheri L
AU  - Holmen SL
AD  - Department of Surgery, University of Utah Health Sciences Center & Huntsman
      Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
FAU - Peeper, Daniel S
AU  - Peeper DS
AD  - Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 
      1066 CX Amsterdam, the Netherlands.
FAU - Samuels, Yardena
AU  - Samuels Y
AD  - Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot
      7610001, Israel.
FAU - Schmitt, Clemens A
AU  - Schmitt CA
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie 
      Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow 
      Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, Germany; Deutsches 
      Konsortium fur Translationale Krebsforschung (German Cancer Consortium), Partner 
      Site Berlin, Germany. Electronic address: clemens.schmitt@charite.de.
FAU - Lee, Soyoung
AU  - Lee S
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie 
      Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow 
      Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, Germany; Deutsches 
      Konsortium fur Translationale Krebsforschung (German Cancer Consortium), Partner 
      Site Berlin, Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - H3K9
OT  - JMJD2C
OT  - LSD1
OT  - Ras/Braf
OT  - animal models
OT  - cellular senescence
OT  - histone demethylation
OT  - melanoma
OT  - patient-derived xenograft
OT  - targeted therapy
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2015/12/26 00:00 [received]
PHST- 2017/10/16 00:00 [revised]
PHST- 2018/01/04 00:00 [accepted]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30002-3 [pii]
AID - 10.1016/j.ccell.2018.01.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):322-336.e8. doi: 10.1016/j.ccell.2018.01.002.

PMID- 29438699
OWN - NLM
STAT- In-Data-Review
LR  - 20180216
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - DNA Methylation Patterns Separate Senescence from Transformation Potential and
      Indicate Cancer Risk.
PG  - 309-321.e5
LID - S1535-6108(18)30008-4 [pii]
LID - 10.1016/j.ccell.2018.01.008 [doi]
AB  - Overall shared DNA methylation patterns between senescence (Sen) and cancers have
      led to the model that tumor-promoting epigenetic patterns arise through
      senescence. We show that transformation-associated methylation changes arise
      stochastically and independently of programmatic changes during senescence.
      Promoter hypermethylation events in transformation involve primarily pro-survival
      and developmental genes, similarly modified in primary tumors.
      Senescence-associated hypermethylation mainly involves metabolic regulators and
      appears early in proliferating "near-senescent" cells, which can be immortalized 
      but are refractory to transformation. Importantly, a subset of
      transformation-associated hypermethylated developmental genes exhibits highest
      methylation gains at all age-associated cancer risk states across tissue types.
      These epigenetic changes favoring cell self-renewal and survival, arising during 
      tissue aging, are fundamentally important for stratifying cancer risk and
      concepts for cancer prevention.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Xie, Wenbing
AU  - Xie W
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Kagiampakis, Ioannis
AU  - Kagiampakis I
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Pan, Lixia
AU  - Pan L
AD  - Laboratory of Biochemistry and Molecular Biology, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Zhang, Yang W
AU  - Zhang YW
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Murphy, Lauren
AU  - Murphy L
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Tao, Yong
AU  - Tao Y
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Kong, Xiangqian
AU  - Kong X
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Kang, Byunghak
AU  - Kang B
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Xia, Limin
AU  - Xia L
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Carvalho, Filipe L F
AU  - Carvalho FLF
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Sen, Subhojit
AU  - Sen S
AD  - UM-DAE Center for Excellence in Basic Sciences (CBS), Mumbai University, Mumbai
      400098, India.
FAU - Chiu Yen, Ray-Whay
AU  - Chiu Yen RW
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Zahnow, Cynthia A
AU  - Zahnow CA
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Ahuja, Nita
AU  - Ahuja N
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Baylin, Stephen B
AU  - Baylin SB
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA. Electronic address:
      sbaylin@jhmi.edu.
FAU - Easwaran, Hariharan
AU  - Easwaran H
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA. Electronic address:
      heaswar2@jhmi.edu.
LA  - eng
GR  - R01 CA170550/CA/NCI NIH HHS/United States
GR  - R01 CA185357/CA/NCI NIH HHS/United States
GR  - R21 CA212495/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5813821
MID - NIHMS936396
OTO - NOTNLM
OT  - DNA methylation
OT  - aging
OT  - cancer
OT  - cancer risk
OT  - epigenetic
OT  - malignant transformation
OT  - oncogene-induced senescence
OT  - promoter CpG-island
OT  - senescence
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PMCR- 2019/02/12 00:00
PHST- 2017/05/30 00:00 [received]
PHST- 2017/10/24 00:00 [revised]
PHST- 2018/01/17 00:00 [accepted]
PHST- 2019/02/12 00:00 [pmc-release]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30008-4 [pii]
AID - 10.1016/j.ccell.2018.01.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):309-321.e5. doi: 10.1016/j.ccell.2018.01.008.

PMID- 29438698
OWN - NLM
STAT- In-Data-Review
LR  - 20180227
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant
      Peripheral Nerve Sheath Tumorigenesis.
PG  - 292-308.e7
LID - S1535-6108(18)30005-9 [pii]
LID - 10.1016/j.ccell.2018.01.005 [doi]
AB  - Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive Schwann
      cell (SC)-lineage-derived sarcomas. Molecular events driving SC-to-MPNST
      transformation are incompletely understood. Here, we show that human MPNSTs
      exhibit elevated HIPPO-TAZ/YAP expression, and that TAZ/YAP hyperactivity in SCs 
      caused by Lats1/2 loss potently induces high-grade nerve-associated tumors with
      full penetrance. Lats1/2 deficiency reprograms SCs to a cancerous,
      progenitor-like phenotype and promotes hyperproliferation. Conversely, disruption
      of TAZ/YAP activity alleviates tumor burden in Lats1/2-deficient mice and
      inhibits human MPNST cell proliferation. Moreover, genome-wide profiling reveals 
      that TAZ/YAP-TEAD1 directly activates oncogenic programs, including
      platelet-derived growth factor receptor (PDGFR) signaling. Co-targeting TAZ/YAP
      and PDGFR pathways inhibits tumor growth. Thus, our findings establish a
      previously unrecognized convergence between Lats1/2-TAZ/YAP signaling and MPNST
      pathogenesis, revealing potential therapeutic targets in these untreatable
      tumors.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Wu, Lai Man Natalie
AU  - Wu LMN
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Deng, Yaqi
AU  - Deng Y
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Wang, Jincheng
AU  - Wang J
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Zhao, Chuntao
AU  - Zhao C
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Wang, Jiajia
AU  - Wang J
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Rao, Rohit
AU  - Rao R
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Xu, Lingli
AU  - Xu L
AD  - Key Laboratory of Birth Defects, Children's Hospital of Fudan University,
      Shanghai, China.
FAU - Zhou, Wenhao
AU  - Zhou W
AD  - Key Laboratory of Birth Defects, Children's Hospital of Fudan University,
      Shanghai, China.
FAU - Choi, Kwangmin
AU  - Choi K
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Rizvi, Tilat A
AU  - Rizvi TA
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Remke, Marc
AU  - Remke M
AD  - Departments of Pediatric Oncology, Neuropathology, Hematology, and Clinical
      Immunology, Medical Faculty, University Hospital Dusseldorf, Dusseldorf 40225,
      Germany; Department of Pediatric Neuro-Oncogenomics, German Cancer Consortium
      (DKTK) and German Cancer Research Center (DKFZ), Dusseldorf 40225, Germany.
FAU - Rubin, Joshua B
AU  - Rubin JB
AD  - Departments of Pediatrics and Neuroscience, Washington University School of
      Medicine, St. Louis, MO 63110, USA.
FAU - Johnson, Randy L
AU  - Johnson RL
AD  - Department of Cancer Biology, MD Anderson Cancer Center, University of Texas,
      Houston, TX 77054, USA.
FAU - Carroll, Thomas J
AU  - Carroll TJ
AD  - Departments of Internal Medicine and Molecular Biology, University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Stemmer-Rachamimov, Anat O
AU  - Stemmer-Rachamimov AO
AD  - Department of Pathology, Massachusetts General Hospital, Dana-Farber/Harvard
      Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
FAU - Wu, Jianqiang
AU  - Wu J
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Zheng, Yi
AU  - Zheng Y
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Xin, Mei
AU  - Xin M
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Ratner, Nancy
AU  - Ratner N
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Lu, Q Richard
AU  - Lu QR
AD  - Division of Experimental Hematology and Cancer Biology, Brain Tumor Center,
      Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Key
      Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai,
      China. Electronic address: richard.lu@cchmc.org.
LA  - eng
GR  - R01 NS072427/NS/NINDS NIH HHS/United States
GR  - R01 NS078092/NS/NINDS NIH HHS/United States
GR  - R01 NS075243/NS/NINDS NIH HHS/United States
GR  - R01 HL132211/HL/NHLBI NIH HHS/United States
GR  - R37 NS096359/NS/NINDS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5813693
MID - NIHMS934388
OTO - NOTNLM
OT  - Lats1/2
OT  - MPNST
OT  - PDGF signaling
OT  - Schwann cells
OT  - TAZ
OT  - YAP
OT  - hippo signaling
OT  - murine models
OT  - peripheral nerve sheath tumor
OT  - tumor suppressor
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PMCR- 2019/02/12 00:00
PHST- 2017/05/26 00:00 [received]
PHST- 2017/10/04 00:00 [revised]
PHST- 2018/01/08 00:00 [accepted]
PHST- 2019/02/12 00:00 [pmc-release]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30005-9 [pii]
AID - 10.1016/j.ccell.2018.01.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):292-308.e7. doi: 10.1016/j.ccell.2018.01.005.

PMID- 29438697
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early
      Thymic Progenitors.
PG  - 274-291.e8
LID - S1535-6108(18)30006-0 [pii]
LID - 10.1016/j.ccell.2018.01.006 [doi]
AB  - Lympho-myeloid restricted early thymic progenitors (ETPs) are postulated to be
      the cell of origin for ETP leukemias, a therapy-resistant leukemia associated
      with frequent co-occurrence of EZH2 and RUNX1 inactivating mutations, and
      constitutively activating signaling pathway mutations. In a mouse model, we
      demonstrate that Ezh2 and Runx1 inactivation targeted to early lymphoid
      progenitors causes a marked expansion of pre-leukemic ETPs, showing
      transcriptional signatures characteristic of ETP leukemia. Addition of a
      RAS-signaling pathway mutation (Flt3-ITD) results in an aggressive leukemia
      co-expressing myeloid and lymphoid genes, which can be established and propagated
      in vivo by the expanded ETPs. Both mouse and human ETP leukemias show sensitivity
      to BET inhibition in vitro and in vivo, which reverses aberrant gene expression
      induced by Ezh2 inactivation.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Booth, Christopher A G
AU  - Booth CAG
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Barkas, Nikolaos
AU  - Barkas N
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Neo, Wen Hao
AU  - Neo WH
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Boukarabila, Hanane
AU  - Boukarabila H
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Soilleux, Elizabeth J
AU  - Soilleux EJ
AD  - Division of Cellular and Molecular Pathology, Department of Pathology, University
      of Cambridge, Cambridge, UK.
FAU - Giotopoulos, George
AU  - Giotopoulos G
AD  - Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, UK; Department of
      Haematology, University of Cambridge, Cambridge, UK; Cambridge Institute for
      Medical Research, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK.
FAU - Farnoud, Noushin
AU  - Farnoud N
AD  - Center for Molecular Oncology, Center for Heme Malignancies and Department of
      Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York,
      NY 10065, USA.
FAU - Giustacchini, Alice
AU  - Giustacchini A
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; Department of Cell and Developmental Biology, University
      College London, London WC1E 6BT, UK.
FAU - Ashley, Neil
AU  - Ashley N
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Carrelha, Joana
AU  - Carrelha J
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Jamieson, Lauren
AU  - Jamieson L
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Atkinson, Deborah
AU  - Atkinson D
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Bouriez-Jones, Tiphaine
AU  - Bouriez-Jones T
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK.
FAU - Prinjha, Rab K
AU  - Prinjha RK
AD  - Epigenetics DPU, Oncology and Immuno-Inflammation Therapy Area Units,
      GlaxoSmithKline, Stevenage, UK.
FAU - Milne, Thomas A
AU  - Milne TA
AD  - MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine,
      Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK.
FAU - Teachey, David T
AU  - Teachey DT
AD  - Division of Oncology, Children's Hospital of Philadelphia and Department of
      Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia,
      PA, USA.
FAU - Papaemmanuil, Elli
AU  - Papaemmanuil E
AD  - Center for Molecular Oncology, Center for Heme Malignancies and Department of
      Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York,
      NY 10065, USA.
FAU - Huntly, Brian J P
AU  - Huntly BJP
AD  - Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, UK; Department of
      Haematology, University of Cambridge, Cambridge, UK; Cambridge Institute for
      Medical Research, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK.
FAU - Jacobsen, Sten Eirik W
AU  - Jacobsen SEW
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; Center for Hematology and Regenerative Medicine, Department
      of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital,
      SE-141 86 Stockholm, Sweden; Department of Cell and Molecular Biology, Karolinska
      Institutet, SE-171 77 Stockholm, Sweden. Electronic address:
      sten.jacobsen@imm.ox.ac.uk.
FAU - Mead, Adam J
AU  - Mead AJ
AD  - Haematopoietic Stem Cell Biology Laboratory, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; MRC Molecular Haematology Unit, MRC Weatherall Institute of
      Molecular Medicine, Radcliffe Department of Medicine, University of Oxford,
      Oxford OX3 9DS, UK; NIHR Biomedical Research Centre, Churchill Hospital, Oxford
      OX3 7LE, UK. Electronic address: adam.mead@imm.ox.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - BET inhibition
OT  - EZH2
OT  - FLT3-ITD
OT  - RUNX1
OT  - early thymic progenitor leukemia
OT  - early thymic progenitors
OT  - leukemia propagating cells
OT  - leukemic stem cells
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2016/08/04 00:00 [received]
PHST- 2017/11/13 00:00 [revised]
PHST- 2018/01/08 00:00 [accepted]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30006-0 [pii]
AID - 10.1016/j.ccell.2018.01.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.

PMID- 29438696
OWN - NLM
STAT- In-Data-Review
LR  - 20180314
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - The Integrated Genomic Landscape of Thymic Epithelial Tumors.
PG  - 244-258.e10
LID - S1535-6108(18)30003-5 [pii]
LID - 10.1016/j.ccell.2018.01.003 [doi]
AB  - Thymic epithelial tumors (TETs) are one of the rarest adult malignancies. Among
      TETs, thymoma is the most predominant, characterized by a unique association with
      autoimmune diseases, followed by thymic carcinoma, which is less common but more 
      clinically aggressive. Using multi-platform omics analyses on 117 TETs, we define
      four subtypes of these tumors defined by genomic hallmarks and an association
      with survival and World Health Organization histological subtype. We further
      demonstrate a marked prevalence of a thymoma-specific mutated oncogene, GTF2I,
      and explore its biological effects on multi-platform analysis. We further observe
      enrichment of mutations in HRAS, NRAS, and TP53. Last, we identify a molecular
      link between thymoma and the autoimmune disease myasthenia gravis, characterized 
      by tumoral overexpression of muscle autoantigens, and increased aneuploidy.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Radovich, Milan
AU  - Radovich M
AD  - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202,
      USA.
FAU - Pickering, Curtis R
AU  - Pickering CR
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Felau, Ina
AU  - Felau I
AD  - National Cancer Institute, Bethesda, MD 20892, USA.
FAU - Ha, Gavin
AU  - Ha G
AD  - Broad Institute, Cambridge, MA 02142, USA.
FAU - Zhang, Hailei
AU  - Zhang H
AD  - Broad Institute, Cambridge, MA 02142, USA.
FAU - Jo, Heejoon
AU  - Jo H
AD  - Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill,
      NC 27599, USA.
FAU - Hoadley, Katherine A
AU  - Hoadley KA
AD  - Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill,
      NC 27599, USA.
FAU - Anur, Pavana
AU  - Anur P
AD  - Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Zhang, Jiexin
AU  - Zhang J
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - McLellan, Mike
AU  - McLellan M
AD  - McDonnell Genome Institute at Washington University, St. Louis, MO 63108, USA.
FAU - Bowlby, Reanne
AU  - Bowlby R
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Matthew, Thomas
AU  - Matthew T
AD  - University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
FAU - Danilova, Ludmila
AU  - Danilova L
AD  - John Hopkins University, Baltimore, MD 21231, USA.
FAU - Hegde, Apurva M
AU  - Hegde AM
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kim, Jaegil
AU  - Kim J
AD  - Broad Institute, Cambridge, MA 02142, USA.
FAU - Leiserson, Mark D M
AU  - Leiserson MDM
AD  - Department of Computer Science & Center for Computational Molecular Biology,
      Brown University, Providence, RI 02912, USA.
FAU - Sethi, Geetika
AU  - Sethi G
AD  - Institute for Systems Biology, Seattle, WA 98109, USA.
FAU - Lu, Charles
AU  - Lu C
AD  - McDonnell Genome Institute at Washington University, St. Louis, MO 63108, USA.
FAU - Ryan, Michael
AU  - Ryan M
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Su, Xiaoping
AU  - Su X
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Cherniack, Andrew D
AU  - Cherniack AD
AD  - Broad Institute, Cambridge, MA 02142, USA.
FAU - Robertson, Gordon
AU  - Robertson G
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Spellman, Paul
AU  - Spellman P
AD  - Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Weinstein, John N
AU  - Weinstein JN
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hayes, D Neil
AU  - Hayes DN
AD  - Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill,
      NC 27599, USA.
FAU - Raphael, Ben
AU  - Raphael B
AD  - Department of Computer Science & Center for Computational Molecular Biology,
      Brown University, Providence, RI 02912, USA.
FAU - Lichtenberg, Tara
AU  - Lichtenberg T
AD  - Nationwide Children's Hospital, Columbus, OH 43205, USA.
FAU - Leraas, Kristen
AU  - Leraas K
AD  - Nationwide Children's Hospital, Columbus, OH 43205, USA.
FAU - Zenklusen, Jean Claude
AU  - Zenklusen JC
AD  - National Cancer Institute, Bethesda, MD 20892, USA.
CN  - Cancer Genome Atlas Network
FAU - Fujimoto, Junya
AU  - Fujimoto J
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Scapulatempo-Neto, Cristovam
AU  - Scapulatempo-Neto C
AD  - Pathology Department and Molecular Oncology Research Center, Barretos Cancer
      Hospital, Barretos, SP, Brazil.
FAU - Moreira, Andre L
AU  - Moreira AL
AD  - New York University, New York City, NY 10012, USA.
FAU - Hwang, David
AU  - Hwang D
AD  - University Health Network, Toronto, ON M5G 2C4, Canada.
FAU - Huang, James
AU  - Huang J
AD  - Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Marino, Mirella
AU  - Marino M
AD  - Department of Pathology, Regina Elena National Cancer Institute, Rome 00144,
      Italy.
FAU - Korst, Robert
AU  - Korst R
AD  - Valley Health System, Ridgewood, NJ 07450, USA.
FAU - Giaccone, Giuseppe
AU  - Giaccone G
AD  - Georgetown University, Washington, DC 20057, USA.
FAU - Gokmen-Polar, Yesim
AU  - Gokmen-Polar Y
AD  - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202,
      USA.
FAU - Badve, Sunil
AU  - Badve S
AD  - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202,
      USA.
FAU - Rajan, Arun
AU  - Rajan A
AD  - National Cancer Institute, Bethesda, MD 20892, USA.
FAU - Strobel, Philipp
AU  - Strobel P
AD  - University Medical Center, Gottingen 37075, Germany.
FAU - Girard, Nicolas
AU  - Girard N
AD  - Institute of Oncology, Cardiobiotec, Hospices Civils de Lyon, Lyon 69002, France.
FAU - Tsao, Ming S
AU  - Tsao MS
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Marx, Alexander
AU  - Marx A
AD  - University Medical Centre Mannheim, University of Heidelberg, Mannheim 68167,
      Germany.
FAU - Tsao, Anne S
AU  - Tsao AS
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:
      astsao@mdanderson.org.
FAU - Loehrer, Patrick J
AU  - Loehrer PJ
AD  - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202,
      USA. Electronic address: ploehrer@iu.edu.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30 CA051008/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - TCGA
OT  - autoimmunity
OT  - genomics
OT  - myasthenia gravis
OT  - proteomics
OT  - thymic carcinoma
OT  - thymic epithelial tumors
OT  - thymoma
OT  - transcriptomics
IR  - Ally A
FIR - Ally, Adrian
IR  - Appelbaum EL
FIR - Appelbaum, Elizabeth L
IR  - Auman JT
FIR - Auman, J Todd
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Balu S
FIR - Balu, Saianand
IR  - Behera M
FIR - Behera, Madhusmita
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Berrios M
FIR - Berrios, Mario
IR  - Blandino G
FIR - Blandino, Giovanni
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Bowen J
FIR - Bowen, Jay
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carcano FM
FIR - Carcano, Flavio M
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Carvalho AL
FIR - Carvalho, Andre L
IR  - Castro P
FIR - Castro, Patricia
IR  - Chalabreysse L
FIR - Chalabreysse, Lara
IR  - Chin L
FIR - Chin, Lynda
IR  - Cho J
FIR - Cho, Juok
IR  - Choe G
FIR - Choe, Gina
IR  - Chuah E
FIR - Chuah, Eric
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Cope L
FIR - Cope, Leslie
IR  - Cordes MG
FIR - Cordes, Matthew G
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Defreitas T
FIR - Defreitas, Timothy
IR  - Demchok JA
FIR - Demchok, John A
IR  - Detterbeck F
FIR - Detterbeck, Frank
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Dienemann H
FIR - Dienemann, Hendrik
IR  - Edenfield WJ
FIR - Edenfield, W Jeff
IR  - Facciolo F
FIR - Facciolo, Francesco
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Frazer S
FIR - Frazer, Scott
IR  - Fronick CC
FIR - Fronick, Catrina C
IR  - Fulton LA
FIR - Fulton, Lucinda A
IR  - Fulton RS
FIR - Fulton, Robert S
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Gerken M
FIR - Gerken, Mark
IR  - Getz G
FIR - Getz, Gad
IR  - Heiman DI
FIR - Heiman, David I
IR  - Hobensack S
FIR - Hobensack, Shital
IR  - Holbrook A
FIR - Holbrook, Andrea
IR  - Holt RA
FIR - Holt, Robert A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Ittmann M
FIR - Ittmann, Michael
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Kim J
FIR - Kim, Jaegil
IR  - Kimes PK
FIR - Kimes, Patrick K
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Laird PW
FIR - Laird, Peter W
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lin P
FIR - Lin, Pei
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Lu Y
FIR - Lu, Yiling
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Mallery D
FIR - Mallery, David
IR  - Mardis ER
FIR - Mardis, Elaine R
IR  - Marra MA
FIR - Marra, Marco A
IR  - Martin J
FIR - Martin, Julie
IR  - Mayo M
FIR - Mayo, Michael
IR  - Meier S
FIR - Meier, Sam
IR  - Meister M
FIR - Meister, Michael
IR  - Meng S
FIR - Meng, Shaowu
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Miller CA
FIR - Miller, Christopher A
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Moore RA
FIR - Moore, Richard A
IR  - Morris S
FIR - Morris, Scott
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Muley T
FIR - Muley, Thomas
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Newton Y
FIR - Newton, Yulia
IR  - Noble MS
FIR - Noble, Michael S
IR  - Owonikoko T
FIR - Owonikoko, Taofeek
IR  - Parker JS
FIR - Parker, Joel S
IR  - Paulaskis J
FIR - Paulaskis, Joseph
IR  - Penny R
FIR - Penny, Robert
IR  - Perou CM
FIR - Perou, Charles M
IR  - Perrin C
FIR - Perrin, Corinne
IR  - Pihl T
FIR - Pihl, Todd
IR  - Radenbaugh A
FIR - Radenbaugh, Amie
IR  - Ramalingam S
FIR - Ramalingam, Suresh
IR  - Ramirez N
FIR - Ramirez, Nilsa
IR  - Rieker R
FIR - Rieker, Ralf
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Schmidt HK
FIR - Schmidt, Heather K
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Shi Y
FIR - Shi, Yan
IR  - Shih J
FIR - Shih, Juliann
IR  - Sica G
FIR - Sica, Gabriel
IR  - Silveira HCS
FIR - Silveira, Henrique C S
IR  - Simons JV
FIR - Simons, Janae V
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Skelly T
FIR - Skelly, Tara
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Stuart J
FIR - Stuart, Joshua
IR  - Sun Q
FIR - Sun, Qiang
IR  - Tam A
FIR - Tam, Angela
IR  - Tan D
FIR - Tan, Donghui
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Vasef MA
FIR - Vasef, Mohammad A
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Voet D
FIR - Voet, Doug
IR  - Walter V
FIR - Walter, Vonn
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wang Z
FIR - Wang, Zhining
IR  - Warth A
FIR - Warth, Arne
IR  - Weis CA
FIR - Weis, Cleo-Aron
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Wise L
FIR - Wise, Lisa
IR  - Wong T
FIR - Wong, Tina
IR  - Wu HT
FIR - Wu, Hsin-Ta
IR  - Wu Y
FIR - Wu, Ye
IR  - Yang L
FIR - Yang, Liming
IR  - Zhang J
FIR - Zhang, Jiashan
IR  - Zmuda E
FIR - Zmuda, Erik
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2017/06/26 00:00 [received]
PHST- 2017/10/15 00:00 [revised]
PHST- 2018/01/09 00:00 [accepted]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30003-5 [pii]
AID - 10.1016/j.ccell.2018.01.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

PMID- 29438695
OWN - NLM
STAT- In-Data-Review
LR  - 20180227
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated
      PD-L1.
PG  - 187-201.e10
LID - S1535-6108(18)30009-6 [pii]
LID - 10.1016/j.ccell.2018.01.009 [doi]
AB  - Protein glycosylation provides proteomic diversity in regulating protein
      localization, stability, and activity; it remains largely unknown whether the
      sugar moiety contributes to immunosuppression. In the study of immune receptor
      glycosylation, we showed that EGF induces programmed death ligand 1 (PD-L1) and
      receptor programmed cell death protein 1 (PD-1) interaction, requiring
      beta-1,3-N-acetylglucosaminyl transferase (B3GNT3) expression in triple-negative 
      breast cancer. Downregulation of B3GNT3 enhances cytotoxic T cell-mediated
      anti-tumor immunity. A monoclonal antibody targeting glycosylated PD-L1 (gPD-L1) 
      blocks PD-L1/PD-1 interaction and promotes PD-L1 internalization and degradation.
      In addition to immune reactivation, drug-conjugated gPD-L1 antibody induces a
      potent cell-killing effect as well as a bystander-killing effect on adjacent
      cancer cells lacking PD-L1 expression without any detectable toxicity. Our work
      suggests targeting protein glycosylation as a potential strategy to enhance
      immune checkpoint therapy.
CI  - Published by Elsevier Inc.
FAU - Li, Chia-Wei
AU  - Li CW
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Lim, Seung-Oe
AU  - Lim SO
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue
      University, West Lafayette, IN 47907, USA.
FAU - Chung, Ezra M
AU  - Chung EM
AD  - STCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD
      20879, USA.
FAU - Kim, Yong-Soo
AU  - Kim YS
AD  - STCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD
      20879, USA.
FAU - Park, Andrew H
AU  - Park AH
AD  - STCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD
      20879, USA.
FAU - Yao, Jun
AU  - Yao J
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Cha, Jong-Ho
AU  - Cha JH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Tumor Microenvironment Global Core Research Center, College of Pharmacy,
      Seoul National University, Seoul 151-742, Korea.
FAU - Xia, Weiya
AU  - Xia W
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Chan, Li-Chuan
AU  - Chan LC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center at Houston, Houston, TX 77030, USA.
FAU - Kim, Taewan
AU  - Kim T
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Chang, Shih-Shin
AU  - Chang SS
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Lee, Heng-Huan
AU  - Lee HH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Chou, Chao-Kai
AU  - Chou CK
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Liu, Yen-Liang
AU  - Liu YL
AD  - Department of Biomedical Engineering, The University of Texas at Austin, Austin, 
      TX 78712, USA.
FAU - Yeh, Hsin-Chih
AU  - Yeh HC
AD  - Department of Biomedical Engineering, The University of Texas at Austin, Austin, 
      TX 78712, USA.
FAU - Perillo, Evan P
AU  - Perillo EP
AD  - Department of Biomedical Engineering, The University of Texas at Austin, Austin, 
      TX 78712, USA.
FAU - Dunn, Andrew K
AU  - Dunn AK
AD  - Department of Biomedical Engineering, The University of Texas at Austin, Austin, 
      TX 78712, USA.
FAU - Kuo, Chu-Wei
AU  - Kuo CW
AD  - Core Facilities for Protein Structural Analysis, Academia Sinica, Taipei 115,
      Taiwan; Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan.
FAU - Khoo, Kay-Hooi
AU  - Khoo KH
AD  - Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan.
FAU - Hsu, Jennifer L
AU  - Hsu JL
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine,
      China Medical University, Taichung 404, Taiwan.
FAU - Wu, Yun
AU  - Wu Y
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Hsu, Jung-Mao
AU  - Hsu JM
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Yamaguchi, Hirohito
AU  - Yamaguchi H
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Huang, Tzu-Hsuan
AU  - Huang TH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Sahin, Aysegul A
AU  - Sahin AA
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Hortobagyi, Gabriel N
AU  - Hortobagyi GN
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Yoo, Stephen S
AU  - Yoo SS
AD  - STCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD
      20879, USA.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center at Houston, Houston, TX 77030, USA; Graduate Institute of
      Biomedical Sciences and Center for Molecular Medicine, China Medical University, 
      Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413,
      Taiwan. Electronic address: mhung@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R21 CA193038/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5824730
MID - NIHMS936357
OTO - NOTNLM
OT  - B3GNT3
OT  - PD-1
OT  - PD-L1
OT  - TNBC
OT  - antibody-drug conjugate
OT  - glycosylation
OT  - immune checkpoint blockade
OT  - immunosuppression
OT  - immunotherapy
OT  - receptor internalization
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PMCR- 2019/02/12 00:00
PHST- 2017/05/08 00:00 [received]
PHST- 2017/10/09 00:00 [revised]
PHST- 2018/01/17 00:00 [accepted]
PHST- 2019/02/12 00:00 [pmc-release]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30009-6 [pii]
AID - 10.1016/j.ccell.2018.01.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):187-201.e10. doi: 10.1016/j.ccell.2018.01.009.

PMID- 29438694
OWN - NLM
STAT- In-Data-Review
LR  - 20180227
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1
      Activating Mutations.
PG  - 173-186.e5
LID - S1535-6108(18)30004-7 [pii]
LID - 10.1016/j.ccell.2018.01.004 [doi]
AB  - Estrogen receptor alpha (ER) ligand-binding domain (LBD) mutations are found in a
      substantial number of endocrine treatment-resistant metastatic ER-positive
      (ER(+)) breast cancers. We investigated the chromatin recruitment,
      transcriptional network, and genetic vulnerabilities in breast cancer models
      harboring the clinically relevant ER mutations. These mutants exhibit both
      ligand-independent functions that mimic estradiol-bound wild-type ER as well as
      allele-specific neomorphic properties that promote a pro-metastatic phenotype.
      Analysis of the genome-wide ER binding sites identified mutant ER unique
      recruitment mediating the allele-specific transcriptional program. Genetic
      screens identified genes that are essential for the ligand-independent growth
      driven by the mutants. These studies provide insights into the mechanism of
      endocrine therapy resistance engendered by ER mutations and potential therapeutic
      targets.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Jeselsohn, Rinath
AU  - Jeselsohn R
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA; Department of Medicine, Brigham and Women's Hospital and
      Harvard Medical School, Boston, MA 02210, USA.
FAU - Bergholz, Johann S
AU  - Bergholz JS
AD  - Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02215, USA.
FAU - Pun, Matthew
AU  - Pun M
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA.
FAU - Cornwell, MacIntosh
AU  - Cornwell M
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA.
FAU - Liu, Weihan
AU  - Liu W
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA.
FAU - Nardone, Agostina
AU  - Nardone A
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA.
FAU - Xiao, Tengfei
AU  - Xiao T
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA.
FAU - Li, Wei
AU  - Li W
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Biostatistics and Computational Biology, Dana Farber
      Cancer Institute and Harvard School of Public Health, Boston, MA 02215, USA.
FAU - Qiu, Xintao
AU  - Qiu X
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA.
FAU - Buchwalter, Gilles
AU  - Buchwalter G
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA.
FAU - Feiglin, Ariel
AU  - Feiglin A
AD  - Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02215,
      USA.
FAU - Abell-Hart, Kayley
AU  - Abell-Hart K
AD  - Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02215, USA.
FAU - Fei, Teng
AU  - Fei T
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA.
FAU - Rao, Prakash
AU  - Rao P
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA.
FAU - Long, Henry
AU  - Long H
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA.
FAU - Kwiatkowski, Nicholas
AU  - Kwiatkowski N
AD  - Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02215, USA.
FAU - Zhang, Tinghu
AU  - Zhang T
AD  - Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02215, USA.
FAU - Gray, Nathanael
AU  - Gray N
AD  - Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02215, USA.
FAU - Melchers, Diane
AU  - Melchers D
AD  - PamGene International BV, Hertogenbosch 5211, the Netherlands.
FAU - Houtman, Rene
AU  - Houtman R
AD  - PamGene International BV, Hertogenbosch 5211, the Netherlands.
FAU - Liu, X Shirley
AU  - Liu XS
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Biostatistics and Computational Biology, Dana Farber
      Cancer Institute and Harvard School of Public Health, Boston, MA 02215, USA.
FAU - Cohen, Ofir
AU  - Cohen O
AD  - Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02210,
      USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Wagle, Nikhil
AU  - Wagle N
AD  - Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02210,
      USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical
      School, Boston, MA 02210, USA; Broad Institute of MIT and Harvard, Cambridge, MA 
      02142, USA.
FAU - Winer, Eric P
AU  - Winer EP
AD  - Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02210,
      USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical
      School, Boston, MA 02210, USA.
FAU - Zhao, Jean
AU  - Zhao J
AD  - Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02215, USA.
FAU - Brown, Myles
AU  - Brown M
AD  - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston,
      MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute,
      Boston, MA 02210, USA; Department of Medicine, Brigham and Women's Hospital and
      Harvard Medical School, Boston, MA 02210, USA. Electronic address:
      myles_brown@dfci.harvard.edu.
LA  - eng
GR  - P01 CA080111/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5813700
MID - NIHMS938148
OTO - NOTNLM
OT  - CDK7
OT  - breast cancer
OT  - cistrome
OT  - endocrine therapy resistance
OT  - estrogen receptor
OT  - estrogen recptor mutations
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PMCR- 2019/02/12 00:00
PHST- 2017/07/18 00:00 [received]
PHST- 2017/11/02 00:00 [revised]
PHST- 2018/01/09 00:00 [accepted]
PHST- 2019/02/12 00:00 [pmc-release]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30004-7 [pii]
AID - 10.1016/j.ccell.2018.01.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):173-186.e5. doi: 10.1016/j.ccell.2018.01.004.

PMID- 29438693
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Cellular Pliancy and the Multistep Process of Tumorigenesis.
PG  - 164-172
LID - S1535-6108(18)30007-2 [pii]
LID - 10.1016/j.ccell.2018.01.007 [doi]
AB  - Completion of early stages of tumorigenesis relies on the dynamic interplay
      between the initiating oncogenic event and the cellular context. Here, we review 
      recent findings indicating that each differentiation stage within a defined
      cellular lineage is associated with a unique susceptibility to malignant
      transformation when subjected to a specific oncogenic insult. This emerging
      notion, named cellular pliancy, provides a rationale for the short delay in the
      development of pediatric cancers of prenatal origin. It also highlights the
      critical role of cellular reprogramming in early steps of malignant
      transformation of adult differentiated cells and its impact on the natural
      history of tumorigenesis.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Puisieux, Alain
AU  - Puisieux A
AD  - Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon 
      Berard, Cancer Research Center of Lyon, Equipe labellisee Ligue Contre le Cancer 
      "EMT and Cancer Cell Plasticity", Lyon 69008, France; LabEx DEVweCAN, Universite 
      de Lyon, 69000 Lyon, France. Electronic address:
      alain.puisieux@lyon.unicancer.fr.
FAU - Pommier, Roxane M
AU  - Pommier RM
AD  - Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon 
      Berard, Cancer Research Center of Lyon, Equipe labellisee Ligue Contre le Cancer 
      "EMT and Cancer Cell Plasticity", Lyon 69008, France; LabEx DEVweCAN, Universite 
      de Lyon, 69000 Lyon, France.
FAU - Morel, Anne-Pierre
AU  - Morel AP
AD  - Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon 
      Berard, Cancer Research Center of Lyon, Equipe labellisee Ligue Contre le Cancer 
      "EMT and Cancer Cell Plasticity", Lyon 69008, France; LabEx DEVweCAN, Universite 
      de Lyon, 69000 Lyon, France.
FAU - Lavial, Fabrice
AU  - Lavial F
AD  - Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon 
      Berard, Cancer Research Center of Lyon, Equipe "Cellular Reprogramming and
      Oncogenesis", Lyon 69008, France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - cell reprogramming
OT  - developmental pliancy
OT  - differentiation
OT  - malignant transformation
OT  - pediatric cancers
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2017/09/22 00:00 [received]
PHST- 2017/12/22 00:00 [revised]
PHST- 2018/01/11 00:00 [accepted]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30007-2 [pii]
AID - 10.1016/j.ccell.2018.01.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):164-172. doi: 10.1016/j.ccell.2018.01.007.

PMID- 29438692
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - An Epigenetic Switch: From Senescent Melanocytes to Malignant Melanoma (and
      Back).
PG  - 162-163
LID - S1535-6108(18)30013-8 [pii]
LID - 10.1016/j.ccell.2018.01.013 [doi]
AB  - Oncogene-induced senescence is an important barrier during melanomagenesis. In
      this issue of Cancer Cell, Yu et al. show how elevated expression of structurally
      unrelated H3K9 demethylases disables senescence and constitutes a liability that 
      can be exploited to restore senescence in melanoma by pharmacological inhibition 
      of these epigenetic regulators.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Wagner, Verena
AU  - Wagner V
AD  - MRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK;
      Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College
      London, Du Cane Road, London W12 0NN, UK.
FAU - Gil, Jesus
AU  - Gil J
AD  - MRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK;
      Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College
      London, Du Cane Road, London W12 0NN, UK. Electronic address:
      jesus.gil@imperial.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30013-8 [pii]
AID - 10.1016/j.ccell.2018.01.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):162-163. doi: 10.1016/j.ccell.2018.01.013.

PMID- 29438691
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - HIPPO Stampede in Nerve Sheath Tumors.
PG  - 160-161
LID - S1535-6108(18)30016-3 [pii]
LID - 10.1016/j.ccell.2018.01.016 [doi]
AB  - Current therapies for malignant peripheral nerve sheath tumors (MPNSTs) are
      ineffective. The study by Wu et al. in this issue of Cancer Cell provides
      evidence that the HIPPO pathway is overactive in human MPNSTs and that combined
      modulation of LATS1/2-YAP/TAZ and PDGFR signaling in Schwann cells reduces MPNST 
      growth.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Feltri, M Laura
AU  - Feltri ML
AD  - Hunter James Kelly Research Institute, Departments of Biochemistry and Neurology,
      University at Buffalo, Buffalo, NY 14203, USA. Electronic address:
      mlfeltri@buffalo.edu.
FAU - Poitelon, Yannick
AU  - Poitelon Y
AD  - Albany Medical College, Department of Neuroscience and Experimental Therapeutics,
      Albany, NY 12208, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30016-3 [pii]
AID - 10.1016/j.ccell.2018.01.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):160-161. doi: 10.1016/j.ccell.2018.01.016.

PMID- 29438690
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - c-Raf in KRas Mutant Cancers: A Moving Target.
PG  - 158-159
LID - S1535-6108(18)30017-5 [pii]
LID - 10.1016/j.ccell.2018.01.017 [doi]
AB  - Therapies for KRas cancers remain a major clinical need. In the current issue of 
      Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf
      as a prime target for these cancers. c-Raf ablation caused regression of advanced
      KRas(G12V)/Trp53 tumors, without obvious systemic toxicity and without affecting 
      MAPK signaling.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - McCormick, Frank
AU  - McCormick F
AD  - University of California San Francisco, Helen Diller Family Comprehensive Cancer 
      Center, San Francisco, CA, USA. Electronic address: frank.mccormick@ucsf.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30017-5 [pii]
AID - 10.1016/j.ccell.2018.01.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):158-159. doi: 10.1016/j.ccell.2018.01.017.

PMID- 29438689
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer.
PG  - 155-157
LID - S1535-6108(18)30015-1 [pii]
LID - 10.1016/j.ccell.2018.01.015 [doi]
AB  - The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still
      limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1
      glycosylation-based mechanism in triple-negative breast cancer that fosters
      immunosuppression by enhancing interactions with PD-1. Targeting glycosylated
      PD-L1 with a drug-conjugated antibody opens new avenues for treatment.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Salatino, Mariana
AU  - Salatino M
AD  - Laboratorio de Inmunopatologia, Instituto de Biologia y Medicina Experimental
      (IBYME), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina.
FAU - Girotti, Maria Romina
AU  - Girotti MR
AD  - Laboratorio de Inmuno-Oncologia Traslacional, Instituto de Biologia y Medicina
      Experimental (IBYME), Consejo Nacional de Investigaciones Cientificas y Tecnicas 
      (CONICET), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina.
FAU - Rabinovich, Gabriel A
AU  - Rabinovich GA
AD  - Laboratorio de Inmunopatologia, Instituto de Biologia y Medicina Experimental
      (IBYME), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina; Laboratorio de
      Inmuno-Oncologia Traslacional, Instituto de Biologia y Medicina Experimental
      (IBYME), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina; Departamento de
      Quimica Biologica, Facultad de Ciencias Exactas y Naturales, Universidad de
      Buenos Aires, Intendente Guiraldes 2160, C1428EGA Buenos Aires, Argentina.
      Electronic address: gabyrabi@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30015-1 [pii]
AID - 10.1016/j.ccell.2018.01.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):155-157. doi: 10.1016/j.ccell.2018.01.015.

PMID- 29438688
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Neomorphic ERalpha Mutations Drive Progression in Breast Cancer and Present a
      Challenge for New Drug Discovery.
PG  - 153-155
LID - S1535-6108(18)30014-X [pii]
LID - 10.1016/j.ccell.2018.01.014 [doi]
AB  - In this issue of Cancer Cell, Jeselsohn et al. dissect the function of several of
      the most clinically important estrogen receptor alpha mutants associated with
      endocrine therapy resistance in breast cancer and demonstrate that they manifest 
      disease-relevant neomorphic activities that likely contribute to tumor
      pathogenesis.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - McDonnell, Donald P
AU  - McDonnell DP
AD  - Department of Pharmacology and Cancer Biology, Duke University School of
      Medicine, Durham, NC 27710, USA. Electronic address: donald.mcdonnell@duke.edu.
FAU - Norris, John D
AU  - Norris JD
AD  - Department of Pharmacology and Cancer Biology, Duke University School of
      Medicine, Durham, NC 27710, USA.
FAU - Chang, Ching-Yi
AU  - Chang CY
AD  - Department of Pharmacology and Cancer Biology, Duke University School of
      Medicine, Durham, NC 27710, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/02/14 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/14 06:00
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - S1535-6108(18)30014-X [pii]
AID - 10.1016/j.ccell.2018.01.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):153-155. doi: 10.1016/j.ccell.2018.01.014.

PMID- 29398449
OWN - NLM
STAT- In-Data-Review
LR  - 20180216
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - RHOA G17V Induces T Follicular Helper Cell Specification and Promotes
      Lymphomagenesis.
PG  - 259-273.e7
LID - S1535-6108(18)30001-1 [pii]
LID - 10.1016/j.ccell.2018.01.001 [doi]
AB  - Angioimmunoblastic T cell lymphoma (AITL) is an aggressive tumor derived from
      malignant transformation of T follicular helper (Tfh) cells. AITL is
      characterized by loss-of-function mutations in Ten-Eleven Translocation 2 (TET2) 
      epigenetic tumor suppressor and a highly recurrent mutation (p.Gly17Val) in the
      RHOA small GTPase. Yet, the specific role of RHOA G17V in AITL remains unknown.
      Expression of Rhoa G17V in CD4(+) T cells induces Tfh cell specification;
      increased proliferation associated with inducible co-stimulator (ICOS)
      upregulation and increased phosphoinositide 3-kinase (PI3K) and mitogen-activated
      protein kinase signaling. Moreover, RHOA G17V expression together with Tet2 loss 
      resulted in development of AITL in mice. Importantly, Tet2(-/-)RHOA G17V tumor
      proliferation in vivo can be inhibited by ICOS/PI3K-specific blockade, supporting
      a driving role for ICOS signaling in Tfh cell transformation.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Cortes, Jose R
AU  - Cortes JR
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - Ambesi-Impiombato, Alberto
AU  - Ambesi-Impiombato A
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - Couronne, Lucile
AU  - Couronne L
AD  - Department of Adult Hematology, Necker Hospital, Paris 75993, France; INSERM U
      1163, CNRS ERL 8254, Institut Imagine, Paris 75015, France; Paris Descartes
      University, Paris 75006, France.
FAU - Quinn, S Aidan
AU  - Quinn SA
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - Kim, Christine S
AU  - Kim CS
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - da Silva Almeida, Ana C
AU  - da Silva Almeida AC
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - West, Zachary
AU  - West Z
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - Belver, Laura
AU  - Belver L
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - Martin, Marta Sanchez
AU  - Martin MS
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
FAU - Scourzic, Laurianne
AU  - Scourzic L
AD  - Gustave Roussy, Villejuif 94805, France; INSERM U1170, Villejuif 94805, France;
      Universite Paris-Sud, Orsay 91400, France.
FAU - Bhagat, Govind
AU  - Bhagat G
AD  - Department of Pathology and Cell Biology, Columbia University Medical Center,
      1130 St Nicholas Avenue, ICRC-401B, New York, NY 10032, USA.
FAU - Bernard, Olivier A
AU  - Bernard OA
AD  - Gustave Roussy, Villejuif 94805, France; INSERM U1170, Villejuif 94805, France;
      Universite Paris-Sud, Orsay 91400, France.
FAU - Ferrando, Adolfo A
AU  - Ferrando AA
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA;
      Department of Pathology and Cell Biology, Columbia University Medical Center,
      1130 St Nicholas Avenue, ICRC-401B, New York, NY 10032, USA; Department of
      Pediatrics, Columbia University Medical Center, New York, NY 10032, USA.
FAU - Palomero, Teresa
AU  - Palomero T
AD  - Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA;
      Department of Pathology and Cell Biology, Columbia University Medical Center,
      1130 St Nicholas Avenue, ICRC-401B, New York, NY 10032, USA. Electronic address: 
      tp2151@columbia.edu.
LA  - eng
GR  - R01 CA197945/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180202
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5811310
MID - NIHMS938147
OTO - NOTNLM
OT  - ICOS
OT  - RHOA G17V
OT  - T follicular helper cells
OT  - TET2
OT  - angioimmunoblastic T cell lymphoma
EDAT- 2018/02/06 06:00
MHDA- 2018/02/06 06:00
CRDT- 2018/02/06 06:00
PMCR- 2019/02/12 00:00
PHST- 2017/03/06 00:00 [received]
PHST- 2017/07/06 00:00 [revised]
PHST- 2018/01/03 00:00 [accepted]
PHST- 2019/02/12 00:00 [pmc-release]
PHST- 2018/02/06 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2018/02/06 06:00 [entrez]
AID - S1535-6108(18)30001-1 [pii]
AID - 10.1016/j.ccell.2018.01.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):259-273.e7. doi: 10.1016/j.ccell.2018.01.001. Epub
      2018 Feb 2.

PMID- 29395869
OWN - NLM
STAT- In-Data-Review
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung
      Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
PG  - 217-228.e4
LID - S1535-6108(17)30566-4 [pii]
LID - 10.1016/j.ccell.2017.12.014 [doi]
AB  - A quarter of all solid tumors harbor KRAS oncogenes. Yet, no selective drugs have
      been approved to treat these malignancies. Genetic interrogation of the MAPK
      pathway revealed that systemic ablation of MEK or ERK kinases in adult mice
      prevent tumor development but are unacceptably toxic. Here, we demonstrate that
      ablation of c-RAF expression in advanced tumors driven by Kras(G12V)/Trp53
      mutations leads to significant tumor regression with no detectable appearance of 
      resistance mechanisms. Tumor regression results from massive apoptosis.
      Importantly, systemic abrogation of c-RAF expression does not inhibit canonical
      MAPK signaling, hence, resulting in limited toxicities. These results are of
      significant relevance for the design of therapeutic strategies to treat K-RAS
      mutant cancers.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Sanclemente, Manuel
AU  - Sanclemente M
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain.
FAU - Francoz, Sarah
AU  - Francoz S
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain.
FAU - Esteban-Burgos, Laura
AU  - Esteban-Burgos L
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain.
FAU - Bousquet-Mur, Emilie
AU  - Bousquet-Mur E
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain.
FAU - Djurec, Magdolna
AU  - Djurec M
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain.
FAU - Lopez-Casas, Pedro P
AU  - Lopez-Casas PP
AD  - Clinical Research Program, Centro Nacional de Investigaciones Oncologicas (CNIO),
      Madrid 28029, Spain.
FAU - Hidalgo, Manuel
AU  - Hidalgo M
AD  - Clinical Research Program, Centro Nacional de Investigaciones Oncologicas (CNIO),
      Madrid 28029, Spain.
FAU - Guerra, Carmen
AU  - Guerra C
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain.
FAU - Drosten, Matthias
AU  - Drosten M
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain.
FAU - Musteanu, Monica
AU  - Musteanu M
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain. Electronic address: mmusteanu@cnio.es.
FAU - Barbacid, Mariano
AU  - Barbacid M
AD  - Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Madrid 28029, Spain. Electronic address: mbarbacid@cnio.es.
LA  - eng
PT  - Journal Article
DEP - 20180127
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - Kras oncogene
OT  - MAPK signaling
OT  - c-RAF
OT  - lung cancer
OT  - mouse models of cancer
OT  - therapy strategy
OT  - toxicity
EDAT- 2018/02/06 06:00
MHDA- 2018/02/06 06:00
CRDT- 2018/02/04 06:00
PHST- 2017/07/06 00:00 [received]
PHST- 2017/10/24 00:00 [revised]
PHST- 2017/12/21 00:00 [accepted]
PHST- 2018/02/06 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2018/02/04 06:00 [entrez]
AID - S1535-6108(17)30566-4 [pii]
AID - 10.1016/j.ccell.2017.12.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub
      2018 Jan 27.

PMID- 29395868
OWN - NLM
STAT- In-Data-Review
LR  - 20180216
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell
      Carcinoma.
PG  - 229-243.e4
LID - S1535-6108(17)30567-6 [pii]
LID - 10.1016/j.ccell.2017.12.015 [doi]
AB  - Hedgehog (Hh) pathway inhibitors such as vismodegib are highly effective for
      treating basal cell carcinoma (BCC); however, residual tumor cells frequently
      persist and regenerate the primary tumor upon drug discontinuation. Here, we show
      that BCCs are organized into two molecularly and functionally distinct
      compartments. Whereas interior Hh(+)/Notch(+) suprabasal cells undergo apoptosis 
      in response to vismodegib, peripheral Hh(+++)/Notch(-) basal cells survive
      throughout treatment. Inhibiting Notch specifically promotes tumor persistence
      without causing drug resistance, while activating Notch is sufficient to regress 
      already established lesions. Altogether, these findings suggest that the
      three-dimensional architecture of BCCs establishes a natural hierarchy of drug
      response in the tumor and that this hierarchy can be overcome, for better or
      worse, by modulating Notch.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Eberl, Markus
AU  - Eberl M
AD  - Departments of Dermatology, and Cell and Developmental Biology, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Mangelberger, Doris
AU  - Mangelberger D
AD  - Departments of Dermatology, and Cell and Developmental Biology, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Swanson, Jacob B
AU  - Swanson JB
AD  - Departments of Dermatology, and Cell and Developmental Biology, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Verhaegen, Monique E
AU  - Verhaegen ME
AD  - Departments of Dermatology, and Cell and Developmental Biology, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Harms, Paul W
AU  - Harms PW
AD  - Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, MI
      48109, USA.
FAU - Frohm, Marcus L
AU  - Frohm ML
AD  - Departments of Dermatology, and Cell and Developmental Biology, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Dlugosz, Andrzej A
AU  - Dlugosz AA
AD  - Departments of Dermatology, and Cell and Developmental Biology, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Wong, Sunny Y
AU  - Wong SY
AD  - Departments of Dermatology, and Cell and Developmental Biology, University of
      Michigan, Ann Arbor, MI 48109, USA. Electronic address: sunnyw@umich.edu.
LA  - eng
GR  - P30 CA046592/CA/NCI NIH HHS/United States
GR  - R21 CA209166/CA/NCI NIH HHS/United States
GR  - R00 AR059796/AR/NIAMS NIH HHS/United States
GR  - R01 CA087837/CA/NCI NIH HHS/United States
GR  - R01 AR065409/AR/NIAMS NIH HHS/United States
PT  - Journal Article
DEP - 20180127
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5811398
MID - NIHMS930844
OTO - NOTNLM
OT  - Hedgehog
OT  - Notch
OT  - basal cell carcinoma
OT  - skin cancer
OT  - vismodegib
EDAT- 2018/02/06 06:00
MHDA- 2018/02/06 06:00
CRDT- 2018/02/04 06:00
PMCR- 2019/02/12 00:00
PHST- 2017/04/24 00:00 [received]
PHST- 2017/09/03 00:00 [revised]
PHST- 2017/12/20 00:00 [accepted]
PHST- 2019/02/12 00:00 [pmc-release]
PHST- 2018/02/06 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2018/02/04 06:00 [entrez]
AID - S1535-6108(17)30567-6 [pii]
AID - 10.1016/j.ccell.2017.12.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):229-243.e4. doi: 10.1016/j.ccell.2017.12.015. Epub
      2018 Jan 27.

PMID- 29358035
OWN - NLM
STAT- In-Data-Review
LR  - 20180316
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb 12
TI  - EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing
      Sarcoma.
PG  - 202-216.e6
LID - S1535-6108(17)30561-5 [pii]
LID - 10.1016/j.ccell.2017.12.009 [doi]
AB  - Many cancer types are driven by oncogenic transcription factors that have been
      difficult to drug. Transcriptional inhibitors, however, may offer inroads into
      targeting these cancers. Through chemical genomics screening, we identified that 
      Ewing sarcoma is a disease with preferential sensitivity to THZ1, a covalent
      small-molecule CDK7/12/13 inhibitor. The selective CDK12/13 inhibitor, THZ531,
      impairs DNA damage repair in an EWS/FLI-dependent manner, supporting a synthetic 
      lethal relationship between response to THZ1/THZ531 and EWS/FLI expression. The
      combination of these molecules with PARP inhibitors showed striking synergy in
      cell viability and DNA damage assays in vitro and in multiple models of Ewing
      sarcoma, including a PDX, in vivo without hematopoietic toxicity.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Iniguez, Amanda Balboni
AU  - Iniguez AB
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA
      02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Stolte, Bjorn
AU  - Stolte B
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA
      02215, USA; Ludwig Maximilians University of Munich, Munich 80539, Germany.
FAU - Wang, Emily Jue
AU  - Wang EJ
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA
      02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Conway, Amy Saur
AU  - Conway AS
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA
      02215, USA.
FAU - Alexe, Gabriela
AU  - Alexe G
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA
      02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA;
      Bioinformatics Graduate Program, Boston University, Boston, MA 02215, USA.
FAU - Dharia, Neekesh V
AU  - Dharia NV
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA
      02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Kwiatkowski, Nicholas
AU  - Kwiatkowski N
AD  - The Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA;
      Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Zhang, Tinghu
AU  - Zhang T
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Abraham, Brian J
AU  - Abraham BJ
AD  - The Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Mora, Jaume
AU  - Mora J
AD  - Development Tumor Biology Laboratory and Department of Pediatric Oncology and
      Hematology, Hospital Sant Joan de Deu Barcelona, Barcelona 08950, Spain.
FAU - Kalev, Peter
AU  - Kalev P
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Leggett, Alan
AU  - Leggett A
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Chowdhury, Dipanjan
AU  - Chowdhury D
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Benes, Cyril H
AU  - Benes CH
AD  - Massachusetts General Hospital, Center for Cancer Research, Boston, MA 02114,
      USA.
FAU - Young, Richard A
AU  - Young RA
AD  - The Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA;
      Department of Biology, Massachusetts Institute of Technology, Cambridge, MA
      02139, USA.
FAU - Gray, Nathanael S
AU  - Gray NS
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA
      02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
      Electronic address: kimberly_stegmaier@dfci.harvard.edu.
LA  - eng
GR  - R01 HG002668/HG/NHGRI NIH HHS/United States
GR  - R35 CA210030/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180118
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5846483
MID - NIHMS935677
OTO - NOTNLM
OT  - CDK12
OT  - DNA damage repair
OT  - EWS/FLI
OT  - Ewing sarcoma
OT  - PARP inhibitors
OT  - THZ1
OT  - THZ531
OT  - synthetic lethal
EDAT- 2018/01/24 06:00
MHDA- 2018/01/24 06:00
CRDT- 2018/01/24 06:00
PMCR- 2019/02/12 00:00
PHST- 2016/08/30 00:00 [received]
PHST- 2017/09/15 00:00 [revised]
PHST- 2017/12/19 00:00 [accepted]
PHST- 2019/02/12 00:00 [pmc-release]
PHST- 2018/01/24 06:00 [pubmed]
PHST- 2018/01/24 06:00 [medline]
PHST- 2018/01/24 06:00 [entrez]
AID - S1535-6108(17)30561-5 [pii]
AID - 10.1016/j.ccell.2017.12.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Feb 12;33(2):202-216.e6. doi: 10.1016/j.ccell.2017.12.009. Epub
      2018 Jan 18.

PMID- 29316436
OWN - NLM
STAT- In-Data-Review
LR  - 20180311
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via
      ATF4 and Alters Sensitivity to L-Asparaginase.
PG  - 91-107.e6
LID - S1535-6108(17)30555-X [pii]
LID - 10.1016/j.ccell.2017.12.003 [doi]
AB  - KRAS is a regulator of the nutrient stress response in non-small-cell lung cancer
      (NSCLC). Induction of the ATF4 pathway during nutrient depletion requires AKT and
      NRF2 downstream of KRAS. The tumor suppressor KEAP1 strongly influences the
      outcome of activation of this pathway during nutrient stress; loss of KEAP1 in
      KRAS mutant cells leads to apoptosis. Through ATF4 regulation, KRAS alters amino 
      acid uptake and asparagine biosynthesis. The ATF4 target asparagine synthetase
      (ASNS) contributes to apoptotic suppression, protein biosynthesis, and mTORC1
      activation. Inhibition of AKT suppressed ASNS expression and, combined with
      depletion of extracellular asparagine, decreased tumor growth. Therefore, KRAS is
      important for the cellular response to nutrient stress, and ASNS represents a
      promising therapeutic target in KRAS mutant NSCLC.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gwinn, Dana M
AU  - Gwinn DM
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA.
FAU - Lee, Alex G
AU  - Lee AG
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA.
FAU - Briones-Martin-Del-Campo, Marcela
AU  - Briones-Martin-Del-Campo M
AD  - Division of Hematology and Oncology, Department of Pediatrics, University of
      California San Francisco, San Francisco, CA 94158, USA.
FAU - Conn, Crystal S
AU  - Conn CS
AD  - School of Medicine and Department of Urology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94158, 
      USA.
FAU - Simpson, David R
AU  - Simpson DR
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA.
FAU - Scott, Anna I
AU  - Scott AI
AD  - Stanford University, Department of Pathology, Stanford, CA 94305, USA.
FAU - Le, Anthony
AU  - Le A
AD  - Stanford University, Department of Pathology, Stanford, CA 94305, USA.
FAU - Cowan, Tina M
AU  - Cowan TM
AD  - Stanford University, Department of Pathology, Stanford, CA 94305, USA.
FAU - Ruggero, Davide
AU  - Ruggero D
AD  - School of Medicine and Department of Urology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94158, 
      USA.
FAU - Sweet-Cordero, E Alejandro
AU  - Sweet-Cordero EA
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA. Electronic address:
      alejandro.sweet-cordero@ucsf.edu.
LA  - eng
GR  - R01 CA129562/CA/NCI NIH HHS/United States
GR  - R01 NS089868/NS/NINDS NIH HHS/United States
GR  - T32 CA009302/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5761662
MID - NIHMS927863
OTO - NOTNLM
OT  - ASNS
OT  - ATF4
OT  - KEAP1
OT  - KRAS
OT  - L-asparaginase
OT  - NRF2
OT  - PI3K
OT  - asparagine
OT  - glutamine
OT  - synthetic vulnerability
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2016/06/13 00:00 [received]
PHST- 2017/05/25 00:00 [revised]
PHST- 2017/12/07 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30555-X [pii]
AID - 10.1016/j.ccell.2017.12.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):91-107.e6. doi: 10.1016/j.ccell.2017.12.003.

PMID- 29316435
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Molecular Predictors of Gastric Neoplastic Progression.
PG  - 9-11
LID - S1535-6108(17)30558-5 [pii]
LID - 10.1016/j.ccell.2017.12.006 [doi]
AB  - In this issue of Cancer Cell, Huang et al. describe comprehensive genetic and
      epigenetic profiling of gastric intestinal metaplasia lesions from a longitudinal
      cohort in which outcome data allowed for identification of potential markers of
      gastric neoplastic progression.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Lochhead, Paul
AU  - Lochhead P
AD  - Clinical and Translational Epidemiology Unit and Division of Gastroenterology,
      Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
FAU - El-Omar, Emad M
AU  - El-Omar EM
AD  - St George and Sutherland Clinical School, University of New South Wales, Sydney
      NSW 2052, Australia. Electronic address: e.el-omar@unsw.edu.au.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30558-5 [pii]
AID - 10.1016/j.ccell.2017.12.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):9-11. doi: 10.1016/j.ccell.2017.12.006.

PMID- 29316434
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Characterizing the Killer Colorectal Carcinomas.
PG  - 7-9
LID - S1535-6108(17)30562-7 [pii]
LID - 10.1016/j.ccell.2017.12.010 [doi]
AB  - In this issue of Cancer Cell, Yaeger et al. report mutations, copy number
      variations, and selected rearrangements from a large series of metastatic
      colorectal carcinomas and primaries that produced metastases. The results provide
      important insights into differences in anatomical site of origin, age at onset,
      etiologic factors, and therapeutic responses.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hamilton, Stanley R
AU  - Hamilton SR
AD  - Head, Pathology and Laboratory Medicine, The University of Texas MD Anderson
      Cancer Center, Houston, TX, USA. Electronic address: shamilto@mdanderson.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30562-7 [pii]
AID - 10.1016/j.ccell.2017.12.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):7-9. doi: 10.1016/j.ccell.2017.12.010.

PMID- 29316433
OWN - NLM
STAT- In-Data-Review
LR  - 20180210
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in 
      Breast Cancer.
PG  - 60-74.e6
LID - S1535-6108(17)30523-8 [pii]
LID - 10.1016/j.ccell.2017.11.019 [doi]
AB  - Intratumoral CD103(+) dendritic cells (DCs) are necessary for anti-tumor
      immunity. Here we evaluated the expression of immune regulators by CD103(+) DCs
      in a murine model of breast cancer and identified expression of TIM-3 as a target
      for therapy. Anti-TIM-3 antibody improved response to paclitaxel chemotherapy in 
      models of triple-negative and luminal B disease, with no evidence of toxicity.
      Combined efficacy was CD8(+) T cell dependent and associated with increased
      granzyme B expression; however, TIM-3 expression was predominantly localized to
      myeloid cells in both human and murine tumors. Gene expression analysis
      identified upregulation of Cxcl9 within intratumoral DCs during combination
      therapy, and therapeutic efficacy was ablated by CXCR3 blockade, Batf3
      deficiency, or Irf8 deficiency.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - de Mingo Pulido, Alvaro
AU  - de Mingo Pulido A
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA.
FAU - Gardner, Alycia
AU  - Gardner A
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA; Cancer Biology PhD Program,
      University of South Florida, Tampa, FL 33620, USA.
FAU - Hiebler, Shandi
AU  - Hiebler S
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA.
FAU - Soliman, Hatem
AU  - Soliman H
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA; Department of Breast Oncology, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
FAU - Rugo, Hope S
AU  - Rugo HS
AD  - Department of Medicine and Helen Diller Family Comprehensive Cancer Center,
      University of California, San Francisco, CA 94143, USA.
FAU - Krummel, Matthew F
AU  - Krummel MF
AD  - Department of Pathology, University of California, San Francisco, CA 94143, USA.
FAU - Coussens, Lisa M
AU  - Coussens LM
AD  - Department of Cell, Developmental & Cancer Biology, and Knight Cancer Institute, 
      Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Ruffell, Brian
AU  - Ruffell B
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA; Department of Breast Oncology, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
      Electronic address: brian.ruffell@moffitt.org.
LA  - eng
GR  - R00 CA185325/CA/NCI NIH HHS/United States
GR  - R01 CA155331/CA/NCI NIH HHS/United States
GR  - P30 CA076292/CA/NCI NIH HHS/United States
GR  - U54 CA163123/CA/NCI NIH HHS/United States
GR  - K99 CA185325/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5764109
MID - NIHMS925918
OTO - NOTNLM
OT  - TIM-3
OT  - breast cancer
OT  - chemotherapy
OT  - dendritic cells
OT  - galectin-9
OT  - immunotherapy
OT  - paclitaxel
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/08/13 00:00 [revised]
PHST- 2017/11/29 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30523-8 [pii]
AID - 10.1016/j.ccell.2017.11.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):60-74.e6. doi: 10.1016/j.ccell.2017.11.019.

PMID- 29316432
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - What's in a Name? Cell Fate Reprogramming in Sarcomagenesis.
PG  - 5-7
LID - S1535-6108(17)30557-3 [pii]
LID - 10.1016/j.ccell.2017.12.005 [doi]
AB  - Differentiation features in cancer cells are typically attributed to the cell of 
      origin. In this issue of Cancer Cell, Drummond et al. demonstrate a
      transdifferentiation program apparent in rhabdomyosarcomas (cancers with skeletal
      muscle differentiation features) arising through cell fate reprogramming from a
      single oncogene activation in endothelial cell precursors.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Jones, Kevin B
AU  - Jones KB
AD  - Departments of Orthopaedics and Oncological Sciences, Huntsman Cancer Institute, 
      University of Utah, 2000 Circle of Hope Drive, Room 3726, Salt Lake City, UT
      84112, USA. Electronic address: kevin.jones@hci.utah.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30557-3 [pii]
AID - 10.1016/j.ccell.2017.12.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):5-7. doi: 10.1016/j.ccell.2017.12.005.

PMID- 29316431
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for
      Myeloproliferative Neoplasms.
PG  - 3-5
LID - S1535-6108(17)30559-7 [pii]
LID - 10.1016/j.ccell.2017.12.007 [doi]
AB  - In this issue of Cancer Cell, Kleppe et al. describe a combination strategy
      designed to inhibit BET bromodomain and JAK/STAT signaling as a method for
      effectively inhibiting NF-kappaB and cytokine production in myeloproliferative
      neoplasms (MPNs). The results provide a strong rationale for clinical evaluation 
      of dual BET/JAK inhibition in MPNs.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Jiang, Qingfei
AU  - Jiang Q
AD  - Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center
      and Sanford Consortium for Regenerative Medicine, University of California, San
      Diego, La Jolla, CA, USA.
FAU - Jamieson, Catriona
AU  - Jamieson C
AD  - Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center
      and Sanford Consortium for Regenerative Medicine, University of California, San
      Diego, La Jolla, CA, USA. Electronic address: cjamieson@ucsd.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30559-7 [pii]
AID - 10.1016/j.ccell.2017.12.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):3-5. doi: 10.1016/j.ccell.2017.12.007.

PMID- 29316430
OWN - NLM
STAT- In-Data-Review
LR  - 20180126
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with
      Immunological Changes in the Microenvironment.
PG  - 152
LID - S1535-6108(17)30564-0 [pii]
LID - 10.1016/j.ccell.2017.12.012 [doi]
FAU - Wang, Qianghu
AU  - Wang Q
FAU - Hu, Baoli
AU  - Hu B
FAU - Hu, Xin
AU  - Hu X
FAU - Kim, Hoon
AU  - Kim H
FAU - Squatrito, Massimo
AU  - Squatrito M
FAU - Scarpace, Lisa
AU  - Scarpace L
FAU - deCarvalho, Ana C
AU  - deCarvalho AC
FAU - Lyu, Sali
AU  - Lyu S
FAU - Li, Pengping
AU  - Li P
FAU - Li, Yan
AU  - Li Y
FAU - Barthel, Floris
AU  - Barthel F
FAU - Cho, Hee Jin
AU  - Cho HJ
FAU - Lin, Yu-Hsi
AU  - Lin YH
FAU - Satani, Nikunj
AU  - Satani N
FAU - Martinez-Ledesma, Emmanuel
AU  - Martinez-Ledesma E
FAU - Zheng, Siyuan
AU  - Zheng S
FAU - Chang, Edward
AU  - Chang E
FAU - Gabriel Sauve, Charles-Etienne
AU  - Gabriel Sauve CE
FAU - Olar, Adriana
AU  - Olar A
FAU - Lan, Zheng D
AU  - Lan ZD
FAU - Finocchiaro, Gaetano
AU  - Finocchiaro G
FAU - Phillips, Joanna J
AU  - Phillips JJ
FAU - Berger, Mitchel S
AU  - Berger MS
FAU - Gabrusiewicz, Konrad R
AU  - Gabrusiewicz KR
FAU - Wang, Guocan
AU  - Wang G
FAU - Eskilsson, Eskil
AU  - Eskilsson E
FAU - Hu, Jian
AU  - Hu J
FAU - Mikkelsen, Tom
AU  - Mikkelsen T
FAU - DePinho, Ronald A
AU  - DePinho RA
FAU - Muller, Florian
AU  - Muller F
FAU - Heimberger, Amy B
AU  - Heimberger AB
FAU - Sulman, Erik P
AU  - Sulman EP
FAU - Nam, Do-Hyun
AU  - Nam DH
FAU - Verhaak, Roel G W
AU  - Verhaak RGW
LA  - eng
GR  - R01 CA120813/CA/NCI NIH HHS/United States
GR  - R01 CA190121/CA/NCI NIH HHS/United States
GR  - P30 CA034196/CA/NCI NIH HHS/United States
GR  - P50 CA097257/CA/NCI NIH HHS/United States
GR  - P50 CA127001/CA/NCI NIH HHS/United States
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Jul 10;32(1):42-56.e6. PMID: 28697342
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30564-0 [pii]
AID - 10.1016/j.ccell.2017.12.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):152. doi: 10.1016/j.ccell.2017.12.012.

PMID- 29316429
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal
      Melanoma.
PG  - 151
LID - S1535-6108(17)30565-2 [pii]
LID - 10.1016/j.ccell.2017.12.013 [doi]
FAU - Robertson, A Gordon
AU  - Robertson AG
FAU - Shih, Juliann
AU  - Shih J
FAU - Yau, Christina
AU  - Yau C
FAU - Gibb, Ewan A
AU  - Gibb EA
FAU - Oba, Junna
AU  - Oba J
FAU - Mungall, Karen L
AU  - Mungall KL
FAU - Hess, Julian M
AU  - Hess JM
FAU - Uzunangelov, Vladislav
AU  - Uzunangelov V
FAU - Walter, Vonn
AU  - Walter V
FAU - Danilova, Ludmila
AU  - Danilova L
FAU - Lichtenberg, Tara M
AU  - Lichtenberg TM
FAU - Kucherlapati, Melanie
AU  - Kucherlapati M
FAU - Kimes, Patrick K
AU  - Kimes PK
FAU - Tang, Ming
AU  - Tang M
FAU - Penson, Alexander
AU  - Penson A
FAU - Babur, Ozgun
AU  - Babur O
FAU - Akbani, Rehan
AU  - Akbani R
FAU - Bristow, Christopher A
AU  - Bristow CA
FAU - Hoadley, Katherine A
AU  - Hoadley KA
FAU - Iype, Lisa
AU  - Iype L
FAU - Chang, Matthew T
AU  - Chang MT
CN  - TCGA Research Network
FAU - Cherniack, Andrew D
AU  - Cherniack AD
FAU - Benz, Christopher
AU  - Benz C
FAU - Mills, Gordon B
AU  - Mills GB
FAU - Verhaak, Roel G W
AU  - Verhaak RGW
FAU - Griewank, Klaus G
AU  - Griewank KG
FAU - Felau, Ina
AU  - Felau I
FAU - Zenklusen, Jean C
AU  - Zenklusen JC
FAU - Gershenwald, Jeffrey E
AU  - Gershenwald JE
FAU - Schoenfield, Lynn
AU  - Schoenfield L
FAU - Lazar, Alexander J
AU  - Lazar AJ
FAU - Abdel-Rahman, Mohamed H
AU  - Abdel-Rahman MH
FAU - Roman-Roman, Sergio
AU  - Roman-Roman S
FAU - Stern, Marc-Henri
AU  - Stern MH
FAU - Cebulla, Colleen M
AU  - Cebulla CM
FAU - Williams, Michelle D
AU  - Williams MD
FAU - Jager, Martine J
AU  - Jager MJ
FAU - Coupland, Sarah E
AU  - Coupland SE
FAU - Esmaeli, Bita
AU  - Esmaeli B
FAU - Kandoth, Cyriac
AU  - Kandoth C
FAU - Woodman, Scott E
AU  - Woodman SE
LA  - eng
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Aug 14;32(2):204-220.e15. PMID: 28810145
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30565-2 [pii]
AID - 10.1016/j.ccell.2017.12.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):151. doi: 10.1016/j.ccell.2017.12.013.

PMID- 29316428
OWN - NLM
STAT- In-Data-Review
LR  - 20180125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver
      Cancer.
PG  - 151-152
LID - S1535-6108(17)30563-9 [pii]
LID - 10.1016/j.ccell.2017.12.011 [doi]
FAU - Sun, Xuxu
AU  - Sun X
FAU - Wang, Sam C
AU  - Wang SC
FAU - Wei, Yonglong
AU  - Wei Y
FAU - Luo, Xin
AU  - Luo X
FAU - Jia, Yuemeng
AU  - Jia Y
FAU - Li, Lin
AU  - Li L
FAU - Gopal, Purva
AU  - Gopal P
FAU - Zhu, Min
AU  - Zhu M
FAU - Nassour, Ibrahim
AU  - Nassour I
FAU - Chuang, Jen-Chieh
AU  - Chuang JC
FAU - Maples, Thomas
AU  - Maples T
FAU - Celen, Cemre
AU  - Celen C
FAU - Nguyen, Liem H
AU  - Nguyen LH
FAU - Wu, Linwei
AU  - Wu L
FAU - Fu, Shunjun
AU  - Fu S
FAU - Li, Weiping
AU  - Li W
FAU - Hui, Lijian
AU  - Hui L
FAU - Tian, Feng
AU  - Tian F
FAU - Ji, Yuan
AU  - Ji Y
FAU - Zhang, Shuyuan
AU  - Zhang S
FAU - Sorouri, Mahsa
AU  - Sorouri M
FAU - Hwang, Tae Hyun
AU  - Hwang TH
FAU - Letzig, Lynda
AU  - Letzig L
FAU - James, Laura
AU  - James L
FAU - Wang, Zixi
AU  - Wang Z
FAU - Yopp, Adam C
AU  - Yopp AC
FAU - Singal, Amit G
AU  - Singal AG
FAU - Zhu, Hao
AU  - Zhu H
LA  - eng
GR  - R01 CA190525/CA/NCI NIH HHS/United States
GR  - R01 DK111588/DK/NIDDK NIH HHS/United States
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Nov 13;32(5):574-589.e6. PMID: 29136504
PMC - PMC5783571
MID - NIHMS932545
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30563-9 [pii]
AID - 10.1016/j.ccell.2017.12.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):151-152. doi: 10.1016/j.ccell.2017.12.011.

PMID- 29316427
OWN - NLM
STAT- In-Data-Review
LR  - 20180113
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia.
PG  - 13-28.e8
LID - S1535-6108(17)30554-8 [pii]
LID - 10.1016/j.ccell.2017.12.002 [doi]
AB  - Targeting of general coactivators is an emerging strategy to interfere with
      oncogenic transcription factors (TFs). However, coactivator perturbations often
      lead to pleiotropic effects by influencing numerous TFs. Here we identify TAF12, 
      a subunit of TFIID and SAGA coactivator complexes, as a selective requirement for
      acute myeloid leukemia (AML) progression. We trace this dependency to a direct
      interaction between the TAF12/TAF4 histone-fold heterodimer and the
      transactivation domain of MYB, a TF with established roles in leukemogenesis.
      Ectopic expression of the TAF4 histone-fold fragment can efficiently squelch
      TAF12 in cells, suppress MYB, and regress AML in mice. Our study reveals a
      strategy for potent MYB inhibition in AML and highlights how an oncogenic TF can 
      be selectively neutralized by targeting a general coactivator complex.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Xu, Yali
AU  - Xu Y
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA; Molecular and
      Cellular Biology Program, Stony Brook University, New York, NY 11794, USA.
FAU - Milazzo, Joseph P
AU  - Milazzo JP
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
FAU - Somerville, Tim D D
AU  - Somerville TDD
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
FAU - Tarumoto, Yusuke
AU  - Tarumoto Y
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
FAU - Huang, Yu-Han
AU  - Huang YH
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
FAU - Ostrander, Elizabeth L
AU  - Ostrander EL
AD  - Division of Oncology, Department of Internal Medicine, Washington University
      School of Medicine, St. Louis, MO 63110, USA.
FAU - Wilkinson, John E
AU  - Wilkinson JE
AD  - ULAM/Department of Pathology, University of Michigan School of Medicine, Ann
      Arbor, MI 48109, USA.
FAU - Challen, Grant A
AU  - Challen GA
AD  - Division of Oncology, Department of Internal Medicine, Washington University
      School of Medicine, St. Louis, MO 63110, USA.
FAU - Vakoc, Christopher R
AU  - Vakoc CR
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA. Electronic
      address: vakoc@cshl.edu.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - P01 CA013106/CA/NCI NIH HHS/United States
GR  - R01 CA174793/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5764110
MID - NIHMS927357
OTO - NOTNLM
OT  - MYB
OT  - SAGA
OT  - TAF12
OT  - TFIID
OT  - acute myeloid leukemia
OT  - coactivator
OT  - epigenetics
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/06/06 00:00 [received]
PHST- 2017/09/22 00:00 [revised]
PHST- 2017/12/05 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30554-8 [pii]
AID - 10.1016/j.ccell.2017.12.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):13-28.e8. doi: 10.1016/j.ccell.2017.12.002.

PMID- 29316426
OWN - NLM
STAT- In-Data-Review
LR  - 20180210
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal
      Cancer.
PG  - 125-136.e3
LID - S1535-6108(17)30556-1 [pii]
LID - 10.1016/j.ccell.2017.12.004 [doi]
AB  - Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the
      genomic basis of this variability remains poorly understood. We performed
      prospective targeted sequencing of 1,134 CRCs. We identified splice alterations
      in intronic regions of APC and large in-frame deletions in CTNNB1, increasing
      oncogenic WNT pathway alterations to 96% of CRCs. Right-sided primary site in
      microsatellite stable mCRC was associated with shorter survival, older age at
      diagnosis, increased mutations, and enrichment of oncogenic alterations in KRAS, 
      BRAF, PIK3CA, AKT1, RNF43, and SMAD4 compared with left-sided primaries.
      Left-sided tumors frequently had no identifiable genetic alteration in mitogenic 
      signaling, but exhibited higher mitogenic ligand expression. Our results suggest 
      different pathways to tumorigenesis in right- and left-sided microsatellite
      stable CRC that may underlie clinical differences.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Yaeger, Rona
AU  - Yaeger R
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Chatila, Walid K
AU  - Chatila WK
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Lipsyc, Marla D
AU  - Lipsyc MD
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Hechtman, Jaclyn F
AU  - Hechtman JF
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Cercek, Andrea
AU  - Cercek A
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Sanchez-Vega, Francisco
AU  - Sanchez-Vega F
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Jayakumaran, Gowtham
AU  - Jayakumaran G
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Middha, Sumit
AU  - Middha S
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Zehir, Ahmet
AU  - Zehir A
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Donoghue, Mark T A
AU  - Donoghue MTA
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - You, Daoqi
AU  - You D
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Viale, Agnes
AU  - Viale A
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Kemeny, Nancy
AU  - Kemeny N
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Segal, Neil H
AU  - Segal NH
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Stadler, Zsofia K
AU  - Stadler ZK
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Varghese, Anna M
AU  - Varghese AM
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Kundra, Ritika
AU  - Kundra R
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Gao, Jianjiong
AU  - Gao J
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Syed, Aijazuddin
AU  - Syed A
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Hyman, David M
AU  - Hyman DM
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Vakiani, Efsevia
AU  - Vakiani E
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Rosen, Neal
AU  - Rosen N
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Taylor, Barry S
AU  - Taylor BS
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Departments of Epidemiology and
      Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ladanyi, Marc
AU  - Ladanyi M
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Berger, Michael F
AU  - Berger MF
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Departments of Pathology,
      Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology
      and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Solit, David B
AU  - Solit DB
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology,
      Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology
      and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Shia, Jinru
AU  - Shia J
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Saltz, Leonard
AU  - Saltz L
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Schultz, Nikolaus
AU  - Schultz N
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Departments of Epidemiology and
      Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA. Electronic address: schultzn@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5765991
MID - NIHMS928716
OTO - NOTNLM
OT  - APC
OT  - CTNNB1
OT  - colorectal cancer
OT  - integrative genomics analysis
OT  - intronic alterations
OT  - location
OT  - prognosis
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/08/02 00:00 [received]
PHST- 2017/10/26 00:00 [revised]
PHST- 2017/12/09 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30556-1 [pii]
AID - 10.1016/j.ccell.2017.12.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):125-136.e3. doi: 10.1016/j.ccell.2017.12.004.

PMID- 29316425
OWN - NLM
STAT- In-Data-Review
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From
      Non-myogenic Endothelial Progenitors.
PG  - 108-124.e5
LID - S1535-6108(17)30524-X [pii]
LID - 10.1016/j.ccell.2017.12.001 [doi]
AB  - Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma that histologically
      resembles embryonic skeletal muscle. RMS occurs throughout the body and an
      exclusively myogenic origin does not account for RMS occurring in sites devoid of
      skeletal muscle. We previously described an RMS model activating a conditional
      constitutively active Smoothened mutant (SmoM2) with aP2-Cre. Using genetic fate 
      mapping, we show SmoM2 expression in Cre-expressing endothelial progenitors
      results in myogenic transdifferentiation and RMS. We show that endothelium and
      skeletal muscle within the head and neck arise from Kdr-expressing progenitors,
      and that hedgehog pathway activation results in aberrant expression of myogenic
      specification factors as a potential mechanism driving RMS genesis. These
      findings suggest that RMS can originate from aberrant development of non-myogenic
      cells.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Drummond, Catherine J
AU  - Drummond CJ
AD  - Department of Oncology, MS-352, St. Jude Children's Research Hospital, 262 Danny 
      Thomas Place, Memphis, TN 38105, USA.
FAU - Hanna, Jason A
AU  - Hanna JA
AD  - Department of Oncology, MS-352, St. Jude Children's Research Hospital, 262 Danny 
      Thomas Place, Memphis, TN 38105, USA.
FAU - Garcia, Matthew R
AU  - Garcia MR
AD  - Department of Oncology, MS-352, St. Jude Children's Research Hospital, 262 Danny 
      Thomas Place, Memphis, TN 38105, USA.
FAU - Devine, Daniel J
AU  - Devine DJ
AD  - Department of Oncology, MS-352, St. Jude Children's Research Hospital, 262 Danny 
      Thomas Place, Memphis, TN 38105, USA.
FAU - Heyrana, Alana J
AU  - Heyrana AJ
AD  - Department of Oncology, MS-352, St. Jude Children's Research Hospital, 262 Danny 
      Thomas Place, Memphis, TN 38105, USA.
FAU - Finkelstein, David
AU  - Finkelstein D
AD  - Department of Computational Biology, St. Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Rehg, Jerold E
AU  - Rehg JE
AD  - Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas 
      Place, Memphis, TN 38105, USA.
FAU - Hatley, Mark E
AU  - Hatley ME
AD  - Department of Oncology, MS-352, St. Jude Children's Research Hospital, 262 Danny 
      Thomas Place, Memphis, TN 38105, USA. Electronic address: mark.hatley@stjude.org.
LA  - eng
GR  - K08 CA151649/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - R01 CA216344/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5790179
MID - NIHMS926021
OTO - NOTNLM
OT  - Tbx1
OT  - endothelium
OT  - hedgehog
OT  - myogenesis
OT  - rhabdomyosarcoma
OT  - sarcoma
OT  - skeletal muscle
OT  - transdifferentiation
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/06/15 00:00 [received]
PHST- 2017/10/30 00:00 [revised]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30524-X [pii]
AID - 10.1016/j.ccell.2017.12.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):108-124.e5. doi: 10.1016/j.ccell.2017.12.001.

PMID- 29316424
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - TFIID and MYB Share a Therapeutic Handshake in AML.
PG  - 1-3
LID - S1535-6108(17)30560-3 [pii]
LID - 10.1016/j.ccell.2017.12.008 [doi]
AB  - Selectively disrupting oncogenic transcription factors in cancer remains an
      elusive ambition of targeted therapeutics. In this issue of Cancer Cell, Xu et
      al. provide an elegant proof-of-concept study demonstrating that interaction
      between MYB and the general transcriptional coactivator TFIID can be specifically
      disrupted to mediate a therapeutic effect in AML.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bell, Charles C
AU  - Bell CC
AD  - Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000,
      Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne,
      VIC 3052, Australia.
FAU - Dawson, Mark A
AU  - Dawson MA
AD  - Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000,
      Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne,
      VIC 3052, Australia; Centre for Cancer Research, University of Melbourne,
      Melbourne, VIC, Australia; Department of Haematology, Peter MacCallum Cancer
      Centre, Melbourne, VIC 3000, Australia. Electronic address:
      mark.dawson@petermac.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30560-3 [pii]
AID - 10.1016/j.ccell.2017.12.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):1-3. doi: 10.1016/j.ccell.2017.12.008.

PMID- 29290541
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals
      Molecular Determinants of Progression to Gastric Cancer.
PG  - 137-150.e5
LID - S1535-6108(17)30521-4 [pii]
LID - 10.1016/j.ccell.2017.11.018 [doi]
AB  - Intestinal metaplasia (IM) is a pre-malignant condition of the gastric mucosa
      associated with increased gastric cancer (GC) risk. We performed (epi)genomic
      profiling of 138 IMs from 148 cancer-free patients, recruited through a 10-year
      prospective study. Compared with GCs, IMs exhibit low mutational burdens,
      recurrent mutations in certain tumor suppressors (FBXW7) but not others (TP53,
      ARID1A), chromosome 8q amplification, and shortened telomeres. Sequencing
      identified more IM patients with active Helicobacter pylori infection compared
      with histopathology (11%-27%). Several IMs exhibited hypermethylation at DNA
      methylation valleys; however, IMs generally lack intragenic hypomethylation
      signatures of advanced malignancy. IM patients with shortened telomeres and
      chromosomal alterations were associated with subsequent dysplasia or GC;
      conversely patients exhibiting normal-like epigenomic patterns were associated
      with regression.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Huang, Kie Kyon
AU  - Huang KK
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Ramnarayanan, Kalpana
AU  - Ramnarayanan K
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Zhu, Feng
AU  - Zhu F
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore.
FAU - Srivastava, Supriya
AU  - Srivastava S
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore; Department of Pathology, National
      University of Singapore, Singapore 119228, Singapore.
FAU - Xu, Chang
AU  - Xu C
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore; Cancer Science Institute of Singapore, National University of 
      Singapore, Singapore 117599, Singapore.
FAU - Tan, Angie Lay Keng
AU  - Tan ALK
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Lee, Minghui
AU  - Lee M
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Tay, Suting
AU  - Tay S
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Das, Kakoli
AU  - Das K
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Xing, Manjie
AU  - Xing M
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore; NUS Graduate School for Integrative Sciences and Engineering, 
      Singapore 117456, Singapore; Cancer Therapeutics and Stratified Oncology, Genome 
      Institute of Singapore, Singapore 138672, Singapore.
FAU - Fatehullah, Aliya
AU  - Fatehullah A
AD  - Institute of Medical Biology, A-STAR, Singapore 138648, Singapore.
FAU - Alkaff, Syed Muhammad Fahmy
AU  - Alkaff SMF
AD  - Department of Anatomical Pathology, Singapore General Hospital, Singapore 169608,
      Singapore.
FAU - Lim, Tony Kiat Hon
AU  - Lim TKH
AD  - Department of Anatomical Pathology, Singapore General Hospital, Singapore 169608,
      Singapore.
FAU - Lee, Jonathan
AU  - Lee J
AD  - Department of Gastroenterology and Hepatology, National University Health System,
      Singapore 119074, Singapore.
FAU - Ho, Khek Yu
AU  - Ho KY
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore; Department of Gastroenterology and
      Hepatology, National University Health System, Singapore 119074, Singapore.
FAU - Rozen, Steven George
AU  - Rozen SG
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Teh, Bin Tean
AU  - Teh BT
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Barker, Nick
AU  - Barker N
AD  - Institute of Medical Biology, A-STAR, Singapore 138648, Singapore; Centre for
      Regenerative Medicine, Edinburgh EH16 4UU, UK.
FAU - Chia, Chung King
AU  - Chia CK
AD  - Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore 
      308433, Singapore.
FAU - Khor, Christopher
AU  - Khor C
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore 169854, Singapore.
FAU - Ooi, Choon Jin
AU  - Ooi CJ
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore 169854, Singapore.
FAU - Fock, Kwong Ming
AU  - Fock KM
AD  - Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore
      529889, Singapore.
FAU - So, Jimmy
AU  - So J
AD  - Department of Surgery, National University of Singapore, Singapore 119228,
      Singapore.
FAU - Lim, Wee Chian
AU  - Lim WC
AD  - Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore 
      308433, Singapore.
FAU - Ling, Khoon Lin
AU  - Ling KL
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore 169854, Singapore.
FAU - Ang, Tiing Leong
AU  - Ang TL
AD  - Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore
      529889, Singapore.
FAU - Wong, Andrew
AU  - Wong A
AD  - Department of Surgery, Changi General Hospital, Singapore 529889, Singapore.
FAU - Rao, Jaideepraj
AU  - Rao J
AD  - Department of Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore.
FAU - Rajnakova, Andrea
AU  - Rajnakova A
AD  - Mt. Elizabeth Medical Centre, Singapore 228510, Singapore.
FAU - Lim, Lee Guan
AU  - Lim LG
AD  - Raffles Hospital, Singapore 188770, Singapore.
FAU - Yap, Wai Ming
AU  - Yap WM
AD  - Department of Pathology, Tan Tock Seng Hospital, Singapore 308433, Singapore.
FAU - Teh, Ming
AU  - Teh M
AD  - Department of Pathology, National University of Singapore, Singapore 119228,
      Singapore. Electronic address: pattehm@nus.edu.sg.
FAU - Yeoh, Khay Guan
AU  - Yeoh KG
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore; Department of Gastroenterology and
      Hepatology, National University Health System, Singapore 119074, Singapore;
      Singapore Gastric Cancer Consortium, Singapore 119074, Singapore. Electronic
      address: mdcykg@nus.edu.sg.
FAU - Tan, Patrick
AU  - Tan P
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore; Cancer Science Institute of Singapore, National University of 
      Singapore, Singapore 117599, Singapore; Cancer Therapeutics and Stratified
      Oncology, Genome Institute of Singapore, Singapore 138672, Singapore;
      SingHealth/Duke-NUS Institute of Precision Medicine, National Heart Centre
      Singapore, Singapore 169856, Singapore; Cellular and Molecular Research, National
      Cancer Centre, Singapore 169610, Singapore; Singapore Gastric Cancer Consortium, 
      Singapore 119074, Singapore. Electronic address: gmstanp@duke-nus.edu.sg.
LA  - eng
PT  - Journal Article
DEP - 20171228
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - cancer genomics
OT  - gastric cancer
OT  - intestinal metaplasia
OT  - risk stratification
EDAT- 2018/01/02 06:00
MHDA- 2018/01/02 06:00
CRDT- 2018/01/02 06:00
PHST- 2017/06/09 00:00 [received]
PHST- 2017/10/02 00:00 [revised]
PHST- 2017/11/28 00:00 [accepted]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
PHST- 2018/01/02 06:00 [entrez]
AID - S1535-6108(17)30521-4 [pii]
AID - 10.1016/j.ccell.2017.11.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):137-150.e5. doi: 10.1016/j.ccell.2017.11.018. Epub 
      2017 Dec 28.

PMID- 29275866
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid
      Transformation and MEK Inhibitor Sensitivity.
PG  - 44-59.e8
LID - S1535-6108(17)30515-9 [pii]
LID - 10.1016/j.ccell.2017.11.012 [doi]
AB  - Mutations in epigenetic modifiers and signaling factors often co-occur in myeloid
      malignancies, including TET2 and NRAS mutations. Concurrent Tet2 loss and
      Nras(G12D) expression in hematopoietic cells induced myeloid transformation, with
      a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was
      serially transplantable. Tet2 loss and Nras mutation cooperatively led to
      decrease in negative regulators of mitogen-activated protein kinase (MAPK)
      activation, including Spry2, thereby causing synergistic activation of MAPK
      signaling by epigenetic silencing. Tet2/Nras double-mutant leukemia showed
      preferential sensitivity to MAPK kinase (MEK) inhibition in both mouse model and 
      patient samples. These data provide insights into how epigenetic and signaling
      mutations cooperate in myeloid transformation and provide a rationale for
      mechanism-based therapy in CMML patients with these high-risk genetic lesions.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kunimoto, Hiroyoshi
AU  - Kunimoto H
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Meydan, Cem
AU  - Meydan C
AD  - Institute for Computational Biomedicine and Department of Physiology and
      Biophysics, Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Nazir, Abbas
AU  - Nazir A
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Whitfield, Justin
AU  - Whitfield J
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Shank, Kaitlyn
AU  - Shank K
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Rapaport, Franck
AU  - Rapaport F
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Hematologic Malignancies, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Maher, Rebecca
AU  - Maher R
AD  - University of Connecticut School of Medicine, Farmington, CT 06032, USA.
FAU - Pronier, Elodie
AU  - Pronier E
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Meyer, Sara C
AU  - Meyer SC
AD  - Division of Hematology, University Hospital Basel, 4031 Basel, Switzerland;
      Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
FAU - Garrett-Bakelman, Francine E
AU  - Garrett-Bakelman FE
AD  - Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical
      College, New York, NY 10065, USA; Department of Medicine, University of Virginia,
      Charlottesville, VA 22908, USA; Department of Biochemistry and Molecular
      Genetics, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Tallman, Martin
AU  - Tallman M
AD  - Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Melnick, Ari
AU  - Melnick A
AD  - Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical
      College, New York, NY 10065, USA; Department of Pharmacology, Weill Cornell
      Medical College, New York, NY 10065, USA.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA. Electronic address: leviner@mskcc.org.
FAU - Shih, Alan H
AU  - Shih AH
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA. Electronic address: shiha@mskcc.org.
LA  - eng
GR  - R01 CA198089/CA/NCI NIH HHS/United States
GR  - U54 OD020355/OD/NIH HHS/United States
GR  - R01 CA173636/CA/NCI NIH HHS/United States
GR  - K08 CA169055/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R35 CA197594/CA/NCI NIH HHS/United States
GR  - K08 CA181507/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171221
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5760367
MID - NIHMS922552
OTO - NOTNLM
OT  - cancer epigenetics
OT  - leukemia biology
OT  - targeted therapeutics
EDAT- 2017/12/26 06:00
MHDA- 2017/12/26 06:00
CRDT- 2017/12/26 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/03/09 00:00 [received]
PHST- 2017/10/02 00:00 [revised]
PHST- 2017/11/17 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2017/12/26 06:00 [pubmed]
PHST- 2017/12/26 06:00 [medline]
PHST- 2017/12/26 06:00 [entrez]
AID - S1535-6108(17)30515-9 [pii]
AID - 10.1016/j.ccell.2017.11.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):44-59.e8. doi: 10.1016/j.ccell.2017.11.012. Epub
      2017 Dec 21.

PMID- 29249692
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - beta2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.
PG  - 75-90.e7
LID - S1535-6108(17)30510-X [pii]
LID - 10.1016/j.ccell.2017.11.007 [doi]
AB  - Catecholamines stimulate epithelial proliferation, but the role of sympathetic
      nerve signaling in pancreatic ductal adenocarcinoma (PDAC) is poorly understood. 
      Catecholamines promoted ADRB2-dependent PDAC development, nerve growth factor
      (NGF) secretion, and pancreatic nerve density. Pancreatic Ngf overexpression
      accelerated tumor development in LSL-Kras(+/G12D);Pdx1-Cre (KC) mice. ADRB2
      blockade together with gemcitabine reduced NGF expression and nerve density, and 
      increased survival of LSL-Kras(+/G12D);LSL-Trp53(+/R172H);Pdx1-Cre (KPC) mice.
      Therapy with a Trk inhibitor together with gemcitabine also increased survival of
      KPC mice. Analysis of PDAC patient cohorts revealed a correlation between
      brain-derived neurotrophic factor (BDNF) expression, nerve density, and increased
      survival of patients on nonselective beta-blockers. These findings suggest that
      catecholamines drive a feedforward loop, whereby upregulation of neurotrophins
      increases sympathetic innervation and local norepinephrine accumulation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Renz, Bernhard W
AU  - Renz BW
AD  - Department of General, Visceral and Transplantation Surgery, Hospital of the
      University of Munich, 81377 Munich, Germany; Department of Digestive and Liver
      Diseases and Herbert Irving Comprehensive Cancer Center, Columbia University
      Medical Center, 1130 St. Nicholas Avenue, New York, NY 10032, USA.
FAU - Takahashi, Ryota
AU  - Takahashi R
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Tanaka, Takayuki
AU  - Tanaka T
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Macchini, Marina
AU  - Macchini M
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA; Department of Oncology, IRCCS San Raffaele Scientific
      Institute, 20132 Milan, Italy.
FAU - Hayakawa, Yoku
AU  - Hayakawa Y
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA; Department of Gastroenterology, Graduate School of Medicine,
      The University of Tokyo, Tokyo 113-8655, Japan.
FAU - Dantes, Zahra
AU  - Dantes Z
AD  - Department of Medicine II, Klinikum Rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Maurer, H Carlo
AU  - Maurer HC
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Chen, Xiaowei
AU  - Chen X
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Jiang, Zhengyu
AU  - Jiang Z
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Westphalen, C Benedikt
AU  - Westphalen CB
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA; Department of Internal Medicine III, Hospital of the
      University of Munich, 81377 Munich, Germany.
FAU - Ilmer, Matthias
AU  - Ilmer M
AD  - Department of General, Visceral and Transplantation Surgery, Hospital of the
      University of Munich, 81377 Munich, Germany.
FAU - Valenti, Giovanni
AU  - Valenti G
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Mohanta, Sarajo K
AU  - Mohanta SK
AD  - Institute for Cardiovascular Prevention, University of Munich, 80336 Munich,
      Germany.
FAU - Habenicht, Andreas J R
AU  - Habenicht AJR
AD  - Institute for Cardiovascular Prevention, University of Munich, 80336 Munich,
      Germany.
FAU - Middelhoff, Moritz
AU  - Middelhoff M
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Chu, Timothy
AU  - Chu T
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Nagar, Karan
AU  - Nagar K
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Tailor, Yagnesh
AU  - Tailor Y
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA.
FAU - Casadei, Riccardo
AU  - Casadei R
AD  - Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum,
      University of Bologna, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
FAU - Di Marco, Mariacristina
AU  - Di Marco M
AD  - Department of Experimental, Diagnostic and Specialty Medicine, University of
      Bologna, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
FAU - Kleespies, Axel
AU  - Kleespies A
AD  - Department of General, Visceral and Transplantation Surgery, Hospital of the
      University of Munich, 81377 Munich, Germany.
FAU - Friedman, Richard A
AU  - Friedman RA
AD  - Biomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer
      Center, Department of Biomedical Informatics, Columbia University Medical Center,
      New York, NY 10032, USA.
FAU - Remotti, Helen
AU  - Remotti H
AD  - Department of Pathology and Cell Biology, Columbia University Medical Center, New
      York, NY 10032, USA.
FAU - Reichert, Maximilian
AU  - Reichert M
AD  - Department of Medicine II, Klinikum Rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Worthley, Daniel L
AU  - Worthley DL
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA; Department of Medicine, University of Adelaide, Adelaide, SA
      5005, Australia.
FAU - Neumann, Jens
AU  - Neumann J
AD  - Department of Pathology, Hospital of the University of Munich, 81377 Munich,
      Germany.
FAU - Werner, Jens
AU  - Werner J
AD  - Department of General, Visceral and Transplantation Surgery, Hospital of the
      University of Munich, 81377 Munich, Germany.
FAU - Iuga, Alina C
AU  - Iuga AC
AD  - Department of Pathology and Cell Biology, Columbia University Medical Center, New
      York, NY 10032, USA.
FAU - Olive, Kenneth P
AU  - Olive KP
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia
      University Medical Center, New York, NY 10032, USA.
FAU - Wang, Timothy C
AU  - Wang TC
AD  - Department of Digestive and Liver Diseases and Herbert Irving Comprehensive
      Cancer Center, Columbia University Medical Center, 1130 St. Nicholas Avenue, New 
      York, NY 10032, USA. Electronic address: tcw21@columbia.edu.
LA  - eng
GR  - P30 CA013696/CA/NCI NIH HHS/United States
GR  - R35 CA210088/CA/NCI NIH HHS/United States
GR  - S10 RR025686/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20171214
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5760435
MID - NIHMS925997
OTO - NOTNLM
OT  - NGF-BDNF
OT  - TRK
OT  - adrenergic signaling
OT  - neurotrophins
OT  - pancreatic cancer
OT  - stress
OT  - beta-blockers
EDAT- 2017/12/19 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/12/19 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/04/03 00:00 [received]
PHST- 2017/08/09 00:00 [revised]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/12/19 06:00 [entrez]
AID - S1535-6108(17)30510-X [pii]
AID - 10.1016/j.ccell.2017.11.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):75-90.e7. doi: 10.1016/j.ccell.2017.11.007. Epub
      2017 Dec 14.

PMID- 29249691
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases
      Therapeutic Efficacy in Myeloproliferative Neoplasms.
PG  - 29-43.e7
LID - S1535-6108(17)30512-3 [pii]
LID - 10.1016/j.ccell.2017.11.009 [doi]
AB  - Genetic and functional studies underscore the central role of JAK/STAT signaling 
      in myeloproliferative neoplasms (MPNs). However, the mechanisms that mediate
      transformation in MPNs are not fully delineated, and clinically utilized JAK
      inhibitors have limited ability to reduce disease burden or reverse
      myelofibrosis. Here we show that MPN progenitor cells are characterized by marked
      alterations in gene regulation through differential enhancer utilization, and
      identify nuclear factor kappaB (NF-kappaB) signaling as a key pathway activated
      in malignant and non-malignant cells in MPN. Inhibition of BET bromodomain
      proteins attenuated NF-kappaB signaling and reduced cytokine production in vivo. 
      Most importantly, combined JAK/BET inhibition resulted in a marked reduction in
      the serum levels of inflammatory cytokines, reduced disease burden, and reversed 
      bone marrow fibrosis in vivo.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kleppe, Maria
AU  - Kleppe M
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA; Center for Epigenetics
      Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Koche, Richard
AU  - Koche R
AD  - Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Zou, Lihua
AU  - Zou L
AD  - Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - van Galen, Peter
AU  - van Galen P
AD  - Department of Pathology Massachusetts General Hospital, Harvard Medical School,
      Broad Institute of Harvard and MIT, Boston, MA, USA.
FAU - Hill, Corinne E
AU  - Hill CE
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Dong, Lauren
AU  - Dong L
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - De Groote, Sofie
AU  - De Groote S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Papalexi, Efthymia
AU  - Papalexi E
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Hanasoge Somasundara, Amritha V
AU  - Hanasoge Somasundara AV
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Cordner, Keith
AU  - Cordner K
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Keller, Matthew
AU  - Keller M
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Farnoud, Noushin
AU  - Farnoud N
AD  - Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer 
      Center, New York, NY 10065, USA.
FAU - Medina, Juan
AU  - Medina J
AD  - Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - McGovern, Erin
AU  - McGovern E
AD  - Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Reyes, Jaime
AU  - Reyes J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street,
      Boston, MA 02115, USA.
FAU - Roberts, Justin
AU  - Roberts J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street,
      Boston, MA 02115, USA.
FAU - Witkin, Matthew
AU  - Witkin M
AD  - Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Rapaport, Franck
AU  - Rapaport F
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Teruya-Feldstein, Julie
AU  - Teruya-Feldstein J
AD  - Department of Pathology, Icahn School of Medicine, Mount Sinai, New York, NY,
      USA.
FAU - Qi, Jun
AU  - Qi J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street,
      Boston, MA 02115, USA.
FAU - Rampal, Raajit
AU  - Rampal R
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA; Leukemia Service, Department
      of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Bernstein, Bradley E
AU  - Bernstein BE
AD  - Department of Pathology Massachusetts General Hospital, Harvard Medical School,
      Broad Institute of Harvard and MIT, Boston, MA, USA.
FAU - Bradner, James E
AU  - Bradner JE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street,
      Boston, MA 02115, USA. Electronic address: james.bradner@novartis.com.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      1275 York Avenue, Box 20, New York, NY 10065, USA; Center for Epigenetics
      Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Center
      for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York,
      NY 10065, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering
      Cancer Center, New York, NY, USA. Electronic address: leviner@mskcc.org.
LA  - eng
GR  - R01 CA173636/CA/NCI NIH HHS/United States
GR  - K99 HL122503/HL/NHLBI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R35 CA197594/CA/NCI NIH HHS/United States
GR  - K08 CA181507/CA/NCI NIH HHS/United States
GR  - R01 CA151949/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171214
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5760343
MID - NIHMS921965
OTO - NOTNLM
OT  - H3K27ac
OT  - JQ1
OT  - NF-kappaB
OT  - chronic inflammation
OT  - myeloproliferative neoplasms
EDAT- 2017/12/19 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/12/19 06:00
PMCR- 2019/01/08 00:00
PHST- 2016/12/07 00:00 [received]
PHST- 2017/07/13 00:00 [revised]
PHST- 2017/11/13 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/12/19 06:00 [entrez]
AID - S1535-6108(17)30512-3 [pii]
AID - 10.1016/j.ccell.2017.11.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):29-43.e7. doi: 10.1016/j.ccell.2017.11.009. Epub
      2017 Dec 14.

PMID- 29232558
OWN - NLM
STAT- In-Data-Review
LR  - 20180120
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - High-throughput Phenotyping of Lung Cancer Somatic Mutations.
PG  - 884
LID - S1535-6108(17)30511-1 [pii]
LID - 10.1016/j.ccell.2017.11.008 [doi]
FAU - Berger, Alice H
AU  - Berger AH
FAU - Brooks, Angela N
AU  - Brooks AN
FAU - Wu, Xiaoyun
AU  - Wu X
FAU - Shrestha, Yashaswi
AU  - Shrestha Y
FAU - Chouinard, Candace
AU  - Chouinard C
FAU - Piccioni, Federica
AU  - Piccioni F
FAU - Bagul, Mukta
AU  - Bagul M
FAU - Kamburov, Atanas
AU  - Kamburov A
FAU - Imielinski, Marcin
AU  - Imielinski M
FAU - Hogstrom, Larson
AU  - Hogstrom L
FAU - Zhu, Cong
AU  - Zhu C
FAU - Yang, Xiaoping
AU  - Yang X
FAU - Pantel, Sasha
AU  - Pantel S
FAU - Sakai, Ryo
AU  - Sakai R
FAU - Watson, Jacqueline
AU  - Watson J
FAU - Kaplan, Nathan
AU  - Kaplan N
FAU - Campbell, Joshua D
AU  - Campbell JD
FAU - Singh, Shantanu
AU  - Singh S
FAU - Root, David E
AU  - Root DE
FAU - Narayan, Rajiv
AU  - Narayan R
FAU - Natoli, Ted
AU  - Natoli T
FAU - Lahr, David L
AU  - Lahr DL
FAU - Tirosh, Itay
AU  - Tirosh I
FAU - Tamayo, Pablo
AU  - Tamayo P
FAU - Getz, Gad
AU  - Getz G
FAU - Wong, Bang
AU  - Wong B
FAU - Doench, John
AU  - Doench J
FAU - Subramanian, Aravind
AU  - Subramanian A
FAU - Golub, Todd R
AU  - Golub TR
FAU - Meyerson, Matthew
AU  - Meyerson M
FAU - Boehm, Jesse S
AU  - Boehm JS
LA  - eng
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Aug 8;30(2):214-228. PMID: 27478040
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - S1535-6108(17)30511-1 [pii]
AID - 10.1016/j.ccell.2017.11.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):884. doi: 10.1016/j.ccell.2017.11.008.

PMID- 29232557
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis.
PG  - 869-883.e5
LID - S1535-6108(17)30507-X [pii]
LID - 10.1016/j.ccell.2017.11.004 [doi]
AB  - Increased oxidative stress has been suggested to initiate and promote
      tumorigenesis by inducing DNA damage and to suppress tumor development by
      triggering apoptosis and senescence. The contribution of individual cell types in
      the tumor microenvironment to these contrasting effects remains poorly
      understood. We provide evidence that during intestinal tumorigenesis, myeloid
      cell-derived H2O2 triggers genome-wide DNA mutations in intestinal epithelial
      cells to stimulate invasive growth. Moreover, increased reactive oxygen species
      (ROS) production in myeloid cells initiates tumor growth in various organs also
      in the absence of a carcinogen challenge in a paracrine manner. Our data identify
      an intricate crosstalk between myeloid cell-derived ROS molecules, oxidative DNA 
      damage, and tumor necrosis factor alpha-mediated signaling to orchestrate a
      tumor-promoting microenvironment causing invasive cancer.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Canli, Ozge
AU  - Canli O
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany.
FAU - Nicolas, Adele M
AU  - Nicolas AM
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany.
FAU - Gupta, Jalaj
AU  - Gupta J
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany.
FAU - Finkelmeier, Fabian
AU  - Finkelmeier F
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany; Department of Gastroenterology, Hepatology and
      Endocrinology, Frankfurt Medical School, 60590 Frankfurt/Main, Germany.
FAU - Goncharova, Olga
AU  - Goncharova O
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany.
FAU - Pesic, Marina
AU  - Pesic M
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany.
FAU - Neumann, Tobias
AU  - Neumann T
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany.
FAU - Horst, David
AU  - Horst D
AD  - Institute of Pathology, University of Munich, 80337 Munich, Germany; German
      Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Lower, Martin
AU  - Lower M
AD  - TRON - Translational Oncology at the University Medical Center of Johannes
      Gutenberg University gGmbH, 55131 Mainz, Germany.
FAU - Sahin, Ugur
AU  - Sahin U
AD  - German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; TRON - Translational Oncology at the University Medical
      Center of Johannes Gutenberg University gGmbH, 55131 Mainz, Germany; University
      Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
FAU - Greten, Florian R
AU  - Greten FR
AD  - Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596
      Frankfurt/Main, Germany; German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), 69120 Heidelberg, Germany. Electronic address:
      greten@gsh.uni-frankfurt.de.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Reactive Oxygen Species)
RN  - BBX060AN9V (Hydrogen Peroxide)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - DNA Damage/drug effects
MH  - Epithelial Cells/metabolism/*pathology
MH  - Hydrogen Peroxide/pharmacology
MH  - Mice
MH  - Mice, Mutant Strains
MH  - Mutagenesis/*physiology
MH  - Mutation
MH  - Myeloid Cells/*metabolism
MH  - Oxidative Stress/*physiology
MH  - Reactive Oxygen Species/*metabolism
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - GPx4
OT  - cancer initiation
OT  - chronic inflammation
OT  - myeloid cells
OT  - oxidative stress
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/04/10 00:00 [received]
PHST- 2017/08/22 00:00 [revised]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30507-X [pii]
AID - 10.1016/j.ccell.2017.11.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):869-883.e5. doi: 10.1016/j.ccell.2017.11.004.

PMID- 29232556
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20180405
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and 
      Radioresistance in Glioblastoma.
PG  - 840-855.e8
LID - S1535-6108(17)30508-1 [pii]
LID - 10.1016/j.ccell.2017.11.005 [doi]
AB  - ATG4B stimulates autophagy by promoting autophagosome formation through
      reversible modification of ATG8. We identify ATG4B as a substrate of mammalian
      sterile20-like kinase (STK) 26/MST4. MST4 phosphorylates ATG4B at serine residue 
      383, which stimulates ATG4B activity and increases autophagic flux. Inhibition of
      MST4 or ATG4B activities using genetic approaches or an inhibitor of ATG4B
      suppresses autophagy and the tumorigenicity of glioblastoma (GBM) cells.
      Furthermore, radiation induces MST4 expression, ATG4B phosphorylation, and
      autophagy. Inhibiting ATG4B in combination with radiotherapy in treating mice
      with intracranial GBM xenograft markedly slows tumor growth and provides a
      significant survival benefit. Our work describes an MST4-ATG4B signaling axis
      that influences GBM autophagy and malignancy, and whose therapeutic targeting
      enhances the anti-tumor effects of radiotherapy.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Huang, Tianzhi
AU  - Huang T
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Kim, Chung Kwon
AU  - Kim CK
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Alvarez, Angel A
AU  - Alvarez AA
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Pangeni, Rajendra P
AU  - Pangeni RP
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Wan, Xuechao
AU  - Wan X
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Song, Xiao
AU  - Song X
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Shi, Taiping
AU  - Shi T
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Yang, Yongyong
AU  - Yang Y
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Sastry, Namratha
AU  - Sastry N
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Horbinski, Craig M
AU  - Horbinski CM
AD  - The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive
      Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
      60611, USA; Department of Neurological Surgery, Northwestern University Feinberg 
      School of Medicine, Chicago, IL 60611, USA.
FAU - Lu, Songjian
AU  - Lu S
AD  - Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
      15206, USA.
FAU - Stupp, Roger
AU  - Stupp R
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Kessler, John A
AU  - Kessler JA
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Nishikawa, Ryo
AU  - Nishikawa R
AD  - Department of Neuro-Oncology/Neurosurgery, Saitama Medical University
      International Medical Center, Saitama 350-1298, Japan.
FAU - Nakano, Ichiro
AU  - Nakano I
AD  - Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL
      35294, USA.
FAU - Sulman, Erik P
AU  - Sulman EP
AD  - Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer
      Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA.
FAU - Lu, Xinghua
AU  - Lu X
AD  - Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
      15206, USA.
FAU - James, Charles David
AU  - James CD
AD  - The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive
      Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
      60611, USA; Department of Neurological Surgery, Northwestern University Feinberg 
      School of Medicine, Chicago, IL 60611, USA.
FAU - Yin, Xiao-Ming
AU  - Yin XM
AD  - Department of Pathology & Laboratory Medicine, Indiana University, Indianapolis, 
      IN 46202, USA.
FAU - Hu, Bo
AU  - Hu B
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic
      address: bo.hu@northwestern.edu.
FAU - Cheng, Shi-Yuan
AU  - Cheng SY
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic
      address: shiyuan.cheng@northwestern.edu.
LA  - eng
GR  - L32 MD010147/MD/NIMHD NIH HHS/United States
GR  - R01 NS083767/NS/NINDS NIH HHS/United States
GR  - R01 NS080619/NS/NINDS NIH HHS/United States
GR  - R01 NS095634/NS/NINDS NIH HHS/United States
GR  - R21 CA209345/CA/NCI NIH HHS/United States
GR  - K99 LM011673/LM/NLM NIH HHS/United States
GR  - R21 CA175875/CA/NCI NIH HHS/United States
GR  - R01 NS102669/NS/NINDS NIH HHS/United States
GR  - R01 CA159467/CA/NCI NIH HHS/United States
GR  - P30 NS081774/NS/NINDS NIH HHS/United States
GR  - R01 CA159811/CA/NCI NIH HHS/United States
GR  - R01 NS093843/NS/NINDS NIH HHS/United States
GR  - R01 AA021751/AA/NIAAA NIH HHS/United States
GR  - T32 CA070085/CA/NCI NIH HHS/United States
GR  - P01 CA163205/CA/NCI NIH HHS/United States
GR  - R00 LM011673/LM/NLM NIH HHS/United States
GR  - R01 LM012011/LM/NLM NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Autophagy-Related Proteins)
RN  - EC 2.7.1.- (MST4 protein, human)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 3.4.22.- (ATG4B protein, human)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
SB  - IM
MH  - Animals
MH  - Autophagy/*physiology
MH  - Autophagy-Related Proteins/*metabolism
MH  - Brain Neoplasms/metabolism/*pathology
MH  - Carcinogenesis/metabolism
MH  - Cell Line, Tumor
MH  - Cysteine Endopeptidases/*metabolism
MH  - Glioblastoma/metabolism/*pathology
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Phosphorylation
MH  - Protein-Serine-Threonine Kinases/*metabolism
MH  - Radiation Tolerance
MH  - Xenograft Model Antitumor Assays
PMC - PMC5734934
OTO - NOTNLM
OT  - ATG4B
OT  - ATG4B inhibitor NSC185058
OT  - MST4/STK26
OT  - autophagy
OT  - combination therapy
OT  - glioblastoma
OT  - glioma stem-like cells
OT  - phosphorylation
OT  - tumor response to radiation
OT  - tumorigenicity
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/09/11 00:00 [revised]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30508-1 [pii]
AID - 10.1016/j.ccell.2017.11.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):840-855.e8. doi: 10.1016/j.ccell.2017.11.005.

PMID- 29232555
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - mTORC2 Promotes Tumorigenesis via Lipid Synthesis.
PG  - 807-823.e12
LID - S1535-6108(17)30514-7 [pii]
LID - 10.1016/j.ccell.2017.11.011 [doi]
AB  - Dysregulated mammalian target of rapamycin (mTOR) promotes cancer, but underlying
      mechanisms are poorly understood. We describe an mTOR-driven mouse model that
      displays hepatosteatosis progressing to hepatocellular carcinoma (HCC).
      Longitudinal proteomic, lipidomics, and metabolomic analyses revealed that
      hepatic mTORC2 promotes de novo fatty acid and lipid synthesis, leading to
      steatosis and tumor development. In particular, mTORC2 stimulated sphingolipid
      (glucosylceramide) and glycerophospholipid (cardiolipin) synthesis. Inhibition of
      fatty acid or sphingolipid synthesis prevented tumor development, indicating a
      causal effect in tumorigenesis. Increased levels of cardiolipin were associated
      with tubular mitochondria and enhanced oxidative phosphorylation. Furthermore,
      increased lipogenesis correlated with elevated mTORC2 activity and HCC in human
      patients. Thus, mTORC2 promotes cancer via formation of lipids essential for
      growth and energy production.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Guri, Yakir
AU  - Guri Y
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Colombi, Marco
AU  - Colombi M
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Dazert, Eva
AU  - Dazert E
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Hindupur, Sravanth K
AU  - Hindupur SK
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Roszik, Jason
AU  - Roszik J
AD  - Departments of Melanoma Medical Oncology and Genomic Medicine, The University of 
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Moes, Suzette
AU  - Moes S
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Jenoe, Paul
AU  - Jenoe P
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Heim, Markus H
AU  - Heim MH
AD  - Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
FAU - Riezman, Isabelle
AU  - Riezman I
AD  - NCCR Chemical Biology, Department of Biochemistry, University of Geneva, 1211
      Geneva, Switzerland.
FAU - Riezman, Howard
AU  - Riezman H
AD  - NCCR Chemical Biology, Department of Biochemistry, University of Geneva, 1211
      Geneva, Switzerland.
FAU - Hall, Michael N
AU  - Hall MN
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland. Electronic address:
      m.hall@unibas.ch.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Lipids)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
SB  - IM
MH  - Animals
MH  - Carcinogenesis/*metabolism
MH  - Carcinoma, Hepatocellular/etiology/*metabolism
MH  - Cell Transformation, Neoplastic/metabolism
MH  - Fatty Liver/complications/*metabolism
MH  - Humans
MH  - Lipids/biosynthesis
MH  - Lipogenesis/*physiology
MH  - Liver Neoplasms/etiology/*metabolism
MH  - Mechanistic Target of Rapamycin Complex 2/*metabolism
MH  - Mice
MH  - Mice, Knockout
OTO - NOTNLM
OT  - NAFLD
OT  - NASH
OT  - cardiolipin
OT  - glycosphingolipid
OT  - hepatocellular carcinoma
OT  - hepatosteatosis
OT  - mTOR
OT  - mitochondria
OT  - oxidative phosphorylation
OT  - sphingolipid
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PHST- 2016/10/28 00:00 [received]
PHST- 2017/08/06 00:00 [revised]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30514-7 [pii]
AID - 10.1016/j.ccell.2017.11.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):807-823.e12. doi: 10.1016/j.ccell.2017.11.011.

PMID- 29232554
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced
      Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
PG  - 761-776.e6
LID - S1535-6108(17)30509-3 [pii]
LID - 10.1016/j.ccell.2017.11.006 [doi]
AB  - Most cancers preserve functional retinoblastoma (Rb) and may, therefore, respond 
      to inhibition of D-cyclin-dependent Rb kinases, CDK4 and CDK6. To date, CDK4/6
      inhibitors have shown promising clinical activity in breast cancer and lymphomas,
      but it is not clear which additional Rb-positive cancers might benefit from these
      agents. No systematic survey to compare relative sensitivities across tumor types
      and define molecular determinants of response has been described. We report a
      subset of cancers highly sensitive to CDK4/6 inhibition and characterized by
      various genomic aberrations known to elevate D-cyclin levels and describe a
      recurrent CCND1 3'UTR mutation associated with increased expression in
      endometrial cancer. The results suggest multiple additional classes of cancer
      that may benefit from CDK4/6-inhibiting drugs such as abemaciclib.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gong, Xueqian
AU  - Gong X
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Litchfield, Lacey M
AU  - Litchfield LM
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Webster, Yue
AU  - Webster Y
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Chio, Li-Chun
AU  - Chio LC
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Wong, Swee Seong
AU  - Wong SS
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Stewart, Trent R
AU  - Stewart TR
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Dowless, Michele
AU  - Dowless M
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Dempsey, Jack
AU  - Dempsey J
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Zeng, Yi
AU  - Zeng Y
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Torres, Raquel
AU  - Torres R
AD  - Eli Lilly and Company, Alcobendas, Madrid, Spain.
FAU - Boehnke, Karsten
AU  - Boehnke K
AD  - Eli Lilly and Company, Alcobendas, Madrid, Spain.
FAU - Mur, Cecilia
AU  - Mur C
AD  - Eli Lilly and Company, Alcobendas, Madrid, Spain.
FAU - Marugan, Carlos
AU  - Marugan C
AD  - Eli Lilly and Company, Alcobendas, Madrid, Spain.
FAU - Baquero, Carmen
AU  - Baquero C
AD  - Eli Lilly and Company, Alcobendas, Madrid, Spain.
FAU - Yu, Chunping
AU  - Yu C
AD  - Eli Lilly and Company, Shanghai, China.
FAU - Bray, Steven M
AU  - Bray SM
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Wulur, Isabella H
AU  - Wulur IH
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Bi, Chen
AU  - Bi C
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Chu, Shaoyou
AU  - Chu S
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Qian, Hui-Rong
AU  - Qian HR
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Iversen, Philip W
AU  - Iversen PW
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Merzoug, Farhana F
AU  - Merzoug FF
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Ye, Xiang S
AU  - Ye XS
AD  - Eli Lilly and Company, Shanghai, China.
FAU - Reinhard, Christoph
AU  - Reinhard C
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - De Dios, Alfonso
AU  - De Dios A
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Du, Jian
AU  - Du J
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Caldwell, Charles W
AU  - Caldwell CW
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Lallena, Maria Jose
AU  - Lallena MJ
AD  - Eli Lilly and Company, Alcobendas, Madrid, Spain.
FAU - Beckmann, Richard P
AU  - Beckmann RP
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Buchanan, Sean G
AU  - Buchanan SG
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA. Electronic address:
      buchananse@lilly.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2
      -methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine)
RN  - 0 (Aminopyridines)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Cyclin D)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
SB  - IM
MH  - Aminopyridines/*pharmacology
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Benzimidazoles/*pharmacology
MH  - Cell Proliferation/drug effects
MH  - Clinical Trials, Phase I as Topic
MH  - Cyclin D/genetics/*metabolism
MH  - Cyclin-Dependent Kinase 4/antagonists & inhibitors
MH  - Cyclin-Dependent Kinase 6/antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Neoplasms/drug therapy/*genetics/metabolism
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - CCND1
OT  - CCND2
OT  - CCND3
OT  - CDK2
OT  - CDKN2A
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/02/20 00:00 [received]
PHST- 2017/08/10 00:00 [revised]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30509-3 [pii]
AID - 10.1016/j.ccell.2017.11.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):761-776.e6. doi: 10.1016/j.ccell.2017.11.006.

PMID- 29232553
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML:
      Mechanisms and Superior Antileukemic Efficacy.
PG  - 748-760.e6
LID - S1535-6108(17)30502-0 [pii]
LID - 10.1016/j.ccell.2017.11.003 [doi]
AB  - Evasion of apoptosis is a hallmark of cancer. Bcl-2 and p53 represent two
      important nodes in apoptosis signaling pathways. We find that concomitant p53
      activation and Bcl-2 inhibition overcome apoptosis resistance and markedly
      prolong survival in three mouse models of resistant acute myeloid leukemia (AML).
      Mechanistically, p53 activation negatively regulates the Ras/Raf/MEK/ERK pathway 
      and activates GSK3 to modulate Mcl-1 phosphorylation and promote its degradation,
      thus overcoming AML resistance to Bcl-2 inhibition. Moreover, Bcl-2 inhibition
      reciprocally overcomes apoptosis resistance to p53 activation by switching
      cellular response from G1 arrest to apoptosis. The efficacy, together with the
      mechanistic findings, reveals the potential of simultaneously targeting these two
      apoptosis regulators and provides a rational basis for clinical testing of this
      therapeutic approach.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Pan, Rongqing
AU  - Pan R
AD  - Section of Molecular Hematology and Therapy, Department of Leukemia, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ruvolo, Vivian
AU  - Ruvolo V
AD  - Section of Molecular Hematology and Therapy, Department of Leukemia, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Mu, Hong
AU  - Mu H
AD  - Section of Molecular Hematology and Therapy, Department of Leukemia, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Leverson, Joel D
AU  - Leverson JD
AD  - AbbVie Inc., North Chicago, IL 60064, USA.
FAU - Nichols, Gwen
AU  - Nichols G
AD  - Roche Pharmaceutical Research & Early Development, Roche Innovation Center New
      York, New York, NY 10016, USA.
FAU - Reed, John C
AU  - Reed JC
AD  - Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070
      Basel, Switzerland.
FAU - Konopleva, Marina
AU  - Konopleva M
AD  - Section of Molecular Hematology and Therapy, Department of Leukemia, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Andreeff, Michael
AU  - Andreeff M
AD  - Section of Molecular Hematology and Therapy, Department of Leukemia, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic
      address: mandreef@mdanderson.org.
LA  - eng
GR  - P01 CA055164/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Pyrrolidines)
RN  - 0 (RG7388)
RN  - 0 (Sulfonamides)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (para-Aminobenzoates)
RN  - N54AIC43PW (venetoclax)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Apoptosis/drug effects
MH  - Bridged Bicyclo Compounds, Heterocyclic/pharmacology
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*pathology
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors
MH  - Pyrrolidines/pharmacology
MH  - Sulfonamides/pharmacology
MH  - Synthetic Lethal Mutations/*drug effects
MH  - Tumor Suppressor Protein p53/*metabolism
MH  - Xenograft Model Antitumor Assays
MH  - para-Aminobenzoates/pharmacology
PMC - PMC5730338
MID - NIHMS922869
OTO - NOTNLM
OT  - ABT-199
OT  - Bcl-2
OT  - G(1) arrest
OT  - MAPK
OT  - MDM2
OT  - Mcl-1
OT  - RG7388
OT  - apoptosis resistance
OT  - leukemia
OT  - p53
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PMCR- 2018/12/11 00:00
PHST- 2016/12/12 00:00 [received]
PHST- 2017/09/16 00:00 [revised]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2018/12/11 00:00 [pmc-release]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30502-0 [pii]
AID - 10.1016/j.ccell.2017.11.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):748-760.e6. doi: 10.1016/j.ccell.2017.11.003.

PMID- 29232552
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1
      Sensitizes Bone Metastasis to Chemotherapy.
PG  - 731-747.e6
LID - S1535-6108(17)30472-5 [pii]
LID - 10.1016/j.ccell.2017.11.002 [doi]
AB  - Bone metastasis is a major health threat to breast cancer patients. Tumor-derived
      Jagged1 represents a central node in mediating tumor-stromal interactions that
      promote osteolytic bone metastasis. Here, we report the development of a highly
      effective fully human monoclonal antibody against Jagged1 (clone 15D11). In
      addition to its inhibitory effect on bone metastasis of Jagged1-expressing tumor 
      cells, 15D11 dramatically sensitizes bone metastasis to chemotherapy, which
      induces Jagged1 expression in osteoblasts to provide a survival niche for cancer 
      cells. We further confirm the bone metastasis-promoting function of
      osteoblast-derived Jagged1 using osteoblast-specific Jagged1 transgenic mouse
      model. These findings establish 15D11 as a potential therapeutic agent for the
      prevention or treatment of bone metastasis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zheng, Hanqiu
AU  - Zheng H
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Bae, Yangjin
AU  - Bae Y
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, One
      Baylor Plaza, Room R814 BCM225, Houston, TX 77030, USA.
FAU - Kasimir-Bauer, Sabine
AU  - Kasimir-Bauer S
AD  - Department of Gynecology and Obstetrics, University Hospital Essen, Essen,
      Germany.
FAU - Tang, Rebecca
AU  - Tang R
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Chen, Jin
AU  - Chen J
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Ren, Guangwen
AU  - Ren G
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Yuan, Min
AU  - Yuan M
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Esposito, Mark
AU  - Esposito M
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Li, Wenyang
AU  - Li W
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Wei, Yong
AU  - Wei Y
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Shen, Minhong
AU  - Shen M
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA.
FAU - Zhang, Lanjing
AU  - Zhang L
AD  - Department of Pathology, University Medical Center of Princeton, Plainsboro, NJ, 
      USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
FAU - Tupitsyn, Nikolai
AU  - Tupitsyn N
AD  - Laboratory of Hematopoiesis Immunology, Cancer Research Center, Moscow, Russia.
FAU - Pantel, Klaus
AU  - Pantel K
AD  - Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Center 
      of Experimental Medicine, Hamburg, Germany.
FAU - King, Chadwick
AU  - King C
AD  - Oncology Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
FAU - Sun, Jan
AU  - Sun J
AD  - Oncology Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
FAU - Moriguchi, Jodi
AU  - Moriguchi J
AD  - Oncology Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
FAU - Jun, Helen Toni
AU  - Jun HT
AD  - MabVax Therapeutics Holdings, Inc., San Diego, CA 92121, USA.
FAU - Coxon, Angela
AU  - Coxon A
AD  - Oncology Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
FAU - Lee, Brendan
AU  - Lee B
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, One
      Baylor Plaza, Room R814 BCM225, Houston, TX 77030, USA. Electronic address:
      blee@bcm.edu.
FAU - Kang, Yibin
AU  - Kang Y
AD  - Department of Molecular Biology, Princeton University, Washington Road, LTL 255, 
      Princeton, NJ 08544, USA; Cancer Metabolism and Growth Program, Rutgers Cancer
      Institute of New Jersey, New Brunswick, NJ 08903, USA. Electronic address:
      ykang@princeton.edu.
LA  - eng
GR  - P30 CA072720/CA/NCI NIH HHS/United States
GR  - R01 CA134519/CA/NCI NIH HHS/United States
GR  - R01 CA141062/CA/NCI NIH HHS/United States
GR  - R01 CA212410/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Jagged-1 Protein)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Bone Neoplasms/*drug therapy/*secondary
MH  - Humans
MH  - Jagged-1 Protein/*antagonists & inhibitors
MH  - Mice
MH  - Mice, Transgenic
MH  - Osteoblasts/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC5729937
MID - NIHMS919652
OTO - NOTNLM
OT  - Jagged1
OT  - bone metastasis
OT  - breast cancer
OT  - chemoresistance
OT  - neutralizing antibody
OT  - osteoblastic niche
OT  - osteoblasts
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PMCR- 2018/12/11 00:00
PHST- 2017/05/26 00:00 [received]
PHST- 2017/09/22 00:00 [revised]
PHST- 2017/11/03 00:00 [accepted]
PHST- 2018/12/11 00:00 [pmc-release]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30472-5 [pii]
AID - 10.1016/j.ccell.2017.11.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):731-747.e6. doi: 10.1016/j.ccell.2017.11.002.

PMID- 29232551
OWN - NLM
STAT- In-Process
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Inflammation, ROS, and Mutagenesis.
PG  - 727-729
LID - S1535-6108(17)30518-4 [pii]
LID - 10.1016/j.ccell.2017.11.015 [doi]
AB  - It has long been hypothesized that reactive oxygen species (ROS) are responsible 
      for the association between chronic inflammatory diseases and increased tumor
      incidence. In this issue of Cancer Cell, Canli et al. now demonstrate that
      amplified ROS production specifically by myeloid cells is sufficient to promote
      intestinal mutagenesis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - El-Kenawi, Asmaa
AU  - El-Kenawi A
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      Tampa, FL 33612, USA.
FAU - Ruffell, Brian
AU  - Ruffell B
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      Tampa, FL 33612, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center
      and Research Institute, Tampa, FL 33612, USA. Electronic address:
      brian.ruffell@moffitt.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - S1535-6108(17)30518-4 [pii]
AID - 10.1016/j.ccell.2017.11.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):727-729. doi: 10.1016/j.ccell.2017.11.015.

PMID- 29232550
OWN - NLM
STAT- In-Process
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Glut3 Addiction: A Druggable Vulnerability in Glioblastoma.
PG  - 726-727
LID - S1535-6108(17)30520-2 [pii]
LID - 10.1016/j.ccell.2017.11.017 [doi]
AB  - The link between GBM molecular subtype and response to treatment remains
      undefined. In this issue of Cancer Cell, Cosset and colleagues define a
      subpopulation of patients within the proneural/classical subtype sensitive to
      integrin blockade because of a Glut3 addiction. These findings reveal
      context-dependent druggable vulnerability in a subpopulation of GBM.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Bunda, Severa
AU  - Bunda S
AD  - Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
FAU - Zadeh, Gelareh
AU  - Zadeh G
AD  - Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
FAU - Aldape, Kenneth D
AU  - Aldape KD
AD  - Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
      Electronic address: kaldape@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - S1535-6108(17)30520-2 [pii]
AID - 10.1016/j.ccell.2017.11.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):726-727. doi: 10.1016/j.ccell.2017.11.017.

PMID- 29232549
OWN - NLM
STAT- In-Process
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Stressing Out PanIN: NRF2 Pushes over the Edge.
PG  - 723-725
LID - S1535-6108(17)30517-2 [pii]
LID - 10.1016/j.ccell.2017.11.014 [doi]
AB  - The mechanisms by which chronic stress promote the development of pancreatic
      ductal adenocarcinoma (PDAC) are poorly defined. In this issue of Cancer Cell,
      Todoric et al. discover a role for impaired autophagy in the development of PDAC 
      through p62-mediated activation of NRF2.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Torrente, Laura
AU  - Torrente L
AD  - Department of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and
      Research Institute, Tampa, FL 33612, USA.
FAU - DeNicola, Gina M
AU  - DeNicola GM
AD  - Department of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and
      Research Institute, Tampa, FL 33612, USA. Electronic address:
      gina.denicola@moffitt.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - S1535-6108(17)30517-2 [pii]
AID - 10.1016/j.ccell.2017.11.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):723-725. doi: 10.1016/j.ccell.2017.11.014.

PMID- 29232548
OWN - NLM
STAT- In-Process
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress
      in an Elusive Search.
PG  - 721-723
LID - S1535-6108(17)30516-0 [pii]
LID - 10.1016/j.ccell.2017.11.013 [doi]
AB  - In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560
      cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers
      with specific genomic "D-cyclin activating features (DCAF)" as particularly
      vulnerable. These findings will facilitate patient selection as development of
      this drug class continues.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Shapiro, Geoffrey I
AU  - Shapiro GI
AD  - Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA. Electronic address:
      geoffrey_shapiro@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - S1535-6108(17)30516-0 [pii]
AID - 10.1016/j.ccell.2017.11.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):721-723. doi: 10.1016/j.ccell.2017.11.013.

PMID- 29232547
OWN - NLM
STAT- In-Process
LR  - 20180403
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - AML Therapy: Wake Up the Guardian and Cut Loose the Executioners.
PG  - 719-720
LID - S1535-6108(17)30513-5 [pii]
LID - 10.1016/j.ccell.2017.11.010 [doi]
AB  - In this issue of Cancer Cell, Pan et al. show that a combination therapy designed
      to reactivate the p53 tumor suppressor while antagonizing the anti-apoptotic
      function of Bcl-2 is highly active in preclinical models of refractory acute
      myeloid leukemia (AML). The results may move the needle in this hard-to-treat
      malignancy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Altieri, Dario C
AU  - Altieri DC
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA. Electronic address: daltieri@wistar.org.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - S1535-6108(17)30513-5 [pii]
AID - 10.1016/j.ccell.2017.11.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):719-720. doi: 10.1016/j.ccell.2017.11.010.

PMID- 29232546
OWN - NLM
STAT- In-Process
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Breaking Down Barriers to Chemoresistance: Role of Chemotherapy-Induced
      Osteoblastic Jagged1.
PG  - 717-718
LID - S1535-6108(17)30519-6 [pii]
LID - 10.1016/j.ccell.2017.11.016 [doi]
AB  - Bone metastases are incurable. The bone microenvironment has always been a
      suspect for this clinical enigma, but the exact mechanisms have been unclear. In 
      this issue of Cancer Cell, Zheng and colleagues provide evidence that
      chemotherapy itself induces chemoresistance of bone metastases, mediated by
      osteoblast Jagged1-induced tumor Notch signaling.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Mohammad, Khalid S
AU  - Mohammad KS
AD  - Department of Medicine, Division of Endocrinology, Indiana University,
      Indianapolis, IN, USA.
FAU - Guise, Theresa A
AU  - Guise TA
AD  - Department of Medicine, Division of Endocrinology, Indiana University,
      Indianapolis, IN, USA. Electronic address: tguise@iu.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - S1535-6108(17)30519-6 [pii]
AID - 10.1016/j.ccell.2017.11.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):717-718. doi: 10.1016/j.ccell.2017.11.016.

PMID- 29198914
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined
      Subpopulation of Glioblastoma.
PG  - 856-868.e5
LID - S1535-6108(17)30469-5 [pii]
LID - 10.1016/j.ccell.2017.10.016 [doi]
AB  - While molecular subtypes of glioblastoma (GBM) are defined using gene expression 
      and mutation profiles, we identify a unique subpopulation based on addiction to
      the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of
      a cancer stem cell phenotype, direct targeting is complicated by its expression
      in neurons. Using established GBM lines and patient-derived stem cells, we
      identify a subset of tumors within the "proneural" and "classical" subtypes that 
      are addicted to aberrant signaling from integrin alphavbeta3, which activates a
      PAK4-YAP/TAZ signaling axis to enhance Glut3 expression. This defined
      subpopulation of GBM is highly sensitive to agents that disrupt this pathway,
      including the integrin antagonist cilengitide, providing a targeted therapeutic
      strategy for this unique subset of GBM tumors.
CI  - Published by Elsevier Inc.
FAU - Cosset, Erika
AU  - Cosset E
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA. Electronic address: erika.cosset@unige.ch.
FAU - Ilmjarv, Sten
AU  - Ilmjarv S
AD  - Department of Pathology and Immunology, Medical School, University of Geneva,
      Geneva, Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne,
      Switzerland.
FAU - Dutoit, Valerie
AU  - Dutoit V
AD  - Laboratory of Tumor Immunology, Centre of Oncology, Geneva University Hospitals, 
      University of Geneva, Geneva, Switzerland.
FAU - Elliott, Kathryn
AU  - Elliott K
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - von Schalscha, Tami
AU  - von Schalscha T
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Camargo, Maria F
AU  - Camargo MF
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Reiss, Alexander
AU  - Reiss A
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Moroishi, Toshiro
AU  - Moroishi T
AD  - Department of Pharmacology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Seguin, Laetitia
AU  - Seguin L
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Gomez, German
AU  - Gomez G
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Moo, Jung-Soon
AU  - Moo JS
AD  - Department of Pharmacology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Preynat-Seauve, Olivier
AU  - Preynat-Seauve O
AD  - Division of Hematology, Departments of Internal Medicine and Human Protein
      Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Krause, Karl-Heinz
AU  - Krause KH
AD  - Department of Pathology and Immunology, Medical School, University of Geneva,
      Geneva, Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne,
      Switzerland.
FAU - Chneiweiss, Herve
AU  - Chneiweiss H
AD  - INSERM U1310, Sorbonne Universites, Paris, France.
FAU - Sarkaria, Jann N
AU  - Sarkaria JN
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Guan, Kun-Liang
AU  - Guan KL
AD  - Department of Pharmacology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Dietrich, Pierre-Yves
AU  - Dietrich PY
AD  - Laboratory of Tumor Immunology, Centre of Oncology, Geneva University Hospitals, 
      University of Geneva, Geneva, Switzerland.
FAU - Weis, Sara M
AU  - Weis SM
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA.
FAU - Mischel, Paul S
AU  - Mischel PS
AD  - Ludwig Institute for Cancer Research, Department of Pathology, Moores Cancer
      Center, University of California San Diego, La Jolla, CA 92093, USA.
FAU - Cheresh, David A
AU  - Cheresh DA
AD  - Department of Pathology, Moores Cancer Center, Sanford Consortium for
      Regenerative Medicine, University of California San Diego, La Jolla, CA 92037,
      USA. Electronic address: dcheresh@ucsd.edu.
LA  - eng
GR  - P50 CA108961/CA/NCI NIH HHS/United States
GR  - R01 CA045726/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171130
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Glucose Transporter Type 3)
RN  - 0 (Integrin alphaVbeta3)
RN  - 0 (SLC2A3 protein, human)
RN  - 0 (Snake Venoms)
RN  - 4EDF46E4GI (Cilengitide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Brain Neoplasms/*metabolism/mortality
MH  - Cell Line, Tumor
MH  - Gene Expression Profiling
MH  - Glioblastoma/*metabolism/mortality
MH  - Glucose Transporter Type 3/*metabolism
MH  - Humans
MH  - Integrin alphaVbeta3/*metabolism
MH  - Kaplan-Meier Estimate
MH  - Mice
MH  - Mice, Nude
MH  - Signal Transduction
MH  - Snake Venoms/pharmacology
MH  - *Transcriptome
MH  - Xenograft Model Antitumor Assays
PMC - PMC5730343
MID - NIHMS918250
OTO - NOTNLM
OT  - Glut3
OT  - cancer stem cells
OT  - glioblastoma
OT  - glucose metabolism
OT  - integrin
EDAT- 2017/12/05 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/05 06:00
PMCR- 2018/12/11 00:00
PHST- 2017/06/09 00:00 [received]
PHST- 2017/08/31 00:00 [revised]
PHST- 2017/10/29 00:00 [accepted]
PHST- 2018/12/11 00:00 [pmc-release]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - S1535-6108(17)30469-5 [pii]
AID - 10.1016/j.ccell.2017.10.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub
      2017 Nov 30.

PMID- 29198913
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171222
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid
      Recruitment.
PG  - 777-791.e6
LID - S1535-6108(17)30471-3 [pii]
LID - 10.1016/j.ccell.2017.11.001 [doi]
AB  - Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as
      myeloid cells, or targeting immunomodulatory receptors to promote cytotoxic T
      cell responses. Here, we examined the therapeutic potential of combining a direct
      tumor-targeting mAb, anti-CD20, with an extended panel of immunomodulatory mAbs. 
      Only the anti-CD27/CD20 combination provided cures. This was apparent in multiple
      lymphoma models, including huCD27 transgenic mice using the anti-huCD27,
      varlilumab. Detailed mechanistic analysis using single-cell RNA sequencing
      demonstrated that anti-CD27 stimulated CD8(+) T and natural killer cells to
      release myeloid chemo-attractants and interferon gamma, to elicit myeloid
      infiltration and macrophage activation. This study demonstrates the therapeutic
      advantage of using an immunomodulatory mAb to regulate lymphoid cells, which then
      recruit and activate myeloid cells for enhanced killing of mAb-opsonized tumors.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Turaj, Anna H
AU  - Turaj AH
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer
      Research UK Centre, Faculty of Medicine, University of Southampton, Southampton
      General Hospital, Southampton SO16 6YD, UK.
FAU - Hussain, Khiyam
AU  - Hussain K
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Cox, Kerry L
AU  - Cox KL
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Rose-Zerilli, Matthew J J
AU  - Rose-Zerilli MJJ
AD  - Cancer Research UK Centre, Faculty of Medicine, University of Southampton,
      Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Testa, James
AU  - Testa J
AD  - Celldex Therapeutics, Inc., Hampton, NJ 08827, USA.
FAU - Dahal, Lekh N
AU  - Dahal LN
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Chan, H T Claude
AU  - Chan HTC
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - James, Sonya
AU  - James S
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Field, Vikki L
AU  - Field VL
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Carter, Matthew J
AU  - Carter MJ
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Kim, Hyung J
AU  - Kim HJ
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - West, Jonathan J
AU  - West JJ
AD  - Institute for Life Sciences, Faculty of Medicine, University of Southampton,
      Southampton SO17 1BJ, UK.
FAU - Thomas, Lawrence J
AU  - Thomas LJ
AD  - Celldex Therapeutics, Inc., Hampton, NJ 08827, USA.
FAU - He, Li-Zhen
AU  - He LZ
AD  - Celldex Therapeutics, Inc., Hampton, NJ 08827, USA.
FAU - Keler, Tibor
AU  - Keler T
AD  - Celldex Therapeutics, Inc., Hampton, NJ 08827, USA.
FAU - Johnson, Peter W M
AU  - Johnson PWM
AD  - Cancer Research UK Centre, Faculty of Medicine, University of Southampton,
      Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Al-Shamkhani, Aymen
AU  - Al-Shamkhani A
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Thirdborough, Stephen M
AU  - Thirdborough SM
AD  - Cancer Research UK Centre, Faculty of Medicine, University of Southampton,
      Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Beers, Stephen A
AU  - Beers SA
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer
      Research UK Centre, Faculty of Medicine, University of Southampton, Southampton
      General Hospital, Southampton SO16 6YD, UK.
FAU - Cragg, Mark S
AU  - Cragg MS
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer
      Research UK Centre, Faculty of Medicine, University of Southampton, Southampton
      General Hospital, Southampton SO16 6YD, UK; Institute for Life Sciences, Faculty 
      of Medicine, University of Southampton, Southampton SO17 1BJ, UK.
FAU - Glennie, Martin J
AU  - Glennie MJ
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Lim, Sean H
AU  - Lim SH
AD  - Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer
      Research UK Centre, Faculty of Medicine, University of Southampton, Southampton
      General Hospital, Southampton SO16 6YD, UK. Electronic address:
      s.h.lim@soton.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20171130
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Tumor Necrosis Factor Receptor Superfamily, Member 7)
RN  - 0 (varlilumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Lymphocyte Activation/drug effects/immunology
MH  - Lymphoma/*immunology
MH  - Macrophage Activation/drug effects/immunology
MH  - Mice
MH  - Mice, Transgenic
MH  - Tumor Necrosis Factor Receptor Superfamily, Member 7/*agonists
PMC - PMC5734932
OTO - NOTNLM
OT  - CD20
OT  - CD27
OT  - NK cell
OT  - T cell
OT  - cancer
OT  - macrophage
OT  - monoclonal antibody
EDAT- 2017/12/05 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/04/11 00:00 [received]
PHST- 2017/08/28 00:00 [revised]
PHST- 2017/10/27 00:00 [accepted]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - S1535-6108(17)30471-3 [pii]
AID - 10.1016/j.ccell.2017.11.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):777-791.e6. doi: 10.1016/j.ccell.2017.11.001. Epub
      2017 Nov 30.

PMID- 29153843
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171226
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate
      Cancer Mediates Castration Resistance.
PG  - 792-806.e7
LID - S1535-6108(17)30461-0 [pii]
LID - 10.1016/j.ccell.2017.10.008 [doi]
AB  - Prostate cancer exhibits a lineage-specific dependence on androgen signaling.
      Castration resistance involves reactivation of androgen signaling or activation
      of alternative lineage programs to bypass androgen requirement. We describe an
      aberrant gastrointestinal-lineage transcriptome expressed in approximately 5% of 
      primary prostate cancer that is characterized by abbreviated response to
      androgen-deprivation therapy and in approximately 30% of castration-resistant
      prostate cancer. This program is governed by a transcriptional circuit consisting
      of HNF4G and HNF1A. Cistrome and chromatin analyses revealed that HNF4G is a
      pioneer factor that generates and maintains enhancer landscape at
      gastrointestinal-lineage genes, independent of androgen-receptor signaling. In
      HNF4G/HNF1A-double-negative prostate cancer, exogenous expression of HNF4G at
      physiologic levels recapitulates the gastrointestinal transcriptome, chromatin
      landscape, and leads to relative castration resistance.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Shukla, Shipra
AU  - Shukla S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Cyrta, Joanna
AU  - Cyrta J
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine of Weill Cornell 
      Medicine and New York-Presbyterian, New York, NY 10065, USA.
FAU - Murphy, Devan A
AU  - Murphy DA
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Walczak, Edward G
AU  - Walczak EG
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ran, Leili
AU  - Ran L
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Agrawal, Praveen
AU  - Agrawal P
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA.
FAU - Xie, Yuanyuan
AU  - Xie Y
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Chen, Yuedan
AU  - Chen Y
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Wang, Shangqian
AU  - Wang S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Zhan, Yu
AU  - Zhan Y
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Li, Dan
AU  - Li D
AD  - Yale School of Medicine, New Haven, CT 06511, USA.
FAU - Wong, Elissa W P
AU  - Wong EWP
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Sboner, Andrea
AU  - Sboner A
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine of Weill Cornell 
      Medicine and New York-Presbyterian, New York, NY 10065, USA; Institute for
      Computational Biomedicine, Weill Medical College, New York, NY 10065, USA.
FAU - Beltran, Himisha
AU  - Beltran H
AD  - Englander Institute for Precision Medicine of Weill Cornell Medicine and New
      York-Presbyterian, New York, NY 10065, USA; Department of Medicine, Division of
      Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Mosquera, Juan Miguel
AU  - Mosquera JM
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine of Weill Cornell 
      Medicine and New York-Presbyterian, New York, NY 10065, USA.
FAU - Sher, Jessica
AU  - Sher J
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Cao, Zhen
AU  - Cao Z
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Wongvipat, John
AU  - Wongvipat J
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Koche, Richard P
AU  - Koche RP
AD  - Center of Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York,
      NY 10065, USA.
FAU - Gopalan, Anuradha
AU  - Gopalan A
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Zheng, Deyou
AU  - Zheng D
AD  - Departments of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Departments of Genetics, Albert Einstein College of Medicine, Bronx, NY
      10461, USA; Departments of Neuroscience, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Rubin, Mark A
AU  - Rubin MA
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine of Weill Cornell 
      Medicine and New York-Presbyterian, New York, NY 10065, USA.
FAU - Scher, Howard I
AU  - Scher HI
AD  - Department of Medicine, Division of Hematology and Medical Oncology, Weill
      Cornell Medicine, New York, NY 10065, USA; Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Chi, Ping
AU  - Chi P
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Department of Medicine, Division of Hematology and
      Medical Oncology, Weill Cornell Medicine, New York, NY 10065, USA; Department of 
      Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
      Electronic address: chip@mskcc.org.
FAU - Chen, Yu
AU  - Chen Y
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Department of Medicine, Division of Hematology and
      Medical Oncology, Weill Cornell Medicine, New York, NY 10065, USA; Department of 
      Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
      Electronic address: cheny1@mskcc.org.
LA  - eng
GR  - R01 CA193837/CA/NCI NIH HHS/United States
GR  - P50 CA092629/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - K08 CA140946/CA/NCI NIH HHS/United States
GR  - R01 CA208100/CA/NCI NIH HHS/United States
GR  - DP2 CA174499/CA/NCI NIH HHS/United States
GR  - K08 CA151660/CA/NCI NIH HHS/United States
GR  - U01 CA111275/CA/NCI NIH HHS/United States
GR  - P50 CA140146/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171116
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (HNF1A protein, human)
RN  - 0 (HNF4G protein, human)
RN  - 0 (Hepatocyte Nuclear Factor 1-alpha)
RN  - 0 (Hepatocyte Nuclear Factor 4)
RN  - 0 (SPINK1 protein, human)
RN  - 50936-63-5 (Trypsin Inhibitor, Kazal Pancreatic)
SB  - IM
MH  - Animals
MH  - Drug Resistance, Neoplasm/*physiology
MH  - Gene Expression Regulation, Neoplastic/*physiology
MH  - Hepatocyte Nuclear Factor 1-alpha/*metabolism
MH  - Hepatocyte Nuclear Factor 4/*metabolism
MH  - Heterografts
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, SCID
MH  - Prostatic Neoplasms, Castration-Resistant/*metabolism/pathology
MH  - Trypsin Inhibitor, Kazal Pancreatic/biosynthesis
PMC - PMC5728174
MID - NIHMS914919
OTO - NOTNLM
OT  - ChIP-seq
OT  - HNF1A
OT  - HNF4G
OT  - SPINK1
OT  - androgen-deprivation therapy
OT  - castration resistance
OT  - enzalutamide
OT  - pioneer factor
OT  - prostate cancer
EDAT- 2017/11/21 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/11/21 06:00
PMCR- 2018/12/11 00:00
PHST- 2016/12/16 00:00 [received]
PHST- 2017/07/13 00:00 [revised]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2018/12/11 00:00 [pmc-release]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S1535-6108(17)30461-0 [pii]
AID - 10.1016/j.ccell.2017.10.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):792-806.e7. doi: 10.1016/j.ccell.2017.10.008. Epub
      2017 Nov 16.

PMID- 29153842
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas.
PG  - 824-839.e8
LID - S1535-6108(17)30464-6 [pii]
LID - 10.1016/j.ccell.2017.10.011 [doi]
AB  - Despite expression of oncogenic KRAS, premalignant pancreatic intraepithelial
      neoplasia 1 (PanIN1) lesions rarely become fully malignant pancreatic ductal
      adenocarcinoma (PDAC). The molecular mechanisms through which established risk
      factors, such as chronic pancreatitis, acinar cell damage, and/or defective
      autophagy increase the likelihood of PDAC development are poorly understood. We
      show that accumulation of the autophagy substrate p62/SQSTM1 in stressed
      Kras(G12D) acinar cells is associated with PDAC development and maintenance of
      malignancy in human cells and mice. p62 accumulation promotes neoplastic
      progression by controlling the NRF2-mediated induction of MDM2, which acts
      through p53-dependent and -independent mechanisms to abrogate checkpoints that
      prevent conversion of differentiated acinar cells to proliferative ductal
      progenitors. MDM2 targeting may be useful for preventing PDAC development in
      high-risk individuals.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Todoric, Jelena
AU  - Todoric J
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA; Department of Laboratory Medicine, Medical University of Vienna,
      1090 Vienna, Austria.
FAU - Antonucci, Laura
AU  - Antonucci L
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Di Caro, Giuseppe
AU  - Di Caro G
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Li, Ning
AU  - Li N
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Wu, Xuefeng
AU  - Wu X
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Lytle, Nikki K
AU  - Lytle NK
AD  - Departments of Pharmacology and Medicine, Moores Cancer Center, University of
      California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford
      Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
FAU - Dhar, Debanjan
AU  - Dhar D
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Banerjee, Sourav
AU  - Banerjee S
AD  - Department of Pharmacology, School of Medicine, University of California San
      Diego, La Jolla, CA 92093, USA.
FAU - Fagman, Johan B
AU  - Fagman JB
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Browne, Cecille D
AU  - Browne CD
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Umemura, Atsushi
AU  - Umemura A
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA; Department of Molecular Gastroenterology and Hepatology, Graduate 
      School of Medical Science, Kyoto Prefectural University of Medicine, 602-8566
      Kyoto, Japan.
FAU - Valasek, Mark A
AU  - Valasek MA
AD  - Department of Pathology, School of Medicine, University of California San Diego, 
      La Jolla, CA 92093, USA.
FAU - Kessler, Hannes
AU  - Kessler H
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Tarin, David
AU  - Tarin D
AD  - Department of Pathology, School of Medicine, University of California San Diego, 
      La Jolla, CA 92093, USA.
FAU - Goggins, Michael
AU  - Goggins M
AD  - Departments of Medicine (Gastroenterology) and Radiology, The Sol Goldman
      Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore,
      MD 21287, USA.
FAU - Reya, Tannishtha
AU  - Reya T
AD  - Departments of Pharmacology and Medicine, Moores Cancer Center, University of
      California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford
      Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
FAU - Diaz-Meco, Maria
AU  - Diaz-Meco M
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, La Jolla, CA 92037, USA.
FAU - Moscat, Jorge
AU  - Moscat J
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, La Jolla, CA 92037, USA.
FAU - Karin, Michael
AU  - Karin M
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA; Department of Pathology, School of Medicine, University of
      California San Diego, La Jolla, CA 92093, USA. Electronic address:
      karinoffice@ucsd.edu.
LA  - eng
GR  - R01 CA192642/CA/NCI NIH HHS/United States
GR  - R01 CA218254/CA/NCI NIH HHS/United States
GR  - P50 CA062924/CA/NCI NIH HHS/United States
GR  - R01 CA172025/CA/NCI NIH HHS/United States
GR  - R01 CA211794/CA/NCI NIH HHS/United States
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - R01 CA186043/CA/NCI NIH HHS/United States
GR  - T32 GM007752/GM/NIGMS NIH HHS/United States
GR  - R01 CA132847/CA/NCI NIH HHS/United States
GR  - R01 CA163798/CA/NCI NIH HHS/United States
GR  - R03 CA167120/CA/NCI NIH HHS/United States
GR  - F31 CA206416/CA/NCI NIH HHS/United States
GR  - R01 AI043477/AI/NIAID NIH HHS/United States
GR  - R01 CA134530/CA/NCI NIH HHS/United States
GR  - R35 CA197699/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171116
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
MH  - Acinar Cells/metabolism/pathology
MH  - Adenocarcinoma in Situ/metabolism/*pathology
MH  - Animals
MH  - Carcinoma, Pancreatic Ductal/metabolism/*pathology
MH  - Disease Progression
MH  - Heterografts
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - NF-E2-Related Factor 2/*metabolism
MH  - Pancreatic Neoplasms/metabolism/*pathology
MH  - Proto-Oncogene Proteins c-mdm2/*metabolism
MH  - Signal Transduction/physiology
PMC - PMC5730340
MID - NIHMS919646
OTO - NOTNLM
OT  - IKKalpha
OT  - MDM2
OT  - NRF2
OT  - acinar cell reprogramming
OT  - impaired autophagy
OT  - p62
OT  - pancreatic ductal adenocarcinoma
EDAT- 2017/11/21 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/11/21 06:00
PMCR- 2018/12/11 00:00
PHST- 2017/01/31 00:00 [received]
PHST- 2017/08/21 00:00 [revised]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2018/12/11 00:00 [pmc-release]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S1535-6108(17)30464-6 [pii]
AID - 10.1016/j.ccell.2017.10.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):824-839.e8. doi: 10.1016/j.ccell.2017.10.011. Epub
      2017 Nov 16.

PMID- 29136511
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20180407
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - SnapShot: Chronic Lymphocytic Leukemia.
PG  - 716-716.e1
LID - S1535-6108(17)30468-3 [pii]
LID - 10.1016/j.ccell.2017.10.015 [doi]
AB  - Despite the recent advances in the therapeutic management of Chronic Lymphocytic 
      Leukemia (CLL) patients, this common B cell malignancy still remains incurable.
      This SnapShot provides an overview of CLL biology and therapy, with a focus on
      genetics and microenvironmental interactions, which contribute to disease
      progression and therapy resistance. To view this SnapShot, open or download the
      PDF.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Ten Hacken, Elisa
AU  - Ten Hacken E
AD  - Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
FAU - Guieze, Romain
AU  - Guieze R
AD  - CHU Clermont-Ferrand, Hematologie Clinique, Clermont-Ferrand, France.
FAU - Wu, Catherine J
AU  - Wu CJ
AD  - Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA;
      Harvard Medical School, Boston, MA, USA; Broad Institute, Cambridge, MA, USA.
LA  - eng
GR  - R01 CA216273/CA/NCI NIH HHS/United States
GR  - R01 HL131768/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - B-Lymphocytes/metabolism/pathology
MH  - Disease Progression
MH  - Genetic Predisposition to Disease/*genetics
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/pathology/therapy
MH  - Models, Genetic
MH  - *Mutation
MH  - Signal Transduction/genetics
MH  - Tumor Microenvironment/*genetics
PMC - PMC5858912
MID - NIHMS948932
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PMCR- 2018/11/13 00:00
PHST- 2018/11/13 00:00 [pmc-release]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30468-3 [pii]
AID - 10.1016/j.ccell.2017.10.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):716-716.e1. doi: 10.1016/j.ccell.2017.10.015.

PMID- 29136510
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20180125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile
      and Female Gender Bias in KDM6A Mutation Frequency.
PG  - 701-715.e7
LID - S1535-6108(17)30348-3 [pii]
LID - 10.1016/j.ccell.2017.08.005 [doi]
AB  - Bladder cancer incurs a higher lifetime treatment cost than other cancers due to 
      frequent recurrence of non-invasive disease. Improved prognostic biomarkers and
      localized therapy are needed for this large patient group. We defined two major
      genomic subtypes of primary stage Ta tumors. One of these was characterized by
      loss of 9q including TSC1, increased KI67 labeling index, upregulated glycolysis,
      DNA repair, mTORC1 signaling, features of the unfolded protein response, and
      altered cholesterol homeostasis. Comparison with muscle-invasive bladder cancer
      mutation profiles revealed lower overall mutation rates and more frequent
      mutations in RHOB and chromatin modifier genes. More mutations in the histone
      lysine demethylase KDM6A were present in non-invasive tumors from females than
      males.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hurst, Carolyn D
AU  - Hurst CD
AD  - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Alder, Olivia
AU  - Alder O
AD  - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Platt, Fiona M
AU  - Platt FM
AD  - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Droop, Alastair
AU  - Droop A
AD  - Cancer Research UK Leeds Centre, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Stead, Lucy F
AU  - Stead LF
AD  - Section of Brain Tumour Research, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Burns, Julie E
AU  - Burns JE
AD  - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Burghel, George J
AU  - Burghel GJ
AD  - DNA Laboratory, Genetics Service, Ashley Wing, St James University Hospital,
      Beckett Street, Leeds LS9 7TF, UK.
FAU - Jain, Sunjay
AU  - Jain S
AD  - Pyrah Department of Urology, St James's University Hospital, Beckett Street,
      Leeds LS9 7TF, UK.
FAU - Klimczak, Leszek J
AU  - Klimczak LJ
AD  - Integrative Bioinformatics Support Group, National Institute of Environmental
      Health Sciences, NIH, Research Triangle Park, NC 27709, USA.
FAU - Lindsay, Helen
AU  - Lindsay H
AD  - DNA Laboratory, Genetics Service, Ashley Wing, St James University Hospital,
      Beckett Street, Leeds LS9 7TF, UK.
FAU - Roulson, Jo-An
AU  - Roulson JA
AD  - Department of Histopathology, St James's University Hospital, Beckett Street,
      Leeds LS9 7TF, UK.
FAU - Taylor, Claire F
AU  - Taylor CF
AD  - Cancer Research UK Leeds Centre, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Thygesen, Helene
AU  - Thygesen H
AD  - Cancer Research UK Leeds Centre, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
FAU - Cameron, Angus J
AU  - Cameron AJ
AD  - Barts Cancer Institute, Queen Mary University of London, Charterhouse Square,
      London EC1M 6BQ, UK.
FAU - Ridley, Anne J
AU  - Ridley AJ
AD  - Randall Division of Cell and Molecular Biophysics, New Hunt's House, King's
      College London, Guy's Campus, London SE1 1UL, UK.
FAU - Mott, Helen R
AU  - Mott HR
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK.
FAU - Gordenin, Dmitry A
AU  - Gordenin DA
AD  - Genome Integrity and Structural Biology Laboratory, National Institute of
      Environmental Health Sciences, NIH, Research Triangle Park, NC 27709, USA.
FAU - Knowles, Margaret A
AU  - Knowles MA
AD  - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St
      James's University Hospital, Beckett Street, Leeds LS9 7TF, UK. Electronic
      address: m.a.knowles@leeds.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - ZIA ES103266-02/Intramural NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - EC 1.14.11.- (Histone Demethylases)
RN  - EC 1.14.11.- (UTX protein, human)
SB  - IM
MH  - Carcinoma, Transitional Cell/genetics/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Frequency
MH  - Genomics/methods
MH  - HEK293 Cells
MH  - Histone Demethylases/*genetics/metabolism
MH  - Humans
MH  - Male
MH  - Metabolome/genetics
MH  - Metabolomics/*methods
MH  - *Mutation
MH  - Nuclear Proteins/*genetics/metabolism
MH  - Sex Factors
MH  - Urinary Bladder Neoplasms/genetics/*metabolism/pathology
PMC - PMC5774674
MID - NIHMS930003
OTO - NOTNLM
OT  - KDM6A
OT  - RHOB
OT  - bladder cancer
OT  - gender
OT  - genomics
OT  - mTORC1
OT  - metabolism
OT  - recurrence-free survival
OT  - subtypes
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PMCR- 2018/11/13 00:00
PHST- 2016/12/20 00:00 [received]
PHST- 2017/05/13 00:00 [revised]
PHST- 2017/08/09 00:00 [accepted]
PHST- 2018/11/13 00:00 [pmc-release]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30348-3 [pii]
AID - 10.1016/j.ccell.2017.08.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):701-715.e7. doi: 10.1016/j.ccell.2017.08.005.

PMID- 29136509
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171219
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - An HIF-1alpha/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.
PG  - 669-683.e5
LID - S1535-6108(17)30456-7 [pii]
LID - 10.1016/j.ccell.2017.10.003 [doi]
AB  - Cytotoxic T cells infiltrating tumors are thought to utilize HIF transcription
      factors during adaptation to the hypoxic tumor microenvironment. Deletion
      analyses of the two key HIF isoforms found that HIF-1alpha, but not HIF-2alpha,
      was essential for the effector state in CD8(+) T cells. Furthermore, loss of
      HIF-1alpha in CD8(+) T cells reduced tumor infiltration and tumor cell killing,
      and altered tumor vascularization. Deletion of VEGF-A, an HIF target gene, in
      CD8(+) T cells accelerated tumorigenesis while also altering vascularization.
      Analyses of human breast cancer showed inverse correlations between VEGF-A
      expression and CD8(+) T cell infiltration, and a link between T cell infiltration
      and vascularization. These data demonstrate that the HIF-1alpha/VEGF-A axis is an
      essential aspect of tumor immunity.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Palazon, Asis
AU  - Palazon A
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK.
FAU - Tyrakis, Petros A
AU  - Tyrakis PA
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK; Cancer Research UK, Cambridge Institute, Cambridge CB2
      0RE, UK.
FAU - Macias, David
AU  - Macias D
AD  - Cancer Research UK, Cambridge Institute, Cambridge CB2 0RE, UK.
FAU - Velica, Pedro
AU  - Velica P
AD  - Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm,
      Sweden.
FAU - Rundqvist, Helene
AU  - Rundqvist H
AD  - Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm,
      Sweden.
FAU - Fitzpatrick, Susan
AU  - Fitzpatrick S
AD  - Cancer Research UK, Cambridge Institute, Cambridge CB2 0RE, UK.
FAU - Vojnovic, Nikola
AU  - Vojnovic N
AD  - Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm,
      Sweden.
FAU - Phan, Anthony T
AU  - Phan AT
AD  - Molecular Biology Section, Division of Biological Sciences, University of
      California San Diego, La Jolla, CA 92161, USA.
FAU - Loman, Niklas
AU  - Loman N
AD  - Department of Clinical Sciences, Division of Oncology and Pathology, Lund
      University, 223 81 Lund, Sweden.
FAU - Hedenfalk, Ingrid
AU  - Hedenfalk I
AD  - Department of Clinical Sciences, Division of Oncology and Pathology, Lund
      University, 223 81 Lund, Sweden.
FAU - Hatschek, Thomas
AU  - Hatschek T
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Lovrot, John
AU  - Lovrot J
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Foukakis, Theodoros
AU  - Foukakis T
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Goldrath, Ananda W
AU  - Goldrath AW
AD  - Molecular Biology Section, Division of Biological Sciences, University of
      California San Diego, La Jolla, CA 92161, USA.
FAU - Bergh, Jonas
AU  - Bergh J
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Johnson, Randall S
AU  - Johnson RS
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK; Department of Cell and Molecular Biology, Karolinska
      Institute, 171 77 Stockholm, Sweden. Electronic address: rsj33@cam.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - R01 AI096852/AI/NIAID NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/genetics/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics/metabolism
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neoplasms, Experimental/blood supply/*genetics/metabolism
MH  - Neovascularization, Pathologic/genetics/metabolism
MH  - T-Lymphocytes, Cytotoxic/*metabolism
MH  - Vascular Endothelial Growth Factor A/*genetics/metabolism
PMC - PMC5691891
OTO - NOTNLM
OT  - HIF transcription factors
OT  - VEGF
OT  - angiogenesis
OT  - cytotoxic T cells
OT  - hypoxia
OT  - immunotherapy
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2016/09/03 00:00 [received]
PHST- 2017/05/18 00:00 [revised]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30456-7 [pii]
AID - 10.1016/j.ccell.2017.10.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):669-683.e5. doi: 10.1016/j.ccell.2017.10.003.

PMID- 29136508
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20180228
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor
      Blockade by Inducing PMN-MDSC Infiltration of Tumors.
PG  - 654-668.e5
LID - S1535-6108(17)30458-0 [pii]
LID - 10.1016/j.ccell.2017.10.005 [doi]
AB  - Tumor-associated macrophages (TAM) contribute to all aspects of tumor
      progression. Use of CSF1R inhibitors to target TAM is therapeutically appealing, 
      but has had very limited anti-tumor effects. Here, we have identified the
      mechanism that limited the effect of CSF1R targeted therapy. We demonstrated that
      carcinoma-associated fibroblasts (CAF) are major sources of chemokines that
      recruit granulocytes to tumors. CSF1 produced by tumor cells caused
      HDAC2-mediated downregulation of granulocyte-specific chemokine expression in
      CAF, which limited migration of these cells to tumors. Treatment with CSF1R
      inhibitors disrupted this crosstalk and triggered a profound increase in
      granulocyte recruitment to tumors. Combining CSF1R inhibitor with a CXCR2
      antagonist blocked granulocyte infiltration of tumors and showed strong
      anti-tumor effects.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kumar, Vinit
AU  - Kumar V
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Donthireddy, Laxminarasimha
AU  - Donthireddy L
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Marvel, Douglas
AU  - Marvel D
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Condamine, Thomas
AU  - Condamine T
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Wang, Fang
AU  - Wang F
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Lavilla-Alonso, Sergio
AU  - Lavilla-Alonso S
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Hashimoto, Ayumi
AU  - Hashimoto A
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Vonteddu, Prashanthi
AU  - Vonteddu P
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Behera, Reeti
AU  - Behera R
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Goins, Marlee A
AU  - Goins MA
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Mulligan, Charles
AU  - Mulligan C
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Nam, Brian
AU  - Nam B
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Hockstein, Neil
AU  - Hockstein N
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Denstman, Fred
AU  - Denstman F
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Shakamuri, Shanti
AU  - Shakamuri S
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Speicher, David W
AU  - Speicher DW
AD  - Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia,
      PA 19104, USA.
FAU - Weeraratna, Ashani T
AU  - Weeraratna AT
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Chao, Timothy
AU  - Chao T
AD  - University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
FAU - Vonderheide, Robert H
AU  - Vonderheide RH
AD  - University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
FAU - Languino, Lucia R
AU  - Languino LR
AD  - Sidney Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson
      University, Philadelphia, PA 19107, USA.
FAU - Ordentlich, Peter
AU  - Ordentlich P
AD  - Syndax Pharmaceuticals, Inc., Waltham, MA 02451, USA.
FAU - Liu, Qin
AU  - Liu Q
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Xu, Xiaowei
AU  - Xu X
AD  - University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
FAU - Lo, Albert
AU  - Lo A
AD  - University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104,
      USA.
FAU - Pure, Ellen
AU  - Pure E
AD  - University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104,
      USA.
FAU - Zhang, Chunsheng
AU  - Zhang C
AD  - Department of Genetics and Pharmacogenomics, MRL, Merck & Co., Inc., Boston, MA
      02115, USA.
FAU - Loboda, Andrey
AU  - Loboda A
AD  - Department of Genetics and Pharmacogenomics, MRL, Merck & Co., Inc., Boston, MA
      02115, USA.
FAU - Sepulveda, Manuel A
AU  - Sepulveda MA
AD  - Janssen R&D, Spring House, PA 19477, USA.
FAU - Snyder, Linda A
AU  - Snyder LA
AD  - Janssen R&D, Spring House, PA 19477, USA.
FAU - Gabrilovich, Dmitry I
AU  - Gabrilovich DI
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA. Electronic address: dgabrilovich@wistar.org.
LA  - eng
GR  - P01 CA140043/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - P01 CA114046/CA/NCI NIH HHS/United States
GR  - R01 CA084488/CA/NCI NIH HHS/United States
GR  - R01 CA174746/CA/NCI NIH HHS/United States
GR  - P50 CA168536/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Imidazoles)
RN  - 0 (JNJ-40346527)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Interleukin-8B)
RN  - 0 (SB 225002)
RN  - EC 2.7.10.1 (Receptor, Macrophage Colony-Stimulating Factor)
RN  - EC 3.5.1.98 (HDAC2 protein, human)
RN  - EC 3.5.1.98 (Histone Deacetylase 2)
SB  - IM
MH  - Animals
MH  - Cancer-Associated Fibroblasts/drug effects/*metabolism
MH  - Cell Line, Tumor
MH  - Granulocytes/metabolism
MH  - Histone Deacetylase 2
MH  - Humans
MH  - Imidazoles/pharmacology
MH  - Macrophages/metabolism
MH  - Mice, Inbred C57BL
MH  - Monocytes/*metabolism
MH  - Myeloid-Derived Suppressor Cells/*metabolism
MH  - Neoplasms, Experimental/drug therapy/*metabolism/pathology
MH  - Phenylurea Compounds/pharmacology
MH  - Pyridines/pharmacology
MH  - Receptor, Macrophage Colony-Stimulating Factor/antagonists &
      inhibitors/*metabolism
MH  - Receptors, Interleukin-8B/antagonists & inhibitors/metabolism
MH  - Tumor Burden/drug effects
PMC - PMC5827952
MID - NIHMS912493
OTO - NOTNLM
OT  - CSF1R
OT  - M-CSF
OT  - PMN-MDSC
OT  - fibroblasts
OT  - granulocytes
OT  - macrophages
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PMCR- 2018/11/13 00:00
PHST- 2017/03/03 00:00 [received]
PHST- 2017/07/25 00:00 [revised]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2018/11/13 00:00 [pmc-release]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30458-0 [pii]
AID - 10.1016/j.ccell.2017.10.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005.

PMID- 29136507
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171128
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and
      Metastasis.
PG  - 639-653.e6
LID - S1535-6108(17)30454-3 [pii]
LID - 10.1016/j.ccell.2017.10.001 [doi]
AB  - Cancers grow within tissues through molecular mechanisms still unclear.
      Invasiveness correlates with perturbed O-glycosylation, a covalent modification
      of cell-surface proteins. Here, we show that, in human and mouse liver cancers,
      initiation of O-glycosylation by the GALNT glycosyl-transferases increases and
      shifts from the Golgi to the endoplasmic reticulum (ER). In a mouse liver cancer 
      model, expressing an ER-targeted GALNT1 (ER-G1) massively increased tumor
      expansion, with median survival reduced from 23 to 10 weeks. In vitro cell growth
      was unaffected, but ER-G1 strongly enabled matrix degradation and tissue
      invasion. Unlike its Golgi-localized counterpart, ER-G1 glycosylates the matrix
      metalloproteinase MMP14, a process required for tumor expansion. Together, our
      results indicate that GALNTs strongly promote liver tumor growth after relocating
      to the ER.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Nguyen, Anh Tuan
AU  - Nguyen AT
AD  - Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore
      138673, Singapore.
FAU - Chia, Joanne
AU  - Chia J
AD  - Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore
      138673, Singapore.
FAU - Ros, Manon
AU  - Ros M
AD  - Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore
      138673, Singapore.
FAU - Hui, Kam Man
AU  - Hui KM
AD  - Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore
      138673, Singapore; Department of Biochemistry, National University of Singapore, 
      21 Lower Kent Ridge Road, Singapore 119077, Singapore; Division of Cellular and
      Molecular Research, National Cancer Centre Singapore, 11 Hospital Drive,
      Singapore 169610, Singapore; Duke-NUS Graduate Medical School, Singapore, 8
      College Road, Singapore 169857, Singapore.
FAU - Saltel, Frederic
AU  - Saltel F
AD  - INSERM, U1053 Bordeaux Research In Translational Oncology, BaRITOn, 33000
      Bordeaux, France; University of Bordeaux, U1053 Bordeaux Research In
      Translational Oncology, BaRITOn, 33000 Bordeaux, France.
FAU - Bard, Frederic
AU  - Bard F
AD  - Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore
      138673, Singapore; Department of Biochemistry, National University of Singapore, 
      21 Lower Kent Ridge Road, Singapore 119077, Singapore. Electronic address:
      fbard@imcb.a-star.edu.sg.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.4.1.- (N-Acetylgalactosaminyltransferases)
RN  - EC 2.4.1.41 (polypeptide N-acetylgalactosaminyltransferase)
RN  - EC 3.4.24.80 (Matrix Metalloproteinase 14)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - Cell Proliferation/genetics
MH  - Endoplasmic Reticulum/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Glycosylation
MH  - Golgi Apparatus/*metabolism
MH  - Hep G2 Cells
MH  - Humans
MH  - Liver Neoplasms/genetics/*metabolism/pathology
MH  - Male
MH  - Matrix Metalloproteinase 14/genetics/*metabolism
MH  - Mice, Inbred C57BL
MH  - N-Acetylgalactosaminyltransferases/genetics/metabolism
MH  - Neoplasm Metastasis
MH  - Reverse Transcriptase Polymerase Chain Reaction
OTO - NOTNLM
OT  - GALA
OT  - GALNTs
OT  - MMP14
OT  - MT1-MMP
OT  - O-glycosylation
OT  - Tn antigen
OT  - invasion
OT  - membrane trafficking
OT  - metastasis
OT  - tumor growth
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/03/16 00:00 [received]
PHST- 2017/07/14 00:00 [revised]
PHST- 2017/09/28 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30454-3 [pii]
AID - 10.1016/j.ccell.2017.10.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):639-653.e6. doi: 10.1016/j.ccell.2017.10.001.

PMID- 29136506
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171219
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell
      Acute Lymphoblastic Leukemia.
PG  - 608-623.e9
LID - S1535-6108(17)30457-9 [pii]
LID - 10.1016/j.ccell.2017.10.004 [doi]
AB  - Rho guanine exchange factors (GEFs), the enzymes that stimulate Rho GTPases, are 
      deemed as potential therapeutic targets owing to their protumorigenic functions. 
      However, the understanding of the spectrum of their pathobiological roles in
      tumors is still very limited. We report here that the GEF Vav1 unexpectedly
      possesses tumor-suppressor functions in immature T cells. This function entails
      the noncatalytic nucleation of complexes between the ubiquitin ligase Cbl-b and
      the intracellular domain of Notch1 (ICN1) that favors ICN1 ubiquitinylation and
      degradation. Ablation of Vav1 promotes ICN1 signaling and the development of T
      cell acute lymphoblastic leukemia (T-ALL). The downregulation of Vav1 is
      essential for the pathogenesis of human T-ALL of the TLX(+) clinical subtype,
      further underscoring the suppressor role of this pathway.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Robles-Valero, Javier
AU  - Robles-Valero J
AD  - Centro de Investigacion del Cancer, CSIC - University of Salamanca, 37007
      Salamanca, Spain; Instituto de Biologia Molecular y Celular del Cancer, CSIC -
      University of Salamanca, 37007 Salamanca, Spain; Centro de Investigacion
      Biomedica en Red de Cancer (CIBERONC), CSIC - University of Salamanca, 37007
      Salamanca, Spain.
FAU - Lorenzo-Martin, L Francisco
AU  - Lorenzo-Martin LF
AD  - Centro de Investigacion del Cancer, CSIC - University of Salamanca, 37007
      Salamanca, Spain; Instituto de Biologia Molecular y Celular del Cancer, CSIC -
      University of Salamanca, 37007 Salamanca, Spain; Centro de Investigacion
      Biomedica en Red de Cancer (CIBERONC), CSIC - University of Salamanca, 37007
      Salamanca, Spain.
FAU - Menacho-Marquez, Mauricio
AU  - Menacho-Marquez M
AD  - Centro de Investigacion del Cancer, CSIC - University of Salamanca, 37007
      Salamanca, Spain; Instituto de Biologia Molecular y Celular del Cancer, CSIC -
      University of Salamanca, 37007 Salamanca, Spain; Centro de Investigacion
      Biomedica en Red de Cancer (CIBERONC), CSIC - University of Salamanca, 37007
      Salamanca, Spain.
FAU - Fernandez-Pisonero, Isabel
AU  - Fernandez-Pisonero I
AD  - Centro de Investigacion del Cancer, CSIC - University of Salamanca, 37007
      Salamanca, Spain; Instituto de Biologia Molecular y Celular del Cancer, CSIC -
      University of Salamanca, 37007 Salamanca, Spain.
FAU - Abad, Antonio
AU  - Abad A
AD  - Centro de Investigacion del Cancer, CSIC - University of Salamanca, 37007
      Salamanca, Spain; Instituto de Biologia Molecular y Celular del Cancer, CSIC -
      University of Salamanca, 37007 Salamanca, Spain; Centro de Investigacion
      Biomedica en Red de Cancer (CIBERONC), CSIC - University of Salamanca, 37007
      Salamanca, Spain.
FAU - Camos, Mireia
AU  - Camos M
AD  - Hospital Sant Joan de Deu, 08950 Esplugues de Llobregat, Spain.
FAU - Toribio, Maria L
AU  - Toribio ML
AD  - Centro de Biologia Molecular Severo Ochoa, CSIC - Madrid Autonomous University,
      28049 Madrid, Spain.
FAU - Espinosa, Lluis
AU  - Espinosa L
AD  - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), CSIC - University 
      of Salamanca, 37007 Salamanca, Spain; Institut Hospital del Mar d'Investigacions 
      Mediques, 08003 Barcelona, Spain.
FAU - Bigas, Anna
AU  - Bigas A
AD  - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), CSIC - University 
      of Salamanca, 37007 Salamanca, Spain; Institut Hospital del Mar d'Investigacions 
      Mediques, 08003 Barcelona, Spain.
FAU - Bustelo, Xose R
AU  - Bustelo XR
AD  - Centro de Investigacion del Cancer, CSIC - University of Salamanca, 37007
      Salamanca, Spain; Instituto de Biologia Molecular y Celular del Cancer, CSIC -
      University of Salamanca, 37007 Salamanca, Spain; Centro de Investigacion
      Biomedica en Red de Cancer (CIBERONC), CSIC - University of Salamanca, 37007
      Salamanca, Spain. Electronic address: xbustelo@usal.es.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Proto-Oncogene Proteins c-vav)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-cbl)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Jurkat Cells
MH  - Mice, Knockout
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*genetics/metabolism/pathology
MH  - Proto-Oncogene Proteins c-cbl/genetics/metabolism
MH  - Proto-Oncogene Proteins c-vav/*genetics/metabolism
MH  - Receptor, Notch1/genetics/metabolism
MH  - Signal Transduction/genetics
MH  - T-Lymphocytes/*metabolism/pathology
MH  - Tumor Cells, Cultured
MH  - Tumor Suppressor Proteins/*genetics/metabolism
PMC - PMC5691892
OTO - NOTNLM
OT  - Cbl-b
OT  - Notch1
OT  - Rho GTPases
OT  - TLX
OT  - animal models
OT  - gene expression profiling
OT  - lymphoma
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/02/07 00:00 [received]
PHST- 2017/07/31 00:00 [revised]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30457-9 [pii]
AID - 10.1016/j.ccell.2017.10.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):608-623.e9. doi: 10.1016/j.ccell.2017.10.004.

PMID- 29136505
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171128
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in
      Glioblastoma Mouse Models and Patient-Derived Xenografts.
PG  - 590-607.e4
LID - S1535-6108(17)30459-2 [pii]
LID - 10.1016/j.ccell.2017.10.006 [doi]
AB  - Glioblastoma multiforme (GBM) is a deadly and common brain tumor. Poor prognosis 
      is linked to high proliferation and cell heterogeneity, including glioma stem
      cells (GSCs). Telomere genes are frequently mutated. The telomere binding protein
      TRF1 is essential for telomere protection, and for adult and pluripotent stem
      cells. Here, we find TRF1 upregulation in mouse and human GBM. Brain-specific
      Trf1 genetic deletion in GBM mouse models inhibited GBM initiation and
      progression, increasing survival. Trf1 deletion increased telomeric DNA damage
      and reduced proliferation and stemness. TRF1 chemical inhibitors mimicked these
      effects in human GBM cells and also blocked tumor sphere formation and tumor
      growth in xenografts from patient-derived primary GSCs. Thus, targeting telomeres
      throughout TRF1 inhibition is an effective therapeutic strategy for GBM.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bejarano, Leire
AU  - Bejarano L
AD  - Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National
      Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Schuhmacher, Alberto J
AU  - Schuhmacher AJ
AD  - Seve-Ballesteros Foundation Brain Tumor Group, Cancer Cell Biology Program,
      Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, Madrid,
      28029, Spain.
FAU - Mendez, Marinela
AU  - Mendez M
AD  - Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National
      Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Megias, Diego
AU  - Megias D
AD  - Confocal Microscopy Unit, Biotechnology Program, Spanish National Cancer Research
      Centre (CNIO), Madrid, 28029 Spain.
FAU - Blanco-Aparicio, Carmen
AU  - Blanco-Aparicio C
AD  - Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor
      Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Martinez, Sonia
AU  - Martinez S
AD  - Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor
      Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Pastor, Joaquin
AU  - Pastor J
AD  - Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor
      Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Squatrito, Massimo
AU  - Squatrito M
AD  - Seve-Ballesteros Foundation Brain Tumor Group, Cancer Cell Biology Program,
      Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, Madrid,
      28029, Spain.
FAU - Blasco, Maria A
AU  - Blasco MA
AD  - Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National
      Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, Madrid, 28029, Spain.
      Electronic address: mblasco@cnio.es.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Telomeric Repeat Binding Protein 1)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - *Disease Models, Animal
MH  - Disease Progression
MH  - Gene Expression Regulation, Neoplastic
MH  - Glioblastoma/*genetics/metabolism/pathology
MH  - Humans
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - Neoplastic Stem Cells/metabolism
MH  - RNA Interference
MH  - Telomere/genetics/metabolism
MH  - Telomeric Repeat Binding Protein 1/antagonists & inhibitors/*genetics/metabolism
MH  - Transplantation, Heterologous
OTO - NOTNLM
OT  - TRF1
OT  - glioblastoma
OT  - glioma stem cells
OT  - shelterin
OT  - stemness
OT  - telomeres
OT  - therapy
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/07/28 00:00 [revised]
PHST- 2017/10/07 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30459-2 [pii]
AID - 10.1016/j.ccell.2017.10.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):590-607.e4. doi: 10.1016/j.ccell.2017.10.006.

PMID- 29136504
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver
      Cancer.
PG  - 574-589.e6
LID - S1535-6108(17)30460-9 [pii]
LID - 10.1016/j.ccell.2017.10.007 [doi]
AB  - ARID1A, an SWI/SNF chromatin-remodeling gene, is commonly mutated in cancer and
      hypothesized to be tumor suppressive. In some hepatocellular carcinoma patients, 
      ARID1A was highly expressed in primary tumors but not in metastatic lesions,
      suggesting that ARID1A can be lost after initiation. Mice with liver-specific
      homozygous or heterozygous Arid1a loss were resistant to tumor initiation while
      ARID1A overexpression accelerated initiation. In contrast, homozygous or
      heterozygous Arid1a loss in established tumors accelerated progression and
      metastasis. Mechanistically, gain of Arid1a function promoted initiation by
      increasing CYP450-mediated oxidative stress, while loss of Arid1a within tumors
      decreased chromatin accessibility and reduced transcription of genes associated
      with migration, invasion, and metastasis. In summary, ARID1A has
      context-dependent tumor-suppressive and oncogenic roles in cancer.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Sun, Xuxu
AU  - Sun X
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Wang, Sam C
AU  - Wang SC
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA; Department of Surgery, University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Wei, Yonglong
AU  - Wei Y
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Luo, Xin
AU  - Luo X
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA; Department of Bioinformatics, University
      of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Jia, Yuemeng
AU  - Jia Y
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Li, Lin
AU  - Li L
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Gopal, Purva
AU  - Gopal P
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas,
      TX 75390, USA.
FAU - Zhu, Min
AU  - Zhu M
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Nassour, Ibrahim
AU  - Nassour I
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA; Department of Surgery, University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Chuang, Jen-Chieh
AU  - Chuang JC
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Maples, Thomas
AU  - Maples T
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Celen, Cemre
AU  - Celen C
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Nguyen, Liem H
AU  - Nguyen LH
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA; Howard Hughes Medical Institute,
      University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Wu, Linwei
AU  - Wu L
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA; Organ Transplant Center, First Affiliated 
      Hospital of Sun Yat-Sen University, Guangzhou 510080, China.
FAU - Fu, Shunjun
AU  - Fu S
AD  - Organ Transplant Center, First Affiliated Hospital of Sun Yat-Sen University,
      Guangzhou 510080, China.
FAU - Li, Weiping
AU  - Li W
AD  - State Key Laboratory of Cell Biology, Innovation Center for Cell Signaling
      Network, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute 
      of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Hui, Lijian
AU  - Hui L
AD  - State Key Laboratory of Cell Biology, Innovation Center for Cell Signaling
      Network, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute 
      of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of
      Chinese Academy of Sciences, Shanghai 200031, China; School of Life Science and
      Technology, ShanghaiTech University, Shanghai 201210, China.
FAU - Tian, Feng
AU  - Tian F
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032,
      China.
FAU - Ji, Yuan
AU  - Ji Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032,
      China.
FAU - Zhang, Shuyuan
AU  - Zhang S
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Sorouri, Mahsa
AU  - Sorouri M
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Hwang, Tae Hyun
AU  - Hwang TH
AD  - Lerner Research Institute, Department of Quantitative Health Sciences, Cleveland 
      Clinic, Cleveland, OH 44195, USA.
FAU - Letzig, Lynda
AU  - Letzig L
AD  - Clinical Pharmacology and Toxicology, Arkansas Children's Hospital and Department
      of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR
      72202, USA.
FAU - James, Laura
AU  - James L
AD  - Clinical Pharmacology and Toxicology, Arkansas Children's Hospital and Department
      of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR
      72202, USA.
FAU - Wang, Zixi
AU  - Wang Z
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Yopp, Adam C
AU  - Yopp AC
AD  - Department of Surgery, University of Texas Southwestern Medical Center, Dallas,
      TX 75390, USA.
FAU - Singal, Amit G
AU  - Singal AG
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center,
      Dallas, TX 75390, USA.
FAU - Zhu, Hao
AU  - Zhu H
AD  - Children's Research Institute, Departments of Pediatrics and Internal Medicine,
      Center for Regenerative Science and Medicine, University of Texas Southwestern
      Medical Center, Dallas, TX 75390, USA. Electronic address:
      hao.zhu@utsouthwestern.edu.
LA  - eng
GR  - R01 CA190525/CA/NCI NIH HHS/United States
GR  - R01 DK111588/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Arid1a protein, mouse)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Nuclear Proteins)
SB  - IM
EIN - Cancer Cell. 2018 Jan 8;33(1):151-152. PMID: 29316428
MH  - Animals
MH  - Blotting, Western
MH  - Carcinogenesis/genetics
MH  - Carcinoma, Hepatocellular/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/*genetics/metabolism
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Liver Neoplasms/*genetics/metabolism/pathology
MH  - Mice, 129 Strain
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, Knockout
MH  - Mice, SCID
MH  - Neoplasm Metastasis
MH  - Nuclear Proteins/*genetics/metabolism
MH  - Oncogenes/*genetics
MH  - RNA Interference
PMC - PMC5728182
MID - NIHMS913379
OTO - NOTNLM
OT  - ARID1A
OT  - SWI/SNF chromatin-remodeling complex
OT  - epigenetics
OT  - hepatocellular carcinoma
OT  - metastasis
OT  - mouse models
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PMCR- 2018/11/13 00:00
PHST- 2016/11/04 00:00 [received]
PHST- 2017/08/10 00:00 [revised]
PHST- 2017/10/11 00:00 [accepted]
PHST- 2018/11/13 00:00 [pmc-release]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30460-9 [pii]
AID - 10.1016/j.ccell.2017.10.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):574-589.e6. doi: 10.1016/j.ccell.2017.10.007.

PMID- 29136503
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171128
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
PG  - 552-560
LID - S1535-6108(17)30455-5 [pii]
LID - 10.1016/j.ccell.2017.10.002 [doi]
AB  - Recent clinical trials have demonstrated that the immense majority of acute
      promyelocytic leukemia (APL) patients can be definitively cured by the
      combination of two targeted therapies: retinoic acid (RA) and arsenic. Mouse
      models have provided unexpected insights into the mechanisms involved.
      Restoration of PML nuclear bodies upon RA- and/or arsenic-initiated PML/RARA
      degradation is essential, while RA-triggered transcriptional activation is
      dispensable for APL eradication. Mutations of the arsenic-binding site of
      PML/RARA, but also PML, have been detected in therapy-resistant patients,
      demonstrating the key role of PML in APL cure. PML nuclear bodies are druggable
      and could be harnessed in other conditions.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - de The, Hugues
AU  - de The H
AD  - College de France, PSL Research University, Chaire d'Oncologie Cellulaire et
      Moleculaire, Paris, France; Universite Paris Diderot, Sorbonne Paris Cite, INSERM
      UMR 944, CNRS UMR 7212, Hopital St. Louis, Paris, France. Electronic address:
      hugues.dethe@inserm.fr.
FAU - Pandolfi, Pier Paolo
AU  - Pandolfi PP
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA, USA.
FAU - Chen, Zhu
AU  - Chen Z
AD  - Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University 
      School of Medicine, 200025 Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Arsenicals)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Arsenicals/administration & dosage
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*drug therapy/genetics/metabolism
MH  - Oncogene Proteins/*antagonists & inhibitors/genetics/metabolism
MH  - Oncogene Proteins, Fusion/*antagonists & inhibitors/genetics/metabolism
MH  - Tretinoin/administration & dosage
MH  - Tumor Suppressor Proteins/*antagonists & inhibitors/genetics/metabolism
OTO - NOTNLM
OT  - PML
OT  - RARA
OT  - SUMO
OT  - arsenic
OT  - differentiation
OT  - mouse models
OT  - precision medicine
OT  - retinoic acid
OT  - targeted therapy
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/06/12 00:00 [received]
PHST- 2017/08/01 00:00 [revised]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30455-5 [pii]
AID - 10.1016/j.ccell.2017.10.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):552-560. doi: 10.1016/j.ccell.2017.10.002.

PMID- 29136502
OWN - NLM
STAT- In-Process
LR  - 20171114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Molecular Landscape of Non-Muscle Invasive Bladder Cancer.
PG  - 550-551
LID - S1535-6108(17)30360-4 [pii]
LID - 10.1016/j.ccell.2017.08.015 [doi]
AB  - In this issue of Cancer Cell, Hurst et al. report an integrated analysis of
      non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by
      chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from
      female patients have a higher frequency of KDM6A mutations.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Meeks, Joshua J
AU  - Meeks JJ
AD  - Department of Urology, Northwestern University, Feinberg School of Medicine,
      Chicago, IL 60611, USA.
FAU - Lerner, Seth P
AU  - Lerner SP
AD  - Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of
      Medicine, Houston, TX 77030, USA. Electronic address: slerner@bcm.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
AID - S1535-6108(17)30360-4 [pii]
AID - 10.1016/j.ccell.2017.08.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):550-551. doi: 10.1016/j.ccell.2017.08.015.

PMID- 29136501
OWN - NLM
STAT- In-Process
LR  - 20171114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Pontine Infantile Glioma Simplified.
PG  - 548-549
LID - S1535-6108(17)30466-X [pii]
LID - 10.1016/j.ccell.2017.10.013 [doi]
AB  - In this issue of Cancer Cell, Pathania et al. report sporadic childhood histone
      K27M mutant malignant glioma mouse models that faithfully recapitulate the human 
      tumor phenotypes. Beyond emphasizing the importance of correct timing in mouse
      modeling of cancer, these models will facilitate research to effectively treat
      this lethal childhood cancer.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON,
      Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology,
      Hospital for Sick Children, Toronto, ON, Canada. Electronic address:
      mdtaylor@sickkids.ca.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
AID - S1535-6108(17)30466-X [pii]
AID - 10.1016/j.ccell.2017.10.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):548-549. doi: 10.1016/j.ccell.2017.10.013.

PMID- 29136500
OWN - NLM
STAT- In-Process
LR  - 20171114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Does CSF1R Blockade Turn into Friendly Fire?
PG  - 546-547
LID - S1535-6108(17)30465-8 [pii]
LID - 10.1016/j.ccell.2017.10.012 [doi]
AB  - In this issue of Cancer Cell, Kumar et al. describe how CSF1R blockade induces
      not only an expected deprivation of tumor-associated macrophages, but also an
      accumulation of tumor-infiltrating polymorphonuclear mononuclear cells caused by 
      Cxcl-1 released from cancer-associated fibroblasts.
CI  - Published by Elsevier Inc.
FAU - Greten, Tim F
AU  - Greten TF
AD  - Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology
      Branch, Center for Cancer Research, National Cancer Institute, National
      Institutes of Health, Bethesda, MD 20892, USA. Electronic address:
      tim.greten@nih.gov.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
AID - S1535-6108(17)30465-8 [pii]
AID - 10.1016/j.ccell.2017.10.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):546-547. doi: 10.1016/j.ccell.2017.10.012.

PMID- 29136499
OWN - NLM
STAT- In-Process
LR  - 20171114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Early GalNAc O-Glycosylation: Pushing the Tumor Boundaries.
PG  - 544-545
LID - S1535-6108(17)30463-4 [pii]
LID - 10.1016/j.ccell.2017.10.010 [doi]
AB  - Glycosylation alterations are frequently observed in cancer cells and shape tumor
      progression. In this issue of Cancer Cell, Nguyen et al. show that GALNT1
      relocation from Golgi to endoplasmic reticulum drives liver tumor growth and
      invasion, due to enhanced glycosylation and consequential activation of the
      extracellular matrix-degrading metalloproteinase MMP14.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gomes, Joana
AU  - Gomes J
AD  - i3S - Institute for Research and Innovation in Health, University of Porto,
      4200-135 Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and
      Immunology, University of Porto, 4200-465 Porto, Portugal.
FAU - Mereiter, Stefan
AU  - Mereiter S
AD  - i3S - Institute for Research and Innovation in Health, University of Porto,
      4200-135 Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and
      Immunology, University of Porto, 4200-465 Porto, Portugal.
FAU - Magalhaes, Ana
AU  - Magalhaes A
AD  - i3S - Institute for Research and Innovation in Health, University of Porto,
      4200-135 Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and
      Immunology, University of Porto, 4200-465 Porto, Portugal.
FAU - Reis, Celso A
AU  - Reis CA
AD  - i3S - Institute for Research and Innovation in Health, University of Porto,
      4200-135 Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and
      Immunology, University of Porto, 4200-465 Porto, Portugal; Instituto de Ciencias 
      Biomedicas Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal;
      Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. Electronic
      address: celsor@ipatimup.pt.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
AID - S1535-6108(17)30463-4 [pii]
AID - 10.1016/j.ccell.2017.10.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):544-545. doi: 10.1016/j.ccell.2017.10.010.

PMID- 29136498
OWN - NLM
STAT- In-Process
LR  - 20171114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - A Two-Faced mSWI/SNF Subunit: Dual Roles for ARID1A in Tumor Suppression and
      Oncogenicity in the Liver.
PG  - 542-543
LID - S1535-6108(17)30467-1 [pii]
LID - 10.1016/j.ccell.2017.10.014 [doi]
AB  - In this issue of Cancer Cell, Sun et al. describe context-dependent oncogenic and
      tumor-suppressive functions for the mammalian SWI/SNF (BAF) complex subunit
      ARID1A in the development and progression of hepatocellular carcinoma (HCC).
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Otto, Jordan E
AU  - Otto JE
AD  - Chemical Biology Program, Harvard University, Cambridge, MA 02138, USA;
      Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard
      Medical School, Boston, MA 02215, USA.
FAU - Kadoch, Cigall
AU  - Kadoch C
AD  - Chemical Biology Program, Harvard University, Cambridge, MA 02138, USA;
      Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard
      Medical School, Boston, MA 02215, USA. Electronic address:
      cigall_kadoch@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
AID - S1535-6108(17)30467-1 [pii]
AID - 10.1016/j.ccell.2017.10.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):542-543. doi: 10.1016/j.ccell.2017.10.014.

PMID- 29136497
OWN - NLM
STAT- In-Process
LR  - 20171114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Oncogene-Stimulated Congestion at the KEAP1 Stress Signaling Hub Allows Bypass of
      NRF2 and Induction of NRF2-Target Genes that Promote Tumor Survival.
PG  - 539-541
LID - S1535-6108(17)30462-2 [pii]
LID - 10.1016/j.ccell.2017.10.009 [doi]
AB  - In this issue of Cancer Cell, Ge et al. show that overexpression of the
      oncoprotein iASPP in cancer cells provokes NRF2-mediated induction of
      cytoprotective genes, because it logjams the ubiquitin ligase substrate adaptor
      function of KEAP1 by virtue of the fact that it possesses a novel DLT-containing 
      KEAP1-interaction motif.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hayes, John D
AU  - Hayes JD
AD  - Division of Cancer Research, Jacqui Wood Cancer Centre, Ninewells Hospital and
      Medical School, University of Dundee, Dundee DD1 9SY, Scotland.
FAU - Dinkova-Kostova, Albena T
AU  - Dinkova-Kostova AT
AD  - Division of Cancer Research, Jacqui Wood Cancer Centre, Ninewells Hospital and
      Medical School, University of Dundee, Dundee DD1 9SY, Scotland. Electronic
      address: j.d.hayes@dundee.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
AID - S1535-6108(17)30462-2 [pii]
AID - 10.1016/j.ccell.2017.10.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):539-541. doi: 10.1016/j.ccell.2017.10.009.

PMID- 29107533
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171219
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - H3.3(K27M) Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural
      Progenitor Cells to Induce Invasive High-Grade Gliomas.
PG  - 684-700.e9
LID - S1535-6108(17)30418-X [pii]
LID - 10.1016/j.ccell.2017.09.014 [doi]
AB  - Gain-of-function mutations in histone 3 (H3) variants are found in a substantial 
      proportion of pediatric high-grade gliomas (pHGG), often in association with TP53
      loss and platelet-derived growth factor receptor alpha (PDGFRA) amplification.
      Here, we describe a somatic mouse model wherein H3.3(K27M) and Trp53 loss alone
      are sufficient for neoplastic transformation if introduced in utero.
      H3.3(K27M)-driven lesions are clonal, H3K27me3 depleted, Olig2 positive, highly
      proliferative, and diffusely spreading, thus recapitulating hallmark molecular
      and histopathological features of pHGG. Addition of wild-type PDGFRA decreases
      latency and increases tumor invasion, while ATRX knockdown is associated with
      more circumscribed tumors. H3.3(K27M)-tumor cells serially engraft in recipient
      mice, and preliminary drug screening reveals mutation-specific vulnerabilities.
      Overall, we provide a faithful H3.3(K27M)-pHGG model which enables insights into 
      oncohistone pathogenesis and investigation of future therapies.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Pathania, Manav
AU  - Pathania M
AD  - Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, London WC1E 6DD, UK.
FAU - De Jay, Nicolas
AU  - De Jay N
AD  - Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
FAU - Maestro, Nicola
AU  - Maestro N
AD  - Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, London WC1E 6DD, UK.
FAU - Harutyunyan, Ashot S
AU  - Harutyunyan AS
AD  - Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
FAU - Nitarska, Justyna
AU  - Nitarska J
AD  - MRC Laboratory for Molecular Cell Biology, UCL, London WC1E 6BT, UK.
FAU - Pahlavan, Pirasteh
AU  - Pahlavan P
AD  - Nuclear Function Group, German Centre for Neurodegenerative Diseases (DZNE),
      Sigmund-Freud-Strasse 27, Bonn 53127, Germany.
FAU - Henderson, Stephen
AU  - Henderson S
AD  - Bill Lyons Informatics Centre, UCL Cancer Institute, London WC1E 6DD, UK.
FAU - Mikael, Leonie G
AU  - Mikael LG
AD  - Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
FAU - Richard-Londt, Angela
AU  - Richard-Londt A
AD  - UCL Institute of Neurology, London WC1N 3BG, UK.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - UCL Institute of Neurology, London WC1N 3BG, UK.
FAU - Costa, Joana R
AU  - Costa JR
AD  - MRC Laboratory for Molecular Cell Biology, UCL, London WC1E 6BT, UK.
FAU - Hebert, Steven
AU  - Hebert S
AD  - The Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
FAU - Khazaei, Sima
AU  - Khazaei S
AD  - Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
FAU - Ibrahim, Nisreen Samir
AU  - Ibrahim NS
AD  - Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
FAU - Herrero, Javier
AU  - Herrero J
AD  - Bill Lyons Informatics Centre, UCL Cancer Institute, London WC1E 6DD, UK.
FAU - Riccio, Antonella
AU  - Riccio A
AD  - MRC Laboratory for Molecular Cell Biology, UCL, London WC1E 6BT, UK.
FAU - Albrecht, Steffen
AU  - Albrecht S
AD  - Department of Pathology, McGill University, Montreal, QC H3A 2B4, Canada.
FAU - Ketteler, Robin
AU  - Ketteler R
AD  - MRC Laboratory for Molecular Cell Biology, UCL, London WC1E 6BT, UK.
FAU - Brandner, Sebastian
AU  - Brandner S
AD  - UCL Institute of Neurology, London WC1N 3BG, UK.
FAU - Kleinman, Claudia L
AU  - Kleinman CL
AD  - Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada;
      The Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
FAU - Jabado, Nada
AU  - Jabado N
AD  - Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada;
      Department of Pediatrics, McGill University, Montreal, QC H4A 3J1, Canada.
      Electronic address: nada.jabado@mcgill.ca.
FAU - Salomoni, Paolo
AU  - Salomoni P
AD  - Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, London WC1E 6DD, UK;
      Nuclear Function Group, German Centre for Neurodegenerative Diseases (DZNE),
      Sigmund-Freud-Strasse 27, Bonn 53127, Germany. Electronic address:
      p.salomoni@ucl.ac.uk.
LA  - eng
GR  - P01 CA196539/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171026
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor alpha)
RN  - EC 3.6.4.12 (X-linked Nuclear Protein)
SB  - IM
MH  - Animals
MH  - Brain/metabolism/pathology
MH  - Cell Transformation, Neoplastic/genetics
MH  - Embryonic Stem Cells/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Glioma/*genetics/metabolism/pathology
MH  - Histones/*genetics
MH  - Humans
MH  - Mice
MH  - Mutation
MH  - Neoplasm Grading
MH  - Neoplasm Invasiveness
MH  - Neural Stem Cells/*metabolism
MH  - RNA Interference
MH  - Receptor, Platelet-Derived Growth Factor alpha/*genetics/metabolism
MH  - Tumor Suppressor Protein p53/*genetics/metabolism
MH  - X-linked Nuclear Protein/genetics/metabolism
PMC - PMC5687892
MID - NIHMS910096
OTO - NOTNLM
OT  - clonal
OT  - mosaic
OT  - neurodevelopment
OT  - oncohistone
OT  - pediatric high-grade glioma
EDAT- 2017/11/07 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/07 06:00
PMCR- 2018/11/13 00:00
PHST- 2017/03/01 00:00 [received]
PHST- 2017/07/06 00:00 [revised]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2018/11/13 00:00 [pmc-release]
PHST- 2017/11/07 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/11/07 06:00 [entrez]
AID - S1535-6108(17)30418-X [pii]
AID - 10.1016/j.ccell.2017.09.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):684-700.e9. doi: 10.1016/j.ccell.2017.09.014. Epub
      2017 Oct 26.

PMID- 29056426
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20180214
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a
      Targetable Metabolic Vulnerability.
PG  - 624-638.e5
LID - S1535-6108(17)30417-8 [pii]
LID - 10.1016/j.ccell.2017.09.013 [doi]
AB  - The mechanistic target of rapamycin complex 1 (mTORC1) supports proliferation
      through parallel induction of key anabolic processes, including protein, lipid,
      and nucleotide synthesis. We hypothesized that these processes are coupled to
      maintain anabolic balance in cells with mTORC1 activation, a common event in
      human cancers. Loss of the tuberous sclerosis complex (TSC) tumor suppressors
      results in activation of mTORC1 and development of the tumor syndrome TSC. We
      find that pharmacological inhibitors of guanylate nucleotide synthesis have
      selective deleterious effects on TSC-deficient cells, including in mouse tumor
      models. This effect stems from replication stress and DNA damage caused by
      mTORC1-driven rRNA synthesis, which renders nucleotide pools limiting. These
      findings reveal a metabolic vulnerability downstream of mTORC1 triggered by
      anabolic imbalance.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Valvezan, Alexander J
AU  - Valvezan AJ
AD  - Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - Turner, Marc
AU  - Turner M
AD  - Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - Belaid, Amine
AU  - Belaid A
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
FAU - Lam, Hilaire C
AU  - Lam HC
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
FAU - Miller, Spencer K
AU  - Miller SK
AD  - Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - McNamara, Molly C
AU  - McNamara MC
AD  - Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - Baglini, Christian
AU  - Baglini C
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
FAU - Housden, Benjamin E
AU  - Housden BE
AD  - Department of Genetics, Harvard Medical School, Boston, MA, USA.
FAU - Perrimon, Norbert
AU  - Perrimon N
AD  - Department of Genetics, Harvard Medical School, Boston, MA, USA; Howard Hughes
      Medical Institute, Boston, MA, USA.
FAU - Kwiatkowski, David J
AU  - Kwiatkowski DJ
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
FAU - Asara, John M
AU  - Asara JM
AD  - Division of Signal Transduction, Beth Israel Deaconess Medical Center, Department
      of Medicine, Harvard Medical School, Boston, MA, USA.
FAU - Henske, Elizabeth P
AU  - Henske EP
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
FAU - Manning, Brendan D
AU  - Manning BD
AD  - Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA. Electronic address: bmanning@hsph.harvard.edu.
LA  - eng
GR  - P01 CA120964/CA/NCI NIH HHS/United States
GR  - R01 HL118760/HL/NHLBI NIH HHS/United States
GR  - R35 CA197459/CA/NCI NIH HHS/United States
GR  - T32 ES016645/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nucleotides)
RN  - 0 (RNA, Ribosomal)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (tuberous sclerosis complex 1 protein)
RN  - 4JG2LF96VF (tuberous sclerosis complex 2 protein)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - HCT116 Cells
MH  - HeLa Cells
MH  - Humans
MH  - Immunoblotting
MH  - Mechanistic Target of Rapamycin Complex 1/genetics/*metabolism
MH  - Mice, Inbred NOD
MH  - Mice, Knockout
MH  - Mice, SCID
MH  - Neoplasms/genetics/metabolism/pathology
MH  - Nucleotides/genetics/*metabolism
MH  - RNA Interference
MH  - RNA, Ribosomal/genetics/metabolism
MH  - Tuberous Sclerosis/genetics/metabolism/pathology
MH  - Tumor Suppressor Proteins/genetics/*metabolism
PMC - PMC5687294
MID - NIHMS908847
OTO - NOTNLM
OT  - IMPDH
OT  - TSC2
OT  - lymphangioleiomyomatosis
OT  - mTOR
OT  - mizoribine
OT  - mycophenolic acid
OT  - nucleotide synthesis
OT  - rapamycin
OT  - tuberous sclerosis complex
OT  - tumor metabolism
EDAT- 2017/10/24 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/10/24 06:00
PMCR- 2018/11/13 00:00
PHST- 2017/03/17 00:00 [received]
PHST- 2017/07/21 00:00 [revised]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2018/11/13 00:00 [pmc-release]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S1535-6108(17)30417-8 [pii]
AID - 10.1016/j.ccell.2017.09.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):624-638.e5. doi: 10.1016/j.ccell.2017.09.013. Epub
      2017 Oct 19.

PMID- 29033244
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171128
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by 
      Competing with Nrf2 for Keap1 Binding.
PG  - 561-573.e6
LID - S1535-6108(17)30412-9 [pii]
LID - 10.1016/j.ccell.2017.09.008 [doi]
AB  - Reactive oxygen species (ROS) have emerged as important signaling molecules that 
      play crucial roles in carcinogenesis and cytotoxic responses. Nrf2 is the master 
      regulator of ROS balance. Thus, uncovering mechanisms of Nrf2 regulation is
      important for the development of alternative treatment strategies for cancers.
      Here, we demonstrate that iASPP, a known p53 inhibitor, lowers ROS independently 
      of p53. Mechanistically, iASPP competes with Nrf2 for Keap1 binding via a DLT
      motif, leading to decreased Nrf2 ubiquitination and increased Nrf2 accumulation, 
      nuclear translocation, and antioxidative transactivation. This iASPP-Keap1-Nrf2
      axis promotes cancer growth and drug resistance both in vitro and in vivo. Thus, 
      iASPP is an antioxidative factor and represents a promising target to improve
      cancer treatment, regardless of p53 status.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Ge, Wenjie
AU  - Ge W
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Zhao, Kunming
AU  - Zhao K
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Wang, Xingwen
AU  - Wang X
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Li, Huayi
AU  - Li H
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Yu, Miao
AU  - Yu M
AD  - School of Chemistry, Harbin Institute of Technology, Harbin, Heilongjiang
      Province 150001, China.
FAU - He, Mengmeng
AU  - He M
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Xue, Xuting
AU  - Xue X
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Zhu, Yifu
AU  - Zhu Y
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Zhang, Cheng
AU  - Zhang C
AD  - Department of Urology, The First Affiliated Hospital of Harbin Medical
      University, Harbin, Heilongjiang Province 150006, China.
FAU - Cheng, Yiwei
AU  - Cheng Y
AD  - Department of Urology, The First Affiliated Hospital of Harbin Medical
      University, Harbin, Heilongjiang Province 150006, China.
FAU - Jiang, Shijian
AU  - Jiang S
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China.
FAU - Hu, Ying
AU  - Hu Y
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang Province 150001, China; Shenzhen Graduate School of Harbin Institute
      of Technology, Shenzhen 518055, China. Electronic address: huying@hit.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20171012
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antioxidants)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (KEAP1 protein, human)
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (PPP1R13L protein, human)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Repressor Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Antioxidants/metabolism
MH  - Blotting, Western
MH  - Cell Line, Tumor
MH  - *Cell Proliferation
MH  - *Drug Resistance, Neoplasm
MH  - HCT116 Cells
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/genetics/*metabolism
MH  - Kelch-Like ECH-Associated Protein 1/genetics/*metabolism
MH  - NF-E2-Related Factor 2/genetics/*metabolism
MH  - Neoplasms/genetics/metabolism/pathology
MH  - Protein Binding
MH  - RNA Interference
MH  - Reactive Oxygen Species/metabolism
MH  - Repressor Proteins/genetics/*metabolism
MH  - Tumor Suppressor Protein p53/genetics/metabolism
OTO - NOTNLM
OT  - Keap1
OT  - Nrf2
OT  - ROS
OT  - cancer growth
OT  - chemoresistance
OT  - iASPP
OT  - renal cell carcinoma
EDAT- 2017/10/17 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/01/26 00:00 [received]
PHST- 2017/06/15 00:00 [revised]
PHST- 2017/09/15 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - S1535-6108(17)30412-9 [pii]
AID - 10.1016/j.ccell.2017.09.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):561-573.e6. doi: 10.1016/j.ccell.2017.09.008. Epub
      2017 Oct 12.

PMID- 29017060
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20171031
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric 
      Antigen Receptor Therapy of AML.
PG  - 506-519.e5
LID - S1535-6108(17)30408-7 [pii]
LID - 10.1016/j.ccell.2017.09.004 [doi]
AB  - Chimeric antigen receptor (CAR) therapy targeting CD19 has yielded remarkable
      outcomes in patients with acute lymphoblastic leukemia. To identify potential CAR
      targets in acute myeloid leukemia (AML), we probed the AML surfaceome for
      overexpressed molecules with tolerable systemic expression. We integrated large
      transcriptomics and proteomics datasets from malignant and normal tissues, and
      developed an algorithm to identify potential targets expressed in leukemia stem
      cells, but not in normal CD34(+)CD38(-) hematopoietic cells, T cells, or vital
      tissues. As these investigations did not uncover candidate targets with a profile
      as favorable as CD19, we developed a generalizable combinatorial targeting
      strategy fulfilling stringent efficacy and safety criteria. Our findings indicate
      that several target pairings hold great promise for CAR therapy of AML.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Perna, Fabiana
AU  - Perna F
AD  - Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Berman, Samuel H
AU  - Berman SH
AD  - Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Soni, Rajesh K
AU  - Soni RK
AD  - Microchemistry and Proteomics Core Laboratory, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Mansilla-Soto, Jorge
AU  - Mansilla-Soto J
AD  - Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Eyquem, Justin
AU  - Eyquem J
AD  - Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Hamieh, Mohamad
AU  - Hamieh M
AD  - Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Hendrickson, Ronald C
AU  - Hendrickson RC
AD  - Microchemistry and Proteomics Core Laboratory, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Brennan, Cameron W
AU  - Brennan CW
AD  - Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 
      10065, USA.
FAU - Sadelain, Michel
AU  - Sadelain M
AD  - Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA. Electronic address:
      m-sadelain@ski.mskcc.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, CD19)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - *Antigens, CD19
MH  - Cell Line, Tumor
MH  - *Gene Expression Profiling
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Leukemia, Myeloid, Acute/immunology/*therapy
MH  - *Proteomics
MH  - Receptors, Antigen, T-Cell/*metabolism
MH  - Recombinant Fusion Proteins/metabolism
MH  - T-Lymphocytes/*immunology/metabolism
OTO - NOTNLM
OT  - CAR T cell
OT  - acute myeloid leukemia (AML)
OT  - algorithm
OT  - combinatorial strategies
OT  - high-throughput annotation
OT  - immunotherapy
OT  - leukemia
OT  - proteomics
OT  - surfaceome
OT  - target discovery
EDAT- 2017/10/11 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/07/08 00:00 [received]
PHST- 2017/08/02 00:00 [revised]
PHST- 2017/09/07 00:00 [accepted]
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S1535-6108(17)30408-7 [pii]
AID - 10.1016/j.ccell.2017.09.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):506-519.e5. doi: 10.1016/j.ccell.2017.09.004.

PMID- 29017059
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180203
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid
      Leukemia.
PG  - 490-505.e10
LID - S1535-6108(17)30364-1 [pii]
LID - 10.1016/j.ccell.2017.09.001 [doi]
AB  - The BCL-2 family protein BAX is a central mediator of apoptosis. Overexpression
      of anti-apoptotic BCL-2 proteins contributes to tumor development and resistance 
      to therapy by suppressing BAX and its activators. We report the discovery of
      BTSA1, a pharmacologically optimized BAX activator that binds with high affinity 
      and specificity to the N-terminal activation site and induces conformational
      changes to BAX leading to BAX-mediated apoptosis. BTSA1-induced BAX activation
      effectively promotes apoptosis in leukemia cell lines and patient samples while
      sparing healthy cells. BAX expression levels and cytosolic conformation regulate 
      sensitivity to BTSA1. BTSA1 potently suppressed human acute myeloid leukemia
      (AML) xenografts and increased host survival without toxicity. This study
      provides proof-of-concept for direct BAX activation as a treatment strategy in
      AML.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Reyna, Denis E
AU  - Reyna DE
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY
      10461, USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Garner, Thomas P
AU  - Garner TP
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY
      10461, USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Lopez, Andrea
AU  - Lopez A
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY
      10461, USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Kopp, Felix
AU  - Kopp F
AD  - Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA.
FAU - Choudhary, Gaurav S
AU  - Choudhary GS
AD  - Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical
      Center, Bronx, NY 10461, USA.
FAU - Sridharan, Ashwin
AU  - Sridharan A
AD  - Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical
      Center, Bronx, NY 10461, USA.
FAU - Narayanagari, Swathi-Rao
AU  - Narayanagari SR
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx,
      NY 10461, USA; Department of Cell Biology, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Mitchell, Kelly
AU  - Mitchell K
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx,
      NY 10461, USA; Department of Cell Biology, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Dong, Baoxia
AU  - Dong B
AD  - Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical
      Center, Bronx, NY 10461, USA.
FAU - Bartholdy, Boris A
AU  - Bartholdy BA
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx,
      NY 10461, USA; Department of Cell Biology, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Walensky, Loren D
AU  - Walensky LD
AD  - Department of Pediatric Oncology and the Linde Program in Cancer Chemical
      Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Verma, Amit
AU  - Verma A
AD  - Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical
      Center, Bronx, NY 10461, USA.
FAU - Steidl, Ulrich
AU  - Steidl U
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx,
      NY 10461, USA; Department of Cell Biology, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Gavathiotis, Evripidis
AU  - Gavathiotis E
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY
      10461, USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA. Electronic address: evripidis.gavathiotis@einstein.yu.edu.
LA  - eng
GR  - R01 CA217092/CA/NCI NIH HHS/United States
GR  - S10 OD016305/OD/NIH HHS/United States
GR  - R01 CA178394/CA/NCI NIH HHS/United States
GR  - R35 CA197583/CA/NCI NIH HHS/United States
GR  - P30 CA013330/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BAX protein, human)
RN  - 0 (BTSA1 compound)
RN  - 0 (Hydrazones)
RN  - 0 (Thiazoles)
RN  - 0 (bcl-2-Associated X Protein)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Cell Line, Tumor
MH  - Humans
MH  - Hydrazones/*pharmacology
MH  - Leukemia, Myeloid, Acute/*drug therapy/pathology
MH  - Mice
MH  - Protein Conformation
MH  - Thiazoles/*pharmacology
MH  - Xenograft Model Antitumor Assays
MH  - bcl-2-Associated X Protein/chemistry/*physiology
PMC - PMC5793879
MID - NIHMS904573
OTO - NOTNLM
OT  - BAX
OT  - BAX activator
OT  - BCL-2 family
OT  - BH3
OT  - BTSA1
OT  - MOMP
OT  - apoptosis
OT  - cell death
OT  - leukemia
OT  - mitochondria
EDAT- 2017/10/11 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/11 06:00
PMCR- 2018/10/09 00:00
PHST- 2017/01/27 00:00 [received]
PHST- 2017/06/28 00:00 [revised]
PHST- 2017/08/30 00:00 [accepted]
PHST- 2018/10/09 00:00 [pmc-release]
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S1535-6108(17)30364-1 [pii]
AID - 10.1016/j.ccell.2017.09.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):490-505.e10. doi: 10.1016/j.ccell.2017.09.001.

PMID- 29017058
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180329
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF
      Signaling.
PG  - 474-489.e6
LID - S1535-6108(17)30407-5 [pii]
LID - 10.1016/j.ccell.2017.09.003 [doi]
AB  - Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma
      (PC) and represents the major therapeutic target for treating metastatic prostate
      cancer (mPC). Though highly effective, AR antagonism can produce tumors that
      bypass a functional requirement for AR, often through neuroendocrine (NE)
      transdifferentiation. Through the molecular assessment of mPCs over two decades, 
      we find a phenotypic shift has occurred in mPC with the emergence of an AR-null
      NE-null phenotype. These "double-negative" PCs are notable for elevated FGF and
      MAPK pathway activity, which can bypass AR dependence. Pharmacological inhibitors
      of MAPK or FGFR repressed the growth of double-negative PCs in vitro and in vivo.
      Our results indicate that FGF/MAPK blockade may be particularly efficacious
      against mPCs with an AR-null phenotype.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bluemn, Eric G
AU  - Bluemn EG
AD  - Department of Medicine, University of Washington, Seattle, WA, USA; Divisions of 
      Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center,
      Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Coleman, Ilsa M
AU  - Coleman IM
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Lucas, Jared M
AU  - Lucas JM
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Coleman, Roger T
AU  - Coleman RT
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Hernandez-Lopez, Susana
AU  - Hernandez-Lopez S
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Tharakan, Robin
AU  - Tharakan R
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Bianchi-Frias, Daniella
AU  - Bianchi-Frias D
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Dumpit, Ruth F
AU  - Dumpit RF
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Kaipainen, Arja
AU  - Kaipainen A
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Corella, Alexandra N
AU  - Corella AN
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Yang, Yu Chi
AU  - Yang YC
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Nyquist, Michael D
AU  - Nyquist MD
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Mostaghel, Elahe
AU  - Mostaghel E
AD  - Department of Medicine, University of Washington, Seattle, WA, USA; Divisions of 
      Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center,
      Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Hsieh, Andrew C
AU  - Hsieh AC
AD  - Department of Medicine, University of Washington, Seattle, WA, USA; Divisions of 
      Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center,
      Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA.
FAU - Zhang, Xiaotun
AU  - Zhang X
AD  - Department of Urology, University of Washington, 1959 NE Pacific Street, Seattle,
      WA 98195, USA.
FAU - Corey, Eva
AU  - Corey E
AD  - Department of Urology, University of Washington, 1959 NE Pacific Street, Seattle,
      WA 98195, USA.
FAU - Brown, Lisha G
AU  - Brown LG
AD  - Department of Urology, University of Washington, 1959 NE Pacific Street, Seattle,
      WA 98195, USA.
FAU - Nguyen, Holly M
AU  - Nguyen HM
AD  - Department of Urology, University of Washington, 1959 NE Pacific Street, Seattle,
      WA 98195, USA.
FAU - Pienta, Kenneth
AU  - Pienta K
AD  - Johns Hopkins University, Baltimore, MD, USA.
FAU - Ittmann, Michael
AU  - Ittmann M
AD  - Baylor College of Medicine, Houston, TX, USA.
FAU - Schweizer, Michael
AU  - Schweizer M
AD  - Department of Medicine, University of Washington, Seattle, WA, USA.
FAU - True, Lawrence D
AU  - True LD
AD  - Department of Pathology, University of Washington, Seattle, WA, USA.
FAU - Wise, David
AU  - Wise D
AD  - Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
FAU - Rennie, Paul S
AU  - Rennie PS
AD  - Vancouver Prostate Centre, Vancouver, BC, Canada.
FAU - Vessella, Robert L
AU  - Vessella RL
AD  - Department of Urology, University of Washington, 1959 NE Pacific Street, Seattle,
      WA 98195, USA.
FAU - Morrissey, Colm
AU  - Morrissey C
AD  - Department of Urology, University of Washington, 1959 NE Pacific Street, Seattle,
      WA 98195, USA. Electronic address: cmorriss@uw.edu.
FAU - Nelson, Peter S
AU  - Nelson PS
AD  - Department of Medicine, University of Washington, Seattle, WA, USA; Divisions of 
      Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center,
      Mailstop D4-100, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA; Department 
      of Urology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, 
      USA; Department of Pathology, University of Washington, Seattle, WA, USA.
      Electronic address: pnelson@fhcrc.org.
LA  - eng
GR  - P01 CA163227/CA/NCI NIH HHS/United States
GR  - P50 CA097186/CA/NCI NIH HHS/United States
GR  - T32 GM007266/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Androgen Antagonists)
RN  - 0 (ID1 protein, human)
RN  - 0 (Inhibitor of Differentiation Protein 1)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - 62031-54-3 (Fibroblast Growth Factors)
SB  - IM
MH  - Androgen Antagonists/therapeutic use
MH  - Animals
MH  - Cell Differentiation
MH  - Cell Line, Tumor
MH  - Fibroblast Growth Factors/antagonists & inhibitors/*physiology
MH  - Humans
MH  - Inhibitor of Differentiation Protein 1/physiology
MH  - MAP Kinase Signaling System/drug effects
MH  - Male
MH  - Mice
MH  - Neoplasm Metastasis
MH  - Prostatic Neoplasms/drug therapy/*pathology
MH  - Receptors, Androgen/*physiology
MH  - Receptors, Fibroblast Growth Factor/antagonists & inhibitors/physiology
MH  - Signal Transduction/*physiology
PMC - PMC5750052
MID - NIHMS905679
OTO - NOTNLM
OT  - FGF
OT  - ID1
OT  - androgen-pathway independence
OT  - castration-resistant prostate cancer
OT  - neuroendocrine
EDAT- 2017/10/11 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/11 06:00
PMCR- 2018/10/09 00:00
PHST- 2017/06/18 00:00 [received]
PHST- 2017/08/01 00:00 [revised]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2018/10/09 00:00 [pmc-release]
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S1535-6108(17)30407-5 [pii]
AID - 10.1016/j.ccell.2017.09.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.

PMID- 29017057
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180315
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in
      Pancreatic Cancer.
PG  - 460-473.e6
LID - S1535-6108(17)30411-7 [pii]
LID - 10.1016/j.ccell.2017.09.007 [doi]
AB  - The p53 transcription factor is a critical barrier to pancreatic cancer
      progression. To unravel mechanisms of p53-mediated tumor suppression, which have 
      remained elusive, we analyzed pancreatic cancer development in mice expressing
      p53 transcriptional activation domain (TAD) mutants. Surprisingly, the p53(53,54)
      TAD2 mutant behaves as a "super-tumor suppressor," with an enhanced capacity to
      both suppress pancreatic cancer and transactivate select p53 target genes,
      including Ptpn14. Ptpn14 encodes a negative regulator of the Yap oncoprotein and 
      is necessary and sufficient for pancreatic cancer suppression, like p53. We show 
      that p53 deficiency promotes Yap signaling and that PTPN14 and TP53 mutations are
      mutually exclusive in human cancers. These studies uncover a p53-Ptpn14-Yap
      pathway that is integral to p53-mediated tumor suppression.
CI  - Crown Copyright (c) 2017. Published by Elsevier Inc. All rights reserved.
FAU - Mello, Stephano S
AU  - Mello SS
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Valente, Liz J
AU  - Valente LJ
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Raj, Nitin
AU  - Raj N
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Seoane, Jose A
AU  - Seoane JA
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA
      94305, USA; Stanford Cancer Institute, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Flowers, Brittany M
AU  - Flowers BM
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - McClendon, Jacob
AU  - McClendon J
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Bieging-Rolett, Kathryn T
AU  - Bieging-Rolett KT
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Lee, Jonghyeob
AU  - Lee J
AD  - Department of Developmental Biology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Ivanochko, Danton
AU  - Ivanochko D
AD  - Princess Margaret Cancer Centre, Structural Genomics Consortium and Department of
      Medical Biophysics, University of Toronto, Toronto, ON, Canada.
FAU - Kozak, Margaret M
AU  - Kozak MM
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Chang, Daniel T
AU  - Chang DT
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Longacre, Teri A
AU  - Longacre TA
AD  - Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
      94305, USA; Department of Pathology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Koong, Albert C
AU  - Koong AC
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Arrowsmith, Cheryl H
AU  - Arrowsmith CH
AD  - Princess Margaret Cancer Centre, Structural Genomics Consortium and Department of
      Medical Biophysics, University of Toronto, Toronto, ON, Canada.
FAU - Kim, Seung K
AU  - Kim SK
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA
      94305, USA; Stanford Cancer Institute, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Department of Developmental Biology, Stanford University
      School of Medicine, Stanford, CA 94305, USA.
FAU - Vogel, Hannes
AU  - Vogel H
AD  - Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
      94305, USA; Department of Pathology, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Wood, Laura D
AU  - Wood LD
AD  - Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The
      Johns Hopkins University School of Medicine, Baltimore, MD, USA.
FAU - Hruban, Ralph H
AU  - Hruban RH
AD  - Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The
      Johns Hopkins University School of Medicine, Baltimore, MD, USA.
FAU - Curtis, Christina
AU  - Curtis C
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA
      94305, USA; Stanford Cancer Institute, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Department of Genetics, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Attardi, Laura D
AU  - Attardi LD
AD  - Department of Radiation Oncology, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of
      Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University
      School of Medicine, Stanford, CA 94305, USA. Electronic address:
      attardi@stanford.edu.
LA  - eng
GR  - R01 CA140875/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (TP53 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (YY1AP1 protein, human)
RN  - EC 3.1.3.48 (PTPN14 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatases, Non-Receptor)
SB  - IM
CIN - Nat Rev Cancer. 2017 Dec;17 (12 ):706-707. PMID: 29123244
MH  - Animals
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic
MH  - Gene Expression Profiling
MH  - Humans
MH  - Mice
MH  - Mutation
MH  - Nuclear Proteins/*physiology
MH  - Pancreatic Neoplasms/*genetics/pathology/prevention & control
MH  - Protein Tyrosine Phosphatases, Non-Receptor/*physiology
MH  - Signal Transduction
MH  - Transcription Factors/*physiology
MH  - Tumor Suppressor Protein p53/*physiology
PMC - PMC5659188
MID - NIHMS907136
OTO - NOTNLM
OT  - Hippo pathway
OT  - Ptpn14
OT  - YAP
OT  - mouse model
OT  - p53
OT  - pancreas cancer
OT  - transactivation domain
OT  - tumor suppressor
EDAT- 2017/10/11 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/11 06:00
PMCR- 2018/10/09 00:00
PHST- 2017/02/06 00:00 [received]
PHST- 2017/06/19 00:00 [revised]
PHST- 2017/09/08 00:00 [accepted]
PHST- 2018/10/09 00:00 [pmc-release]
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S1535-6108(17)30411-7 [pii]
AID - 10.1016/j.ccell.2017.09.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):460-473.e6. doi: 10.1016/j.ccell.2017.09.007.

PMID- 29017056
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20171031
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require
      PI3K-C2alpha Scaffolding Function.
PG  - 444-459.e7
LID - S1535-6108(17)30406-3 [pii]
LID - 10.1016/j.ccell.2017.09.002 [doi]
AB  - Proper organization of the mitotic spindle is key to genetic stability, but
      molecular components of inter-microtubule bridges that crosslink kinetochore
      fibers (K-fibers) are still largely unknown. Here we identify a
      kinase-independent function of class II phosphoinositide 3-OH kinase alpha
      (PI3K-C2alpha) acting as limiting scaffold protein organizing clathrin and TACC3 
      complex crosslinking K-fibers. Downregulation of PI3K-C2alpha causes spindle
      alterations, delayed anaphase onset, and aneuploidy, indicating that PI3K-C2alpha
      expression is required for genomic stability. Reduced abundance of PI3K-C2alpha
      in breast cancer models initially impairs tumor growth but later leads to the
      convergent evolution of fast-growing clones with mitotic checkpoint defects. As a
      consequence of altered spindle, loss of PI3K-C2alpha increases sensitivity to
      taxane-based therapy in pre-clinical models and in neoadjuvant settings.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gulluni, Federico
AU  - Gulluni F
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Martini, Miriam
AU  - Martini M
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy. Electronic address:
      miriam.martini@unito.it.
FAU - De Santis, Maria Chiara
AU  - De Santis MC
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Campa, Carlo Cosimo
AU  - Campa CC
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Ghigo, Alessandra
AU  - Ghigo A
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Margaria, Jean Piero
AU  - Margaria JP
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Ciraolo, Elisa
AU  - Ciraolo E
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Franco, Irene
AU  - Franco I
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Ala, Ugo
AU  - Ala U
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy.
FAU - Annaratone, Laura
AU  - Annaratone L
AD  - Department of Medical Sciences, University of Torino, Turin, Italy; Pathology
      Unit, Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Citta 
      della Salute e della Scienza di Torino, Turin, Italy.
FAU - Disalvatore, Davide
AU  - Disalvatore D
AD  - IFOM, The FIRC Institute for Molecular Oncology Foundation, Milan, Italy.
FAU - Bertalot, Giovanni
AU  - Bertalot G
AD  - Program of Molecular Medicine, IEO, European Institute of Oncology, Milan, Italy.
FAU - Viale, Giuseppe
AU  - Viale G
AD  - Division of Pathology, European Institute of Oncology, Milan, Italy; Department
      of Oncology and Hemato-oncology (DIPO), University of Milan, Milan, Italy.
FAU - Noatynska, Anna
AU  - Noatynska A
AD  - Department of Cell Physiology and Metabolism, University of Geneva, Geneva,
      Switzerland.
FAU - Compagno, Mara
AU  - Compagno M
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy; Department of Pathology,
      Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
FAU - Sigismund, Sara
AU  - Sigismund S
AD  - IFOM, The FIRC Institute for Molecular Oncology Foundation, Milan, Italy.
FAU - Montemurro, Filippo
AU  - Montemurro F
AD  - Unit of Investigative Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo 
      (TO), Italy.
FAU - Thelen, Marcus
AU  - Thelen M
AD  - Institute for Research in Biomedicine, Universita della Svizzera Italiana,
      Bellinzona, Switzerland.
FAU - Fan, Fan
AU  - Fan F
AD  - Department of Biological Science and Bioengineering, Key Laboratory of Biomedical
      Information Engineering of Ministry of Education, School of Life Science and
      Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.
FAU - Meraldi, Patrick
AU  - Meraldi P
AD  - Department of Cell Physiology and Metabolism, University of Geneva, Geneva,
      Switzerland.
FAU - Marchio, Caterina
AU  - Marchio C
AD  - Department of Medical Sciences, University of Torino, Turin, Italy; Pathology
      Unit, Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Citta 
      della Salute e della Scienza di Torino, Turin, Italy.
FAU - Pece, Salvatore
AU  - Pece S
AD  - Program of Molecular Medicine, IEO, European Institute of Oncology, Milan, Italy;
      Department of Oncology and Hemato-oncology (DIPO), University of Milan, Milan,
      Italy.
FAU - Sapino, Anna
AU  - Sapino A
AD  - Department of Medical Sciences, University of Torino, Turin, Italy; Unit of
      Pathology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo (TO), Italy.
FAU - Chiarle, Roberto
AU  - Chiarle R
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy; Department of Pathology,
      Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
FAU - Di Fiore, Pier Paolo
AU  - Di Fiore PP
AD  - IFOM, The FIRC Institute for Molecular Oncology Foundation, Milan, Italy; Program
      of Molecular Medicine, IEO, European Institute of Oncology, Milan, Italy;
      Department of Oncology and Hemato-oncology (DIPO), University of Milan, Milan,
      Italy.
FAU - Hirsch, Emilio
AU  - Hirsch E
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, Turin 10126, Italy. Electronic address:
      emilio.hirsch@unito.it.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (MAD1L1 protein, human)
RN  - 0 (MAD2L1 protein, human)
RN  - 0 (Mad2 Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (TACC3 protein, human)
RN  - 0 (Taxoids)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3C2A protein, human)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/drug therapy/genetics/*pathology
MH  - Cell Cycle Proteins/physiology
MH  - Cell Proliferation
MH  - *Genomic Instability
MH  - Humans
MH  - MCF-7 Cells
MH  - Mad2 Proteins/physiology
MH  - Mice
MH  - Microtubule-Associated Proteins/physiology
MH  - Nuclear Proteins/physiology
MH  - Phosphatidylinositol 3-Kinases/*physiology
MH  - Spindle Apparatus/*physiology
MH  - Taxoids/therapeutic use
OTO - NOTNLM
OT  - Class II PI3K
OT  - TACC3
OT  - breast cancer
OT  - clathrin
OT  - genomic stability
OT  - inter-microtubule bridge complex
OT  - mitosis
OT  - paclitaxel
OT  - spindle assembly checkpoint
EDAT- 2017/10/11 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/04/06 00:00 [received]
PHST- 2017/07/25 00:00 [revised]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S1535-6108(17)30406-3 [pii]
AID - 10.1016/j.ccell.2017.09.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.

PMID- 29017055
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180315
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors
      Induces a Switch toward Metastasis in Neuroblastoma.
PG  - 427-443.e8
LID - S1535-6108(17)30410-5 [pii]
LID - 10.1016/j.ccell.2017.09.006 [doi]
AB  - Neuroblastoma (NB) is a childhood cancer arising from sympatho-adrenal neural
      crest cells. Disseminated forms have high frequency of multiple tumoral foci
      whose etiology remains unknown; NB embryonic origin limits investigations in
      patients and current models. We developed an avian embryonic model driving human 
      NB tumorigenesis in tissues homologous to patients. We found that aggressive NBs 
      display a metastatic mode, secondary dissemination via peripheral nerves and
      aorta. Through tumor transcriptional profiling, we found that NB dissemination is
      induced by the shutdown of a pro-cohesion autocrine signal, SEMA3C, which
      constrains the tumoral mass. Lowering SEMA3C levels shifts the balance toward
      detachment, triggering NB cells to collectively evade the tumor. Together with
      patient cohort analysis, this identifies a microenvironment-driven pro-metastatic
      switch for NB.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Delloye-Bourgeois, Celine
AU  - Delloye-Bourgeois C
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Bertin, Lorette
AU  - Bertin L
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Thoinet, Karine
AU  - Thoinet K
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Jarrosson, Loraine
AU  - Jarrosson L
AD  - OncoFactory SAS, L'Atrium, 43 boulevard du 11 Novembre 1918, 69100 Villeurbanne, 
      France.
FAU - Kindbeiter, Karine
AU  - Kindbeiter K
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Buffet, Thomas
AU  - Buffet T
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Tauszig-Delamasure, Servane
AU  - Tauszig-Delamasure S
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Bozon, Muriel
AU  - Bozon M
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Marabelle, Aurelien
AU  - Marabelle A
AD  - Drug Development Department (DITEP), Gustave Roussy Cancer Campus (GRCC), INSERM 
      U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.
FAU - Combaret, Valerie
AU  - Combaret V
AD  - Laboratory of Translational Research, Leon Berard Centre, 28 rue Laennec, 69008
      Lyon, France.
FAU - Bergeron, Christophe
AU  - Bergeron C
AD  - Departments of Oncology and Clinical Research, Centre Leon Berard and Institut
      d'Hematologie et d'Oncologie Pediatrique, 1 Place Professeur Joseph Renaut, 69008
      Lyon, France.
FAU - Derrington, Edmund
AU  - Derrington E
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France.
FAU - Castellani, Valerie
AU  - Castellani V
AD  - University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene
      Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon,
      France. Electronic address: valerie.castellani@univ-lyon1.fr.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (PLXNA2 protein, human)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Sema3C protein, human)
RN  - 0 (Semaphorins)
SB  - IM
CIN - Nat Rev Cancer. 2017 Dec;17 (12 ):705. PMID: 29077693
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Cell Adhesion
MH  - Chick Embryo
MH  - Child
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Neoplasm Staging
MH  - Nerve Tissue Proteins/physiology
MH  - Neuroblastoma/etiology/pathology/*secondary
MH  - Receptors, Cell Surface/physiology
MH  - Semaphorins/genetics/physiology
MH  - *Tumor Microenvironment
OTO - NOTNLM
OT  - animal model
OT  - collective migration
OT  - embryonal cancer
OT  - metastatic switch
OT  - microenvironment
OT  - neural crest
OT  - neuroblastoma
OT  - neuroblastoma cell cohesion
OT  - plexin
OT  - semaphorin
EDAT- 2017/10/11 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/02/16 00:00 [received]
PHST- 2017/06/22 00:00 [revised]
PHST- 2017/09/12 00:00 [accepted]
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S1535-6108(17)30410-5 [pii]
AID - 10.1016/j.ccell.2017.09.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):427-443.e8. doi: 10.1016/j.ccell.2017.09.006.

PMID- 29017054
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20171219
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a
      Brake on Malignancy.
PG  - 404-410
LID - S1535-6108(17)30350-1 [pii]
LID - 10.1016/j.ccell.2017.08.007 [doi]
AB  - Stromal restraint of cancer growth and progression-emerging as a widespread
      phenomenon in epithelial cancers such as bladder, pancreas, colon, and
      prostate-appears rooted in stromal cell niche activity. During normal tissue
      repair, stromal niche signals, often Hedgehog-induced, promote epithelial stem
      cell differentiation as well as self-renewal, thus specifying a regenerating
      epithelial pattern. In the case of cancerous tissue, stromal cell-derived
      differentiation signals in particular may provide a brake on malignant growth.
      Understanding and therapeutic harnessing of the role of stroma in cancer
      restraint may hinge on our knowledge of the signaling programs elaborated by the 
      stromal niche.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Roberts, Kelsey J
AU  - Roberts KJ
AD  - Department of Developmental Biology, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Institute of Stem Cell Biology and Regenerative
      Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Kershner, Aaron M
AU  - Kershner AM
AD  - Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 
      94305, USA; Institute of Stem Cell Biology and Regenerative Medicine, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Beachy, Philip A
AU  - Beachy PA
AD  - Department of Developmental Biology, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Department of Biochemistry, Stanford University School
      of Medicine, Stanford, CA 94305, USA; Institute of Stem Cell Biology and
      Regenerative Medicine, Stanford University School of Medicine, Stanford, CA
      94305, USA. Electronic address: pbeachy@stanford.edu.
LA  - eng
GR  - Howard Hughes Medical Institute/United States
GR  - R01 CA157877/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Hedgehog Proteins)
SB  - IM
MH  - Breast Neoplasms/etiology/pathology
MH  - Cell Differentiation
MH  - Female
MH  - Hedgehog Proteins/physiology
MH  - Humans
MH  - Male
MH  - Pancreatic Neoplasms/etiology/pathology
MH  - Prostatic Neoplasms/etiology/pathology
MH  - Regeneration/*physiology
MH  - Stem Cell Niche/*physiology
MH  - Stem Cells/*physiology
MH  - Stromal Cells/*physiology
MH  - Urinary Bladder Neoplasms/etiology/pathology
PMC - PMC5679442
MID - NIHMS901285
OTO - NOTNLM
OT  - cancer progression
OT  - differentiation therapy
OT  - epithelial stem cell niche
OT  - epithelial stromal signaling
OT  - hedgehog signaling
OT  - regeneration
EDAT- 2017/10/11 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/11 06:00
PMCR- 2018/10/09 00:00
PHST- 2017/03/18 00:00 [received]
PHST- 2017/07/06 00:00 [revised]
PHST- 2017/08/11 00:00 [accepted]
PHST- 2018/10/09 00:00 [pmc-release]
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S1535-6108(17)30350-1 [pii]
AID - 10.1016/j.ccell.2017.08.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):404-410. doi: 10.1016/j.ccell.2017.08.007.

PMID- 29017053
OWN - NLM
STAT- In-Process
LR  - 20171010
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Apoptosis, Up the Ante.
PG  - 402-403
LID - S1535-6108(17)30413-0 [pii]
LID - 10.1016/j.ccell.2017.09.009 [doi]
AB  - The clinical success of the BH3-mimetic venetoclax has generated increasing
      interest to target BCL2 family proteins in oncology. In this issue of Cancer
      Cell, Reyna and colleagues demonstrate the potential of a pharmacological
      activator of the pro-apoptotic protein BAX to suppress acute myeloid leukemia
      both alone and together with venetoclax.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Thandapani, Palaniraja
AU  - Thandapani P
AD  - Department of Pathology, Laura & Isaac Perlmutter Cancer Center, NYU School of
      Medicine, New York, NY 10016, USA.
FAU - Aifantis, Iannis
AU  - Aifantis I
AD  - Department of Pathology, Laura & Isaac Perlmutter Cancer Center, NYU School of
      Medicine, New York, NY 10016, USA. Electronic address: iannis.aifantis@nyumc.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/10/11 06:00
MHDA- 2017/10/11 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
AID - S1535-6108(17)30413-0 [pii]
AID - 10.1016/j.ccell.2017.09.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):402-403. doi: 10.1016/j.ccell.2017.09.009.

PMID- 29017052
OWN - NLM
STAT- In-Process
LR  - 20171010
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and
      Implications for Therapy.
PG  - 399-401
LID - S1535-6108(17)30415-4 [pii]
LID - 10.1016/j.ccell.2017.09.011 [doi]
AB  - In this issue of Cancer Cell, Bluemn et al. report that approximately 20% of
      metastatic castration-resistant prostate cancers express neither AR nor
      neuroendocrine genes and show AR pathway-independent growth, driven instead by a 
      FGFR/MAPK/ID1 signaling cascade. These results provide a strong rationale for
      co-targeting AR bypass pathways with initial AR antagonism.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Brennen, W Nathaniel
AU  - Brennen WN
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center (SKCCC),
      The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
FAU - Isaacs, John T
AU  - Isaacs JT
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center (SKCCC),
      The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; The Brady
      Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD 21205, 
      USA. Electronic address: isaacjo@jhmi.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/10/11 06:00
MHDA- 2017/10/11 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
AID - S1535-6108(17)30415-4 [pii]
AID - 10.1016/j.ccell.2017.09.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):399-401. doi: 10.1016/j.ccell.2017.09.011.

PMID- 29017051
OWN - NLM
STAT- In-Process
LR  - 20171010
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Tumor Suppression by p53: Bring in the Hippo!
PG  - 397-399
LID - S1535-6108(17)30414-2 [pii]
LID - 10.1016/j.ccell.2017.09.010 [doi]
AB  - In this issue of Cancer Cell, Mello et al. investigated how p53 suppresses
      pancreatic cancer and discovered a key role for the tyrosine phosphatase PTPN14, 
      a p53 transcriptional target. PTPN14 restrains YAP, curbing its potential
      oncogenic effects. The p53-PTPN14-YAP axis highlights the importance of signaling
      pathway coordination in cancer prevention.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Aylon, Yael
AU  - Aylon Y
AD  - Department of Molecular Cell Biology, The Weizmann Institute, Rehovot 76100,
      Israel. Electronic address: yael.aylon@weizmann.ac.il.
FAU - Oren, Moshe
AU  - Oren M
AD  - Department of Molecular Cell Biology, The Weizmann Institute, Rehovot 76100,
      Israel. Electronic address: moshe.oren@weizmann.ac.il.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/10/11 06:00
MHDA- 2017/10/11 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
AID - S1535-6108(17)30414-2 [pii]
AID - 10.1016/j.ccell.2017.09.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):397-399. doi: 10.1016/j.ccell.2017.09.010.

PMID- 29017050
OWN - NLM
STAT- In-Process
LR  - 20171010
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Neuroblastoma Metastases: Leveraging the Avian Neural Crest.
PG  - 395-397
LID - S1535-6108(17)30416-6 [pii]
LID - 10.1016/j.ccell.2017.09.012 [doi]
AB  - Neuroblastoma, an embryonal cancer of neural crest origin, shows metastases
      frequently at diagnosis. In this issue of Cancer Cell, Delloye-Bourgeois and
      colleagues demonstrate that neuroblastoma cell lines and patient-derived
      xenografts engraft and adopt a metastatic program in chick embryos. They identify
      Sema3C as a candidate switch that regulates metastatic spread.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zheng, Tina
AU  - Zheng T
AD  - Departments of Neurology, Pediatrics, and Neurosurgery, Brain Tumor Research
      Center, University of California, San Francisco, CA 94158, USA; Helen Diller
      Family Comprehensive Cancer Center, University of California, San Francisco, CA
      94158, USA.
FAU - Menard, Marie
AU  - Menard M
AD  - Departments of Neurology, Pediatrics, and Neurosurgery, Brain Tumor Research
      Center, University of California, San Francisco, CA 94158, USA; Helen Diller
      Family Comprehensive Cancer Center, University of California, San Francisco, CA
      94158, USA.
FAU - Weiss, William A
AU  - Weiss WA
AD  - Departments of Neurology, Pediatrics, and Neurosurgery, Brain Tumor Research
      Center, University of California, San Francisco, CA 94158, USA; Helen Diller
      Family Comprehensive Cancer Center, University of California, San Francisco, CA
      94158, USA. Electronic address: waweiss@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/10/11 06:00
MHDA- 2017/10/11 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
AID - S1535-6108(17)30416-6 [pii]
AID - 10.1016/j.ccell.2017.09.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):395-397. doi: 10.1016/j.ccell.2017.09.012.

PMID- 29017049
OWN - NLM
STAT- In-Process
LR  - 20180316
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Exploiting the Hidden Treasure of Detained Introns.
PG  - 393-395
LID - S1535-6108(17)30409-9 [pii]
LID - 10.1016/j.ccell.2017.09.005 [doi]
AB  - Many mammalian genes contain poorly spliced introns, resulting in nuclear
      detention of partially spliced transcripts, which may be exploited to modulate
      gene expression. In this issue of Cancer Cell, Braun et al. report that the
      arginine methyltransferase PRMT5 is critical for tumor cell proliferation by
      regulating numerous detained introns.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Fu, Xiang-Dong
AU  - Fu XD
AD  - Department of Cellular and Molecular Medicine, University of California, San
      Diego, La Jolla, CA 92093-0651, USA. Electronic address: xdfu@ucsd.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2017/10/11 06:00
MHDA- 2017/10/11 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/10/11 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
AID - S1535-6108(17)30409-9 [pii]
AID - 10.1016/j.ccell.2017.09.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):393-395. doi: 10.1016/j.ccell.2017.09.005.

PMID- 28966034
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180228
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts 
      Creates an Exploitable Vulnerability in Malignant Glioma.
PG  - 411-426.e11
LID - S1535-6108(17)30363-X [pii]
LID - 10.1016/j.ccell.2017.08.018 [doi]
AB  - Glioblastoma (GBM) is a devastating malignancy with few therapeutic options. We
      identify PRMT5 in an in vivo GBM shRNA screen and show that PRMT5 knockdown or
      inhibition potently suppresses in vivo GBM tumors, including patient-derived
      xenografts. Pathway analysis implicates splicing in cellular PRMT5 dependency,
      and we identify a biomarker that predicts sensitivity to PRMT5 inhibition. We
      find that PRMT5 deficiency primarily disrupts the removal of detained introns
      (DIs). This impaired DI splicing affects proliferation genes, whose
      downregulation coincides with cell cycle defects, senescence and/or apoptosis. We
      further show that DI programs are evolutionarily conserved and operate during
      neurogenesis, suggesting that they represent a physiological regulatory
      mechanism. Collectively, these findings reveal a PRMT5-regulated DI-splicing
      program as an exploitable cancer vulnerability.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Braun, Christian J
AU  - Braun CJ
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Stanciu, Monica
AU  - Stanciu M
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Boutz, Paul L
AU  - Boutz PL
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Patterson, Jesse C
AU  - Patterson JC
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Calligaris, David
AU  - Calligaris D
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Higuchi, Fumi
AU  - Higuchi F
AD  - Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Neupane, Rachit
AU  - Neupane R
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Fenoglio, Silvia
AU  - Fenoglio S
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Cahill, Daniel P
AU  - Cahill DP
AD  - Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Wakimoto, Hiroaki
AU  - Wakimoto H
AD  - Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Agar, Nathalie Y R
AU  - Agar NYR
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer
      Institute, Harvard Medical School, Boston, MA 02215, USA; Department of
      Radiology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Yaffe, Michael B
AU  - Yaffe MB
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA; Division of Acute Care
      Surgery, Trauma, and Critical Care, Department of Surgery, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, MA 02215, USA.
FAU - Sharp, Phillip A
AU  - Sharp PA
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Hemann, Michael T
AU  - Hemann MT
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA. Electronic address: hemann@mit.edu.
FAU - Lees, Jacqueline A
AU  - Lees JA
AD  - The David H. Koch Institute for Integrative Cancer Research and Department of
      Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA. Electronic address: jalees@mit.edu.
LA  - eng
GR  - R01 CA128803/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170928
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (GSK3235025)
RN  - 0 (Isoquinolines)
RN  - 0 (Pyrimidines)
RN  - EC 2.1.1.319 (PRMT5 protein, human)
RN  - EC 2.1.1.319 (Protein-Arginine N-Methyltransferases)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*pathology
MH  - Cell Cycle/drug effects
MH  - Cell Differentiation
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Glioma/drug therapy/genetics/*pathology
MH  - High-Throughput Screening Assays
MH  - Humans
MH  - *Introns
MH  - Isoquinolines/pharmacology
MH  - Mice
MH  - Protein-Arginine N-Methyltransferases/antagonists & inhibitors/*physiology
MH  - Pyrimidines/pharmacology
MH  - RNA Splicing
OTO - NOTNLM
OT  - CLNS1A
OT  - EPZ015666
OT  - GBM
OT  - PRMT5
OT  - RIOK1
OT  - biomarker
OT  - splicing addiction
EDAT- 2017/10/03 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/03 06:00
PHST- 2017/02/20 00:00 [received]
PHST- 2017/06/05 00:00 [revised]
PHST- 2017/08/30 00:00 [accepted]
PHST- 2017/10/03 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
PHST- 2017/10/03 06:00 [entrez]
AID - S1535-6108(17)30363-X [pii]
AID - 10.1016/j.ccell.2017.08.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):411-426.e11. doi: 10.1016/j.ccell.2017.08.018. Epub
      2017 Sep 28.

PMID- 28966033
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180406
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 4
DP  - 2017 Oct 9
TI  - Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse
      Intrinsic Pontine Glioma.
PG  - 520-537.e5
LID - S1535-6108(17)30362-8 [pii]
LID - 10.1016/j.ccell.2017.08.017 [doi]
AB  - We collated data from 157 unpublished cases of pediatric high-grade glioma and
      diffuse intrinsic pontine glioma and 20 publicly available datasets in an
      integrated analysis of >1,000 cases. We identified co-segregating mutations in
      histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A
      rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type
      subgroups are refined by the presence of key oncogenic events or methylation
      profiles more closely resembling lower-grade tumors. Genomic aberrations increase
      with age, highlighting the infant population as biologically and clinically
      distinct. Uncommon pathway dysregulation is seen in small subsets of tumors,
      further defining the molecular diversity of the disease, opening up avenues for
      biological study and providing a basis for functionally defined future treatment 
      stratification.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Mackay, Alan
AU  - Mackay A
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Burford, Anna
AU  - Burford A
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Carvalho, Diana
AU  - Carvalho D
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Izquierdo, Elisa
AU  - Izquierdo E
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Fazal-Salom, Janat
AU  - Fazal-Salom J
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Taylor, Kathryn R
AU  - Taylor KR
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK;
      Department of Neurology, Stanford University School of Medicine, Stanford, CA,
      USA.
FAU - Bjerke, Lynn
AU  - Bjerke L
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Clarke, Matthew
AU  - Clarke M
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Vinci, Mara
AU  - Vinci M
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Nandhabalan, Meera
AU  - Nandhabalan M
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Temelso, Sara
AU  - Temelso S
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Popov, Sergey
AU  - Popov S
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK;
      Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.
FAU - Molinari, Valeria
AU  - Molinari V
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
FAU - Raman, Pichai
AU  - Raman P
AD  - The Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital 
      of Philadelphia, Philadelphia, PA, USA; Division of Neurosurgery, Children's
      Hospital of Philadelphia, Philadelphia, PA, USA.
FAU - Waanders, Angela J
AU  - Waanders AJ
AD  - The Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital 
      of Philadelphia, Philadelphia, PA, USA; Division of Oncology, Children's Hospital
      of Philadelphia, Philadelphia, PA, USA.
FAU - Han, Harry J
AU  - Han HJ
AD  - The Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital 
      of Philadelphia, Philadelphia, PA, USA; Division of Oncology, Children's Hospital
      of Philadelphia, Philadelphia, PA, USA.
FAU - Gupta, Saumya
AU  - Gupta S
AD  - Institute of Molecular Life Sciences, Swiss Institute of Bioinformatics,
      University of Zurich, Zurich, Switzerland.
FAU - Marshall, Lynley
AU  - Marshall L
AD  - Pediatric Oncology Drug Development Team, Children and Young People's Unit, Royal
      Marsden Hospital, Sutton, UK.
FAU - Zacharoulis, Stergios
AU  - Zacharoulis S
AD  - Pediatric Oncology Drug Development Team, Children and Young People's Unit, Royal
      Marsden Hospital, Sutton, UK.
FAU - Vaidya, Sucheta
AU  - Vaidya S
AD  - Pediatric Oncology Drug Development Team, Children and Young People's Unit, Royal
      Marsden Hospital, Sutton, UK.
FAU - Mandeville, Henry C
AU  - Mandeville HC
AD  - Department of Radiotherapy, Royal Marsden Hospital, Sutton, UK.
FAU - Bridges, Leslie R
AU  - Bridges LR
AD  - Department of Cellular Pathology, St George's Hospital NHS Trust, London, UK.
FAU - Martin, Andrew J
AU  - Martin AJ
AD  - Department of Neurosurgery, St George's Hospital NHS Trust, London, UK.
FAU - Al-Sarraj, Safa
AU  - Al-Sarraj S
AD  - Department of Neuropathology, Kings College Hospital, London, UK.
FAU - Chandler, Christopher
AU  - Chandler C
AD  - Department of Neurosurgery, Kings College Hospital, London, UK.
FAU - Ng, Ho-Keung
AU  - Ng HK
AD  - Department of Anatomical and Cellular Pathology, The Chinese University of Hong
      Kong, Hong Kong, China.
FAU - Li, Xingang
AU  - Li X
AD  - Department of Neurosurgery, Qilu Hospital of Shandong University and Brain
      Science Research Institute, Shandong University, Jinan, China.
FAU - Mu, Kun
AU  - Mu K
AD  - Department of Pathology, Shandong University School of Medicine, Jinan, China.
FAU - Trabelsi, Saoussen
AU  - Trabelsi S
AD  - Department of Cytogenetics and Reproductive Biology, Farhat Hached Hospital,
      Sousse, Tunisia.
FAU - Brahim, Dorra H'mida-Ben
AU  - Brahim DH
AD  - Department of Cytogenetics and Reproductive Biology, Farhat Hached Hospital,
      Sousse, Tunisia.
FAU - Kisljakov, Alexei N
AU  - Kisljakov AN
AD  - Department of Pathology, Morozov Children's Hospital, Moscow, Russian Federation.
FAU - Konovalov, Dmitry M
AU  - Konovalov DM
AD  - Department of Pathology, Dmitrii Rogachev Research and Clinical Centre of
      Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
FAU - Moore, Andrew S
AU  - Moore AS
AD  - UQ Child Health Research Centre, The University of Queensland, Brisbane,
      Australia; Oncology Services Group, Children's Health Queensland Hospital and
      Health Service, Brisbane, Australia; The University of Queensland Diamantina
      Institute, Translational Research Institute, Brisbane, Australia.
FAU - Carcaboso, Angel Montero
AU  - Carcaboso AM
AD  - Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
FAU - Sunol, Mariona
AU  - Sunol M
AD  - Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
FAU - de Torres, Carmen
AU  - de Torres C
AD  - Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
FAU - Cruz, Ofelia
AU  - Cruz O
AD  - Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
FAU - Mora, Jaume
AU  - Mora J
AD  - Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
FAU - Shats, Ludmila I
AU  - Shats LI
AD  - Division of Oncology, Pediatric Oncology and Radiotherapy, St Petersburg State
      Pediatric Medical University, St Petersburg, Russian Federation.
FAU - Stavale, Joao N
AU  - Stavale JN
AD  - Department of Pathology, Federal University of Sao Paulo, Sao Paulo, Sao Paulo,
      Brazil.
FAU - Bidinotto, Lucas T
AU  - Bidinotto LT
AD  - Molecular Oncology Research Centre, Barretos Cancer Hospital, Barretos, Sao
      Paulo, Brazil.
FAU - Reis, Rui M
AU  - Reis RM
AD  - Molecular Oncology Research Centre, Barretos Cancer Hospital, Barretos, Sao
      Paulo, Brazil; Life and Health Sciences Research Institute (ICVS), Medical
      School, University of Minho, Braga, Portugal and ICVS/3B's-PT Government
      Associate Laboratory, Braga/Guimaraes, Portugal.
FAU - Entz-Werle, Natacha
AU  - Entz-Werle N
AD  - Pediatrie Onco-Hematologie - Pediatrie III, Centre Hospitalier Regional et
      Universitaire Hautepierre, Strasbourg, France.
FAU - Farrell, Michael
AU  - Farrell M
AD  - Histopathology Department, Beaumont Hospital, Dublin, Ireland.
FAU - Cryan, Jane
AU  - Cryan J
AD  - Histopathology Department, Beaumont Hospital, Dublin, Ireland.
FAU - Crimmins, Darach
AU  - Crimmins D
AD  - Department of Neurosurgery, Temple Street Children's University Hospital, Dublin,
      Ireland.
FAU - Caird, John
AU  - Caird J
AD  - Department of Neurosurgery, Temple Street Children's University Hospital, Dublin,
      Ireland.
FAU - Pears, Jane
AU  - Pears J
AD  - Department of Paediatric Oncology, Our Lady's Children's Hospital, Dublin,
      Ireland.
FAU - Monje, Michelle
AU  - Monje M
AD  - Department of Neurology, Stanford University School of Medicine, Stanford, CA,
      USA.
FAU - Debily, Marie-Anne
AU  - Debily MA
AD  - Departement de Cancerologie de l'Enfant et de l'Adolescent, Institut Gustav
      Roussy, Villejuif, France.
FAU - Castel, David
AU  - Castel D
AD  - Departement de Cancerologie de l'Enfant et de l'Adolescent, Institut Gustav
      Roussy, Villejuif, France.
FAU - Grill, Jacques
AU  - Grill J
AD  - Departement de Cancerologie de l'Enfant et de l'Adolescent, Institut Gustav
      Roussy, Villejuif, France.
FAU - Hawkins, Cynthia
AU  - Hawkins C
AD  - Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Canada.
FAU - Nikbakht, Hamid
AU  - Nikbakht H
AD  - Department of Pediatrics, McGill University, Montreal, Canada.
FAU - Jabado, Nada
AU  - Jabado N
AD  - The Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital 
      of Philadelphia, Philadelphia, PA, USA.
FAU - Baker, Suzanne J
AU  - Baker SJ
AD  - Department of Developmental Neurobiology, St Jude Children's Research Hospital,
      Memphis, TN, USA.
FAU - Pfister, Stefan M
AU  - Pfister SM
AD  - Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany; Department of Pediatric Hematology and Oncology, Heidelberg 
      University Hospital, Heidelberg, Germany; Hopp-Children's Cancer Center at the
      NCT Heidelberg (KiTZ), Heidelberg, Germany.
FAU - Jones, David T W
AU  - Jones DTW
AD  - Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany; Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), 
      Heidelberg, Germany.
FAU - Fouladi, Maryam
AU  - Fouladi M
AD  - Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati
      Children's Hospital, Cincinnati, OH, USA.
FAU - von Bueren, Andre O
AU  - von Bueren AO
AD  - Department of Pediatrics, Division of Pediatric Hematology and Oncology,
      University Medical Center Goettingen, Goettingen, Germany; Department of
      Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and
      Oncology, University Hospital of Geneva, Geneva, Switzerland; Department of
      Pediatrics, CANSEARCH Research Laboratory, Faculty of Medicine, University of
      Geneva, Geneva, Switzerland.
FAU - Baudis, Michael
AU  - Baudis M
AD  - Institute of Molecular Life Sciences, Swiss Institute of Bioinformatics,
      University of Zurich, Zurich, Switzerland.
FAU - Resnick, Adam
AU  - Resnick A
AD  - The Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital 
      of Philadelphia, Philadelphia, PA, USA; Division of Neurosurgery, Children's
      Hospital of Philadelphia, Philadelphia, PA, USA; Division of Oncology, Children's
      Hospital of Philadelphia, Philadelphia, PA, USA.
FAU - Jones, Chris
AU  - Jones C
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, UK;
      Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
      Electronic address: chris.jones@icr.ac.uk.
LA  - eng
GR  - P01 CA096832/CA/NCI NIH HHS/United States
GR  - R01 CA188516/CA/NCI NIH HHS/United States
GR  - R01 NS085336/NS/NINDS NIH HHS/United States
GR  - R01 NS091620/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170928
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BCOR protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (F-Box Proteins)
RN  - 0 (F-Box-WD Repeat-Containing Protein 7)
RN  - 0 (FBXW7 protein, human)
RN  - 0 (Histones)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Repressor Proteins)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 5.99.1.2 (DNA Topoisomerases, Type I)
RN  - EC 5.99.1.2 (DNA topoisomerase III)
SB  - IM
MH  - Adolescent
MH  - Brain Stem Neoplasms/*genetics/pathology
MH  - Cell Cycle Proteins/genetics
MH  - Child
MH  - Child, Preschool
MH  - DNA Topoisomerases, Type I/genetics
MH  - Exome
MH  - F-Box Proteins/genetics
MH  - F-Box-WD Repeat-Containing Protein 7
MH  - Female
MH  - Gene Dosage
MH  - Glioma/*genetics/pathology
MH  - Histones/*genetics
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - *Mutation
MH  - Proto-Oncogene Proteins/genetics
MH  - Repressor Proteins/genetics
MH  - Ubiquitin-Protein Ligases/genetics
MH  - Young Adult
PMC - PMC5637314
OTO - NOTNLM
OT  - DIPG
OT  - exome
OT  - genome
OT  - glioblastoma
OT  - histone
OT  - methylation
EDAT- 2017/10/03 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/03 06:00
PHST- 2017/05/05 00:00 [received]
PHST- 2017/07/14 00:00 [revised]
PHST- 2017/08/29 00:00 [accepted]
PHST- 2017/10/03 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
PHST- 2017/10/03 06:00 [entrez]
AID - S1535-6108(17)30362-8 [pii]
AID - 10.1016/j.ccell.2017.08.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Oct 9;32(4):520-537.e5. doi: 10.1016/j.ccell.2017.08.017. Epub 
      2017 Sep 28.

PMID- 28898700
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to
      Impart Gemcitabine Resistance to Pancreatic Cancer.
PG  - 392
LID - S1535-6108(17)30352-5 [pii]
LID - 10.1016/j.ccell.2017.08.008 [doi]
FAU - Shukla, Surendra K
AU  - Shukla SK
FAU - Purohit, Vinee
AU  - Purohit V
FAU - Mehla, Kamiya
AU  - Mehla K
FAU - Gunda, Venugopal
AU  - Gunda V
FAU - Chaika, Nina V
AU  - Chaika NV
FAU - Vernucci, Enza
AU  - Vernucci E
FAU - King, Ryan J
AU  - King RJ
FAU - Abrego, Jaime
AU  - Abrego J
FAU - Goode, Gennifer D
AU  - Goode GD
FAU - Dasgupta, Aneesha
AU  - Dasgupta A
FAU - Illies, Alysha L
AU  - Illies AL
FAU - Gebregiworgis, Teklab
AU  - Gebregiworgis T
FAU - Dai, Bingbing
AU  - Dai B
FAU - Augustine, Jithesh J
AU  - Augustine JJ
FAU - Murthy, Divya
AU  - Murthy D
FAU - Attri, Kuldeep S
AU  - Attri KS
FAU - Mashadova, Oksana
AU  - Mashadova O
FAU - Grandgenett, Paul M
AU  - Grandgenett PM
FAU - Powers, Robert
AU  - Powers R
FAU - Ly, Quan P
AU  - Ly QP
FAU - Lazenby, Audrey J
AU  - Lazenby AJ
FAU - Grem, Jean L
AU  - Grem JL
FAU - Yu, Fang
AU  - Yu F
FAU - Mates, Jose M
AU  - Mates JM
FAU - Asara, John M
AU  - Asara JM
FAU - Kim, Jung-Whan
AU  - Kim JW
FAU - Hankins, Jordan H
AU  - Hankins JH
FAU - Weekes, Colin
AU  - Weekes C
FAU - Hollingsworth, Michael A
AU  - Hollingsworth MA
FAU - Serkova, Natalie J
AU  - Serkova NJ
FAU - Sasson, Aaron R
AU  - Sasson AR
FAU - Fleming, Jason B
AU  - Fleming JB
FAU - Oliveto, Jennifer M
AU  - Oliveto JM
FAU - Lyssiotis, Costas A
AU  - Lyssiotis CA
FAU - Cantley, Lewis C
AU  - Cantley LC
FAU - Berim, Lyudmyla
AU  - Berim L
FAU - Singh, Pankaj K
AU  - Singh PK
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Jul 10;32(1):71-87.e7. PMID: 28697344
EDAT- 2017/09/13 06:00
MHDA- 2017/09/13 06:01
CRDT- 2017/09/13 06:00
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/09/13 06:01 [medline]
AID - S1535-6108(17)30352-5 [pii]
AID - 10.1016/j.ccell.2017.08.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.008.

PMID- 28898699
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the
      LATITUDE and STAMPEDE Studies.
PG  - 392
LID - S1535-6108(17)30353-7 [pii]
LID - 10.1016/j.ccell.2017.08.009 [doi]
FAU - Small, Eric J
AU  - Small EJ
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Jul 10;32(1):6-8. PMID: 28697343
EDAT- 2017/09/13 06:00
MHDA- 2017/09/13 06:01
CRDT- 2017/09/13 06:00
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/09/13 06:01 [medline]
AID - S1535-6108(17)30353-7 [pii]
AID - 10.1016/j.ccell.2017.08.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.009.

PMID- 28898698
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20180315
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging 
      Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.
PG  - 377-391.e9
LID - S1535-6108(17)30347-1 [pii]
LID - 10.1016/j.ccell.2017.08.004 [doi]
AB  - How tumor-infiltrating T lymphocytes (TILs) adapt to the metabolic constrains
      within the tumor microenvironment (TME) and to what degree this affects their
      ability to combat tumor progression remain poorly understood. Using mouse
      melanoma models, we report that CD8(+) TILs enhance peroxisome
      proliferator-activated receptor (PPAR)-alpha signaling and catabolism of fatty
      acids (FAs) when simultaneously subjected to hypoglycemia and hypoxia. This
      metabolic switch partially preserves CD8(+) TILs' effector functions, although
      co-inhibitor expression increases during tumor progression regardless of CD8(+)
      TILs' antigen specificity. Further promoting FA catabolism improves the CD8(+)
      TILs' ability to slow tumor progression. PD-1 blockade delays tumor growth
      without changing TIL metabolism or functions. It synergizes with metabolic
      reprogramming of T cells to achieve superior antitumor efficacy and even complete
      cures.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Gene Therapy and Vaccines Program, University of Pennsylvania (U of PA),
      Philadelphia, PA 19104, USA; The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Kurupati, Raj
AU  - Kurupati R
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Liu, Ling
AU  - Liu L
AD  - Lewis-Sigler Institute for Integrative Genomics & Department of Chemistry,
      Princeton University, Princeton, NJ 08540, USA.
FAU - Zhou, Xiang Yang
AU  - Zhou XY
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Zhang, Gao
AU  - Zhang G
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Hudaihed, Abeer
AU  - Hudaihed A
AD  - Biology Program, Temple University, Philadelphia, PA 19122, USA.
FAU - Filisio, Flavia
AU  - Filisio F
AD  - Biology Program, Temple University, Philadelphia, PA 19122, USA.
FAU - Giles-Davis, Wynetta
AU  - Giles-Davis W
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Xu, Xiaowei
AU  - Xu X
AD  - Department of Pathology and Laboratory Medicine, U of PA, Philadelphia, PA 19104,
      USA.
FAU - Karakousis, Giorgos C
AU  - Karakousis GC
AD  - Department of Surgery, Hospital of U of PA, Philadelphia, PA 19104, USA.
FAU - Schuchter, Lynn M
AU  - Schuchter LM
AD  - Department of Medicine, U of PA, Philadelphia, PA 19104, USA.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Medicine, U of PA, Philadelphia, PA 19104, USA.
FAU - Amaravadi, Ravi
AU  - Amaravadi R
AD  - Department of Medicine, U of PA, Philadelphia, PA 19104, USA.
FAU - Xiao, Min
AU  - Xiao M
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Sadek, Norah
AU  - Sadek N
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Krepler, Clemens
AU  - Krepler C
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Herlyn, Meenhard
AU  - Herlyn M
AD  - The Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Freeman, Gordon J
AU  - Freeman GJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115,
      USA.
FAU - Rabinowitz, Joshua D
AU  - Rabinowitz JD
AD  - Lewis-Sigler Institute for Integrative Genomics & Department of Chemistry,
      Princeton University, Princeton, NJ 08540, USA.
FAU - Ertl, Hildegund C J
AU  - Ertl HCJ
AD  - The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address:
      ertl@wistar.org.
LA  - eng
GR  - P01 CA114046/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - P50 CA101942/CA/NCI NIH HHS/United States
GR  - P50 CA174523/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, CD)
RN  - 0 (CD223 antigen)
RN  - 0 (Fatty Acids)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - IY9XDZ35W2 (Glucose)
RN  - S88TT14065 (Oxygen)
SB  - IM
CIN - Cancer Cell. 2017 Sep 11;32(3):280-281. PMID: 28898693
CIN - Nat Rev Cancer. 2017 Nov;17 (11):635. PMID: 28984292
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - CD8-Positive T-Lymphocytes/*immunology/ultrastructure
MH  - Cell Hypoxia
MH  - Disease Progression
MH  - Fatty Acids/*metabolism
MH  - Female
MH  - Gene Knockdown Techniques
MH  - Glucose/pharmacology
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
MH  - *Immunotherapy
MH  - Lymphocyte Activation/immunology
MH  - Lymphocytes, Tumor-Infiltrating/immunology
MH  - Melanoma/*immunology/pathology/*therapy/ultrastructure
MH  - Mice, Inbred C57BL
MH  - Oxygen/pharmacology
MH  - Programmed Cell Death 1 Receptor/metabolism
MH  - Stress, Physiological
MH  - Treatment Outcome
MH  - Tumor Microenvironment/*immunology
PMC - PMC5751418
MID - NIHMS923551
OTO - NOTNLM
OT  - CD8(+) T cells
OT  - HIF-1alpha
OT  - TILs
OT  - co-inhibitors
OT  - fatty acid catabolism
OT  - fenofibrate
OT  - hypoglycemia
OT  - hypoxia
OT  - melanoma
OT  - tumor microenvironment
EDAT- 2017/09/13 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/13 06:00
PMCR- 2018/09/11 00:00
PHST- 2016/08/17 00:00 [received]
PHST- 2017/06/28 00:00 [revised]
PHST- 2017/08/08 00:00 [accepted]
PHST- 2018/09/11 00:00 [pmc-release]
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - S1535-6108(17)30347-1 [pii]
AID - 10.1016/j.ccell.2017.08.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):377-391.e9. doi: 10.1016/j.ccell.2017.08.004.

PMID- 28898697
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20180315
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of
      Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations.
PG  - 360-376.e6
LID - S1535-6108(17)30349-5 [pii]
LID - 10.1016/j.ccell.2017.08.006 [doi]
AB  - We define how chronic cigarette smoke-induced time-dependent epigenetic
      alterations can sensitize human bronchial epithelial cells for transformation by 
      a single oncogene. The smoke-induced chromatin changes include initial repressive
      polycomb marking of genes, later manifesting abnormal DNA methylation by 10
      months. At this time, cells exhibit epithelial-to-mesenchymal changes,
      anchorage-independent growth, and upregulated RAS/MAPK signaling with silencing
      of hypermethylated genes, which normally inhibit these pathways and are
      associated with smoking-related non-small cell lung cancer. These cells, in the
      absence of any driver gene mutations, now transform by introducing a single KRAS 
      mutation and form adenosquamous lung carcinomas in mice. Thus, epigenetic
      abnormalities may prime for changing oncogene senescence to addiction for a
      single key oncogene involved in lung cancer initiation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Vaz, Michelle
AU  - Vaz M
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Hwang, Stephen Y
AU  - Hwang SY
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Kagiampakis, Ioannis
AU  - Kagiampakis I
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Phallen, Jillian
AU  - Phallen J
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Patil, Ashwini
AU  - Patil A
AD  - Krieger School of Arts and Sciences, Baltimore, MD 21218, USA.
FAU - O'Hagan, Heather M
AU  - O'Hagan HM
AD  - Medical Sciences, Indiana University School of Medicine, Bloomington, IN 47405,
      USA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
      46202, USA.
FAU - Murphy, Lauren
AU  - Murphy L
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Zahnow, Cynthia A
AU  - Zahnow CA
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Gabrielson, Edward
AU  - Gabrielson E
AD  - Department of Pathology, The Johns Hopkins University School of Medicine,
      Baltimore, MD 21287, USA.
FAU - Velculescu, Victor E
AU  - Velculescu VE
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Easwaran, Hariharan P
AU  - Easwaran HP
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic
      address: heaswar2@jhmi.edu.
FAU - Baylin, Stephen B
AU  - Baylin SB
AD  - Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns 
      Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic
      address: sbaylin@jhmi.edu.
LA  - eng
GR  - P30 CA006973/CA/NCI NIH HHS/United States
GR  - U10 CA180950/CA/NCI NIH HHS/United States
GR  - R01 ES023183/ES/NIEHS NIH HHS/United States
GR  - R01 CA170550/CA/NCI NIH HHS/United States
GR  - R01 CA121113/CA/NCI NIH HHS/United States
GR  - R01 ES011858/ES/NIEHS NIH HHS/United States
GR  - R01 CA043318/CA/NCI NIH HHS/United States
GR  - R01 CA185357/CA/NCI NIH HHS/United States
GR  - T32 GM008752/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromatin)
RN  - 0 (KRAS protein, human)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 3.5.1.- (Sirtuin 1)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
CIN - Cancer Cell. 2017 Sep 11;32(3):278-280. PMID: 28898692
CIN - Nat Rev Cancer. 2017 Nov;17 (11):634-635. PMID: 29026205
MH  - Animals
MH  - Bronchi/*pathology
MH  - Carcinoma, Non-Small-Cell Lung/genetics/pathology
MH  - Cell Proliferation/genetics
MH  - Cell Transformation, Neoplastic/genetics/*pathology
MH  - Chromatin/metabolism
MH  - DNA (Cytosine-5-)-Methyltransferase 1
MH  - DNA (Cytosine-5-)-Methyltransferases/metabolism
MH  - DNA Damage
MH  - DNA Methylation/genetics
MH  - Enhancer of Zeste Homolog 2 Protein/metabolism
MH  - *Epigenomics
MH  - Epithelial Cells/*metabolism/pathology
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Genome, Human
MH  - Humans
MH  - Lung Neoplasms/genetics/pathology
MH  - Male
MH  - Mice
MH  - Mutation/*genetics
MH  - Phenotype
MH  - Promoter Regions, Genetic/genetics
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Signal Transduction/genetics
MH  - Sirtuin 1/metabolism
MH  - Smoking/*adverse effects/*genetics
PMC - PMC5596892
MID - NIHMS900592
OTO - NOTNLM
OT  - DNA methylation
OT  - HBECs
OT  - Kras
OT  - addiction
OT  - cigarette smoke exposure
OT  - epigenetic
OT  - genetic
OT  - human bronchial epithelial cells
OT  - lung cancer
OT  - oncogene
OT  - polycomb
EDAT- 2017/09/13 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/13 06:00
PMCR- 2018/09/11 00:00
PHST- 2016/08/30 00:00 [received]
PHST- 2017/06/21 00:00 [revised]
PHST- 2017/08/11 00:00 [accepted]
PHST- 2018/09/11 00:00 [pmc-release]
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - S1535-6108(17)30349-5 [pii]
AID - 10.1016/j.ccell.2017.08.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):360-376.e6. doi: 10.1016/j.ccell.2017.08.006.

PMID- 28898696
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20180309
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA
      Damage, a Key Determinant of Liver Cancer Development.
PG  - 342-359.e10
LID - S1535-6108(17)30354-9 [pii]
LID - 10.1016/j.ccell.2017.08.010 [doi]
AB  - Concomitant hepatocyte apoptosis and regeneration is a hallmark of chronic liver 
      diseases (CLDs) predisposing to hepatocellular carcinoma (HCC). Here, we
      mechanistically link caspase-8-dependent apoptosis to HCC development via
      proliferation- and replication-associated DNA damage. Proliferation-associated
      replication stress, DNA damage, and genetic instability are detectable in CLDs
      before any neoplastic changes occur. Accumulated levels of hepatocyte apoptosis
      determine and predict subsequent hepatocarcinogenesis. Proliferation-associated
      DNA damage is sensed by a complex comprising caspase-8, FADD, c-FLIP, and a
      kinase-dependent function of RIPK1. This platform requires a non-apoptotic
      function of caspase-8, but no caspase-3 or caspase-8 cleavage. It may represent a
      DNA damage-sensing mechanism in hepatocytes that can act via JNK and subsequent
      phosphorylation of the histone variant H2AX.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Boege, Yannick
AU  - Boege Y
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Malehmir, Mohsen
AU  - Malehmir M
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Healy, Marc E
AU  - Healy ME
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Bettermann, Kira
AU  - Bettermann K
AD  - Department of Translational Inflammation Research, Institute of Experimental
      Internal Medicine, Otto von Guericke University, 39120 Magdeburg, Germany.
FAU - Lorentzen, Anna
AU  - Lorentzen A
AD  - Institute of Virology, Technische Universitat Munchen, Helmholtz Zentrum Munchen,
      85764 Munich, Germany.
FAU - Vucur, Mihael
AU  - Vucur M
AD  - Department of Medicine III, Division of GI and Hepatobiliary Oncology, University
      Hospital RWTH Aachen, 52056 Aachen, Germany.
FAU - Ahuja, Akshay K
AU  - Ahuja AK
AD  - Institute of Molecular Cancer Research, University of Zurich, 8057 Zurich,
      Switzerland.
FAU - Bohm, Friederike
AU  - Bohm F
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Mertens, Joachim C
AU  - Mertens JC
AD  - Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich,
      Switzerland.
FAU - Shimizu, Yutaka
AU  - Shimizu Y
AD  - Centre for Cell Death, Cancer, and Inflammation, Department of Cancer Biology,
      UCL Cancer Institute, University College London, London WC1E 6DD, UK.
FAU - Frick, Lukas
AU  - Frick L
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Remouchamps, Caroline
AU  - Remouchamps C
AD  - Laboratory of Molecular Immunology and Signal Transduction, GIGA-R, University of
      Liege, 4000 Liege, Belgium.
FAU - Mutreja, Karun
AU  - Mutreja K
AD  - Institute of Molecular Cancer Research, University of Zurich, 8057 Zurich,
      Switzerland.
FAU - Kahne, Thilo
AU  - Kahne T
AD  - Institute of Experimental Internal Medicine, Otto von Guericke University, 39120 
      Magdeburg, Germany.
FAU - Sundaravinayagam, Devakumar
AU  - Sundaravinayagam D
AD  - DNA Repair and Maintenance of Genome Stability, Max-Delbruck Center for Molecular
      Medicine (MDC) Berlin, 13125 Berlin, Germany.
FAU - Wolf, Monika J
AU  - Wolf MJ
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Rehrauer, Hubert
AU  - Rehrauer H
AD  - Functional Genomics Center Zurich, ETH and University Zurich, 8057 Zurich,
      Switzerland.
FAU - Koppe, Christiane
AU  - Koppe C
AD  - Department of Medicine III, Division of GI and Hepatobiliary Oncology, University
      Hospital RWTH Aachen, 52056 Aachen, Germany.
FAU - Speicher, Tobias
AU  - Speicher T
AD  - Department of Biology, Institute of Molecular Health Sciences, ETH, Zurich,
      Switzerland.
FAU - Padrissa-Altes, Susagna
AU  - Padrissa-Altes S
AD  - Department of Biology, Institute of Molecular Health Sciences, ETH, Zurich,
      Switzerland.
FAU - Maire, Renaud
AU  - Maire R
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Schattenberg, Jorn M
AU  - Schattenberg JM
AD  - I. Department of Medicine, University Medical Center, Johannes
      Gutenberg-University, 55122 Mainz, Germany.
FAU - Jeong, Ju-Seong
AU  - Jeong JS
AD  - Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot
      7610001, Israel.
FAU - Liu, Lei
AU  - Liu L
AD  - Department of Surgery, Technische Universitat Munchen, 80333 Munich, Germany.
FAU - Zwirner, Stefan
AU  - Zwirner S
AD  - Department of Internal Medicine VIII, University Hospital Tubingen, 72076
      Tubingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard 
      Karls University Tubingen, 72076 Tubingen, Germany; Translational
      Gastrointestinal Oncology Group, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
FAU - Boger, Regina
AU  - Boger R
AD  - National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
FAU - Huser, Norbert
AU  - Huser N
AD  - Department of Surgery, Technische Universitat Munchen, 80333 Munich, Germany.
FAU - Davis, Roger J
AU  - Davis RJ
AD  - Howard Hughes Medical Institute, University of Massachusetts Medical School,
      Worcester, MA 01605, USA.
FAU - Mullhaupt, Beat
AU  - Mullhaupt B
AD  - Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich,
      Switzerland.
FAU - Moch, Holger
AU  - Moch H
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Schulze-Bergkamen, Henning
AU  - Schulze-Bergkamen H
AD  - National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
FAU - Clavien, Pierre-Alain
AU  - Clavien PA
AD  - Clinic of Visceral and Transplantation Surgery, University Hospital Zurich, 8091 
      Zurich, Switzerland.
FAU - Werner, Sabine
AU  - Werner S
AD  - Department of Biology, Institute of Molecular Health Sciences, ETH, Zurich,
      Switzerland.
FAU - Borsig, Lubor
AU  - Borsig L
AD  - Institute of Physiology, University of Zurich, 8057 Zurich, Switzerland.
FAU - Luther, Sanjiv A
AU  - Luther SA
AD  - Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland.
FAU - Jost, Philipp J
AU  - Jost PJ
AD  - III. Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Weinlich, Ricardo
AU  - Weinlich R
AD  - Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Unger, Kristian
AU  - Unger K
AD  - Research Unit Radiation Cytogenetics, Helmholtz Zentrum Munchen, 85764
      Neuherberg, Germany.
FAU - Behrens, Axel
AU  - Behrens A
AD  - Adult Stem Cell Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
FAU - Hillert, Laura
AU  - Hillert L
AD  - Department of Translational Inflammation Research, Institute of Experimental
      Internal Medicine, Otto von Guericke University, 39120 Magdeburg, Germany.
FAU - Dillon, Christopher
AU  - Dillon C
AD  - Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Di Virgilio, Michela
AU  - Di Virgilio M
AD  - DNA Repair and Maintenance of Genome Stability, Max-Delbruck Center for Molecular
      Medicine (MDC) Berlin, 13125 Berlin, Germany.
FAU - Wallach, David
AU  - Wallach D
AD  - Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot
      7610001, Israel.
FAU - Dejardin, Emmanuel
AU  - Dejardin E
AD  - Laboratory of Molecular Immunology and Signal Transduction, GIGA-R, University of
      Liege, 4000 Liege, Belgium.
FAU - Zender, Lars
AU  - Zender L
AD  - Department of Internal Medicine VIII, University Hospital Tubingen, 72076
      Tubingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard 
      Karls University Tubingen, 72076 Tubingen, Germany; Translational
      Gastrointestinal Oncology Group, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
FAU - Naumann, Michael
AU  - Naumann M
AD  - Institute of Experimental Internal Medicine, Otto von Guericke University, 39120 
      Magdeburg, Germany.
FAU - Walczak, Henning
AU  - Walczak H
AD  - Centre for Cell Death, Cancer, and Inflammation, Department of Cancer Biology,
      UCL Cancer Institute, University College London, London WC1E 6DD, UK.
FAU - Green, Douglas R
AU  - Green DR
AD  - Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Lopes, Massimo
AU  - Lopes M
AD  - Institute of Molecular Cancer Research, University of Zurich, 8057 Zurich,
      Switzerland.
FAU - Lavrik, Inna
AU  - Lavrik I
AD  - Department of Translational Inflammation Research, Institute of Experimental
      Internal Medicine, Otto von Guericke University, 39120 Magdeburg, Germany.
FAU - Luedde, Tom
AU  - Luedde T
AD  - Department of Medicine III, Division of GI and Hepatobiliary Oncology, University
      Hospital RWTH Aachen, 52056 Aachen, Germany.
FAU - Heikenwalder, Mathias
AU  - Heikenwalder M
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland; Institute of Virology, Technische
      Universitat Munchen, Helmholtz Zentrum Munchen, 85764 Munich, Germany; Institute 
      of Chronic Inflammation and Cancer, Deutsches Krebs-Forschungszentrum (DKFZ),
      69120 Heidelberg, Germany. Electronic address: m.heikenwaelder@dkfz.de.
FAU - Weber, Achim
AU  - Weber A
AD  - Department of Pathology and Molecular Pathology, University and University
      Hospital Zurich, 8091 Zurich, Switzerland. Electronic address:
      achim.weber@usz.ch.
LA  - eng
GR  - R01 DK107220/DK/NIDDK NIH HHS/United States
GR  - R37 AI044828/AI/NIAID NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Fadd protein, mouse)
RN  - 0 (Fas-Associated Death Domain Protein)
RN  - 0 (Histones)
RN  - 0 (Mcl1 protein, mouse)
RN  - 0 (Myeloid Cell Leukemia Sequence 1 Protein)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (gamma-H2AX protein, mouse)
RN  - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Ripk1 protein, mouse)
RN  - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases)
RN  - EC 3.4.22.- (Caspase 8)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Carcinogenesis/*metabolism/*pathology
MH  - Carcinoma, Hepatocellular/pathology
MH  - Caspase 8/*metabolism
MH  - Cell Proliferation
MH  - Cellular Senescence
MH  - Chronic Disease
MH  - Crosses, Genetic
MH  - *DNA Damage
MH  - DNA Repair
MH  - Fas-Associated Death Domain Protein/metabolism
MH  - Female
MH  - Genomic Instability
MH  - Hepatectomy
MH  - Hepatocytes/pathology
MH  - Histones/metabolism
MH  - Humans
MH  - JNK Mitogen-Activated Protein Kinases/metabolism
MH  - Liver/metabolism/pathology
MH  - Liver Neoplasms/*enzymology/*pathology
MH  - Liver Regeneration
MH  - Male
MH  - Mice
MH  - Myeloid Cell Leukemia Sequence 1 Protein/metabolism
MH  - Phosphorylation
MH  - Receptor-Interacting Protein Serine-Threonine Kinases/metabolism
MH  - Receptors, Tumor Necrosis Factor, Type I/metabolism
MH  - Risk Factors
PMC - PMC5598544
OTO - NOTNLM
OT  - DNA damage response
OT  - apoptosis
OT  - hepatocellular carcinoma
OT  - liver
OT  - replication stress
EDAT- 2017/09/13 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/13 06:00
PHST- 2016/01/23 00:00 [received]
PHST- 2017/06/30 00:00 [revised]
PHST- 2017/08/16 00:00 [accepted]
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - S1535-6108(17)30354-9 [pii]
AID - 10.1016/j.ccell.2017.08.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):342-359.e10. doi: 10.1016/j.ccell.2017.08.010.

PMID- 28898695
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20171026
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target
      in High-Risk Neuroblastoma.
PG  - 295-309.e12
LID - S1535-6108(17)30346-X [pii]
LID - 10.1016/j.ccell.2017.08.003 [doi]
AB  - We developed an RNA-sequencing-based pipeline to discover differentially
      expressed cell-surface molecules in neuroblastoma that meet criteria for optimal 
      immunotherapeutic target safety and efficacy. Here, we show that GPC2 is a strong
      candidate immunotherapeutic target in this childhood cancer. We demonstrate high 
      GPC2 expression in neuroblastoma due to MYCN transcriptional activation and/or
      somatic gain of the GPC2 locus. We confirm GPC2 to be highly expressed on most
      neuroblastomas, but not detectable at appreciable levels in normal childhood
      tissues. In addition, we demonstrate that GPC2 is required for neuroblastoma
      proliferation. Finally, we develop a GPC2-directed antibody-drug conjugate that
      is potently cytotoxic to GPC2-expressing neuroblastoma cells. Collectively, these
      findings validate GPC2 as a non-mutated neuroblastoma oncoprotein and candidate
      immunotherapeutic target.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bosse, Kristopher R
AU  - Bosse KR
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman
      School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104,
      USA.
FAU - Raman, Pichai
AU  - Raman P
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA; Department of Biomedical and
      Health Informatics and Center for Data-Driven Discovery in Biomedicine,
      Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Zhu, Zhongyu
AU  - Zhu Z
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, Frederick, MD 21701, USA.
FAU - Lane, Maria
AU  - Lane M
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA.
FAU - Martinez, Daniel
AU  - Martinez D
AD  - Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA
      19104, USA.
FAU - Heitzeneder, Sabine
AU  - Heitzeneder S
AD  - Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
FAU - Rathi, Komal S
AU  - Rathi KS
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA; Department of Biomedical and
      Health Informatics and Center for Data-Driven Discovery in Biomedicine,
      Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Kendsersky, Nathan M
AU  - Kendsersky NM
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA.
FAU - Randall, Michael
AU  - Randall M
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA.
FAU - Donovan, Laura
AU  - Donovan L
AD  - Division of Neurosurgery and the Arthur and Sonia Labatt Brain Tumor Research
      Center, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Morrissy, Sorana
AU  - Morrissy S
AD  - Division of Neurosurgery and the Arthur and Sonia Labatt Brain Tumor Research
      Center, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Sussman, Robyn T
AU  - Sussman RT
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA.
FAU - Zhelev, Doncho V
AU  - Zhelev DV
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, Frederick, MD 21701, USA.
FAU - Feng, Yang
AU  - Feng Y
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, Frederick, MD 21701, USA.
FAU - Wang, Yanping
AU  - Wang Y
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, Frederick, MD 21701, USA.
FAU - Hwang, Jennifer
AU  - Hwang J
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, Frederick, MD 21701, USA.
FAU - Lopez, Gonzalo
AU  - Lopez G
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA.
FAU - Harenza, Jo Lynne
AU  - Harenza JL
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA.
FAU - Wei, Jun S
AU  - Wei JS
AD  - Oncogenomics Section, Genetics Branch, Center for Cancer Research, National
      Cancer Institute, Bethesda, MD 20892, USA.
FAU - Pawel, Bruce
AU  - Pawel B
AD  - Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA
      19104, USA.
FAU - Bhatti, Tricia
AU  - Bhatti T
AD  - Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA
      19104, USA.
FAU - Santi, Mariarita
AU  - Santi M
AD  - Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA
      19104, USA.
FAU - Ganguly, Arupa
AU  - Ganguly A
AD  - Department of Genetics, Perelman School of Medicine at the University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Khan, Javed
AU  - Khan J
AD  - Oncogenomics Section, Genetics Branch, Center for Cancer Research, National
      Cancer Institute, Bethesda, MD 20892, USA.
FAU - Marra, Marco A
AU  - Marra MA
AD  - Genome Sciences Center, British Columbia Cancer Agency, University of British
      Columbia, Vancouver, BC V6T 1Z4, Canada; Department of Medical Genetics,
      University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Division of Neurosurgery and the Arthur and Sonia Labatt Brain Tumor Research
      Center, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Dimitrov, Dimiter S
AU  - Dimitrov DS
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, Frederick, MD 21701, USA.
FAU - Mackall, Crystal L
AU  - Mackall CL
AD  - Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA;
      Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Maris, John M
AU  - Maris JM
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic
      Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman
      School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104,
      USA. Electronic address: maris@chop.edu.
LA  - eng
GR  - T32 CA009615/CA/NCI NIH HHS/United States
GR  - T32 GM008638/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (GPC2 protein, human)
RN  - 0 (Glypicans)
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Oncogene Proteins)
RN  - 0 (RNA, Messenger)
SB  - IM
CIN - Cancer Cell. 2017 Sep 11;32(3):271-273. PMID: 28898689
MH  - Animals
MH  - Antibodies, Neoplasm/metabolism
MH  - Cell Death
MH  - Cell Line, Tumor
MH  - Cell Membrane/metabolism
MH  - Cell Proliferation
MH  - Child
MH  - Gene Expression Regulation, Neoplastic
MH  - Genome, Human
MH  - Glypicans/*metabolism
MH  - Humans
MH  - *Immunotherapy
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - *Molecular Targeted Therapy
MH  - N-Myc Proto-Oncogene Protein/metabolism
MH  - Neuroblastoma/genetics/*immunology/pathology/*therapy
MH  - Oncogene Proteins/*metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - Risk Factors
PMC - PMC5600520
MID - NIHMS902274
OTO - NOTNLM
OT  - MYCN
OT  - antibody-drug conjugate
OT  - glypican
OT  - immunotherapy
OT  - medulloblastoma
OT  - neuroblastoma
EDAT- 2017/09/13 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/13 06:00
PMCR- 2018/09/11 00:00
PHST- 2017/03/10 00:00 [received]
PHST- 2017/07/03 00:00 [revised]
PHST- 2017/08/07 00:00 [accepted]
PHST- 2018/09/11 00:00 [pmc-release]
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - S1535-6108(17)30346-X [pii]
AID - 10.1016/j.ccell.2017.08.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003.

PMID- 28898694
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20170925
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Intravascular Survival and Extravasation of Tumor Cells.
PG  - 282-293
LID - S1535-6108(17)30293-3 [pii]
LID - 10.1016/j.ccell.2017.07.001 [doi]
AB  - Most metastasizing tumor cells reach distant sites by entering the circulatory
      system. Within the bloodstream, they are exposed to severe stress due to loss of 
      adhesion to extracellular matrix, hemodynamic shear forces, and attacks of the
      immune system, and only a few cells manage to extravasate and to form metastases.
      We review the current understanding of the cellular and molecular mechanisms that
      allow tumor cells to survive in the intravascular environment and that mediate
      and promote tumor cell extravasation. As these processes are critical for the
      metastatic spread of tumor cells, we discuss implications for potential
      therapeutic approaches and future research.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Strilic, Boris
AU  - Strilic B
AD  - Max Planck Institute for Heart and Lung Research, Department of Pharmacology,
      Ludwigstr. 43, 61231 Bad Nauheim, Germany.
FAU - Offermanns, Stefan
AU  - Offermanns S
AD  - Max Planck Institute for Heart and Lung Research, Department of Pharmacology,
      Ludwigstr. 43, 61231 Bad Nauheim, Germany; J.W. Goethe University Frankfurt,
      Center for Molecular Medicine, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
      Electronic address: stefan.offermanns@mpi-bn.mpg.de.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Animals
MH  - Anoikis
MH  - Cell Survival
MH  - Extravasation of Diagnostic and Therapeutic Materials/*pathology/therapy
MH  - Humans
MH  - Immune System/pathology
MH  - Neoplastic Cells, Circulating/*pathology
MH  - Stress, Mechanical
OTO - NOTNLM
OT  - anoikis
OT  - metastasis
OT  - tumor cell extravasation
OT  - tumor cell survival
EDAT- 2017/09/13 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/13 06:00
PHST- 2017/04/25 00:00 [received]
PHST- 2017/06/24 00:00 [revised]
PHST- 2017/07/05 00:00 [accepted]
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - S1535-6108(17)30293-3 [pii]
AID - 10.1016/j.ccell.2017.07.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):282-293. doi: 10.1016/j.ccell.2017.07.001.

PMID- 28898693
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20180407
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - No Oxygen? No Glucose? No Problem: Fatty Acid Catabolism Enhances Effector CD8(+)
      TILs.
PG  - 280-281
LID - S1535-6108(17)30358-6 [pii]
LID - 10.1016/j.ccell.2017.08.013 [doi]
AB  - The tumor microenvironment presents metabolic constraints to immunosurveiling
      cells. In this issue of Cancer Cell, Zhang et al. demonstrate that CD8(+) TILs
      reprogram under hypoxic and hypoglycemic conditions, regaining effector function 
      by engaging fatty acid catabolism, which is promoted by fenofibrate and
      synergistic with immune checkpoint blockade therapy.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Bailis, Will
AU  - Bailis W
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520, USA.
FAU - Shyer, Justin A
AU  - Shyer JA
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520, USA.
FAU - Chiorazzi, Michael
AU  - Chiorazzi M
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520, USA.
FAU - Flavell, Richard A
AU  - Flavell RA
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520, USA. Electronic address: richard.flavell@yale.edu.
LA  - eng
GR  - T32 AI007019/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Fatty Acids)
RN  - IY9XDZ35W2 (Glucose)
RN  - S88TT14065 (Oxygen)
SB  - IM
CON - Cancer Cell. 2017 Sep 11;32(3):377-391.e9. PMID: 28898698
MH  - Fatty Acids
MH  - *Glucose
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Oxygen
MH  - Tumor Microenvironment/immunology
EDAT- 2017/09/13 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/09/13 06:00
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1535-6108(17)30358-6 [pii]
AID - 10.1016/j.ccell.2017.08.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):280-281. doi: 10.1016/j.ccell.2017.08.013.

PMID- 28898692
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20171026
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Smoke-Induced Changes to the Epigenome Provide Fertile Ground for Oncogenic
      Mutation.
PG  - 278-280
LID - S1535-6108(17)30361-6 [pii]
LID - 10.1016/j.ccell.2017.08.016 [doi]
AB  - How genetic and epigenetic events synergize to generate the oncogenic state is
      not well understood. In this issue of Cancer Cell, Vaz et al. provide compelling 
      evidence that exposure to chronic cigarette smoke causes progressive epigenetic
      alterations that prime for key genetic events to drive the development of lung
      cancer.
CI  - Crown Copyright (c) 2017. Published by Elsevier Inc. All rights reserved.
FAU - Clark, Susan J
AU  - Clark SJ
AD  - Epigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan
      Institute of Medical Research, Sydney, NSW 2010, Australia; St. Vincent's
      Clinical School, UNSW Sydney, Sydney, NSW 1466, Australia. Electronic address:
      s.clark@garvan.org.au.
FAU - Molloy, Peter L
AU  - Molloy PL
AD  - CSIRO Health and Biosecurity, PO Box 52, North Ryde, NSW 1670, Australia.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Smoke)
SB  - IM
CON - Cancer Cell. 2017 Sep 11;32(3):360-376.e6. PMID: 28898697
MH  - Carcinogenesis
MH  - Humans
MH  - Lung
MH  - Lung Neoplasms
MH  - Mutation
MH  - *Smoke
MH  - *Tobacco
EDAT- 2017/09/13 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/09/13 06:00
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1535-6108(17)30361-6 [pii]
AID - 10.1016/j.ccell.2017.08.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):278-280. doi: 10.1016/j.ccell.2017.08.016.

PMID- 28898691
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20171026
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Leukemic Cells "Gas Up" Leaky Bone Marrow Blood Vessels.
PG  - 276-278
LID - S1535-6108(17)30357-4 [pii]
LID - 10.1016/j.ccell.2017.08.012 [doi]
AB  - In this issue of Cancer Cell, Passaro et al. demonstrate how leukemia through
      aberrant induction of reactive oxygen species and nitric oxide production trigger
      marrow vessel leakiness, instigating pro-leukemic function. Disrupted tumor blood
      vessels promote exhaustion of non-malignant stem and progenitor cells and may
      facilitate leukemia relapse following chemotherapeutic treatment.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Itkin, Tomer
AU  - Itkin T
AD  - Division of Regenerative Medicine, Ansary Stem Cell Institute, Department of
      Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Rafii, Shahin
AU  - Rafii S
AD  - Division of Regenerative Medicine, Ansary Stem Cell Institute, Department of
      Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:
      srafii@med.cornell.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 31C4KY9ESH (Nitric Oxide)
SB  - IM
CON - Cancer Cell. 2017 Sep 11;32(3):324-341.e6. PMID: 28870739
MH  - *Bone Marrow
MH  - Bone Marrow Cells
MH  - Hematopoietic Stem Cells
MH  - Humans
MH  - *Leukemia
MH  - Nitric Oxide
MH  - Stem Cells
EDAT- 2017/09/13 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/09/13 06:00
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1535-6108(17)30357-4 [pii]
AID - 10.1016/j.ccell.2017.08.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):276-278. doi: 10.1016/j.ccell.2017.08.012.

PMID- 28898690
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20171026
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.
PG  - 273-275
LID - S1535-6108(17)30359-8 [pii]
LID - 10.1016/j.ccell.2017.08.014 [doi]
AB  - LMO1 is a high-risk neuroblastoma susceptibility gene, but how LMO1 cooperates
      with MYCN in neuroblastoma tumorigenesis is unclear. In this issue of Cancer
      Cell, Zhu et al. develop a novel zebrafish model that elucidates a mechanism by
      which LMO1 and MYCN synergistically initiate neuroblastoma and contribute to
      metastatic disease progression.
CI  - Published by Elsevier Inc.
FAU - Liu, Zhihui
AU  - Liu Z
AD  - Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research,
      9000 Rockville Pike, Bethesda, MD 20892, USA.
FAU - Thiele, Carol J
AU  - Thiele CJ
AD  - Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research,
      9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: ct47a@nih.gov.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins)
SB  - IM
CON - Cancer Cell. 2017 Sep 11;32(3):310-323.e5. PMID: 28867147
MH  - Animals
MH  - Carcinogenesis/genetics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Neuroblastoma/*genetics
MH  - Nuclear Proteins/genetics
MH  - Oncogene Proteins/genetics
MH  - Zebrafish
EDAT- 2017/09/13 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/09/13 06:00
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1535-6108(17)30359-8 [pii]
AID - 10.1016/j.ccell.2017.08.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):273-275. doi: 10.1016/j.ccell.2017.08.014.

PMID- 28898689
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20171026
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.
PG  - 271-273
LID - S1535-6108(17)30356-2 [pii]
LID - 10.1016/j.ccell.2017.08.011 [doi]
AB  - In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in
      neuroblastoma. They show that GPC2 is selectively expressed on the cell surface
      of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate 
      the therapeutic potential of an antibody-drug conjugate targeting GPC2.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Malone, Clare F
AU  - Malone CF
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, Boston, MA 02215, USA; Broad
      Institute, Cambridge, MA 02142, USA.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Harvard Medical School, Boston, MA 02215, USA; Broad
      Institute, Cambridge, MA 02142, USA. Electronic address:
      kimberly_stegmaier@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Sep 11;32(3):295-309.e12. PMID: 28898695
MH  - *Cell Line, Tumor
MH  - Humans
MH  - *Neuroblastoma
EDAT- 2017/09/13 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/09/13 06:00
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1535-6108(17)30356-2 [pii]
AID - 10.1016/j.ccell.2017.08.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):271-273. doi: 10.1016/j.ccell.2017.08.011.

PMID- 28870739
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20171026
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes
      to Disease Progression and Drug Response in Acute Myeloid Leukemia.
PG  - 324-341.e6
LID - S1535-6108(17)30306-9 [pii]
LID - 10.1016/j.ccell.2017.08.001 [doi]
AB  - The biological and clinical behaviors of hematological malignancies can be
      influenced by the active crosstalk with an altered bone marrow (BM)
      microenvironment. In the present study, we provide a detailed picture of the BM
      vasculature in acute myeloid leukemia using intravital two-photon microscopy. We 
      found several abnormalities in the vascular architecture and function in
      patient-derived xenografts (PDX), such as vascular leakiness and increased
      hypoxia. Transcriptomic analysis in endothelial cells identified nitric oxide
      (NO) as major mediator of this phenotype in PDX and in patient-derived biopsies. 
      Moreover, induction chemotherapy failing to restore normal vasculature was
      associated with a poor prognosis. Inhibition of NO production reduced vascular
      permeability, preserved normal hematopoietic stem cell function, and improved
      treatment response in PDX.
CI  - Copyright (c) 2017 The Francis Crick Institute. Published by Elsevier Inc. All
      rights reserved.
FAU - Passaro, Diana
AU  - Passaro D
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Di Tullio, Alessandro
AU  - Di Tullio A
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Abarrategi, Ander
AU  - Abarrategi A
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Rouault-Pierre, Kevin
AU  - Rouault-Pierre K
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Foster, Katie
AU  - Foster K
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Ariza-McNaughton, Linda
AU  - Ariza-McNaughton L
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Montaner, Beatriz
AU  - Montaner B
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Chakravarty, Probir
AU  - Chakravarty P
AD  - Bioinformatic Core Unit, The Francis Crick Institute, 1 Midland Road, London NW1 
      1AT, UK.
FAU - Bhaw, Leena
AU  - Bhaw L
AD  - Advanced Sequencing Unit, The Francis Crick Institute, 1 Midland Road, London NW1
      1AT, UK.
FAU - Diana, Giovanni
AU  - Diana G
AD  - MRC Centre for Developmental Neurobiology, King's College London, London, UK.
FAU - Lassailly, Francois
AU  - Lassailly F
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK.
FAU - Gribben, John
AU  - Gribben J
AD  - Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of 
      London, London EC1M 6BQ, UK.
FAU - Bonnet, Dominique
AU  - Bonnet D
AD  - Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road,
      London NW1 1AT, UK. Electronic address: dominique.bonnet@crick.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20170901
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
SB  - IM
CIN - Cancer Cell. 2017 Sep 11;32(3):276-278. PMID: 28898691
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Bone Marrow/drug effects/*pathology
MH  - *Capillary Permeability/drug effects
MH  - *Cellular Microenvironment/drug effects
MH  - *Disease Progression
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Leukemic/drug effects
MH  - Hematopoietic Stem Cells/drug effects/metabolism
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/genetics/*pathology
MH  - Mice
MH  - Neoplasm Transplantation/pathology
MH  - Nitric Oxide/metabolism
MH  - Treatment Outcome
PMC - PMC5598545
OTO - NOTNLM
OT  - NOS inhibitors
OT  - acute myeloid leukemia
OT  - chemotherapy
OT  - endothelial cells
OT  - hematopoietic stem cells
OT  - hypoxia
OT  - intravital 2P microscopy
OT  - microenvironment
OT  - nitric oxide
OT  - vascular permeability
EDAT- 2017/09/06 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/06 06:00
PHST- 2016/10/07 00:00 [received]
PHST- 2017/04/25 00:00 [revised]
PHST- 2017/08/01 00:00 [accepted]
PHST- 2017/09/06 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
PHST- 2017/09/06 06:00 [entrez]
AID - S1535-6108(17)30306-9 [pii]
AID - 10.1016/j.ccell.2017.08.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):324-341.e6. doi: 10.1016/j.ccell.2017.08.001. Epub
      2017 Sep 1.

PMID- 28867147
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20171026
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Sep 11
TI  - LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.
PG  - 310-323.e5
LID - S1535-6108(17)30345-8 [pii]
LID - 10.1016/j.ccell.2017.08.002 [doi]
AB  - A genome-wide association study identified LMO1, which encodes an LIM-domain-only
      transcriptional cofactor, as a neuroblastoma susceptibility gene that functions
      as an oncogene in high-risk neuroblastoma. Here we show that dbetah
      promoter-mediated expression of LMO1 in zebrafish synergizes with MYCN to
      increase the proliferation of hyperplastic sympathoadrenal precursor cells,
      leading to a reduced latency and increased penetrance of neuroblastomagenesis.
      The transgenic expression of LMO1 also promoted hematogenous dissemination and
      distant metastasis, which was linked to neuroblastoma cell invasion and
      migration, and elevated expression levels of genes affecting tumor
      cell-extracellular matrix interaction, including loxl3, itga2b, itga3, and itga5.
      Our results provide in vivo validation of LMO1 as an important oncogene that
      promotes neuroblastoma initiation, progression, and widespread metastatic
      dissemination.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zhu, Shizhen
AU  - Zhu S
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA. Electronic
      address: zhu.shizhen@mayo.edu.
FAU - Zhang, Xiaoling
AU  - Zhang X
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - Weichert-Leahey, Nina
AU  - Weichert-Leahey N
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Dong, Zhiwei
AU  - Dong Z
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - Zhang, Cheng
AU  - Zhang C
AD  - Department of Molecular Pharmacology & Experimental Therapeutics, Center for
      Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55902,
      USA.
FAU - Lopez, Gonzalo
AU  - Lopez G
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Tao, Ting
AU  - Tao T
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - He, Shuning
AU  - He S
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Wood, Andrew C
AU  - Wood AC
AD  - Department of Molecular Medicine, University of Auckland, Auckland, New Zealand.
FAU - Oldridge, Derek
AU  - Oldridge D
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Ung, Choong Yong
AU  - Ung CY
AD  - Department of Molecular Pharmacology & Experimental Therapeutics, Center for
      Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55902,
      USA.
FAU - van Ree, Janine H
AU  - van Ree JH
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - Khan, Amish
AU  - Khan A
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - Salazar, Brittany M
AU  - Salazar BM
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - Lummertz da Rocha, Edroaldo
AU  - Lummertz da Rocha E
AD  - Department of Molecular Pharmacology & Experimental Therapeutics, Center for
      Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55902,
      USA.
FAU - Zimmerman, Mark W
AU  - Zimmerman MW
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Guo, Feng
AU  - Guo F
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Cao, Hong
AU  - Cao H
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - Hou, Xiaonan
AU  - Hou X
AD  - Departments of Oncology, Radiation Oncology, and Molecular Pharmacology and
      Experimental Therapeutics, Mayo Clinic, Rochester, MN 55902, USA.
FAU - Weroha, S John
AU  - Weroha SJ
AD  - Departments of Oncology, Radiation Oncology, and Molecular Pharmacology and
      Experimental Therapeutics, Mayo Clinic, Rochester, MN 55902, USA.
FAU - Perez-Atayde, Antonio R
AU  - Perez-Atayde AR
AD  - Department of Pathology, Children's Hospital Boston, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Neuberg, Donna S
AU  - Neuberg DS
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Meves, Alexander
AU  - Meves A
AD  - Department of Dermatology, Mayo Clinic, Rochester, MN 55902, USA.
FAU - McNiven, Mark A
AU  - McNiven MA
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - van Deursen, Jan M
AU  - van Deursen JM
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
FAU - Li, Hu
AU  - Li H
AD  - Department of Molecular Pharmacology & Experimental Therapeutics, Center for
      Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55902,
      USA.
FAU - Maris, John M
AU  - Maris JM
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, 
      Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
      19104, USA; Abramson Family Cancer Research Institute, Philadelphia, PA 19104,
      USA.
FAU - Look, A Thomas
AU  - Look AT
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA. Electronic address: thomas_look@dfci.harvard.edu.
LA  - eng
GR  - R00 CA178189/CA/NCI NIH HHS/United States
GR  - R01 CA124709/CA/NCI NIH HHS/United States
GR  - R01 CA180692/CA/NCI NIH HHS/United States
GR  - R01 CA196631/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170831
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (LIM Domain Proteins)
RN  - 0 (LMO1 protein, human)
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Transcription Factors)
SB  - IM
CIN - Cancer Cell. 2017 Sep 11;32(3):273-275. PMID: 28898690
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Carcinogenesis/metabolism/*pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - DNA-Binding Proteins/*metabolism
MH  - Extracellular Matrix/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Hyperplasia
MH  - LIM Domain Proteins/*metabolism
MH  - Models, Biological
MH  - N-Myc Proto-Oncogene Protein/*metabolism
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neuroblastoma/genetics/*metabolism/*pathology
MH  - Signal Transduction/genetics
MH  - Transcription Factors/*metabolism
MH  - Transgenes
MH  - Zebrafish
PMC - PMC5605802
MID - NIHMS902684
OTO - NOTNLM
OT  - ECM
OT  - LMO1
OT  - MYCN
OT  - metastasis
OT  - neuroblastoma
OT  - tumorigenesis
OT  - zebrafish model
EDAT- 2017/09/05 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/05 06:00
PMCR- 2018/09/11 00:00
PHST- 2017/01/06 00:00 [received]
PHST- 2017/06/01 00:00 [revised]
PHST- 2017/08/07 00:00 [accepted]
PHST- 2018/09/11 00:00 [pmc-release]
PHST- 2017/09/05 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
PHST- 2017/09/05 06:00 [entrez]
AID - S1535-6108(17)30345-8 [pii]
AID - 10.1016/j.ccell.2017.08.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Sep 11;32(3):310-323.e5. doi: 10.1016/j.ccell.2017.08.002. Epub
      2017 Aug 31.

PMID- 28810149
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20180216
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - O2(-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential
      Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.
PG  - 268
LID - S1535-6108(17)30301-X [pii]
LID - 10.1016/j.ccell.2017.07.008 [doi]
FAU - Schoenfeld, Joshua D
AU  - Schoenfeld JD
FAU - Sibenaller, Zita A
AU  - Sibenaller ZA
FAU - Mapuskar, Kranti A
AU  - Mapuskar KA
FAU - Wagner, Brett A
AU  - Wagner BA
FAU - Cramer-Morales, Kimberly L
AU  - Cramer-Morales KL
FAU - Furqan, Muhammad
AU  - Furqan M
FAU - Sandhu, Sonia
AU  - Sandhu S
FAU - Carlisle, Thomas L
AU  - Carlisle TL
FAU - Smith, Mark C
AU  - Smith MC
FAU - Abu Hejleh, Taher
AU  - Abu Hejleh T
FAU - Berg, Daniel J
AU  - Berg DJ
FAU - Zhang, Jun
AU  - Zhang J
FAU - Keech, John
AU  - Keech J
FAU - Parekh, Kalpaj R
AU  - Parekh KR
FAU - Bhatia, Sudershan
AU  - Bhatia S
FAU - Monga, Varun
AU  - Monga V
FAU - Bodeker, Kellie L
AU  - Bodeker KL
FAU - Ahmann, Logan
AU  - Ahmann L
FAU - Vollstedt, Sandy
AU  - Vollstedt S
FAU - Brown, Heather
AU  - Brown H
FAU - Kauffman, Erin P Shanahan
AU  - Kauffman EPS
FAU - Schall, Mary E
AU  - Schall ME
FAU - Hohl, Ray J
AU  - Hohl RJ
FAU - Clamon, Gerald H
AU  - Clamon GH
FAU - Greenlee, Jeremy D
AU  - Greenlee JD
FAU - Howard, Matthew A
AU  - Howard MA
FAU - Schultz, Michael K
AU  - Schultz MK
FAU - Smith, Brian J
AU  - Smith BJ
FAU - Riley, Dennis P
AU  - Riley DP
FAU - Domann, Frederick E
AU  - Domann FE
FAU - Cullen, Joseph J
AU  - Cullen JJ
FAU - Buettner, Garry R
AU  - Buettner GR
FAU - Buatti, John M
AU  - Buatti JM
FAU - Spitz, Douglas R
AU  - Spitz DR
FAU - Allen, Bryan G
AU  - Allen BG
LA  - eng
GR  - P30 ES005605/ES/NIEHS NIH HHS/United States
GR  - T32 GM007337/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Apr 10;31(4):487-500.e8. PMID: 28366679
EDAT- 2017/08/16 06:00
MHDA- 2017/08/16 06:01
CRDT- 2017/08/16 06:00
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/08/16 06:01 [medline]
AID - S1535-6108(17)30301-X [pii]
AID - 10.1016/j.ccell.2017.07.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):268. doi: 10.1016/j.ccell.2017.07.008.

PMID- 28810148
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.
PG  - 268-270
LID - S1535-6108(17)30303-3 [pii]
LID - 10.1016/j.ccell.2017.07.010 [doi]
FAU - Blagg, Julian
AU  - Blagg J
FAU - Workman, Paul
AU  - Workman P
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Jul 10;32(1):9-25. PMID: 28697345
PMC - PMC5559281
EDAT- 2017/08/16 06:00
MHDA- 2017/08/16 06:01
CRDT- 2017/08/16 06:00
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/08/16 06:01 [medline]
AID - S1535-6108(17)30303-3 [pii]
AID - 10.1016/j.ccell.2017.07.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):268-270. doi: 10.1016/j.ccell.2017.07.010.

PMID- 28810147
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Macrophage Polarization Contributes to Glioblastoma Eradication by Combination
      Immunovirotherapy and Immune Checkpoint Blockade.
PG  - 253-267.e5
LID - S1535-6108(17)30298-2 [pii]
LID - 10.1016/j.ccell.2017.07.006 [doi]
AB  - Glioblastoma is an immunosuppressive, fatal brain cancer that contains
      glioblastoma stem-like cells (GSCs). Oncolytic herpes simplex virus (oHSV)
      selectively replicates in cancer cells while inducing anti-tumor immunity. oHSV
      G47Delta expressing murine IL-12 (G47Delta-mIL12), antibodies to immune
      checkpoints (CTLA-4, PD-1, PD-L1), or dual combinations modestly extended
      survival of a mouse glioma model. However, the triple combination of anti-CTLA-4,
      anti-PD-1, and G47Delta-mIL12 cured most mice in two glioma models. This
      treatment was associated with macrophage influx and M1-like polarization, along
      with increased T effector to T regulatory cell ratios. Immune cell depletion
      studies demonstrated that CD4(+) and CD8(+) T cells as well as macrophages are
      required for synergistic curative activity. This combination should be
      translatable to the clinic and other immunosuppressive cancers.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Saha, Dipongkor
AU  - Saha D
AD  - Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department
      of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of
      Neurosurgery, Harvard Medical School, Boston, MA, USA.
FAU - Martuza, Robert L
AU  - Martuza RL
AD  - Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department
      of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of
      Neurosurgery, Harvard Medical School, Boston, MA, USA.
FAU - Rabkin, Samuel D
AU  - Rabkin SD
AD  - Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department
      of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of
      Neurosurgery, Harvard Medical School, Boston, MA, USA. Electronic address:
      rabkin@mgh.harvard.edu.
LA  - eng
GR  - R01 CA160762/CA/NCI NIH HHS/United States
GR  - R01 NS032677/NS/NINDS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (CTLA4 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
CIN - Cancer Cell. 2017 Aug 14;32(2):133-134. PMID: 28810141
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - B7-H1 Antigen/antagonists & inhibitors
MH  - CD4-Positive T-Lymphocytes/immunology/metabolism/pathology
MH  - CD8-Positive T-Lymphocytes/immunology/metabolism/pathology
MH  - CTLA-4 Antigen/*antagonists & inhibitors
MH  - Cell Cycle Checkpoints/drug effects
MH  - Combined Modality Therapy
MH  - Disease Models, Animal
MH  - Female
MH  - Glioblastoma/immunology/*therapy
MH  - Humans
MH  - *Immunotherapy
MH  - Interleukin-12/*genetics
MH  - Macrophage Activation
MH  - Macrophages/*immunology/metabolism/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - *Oncolytic Virotherapy
MH  - Oncolytic Viruses/genetics
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Tumor Cells, Cultured
PMC - PMC5568814
MID - NIHMS894299
OTO - NOTNLM
OT  - HSV
OT  - cancer stem cells
OT  - glioma
OT  - immunotherapy
OT  - oncolytic virus
EDAT- 2017/08/16 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/16 06:00
PMCR- 2018/08/14 00:00
PHST- 2016/08/09 00:00 [received]
PHST- 2017/04/07 00:00 [revised]
PHST- 2017/07/17 00:00 [accepted]
PHST- 2018/08/14 00:00 [pmc-release]
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - S1535-6108(17)30298-2 [pii]
AID - 10.1016/j.ccell.2017.07.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):253-267.e5. doi: 10.1016/j.ccell.2017.07.006.

PMID- 28810146
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20170911
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using
      Tumor-Educated Platelets.
PG  - 238-252.e9
LID - S1535-6108(17)30296-9 [pii]
LID - 10.1016/j.ccell.2017.07.004 [doi]
AB  - Blood-based liquid biopsies, including tumor-educated blood platelets (TEPs),
      have emerged as promising biomarker sources for non-invasive detection of cancer.
      Here we demonstrate that particle-swarm optimization (PSO)-enhanced algorithms
      enable efficient selection of RNA biomarker panels from platelet RNA-sequencing
      libraries (n = 779). This resulted in accurate TEP-based detection of early- and 
      late-stage non-small-cell lung cancer (n = 518 late-stage validation cohort,
      accuracy, 88%; AUC, 0.94; 95% CI, 0.92-0.96; p < 0.001; n = 106 early-stage
      validation cohort, accuracy, 81%; AUC, 0.89; 95% CI, 0.83-0.95; p < 0.001),
      independent of age of the individuals, smoking habits, whole-blood storage time, 
      and various inflammatory conditions. PSO enabled selection of gene panels to
      diagnose cancer from TEPs, suggesting that swarm intelligence may also benefit
      the optimization of diagnostics readout of other liquid biopsy biosources.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Best, Myron G
AU  - Best MG
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Pathology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor Center Amsterdam, VU
      University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV
      Amsterdam, the Netherlands. Electronic address: m.best@vumc.nl.
FAU - Sol, Nik
AU  - Sol N
AD  - Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Neurology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - In 't Veld, Sjors G J G
AU  - In 't Veld SGJG
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Vancura, Adrienne
AU  - Vancura A
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Muller, Mirte
AU  - Muller M
AD  - Department of Thoracic Oncology, The Netherlands Cancer Institute - Antoni van
      Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
FAU - Niemeijer, Anna-Larissa N
AU  - Niemeijer AN
AD  - Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Fejes, Aniko V
AU  - Fejes AV
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Clinical Institute of
      Laboratory Medicine, Medical University of Vienna, Spitalgasse 23, 1090 Vienna,
      Austria.
FAU - Tjon Kon Fat, Lee-Ann
AU  - Tjon Kon Fat LA
AD  - Department of Radiation Sciences, Oncology, Umea University, 90185 Umea, Sweden.
FAU - Huis In 't Veld, Anna E
AU  - Huis In 't Veld AE
AD  - Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Leurs, Cyra
AU  - Leurs C
AD  - Department of Neurology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; MS Center Amsterdam, VU
      University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Le Large, Tessa Y
AU  - Le Large TY
AD  - Department of Surgery, VU University Medical Center, Cancer Center Amsterdam, De 
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Meijer, Laura L
AU  - Meijer LL
AD  - Department of Surgery, VU University Medical Center, Cancer Center Amsterdam, De 
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Kooi, Irsan E
AU  - Kooi IE
AD  - Department of Clinical Genetics, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Rustenburg, Francois
AU  - Rustenburg F
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Pathology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor Center Amsterdam, VU
      University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV
      Amsterdam, the Netherlands.
FAU - Schellen, Pepijn
AU  - Schellen P
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Verschueren, Heleen
AU  - Verschueren H
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V., 1098 EA
      Amsterdam, the Netherlands.
FAU - Post, Edward
AU  - Post E
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V., 1098 EA
      Amsterdam, the Netherlands.
FAU - Wedekind, Laurine E
AU  - Wedekind LE
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Bracht, Jillian
AU  - Bracht J
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Esenkbrink, Michelle
AU  - Esenkbrink M
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Wils, Leon
AU  - Wils L
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Favaro, Francesca
AU  - Favaro F
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Schoonhoven, Jilian D
AU  - Schoonhoven JD
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Tannous, Jihane
AU  - Tannous J
AD  - Department of Neurology, Massachusetts General Hospital and Neuroscience Program,
      Harvard Medical School, 149 13(th) Street, Charlestown, MA 02129, USA.
FAU - Meijers-Heijboer, Hanne
AU  - Meijers-Heijboer H
AD  - Department of Clinical Genetics, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Kazemier, Geert
AU  - Kazemier G
AD  - Department of Surgery, VU University Medical Center, Cancer Center Amsterdam, De 
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Giovannetti, Elisa
AU  - Giovannetti E
AD  - Department of Medical Oncology, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Reijneveld, Jaap C
AU  - Reijneveld JC
AD  - Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Neurology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Idema, Sander
AU  - Idema S
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Killestein, Joep
AU  - Killestein J
AD  - Department of Neurology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; MS Center Amsterdam, VU
      University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Heger, Michal
AU  - Heger M
AD  - Department of Surgery, Amsterdam Medical Center, Meibergdreef 9, 1105 AZ
      Amsterdam, the Netherlands.
FAU - de Jager, Saskia C
AU  - de Jager SC
AD  - Department of Experimental Cardiology, Utrecht University Medical Center,
      Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
FAU - Urbanus, Rolf T
AU  - Urbanus RT
AD  - Laboratory of Clinical Chemistry and Hematology, Utrecht University Medical
      Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
FAU - Hoefer, Imo E
AU  - Hoefer IE
AD  - Laboratory of Clinical Chemistry and Hematology, Utrecht University Medical
      Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
FAU - Pasterkamp, Gerard
AU  - Pasterkamp G
AD  - Department of Experimental Cardiology, Utrecht University Medical Center,
      Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
FAU - Mannhalter, Christine
AU  - Mannhalter C
AD  - Clinical Institute of Laboratory Medicine, Medical University of Vienna,
      Spitalgasse 23, 1090 Vienna, Austria.
FAU - Gomez-Arroyo, Jose
AU  - Gomez-Arroyo J
AD  - Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Bogaard, Harm-Jan
AU  - Bogaard HJ
AD  - Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Noske, David P
AU  - Noske DP
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Vandertop, W Peter
AU  - Vandertop WP
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - van den Broek, Daan
AU  - van den Broek D
AD  - Department of Clinical Chemistry, The Netherlands Cancer Institute - Antoni van
      Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
FAU - Ylstra, Bauke
AU  - Ylstra B
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Nilsson, R Jonas A
AU  - Nilsson RJA
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Radiation Sciences, Oncology, Umea University, 90185 Umea, Sweden.
FAU - Wesseling, Pieter
AU  - Wesseling P
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor Center
      Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands; Department of Pathology, Princess
      Maxima Center for Pediatric Oncology and University Medical Center Utrecht,
      Lundlaan 6, 3584 EA Utrecht, the Netherlands.
FAU - Karachaliou, Niki
AU  - Karachaliou N
AD  - Translational Research Unit, Dr. Rosell Oncology Institute, Quiron Dexeus
      University Hospital, Calle Sabine Arana 5-19, 08028 Barcelona, Spain.
FAU - Rosell, Rafael
AU  - Rosell R
AD  - Translational Research Unit, Dr. Rosell Oncology Institute, Quiron Dexeus
      University Hospital, Calle Sabine Arana 5-19, 08028 Barcelona, Spain; Pangaea
      Biotech SL, Calle Sabine Arana 5-19, 08028 Barcelona, Spain; Catalan Institute of
      Oncology, Hospital Germans Trias i Pujol, Carretera de Canyet, 08916 Barcelona,
      Spain; Molecular Oncology Research (MORe) Foundation, Calle Sabine Arana 5-19,
      08028 Barcelona, Spain.
FAU - Lee-Lewandrowski, Elizabeth
AU  - Lee-Lewandrowski E
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      149 13(th) Street, Charlestown, MA 02129, USA.
FAU - Lewandrowski, Kent B
AU  - Lewandrowski KB
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      149 13(th) Street, Charlestown, MA 02129, USA.
FAU - Tannous, Bakhos A
AU  - Tannous BA
AD  - Department of Neurology, Massachusetts General Hospital and Neuroscience Program,
      Harvard Medical School, 149 13(th) Street, Charlestown, MA 02129, USA.
FAU - de Langen, Adrianus J
AU  - de Langen AJ
AD  - Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Smit, Egbert F
AU  - Smit EF
AD  - Department of Thoracic Oncology, The Netherlands Cancer Institute - Antoni van
      Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands;
      Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - van den Heuvel, Michel M
AU  - van den Heuvel MM
AD  - Department of Thoracic Oncology, The Netherlands Cancer Institute - Antoni van
      Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands;
      Department of Respiratory Diseases, Radboud University Medical Center, 6500 HB
      Nijmegen, the Netherlands.
FAU - Wurdinger, Thomas
AU  - Wurdinger T
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor
      Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De
      Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Neurology,
      Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, 
      149 13(th) Street, Charlestown, MA 02129, USA. Electronic address:
      t.wurdinger@vumc.nl.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Algorithms
MH  - *Artificial Intelligence
MH  - Biomarkers, Tumor
MH  - Blood Platelets/*physiology
MH  - Carcinoma, Non-Small-Cell Lung/blood/*diagnosis/genetics
MH  - Cohort Studies
MH  - Diagnosis, Computer-Assisted/*methods
MH  - Female
MH  - Gene Expression Profiling
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Inflammation/blood/diagnosis/genetics
MH  - Lung Neoplasms/blood/*diagnosis/genetics
MH  - Male
MH  - Middle Aged
MH  - Support Vector Machine
OTO - NOTNLM
OT  - NSCLC
OT  - RNA
OT  - blood platelets
OT  - cancer diagnostics
OT  - liquid biopsies
OT  - particle-swarm optimization
OT  - self-learning algorithms
OT  - splicing
OT  - swarm intelligence
OT  - tumor-educated platelets
EDAT- 2017/08/16 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/16 06:00
PHST- 2017/02/03 00:00 [received]
PHST- 2017/05/17 00:00 [revised]
PHST- 2017/07/13 00:00 [accepted]
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - S1535-6108(17)30296-9 [pii]
AID - 10.1016/j.ccell.2017.07.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004.

PMID- 28810145
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20180309
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal
      Melanoma.
PG  - 204-220.e15
LID - S1535-6108(17)30295-7 [pii]
LID - 10.1016/j.ccell.2017.07.003 [doi]
AB  - Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four
      molecularly distinct, clinically relevant subtypes: two associated with
      poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We
      show that BAP1 loss follows M3 occurrence and correlates with a global DNA
      methylation state that is distinct from D3-UM. Poor-prognosis M3-UM divide into
      subsets with divergent genomic aberrations, transcriptional features, and
      clinical outcomes. We report change-of-function SRSF2 mutations. Within D3-UM,
      EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number
      alterations and DNA methylation profiles, providing insight into the biology of
      these low- versus intermediate-risk clinical mutation subtypes.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Robertson, A Gordon
AU  - Robertson AG
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Shih, Juliann
AU  - Shih J
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Yau, Christina
AU  - Yau C
AD  - Buck Institute for Research on Aging, Novato, CA 94945, USA.
FAU - Gibb, Ewan A
AU  - Gibb EA
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Oba, Junna
AU  - Oba J
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Mungall, Karen L
AU  - Mungall KL
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Hess, Julian M
AU  - Hess JM
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Uzunangelov, Vladislav
AU  - Uzunangelov V
AD  - Department of Biomolecular Engineering, Center for Biomolecular Sciences and
      Engineering, University of California, Santa Cruz, CA 95064, USA.
FAU - Walter, Vonn
AU  - Walter V
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA; Department of Public Health Sciences, Penn
      State College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
FAU - Danilova, Ludmila
AU  - Danilova L
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
      Baltimore, MD 21287, USA.
FAU - Lichtenberg, Tara M
AU  - Lichtenberg TM
AD  - The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205,
      USA.
FAU - Kucherlapati, Melanie
AU  - Kucherlapati M
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Division
      of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Kimes, Patrick K
AU  - Kimes PK
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Tang, Ming
AU  - Tang M
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Penson, Alexander
AU  - Penson A
AD  - Human Oncology and Pathogenesis Program, Department of Epidemiology and
      Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA;
      Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10021, USA.
FAU - Babur, Ozgun
AU  - Babur O
AD  - Molecular and Medical Genetics, Computational Biology, Oregon Health and Science 
      University, Portland, OR 97239, USA.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Bristow, Christopher A
AU  - Bristow CA
AD  - Institute for Applied Cancer Science, Department of Genomic Medicine, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hoadley, Katherine A
AU  - Hoadley KA
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA; Department of Genetics, University of North
      Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Iype, Lisa
AU  - Iype L
AD  - Institute for Systems Biology, Seattle, WA 98109, USA.
FAU - Chang, Matthew T
AU  - Chang MT
AD  - Human Oncology and Pathogenesis Program, Department of Epidemiology and
      Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA;
      Departments of Bioengineering and Therapeutic Sciences, University of California,
      San Francisco, CA 94122, USA.
CN  - TCGA Research Network
FAU - Cherniack, Andrew D
AU  - Cherniack AD
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Benz, Christopher
AU  - Benz C
AD  - Buck Institute for Research on Aging, Novato, CA 94945, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Verhaak, Roel G W
AU  - Verhaak RGW
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational
      Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030,
      USA.
FAU - Griewank, Klaus G
AU  - Griewank KG
AD  - Department of Dermatology, University Hospital Essen, 45157 Essen, Germany.
FAU - Felau, Ina
AU  - Felau I
AD  - Center for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
FAU - Zenklusen, Jean C
AU  - Zenklusen JC
AD  - Center for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
FAU - Gershenwald, Jeffrey E
AU  - Gershenwald JE
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Schoenfield, Lynn
AU  - Schoenfield L
AD  - Department of Pathology, The Ohio State University, Wexner Medical Center,
      Columbus, OH 43210, USA.
FAU - Lazar, Alexander J
AU  - Lazar AJ
AD  - Department of Pathology, Dermatology and Translational Molecular Pathology, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Abdel-Rahman, Mohamed H
AU  - Abdel-Rahman MH
AD  - Departments of Ophthalmology and Internal Medicine, Division of Human Genetics,
      The Ohio State University, Columbus, OH 43210, USA.
FAU - Roman-Roman, Sergio
AU  - Roman-Roman S
AD  - Department of Translational Research, Institut Curie, PSL Research University,
      Paris 75248, France.
FAU - Stern, Marc-Henri
AU  - Stern MH
AD  - Department of Translational Research, Institut Curie, PSL Research University,
      Paris 75248, France.
FAU - Cebulla, Colleen M
AU  - Cebulla CM
AD  - Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus,
      OH 43212, USA.
FAU - Williams, Michelle D
AU  - Williams MD
AD  - Department of Pathology, Dermatology and Translational Molecular Pathology, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Jager, Martine J
AU  - Jager MJ
AD  - Department of Ophthalmology, Leiden University Medical Center, Leiden, the
      Netherlands.
FAU - Coupland, Sarah E
AU  - Coupland SE
AD  - Department of Molecular & Clinical Cancer Medicine, Institute of Translational
      Medicine, University of Liverpool, Liverpool L7 8TX, UK; Department of Cellular
      Pathology, Royal Liverpool University Hospital, Liverpool, L69 3GA, UK.
FAU - Esmaeli, Bita
AU  - Esmaeli B
AD  - Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic
      address: besmaeli@mdanderson.org.
FAU - Kandoth, Cyriac
AU  - Kandoth C
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10021, USA. Electronic address:
      kandothc@mskcc.org.
FAU - Woodman, Scott E
AU  - Woodman SE
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic
      address: swoodman@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U24 CA143882/CA/NCI NIH HHS/United States
GR  - U54 HG003067/HG/NHGRI NIH HHS/United States
GR  - U24 CA143835/CA/NCI NIH HHS/United States
GR  - U24 CA143866/CA/NCI NIH HHS/United States
GR  - U24 CA143845/CA/NCI NIH HHS/United States
GR  - U24 CA143799/CA/NCI NIH HHS/United States
GR  - U54 HG003273/HG/NHGRI NIH HHS/United States
GR  - U24 CA144025/CA/NCI NIH HHS/United States
GR  - U24 CA143840/CA/NCI NIH HHS/United States
GR  - U24 CA143843/CA/NCI NIH HHS/United States
GR  - U24 CA143858/CA/NCI NIH HHS/United States
GR  - U24 CA143848/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
GR  - U54 HG003079/HG/NHGRI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - K08 EY022672/EY/NEI NIH HHS/United States
GR  - U24 CA143867/CA/NCI NIH HHS/United States
GR  - U24 CA210990/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Eukaryotic Initiation Factor-1)
RN  - 0 (Phosphoproteins)
RN  - 0 (RNA Splicing Factors)
RN  - 0 (SF3B1 protein, human)
RN  - 0 (SRSF3 protein, human)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (eukaryotic peptide initiation factor-1A)
RN  - 170974-22-8 (Serine-Arginine Splicing Factors)
RN  - EC 3.1.2.15 (BAP1 protein, human)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
RN  - Uveal melanoma
SB  - IM
EIN - Cancer Cell. 2018 Jan 8;33(1):151. PMID: 29316429
MH  - Biomarkers, Tumor/*genetics
MH  - DNA Copy Number Variations
MH  - *DNA Methylation
MH  - Eukaryotic Initiation Factor-1/genetics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Melanoma/classification/*genetics
MH  - Monosomy
MH  - *Mutation
MH  - Phosphoproteins/genetics
MH  - Prognosis
MH  - RNA Splicing Factors/genetics
MH  - Serine-Arginine Splicing Factors/genetics
MH  - Tumor Suppressor Proteins/genetics
MH  - Ubiquitin Thiolesterase/genetics
MH  - Uveal Neoplasms/classification/*genetics
PMC - PMC5619925
MID - NIHMS895876
OTO - NOTNLM
OT  - EIF1AX
OT  - GNA11
OT  - GNAQ
OT  - SF3B1
OT  - SRSF2
OT  - TCGA
OT  - molecular subtypes
OT  - monosomy 3
OT  - noncoding RNA
OT  - uveal melanoma
IR  - Abdel-Rahman MH
FIR - Abdel-Rahman, Mohamed H
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Ally A
FIR - Ally, Adrian
IR  - Auman JT
FIR - Auman, J Todd
IR  - Babur O
FIR - Babur, Ozgun
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Balu S
FIR - Balu, Saianand
IR  - Benz C
FIR - Benz, Christopher
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Birol I
FIR - Birol, Inanc
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Bowen J
FIR - Bowen, Jay
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Bristow CA
FIR - Bristow, Christopher A
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Cebulla CM
FIR - Cebulla, Colleen M
IR  - Chang MT
FIR - Chang, Matthew T
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Chin L
FIR - Chin, Lynda
IR  - Cho J
FIR - Cho, Juok
IR  - Chuah E
FIR - Chuah, Eric
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Cibulskis K
FIR - Cibulskis, Kristian
IR  - Cope L
FIR - Cope, Leslie
IR  - Coupland SE
FIR - Coupland, Sarah E
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Defreitas T
FIR - Defreitas, Timothy
IR  - Demchok JA
FIR - Demchok, John A
IR  - Desjardins L
FIR - Desjardins, Laurence
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Esmaeli B
FIR - Esmaeli, Bita
IR  - Felau I
FIR - Felau, Ina
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Gerken M
FIR - Gerken, Mark
IR  - Gershenwald JE
FIR - Gershenwald, Jeffrey E
IR  - Getz G
FIR - Getz, Gad
IR  - Gibb EA
FIR - Gibb, Ewan A
IR  - Griewank KG
FIR - Griewank, Klaus G
IR  - Grimm EA
FIR - Grimm, Elizabeth A
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Hegde AM
FIR - Hegde, Apurva M
IR  - Heiman DI
FIR - Heiman, David I
IR  - Helsel C
FIR - Helsel, Carmen
IR  - Hess JM
FIR - Hess, Julian M
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Hobensack S
FIR - Hobensack, Shital
IR  - Holt RA
FIR - Holt, Robert A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Hu X
FIR - Hu, Xin
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Jager MJ
FIR - Jager, Martine J
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kandoth C
FIR - Kandoth, Cyriac
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Kim J
FIR - Kim, Jaegil
IR  - Kimes PK
FIR - Kimes, Patrick K
IR  - Kucherlapati M
FIR - Kucherlapati, Melanie
IR  - Kucherlapati R
FIR - Kucherlapati, Raju
IR  - Lander E
FIR - Lander, Eric
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lazar AJ
FIR - Lazar, Alexander J
IR  - Lee S
FIR - Lee, Semin
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Lin P
FIR - Lin, Pei
IR  - Liu J
FIR - Liu, Jia
IR  - Liu W
FIR - Liu, Wenbin
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Lu Y
FIR - Lu, Yiling
IR  - Iype L
FIR - Iype, Lisa
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Mahadeshwar HS
FIR - Mahadeshwar, Harshad S
IR  - Mariani O
FIR - Mariani, Odette
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Meier S
FIR - Meier, Sam
IR  - Meng S
FIR - Meng, Shaowu
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall KL
FIR - Mungall, Karen L
IR  - Murray BA
FIR - Murray, Bradley A
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Noble MS
FIR - Noble, Michael S
IR  - Oba J
FIR - Oba, Junna
IR  - Pantazi A
FIR - Pantazi, Angeliki
IR  - Parfenov M
FIR - Parfenov, Michael
IR  - Park PJ
FIR - Park, Peter J
IR  - Parker JS
FIR - Parker, Joel S
IR  - Penson A
FIR - Penson, Alexander
IR  - Perou CM
FIR - Perou, Charles M
IR  - Pihl T
FIR - Pihl, Todd
IR  - Pilarski R
FIR - Pilarski, Robert
IR  - Protopopov A
FIR - Protopopov, Alexei
IR  - Radenbaugh A
FIR - Radenbaugh, Amie
IR  - Rai K
FIR - Rai, Karan
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Ren X
FIR - Ren, Xiaojia
IR  - Reynolds SM
FIR - Reynolds, Sheila M
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Roman-Roman S
FIR - Roman-Roman, Sergio
IR  - Roszik J
FIR - Roszik, Jason
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Sastre X
FIR - Sastre, Xavier
IR  - Schadendorf D
FIR - Schadendorf, Dirk
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Schoenfield L
FIR - Schoenfield, Lynn
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Seidman J
FIR - Seidman, Jonathan
IR  - Seth S
FIR - Seth, Sahil
IR  - Sethi G
FIR - Sethi, Geetika
IR  - Sheth M
FIR - Sheth, Margi
IR  - Shi Y
FIR - Shi, Yan
IR  - Shields C
FIR - Shields, Carol
IR  - Shih J
FIR - Shih, Juliann
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Simons JV
FIR - Simons, Janae V
IR  - Singh AD
FIR - Singh, Arun D
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Skelly T
FIR - Skelly, Tara
IR  - Sofia H
FIR - Sofia, Heidi
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Song X
FIR - Song, Xingzhi
IR  - Stern MH
FIR - Stern, Marc-Henri
IR  - Stuart J
FIR - Stuart, Joshua
IR  - Sun Q
FIR - Sun, Qiang
IR  - Sun H
FIR - Sun, Huandong
IR  - Tam A
FIR - Tam, Angela
IR  - Tan D
FIR - Tan, Donghui
IR  - Tang M
FIR - Tang, Ming
IR  - Tang J
FIR - Tang, Jiabin
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Taylor BS
FIR - Taylor, Barry S
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Thorsson V
FIR - Thorsson, Vesteinn
IR  - Tse K
FIR - Tse, Kane
IR  - Uzunangelov V
FIR - Uzunangelov, Vladislav
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Verhaak RGW
FIR - Verhaak, Roel G W
IR  - Voet D
FIR - Voet, Doug
IR  - Walter V
FIR - Walter, Vonn
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wang Z
FIR - Wang, Zhining
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Williams MD
FIR - Williams, Michelle D
IR  - Wise L
FIR - Wise, Lisa
IR  - Woodman SE
FIR - Woodman, Scott E
IR  - Wong T
FIR - Wong, Tina
IR  - Wu Y
FIR - Wu, Ye
IR  - Yang L
FIR - Yang, Liming
IR  - Yang L
FIR - Yang, Lixing
IR  - Yau C
FIR - Yau, Christina
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang J
FIR - Zhang, Jiashan
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Zmuda E
FIR - Zmuda, Erik
EDAT- 2017/08/16 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/16 06:00
PMCR- 2018/08/14 00:00
PHST- 2016/12/14 00:00 [received]
PHST- 2017/04/24 00:00 [revised]
PHST- 2017/07/09 00:00 [accepted]
PHST- 2018/08/14 00:00 [pmc-release]
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - S1535-6108(17)30295-7 [pii]
AID - 10.1016/j.ccell.2017.07.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003.

PMID- 28810144
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20180120
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
PG  - 185-203.e13
LID - S1535-6108(17)30299-4 [pii]
LID - 10.1016/j.ccell.2017.07.007 [doi]
AB  - We performed integrated genomic, transcriptomic, and proteomic profiling of 150
      pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with
      characteristic low neoplastic cellularity. Deep whole-exome sequencing revealed
      recurrent somatic mutations in KRAS, TP53, CDKN2A, SMAD4, RNF43, ARID1A,
      TGFbetaR2, GNAS, RREB1, and PBRM1. KRAS wild-type tumors harbored alterations in 
      other oncogenic drivers, including GNAS, BRAF, CTNNB1, and additional RAS pathway
      genes. A subset of tumors harbored multiple KRAS mutations, with some showing
      evidence of biallelic mutations. Protein profiling identified a favorable
      prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway
      scores. Associations of non-coding RNAs with tumor-specific mRNA subtypes were
      also identified. Our integrated multi-platform analysis reveals a complex
      molecular landscape of PDAC and provides a roadmap for precision medicine.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
CN  - Cancer Genome Atlas Research Network. Electronic address:
      andrew_aguirre@dfci.harvard.edu
CN  - Cancer Genome Atlas Research Network
LA  - eng
GR  - P01 CA117969/CA/NCI NIH HHS/United States
GR  - R01 CA180776/CA/NCI NIH HHS/United States
GR  - R01 HG007069/HG/NHGRI NIH HHS/United States
GR  - U24 CA211000/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (KRAS protein, human)
RN  - 0 (Proteome)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Carcinoma, Pancreatic Ductal/*genetics/metabolism
MH  - DNA Methylation
MH  - Epigenesis, Genetic/genetics
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genomics/methods
MH  - Humans
MH  - Mutation/*genetics
MH  - Pancreatic Neoplasms/*genetics/metabolism
MH  - Proteome/*analysis
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Transcriptome/*genetics
OTO - NOTNLM
OT  - KRAS
OT  - PDAC
OT  - RPPA
OT  - TCGA
OT  - genomics
OT  - heterogeneity
OT  - miRNA
OT  - molecular subtypes
OT  - pancreatic cancer
OT  - tumor cellularity
IR  - Raphael BJ
FIR - Raphael, Benjamin J
IR  - Hruban RH
FIR - Hruban, Ralph H
IR  - Aguirre AJ
FIR - Aguirre, Andrew J
IR  - Moffitt RA
FIR - Moffitt, Richard A
IR  - Yeh JJ
FIR - Yeh, Jen Jen
IR  - Stewart C
FIR - Stewart, Chip
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Gupta M
FIR - Gupta, Manaswi
IR  - Getz G
FIR - Getz, Gad
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Fei SS
FIR - Fei, Suzanne S
IR  - Hinoue T
FIR - Hinoue, Toshinori
IR  - Shen H
FIR - Shen, Hui
IR  - Laird PW
FIR - Laird, Peter W
IR  - Ling S
FIR - Ling, Shiyun
IR  - Lu Y
FIR - Lu, Yiling
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Loher P
FIR - Loher, Phillipe
IR  - Londin ER
FIR - Londin, Eric R
IR  - Rigoutsos I
FIR - Rigoutsos, Isidore
IR  - Telonis AG
FIR - Telonis, Aristeidis G
IR  - Gibb EA
FIR - Gibb, Ewan A
IR  - Goldenberg A
FIR - Goldenberg, Anna
IR  - Mezlini AM
FIR - Mezlini, Aziz M
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Collisson E
FIR - Collisson, Eric
IR  - Lander E
FIR - Lander, Eric
IR  - Murray BA
FIR - Murray, Bradley A
IR  - Hess J
FIR - Hess, Julian
IR  - Rosenberg M
FIR - Rosenberg, Mara
IR  - Bergelson L
FIR - Bergelson, Louis
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Cho J
FIR - Cho, Juok
IR  - Tiao G
FIR - Tiao, Grace
IR  - Kim J
FIR - Kim, Jaegil
IR  - Livitz D
FIR - Livitz, Dimitri
IR  - Leshchiner I
FIR - Leshchiner, Ignaty
IR  - Reardon B
FIR - Reardon, Brendan
IR  - Van Allen E
FIR - Van Allen, Eliezer
IR  - Kamburov A
FIR - Kamburov, Atanas
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Noble MS
FIR - Noble, Michael S
IR  - Heiman DI
FIR - Heiman, David I
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Adsay V
FIR - Adsay, Volkan
IR  - Petersen G
FIR - Petersen, Gloria
IR  - Klimstra D
FIR - Klimstra, David
IR  - Bardeesy N
FIR - Bardeesy, Nabeel
IR  - Leiserson MDM
FIR - Leiserson, Mark D M
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Birol I
FIR - Birol, Inanc
IR  - Mungall KL
FIR - Mungall, Karen L
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Spellman PT
FIR - Spellman, Paul T
IR  - Liu Y
FIR - Liu, Yuexin
IR  - Amundadottir LT
FIR - Amundadottir, Laufey T
IR  - Tepper J
FIR - Tepper, Joel
IR  - Singhi AD
FIR - Singhi, Aatur D
IR  - Dhir R
FIR - Dhir, Rajiv
IR  - Paul D
FIR - Paul, Drwiega
IR  - Smyrk T
FIR - Smyrk, Thomas
IR  - Zhang L
FIR - Zhang, Lizhi
IR  - Kim P
FIR - Kim, Paula
IR  - Bowen J
FIR - Bowen, Jay
IR  - Frick J
FIR - Frick, Jessica
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gerken M
FIR - Gerken, Mark
IR  - Lau K
FIR - Lau, Kevin
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Renkel J
FIR - Renkel, Jeremy
IR  - Sherman M
FIR - Sherman, Mark
IR  - Wise L
FIR - Wise, Lisa
IR  - Yena P
FIR - Yena, Peggy
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Shih J
FIR - Shih, Juliann
IR  - Ally A
FIR - Ally, Adrian
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Chu A
FIR - Chu, Andy
IR  - Chuah E
FIR - Chuah, Eric
IR  - Clarke A
FIR - Clarke, Amanda
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Holt RA
FIR - Holt, Robert A
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Lee D
FIR - Lee, Darlene
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Tam A
FIR - Tam, Angela
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Tse K
FIR - Tse, Kane
IR  - Wong T
FIR - Wong, Tina
IR  - Brooks D
FIR - Brooks, Denise
IR  - Auman JT
FIR - Auman, J Todd
IR  - Balu S
FIR - Balu, Saianand
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Meng S
FIR - Meng, Shaowu
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Perou CM
FIR - Perou, Charles M
IR  - Perou AH
FIR - Perou, Amy H
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Shi Y
FIR - Shi, Yan
IR  - Simons JV
FIR - Simons, Janae V
IR  - Skelly T
FIR - Skelly, Tara
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Tan D
FIR - Tan, Donghui
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Parker JS
FIR - Parker, Joel S
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Korkut A
FIR - Korkut, Anil
IR  - Senbabaoglu Y
FIR - Senbabaoglu, Yasin
IR  - Burch P
FIR - Burch, Patrick
IR  - McWilliams R
FIR - McWilliams, Robert
IR  - Chaffee K
FIR - Chaffee, Kari
IR  - Oberg A
FIR - Oberg, Ann
IR  - Zhang W
FIR - Zhang, Wei
IR  - Gingras MC
FIR - Gingras, Marie-Claude
IR  - Wheeler DA
FIR - Wheeler, David A
IR  - Xi L
FIR - Xi, Liu
IR  - Albert M
FIR - Albert, Monique
IR  - Bartlett J
FIR - Bartlett, John
IR  - Sekhon H
FIR - Sekhon, Harman
IR  - Stephen Y
FIR - Stephen, Yeager
IR  - Howard Z
FIR - Howard, Zaren
IR  - Judy M
FIR - Judy, Miller
IR  - Breggia A
FIR - Breggia, Anne
IR  - Shroff RT
FIR - Shroff, Rachna T
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Pihl T
FIR - Pihl, Todd
IR  - Sun Q
FIR - Sun, Qiang
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wu Y
FIR - Wu, Ye
IR  - Jennifer S
FIR - Jennifer, Smith
IR  - Roggin K
FIR - Roggin, Kevin
IR  - Becker KF
FIR - Becker, Karl-Friedrich
IR  - Behera M
FIR - Behera, Madhusmita
IR  - Bennett J
FIR - Bennett, Joseph
IR  - Boice L
FIR - Boice, Lori
IR  - Burks E
FIR - Burks, Eric
IR  - Carlotti Junior CG
FIR - Carlotti Junior, Carlos Gilberto
IR  - Chabot J
FIR - Chabot, John
IR  - Pretti da Cunha Tirapelli D
FIR - Pretti da Cunha Tirapelli, Daniela
IR  - Sebastiao Dos Santos J
FIR - Sebastiao Dos Santos, Jose
IR  - Dubina M
FIR - Dubina, Michael
IR  - Eschbacher J
FIR - Eschbacher, Jennifer
IR  - Huang M
FIR - Huang, Mei
IR  - Huelsenbeck-Dill L
FIR - Huelsenbeck-Dill, Lori
IR  - Jenkins R
FIR - Jenkins, Roger
IR  - Karpov A
FIR - Karpov, Alexey
IR  - Kemp R
FIR - Kemp, Rafael
IR  - Lyadov V
FIR - Lyadov, Vladimir
IR  - Maithel S
FIR - Maithel, Shishir
IR  - Manikhas G
FIR - Manikhas, Georgy
IR  - Montgomery E
FIR - Montgomery, Eric
IR  - Noushmehr H
FIR - Noushmehr, Houtan
IR  - Osunkoya A
FIR - Osunkoya, Adeboye
IR  - Owonikoko T
FIR - Owonikoko, Taofeek
IR  - Paklina O
FIR - Paklina, Oxana
IR  - Potapova O
FIR - Potapova, Olga
IR  - Ramalingam S
FIR - Ramalingam, Suresh
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Rieger-Christ K
FIR - Rieger-Christ, Kimberly
IR  - Saller C
FIR - Saller, Charles
IR  - Setdikova G
FIR - Setdikova, Galiya
IR  - Shabunin A
FIR - Shabunin, Alexey
IR  - Sica G
FIR - Sica, Gabriel
IR  - Su T
FIR - Su, Tao
IR  - Sullivan T
FIR - Sullivan, Travis
IR  - Swanson P
FIR - Swanson, Pat
IR  - Tarvin K
FIR - Tarvin, Katherine
IR  - Tavobilov M
FIR - Tavobilov, Michael
IR  - Thorne LB
FIR - Thorne, Leigh B
IR  - Urbanski S
FIR - Urbanski, Stefan
IR  - Voronina O
FIR - Voronina, Olga
IR  - Wang T
FIR - Wang, Timothy
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Mallery D
FIR - Mallery, David
IR  - Morris S
FIR - Morris, Scott
IR  - Paulauskis J
FIR - Paulauskis, Joseph
IR  - Penny R
FIR - Penny, Robert
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Janssen KP
FIR - Janssen, Klaus-Peter
IR  - Bathe O
FIR - Bathe, Oliver
IR  - Bahary N
FIR - Bahary, Nathan
IR  - Slotta-Huspenina J
FIR - Slotta-Huspenina, Julia
IR  - Johns A
FIR - Johns, Amber
IR  - Hibshoosh H
FIR - Hibshoosh, Hanina
IR  - Hwang RF
FIR - Hwang, Rosa F
IR  - Sepulveda A
FIR - Sepulveda, Antonia
IR  - Radenbaugh A
FIR - Radenbaugh, Amie
IR  - Baylin SB
FIR - Baylin, Stephen B
IR  - Berrios M
FIR - Berrios, Mario
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Holbrook A
FIR - Holbrook, Andrea
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Mahurkar S
FIR - Mahurkar, Swapna
IR  - Triche TJ Jr.
FIR - Triche, Timothy J Jr.
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Chin L
FIR - Chin, Lynda
IR  - Kucherlapati R
FIR - Kucherlapati, Raju
IR  - Kucherlapati M
FIR - Kucherlapati, Melanie
IR  - Pantazi A
FIR - Pantazi, Angeliki
IR  - Park P
FIR - Park, Peter
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Voet D
FIR - Voet, Doug
IR  - Lin P
FIR - Lin, Pei
IR  - Frazer S
FIR - Frazer, Scott
IR  - Defreitas T
FIR - Defreitas, Timothy
IR  - Meier S
FIR - Meier, Sam
IR  - Chin L
FIR - Chin, Lynda
IR  - Kwon SY
FIR - Kwon, Sun Young
IR  - Kim YH
FIR - Kim, Yong Hoon
IR  - Park SJ
FIR - Park, Sang-Jae
IR  - Han SS
FIR - Han, Sung-Sik
IR  - Kim SH
FIR - Kim, Seong Hoon
IR  - Kim H
FIR - Kim, Hark
IR  - Furth E
FIR - Furth, Emma
IR  - Tempero M
FIR - Tempero, Margaret
IR  - Sander C
FIR - Sander, Chris
IR  - Biankin A
FIR - Biankin, Andrew
IR  - Chang D
FIR - Chang, David
IR  - Bailey P
FIR - Bailey, Peter
IR  - Gill A
FIR - Gill, Anthony
IR  - Kench J
FIR - Kench, James
IR  - Grimmond S
FIR - Grimmond, Sean
IR  - Johns A
FIR - Johns, Amber
IR  - Cancer Genome Initiative Apgi AP
FIR - Cancer Genome Initiative Apgi, Australian Pancreatic
IR  - Postier R
FIR - Postier, Russell
IR  - Zuna R
FIR - Zuna, Rosemary
IR  - Sicotte H
FIR - Sicotte, Hugues
IR  - Demchok JA
FIR - Demchok, John A
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Mills Shaw KR
FIR - Mills Shaw, Kenna R
IR  - Sheth M
FIR - Sheth, Margi
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Wang Z
FIR - Wang, Zhining
IR  - Yang L
FIR - Yang, Liming
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Felau I
FIR - Felau, Ina
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
EDAT- 2017/08/16 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/16 06:00
PHST- 2016/09/27 00:00 [received]
PHST- 2017/03/27 00:00 [revised]
PHST- 2017/07/17 00:00 [accepted]
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - S1535-6108(17)30299-4 [pii]
AID - 10.1016/j.ccell.2017.07.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.

PMID- 28810143
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20170919
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Genomic Evolution of Breast Cancer Metastasis and Relapse.
PG  - 169-184.e7
LID - S1535-6108(17)30297-0 [pii]
LID - 10.1016/j.ccell.2017.07.005 [doi]
AB  - Patterns of genomic evolution between primary and metastatic breast cancer have
      not been studied in large numbers, despite patients with metastatic breast cancer
      having dismal survival. We sequenced whole genomes or a panel of 365 genes on 299
      samples from 170 patients with locally relapsed or metastatic breast cancer.
      Several lines of analysis indicate that clones seeding metastasis or relapse
      disseminate late from primary tumors, but continue to acquire mutations, mostly
      accessing the same mutational processes active in the primary tumor. Most distant
      metastases acquired driver mutations not seen in the primary tumor, drawing from 
      a wider repertoire of cancer genes than early drivers. These include a number of 
      clinically actionable alterations and mutations inactivating SWI-SNF and
      JAK2-STAT3 pathways.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Yates, Lucy R
AU  - Yates LR
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Department of Clinical
      Oncology, Guys and St Thomas' NHS Trust, London SE1 9RT, UK.
FAU - Knappskog, Stian
AU  - Knappskog S
AD  - Section of Oncology, Department of Clinical Science, University of Bergen,
      Bergen, Norway; Department of Oncology, Haukeland University Hospital, Bergen,
      Norway.
FAU - Wedge, David
AU  - Wedge D
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Big Data Institute,
      University of Oxford, Oxford OX3 7BN, UK.
FAU - Farmery, James H R
AU  - Farmery JHR
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing
      Centre, Robinson Way, Cambridge CB2 0RE, UK.
FAU - Gonzalez, Santiago
AU  - Gonzalez S
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; European Bioinformatics
      Institute EMBL-EBI, Wellcome Genome Campus, Hinxton CB10 1SD, UK.
FAU - Martincorena, Inigo
AU  - Martincorena I
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Alexandrov, Ludmil B
AU  - Alexandrov LB
AD  - Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los
      Alamos, NM 87545, USA; Center for Nonlinear Studies, Los Alamos National
      Laboratory, Los Alamos, NM 87545, USA; University of New Mexico Comprehensive
      Cancer Center, Albuquerque, NM 87102, USA.
FAU - Van Loo, Peter
AU  - Van Loo P
AD  - The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Department of
      Human Genetics, University of Leuven, 3000 Leuven, Belgium.
FAU - Haugland, Hans Kristian
AU  - Haugland HK
AD  - Department of Pathology, Haukeland University Hospital, Bergen, Norway; The Gade 
      Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, 
      Bergen, Norway.
FAU - Lilleng, Peer Kaare
AU  - Lilleng PK
AD  - Department of Pathology, Haukeland University Hospital, Bergen, Norway; The Gade 
      Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, 
      Bergen, Norway.
FAU - Gundem, Gunes
AU  - Gundem G
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Computational Oncology,
      Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Institute, New
      York, NY 10065 USA.
FAU - Gerstung, Moritz
AU  - Gerstung M
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; European Bioinformatics
      Institute EMBL-EBI, Wellcome Genome Campus, Hinxton CB10 1SD, UK.
FAU - Pappaemmanuil, Elli
AU  - Pappaemmanuil E
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Computational Oncology,
      Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Institute, New
      York, NY 10065 USA.
FAU - Gazinska, Patrycja
AU  - Gazinska P
AD  - Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College
      London, London SE1 9RT, UK.
FAU - Bhosle, Shriram G
AU  - Bhosle SG
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Jones, David
AU  - Jones D
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Raine, Keiran
AU  - Raine K
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Mudie, Laura
AU  - Mudie L
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Latimer, Calli
AU  - Latimer C
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Sawyer, Elinor
AU  - Sawyer E
AD  - Department of Clinical Oncology, Guys and St Thomas' NHS Trust, London SE1 9RT,
      UK; Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's
      College London, London SE1 9RT, UK.
FAU - Desmedt, Christine
AU  - Desmedt C
AD  - Breast Cancer Translational Research Laboratory, Universite Libre de Bruxelles,
      Institut Jules Bordet, Bd de Waterloo 121, 1000 Brussels, Belgium.
FAU - Sotiriou, Christos
AU  - Sotiriou C
AD  - Breast Cancer Translational Research Laboratory, Universite Libre de Bruxelles,
      Institut Jules Bordet, Bd de Waterloo 121, 1000 Brussels, Belgium.
FAU - Stratton, Michael R
AU  - Stratton MR
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Sieuwerts, Anieta M
AU  - Sieuwerts AM
AD  - Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University
      Medical Center, Department of Medical Oncology, Rotterdam, the Netherlands.
FAU - Lynch, Andy G
AU  - Lynch AG
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing
      Centre, Robinson Way, Cambridge CB2 0RE, UK.
FAU - Martens, John W
AU  - Martens JW
AD  - Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University
      Medical Center, Department of Medical Oncology, Rotterdam, the Netherlands.
FAU - Richardson, Andrea L
AU  - Richardson AL
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA;
      Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Tutt, Andrew
AU  - Tutt A
AD  - Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College
      London, London SE1 9RT, UK; Breast Cancer Now Research Unit, King's College
      London, London SE1 9RT, UK; The Breast Cancer Now Toby Robins Research Centre,
      The Institute of Cancer Research, London SW3 6JB, UK.
FAU - Lonning, Per Eystein
AU  - Lonning PE
AD  - Section of Oncology, Department of Clinical Science, University of Bergen,
      Bergen, Norway; Department of Oncology, Haukeland University Hospital, Bergen,
      Norway. Electronic address: per.eystein.lonning@helse-bergen.no.
FAU - Campbell, Peter J
AU  - Campbell PJ
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. Electronic address:
      pc8@sanger.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chromosomal Proteins, Non-Histone)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - 0 (SWI-SNF-B chromatin-remodeling complex)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
CIN - Cancer Cell. 2017 Aug 14;32(2):131-133. PMID: 28810140
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Chromosomal Proteins, Non-Histone/antagonists & inhibitors/genetics
MH  - *Evolution, Molecular
MH  - Female
MH  - Humans
MH  - Janus Kinase 2/antagonists & inhibitors/genetics
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasm Metastasis/genetics
MH  - Neoplasm Recurrence, Local/*genetics
MH  - STAT3 Transcription Factor/antagonists & inhibitors/genetics
MH  - Transcription Factors/antagonists & inhibitors/genetics
PMC - PMC5559645
OTO - NOTNLM
OT  - breast cancer
OT  - genomics
OT  - metastasis
OT  - relapse
OT  - somatic mutation
EDAT- 2017/08/16 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/16 06:00
PHST- 2016/12/21 00:00 [received]
PHST- 2017/05/13 00:00 [revised]
PHST- 2017/07/14 00:00 [accepted]
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - S1535-6108(17)30297-0 [pii]
AID - 10.1016/j.ccell.2017.07.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):169-184.e7. doi: 10.1016/j.ccell.2017.07.005.

PMID- 28810142
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20170911
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Control of Metastasis by NK Cells.
PG  - 135-154
LID - S1535-6108(17)30260-X [pii]
LID - 10.1016/j.ccell.2017.06.009 [doi]
AB  - The metastatic spread of malignant cells to distant anatomical locations is a
      prominent cause of cancer-related death. Metastasis is governed by
      cancer-cell-intrinsic mechanisms that enable neoplastic cells to invade the local
      microenvironment, reach the circulation, and colonize distant sites, including
      the so-called epithelial-to-mesenchymal transition. Moreover, metastasis is
      regulated by microenvironmental and systemic processes, such as
      immunosurveillance. Here, we outline the cancer-cell-intrinsic and -extrinsic
      factors that regulate metastasis, discuss the key role of natural killer (NK)
      cells in the control of metastatic dissemination, and present potential
      therapeutic approaches to prevent or target metastatic disease by harnessing NK
      cells.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Lopez-Soto, Alejandro
AU  - Lopez-Soto A
AD  - Departamento de Biologia Funcional, Area de Inmunologia, Universidad de Oviedo,
      Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), 33006
      Oviedo, Asturias, Spain. Electronic address: lopezsalejandro@uniovi.es.
FAU - Gonzalez, Segundo
AU  - Gonzalez S
AD  - Departamento de Biologia Funcional, Area de Inmunologia, Universidad de Oviedo,
      Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), 33006
      Oviedo, Asturias, Spain.
FAU - Smyth, Mark J
AU  - Smyth MJ
AD  - Immunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia.
FAU - Galluzzi, Lorenzo
AU  - Galluzzi L
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY
      10065, USA; Sandra and Edward Meyer Cancer Center, New York, NY 10065, USA;
      Universite Paris Descartes/Paris V, 75006 Paris, France. Electronic address:
      deadoc@vodafone.it.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Animals
MH  - Humans
MH  - Immunologic Surveillance
MH  - Immunotherapy
MH  - Killer Cells, Natural/*immunology
MH  - Neoplasm Metastasis/*immunology/pathology/prevention & control
MH  - Neoplasms/immunology/pathology/*prevention & control
MH  - Tumor Escape
MH  - *Tumor Microenvironment
OTO - NOTNLM
OT  - ADCC
OT  - CTLA4
OT  - DNAM-1
OT  - NKG2D
OT  - PD-1
OT  - TGFB1
OT  - circulating tumor cells
OT  - disseminated tumor cells
OT  - immune checkpoint blockers
OT  - metastatic cascade
EDAT- 2017/08/16 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/16 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/05/21 00:00 [revised]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - S1535-6108(17)30260-X [pii]
AID - 10.1016/j.ccell.2017.06.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):135-154. doi: 10.1016/j.ccell.2017.06.009.

PMID- 28810141
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20170920
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.
PG  - 133-134
LID - S1535-6108(17)30305-7 [pii]
LID - 10.1016/j.ccell.2017.07.012 [doi]
AB  - In this issue of Cancer Cell, Saha et al. systematically test and optimize
      combination therapy strategies in a challenging model of glioblastoma. Durable
      complete responses were seen only when an oncolytic virus expressing IL12 was
      coupled with anti-CTLA-4 and anti-PD-1 therapeutics.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bell, John C
AU  - Bell JC
AD  - Department of Biochemistry, Microbiology and Immunology, University of Ottawa,
      Ottawa, ON, Canada; Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa,
      ON K1H 8L6, Canada. Electronic address: jbell@ohri.ca.
FAU - Ilkow, Carolina S
AU  - Ilkow CS
AD  - Department of Biochemistry, Microbiology and Immunology, University of Ottawa,
      Ottawa, ON, Canada; Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa,
      ON K1H 8L6, Canada.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Aug 14;32(2):253-267.e5. PMID: 28810147
MH  - Combined Modality Therapy
MH  - *Glioblastoma
MH  - Humans
MH  - *Immunotherapy
MH  - Oncolytic Virotherapy
MH  - Oncolytic Viruses
EDAT- 2017/08/16 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/08/16 06:00
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30305-7 [pii]
AID - 10.1016/j.ccell.2017.07.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):133-134. doi: 10.1016/j.ccell.2017.07.012.

PMID- 28810140
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20170920
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - New Views into the Genetic Landscape of Metastatic Breast Cancer.
PG  - 131-133
LID - S1535-6108(17)30304-5 [pii]
LID - 10.1016/j.ccell.2017.07.011 [doi]
AB  - Whether metastasis-specific genetic alterations exist remains controversial. The 
      study by Yates et al. in this issue of Cancer Cell provides evidence that
      metastases emerge late during primary breast cancer progression and that
      additional driver mutations are often acquired, posing both challenges and
      opportunities for precision treatment of metastatic breast cancer.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zhao, Xiaoyu
AU  - Zhao X
AD  - Molecular and Cellular Biology Program, Stony Brook University, Stony Brook, NY
      11794, USA.
FAU - Powers, Scott
AU  - Powers S
AD  - Department of Pathology, Stony Brook Medicine, Stony Brook, NY 11794, USA; Cold
      Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA. Electronic address: 
      scott.powers@stonybrook.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Aug 14;32(2):169-184.e7. PMID: 28810143
MH  - Breast Neoplasms/*genetics
MH  - Disease Progression
MH  - Humans
MH  - *Mutation
MH  - Neoplasm Metastasis
EDAT- 2017/08/16 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/08/16 06:00
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30304-5 [pii]
AID - 10.1016/j.ccell.2017.07.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):131-133. doi: 10.1016/j.ccell.2017.07.011.

PMID- 28810139
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20170920
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Cliques and Schisms of Cancer Genes.
PG  - 129-130
LID - S1535-6108(17)30302-1 [pii]
LID - 10.1016/j.ccell.2017.07.009 [doi]
AB  - With a few exceptions, cancers typically carry more than one driver mutation,
      sometimes five, ten, or more, and these driver mutations do not necessarily
      assort randomly. In this issue of Cancer Cell, Mina et al. systematically
      characterize patterns of co-mutation and mutual exclusivity in 6,456 cancers
      across 23 tumor types.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Campbell, Peter J
AU  - Campbell PJ
AD  - Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
      Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK.
      Electronic address: pc8@sanger.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Aug 14;32(2):155-168.e6. PMID: 28756993
MH  - *Algorithms
MH  - *Computational Biology
MH  - Humans
MH  - Mutation
MH  - Neoplasms/genetics
MH  - Oncogenes
EDAT- 2017/08/16 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/08/16 06:00
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30302-1 [pii]
AID - 10.1016/j.ccell.2017.07.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):129-130. doi: 10.1016/j.ccell.2017.07.009.

PMID- 28781121
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20170911
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell
      Subpopulations from Lethal Drug Exposure.
PG  - 221-237.e13
LID - S1535-6108(17)30294-5 [pii]
LID - 10.1016/j.ccell.2017.07.002 [doi]
AB  - Maintenance of phenotypic heterogeneity within cell populations is an
      evolutionarily conserved mechanism that underlies population survival upon
      stressful exposures. We show that the genomes of a cancer cell subpopulation that
      survives treatment with otherwise lethal drugs, the drug-tolerant persisters
      (DTPs), exhibit a repressed chromatin state characterized by increased
      methylation of histone H3 lysines 9 and 27 (H3K9 and H3K27). We also show that
      survival of DTPs is, in part, maintained by regulators of H3K9me3-mediated
      heterochromatin formation and that the observed increase in H3K9me3 in DTPs is
      most prominent over long interspersed repeat element 1 (LINE-1). Disruption of
      the repressive chromatin over LINE-1 elements in DTPs results in DTP ablation,
      which is partially rescued by reducing LINE-1 expression or function.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Guler, Gulfem Dilek
AU  - Guler GD
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Tindell, Charles Albert
AU  - Tindell CA
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Pitti, Robert
AU  - Pitti R
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Wilson, Catherine
AU  - Wilson C
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Nichols, Katrina
AU  - Nichols K
AD  - Protein Chemistry, Genentech Inc., South San Francisco, CA, USA.
FAU - KaiWai Cheung, Tommy
AU  - KaiWai Cheung T
AD  - Protein Chemistry, Genentech Inc., South San Francisco, CA, USA.
FAU - Kim, Hyo-Jin
AU  - Kim HJ
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Wongchenko, Matthew
AU  - Wongchenko M
AD  - LS Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
FAU - Yan, Yibing
AU  - Yan Y
AD  - LS Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
FAU - Haley, Benjamin
AU  - Haley B
AD  - Molecular Biology, Genentech Inc., South San Francisco, CA, USA.
FAU - Cuellar, Trinna
AU  - Cuellar T
AD  - Molecular Biology, Genentech Inc., South San Francisco, CA, USA.
FAU - Webster, Joshua
AU  - Webster J
AD  - Pathology, Genentech Inc., South San Francisco, CA, USA.
FAU - Alag, Navneet
AU  - Alag N
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Hegde, Ganapati
AU  - Hegde G
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Jackson, Erica
AU  - Jackson E
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Nance, Tracy Leah
AU  - Nance TL
AD  - Epinomics, Menlo Park, CA, USA.
FAU - Giresi, Paul Garrett
AU  - Giresi PG
AD  - Epinomics, Menlo Park, CA, USA.
FAU - Chen, Kuan-Bei
AU  - Chen KB
AD  - Active Motif, Carlsbad, CA, USA.
FAU - Liu, Jinfeng
AU  - Liu J
AD  - Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
FAU - Jhunjhunwala, Suchit
AU  - Jhunjhunwala S
AD  - Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
FAU - Settleman, Jeff
AU  - Settleman J
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA.
FAU - Stephan, Jean-Philippe
AU  - Stephan JP
AD  - Protein Chemistry, Genentech Inc., South San Francisco, CA, USA.
FAU - Arnott, David
AU  - Arnott D
AD  - Protein Chemistry, Genentech Inc., South San Francisco, CA, USA.
FAU - Classon, Marie
AU  - Classon M
AD  - Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080,
      USA. Electronic address: classon.marie@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20170803
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chromatin)
RN  - 0 (Histones)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Chromatin/*genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Epigenetic Repression/*drug effects
MH  - Gene Expression Regulation, Neoplastic
MH  - Genomic Instability/drug effects
MH  - Histone-Lysine N-Methyltransferase/metabolism
MH  - Histones/metabolism
MH  - Humans
MH  - Long Interspersed Nucleotide Elements/*genetics
MH  - Methylation
MH  - Mice
MH  - Mice, Nude
MH  - Mice, SCID
MH  - Neoplasms/drug therapy/genetics/*pathology
MH  - Stress, Physiological
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - ATRX
OT  - G9a
OT  - H3.3
OT  - H3K9-methylation
OT  - HDACs
OT  - HP1gamma
OT  - LINE-1
OT  - SETDB1
OT  - cancer cell heterogeneity
OT  - chromatin
EDAT- 2017/08/07 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/08 06:00
PHST- 2016/08/24 00:00 [received]
PHST- 2017/05/02 00:00 [revised]
PHST- 2017/07/05 00:00 [accepted]
PHST- 2017/08/07 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
PHST- 2017/08/08 06:00 [entrez]
AID - S1535-6108(17)30294-5 [pii]
AID - 10.1016/j.ccell.2017.07.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):221-237.e13. doi: 10.1016/j.ccell.2017.07.002.
      Epub 2017 Aug 3.

PMID- 28756993
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20170919
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Aug 14
TI  - Conditional Selection of Genomic Alterations Dictates Cancer Evolution and
      Oncogenic Dependencies.
PG  - 155-168.e6
LID - S1535-6108(17)30261-1 [pii]
LID - 10.1016/j.ccell.2017.06.010 [doi]
AB  - Cancer evolves through the emergence and selection of molecular alterations.
      Cancer genome profiling has revealed that specific events are more or less likely
      to be co-selected, suggesting that the selection of one event depends on the
      others. However, the nature of these evolutionary dependencies and their impact
      remain unclear. Here, we designed SELECT, an algorithmic approach to
      systematically identify evolutionary dependencies from alteration patterns. By
      analyzing 6,456 genomes from multiple tumor types, we constructed a map of
      oncogenic dependencies associated with cellular pathways, transcriptional
      readouts, and therapeutic response. Finally, modeling of cancer evolution shows
      that alteration dependencies emerge only under conditional selection. These
      results provide a framework for the design of strategies to predict cancer
      progression and therapeutic response.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Mina, Marco
AU  - Mina M
AD  - Department of Computational Biology, University of Lausanne (UNIL), 1011
      Lausanne, Vaud, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne,
      Switzerland.
FAU - Raynaud, Franck
AU  - Raynaud F
AD  - Department of Computational Biology, University of Lausanne (UNIL), 1011
      Lausanne, Vaud, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne,
      Switzerland.
FAU - Tavernari, Daniele
AU  - Tavernari D
AD  - Department of Computational Biology, University of Lausanne (UNIL), 1011
      Lausanne, Vaud, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne,
      Switzerland.
FAU - Battistello, Elena
AU  - Battistello E
AD  - Department of Computational Biology, University of Lausanne (UNIL), 1011
      Lausanne, Vaud, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne,
      Switzerland; Swiss Institute for Experimental Cancer Research (ISREC), Ecole
      Polytechnique Federale Lausanne (EPFL), 1015 Lausanne, Vaud, Switzerland.
FAU - Sungalee, Stephanie
AU  - Sungalee S
AD  - Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique
      Federale Lausanne (EPFL), 1015 Lausanne, Vaud, Switzerland.
FAU - Saghafinia, Sadegh
AU  - Saghafinia S
AD  - Department of Computational Biology, University of Lausanne (UNIL), 1011
      Lausanne, Vaud, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne,
      Switzerland; Swiss Institute for Experimental Cancer Research (ISREC), Ecole
      Polytechnique Federale Lausanne (EPFL), 1015 Lausanne, Vaud, Switzerland.
FAU - Laessle, Titouan
AU  - Laessle T
AD  - Department of Computational Biology, University of Lausanne (UNIL), 1011
      Lausanne, Vaud, Switzerland.
FAU - Sanchez-Vega, Francisco
AU  - Sanchez-Vega F
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY, USA.
FAU - Schultz, Nikolaus
AU  - Schultz N
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and
      Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Oricchio, Elisa
AU  - Oricchio E
AD  - Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique
      Federale Lausanne (EPFL), 1015 Lausanne, Vaud, Switzerland.
FAU - Ciriello, Giovanni
AU  - Ciriello G
AD  - Department of Computational Biology, University of Lausanne (UNIL), 1011
      Lausanne, Vaud, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne,
      Switzerland. Electronic address: giovanni.ciriello@unil.ch.
LA  - eng
PT  - Journal Article
DEP - 20170727
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CIN - Cancer Cell. 2017 Aug 14;32(2):129-130. PMID: 28810139
MH  - *Algorithms
MH  - *Carcinogenesis
MH  - *Evolution, Molecular
MH  - Gene Expression Profiling
MH  - Genomics
MH  - Humans
MH  - Models, Genetic
MH  - Neoplasms/*genetics
MH  - *Selection, Genetic
OTO - NOTNLM
OT  - cancer evolution
OT  - conditional selection
OT  - interdependent therapeutic response
OT  - oncogenic dependencies
OT  - selected events
EDAT- 2017/08/02 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/01 06:00
PHST- 2017/02/28 00:00 [received]
PHST- 2017/06/05 00:00 [revised]
PHST- 2017/06/26 00:00 [accepted]
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
PHST- 2017/08/01 06:00 [entrez]
AID - S1535-6108(17)30261-1 [pii]
AID - 10.1016/j.ccell.2017.06.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Aug 14;32(2):155-168.e6. doi: 10.1016/j.ccell.2017.06.010. Epub
      2017 Jul 27.

PMID- 28697345
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.
PG  - 9-25
LID - S1535-6108(17)30255-6 [pii]
LID - 10.1016/j.ccell.2017.06.005 [doi]
AB  - Small-molecule chemical probes or tools have become progressively more important 
      in recent years as valuable reagents to investigate fundamental biological
      mechanisms and processes causing disease, including cancer. Chemical probes have 
      also achieved greater prominence alongside complementary biological reagents for 
      target validation in drug discovery. However, there is evidence of widespread
      continuing misuse and promulgation of poor-quality and insufficiently selective
      chemical probes, perpetuating a worrisome and misleading pollution of the
      scientific literature. We discuss current challenges with the selection and use
      of chemical probes, and suggest how biologists can and should be more
      discriminating in the probes they employ.
CI  - Crown Copyright (c) 2017. Published by Elsevier Inc. All rights reserved.
FAU - Blagg, Julian
AU  - Blagg J
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK. Electronic address: julian.blagg@icr.ac.uk.
FAU - Workman, Paul
AU  - Workman P
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK. Electronic address: paul.workman@icr.ac.uk.
LA  - eng
GR  - C309/A11566/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Molecular Probes)
SB  - IM
EIN - Cancer Cell. 2017 Aug 14;32(2):268-270. PMID: 28810148
MH  - Humans
MH  - Molecular Probes/chemistry/*standards
MH  - Neoplasms/metabolism/*pathology/physiopathology
MH  - Research Design/*standards
PMC - PMC5511331
OTO - NOTNLM
OT  - *PAINS
OT  - *Pan-Assay Interference Compounds
OT  - *biochemical selectivity
OT  - *chemical probe
OT  - *chemical reactivity
OT  - *chemical tool
OT  - *ligand promiscuity
OT  - *lipophilicity
OT  - *pharmacological audit trail
OT  - *pharmacophore crossing
OT  - *target validation
EDAT- 2017/07/12 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/03/27 00:00 [received]
PHST- 2017/05/31 00:00 [revised]
PHST- 2017/06/09 00:00 [accepted]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - S1535-6108(17)30255-6 [pii]
AID - 10.1016/j.ccell.2017.06.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):9-25. doi: 10.1016/j.ccell.2017.06.005.

PMID- 28697344
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to
      Impart Gemcitabine Resistance to Pancreatic Cancer.
PG  - 71-87.e7
LID - S1535-6108(17)30254-4 [pii]
LID - 10.1016/j.ccell.2017.06.004 [doi]
AB  - Poor response to cancer therapy due to resistance remains a clinical challenge.
      The present study establishes a widely prevalent mechanism of resistance to
      gemcitabine in pancreatic cancer, whereby increased glycolytic flux leads to
      glucose addiction in cancer cells and a corresponding increase in pyrimidine
      biosynthesis to enhance the intrinsic levels of deoxycytidine triphosphate
      (dCTP). Increased levels of dCTP diminish the effective levels of gemcitabine
      through molecular competition. We also demonstrate that MUC1-regulated
      stabilization of hypoxia inducible factor-1alpha (HIF-1alpha) mediates such
      metabolic reprogramming. Targeting HIF-1alpha or de novo pyrimidine biosynthesis,
      in combination with gemcitabine, strongly diminishes tumor burden. Finally,
      reduced expression of TKT and CTPS, which regulate flux into pyrimidine
      biosynthesis, correlates with better prognosis in pancreatic cancer patients on
      fluoropyrimidine analogs.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Shukla, Surendra K
AU  - Shukla SK
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Purohit, Vinee
AU  - Purohit V
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA; Department of Pathology and
      Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
FAU - Mehla, Kamiya
AU  - Mehla K
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Gunda, Venugopal
AU  - Gunda V
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Chaika, Nina V
AU  - Chaika NV
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Vernucci, Enza
AU  - Vernucci E
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - King, Ryan J
AU  - King RJ
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Abrego, Jaime
AU  - Abrego J
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Goode, Gennifer D
AU  - Goode GD
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Dasgupta, Aneesha
AU  - Dasgupta A
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Illies, Alysha L
AU  - Illies AL
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Gebregiworgis, Teklab
AU  - Gebregiworgis T
AD  - Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
FAU - Dai, Bingbing
AU  - Dai B
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Augustine, Jithesh J
AU  - Augustine JJ
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Murthy, Divya
AU  - Murthy D
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Attri, Kuldeep S
AU  - Attri KS
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Mashadova, Oksana
AU  - Mashadova O
AD  - Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Grandgenett, Paul M
AU  - Grandgenett PM
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Powers, Robert
AU  - Powers R
AD  - Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
FAU - Ly, Quan P
AU  - Ly QP
AD  - Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198,
      USA.
FAU - Lazenby, Audrey J
AU  - Lazenby AJ
AD  - Department of Pathology and Microbiology, University of Nebraska Medical Center, 
      Omaha, NE 68198, USA.
FAU - Grem, Jean L
AU  - Grem JL
AD  - Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
      68198, USA.
FAU - Yu, Fang
AU  - Yu F
AD  - Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE
      68198, USA.
FAU - Mates, Jose M
AU  - Mates JM
AD  - Department of Molecular Biology and Biochemistry, University of Malaga and IBIMA,
      29071 Malaga, Spain.
FAU - Asara, John M
AU  - Asara JM
AD  - Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Kim, Jung-Whan
AU  - Kim JW
AD  - Department of Biological Sciences, The University of Texas at Dallas, 800 West
      Campbell Road, Richardson, TX 75080, USA.
FAU - Hankins, Jordan H
AU  - Hankins JH
AD  - Department of Radiology, University of Nebraska Medical Center, Omaha, NE 68198, 
      USA.
FAU - Weekes, Colin
AU  - Weekes C
AD  - Division of Medical Oncology, University of Colorado School of Medicine, Aurora, 
      CO 80045, USA.
FAU - Hollingsworth, Michael A
AU  - Hollingsworth MA
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA.
FAU - Serkova, Natalie J
AU  - Serkova NJ
AD  - Department of Anesthesiology, University of Colorado Denver, Aurora, CO 80045,
      USA.
FAU - Sasson, Aaron R
AU  - Sasson AR
AD  - Department of Surgery, Health Sciences Center T18-065, Stony Brook Medicine,
      Stony Brook, NY 11794, USA.
FAU - Fleming, Jason B
AU  - Fleming JB
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Oliveto, Jennifer M
AU  - Oliveto JM
AD  - Department of Radiology, University of Nebraska Medical Center, Omaha, NE 68198, 
      USA.
FAU - Lyssiotis, Costas A
AU  - Lyssiotis CA
AD  - Department of Molecular and Integrative Physiology, University of Michigan, Ann
      Arbor, MI 48103, USA.
FAU - Cantley, Lewis C
AU  - Cantley LC
AD  - Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Berim, Lyudmyla
AU  - Berim L
AD  - Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
      68198, USA.
FAU - Singh, Pankaj K
AU  - Singh PK
AD  - Eppley Institute for Research in Cancer and Allied Diseases, University of
      Nebraska Medical Center, Omaha, NE 68198-5950, USA; Department of Pathology and
      Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
      Electronic address: pankaj.singh@unmc.edu.
LA  - eng
GR  - R01 CA216853/CA/NCI NIH HHS/United States
GR  - U54 CA163120/CA/NCI NIH HHS/United States
GR  - P01 CA117969/CA/NCI NIH HHS/United States
GR  - 13-20-25-SING/None/International
GR  - P30 GM106397/GM/NIGMS NIH HHS/United States
GR  - P30 CA046934/CA/NCI NIH HHS/United States
GR  - P50 CA127297/CA/NCI NIH HHS/United States
GR  - P30 CA036727/CA/NCI NIH HHS/United States
GR  - R01 CA163649/CA/NCI NIH HHS/United States
GR  - R01 CA210439/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - 0 (Pyrimidines)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 73K4184T59 (Digoxin)
RN  - 7440-44-0 (Carbon)
RN  - B76N6SBZ8R (gemcitabine)
RN  - IY9XDZ35W2 (Glucose)
RN  - K8CXK5Q32L (pyrimidine)
SB  - IM
CIN - Cancer Cell. 2017 Jul 10;32(1):3-5. PMID: 28697341
EIN - Cancer Cell. 2017 Sep 11;32(3):392. PMID: 28898700
MH  - Carbon/metabolism
MH  - Deoxycytidine/*analogs & derivatives/therapeutic use
MH  - Digoxin/pharmacology
MH  - *Drug Resistance, Neoplasm
MH  - Glucose/*metabolism
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors/*metabolism
MH  - Mucin-1/*metabolism
MH  - Pancreatic Neoplasms/*drug therapy/genetics/metabolism
MH  - Pentose Phosphate Pathway
MH  - Prognosis
MH  - Pyrimidines/biosynthesis
MH  - Signal Transduction
PMC - PMC5533091
MID - NIHMS884517
OTO - NOTNLM
OT  - *HIF-1alpha
OT  - *MUC1
OT  - *cancer metabolism
OT  - *chemotherapy resistance
OT  - *gemcitabine
OT  - *mucin
OT  - *non-oxidative pentose phosphate pathway
OT  - *nucleotide synthesis
OT  - *pancreatic cancer
OT  - *pyrimidine biosynthesis
EDAT- 2017/07/12 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/12 06:00
PMCR- 2018/07/10 00:00
PHST- 2016/06/13 00:00 [received]
PHST- 2017/03/01 00:00 [revised]
PHST- 2017/06/08 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - S1535-6108(17)30254-4 [pii]
AID - 10.1016/j.ccell.2017.06.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004.

PMID- 28697343
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the
      LATITUDE and STAMPEDE Studies.
PG  - 6-8
LID - S1535-6108(17)30258-1 [pii]
LID - 10.1016/j.ccell.2017.06.007 [doi]
AB  - Two papers published recently in the New England Journal of Medicine describe the
      utility of abiraterone acetate, an androgen biosynthesis inhibitor, in the early 
      treatment of metastatic prostate cancer. In addition to establishing a new
      standard of care, these two articles pose a number of important questions for
      future investigation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Small, Eric J
AU  - Small EJ
AD  - University of California, San Francisco, CA, USA. Electronic address:
      eric.small@ucsf.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - EC 1.14.14.19 (CYP17A1 protein, human)
RN  - EC 1.14.14.19 (Steroid 17-alpha-Hydroxylase)
RN  - EM5OCB9YJ6 (Abiraterone Acetate)
SB  - IM
EIN - Cancer Cell. 2017 Sep 11;32(3):392. PMID: 28898699
MH  - Abiraterone Acetate/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*drug therapy/pathology
MH  - Steroid 17-alpha-Hydroxylase/antagonists & inhibitors
EDAT- 2017/07/12 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - S1535-6108(17)30258-1 [pii]
AID - 10.1016/j.ccell.2017.06.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):6-8. doi: 10.1016/j.ccell.2017.06.007.

PMID- 28697342
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with
      Immunological Changes in the Microenvironment.
PG  - 42-56.e6
LID - S1535-6108(17)30253-2 [pii]
LID - 10.1016/j.ccell.2017.06.003 [doi]
AB  - We leveraged IDH wild-type glioblastomas, derivative neurospheres, and
      single-cell gene expression profiles to define three tumor-intrinsic
      transcriptional subtypes designated as proneural, mesenchymal, and classical.
      Transcriptomic subtype multiplicity correlated with increased intratumoral
      heterogeneity and presence of tumor microenvironment. In silico cell sorting
      identified macrophages/microglia, CD4(+) T lymphocytes, and neutrophils in the
      glioma microenvironment. NF1 deficiency resulted in increased tumor-associated
      macrophages/microglia infiltration. Longitudinal transcriptome analysis showed
      that expression subtype is retained in 55% of cases. Gene signature-based tumor
      microenvironment inference revealed a decrease in invading monocytes and a
      subtype-dependent increase in macrophages/microglia cells upon disease
      recurrence. Hypermutation at diagnosis or at recurrence associated with CD8(+) T 
      cell enrichment. Frequency of M2 macrophages detection associated with short-term
      relapse after radiation therapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Wang, Qianghu
AU  - Wang Q
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Radiation Oncology, The University 
      of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of
      Bioinformatics and Computational Biology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Hu, Baoli
AU  - Hu B
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Hu, Xin
AU  - Hu X
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; University of Texas-Houston Graduate School in
      Biomedical Sciences, Houston, TX 77030, USA.
FAU - Kim, Hoon
AU  - Kim H
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; The Jackson Laboratory for Genomic Medicine,
      Farmington, CT, USA.
FAU - Squatrito, Massimo
AU  - Squatrito M
AD  - Cancer Cell Biology Programme, Seve Ballesteros Foundation Brain Tumor Group,
      Centro Nacional de Investigaciones Oncologicas, CNIO, 28029 Madrid, Spain.
FAU - Scarpace, Lisa
AU  - Scarpace L
AD  - Departments of Neurology and Neurosurgery, Henry Ford Hospital, Detroit, MI
      48202, USA.
FAU - deCarvalho, Ana C
AU  - deCarvalho AC
AD  - Departments of Neurology and Neurosurgery, Henry Ford Hospital, Detroit, MI
      48202, USA.
FAU - Lyu, Sali
AU  - Lyu S
AD  - Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical 
      University, Nanjing 211166, China; Collaborative Innovation Center for
      Cardiovascular Disease, Nanjing Medical University, Nanjing 211166, China.
FAU - Li, Pengping
AU  - Li P
AD  - Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical 
      University, Nanjing 211166, China; Collaborative Innovation Center for
      Cardiovascular Disease, Nanjing Medical University, Nanjing 211166, China.
FAU - Li, Yan
AU  - Li Y
AD  - Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical 
      University, Nanjing 211166, China; Collaborative Innovation Center for
      Cardiovascular Disease, Nanjing Medical University, Nanjing 211166, China.
FAU - Barthel, Floris
AU  - Barthel F
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; The Jackson Laboratory for Genomic Medicine,
      Farmington, CT, USA.
FAU - Cho, Hee Jin
AU  - Cho HJ
AD  - Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351,
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute
      for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea.
FAU - Lin, Yu-Hsi
AU  - Lin YH
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, Houston, TX 77030, USA.
FAU - Satani, Nikunj
AU  - Satani N
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, Houston, TX 77030, USA.
FAU - Martinez-Ledesma, Emmanuel
AU  - Martinez-Ledesma E
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Zheng, Siyuan
AU  - Zheng S
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Chang, Edward
AU  - Chang E
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Sauve, Charles-Etienne Gabriel
AU  - Sauve CG
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Olar, Adriana
AU  - Olar A
AD  - Departments of Pathology and Laboratory Medicine, Neurosurgery Medical University
      of South Carolina, and Hollings Cancer Center, Charleston, SC 29425, USA.
FAU - Lan, Zheng D
AU  - Lan ZD
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Finocchiaro, Gaetano
AU  - Finocchiaro G
AD  - Unit of Molecular Neuro-Oncology, Fondazione IRCCS Istituto Neurologico C. Besta,
      20133 Milano, Italy.
FAU - Phillips, Joanna J
AU  - Phillips JJ
AD  - Department of Neurological Surgery, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Berger, Mitchel S
AU  - Berger MS
AD  - Department of Neurological Surgery, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Gabrusiewicz, Konrad R
AU  - Gabrusiewicz KR
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Wang, Guocan
AU  - Wang G
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Eskilsson, Eskil
AU  - Eskilsson E
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Hu, Jian
AU  - Hu J
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Mikkelsen, Tom
AU  - Mikkelsen T
AD  - Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical 
      University, Nanjing 211166, China.
FAU - DePinho, Ronald A
AU  - DePinho RA
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Muller, Florian
AU  - Muller F
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Cancer Systems Imaging, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Heimberger, Amy B
AU  - Heimberger AB
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Sulman, Erik P
AU  - Sulman EP
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Radiation Oncology, The University 
      of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of
      Translational Molecular Pathology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA. Electronic address: epsulman@mdanderson.org.
FAU - Nam, Do-Hyun
AU  - Nam DH
AD  - Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351,
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute
      for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea; 
      Department of Neurosurgery Samsung Medical Center, Sungkyunkwan University School
      of Medicine, Seoul, 06351, Korea. Electronic address: nsnam@skku.edu.
FAU - Verhaak, Roel G W
AU  - Verhaak RGW
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational
      Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030,
      USA; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic
      address: roel.verhaak@jax.org.
LA  - eng
GR  - R01 CA120813/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA190121/CA/NCI NIH HHS/United States
GR  - P30 CA034196/CA/NCI NIH HHS/United States
GR  - K99 CA194289/CA/NCI NIH HHS/United States
GR  - P50 CA097257/CA/NCI NIH HHS/United States
GR  - P50 CA127001/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
EIN - Cancer Cell. 2018 Jan 8;33(1):152. PMID: 29316430
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Glioblastoma/*genetics/immunology/pathology
MH  - Humans
MH  - Phenotype
MH  - Recurrence
MH  - Survival Analysis
MH  - T-Lymphocytes/immunology
MH  - Tumor Microenvironment/*immunology
PMC - PMC5599156
MID - NIHMS885291
OTO - NOTNLM
OT  - *disease recurrence
OT  - *glioblastoma
OT  - *immune cells
OT  - *macrophages/microglia
OT  - *mesenchymal subtype
OT  - *proneural to mesenchymal transition
OT  - *tumor evolution
OT  - *tumor microenvironment
EDAT- 2017/07/12 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/12 06:00
PMCR- 2018/07/10 00:00
PHST- 2016/08/19 00:00 [received]
PHST- 2017/04/17 00:00 [revised]
PHST- 2017/06/08 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - S1535-6108(17)30253-2 [pii]
AID - 10.1016/j.ccell.2017.06.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003.

PMID- 28697341
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine
      Resistance in Pancreatic Cancer.
PG  - 3-5
LID - S1535-6108(17)30257-X [pii]
LID - 10.1016/j.ccell.2017.06.006 [doi]
AB  - In this issue of Cancer Cell, Singh and colleagues report a role for MUC1-induced
      HIF expression in rewiring ribose synthesis, which drives pyridimine production
      as a possible resistance mechanism to gemcitabine, adding to complexity and
      multiple paths to resistance.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Dang, Chi V
AU  - Dang CV
AD  - Ludwig Institute for Cancer Research, New York, NY 10017, USA; The Wistar
      Institute, Philadelphia, PA 19104, USA. Electronic address: cdang@licr.org.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA057341/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Pyrimidines)
RN  - 0W860991D6 (Deoxycytidine)
SB  - IM
CON - Cancer Cell. 2017 Jul 10;32(1):71-87.e7. PMID: 28697344
MH  - Antimetabolites, Antineoplastic
MH  - *Cell Line, Tumor
MH  - Deoxycytidine
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Humans
MH  - Pancreatic Neoplasms
MH  - Pyrimidines
EDAT- 2017/07/12 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30257-X [pii]
AID - 10.1016/j.ccell.2017.06.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):3-5. doi: 10.1016/j.ccell.2017.06.006.

PMID- 28697340
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - Stabilization of the c-Myc Protein by CAMKIIgamma Promotes T Cell Lymphoma.
PG  - 115-128.e7
LID - S1535-6108(17)30251-9 [pii]
LID - 10.1016/j.ccell.2017.06.001 [doi]
AB  - Although high c-Myc protein expression is observed alongside MYC amplification in
      some cancers, in most cases protein overexpression occurs in the absence of gene 
      amplification, e.g., T cell lymphoma (TCL). Here, Ca(2+)/calmodulin-dependent
      protein kinase II gamma (CAMKIIgamma) was shown to stabilize the c-Myc protein by
      directly phosphorylating it at serine 62 (S62). Furthermore, CAMKIIgamma was
      shown to be essential for tumor maintenance. Inhibition of CAMKIIgamma with a
      specific inhibitor destabilized c-Myc and reduced tumor burden. Importantly, high
      CAMKIIgamma levels in patient TCL specimens correlate with increased c-Myc and
      pS62-c-Myc levels. Together, the CAMKIIgamma:c-Myc axis critically influences the
      development and maintenance of TCL and represents a potential therapeutic target 
      for TCL.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gu, Ying
AU  - Gu Y
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA.
FAU - Zhang, Jiawei
AU  - Zhang J
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA.
FAU - Ma, Xiaoxiao
AU  - Ma X
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA; Irell & Manella Graduate School of Biological Sciences, Beckman
      Research Institute, City of Hope, Duarte, CA 91010, USA.
FAU - Kim, Byung-Wook
AU  - Kim BW
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA; Irell & Manella Graduate School of Biological Sciences, Beckman
      Research Institute, City of Hope, Duarte, CA 91010, USA.
FAU - Wang, Hailong
AU  - Wang H
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA.
FAU - Li, Jinfan
AU  - Li J
AD  - Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang
      University, Hangzhou 310009, China.
FAU - Pan, Yi
AU  - Pan Y
AD  - Department of Pathology, National Clinical Research Center for Cancer, Key
      Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer
      Institute and Hospital, Tianjin 300060, China.
FAU - Xu, Yang
AU  - Xu Y
AD  - Department of Hematology, Second Affiliated Hospital, School of Medicine,
      Zhejiang University, Hangzhou 310009, China; Cancer Institute (Key Laboratory of 
      Cancer Prevention and Intervention, China National Ministry of Education), Second
      Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009,
      China.
FAU - Ding, Lili
AU  - Ding L
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA.
FAU - Yang, Lu
AU  - Yang L
AD  - The Integrative Genomics Core, Beckman Research Institute, City of Hope, Duarte, 
      CA 91010, USA.
FAU - Guo, Chao
AU  - Guo C
AD  - The Integrative Genomics Core, Beckman Research Institute, City of Hope, Duarte, 
      CA 91010, USA.
FAU - Wu, Xiwei
AU  - Wu X
AD  - The Integrative Genomics Core, Beckman Research Institute, City of Hope, Duarte, 
      CA 91010, USA.
FAU - Wu, Jun
AU  - Wu J
AD  - Division of Comparative Medicine, Beckman Research Institute, City of Hope,
      Duarte, CA 91010, USA.
FAU - Wu, Kirk
AU  - Wu K
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA.
FAU - Gan, Xiaoxian
AU  - Gan X
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA.
FAU - Li, Gang
AU  - Li G
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA.
FAU - Li, Ling
AU  - Li L
AD  - Division of Hematopoietic Stem Cell & Leukemia Research, Beckman Research
      Institute, City of Hope, Duarte, CA 91010, USA.
FAU - Forman, Stephen J
AU  - Forman SJ
AD  - Irell & Manella Graduate School of Biological Sciences, Beckman Research
      Institute, City of Hope, Duarte, CA 91010, USA; Department of Hematology &
      Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope,
      Duarte, CA 91010, USA.
FAU - Chan, Wing-Chung
AU  - Chan WC
AD  - Irell & Manella Graduate School of Biological Sciences, Beckman Research
      Institute, City of Hope, Duarte, CA 91010, USA; Department of Pathology, Beckman 
      Research Institute, City of Hope, Duarte, CA 91010, USA.
FAU - Xu, Rongzhen
AU  - Xu R
AD  - Department of Hematology, Second Affiliated Hospital, School of Medicine,
      Zhejiang University, Hangzhou 310009, China; Cancer Institute (Key Laboratory of 
      Cancer Prevention and Intervention, China National Ministry of Education), Second
      Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009,
      China. Electronic address: zrxyk10@zju.edu.cn.
FAU - Huang, Wendong
AU  - Huang W
AD  - Molecular and Cellular Biology of Cancer Program & Department of Diabetes
      Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte,
      CA 91010, USA; Irell & Manella Graduate School of Biological Sciences, Beckman
      Research Institute, City of Hope, Duarte, CA 91010, USA. Electronic address:
      whuang@coh.org.
LA  - eng
GR  - P30 CA033572/CA/NCI NIH HHS/United States
GR  - R00 CA184411/CA/NCI NIH HHS/United States
GR  - R01 CA139158/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Benzylisoquinolines)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinase Type 2)
RN  - V5KM4XJ0WM (berbamine)
SB  - IM
MH  - Animals
MH  - Benzylisoquinolines/pharmacology
MH  - Calcium-Calmodulin-Dependent Protein Kinase Type 2/antagonists &
      inhibitors/genetics/*physiology
MH  - Cell Proliferation
MH  - Gene Deletion
MH  - Heterografts/metabolism
MH  - Humans
MH  - Lymphoma, T-Cell/*metabolism/pathology
MH  - Mice
MH  - Models, Molecular
MH  - Phosphorylation
MH  - Proto-Oncogene Proteins c-myc/genetics/metabolism/*physiology
PMC - PMC5552197
MID - NIHMS887301
OTO - NOTNLM
OT  - *CAMKIIgamma
OT  - *T cell lymphoma
OT  - *c-MYC
OT  - *c-Myc stabilization
OT  - *phosphorylation
EDAT- 2017/07/12 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/12 06:00
PMCR- 2018/07/10 00:00
PHST- 2016/06/24 00:00 [received]
PHST- 2017/04/19 00:00 [revised]
PHST- 2017/06/08 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - S1535-6108(17)30251-9 [pii]
AID - 10.1016/j.ccell.2017.06.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):115-128.e7. doi: 10.1016/j.ccell.2017.06.001.

PMID- 28697339
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in
      Hepatocellular Carcinoma.
PG  - 101-114.e8
LID - S1535-6108(17)30252-0 [pii]
LID - 10.1016/j.ccell.2017.06.002 [doi]
AB  - Global transcriptomic imbalance is a ubiquitous feature associated with cancer,
      including hepatocellular carcinoma (HCC). Analyses of 1,225 clinical HCC samples 
      revealed that a large numbers of RNA binding proteins (RBPs) are dysregulated and
      that RBP dysregulation is associated with poor prognosis. We further identified
      that oncogenic activation of a top candidate RBP, negative elongation factor E
      (NELFE), via somatic copy-number alterations enhanced MYC signaling and promoted 
      HCC progression. Interestingly, NELFE induces a unique tumor transcriptome by
      selectively regulating MYC-associated genes. Thus, our results revealed NELFE as 
      an oncogenic protein that may contribute to transcriptome imbalance in HCC
      through the regulation of MYC signaling.
CI  - Published by Elsevier Inc.
FAU - Dang, Hien
AU  - Dang H
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Takai, Atsushi
AU  - Takai A
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Forgues, Marshonna
AU  - Forgues M
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Pomyen, Yotsowat
AU  - Pomyen Y
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Mou, Haiwei
AU  - Mou H
AD  - RNA Therapeutics Institute, University of Massachusetts Medical School,
      Worcester, MA 01605, USA.
FAU - Xue, Wen
AU  - Xue W
AD  - RNA Therapeutics Institute, University of Massachusetts Medical School,
      Worcester, MA 01605, USA; Program in Molecular Medicine, Department of Molecular,
      Cell and Cancer Biology, University of Massachusetts Medical School, Worcester,
      MA 01605, USA.
FAU - Ray, Debashish
AU  - Ray D
AD  - Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada.
FAU - Ha, Kevin C H
AU  - Ha KCH
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 3E1,
      Canada.
FAU - Morris, Quaid D
AU  - Morris QD
AD  - Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada; Department
      of Molecular Genetics, University of Toronto, Toronto, ON M5S 3E1, Canada;
      Department of Computer Science, University of Toronto, Toronto, ON M5S 3E1,
      Canada.
FAU - Hughes, Timothy R
AU  - Hughes TR
AD  - Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada; Department
      of Molecular Genetics, University of Toronto, Toronto, ON M5S 3E1, Canada.
FAU - Wang, Xin Wei
AU  - Wang XW
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA. Electronic address: xw3u@nih.gov.
LA  - eng
GR  - Z01 BC010877/BC/NCI NIH HHS/United States
GR  - P01 HL131471/HL/NHLBI NIH HHS/United States
GR  - ZIA BC010877-09/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010876/BC/NCI NIH HHS/United States
GR  - Z01 BC010876-01/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Transcription Factors)
RN  - 0 (negative elongation factor)
SB  - IM
MH  - Carcinoma, Hepatocellular/*genetics/metabolism
MH  - Cell Transformation, Neoplastic
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Liver Neoplasms/*genetics/metabolism
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Signal Transduction
MH  - Transcription Factors/genetics/metabolism/*physiology
PMC - PMC5539779
MID - NIHMS883933
OTO - NOTNLM
OT  - *MYC
OT  - *NELFE
OT  - *RDBP
OT  - *RNA binding proteins
OT  - *cancer
OT  - *hepatocellular carcinoma
OT  - *oncogene
OT  - *transcriptome
EDAT- 2017/07/12 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/12 06:00
PMCR- 2018/07/10 00:00
PHST- 2016/05/24 00:00 [received]
PHST- 2017/04/18 00:00 [revised]
PHST- 2017/06/08 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - S1535-6108(17)30252-0 [pii]
AID - 10.1016/j.ccell.2017.06.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):101-114.e8. doi: 10.1016/j.ccell.2017.06.002.

PMID- 28697338
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.
PG  - 1-3
LID - S1535-6108(17)30259-3 [pii]
LID - 10.1016/j.ccell.2017.06.008 [doi]
AB  - In this issue of Cancer Cell, Qu et al. describe the chromatin accessibility
      profiles of cutaneous T cell lymphoma, with dynamic assessments of response and
      resistance to histone deacetylase inhibitor therapy. Their "personal regulome"
      analysis framework reveals chromatin features that may be predictive of clinical 
      response to epigenetic therapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Ott, Christopher J
AU  - Ott CJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 
      02142, USA.
FAU - Wu, Catherine J
AU  - Wu CJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 
      02142, USA. Electronic address: cwu@partners.org.
LA  - eng
GR  - K99 CA190861/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromatin)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - EC 3.5.1.98 (Histone Deacetylases)
SB  - IM
CON - Cancer Cell. 2017 Jul 10;32(1):27-41.e4. PMID: 28625481
MH  - *Chromatin
MH  - Epigenomics
MH  - *Histone Deacetylase Inhibitors
MH  - Histone Deacetylases
MH  - Humans
MH  - Lymphoma, T-Cell, Cutaneous
EDAT- 2017/07/12 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30259-3 [pii]
AID - 10.1016/j.ccell.2017.06.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):1-3. doi: 10.1016/j.ccell.2017.06.008.

PMID- 28669490
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified
      Multiple Myeloma.
PG  - 88-100.e6
LID - S1535-6108(17)30207-6 [pii]
LID - 10.1016/j.ccell.2017.05.011 [doi]
AB  - Amplification of 1q21 occurs in approximately 30% of de novo and 70% of relapsed 
      multiple myeloma (MM) and is correlated with disease progression and drug
      resistance. Here, we provide evidence that the 1q21 amplification-driven
      overexpression of ILF2 in MM promotes tolerance of genomic instability and drives
      resistance to DNA-damaging agents. Mechanistically, elevated ILF2 expression
      exerts resistance to genotoxic agents by modulating YB-1 nuclear localization and
      interaction with the splicing factor U2AF65, which promotes mRNA processing and
      the stabilization of transcripts involved in homologous recombination in response
      to DNA damage. The intimate link between 1q21-amplified ILF2 and the regulation
      of RNA splicing of DNA repair genes may be exploited to optimize the use of
      DNA-damaging agents in patients with high-risk MM.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Marchesini, Matteo
AU  - Marchesini M
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ogoti, Yamini
AU  - Ogoti Y
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Fiorini, Elena
AU  - Fiorini E
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Aktas Samur, Anil
AU  - Aktas Samur A
AD  - Department of Biostatistics and Computational Biology, Dana Farber Cancer
      Institute and Harvard Medical School, Boston, MA 02215, USA.
FAU - Nezi, Luigi
AU  - Nezi L
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - D'Anca, Marianna
AU  - D'Anca M
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Storti, Paola
AU  - Storti P
AD  - Department of Clinical and Experimental Medicine, University of Parma, Parma
      43100, Italy.
FAU - Samur, Mehmet Kemal
AU  - Samur MK
AD  - Department of Biostatistics and Computational Biology, Dana Farber Cancer
      Institute and Harvard Medical School, Boston, MA 02215, USA.
FAU - Ganan-Gomez, Irene
AU  - Ganan-Gomez I
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Fulciniti, Maria Teresa
AU  - Fulciniti MT
AD  - LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma
      Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
      02215, USA.
FAU - Mistry, Nipun
AU  - Mistry N
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Jiang, Shan
AU  - Jiang S
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Bao, Naran
AU  - Bao N
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Marchica, Valentina
AU  - Marchica V
AD  - Department of Clinical and Experimental Medicine, University of Parma, Parma
      43100, Italy.
FAU - Neri, Antonino
AU  - Neri A
AD  - Department of Oncology and Hemato-Oncology, University of Milano, Milan 20122,
      Italy.
FAU - Bueso-Ramos, Carlos
AU  - Bueso-Ramos C
AD  - Department of Hematopathology, The University of Texas MD Cancer Center, Houston,
      TX 77030, USA.
FAU - Wu, Chang-Jiun
AU  - Wu CJ
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Peng, Xinxin
AU  - Peng X
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Giuliani, Nicola
AU  - Giuliani N
AD  - Department of Clinical and Experimental Medicine, University of Parma, Parma
      43100, Italy.
FAU - Draetta, Giulio
AU  - Draetta G
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Clise-Dwyer, Karen
AU  - Clise-Dwyer K
AD  - Department of Stem Cell Transplantation and Cellular Therapy, The University of
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kantarjian, Hagop
AU  - Kantarjian H
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Munshi, Nikhil
AU  - Munshi N
AD  - LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma
      Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
      02215, USA.
FAU - Orlowski, Robert
AU  - Orlowski R
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Cancer Center,
      Houston, TX 77030, USA.
FAU - Garcia-Manero, Guillermo
AU  - Garcia-Manero G
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - DePinho, Ronald A
AU  - DePinho RA
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Colla, Simona
AU  - Colla S
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA. Electronic address: scolla@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA100632/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20170629
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ILF2 protein, human)
RN  - 0 (Nuclear Factor 45 Protein)
RN  - 0 (Splicing Factor U2AF)
RN  - 0 (Y-Box-Binding Protein 1)
RN  - 0 (YBX1 protein, human)
SB  - IM
MH  - DNA Damage
MH  - DNA Repair
MH  - Homologous Recombination
MH  - Humans
MH  - Multiple Myeloma/*genetics
MH  - Nuclear Factor 45 Protein/genetics/metabolism/*physiology
MH  - RNA Splicing/*genetics
MH  - Splicing Factor U2AF/metabolism
MH  - Tumor Cells, Cultured
MH  - Y-Box-Binding Protein 1/metabolism
PMC - PMC5593798
MID - NIHMS898157
OTO - NOTNLM
OT  - *1q21 amplification
OT  - *DNA damage
OT  - *DNA repair
OT  - *ILF2
OT  - *multiple myeloma
OT  - *splicing
EDAT- 2017/07/04 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/04 06:00
PMCR- 2018/07/10 00:00
PHST- 2016/06/15 00:00 [received]
PHST- 2017/01/20 00:00 [revised]
PHST- 2017/05/22 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2017/07/04 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
PHST- 2017/07/04 06:00 [entrez]
AID - S1535-6108(17)30207-6 [pii]
AID - 10.1016/j.ccell.2017.05.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):88-100.e6. doi: 10.1016/j.ccell.2017.05.011. Epub 
      2017 Jun 29.

PMID- 28648284
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and
      Cholangiocarcinoma.
PG  - 57-70.e3
LID - S1535-6108(17)30205-2 [pii]
LID - 10.1016/j.ccell.2017.05.009 [doi]
AB  - Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are
      clinically disparate primary liver cancers with etiological and biological
      heterogeneity. We identified common molecular subtypes linked to similar
      prognosis among 199 Thai ICC and HCC patients through systems integration of
      genomics, transcriptomics, and metabolomics. While ICC and HCC share recurrently 
      mutated genes, including TP53, ARID1A, and ARID2, mitotic checkpoint anomalies
      distinguish the C1 subtype with key drivers PLK1 and ECT2, whereas the C2 subtype
      is linked to obesity, T cell infiltration, and bile acid metabolism. These
      molecular subtypes are found in 582 Asian, but less so in 265 Caucasian patients.
      Thus, Asian ICC and HCC, while clinically treated as separate entities, share
      common molecular subtypes with similar actionable drivers to improve precision
      therapy.
CI  - Published by Elsevier Inc.
FAU - Chaisaingmongkol, Jittiporn
AU  - Chaisaingmongkol J
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA; Laboratory of Chemical Carcinogenesis,
      Chulabhorn Research Institute, Bangkok 10210, Thailand; Center of Excellence on
      Environmental Health and Toxicology, Office of Higher Education Commission,
      Ministry of Education, Bangkok 10400, Thailand.
FAU - Budhu, Anuradha
AU  - Budhu A
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Dang, Hien
AU  - Dang H
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Rabibhadana, Siritida
AU  - Rabibhadana S
AD  - Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok
      10210, Thailand.
FAU - Pupacdi, Benjarath
AU  - Pupacdi B
AD  - Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok
      10210, Thailand.
FAU - Kwon, So Mee
AU  - Kwon SM
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Forgues, Marshonna
AU  - Forgues M
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Pomyen, Yotsawat
AU  - Pomyen Y
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA; Laboratory of Chemical Carcinogenesis,
      Chulabhorn Research Institute, Bangkok 10210, Thailand.
FAU - Bhudhisawasdi, Vajarabhongsa
AU  - Bhudhisawasdi V
AD  - Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
FAU - Lertprasertsuke, Nirush
AU  - Lertprasertsuke N
AD  - Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
FAU - Chotirosniramit, Anon
AU  - Chotirosniramit A
AD  - Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
FAU - Pairojkul, Chawalit
AU  - Pairojkul C
AD  - Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
FAU - Auewarakul, Chirayu U
AU  - Auewarakul CU
AD  - HRH Princess Chulabhorn College of Medical Science, Bangkok 10210, Thailand.
FAU - Sricharunrat, Thaniya
AU  - Sricharunrat T
AD  - Chulabhorn Hospital, Bangkok 10210, Thailand.
FAU - Phornphutkul, Kannika
AU  - Phornphutkul K
AD  - Rajavej Hospital, Chiang Mai 50000, Thailand.
FAU - Sangrajrang, Suleeporn
AU  - Sangrajrang S
AD  - National Cancer Institute, Bangkok 10400, Thailand.
FAU - Cam, Maggie
AU  - Cam M
AD  - Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
FAU - He, Ping
AU  - He P
AD  - FDA, Silver Spring, MD 20993, USA.
FAU - Hewitt, Stephen M
AU  - Hewitt SM
AD  - Laboratory of Pathology, Center for Cancer Research, National Cancer Institute,
      Bethesda, MD 20892, USA.
FAU - Ylaya, Kris
AU  - Ylaya K
AD  - Laboratory of Pathology, Center for Cancer Research, National Cancer Institute,
      Bethesda, MD 20892, USA.
FAU - Wu, Xiaolin
AU  - Wu X
AD  - Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
FAU - Andersen, Jesper B
AU  - Andersen JB
AD  - Biotech Research and Innovation Centre (BRIC), Department of Health and Medical
      Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
FAU - Thorgeirsson, Snorri S
AU  - Thorgeirsson SS
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Waterfall, Joshua J
AU  - Waterfall JJ
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda,
      MD 20892, USA.
FAU - Zhu, Yuelin J
AU  - Zhu YJ
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda,
      MD 20892, USA.
FAU - Walling, Jennifer
AU  - Walling J
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda,
      MD 20892, USA.
FAU - Stevenson, Holly S
AU  - Stevenson HS
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda,
      MD 20892, USA.
FAU - Edelman, Daniel
AU  - Edelman D
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda,
      MD 20892, USA.
FAU - Meltzer, Paul S
AU  - Meltzer PS
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda,
      MD 20892, USA.
FAU - Loffredo, Christopher A
AU  - Loffredo CA
AD  - Georgetown University Medical Center, Washington, DC 20057, USA.
FAU - Hama, Natsuko
AU  - Hama N
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, The
      University of Tokyo, Tokyo 104-0045, Japan.
FAU - Shibata, Tatsuhiro
AU  - Shibata T
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, The
      University of Tokyo, Tokyo 104-0045, Japan; Laboratory of Molecular Medicine,
      Human Genome Center, The Institute of Medical Science, The University of Tokyo,
      Tokyo 104-0045, Japan.
FAU - Wiltrout, Robert H
AU  - Wiltrout RH
AD  - Cancer Inflammation Program, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Harris, Curtis C
AU  - Harris CC
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Mahidol, Chulabhorn
AU  - Mahidol C
AD  - Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok
      10210, Thailand; HRH Princess Chulabhorn College of Medical Science, Bangkok
      10210, Thailand. Electronic address: pc@cri.or.th.
FAU - Ruchirawat, Mathuros
AU  - Ruchirawat M
AD  - Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok
      10210, Thailand; Center of Excellence on Environmental Health and Toxicology,
      Office of Higher Education Commission, Ministry of Education, Bangkok 10400,
      Thailand. Electronic address: mathuros@cri.or.th.
FAU - Wang, Xin W
AU  - Wang XW
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA. Electronic address: xw3u@nih.gov.
CN  - TIGER-LC Consortium
LA  - eng
GR  - Z01 BC005793-13/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010313-09/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010313-10/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20170622
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Asian Continental Ancestry Group/*genetics
MH  - Carcinoma, Hepatocellular/diagnosis/*genetics
MH  - Cholangiocarcinoma/diagnosis/*genetics
MH  - Cluster Analysis
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/diagnosis/*genetics
MH  - Prognosis
MH  - Transcriptome
PMC - PMC5524207
MID - NIHMS878337
OTO - NOTNLM
OT  - *TIGER-LC
OT  - *cancer driver
OT  - *cancer genomics
OT  - *hepatocellular carcinoma
OT  - *integrated genomics
OT  - *intrahepatic cholangiocarcinoma
OT  - *liver cancer
OT  - *metabolomics
OT  - *molecular subtypes
OT  - *transcriptomics
EDAT- 2017/06/27 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/06/27 06:00
PMCR- 2018/07/10 00:00
PHST- 2016/08/04 00:00 [received]
PHST- 2017/03/31 00:00 [revised]
PHST- 2017/05/16 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2017/06/27 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
PHST- 2017/06/27 06:00 [entrez]
AID - S1535-6108(17)30205-2 [pii]
AID - 10.1016/j.ccell.2017.05.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):57-70.e3. doi: 10.1016/j.ccell.2017.05.009. Epub
      2017 Jun 22.

PMID- 28625481
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jul 10
TI  - Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic
      Response to HDAC Inhibitors.
PG  - 27-41.e4
LID - S1535-6108(17)30204-0 [pii]
LID - 10.1016/j.ccell.2017.05.008 [doi]
AB  - Here, we define the landscape and dynamics of active regulatory DNA in cutaneous 
      T cell lymphoma (CTCL) by ATAC-seq. Analysis of 111 human CTCL and control
      samples revealed extensive chromatin signatures that distinguished leukemic,
      host, and normal CD4(+) T cells. We identify three dominant patterns of
      transcription factor (TF) activation that drive leukemia regulomes, as well as TF
      deactivations that alter host T cells in CTCL patients. Clinical response to
      histone deacetylase inhibitors (HDACi) is strongly associated with a concurrent
      gain in chromatin accessibility. HDACi causes distinct chromatin responses in
      leukemic and host CD4(+) T cells, reprogramming host T cells toward normalcy.
      These results provide a foundational framework to study personal regulomes in
      human cancer and epigenetic therapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Qu, Kun
AU  - Qu K
AD  - CAS Key Laboratory of Innate Immunity and Chronic Diseases, School of Life
      Sciences and Medical Center, University of Science and Technology of China, Hefei
      230027, China; Center for Personal Dynamic Regulomes and Program in Epithelial
      Biology, Stanford University School of Medicine, CCSR 2155c, 269 Campus Drive,
      Stanford, CA 94305-5168, USA.
FAU - Zaba, Lisa C
AU  - Zaba LC
AD  - Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford
      University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA
      94305-5168, USA; Department of Dermatology, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Satpathy, Ansuman T
AU  - Satpathy AT
AD  - Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford
      University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA
      94305-5168, USA; Department of Dermatology, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Giresi, Paul G
AU  - Giresi PG
AD  - Epinomics, Menlo Park, CA 94035, USA.
FAU - Li, Rui
AU  - Li R
AD  - Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford
      University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA
      94305-5168, USA.
FAU - Jin, Yonghao
AU  - Jin Y
AD  - CAS Key Laboratory of Innate Immunity and Chronic Diseases, School of Life
      Sciences and Medical Center, University of Science and Technology of China, Hefei
      230027, China.
FAU - Armstrong, Randall
AU  - Armstrong R
AD  - Stanford Blood and Marrow Transplantation Cellular Therapy Facility, Department
      of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Jin, Chen
AU  - Jin C
AD  - CAS Key Laboratory of Innate Immunity and Chronic Diseases, School of Life
      Sciences and Medical Center, University of Science and Technology of China, Hefei
      230027, China.
FAU - Schmitt, Nathalie
AU  - Schmitt N
AD  - CNRSUMR 5164, Universite de Bordeaux, Bordeaux 33076, France.
FAU - Rahbar, Ziba
AU  - Rahbar Z
AD  - Department of Dermatology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Ueno, Hideki
AU  - Ueno H
AD  - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Greenleaf, William J
AU  - Greenleaf WJ
AD  - Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford
      University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA
      94305-5168, USA; Department of Genetics, Stanford University School of Medicine, 
      Stanford, CA 94305, USA.
FAU - Kim, Youn H
AU  - Kim YH
AD  - Department of Dermatology, Stanford University School of Medicine, Stanford, CA
      94305, USA. Electronic address: younkim@stanford.edu.
FAU - Chang, Howard Y
AU  - Chang HY
AD  - Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford
      University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA
      94305-5168, USA; Department of Dermatology, Stanford University School of
      Medicine, Stanford, CA 94305, USA. Electronic address: howchang@stanford.edu.
LA  - eng
GR  - P50 HG007735/HG/NHGRI NIH HHS/United States
GR  - R35 CA209919/CA/NCI NIH HHS/United States
GR  - T32 AR050942/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20170615
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromatin)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (RNA, Messenger)
SB  - IM
CIN - Cancer Cell. 2017 Jul 10;32(1):1-3. PMID: 28697338
MH  - Chromatin/chemistry/*drug effects
MH  - Cluster Analysis
MH  - Epigenomics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Histone Deacetylase Inhibitors/*therapeutic use
MH  - Humans
MH  - Lymphoma, T-Cell, Cutaneous/drug therapy/*genetics
MH  - RNA, Messenger/metabolism
PMC - PMC5559384
MID - NIHMS882059
OTO - NOTNLM
OT  - *CTCL
OT  - *HDAC inhibitor
OT  - *cancer epigenetics
OT  - *response predictor
EDAT- 2017/06/20 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/06/20 06:00
PMCR- 2018/07/10 00:00
PHST- 2016/10/24 00:00 [received]
PHST- 2017/03/17 00:00 [revised]
PHST- 2017/05/15 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2017/06/20 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
PHST- 2017/06/20 06:00 [entrez]
AID - S1535-6108(17)30204-0 [pii]
AID - 10.1016/j.ccell.2017.05.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jul 10;32(1):27-41.e4. doi: 10.1016/j.ccell.2017.05.008. Epub
      2017 Jun 15.

PMID- 28609660
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - SnapShot: Immune Checkpoint Inhibitors.
PG  - 848-848.e1
LID - S1535-6108(17)30206-4 [pii]
LID - 10.1016/j.ccell.2017.05.010 [doi]
AB  - Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade 
      therapies unleash breaks in the immune system and induce long-lasting responses. 
      However, a significant number of patients do not respond (innate resistance), and
      a subset progress after responding (acquired resistance). A better understanding 
      of the molecular mechanisms underlying checkpoint blockade therapies will
      facilitate the design of novel strategies to treat and prevent resistance. To
      view this SnapShot, open or download the PDF.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Abril-Rodriguez, Gabriel
AU  - Abril-Rodriguez G
AD  - Department of Medicine, Division of Hematology-Oncology, University of
      California, Los Angeles, CA 90095, USA.
FAU - Ribas, Antoni
AU  - Ribas A
AD  - Department of Medicine, Division of Hematology-Oncology, University of
      California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, Los 
      Angeles, CA 90095, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adaptive Immunity/drug effects
MH  - Cell Cycle Checkpoints/drug effects
MH  - Drug Resistance, Neoplasm/immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Interferons/drug effects/physiology
MH  - Neoplasms/*drug therapy/immunology
EDAT- 2017/06/14 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/06/14 06:00
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
AID - S1535-6108(17)30206-4 [pii]
AID - 10.1016/j.ccell.2017.05.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):848-848.e1. doi: 10.1016/j.ccell.2017.05.010.

PMID- 28609659
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in
      Prostate Cancer.
PG  - 844-847
LID - S1535-6108(17)30197-6 [pii]
LID - 10.1016/j.ccell.2017.05.001 [doi]
FAU - Wang, Xiaoju
AU  - Wang X
FAU - Qiao, Yuanyuan
AU  - Qiao Y
FAU - Asangani, Irfan A
AU  - Asangani IA
FAU - Ateeq, Bushra
AU  - Ateeq B
FAU - Poliakov, Anton
AU  - Poliakov A
FAU - Cieslik, Marcin
AU  - Cieslik M
FAU - Pitchiaya, Sethuramasundaram
AU  - Pitchiaya S
FAU - Chakravarthi, Balabhadrapatruni V S K
AU  - Chakravarthi BVSK
FAU - Cao, Xuhong
AU  - Cao X
FAU - Jing, Xiaojun
AU  - Jing X
FAU - Wang, Cynthia X
AU  - Wang CX
FAU - Apel, Ingrid J
AU  - Apel IJ
FAU - Wang, Rui
AU  - Wang R
FAU - Tien, Jean Ching-Yi
AU  - Tien JC
FAU - Juckette, Kristin M
AU  - Juckette KM
FAU - Yan, Wei
AU  - Yan W
FAU - Jiang, Hui
AU  - Jiang H
FAU - Wang, Shaomeng
AU  - Wang S
FAU - Varambally, Sooryanarayana
AU  - Varambally S
FAU - Chinnaiyan, Arul M
AU  - Chinnaiyan AM
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2017 Apr 10;31(4):532-548.e7. PMID: 28344039
EDAT- 2017/06/14 06:00
MHDA- 2017/06/14 06:01
CRDT- 2017/06/14 06:00
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/06/14 06:01 [medline]
AID - S1535-6108(17)30197-6 [pii]
AID - 10.1016/j.ccell.2017.05.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):844-847. doi: 10.1016/j.ccell.2017.05.001.

PMID- 28609658
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis.
PG  - 804-819.e7
LID - S1535-6108(17)30203-9 [pii]
LID - 10.1016/j.ccell.2017.05.007 [doi]
AB  - Association of aberrant glycosylation with melanoma progression is based mainly
      on analyses of cell lines. Here we present a systems-based study of glycomic
      changes and corresponding enzymes associated with melanoma metastasis in patient 
      samples. Upregulation of core fucosylation (FUT8) and downregulation of alpha-1,2
      fucosylation (FUT1, FUT2) were identified as features of metastatic melanoma.
      Using both in vitro and in vivo studies, we demonstrate FUT8 is a driver of
      melanoma metastasis which, when silenced, suppresses invasion and tumor
      dissemination. Glycoprotein targets of FUT8 were enriched in cell migration
      proteins including the adhesion molecule L1CAM. Core fucosylation impacted L1CAM 
      cleavage and the ability of L1CAM to support melanoma invasion. FUT8 and its
      targets represent therapeutic targets in melanoma metastasis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Agrawal, Praveen
AU  - Agrawal P
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA; Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer
      Center, New York University School of Medicine, New York, NY 10016, USA;
      Biomedical Chemistry Institute, Department of Chemistry, New York University, New
      York, NY 10003, USA.
FAU - Fontanals-Cirera, Barbara
AU  - Fontanals-Cirera B
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA; Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer
      Center, New York University School of Medicine, New York, NY 10016, USA.
FAU - Sokolova, Elena
AU  - Sokolova E
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA; Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer
      Center, New York University School of Medicine, New York, NY 10016, USA.
FAU - Jacob, Samson
AU  - Jacob S
AD  - Department of Biochemistry and Molecular Pharmacology, New York University School
      of Medicine, New York, NY 10016, USA; Institute for Systems Genetics, New York
      University School of Medicine, New York, NY 10016, USA.
FAU - Vaiana, Christopher A
AU  - Vaiana CA
AD  - Biomedical Chemistry Institute, Department of Chemistry, New York University, New
      York, NY 10003, USA.
FAU - Argibay, Diana
AU  - Argibay D
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA; Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer
      Center, New York University School of Medicine, New York, NY 10016, USA.
FAU - Davalos, Veronica
AU  - Davalos V
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA; Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer
      Center, New York University School of Medicine, New York, NY 10016, USA.
FAU - McDermott, Meagan
AU  - McDermott M
AD  - Biomedical Chemistry Institute, Department of Chemistry, New York University, New
      York, NY 10003, USA.
FAU - Nayak, Shruti
AU  - Nayak S
AD  - Department of Biochemistry and Molecular Pharmacology, New York University School
      of Medicine, New York, NY 10016, USA.
FAU - Darvishian, Farbod
AU  - Darvishian F
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA; Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer
      Center, New York University School of Medicine, New York, NY 10016, USA.
FAU - Castillo, Mireia
AU  - Castillo M
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, Mount Sinai
      Health System, New York, NY 10029, USA.
FAU - Ueberheide, Beatrix
AU  - Ueberheide B
AD  - Department of Biochemistry and Molecular Pharmacology, New York University School
      of Medicine, New York, NY 10016, USA.
FAU - Osman, Iman
AU  - Osman I
AD  - Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer Center, New York 
      University School of Medicine, New York, NY 10016, USA; Department of
      Dermatology, New York University School of Medicine, New York, NY 10016, USA.
FAU - Fenyo, David
AU  - Fenyo D
AD  - Department of Biochemistry and Molecular Pharmacology, New York University School
      of Medicine, New York, NY 10016, USA; Institute for Systems Genetics, New York
      University School of Medicine, New York, NY 10016, USA.
FAU - Mahal, Lara K
AU  - Mahal LK
AD  - Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer Center, New York 
      University School of Medicine, New York, NY 10016, USA; Biomedical Chemistry
      Institute, Department of Chemistry, New York University, New York, NY 10003, USA.
      Electronic address: lkmahal@nyu.edu.
FAU - Hernando, Eva
AU  - Hernando E
AD  - Department of Pathology, New York University School of Medicine, New York, NY
      10016, USA; Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer
      Center, New York University School of Medicine, New York, NY 10016, USA.
      Electronic address: eva.hernando-monge@nyumc.org.
LA  - eng
GR  - P30 CA016087/CA/NCI NIH HHS/United States
GR  - R01 CA202027/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Glycoproteins)
RN  - EC 2.4.1.- (Fucosyltransferases)
RN  - EC 2.4.1.68 (Glycoprotein 6-alpha-L-fucosyltransferase)
SB  - IM
CIN - Cancer Cell. 2017 Jun 12;31(6):733-735. PMID: 28609653
MH  - Animals
MH  - Fucosyltransferases/*genetics/metabolism/physiology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Gene Silencing
MH  - Glycoproteins/metabolism
MH  - Glycosylation
MH  - Humans
MH  - Melanoma/*genetics/pathology
MH  - Mice
MH  - Neoplasm Invasiveness/genetics
MH  - Neoplasm Metastasis/genetics
MH  - Systems Biology/methods
PMC - PMC5649440
MID - NIHMS878444
OTO - NOTNLM
OT  - *FUT8
OT  - *L1CAM
OT  - *core fucosylation
OT  - *glycomics
OT  - *glycosylation
OT  - *lectin array
OT  - *lectin microarray
OT  - *metastasis
OT  - *metastatic melanoma
OT  - *primary melanoma
EDAT- 2017/06/14 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/06/14 06:00
PMCR- 2018/06/12 00:00
PHST- 2016/10/17 00:00 [received]
PHST- 2017/03/12 00:00 [revised]
PHST- 2017/05/15 00:00 [accepted]
PHST- 2018/06/12 00:00 [pmc-release]
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
AID - S1535-6108(17)30203-9 [pii]
AID - 10.1016/j.ccell.2017.05.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):804-819.e7. doi: 10.1016/j.ccell.2017.05.007.

PMID- 28609657
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in
      Castration-Resistant Prostate Cancer.
PG  - 790-803.e8
LID - S1535-6108(17)30199-X [pii]
LID - 10.1016/j.ccell.2017.05.003 [doi]
AB  - The androgen receptor (AR) is critical for the progression of prostate cancer to 
      a castration-resistant (CRPC) state. AR antagonists are ineffective due to their 
      inability to repress the expression of AR or its splice variant, AR-V7. Here, we 
      report that the tyrosine kinase ACK1 (TNK2) phosphorylates histone H4 at tyrosine
      88 upstream of the AR transcription start site. The WDR5/MLL2 complex reads the
      H4-Y88-phosphorylation marks and deposits the transcriptionally activating
      H3K4-trimethyl marks promoting AR transcription. Reversal of the pY88-H4
      epigenetic marks by the ACK1 inhibitor (R)-9bMS-sensitized naive and
      enzalutamide-resistant prostate cancer cells and reduced AR and AR-V7 levels to
      mitigate CRPC tumor growth. Thus, a feedforward ACK1/pY88-H4/WDR5/MLL2/AR
      epigenetic circuit drives CRPC and is necessary for maintenance of the malignant 
      state.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Mahajan, Kiran
AU  - Mahajan K
AD  - Tumor Biology Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 
      33612, USA; Department of Oncological Sciences, University of South Florida,
      Tampa, FL 33612, USA.
FAU - Malla, Pavani
AU  - Malla P
AD  - Drug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL
      33612, USA.
FAU - Lawrence, Harshani R
AU  - Lawrence HR
AD  - Chemical Biology Core, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL
      33612, USA; Department of Oncological Sciences, University of South Florida,
      Tampa, FL 33612, USA.
FAU - Chen, Zhihua
AU  - Chen Z
AD  - Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, 12902
      Magnolia Drive, Tampa, FL 33612, USA.
FAU - Kumar-Sinha, Chandan
AU  - Kumar-Sinha C
AD  - Department of Pathology, Michigan Center for Translational Pathology, University 
      of Michigan Medical School, Ann Arbor, MI 48109, USA.
FAU - Malik, Rohit
AU  - Malik R
AD  - Department of Pathology, Michigan Center for Translational Pathology, University 
      of Michigan Medical School, Ann Arbor, MI 48109, USA.
FAU - Shukla, Sudhanshu
AU  - Shukla S
AD  - Department of Pathology, Michigan Center for Translational Pathology, University 
      of Michigan Medical School, Ann Arbor, MI 48109, USA.
FAU - Kim, Jongphil
AU  - Kim J
AD  - Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, 12902
      Magnolia Drive, Tampa, FL 33612, USA; Department of Oncological Sciences,
      University of South Florida, Tampa, FL 33612, USA.
FAU - Coppola, Domenico
AU  - Coppola D
AD  - Department of Anatomic Pathology, Moffitt Cancer Center, 12902 Magnolia Drive,
      Tampa, FL 33612, USA.
FAU - Lawrence, Nicholas J
AU  - Lawrence NJ
AD  - Drug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL
      33612, USA; Department of Oncological Sciences, University of South Florida,
      Tampa, FL 33612, USA.
FAU - Mahajan, Nupam P
AU  - Mahajan NP
AD  - Drug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL
      33612, USA; Department of Oncological Sciences, University of South Florida,
      Tampa, FL 33612, USA. Electronic address: nupam.mahajan@moffitt.org.
LA  - eng
GR  - P30 CA076292/CA/NCI NIH HHS/United States
GR  - R01 CA135328/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - 0 (MDV 3100)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Androgen)
RN  - 2010-15-3 (Phenylthiohydantoin)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (TNK2 protein, human)
SB  - IM
MH  - Cell Proliferation/drug effects
MH  - Drug Resistance, Neoplasm
MH  - Epigenesis, Genetic
MH  - *Gene Expression Regulation, Neoplastic
MH  - Histones/*metabolism
MH  - Humans
MH  - Male
MH  - Phenylthiohydantoin/analogs & derivatives/therapeutic use
MH  - Phosphorylation
MH  - Prostatic Neoplasms, Castration-Resistant/*genetics
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors/genetics/*physiology
MH  - RNA, Messenger/metabolism
MH  - Receptors, Androgen/*genetics/metabolism
MH  - Tumor Cells, Cultured
PMC - PMC5512571
MID - NIHMS875764
OTO - NOTNLM
OT  - *ACK1
OT  - *AR
OT  - *AR-V7
OT  - *TNK2
OT  - *castration resistance
OT  - *enzalutamide
OT  - *epigenetics
OT  - *histone
OT  - *prostate cancer
OT  - *small-molecule inhibitor
OT  - *tyrosine phosphorylation
EDAT- 2017/06/14 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/06/14 06:00
PMCR- 2018/06/12 00:00
PHST- 2016/03/15 00:00 [received]
PHST- 2017/03/10 00:00 [revised]
PHST- 2017/05/04 00:00 [accepted]
PHST- 2018/06/12 00:00 [pmc-release]
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
AID - S1535-6108(17)30199-X [pii]
AID - 10.1016/j.ccell.2017.05.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):790-803.e8. doi: 10.1016/j.ccell.2017.05.003.

PMID- 28609656
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due
      to Chronic Mitochondrial Dysfunction and ROS.
PG  - 771-789.e6
LID - S1535-6108(17)30202-7 [pii]
LID - 10.1016/j.ccell.2017.05.006 [doi]
AB  - Intrahepatic cholangiocarcinoma (ICC) is a highly malignant, heterogeneous cancer
      with poor treatment options. We found that mitochondrial dysfunction and
      oxidative stress trigger a niche favoring cholangiocellular overgrowth and
      tumorigenesis. Liver damage, reactive oxygen species (ROS) and paracrine tumor
      necrosis factor (Tnf) from Kupffer cells caused JNK-mediated cholangiocellular
      proliferation and oncogenic transformation. Anti-oxidant treatment, Kupffer cell 
      depletion, Tnfr1 deletion, or JNK inhibition reduced cholangiocellular
      pre-neoplastic lesions. Liver-specific JNK1/2 deletion led to tumor reduction and
      enhanced survival in Akt/Notch- or p53/Kras-induced ICC models. In human ICC,
      high Tnf expression near ICC lesions, cholangiocellular JNK-phosphorylation, and 
      ROS accumulation in surrounding hepatocytes are present. Thus, Kupffer
      cell-derived Tnf favors cholangiocellular proliferation/differentiation and
      carcinogenesis. Targeting the ROS/Tnf/JNK axis may provide opportunities for ICC 
      therapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Yuan, Detian
AU  - Yuan D
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany; Division of Chronic Inflammation and Cancer,
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Huang, Shan
AU  - Huang S
AD  - Division of Chronic Inflammation and Cancer, German Cancer Research Center
      (DKFZ), 69120 Heidelberg, Germany.
FAU - Berger, Emanuel
AU  - Berger E
AD  - Chair of Nutrition and Immunology, Technische Universitat Munchen,
      Gregor-Mendel-Strasse 2, 85350 Freising-Weihenstephan, Germany.
FAU - Liu, Lei
AU  - Liu L
AD  - Department of Surgery, Technische Universitat Munchen, 81675 Munich, Germany.
FAU - Gross, Nina
AU  - Gross N
AD  - 2nd Department of Internal Medicine, Klinikum Rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Heinzmann, Florian
AU  - Heinzmann F
AD  - Department of Internal Medicine VIII, University Hospital Tubingen, 72076
      Tubingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard 
      Karls University Tubingen, 72076 Tubingen, Germany.
FAU - Ringelhan, Marc
AU  - Ringelhan M
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany; 2nd Department of Internal Medicine, Klinikum
      Rechts der Isar, Technische Universitat Munchen, 81675 Munich, Germany.
FAU - Connor, Tracy O
AU  - Connor TO
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany; Division of Chronic Inflammation and Cancer,
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Stadler, Mira
AU  - Stadler M
AD  - Division of Chronic Inflammation and Cancer, German Cancer Research Center
      (DKFZ), 69120 Heidelberg, Germany.
FAU - Meister, Michael
AU  - Meister M
AD  - Division of Chronic Inflammation and Cancer, German Cancer Research Center
      (DKFZ), 69120 Heidelberg, Germany.
FAU - Weber, Julia
AU  - Weber J
AD  - 2nd Department of Internal Medicine, Klinikum Rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Ollinger, Rupert
AU  - Ollinger R
AD  - 2nd Department of Internal Medicine, Klinikum Rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Simonavicius, Nicole
AU  - Simonavicius N
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany.
FAU - Reisinger, Florian
AU  - Reisinger F
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany.
FAU - Hartmann, Daniel
AU  - Hartmann D
AD  - Department of Surgery, Technische Universitat Munchen, 81675 Munich, Germany.
FAU - Meyer, Rudiger
AU  - Meyer R
AD  - Genome Technology Branch, National Human Genome Research Institute, U.S. National
      Institutes of Health, Bethesda, MD 20892, USA.
FAU - Reich, Maria
AU  - Reich M
AD  - Clinic for Gastroenterology, Hepatology, and Infectious Diseases, Heinrich-Heine 
      University, 40204 Dusseldorf, Germany.
FAU - Seehawer, Marco
AU  - Seehawer M
AD  - Department of Internal Medicine VIII, University Hospital Tubingen, 72076
      Tubingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard 
      Karls University Tubingen, 72076 Tubingen, Germany.
FAU - Leone, Valentina
AU  - Leone V
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany.
FAU - Hochst, Bastian
AU  - Hochst B
AD  - Institute of Molecular Immunology, Klinikum rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Wohlleber, Dirk
AU  - Wohlleber D
AD  - Institute of Molecular Immunology, Klinikum rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Jors, Simone
AU  - Jors S
AD  - 2nd Department of Internal Medicine, Klinikum Rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Prinz, Marco
AU  - Prinz M
AD  - Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany;
      BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79106
      Freiburg, Germany.
FAU - Spalding, Duncan
AU  - Spalding D
AD  - Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK.
FAU - Protzer, Ulrike
AU  - Protzer U
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany.
FAU - Luedde, Tom
AU  - Luedde T
AD  - Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen 
      University, 52074 Aachen, Germany.
FAU - Terracciano, Luigi
AU  - Terracciano L
AD  - Institute of Pathology, University Hospital of Basel, 4003 Basel, Switzerland.
FAU - Matter, Matthias
AU  - Matter M
AD  - Institute of Pathology, University Hospital of Basel, 4003 Basel, Switzerland.
FAU - Longerich, Thomas
AU  - Longerich T
AD  - Institute of Pathology, University Hospital RWTH, 52074 Aachen, Germany.
FAU - Knolle, Percy
AU  - Knolle P
AD  - Institute of Molecular Immunology, Klinikum rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Ried, Thomas
AU  - Ried T
AD  - Genome Technology Branch, National Human Genome Research Institute, U.S. National
      Institutes of Health, Bethesda, MD 20892, USA.
FAU - Keitel, Verena
AU  - Keitel V
AD  - Clinic for Gastroenterology, Hepatology, and Infectious Diseases, Heinrich-Heine 
      University, 40204 Dusseldorf, Germany.
FAU - Geisler, Fabian
AU  - Geisler F
AD  - 2nd Department of Internal Medicine, Klinikum Rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Unger, Kristian
AU  - Unger K
AD  - Research Unit of Radiation Cytogenetics, Helmholtz Zentrum Munchen, 85764
      Neuherberg, Germany.
FAU - Cinnamon, Einat
AU  - Cinnamon E
AD  - The Lautenberg Center for Immunology and Cancer Research, IMRIC, Hebrew
      University-Hadassah Medical School, Jerusalem 91120, Israel.
FAU - Pikarsky, Eli
AU  - Pikarsky E
AD  - The Lautenberg Center for Immunology and Cancer Research, IMRIC, Hebrew
      University-Hadassah Medical School, Jerusalem 91120, Israel; Department of
      Pathology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel.
FAU - Huser, Norbert
AU  - Huser N
AD  - Department of Surgery, Technische Universitat Munchen, 81675 Munich, Germany.
FAU - Davis, Roger J
AU  - Davis RJ
AD  - Howard Hughes Medical Institute and Program in Molecular Medicine, University of 
      Massachusetts Medical School, Worcester, MA 01605, USA.
FAU - Tschaharganeh, Darjus F
AU  - Tschaharganeh DF
AD  - Helmholtz-University Group "Cell Plasticity and Epigenetic Remodeling", German
      Cancer Research Center (DKFZ) & Institute of Pathology University Hospital, 69120
      Heidelberg, Germany.
FAU - Rad, Roland
AU  - Rad R
AD  - 2nd Department of Internal Medicine, Klinikum Rechts der Isar, Technische
      Universitat Munchen, 81675 Munich, Germany.
FAU - Weber, Achim
AU  - Weber A
AD  - Department of Pathology and Molecular Pathology, University Zurich and University
      Hospital Zurich, 8091 Zurich, Switzerland.
FAU - Zender, Lars
AU  - Zender L
AD  - Department of Internal Medicine VIII, University Hospital Tubingen, 72076
      Tubingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard 
      Karls University Tubingen, 72076 Tubingen, Germany; Translational
      Gastrointestinal Oncology Group within the German Consortium for Translational
      Cancer Research (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg,
      Germany.
FAU - Haller, Dirk
AU  - Haller D
AD  - Chair of Nutrition and Immunology, Technische Universitat Munchen,
      Gregor-Mendel-Strasse 2, 85350 Freising-Weihenstephan, Germany; ZIEL - Institute 
      for Food & Health, Technische Universitat Munchen, 85350 Freising-Weihenstephan, 
      Germany. Electronic address: dirk.haller@tum.de.
FAU - Heikenwalder, Mathias
AU  - Heikenwalder M
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany; Division of Chronic Inflammation and Cancer,
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. Electronic
      address: m.heikenwaelder@dkfz-heidelberg.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 25013-16-5 (Butylated Hydroxyanisole)
SB  - IM
MH  - Animals
MH  - Bile Duct Neoplasms/*metabolism/pathology
MH  - Butylated Hydroxyanisole/therapeutic use
MH  - Carcinogenesis
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Transformation, Neoplastic/drug effects
MH  - Cholangiocarcinoma/*metabolism/pathology
MH  - Humans
MH  - Kupffer Cells/drug effects/*metabolism
MH  - Liver/drug effects/pathology
MH  - *MAP Kinase Signaling System
MH  - Mice
MH  - Mitochondria/drug effects/metabolism/physiology
MH  - Oxidative Stress/drug effects
MH  - Reactive Oxygen Species/metabolism
MH  - Receptors, Tumor Necrosis Factor/genetics/metabolism
MH  - Signal Transduction
MH  - Tumor Microenvironment
MH  - Tumor Necrosis Factor-alpha/*metabolism
OTO - NOTNLM
OT  - *JNK
OT  - *Kupffer cell
OT  - *Tnf
OT  - *cholastasis
OT  - *intrahepatic cholangiocarcinoma
OT  - *mitochondrial dysfunction
OT  - *pro-inflammatory niche
OT  - *reactive oxygen species
OT  - *unfolded protein response
EDAT- 2017/06/14 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/06/14 06:00
PHST- 2016/06/23 00:00 [received]
PHST- 2017/01/31 00:00 [revised]
PHST- 2017/05/11 00:00 [accepted]
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
AID - S1535-6108(17)30202-7 [pii]
AID - 10.1016/j.ccell.2017.05.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):771-789.e6. doi: 10.1016/j.ccell.2017.05.006.

PMID- 28609655
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid
      Leukemia.
PG  - 755-770.e6
LID - S1535-6108(17)30198-8 [pii]
LID - 10.1016/j.ccell.2017.05.002 [doi]
AB  - The MLL1 histone methyltransferase gene undergoes many distinct chromosomal
      rearrangements to yield poor-prognosis leukemia. The remaining wild-type allele
      is most commonly, but not always, retained. To what extent the wild-type allele
      contributes to leukemogenesis is unclear. Here we show, using rigorous,
      independent animal models, that endogenous MLL1 is dispensable for MLL-rearranged
      leukemia. Potential redundancy was addressed by co-deleting the closest paralog, 
      Mll2. Surprisingly, Mll2 deletion alone had a significant impact on survival of
      MLL-AF9-transformed cells, and additional Mll1 loss further reduced viability and
      proliferation. We show that MLL1/MLL2 collaboration is not through redundancy,
      but regulation of distinct pathways. These findings highlight the relevance of
      MLL2 as a drug target in MLL-rearranged leukemia and suggest its broader
      significance in AML.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Chen, Yufei
AU  - Chen Y
AD  - Department of Pediatrics, Section of Hematology/Oncology/BMT, University of
      Colorado, Denver/Anschutz Medical Campus, Aurora, CO 80045, USA; Department of
      Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
FAU - Anastassiadis, Konstantinos
AU  - Anastassiadis K
AD  - Genomics and Stem Cell Engineering, Biotechnology Center, Technische Universitat 
      Dresden, BioInnovations Zentrum, Tatzberg 47, Dresden 01307, Germany.
FAU - Kranz, Andrea
AU  - Kranz A
AD  - Genomics and Stem Cell Engineering, Biotechnology Center, Technische Universitat 
      Dresden, BioInnovations Zentrum, Tatzberg 47, Dresden 01307, Germany.
FAU - Stewart, A Francis
AU  - Stewart AF
AD  - Genomics and Stem Cell Engineering, Biotechnology Center, Technische Universitat 
      Dresden, BioInnovations Zentrum, Tatzberg 47, Dresden 01307, Germany.
FAU - Arndt, Kathrin
AU  - Arndt K
AD  - Regeneration in Hematopoiesis and Animal Models in Hematopoiesis, Institute for
      Immunology, Medical Faculty, Technische Universitat Dresden, Fetscherstrasse 74, 
      01307 Dresden, Germany.
FAU - Waskow, Claudia
AU  - Waskow C
AD  - Regeneration in Hematopoiesis and Animal Models in Hematopoiesis, Institute for
      Immunology, Medical Faculty, Technische Universitat Dresden, Fetscherstrasse 74, 
      01307 Dresden, Germany.
FAU - Yokoyama, Akihiko
AU  - Yokoyama A
AD  - Tsuruoka Metabolomics Laboratory, National Cancer Center, Mizukami 246-2,
      Kakuganji, Tsuruoka, Yamagata 997-0052, Japan.
FAU - Jones, Kenneth
AU  - Jones K
AD  - Department of Pediatrics, Section of Hematology/Oncology/BMT, University of
      Colorado, Denver/Anschutz Medical Campus, Aurora, CO 80045, USA.
FAU - Neff, Tobias
AU  - Neff T
AD  - Department of Pediatrics, Section of Hematology/Oncology/BMT, University of
      Colorado, Denver/Anschutz Medical Campus, Aurora, CO 80045, USA.
FAU - Lee, Yoo
AU  - Lee Y
AD  - Department of Pediatrics, Section of Hematology/Oncology/BMT, University of
      Colorado, Denver/Anschutz Medical Campus, Aurora, CO 80045, USA.
FAU - Ernst, Patricia
AU  - Ernst P
AD  - Department of Pediatrics, Section of Hematology/Oncology/BMT, University of
      Colorado, Denver/Anschutz Medical Campus, Aurora, CO 80045, USA; Department of
      Pharmacology, University of Colorado, Denver/Anschutz Medical Campus, Aurora, CO 
      80045, USA. Electronic address: patricia.ernst@ucdenver.edu.
LA  - eng
GR  - P30 CA046934/CA/NCI NIH HHS/United States
GR  - R01 HL090036/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MLL protein, human)
RN  - 0 (MLL2 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
CIN - Cancer Cell. 2017 Jun 12;31(6):729-731. PMID: 28609652
MH  - Animals
MH  - Cell Proliferation/genetics
MH  - DNA-Binding Proteins/*genetics/metabolism/physiology
MH  - Gene Deletion
MH  - Gene Expression Regulation, Neoplastic
MH  - *Gene Rearrangement
MH  - Histone-Lysine N-Methyltransferase/*genetics/metabolism/physiology
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Mice
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics/metabolism/physiology
MH  - Neoplasm Proteins/*genetics/metabolism/physiology
MH  - Recombinant Fusion Proteins/genetics
PMC - PMC5598468
MID - NIHMS880245
OTO - NOTNLM
OT  - *AML
OT  - *CD123
OT  - *H3K4
OT  - *MLL1
OT  - *MLL2
OT  - *NF-kB
OT  - *Wbp7
OT  - *histone methyltransferase
OT  - *integrin beta3
OT  - *leukemia
EDAT- 2017/06/14 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/06/14 06:00
PMCR- 2018/06/12 00:00
PHST- 2016/11/20 00:00 [received]
PHST- 2017/03/09 00:00 [revised]
PHST- 2017/05/05 00:00 [accepted]
PHST- 2018/06/12 00:00 [pmc-release]
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
AID - S1535-6108(17)30198-8 [pii]
AID - 10.1016/j.ccell.2017.05.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):755-770.e6. doi: 10.1016/j.ccell.2017.05.002.

PMID- 28609654
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - Intertumoral Heterogeneity within Medulloblastoma Subgroups.
PG  - 737-754.e6
LID - S1535-6108(17)30201-5 [pii]
LID - 10.1016/j.ccell.2017.05.005 [doi]
AB  - While molecular subgrouping has revolutionized medulloblastoma classification,
      the extent of heterogeneity within subgroups is unknown. Similarity network
      fusion (SNF) applied to genome-wide DNA methylation and gene expression data
      across 763 primary samples identifies very homogeneous clusters of patients,
      supporting the presence of medulloblastoma subtypes. After integration of somatic
      copy-number alterations, and clinical features specific to each cluster, we
      identify 12 different subtypes of medulloblastoma. Integrative analysis using SNF
      further delineates group 3 from group 4 medulloblastoma, which is not as readily 
      apparent through analyses of individual data types. Two clear subtypes of infants
      with Sonic Hedgehog medulloblastoma with disparate outcomes and biology are
      identified. Medulloblastoma subtypes identified through integrative clustering
      have important implications for stratification of future clinical trials.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Cavalli, Florence M G
AU  - Cavalli FMG
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Remke, Marc
AU  - Remke M
AD  - Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical
      Faculty, University Hospital Dusseldorf, Dusseldorf 40225, Germany; Department of
      Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1,
      Canada; Department of Pediatric Neuro-Oncogenomics, German Cancer Consortium
      (DKTK) and German Cancer Research Center (DKFZ), Dusseldorf 40225, Germany.
FAU - Rampasek, Ladislav
AU  - Rampasek L
AD  - Department of Computer Science, University of Toronto, Toronto, ON M5S 2E4,
      Canada; Program in Genetics and Genome Biology, The Hospital for Sick Children,
      Toronto, ON M5G 1X8, Canada.
FAU - Peacock, John
AU  - Peacock J
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of
      Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1,
      Canada.
FAU - Shih, David J H
AU  - Shih DJH
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of
      Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1,
      Canada.
FAU - Luu, Betty
AU  - Luu B
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Garzia, Livia
AU  - Garzia L
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Torchia, Jonathon
AU  - Torchia J
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and
      Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada.
FAU - Nor, Carolina
AU  - Nor C
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Morrissy, A Sorana
AU  - Morrissy AS
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Agnihotri, Sameer
AU  - Agnihotri S
AD  - UPCI Brain Tumor Program, University of Pittsburgh, Children's Hospital of
      Pittsburgh, Pittsburgh, PA 15224, USA.
FAU - Thompson, Yuan Yao
AU  - Thompson YY
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of
      Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1,
      Canada.
FAU - Kuzan-Fischer, Claudia M
AU  - Kuzan-Fischer CM
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Farooq, Hamza
AU  - Farooq H
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of
      Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1,
      Canada.
FAU - Isaev, Keren
AU  - Isaev K
AD  - Informatics Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, 
      Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Daniels, Craig
AU  - Daniels C
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Cho, Byung-Kyu
AU  - Cho BK
AD  - Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National
      University Children's Hospital, Seoul 30322, South Korea.
FAU - Kim, Seung-Ki
AU  - Kim SK
AD  - Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National
      University Children's Hospital, Seoul 30322, South Korea.
FAU - Wang, Kyu-Chang
AU  - Wang KC
AD  - Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National
      University Children's Hospital, Seoul 30322, South Korea.
FAU - Lee, Ji Yeoun
AU  - Lee JY
AD  - Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National
      University Children's Hospital, Seoul 30322, South Korea.
FAU - Grajkowska, Wieslawa A
AU  - Grajkowska WA
AD  - Department of Pathology, The Children's Memorial Health Institute, University of 
      Warsaw, Warsaw 04-730, Poland.
FAU - Perek-Polnik, Marta
AU  - Perek-Polnik M
AD  - Department of Oncology, The Children's Memorial Health Institute, University of
      Warsaw, Warsaw 04-730, Poland.
FAU - Vasiljevic, Alexandre
AU  - Vasiljevic A
AD  - Centre de Pathologie et Neuropathologie Est, Centre de Biologie et Pathologie
      Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69677, France;
      ONCOFLAM - Neuro-Oncologie et Neuro-Inflammation Centre de Recherche en
      Neurosciences de Lyon, Lyon 69008, France.
FAU - Faure-Conter, Cecile
AU  - Faure-Conter C
AD  - Institute of Pediatric Hematology and Oncology, Lyon 69008, France.
FAU - Jouvet, Anne
AU  - Jouvet A
AD  - Centre de Pathologie EST, Groupement Hospitalier EST, Universite de Lyon, Bron
      69677, France.
FAU - Giannini, Caterina
AU  - Giannini C
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
      55905, USA.
FAU - Nageswara Rao, Amulya A
AU  - Nageswara Rao AA
AD  - Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Li, Kay Ka Wai
AU  - Li KKW
AD  - Department of Anatomical and Cellular Pathology, The Chinese University of Hong
      Kong, Shatin, New Territories, Hong Kong, China.
FAU - Ng, Ho-Keung
AU  - Ng HK
AD  - Department of Anatomical and Cellular Pathology, The Chinese University of Hong
      Kong, Shatin, New Territories, Hong Kong, China.
FAU - Eberhart, Charles G
AU  - Eberhart CG
AD  - Departments of Pathology, Ophthalmology and Oncology, John Hopkins University
      School of Medicine, Baltimore, MD 21287, USA.
FAU - Pollack, Ian F
AU  - Pollack IF
AD  - Department of Neurological Surgery, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA 15213, USA.
FAU - Hamilton, Ronald L
AU  - Hamilton RL
AD  - Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh,
      PA 15261, USA.
FAU - Gillespie, G Yancey
AU  - Gillespie GY
AD  - Department of Surgery, Division of Neurosurgery, University of Alabama at
      Birmingham, Birmingham, AL 35233, USA.
FAU - Olson, James M
AU  - Olson JM
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109-1024, USA; Division of Pediatric Hematology/Oncology, University of
      Washington School of Medicine, Seattle Children's Hospital, Seattle, WA
      98145-5005, USA.
FAU - Leary, Sarah
AU  - Leary S
AD  - Division of Pediatric Hematology/Oncology, University of Washington School of
      Medicine, Seattle Children's Hospital, Seattle, WA 98145-5005, USA.
FAU - Weiss, William A
AU  - Weiss WA
AD  - Departments of Pediatrics, Neurological Surgery and Neurology, University of
      California San Francisco, San Francisco, CA 94143-0112, USA.
FAU - Lach, Boleslaw
AU  - Lach B
AD  - Division of Anatomical Pathology, Department of Pathology and Molecular Medicine,
      McMaster University, Hamilton, ON L8S 4K1, Canada; Department of Pathology and
      Laboratory Medicine, Hamilton General Hospital, Hamilton, ON L8L 2X2, Canada.
FAU - Chambless, Lola B
AU  - Chambless LB
AD  - Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN
      37232, USA.
FAU - Thompson, Reid C
AU  - Thompson RC
AD  - Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN
      37232, USA.
FAU - Cooper, Michael K
AU  - Cooper MK
AD  - Department of Neurology, Vanderbilt Medical Center, Nashville, TN 37232, USA.
FAU - Vibhakar, Rajeev
AU  - Vibhakar R
AD  - Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA.
FAU - Hauser, Peter
AU  - Hauser P
AD  - 2nd Department of Pediatrics, Semmelweis University, Budapest 1094, Hungary.
FAU - van Veelen, Marie-Lise C
AU  - van Veelen MC
AD  - Department of Neurosurgery, Erasmus University Medical Center, Rotterdam 3015 CE,
      the Netherlands.
FAU - Kros, Johan M
AU  - Kros JM
AD  - Department of Pathology, Erasmus University Medical Center, Rotterdam 3015 CN,
      the Netherlands.
FAU - French, Pim J
AU  - French PJ
AD  - Department of Neurology, Erasmus University Medical Center, Rotterdam 3015 CE,
      the Netherlands.
FAU - Ra, Young Shin
AU  - Ra YS
AD  - Department of Neurosurgery, University of Ulsan, Asan Medical Center, Seoul
      05505, South Korea.
FAU - Kumabe, Toshihiro
AU  - Kumabe T
AD  - Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara,
      Kanagawa 252-0374, Japan.
FAU - Lopez-Aguilar, Enrique
AU  - Lopez-Aguilar E
AD  - Division of Pediatric Hematology/Oncology, Hospital Pediatria Centro Medico
      Nacional Century XXI, Mexico City 06720, Mexico.
FAU - Zitterbart, Karel
AU  - Zitterbart K
AD  - Department of Pediatric Oncology, School of Medicine, Masaryk University, Brno
      625 00, Czech Republic.
FAU - Sterba, Jaroslav
AU  - Sterba J
AD  - Department of Pediatric Oncology, School of Medicine, Masaryk University, Brno
      625 00, Czech Republic.
FAU - Finocchiaro, Gaetano
AU  - Finocchiaro G
AD  - Department of Neuro-Oncology, Istituto Neurologico Besta, Milan 20133, Italy.
FAU - Massimino, Maura
AU  - Massimino M
AD  - Fondazione IRCCS Istituto Nazionale Tumori, Milan 20133, Italy.
FAU - Van Meir, Erwin G
AU  - Van Meir EG
AD  - Department of Hematology & Medical Oncology, School of Medicine and Winship
      Cancer Institute, Emory University, Atlanta, GA 30322, USA.
FAU - Osuka, Satoru
AU  - Osuka S
AD  - Department of Hematology & Medical Oncology, School of Medicine and Winship
      Cancer Institute, Emory University, Atlanta, GA 30322, USA.
FAU - Shofuda, Tomoko
AU  - Shofuda T
AD  - Division of Stem Cell Research, Institute for Clinical Research, Osaka National
      Hospital, Osaka 540-0006, Japan.
FAU - Klekner, Almos
AU  - Klekner A
AD  - Department of Neurosurgery, University of Debrecen, Medical and Health Science
      Centre, Debrecen 4032, Hungary.
FAU - Zollo, Massimo
AU  - Zollo M
AD  - Dipartimento di Biochimica e Biotecnologie Mediche, University of Naples, Naples 
      80145, Italy.
FAU - Leonard, Jeffrey R
AU  - Leonard JR
AD  - Division of Pediatric Neurosurgery, Department of Neurosurgery, Washington
      University School of Medicine and St. Louis Children's Hospital, St. Louis, MO
      63110, USA.
FAU - Rubin, Joshua B
AU  - Rubin JB
AD  - Departments of Pediatrics, Anatomy and Neurobiology, Washington University School
      of Medicine and St. Louis Children's Hospital, St. Louis, MO 63110, USA.
FAU - Jabado, Nada
AU  - Jabado N
AD  - Division of Hematology/Oncology, Department of Pediatrics, McGill University,
      Montreal, QC H4A 3J1, Canada.
FAU - Albrecht, Steffen
AU  - Albrecht S
AD  - Department of Pathology, McGill University, Montreal, QC H4A 3J1, Canada;
      Department of Pathology, Montreal Children's Hospital, Montreal, QC H4A 3J1,
      Canada.
FAU - Mora, Jaume
AU  - Mora J
AD  - Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Esplugues de
      Llobregat, Barcelona 08950, Spain.
FAU - Van Meter, Timothy E
AU  - Van Meter TE
AD  - Department of Pediatrics, Virginia Commonwealth University, School of Medicine,
      Richmond, VA 23298-0646, USA.
FAU - Jung, Shin
AU  - Jung S
AD  - Department of Neurosurgery, Chonnam National University Research Institute of
      Medical Sciences, Chonnam National University Hwasun Hospital and Medical School,
      Hwasun-gun 519-763, Chonnam South Korea.
FAU - Moore, Andrew S
AU  - Moore AS
AD  - Lady Cilento Children's Hospital, The University of Queensland, Brisbane QLD
      4102, Australia; Oncology Service, Children's Health Queensland Hospital and
      Health Service, South Brisbane, QLD 4029, Australia.
FAU - Hallahan, Andrew R
AU  - Hallahan AR
AD  - Lady Cilento Children's Hospital, The University of Queensland, Brisbane QLD
      4102, Australia; Oncology Service, Children's Health Queensland Hospital and
      Health Service, South Brisbane, QLD 4029, Australia.
FAU - Chan, Jennifer A
AU  - Chan JA
AD  - Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, 
      AB T2N 2T9, Canada.
FAU - Tirapelli, Daniela P C
AU  - Tirapelli DPC
AD  - Department of Surgery and Anatomy, Faculty of Medicine of Ribeirao Preto,
      University of Sao Paulo, Sao Paulo 14049-900, Brazil.
FAU - Carlotti, Carlos G
AU  - Carlotti CG
AD  - Department of Surgery and Anatomy, Faculty of Medicine of Ribeirao Preto,
      University of Sao Paulo, Sao Paulo 14049-900, Brazil.
FAU - Fouladi, Maryam
AU  - Fouladi M
AD  - Division of Hematology/Oncology, University of Cincinnati, Cincinnati Children's 
      Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Pimentel, Jose
AU  - Pimentel J
AD  - Divison of Pathology, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria,
      Lisbon 1649-035, Portugal.
FAU - Faria, Claudia C
AU  - Faria CC
AD  - Division of Neurosurgery, Centro Hospitalar Lisboa Norte, Hospital de Santa
      Maria, Lisbon 1649-035, Portugal.
FAU - Saad, Ali G
AU  - Saad AG
AD  - Department of Pathology, University of Arkansas for Medical Sciences, Little
      Rock, AR 72205, USA.
FAU - Massimi, Luca
AU  - Massimi L
AD  - Department of Pediatric Neurosurgery, Catholic University Medical School, Rome
      00198, Italy.
FAU - Liau, Linda M
AU  - Liau LM
AD  - Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles,
      CA 90095, USA.
FAU - Wheeler, Helen
AU  - Wheeler H
AD  - Kolling Institute of Medical Research, The University of Sydney, Sydney, NSW
      2065, Australia.
FAU - Nakamura, Hideo
AU  - Nakamura H
AD  - Department of Neurosurgery, Kumamoto University Graduate School of Medical
      Science, Kumamoto 860-8555, Japan.
FAU - Elbabaa, Samer K
AU  - Elbabaa SK
AD  - Division of Pediatric Neurosurgery, Department of Neurosurgery, Saint Louis
      University School of Medicine, St. Louis, MO, USA.
FAU - Perezpena-Diazconti, Mario
AU  - Perezpena-Diazconti M
AD  - Department of Pathology, Hospital Infantil de Mexico Federico Gomez, Mexico City 
      06720, Mexico.
FAU - Chico Ponce de Leon, Fernando
AU  - Chico Ponce de Leon F
AD  - Department of Neurosurgery, Hospital Infantil de Mexico Federico Gomez, Mexico
      City 06720, Mexico.
FAU - Robinson, Shenandoah
AU  - Robinson S
AD  - Division of Pediatric Neurosurgery, Rainbow & Babies Children's Hospital, Case
      Western Reserve, Cleveland, OH 44106, USA.
FAU - Zapotocky, Michal
AU  - Zapotocky M
AD  - Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON
      M5G 1X8, Canada.
FAU - Lassaletta, Alvaro
AU  - Lassaletta A
AD  - Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON
      M5G 1X8, Canada.
FAU - Huang, Annie
AU  - Huang A
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Hawkins, Cynthia E
AU  - Hawkins CE
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Division of Pathology, The Hospital for
      Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Tabori, Uri
AU  - Tabori U
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Bouffet, Eric
AU  - Bouffet E
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Bartels, Ute
AU  - Bartels U
AD  - Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON
      M5G 1X8, Canada.
FAU - Dirks, Peter B
AU  - Dirks PB
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Division of Neurosurgery, The Hospital for
      Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Rutka, James T
AU  - Rutka JT
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and
      Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Division of
      Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Bader, Gary D
AU  - Bader GD
AD  - The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada; Banting 
      and Best Department of Medical Research, University of Toronto, Toronto, ON M5G
      1L6, Canada; McLaughlin Centre, University of Toronto, Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada; Samuel Lunenfeld Research Institute at Mount Sinai Hospital,
      University of Toronto, Toronto, ON M5G 1X5, Canada.
FAU - Reimand, Juri
AU  - Reimand J
AD  - Informatics Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, 
      Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Goldenberg, Anna
AU  - Goldenberg A
AD  - Department of Computer Science, University of Toronto, Toronto, ON M5S 2E4,
      Canada; Program in Genetics and Genome Biology, The Hospital for Sick Children,
      Toronto, ON M5G 1X8, Canada. Electronic address: anna.goldenberg@utoronto.ca.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Program in Neuroscience 
      and Mental Health and Division of Neurology, The Hospital for Sick Children,
      Toronto, ON M5G 1X8, Canada. Electronic address: vijay.ramaswamy@sickkids.ca.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program,
      The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of
      Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1,
      Canada; Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G
      1X8, Canada. Electronic address: mdtaylor@sickkids.ca.
LA  - eng
GR  - R01 NS055089/NS/NINDS NIH HHS/United States
GR  - R01 CA159859/CA/NCI NIH HHS/United States
GR  - R01 CA148699/CA/NCI NIH HHS/United States
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CIN - Cancer Cell. 2017 Jun 12;31(6):727-729. PMID: 28609651
MH  - Cluster Analysis
MH  - Cohort Studies
MH  - DNA Copy Number Variations
MH  - DNA Methylation
MH  - Gene Expression Profiling
MH  - Genomics
MH  - Humans
MH  - Medulloblastoma/*classification/genetics/therapy
MH  - *Precision Medicine
OTO - NOTNLM
OT  - *copy number
OT  - *gene expression
OT  - *integrative clustering
OT  - *medulloblastoma
OT  - *methylation
OT  - *subgroups
EDAT- 2017/06/14 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/06/14 06:00
PHST- 2016/09/23 00:00 [received]
PHST- 2017/03/24 00:00 [revised]
PHST- 2017/05/08 00:00 [accepted]
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
AID - S1535-6108(17)30201-5 [pii]
AID - 10.1016/j.ccell.2017.05.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):737-754.e6. doi: 10.1016/j.ccell.2017.05.005.

PMID- 28609653
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - Aberrant Glycosylation in Cancer: A Novel Molecular Mechanism Controlling
      Metastasis.
PG  - 733-735
LID - S1535-6108(17)30208-8 [pii]
LID - 10.1016/j.ccell.2017.05.012 [doi]
AB  - Glycosylation alterations are involved in several steps of human cancer
      pathogenesis. In this issue of Cancer Cell, Agrawal et al. identified the
      glycosyltransferase FUT8 as a previously unrecognized mediator of melanoma
      metastasis, establishing core fucosylation as a potential therapeutic target for 
      prevention and treatment of metastatic tumors.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Magalhaes, Ana
AU  - Magalhaes A
AD  - Institute for Research and Innovation in Health (i3S), University of Porto,
      4200-135 Porto, Portugal; Institute of Molecular Pathology and Immunology of the 
      University of Porto (IPATIMUP), 4200-135 Porto, Portugal.
FAU - Duarte, Henrique O
AU  - Duarte HO
AD  - Institute for Research and Innovation in Health (i3S), University of Porto,
      4200-135 Porto, Portugal; Institute of Molecular Pathology and Immunology of the 
      University of Porto (IPATIMUP), 4200-135 Porto, Portugal; Instituto de Ciencias
      Biomedicas Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
FAU - Reis, Celso A
AU  - Reis CA
AD  - Institute for Research and Innovation in Health (i3S), University of Porto,
      4200-135 Porto, Portugal; Institute of Molecular Pathology and Immunology of the 
      University of Porto (IPATIMUP), 4200-135 Porto, Portugal; Instituto de Ciencias
      Biomedicas Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal;
      Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal.
      Electronic address: celsor@ipatimup.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 28RYY2IV3F (Fucose)
RN  - EC 2.4.1.- (Fucosyltransferases)
SB  - IM
CON - Cancer Cell. 2017 Jun 12;31(6):804-819.e7. PMID: 28609658
MH  - *Fucose
MH  - *Fucosyltransferases
MH  - Glycosylation
MH  - Humans
MH  - *Melanoma
MH  - *Neoplasm Metastasis
MH  - *Skin Neoplasms
EDAT- 2017/06/14 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/06/14 06:00
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30208-8 [pii]
AID - 10.1016/j.ccell.2017.05.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):733-735. doi: 10.1016/j.ccell.2017.05.012.

PMID- 28609652
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180314
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - Paradoxical Effects of MLL Paralogs in MLL-Rearranged Leukemia.
PG  - 729-731
LID - S1535-6108(17)30210-6 [pii]
LID - 10.1016/j.ccell.2017.05.014 [doi]
AB  - Conflicting data exist on the requirement for wild-type MLL1 in MLL-rearranged
      leukemia. In this issue of Cancer Cell, Chen et al. describe complementary
      approaches demonstrating that MLL1 is dispensable for MLL-fusion-mediated
      leukemogenesis. They also observe an unexpected role for MLL2 in MLL-rearranged
      leukemia cells and identify potential therapeutic targets.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Thirman, Michael J
AU  - Thirman MJ
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA. Electronic address: mthirman@medicine.bsd.uchicago.edu.
LA  - eng
GR  - K23 GM112128/GM/NIGMS NIH HHS/United States
GR  - R01 CA215504/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
CON - Cancer Cell. 2017 Jun 12;31(6):755-770.e6. PMID: 28609655
MH  - Histone-Lysine N-Methyltransferase
MH  - Humans
MH  - *Leukemia
MH  - *Myeloid-Lymphoid Leukemia Protein
PMC - PMC5783294
MID - NIHMS935221
EDAT- 2017/06/14 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/06/14 06:00
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30210-6 [pii]
AID - 10.1016/j.ccell.2017.05.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):729-731. doi: 10.1016/j.ccell.2017.05.014.

PMID- 28609651
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - From One to Many: Further Refinement of Medulloblastoma Subtypes Offers Promise
      for Personalized Therapy.
PG  - 727-729
LID - S1535-6108(17)30209-X [pii]
LID - 10.1016/j.ccell.2017.05.013 [doi]
AB  - There is significant intertumoral heterogeneity within the four molecular
      subgroups of medulloblastoma. In this issue of Cancer Cell, Cavalli et al. apply 
      similarity network fusion to gene expression and DNA methylation data to identify
      12 medulloblastoma subtypes with distinct molecular and clinical profiles, making
      an important step toward molecularly tailored therapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bavle, Abhishek
AU  - Bavle A
AD  - Section of Hematology/Oncology, Department of Pediatrics, Baylor College of
      Medicine, Houston, TX 77030, USA; Texas Children's Cancer Center, Houston, TX
      77030, USA.
FAU - Parsons, D Williams
AU  - Parsons DW
AD  - Section of Hematology/Oncology, Department of Pediatrics, Baylor College of
      Medicine, Houston, TX 77030, USA; Texas Children's Cancer Center, Houston, TX
      77030, USA. Electronic address: dwparson@bcm.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Jun 12;31(6):737-754.e6. PMID: 28609654
MH  - Cerebellar Neoplasms/genetics
MH  - *DNA Methylation
MH  - Humans
MH  - Medulloblastoma/*genetics
EDAT- 2017/06/14 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/06/14 06:00
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30209-X [pii]
AID - 10.1016/j.ccell.2017.05.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):727-729. doi: 10.1016/j.ccell.2017.05.013.

PMID- 28552327
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
PG  - 833-843.e5
LID - S1535-6108(17)30167-8 [pii]
LID - 10.1016/j.ccell.2017.04.012 [doi]
AB  - Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B cell receptor
      (BCR) signaling. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets
      BCR signaling and is particularly active in lymphomas with mutations altering the
      BCR subunit CD79B and MYD88. We performed a proof-of-concept phase Ib study of
      ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R). In 18
      PCNSL patients, 94% showed tumor reductions with ibrutinib alone, including
      patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of evaluable
      patients achieved complete remission with DA-TEDDi-R. Increased aspergillosis was
      observed with ibrutinib monotherapy and DA-TEDDi-R. Aspergillosis was linked to
      BTK-dependent fungal immunity in a murine model. PCNSL is highly dependent on BCR
      signaling, and ibrutinib appears to enhance the efficacy of chemotherapy.
CI  - Published by Elsevier Inc.
FAU - Lionakis, Michail S
AU  - Lionakis MS
AD  - Laboratory of Clinical Infectious Diseases, National Institute of Allergy and
      Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Dunleavy, Kieron
AU  - Dunleavy K
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Roschewski, Mark
AU  - Roschewski M
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Widemann, Brigitte C
AU  - Widemann BC
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Butman, John A
AU  - Butman JA
AD  - Radiology and Imaging Sciences, Clinical Center, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Schmitz, Roland
AU  - Schmitz R
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Yang, Yandan
AU  - Yang Y
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Cole, Diane E
AU  - Cole DE
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Melani, Christopher
AU  - Melani C
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Higham, Christine S
AU  - Higham CS
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Desai, Jigar V
AU  - Desai JV
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Ceribelli, Michele
AU  - Ceribelli M
AD  - Division of Preclinical Innovation, National Center for Advancing Translational
      Sciences, National Institutes of Health, Gaithersburg, MD 20850, USA.
FAU - Chen, Lu
AU  - Chen L
AD  - Division of Preclinical Innovation, National Center for Advancing Translational
      Sciences, National Institutes of Health, Gaithersburg, MD 20850, USA.
FAU - Thomas, Craig J
AU  - Thomas CJ
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA; Division of
      Preclinical Innovation, National Center for Advancing Translational Sciences,
      National Institutes of Health, Gaithersburg, MD 20850, USA.
FAU - Little, Richard F
AU  - Little RF
AD  - Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes
      of Health, Bethesda, MD 20892, USA.
FAU - Gea-Banacloche, Juan
AU  - Gea-Banacloche J
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Bhaumik, Sucharita
AU  - Bhaumik S
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Stetler-Stevenson, Maryalice
AU  - Stetler-Stevenson M
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Pittaluga, Stefania
AU  - Pittaluga S
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Jaffe, Elaine S
AU  - Jaffe ES
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Heiss, John
AU  - Heiss J
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Lucas, Nicole
AU  - Lucas N
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Steinberg, Seth M
AU  - Steinberg SM
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Staudt, Louis M
AU  - Staudt LM
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic
      address: lstaudt@mail.nih.gov.
FAU - Wilson, Wyndham H
AU  - Wilson WH
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic
      address: wilsonw@mail.nih.gov.
LA  - eng
GR  - ZIA BC011354-06/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011354-05/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011354-01/ImNIH/Intramural NIH HHS/United States
GR  - Z01 SC006741-14/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011354-04/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011654-01/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011354-02/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011654-02/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011354-07/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011354-03/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, N.I.H., Extramural
DEP - 20170525
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CD79 Antigens)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (MYD88 protein, human)
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (PCI 32765)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Antigen, B-Cell)
RN  - EC 2.7.10.1 (Agammaglobulinaemia tyrosine kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
CIN - Cancer Cell. 2017 Jun 12;31(6):731-733. PMID: 28552326
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Aspergillosis/epidemiology/immunology
MH  - Brain Neoplasms/*drug therapy/metabolism
MH  - CD79 Antigens/genetics
MH  - Drug Therapy, Combination
MH  - Enzyme Inhibitors/adverse effects/pharmacokinetics/*therapeutic use
MH  - Female
MH  - Gene Knockout Techniques
MH  - Humans
MH  - Lymphoma/*drug therapy/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Middle Aged
MH  - Myeloid Differentiation Factor 88/genetics
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors/genetics/immunology
MH  - Pyrazoles/adverse effects/pharmacokinetics/*therapeutic use
MH  - Pyrimidines/adverse effects/pharmacokinetics/*therapeutic use
MH  - Receptors, Antigen, B-Cell/metabolism
MH  - Signal Transduction/drug effects
PMC - PMC5571650
MID - NIHMS877934
OTO - NOTNLM
OT  - *ABC DLBCL
OT  - *Aspergillus fumigatus
OT  - *B cell receptor signaling
OT  - *BTK
OT  - *ibrutinib
OT  - *macrophage
OT  - *primary CNS lymphoma
EDAT- 2017/05/30 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/05/30 06:00
PMCR- 2018/06/12 00:00
PHST- 2016/12/25 00:00 [received]
PHST- 2017/03/09 00:00 [revised]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2018/06/12 00:00 [pmc-release]
PHST- 2017/05/30 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
PHST- 2017/05/30 06:00 [entrez]
AID - S1535-6108(17)30167-8 [pii]
AID - 10.1016/j.ccell.2017.04.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub
      2017 May 25.

PMID- 28552326
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
PG  - 731-733
LID - S1535-6108(17)30200-3 [pii]
LID - 10.1016/j.ccell.2017.05.004 [doi]
AB  - In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of
      temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton
      tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients 
      with primary central nervous system lymphoma but was associated with significant 
      toxicity, including pulmonary and cerebral aspergillosis infections.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Grommes, Christian
AU  - Grommes C
AD  - Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Younes, Anas
AU  - Younes A
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA. Electronic address: younesa@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P50 CA192937/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Comment
DEP - 20170525
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
CON - Cancer Cell. 2017 Jun 12;31(6):833-843.e5. PMID: 28552327
MH  - Aspergillosis
MH  - Central Nervous System Neoplasms
MH  - Doxorubicin
MH  - Humans
MH  - Lymphoma, Non-Hodgkin
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Pyrazoles
MH  - *Pyrimidines
PMC - PMC5572136
MID - NIHMS897643
EDAT- 2017/05/30 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/05/30 06:00
PHST- 2017/05/30 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
PHST- 2017/05/30 06:00 [entrez]
AID - S1535-6108(17)30200-3 [pii]
AID - 10.1016/j.ccell.2017.05.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):731-733. doi: 10.1016/j.ccell.2017.05.004. Epub
      2017 May 25.

PMID- 28528867
OWN - NLM
STAT- MEDLINE
DCOM- 20170825
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun 12
TI  - A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.
PG  - 820-832.e3
LID - S1535-6108(17)30168-X [pii]
LID - 10.1016/j.ccell.2017.04.013 [doi]
AB  - Molecular alterations involving the PI3K/AKT/mTOR pathway (including mutation,
      copy number, protein, or RNA) were examined across 11,219 human cancers
      representing 32 major types. Within specific mutated genes, frequency, mutation
      hotspot residues, in silico predictions, and functional assays were all
      informative in distinguishing the subset of genetic variants more likely to have 
      functional relevance. Multiple oncogenic pathways including PI3K/AKT/mTOR
      converged on similar sets of downstream transcriptional targets. In addition to
      mutation, structural variations and partial copy losses involving PTEN and STK11 
      showed evidence for having functional relevance. A substantial fraction of
      cancers showed high mTOR pathway activity without an associated canonical genetic
      or genomic alteration, including cancers harboring IDH1 or VHL mutations,
      suggesting multiple mechanisms for pathway activation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zhang, Yiqun
AU  - Zhang Y
AD  - Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston,
      TX 77030, USA.
FAU - Kwok-Shing Ng, Patrick
AU  - Kwok-Shing Ng P
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77054, USA; Sheikh Khalifa Bin Zayed Al Nahyan Institute for
      Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Kucherlapati, Melanie
AU  - Kucherlapati M
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Division
      of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Chen, Fengju
AU  - Chen F
AD  - Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston,
      TX 77030, USA.
FAU - Liu, Yuexin
AU  - Liu Y
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Tsang, Yiu Huen
AU  - Tsang YH
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - de Velasco, Guillermo
AU  - de Velasco G
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid
      28041, Spain.
FAU - Jeong, Kang Jin
AU  - Jeong KJ
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77054, USA.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hadjipanayis, Angela
AU  - Hadjipanayis A
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Division
      of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Pantazi, Angeliki
AU  - Pantazi A
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; KEW Inc., 
      Cambridge, MA 02139, USA.
FAU - Bristow, Christopher A
AU  - Bristow CA
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Lee, Eunjung
AU  - Lee E
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Division
      of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Mahadeshwar, Harshad S
AU  - Mahadeshwar HS
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Tang, Jiabin
AU  - Tang J
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zhang, Jianhua
AU  - Zhang J
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yang, Lixing
AU  - Yang L
AD  - Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Seth, Sahil
AU  - Seth S
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Lee, Semin
AU  - Lee S
AD  - Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Ren, Xiaojia
AU  - Ren X
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; KEW Inc., 
      Cambridge, MA 02139, USA.
FAU - Song, Xingzhi
AU  - Song X
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Sun, Huandong
AU  - Sun H
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Seidman, Jonathan
AU  - Seidman J
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Luquette, Lovelace J
AU  - Luquette LJ
AD  - Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Xi, Ruibin
AU  - Xi R
AD  - Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Chin, Lynda
AU  - Chin L
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The Eli
      and Edythe L. Broad Institute of Massachusetts Institute of Technology, Harvard
      University Cambridge, Cambridge, MA 02142, USA.
FAU - Protopopov, Alexei
AU  - Protopopov A
AD  - Department of Genomic Medicine, Institute for Applied Cancer Science, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; KEW Inc., 
      Cambridge, MA 02139, USA.
FAU - Westbrook, Thomas F
AU  - Westbrook TF
AD  - Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston,
      TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of
      Medicine, Houston, TX 77030, USA; Department of Biochemistry & Molecular Biology,
      Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Shelley, Carl Simon
AU  - Shelley CS
AD  - Department of Medicine, University of Wisconsin School of Medicine and Public
      Health, Madison, WI 53726, USA.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Ittmann, Michael
AU  - Ittmann M
AD  - Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX
      77030, USA.
FAU - Van Waes, Carter
AU  - Van Waes C
AD  - Tumor Biology Section, Head and Neck Surgery Branch, National Institute on
      Deafness and Other Communication Disorders, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Weinstein, John N
AU  - Weinstein JN
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology,
      University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
FAU - Henske, Elizabeth P
AU  - Henske EP
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology,
      Harvard University, Cambridge, MA 02142, USA; Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02215, USA.
FAU - Godwin, Andrew K
AU  - Godwin AK
AD  - Department of Pathology & Laboratory Medicine, University of Kansas Medical
      Center, Kansas City, KS 66160, USA.
FAU - Park, Peter J
AU  - Park PJ
AD  - Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA;
      Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Kucherlapati, Raju
AU  - Kucherlapati R
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Division
      of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Scott, Kenneth L
AU  - Scott KL
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77054, USA. Electronic address: gmills@mdanderson.org.
FAU - Kwiatkowski, David J
AU  - Kwiatkowski DJ
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology,
      Harvard University, Cambridge, MA 02142, USA; Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02215, USA. Electronic address:
      dkwiatkowski@rics.bwh.harvard.edu.
FAU - Creighton, Chad J
AU  - Creighton CJ
AD  - Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston,
      TX 77030, USA; Department of Bioinformatics and Computational Biology, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department
      of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; Human Genome
      Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic
      address: creighto@bcm.edu.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA101942/CA/NCI NIH HHS/United States
GR  - U24 CA210950/CA/NCI NIH HHS/United States
GR  - P01 CA120964/CA/NCI NIH HHS/United States
GR  - P50 CA098258/CA/NCI NIH HHS/United States
GR  - U01 CA168394/CA/NCI NIH HHS/United States
GR  - P30 CA125123/CA/NCI NIH HHS/United States
GR  - R01 CA175486/CA/NCI NIH HHS/United States
GR  - U24 CA210949/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - R21 CA191687/CA/NCI NIH HHS/United States
GR  - U24 CA209851/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20170518
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Databases, Genetic
MH  - Gene Expression Profiling
MH  - Humans
MH  - Mutation
MH  - Neoplasms/*genetics/metabolism
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - *Proteogenomics
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction
MH  - Survival Analysis
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC5502825
MID - NIHMS875296
OTO - NOTNLM
OT  - *PI3K/AKT/mTOR pathway
OT  - *The Cancer Genome Atlas
OT  - *integrative genomics analysis
OT  - *pan-cancer analysis
OT  - *proteomics
OT  - *reverse-phase protein arrays
EDAT- 2017/05/23 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/05/23 06:00
PMCR- 2018/06/12 00:00
PHST- 2017/01/10 00:00 [received]
PHST- 2017/03/17 00:00 [revised]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2018/06/12 00:00 [pmc-release]
PHST- 2017/05/23 06:00 [pubmed]
PHST- 2017/08/26 06:00 [medline]
PHST- 2017/05/23 06:00 [entrez]
AID - S1535-6108(17)30168-X [pii]
AID - 10.1016/j.ccell.2017.04.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub
      2017 May 18.

PMID- 28486110
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for
      Efficient Apoptosis.
PG  - 724-726
LID - S1535-6108(17)30170-8 [pii]
LID - 10.1016/j.ccell.2017.04.014 [doi]
FAU - Grinkevich, Vera V
AU  - Grinkevich VV
FAU - Nikulenkov, Fedor
AU  - Nikulenkov F
FAU - Shi, Yao
AU  - Shi Y
FAU - Enge, Martin
AU  - Enge M
FAU - Bao, Wenjie
AU  - Bao W
FAU - Maljukova, Alena
AU  - Maljukova A
FAU - Gluch, Angela
AU  - Gluch A
FAU - Kel, Alexander
AU  - Kel A
FAU - Sangfelt, Olle
AU  - Sangfelt O
FAU - Selivanova, Galina
AU  - Selivanova G
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2009 May 5;15(5):441-53. PMID: 19411072
EDAT- 2017/05/10 06:00
MHDA- 2017/05/10 06:01
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/05/10 06:01 [medline]
AID - S1535-6108(17)30170-8 [pii]
AID - 10.1016/j.ccell.2017.04.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):724-726. doi: 10.1016/j.ccell.2017.04.014.

PMID- 28486109
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking
      and Adoptive T Cell Therapy.
PG  - 711-723.e4
LID - S1535-6108(17)30158-7 [pii]
LID - 10.1016/j.ccell.2017.04.003 [doi]
AB  - Effector T cells have the capability of recognizing and killing cancer cells.
      However, whether tumors can become immune resistant through exclusion of effector
      T cells from the tumor microenvironment is not known. By using a tumor model
      resembling non-T cell-inflamed human tumors, we assessed whether adoptive T cell 
      transfer might overcome failed spontaneous priming. Flow cytometric assays
      combined with intra-vital imaging indicated failed trafficking of effector T
      cells into tumors. Mechanistically, this was due to the absence of CXCL9/10,
      which we found to be produced by CD103(+) dendritic cells (DCs) in T
      cell-inflamed tumors. Our data indicate that lack of CD103(+) DCs within the
      tumor microenvironment dominantly resists the effector phase of an anti-tumor T
      cell response, contributing to immune escape.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Spranger, Stefani
AU  - Spranger S
AD  - Department of Pathology, The University of Chicago, 5841 South Maryland Avenue,
      MC2115, Chicago, IL 60637, USA.
FAU - Dai, Daisy
AU  - Dai D
AD  - Department of Pathology, The University of Chicago, 5841 South Maryland Avenue,
      MC2115, Chicago, IL 60637, USA.
FAU - Horton, Brendan
AU  - Horton B
AD  - Department of Pathology, The University of Chicago, 5841 South Maryland Avenue,
      MC2115, Chicago, IL 60637, USA.
FAU - Gajewski, Thomas F
AU  - Gajewski TF
AD  - Department of Pathology, The University of Chicago, 5841 South Maryland Avenue,
      MC2115, Chicago, IL 60637, USA; Department of Medicine, The University of
      Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA. Electronic
      address: tgajewsk@medicine.bsd.uchicago.edu.
LA  - eng
GR  - K99 CA204595/CA/NCI NIH HHS/United States
GR  - R01 CA198496/CA/NCI NIH HHS/United States
GR  - R35 CA210098/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, CD)
RN  - 0 (Basic-Leucine Zipper Transcription Factors)
RN  - 0 (CTNNB1 protein, mouse)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokine CXCL9)
RN  - 0 (Cxcl10 protein, mouse)
RN  - 0 (Cxcl9 protein, mouse)
RN  - 0 (Integrin alpha Chains)
RN  - 0 (Repressor Proteins)
RN  - 0 (SNFT protein, human)
RN  - 0 (SNFT protein, mouse)
RN  - 0 (alpha E integrins)
RN  - 0 (beta Catenin)
SB  - IM
CIN - Cancer Cell. 2017 May 8;31(5):614-615. PMID: 28486102
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Basic-Leucine Zipper Transcription Factors/deficiency/genetics/*metabolism
MH  - CD8-Positive T-Lymphocytes/immunology/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Chemokine CXCL10/metabolism
MH  - Chemokine CXCL9/metabolism
MH  - *Chemotaxis, Leukocyte
MH  - Dendritic Cells/immunology/*metabolism
MH  - Genotype
MH  - Immunologic Memory
MH  - Immunotherapy, Adoptive/*methods
MH  - Integrin alpha Chains/metabolism
MH  - Melanoma/immunology/metabolism/pathology/*therapy
MH  - Mice, Knockout
MH  - Phenotype
MH  - Repressor Proteins/deficiency/genetics/*metabolism
MH  - Signal Transduction
MH  - Skin Neoplasms/immunology/metabolism/pathology/*therapy
MH  - T-Lymphocytes/immunology/metabolism/*transplantation
MH  - Time Factors
MH  - Tumor Burden
MH  - *Tumor Escape
MH  - Tumor Microenvironment
MH  - beta Catenin/metabolism
PMC - PMC5650691
MID - NIHMS910886
OTO - NOTNLM
OT  - *T cell-inflamed tumor microenvironment
OT  - *adoptive T cell transfer
OT  - *immune escape
OT  - *immunotherapy resistance
OT  - *non-T cell-inflamed tumor microenvironment
EDAT- 2017/05/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/05/10 06:00
PMCR- 2018/05/08 00:00
PHST- 2016/09/25 00:00 [received]
PHST- 2017/02/16 00:00 [revised]
PHST- 2017/04/04 00:00 [accepted]
PHST- 2018/05/08 00:00 [pmc-release]
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(17)30158-7 [pii]
AID - 10.1016/j.ccell.2017.04.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: 10.1016/j.ccell.2017.04.003.

PMID- 28486108
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein
      PML-RARalpha and Inhibition of p53-Mediated Senescence.
PG  - 697-710.e7
LID - S1535-6108(17)30161-7 [pii]
LID - 10.1016/j.ccell.2017.04.006 [doi]
AB  - Acute promyelocytic leukemia (APL) is driven by the oncoprotein PML-RARalpha,
      which antagonizes myeloid differentiation and promotes APL-initiating cell
      self-renewal. Combined all-trans retinoic acid (ATRA) with arsenic trioxide
      (As2O3) or chemotherapy dramatically improves the prognosis of APL patients. Here
      we report that expression of pseudokinase Tribble 3 (TRIB3) associates positively
      with APL progression and therapeutic resistance. The elevated TRIB3 expression
      promotes APL by interacting with PML-RARalpha and suppressing its sumoylation,
      ubiquitylation, and degradation. This represses PML nuclear body assembly,
      p53-mediated senescence, and cell differentiation, and supports cellular
      self-renewal. Genetically inhibiting TRIB3 expression or combination of a peptide
      disturbing TRIB3/PML-RARalpha interaction with ATRA/As2O3 eradicates APL by
      accelerating PML-RARalpha degradation. Our study provides insight into APL
      pathogenesis and a potential therapeutic option against APL.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Li, Ke
AU  - Li K
AD  - Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &
      Peking Union Medical College, Beijing 100050, P.R. China.
FAU - Wang, Feng
AU  - Wang F
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Cao, Wen-Bin
AU  - Cao WB
AD  - Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood
      Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical
      College, Tianjin 300020, P.R. China.
FAU - Lv, Xiao-Xi
AU  - Lv XX
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Hua, Fang
AU  - Hua F
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Cui, Bing
AU  - Cui B
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Yu, Jiao-Jiao
AU  - Yu JJ
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Zhang, Xiao-Wei
AU  - Zhang XW
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Shang, Shuang
AU  - Shang S
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Liu, Shan-Shan
AU  - Liu SS
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Yu, Jin-Mei
AU  - Yu JM
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China.
FAU - Han, Ming-Zhe
AU  - Han MZ
AD  - Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood
      Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical
      College, Tianjin 300020, P.R. China.
FAU - Huang, Bo
AU  - Huang B
AD  - Institute of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union
      Medical College, Beijing 100005, P.R. China.
FAU - Zhang, Ting-Ting
AU  - Zhang TT
AD  - Department of Pharmacy, Marine College, Shandong University, Weihai 264209, P.R. 
      China.
FAU - Li, Xia
AU  - Li X
AD  - Department of Pharmacy, Marine College, Shandong University, Weihai 264209, P.R. 
      China.
FAU - Jiang, Jian-Dong
AU  - Jiang JD
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences 
      & Peking Union Medical College, Beijing 100050, P.R. China.
FAU - Hu, Zhuo-Wei
AU  - Hu ZW
AD  - Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive
      Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. 
      China. Electronic address: huzhuowei@imm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Arsenicals)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Oxides)
RN  - 0 (Peptides)
RN  - 0 (Repressor Proteins)
RN  - 0 (TP53 protein, human)
RN  - 0 (TRB3 protein, mouse)
RN  - 0 (TRIB3 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - 5688UTC01R (Tretinoin)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - S7V92P67HO (arsenic trioxide)
SB  - IM
CIN - Cancer Cell. 2017 May 8;31(5):612-613. PMID: 28486101
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology
MH  - Arsenicals/pharmacology
MH  - Cell Cycle Proteins/deficiency/genetics/*metabolism
MH  - Cell Differentiation/drug effects
MH  - Cell Line, Tumor
MH  - *Cell Proliferation
MH  - *Cellular Senescence
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Gene Expression Regulation
MH  - Gene Fusion
MH  - HEK293 Cells
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/drug therapy/genetics/*metabolism/pathology
MH  - Male
MH  - Mice, 129 Strain
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Mice, Transgenic
MH  - Oncogene Proteins, Fusion/genetics/*metabolism
MH  - Oxides/pharmacology
MH  - Peptides/pharmacology
MH  - Protein Stability
MH  - Protein-Serine-Threonine Kinases/*antagonists & inhibitors/genetics/metabolism
MH  - Proteolysis
MH  - Repressor Proteins/genetics/*metabolism
MH  - Signal Transduction
MH  - Sumoylation
MH  - Time Factors
MH  - Transfection
MH  - Tretinoin/pharmacology
MH  - Tumor Suppressor Protein p53/genetics/*metabolism
MH  - Ubiquitination
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - *AML
OT  - *UPS
OT  - *cell differentiation
OT  - *leukemia-initiating cells
OT  - *protein quality control
OT  - *protein-protein interaction
OT  - *psuedokinase
OT  - *sumoylation
OT  - *tribbles
EDAT- 2017/05/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/05/10 06:00
PHST- 2016/07/28 00:00 [received]
PHST- 2016/12/10 00:00 [revised]
PHST- 2017/04/12 00:00 [accepted]
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(17)30161-7 [pii]
AID - 10.1016/j.ccell.2017.04.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):697-710.e7. doi: 10.1016/j.ccell.2017.04.006.

PMID- 28486107
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
PG  - 685-696.e6
LID - S1535-6108(17)30157-5 [pii]
LID - 10.1016/j.ccell.2017.04.002 [doi]
AB  - Constitutive activation of Galphaq signaling by mutations in GNAQ or GNA11 occurs
      in over 80% of uveal melanomas (UMs) and activates MAPK. Protein kinase C (PKC)
      has been implicated as a link, but the mechanistic details remained unclear. We
      identified PKC delta and varepsilon as required and sufficient to activate MAPK
      in GNAQ mutant melanomas. MAPK activation depends on Ras and is caused by
      RasGRP3, which is significantly and selectively overexpressed in response to
      GNAQ/11 mutation in UM. RasGRP3 activation occurs via PKC delta- and
      varepsilon-dependent phosphorylation and PKC-independent, DAG-mediated membrane
      recruitment, possibly explaining the limited effect of PKC inhibitors to durably 
      suppress MAPK in UM. The findings nominate RasGRP3 as a therapeutic target for
      cancers driven by oncogenic GNAQ/11.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Chen, Xu
AU  - Chen X
AD  - Departments of Dermatology and Pathology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94143, 
      USA. Electronic address: xu.chen@ucsf.edu.
FAU - Wu, Qiuxia
AU  - Wu Q
AD  - Departments of Dermatology and Pathology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94143, 
      USA.
FAU - Depeille, Philippe
AU  - Depeille P
AD  - Department of Anatomy, University of California, San Francisco, San Francisco, CA
      94143, USA.
FAU - Chen, Peirong
AU  - Chen P
AD  - Departments of Dermatology and Pathology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94143, 
      USA.
FAU - Thornton, Sophie
AU  - Thornton S
AD  - Department of Molecular and Clinical Cancer Medicine, Institute of Translational 
      Mewdicine, University of Liverpool, Liverpool L7 8TX, UK.
FAU - Kalirai, Helen
AU  - Kalirai H
AD  - Department of Molecular and Clinical Cancer Medicine, Institute of Translational 
      Mewdicine, University of Liverpool, Liverpool L7 8TX, UK.
FAU - Coupland, Sarah E
AU  - Coupland SE
AD  - Department of Molecular and Clinical Cancer Medicine, Institute of Translational 
      Mewdicine, University of Liverpool, Liverpool L7 8TX, UK.
FAU - Roose, Jeroen P
AU  - Roose JP
AD  - Department of Anatomy, University of California, San Francisco, San Francisco, CA
      94143, USA.
FAU - Bastian, Boris C
AU  - Bastian BC
AD  - Departments of Dermatology and Pathology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94143, 
      USA. Electronic address: boris.bastian@ucsf.edu.
LA  - eng
GR  - P01 AI091580/AI/NIAID NIH HHS/United States
GR  - R01 CA142873/CA/NCI NIH HHS/United States
GR  - U54 CA143874/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Diglycerides)
RN  - 0 (GNA11 protein, human)
RN  - 0 (GNAQ protein, human)
RN  - 0 (GTP-Binding Protein alpha Subunits)
RN  - 0 (Guanine Nucleotide Exchange Factors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (RASGRP3 protein, human)
RN  - EC 2.7.11.13 (PRKCD protein, human)
RN  - EC 2.7.11.13 (PRKCE protein, human)
RN  - EC 2.7.11.13 (Protein Kinase C-delta)
RN  - EC 2.7.11.13 (Protein Kinase C-epsilon)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 3.6.5.1 (GTP-Binding Protein alpha Subunits, Gq-G11)
RN  - Uveal melanoma
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Diglycerides/metabolism
MH  - Enzyme Activation
MH  - Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors/*metabolism
MH  - GTP-Binding Protein alpha Subunits/genetics
MH  - GTP-Binding Protein alpha Subunits, Gq-G11/*genetics/metabolism
MH  - Guanine Nucleotide Exchange Factors/genetics/*metabolism
MH  - Humans
MH  - *MAP Kinase Signaling System/drug effects
MH  - Melanoma/drug therapy/*enzymology/genetics/pathology
MH  - Mice, Nude
MH  - *Mutation
MH  - Phosphorylation
MH  - Protein Kinase C-delta/antagonists & inhibitors/genetics/metabolism
MH  - Protein Kinase C-epsilon/antagonists & inhibitors/genetics/metabolism
MH  - Protein Kinase Inhibitors/pharmacology
MH  - RNA Interference
MH  - Time Factors
MH  - Transfection
MH  - Tumor Burden
MH  - Uveal Neoplasms/drug therapy/*enzymology/genetics/pathology
PMC - PMC5499527
MID - NIHMS867127
OTO - NOTNLM
OT  - *DAG
OT  - *GNA11
OT  - *GNAQ
OT  - *MAPK
OT  - *PKC
OT  - *RasGEF
OT  - *RasGRP3
OT  - *melanoma
OT  - *uveal melanoma
EDAT- 2017/05/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/05/10 06:00
PMCR- 2018/05/08 00:00
PHST- 2015/04/21 00:00 [received]
PHST- 2016/12/07 00:00 [revised]
PHST- 2017/04/05 00:00 [accepted]
PHST- 2018/05/08 00:00 [pmc-release]
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(17)30157-5 [pii]
AID - 10.1016/j.ccell.2017.04.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):685-696.e6. doi: 10.1016/j.ccell.2017.04.002.

PMID- 28486106
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180329
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2.
PG  - 669-684.e7
LID - S1535-6108(17)30159-9 [pii]
LID - 10.1016/j.ccell.2017.04.004 [doi]
AB  - Polyploidy can lead to aneuploidy and tumorigenesis. Here, we report that the
      Hippo pathway effector Yap promotes the diploid-polyploid conversion and
      polyploid cell growth through the Akt-Skp2 axis. Yap strongly induces the
      acetyltransferase p300-mediated acetylation of the E3 ligase Skp2 via Akt
      signaling. Acetylated Skp2 is exclusively localized to the cytosol, which causes 
      hyper-accumulation of the cyclin-dependent kinase inhibitor p27, leading to
      mitotic arrest and subsequently cell polyploidy. In addition, the pro-apoptotic
      factors FoxO1/3 are overly degraded by acetylated Skp2, resulting in polyploid
      cell division, genomic instability, and oncogenesis. Importantly, the depletion
      or inactivation of Akt or Skp2 abrogated Hippo signal deficiency-induced liver
      tumorigenesis, indicating their epistatic interaction. Thus, we conclude that
      Hippo-Yap signaling suppresses cell polyploidy and oncogenesis through Skp2.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zhang, Shihao
AU  - Zhang S
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Chen, Qinghua
AU  - Chen Q
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Liu, Qingxu
AU  - Liu Q
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Li, Yuxi
AU  - Li Y
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Sun, Xiufeng
AU  - Sun X
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Hong, Lixin
AU  - Hong L
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Ji, Suyuan
AU  - Ji S
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Liu, Chengyan
AU  - Liu C
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Geng, Jing
AU  - Geng J
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Zhang, Weiji
AU  - Zhang W
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Lu, Zhonglei
AU  - Lu Z
AD  - Department of Developmental and Molecular Biology, Albert Einstein College of
      Medicine, Bronx, NY 10461, USA.
FAU - Yin, Zhen-Yu
AU  - Yin ZY
AD  - Department of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University,
      Xiamen, Fujian 361004, China.
FAU - Zeng, Yuanyuan
AU  - Zeng Y
AD  - Department of Translational Medicine, Medical College of Xiamen University,
      Xiamen, Fujian 361102, China.
FAU - Lin, Kwang-Huei
AU  - Lin KH
AD  - Department of Biochemistry, College of Medicine, Chang Gung University, Liver
      Research Center, Chang Gung Memorial Hospital, TaoYuan 333, Taiwan, ROC.
FAU - Wu, Qiao
AU  - Wu Q
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Li, Qiyuan
AU  - Li Q
AD  - Department of Translational Medicine, Medical College of Xiamen University,
      Xiamen, Fujian 361102, China.
FAU - Nakayama, Keiko
AU  - Nakayama K
AD  - Division of Cell Proliferation, United Centers for Advanced Research and
      Translational Medicine, Tohoku University Graduate School of Medicine, Sendai
      980-8575, Japan.
FAU - Nakayama, Keiich I
AU  - Nakayama KI
AD  - Division of Cell Regulation Systems, Medical Institute of Bioregulation, Kyushu
      University, Fukuoka 812-8582, Japan.
FAU - Deng, Xianming
AU  - Deng X
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China.
FAU - Johnson, Randy L
AU  - Johnson RL
AD  - Department of Biochemistry and Molecular Biology, University of Texas, M.D.
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zhu, Liang
AU  - Zhu L
AD  - Department of Developmental and Molecular Biology, Albert Einstein College of
      Medicine, Bronx, NY 10461, USA.
FAU - Gao, Daming
AU  - Gao D
AD  - Key Laboratory of System Biology, CAS Center for Excellence in Molecular Cell
      Science, Innovation Center for Cell Signaling Network, Institute of Biochemistry 
      and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of
      Sciences, Shanghai 200031, China.
FAU - Chen, Lanfen
AU  - Chen L
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China. Electronic address: chenlanfen@xmu.edu.cn.
FAU - Zhou, Dawang
AU  - Zhou D
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian
      361102, China. Electronic address: dwzhou@xmu.edu.cn.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P30 DK041296/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (CDKN1B protein, human)
RN  - 0 (Cdkn1b protein, mouse)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Phosphoproteins)
RN  - 0 (S-Phase Kinase-Associated Proteins)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - 0 (Yap protein, mouse)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - EC 2.3.1.48 (p300-CBP Transcription Factors)
RN  - EC 2.3.1.48 (p300-CBP-associated factor)
RN  - EC 2.7.11.1 (Akt1 protein, mouse)
RN  - EC 2.7.11.1 (Hippo protein, human)
RN  - EC 2.7.11.1 (Hippo protein, mouse)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Acetylation
MH  - Adaptor Proteins, Signal Transducing/genetics/metabolism
MH  - Animals
MH  - Carcinoma, Hepatocellular/*enzymology/genetics/pathology
MH  - *Cell Proliferation
MH  - Cell Transformation, Neoplastic/genetics/*metabolism/pathology
MH  - Cyclin-Dependent Kinase Inhibitor p27/genetics/metabolism
MH  - Cytosol/enzymology
MH  - Epistasis, Genetic
MH  - Female
MH  - Forkhead Transcription Factors/genetics/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Hep G2 Cells
MH  - Humans
MH  - Liver Neoplasms/*enzymology/genetics/pathology
MH  - Mice
MH  - Mice, Transgenic
MH  - Phenotype
MH  - Phosphoproteins/genetics/metabolism
MH  - *Ploidies
MH  - Pregnancy
MH  - Protein Stability
MH  - Protein-Serine-Threonine Kinases/genetics/*metabolism
MH  - Proteolysis
MH  - Proto-Oncogene Proteins c-akt/genetics/metabolism
MH  - RNA Interference
MH  - S-Phase Kinase-Associated Proteins/genetics/*metabolism
MH  - Signal Transduction
MH  - Time Factors
MH  - Transfection
MH  - p300-CBP Transcription Factors/metabolism
PMC - PMC5863541
MID - NIHMS949530
OTO - NOTNLM
OT  - *Hippo
OT  - *Skp2
OT  - *Yap
OT  - *genomic instability
OT  - *p27
OT  - *polyploidy
OT  - *tumorigenesis
EDAT- 2017/05/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/05/10 06:00
PHST- 2016/05/23 00:00 [received]
PHST- 2016/11/15 00:00 [revised]
PHST- 2017/04/05 00:00 [accepted]
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(17)30159-9 [pii]
AID - 10.1016/j.ccell.2017.04.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):669-684.e7. doi: 10.1016/j.ccell.2017.04.004.

PMID- 28486105
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180309
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression
      of Multiple Tumor Suppressor Genes.
PG  - 653-668.e7
LID - S1535-6108(17)30160-5 [pii]
LID - 10.1016/j.ccell.2017.04.005 [doi]
AB  - An oncogenic role for CHD4, a NuRD component, is defined for initiating and
      supporting tumor suppressor gene (TSG) silencing in human colorectal cancer. CHD4
      recruits repressive chromatin proteins to sites of DNA damage repair, including
      DNA methyltransferases where it imposes de novo DNA methylation. At TSGs, CHD4
      retention helps maintain DNA hypermethylation-associated transcriptional
      silencing. CHD4 is recruited by the excision repair protein OGG1 for oxidative
      damage to interact with the damage-induced base 8-hydroxydeoxyguanosine (8-OHdG),
      while ZMYND8 recruits it to double-strand breaks. CHD4 knockdown activates
      silenced TSGs, revealing their role for blunting colorectal cancer cell
      proliferation, invasion, and metastases. High CHD4 and 8-OHdG levels plus low
      expression of TSGs strongly correlates with early disease recurrence and
      decreased overall survival.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Xia, Limin
AU  - Xia L
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA; State Key Laboratory of Cancer Biology, National Clinical Research Center
      for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an 710032, Shaanxi, China.
FAU - Huang, Wenjie
AU  - Huang W
AD  - State Key Laboratory of Cancer Biology, National Clinical Research Center for
      Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an 710032, Shaanxi, China.
FAU - Bellani, Marina
AU  - Bellani M
AD  - Laboratory of Molecular Gerontology, National Institute on Aging, Baltimore, MD
      21224, USA.
FAU - Seidman, Michael M
AU  - Seidman MM
AD  - Laboratory of Molecular Gerontology, National Institute on Aging, Baltimore, MD
      21224, USA.
FAU - Wu, Kaichun
AU  - Wu K
AD  - State Key Laboratory of Cancer Biology, National Clinical Research Center for
      Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an 710032, Shaanxi, China.
FAU - Fan, Daiming
AU  - Fan D
AD  - State Key Laboratory of Cancer Biology, National Clinical Research Center for
      Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an 710032, Shaanxi, China.
FAU - Nie, Yongzhan
AU  - Nie Y
AD  - State Key Laboratory of Cancer Biology, National Clinical Research Center for
      Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an 710032, Shaanxi, China.
FAU - Cai, Yi
AU  - Cai Y
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA.
FAU - Zhang, Yang W
AU  - Zhang YW
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA.
FAU - Yu, Li-Rong
AU  - Yu LR
AD  - Biomarkers and Alternative Models Branch, Division of Systems Biology, National
      Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR
      72079, USA.
FAU - Li, Huili
AU  - Li H
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA.
FAU - Zahnow, Cynthia A
AU  - Zahnow CA
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA.
FAU - Xie, Wenbing
AU  - Xie W
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA.
FAU - Chiu Yen, Ray-Whay
AU  - Chiu Yen RW
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA.
FAU - Rassool, Feyruz V
AU  - Rassool FV
AD  - Department of Radiation Oncology, University of Maryland School of Medicine,
      Baltimore, MD 21201, USA. Electronic address: frassool@som.umaryland.edu.
FAU - Baylin, Stephen B
AU  - Baylin SB
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21287,
      USA. Electronic address: sbaylin@jhmi.edu.
LA  - eng
GR  - R01 CA170550/CA/NCI NIH HHS/United States
GR  - R01 ES011858/ES/NIEHS NIH HHS/United States
GR  - Z01 AG000746-01/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Autoantigens)
RN  - 0 (CHD4 protein, human)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Receptors for Activated C Kinase)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (ZMYND8 protein, human)
RN  - 88847-89-6 (8-oxo-7-hydrodeoxyguanosine)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
RN  - EC 2.1.1.43 (EHMT2 protein, human)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 3.2.2.- (DNA Glycosylases)
RN  - EC 3.2.2.- (oxoguanine glycosylase 1, human)
RN  - EC 3.5.1.98 (Mi-2 Nucleosome Remodeling and Deacetylase Complex)
RN  - G9481N71RO (Deoxyguanosine)
SB  - IM
MH  - Animals
MH  - Autoantigens/*genetics/metabolism
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Clustered Regularly Interspaced Short Palindromic Repeats
MH  - Colorectal Neoplasms/enzymology/*genetics/pathology/surgery
MH  - DNA (Cytosine-5-)-Methyltransferases/genetics/metabolism
MH  - DNA Damage
MH  - DNA Glycosylases/genetics/metabolism
MH  - *DNA Methylation
MH  - Deoxyguanosine/analogs & derivatives/metabolism
MH  - Disease-Free Survival
MH  - Down-Regulation
MH  - Enhancer of Zeste Homolog 2 Protein/genetics/metabolism
MH  - *Epigenetic Repression
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Gene Silencing
MH  - *Genes, Tumor Suppressor
MH  - HCT116 Cells
MH  - Histocompatibility Antigens/genetics/metabolism
MH  - Histone-Lysine N-Methyltransferase/genetics/metabolism
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Mi-2 Nucleosome Remodeling and Deacetylase Complex/*genetics/metabolism
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Neoplasm Metastasis
MH  - Oxidative Stress
MH  - Proportional Hazards Models
MH  - RNA Interference
MH  - Receptors for Activated C Kinase
MH  - Receptors, Cell Surface/genetics/metabolism
MH  - Time Factors
MH  - Transcription, Genetic
MH  - Transfection
MH  - Tumor Suppressor Proteins
PMC - PMC5587180
MID - NIHMS899985
OTO - NOTNLM
OT  - *Chromodomain helicase DNA-binding protein 4
OT  - *DNA methylation
OT  - *DNA methyltransferase
OT  - *colorectal cancer
OT  - *double strand break
OT  - *histone modification
OT  - *metastases
OT  - *nucleosome remodeling and histone deacetylation complex
OT  - *oxidative damage
OT  - *tumor suppressor gene
EDAT- 2017/05/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/05/10 06:00
PHST- 2016/09/09 00:00 [received]
PHST- 2017/01/30 00:00 [revised]
PHST- 2017/04/07 00:00 [accepted]
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(17)30160-5 [pii]
AID - 10.1016/j.ccell.2017.04.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):653-668.e7. doi: 10.1016/j.ccell.2017.04.005.

PMID- 28486104
OWN - NLM
STAT- MEDLINE
DCOM- 20171025
LR  - 20171025
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation.
PG  - 619-620
LID - S1535-6108(17)30156-3 [pii]
LID - 10.1016/j.ccell.2017.04.001 [doi]
FAU - Elkashef, Sara M
AU  - Elkashef SM
AD  - Division of Hematology and Medical Oncology, Department of Medicine, University
      of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San
      Antonio, TX 78229, USA.
FAU - Lin, An-Ping
AU  - Lin AP
AD  - Division of Hematology and Medical Oncology, Department of Medicine, University
      of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San
      Antonio, TX 78229, USA.
FAU - Myers, Jamie
AU  - Myers J
AD  - Division of Hematology and Medical Oncology, Department of Medicine, University
      of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San
      Antonio, TX 78229, USA.
FAU - Sill, Heinz
AU  - Sill H
AD  - Division of Hematology, Medical University of Graz, A-8036 Graz, Austria.
FAU - Jiang, Daifeng
AU  - Jiang D
AD  - Division of Hematology and Medical Oncology, Department of Medicine, University
      of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San
      Antonio, TX 78229, USA.
FAU - Dahia, Patricia L M
AU  - Dahia PLM
AD  - Division of Hematology and Medical Oncology, Department of Medicine, University
      of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San
      Antonio, TX 78229, USA; Greehey Children's Cancer Research Institute, University 
      of Texas Health Sciences Center at San Antonio, San Antonio, TX 78229, USA.
FAU - Aguiar, Ricardo C T
AU  - Aguiar RCT
AD  - Division of Hematology and Medical Oncology, Department of Medicine, University
      of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San
      Antonio, TX 78229, USA; Greehey Children's Cancer Research Institute, University 
      of Texas Health Sciences Center at San Antonio, San Antonio, TX 78229, USA; South
      Texas Veterans Health Care System, Audie Murphy VA Hospital, San Antonio, TX
      78229, USA. Electronic address: aguiarr@uthscsa.edu.
LA  - eng
GR  - I01 BX001882/BX/BLRD VA/United States
GR  - P30 CA054174/CA/NCI NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 63231-63-0 (RNA)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
SB  - IM
CON - Cancer Cell. 2017 Jan 9;31(1):127-141. PMID: 28017614
MH  - Glioma/*genetics
MH  - Humans
MH  - Isocitrate Dehydrogenase/*genetics
MH  - Methylation
MH  - Mutation
MH  - RNA
PMC - PMC5506849
MID - NIHMS870226
EDAT- 2017/05/10 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/05/10 06:00
PMCR- 2018/05/08 00:00
PHST- 2017/03/09 00:00 [received]
PHST- 2017/03/28 00:00 [revised]
PHST- 2017/03/31 00:00 [accepted]
PHST- 2018/05/08 00:00 [pmc-release]
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1535-6108(17)30156-3 [pii]
AID - 10.1016/j.ccell.2017.04.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):619-620. doi: 10.1016/j.ccell.2017.04.001.

PMID- 28486103
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.
PG  - 616-618
LID - S1535-6108(17)30165-4 [pii]
LID - 10.1016/j.ccell.2017.04.010 [doi]
AB  - Phosphoinositide-3-kinase (PI3K) pathway inhibitors have emerged as promising
      therapeutic agents for estrogen receptor (ERalpha)-positive breast cancers.
      However, incipient resistance limits the clinical benefit. Toska and colleagues
      identified that the epigenetic regulator KMT2D enhances ERalpha activity in
      BYL719-treated PIK3CA mutant breast cancer, leading to a rationale for targeting 
      the epigenome and PI3K signaling.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Koren, Shany
AU  - Koren S
AD  - Department of Biomedicine, University of Basel, University Hospital Basel, 4031
      Basel, Switzerland.
FAU - Bentires-Alj, Mohamed
AU  - Bentires-Alj M
AD  - Department of Biomedicine, University of Basel, University Hospital Basel, 4031
      Basel, Switzerland. Electronic address: m.bentires-alj@unibas.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
SB  - IM
CON - Science. 2017 Mar 24;355(6331):1324-1330. PMID: 28336670
MH  - Breast Neoplasms
MH  - *Cell Line, Tumor
MH  - Estrogen Receptor alpha
MH  - Humans
MH  - Mutation/drug effects
MH  - Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
MH  - Protein Kinase Inhibitors
MH  - Receptors, Estrogen
MH  - Signal Transduction/drug effects
EDAT- 2017/05/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30165-4 [pii]
AID - 10.1016/j.ccell.2017.04.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):616-618. doi: 10.1016/j.ccell.2017.04.010.

PMID- 28486102
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - Tumor Microenvironment: No Effector T Cells without Dendritic Cells.
PG  - 614-615
LID - S1535-6108(17)30162-9 [pii]
LID - 10.1016/j.ccell.2017.04.007 [doi]
AB  - Successful antitumor immunity is thought to require T cell entry into tumors,
      though mechanisms regulating this process remain unclear. In this issue of Cancer
      Cell, Spranger et al. indicate that chemokines produced by intratumoral Batf3
      dendritic cells are critical for effector T cell recruitment. The findings have
      implications for immunotherapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Pfirschke, Christina
AU  - Pfirschke C
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Siwicki, Marie
AU  - Siwicki M
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Liao, Hsin-Wei
AU  - Liao HW
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Pittet, Mikael J
AU  - Pittet MJ
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA. Electronic address: mpittet@mgh.harvard.edu.
LA  - eng
GR  - R01 AI084880/AI/NIAID NIH HHS/United States
GR  - R01 CA206890/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chemokines)
SB  - IM
CON - Cancer Cell. 2017 May 8;31(5):711-723.e4. PMID: 28486109
MH  - Chemokines/immunology
MH  - Dendritic Cells/immunology
MH  - Humans
MH  - Immunotherapy
MH  - T-Lymphocytes/*immunology
MH  - Tumor Microenvironment/*immunology
EDAT- 2017/05/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30162-9 [pii]
AID - 10.1016/j.ccell.2017.04.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):614-615. doi: 10.1016/j.ccell.2017.04.007.

PMID- 28486101
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - The Tribble with APL: A New Road to Therapy.
PG  - 612-613
LID - S1535-6108(17)30166-6 [pii]
LID - 10.1016/j.ccell.2017.04.011 [doi]
AB  - The t(15;17) translocation generates a PML-RARalpha fusion protein causative for 
      acute promyelocytic leukemia (APL). Li et al. now identify the pseudokinase
      stress protein TRIB3 as an important factor in APL disease progression and
      therapy resistance. Targeting the interaction of TRIB3 and PML-RARalpha using
      peptide technology provides a novel therapeutic approach.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Carmody, Ruaidhri
AU  - Carmody R
AD  - Centre for Immunobiology, Institute of Infection, Immunity and Inflammation,
      College of Medicine, Veterinary and Life Sciences, University of Glasgow,
      Glasgow, G12 8TA, UK.
FAU - Keeshan, Karen
AU  - Keeshan K
AD  - Paul O'Gorman Leukaemia Research Centre, College of Medicine, Veterinary and Life
      Sciences, Institute of Cancer Sciences, University of Glasgow, Glasgow, G12 0XB, 
      UK. Electronic address: karen.keeshan@glasgow.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
CON - Cancer Cell. 2017 May 8;31(5):697-710.e7. PMID: 28486108
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute
MH  - Neoplasm Proteins/*genetics
MH  - Oncogene Proteins, Fusion/genetics
MH  - Translocation, Genetic
MH  - *Tretinoin
EDAT- 2017/05/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30166-6 [pii]
AID - 10.1016/j.ccell.2017.04.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):612-613. doi: 10.1016/j.ccell.2017.04.011.

PMID- 28486100
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer.
PG  - 609-611
LID - S1535-6108(17)30163-0 [pii]
LID - 10.1016/j.ccell.2017.04.008 [doi]
AB  - In this issue of Cancer Cell, Nagaraja et al. dissect the molecular mechanisms
      underlying therapeutic responses to transcriptional disruptors in the fatal
      pediatric brain tumor, diffuse intrinsic pontine glioma (DIPG). Moreover, they
      identify super-enhancers mediating these effects, highlighting how normal brain
      developmental programs can be hijacked in cancer.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Chheda, Milan G
AU  - Chheda MG
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO
      63110, USA; Department of Neurology, Washington University School of Medicine,
      St. Louis, MO 63110, USA.
FAU - Gutmann, David H
AU  - Gutmann DH
AD  - Department of Neurology, Washington University School of Medicine, St. Louis, MO 
      63110, USA. Electronic address: gutmannd@wustl.edu.
LA  - eng
GR  - R35 NS097211/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 May 8;31(5):635-652.e6. PMID: 28434841
MH  - Brain
MH  - *Brain Stem Neoplasms
MH  - Child
MH  - Epigenomics
MH  - *Glioma
MH  - Humans
EDAT- 2017/05/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30163-0 [pii]
AID - 10.1016/j.ccell.2017.04.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):609-611. doi: 10.1016/j.ccell.2017.04.008.

PMID- 28486099
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - A TIAM Double Hit to Oppose YAP/TAZ.
PG  - 607-608
LID - S1535-6108(17)30164-2 [pii]
LID - 10.1016/j.ccell.2017.04.009 [doi]
AB  - In this issue of Cancer Cell, Diamantopoulou et al. uncover dual mechanisms of
      inhibiting YAP/TAZ by TIAM1 that oppose invasiveness of colorectal cancer cells: 
      TIAM1 interacts with TAZ in the cytoplasm to promote TAZ degradation by the
      destruction complex, whereas it antagonizes binding of TAZ/YAP to TEAD in the
      nucleus.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Azzolin, Luca
AU  - Azzolin L
AD  - Department of Molecular Medicine, University of Padua School of Medicine, viale
      Colombo 3, 35126 Padua, Italy.
FAU - Piccolo, Stefano
AU  - Piccolo S
AD  - Department of Molecular Medicine, University of Padua School of Medicine, viale
      Colombo 3, 35126 Padua, Italy. Electronic address: piccolo@bio.unipd.it.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Phosphoproteins)
RN  - 0 (Transcription Factors)
SB  - IM
CON - Cancer Cell. 2017 May 8;31(5):621-634.e6. PMID: 28416184
MH  - *Adaptor Proteins, Signal Transducing
MH  - Cell Nucleus
MH  - Colorectal Neoplasms
MH  - Humans
MH  - *Phosphoproteins
MH  - Signal Transduction
MH  - Transcription Factors
EDAT- 2017/05/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(17)30164-2 [pii]
AID - 10.1016/j.ccell.2017.04.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):607-608. doi: 10.1016/j.ccell.2017.04.009.

PMID- 28434841
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180319
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
PG  - 635-652.e6
LID - S1535-6108(17)30107-1 [pii]
LID - 10.1016/j.ccell.2017.03.011 [doi]
AB  - Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric cancer with limited 
      therapeutic options. The majority of cases of DIPG exhibit a mutation in
      histone-3 (H3K27M) that results in oncogenic transcriptional aberrancies. We show
      here that DIPG is vulnerable to transcriptional disruption using bromodomain
      inhibition or CDK7 blockade. Targeting oncogenic transcription through either of 
      these methods synergizes with HDAC inhibition, and DIPG cells resistant to HDAC
      inhibitor therapy retain sensitivity to CDK7 blockade. Identification of
      super-enhancers in DIPG provides insights toward the cell of origin, highlighting
      oligodendroglial lineage genes, and reveals unexpected mechanisms mediating tumor
      viability and invasion, including potassium channel function and EPH receptor
      signaling. The findings presented demonstrate transcriptional vulnerabilities and
      elucidate previously unknown mechanisms of DIPG pathobiology.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Nagaraja, Surya
AU  - Nagaraja S
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA.
FAU - Vitanza, Nicholas A
AU  - Vitanza NA
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA.
FAU - Woo, Pamelyn J
AU  - Woo PJ
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA.
FAU - Taylor, Kathryn R
AU  - Taylor KR
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA.
FAU - Liu, Fang
AU  - Liu F
AD  - Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of
      Education, Department of Pathophysiology, Shanghai Jiao Tong University School of
      Medicine, 280 South Chongqing Road, Shanghai 200025, P.R. China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of
      Education, Department of Pathophysiology, Shanghai Jiao Tong University School of
      Medicine, 280 South Chongqing Road, Shanghai 200025, P.R. China.
FAU - Li, Meng
AU  - Li M
AD  - Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of
      Education, Department of Pathophysiology, Shanghai Jiao Tong University School of
      Medicine, 280 South Chongqing Road, Shanghai 200025, P.R. China.
FAU - Meng, Wei
AU  - Meng W
AD  - Department of Pediatric Neurosurgery, Xin Hua Hospital Affiliated to Shanghai
      Jiao Tong University School of Medicine, Shanghai 200092, P.R. China.
FAU - Ponnuswami, Anitha
AU  - Ponnuswami A
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA.
FAU - Sun, Wenchao
AU  - Sun W
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA.
FAU - Ma, Jie
AU  - Ma J
AD  - Department of Pediatric Neurosurgery, Xin Hua Hospital Affiliated to Shanghai
      Jiao Tong University School of Medicine, Shanghai 200092, P.R. China.
FAU - Hulleman, Esther
AU  - Hulleman E
AD  - Department of Pediatric Oncology, VU University Medical Center, 1081 HV
      Amsterdam, the Netherlands.
FAU - Swigut, Tomek
AU  - Swigut T
AD  - Department of Chemical and Systems Biology, Stanford University, Palo Alto, CA
      94305, USA.
FAU - Wysocka, Joanna
AU  - Wysocka J
AD  - Department of Chemical and Systems Biology, Stanford University, Palo Alto, CA
      94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford
      University, Palo Alto, California 94305, USA; Department of Developmental
      Biology, Stanford University, Palo Alto, California 94305, USA; Howard Hughes
      Medical Institute, Stanford School of Medicine, Stanford University, Palo Alto,
      California 94305, USA.
FAU - Tang, Yujie
AU  - Tang Y
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA; Key
      Laboratory of Cell Differentiation and Apoptosis of National Ministry of
      Education, Department of Pathophysiology, Shanghai Jiao Tong University School of
      Medicine, 280 South Chongqing Road, Shanghai 200025, P.R. China; Department of
      Pediatric Neurosurgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong
      University School of Medicine, Shanghai 200092, P.R. China. Electronic address:
      yujietang@shsmu.edu.cn.
FAU - Monje, Michelle
AU  - Monje M
AD  - Department of Neurology, Stanford University, Palo Alto, CA 94305, USA; Institute
      for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, 
      California 94305, USA. Electronic address: mmonje@stanford.edu.
LA  - eng
GR  - P30 CA124435/CA/NCI NIH HHS/United States
GR  - R01 NS092597/NS/NINDS NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - R01 GM112720/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20170420
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 ((+)-JQ1 compound)
RN  - 0 (Azepines)
RN  - 0 (BRD4 protein, human)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Histones)
RN  - 0 (Hydroxamic Acids)
RN  - 0 (Indoles)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Phenylenediamines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (THZ1 compound)
RN  - 0 (Transcription Factors)
RN  - 0 (Triazoles)
RN  - 9647FM7Y3Z (panobinostat)
RN  - EC 2.7.10.1 (Receptors, Eph Family)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
RN  - EC 2.7.11.22 (cyclin-dependent kinase-activating kinase)
SB  - IM
CIN - Cancer Cell. 2017 May 8;31(5):609-611. PMID: 28486100
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Azepines/*pharmacology
MH  - Brain Stem Neoplasms/*drug therapy/genetics/metabolism/pathology
MH  - Cell Proliferation/drug effects
MH  - Chromatin Assembly and Disassembly/drug effects
MH  - Cyclin-Dependent Kinases/antagonists & inhibitors/genetics/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance, Neoplasm
MH  - Drug Synergism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Glioma/*drug therapy/genetics/metabolism/pathology
MH  - Histone Deacetylase Inhibitors/*pharmacology
MH  - Histones/genetics/metabolism
MH  - Humans
MH  - Hydroxamic Acids/*pharmacology
MH  - Indoles/*pharmacology
MH  - Male
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Mutation
MH  - Nuclear Proteins/antagonists & inhibitors/genetics/metabolism
MH  - Phenylenediamines/*pharmacology
MH  - Primary Cell Culture
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Pyrimidines/*pharmacology
MH  - RNA Interference
MH  - Receptors, Eph Family/genetics/metabolism
MH  - Signal Transduction/drug effects
MH  - Time Factors
MH  - Transcription Factors/antagonists & inhibitors/genetics/metabolism
MH  - Transcription, Genetic/*drug effects
MH  - Transfection
MH  - Triazoles/*pharmacology
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC5462626
MID - NIHMS863827
OTO - NOTNLM
OT  - *BRD4
OT  - *CDK7
OT  - *DIPG
OT  - *EPH
OT  - *oligodendrocyte precursor cell
OT  - *potassium channel
OT  - *super-enhancer
EDAT- 2017/04/25 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/04/25 06:00
PMCR- 2018/05/08 00:00
PHST- 2016/08/29 00:00 [received]
PHST- 2016/12/27 00:00 [revised]
PHST- 2017/03/22 00:00 [accepted]
PHST- 2018/05/08 00:00 [pmc-release]
PHST- 2017/04/25 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
PHST- 2017/04/25 06:00 [entrez]
AID - S1535-6108(17)30107-1 [pii]
AID - 10.1016/j.ccell.2017.03.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):635-652.e6. doi: 10.1016/j.ccell.2017.03.011. Epub 
      2017 Apr 20.

PMID- 28416184
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May 8
TI  - TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in
      the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells.
PG  - 621-634.e6
LID - S1535-6108(17)30103-4 [pii]
LID - 10.1016/j.ccell.2017.03.007 [doi]
AB  - Aberrant WNT signaling drives colorectal cancer (CRC). Here, we identify TIAM1 as
      a critical antagonist of CRC progression through inhibiting TAZ and YAP,
      effectors of WNT signaling. We demonstrate that TIAM1 shuttles between the
      cytoplasm and nucleus antagonizing TAZ/YAP by distinct mechanisms in the two
      compartments. In the cytoplasm, TIAM1 localizes to the destruction complex and
      promotes TAZ degradation by enhancing its interaction with betaTrCP. Nuclear
      TIAM1 suppresses TAZ/YAP interaction with TEADs, inhibiting expression of TAZ/YAP
      target genes implicated in epithelial-mesenchymal transition, cell migration, and
      invasion, and consequently suppresses CRC cell migration and invasion.
      Importantly, high nuclear TIAM1 in clinical specimens associates with increased
      CRC patient survival. Together, our findings suggest that in CRC TIAM1 suppresses
      tumor progression by regulating YAP/TAZ activity.
CI  - Copyright (c) 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Diamantopoulou, Zoi
AU  - Diamantopoulou Z
AD  - Cell Signalling Group, Cancer Research UK Manchester Institute, The University of
      Manchester, Manchester M20 4BX, UK.
FAU - White, Gavin
AU  - White G
AD  - Cell Signalling Group, Cancer Research UK Manchester Institute, The University of
      Manchester, Manchester M20 4BX, UK.
FAU - Fadlullah, Muhammad Z H
AU  - Fadlullah MZH
AD  - Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK; Stem Cell Biology Group, Cancer
      Research UK Manchester Institute, The University of Manchester, Manchester M20
      4BX, UK.
FAU - Dreger, Marcel
AU  - Dreger M
AD  - School of Medical Sciences, Faculty of Biology, Medicine and Health, The
      University of Manchester, Manchester M13 9PT, UK.
FAU - Pickering, Karen
AU  - Pickering K
AD  - Colorectal Cancer and Wnt Signalling, Cancer Research UK Beatson Institute,
      Glasgow G61 1BD, UK.
FAU - Maltas, Joe
AU  - Maltas J
AD  - Cell Signalling Group, Cancer Research UK Manchester Institute, The University of
      Manchester, Manchester M20 4BX, UK.
FAU - Ashton, Garry
AU  - Ashton G
AD  - Histology, Cancer Research UK Manchester Institute, The University of Manchester,
      Manchester M20 4BX, UK.
FAU - MacLeod, Ruth
AU  - MacLeod R
AD  - Institute of Cardiovascular and Medical Science, College of Medical Veterinary
      and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
FAU - Baillie, George S
AU  - Baillie GS
AD  - Institute of Cardiovascular and Medical Science, College of Medical Veterinary
      and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
FAU - Kouskoff, Valerie
AU  - Kouskoff V
AD  - Stem Cell Haematopoiesis Group, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Lacaud, Georges
AU  - Lacaud G
AD  - Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University 
      of Manchester, Manchester M20 4BX, UK.
FAU - Murray, Graeme I
AU  - Murray GI
AD  - Pathology, School of Medicine, Medical Sciences and Nutrition, University of
      Aberdeen, Aberdeen AB25 2ZD, UK.
FAU - Sansom, Owen J
AU  - Sansom OJ
AD  - Colorectal Cancer and Wnt Signalling, Cancer Research UK Beatson Institute,
      Glasgow G61 1BD, UK.
FAU - Hurlstone, Adam F L
AU  - Hurlstone AFL
AD  - School of Medical Sciences, Faculty of Biology, Medicine and Health, The
      University of Manchester, Manchester M13 9PT, UK.
FAU - Malliri, Angeliki
AU  - Malliri A
AD  - Cell Signalling Group, Cancer Research UK Manchester Institute, The University of
      Manchester, Manchester M20 4BX, UK. Electronic address:
      angeliki.malliri@cruk.manchester.ac.uk.
LA  - eng
GR  - MR/L007495/1/Medical Research Council/United Kingdom
GR  - C5759/A12328/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170413
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (BTRC protein, human)
RN  - 0 (Guanine Nucleotide Exchange Factors)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (T-Lymphoma Invasion and Metastasis-inducing Protein 1)
RN  - 0 (TIAM1 protein, human)
RN  - 0 (Tiam1 protein, mouse)
RN  - 0 (WWTR1 protein, human)
RN  - 0 (Wwtr1 protein, mouse)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - 0 (Yap protein, mouse)
RN  - 0 (beta-Transducin Repeat-Containing Proteins)
SB  - IM
CIN - Cancer Cell. 2017 May 8;31(5):607-608. PMID: 28486099
MH  - Active Transport, Cell Nucleus
MH  - Adaptor Proteins, Signal Transducing/genetics/*metabolism
MH  - Animals
MH  - Caco-2 Cells
MH  - *Cell Movement
MH  - Cell Nucleus/metabolism
MH  - Cell Proliferation
MH  - Colorectal Neoplasms/genetics/*metabolism/pathology
MH  - Cytoplasm/metabolism
MH  - Epithelial Cells/*metabolism/pathology
MH  - Epithelial-Mesenchymal Transition
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Guanine Nucleotide Exchange Factors/deficiency/genetics/*metabolism
MH  - Humans
MH  - Intestinal Mucosa/*metabolism/pathology
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Mice, 129 Strain
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neoplasm Invasiveness
MH  - Phenotype
MH  - Phosphoproteins/genetics/*metabolism
MH  - Proteolysis
MH  - RNA Interference
MH  - T-Lymphoma Invasion and Metastasis-inducing Protein 1
MH  - Transcription, Genetic
MH  - Transfection
MH  - Wnt Signaling Pathway
MH  - Zebrafish/embryology
MH  - beta-Transducin Repeat-Containing Proteins/genetics/metabolism
PMC - PMC5425402
OTO - NOTNLM
OT  - *TAZ
OT  - *TIAM1
OT  - *WNT
OT  - *YAP
OT  - *cell migration
OT  - *colorectal cancer
OT  - *intestinal tumorigenesis
OT  - *invasion
OT  - *malignant progression
EDAT- 2017/04/19 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/04/19 06:00
PHST- 2016/07/26 00:00 [received]
PHST- 2017/02/07 00:00 [revised]
PHST- 2017/03/20 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - S1535-6108(17)30103-4 [pii]
AID - 10.1016/j.ccell.2017.03.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 May 8;31(5):621-634.e6. doi: 10.1016/j.ccell.2017.03.007. Epub 
      2017 Apr 13.

PMID- 28399412
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180403
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
PG  - 576-590.e8
LID - S1535-6108(17)30100-9 [pii]
LID - 10.1016/j.ccell.2017.03.004 [doi]
AB  - Cyclins and cyclin-dependent kinases (CDKs) are hyperactivated in numerous human 
      tumors. To identify means of interfering with cyclins/CDKs, we performed nine
      genome-wide screens for human microRNAs (miRNAs) directly regulating cell-cycle
      proteins. We uncovered a distinct class of miRNAs that target nearly all
      cyclins/CDKs, which are very effective in inhibiting cancer cell proliferation.
      By profiling the response of over 120 human cancer cell lines, we derived an
      expression-based algorithm that can predict the response of tumors to
      cell-cycle-targeting miRNAs. Using systemic administration of
      nanoparticle-formulated miRNAs, we inhibited tumor progression in seven mouse
      xenograft models, including three treatment-refractory patient-derived tumors,
      without affecting normal tissues. Our results highlight the utility of using
      cell-cycle-targeting miRNAs for treatment of refractory cancer types.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hydbring, Per
AU  - Hydbring P
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA;
      Department of Oncology-Pathology, Karolinska Institutet, 17176 Stockholm, Sweden.
FAU - Wang, Yinan
AU  - Wang Y
AD  - Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary 
      Studies, School of Life Sciences, Center for Life Sciences and Center for
      Statistical Science, Peking University, Beijing 100871, China.
FAU - Fassl, Anne
AU  - Fassl A
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Li, Xiaoting
AU  - Li X
AD  - School of Life Sciences, Tsinghua University, Beijing 100084, China.
FAU - Matia, Veronica
AU  - Matia V
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Otto, Tobias
AU  - Otto T
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Choi, Yoon Jong
AU  - Choi YJ
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Sweeney, Katharine E
AU  - Sweeney KE
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Suski, Jan M
AU  - Suski JM
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Yin, Hao
AU  - Yin H
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02142, USA.
FAU - Bogorad, Roman L
AU  - Bogorad RL
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02142, USA.
FAU - Goel, Shom
AU  - Goel S
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - Yuzugullu, Haluk
AU  - Yuzugullu H
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Kauffman, Kevin J
AU  - Kauffman KJ
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02142, USA.
FAU - Yang, Junghoon
AU  - Yang J
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02142, USA.
FAU - Jin, Chong
AU  - Jin C
AD  - Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary 
      Studies, School of Life Sciences, Center for Life Sciences and Center for
      Statistical Science, Peking University, Beijing 100871, China.
FAU - Li, Yingxiang
AU  - Li Y
AD  - Department of Bioinformatics, School of Life Science and Technology, Tongji
      University, Shanghai 200092, China.
FAU - Floris, Davide
AU  - Floris D
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Swanson, Richard
AU  - Swanson R
AD  - Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Ng, Kimmie
AU  - Ng K
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Sicinska, Ewa
AU  - Sicinska E
AD  - Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - Anders, Lars
AU  - Anders L
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Zhao, Jean J
AU  - Zhao JJ
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Polyak, Kornelia
AU  - Polyak K
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
FAU - Anderson, Daniel G
AU  - Anderson DG
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02142, USA; Department of Chemical Engineering,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Institute for
      Medical Engineering and Science, Massachusetts Institute of Technology,
      Cambridge, MA 02142, USA; Harvard-MIT Division of Health Sciences & Technology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
FAU - Li, Cheng
AU  - Li C
AD  - Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary 
      Studies, School of Life Sciences, Center for Life Sciences and Center for
      Statistical Science, Peking University, Beijing 100871, China. Electronic
      address: cheng_li@pku.edu.cn.
FAU - Sicinski, Piotr
AU  - Sicinski P
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
      Electronic address: peter_sicinski@dfci.harvard.edu.
LA  - eng
GR  - R01 CA083688/CA/NCI NIH HHS/United States
GR  - P01 CA080111/CA/NCI NIH HHS/United States
GR  - R01 CA202634/CA/NCI NIH HHS/United States
GR  - R01 CA132740/CA/NCI NIH HHS/United States
GR  - R01 CA190509/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (KRAS protein, human)
RN  - 0 (MIRN193 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
CIN - Cancer Cell. 2017 Apr 10;31(4):471-473. PMID: 28399406
MH  - 3' Untranslated Regions
MH  - Algorithms
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Breast Neoplasms/drug therapy/genetics
MH  - Cell Cycle/*genetics
MH  - Cell Line, Tumor
MH  - Drug Delivery Systems/methods
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genome-Wide Association Study
MH  - Humans
MH  - Mice, Inbred Strains
MH  - MicroRNAs/administration & dosage/*genetics/pharmacology
MH  - Mutation
MH  - Nanoparticles
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC5425285
MID - NIHMS860727
OTO - NOTNLM
OT  - *cancers
OT  - *cell cycle
OT  - *cyclin-dependent kinases
OT  - *cyclins
OT  - *microRNAs
EDAT- 2017/04/12 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/04/12 06:00
PMCR- 2018/04/10 00:00
PHST- 2016/01/22 00:00 [received]
PHST- 2016/12/06 00:00 [revised]
PHST- 2017/03/09 00:00 [accepted]
PHST- 2018/04/10 00:00 [pmc-release]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - S1535-6108(17)30100-9 [pii]
AID - 10.1016/j.ccell.2017.03.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):576-590.e8. doi: 10.1016/j.ccell.2017.03.004.

PMID- 28399411
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated
      Colon Cancer Progression.
PG  - 563-575.e5
LID - S1535-6108(17)30102-2 [pii]
LID - 10.1016/j.ccell.2017.03.006 [doi]
AB  - Aberrant activation of the SRC family kinase hematopoietic cell kinase (HCK)
      triggers hematological malignancies as a tumor cell-intrinsic oncogene. Here we
      find that high HCK levels correlate with reduced survival of colorectal cancer
      patients. Likewise, increased Hck activity in mice promotes the growth of
      endogenous colonic malignancies and of human colorectal cancer cell xenografts.
      Furthermore, tumor-associated macrophages of the corresponding tumors show a
      pronounced alternatively activated endotype, which occurs independently of mature
      lymphocytes or of Stat6-dependent Th2 cytokine signaling. Accordingly,
      pharmacological inhibition or genetic reduction of Hck activity suppresses
      alternative activation of tumor-associated macrophages and the growth of colon
      cancer xenografts. Thus, Hck may serve as a promising therapeutic target for
      solid malignancies.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Poh, Ashleigh R
AU  - Poh AR
AD  - Olivia Newton-John Cancer Research Institute, La Trobe University School of
      Cancer Medicine, Heidelberg, VIC 3084, Australia; The Walter and Eliza Hall
      Institute of Medical Research, Department of Medical Biology, University of
      Melbourne, Melbourne, VIC 3052, Australia.
FAU - Love, Christopher G
AU  - Love CG
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia.
FAU - Masson, Frederick
AU  - Masson F
AD  - Olivia Newton-John Cancer Research Institute, La Trobe University School of
      Cancer Medicine, Heidelberg, VIC 3084, Australia.
FAU - Preaudet, Adele
AU  - Preaudet A
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia.
FAU - Tsui, Cary
AU  - Tsui C
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia.
FAU - Whitehead, Lachlan
AU  - Whitehead L
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia.
FAU - Monard, Simon
AU  - Monard S
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia.
FAU - Khakham, Yelena
AU  - Khakham Y
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia.
FAU - Burstroem, Lotta
AU  - Burstroem L
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia.
FAU - Lessene, Guillaume
AU  - Lessene G
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia; Department of
      Pharmacology and Therapeutics, University of Melbourne, Melbourne, VIC 3010,
      Australia.
FAU - Sieber, Oliver
AU  - Sieber O
AD  - The Walter and Eliza Hall Institute of Medical Research, Department of Medical
      Biology, University of Melbourne, Melbourne, VIC 3052, Australia; Department of
      Colorectal Surgery, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia;
      School of Biomedical Sciences, Monash University, Clayton, VIC 3800, Australia.
FAU - Lowell, Clifford
AU  - Lowell C
AD  - Department of Pathology and Laboratory Medicine, University of California, San
      Francisco, CA 94143, USA.
FAU - Putoczki, Tracy L
AU  - Putoczki TL
AD  - Olivia Newton-John Cancer Research Institute, La Trobe University School of
      Cancer Medicine, Heidelberg, VIC 3084, Australia; The Walter and Eliza Hall
      Institute of Medical Research, Department of Medical Biology, University of
      Melbourne, Melbourne, VIC 3052, Australia.
FAU - O'Donoghue, Robert J J
AU  - O'Donoghue RJJ
AD  - Olivia Newton-John Cancer Research Institute, La Trobe University School of
      Cancer Medicine, Heidelberg, VIC 3084, Australia; The Walter and Eliza Hall
      Institute of Medical Research, Department of Medical Biology, University of
      Melbourne, Melbourne, VIC 3052, Australia. Electronic address:
      robert.odonoghue@onjcri.org.au.
FAU - Ernst, Matthias
AU  - Ernst M
AD  - Olivia Newton-John Cancer Research Institute, La Trobe University School of
      Cancer Medicine, Heidelberg, VIC 3084, Australia; The Walter and Eliza Hall
      Institute of Medical Research, Department of Medical Biology, University of
      Melbourne, Melbourne, VIC 3052, Australia. Electronic address:
      matthias.ernst@onjcri.org.au.
LA  - eng
GR  - R01 AI065495/AI/NIAID NIH HHS/United States
GR  - R01 AI068150/AI/NIAID NIH HHS/United States
GR  - R01 AI113272/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 0 (RK-20449)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - 0 (Stat3 protein, mouse)
RN  - EC 2.7.10.2 (HCK protein, human)
RN  - EC 2.7.10.2 (Hck protein, mouse)
RN  - EC 2.7.10.2 (Proto-Oncogene Proteins c-hck)
SB  - IM
MH  - Animals
MH  - Colonic Neoplasms/genetics/metabolism/*pathology
MH  - Colorectal Neoplasms/genetics/*metabolism/*mortality/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Macrophage Activation/genetics
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Proto-Oncogene Proteins c-hck/antagonists & inhibitors/genetics/*metabolism
MH  - Pyrimidines/pharmacology
MH  - Pyrroles/pharmacology
MH  - STAT3 Transcription Factor/metabolism
MH  - Signal Transduction
MH  - Stromal Cells/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5479329
MID - NIHMS867943
OTO - NOTNLM
OT  - *SRC family kinases
OT  - *alternative macrophage polarization
OT  - *colitis-associated colon cancer
OT  - *colorectal cancer
OT  - *hematopoietic cell kinase
OT  - *mouse model
OT  - *stat3
OT  - *tumor microenvironment
OT  - *tyrosine kinase inhibitor
OT  - *xenograft
EDAT- 2017/04/12 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/04/12 06:00
PHST- 2016/06/15 00:00 [received]
PHST- 2017/01/08 00:00 [revised]
PHST- 2017/03/16 00:00 [accepted]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - S1535-6108(17)30102-2 [pii]
AID - 10.1016/j.ccell.2017.03.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):563-575.e5. doi: 10.1016/j.ccell.2017.03.006.

PMID- 28399410
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing
      miR-146a in Acute Myeloid Leukemia.
PG  - 549-562.e11
LID - S1535-6108(17)30063-6 [pii]
LID - 10.1016/j.ccell.2017.03.001 [doi]
AB  - The transcription factor Meis1 drives myeloid leukemogenesis in the context of
      Hox gene overexpression but is currently considered undruggable. We therefore
      investigated whether myeloid progenitor cells transformed by Hoxa9 and Meis1
      become addicted to targetable signaling pathways. A comprehensive
      (phospho)proteomic analysis revealed that Meis1 increased Syk protein expression 
      and activity. Syk upregulation occurs through a Meis1-dependent feedback loop. By
      dissecting this loop, we show that Syk is a direct target of miR-146a, whose
      expression is indirectly regulated by Meis1 through the transcription factor
      PU.1. In the context of Hoxa9 overexpression, Syk signaling induces Meis1,
      recapitulating several leukemogenic features of Hoxa9/Meis1-driven leukemia.
      Finally, Syk inhibition disrupts the identified regulatory loop, prolonging
      survival of mice with Hoxa9/Meis1-driven leukemia.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Mohr, Sebastian
AU  - Mohr S
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
FAU - Doebele, Carmen
AU  - Doebele C
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
FAU - Comoglio, Federico
AU  - Comoglio F
AD  - Department of Haematology, University of Cambridge, Hills Road, Cambridge CB2
      0XY, UK; Cambridge Institute for Medical Research, Wellcome Trust/MRC Stem Cell
      Institute, Cambridge CB2 0XY, UK.
FAU - Berg, Tobias
AU  - Berg T
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; German Cancer Research Center and 
      German Cancer Consortium, 69120 Heidelberg, Germany.
FAU - Beck, Julia
AU  - Beck J
AD  - Chronix Biomedical, Goetheallee 8, 37073 Gottingen, Germany.
FAU - Bohnenberger, Hanibal
AU  - Bohnenberger H
AD  - Institute of Pathology, University Medical Center Gottingen, Robert-Koch-Strasse 
      40, 37073 Gottingen, Germany.
FAU - Alexe, Gabriela
AU  - Alexe G
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, MA 02115, USA; Broad Institute, Cambridge, MA 02142,
      USA.
FAU - Corso, Jasmin
AU  - Corso J
AD  - Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical
      Chemistry, Am Fassberg 11, 37077 Gottingen, Germany.
FAU - Strobel, Philipp
AU  - Strobel P
AD  - Institute of Pathology, University Medical Center Gottingen, Robert-Koch-Strasse 
      40, 37073 Gottingen, Germany.
FAU - Wachter, Astrid
AU  - Wachter A
AD  - Institute of Medical Statistics, University Medical Center Gottingen,
      Humboldtallee 32, 37073 Gottingen, Germany.
FAU - Beissbarth, Tim
AU  - Beissbarth T
AD  - Institute of Medical Statistics, University Medical Center Gottingen,
      Humboldtallee 32, 37073 Gottingen, Germany.
FAU - Schnutgen, Frank
AU  - Schnutgen F
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
FAU - Cremer, Anjali
AU  - Cremer A
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
FAU - Haetscher, Nadine
AU  - Haetscher N
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
FAU - Gollner, Stefanie
AU  - Gollner S
AD  - Department of Hematology and Oncology, University of Halle, Ernst-Grube-Street
      40, 06120 Halle, Germany.
FAU - Rouhi, Arefeh
AU  - Rouhi A
AD  - Department of Internal Medicine III, University Hospital of Ulm,
      Albert-Einstein-Allee 23, 89081 Ulm, Germany.
FAU - Palmqvist, Lars
AU  - Palmqvist L
AD  - Department of Clinical Chemistry and Transfusion Medicine, Institute of
      Biomedicine, Sahlgrenska Academy at University of Gothenburg, Su sahlgrenska,
      41345 Gothenburg, Sweden.
FAU - Rieger, Michael A
AU  - Rieger MA
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; German Cancer Research Center and 
      German Cancer Consortium, 69120 Heidelberg, Germany.
FAU - Schroeder, Timm
AU  - Schroeder T
AD  - Department of Biosystems Science and Engineering, Eidgenossische Technische
      Hochschule (ETH) Zurich, 4058 Basel, Switzerland.
FAU - Bonig, Halvard
AU  - Bonig H
AD  - Institute for Transfusion Medicine and Immunohematology, Goethe University,
      Sandhofstrasse 1, 60590 Frankfurt, Germany.
FAU - Muller-Tidow, Carsten
AU  - Muller-Tidow C
AD  - Department of Hematology and Oncology, University of Halle, Ernst-Grube-Street
      40, 06120 Halle, Germany.
FAU - Kuchenbauer, Florian
AU  - Kuchenbauer F
AD  - Department of Internal Medicine III, University Hospital of Ulm,
      Albert-Einstein-Allee 23, 89081 Ulm, Germany.
FAU - Schutz, Ekkehard
AU  - Schutz E
AD  - Chronix Biomedical, Goetheallee 8, 37073 Gottingen, Germany.
FAU - Green, Anthony R
AU  - Green AR
AD  - Department of Haematology, University of Cambridge, Hills Road, Cambridge CB2
      0XY, UK; Cambridge Institute for Medical Research, Wellcome Trust/MRC Stem Cell
      Institute, Cambridge CB2 0XY, UK.
FAU - Urlaub, Henning
AU  - Urlaub H
AD  - Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical
      Chemistry, Am Fassberg 11, 37077 Gottingen, Germany; Bioanalytics, Georg August
      University, Robert-Koch-Strasse 40, 37073 Gottingen, Germany.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, MA 02115, USA; Broad Institute, Cambridge, MA 02142,
      USA.
FAU - Humphries, R Keith
AU  - Humphries RK
AD  - Terry Fox Laboratory, British Columbia Cancer Agency, 675 West 10th Avenue,
      Vancouver, BC V5Z 1L3, Canada; Department of Medicine, University of British
      Columbia, Vancouver, BC V5Z 1M9, Canada.
FAU - Serve, Hubert
AU  - Serve H
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; German Cancer Research Center and 
      German Cancer Consortium, 69120 Heidelberg, Germany.
FAU - Oellerich, Thomas
AU  - Oellerich T
AD  - Department of Medicine II, Hematology/Oncology, Goethe University,
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of Haematology,
      University of Cambridge, Hills Road, Cambridge CB2 0XY, UK; Cambridge Institute
      for Medical Research, Wellcome Trust/MRC Stem Cell Institute, Cambridge CB2 0XY, 
      UK; German Cancer Research Center and German Cancer Consortium, 69120 Heidelberg,
      Germany. Electronic address: thomas.oellerich@kgu.de.
LA  - eng
GR  - MC_PC_12009/Medical Research Council/United Kingdom
GR  - R01 CA140292/CA/NCI NIH HHS/United States
GR  - R35 CA210030/CA/NCI NIH HHS/United States
GR  - CIHR/Canada
GR  - 104710/Z/14/Z/Wellcome Trust/United Kingdom
GR  - 100140/Z/12/Z/Wellcome Trust/United Kingdom
GR  - 097922/Z/11/Z/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Integrin beta3)
RN  - 0 (MEIS1 protein, human)
RN  - 0 (MIRN146 microRNA, human)
RN  - 0 (Meis1 protein, mouse)
RN  - 0 (MicroRNAs)
RN  - 0 (Myeloid Ecotropic Viral Integration Site 1 Protein)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (homeobox protein HOXA9)
RN  - EC 2.7.10.2 (SYK protein, human)
RN  - EC 2.7.10.2 (Syk Kinase)
SB  - IM
MH  - Animals
MH  - Gene Expression Regulation, Leukemic
MH  - Homeodomain Proteins/genetics/*metabolism
MH  - Humans
MH  - Integrin beta3/metabolism
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/genetics/*metabolism/mortality
MH  - Mice, Inbred C57BL
MH  - MicroRNAs/*genetics
MH  - Myeloid Ecotropic Viral Integration Site 1 Protein
MH  - Neoplasm Proteins/genetics/*metabolism
MH  - Signal Transduction
MH  - Syk Kinase/genetics/*metabolism
PMC - PMC5389883
OTO - NOTNLM
OT  - *Hox genes
OT  - *PU.1
OT  - *Syk
OT  - *leukemia
OT  - *microRNA
OT  - *signal transduction
EDAT- 2017/04/12 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/04/12 06:00
PHST- 2016/06/07 00:00 [received]
PHST- 2017/01/09 00:00 [revised]
PHST- 2017/03/03 00:00 [accepted]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - S1535-6108(17)30063-6 [pii]
AID - 10.1016/j.ccell.2017.03.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):549-562.e11. doi: 10.1016/j.ccell.2017.03.001.

PMID- 28399409
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills
      Tumor Cells In Vivo.
PG  - 516-531.e10
LID - S1535-6108(17)30099-5 [pii]
LID - 10.1016/j.ccell.2017.03.003 [doi]
AB  - The potassium channel Kv1.3 is highly expressed in the mitochondria of various
      cancerous cells. Here we show that direct inhibition of Kv1.3 using two
      mitochondria-targeted inhibitors alters mitochondrial function and leads to
      reactive oxygen species (ROS)-mediated death of even chemoresistant cells
      independently of p53 status. These inhibitors killed 98% of ex vivo primary
      chronic B-lymphocytic leukemia tumor cells while sparing healthy B cells. In
      orthotopic mouse models of melanoma and pancreatic ductal adenocarcinoma, the
      compounds reduced tumor size by more than 90% and 60%, respectively, while
      sparing immune and cardiac functions. Our work provides direct evidence that
      specific pharmacological targeting of a mitochondrial potassium channel can lead 
      to ROS-mediated selective apoptosis of cancer cells in vivo, without causing
      significant side effects.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Leanza, Luigi
AU  - Leanza L
AD  - Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova,
      Italy.
FAU - Romio, Matteo
AU  - Romio M
AD  - Department of Chemical Sciences, University of Padova, via F. Marzolo 1, 35121
      Padova, Italy.
FAU - Becker, Katrin Anne
AU  - Becker KA
AD  - Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse
      55, 45122 Essen, Germany.
FAU - Azzolini, Michele
AU  - Azzolini M
AD  - Department of Biomedical Sciences, University of Padova, viale G. Colombo 3,
      35121 Padova, Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121
      Padova, Italy.
FAU - Trentin, Livio
AU  - Trentin L
AD  - Department of Medicine, Hematology and Immunological Branch, University of
      Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2,
      35129 Padova, Italy.
FAU - Manago, Antonella
AU  - Manago A
AD  - Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova,
      Italy.
FAU - Venturini, Elisa
AU  - Venturini E
AD  - Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse
      55, 45122 Essen, Germany.
FAU - Zaccagnino, Angela
AU  - Zaccagnino A
AD  - Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and
      Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17),
      24105 Kiel, Germany.
FAU - Mattarei, Andrea
AU  - Mattarei A
AD  - Department of Chemical Sciences, University of Padova, via F. Marzolo 1, 35121
      Padova, Italy.
FAU - Carraretto, Luca
AU  - Carraretto L
AD  - Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova,
      Italy.
FAU - Urbani, Andrea
AU  - Urbani A
AD  - Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova,
      Italy.
FAU - Kadow, Stephanie
AU  - Kadow S
AD  - Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse
      55, 45122 Essen, Germany.
FAU - Biasutto, Lucia
AU  - Biasutto L
AD  - Department of Biomedical Sciences, University of Padova, viale G. Colombo 3,
      35121 Padova, Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121
      Padova, Italy.
FAU - Martini, Veronica
AU  - Martini V
AD  - Department of Medicine, Hematology and Immunological Branch, University of
      Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2,
      35129 Padova, Italy.
FAU - Severin, Filippo
AU  - Severin F
AD  - Department of Medicine, Hematology and Immunological Branch, University of
      Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2,
      35129 Padova, Italy.
FAU - Peruzzo, Roberta
AU  - Peruzzo R
AD  - Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova,
      Italy.
FAU - Trimarco, Valentina
AU  - Trimarco V
AD  - Department of Medicine, Hematology and Immunological Branch, University of
      Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2,
      35129 Padova, Italy.
FAU - Egberts, Jan-Hendrik
AU  - Egberts JH
AD  - Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and
      Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17),
      24105 Kiel, Germany.
FAU - Hauser, Charlotte
AU  - Hauser C
AD  - Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and
      Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17),
      24105 Kiel, Germany.
FAU - Visentin, Andrea
AU  - Visentin A
AD  - Department of Medicine, Hematology and Immunological Branch, University of
      Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2,
      35129 Padova, Italy.
FAU - Semenzato, Gianpietro
AU  - Semenzato G
AD  - Department of Medicine, Hematology and Immunological Branch, University of
      Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2,
      35129 Padova, Italy.
FAU - Kalthoff, Holger
AU  - Kalthoff H
AD  - Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and
      Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17),
      24105 Kiel, Germany.
FAU - Zoratti, Mario
AU  - Zoratti M
AD  - Department of Biomedical Sciences, University of Padova, viale G. Colombo 3,
      35121 Padova, Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121
      Padova, Italy.
FAU - Gulbins, Erich
AU  - Gulbins E
AD  - Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse
      55, 45122 Essen, Germany; Department of Surgery, University of Cincinnati, 231
      Albert Sabin Way, Cincinnati, OH 45267-0558, USA. Electronic address:
      erich.gulbins@uni-due.de.
FAU - Paradisi, Cristina
AU  - Paradisi C
AD  - Department of Chemical Sciences, University of Padova, via F. Marzolo 1, 35121
      Padova, Italy. Electronic address: cristina.paradisi@unipd.it.
FAU - Szabo, Ildiko
AU  - Szabo I
AD  - Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova,
      Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121 Padova, Italy.
      Electronic address: ildi@civ.bio.unipd.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Coumarins)
RN  - 0 (Kv1.3 Potassium Channel)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (PAPTP compound)
RN  - 0 (PCARBTP compound)
RN  - 0 (Potassium Channel Blockers)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology
MH  - Carcinoma, Pancreatic Ductal/drug therapy/pathology
MH  - Case-Control Studies
MH  - Coumarins/pharmacology
MH  - Drug Stability
MH  - Female
MH  - Humans
MH  - Kv1.3 Potassium Channel/*antagonists & inhibitors/metabolism
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/pathology
MH  - Male
MH  - Melanoma/drug therapy/pathology
MH  - Mice, Inbred C57BL
MH  - Middle Aged
MH  - Mitochondria/drug effects/metabolism
MH  - Molecular Targeted Therapy
MH  - Organophosphorus Compounds/pharmacology
MH  - Pancreatic Neoplasms/drug therapy/pathology
MH  - Potassium Channel Blockers/chemical synthesis/chemistry/*pharmacology
OTO - NOTNLM
OT  - *ROS-induced apoptosis
OT  - *bioenergetics
OT  - *chronic lymphocytic leukemia
OT  - *ion channels and cancer
OT  - *mitochondrial metabolism
OT  - *mitochondrial potassium channels
OT  - *mitochondriotropic inhibitors
OT  - *orthotopic melanoma model
OT  - *pancreatic ductal adenocarcinoma
OT  - *pharmacokinetics
EDAT- 2017/04/12 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/04/12 06:00
PHST- 2016/05/25 00:00 [received]
PHST- 2017/02/03 00:00 [revised]
PHST- 2017/03/07 00:00 [accepted]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - S1535-6108(17)30099-5 [pii]
AID - 10.1016/j.ccell.2017.03.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):516-531.e10. doi: 10.1016/j.ccell.2017.03.003.

PMID- 28399408
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor
      Cells and Tumor Vasculature.
PG  - 501-515.e8
LID - S1535-6108(17)30101-0 [pii]
LID - 10.1016/j.ccell.2017.03.005 [doi]
AB  - Targeting the tumor vasculature with antibody-drug conjugates (ADCs) is a
      promising anti-cancer strategy that in order to be realized must overcome several
      obstacles, including identification of suitable targets and optimal warheads.
      Here, we demonstrate that the cell-surface protein CD276/B7-H3 is broadly
      overexpressed by multiple tumor types on both cancer cells and tumor-infiltrating
      blood vessels, making it a potentially ideal dual-compartment therapeutic target.
      In preclinical studies CD276 ADCs armed with a conventional MMAE warhead
      destroyed CD276-positive cancer cells, but were ineffective against tumor
      vasculature. In contrast, pyrrolobenzodiazepine-conjugated CD276 ADCs killed both
      cancer cells and tumor vasculature, eradicating large established tumors and
      metastases, and improving long-term overall survival. CD276-targeted
      dual-compartment ablation could aid in the development of highly selective
      broad-acting anti-cancer therapies.
CI  - Published by Elsevier Inc.
FAU - Seaman, Steven
AU  - Seaman S
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA.
FAU - Zhu, Zhongyu
AU  - Zhu Z
AD  - Protein Interactions Section, Cancer and Inflammation Program (CIP), NCI, NIH,
      Frederick, MD 21702, USA.
FAU - Saha, Saurabh
AU  - Saha S
AD  - BioMed Valley Discoveries, Inc, Kansas City, MO 64111, USA.
FAU - Zhang, Xiaoyan M
AU  - Zhang XM
AD  - BioMed Valley Discoveries, Inc, Kansas City, MO 64111, USA.
FAU - Yang, Mi Young
AU  - Yang MY
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA.
FAU - Hilton, Mary Beth
AU  - Hilton MB
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA; Basic Research Program, Leidos
      Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NCI,
      Frederick, MD 21702, USA.
FAU - Morris, Karen
AU  - Morris K
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA; Basic Research Program, Leidos
      Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NCI,
      Frederick, MD 21702, USA.
FAU - Szot, Christopher
AU  - Szot C
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA.
FAU - Morris, Holly
AU  - Morris H
AD  - Transgenic Core Facility, MCGP, NCI, NIH, Frederick, MD 21702, USA.
FAU - Swing, Deborah A
AU  - Swing DA
AD  - Transgenic Core Facility, MCGP, NCI, NIH, Frederick, MD 21702, USA.
FAU - Tessarollo, Lino
AU  - Tessarollo L
AD  - Neural Development Section, MCGP, NCI, NIH, Frederick, MD 21702, USA.
FAU - Smith, Sean W
AU  - Smith SW
AD  - Abzena, Bristol, PA 19007, USA.
FAU - Degrado, Sylvia
AU  - Degrado S
AD  - Abzena, Bristol, PA 19007, USA.
FAU - Borkin, Dmitry
AU  - Borkin D
AD  - Abzena, Bristol, PA 19007, USA.
FAU - Jain, Nareshkumar
AU  - Jain N
AD  - Abzena, Bristol, PA 19007, USA.
FAU - Scheiermann, Julia
AU  - Scheiermann J
AD  - Immune Modulation Section, CIP, NCI, NIH, Frederick, MD 21702, USA.
FAU - Feng, Yang
AU  - Feng Y
AD  - Protein Interactions Section, Cancer and Inflammation Program (CIP), NCI, NIH,
      Frederick, MD 21702, USA.
FAU - Wang, Yanping
AU  - Wang Y
AD  - Protein Interactions Section, Cancer and Inflammation Program (CIP), NCI, NIH,
      Frederick, MD 21702, USA.
FAU - Li, Jinyu
AU  - Li J
AD  - Protein Interactions Section, Cancer and Inflammation Program (CIP), NCI, NIH,
      Frederick, MD 21702, USA.
FAU - Welsch, Dean
AU  - Welsch D
AD  - BioMed Valley Discoveries, Inc, Kansas City, MO 64111, USA.
FAU - DeCrescenzo, Gary
AU  - DeCrescenzo G
AD  - BioMed Valley Discoveries, Inc, Kansas City, MO 64111, USA.
FAU - Chaudhary, Amit
AU  - Chaudhary A
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA.
FAU - Zudaire, Enrique
AU  - Zudaire E
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA.
FAU - Klarmann, Kimberly D
AU  - Klarmann KD
AD  - Basic Research Program, Leidos Biomedical Research Inc., Frederick National
      Laboratory for Cancer Research, NCI, Frederick, MD 21702, USA; Hematopoiesis and 
      Stem Cell Biology Section, MCGP, NCI, NIH, Frederick, MD 21702, USA.
FAU - Keller, Jonathan R
AU  - Keller JR
AD  - Basic Research Program, Leidos Biomedical Research Inc., Frederick National
      Laboratory for Cancer Research, NCI, Frederick, MD 21702, USA; Hematopoiesis and 
      Stem Cell Biology Section, MCGP, NCI, NIH, Frederick, MD 21702, USA.
FAU - Dimitrov, Dimiter S
AU  - Dimitrov DS
AD  - Protein Interactions Section, Cancer and Inflammation Program (CIP), NCI, NIH,
      Frederick, MD 21702, USA.
FAU - St Croix, Brad
AU  - St Croix B
AD  - Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer
      Institute (NCI), NIH, Frederick, MD 21702, USA. Electronic address:
      stcroixb@mail.nih.gov.
LA  - eng
GR  - ZIA BC010578-13/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC010736-11/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7 Antigens)
RN  - 0 (CD276 protein, human)
RN  - 0 (Cd276 protein, mouse)
RN  - 0 (Immunoconjugates)
RN  - 0 (Oligopeptides)
RN  - 0 (Pyrroles)
RN  - 0 (pyrrolo(2,1-c)(1,4)benzodiazepine)
RN  - 12794-10-4 (Benzodiazepines)
RN  - V7I58RC5EJ (monomethyl auristatin E)
SB  - IM
CIN - Cancer Cell. 2017 Apr 10;31(4):469-471. PMID: 28399405
MH  - Animals
MH  - Antineoplastic Agents/immunology/pharmacology
MH  - B7 Antigens/*genetics/immunology/*metabolism
MH  - Benzodiazepines/pharmacology
MH  - Blood Vessels/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Endothelium, Vascular/drug effects/pathology
MH  - Female
MH  - Humans
MH  - Immunoconjugates/immunology/*pharmacology
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasms/*blood supply/pathology/therapy
MH  - Oligopeptides/pharmacology
MH  - Pyrroles/pharmacology
MH  - Rabbits
PMC - PMC5458750
MID - NIHMS861365
OTO - NOTNLM
OT  - *ADC
OT  - *Abcb1
OT  - *B7H3
OT  - *P-glycoprotein
OT  - *P-gp
OT  - *PBD
OT  - *TEM
OT  - *angiogenesis
OT  - *cancer
OT  - *endothelium
EDAT- 2017/04/12 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/04/12 06:00
PMCR- 2018/04/10 00:00
PHST- 2016/10/04 00:00 [received]
PHST- 2017/01/28 00:00 [revised]
PHST- 2017/03/13 00:00 [accepted]
PHST- 2018/04/10 00:00 [pmc-release]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - S1535-6108(17)30101-0 [pii]
AID - 10.1016/j.ccell.2017.03.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):501-515.e8. doi: 10.1016/j.ccell.2017.03.005.

PMID- 28399407
OWN - NLM
STAT- MEDLINE
DCOM- 20170809
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Messenger RNA Methylation Regulates Glioblastoma Tumorigenesis.
PG  - 474-475
LID - S1535-6108(17)30106-X [pii]
LID - 10.1016/j.ccell.2017.03.010 [doi]
AB  - Messenger RNA (mRNA) modification provides an additional layer of gene regulation
      in cells. In this issue of Cancer Cell, Zhang et al. report that ALKBH5, a
      demethylase of the mRNA modification N(6)-methyladenosine, regulates
      proliferation and self-renewal of glioblastoma stem-like cells by modulating
      pre-mRNA stability and expression of the FOXM1 gene.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Dixit, Deobrat
AU  - Dixit D
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Xie, Qi
AU  - Xie Q
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Rich, Jeremy N
AU  - Rich JN
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address:
      drjeremyrich@gmail.com.
FAU - Zhao, Jing Crystal
AU  - Zhao JC
AD  - Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical
      Discovery Institute, La Jolla, CA 92037, USA. Electronic address:
      czhao@sbpdiscovery.org.
LA  - eng
GR  - R01 GM110090/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (RNA, Messenger)
SB  - IM
CON - Cancer Cell. 2017 Apr 10;31(4):591-606.e6. PMID: 28344040
MH  - Carcinogenesis
MH  - Cell Transformation, Neoplastic
MH  - Glioblastoma/*genetics
MH  - Humans
MH  - Methylation
MH  - *RNA, Messenger
EDAT- 2017/04/12 06:00
MHDA- 2017/08/10 06:00
CRDT- 2017/04/12 06:00
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/08/10 06:00 [medline]
AID - S1535-6108(17)30106-X [pii]
AID - 10.1016/j.ccell.2017.03.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):474-475. doi: 10.1016/j.ccell.2017.03.010.

PMID- 28399406
OWN - NLM
STAT- MEDLINE
DCOM- 20170809
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle.
PG  - 471-473
LID - S1535-6108(17)30108-3 [pii]
LID - 10.1016/j.ccell.2017.03.012 [doi]
AB  - In this issue of Cancer Cell, Hydbring and colleagues define a novel class of
      microRNAs (miRNAs), deemed "cell-cycle-targeting miRNAs," that target several
      cyclins/CDKs, reduce tumor cell growth, and induce apoptosis. These miRNAs
      effectively suppressed chemoresistant patient-derived xenograft growth in vivo,
      and efficacy could be prospectively predicted with an expression-based algorithm.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Schiewer, Matthew J
AU  - Schiewer MJ
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA; The Sidney Kimmel Cancer Center, Thomas Jefferson University,
      Philadelphia, PA 19107, USA.
FAU - Knudsen, Karen E
AU  - Knudsen KE
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA; Department of Medical Oncology, Thomas Jefferson University,
      Philadelphia, PA 19107, USA; Department of Urology, Thomas Jefferson University, 
      Philadelphia, PA 19107, USA; Department of Radiation Oncology, Thomas Jefferson
      University, Philadelphia, PA 19107, USA; The Sidney Kimmel Cancer Center, Thomas 
      Jefferson University, Philadelphia, PA 19107, USA. Electronic address:
      karen.knudsen@jefferson.edu.
LA  - eng
GR  - P30 CA056036/CA/NCI NIH HHS/United States
GR  - R01 CA176401/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MicroRNAs)
SB  - IM
CON - Cancer Cell. 2017 Apr 10;31(4):576-590.e8. PMID: 28399412
MH  - Apoptosis
MH  - *Cell Cycle
MH  - Cell Division
MH  - Cell Line, Tumor
MH  - Humans
MH  - *MicroRNAs
MH  - Neoplasms
PMC - PMC5709809
MID - NIHMS921139
EDAT- 2017/04/12 06:00
MHDA- 2017/08/10 06:00
CRDT- 2017/04/12 06:00
PMCR- 2018/04/10 00:00
PHST- 2018/04/10 00:00 [pmc-release]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/08/10 06:00 [medline]
AID - S1535-6108(17)30108-3 [pii]
AID - 10.1016/j.ccell.2017.03.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):471-473. doi: 10.1016/j.ccell.2017.03.012.

PMID- 28399405
OWN - NLM
STAT- MEDLINE
DCOM- 20170809
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and
      Its Vasculature.
PG  - 469-471
LID - S1535-6108(17)30105-8 [pii]
LID - 10.1016/j.ccell.2017.03.009 [doi]
AB  - In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug
      conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature
      have promising anti-tumor activity while showing little toxicity. Importantly,
      these agents have the potential to target both angiogenic vessels and
      non-angiogenic vessels co-opted by tumor cells.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Khan, Kabir A
AU  - Khan KA
AD  - Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada. 
      Electronic address: kkhan@sri.utoronto.ca.
FAU - Kerbel, Robert S
AU  - Kerbel RS
AD  - Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada; 
      Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies)
RN  - 0 (Immunoconjugates)
SB  - IM
CON - Cancer Cell. 2017 Apr 10;31(4):501-515.e8. PMID: 28399408
MH  - *Antibodies
MH  - *Cell Line, Tumor
MH  - Humans
MH  - Immunoconjugates
EDAT- 2017/04/12 06:00
MHDA- 2017/08/10 06:00
CRDT- 2017/04/12 06:00
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/08/10 06:00 [medline]
AID - S1535-6108(17)30105-8 [pii]
AID - 10.1016/j.ccell.2017.03.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):469-471. doi: 10.1016/j.ccell.2017.03.009.

PMID- 28399404
OWN - NLM
STAT- MEDLINE
DCOM- 20170809
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Data Triumph at C.
PG  - 467-469
LID - S1535-6108(17)30104-6 [pii]
LID - 10.1016/j.ccell.2017.03.008 [doi]
AB  - Despite historical controversy, pharmacologic ascorbate is emerging as promising 
      cancer therapy via pro-oxidant chemistry. In this issue of Cancer Cell,
      Schoenfeld et al. describe how intracellular iron pools and reactive oxygen
      species drive pharmacologic ascorbate's selective toxicity to cancer cells in
      vitro, in mice, and in humans.
CI  - Published by Elsevier Inc.
FAU - Levine, Mark
AU  - Levine M
AD  - Molecular and Clinical Nutrition Section, Intramural Research Program, National
      Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
      Health, Bethesda, MD 20892-1372, USA. Electronic address: markl@mail.nih.gov.
FAU - Violet, Pierre-Christian
AU  - Violet PC
AD  - Molecular and Clinical Nutrition Section, Intramural Research Program, National
      Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
      Health, Bethesda, MD 20892-1372, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Reactive Oxygen Species)
RN  - E1UOL152H7 (Iron)
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - IM
CON - Cancer Cell. 2017 Apr 10;31(4):487-500.e8. PMID: 28366679
MH  - Animals
MH  - *Ascorbic Acid
MH  - Humans
MH  - *Iron
MH  - Mice
MH  - Reactive Oxygen Species
EDAT- 2017/04/12 06:00
MHDA- 2017/08/10 06:00
CRDT- 2017/04/12 06:00
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/08/10 06:00 [medline]
AID - S1535-6108(17)30104-6 [pii]
AID - 10.1016/j.ccell.2017.03.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):467-469. doi: 10.1016/j.ccell.2017.03.008.

PMID- 28366679
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - O2(-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential
      Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.
PG  - 487-500.e8
LID - S1535-6108(17)30062-4 [pii]
LID - 10.1016/j.ccell.2017.02.018 [doi]
AB  - Pharmacological ascorbate has been proposed as a potential anti-cancer agent when
      combined with radiation and chemotherapy. The anti-cancer effects of ascorbate
      are hypothesized to involve the autoxidation of ascorbate leading to increased
      steady-state levels of H2O2; however, the mechanism(s) for cancer cell-selective 
      toxicity remain unknown. The current study shows that alterations in cancer cell 
      mitochondrial oxidative metabolism resulting in increased levels of O2(-) and
      H2O2 are capable of disrupting intracellular iron metabolism, thereby selectively
      sensitizing non-small-cell lung cancer (NSCLC) and glioblastoma (GBM) cells to
      ascorbate through pro-oxidant chemistry involving redox-active labile iron and
      H2O2. In addition, preclinical studies and clinical trials demonstrate the
      feasibility, selective toxicity, tolerability, and potential efficacy of
      pharmacological ascorbate in GBM and NSCLC therapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Schoenfeld, Joshua D
AU  - Schoenfeld JD
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Sibenaller, Zita A
AU  - Sibenaller ZA
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Mapuskar, Kranti A
AU  - Mapuskar KA
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Wagner, Brett A
AU  - Wagner BA
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Cramer-Morales, Kimberly L
AU  - Cramer-Morales KL
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Furqan, Muhammad
AU  - Furqan M
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Sandhu, Sonia
AU  - Sandhu S
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Carlisle, Thomas L
AU  - Carlisle TL
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Smith, Mark C
AU  - Smith MC
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Abu Hejleh, Taher
AU  - Abu Hejleh T
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Berg, Daniel J
AU  - Berg DJ
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Keech, John
AU  - Keech J
AD  - Department of Surgery, Holden Comprehensive Cancer Center, The University of
      Iowa, Iowa City, IA 52242, USA.
FAU - Parekh, Kalpaj R
AU  - Parekh KR
AD  - Department of Surgery, Holden Comprehensive Cancer Center, The University of
      Iowa, Iowa City, IA 52242, USA.
FAU - Bhatia, Sudershan
AU  - Bhatia S
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Monga, Varun
AU  - Monga V
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Bodeker, Kellie L
AU  - Bodeker KL
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Ahmann, Logan
AU  - Ahmann L
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Vollstedt, Sandy
AU  - Vollstedt S
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Brown, Heather
AU  - Brown H
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Shanahan Kauffman, Erin P
AU  - Shanahan Kauffman EP
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Schall, Mary E
AU  - Schall ME
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Hohl, Ray J
AU  - Hohl RJ
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Clamon, Gerald H
AU  - Clamon GH
AD  - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department 
      of Internal Medicine, Holden Comprehensive Cancer Center, The University of Iowa,
      Iowa City, IA 52242, USA.
FAU - Greenlee, Jeremy D
AU  - Greenlee JD
AD  - Department of Neurosurgery, Holden Comprehensive Cancer Center, The University of
      Iowa, Iowa City, IA 52242, USA.
FAU - Howard, Matthew A
AU  - Howard MA
AD  - Department of Neurosurgery, Holden Comprehensive Cancer Center, The University of
      Iowa, Iowa City, IA 52242, USA.
FAU - Schultz, Michael K
AU  - Schultz MK
AD  - Department of Radiology, Holden Comprehensive Cancer Center, The University of
      Iowa, Iowa City, IA 52242, USA.
FAU - Smith, Brian J
AU  - Smith BJ
AD  - Departmet of Biostatistics, Holden Comprehensive Cancer Center, The University of
      Iowa, Iowa City, IA 52242, USA.
FAU - Riley, Dennis P
AU  - Riley DP
AD  - Galera Therapeutics, Malvern, PA 19355, USA.
FAU - Domann, Frederick E
AU  - Domann FE
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Cullen, Joseph J
AU  - Cullen JJ
AD  - Department of Surgery, Holden Comprehensive Cancer Center, The University of
      Iowa, Iowa City, IA 52242, USA.
FAU - Buettner, Garry R
AU  - Buettner GR
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Buatti, John M
AU  - Buatti JM
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA.
FAU - Spitz, Douglas R
AU  - Spitz DR
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA. Electronic address: douglas-spitz@uiowa.edu.
FAU - Allen, Bryan G
AU  - Allen BG
AD  - Free Radical and Radiation Biology Program, Department of Radiation Oncology,
      Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, 
      USA. Electronic address: bryan-allen@uiowa.edu.
LA  - eng
GR  - R01 CA184051/CA/NCI NIH HHS/United States
GR  - U01 CA140206/CA/NCI NIH HHS/United States
GR  - P30 ES005605/ES/NIEHS NIH HHS/United States
GR  - U01 CA166800/CA/NCI NIH HHS/United States
GR  - P30 CA086862/CA/NCI NIH HHS/United States
GR  - R01 CA169046/CA/NCI NIH HHS/United States
GR  - T32 CA078586/CA/NCI NIH HHS/United States
GR  - R01 CA182804/CA/NCI NIH HHS/United States
GR  - T32 GM007337/GM/NIGMS NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20170330
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Radiation-Sensitizing Agents)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - E1UOL152H7 (Iron)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - S88TT14065 (Oxygen)
SB  - IM
CIN - Cancer Cell. 2017 Apr 10;31(4):467-469. PMID: 28399404
EIN - Cancer Cell. 2017 Aug 14;32(2):268. PMID: 28810149
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Ascorbic Acid/administration & dosage/adverse effects/*pharmacology
MH  - Brain Neoplasms/*drug therapy
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/mortality/radiotherapy
MH  - Cell Line, Tumor
MH  - Chemoradiotherapy/methods
MH  - Female
MH  - Glioblastoma/*drug therapy/metabolism
MH  - Humans
MH  - Hydrogen Peroxide/pharmacology
MH  - Iron/*metabolism
MH  - Lung Neoplasms/*drug therapy/metabolism/mortality/radiotherapy
MH  - Male
MH  - Mice, Nude
MH  - Oxygen/metabolism
MH  - Radiation-Sensitizing Agents/pharmacology
MH  - Xenograft Model Antitumor Assays
PMC - PMC5497844
MID - NIHMS857911
OTO - NOTNLM
OT  - *ferritin
OT  - *glioblastoma multiforme
OT  - *hydrogen peroxide
OT  - *labile iron metabolism
OT  - *non-small cell lung cancer
OT  - *oxidative stress
OT  - *pharmacological ascorbate
OT  - *superoxide
OT  - *superoxide dismutase
OT  - *transferrin receptor
EDAT- 2017/04/04 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/04/04 06:00
PMCR- 2018/04/10 00:00
PHST- 2016/06/03 00:00 [received]
PHST- 2016/12/13 00:00 [revised]
PHST- 2017/02/27 00:00 [accepted]
PHST- 2018/04/10 00:00 [pmc-release]
PHST- 2017/04/04 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
PHST- 2017/04/04 06:00 [entrez]
AID - S1535-6108(17)30062-4 [pii]
AID - 10.1016/j.ccell.2017.02.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub
      2017 Mar 30.

PMID- 28366678
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers.
PG  - 476-485
LID - S1535-6108(17)30064-8 [pii]
LID - 10.1016/j.ccell.2017.03.002 [doi]
AB  - Cancer immunotherapies can be classified into agents that amplify natural immune 
      responses (e.g., checkpoint inhibitors) versus synthetic immunotherapies designed
      to initiate new responses (e.g., monoclonal antibodies [mAbs], chimeric antigen
      receptors [CARs]). Checkpoint inhibitors mediate unprecedented benefit in some
      adult cancers, but have not demonstrated significant activity in pediatric
      cancers, likely due their paucity of neoantigens. In contrast, synthetic
      immunotherapies such as mAbs and CAR T cells demonstrate impressive effects
      against childhood cancers. Intense efforts are underway to enhance the
      effectiveness of pediatric cancer immunotherapies through improved engineering of
      synthetic immunotherapies and by combining these with agents designed to amplify 
      immune responses.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Majzner, Robbie G
AU  - Majzner RG
AD  - Department of Pediatrics, Stanford University, Stanford, CA 94305, USA.
FAU - Heitzeneder, Sabine
AU  - Heitzeneder S
AD  - Department of Pediatrics, Stanford University, Stanford, CA 94305, USA.
FAU - Mackall, Crystal L
AU  - Mackall CL
AD  - Department of Pediatrics, Stanford University, Stanford, CA 94305, USA; Parker
      Institute for Cancer Immunotherapy at Stanford, Stanford Cancer Institute,
      Stanford University, 265 Campus Drive, G3141A, MC5456, Stanford, CA 94305, USA.
      Electronic address: cmackall@stanford.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
DEP - 20170330
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD19)
RN  - 0 (CD19 molecule, human)
RN  - 0 (Receptors, Antigen)
RN  - 0 (Recombinant Proteins)
RN  - 4FR53SIF3A (blinatumomab)
RN  - 7SQY4ZUD30 (ch14.18 monoclonal antibody)
SB  - IM
MH  - Antibodies, Bispecific/pharmacology/therapeutic use
MH  - Antibodies, Monoclonal/pharmacology/therapeutic use
MH  - Antigens, CD19/genetics/immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Mutation
MH  - Neoplasms/genetics/*therapy
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunology/therapy
MH  - Receptors, Antigen/genetics/immunology
MH  - Recombinant Proteins/genetics/immunology
OTO - NOTNLM
OT  - *adoptive T cell therapy
OT  - *checkpoint inhibitor
OT  - *chimeric antigen receptor
OT  - *immunotherapy
OT  - *monoclonal antibody
OT  - *pediatric oncology
EDAT- 2017/04/04 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/04/04 06:00
PHST- 2017/01/17 00:00 [received]
PHST- 2017/02/21 00:00 [revised]
PHST- 2017/03/03 00:00 [accepted]
PHST- 2017/04/04 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
PHST- 2017/04/04 06:00 [entrez]
AID - S1535-6108(17)30064-8 [pii]
AID - 10.1016/j.ccell.2017.03.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):476-485. doi: 10.1016/j.ccell.2017.03.002. Epub
      2017 Mar 30.

PMID- 28344040
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180315
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells
      by Sustaining FOXM1 Expression and Cell Proliferation Program.
PG  - 591-606.e6
LID - S1535-6108(17)30056-9 [pii]
LID - 10.1016/j.ccell.2017.02.013 [doi]
AB  - The dynamic and reversible N(6)-methyladenosine (m(6)A) RNA modification
      installed and erased by N(6)-methyltransferases and demethylases regulates gene
      expression and cell fate. We show that the m(6)A demethylase ALKBH5 is highly
      expressed in glioblastoma stem-like cells (GSCs). Silencing ALKBH5 suppresses the
      proliferation of patient-derived GSCs. Integrated transcriptome and m(6)A-seq
      analyses revealed altered expression of certain ALKBH5 target genes, including
      the transcription factor FOXM1. ALKBH5 demethylates FOXM1 nascent transcripts,
      leading to enhanced FOXM1 expression. Furthermore, a long non-coding RNA
      antisense to FOXM1 (FOXM1-AS) promotes the interaction of ALKBH5 with FOXM1
      nascent transcripts. Depleting ALKBH5 and FOXM1-AS disrupted GSC tumorigenesis
      through the FOXM1 axis. Our work uncovers a critical function for ALKBH5 and
      provides insight into critical roles of m(6)A methylation in glioblastoma.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Zhang, Sicong
AU  - Zhang S
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Program in Cancer Biology, The University of Texas MD
      Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, 
      TX 77030, USA.
FAU - Zhao, Boxuan Simen
AU  - Zhao BS
AD  - Department of Chemistry and Institute for Biophysical Dynamics, The University of
      Chicago, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University 
      of Chicago, Chicago, IL 60637, USA.
FAU - Zhou, Aidong
AU  - Zhou A
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Lin, Kangyu
AU  - Lin K
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Zheng, Shaoping
AU  - Zheng S
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Lu, Zhike
AU  - Lu Z
AD  - Department of Chemistry and Institute for Biophysical Dynamics, The University of
      Chicago, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University 
      of Chicago, Chicago, IL 60637, USA.
FAU - Chen, Yaohui
AU  - Chen Y
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Sulman, Erik P
AU  - Sulman EP
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Xie, Keping
AU  - Xie K
AD  - Program in Cancer Biology, The University of Texas MD Anderson Cancer Center
      UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA;
      Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Bogler, Oliver
AU  - Bogler O
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Program in Cancer Biology, The University of Texas MD
      Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, 
      TX 77030, USA.
FAU - Majumder, Sadhan
AU  - Majumder S
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - He, Chuan
AU  - He C
AD  - Department of Chemistry and Institute for Biophysical Dynamics, The University of
      Chicago, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University 
      of Chicago, Chicago, IL 60637, USA; Department of Biochemistry and Molecular
      Biology, The University of Chicago, Chicago, IL 60637, USA.
FAU - Huang, Suyun
AU  - Huang S
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Program in Cancer Biology, The University of Texas MD
      Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, 
      TX 77030, USA. Electronic address: suhuang@mdanderson.org.
LA  - eng
GR  - R01 CA182684/CA/NCI NIH HHS/United States
GR  - R01 GM071440/GM/NIGMS NIH HHS/United States
GR  - R01 CA201327/CA/NCI NIH HHS/United States
GR  - R01 CA198090/CA/NCI NIH HHS/United States
GR  - R01 CA157933/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - R01 CA152309/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20170323
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (3' Untranslated Regions)
RN  - 0 (ELAV-Like Protein 1)
RN  - 0 (ELAVL1 protein, human)
RN  - 0 (FOXM1 protein, human)
RN  - 0 (Forkhead Box Protein M1)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 1.14.11.- (ALKBH5 protein, human)
RN  - EC 1.14.11.- (AlkB Homolog 5, RNA Demethylase)
SB  - IM
CIN - Cancer Cell. 2017 Apr 10;31(4):474-475. PMID: 28399407
MH  - 3' Untranslated Regions
MH  - AlkB Homolog 5, RNA Demethylase/genetics/*metabolism
MH  - Animals
MH  - Brain Neoplasms/genetics/mortality/*pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - ELAV-Like Protein 1/genetics/metabolism
MH  - Forkhead Box Protein M1/genetics/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Glioblastoma/genetics/mortality/*pathology
MH  - Male
MH  - Mice, Nude
MH  - Neoplastic Stem Cells/metabolism/pathology
MH  - RNA, Long Noncoding/genetics/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5427719
MID - NIHMS856291
OTO - NOTNLM
OT  - *ALKBH5
OT  - *FOXM1
OT  - *glioblastoma
OT  - *m(6)A modification
EDAT- 2017/03/28 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/03/28 06:00
PMCR- 2018/04/10 00:00
PHST- 2016/09/29 00:00 [received]
PHST- 2017/01/11 00:00 [revised]
PHST- 2017/02/23 00:00 [accepted]
PHST- 2018/04/10 00:00 [pmc-release]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
PHST- 2017/03/28 06:00 [entrez]
AID - S1535-6108(17)30056-9 [pii]
AID - 10.1016/j.ccell.2017.02.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):591-606.e6. doi: 10.1016/j.ccell.2017.02.013. Epub
      2017 Mar 23.

PMID- 28344039
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 4
DP  - 2017 Apr 10
TI  - Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in
      Prostate Cancer.
PG  - 532-548.e7
LID - S1535-6108(17)30060-0 [pii]
LID - 10.1016/j.ccell.2017.02.017 [doi]
AB  - Transcription factors play a key role in the development of diverse cancers, and 
      therapeutically targeting them has remained a challenge. In prostate cancer, the 
      gene encoding the transcription factor ERG is recurrently rearranged and plays a 
      critical role in prostate oncogenesis. Here, we identified a series of peptides
      that interact specifically with the DNA binding domain of ERG. ERG inhibitory
      peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and
      specificity, leading to proteolytic degradation of the ERG protein. The EIPs
      attenuated ERG-mediated transcription, chromatin recruitment, protein-protein
      interactions, cell invasion and proliferation, and tumor growth. Thus,
      peptidomimetic targeting of transcription factor fusion products may provide a
      promising therapeutic strategy for prostate cancer as well as other malignancies.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Wang, Xiaoju
AU  - Wang X
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, 1400
      East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA.
FAU - Qiao, Yuanyuan
AU  - Qiao Y
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Asangani, Irfan A
AU  - Asangani IA
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Ateeq, Bushra
AU  - Ateeq B
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA; Department of Biological Sciences & Bioengineering, Indian 
      Institute of Technology Kanpur, Kanpur 208016, UP, India.
FAU - Poliakov, Anton
AU  - Poliakov A
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Cieslik, Marcin
AU  - Cieslik M
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Pitchiaya, Sethuramasundaram
AU  - Pitchiaya S
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Chakravarthi, Balabhadrapatruni V S K
AU  - Chakravarthi BVSK
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
FAU - Cao, Xuhong
AU  - Cao X
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Jing, Xiaojun
AU  - Jing X
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Wang, Cynthia X
AU  - Wang CX
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Apel, Ingrid J
AU  - Apel IJ
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Wang, Rui
AU  - Wang R
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Tien, Jean Ching-Yi
AU  - Tien JC
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Juckette, Kristin M
AU  - Juckette KM
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Yan, Wei
AU  - Yan W
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA.
FAU - Jiang, Hui
AU  - Jiang H
AD  - Department of Biostatistics, University of Michigan, 1400 East Medical Center
      Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Center for Computational Medicine and
      Bioinformatics, University of Michigan, 1400 East Medical Center Drive, 5316
      CCGC, Ann Arbor, MI 48109, USA.
FAU - Wang, Shaomeng
AU  - Wang S
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of Internal
      Medicine, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann 
      Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, 1400
      East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pharmacology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, 
      Ann Arbor, MI 48109, USA; Department of Medicinal Chemistry, University of
      Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA.
FAU - Varambally, Sooryanarayana
AU  - Varambally S
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA; Department of Pathology, University of Alabama at
      Birmingham, Birmingham, AL 35233, USA; Comprehensive Cancer Center, University of
      Alabama at Birmingham, Birmingham, AL 35233, USA.
FAU - Chinnaiyan, Arul M
AU  - Chinnaiyan AM
AD  - Michigan Center for Translational Pathology, University of Michigan, 1400 East
      Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of
      Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann
      Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan,
      1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department
      of Urology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC,
      Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan,
      1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA. Electronic
      address: arul@umich.edu.
LA  - eng
GR  - U01 CA214170/CA/NCI NIH HHS/United States
GR  - R01 CA132874/CA/NCI NIH HHS/United States
GR  - R01 CA157845/CA/NCI NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - U01 CA113913/CA/NCI NIH HHS/United States
GR  - R01 CA154980/CA/NCI NIH HHS/United States
GR  - P50 CA069568/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20170323
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Peptide Library)
RN  - 0 (Peptidomimetics)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - 0 (Transcriptional Regulator ERG)
RN  - 9007-49-2 (DNA)
SB  - IM
EIN - Cancer Cell. 2017 Jun 12;31(6):844-847. PMID: 28609659
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Chick Embryo
MH  - DNA/metabolism
MH  - Humans
MH  - Male
MH  - Mice, Nude
MH  - Neovascularization, Physiologic/drug effects
MH  - Oncogene Proteins, Fusion/*antagonists & inhibitors/genetics
MH  - Peptide Library
MH  - Peptidomimetics/chemistry/*pharmacology
MH  - Prostatic Neoplasms/*drug therapy/genetics/pathology
MH  - Protein Domains
MH  - Transcriptional Regulator ERG/antagonists & inhibitors/genetics/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5443258
MID - NIHMS857598
OTO - NOTNLM
OT  - *ERG transcription factor
OT  - *peptidomimetic inhibitor
OT  - *prostate cancer
EDAT- 2017/03/28 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/03/28 06:00
PMCR- 2018/04/10 00:00
PHST- 2016/09/30 00:00 [received]
PHST- 2017/01/19 00:00 [revised]
PHST- 2017/02/24 00:00 [accepted]
PHST- 2018/04/10 00:00 [pmc-release]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
PHST- 2017/03/28 06:00 [entrez]
AID - S1535-6108(17)30060-0 [pii]
AID - 10.1016/j.ccell.2017.02.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Apr 10;31(4):532-548.e7. doi: 10.1016/j.ccell.2017.02.017. Epub
      2017 Mar 23.

PMID- 28292443
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20180110
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in
      Drug-Resistant BRAF Mutant Melanoma.
PG  - 466
LID - S1535-6108(17)30050-8 [pii]
LID - 10.1016/j.ccell.2017.02.007 [doi]
FAU - Girotti, Maria Romina
AU  - Girotti MR
FAU - Lopes, Filipa
AU  - Lopes F
FAU - Preece, Natasha
AU  - Preece N
FAU - Niculescu-Duvaz, Dan
AU  - Niculescu-Duvaz D
FAU - Zambon, Alfonso
AU  - Zambon A
FAU - Davies, Lawrence
AU  - Davies L
FAU - Whittaker, Steven
AU  - Whittaker S
FAU - Saturno, Grazia
AU  - Saturno G
FAU - Viros, Amaya
AU  - Viros A
FAU - Pedersen, Malin
AU  - Pedersen M
FAU - Suijkerbuijk, Bart M J M
AU  - Suijkerbuijk BMJM
FAU - Menard, Delphine
AU  - Menard D
FAU - McLeary, Robert
AU  - McLeary R
FAU - Johnson, Louise
AU  - Johnson L
FAU - Fish, Laura
AU  - Fish L
FAU - Ejiama, Sarah
AU  - Ejiama S
FAU - Sanchez-Laorden, Berta
AU  - Sanchez-Laorden B
FAU - Hohloch, Juliane
AU  - Hohloch J
FAU - Carragher, Neil
AU  - Carragher N
FAU - Macleod, Kenneth
AU  - Macleod K
FAU - Ashton, Garry
AU  - Ashton G
FAU - Marusiak, Anna A
AU  - Marusiak AA
FAU - Fusi, Alberto
AU  - Fusi A
FAU - Brognard, John
AU  - Brognard J
FAU - Frame, Margaret
AU  - Frame M
FAU - Lorigan, Paul
AU  - Lorigan P
FAU - Marais, Richard
AU  - Marais R
FAU - Springer, Caroline
AU  - Springer C
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2015 Jan 12;27(1):85-96. PMID: 25500121
EDAT- 2017/03/16 06:00
MHDA- 2017/03/16 06:01
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/03/16 06:01 [medline]
AID - S1535-6108(17)30050-8 [pii]
AID - 10.1016/j.ccell.2017.02.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):466. doi: 10.1016/j.ccell.2017.02.007.

PMID- 28292442
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and
      Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.
PG  - 452-465
LID - S1535-6108(17)30049-1 [pii]
LID - 10.1016/j.ccell.2017.02.006 [doi]
AB  - Chimeric transcription factors are a hallmark of human leukemia, but the
      molecular mechanisms by which they block differentiation and promote aberrant
      self-renewal remain unclear. Here, we demonstrate that the ETO2-GLIS2 fusion
      oncoprotein, which is found in aggressive acute megakaryoblastic leukemia,
      confers megakaryocytic identity via the GLIS2 moiety while both ETO2 and GLIS2
      domains are required to drive increased self-renewal properties. ETO2-GLIS2
      directly binds DNA to control transcription of associated genes by upregulation
      of expression and interaction with the ETS-related ERG protein at enhancer
      elements. Importantly, specific interference with ETO2-GLIS2 oligomerization
      reverses the transcriptional activation at enhancers and promotes megakaryocytic 
      differentiation, providing a relevant interface to target in this poor-prognosis 
      pediatric leukemia.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Thirant, Cecile
AU  - Thirant C
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Ignacimouttou, Cathy
AU  - Ignacimouttou C
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Universite Paris Diderot,
      75013 Paris, France.
FAU - Lopez, Cecile K
AU  - Lopez CK
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Universite Paris-Sud, 91405
      Orsay, France.
FAU - Diop, M'Boyba
AU  - Diop M
AD  - Gustave Roussy, 94800 Villejuif, France.
FAU - Le Mouel, Lou
AU  - Le Mouel L
AD  - Gustave Roussy, 94800 Villejuif, France; Universite Paris-Sud, 91405 Orsay,
      France.
FAU - Thiollier, Clarisse
AU  - Thiollier C
AD  - Gustave Roussy, 94800 Villejuif, France; Universite Paris Diderot, 75013 Paris,
      France.
FAU - Siret, Aurelie
AU  - Siret A
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Dessen, Phillipe
AU  - Dessen P
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Aid, Zakia
AU  - Aid Z
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Riviere, Julie
AU  - Riviere J
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Rameau, Philippe
AU  - Rameau P
AD  - Gustave Roussy, 94800 Villejuif, France.
FAU - Lefebvre, Celine
AU  - Lefebvre C
AD  - Gustave Roussy, 94800 Villejuif, France.
FAU - Khaled, Mehdi
AU  - Khaled M
AD  - Gustave Roussy, 94800 Villejuif, France.
FAU - Leverger, Guy
AU  - Leverger G
AD  - Hopital Trousseau, AP-HP, 75012 Paris, France.
FAU - Ballerini, Paola
AU  - Ballerini P
AD  - Hopital Trousseau, AP-HP, 75012 Paris, France.
FAU - Petit, Arnaud
AU  - Petit A
AD  - Hopital Trousseau, AP-HP, 75012 Paris, France.
FAU - Raslova, Hana
AU  - Raslova H
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Carmichael, Catherine L
AU  - Carmichael CL
AD  - Walter and Eliza Hall Institute, Parkville, VIC 3052, Australia.
FAU - Kile, Benjamin T
AU  - Kile BT
AD  - Walter and Eliza Hall Institute, Parkville, VIC 3052, Australia.
FAU - Soler, Eric
AU  - Soler E
AD  - INSERM UMR967, 92265 Fontenay-aux-Roses, France.
FAU - Crispino, John D
AU  - Crispino JD
AD  - Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA.
FAU - Wichmann, Christian
AU  - Wichmann C
AD  - Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology,
      Ludwig-Maximilian University Hospital, Munich, Germany.
FAU - Pflumio, Francoise
AU  - Pflumio F
AD  - INSERM UMR967, 92265 Fontenay-aux-Roses, France.
FAU - Schwaller, Jurg
AU  - Schwaller J
AD  - University Children's Hospital Beider Basel (UKBB), Departement of Biomedicine,
      University of Basel, 4031 Basel, Switzerland.
FAU - Vainchenker, William
AU  - Vainchenker W
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Lobry, Camille
AU  - Lobry C
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Droin, Nathalie
AU  - Droin N
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France; Universite Paris-Sud, 91405 Orsay, France; INSERM U523, CNRS
      UMS3655, Gustave Roussy, 94800 Villejuif, France.
FAU - Bernard, Olivier A
AU  - Bernard OA
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France; Universite Paris-Sud, 91405 Orsay, France.
FAU - Malinge, Sebastien
AU  - Malinge S
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France.
FAU - Mercher, Thomas
AU  - Mercher T
AD  - INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Gustave Roussy Institute,
      39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800
      Villejuif, France; Universite Paris Diderot, 75013 Paris, France; Universite
      Paris-Sud, 91405 Orsay, France. Electronic address: thomas.mercher@inserm.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ERG protein, human)
RN  - 0 (ETO2-GLIS2 fusion protein, human)
RN  - 0 (GATA1 Transcription Factor)
RN  - 0 (GATA1 protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Transcriptional Regulator ERG)
SB  - IM
CIN - Cancer Cell. 2017 Mar 13;31(3):307-308. PMID: 28292433
MH  - Animals
MH  - Cell Differentiation
MH  - Child
MH  - Enhancer Elements, Genetic
MH  - GATA1 Transcription Factor/genetics
MH  - Humans
MH  - Leukemia, Megakaryoblastic, Acute/*pathology
MH  - Mice
MH  - Oncogene Proteins, Fusion/chemistry/*physiology
MH  - *Transcriptional Activation
MH  - Transcriptional Regulator ERG/physiology
OTO - NOTNLM
OT  - *AMKL
OT  - *CBFA2T3
OT  - *CRISPR
OT  - *ChIP
OT  - *ERG
OT  - *GLIS
OT  - *enhancer
OT  - *leukemia
OT  - *pediatric
OT  - *transcription factor
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/05/02 00:00 [received]
PHST- 2016/12/22 00:00 [revised]
PHST- 2017/02/09 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30049-1 [pii]
AID - 10.1016/j.ccell.2017.02.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.

PMID- 28292441
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation
      of PI3K/mTOR and AR Signaling.
PG  - 436-451
LID - S1535-6108(17)30047-8 [pii]
LID - 10.1016/j.ccell.2017.02.004 [doi]
AB  - Recurrent point mutations in SPOP define a distinct molecular subclass of
      prostate cancer. Here, we describe a mouse model showing that mutant SPOP drives 
      prostate tumorigenesis in vivo. Conditional expression of mutant SPOP in the
      prostate dramatically altered phenotypes in the setting of Pten loss, with early 
      neoplastic lesions (high-grade prostatic intraepithelial neoplasia) with striking
      nuclear atypia and invasive, poorly differentiated carcinoma. In mouse prostate
      organoids, mutant SPOP drove increased proliferation and a transcriptional
      signature consistent with human prostate cancer. Using these models and human
      prostate cancer samples, we show that SPOP mutation activates both PI3K/mTOR and 
      androgen receptor signaling, effectively uncoupling the normal negative feedback 
      between these two pathways.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Blattner, Mirjam
AU  - Blattner M
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell
      Medicine, New York, NY 10065, USA.
FAU - Liu, Deli
AU  - Liu D
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA; Department of Urology, Weill Cornell Medicine, New York, NY 10065,
      USA; HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for
      Computational Biomedicine, Weill Cornell Medical College, New York, NY 10065,
      USA.
FAU - Robinson, Brian D
AU  - Robinson BD
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Huang, Dennis
AU  - Huang D
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA.
FAU - Poliakov, Anton
AU  - Poliakov A
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI 48109, USA.
FAU - Gao, Dong
AU  - Gao D
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
      (MSKCC), New York, NY 10065, USA.
FAU - Nataraj, Srilakshmi
AU  - Nataraj S
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA.
FAU - Deonarine, Lesa D
AU  - Deonarine LD
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA.
FAU - Augello, Michael A
AU  - Augello MA
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA; Department of Urology, Weill Cornell Medicine, New York, NY 10065,
      USA.
FAU - Sailer, Verena
AU  - Sailer V
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Ponnala, Lalit
AU  - Ponnala L
AD  - Computational Biology Service Unit, Cornell University, Ithaca, NY 14853, USA.
FAU - Ittmann, Michael
AU  - Ittmann M
AD  - Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX
      77030, USA.
FAU - Chinnaiyan, Arul M
AU  - Chinnaiyan AM
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI 48109, USA; Departments of Pathology and Urology, and Howard Hughes Medical
      Institute, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Sboner, Andrea
AU  - Sboner A
AD  - HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational
      Biomedicine, Weill Cornell Medical College, New York, NY 10065, USA; Englander
      Institute for Precision Medicine of Weill Cornell Medicine, and New
      York-Presbyterian Hospital, New York, NY 10065, USA.
FAU - Chen, Yu
AU  - Chen Y
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI 48109, USA; Department of Medicine, MSKCC, New York, NY 10065, USA.
FAU - Rubin, Mark A
AU  - Rubin MA
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell
      Medicine, New York, NY 10065, USA; Department of Urology, Weill Cornell Medicine,
      New York, NY 10065, USA; Englander Institute for Precision Medicine of Weill
      Cornell Medicine, and New York-Presbyterian Hospital, New York, NY 10065, USA.
      Electronic address: rubinma@med.cornell.edu.
FAU - Barbieri, Christopher E
AU  - Barbieri CE
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA; Department of Urology, Weill Cornell Medicine, New York, NY 10065,
      USA. Electronic address: chb9074@med.cornell.edu.
LA  - eng
GR  - R01 CA193837/CA/NCI NIH HHS/United States
GR  - U01 CA214170/CA/NCI NIH HHS/United States
GR  - P50 CA092629/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - K08 CA140946/CA/NCI NIH HHS/United States
GR  - R01 CA125612/CA/NCI NIH HHS/United States
GR  - K08 CA187417/CA/NCI NIH HHS/United States
GR  - P50 CA186786/CA/NCI NIH HHS/United States
GR  - P50 CA069568/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Repressor Proteins)
RN  - 0 (SPOP protein, human)
RN  - EC 2.3.1.48 (NCOA3 protein, human)
RN  - EC 2.3.1.48 (Nuclear Receptor Coactivator 3)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
MH  - Animals
MH  - Cell Proliferation
MH  - Humans
MH  - Male
MH  - Mice
MH  - *Mutation
MH  - Nuclear Proteins/*genetics
MH  - Nuclear Receptor Coactivator 3/physiology
MH  - PTEN Phosphohydrolase/genetics
MH  - Phosphatidylinositol 3-Kinases/*physiology
MH  - Prostatic Neoplasms/*etiology/genetics/pathology
MH  - Proto-Oncogene Proteins c-ets/physiology
MH  - Receptors, Androgen/*physiology
MH  - Repressor Proteins/*genetics
MH  - Signal Transduction/*physiology
MH  - TOR Serine-Threonine Kinases/*physiology
PMC - PMC5384998
MID - NIHMS851730
OTO - NOTNLM
OT  - *PI3K/mTOR
OT  - *SPOP
OT  - *androgen receptor
OT  - *cancer genomics
OT  - *organoids
OT  - *prostate cancer
OT  - *proteomics
OT  - *transgenic mouse model
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/05/19 00:00 [received]
PHST- 2016/09/18 00:00 [revised]
PHST- 2017/02/03 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30047-8 [pii]
AID - 10.1016/j.ccell.2017.02.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):436-451. doi: 10.1016/j.ccell.2017.02.004.

PMID- 28292440
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
PG  - 424-435
LID - S1535-6108(17)30014-4 [pii]
LID - 10.1016/j.ccell.2017.01.014 [doi]
AB  - Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to
      mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade 
      glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR
      activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely
      block mTORC1 compared with mTOR kinase inhibitors (TORKi). Here, we compared
      RapaLink-1, a TORKi linked to rapamycin, with earlier-generation mTOR inhibitors.
      Compared with rapamycin and Rapalink-1, TORKi showed poor durability. RapaLink-1 
      associated with FKBP12, an abundant mTOR-interacting protein, enabling
      accumulation of RapaLink-1. RapaLink-1 showed better efficacy than rapamycin or
      TORKi, potently blocking cancer-derived, activating mutants of mTOR. Our study
      re-establishes mTOR as a central target in glioma and traces the failure of
      existing drugs to incomplete/nondurable inhibition of mTORC1.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Fan, QiWen
AU  - Fan Q
AD  - Department of Neurology, University of California, San Francisco, CA 94158, USA; 
      Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
FAU - Aksoy, Ozlem
AU  - Aksoy O
AD  - Department of Neurology, University of California, San Francisco, CA 94158, USA; 
      Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
FAU - Wong, Robyn A
AU  - Wong RA
AD  - Department of Neurology, University of California, San Francisco, CA 94158, USA; 
      Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
FAU - Ilkhanizadeh, Shirin
AU  - Ilkhanizadeh S
AD  - Department of Neurology, University of California, San Francisco, CA 94158, USA; 
      Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
FAU - Novotny, Chris J
AU  - Novotny CJ
AD  - Howard Hughes Medical Institute, Department of Cellular and Molecular
      Pharmacology, University of California, San Francisco, CA 94158, USA.
FAU - Gustafson, William C
AU  - Gustafson WC
AD  - Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA;
      Department of Pediatrics, University of California, San Francisco, CA 94158, USA.
FAU - Truong, Albert Yi-Que
AU  - Truong AY
AD  - Department of Pediatrics, University of California, San Francisco, CA 94158, USA;
      Department of Neurological Surgery, University of California, San Francisco, CA
      94158, USA.
FAU - Cayanan, Geraldine
AU  - Cayanan G
AD  - Department of Neurology, University of California, San Francisco, CA 94158, USA; 
      Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
FAU - Simonds, Erin F
AU  - Simonds EF
AD  - Department of Neurology, University of California, San Francisco, CA 94158, USA; 
      Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
FAU - Haas-Kogan, Daphne
AU  - Haas-Kogan D
AD  - Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Phillips, Joanna J
AU  - Phillips JJ
AD  - Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA;
      Department of Neurological Surgery, University of California, San Francisco, CA
      94158, USA.
FAU - Nicolaides, Theodore
AU  - Nicolaides T
AD  - Department of Pediatrics, University of California, San Francisco, CA 94158, USA;
      Department of Neurological Surgery, University of California, San Francisco, CA
      94158, USA.
FAU - Okaniwa, Masanori
AU  - Okaniwa M
AD  - Howard Hughes Medical Institute, Department of Cellular and Molecular
      Pharmacology, University of California, San Francisco, CA 94158, USA.
FAU - Shokat, Kevan M
AU  - Shokat KM
AD  - Howard Hughes Medical Institute, Department of Cellular and Molecular
      Pharmacology, University of California, San Francisco, CA 94158, USA.
FAU - Weiss, William A
AU  - Weiss WA
AD  - Department of Neurology, University of California, San Francisco, CA 94158, USA; 
      Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA;
      Department of Pediatrics, University of California, San Francisco, CA 94158, USA;
      Department of Neurological Surgery, University of California, San Francisco, CA
      94158, USA. Electronic address: waweiss@gmail.com.
LA  - eng
GR  - U54 CA163155/CA/NCI NIH HHS/United States
GR  - U01 CA176287/CA/NCI NIH HHS/United States
GR  - R01 NS091620/NS/NINDS NIH HHS/United States
GR  - P01 CA118816/CA/NCI NIH HHS/United States
GR  - P30 CA082103/CA/NCI NIH HHS/United States
GR  - R01 CA148699/CA/NCI NIH HHS/United States
GR  - R01 NS089868/NS/NINDS NIH HHS/United States
GR  - T32 GM064337/GM/NIGMS NIH HHS/United States
GR  - P50 AA017072/AA/NIAAA NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 5.2.1.- (Tacrolimus Binding Protein 1A)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*drug therapy
MH  - Cell Line, Tumor
MH  - Female
MH  - Glioblastoma/*drug therapy
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Multiprotein Complexes/*antagonists & inhibitors
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Sirolimus/therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Tacrolimus Binding Protein 1A/physiology
PMC - PMC5386178
MID - NIHMS854301
OTO - NOTNLM
OT  - *FKBP12, FK506 binding protein 12
OT  - *FRB, FK506 rapamycin binding
OT  - *GBM, glioblastoma
OT  - *PI3K, phosphatidylinositol 3' kinase
OT  - *TORKi, mTOR kinase inhibitor
OT  - *mTOR mechanistic target of rapamycin
OT  - *mTORC1, mTOR complex 1
OT  - *mTORC2, mTOR complex 2
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/01/26 00:00 [received]
PHST- 2016/08/19 00:00 [revised]
PHST- 2017/01/26 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30014-4 [pii]
AID - 10.1016/j.ccell.2017.01.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.

PMID- 28292439
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Integrated Molecular Characterization of Uterine Carcinosarcoma.
PG  - 411-423
LID - S1535-6108(17)30053-3 [pii]
LID - 10.1016/j.ccell.2017.02.010 [doi]
AB  - We performed genomic, epigenomic, transcriptomic, and proteomic characterizations
      of uterine carcinosarcomas (UCSs). Cohort samples had extensive copy-number
      alterations and highly recurrent somatic mutations. Frequent mutations were found
      in TP53, PTEN, PIK3CA, PPP2R1A, FBXW7, and KRAS, similar to endometrioid and
      serous uterine carcinomas. Transcriptome sequencing identified a strong
      epithelial-to-mesenchymal transition (EMT) gene signature in a subset of cases
      that was attributable to epigenetic alterations at microRNA promoters. The range 
      of EMT scores in UCS was the largest among all tumor types studied via The Cancer
      Genome Atlas. UCSs shared proteomic features with gynecologic carcinomas and
      sarcomas with intermediate EMT features. Multiple somatic mutations and
      copy-number alterations in genes that are therapeutic targets were identified.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Cherniack, Andrew D
AU  - Cherniack AD
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Shen, Hui
AU  - Shen H
AD  - Van Andel Research Institute, Center for Epigenetics, Grand Rapids, MI 49503,
      USA.
FAU - Walter, Vonn
AU  - Walter V
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Stewart, Chip
AU  - Stewart C
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Murray, Bradley A
AU  - Murray BA
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Bowlby, Reanne
AU  - Bowlby R
AD  - Canada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Hu, Xin
AU  - Hu X
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ling, Shiyun
AU  - Ling S
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Soslow, Robert A
AU  - Soslow RA
AD  - Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Broaddus, Russell R
AU  - Broaddus RR
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zuna, Rosemary E
AU  - Zuna RE
AD  - Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma
      City, OK 73104, USA.
FAU - Robertson, Gordon
AU  - Robertson G
AD  - Canada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Laird, Peter W
AU  - Laird PW
AD  - Van Andel Research Institute, Center for Epigenetics, Grand Rapids, MI 49503,
      USA.
FAU - Kucherlapati, Raju
AU  - Kucherlapati R
AD  - Harvard Medical School, Boston, MA 02115, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
CN  - Cancer Genome Atlas Research Network
FAU - Weinstein, John N
AU  - Weinstein JN
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zhang, Jiashan
AU  - Zhang J
AD  - National Cancer Institute, Bethesda, MD 20892, USA.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
      Electronic address: rakbani@mdanderson.org.
FAU - Levine, Douglas A
AU  - Levine DA
AD  - Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical
      Center, New York, NY 10016, USA. Electronic address: douglas.levine@nyumc.org.
LA  - eng
GR  - U24 CA210978/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U24 CA143882/CA/NCI NIH HHS/United States
GR  - U54 HG003067/HG/NHGRI NIH HHS/United States
GR  - U24 CA143835/CA/NCI NIH HHS/United States
GR  - U24 CA143866/CA/NCI NIH HHS/United States
GR  - U24 CA210950/CA/NCI NIH HHS/United States
GR  - U24 CA143845/CA/NCI NIH HHS/United States
GR  - U24 CA143799/CA/NCI NIH HHS/United States
GR  - U54 HG003273/HG/NHGRI NIH HHS/United States
GR  - U24 CA144025/CA/NCI NIH HHS/United States
GR  - U24 CA180951/CA/NCI NIH HHS/United States
GR  - U24 CA143840/CA/NCI NIH HHS/United States
GR  - U24 CA143843/CA/NCI NIH HHS/United States
GR  - U24 CA210974/CA/NCI NIH HHS/United States
GR  - U24 CA143858/CA/NCI NIH HHS/United States
GR  - U24 CA143848/CA/NCI NIH HHS/United States
GR  - U54 HG003079/HG/NHGRI NIH HHS/United States
GR  - U24 CA210949/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - U24 CA143867/CA/NCI NIH HHS/United States
GR  - U24 CA199461/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Carcinosarcoma/*genetics/pathology
MH  - DNA Copy Number Variations
MH  - Epithelial-Mesenchymal Transition
MH  - Female
MH  - Humans
MH  - Mutation
MH  - Uterine Neoplasms/*genetics/pathology
PMC - PMC5599133
MID - NIHMS891671
OTO - NOTNLM
OT  - *EMT
OT  - *TGGA
OT  - *The Cancer Genome Atlas
OT  - *UCS
OT  - *endometrial cancer
OT  - *epithelial-to-mesenchymal transition
OT  - *gynecologic cancer
OT  - *gynecologic oncology
OT  - *translational science
OT  - *uterine carcinosarcoma
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Ally A
FIR - Ally, Adrian
IR  - Auman JT
FIR - Auman, J Todd
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Balu S
FIR - Balu, Saianand
IR  - Baylin SB
FIR - Baylin, Stephen B
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Bogomolniy F
FIR - Bogomolniy, Faina
IR  - Boice L
FIR - Boice, Lori
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Bowen J
FIR - Bowen, Jay
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Broaddus R
FIR - Broaddus, Russell
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Cho J
FIR - Cho, Juok
IR  - Chuah E
FIR - Chuah, Eric
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Cibulskis K
FIR - Cibulskis, Kristian
IR  - Cline M
FIR - Cline, Melissa
IR  - Dao F
FIR - Dao, Fanny
IR  - David M
FIR - David, Mutch
IR  - Demchok JA
FIR - Demchok, John A
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Dowdy S
FIR - Dowdy, Sean
IR  - Felau I
FIR - Felau, Ina
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Frazer S
FIR - Frazer, Scott
IR  - Frick J
FIR - Frick, Jessica
IR  - Gabriel S
FIR - Gabriel, Stacey
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Gerken M
FIR - Gerken, Mark
IR  - Getz G
FIR - Getz, Gad
IR  - Gupta M
FIR - Gupta, Manaswi
IR  - Haussler D
FIR - Haussler, David
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Heiman DI
FIR - Heiman, David I
IR  - Hess J
FIR - Hess, Julian
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Hoffmann R
FIR - Hoffmann, Robert
IR  - Holt RA
FIR - Holt, Robert A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Hu X
FIR - Hu, Xin
IR  - Huang M
FIR - Huang, Mei
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Kanchi RS
FIR - Kanchi, Rupa S
IR  - Kandoth C
FIR - Kandoth, Cyriac
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Kerr S
FIR - Kerr, Sarah
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Laird PW
FIR - Laird, Peter W
IR  - Lander E
FIR - Lander, Eric
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lee D
FIR - Lee, Darlene
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Leshchiner I
FIR - Leshchiner, Ignaty
IR  - Levine DA
FIR - Levine, Douglas A
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Lin P
FIR - Lin, Pei
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu J
FIR - Liu, Jia
IR  - Liu W
FIR - Liu, Wenbin
IR  - Liu Y
FIR - Liu, Yuexin
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Lu Y
FIR - Lu, Yiling
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Meng S
FIR - Meng, Shaowu
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Murray BA
FIR - Murray, Bradley A
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Noble MS
FIR - Noble, Michael S
IR  - Olvera N
FIR - Olvera, Narciso
IR  - Parker JS
FIR - Parker, Joel S
IR  - Perou CM
FIR - Perou, Charles M
IR  - Perou AH
FIR - Perou, Amy H
IR  - Pihl T
FIR - Pihl, Todd
IR  - Radenbaugh AJ
FIR - Radenbaugh, Amie J
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Salvesen HB
FIR - Salvesen, Helga B
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Shen H
FIR - Shen, Hui
IR  - Sheth M
FIR - Sheth, Margi
IR  - Shi Y
FIR - Shi, Yan
IR  - Shih J
FIR - Shih, Juliann
IR  - Simons JV
FIR - Simons, Janae V
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Skelly T
FIR - Skelly, Tara
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Soslow RA
FIR - Soslow, Robert A
IR  - Sougnez C
FIR - Sougnez, Carrie
IR  - Stewart C
FIR - Stewart, Chip
IR  - Sun C
FIR - Sun, Charlie
IR  - Tam A
FIR - Tam, Angela
IR  - Tan D
FIR - Tan, Donghui
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Thorne LB
FIR - Thorne, Leigh B
IR  - Tse K
FIR - Tse, Kane
IR  - Tseng J
FIR - Tseng, Jill
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Verhaak RGW
FIR - Verhaak, Roel G W
IR  - Voet D
FIR - Voet, Doug
IR  - von Bismarck A
FIR - von Bismarck, Amanda
IR  - Walter V
FIR - Walter, Vonn
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wang Z
FIR - Wang, Zhining
IR  - Wang C
FIR - Wang, Chen
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Winterhoff B
FIR - Winterhoff, Boris
IR  - Wise L
FIR - Wise, Lisa
IR  - Wong T
FIR - Wong, Tina
IR  - Wu Y
FIR - Wu, Ye
IR  - Yang L
FIR - Yang, Liming
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Zhang W
FIR - Zhang, Wei
IR  - Zhu JC
FIR - Zhu, Jing-Chun
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Zuna RE
FIR - Zuna, Rosemary E
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/05/09 00:00 [received]
PHST- 2016/09/20 00:00 [revised]
PHST- 2017/02/14 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30053-3 [pii]
AID - 10.1016/j.ccell.2017.02.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):411-423. doi: 10.1016/j.ccell.2017.02.010.

PMID- 28292438
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate
      Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.
PG  - 368-382
LID - S1535-6108(17)30046-6 [pii]
LID - 10.1016/j.ccell.2017.02.003 [doi]
AB  - Metastasis is a predominant cause of death for prostate cancer (PCa) patients;
      however, the underlying mechanisms are poorly understood. We report that
      monoamine oxidase A (MAOA) is a clinically and functionally important mediator of
      PCa bone and visceral metastases, activating paracrine Shh signaling in
      tumor-stromal interactions. MAOA provides tumor cell growth advantages in the
      bone microenvironment by stimulating interleukin-6 (IL6) release from
      osteoblasts, and triggers skeletal colonization by activating osteoclastogenesis 
      through osteoblast production of RANKL and IL6. MAOA inhibitor treatment
      effectively reduces metastasis and prolongs mouse survival by disengaging the
      Shh-IL6-RANKL signaling network in stromal cells in the tumor microenvironment.
      These findings provide a rationale for targeting MAOA and its associated
      molecules to treat PCa metastasis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Wu, Jason Boyang
AU  - Wu JB
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; 
      Department of Pharmaceutical Sciences, College of Pharmacy, Washington State
      University, Spokane, WA 99210, USA. Electronic address: boyang.wu@wsu.edu.
FAU - Yin, Lijuan
AU  - Yin L
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FAU - Shi, Changhong
AU  - Shi C
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FAU - Li, Qinlong
AU  - Li Q
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; 
      Department of Pathology, Xijing Hospital, the Fourth Military Medical University,
      Xi'an, Shaanxi 710032, China.
FAU - Duan, Peng
AU  - Duan P
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FAU - Huang, Jen-Ming
AU  - Huang JM
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FAU - Liu, Chunyan
AU  - Liu C
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FAU - Wang, Fubo
AU  - Wang F
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; 
      Department of Urology, Changhai Hospital, the Secondary Military Medical
      University, Shanghai 200433, China.
FAU - Lewis, Michael
AU  - Lewis M
AD  - West Los Angeles VA Medical Center, Los Angeles, CA 90073, USA.
FAU - Wang, Yang
AU  - Wang Y
AD  - Department of Pathology, Changhai Hospital, the Secondary Military Medical
      University, Shanghai 200433, China.
FAU - Lin, Tzu-Ping
AU  - Lin TP
AD  - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan 11217,
      ROC; Department of Urology, School of Medicine and Shu-Tien Urological Research
      Center, National Yang-Ming University, Taipei, Taiwan 11217, ROC.
FAU - Pan, Chin-Chen
AU  - Pan CC
AD  - Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan 11217, 
      ROC.
FAU - Posadas, Edwin M
AU  - Posadas EM
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; 
      Division of Hematology/Oncology, Department of Medicine, Cedars-Sinai Medical
      Center, Los Angeles, CA 90048, USA.
FAU - Zhau, Haiyen E
AU  - Zhau HE
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FAU - Chung, Leland W K
AU  - Chung LWK
AD  - Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute,
      Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 
      Electronic address: Leland.Chung@cshs.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Hedgehog Proteins)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (RANK Ligand)
RN  - 0 (SHH protein, human)
RN  - 0 (TNFSF11 protein, human)
RN  - EC 1.4.3.4 (Monoamine Oxidase)
SB  - IM
CIN - Cancer Cell. 2017 Mar 13;31(3):303-305. PMID: 28292431
MH  - Animals
MH  - Bone Neoplasms/secondary
MH  - *Cell Communication
MH  - Hedgehog Proteins/*physiology
MH  - Humans
MH  - Interleukin-6/*physiology
MH  - Male
MH  - Mice
MH  - Mice, SCID
MH  - Monoamine Oxidase/analysis/*physiology
MH  - Osteoblasts/physiology
MH  - Prostatic Neoplasms/*pathology
MH  - RANK Ligand/*physiology
MH  - Signal Transduction/*physiology
MH  - Stromal Cells/physiology
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - *bone metastasis
OT  - *interleukin-6
OT  - *monoamine oxidase A
OT  - *osteoblast
OT  - *osteoclast
OT  - *prostate cancer
OT  - *receptor activator of NF-kB ligand
OT  - *sonic hedgehog signaling
OT  - *tumor-stromal interactions
OT  - *visceral metastasis
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2015/12/09 00:00 [received]
PHST- 2016/08/29 00:00 [revised]
PHST- 2017/02/03 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30046-6 [pii]
AID - 10.1016/j.ccell.2017.02.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):368-382. doi: 10.1016/j.ccell.2017.02.003.

PMID- 28292437
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Nerve Dependence: From Regeneration to Cancer.
PG  - 342-354
LID - S1535-6108(17)30048-X [pii]
LID - 10.1016/j.ccell.2017.02.005 [doi]
AB  - Nerve dependence has long been described in animal regeneration, where the
      outgrowth of axons is necessary to the reconstitution of lost body parts and
      tissue remodeling in various species. Recent discoveries have demonstrated that
      denervation can suppress tumor growth and metastasis, pointing to nerve
      dependence in cancer. Regeneration and cancer share similarities in regard to the
      stimulatory role of nerves, and there are indications that the stem cell
      compartment is a preferred target of innervation. Thus, the neurobiology of
      cancer is an emerging discipline that opens new perspectives in oncology.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Boilly, Benoni
AU  - Boilly B
AD  - UFR de Biologie, Universite de Lille, 59655 Villeneuve d'Ascq, France.
FAU - Faulkner, Sam
AU  - Faulkner S
AD  - School of Biomedical Sciences and Pharmacy, Hunter Medical Research Institute,
      University of Newcastle, Callaghan, NSW 2308, Australia.
FAU - Jobling, Phillip
AU  - Jobling P
AD  - School of Biomedical Sciences and Pharmacy, Hunter Medical Research Institute,
      University of Newcastle, Callaghan, NSW 2308, Australia.
FAU - Hondermarck, Hubert
AU  - Hondermarck H
AD  - School of Biomedical Sciences and Pharmacy, Hunter Medical Research Institute,
      University of Newcastle, Callaghan, NSW 2308, Australia. Electronic address:
      hubert.hondermarck@newcastle.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Neuropeptides)
RN  - 0 (Neurotransmitter Agents)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Axons/physiology
MH  - Cell Proliferation
MH  - Humans
MH  - Neoplasms/*physiopathology
MH  - Nerve Growth Factor/physiology
MH  - Nerve Regeneration/*physiology
MH  - Neural Stem Cells/physiology
MH  - Neuropeptides/physiology
MH  - Neurotransmitter Agents/physiology
OTO - NOTNLM
OT  - *Schwann cells
OT  - *cancer
OT  - *nerve dependence
OT  - *nerve infiltration
OT  - *neurotrophic growth factors
OT  - *regeneration
OT  - *tumor microenvironment
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/09/08 00:00 [received]
PHST- 2016/12/07 00:00 [revised]
PHST- 2017/02/08 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30048-X [pii]
AID - 10.1016/j.ccell.2017.02.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):342-354. doi: 10.1016/j.ccell.2017.02.005.

PMID- 28292436
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - The Microenvironmental Landscape of Brain Tumors.
PG  - 326-341
LID - S1535-6108(17)30052-1 [pii]
LID - 10.1016/j.ccell.2017.02.009 [doi]
AB  - The brain tumor microenvironment (TME) is emerging as a critical regulator of
      cancer progression in primary and metastatic brain malignancies. The unique
      properties of this organ require a specific framework for designing TME-targeted 
      interventions. Here, we discuss a number of these distinct features, including
      brain-resident cell types, the blood-brain barrier, and various aspects of the
      immune-suppressive environment. We also highlight recent advances in
      therapeutically targeting the brain TME in cancer. By developing a comprehensive 
      understanding of the complex and interconnected microenvironmental landscape of
      brain malignancies we will greatly expand the range of therapeutic strategies
      available to target these deadly diseases.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Quail, Daniela F
AU  - Quail DF
AD  - Goodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada; 
      Department of Physiology, McGill University, Montreal, QC H3A 1A3, Canada.
FAU - Joyce, Johanna A
AU  - Joyce JA
AD  - Ludwig Institute for Cancer Research, University of Lausanne, 1066 Lausanne,
      Switzerland; Department of Oncology, University of Lausanne, Chemin des
      Boveresses 155, 1066 Lausanne, Switzerland. Electronic address:
      johanna@joycelab.org.
LA  - eng
GR  - R01 CA181355/CA/NCI NIH HHS/United States
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Review
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Blood-Brain Barrier
MH  - Brain Neoplasms/*immunology/therapy
MH  - Dendritic Cells/physiology
MH  - Humans
MH  - Macrophages/physiology
MH  - Microglia/physiology
MH  - Neovascularization, Physiologic
MH  - Neutrophils/physiology
MH  - T-Lymphocytes/immunology
MH  - *Tumor Microenvironment
MH  - Wound Healing
PMC - PMC5424263
MID - NIHMS854681
OTO - NOTNLM
OT  - *blood-brain barrier
OT  - *brain metastasis
OT  - *brain tumor microenvironment
OT  - *glioma
OT  - *immunotherapy
OT  - *tumor-associated macrophage
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/01/04 00:00 [received]
PHST- 2017/02/06 00:00 [revised]
PHST- 2017/02/14 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30052-1 [pii]
AID - 10.1016/j.ccell.2017.02.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):326-341. doi: 10.1016/j.ccell.2017.02.009.

PMID- 28292435
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for
      Synergistic Therapies.
PG  - 311-325
LID - S1535-6108(17)30051-X [pii]
LID - 10.1016/j.ccell.2017.02.008 [doi]
AB  - T cell dysfunction in solid tumors results from multiple mechanisms. Altered
      signaling pathways in tumor cells help produce a suppressive tumor
      microenvironment enriched for inhibitory cells, posing a major obstacle for
      cancer immunity. Metabolic constraints to cell function and survival shape tumor 
      progression and immune cell function. In the face of persistent antigen, chronic 
      T cell receptor signaling drives T lymphocytes to a functionally exhausted state.
      Here we discuss how the tumor and its microenvironment influences T cell
      trafficking and function with a focus on melanoma, and pancreatic and ovarian
      cancer, and discuss how scientific advances may help overcome these hurdles.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Anderson, Kristin G
AU  - Anderson KG
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Mail Stop
      D3-100, P.O. Box 19024, Seattle, WA 98109, USA; Program in Immunology, Fred
      Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Departments of
      Medicine/Oncology and Immunology, University of Washington School of Medicine,
      Seattle, WA 98109, USA.
FAU - Stromnes, Ingunn M
AU  - Stromnes IM
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Mail Stop
      D3-100, P.O. Box 19024, Seattle, WA 98109, USA; Program in Immunology, Fred
      Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address:
      istromne@fredhutch.org.
FAU - Greenberg, Philip D
AU  - Greenberg PD
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Mail Stop
      D3-100, P.O. Box 19024, Seattle, WA 98109, USA; Program in Immunology, Fred
      Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Departments of
      Medicine/Oncology and Immunology, University of Washington School of Medicine,
      Seattle, WA 98109, USA. Electronic address: pgreen@u.washington.edu.
LA  - eng
GR  - P01 CA018029/CA/NCI NIH HHS/United States
GR  - R01 CA033084/CA/NCI NIH HHS/United States
GR  - R37 CA033084/CA/NCI NIH HHS/United States
GR  - T32 CA009657/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Amino Acids)
RN  - 0 (Fatty Acids)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 33X04XA5AT (Lactic Acid)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Amino Acids/metabolism
MH  - Cytotoxicity, Immunologic
MH  - Fatty Acids/metabolism
MH  - Genes, p53
MH  - Glucose/metabolism
MH  - Humans
MH  - Lactic Acid/metabolism
MH  - Neoplasms/*immunology/metabolism/therapy
MH  - Receptors, Antigen, T-Cell/physiology
MH  - T-Lymphocytes/*immunology
MH  - *Tumor Microenvironment
PMC - PMC5423788
MID - NIHMS857984
OTO - NOTNLM
OT  - *T cell dysfunction
OT  - *TME
OT  - *adoptive T cell therapy
OT  - *genetic engineering
OT  - *immunotherapy
OT  - *tumor microenvironment
EDAT- 2017/03/16 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/12/19 00:00 [received]
PHST- 2017/02/13 00:00 [revised]
PHST- 2017/02/15 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(17)30051-X [pii]
AID - 10.1016/j.ccell.2017.02.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):311-325. doi: 10.1016/j.ccell.2017.02.008.

PMID- 28292434
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20171101
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Pancreatic Cancer Genomics 2.0: Profiling Metastases.
PG  - 309-310
LID - S1535-6108(17)30057-0 [pii]
LID - 10.1016/j.ccell.2017.02.014 [doi]
AB  - Pancreatic ductal adenocarcinoma, even when diagnosed early, nearly always
      metastasizes. Recurrent mutations and genomic instability are early events in the
      disease. Two recent papers advance our understanding of how the cancer genome
      evolves as the primary tumor migrates from its origin in the pancreas to colonize
      distant metastatic sites.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Collisson, Eric A
AU  - Collisson EA
AD  - Helen Diller Comprehensive Cancer Center, Department of Medicine, University of
      California San Francisco, San Francisco, CA 94158, USA. Electronic address:
      collissonlab@gmail.com.
FAU - Maitra, Anirban
AU  - Maitra A
AD  - Departments of Pathology and Translational Molecular Pathology, Sheikh Ahmed
      Pancreatic Cancer Research Center, UT MD Anderson Cancer Center, Houston, TX
      77030, USA. Electronic address: amaitra@mdanderson.org.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Nat Genet. 2017 Mar;49(3):358-366. PMID: 28092682
CON - Nat Genet. 2017 Mar;49(3):367-376. PMID: 28092686
MH  - Adenocarcinoma/*diagnosis
MH  - Carcinoma, Pancreatic Ductal
MH  - Genomics
MH  - Humans
MH  - Pancreas
MH  - Pancreatic Neoplasms/*diagnosis
EDAT- 2017/03/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30057-0 [pii]
AID - 10.1016/j.ccell.2017.02.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):309-310. doi: 10.1016/j.ccell.2017.02.014.

PMID- 28292433
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20171016
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - ETO2-GLIS2: A Chimeric Transcription Factor Drives Leukemogenesis through a
      Neomorphic Transcription Network.
PG  - 307-308
LID - S1535-6108(17)30058-2 [pii]
LID - 10.1016/j.ccell.2017.02.015 [doi]
AB  - Acute megakaryoblastic leukemia (AMKL) is a heterogeneous disease with a
      relatively poorly understood pathogenesis. In this issue of Cancer Cell, Thirant 
      and colleagues systematically examine unique transcriptional and functional
      effects of ETO2-GLIS2, an oncogenic fusion protein frequently encountered in
      AMKL, and elucidate a therapeutic vulnerability in this poor-prognosis leukemia.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Wheat, Justin C
AU  - Wheat JC
AD  - Department of Cell Biology, Albert Einstein College of Medicine, Montefiore
      Medical Center, Bronx, NY 10461, USA.
FAU - Steidl, Ulrich
AU  - Steidl U
AD  - Department of Cell Biology, Albert Einstein College of Medicine, Montefiore
      Medical Center, Bronx, NY 10461, USA; Department of Medicine, Albert Einstein
      College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA; Albert
      Einstein Cancer Center, Albert Einstein College of Medicine, Montefiore Medical
      Center, Bronx, NY 10461, USA; Ruth L. and David S. Gottesman Institute for Stem
      Cell Research and Regenerative Medicine, Albert Einstein College of Medicine,
      Montefiore Medical Center, Bronx, NY 10461, USA. Electronic address:
      ulrich.steidl@einstein.yu.edu.
LA  - eng
GR  - F30 GM122308/GM/NIGMS NIH HHS/United States
GR  - T32 GM007288/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Transcription Factors)
SB  - IM
CON - Cancer Cell. 2017 Mar 13;31(3):452-465. PMID: 28292442
MH  - Humans
MH  - Leukemia, Megakaryoblastic, Acute/*drug therapy
MH  - Oncogene Proteins, Fusion/metabolism
MH  - Transcription Factors/*therapeutic use
EDAT- 2017/03/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30058-2 [pii]
AID - 10.1016/j.ccell.2017.02.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):307-308. doi: 10.1016/j.ccell.2017.02.015.

PMID- 28292432
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20170630
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Antibodies Create Killer Bonds in Myeloma.
PG  - 305-307
LID - S1535-6108(17)30054-5 [pii]
LID - 10.1016/j.ccell.2017.02.011 [doi]
AB  - In this issue of Cancer Cell, Li et al. and Seckinger et al. describe promising
      results of two T-cell-dependent bi-specific antibodies for the treatment of
      multiple myeloma: one targets FcRH5 expressed on B cells, whereas the other
      targets the B cell maturation antigen expressed on plasma cells.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Chesi, Marta
AU  - Chesi M
AD  - Mayo Clinic in Arizona, Phoenix, AZ 85054, USA.
FAU - Fonseca, Rafael
AU  - Fonseca R
AD  - Mayo Clinic in Arizona, Phoenix, AZ 85054, USA. Electronic address:
      fonseca.rafael@mayo.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (B-Cell Maturation Antigen)
SB  - IM
CON - Cancer Cell. 2017 Mar 13;31(3):383-395. PMID: 28262555
CON - Cancer Cell. 2017 Mar 13;31(3):396-410. PMID: 28262554
MH  - Antibodies/immunology
MH  - Antibodies, Monoclonal/immunology
MH  - B-Cell Maturation Antigen/*immunology
MH  - B-Lymphocytes
MH  - Humans
MH  - Multiple Myeloma/*drug therapy
MH  - Plasma Cells
EDAT- 2017/03/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30054-5 [pii]
AID - 10.1016/j.ccell.2017.02.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):305-307. doi: 10.1016/j.ccell.2017.02.011.

PMID- 28292431
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone
      Metastases.
PG  - 303-305
LID - S1535-6108(17)30055-7 [pii]
LID - 10.1016/j.ccell.2017.02.012 [doi]
AB  - In this issue of Cancer Cell, Wu et al. identify MAOA as a key mediator of
      osteolytic bone responses that involve complex paracrine interactions between
      tumor cells, osteoblasts, and osteoclasts. Pharmacological inhibition of MAOA
      enzymatic activity effectively interrupted osteolysis and metastatic progression 
      in preclinical models, suggesting a new treatment opportunity.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Nyquist, Michael D
AU  - Nyquist MD
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Seattle, WA 98109, USA.
FAU - Nelson, Peter S
AU  - Nelson PS
AD  - Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research
      Center, Seattle, WA 98109, USA; Division of Medical Oncology, Department of
      Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address:
      pnelson@fhcrc.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Mar 13;31(3):368-382. PMID: 28292438
MH  - *Bone Neoplasms
MH  - Cell Line, Tumor
MH  - Humans
MH  - Male
MH  - Osteoblasts
MH  - Osteoclasts/drug effects
MH  - *Osteolysis
MH  - Prostatic Neoplasms
EDAT- 2017/03/16 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - S1535-6108(17)30055-7 [pii]
AID - 10.1016/j.ccell.2017.02.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):303-305. doi: 10.1016/j.ccell.2017.02.012.

PMID- 28292430
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20170630
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Dangerous Liaisons: Deviant Endothelium NOTCHes toward Tumor Metastasis.
PG  - 301-303
LID - S1535-6108(17)30059-4 [pii]
LID - 10.1016/j.ccell.2017.02.016 [doi]
AB  - In this issue of Cancer Cell, Wieland et al. uncover a feedback loop in which
      tumor cells, by augmenting Notch signaling, provoke a senescent and
      pro-inflammatory state in endothelial cells, promoting neutrophil infiltration,
      tumor cell adhesion, and metastasis. Interfering with this Notch-dependent
      crosstalk may be a therapeutic approach to block metastasis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Guo, Peipei
AU  - Guo P
AD  - Department of Medicine, Division of Regenerative Medicine, Ansary Stem Cell
      Institute, Weill Cornell Medicine, New York, NY 10021, USA.
FAU - Rafii, Shahin
AU  - Rafii S
AD  - Department of Medicine, Division of Regenerative Medicine, Ansary Stem Cell
      Institute, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address:
      srafii@med.cornell.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Mar 13;31(3):355-367. PMID: 28238683
MH  - Cell Adhesion
MH  - *Cell Line, Tumor
MH  - Endothelial Cells/metabolism
MH  - *Endothelium
MH  - Endothelium, Vascular
MH  - Humans
MH  - Signal Transduction
EDAT- 2017/03/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30059-4 [pii]
AID - 10.1016/j.ccell.2017.02.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):301-303. doi: 10.1016/j.ccell.2017.02.016.

PMID- 28262555
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by
      Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
PG  - 383-395
LID - S1535-6108(17)30015-6 [pii]
LID - 10.1016/j.ccell.2017.02.001 [doi]
AB  - The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell 
      lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We
      demonstrate that TDBs trigger T cell receptor activation by inducing target
      clustering and exclusion of CD45 phosphatase from the synapse. The dimensions of 
      the target molecule play a key role in the efficiency of the synapse formation.
      The anti-FcRH5/CD3 TDB kills human plasma cells and patient-derived myeloma cells
      at picomolar concentrations and results in complete depletion of B cells and bone
      marrow plasma cells in cynomolgus monkeys. These data demonstrate the potential
      for the anti-FcRH5/CD3 TDB, alone or in combination with inhibition of PD-1/PD-L1
      signaling, in the treatment of MM and other B cell malignancies.
CI  - Copyright (c) 2017 Genentech. Published by Elsevier Inc. All rights reserved.
FAU - Li, Ji
AU  - Li J
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Stagg, Nicola J
AU  - Stagg NJ
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Johnston, Jennifer
AU  - Johnston J
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Harris, Michael J
AU  - Harris MJ
AD  - Molecular Immunity Unit, Department of Medicine, University of Cambridge,
      MRC-LMB, Cambridge, CB2 0QH, UK.
FAU - Menzies, Sam A
AU  - Menzies SA
AD  - Molecular Immunity Unit, Department of Medicine, University of Cambridge,
      MRC-LMB, Cambridge, CB2 0QH, UK.
FAU - DiCara, Danielle
AU  - DiCara D
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Clark, Vanessa
AU  - Clark V
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Hristopoulos, Maria
AU  - Hristopoulos M
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Cook, Ryan
AU  - Cook R
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Slaga, Dionysos
AU  - Slaga D
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Nakamura, Rin
AU  - Nakamura R
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - McCarty, Luke
AU  - McCarty L
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Sukumaran, Siddharth
AU  - Sukumaran S
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Luis, Elizabeth
AU  - Luis E
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Ye, Zhengmao
AU  - Ye Z
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Wu, Thomas D
AU  - Wu TD
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Sumiyoshi, Teiko
AU  - Sumiyoshi T
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Danilenko, Dimitry
AU  - Danilenko D
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Lee, Genee Y
AU  - Lee GY
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Totpal, Klara
AU  - Totpal K
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Ellerman, Diego
AU  - Ellerman D
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - Hotzel, Isidro
AU  - Hotzel I
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
FAU - James, John R
AU  - James JR
AD  - Molecular Immunity Unit, Department of Medicine, University of Cambridge,
      MRC-LMB, Cambridge, CB2 0QH, UK.
FAU - Junttila, Teemu T
AU  - Junttila TT
AD  - Genentech, Inc., 1 DNA Way, South San Francisco, San Francisco, CA 94080, USA.
      Electronic address: junttila.teemu@gene.com.
LA  - eng
GR  - 099966/Z/12/Z/Wellcome Trust/United Kingdom
GR  - 102195/Z/13/Z/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170302
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (CD3 Complex)
RN  - 0 (Cytokines)
RN  - 0 (Epitopes)
RN  - 0 (FCRL5 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Receptors, Fc)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
RN  - EC 3.1.3.48 (PTPRC protein, human)
SB  - IM
CIN - Cancer Cell. 2017 Mar 13;31(3):305-307. PMID: 28292432
MH  - Animals
MH  - Antibodies, Bispecific/*therapeutic use
MH  - CD3 Complex/*immunology
MH  - Cytokines/secretion
MH  - *Epitopes
MH  - Humans
MH  - Immunological Synapses/*physiology
MH  - Leukocyte Common Antigens/physiology
MH  - Lymphocyte Activation
MH  - Macaca fascicularis
MH  - Mice
MH  - Multiple Myeloma/*drug therapy/immunology/pathology
MH  - Programmed Cell Death 1 Receptor/physiology
MH  - Receptors, Antigen, T-Cell/physiology
MH  - Receptors, Fc/analysis/*immunology
MH  - T-Lymphocytes/*immunology
PMC - PMC5357723
OTO - NOTNLM
OT  - *CD3
OT  - *FCRL5
OT  - *FcRH5
OT  - *T cell
OT  - *bispecific antibody
OT  - *multiple myeloma
EDAT- 2017/03/07 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/07 06:00
PHST- 2016/08/10 00:00 [received]
PHST- 2016/11/23 00:00 [revised]
PHST- 2017/01/31 00:00 [accepted]
PHST- 2017/03/07 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2017/03/07 06:00 [entrez]
AID - S1535-6108(17)30015-6 [pii]
AID - 10.1016/j.ccell.2017.02.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):383-395. doi: 10.1016/j.ccell.2017.02.001. Epub
      2017 Mar 2.

PMID- 28262554
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the 
      BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
PG  - 396-410
LID - S1535-6108(17)30016-8 [pii]
LID - 10.1016/j.ccell.2017.02.002 [doi]
AB  - We identified B cell maturation antigen (BCMA) as a potential therapeutic target 
      in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based
      BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3(+) T
      cell/myeloma cell crosslinking, followed by CD4(+)/CD8(+) T cell activation, and 
      secretion of interferon-gamma, granzyme B, and perforin. This effect is CD4 and
      CD8 T cell mediated. EM801 induced, at nanomolar concentrations, myeloma cell
      death by autologous T cells in 34 of 43 bone marrow aspirates, including those
      from high-risk patients and patients after multiple lines of treatment, tumor
      regression in six of nine mice in a myeloma xenograft model, and depletion of
      BCMA(+) cells in cynomolgus monkeys. Pharmacokinetics and pharmacodynamics
      indicate weekly intravenous/subcutaneous administration.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Seckinger, Anja
AU  - Seckinger A
AD  - Universitatsklinikum Heidelberg, Labor fur Myelomforschung and Medizinische
      Klinik V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
FAU - Delgado, Jose Antonio
AU  - Delgado JA
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, 
      Avda. Pio XII, 55, 31008 Pamplona, Spain.
FAU - Moser, Samuel
AU  - Moser S
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Moreno, Laura
AU  - Moreno L
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, 
      Avda. Pio XII, 55, 31008 Pamplona, Spain.
FAU - Neuber, Brigitte
AU  - Neuber B
AD  - Universitatsklinikum Heidelberg, Medizinische Klinik V, Im Neuenheimer Feld 410, 
      69120 Heidelberg, Germany.
FAU - Grab, Anna
AU  - Grab A
AD  - Universitatsklinikum Heidelberg, Labor fur Myelomforschung and Medizinische
      Klinik V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
FAU - Lipp, Susanne
AU  - Lipp S
AD  - Universitatsklinikum Heidelberg, Labor fur Myelomforschung and Medizinische
      Klinik V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
FAU - Merino, Juana
AU  - Merino J
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, 
      Avda. Pio XII, 55, 31008 Pamplona, Spain.
FAU - Prosper, Felipe
AU  - Prosper F
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, 
      Avda. Pio XII, 55, 31008 Pamplona, Spain.
FAU - Emde, Martina
AU  - Emde M
AD  - Universitatsklinikum Heidelberg, Labor fur Myelomforschung and Medizinische
      Klinik V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
FAU - Delon, Camille
AU  - Delon C
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Latzko, Melanie
AU  - Latzko M
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Gianotti, Reto
AU  - Gianotti R
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Luoend, Remo
AU  - Luoend R
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Murr, Ramona
AU  - Murr R
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Hosse, Ralf J
AU  - Hosse RJ
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Harnisch, Lydia Jasmin
AU  - Harnisch LJ
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Bacac, Marina
AU  - Bacac M
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Fauti, Tanja
AU  - Fauti T
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Klein, Christian
AU  - Klein C
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Zabaleta, Aintzane
AU  - Zabaleta A
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, 
      Avda. Pio XII, 55, 31008 Pamplona, Spain.
FAU - Hillengass, Jens
AU  - Hillengass J
AD  - Universitatsklinikum Heidelberg, Medizinische Klinik V, Im Neuenheimer Feld 410, 
      69120 Heidelberg, Germany.
FAU - Cavalcanti-Adam, Elisabetta Ada
AU  - Cavalcanti-Adam EA
AD  - University of Heidelberg, Institute for Physical Chemistry and Max Planck
      Institute for Medical Research, 69120 Heidelberg, Germany.
FAU - Ho, Anthony D
AU  - Ho AD
AD  - Universitatsklinikum Heidelberg, Medizinische Klinik V, Im Neuenheimer Feld 410, 
      69120 Heidelberg, Germany.
FAU - Hundemer, Michael
AU  - Hundemer M
AD  - Universitatsklinikum Heidelberg, Medizinische Klinik V, Im Neuenheimer Feld 410, 
      69120 Heidelberg, Germany.
FAU - San Miguel, Jesus F
AU  - San Miguel JF
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, 
      Avda. Pio XII, 55, 31008 Pamplona, Spain.
FAU - Strein, Klaus
AU  - Strein K
AD  - EngMab AG, 8808 Pfaffikon, Switzerland.
FAU - Umana, Pablo
AU  - Umana P
AD  - Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
FAU - Hose, Dirk
AU  - Hose D
AD  - Universitatsklinikum Heidelberg, Labor fur Myelomforschung and Medizinische
      Klinik V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Electronic address:
      dirk.hose@med.uni-heidelberg.de.
FAU - Paiva, Bruno
AU  - Paiva B
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, 
      Avda. Pio XII, 55, 31008 Pamplona, Spain. Electronic address: bpaiva@unav.es.
FAU - Vu, Minh Diem
AU  - Vu MD
AD  - EngMab AG, 8808 Pfaffikon, Switzerland. Electronic address: dv@engmab.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170302
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (B-Cell Maturation Antigen)
SB  - IM
CIN - Cancer Cell. 2017 Mar 13;31(3):305-307. PMID: 28292432
MH  - Animals
MH  - Antibodies, Bispecific/biosynthesis/pharmacokinetics/pharmacology/*therapeutic
      use
MH  - B-Cell Maturation Antigen/*immunology
MH  - Humans
MH  - Lymphocyte Activation
MH  - Macaca fascicularis
MH  - Mice
MH  - Multiple Myeloma/*drug therapy
MH  - T-Lymphocytes/*immunology
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - *BCMA
OT  - *T cell bispecific antibody
OT  - *immunotherapy
OT  - *multiple myeloma
OT  - *redirected cell killing
EDAT- 2017/03/07 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/03/07 06:00
PHST- 2016/06/09 00:00 [received]
PHST- 2016/10/07 00:00 [revised]
PHST- 2017/01/31 00:00 [accepted]
PHST- 2017/03/07 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2017/03/07 06:00 [entrez]
AID - S1535-6108(17)30016-8 [pii]
AID - 10.1016/j.ccell.2017.02.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub
      2017 Mar 2.

PMID- 28238683
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar 13
TI  - Endothelial Notch1 Activity Facilitates Metastasis.
PG  - 355-367
LID - S1535-6108(17)30007-7 [pii]
LID - 10.1016/j.ccell.2017.01.007 [doi]
AB  - Endothelial cells (ECs) provide angiocrine factors orchestrating tumor
      progression. Here, we show that activated Notch1 receptors (N1ICD) are frequently
      observed in ECs of human carcinomas and melanoma, and in ECs of the
      pre-metastatic niche in mice. EC N1ICD expression in melanoma correlated with
      shorter progression-free survival. Sustained N1ICD activity induced EC
      senescence, expression of chemokines and the adhesion molecule VCAM1. This
      promoted neutrophil infiltration, tumor cell (TC) adhesion to the endothelium,
      intravasation, lung colonization, and postsurgical metastasis. Thus, sustained
      vascular Notch signaling facilitates metastasis by generating a senescent,
      pro-inflammatory endothelium. Consequently, treatment with Notch1 or
      VCAM1-blocking antibodies prevented Notch-driven metastasis, and genetic ablation
      of EC Notch signaling inhibited peritoneal neutrophil infiltration in an ovarian 
      carcinoma mouse model.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Wieland, Elfriede
AU  - Wieland E
AD  - Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Rodriguez-Vita, Juan
AU  - Rodriguez-Vita J
AD  - Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Liebler, Sven S
AU  - Liebler SS
AD  - Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; Vascular Biology, CBTM, Medical Faculty Mannheim, Heidelberg
      University, 68167 Mannheim, Germany.
FAU - Mogler, Carolin
AU  - Mogler C
AD  - Institute of Pathology, Heidelberg University Hospital, Vascular Oncology and
      Metastasis (A190), German Cancer Research Center, 69120 Heidelberg, Germany.
FAU - Moll, Iris
AU  - Moll I
AD  - Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Herberich, Stefanie E
AU  - Herberich SE
AD  - Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; Vascular Biology, CBTM, Medical Faculty Mannheim, Heidelberg
      University, 68167 Mannheim, Germany.
FAU - Espinet, Elisa
AU  - Espinet E
AD  - Division of Stem Cells and Cancer (A010), German Cancer Research Center (DKFZ),
      DKFZ-ZMBH Alliance and the German Cancer Consortium (DKTK), Heidelberg Institute 
      for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120
      Heidelberg, Germany.
FAU - Herpel, Esther
AU  - Herpel E
AD  - Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Institute
      of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
FAU - Menuchin, Amitai
AU  - Menuchin A
AD  - Department of Biochemistry and Molecular Biology, George S. Wise Faculty of Life 
      Sciences, Tel-Aviv University, 69978 Tel Aviv, Israel.
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AD  - Division of Cancer Epidemiology (C020), German Cancer Research Center, 69120
      Heidelberg, Germany; Research Group Genetic Cancer Epidemiology, University
      Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
FAU - Hoffmeister, Michael
AU  - Hoffmeister M
AD  - Division of Clinical Epidemiology and Aging Research (C070), German Cancer
      Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Gebhardt, Christoffer
AU  - Gebhardt C
AD  - Clinical Cooperation Unit Dermato-Oncology (G300), German Cancer Research Center 
      (DKFZ), Department of Dermatology, Venereology and Allergology, University
      Medical Center Mannheim, Heidelberg University, 69120 Heidelberg, Germany.
FAU - Brenner, Hermann
AU  - Brenner H
AD  - Division of Clinical Epidemiology and Aging Research (C070), German Cancer
      Research Center (DKFZ), 69120 Heidelberg, Germany; Division of Preventive
      Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer
      Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg,
      Germany.
FAU - Trumpp, Andreas
AU  - Trumpp A
AD  - Division of Stem Cells and Cancer (A010), German Cancer Research Center (DKFZ),
      DKFZ-ZMBH Alliance and the German Cancer Consortium (DKTK), Heidelberg Institute 
      for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120
      Heidelberg, Germany.
FAU - Siebel, Christian W
AU  - Siebel CW
AD  - Department of Discovery Oncology, Genentech, Inc., 1 DNA Way, South San
      Francisco, CA 94080, USA.
FAU - Hecker, Markus
AU  - Hecker M
AD  - Department of Cardiovascular Physiology, Heidelberg University and Deutsches
      Zentrum fur Herz-Kreislauf-Forschung e.V. (DZHK), Partner Site
      Heidelberg/Mannheim, 69120 Heidelberg, Germany.
FAU - Utikal, Jochen
AU  - Utikal J
AD  - Clinical Cooperation Unit Dermato-Oncology (G300), German Cancer Research Center 
      (DKFZ), Department of Dermatology, Venereology and Allergology, University
      Medical Center Mannheim, Heidelberg University, 69120 Heidelberg, Germany.
FAU - Sprinzak, David
AU  - Sprinzak D
AD  - Department of Biochemistry and Molecular Biology, George S. Wise Faculty of Life 
      Sciences, Tel-Aviv University, 69978 Tel Aviv, Israel.
FAU - Fischer, Andreas
AU  - Fischer A
AD  - Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; Vascular Biology, CBTM, Medical Faculty Mannheim, Heidelberg
      University, 68167 Mannheim, Germany; Department of Medicine I and Clinical
      Chemistry, Heidelberg University Hospital, 69120 Heidelberg, Germany. Electronic 
      address: a.fischer@dkfz.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170223
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Notch1 protein, mouse)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
SB  - IM
CIN - Cancer Cell. 2017 Mar 13;31(3):301-303. PMID: 28292430
MH  - Animals
MH  - Cell Movement
MH  - Cells, Cultured
MH  - Humans
MH  - Lung Neoplasms/secondary
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neutrophil Infiltration
MH  - Receptor, Notch1/*physiology
MH  - Signal Transduction/physiology
MH  - Vascular Cell Adhesion Molecule-1/analysis/physiology
OTO - NOTNLM
OT  - *Notch signaling
OT  - *angiogenesis
OT  - *endothelial cell
OT  - *extravasation
OT  - *intravasation
OT  - *metastasis
OT  - *mouse models
OT  - *neutrophils
OT  - *senescence
OT  - *vascular biology
EDAT- 2017/02/28 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/02/28 06:00
PHST- 2016/01/20 00:00 [received]
PHST- 2016/09/28 00:00 [revised]
PHST- 2017/01/25 00:00 [accepted]
PHST- 2017/02/28 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2017/02/28 06:00 [entrez]
AID - S1535-6108(17)30007-7 [pii]
AID - 10.1016/j.ccell.2017.01.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Mar 13;31(3):355-367. doi: 10.1016/j.ccell.2017.01.007. Epub
      2017 Feb 23.

PMID- 28196596
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 
      Axis.
PG  - 286-299
LID - S1535-6108(17)30006-5 [pii]
LID - 10.1016/j.ccell.2017.01.006 [doi]
AB  - Small cell lung cancer is initially highly responsive to cisplatin and etoposide 
      but in almost every case becomes rapidly chemoresistant, leading to death within 
      1 year. We modeled acquired chemoresistance in vivo using a series of
      patient-derived xenografts to generate paired chemosensitive and chemoresistant
      cancers. Multiple chemoresistant models demonstrated suppression of SLFN11, a
      factor implicated in DNA-damage repair deficiency. In vivo silencing of SLFN11
      was associated with marked deposition of H3K27me3, a histone modification placed 
      by EZH2, within the gene body of SLFN11, inducing local chromatin condensation
      and gene silencing. Inclusion of an EZH2 inhibitor with standard cytotoxic
      therapies prevented emergence of acquired resistance and augmented
      chemotherapeutic efficacy in both chemosensitive and chemoresistant models of
      small cell lung cancer.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gardner, Eric E
AU  - Gardner EE
AD  - Pharmacology Graduate Training Program, Department of Pharmacology and Molecular 
      Sciences, Johns Hopkins University, Baltimore, MD, USA; Molecular Pharmacology
      Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Lok, Benjamin H
AU  - Lok BH
AD  - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York,
      NY, USA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
FAU - Schneeberger, Valentina E
AU  - Schneeberger VE
AD  - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York,
      NY, USA.
FAU - Desmeules, Patrice
AU  - Desmeules P
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY,
      USA.
FAU - Miles, Linde A
AU  - Miles LA
AD  - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York,
      NY, USA.
FAU - Arnold, Paige K
AU  - Arnold PK
AD  - Louis V. Gerstner, Jr., Graduate School of Biomedical Sciences, Memorial Sloan
      Kettering Cancer Center, New York, NY, USA.
FAU - Ni, Andy
AU  - Ni A
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
FAU - Khodos, Inna
AU  - Khodos I
AD  - Anti-Tumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New 
      York, NY, USA.
FAU - de Stanchina, Elisa
AU  - de Stanchina E
AD  - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York,
      NY, USA; Anti-Tumor Assessment Core Facility, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
FAU - Nguyen, Thuyen
AU  - Nguyen T
AD  - Departments of Pediatrics and Genetics, Stanford University, Stanford, CA, USA.
FAU - Sage, Julien
AU  - Sage J
AD  - Departments of Pediatrics and Genetics, Stanford University, Stanford, CA, USA.
FAU - Campbell, John E
AU  - Campbell JE
AD  - Epizyme, Inc., 400 Technology Square, Cambridge, MA, USA.
FAU - Ribich, Scott
AU  - Ribich S
AD  - Epizyme, Inc., 400 Technology Square, Cambridge, MA, USA.
FAU - Rekhtman, Natasha
AU  - Rekhtman N
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY,
      USA.
FAU - Dowlati, Afshin
AU  - Dowlati A
AD  - Case Western Reserve University and University Hospitals Case Medical Center,
      Cleveland, OH, USA.
FAU - Massion, Pierre P
AU  - Massion PP
AD  - Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville,
      TN, USA.
FAU - Rudin, Charles M
AU  - Rudin CM
AD  - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York,
      NY, USA; Weill Cornell Medical College, New York, NY, USA; Department of
      Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic
      address: rudinc@mskcc.org.
FAU - Poirier, John T
AU  - Poirier JT
AD  - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York,
      NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New
      York, NY, USA. Electronic address: poirierj@mskcc.org.
LA  - eng
GR  - U54 OD020355/OD/NIH HHS/United States
GR  - R01 CA197936/CA/NCI NIH HHS/United States
GR  - I01 CX001425/CX/CSRD VA/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - UL1 TR000457/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (SLFN11 protein, human)
RN  - 0 (TWIST1 protein, human)
RN  - 0 (Twist-Related Protein 1)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
SB  - IM
CIN - Cancer Cell. 2017 Feb 13;31(2):169-171. PMID: 28196592
MH  - Animals
MH  - Drug Resistance, Neoplasm
MH  - Enhancer of Zeste Homolog 2 Protein/antagonists & inhibitors/*physiology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Mice
MH  - Nuclear Proteins/analysis/genetics/*physiology
MH  - Small Cell Lung Carcinoma/*drug therapy
MH  - Twist-Related Protein 1/physiology
PMC - PMC5313262
MID - NIHMS845798
OTO - NOTNLM
OT  - EPZ011989
OT  - EZH2
OT  - SLFN11
OT  - TWIST1
OT  - acquired resistance
OT  - cisplatin
OT  - etoposide
OT  - patient-derived xenograft
OT  - small cell lung cancer
EDAT- 2017/02/16 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/02/16 06:00
PHST- 2016/08/30 00:00 [received]
PHST- 2016/11/22 00:00 [revised]
PHST- 2017/01/17 00:00 [accepted]
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
AID - S1535-6108(17)30006-5 [pii]
AID - 10.1016/j.ccell.2017.01.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.

PMID- 28196595
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.
PG  - 225-239
LID - S1535-6108(17)30005-3 [pii]
LID - 10.1016/j.ccell.2017.01.005 [doi]
AB  - Cancer cell lines are major model systems for mechanistic investigation and drug 
      development. However, protein expression data linked to high-quality DNA, RNA,
      and drug-screening data have not been available across a large number of cancer
      cell lines. Using reverse-phase protein arrays, we measured expression levels of 
      approximately 230 key cancer-related proteins in >650 independent cell lines,
      many of which have publically available genomic, transcriptomic, and
      drug-screening data. Our dataset recapitulates the effects of mutated pathways on
      protein expression observed in patient samples, and demonstrates that proteins
      and particularly phosphoproteins provide information for predicting drug
      sensitivity that is not available from the corresponding mRNAs. We also developed
      a user-friendly bioinformatic resource, MCLP, to help serve the biomedical
      research community.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Li, Jun
AU  - Li J
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Liu, Wenbin
AU  - Liu W
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ju, Zhenlin
AU  - Ju Z
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ling, Shiyun
AU  - Ling S
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Vellano, Christopher P
AU  - Vellano CP
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Roebuck, Paul
AU  - Roebuck P
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yu, Qinghua
AU  - Yu Q
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Eterovic, A Karina
AU  - Eterovic AK
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Byers, Lauren A
AU  - Byers LA
AD  - Department of Thoracic, Head and Neck Medical Oncology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Davies, Michael A
AU  - Davies MA
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Department of Melanoma Medical Oncology, The University
      of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Deng, Wanleng
AU  - Deng W
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Gopal, Y N Vashisht
AU  - Gopal YN
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Chen, Guo
AU  - Chen G
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - von Euw, Erika M
AU  - von Euw EM
AD  - Division of Hematology/Oncology, Department of Medicine, David Geffen School of
      Medicine at UCLA, Los Angeles, CA 90404, USA.
FAU - Slamon, Dennis
AU  - Slamon D
AD  - Division of Hematology/Oncology, Department of Medicine, David Geffen School of
      Medicine at UCLA, Los Angeles, CA 90404, USA.
FAU - Conklin, Dylan
AU  - Conklin D
AD  - Division of Hematology/Oncology, Department of Medicine, David Geffen School of
      Medicine at UCLA, Los Angeles, CA 90404, USA.
FAU - Heymach, John V
AU  - Heymach JV
AD  - Department of Thoracic, Head and Neck Medical Oncology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, 
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Gazdar, Adi F
AU  - Gazdar AF
AD  - Hamon Center for Therapeutic Oncology Research, The University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Minna, John D
AU  - Minna JD
AD  - Hamon Center for Therapeutic Oncology Research, The University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Myers, Jeffrey N
AU  - Myers JN
AD  - Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Lu, Yiling
AU  - Lu Y
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA. Electronic address: gmills@mdanderson.org.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology,
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
      Electronic address: hliang1@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U54 HG008100/HG/NHGRI NIH HHS/United States
GR  - U24 CA210950/CA/NCI NIH HHS/United States
GR  - P50 CA098258/CA/NCI NIH HHS/United States
GR  - U01 CA168394/CA/NCI NIH HHS/United States
GR  - P50 CA070907/CA/NCI NIH HHS/United States
GR  - R01 CA175486/CA/NCI NIH HHS/United States
GR  - U01 CA176284/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - U24 CA199461/CA/NCI NIH HHS/United States
GR  - U24 CA209851/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ARID1A protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
MH  - Cell Line, Tumor
MH  - Computational Biology
MH  - Epithelial-Mesenchymal Transition
MH  - Humans
MH  - Mutation
MH  - Neoplasm Proteins/*analysis
MH  - Nuclear Proteins/analysis
MH  - Protein Array Analysis/*methods
MH  - Proteomics
MH  - RNA, Messenger/analysis
MH  - Receptor, Epidermal Growth Factor/physiology
MH  - Transcription Factors/analysis
PMC - PMC5501076
MID - NIHMS873196
OTO - NOTNLM
OT  - biomarker
OT  - cancer cell lines
OT  - data portal
OT  - drug sensitivity
OT  - proteomics
OT  - reverse-phase protein array
OT  - signaling pathways
EDAT- 2017/02/16 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/02/16 06:00
PHST- 2016/03/24 00:00 [received]
PHST- 2016/07/18 00:00 [revised]
PHST- 2017/01/13 00:00 [accepted]
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
AID - S1535-6108(17)30005-3 [pii]
AID - 10.1016/j.ccell.2017.01.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):225-239. doi: 10.1016/j.ccell.2017.01.005.

PMID- 28196594
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Inactivation of Interferon Receptor Promotes the Establishment of Immune
      Privileged Tumor Microenvironment.
PG  - 194-207
LID - S1535-6108(17)30004-1 [pii]
LID - 10.1016/j.ccell.2017.01.004 [doi]
AB  - Refractoriness of solid tumors, including colorectal cancers (CRCs), to
      immunotherapies is attributed to the immunosuppressive tumor microenvironment
      that protects malignant cells from cytotoxic T lymphocytes (CTLs). We found that 
      downregulation of the type I interferon receptor chain IFNAR1 occurs in human CRC
      and mouse models of CRC. Downregulation of IFNAR1 in tumor stroma stimulated CRC 
      development and growth, played a key role in formation of the immune-privileged
      niche, and predicted poor prognosis in human CRC patients. Genetic stabilization 
      of IFNAR1 improved CTL survival and increased the efficacy of the chimeric
      antigen receptor T cell transfer and PD-1 inhibition. Likewise, pharmacologic
      stabilization of IFNAR1 suppressed tumor growth providing the rationale for
      upregulating IFNAR1 to improve anti-cancer therapies.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Katlinski, Kanstantsin V
AU  - Katlinski KV
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Gui, Jun
AU  - Gui J
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Katlinskaya, Yuliya V
AU  - Katlinskaya YV
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Ortiz, Angelica
AU  - Ortiz A
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Chakraborty, Riddhita
AU  - Chakraborty R
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Bhattacharya, Sabyasachi
AU  - Bhattacharya S
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Carbone, Christopher J
AU  - Carbone CJ
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Beiting, Daniel P
AU  - Beiting DP
AD  - Department of Pathobiology, School of Veterinary Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Girondo, Melanie A
AU  - Girondo MA
AD  - Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
FAU - Peck, Amy R
AU  - Peck AR
AD  - Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
FAU - Pure, Ellen
AU  - Pure E
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Chatterji, Priya
AU  - Chatterji P
AD  - Division of Gastroenterology, Department of Medicine, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Rustgi, Anil K
AU  - Rustgi AK
AD  - Division of Gastroenterology, Department of Medicine, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Diehl, J Alan
AU  - Diehl JA
AD  - Department of Biochemistry, Hollings Cancer Center, Medical University of South
      Carolina, Charleston, SC 29425, USA.
FAU - Koumenis, Constantinos
AU  - Koumenis C
AD  - Department of Radiation Oncology, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Rui, Hallgeir
AU  - Rui H
AD  - Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
FAU - Fuchs, Serge Y
AU  - Fuchs SY
AD  - Department of Biomedical Sciences, Mari Lowe Center for Comparative Oncology,
      School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA. Electronic address: syfuchs@upenn.edu.
LA  - eng
GR  - P01 CA165997/CA/NCI NIH HHS/United States
GR  - P30 CA016520/CA/NCI NIH HHS/United States
GR  - R01 CA092900/CA/NCI NIH HHS/United States
GR  - T32 CA009140/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (IFNAR1 protein, human)
RN  - 156986-95-7 (Receptor, Interferon alpha-beta)
SB  - IM
CIN - Cancer Cell. 2017 Feb 13;31(2):161-163. PMID: 28196588
MH  - Animals
MH  - Cell Survival
MH  - Colorectal Neoplasms/etiology/*immunology/pathology
MH  - Down-Regulation
MH  - Humans
MH  - Immune Tolerance
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Receptor, Interferon alpha-beta/analysis/genetics/*physiology
MH  - Signal Transduction
MH  - T-Lymphocytes, Cytotoxic/physiology
MH  - Tumor Microenvironment
PMC - PMC5313042
MID - NIHMS843245
OTO - NOTNLM
OT  - IFNAR1
OT  - colorectal cancer
OT  - cytotoxic T cells
OT  - immunosuppression
OT  - interferon
OT  - receptor
OT  - tumor microenvironment
EDAT- 2017/02/16 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/02/16 06:00
PHST- 2016/05/23 00:00 [received]
PHST- 2016/09/15 00:00 [revised]
PHST- 2017/01/09 00:00 [accepted]
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
AID - S1535-6108(17)30004-1 [pii]
AID - 10.1016/j.ccell.2017.01.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):194-207. doi: 10.1016/j.ccell.2017.01.004.

PMID- 28196593
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20170608
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Liquid Biopsies, What We Do Not Know (Yet).
PG  - 172-179
LID - S1535-6108(17)30002-8 [pii]
LID - 10.1016/j.ccell.2017.01.002 [doi]
AB  - The inherent molecular heterogeneity of metastatic tumors and the ability of
      cancer genomes to dynamically evolve are not properly captured by tissue
      specimens. Analysis of cell-free DNA and circulating tumor cells has the
      potential to change clinical practice by exploiting blood rather than tissue as a
      source of information. Liquid biopsies are already used to monitor disease
      response and track the emergence of drug resistance. The suitability of
      blood-based molecular profiles for early detection and monitoring minimal
      residual disease is being evaluated. In this review, we address open questions in
      this fast-evolving field of research.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bardelli, Alberto
AU  - Bardelli A
AD  - University of Torino, Department of Oncology, SP 142, Km 3.95, 10060 Candiolo,
      Torino, Italy; Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Torino, Italy.
      Electronic address: alberto.bardelli@unito.it.
FAU - Pantel, Klaus
AU  - Pantel K
AD  - Department of Tumor Biology, Center of Experimental Medicine, University Cancer
      Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrabetae 52,
      20246 Hamburg, Germany. Electronic address: pantel@uke.de.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - *Biopsy
MH  - DNA, Neoplasm/*blood
MH  - Early Detection of Cancer
MH  - Exosomes
MH  - Genotyping Techniques
MH  - Humans
MH  - Neoplasms/*diagnosis/therapy
MH  - Neoplastic Cells, Circulating
EDAT- 2017/02/16 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/02/16 06:00
PHST- 2016/05/20 00:00 [received]
PHST- 2016/10/28 00:00 [revised]
PHST- 2017/01/05 00:00 [accepted]
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
AID - S1535-6108(17)30002-8 [pii]
AID - 10.1016/j.ccell.2017.01.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):172-179. doi: 10.1016/j.ccell.2017.01.002.

PMID- 28196592
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20170630
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Awakening of "Schlafen11" to Tackle Chemotherapy Resistance in SCLC.
PG  - 169-171
LID - S1535-6108(17)30013-2 [pii]
LID - 10.1016/j.ccell.2017.01.013 [doi]
AB  - Chemotherapy resistance arises invariably in small cell lung cancer (SCLC). In
      this issue of Cancer Cell, Gardner et al. find that in some SCLC, EZH2 mediates
      resistance via downregulation of Schlafen11 (SLFN11). Combining EZH2 inhibition
      with chemotherapy effectively overcomes drug resistance of xenografted SCLC,
      holding promise for new treatment paradigms.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Berns, Katrien
AU  - Berns K
AD  - The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the
      Netherlands. Electronic address: k.berns@nki.nl.
FAU - Berns, Anton
AU  - Berns A
AD  - The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the
      Netherlands. Electronic address: a.berns@nki.nl.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Feb 13;31(2):286-299. PMID: 28196596
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma, Small Cell/drug therapy
MH  - Down-Regulation
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Small Cell Lung Carcinoma/*drug therapy
EDAT- 2017/02/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/02/16 06:00
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30013-2 [pii]
AID - 10.1016/j.ccell.2017.01.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):169-171. doi: 10.1016/j.ccell.2017.01.013.

PMID- 28196591
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20170630
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Nuclear PKCiota-ECT2-Rac1 and Ribosome Biogenesis: A Novel Axis in Lung
      Tumorigenesis.
PG  - 167-169
LID - S1535-6108(17)30008-9 [pii]
LID - 10.1016/j.ccell.2017.01.008 [doi]
AB  - The RhoGEF Ect2 controls cell division and exerts oncogenic functions in multiple
      cancers. In this issue of Cancer Cell, Justilien et al. report that Ect2 is
      required for lung tumorigenesis and identified a role for this GEF in ribosomal
      RNA (rRNA) synthesis that is mediated by Rac1 and PKCiota-dependent
      phosphorylation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Baker, Martin J
AU  - Baker MJ
AD  - Department of Systems Pharmacology and Translational Therapeutics, Perelman
      School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Cooke, Mariana
AU  - Cooke M
AD  - Department of Systems Pharmacology and Translational Therapeutics, Perelman
      School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Kazanietz, Marcelo G
AU  - Kazanietz MG
AD  - Department of Systems Pharmacology and Translational Therapeutics, Perelman
      School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
      Electronic address: marcelog@upenn.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Isoenzymes)
RN  - EC 2.7.11.13 (Protein Kinase C)
SB  - IM
CON - Cancer Cell. 2017 Feb 13;31(2):256-269. PMID: 28110998
MH  - Carcinogenesis
MH  - Cell Line, Tumor
MH  - Humans
MH  - Isoenzymes/*genetics
MH  - Protein Kinase C/*genetics
MH  - Ribosomes
EDAT- 2017/02/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/02/16 06:00
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30008-9 [pii]
AID - 10.1016/j.ccell.2017.01.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):167-169. doi: 10.1016/j.ccell.2017.01.008.

PMID- 28196590
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20171205
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Singling Out Chromosome Gains in Tumor Evolution.
PG  - 165-166
LID - S1535-6108(17)30011-9 [pii]
LID - 10.1016/j.ccell.2017.01.011 [doi]
AB  - In this issue of Cancer Cell, Sheltzer et al. shed new light on Theodor Boveri's 
      century-old hypothesis by demonstrating that aneuploidy characterized by
      single-chromosome gains acts to suppress tumorigenesis and that aneuploidy itself
      is a nidus for genomic instability.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Naylor, Ryan M
AU  - Naylor RM
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street
      SW, Rochester, MN 55905, USA.
FAU - van Deursen, Jan M
AU  - van Deursen JM
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street
      SW, Rochester, MN 55905, USA; Department of Pediatric and Adolescent Medicine,
      Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address:
      vandeursen.jan@mayo.edu.
LA  - eng
GR  - F30 CA189339/CA/NCI NIH HHS/United States
GR  - R01 CA096985/CA/NCI NIH HHS/United States
GR  - R01 CA126828/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Feb 13;31(2):240-255. PMID: 28089890
MH  - Aneuploidy
MH  - Chromosome Aberrations
MH  - *Chromosomes
MH  - Genomic Instability
MH  - Humans
MH  - Neoplasms/*genetics
PMC - PMC5446207
MID - NIHMS865609
EDAT- 2017/02/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/02/16 06:00
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30011-9 [pii]
AID - 10.1016/j.ccell.2017.01.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):165-166. doi: 10.1016/j.ccell.2017.01.011.

PMID- 28196589
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - An Oncogenic Role for the Ubiquitin Ligase UBE2O by Targeting AMPK-alpha2 for
      Degradation.
PG  - 163-165
LID - S1535-6108(17)30010-7 [pii]
LID - 10.1016/j.ccell.2017.01.010 [doi]
AB  - There has been controversy regarding the role of AMPK in cancer, some of which
      may be due to functional differences between isoforms. In this issue of Cancer
      Cell, Vila et al. report that UBE2O, a ubiquitin ligase overexpressed in some
      human cancers, specifically triggers the ubiquitination and degradation of
      AMPK-alpha2.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hardie, D Grahame
AU  - Hardie DG
AD  - Division of Cell Signalling & Immunology, School of Life Sciences, University of 
      Dundee, Dow Street, Dundee DD1 5EH, Scotland, UK. Electronic address:
      d.g.hardie@dundee.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Ubiquitin)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
CON - Cancer Cell. 2017 Feb 13;31(2):208-224. PMID: 28162974
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Humans
MH  - Oncogenes
MH  - Ubiquitin/*metabolism
MH  - Ubiquitin-Protein Ligases/genetics
MH  - Ubiquitination
EDAT- 2017/02/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/02/16 06:00
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30010-7 [pii]
AID - 10.1016/j.ccell.2017.01.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):163-165. doi: 10.1016/j.ccell.2017.01.010.

PMID- 28196588
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20170630
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?
PG  - 161-163
LID - S1535-6108(17)30012-0 [pii]
LID - 10.1016/j.ccell.2017.01.012 [doi]
AB  - Type I interferons have been shown to play a major role in anti-cancer immunity. 
      In this issue of Cancer Cell, Katlinski et al. describe tumor-induced degradation
      of type I interferon receptor IFNAR1 chain as a new immune-evasion mechanism in
      colorectal cancers. Stabilizing IFNAR1 inhibits tumor growth and improves
      immunotherapy efficacy.
CI  - Published by Elsevier Inc.
FAU - Araya, Romina E
AU  - Araya RE
AD  - Inflammatory Cell Dynamics Section, Cancer and Inflammation Program, Center for
      Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
FAU - Goldszmid, Romina S
AU  - Goldszmid RS
AD  - Inflammatory Cell Dynamics Section, Cancer and Inflammation Program, Center for
      Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
      Electronic address: rgoldszmid@mail.nih.gov.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Interferon Type I)
SB  - IM
CON - Cancer Cell. 2017 Feb 13;31(2):194-207. PMID: 28196594
MH  - Humans
MH  - Interferon Type I/*metabolism
MH  - *Tumor Escape
EDAT- 2017/02/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/02/16 06:00
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(17)30012-0 [pii]
AID - 10.1016/j.ccell.2017.01.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):161-163. doi: 10.1016/j.ccell.2017.01.012.

PMID- 28196587
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20170623
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at 
      Once!
PG  - 159-161
LID - S1535-6108(17)30009-0 [pii]
LID - 10.1016/j.ccell.2017.01.009 [doi]
AB  - Pheochromocytomas and paragangliomas are infrequent, genetically heterogeneous
      neuroendocrine tumors. In this issue of Cancer Cell, Fishbein et al. report novel
      driver genes, pathogenic mechanisms, and markers of malignancy. Notably, the new 
      findings support the long-held view that these tumors distinctively arise from a 
      single driver event, either inherited or acquired.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Dahia, Patricia L M
AU  - Dahia PL
AD  - Division of Hematology and Medical Oncology, Department of Medicine, University
      of Texas Health Science Center, San Antonio, TX 78229, USA. Electronic address:
      dahia@uthscsa.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):792-805. PMID: 27908736
MH  - Adrenal Gland Neoplasms/*genetics
MH  - Genetic Variation
MH  - Humans
MH  - Neuroendocrine Tumors
MH  - Paraganglioma/genetics
MH  - Pheochromocytoma/*genetics
EDAT- 2017/02/16 06:00
MHDA- 2017/06/24 06:00
CRDT- 2017/02/16 06:00
PHST- 2017/02/16 06:00 [entrez]
PHST- 2017/02/16 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(17)30009-0 [pii]
AID - 10.1016/j.ccell.2017.01.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):159-161. doi: 10.1016/j.ccell.2017.01.009.

PMID- 28162975
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180228
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.
PG  - 181-193
LID - S1535-6108(17)30001-6 [pii]
LID - 10.1016/j.ccell.2017.01.001 [doi]
AB  - We report a comprehensive molecular characterization of pheochromocytomas and
      paragangliomas (PCCs/PGLs), a rare tumor type. Multi-platform integration
      revealed that PCCs/PGLs are driven by diverse alterations affecting multiple
      genes and pathways. Pathogenic germline mutations occurred in eight PCC/PGL
      susceptibility genes. We identified CSDE1 as a somatically mutated driver gene,
      complementing four known drivers (HRAS, RET, EPAS1, and NF1). We also discovered 
      fusion genes in PCCs/PGLs, involving MAML3, BRAF, NGFR, and NF1. Integrated
      analysis classified PCCs/PGLs into four molecularly defined groups: a kinase
      signaling subtype, a pseudohypoxia subtype, a Wnt-altered subtype, driven by
      MAML3 and CSDE1, and a cortical admixture subtype. Correlates of metastatic
      PCCs/PGLs included the MAML3 fusion gene. This integrated molecular
      characterization provides a comprehensive foundation for developing PCC/PGL
      precision medicine.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Fishbein, Lauren
AU  - Fishbein L
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
      Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Leshchiner, Ignaty
AU  - Leshchiner I
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Walter, Vonn
AU  - Walter V
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Danilova, Ludmila
AU  - Danilova L
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
      Baltimore, MD 21287, USA.
FAU - Robertson, A Gordon
AU  - Robertson AG
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Johnson, Amy R
AU  - Johnson AR
AD  - Department of Nutrition, University of North Carolina at Chapel Hill, Chapel
      Hill, NC 27599, USA.
FAU - Lichtenberg, Tara M
AU  - Lichtenberg TM
AD  - The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205,
      USA.
FAU - Murray, Bradley A
AU  - Murray BA
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA.
FAU - Ghayee, Hans K
AU  - Ghayee HK
AD  - Division of Endocrinology & Metabolism, Department of Medicine, University of
      Florida College of Medicine & Malcom Randall VA Medical Center, Gainesville, FL
      32608, USA.
FAU - Else, Tobias
AU  - Else T
AD  - Division of Metabolism, Endocrinology, & Diabetes, Department of Internal
      Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA.
FAU - Ling, Shiyun
AU  - Ling S
AD  - University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Jefferys, Stuart R
AU  - Jefferys SR
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - de Cubas, Aguirre A
AU  - de Cubas AA
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA; Division of Hematology and Oncology, Department
      of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, 
      USA.
FAU - Wenz, Brandon
AU  - Wenz B
AD  - Division of Translational Medicine and Human Genetics, Department of Medicine,
      Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Korpershoek, Esther
AU  - Korpershoek E
AD  - Department of Pathology, Erasmus MC University Medical Center Rotterdam,
      Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
FAU - Amelio, Antonio L
AU  - Amelio AL
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Makowski, Liza
AU  - Makowski L
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA; Department of Nutrition, University of North
      Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Rathmell, W Kimryn
AU  - Rathmell WK
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA; Division of Hematology and Oncology, Department
      of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, 
      USA.
FAU - Gimenez-Roqueplo, Anne-Paule
AU  - Gimenez-Roqueplo AP
AD  - INSERM, UMR970, Paris-Cardiovascular Research Center, F-75015 Paris, France.
FAU - Giordano, Thomas J
AU  - Giordano TJ
AD  - Department of Pathology, University of Michigan Health System, Ann Arbor, MI
      48109, USA.
FAU - Asa, Sylvia L
AU  - Asa SL
AD  - Department of Pathology, University Health Network, Toronto, ON M5G 2C4, Canada; 
      Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G 2C4, Canada.
FAU - Tischler, Arthur S
AU  - Tischler AS
AD  - Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA
      02111, USA.
CN  - Cancer Genome Atlas Research Network
FAU - Pacak, Karel
AU  - Pacak K
AD  - Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute 
      of Child Health and Human Development, Bethesda, MD 20892, USA. Electronic
      address: karel@mail.nih.gov.
FAU - Nathanson, Katherine L
AU  - Nathanson KL
AD  - Division of Translational Medicine and Human Genetics, Department of Medicine,
      Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
      19104, USA; Abramson Cancer Center, Perelman School of Medicine at the University
      of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
      knathans@exchange.upenn.edu.
FAU - Wilkerson, Matthew D
AU  - Wilkerson MD
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA; Department of Genetics, University of North
      Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address:
      mdwilkerson@outlook.com.
LA  - eng
GR  - U24 CA210978/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U24 CA143882/CA/NCI NIH HHS/United States
GR  - U54 HG003067/HG/NHGRI NIH HHS/United States
GR  - T32 CA009582/CA/NCI NIH HHS/United States
GR  - U24 CA143835/CA/NCI NIH HHS/United States
GR  - U24 CA143866/CA/NCI NIH HHS/United States
GR  - U24 CA210950/CA/NCI NIH HHS/United States
GR  - U24 CA143845/CA/NCI NIH HHS/United States
GR  - U24 CA143799/CA/NCI NIH HHS/United States
GR  - U54 HG003273/HG/NHGRI NIH HHS/United States
GR  - U24 CA144025/CA/NCI NIH HHS/United States
GR  - U24 CA180951/CA/NCI NIH HHS/United States
GR  - U24 CA143840/CA/NCI NIH HHS/United States
GR  - U24 CA143843/CA/NCI NIH HHS/United States
GR  - U24 CA210974/CA/NCI NIH HHS/United States
GR  - U24 CA143858/CA/NCI NIH HHS/United States
GR  - U24 CA143848/CA/NCI NIH HHS/United States
GR  - U54 HG003079/HG/NHGRI NIH HHS/United States
GR  - U24 CA210949/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - U24 CA143867/CA/NCI NIH HHS/United States
GR  - U24 CA199461/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170202
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CSDE1 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MAML3 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Pol1 Transcription Initiation Complex Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (transcription factor UBF)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (RET protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - DNA-Binding Proteins/genetics
MH  - Female
MH  - Gene Fusion
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Nuclear Proteins/genetics
MH  - Paraganglioma/etiology/*genetics
MH  - Pheochromocytoma/etiology/*genetics
MH  - Pol1 Transcription Initiation Complex Proteins/genetics
MH  - Proto-Oncogene Proteins c-ret/genetics
MH  - RNA-Binding Proteins/genetics
MH  - Transcription Factors/genetics
PMC - PMC5643159
MID - NIHMS849815
OTO - NOTNLM
OT  - CSDE1
OT  - MAML3
OT  - TCGA
OT  - expression subtypes
OT  - genomics
OT  - metastasis
OT  - molecular profiling
OT  - paraganglioma
OT  - pheochromocytoma
OT  - sequencing
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Ally A
FIR - Ally, Adrian
IR  - Amar L
FIR - Amar, Laurence
IR  - Amelio AL
FIR - Amelio, Antonio L
IR  - Arachchi H
FIR - Arachchi, Harindra
IR  - Asa SL
FIR - Asa, Sylvia L
IR  - Auchus RJ
FIR - Auchus, Richard J
IR  - Auman JT
FIR - Auman, J Todd
IR  - Baertsch R
FIR - Baertsch, Robert
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Balu S
FIR - Balu, Saianand
IR  - Bartsch DK
FIR - Bartsch, Detlef K
IR  - Baudin E
FIR - Baudin, Eric
IR  - Bauer T
FIR - Bauer, Thomas
IR  - Beaver A
FIR - Beaver, Allison
IR  - Benz C
FIR - Benz, Christopher
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Beuschlein F
FIR - Beuschlein, Felix
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Boice L
FIR - Boice, Lori
IR  - Bowen J
FIR - Bowen, Jay
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Brooks D
FIR - Brooks, Denise
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Carter S
FIR - Carter, Suzie
IR  - Cassol CA
FIR - Cassol, Clarissa A
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Chin L
FIR - Chin, Lynda
IR  - Cho J
FIR - Cho, Juok
IR  - Chuah E
FIR - Chuah, Eric
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Cope L
FIR - Cope, Leslie
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - de Cubas AA
FIR - de Cubas, Aguirre A
IR  - de Krijger RR
FIR - de Krijger, Ronald R
IR  - Demchok JA
FIR - Demchok, John A
IR  - Deutschbein T
FIR - Deutschbein, Timo
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Dimmock D
FIR - Dimmock, David
IR  - Dinjens WN
FIR - Dinjens, Winand N M
IR  - Else T
FIR - Else, Tobias
IR  - Eng C
FIR - Eng, Charis
IR  - Eschbacher J
FIR - Eschbacher, Jennifer
IR  - Fassnacht M
FIR - Fassnacht, Martin
IR  - Felau I
FIR - Felau, Ina
IR  - Feldman M
FIR - Feldman, Michael
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Fiddes I
FIR - Fiddes, Ian
IR  - Fishbein L
FIR - Fishbein, Lauren
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Gerken M
FIR - Gerken, Mark
IR  - Getz G
FIR - Getz, Gad
IR  - Geurts J
FIR - Geurts, Jennifer
IR  - Ghayee HK
FIR - Ghayee, Hans K
IR  - Gimenez-Roqueplo AP
FIR - Gimenez-Roqueplo, Anne-Paule
IR  - Giordano TJ
FIR - Giordano, Thomas J
IR  - Goldman M
FIR - Goldman, Mary
IR  - Graim K
FIR - Graim, Kiley
IR  - Gupta M
FIR - Gupta, Manaswi
IR  - Haan D
FIR - Haan, David
IR  - Hahner S
FIR - Hahner, Stefanie
IR  - Hantel C
FIR - Hantel, Constanze
IR  - Haussler D
FIR - Haussler, David
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Heiman DI
FIR - Heiman, David I
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Holt RA
FIR - Holt, Robert A
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Huang M
FIR - Huang, Mei
IR  - Hunt B
FIR - Hunt, Bryan
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Johnson AR
FIR - Johnson, Amy R
IR  - Jones SJ
FIR - Jones, Steven J M
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Kebebew E
FIR - Kebebew, Electron
IR  - Kim J
FIR - Kim, Jaegil
IR  - Kimes P
FIR - Kimes, Patrick
IR  - Knijnenburg T
FIR - Knijnenburg, Theo
IR  - Korpershoek E
FIR - Korpershoek, Esther
IR  - Lander E
FIR - Lander, Eric
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lechan R
FIR - Lechan, Ronald
IR  - Lee D
FIR - Lee, Darlene
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lerario A
FIR - Lerario, Antonio
IR  - Leshchiner I
FIR - Leshchiner, Ignaty
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Lin P
FIR - Lin, Pei
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu J
FIR - Liu, Jia
IR  - LiVolsi VA
FIR - LiVolsi, Virginia A
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Lotan Y
FIR - Lotan, Yair
IR  - Lu Y
FIR - Lu, Yiling
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Maison N
FIR - Maison, Nicole
IR  - Makowski L
FIR - Makowski, Liza
IR  - Mallery D
FIR - Mallery, David
IR  - Mannelli M
FIR - Mannelli, Massimo
IR  - Marquard J
FIR - Marquard, Jessica
IR  - Marra MA
FIR - Marra, Marco A
IR  - Matthew T
FIR - Matthew, Thomas
IR  - Mayo M
FIR - Mayo, Michael
IR  - Meatchi T
FIR - Meatchi, Tchao
IR  - Meng S
FIR - Meng, Shaowu
IR  - Merino MJ
FIR - Merino, Maria J
IR  - Mete O
FIR - Mete, Ozgur
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Moore RA
FIR - Moore, Richard A
IR  - Morozova O
FIR - Morozova, Olena
IR  - Morris S
FIR - Morris, Scott
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Murray BA
FIR - Murray, Bradley A
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Nathanson KL
FIR - Nathanson, Katherine L
IR  - Newton Y
FIR - Newton, Yulia
IR  - Ng S
FIR - Ng, Sam
IR  - Ni Y
FIR - Ni, Ying
IR  - Noble MS
FIR - Noble, Michael S
IR  - Nwariaku F
FIR - Nwariaku, Fiemu
IR  - Pacak K
FIR - Pacak, Karel
IR  - Parker JS
FIR - Parker, Joel S
IR  - Paul E
FIR - Paul, Evan
IR  - Penny R
FIR - Penny, Robert
IR  - Perou CM
FIR - Perou, Charles M
IR  - Perou AH
FIR - Perou, Amy H
IR  - Pihl T
FIR - Pihl, Todd
IR  - Powers J
FIR - Powers, James
IR  - Rabaglia J
FIR - Rabaglia, Jennifer
IR  - Radenbaugh A
FIR - Radenbaugh, Amie
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Rao A
FIR - Rao, Arjun
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Riester A
FIR - Riester, Anna
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Salama S
FIR - Salama, Sofie
IR  - Saller C
FIR - Saller, Charles
IR  - Sandusky G
FIR - Sandusky, George
IR  - Sbiera S
FIR - Sbiera, Silviu
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Sheth M
FIR - Sheth, Margi
IR  - Shi Y
FIR - Shi, Yan
IR  - Shih J
FIR - Shih, Juliann
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Simons JV
FIR - Simons, Janae V
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Skelly T
FIR - Skelly, Tara
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Sokolov A
FIR - Sokolov, Artem
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Sougnez C
FIR - Sougnez, Carrie
IR  - Stuart J
FIR - Stuart, Josh
IR  - Sun C
FIR - Sun, Charlie
IR  - Swatloski T
FIR - Swatloski, Teresa
IR  - Tam A
FIR - Tam, Angela
IR  - Tan D
FIR - Tan, Donghui
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Tarvin K
FIR - Tarvin, Katherine
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Thorne LB
FIR - Thorne, Leigh B
IR  - Timmers HJ
FIR - Timmers, Henri J
IR  - Tischler AS
FIR - Tischler, Arthur S
IR  - Tse K
FIR - Tse, Kane
IR  - Uzunangelov V
FIR - Uzunangelov, Vlado
IR  - van Berkel A
FIR - van Berkel, Anouk
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Vicha A
FIR - Vicha, Ales
IR  - Voet D
FIR - Voet, Doug
IR  - Waldmann J
FIR - Waldmann, Jens
IR  - Walter V
FIR - Walter, Vonn
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wang Z
FIR - Wang, Zhining
IR  - Wang TS
FIR - Wang, Tracy S
IR  - Weaver J
FIR - Weaver, Joellen
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Weismann D
FIR - Weismann, Dirk
IR  - Wenz B
FIR - Wenz, Brandon
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Wise L
FIR - Wise, Lisa
IR  - Wong T
FIR - Wong, Tina
IR  - Wong C
FIR - Wong, Christopher
IR  - Wu Y
FIR - Wu, Ye
IR  - Yang L
FIR - Yang, Liming
IR  - Zelinka T
FIR - Zelinka, Tomas
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Zhang W
FIR - Zhang, Wei
IR  - Zhu J
FIR - Zhu, Jingchun
IR  - Zinzindohoue F
FIR - Zinzindohoue, Franck
IR  - Zmuda E
FIR - Zmuda, Erik
EDAT- 2017/02/07 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/02/07 06:00
PHST- 2016/06/07 00:00 [received]
PHST- 2016/10/07 00:00 [revised]
PHST- 2017/01/04 00:00 [accepted]
PHST- 2017/02/07 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/02/07 06:00 [entrez]
AID - S1535-6108(17)30001-6 [pii]
AID - 10.1016/j.ccell.2017.01.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):181-193. doi: 10.1016/j.ccell.2017.01.001. Epub
      2017 Feb 2.

PMID- 28162974
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - A UBE2O-AMPKalpha2 Axis that Promotes Tumor Initiation and Progression Offers
      Opportunities for Therapy.
PG  - 208-224
LID - S1535-6108(17)30003-X [pii]
LID - 10.1016/j.ccell.2017.01.003 [doi]
AB  - UBE2O is localized in the 17q25 locus, which is known to be amplified in human
      cancers, but its role in tumorigenesis remains undefined. Here we show that Ube2o
      deletion in MMTV-PyVT or TRAMP mice profoundly impairs tumor initiation, growth, 
      and metastasis, while switching off the metabolic reprogramming of tumor cells.
      Mechanistically, UBE2O specifically targets AMPKalpha2 for ubiquitination and
      degradation, and thereby promotes activation of the mTOR-HIF1alpha pathway.
      Notably, inactivation of AMPKalpha2, but not AMPKalpha1, abrogates the tumor
      attenuation caused by UBE2O loss, while treatment with rapamycin or inhibition of
      HIF1alpha ablates UBE2O-dependent tumor biology. Finally, pharmacological
      blockade of UBE2O inhibits tumorigenesis through the restoration of AMPKalpha2,
      suggesting the UBE2O-AMPKalpha2 axis as a potential cancer therapeutic target.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Vila, Isabelle K
AU  - Vila IK
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yao, Yixin
AU  - Yao Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kim, Goeun
AU  - Kim G
AD  - Soonchunhyang Institute of Medi-bio Science, Soonchunhyang University,
      Cheonan-si, Chungcheongnam-do 31151, Republic of Korea.
FAU - Xia, Weiya
AU  - Xia W
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kim, Hyejin
AU  - Kim H
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kim, Sun-Joong
AU  - Kim SJ
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Park, Mi-Kyung
AU  - Park MK
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hwang, James P
AU  - Hwang JP
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Gonzalez-Billalabeitia, Enrique
AU  - Gonzalez-Billalabeitia E
AD  - Department of Clinical Oncology, Hospital Universitario Morales Meseguer, Murcia 
      30008, Spain.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; Cancer Biology Program, The
      University of Texas Graduate School of Biomedical Sciences, The University of
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Molecular
      Medicine and Graduate Institute of Cancer Biology, China Medical University,
      Taichung 404, Taiwan.
FAU - Song, Su Jung
AU  - Song SJ
AD  - Soonchunhyang Institute of Medi-bio Science, Soonchunhyang University,
      Cheonan-si, Chungcheongnam-do 31151, Republic of Korea. Electronic address:
      ssong1@sch.ac.kr.
FAU - Song, Min Sup
AU  - Song MS
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; Cancer Biology Program, The
      University of Texas Graduate School of Biomedical Sciences, The University of
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:
      msong1@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA196740/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170202
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.3.2.23 (Ubiquitin-Conjugating Enzymes)
RN  - EC 2.3.2.24 (UBE2O protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (PRKAA2 protein, human)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
CIN - Cancer Cell. 2017 Feb 13;31(2):163-165. PMID: 28196589
MH  - AMP-Activated Protein Kinases/antagonists & inhibitors/*physiology
MH  - Animals
MH  - Antigens, Neoplasm/metabolism
MH  - Disease Progression
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/physiology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Proteins/metabolism
MH  - Neoplasms/drug therapy/*etiology
MH  - TOR Serine-Threonine Kinases/physiology
MH  - Ubiquitin-Conjugating Enzymes/antagonists & inhibitors/*physiology
MH  - Ubiquitination
PMC - PMC5463996
MID - NIHMS843025
OTO - NOTNLM
OT  - AMPK
OT  - AMPKalpha2
OT  - HIF1alpha
OT  - UBE2O
OT  - arsenite
OT  - breast cancer
OT  - cancer metabolism
OT  - mTOR
OT  - prostate cancer
OT  - ubiquitination
EDAT- 2017/02/07 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/02/07 06:00
PHST- 2016/04/27 00:00 [received]
PHST- 2016/10/10 00:00 [revised]
PHST- 2017/01/05 00:00 [accepted]
PHST- 2017/02/07 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/02/07 06:00 [entrez]
AID - S1535-6108(17)30003-X [pii]
AID - 10.1016/j.ccell.2017.01.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):208-224. doi: 10.1016/j.ccell.2017.01.003. Epub
      2017 Feb 2.

PMID- 28110998
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung
      Adenocarcinoma.
PG  - 256-269
LID - S1535-6108(16)30605-5 [pii]
LID - 10.1016/j.ccell.2016.12.010 [doi]
AB  - The guanine nucleotide exchange factor (GEF) epithelial cell transforming
      sequence 2 (Ect2) has been implicated in cancer. However, it is not clear how
      Ect2 causes transformation and whether Ect2 is necessary for tumorigenesis in
      vivo. Here, we demonstrate that nuclear Ect2 GEF activity is required for
      Kras-Trp53 lung tumorigenesis in vivo and that Ect2-mediated transformation
      requires Ect2-dependent rDNA transcription. Ect2 activates rRNA synthesis by
      binding the nucleolar transcription factor upstream binding factor 1 (UBF1) on
      rDNA promoters and recruiting Rac1 and its downstream effector nucleophosmin
      (NPM) to rDNA. Protein kinase Ciota (PKCiota)-mediated Ect2 phosphorylation
      stimulates Ect2-dependent rDNA transcription. Thus, Ect2 regulates rRNA synthesis
      through a PKCiota-Ect2-Rac1-NPM signaling axis that is required for lung
      tumorigenesis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Justilien, Verline
AU  - Justilien V
AD  - Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Griffin
      Cancer Research Building, Room 212, 4500 San Pablo Road, Jacksonville, FL 32224, 
      USA.
FAU - Ali, Syed A
AU  - Ali SA
AD  - Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Griffin
      Cancer Research Building, Room 212, 4500 San Pablo Road, Jacksonville, FL 32224, 
      USA.
FAU - Jamieson, Lee
AU  - Jamieson L
AD  - Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Griffin
      Cancer Research Building, Room 212, 4500 San Pablo Road, Jacksonville, FL 32224, 
      USA.
FAU - Yin, Ning
AU  - Yin N
AD  - Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Griffin
      Cancer Research Building, Room 212, 4500 San Pablo Road, Jacksonville, FL 32224, 
      USA.
FAU - Cox, Adrienne D
AU  - Cox AD
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Der, Channing J
AU  - Der CJ
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Murray, Nicole R
AU  - Murray NR
AD  - Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Griffin
      Cancer Research Building, Room 212, 4500 San Pablo Road, Jacksonville, FL 32224, 
      USA.
FAU - Fields, Alan P
AU  - Fields AP
AD  - Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Griffin
      Cancer Research Building, Room 212, 4500 San Pablo Road, Jacksonville, FL 32224, 
      USA. Electronic address: fields.alan@mayo.edu.
LA  - eng
GR  - R01 CA081436/CA/NCI NIH HHS/United States
GR  - R01 CA206367/CA/NCI NIH HHS/United States
GR  - R01 CA042978/CA/NCI NIH HHS/United States
GR  - R21 CA180997/CA/NCI NIH HHS/United States
GR  - R21 CA204938/CA/NCI NIH HHS/United States
GR  - R21 CA151250/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170119
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ECT2 protein, human)
RN  - 0 (Isoenzymes)
RN  - 0 (KRAS protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RAC1 protein, human)
RN  - 0 (RNA, Ribosomal)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 117896-08-9 (nucleophosmin)
RN  - 3H04W2810V (Auranofin)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 2.7.11.13 (protein kinase C lambda)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (rac1 GTP-Binding Protein)
RN  - Adenocarcinoma of lung
SB  - IM
CIN - Cancer Cell. 2017 Feb 13;31(2):167-169. PMID: 28196591
MH  - Adenocarcinoma/*etiology
MH  - Animals
MH  - Auranofin/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Nucleolus/metabolism
MH  - Cytokinesis
MH  - Humans
MH  - Isoenzymes/physiology
MH  - Lung Neoplasms/*etiology
MH  - Mice
MH  - Nuclear Proteins/physiology
MH  - Protein Kinase C/physiology
MH  - Proto-Oncogene Proteins/*physiology
MH  - Proto-Oncogene Proteins p21(ras)/*physiology
MH  - RNA, Ribosomal/*biosynthesis
MH  - Signal Transduction/physiology
MH  - Tumor Suppressor Protein p53/*physiology
MH  - rac1 GTP-Binding Protein/physiology
PMC - PMC5310966
MID - NIHMS839338
OTO - NOTNLM
OT  - Ect2
OT  - nucleophosmin, NPM
OT  - protein kinase Ciota, PKCiota
OT  - rRNA synthesis
OT  - tumor initiation
OT  - upstream binding factor 1, UBF1
EDAT- 2017/01/24 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/01/24 06:00
PHST- 2015/12/03 00:00 [received]
PHST- 2016/10/07 00:00 [revised]
PHST- 2016/12/21 00:00 [accepted]
PHST- 2017/01/24 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/01/24 06:00 [entrez]
AID - S1535-6108(16)30605-5 [pii]
AID - 10.1016/j.ccell.2016.12.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):256-269. doi: 10.1016/j.ccell.2016.12.010. Epub
      2017 Jan 19.

PMID- 28089890
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180309
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - Single-chromosome Gains Commonly Function as Tumor Suppressors.
PG  - 240-255
LID - S1535-6108(16)30599-2 [pii]
LID - 10.1016/j.ccell.2016.12.004 [doi]
AB  - Aneuploidy is a hallmark of cancer, although its effects on tumorigenesis are
      unclear. Here, we investigated the relationship between aneuploidy and cancer
      development using cells engineered to harbor single extra chromosomes. We found
      that nearly all trisomic cell lines grew poorly in vitro and as xenografts,
      relative to genetically matched euploid cells. Moreover, the activation of
      several oncogenic pathways failed to alleviate the fitness defect induced by
      aneuploidy. However, following prolonged growth, trisomic cells acquired
      additional chromosomal alterations that were largely absent from their euploid
      counterparts and that correlated with improved fitness. Thus, while
      single-chromosome gains can suppress transformation, the genome-destabilizing
      effects of aneuploidy confer an evolutionary flexibility that may contribute to
      the aggressive growth of advanced malignancies with complex karyotypes.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Sheltzer, Jason M
AU  - Sheltzer JM
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA; David H. Koch
      Institute for Integrative Cancer Research, Howard Hughes Medical Institute,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic
      address: sheltzer@cshl.edu.
FAU - Ko, Julie H
AU  - Ko JH
AD  - David H. Koch Institute for Integrative Cancer Research, Howard Hughes Medical
      Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Replogle, John M
AU  - Replogle JM
AD  - David H. Koch Institute for Integrative Cancer Research, Howard Hughes Medical
      Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Habibe Burgos, Nicole C
AU  - Habibe Burgos NC
AD  - David H. Koch Institute for Integrative Cancer Research, Howard Hughes Medical
      Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Chung, Erica S
AU  - Chung ES
AD  - Albert Einstein College of Medicine, Bronx, NY 10461, USA.
FAU - Meehl, Colleen M
AU  - Meehl CM
AD  - David H. Koch Institute for Integrative Cancer Research, Howard Hughes Medical
      Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Sayles, Nicole M
AU  - Sayles NM
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
FAU - Passerini, Verena
AU  - Passerini V
AD  - Group Maintenance of Genome Stability, Max Planck Institute of Biochemistry,
      82152 Martinsried, Germany.
FAU - Storchova, Zuzana
AU  - Storchova Z
AD  - Group Maintenance of Genome Stability, Max Planck Institute of Biochemistry,
      82152 Martinsried, Germany; Department of Molecular Genetics, University of
      Kaiserslautern, 67663 Kaiserslautern, Germany.
FAU - Amon, Angelika
AU  - Amon A
AD  - David H. Koch Institute for Integrative Cancer Research, Howard Hughes Medical
      Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
      Electronic address: angelika@mit.edu.
LA  - eng
GR  - R01 CA206157/CA/NCI NIH HHS/United States
GR  - R35 GM118066/GM/NIGMS NIH HHS/United States
GR  - P30 CA014051/CA/NCI NIH HHS/United States
GR  - R29 GM056800/GM/NIGMS NIH HHS/United States
GR  - R01 GM056800/GM/NIGMS NIH HHS/United States
GR  - P30 CA045508/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170112
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CIN - Cancer Cell. 2017 Feb 13;31(2):165-166. PMID: 28196590
CIN - Nat Rev Cancer. 2017 Mar;17 (3):142-143. PMID: 28184042
MH  - *Aneuploidy
MH  - Animals
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic
MH  - *Chromosome Aberrations
MH  - Genes, ras
MH  - Genomic Instability
MH  - HCT116 Cells
MH  - Humans
MH  - Neoplasms/*genetics/prevention & control
MH  - Oncogenes
PMC - PMC5713901
MID - NIHMS908957
OTO - NOTNLM
OT  - aneuploidy
OT  - chromosomal instability
OT  - genome dosage imbalance
OT  - genomic instability
OT  - transformation
EDAT- 2017/01/17 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/01/17 06:00
PHST- 2015/09/24 00:00 [received]
PHST- 2016/10/10 00:00 [revised]
PHST- 2016/12/13 00:00 [accepted]
PHST- 2017/01/17 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/01/17 06:00 [entrez]
AID - S1535-6108(16)30599-2 [pii]
AID - 10.1016/j.ccell.2016.12.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):240-255. doi: 10.1016/j.ccell.2016.12.004. Epub
      2017 Jan 12.

PMID- 28089889
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb 13
TI  - MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine
      Subtype with Vulnerability to Aurora Kinase Inhibition.
PG  - 270-285
LID - S1535-6108(16)30600-6 [pii]
LID - 10.1016/j.ccell.2016.12.005 [doi]
AB  - Loss of the tumor suppressors RB1 and TP53 and MYC amplification are frequent
      oncogenic events in small cell lung cancer (SCLC). We show that Myc expression
      cooperates with Rb1 and Trp53 loss in the mouse lung to promote aggressive,
      highly metastatic tumors, that are initially sensitive to chemotherapy followed
      by relapse, similar to human SCLC. Importantly, MYC drives a neuroendocrine-low
      "variant" subset of SCLC with high NEUROD1 expression corresponding to
      transcriptional profiles of human SCLC. Targeted drug screening reveals that SCLC
      with high MYC expression is vulnerable to Aurora kinase inhibition, which,
      combined with chemotherapy, strongly suppresses tumor progression and increases
      survival. These data identify molecular features for patient stratification and
      uncover a potential targeted treatment approach for MYC-driven SCLC.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Mollaoglu, Gurkan
AU  - Mollaoglu G
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Guthrie, Matthew R
AU  - Guthrie MR
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Bohm, Stefanie
AU  - Bohm S
AD  - Molecular Pathology, Institute for Pathology, Medical Faculty, University of
      Cologne, 50937 Cologne, Germany; Department of Translational Genomics, Center of 
      Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931
      Cologne, Germany.
FAU - Bragelmann, Johannes
AU  - Bragelmann J
AD  - Molecular Pathology, Institute for Pathology, Medical Faculty, University of
      Cologne, 50937 Cologne, Germany; Department of Translational Genomics, Center of 
      Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931
      Cologne, Germany.
FAU - Can, Ismail
AU  - Can I
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Ballieu, Paul M
AU  - Ballieu PM
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Marx, Annika
AU  - Marx A
AD  - Molecular Pathology, Institute for Pathology, Medical Faculty, University of
      Cologne, 50937 Cologne, Germany; Department of Translational Genomics, Center of 
      Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931
      Cologne, Germany.
FAU - George, Julie
AU  - George J
AD  - Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn,
      Medical Faculty, University of Cologne, 50931 Cologne, Germany.
FAU - Heinen, Christine
AU  - Heinen C
AD  - Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn,
      Medical Faculty, University of Cologne, 50931 Cologne, Germany.
FAU - Chalishazar, Milind D
AU  - Chalishazar MD
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Cheng, Haixia
AU  - Cheng H
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Ireland, Abbie S
AU  - Ireland AS
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Denning, Kendall E
AU  - Denning KE
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Mukhopadhyay, Anandaroop
AU  - Mukhopadhyay A
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Vahrenkamp, Jeffery M
AU  - Vahrenkamp JM
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Berrett, Kristofer C
AU  - Berrett KC
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Mosbruger, Timothy L
AU  - Mosbruger TL
AD  - Huntsman Cancer Institute, Bioinformatics Shared Resource, Salt Lake City, UT
      84112, USA.
FAU - Wang, Jun
AU  - Wang J
AD  - Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical
      Discovery Institute, La Jolla, CA 92037, USA.
FAU - Kohan, Jessica L
AU  - Kohan JL
AD  - Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake
      City, UT 84112, USA.
FAU - Salama, Mohamed E
AU  - Salama ME
AD  - Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake
      City, UT 84112, USA.
FAU - Witt, Benjamin L
AU  - Witt BL
AD  - Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake
      City, UT 84112, USA.
FAU - Peifer, Martin
AU  - Peifer M
AD  - Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn,
      Medical Faculty, University of Cologne, 50931 Cologne, Germany; Center for
      Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany.
FAU - Thomas, Roman K
AU  - Thomas RK
AD  - Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn,
      Medical Faculty, University of Cologne, 50931 Cologne, Germany; Department of
      Pathology, University Hospital Cologne, 50937 Cologne, Germany; German Cancer
      Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
FAU - Gertz, Jason
AU  - Gertz J
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA.
FAU - Johnson, Jane E
AU  - Johnson JE
AD  - Department of Neuroscience, University of Texas Southwestern Medical Center,
      Dallas, TX 75390, USA.
FAU - Gazdar, Adi F
AU  - Gazdar AF
AD  - Department of Pathology, Hamon Center for Therapeutic Oncology Research, UT
      Southwestern Medical Center, Dallas, TX 75235, USA.
FAU - Wechsler-Reya, Robert J
AU  - Wechsler-Reya RJ
AD  - Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical
      Discovery Institute, La Jolla, CA 92037, USA.
FAU - Sos, Martin L
AU  - Sos ML
AD  - Molecular Pathology, Institute for Pathology, Medical Faculty, University of
      Cologne, 50937 Cologne, Germany; Department of Translational Genomics, Center of 
      Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931
      Cologne, Germany. Electronic address: martin.sos@uni-koeln.de.
FAU - Oliver, Trudy G
AU  - Oliver TG
AD  - Department of Oncological Sciences, University of Utah, Huntsman Cancer
      Institute, Salt Lake City, UT 84112, USA. Electronic address:
      trudy.oliver@hci.utah.edu.
LA  - eng
GR  - P50 CA070907/CA/NCI NIH HHS/United States
GR  - R01 CA187457/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170112
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (MYC protein, human)
RN  - 0 (NEUROD1 protein, human)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 2.7.11.1 (Aurora Kinases)
SB  - IM
MH  - Animals
MH  - Aurora Kinases/*antagonists & inhibitors
MH  - Basic Helix-Loop-Helix Transcription Factors/physiology
MH  - Disease Progression
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/etiology
MH  - Mice
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Proto-Oncogene Proteins c-myc/*physiology
MH  - Small Cell Lung Carcinoma/*drug therapy/etiology
PMC - PMC5310991
MID - NIHMS838387
OTO - NOTNLM
OT  - ASCL1
OT  - Aurora kinase inhibitor
OT  - MYC
OT  - NEUROD1
OT  - chemotherapy
OT  - genetically engineered mouse model
OT  - neuroendocrine
OT  - small-cell lung cancer
EDAT- 2017/01/17 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/01/17 06:00
PHST- 2016/05/31 00:00 [received]
PHST- 2016/09/15 00:00 [revised]
PHST- 2016/12/13 00:00 [accepted]
PHST- 2017/01/17 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/01/17 06:00 [entrez]
AID - S1535-6108(16)30600-6 [pii]
AID - 10.1016/j.ccell.2016.12.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005. Epub
      2017 Jan 12.

PMID- 28073006
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in
      Colorectal Cancer.
PG  - 79-93
LID - S1535-6108(16)30507-4 [pii]
LID - 10.1016/j.ccell.2016.11.001 [doi]
AB  - Chromosomal instability (CIN) contributes to cancer evolution, intratumor
      heterogeneity, and drug resistance. CIN is driven by chromosome segregation
      errors and a tolerance phenotype that permits the propagation of aneuploid
      genomes. Through genomic analysis of colorectal cancers and cell lines, we find
      frequent loss of heterozygosity and mutations in BCL9L in aneuploid tumors. BCL9L
      deficiency promoted tolerance of chromosome missegregation events, propagation of
      aneuploidy, and genetic heterogeneity in xenograft models likely through
      modulation of Wnt signaling. We find that BCL9L dysfunction contributes to
      aneuploidy tolerance in both TP53-WT and mutant cells by reducing basal caspase-2
      levels and preventing cleavage of MDM2 and BID. Efforts to exploit aneuploidy
      tolerance mechanisms and the BCL9L/caspase-2/BID axis may limit cancer diversity 
      and evolution.
CI  - Copyright (c) 2017 The Francis Crick Institute. Published by Elsevier Inc. All
      rights reserved.
FAU - Lopez-Garcia, Carlos
AU  - Lopez-Garcia C
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Sansregret, Laurent
AU  - Sansregret L
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Domingo, Enric
AU  - Domingo E
AD  - Oxford Centre for Cancer Gene Research, The Wellcome Trust Centre for Human
      Genetics, Roosevelt Drive, Oxford, OX3 7BN UK; Department of Oncology, University
      of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK.
FAU - McGranahan, Nicholas
AU  - McGranahan N
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK; Translational Cancer Therapeutics Laboratory,
      University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley
      Street, London WC2E 6DD, UK.
FAU - Hobor, Sebastijan
AU  - Hobor S
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Birkbak, Nicolai Juul
AU  - Birkbak NJ
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK; Translational Cancer Therapeutics Laboratory,
      University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley
      Street, London WC2E 6DD, UK.
FAU - Horswell, Stuart
AU  - Horswell S
AD  - Bioinformatics Science Technology Platform, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Gronroos, Eva
AU  - Gronroos E
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Favero, Francesco
AU  - Favero F
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK; Cancer System Biology, Centre for Biological
      Sequence Analysis, Department of Systems Biology, Technical University of
      Denmark, Lyngby 2800, Denmark.
FAU - Rowan, Andrew J
AU  - Rowan AJ
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Matthews, Nicholas
AU  - Matthews N
AD  - Advanced Sequencing Facility, The Francis Crick Institute, 1 Midland Road, London
      NW1 1AT, UK.
FAU - Begum, Sharmin
AU  - Begum S
AD  - Advanced Sequencing Facility, The Francis Crick Institute, 1 Midland Road, London
      NW1 1AT, UK.
FAU - Phillimore, Benjamin
AU  - Phillimore B
AD  - Advanced Sequencing Facility, The Francis Crick Institute, 1 Midland Road, London
      NW1 1AT, UK.
FAU - Burrell, Rebecca
AU  - Burrell R
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Oukrif, Dahmane
AU  - Oukrif D
AD  - Research Department of Pathology, University College London Medical School,
      University Street, London WC1E 6JJ, UK.
FAU - Spencer-Dene, Bradley
AU  - Spencer-Dene B
AD  - Experimental Histopathology Laboratory, The Francis Crick Institute, 1 Midland
      Road, London NW1 1AT, UK.
FAU - Kovac, Michal
AU  - Kovac M
AD  - Oxford Centre for Cancer Gene Research, The Wellcome Trust Centre for Human
      Genetics, Roosevelt Drive, Oxford, OX3 7BN UK.
FAU - Stamp, Gordon
AU  - Stamp G
AD  - Experimental Histopathology Laboratory, The Francis Crick Institute, 1 Midland
      Road, London NW1 1AT, UK.
FAU - Stewart, Aengus
AU  - Stewart A
AD  - Bioinformatics Science Technology Platform, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Danielsen, Havard
AU  - Danielsen H
AD  - Institute for Cancer Genetics and Informatics, Norwegian Radium Hospital, Oslo
      University Hospital, Ullernchausseen 70, 0379 Oslo, Norway.
FAU - Novelli, Marco
AU  - Novelli M
AD  - Research Department of Pathology, University College London Medical School,
      University Street, London WC1E 6JJ, UK.
FAU - Tomlinson, Ian
AU  - Tomlinson I
AD  - Oxford Centre for Cancer Gene Research, The Wellcome Trust Centre for Human
      Genetics, Roosevelt Drive, Oxford, OX3 7BN UK.
FAU - Swanton, Charles
AU  - Swanton C
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK; Translational Cancer Therapeutics Laboratory,
      University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley
      Street, London WC2E 6DD, UK. Electronic address: charles.swanton@crick.ac.uk.
LA  - eng
GR  - 617844/European Research Council/International
GR  - FC001169/Cancer Research UK/United Kingdom
GR  - FC001169/Medical Research Council/United Kingdom
GR  - FC001169/Wellcome Trust/United Kingdom
GR  - MR/FC001169/1/Medical Research Council/United Kingdom
GR  - 090532/Z/09/Z/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BCL9L protein, human)
RN  - 0 (BH3 Interacting Domain Death Agonist Protein)
RN  - 0 (BID protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (TP53 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
RN  - EC 3.4.22.- (CASP2 protein, human)
RN  - EC 3.4.22.- (Caspase 2)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aneuploidy
MH  - Animals
MH  - BH3 Interacting Domain Death Agonist Protein/physiology
MH  - Caspase 2/analysis/*physiology
MH  - Chromosome Segregation
MH  - Colorectal Neoplasms/*genetics
MH  - Cysteine Endopeptidases/analysis/*physiology
MH  - DNA-Binding Proteins/genetics/*physiology
MH  - HCT116 Cells
MH  - Humans
MH  - Mice
MH  - Middle Aged
MH  - Mutation
MH  - Proto-Oncogene Proteins c-mdm2/physiology
MH  - Transcription Factors/genetics/*physiology
MH  - Tumor Suppressor Protein p53/physiology
PMC - PMC5225404
OTO - NOTNLM
OT  - *BCL9L
OT  - *BID
OT  - *aneuploidy tolerance
OT  - *caspase-2
OT  - *chromosomal instability
OT  - *chromosome segregation errors
OT  - *colorectal cancer evolution
OT  - *intratumor heterogeneity
OT  - *mitotic checkpoint
OT  - *p53
EDAT- 2017/01/11 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/01/11 06:00
PHST- 2016/02/09 00:00 [received]
PHST- 2016/08/05 00:00 [revised]
PHST- 2016/10/28 00:00 [accepted]
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(16)30507-4 [pii]
AID - 10.1016/j.ccell.2016.11.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):79-93. doi: 10.1016/j.ccell.2016.11.001.

PMID- 28073005
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Simultaneous Inhibition of PI3Kdelta and PI3Kalpha Induces ABC-DLBCL Regression
      by Blocking BCR-Dependent and -Independent Activation of NF-kappaB and AKT.
PG  - 64-78
LID - S1535-6108(16)30598-0 [pii]
LID - 10.1016/j.ccell.2016.12.003 [doi]
AB  - Compared with follicular lymphoma, high PI3Kalpha expression was more prevalent
      in diffuse large B cell lymphoma (DLBCL), although both tumor types expressed
      substantial PI3Kdelta. Simultaneous inhibition of PI3Kalpha and PI3Kdelta
      dramatically enhanced the anti-tumor profile in ABC-DLBCL models compared with
      selective inhibition of PI3Kdelta, PI3Kalpha, or BTK. The anti-tumor activity was
      associated with suppression of p-AKT and a mechanism of blocking nuclear
      factor-kappaB activation driven by CD79(mut), CARD11(mut), TNFAIP3(mut), or
      MYD88(mut). Inhibition of PI3Kalpha/delta resulted in tumor regression in an
      ibrutinib-resistant CD79B(WT)/MYD88(mut) patient-derived ABC-DLBCL model.
      Furthermore, rebound activation of BTK and AKT was identified as a mechanism
      limiting CD79B(mut)-ABC-DLBCL to show a robust response to PI3K and BTK inhibitor
      monotherapies. A combination of ibrutinib with the PI3Kalpha/delta inhibitor
      copanlisib produced a sustained complete response in vivo in
      CD79B(mut)/MYD88(mut) ABC-DLBCL models.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Paul, Juliane
AU  - Paul J
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Soujon, Maurice
AU  - Soujon M
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Wengner, Antje M
AU  - Wengner AM
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Zitzmann-Kolbe, Sabine
AU  - Zitzmann-Kolbe S
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Sturz, Andrea
AU  - Sturz A
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Haike, Katja
AU  - Haike K
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Keng Magdalene, Koh Hui
AU  - Keng Magdalene KH
AD  - Advanced Molecular Pathology Laboratory, Singapore Health Services Pte Ltd, 20
      College Road, 169856 Singapore, Singapore.
FAU - Tan, Sze Huey
AU  - Tan SH
AD  - Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore,
      11 Hospital Drive, 169610 Singapore, Singapore.
FAU - Lange, Martin
AU  - Lange M
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Tan, Soo Yong
AU  - Tan SY
AD  - Advanced Molecular Pathology Laboratory, Singapore Health Services Pte Ltd, 20
      College Road, 169856 Singapore, Singapore.
FAU - Mumberg, Dominik
AU  - Mumberg D
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Lim, Soon Thye
AU  - Lim ST
AD  - Office of Education, Duke-NUS Graduate Medical School, 8 College Road, 169857
      Singapore, Singapore.
FAU - Ziegelbauer, Karl
AU  - Ziegelbauer K
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
FAU - Liu, Ningshu
AU  - Liu N
AD  - Bayer AG, Drug Discovery Oncology, Muellerstrasse 178, 13353 Berlin, Germany.
      Electronic address: ningshu.liu@bayer.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin
      -4-yl)pyrimidine-5-carboxamide)
RN  - 0 (NF-kappa B)
RN  - 0 (PCI 32765)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Quinazolines)
RN  - 0 (Receptors, Antigen, B-Cell)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - EC 2.7.1.137 (PIK3CD protein, human)
RN  - EC 2.7.10.1 (Agammaglobulinaemia tyrosine kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Cell Line, Tumor
MH  - Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/*drug therapy/mortality/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Middle Aged
MH  - NF-kappa B/*physiology
MH  - Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Proto-Oncogene Proteins c-akt/*physiology
MH  - Pyrazoles/pharmacology
MH  - Pyrimidines/pharmacology
MH  - Quinazolines/pharmacology
MH  - Receptors, Antigen, B-Cell/*physiology
OTO - NOTNLM
OT  - *BCR
OT  - *CARD11
OT  - *DLBCL
OT  - *MYD88
OT  - *NF-kappaB
OT  - *PI3Kalpha
OT  - *PI3Kdelta
OT  - *copanlisib
OT  - *follicular lymphoma
OT  - *ibrutinib-resistance
EDAT- 2017/01/11 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/01/11 06:00
PHST- 2016/04/20 00:00 [received]
PHST- 2016/10/07 00:00 [revised]
PHST- 2016/12/05 00:00 [accepted]
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(16)30598-0 [pii]
AID - 10.1016/j.ccell.2016.12.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):64-78. doi: 10.1016/j.ccell.2016.12.003.

PMID- 28073004
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic 
      Strategy for p53 Activation in High-Risk Neuroblastoma.
PG  - 50-63
LID - S1535-6108(16)30597-9 [pii]
LID - 10.1016/j.ccell.2016.12.002 [doi]
AB  - Given the paucity of druggable mutations in high-risk neuroblastoma (NB), we
      undertook chromatin-focused small interfering RNA and chemical screens to uncover
      epigenetic regulators critical for the differentiation block in high-risk NB.
      High-content Opera imaging identified 53 genes whose loss of expression led to a 
      decrease in NB cell proliferation and 16 also induced differentiation. From
      these, the secondary chemical screen identified SETD8, the H4(K20me1)
      methyltransferase, as a druggable NB target. Functional studies revealed that
      SETD8 ablation rescued the pro-apoptotic and cell-cycle arrest functions of p53
      by decreasing p53(K382me1), leading to activation of the p53 canonical pathway.
      In pre-clinical xenograft NB models, genetic or pharmacological (UNC0379) SETD8
      inhibition conferred a significant survival advantage, providing evidence for
      SETD8 as a therapeutic target in NB.
CI  - Published by Elsevier Inc.
FAU - Veschi, Veronica
AU  - Veschi V
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105,
      Bethesda, MD 20892, USA.
FAU - Liu, Zhihui
AU  - Liu Z
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105,
      Bethesda, MD 20892, USA.
FAU - Voss, Ty C
AU  - Voss TC
AD  - High-Throughput Imaging Facility, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Ozbun, Laurent
AU  - Ozbun L
AD  - High-Throughput Imaging Facility, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Gryder, Berkley
AU  - Gryder B
AD  - Oncogenomics Section, Genetics Branch, Center for Cancer Research, National
      Cancer Institute, Bethesda, MD 20892, USA.
FAU - Yan, Chunhua
AU  - Yan C
AD  - Center for Biomedical Informatics and Information Technology, Center for Cancer
      Research, National Cancer Institute, Rockville, MD 20850, USA.
FAU - Hu, Ying
AU  - Hu Y
AD  - Center for Biomedical Informatics and Information Technology, Center for Cancer
      Research, National Cancer Institute, Rockville, MD 20850, USA.
FAU - Ma, Anqi
AU  - Ma A
AD  - Department of Structural and Chemical Biology, Oncological Sciences, Pharmacology
      and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Jin, Jian
AU  - Jin J
AD  - Department of Structural and Chemical Biology, Oncological Sciences, Pharmacology
      and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Mazur, Sharlyn J
AU  - Mazur SJ
AD  - Chemical Immunology Section, Laboratory of Cell Biology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Lam, Norris
AU  - Lam N
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105,
      Bethesda, MD 20892, USA.
FAU - Souza, Barbara K
AU  - Souza BK
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105,
      Bethesda, MD 20892, USA.
FAU - Giannini, Giuseppe
AU  - Giannini G
AD  - Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Molecular Medicine,
      University La Sapienza, 00161 Rome, Italy.
FAU - Hager, Gordon L
AU  - Hager GL
AD  - Laboratory of Receptor Biology and Gene Expression, Center for Cancer Research,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Arrowsmith, Cheryl H
AU  - Arrowsmith CH
AD  - Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7,
      Canada.
FAU - Khan, Javed
AU  - Khan J
AD  - Oncogenomics Section, Genetics Branch, Center for Cancer Research, National
      Cancer Institute, Bethesda, MD 20892, USA.
FAU - Appella, Ettore
AU  - Appella E
AD  - Chemical Immunology Section, Laboratory of Cell Biology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Thiele, Carol J
AU  - Thiele CJ
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105,
      Bethesda, MD 20892, USA. Electronic address: ct47a@nih.gov.
LA  - eng
GR  - R01 GM103893/GM/NIGMS NIH HHS/United States
GR  - R01 GM122749/GM/NIGMS NIH HHS/United States
GR  - Z99 CA999999/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC010788-09/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC010788-10/ImNIH/Intramural NIH HHS/United States
GR  - Wellcome Trust/United Kingdom
GR  - ZIA BC010788-08/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amin
      e)
RN  - 0 (Quinazolines)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.1.1.43 (SETD8 protein, human)
SB  - IM
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - *Epigenesis, Genetic
MH  - Histone-Lysine N-Methyltransferase/*antagonists & inhibitors/genetics/physiology
MH  - Humans
MH  - Neuroblastoma/*drug therapy/genetics/pathology
MH  - Quinazolines/pharmacology
MH  - RNA, Small Interfering/*genetics
MH  - Tumor Suppressor Protein p53/analysis/*physiology
PMC - PMC5233415
MID - NIHMS836091
OTO - NOTNLM
OT  - *SETD8
OT  - *differentiation
OT  - *epigenetics
OT  - *neuroblastoma
OT  - *p53
OT  - *siRNA screen
EDAT- 2017/01/11 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/01/11 06:00
PHST- 2016/06/15 00:00 [received]
PHST- 2016/09/26 00:00 [revised]
PHST- 2016/12/05 00:00 [accepted]
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(16)30597-9 [pii]
AID - 10.1016/j.ccell.2016.12.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):50-63. doi: 10.1016/j.ccell.2016.12.002.

PMID- 28073003
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
PG  - 5-19
LID - S1535-6108(16)30601-8 [pii]
LID - 10.1016/j.ccell.2016.12.006 [doi]
AB  - Pancreatic ductal adenocarcinoma is on pace to become the second leading cause of
      cancer-related death. The high mortality rate results from a lack of methods for 
      early detection and the inability to successfully treat patients once diagnosed. 
      Pancreatic cancer cells have extensively reprogrammed metabolism, which is driven
      by oncogene-mediated cell-autonomous pathways, the unique physiology of the tumor
      microenvironment, and interactions with non-cancer cells. In this review, we
      discuss how recent efforts delineating rewired metabolic networks in pancreatic
      cancer have revealed new in-roads to develop detection and treatment strategies
      for this dreadful disease.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Halbrook, Christopher J
AU  - Halbrook CJ
AD  - Department of Molecular and Integrative Physiology, University of Michigan, Ann
      Arbor, MI 48109, USA.
FAU - Lyssiotis, Costas A
AU  - Lyssiotis CA
AD  - Department of Molecular and Integrative Physiology, University of Michigan, Ann
      Arbor, MI 48109, USA; Department of Internal Medicine, Division of
      Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic
      address: clyssiot@med.umich.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0RH81L854J (Glutamine)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 9100L32L2N (Metformin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Carcinoma, Pancreatic Ductal/diagnosis/*metabolism/therapy
MH  - Cellular Reprogramming
MH  - Fluorodeoxyglucose F18
MH  - Glucose/metabolism
MH  - Glutamine/metabolism
MH  - Humans
MH  - Metformin/therapeutic use
MH  - Pancreatic Neoplasms/diagnosis/*metabolism/therapy
MH  - Positron-Emission Tomography
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - *FDG-PET
OT  - *HP-MRI
OT  - *Kras
OT  - *PDAC
OT  - *metabolic crosstalk
OT  - *metabolic imaging
OT  - *metabolic reprogramming
OT  - *pancreatic cancer
OT  - *stroma
OT  - *tumor metabolism
EDAT- 2017/01/11 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/01/11 06:00
PHST- 2016/08/10 00:00 [received]
PHST- 2016/10/03 00:00 [revised]
PHST- 2016/12/14 00:00 [accepted]
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1535-6108(16)30601-8 [pii]
AID - 10.1016/j.ccell.2016.12.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):5-19. doi: 10.1016/j.ccell.2016.12.006.

PMID- 28073002
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20170630
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Cancer and Apoptosis: Who Is Built to Last?
PG  - 2-4
LID - S1535-6108(16)30602-X [pii]
LID - 10.1016/j.ccell.2016.12.007 [doi]
AB  - Effective cancer therapy requires that a cancer be more susceptible to a
      treatment than are the essential tissues in the body. A paper by Sarosiek et al. 
      in this issue now shows that, unlike those of cancer cells, mitochondria in many 
      tissues in adults are in an apoptosis-resistant state.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Green, Douglas R
AU  - Green DR
AD  - Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA. Electronic address: douglas.green@stjude.org.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Jan 9;31(1):142-156. PMID: 28017613
MH  - *Apoptosis
MH  - Humans
MH  - Mitochondria
MH  - *Neoplasms
EDAT- 2017/01/11 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/01/11 06:00
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(16)30602-X [pii]
AID - 10.1016/j.ccell.2016.12.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):2-4. doi: 10.1016/j.ccell.2016.12.007.

PMID- 28073001
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances
      Drug Delivery and Produces a Favorable Tumor Microenvironment.
PG  - 157-158
LID - S1535-6108(16)30604-3 [pii]
LID - 10.1016/j.ccell.2016.12.009 [doi]
FAU - Park, Jin-Sung
AU  - Park JS
FAU - Kim, Il-Kug
AU  - Kim IK
FAU - Han, Sangyeul
AU  - Han S
FAU - Park, Intae
AU  - Park I
FAU - Kim, Chan
AU  - Kim C
FAU - Bae, Jeomil
AU  - Bae J
FAU - Oh, Seung Ja
AU  - Oh SJ
FAU - Lee, Seungjoo
AU  - Lee S
FAU - Kim, Jeong Hoon
AU  - Kim JH
FAU - Woo, Dong-Cheol
AU  - Woo DC
FAU - He, Yulong
AU  - He Y
FAU - Augustin, Hellmut G
AU  - Augustin HG
FAU - Kim, Injune
AU  - Kim I
FAU - Lee, Doheon
AU  - Lee D
FAU - Koh, Gou Young
AU  - Koh GY
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Dec 12;30(6):953-967. PMID: 27960088
EDAT- 2017/01/11 06:00
MHDA- 2017/01/11 06:01
CRDT- 2017/01/11 06:00
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/01/11 06:01 [medline]
AID - S1535-6108(16)30604-3 [pii]
AID - 10.1016/j.ccell.2016.12.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):157-158. doi: 10.1016/j.ccell.2016.12.009.

PMID- 28073000
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20170630
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Settling a Nervous Stomach: The Neural Regulation of Enteric Cancer.
PG  - 1-2
LID - S1535-6108(16)30603-1 [pii]
LID - 10.1016/j.ccell.2016.12.008 [doi]
AB  - The nervous system is emerging as a regulator of malignancy. In this issue of
      Cancer Cell, Hayakawa et al. demonstrate a feedforward signaling loop in which
      tumor-derived nerve growth factor promotes enteric tumor innervation, and
      recruited nerves drive cancer growth through acetylcholine-regulated Wnt
      signaling and stimulation of further NGF release.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Monje, Michelle
AU  - Monje M
AD  - Department of Neurology, Stanford University, Stanford, CA 94305, USA. Electronic
      address: mmonje@stanford.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2017 Jan 9;31(1):21-34. PMID: 27989802
MH  - Humans
MH  - *Neoplasms
MH  - *Signal Transduction
MH  - Stomach
EDAT- 2017/01/11 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/01/11 06:00
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(16)30603-1 [pii]
AID - 10.1016/j.ccell.2016.12.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):1-2. doi: 10.1016/j.ccell.2016.12.008.

PMID- 28041841
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP
      Activation, Regenerative Proliferation, and Poor Prognosis.
PG  - 35-49
LID - S1535-6108(16)30561-X [pii]
LID - 10.1016/j.ccell.2016.12.001 [doi]
AB  - Loss-of-function mutations in SWI/SNF chromatin-remodeling subunit genes are
      observed in many cancers, but an oncogenic role for SWI/SNF is not well
      established. Here, we reveal that ACTL6A, encoding an SWI/SNF subunit linked to
      stem cell and progenitor cell function, is frequently co-amplified and highly
      expressed together with the p53 family member p63 in head and neck squamous cell 
      carcinoma (HNSCC). ACTL6A and p63 physically interact, cooperatively controlling 
      a transcriptional program that promotes proliferation and suppresses
      differentiation, in part through activation of the Hippo-YAP pathway via
      regulators including WWC1. Ectopic ACTL6A/p63 expression promotes tumorigenesis, 
      while ACTL6A expression and YAP activation are highly correlated in primary HNSCC
      and predict poor patient survival. Thus, ACTL6A and p63 collaborate as oncogenic 
      drivers in HNSCC.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Saladi, Srinivas Vinod
AU  - Saladi SV
AD  - Massachusetts General Hospital Cancer Center, GRJ-904, 55 Fruit Street, Boston,
      MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
FAU - Ross, Kenneth
AU  - Ross K
AD  - Massachusetts General Hospital Cancer Center, GRJ-904, 55 Fruit Street, Boston,
      MA 02114, USA.
FAU - Karaayvaz, Mihriban
AU  - Karaayvaz M
AD  - Massachusetts General Hospital Cancer Center, GRJ-904, 55 Fruit Street, Boston,
      MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
FAU - Tata, Purushothama R
AU  - Tata PR
AD  - Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA
      02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Mou, Hongmei
AU  - Mou H
AD  - Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA
      02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Rajagopal, Jayaraj
AU  - Rajagopal J
AD  - Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA
      02114, USA; Department of Internal Medicine, Pulmonary and Critical Care Unit,
      Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell
      Institute, Cambridge, MA 02138, USA; Harvard Medical School, Boston, MA 02115,
      USA.
FAU - Ramaswamy, Sridhar
AU  - Ramaswamy S
AD  - Massachusetts General Hospital Cancer Center, GRJ-904, 55 Fruit Street, Boston,
      MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of 
      MIT and Harvard, Cambridge, MA 02138, USA.
FAU - Ellisen, Leif W
AU  - Ellisen LW
AD  - Massachusetts General Hospital Cancer Center, GRJ-904, 55 Fruit Street, Boston,
      MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:
      lellisen@mgh.harvard.edu.
LA  - eng
GR  - R01 DE015945/DE/NIDCR NIH HHS/United States
GR  - R01 HL116756/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20161229
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ACTL6A protein, human)
RN  - 0 (Actins)
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (CKAP4 protein, human)
RN  - 0 (Chromosomal Proteins, Non-Histone)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (WWC1 protein, human)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - EC 2.7.11.1 (Hippo protein, human)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - Carcinoma, squamous cell of head and neck
SB  - IM
MH  - Actins/*physiology
MH  - Adaptor Proteins, Signal Transducing/*physiology
MH  - Animals
MH  - Carcinoma, Squamous Cell/*etiology/mortality
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Chromosomal Proteins, Non-Histone/*physiology
MH  - DNA-Binding Proteins/*physiology
MH  - Head and Neck Neoplasms/*etiology/mortality
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/physiology
MH  - Membrane Proteins/*physiology
MH  - Mice
MH  - Phosphoproteins/*physiology
MH  - Prognosis
MH  - Protein-Serine-Threonine Kinases/physiology
MH  - Transcriptome
PMC - PMC5225026
MID - NIHMS835049
OTO - NOTNLM
OT  - *ACTL6A
OT  - *HNSCC
OT  - *SWI/SNF (BAF) complex
OT  - *YAP1
OT  - *chromatin remodeling
OT  - *hippo pathway
OT  - *p63
OT  - *squamous cell carcinoma
EDAT- 2017/01/04 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/01/03 06:00
PHST- 2016/02/17 00:00 [received]
PHST- 2016/08/18 00:00 [revised]
PHST- 2016/11/30 00:00 [accepted]
PHST- 2017/01/04 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2017/01/03 06:00 [entrez]
AID - S1535-6108(16)30561-X [pii]
AID - 10.1016/j.ccell.2016.12.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):35-49. doi: 10.1016/j.ccell.2016.12.001. Epub 2016 
      Dec 29.

PMID- 28017614
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine
      RNA Demethylase.
PG  - 127-141
LID - S1535-6108(16)30560-8 [pii]
LID - 10.1016/j.ccell.2016.11.017 [doi]
AB  - N(6)-Methyladenosine (m(6)A) represents the most prevalent internal modification 
      in mammalian mRNAs. Despite its functional importance in various fundamental
      bioprocesses, the studies of m(6)A in cancer have been limited. Here we show that
      FTO, as an m(6)A demethylase, plays a critical oncogenic role in acute myeloid
      leukemia (AML). FTO is highly expressed in AMLs with t(11q23)/MLL rearrangements,
      t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1 mutations. FTO enhances leukemic
      oncogene-mediated cell transformation and leukemogenesis, and inhibits
      all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through
      regulating expression of targets such as ASB2 and RARA by reducing m(6)A levels
      in these mRNA transcripts. Collectively, our study demonstrates the functional
      importance of the m(6)A methylation and the corresponding proteins in cancer, and
      provides profound insights into leukemogenesis and drug response.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Li, Zejuan
AU  - Li Z
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA; Department of Human Genetics, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Weng, Hengyou
AU  - Weng H
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA; Department of Cancer Biology, University of Cincinnati
      College of Medicine, Cincinnati, OH 45219, USA.
FAU - Su, Rui
AU  - Su R
AD  - Department of Cancer Biology, University of Cincinnati College of Medicine,
      Cincinnati, OH 45219, USA.
FAU - Weng, Xiaocheng
AU  - Weng X
AD  - Departments of Chemistry, Biochemistry and Molecular Biology, Institute for
      Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago,
      Chicago, IL 60637, USA; College of Chemistry and Molecular Sciences, Key
      Laboratory of Biomedical Polymers of Ministry of Education, Wuhan University,
      Hubei, Wuhan 430072, PR China.
FAU - Zuo, Zhixiang
AU  - Zuo Z
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA; Department of Cancer Biology, University of Cincinnati
      College of Medicine, Cincinnati, OH 45219, USA; Sun Yat-sen University Cancer
      Center, State Key Laboratory of Oncology in South China, Collaborative Innovation
      Center for Cancer Medicine, Guangzhou 510060, China.
FAU - Li, Chenying
AU  - Li C
AD  - Department of Cancer Biology, University of Cincinnati College of Medicine,
      Cincinnati, OH 45219, USA; Key Laboratory of Hematopoietic Malignancies,
      Department of Hematology, The First Affiliated Hospital of Zhejiang University,
      Hangzhou, Zhejiang 310003, China.
FAU - Huang, Huilin
AU  - Huang H
AD  - Department of Cancer Biology, University of Cincinnati College of Medicine,
      Cincinnati, OH 45219, USA.
FAU - Nachtergaele, Sigrid
AU  - Nachtergaele S
AD  - Departments of Chemistry, Biochemistry and Molecular Biology, Institute for
      Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Dong, Lei
AU  - Dong L
AD  - Department of Cancer Biology, University of Cincinnati College of Medicine,
      Cincinnati, OH 45219, USA.
FAU - Hu, Chao
AU  - Hu C
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA; Department of Cancer Biology, University of Cincinnati
      College of Medicine, Cincinnati, OH 45219, USA; Key Laboratory of Hematopoietic
      Malignancies, Department of Hematology, The First Affiliated Hospital of Zhejiang
      University, Hangzhou, Zhejiang 310003, China.
FAU - Qin, Xi
AU  - Qin X
AD  - Department of Cancer Biology, University of Cincinnati College of Medicine,
      Cincinnati, OH 45219, USA.
FAU - Tang, Lichun
AU  - Tang L
AD  - Department of Molecular Physiology and Biophysics, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Wang, Yungui
AU  - Wang Y
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA; Department of Cancer Biology, University of Cincinnati
      College of Medicine, Cincinnati, OH 45219, USA; Key Laboratory of Hematopoietic
      Malignancies, Department of Hematology, The First Affiliated Hospital of Zhejiang
      University, Hangzhou, Zhejiang 310003, China.
FAU - Hong, Gia-Ming
AU  - Hong GM
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Huang, Hao
AU  - Huang H
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Wang, Xiao
AU  - Wang X
AD  - Departments of Chemistry, Biochemistry and Molecular Biology, Institute for
      Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Chen, Ping
AU  - Chen P
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Gurbuxani, Sandeep
AU  - Gurbuxani S
AD  - Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
FAU - Arnovitz, Stephen
AU  - Arnovitz S
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Li, Yuanyuan
AU  - Li Y
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Li, Shenglai
AU  - Li S
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Strong, Jennifer
AU  - Strong J
AD  - Department of Cancer Biology, University of Cincinnati College of Medicine,
      Cincinnati, OH 45219, USA.
FAU - Neilly, Mary Beth
AU  - Neilly MB
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Larson, Richard A
AU  - Larson RA
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Jiang, Xi
AU  - Jiang X
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA; Department of Cancer Biology, University of Cincinnati
      College of Medicine, Cincinnati, OH 45219, USA.
FAU - Zhang, Pumin
AU  - Zhang P
AD  - Department of Molecular Physiology and Biophysics, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Jin, Jie
AU  - Jin J
AD  - Key Laboratory of Hematopoietic Malignancies, Department of Hematology, The First
      Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310003, China.
FAU - He, Chuan
AU  - He C
AD  - Departments of Chemistry, Biochemistry and Molecular Biology, Institute for
      Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago,
      Chicago, IL 60637, USA. Electronic address: chuanhe@uchicago.edu.
FAU - Chen, Jianjun
AU  - Chen J
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago,
      Chicago, IL 60637, USA; Department of Cancer Biology, University of Cincinnati
      College of Medicine, Cincinnati, OH 45219, USA. Electronic address:
      chen3jj@ucmail.uc.edu.
LA  - eng
GR  - R01 CA122623/CA/NCI NIH HHS/United States
GR  - R01 CA182528/CA/NCI NIH HHS/United States
GR  - R01 CA116097/CA/NCI NIH HHS/United States
GR  - R01 GM071440/GM/NIGMS NIH HHS/United States
GR  - R01 CA214965/CA/NCI NIH HHS/United States
GR  - R01 CA178454/CA/NCI NIH HHS/United States
GR  - R01 CA211614/CA/NCI NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20161222
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ASB2 protein, human)
RN  - 0 (RARA protein, human)
RN  - 0 (Retinoic Acid Receptor alpha)
RN  - 0 (Suppressor of Cytokine Signaling Proteins)
RN  - 1867-73-8 (N(6)-methyladenosine)
RN  - 5688UTC01R (Tretinoin)
RN  - EC 1.14.11.33 (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
RN  - EC 1.14.11.33 (FTO protein, human)
RN  - K72T3FS567 (Adenosine)
SB  - IM
CIN - Cancer Cell. 2017 May 8;31(5):619-620. PMID: 28486104
MH  - Adenosine/*analogs & derivatives/metabolism
MH  - Alpha-Ketoglutarate-Dependent Dioxygenase FTO/*physiology
MH  - Apoptosis
MH  - Cell Proliferation
MH  - Humans
MH  - Leukemia, Myeloid, Acute/drug therapy/enzymology/*etiology/pathology
MH  - Methylation
MH  - Retinoic Acid Receptor alpha/physiology
MH  - Suppressor of Cytokine Signaling Proteins/physiology
MH  - Transcriptome
MH  - Tretinoin/pharmacology
PMC - PMC5234852
MID - NIHMS837597
OTO - NOTNLM
OT  - *AML
OT  - *ASB2
OT  - *ATRA
OT  - *FTO
OT  - *RARA
OT  - *RNA modification
OT  - *RNA stability
OT  - *cell differentiation
OT  - *leukemogenesis
OT  - *m6A
COIS- The authors declare no competing financial interests.
EDAT- 2016/12/27 06:00
MHDA- 2017/06/14 06:00
CRDT- 2016/12/27 06:00
PHST- 2016/01/12 00:00 [received]
PHST- 2016/06/02 00:00 [revised]
PHST- 2016/11/21 00:00 [accepted]
PHST- 2016/12/27 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2016/12/27 06:00 [entrez]
AID - S1535-6108(16)30560-8 [pii]
AID - 10.1016/j.ccell.2016.11.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):127-141. doi: 10.1016/j.ccell.2016.11.017. Epub
      2016 Dec 22.

PMID- 28017613
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and
      Tissue-Specific Sensitivity to Cancer Therapeutics.
PG  - 142-156
LID - S1535-6108(16)30554-2 [pii]
LID - 10.1016/j.ccell.2016.11.011 [doi]
AB  - It is not understood why healthy tissues can exhibit varying levels of
      sensitivity to the same toxic stimuli. Using BH3 profiling, we find that
      mitochondria of many adult somatic tissues, including brain, heart, and kidneys, 
      are profoundly refractory to pro-apoptotic signaling, leading to cellular
      resistance to cytotoxic chemotherapies and ionizing radiation. In contrast,
      mitochondria from these tissues in young mice and humans are primed for
      apoptosis, predisposing them to undergo cell death in response to genotoxic
      damage. While expression of the apoptotic protein machinery is nearly absent by
      adulthood, in young tissues its expression is driven by c-Myc, linking
      developmental growth to cell death. These differences may explain why pediatric
      cancer patients have a higher risk of developing treatment-associated toxicities.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Sarosiek, Kristopher A
AU  - Sarosiek KA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA; Harvard Medical School, Boston, MA
      02115, USA.
FAU - Fraser, Cameron
AU  - Fraser C
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA.
FAU - Muthalagu, Nathiya
AU  - Muthalagu N
AD  - Cancer Research UK Beatson Institute, Glasgow G61 1BD, Scotland.
FAU - Bhola, Patrick D
AU  - Bhola PD
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA; Harvard Medical School, Boston, MA
      02115, USA.
FAU - Chang, Weiting
AU  - Chang W
AD  - Harvard Medical School, Boston, MA 02115, USA; Division of Genetics and Division 
      of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital,
      Boston, MA 02115, USA.
FAU - McBrayer, Samuel K
AU  - McBrayer SK
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA; Harvard Medical School, Boston, MA
      02115, USA.
FAU - Cantlon, Adam
AU  - Cantlon A
AD  - Harvard Medical School, Boston, MA 02115, USA; Division of Genetics and Division 
      of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital,
      Boston, MA 02115, USA.
FAU - Fisch, Sudeshna
AU  - Fisch S
AD  - Harvard Medical School, Boston, MA 02115, USA; Division of Genetics and Division 
      of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital,
      Boston, MA 02115, USA.
FAU - Golomb-Mello, Gail
AU  - Golomb-Mello G
AD  - Department of Molecular Biology, Cell Biology and Biochemistry, Brown University,
      Providence, RI 02912, USA.
FAU - Ryan, Jeremy A
AU  - Ryan JA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA; Harvard Medical School, Boston, MA
      02115, USA.
FAU - Deng, Jing
AU  - Deng J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA; Harvard Medical School, Boston, MA
      02115, USA.
FAU - Jian, Brian
AU  - Jian B
AD  - Department of Neurosurgery, Kaiser Permanente, Sacramento, CA 95815, USA.
FAU - Corbett, Chris
AU  - Corbett C
AD  - Department of Neurosurgery, Boston Children's Hospital, Boston, MA 02115, USA.
FAU - Goldenberg, Marti
AU  - Goldenberg M
AD  - Department of Neurosurgery, Boston Children's Hospital, Boston, MA 02115, USA.
FAU - Madsen, Joseph R
AU  - Madsen JR
AD  - Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Boston
      Children's Hospital, Boston, MA 02115, USA.
FAU - Liao, Ronglih
AU  - Liao R
AD  - Harvard Medical School, Boston, MA 02115, USA; Division of Genetics and Division 
      of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital,
      Boston, MA 02115, USA.
FAU - Walsh, Dominic
AU  - Walsh D
AD  - Harvard Medical School, Boston, MA 02115, USA; Division of Genetics and Division 
      of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital,
      Boston, MA 02115, USA.
FAU - Sedivy, John
AU  - Sedivy J
AD  - Department of Molecular Biology, Cell Biology and Biochemistry, Brown University,
      Providence, RI 02912, USA.
FAU - Murphy, Daniel J
AU  - Murphy DJ
AD  - Cancer Research UK Beatson Institute, Glasgow G61 1BD, Scotland; Institute of
      Cancer Sciences, University of Glasgow, Glasgow G61 1BD, Scotland.
FAU - Carrasco, Daniel Ruben
AU  - Carrasco DR
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA; Harvard Medical School, Boston, MA
      02115, USA.
FAU - Robinson, Shenandoah
AU  - Robinson S
AD  - Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Boston
      Children's Hospital, Boston, MA 02115, USA.
FAU - Moslehi, Javid
AU  - Moslehi J
AD  - Division of Cardiovascular Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt 
      University School of Medicine, Nashville, TN 37232, USA; Division of
      Hematology-Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University
      School of Medicine, Nashville, TN 37232, USA; Cardio-Oncology Program, Department
      of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of
      Medicine, Nashville, TN 37232, USA.
FAU - Letai, Anthony
AU  - Letai A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Mayer 430, Boston, MA 02115, USA; Harvard Medical School, Boston, MA
      02115, USA. Electronic address: anthony_letai@dfci.harvard.edu.
LA  - eng
GR  - K99 CA188679/CA/NCI NIH HHS/United States
GR  - R00 CA188679/CA/NCI NIH HHS/United States
GR  - R01 CA129974/CA/NCI NIH HHS/United States
GR  - R37 AG016694/AG/NIA NIH HHS/United States
GR  - P01 CA066996/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20161222
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (bcl-2 Homologous Antagonist-Killer Protein)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 80168379AG (Doxorubicin)
SB  - IM
CIN - Cancer Cell. 2017 Jan 9;31(1):2-4. PMID: 28073002
MH  - Age Factors
MH  - Animals
MH  - *Apoptosis
MH  - Doxorubicin/toxicity
MH  - Humans
MH  - Mice
MH  - Mitochondria/*physiology
MH  - Neoplasms/*drug therapy/pathology
MH  - Organ Specificity
MH  - Proto-Oncogene Proteins c-myc/*physiology
MH  - bcl-2 Homologous Antagonist-Killer Protein/physiology
MH  - bcl-2-Associated X Protein/physiology
PMC - PMC5363285
MID - NIHMS832231
OTO - NOTNLM
OT  - *apoptosis
OT  - *c-Myc
OT  - *cardiotoxicity
OT  - *cell death regulation
OT  - *chemosensitivity
OT  - *neurotoxicity
OT  - *pediatric cancer
OT  - *radiosensitivity
OT  - *side effects of chemotherapy
OT  - *side effects of radiation therapy
EDAT- 2016/12/27 06:00
MHDA- 2017/06/14 06:00
CRDT- 2016/12/27 06:00
PHST- 2015/09/01 00:00 [received]
PHST- 2016/09/13 00:00 [revised]
PHST- 2016/11/17 00:00 [accepted]
PHST- 2016/12/27 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2016/12/27 06:00 [entrez]
AID - S1535-6108(16)30554-2 [pii]
AID - 10.1016/j.ccell.2016.11.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):142-156. doi: 10.1016/j.ccell.2016.11.011. Epub
      2016 Dec 22.

PMID- 28017612
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer.
PG  - 94-109
LID - S1535-6108(16)30552-9 [pii]
LID - 10.1016/j.ccell.2016.11.009 [doi]
AB  - Receptor-interacting protein kinase 1 (RIPK1) represents an essential signaling
      node in cell death and inflammation. Ablation of Ripk1 in liver parenchymal cells
      (LPC) did not cause a spontaneous phenotype, but led to tumor necrosis factor
      (TNF)-dependent hepatocyte apoptosis and liver injury without affecting inducible
      nuclear factor kappaB (NF-kappaB) activation. Loss of Ripk1 induced the
      TNF-dependent proteasomal degradation of the E3-ligase, TNF receptor-associated
      factor 2 (TRAF2), in a kinase-independent manner, thereby activating caspase-8.
      Moreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8
      hyperactivation but also impaired NF-kappaB activation, promoting the spontaneous
      development of hepatocellular carcinoma. In line, low RIPK1 and TRAF2 expression 
      in human HCCs was associated with an unfavorable prognosis, suggesting that RIPK1
      collaborates with TRAF2 to inhibit murine and human hepatocarcinogenesis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Schneider, Anne T
AU  - Schneider AT
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany;
      Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen 
      University, 52074 Aachen, Germany.
FAU - Gautheron, Jeremie
AU  - Gautheron J
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany;
      Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen 
      University, 52074 Aachen, Germany.
FAU - Feoktistova, Maria
AU  - Feoktistova M
AD  - Department of Dermatology and Allergology, RWTH Aachen University, 52074 Aachen, 
      Germany.
FAU - Roderburg, Christoph
AU  - Roderburg C
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Loosen, Sven H
AU  - Loosen SH
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Roy, Sanchari
AU  - Roy S
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Benz, Fabian
AU  - Benz F
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Schemmer, Peter
AU  - Schemmer P
AD  - Department of Visceral and Transplantation Surgery, University of Heidelberg,
      69120 Heidelberg, Germany.
FAU - Buchler, Markus W
AU  - Buchler MW
AD  - Department of Visceral and Transplantation Surgery, University of Heidelberg,
      69120 Heidelberg, Germany.
FAU - Nachbur, Ueli
AU  - Nachbur U
AD  - Department of Medical Biology, Walter and Eliza Hall Institute of Medical
      Research and University of Melbourne, Parkville, VIC 3050/3052, Australia.
FAU - Neumann, Ulf P
AU  - Neumann UP
AD  - Department of Visceral and Transplantation Surgery, RWTH Aachen University, 52074
      Aachen, Germany.
FAU - Tolba, Rene
AU  - Tolba R
AD  - Department of Laboratory Animal Research, RWTH Aachen University, 52074 Aachen,
      Germany.
FAU - Luedde, Mark
AU  - Luedde M
AD  - Department of Cardiology, University Hospital, 24105 Kiel, Germany.
FAU - Zucman-Rossi, Jessica
AU  - Zucman-Rossi J
AD  - INSERM, UMR-1162, Functional Genomic of Solid Tumors, 75010 Paris, France.
FAU - Panayotova-Dimitrova, Diana
AU  - Panayotova-Dimitrova D
AD  - Department of Dermatology and Allergology, RWTH Aachen University, 52074 Aachen, 
      Germany.
FAU - Leverkus, Martin
AU  - Leverkus M
AD  - Department of Dermatology and Allergology, RWTH Aachen University, 52074 Aachen, 
      Germany.
FAU - Preisinger, Christian
AU  - Preisinger C
AD  - Proteomics Facility, IZKF, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Tacke, Frank
AU  - Tacke F
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Trautwein, Christian
AU  - Trautwein C
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Longerich, Thomas
AU  - Longerich T
AD  - Department of Pathology, RWTH Aachen University, 52074 Aachen, Germany.
FAU - Vucur, Mihael
AU  - Vucur M
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany;
      Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen 
      University, 52074 Aachen, Germany. Electronic address: mvucur@ukaachen.de.
FAU - Luedde, Tom
AU  - Luedde T
AD  - Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany;
      Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen 
      University, 52074 Aachen, Germany. Electronic address: tluedde@ukaachen.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161222
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (NF-kappa B)
RN  - 0 (PSMD2 protein, human)
RN  - 0 (TNF Receptor-Associated Factor 2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 2.7.11.1 (RIPK1 protein, human)
RN  - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinases)
RN  - EC 3.4.22.- (Caspase 8)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
SB  - IM
CIN - Hepatology. 2017 Sep;66(3):983-985. PMID: 28520112
MH  - Animals
MH  - Caspase 8/metabolism
MH  - Hepatocytes/physiology
MH  - Humans
MH  - Liver Neoplasms/*etiology/prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/physiology
MH  - Proteasome Endopeptidase Complex/metabolism
MH  - Receptor-Interacting Protein Serine-Threonine Kinases/*physiology
MH  - TNF Receptor-Associated Factor 2/*physiology
MH  - Tumor Necrosis Factor-alpha/pharmacology
OTO - NOTNLM
OT  - *HCC
OT  - *NF-kappaB
OT  - *RIP1
OT  - *RIP3
OT  - *RIPK3
OT  - *apoptosis
OT  - *cIAP-1
OT  - *caspase-8
OT  - *hepatocarcinogenesis
OT  - *necroptosis
EDAT- 2016/12/27 06:00
MHDA- 2017/06/14 06:00
CRDT- 2016/12/27 06:00
PHST- 2016/01/15 00:00 [received]
PHST- 2016/10/11 00:00 [revised]
PHST- 2016/11/15 00:00 [accepted]
PHST- 2016/12/27 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2016/12/27 06:00 [entrez]
AID - S1535-6108(16)30552-9 [pii]
AID - 10.1016/j.ccell.2016.11.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):94-109. doi: 10.1016/j.ccell.2016.11.009. Epub 2016
      Dec 22.

PMID- 27989802
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic
      Signaling.
PG  - 21-34
LID - 10.1016/j.ccell.2016.11.005 [doi]
AB  - Within the gastrointestinal stem cell niche, nerves help to regulate both normal 
      and neoplastic stem cell dynamics. Here, we reveal the mechanisms underlying the 
      cancer-nerve partnership. We find that Dclk1(+) tuft cells and nerves are the
      main sources of acetylcholine (ACh) within the gastric mucosa. Cholinergic
      stimulation of the gastric epithelium induced nerve growth factor (NGF)
      expression, and in turn NGF overexpression within gastric epithelium expanded
      enteric nerves and promoted carcinogenesis. Ablation of Dclk1(+) cells or
      blockade of NGF/Trk signaling inhibited epithelial proliferation and
      tumorigenesis in an ACh muscarinic receptor-3 (M3R)-dependent manner, in part
      through suppression of yes-associated protein (YAP) function. This feedforward
      ACh-NGF axis activates the gastric cancer niche and offers a compelling target
      for tumor treatment and prevention.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hayakawa, Yoku
AU  - Hayakawa Y
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
AD  - Department of Gastroenterology, Graduate school of Medicine, the University of
      Tokyo, Tokyo, 1138655, Japan.
FAU - Sakitani, Kosuke
AU  - Sakitani K
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Konishi, Mitsuru
AU  - Konishi M
AD  - Department of Gastroenterology, Graduate school of Medicine, the University of
      Tokyo, Tokyo, 1138655, Japan.
FAU - Asfaha, Samuel
AU  - Asfaha S
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
AD  - Department of Medicine, University of Western Ontario, London, ON N6A 5W9,
      Canada.
FAU - Niikura, Ryota
AU  - Niikura R
AD  - Department of Gastroenterology, Graduate school of Medicine, the University of
      Tokyo, Tokyo, 1138655, Japan.
FAU - Tomita, Hiroyuki
AU  - Tomita H
AD  - Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu,
      5011194, Japan.
FAU - Renz, Bernhard W
AU  - Renz BW
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
AD  - Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, 
      Hospital of the University of Munich, Munich, 81377, Germany.
FAU - Tailor, Yagnesh
AU  - Tailor Y
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Macchini, Marina
AU  - Macchini M
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Middelhoff, Moritz
AU  - Middelhoff M
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Jiang, Zhengyu
AU  - Jiang Z
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Tanaka, Takayuki
AU  - Tanaka T
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Dubeykovskaya, Zinaida A
AU  - Dubeykovskaya ZA
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Kim, Woosook
AU  - Kim W
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Chen, Xiaowei
AU  - Chen X
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Urbanska, Aleksandra M
AU  - Urbanska AM
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Nagar, Karan
AU  - Nagar K
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
FAU - Westphalen, Christoph B
AU  - Westphalen CB
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
AD  - Department of Internal Medicine III, Klinikum der Universitat Munchen, Munich,
      81377, Germany.
FAU - Quante, Michael
AU  - Quante M
AD  - Department of Internal Medicine II, Klinikum rechts der Isar, II. Technische
      Universitat Munchen, Munich, 81675, Germany.
FAU - Lin, Chyuan-Sheng
AU  - Lin CS
AD  - Department of Pathology and Cell Biology, Columbia University, New York, NY,
      10032, USA.
AD  - Transgenic Mouse Shared Resource, Columbia University, New York, NY, 10032, USA.
FAU - Gershon, Michael D
AU  - Gershon MD
AD  - Department of Pathology and Cell Biology, Columbia University, New York, NY,
      10032, USA.
FAU - Hara, Akira
AU  - Hara A
AD  - Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu,
      5011194, Japan.
FAU - Zhao, Chun-Mei
AU  - Zhao CM
AD  - Department of Cancer Research and Molecular Medicine, NTNU - Norwegian University
      of Science and Technology, Trondheim, 7491, Norway.
FAU - Chen, Duan
AU  - Chen D
AD  - Department of Cancer Research and Molecular Medicine, NTNU - Norwegian University
      of Science and Technology, Trondheim, 7491, Norway.
FAU - Worthley, Daniel L
AU  - Worthley DL
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
AD  - Cancer theme, SAHMRI and Department of Medicine, University of Adelaide, SA,
      5000, Australia.
FAU - Koike, Kazuhiko
AU  - Koike K
AD  - Department of Gastroenterology, Graduate school of Medicine, the University of
      Tokyo, Tokyo, 1138655, Japan.
FAU - Wang, Timothy C
AU  - Wang TC
AD  - Division of Digestive and Liver Diseases, Department of Medicine, Columbia
      University, New York, NY, 10032, USA.
LA  - eng
GR  - R01 CA093405/CA/NCI NIH HHS/United States
GR  - U54 CA126513/CA/NCI NIH HHS/United States
GR  - R35 CA210088/CA/NCI NIH HHS/United States
GR  - R01 CA120979/CA/NCI NIH HHS/United States
GR  - R01 DK052778/DK/NIDDK NIH HHS/United States
GR  - R01 DK097016/DK/NIDDK NIH HHS/United States
GR  - U01 DK103155/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20161215
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Phosphoproteins)
RN  - 0 (Receptor, Muscarinic M3)
RN  - 0 (Yap protein, mouse)
RN  - 9061-61-4 (Nerve Growth Factor)
RN  - EC 2.7.1.- (Dcamkl1 protein, mouse)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - N9YNS0M02X (Acetylcholine)
SB  - IM
CIN - Cancer Cell. 2017 Jan 9;31(1):1-2. PMID: 28073000
MH  - Acetylcholine/*physiology
MH  - Adaptor Proteins, Signal Transducing/physiology
MH  - Animals
MH  - Gastric Mucosa/innervation
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Nerve Growth Factor/*physiology
MH  - Phosphoproteins/physiology
MH  - Protein-Serine-Threonine Kinases/analysis
MH  - Receptor, Muscarinic M3/physiology
MH  - Signal Transduction/*physiology
MH  - Stomach Neoplasms/*etiology
PMC - PMC5225031
MID - NIHMS830577
OTO - NOTNLM
OT  - *Dclk1
OT  - *Lgr5
OT  - *NGF
OT  - *YAP
OT  - *acetylcholine
OT  - *gastric cancer
OT  - *muscarinic acetylcholine receptor type 3
OT  - *stem cell
OT  - *tuft cell
OT  - *wnt
EDAT- 2016/12/19 06:00
MHDA- 2017/06/14 06:00
CRDT- 2016/12/20 06:00
PHST- 2016/06/18 00:00 [received]
PHST- 2016/09/17 00:00 [revised]
PHST- 2016/11/10 00:00 [accepted]
PHST- 2016/12/19 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2016/12/20 06:00 [entrez]
AID - 10.1016/j.ccell.2016.11.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):21-34. doi: 10.1016/j.ccell.2016.11.005. Epub 2016 
      Dec 15.

PMID- 27989801
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan 9
TI  - Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform
      Indolent Tumor Cells into Chemoresistant Cancer Stem Cells.
PG  - 110-126
LID - S1535-6108(16)30553-0 [pii]
LID - 10.1016/j.ccell.2016.11.010 [doi]
AB  - Tumor-associated endothelial cells (TECs) regulate tumor cell aggressiveness.
      However, the core mechanism by which TECs confer stem cell-like activity to
      indolent tumors is unknown. Here, we used in vivo murine and human tumor models
      to identify the tumor-suppressive checkpoint role of TEC-expressed insulin growth
      factor (IGF) binding protein-7 (IGFBP7/angiomodulin). During tumorigenesis,
      IGFBP7 blocks IGF1 and inhibits expansion and aggresiveness of tumor stem-like
      cells (TSCs) expressing IGF1 receptor (IGF1R). However, chemotherapy triggers
      TECs to suppress IGFBP7, and this stimulates IGF1R(+) TSCs to express FGF4,
      inducing a feedforward FGFR1-ETS2 angiocrine cascade that obviates TEC IGFBP7.
      Thus, loss of IGFBP7 and upregulation of IGF1 activates the FGF4-FGFR1-ETS2
      pathway in TECs and converts naive tumor cells to chemoresistant TSCs, thereby
      facilitating their invasiveness and progression.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Cao, Zhongwei
AU  - Cao Z
AD  - Division of Regenerative Medicine, Department of Medicine, Ansary Stem Cell
      Institute, Weill Cornell Medicine, New York, NY 10065, USA; Laboratory of Birth
      Defects and Related Diseases of Women and Children, State Key Laboratory of
      Biotherapy, West China Second University Hospital, Sichuan University,
      Collaborative Innovation Center for Biotherapy, Chengdu 610041, China. Electronic
      address: zhc2007@med.cornell.edu.
FAU - Scandura, Joseph M
AU  - Scandura JM
AD  - Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, 
      New York, NY 10065, USA.
FAU - Inghirami, Giorgio G
AU  - Inghirami GG
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Shido, Koji
AU  - Shido K
AD  - Division of Regenerative Medicine, Department of Medicine, Ansary Stem Cell
      Institute, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Ding, Bi-Sen
AU  - Ding BS
AD  - Division of Regenerative Medicine, Department of Medicine, Ansary Stem Cell
      Institute, Weill Cornell Medicine, New York, NY 10065, USA; Laboratory of Birth
      Defects and Related Diseases of Women and Children, State Key Laboratory of
      Biotherapy, West China Second University Hospital, Sichuan University,
      Collaborative Innovation Center for Biotherapy, Chengdu 610041, China. Electronic
      address: bid2004@med.cornell.edu.
FAU - Rafii, Shahin
AU  - Rafii S
AD  - Division of Regenerative Medicine, Department of Medicine, Ansary Stem Cell
      Institute, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:
      srafii@med.cornell.edu.
LA  - eng
GR  - R01 HL128158/HL/NHLBI NIH HHS/United States
GR  - R01 DK095039/DK/NIDDK NIH HHS/United States
GR  - R01 HL097797/HL/NHLBI NIH HHS/United States
GR  - R01 HL130826/HL/NHLBI NIH HHS/United States
GR  - R01 HL119872/HL/NHLBI NIH HHS/United States
GR  - R56 HL116436/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20161215
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ETS2 protein, human)
RN  - 0 (FGF4 protein, human)
RN  - 0 (Fibroblast Growth Factor 4)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 0 (Proto-Oncogene Protein c-ets-2)
RN  - 0 (insulin-like growth factor binding protein-related protein 1)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Animals
MH  - Cell Transformation, Neoplastic
MH  - Drug Resistance, Neoplasm
MH  - Endothelial Cells/physiology
MH  - Fibroblast Growth Factor 4/physiology
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Proteins/*physiology
MH  - Insulin-Like Growth Factor I/physiology
MH  - Mice
MH  - Neoplastic Stem Cells/*drug effects
MH  - Proto-Oncogene Protein c-ets-2/physiology
MH  - Receptor, IGF Type 1/physiology
PMC - PMC5497495
MID - NIHMS870374
OTO - NOTNLM
OT  - *ETS2
OT  - *IGFBP7/angiomodullin
OT  - *angiocrine factors
OT  - *cancer stem cells
OT  - *chemoresistance
OT  - *insulin growth factor-1
OT  - *tumor aggressiveness
OT  - *tumor endothelial cell
OT  - *tumor microenvironment
OT  - *vascular niche
EDAT- 2016/12/19 06:00
MHDA- 2017/06/14 06:00
CRDT- 2016/12/20 06:00
PHST- 2015/08/28 00:00 [received]
PHST- 2016/04/10 00:00 [revised]
PHST- 2016/11/17 00:00 [accepted]
PHST- 2016/12/19 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2016/12/20 06:00 [entrez]
AID - S1535-6108(16)30553-0 [pii]
AID - 10.1016/j.ccell.2016.11.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Jan 9;31(1):110-126. doi: 10.1016/j.ccell.2016.11.010. Epub
      2016 Dec 15.

PMID- 27960089
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through
      Glypican Release and Is a Marker of Clinical Outcome.
PG  - 986
LID - S1535-6108(16)30551-7 [pii]
LID - 10.1016/j.ccell.2016.11.008 [doi]
FAU - Matas-Rico, Elisa
AU  - Matas-Rico E
FAU - van Veen, Michiel
AU  - van Veen M
FAU - Leyton-Puig, Daniela
AU  - Leyton-Puig D
FAU - van den Berg, Jeroen
AU  - van den Berg J
FAU - Koster, Jan
AU  - Koster J
FAU - Kedziora, Katarzyna M
AU  - Kedziora KM
FAU - Molenaar, Bas
AU  - Molenaar B
FAU - Weerts, Marjolein J A
AU  - Weerts MJA
FAU - de Rink, Iris
AU  - de Rink I
FAU - Medema, Rene H
AU  - Medema RH
FAU - Giepmans, Ben N G
AU  - Giepmans BNG
FAU - Perrakis, Anastassis
AU  - Perrakis A
FAU - Jalink, Kees
AU  - Jalink K
FAU - Versteeg, Rogier
AU  - Versteeg R
FAU - Moolenaar, Wouter H
AU  - Moolenaar WH
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Oct 10;30(4):548-562. PMID: 27693046
EDAT- 2016/12/14 06:00
MHDA- 2016/12/14 06:01
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2016/12/14 06:01 [medline]
AID - S1535-6108(16)30551-7 [pii]
AID - 10.1016/j.ccell.2016.11.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):986. doi: 10.1016/j.ccell.2016.11.008.

PMID- 27960088
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances
      Drug Delivery and Produces a Favorable Tumor Microenvironment.
PG  - 953-967
LID - S1535-6108(16)30505-0 [pii]
LID - 10.1016/j.ccell.2016.10.018 [doi]
AB  - A destabilized tumor vasculature leads to limited drug delivery, hypoxia,
      detrimental tumor microenvironment, and even metastasis. We performed a
      side-by-side comparison of ABTAA (Ang2-Binding and Tie2-Activating Antibody) and 
      ABA (Ang2-Blocking Antibody) in mice with orthotopically implanted glioma, with
      subcutaneously implanted Lewis lung carcinoma, and with spontaneous mammary
      cancer. We found that Tie2 activation induced tumor vascular normalization,
      leading to enhanced blood perfusion and chemotherapeutic drug delivery, markedly 
      lessened lactate acidosis, and reduced tumor growth and metastasis. Moreover,
      ABTAA favorably altered the immune cell profile within tumors. Together, our
      findings establish that simultaneous Tie2 activation and Ang2 inhibition form a
      powerful therapeutic strategy to elicit a favorable tumor microenvironment and
      enhanced delivery of a chemotherapeutic agent into tumors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Park, Jin-Sung
AU  - Park JS
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of
      Science and Technology (KAIST), Daejeon 34141, Republic of Korea; Center for
      Vascular Research, Institute for Basic Science (IBS), Daejeon 34141, Republic of 
      Korea.
FAU - Kim, Il-Kug
AU  - Kim IK
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of
      Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
FAU - Han, Sangyeul
AU  - Han S
AD  - Center for Vascular Research, Institute for Basic Science (IBS), Daejeon 34141,
      Republic of Korea; Samsung Advanced Institute of Technology, Suwon 16678,
      Republic of Korea.
FAU - Park, Intae
AU  - Park I
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of
      Science and Technology (KAIST), Daejeon 34141, Republic of Korea; Center for
      Vascular Research, Institute for Basic Science (IBS), Daejeon 34141, Republic of 
      Korea.
FAU - Kim, Chan
AU  - Kim C
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of
      Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
FAU - Bae, Jeomil
AU  - Bae J
AD  - Center for Vascular Research, Institute for Basic Science (IBS), Daejeon 34141,
      Republic of Korea.
FAU - Oh, Seung Ja
AU  - Oh SJ
AD  - Samsung Advanced Institute of Technology, Suwon 16678, Republic of Korea.
FAU - Lee, Seungjoo
AU  - Lee S
AD  - Department of Neurosurgery, Asan Medical Center, Seoul 05505, Republic of Korea.
FAU - Kim, Jeong Hoon
AU  - Kim JH
AD  - Department of Neurosurgery, Asan Medical Center, Seoul 05505, Republic of Korea.
FAU - Woo, Dong-Cheol
AU  - Woo DC
AD  - Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of
      Korea.
FAU - He, Yulong
AU  - He Y
AD  - Cyrus Tang Hematology Center, Soochow University, Suzhou 215123, China.
FAU - Augustin, Hellmut G
AU  - Augustin HG
AD  - Division of Vascular Oncology and Metastasis, German Cancer Research Center
      Heidelberg (DKFZ-ZMBH Alliance), 69121 Heidelberg, Germany.
FAU - Kim, Injune
AU  - Kim I
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of
      Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
FAU - Lee, Doheon
AU  - Lee D
AD  - Department of Bio and Brain Engineering, KAIST, Daejeon 34141, Republic of Korea;
      Bio-Synergy Research Center, Daejeon 34141, Republic of Korea. Electronic
      address: dhlee@kaist.ac.kr.
FAU - Koh, Gou Young
AU  - Koh GY
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of
      Science and Technology (KAIST), Daejeon 34141, Republic of Korea; Center for
      Vascular Research, Institute for Basic Science (IBS), Daejeon 34141, Republic of 
      Korea. Electronic address: gykoh@kaist.ac.kr.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies)
RN  - 0 (Antineoplastic Agents)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - EC 2.7.10.1 (Receptor, TIE-2)
RN  - EC 2.7.10.1 (Tek protein, mouse)
RN  - EC 3.1.27.5 (Ang2 protein, mouse)
RN  - EC 3.1.27.5 (Ribonuclease, Pancreatic)
RN  - YF1K15M17Y (temozolomide)
SB  - IM
EIN - Cancer Cell. 2017 Jan 9;31(1):157-158. PMID: 28073001
MH  - Animals
MH  - Antibodies/*administration & dosage/pharmacology
MH  - Antineoplastic Agents/administration & dosage/pharmacology
MH  - Breast Neoplasms/blood supply/*drug therapy
MH  - Carcinoma, Lewis Lung/blood supply/*drug therapy
MH  - Dacarbazine/administration & dosage/analogs & derivatives
MH  - Drug Synergism
MH  - Female
MH  - Glioma/blood supply/*drug therapy
MH  - Humans
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Protein Binding/drug effects
MH  - Receptor, TIE-2/*metabolism
MH  - Ribonuclease, Pancreatic/*antagonists & inhibitors
MH  - Treatment Outcome
MH  - Tumor Microenvironment/drug effects
OTO - NOTNLM
OT  - *M2-like TAM
OT  - *Tie2 activation
OT  - *angiopoietin-2
OT  - *enhanced drug delivery
OT  - *tumor microenvironment
OT  - *tumor vasculature
OT  - *tumor vessel normalization
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/02/19 00:00 [received]
PHST- 2016/07/29 00:00 [revised]
PHST- 2016/10/26 00:00 [accepted]
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30505-0 [pii]
AID - 10.1016/j.ccell.2016.10.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):953-967. doi: 10.1016/j.ccell.2016.10.018.

PMID- 27960087
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of
      Poly(ADP-ribose) Polymerase Inhibitors.
PG  - 940-952
LID - S1535-6108(16)30548-7 [pii]
LID - 10.1016/j.ccell.2016.11.006 [doi]
AB  - Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase
      (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors
      and beta-lapachone are combined, synergistic antitumor activity results from
      sustained NAD(P)H levels that refuel NQO1-dependent futile redox drug recycling. 
      Significant oxygen-consumption-rate/reactive oxygen species cause dramatic DNA
      lesion increases that are not repaired due to PARP inhibition. In NQO1(+)
      cancers, such as non-small-cell lung, pancreatic, and breast cancers, cell death 
      mechanism switches from PARP1 hyperactivation-mediated programmed necrosis with
      beta-lapachone monotherapy to synergistic tumor-selective, caspase-dependent
      apoptosis with PARP inhibitors and beta-lapachone. Synergistic antitumor efficacy
      and prolonged survival were noted in human orthotopic pancreatic and
      non-small-cell lung xenograft models, expanding use and efficacy of PARP
      inhibitors for human cancer therapy.
CI  - Published by Elsevier Inc.
FAU - Huang, Xiumei
AU  - Huang X
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Motea, Edward A
AU  - Motea EA
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Moore, Zachary R
AU  - Moore ZR
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Yao, Jun
AU  - Yao J
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Dong, Ying
AU  - Dong Y
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Chakrabarti, Gaurab
AU  - Chakrabarti G
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Kilgore, Jessica A
AU  - Kilgore JA
AD  - Department of Biochemistry, SCCC, UTSW, Dallas, TX 75390, USA.
FAU - Silvers, Molly A
AU  - Silvers MA
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Patidar, Praveen L
AU  - Patidar PL
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Cholka, Agnieszka
AU  - Cholka A
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Fattah, Farjana
AU  - Fattah F
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
FAU - Cha, Yoonjeong
AU  - Cha Y
AD  - Immuneering Corporation, One Broadway 14th Floor, Cambridge, MA 02142, USA.
FAU - Anderson, Glenda G
AU  - Anderson GG
AD  - 5Degrees Bio., Inc., 111 North Market Street #300, San Jose, CA 95113, USA.
FAU - Kusko, Rebecca
AU  - Kusko R
AD  - Immuneering Corporation, One Broadway 14th Floor, Cambridge, MA 02142, USA.
FAU - Peyton, Michael
AU  - Peyton M
AD  - Department of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas,
      TX 75390, USA.
FAU - Yan, Jingsheng
AU  - Yan J
AD  - Department of Biostatistics, UTSW, Dallas, TX 75390, USA.
FAU - Xie, Xian-Jin
AU  - Xie XJ
AD  - Department of Biostatistics, UTSW, Dallas, TX 75390, USA.
FAU - Sarode, Venetia
AU  - Sarode V
AD  - Department of Pathology, UTSW, Dallas, TX 75390, USA.
FAU - Williams, Noelle S
AU  - Williams NS
AD  - Department of Biochemistry, SCCC, UTSW, Dallas, TX 75390, USA.
FAU - Minna, John D
AU  - Minna JD
AD  - Department of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas,
      TX 75390, USA.
FAU - Beg, Muhammad
AU  - Beg M
AD  - Department of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas,
      TX 75390, USA.
FAU - Gerber, David E
AU  - Gerber DE
AD  - Department of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas,
      TX 75390, USA.
FAU - Bey, Erik A
AU  - Bey EA
AD  - Department of Pharmaceutical Sciences, West Virginia University Cancer Institute,
      Morgantown, WV 26506, USA. Electronic address: erik.bey@hsc.wvu.edu.
FAU - Boothman, David A
AU  - Boothman DA
AD  - Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer 
      Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
      Electronic address: david.boothman@utsouthwestern.edu.
LA  - eng
GR  - R01 CA102792/CA/NCI NIH HHS/United States
GR  - P30 RR032138/RR/NCRR NIH HHS/United States
GR  - U54 GM104942/GM/NIGMS NIH HHS/United States
GR  - P30 CA142543/CA/NCI NIH HHS/United States
GR  - P50 CA070907/CA/NCI NIH HHS/United States
GR  - P30 GM103488/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Naphthoquinones)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 0 (Reactive Oxygen Species)
RN  - 4707-32-8 (beta-lapachone)
RN  - EC 1.6.5.2 (NAD(P)H Dehydrogenase (Quinone))
RN  - EC 1.6.5.2 (NQO1 protein, human)
SB  - IM
MH  - Animals
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - DNA Damage
MH  - Drug Synergism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Mice
MH  - NAD(P)H Dehydrogenase (Quinone)/*genetics
MH  - Naphthoquinones/*administration & dosage/pharmacology
MH  - Pancreatic Neoplasms/*drug therapy/genetics
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*administration & dosage
MH  - Reactive Oxygen Species/metabolism
MH  - Up-Regulation
MH  - Xenograft Model Antitumor Assays
PMC - PMC5161231
MID - NIHMS830578
OTO - NOTNLM
OT  - *ARQ761
OT  - *NQO1
OT  - *NQO1 bioctivatable drugs
OT  - *NSCLC
OT  - *Olaparib
OT  - *PARP1
OT  - *PDA
OT  - *ROS
OT  - *Rucaparib
OT  - *combination chemotherapy
OT  - *synthetic lethality
OT  - *beta-lapachone
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2015/09/11 00:00 [received]
PHST- 2016/06/18 00:00 [revised]
PHST- 2016/11/11 00:00 [accepted]
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30548-7 [pii]
AID - 10.1016/j.ccell.2016.11.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006.

PMID- 27960086
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets 
      in CNS Rhabdoid Tumors.
PG  - 891-908
LID - S1535-6108(16)30509-8 [pii]
LID - 10.1016/j.ccell.2016.11.003 [doi]
AB  - We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at
      least two transcriptional subtypes with different clinical outcomes; however, the
      mechanisms underlying therapeutic heterogeneity remained unclear. In this study, 
      we analyzed 191 primary ATRTs and 10 ATRT cell lines to define the genomic and
      epigenomic landscape of ATRTs and identify subgroup-specific therapeutic targets.
      We found ATRTs segregated into three epigenetic subgroups with distinct genomic
      profiles, SMARCB1 genotypes, and chromatin landscape that correlated with
      differential cellular responses to a panel of signaling and epigenetic
      inhibitors. Significantly, we discovered that differential methylation of a
      PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to 
      dasatinib and nilotinib, and suggest that these are promising therapies for this 
      highly lethal ATRT subtype.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Torchia, Jonathon
AU  - Torchia J
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G0A4, Canada; Department of Paediatrics, University of Toronto,
      Toronto, ON M5G0A4, Canada; Division of Hematology/Oncology, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour
      Research Centre, Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Golbourn, Brian
AU  - Golbourn B
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G0A4, Canada; Division of Neurosurgery, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour Research Centre,
      Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Feng, Shengrui
AU  - Feng S
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON M5G0A4,
      Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON
      M5G1L7, Canada.
FAU - Ho, King Ching
AU  - Ho KC
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Sin-Chan, Patrick
AU  - Sin-Chan P
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G0A4, Canada; Department of Paediatrics, University of Toronto,
      Toronto, ON M5G0A4, Canada; Division of Hematology/Oncology, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour
      Research Centre, Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Vasiljevic, Alexandre
AU  - Vasiljevic A
AD  - Department of Pathology, Groupement Hospitalier Est, CHU de Lyon, Lyon-Bron
      69677, France.
FAU - Norman, Joseph D
AU  - Norman JD
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Guilhamon, Paul
AU  - Guilhamon P
AD  - Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1L7,
      Canada.
FAU - Garzia, Livia
AU  - Garzia L
AD  - Program in Developmental & Stem Cell Biology, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour Research Centre,
      Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Agamez, Natalia R
AU  - Agamez NR
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Lu, Mei
AU  - Lu M
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Chan, Tiffany S
AU  - Chan TS
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G0A4, Canada; Department of Paediatrics, University of Toronto,
      Toronto, ON M5G0A4, Canada; Division of Hematology/Oncology, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour
      Research Centre, Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Picard, Daniel
AU  - Picard D
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - de Antonellis, Pasqualino
AU  - de Antonellis P
AD  - Program in Developmental & Stem Cell Biology, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour Research Centre,
      Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Khuong-Quang, Dong-Anh
AU  - Khuong-Quang DA
AD  - Department of Pediatrics, McGill University, Montreal, QC H3Z2Z3, Canada;
      Department of Human Genetics, McGill University, Montreal, QC H3Z2Z3, Canada.
FAU - Planello, Aline C
AU  - Planello AC
AD  - Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1L7,
      Canada.
FAU - Zeller, Constanze
AU  - Zeller C
AD  - Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1L7,
      Canada.
FAU - Barsyte-Lovejoy, Dalia
AU  - Barsyte-Lovejoy D
AD  - Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1L7,
      Canada.
FAU - Lafay-Cousin, Lucie
AU  - Lafay-Cousin L
AD  - Division of Pediatric Hematology/Oncology, Alberta Children's Hospital, AB
      T3B6A8, Canada.
FAU - Letourneau, Louis
AU  - Letourneau L
AD  - Genome Quebec Innovation Centre, McGill University, Montreal, QC H3A1A4, Canada.
FAU - Bourgey, Mathieu
AU  - Bourgey M
AD  - Genome Quebec Innovation Centre, McGill University, Montreal, QC H3A1A4, Canada.
FAU - Yu, Man
AU  - Yu M
AD  - Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada.
FAU - Gendoo, Deena M A
AU  - Gendoo DMA
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Dzamba, Misko
AU  - Dzamba M
AD  - Department of Computer Science, University of Toronto, Toronto, ON M5G0A4,
      Canada.
FAU - Barszczyk, Mark
AU  - Barszczyk M
AD  - Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada.
FAU - Medina, Tiago
AU  - Medina T
AD  - Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1L7,
      Canada.
FAU - Riemenschneider, Alexandra N
AU  - Riemenschneider AN
AD  - Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G1X8, Canada;
      Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada.
FAU - Morrissy, A Sorana
AU  - Morrissy AS
AD  - Program in Developmental & Stem Cell Biology, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour Research Centre,
      Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Ra, Young-Shin
AU  - Ra YS
AD  - Department of Neurosurgery, Asan Medical Center, Seoul 138-736, Korea.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Remke, Marc
AU  - Remke M
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Dunham, Christopher P
AU  - Dunham CP
AD  - Division of Anatomic Pathology, Children's and Women's Health Centre of B.C,
      University of British Columbia, Vancouver, BC V6H3N1, Canada.
FAU - Yip, Stephen
AU  - Yip S
AD  - Department of Pathology & Laboratory Medicine, University of British Columbia,
      V6T1Z3, Canada.
FAU - Ng, Ho-Keung
AU  - Ng HK
AD  - Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Lu, Jian-Qiang
AU  - Lu JQ
AD  - Laboratory Medicine and Pathology, Stollery Children's Hospital, University of
      Alberta, Edmonton, AB T2W3N2, Canada.
FAU - Mehta, Vivek
AU  - Mehta V
AD  - Division of Neurosurgery, Stollery Children's Hospital, University of Alberta,
      Edmonton, AB T2W3N2, Canada.
FAU - Albrecht, Steffen
AU  - Albrecht S
AD  - Department of Pathology, McGill University, Montreal, QC H3Z2Z3, Canada.
FAU - Pimentel, Jose
AU  - Pimentel J
AD  - Divison of Pathology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte,
      Lisbon 1649-035, Portugal.
FAU - Chan, Jennifer A
AU  - Chan JA
AD  - Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, 
      AB T2N1N4, Canada.
FAU - Somers, Gino R
AU  - Somers GR
AD  - Department of Paediatric Laboratory Medicine, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada.
FAU - Faria, Claudia C
AU  - Faria CC
AD  - Department of Neurosurgery, Hospital de Santa Maria, Centro Hospitalar Lisboa
      Norte, Lisbon 1649-035, Portugal.
FAU - Roque, Lucia
AU  - Roque L
AD  - Cytometry and Cytogenetic Laboratory, CIPM, Portuguese Cancer Institute, Lisbon
      1099-023, Portugal.
FAU - Fouladi, Maryam
AU  - Fouladi M
AD  - Division of Oncology, Department of Cancer and Blood Diseases, Cincinnati
      Children's Hospital, Cincinnati, OH 45229, USA.
FAU - Hoffman, Lindsey M
AU  - Hoffman LM
AD  - Department of Pediatrics, University of Colorado, Denver, CO 80045, USA.
FAU - Moore, Andrew S
AU  - Moore AS
AD  - Oncology Service, Children's Health Queensland Hospital; University of Queensland
      Diamantina Institute, Brisbane, QLD 4102, Australia.
FAU - Wang, Yin
AU  - Wang Y
AD  - Research Institute of Health Development Strategies, Fudan University, Shanghai
      200032, China.
FAU - Choi, Seung Ah
AU  - Choi SA
AD  - Division of Pediatric Neurosurgery, Seoul National University Children's
      Hospital, Seoul 03080, Korea.
FAU - Hansford, Jordan R
AU  - Hansford JR
AD  - Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne, VIC 
      3052, Australia.
FAU - Catchpoole, Daniel
AU  - Catchpoole D
AD  - Children's Cancer Research Unit, Children's Hospital at Westmead, Westmead, NSW
      2145, Australia.
FAU - Birks, Diane K
AU  - Birks DK
AD  - Department of Pediatrics, University of Colorado, Denver, CO 80045, USA.
FAU - Foreman, Nicholas K
AU  - Foreman NK
AD  - Department of Pediatrics, University of Colorado, Denver, CO 80045, USA.
FAU - Strother, Doug
AU  - Strother D
AD  - Division of Pediatric Hematology/Oncology, Stollery Children's Hospital,
      University of Alberta, Edmonton, AB T2W3N2, Canada.
FAU - Klekner, Almos
AU  - Klekner A
AD  - Department of Neurosurgery, University of Debrecen, Debrecen 4032, Hungary.
FAU - Bognar, Laszlo
AU  - Bognar L
AD  - Department of Neurosurgery, University of Debrecen, Debrecen 4032, Hungary.
FAU - Garami, Miklos
AU  - Garami M
AD  - Second Department of Pediatrics, Semmelweis University, Budapest 1094, Hungary.
FAU - Hauser, Peter
AU  - Hauser P
AD  - Second Department of Pediatrics, Semmelweis University, Budapest 1094, Hungary.
FAU - Hortobagyi, Tibor
AU  - Hortobagyi T
AD  - Department of Histopathology, University of Szeged, Szeged 6720, Hungary.
FAU - Wilson, Beverly
AU  - Wilson B
AD  - Division of Pediatric Hematology/Oncology, Stollery Children's Hospital,
      University of Alberta, Edmonton, AB T2W3N2, Canada.
FAU - Hukin, Juliette
AU  - Hukin J
AD  - Division of Hematology and Oncology, Children's and Women's Health Centre of B.C,
      University of British Columbia, Vancouver, BC V6H3N1, Canada.
FAU - Carret, Anne-Sophie
AU  - Carret AS
AD  - Department of Pediatrics, Division of Hematology-Oncology, Universite de
      Montreal/CHU Sainte-Justine, Montreal, QC H3T1C5, Canada.
FAU - Van Meter, Timothy E
AU  - Van Meter TE
AD  - Department of Neurosurgery, Virginia Commonwealth University, Richmond, VA
      23298-0631, USA.
FAU - Hwang, Eugene I
AU  - Hwang EI
AD  - Department of Oncology, Children's National Medical Center, Washington, DC 20010,
      USA.
FAU - Gajjar, Amar
AU  - Gajjar A
AD  - Division of Neuro-Oncology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Chiou, Shih-Hwa
AU  - Chiou SH
AD  - Department of Medical Research, Taipei Veterans General Hospital and National
      Yang-Ming University, Taipei 112, Taiwan.
FAU - Nakamura, Hideo
AU  - Nakamura H
AD  - Department of Neurosurgery, Kumamoto University, Kumamoto 860-8556, Japan.
FAU - Toledano, Helen
AU  - Toledano H
AD  - Department of Pediatric Hematology Oncology, Children's Medical Center of Israel,
      Petach Tikva 49202, Isreal.
FAU - Fried, Iris
AU  - Fried I
AD  - Department of Pediatric Hematology-Oncology, Hadassah Hebrew University Medical
      Center, Jerusalem 91120, Israel.
FAU - Fults, Daniel
AU  - Fults D
AD  - Department of Neurosurgery, University of Utah, School of Medicine, Salt Lake
      City, UT 84132, USA.
FAU - Wataya, Takafumi
AU  - Wataya T
AD  - Department of Neurosurgery, Shizuoka Children's Hospital, Shizuoka 420-8660,
      Japan.
FAU - Fryer, Chris
AU  - Fryer C
AD  - Division of Hematology and Oncology, Children's and Women's Health Centre of B.C,
      University of British Columbia, Vancouver, BC V6H3N1, Canada.
FAU - Eisenstat, David D
AU  - Eisenstat DD
AD  - Division of Pediatric Hematology/Oncology, Stollery Children's Hospital,
      University of Alberta, Edmonton, AB T2W3N2, Canada.
FAU - Scheinemann, Katrin
AU  - Scheinemann K
AD  - Department of Pediatrics, McMaster University, Hamilton, ON L8S4K1, Canada.
FAU - Fleming, Adam J
AU  - Fleming AJ
AD  - Department of Pediatrics, McMaster University, Hamilton, ON L8S4K1, Canada.
FAU - Johnston, Donna L
AU  - Johnston DL
AD  - Department of Pediatrics, Children's Hospital of Eastern Ontario, University of
      Ottawa, Ottawa, ON K1H8L1, Canada.
FAU - Michaud, Jean
AU  - Michaud J
AD  - Pathology and Laboratory Medicine, Children's Hospital of Eastern Ontario,
      University of Ottawa, Ottawa, ON K1H8L1, Canada.
FAU - Zelcer, Shayna
AU  - Zelcer S
AD  - Division of Pediatric Hematology/Oncology, Children's Hospital, London Health
      Sciences Center, London, ON N6A5A5, Canada.
FAU - Hammond, Robert
AU  - Hammond R
AD  - Department of Pathology and Laboratory Medicine, Children's Hospital of Western
      Ontario, University of Western Ontario, London, ON N6A5W9, Canada.
FAU - Afzal, Samina
AU  - Afzal S
AD  - Department of Pediatrics, Dalhousie University, Halifax, NS B3H4R2, Canada.
FAU - Ramsay, David A
AU  - Ramsay DA
AD  - Department of Pathology and Laboratory Medicine, Children's Hospital of Western
      Ontario, University of Western Ontario, London, ON N6A5W9, Canada.
FAU - Sirachainan, Nongnuch
AU  - Sirachainan N
AD  - Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol
      University, Bangkok 10300, Thailand.
FAU - Hongeng, Suradej
AU  - Hongeng S
AD  - Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol
      University, Bangkok 10300, Thailand.
FAU - Larbcharoensub, Noppadol
AU  - Larbcharoensub N
AD  - Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol
      University, Bangkok 10400, Thailand.
FAU - Grundy, Richard G
AU  - Grundy RG
AD  - Children's Brain Tumour Research Centre, University of Nottingham, Nottingham
      NG72RD, England.
FAU - Lulla, Rishi R
AU  - Lulla RR
AD  - Division of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ann and 
      Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
FAU - Fangusaro, Jason R
AU  - Fangusaro JR
AD  - Division of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ann and 
      Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
FAU - Druker, Harriet
AU  - Druker H
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada.
FAU - Bartels, Ute
AU  - Bartels U
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada.
FAU - Grant, Ronald
AU  - Grant R
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada.
FAU - Malkin, David
AU  - Malkin D
AD  - Department of Paediatrics, University of Toronto, Toronto, ON M5G0A4, Canada;
      Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Program in Genetics & Genome Biology, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada.
FAU - McGlade, C Jane
AU  - McGlade CJ
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON M5G0A4,
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Nicolaides, Theodore
AU  - Nicolaides T
AD  - Department of Pediatrics (Hematology/Oncology), University of California, San
      Francisco, San Francisco, CA 94143-0112, USA.
FAU - Tihan, Tarik
AU  - Tihan T
AD  - Department of Neurosurgery, University of California, San Francisco, San
      Francisco, CA 94143-0112, USA.
FAU - Phillips, Joanna
AU  - Phillips J
AD  - Department of Neurosurgery, University of California, San Francisco, San
      Francisco, CA 94143-0112, USA.
FAU - Majewski, Jacek
AU  - Majewski J
AD  - Department of Human Genetics, McGill University, Montreal, QC H3Z2Z3, Canada;
      Genome Quebec Innovation Centre, McGill University, Montreal, QC H3A1A4, Canada.
FAU - Montpetit, Alexandre
AU  - Montpetit A
AD  - Genome Quebec Innovation Centre, McGill University, Montreal, QC H3A1A4, Canada.
FAU - Bourque, Guillaume
AU  - Bourque G
AD  - Department of Human Genetics, McGill University, Montreal, QC H3Z2Z3, Canada;
      Genome Quebec Innovation Centre, McGill University, Montreal, QC H3A1A4, Canada.
FAU - Bader, Gary D
AU  - Bader GD
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5G0A4,
      Canada.
FAU - Reddy, Alyssa T
AU  - Reddy AT
AD  - Department of Pediatric Hematology and Oncology, University of Alabama,
      Birmingham, AL 35233, USA.
FAU - Gillespie, G Yancey
AU  - Gillespie GY
AD  - Department of Neurosurgery, University of Alabama, Birmingham, AL 35233, USA.
FAU - Warmuth-Metz, Monika
AU  - Warmuth-Metz M
AD  - Department of Neuroradiology, University of Wurzburg, Wurzburg 97070, Germany.
FAU - Rutkowski, Stefan
AU  - Rutkowski S
AD  - Department of Pediatric Hematology and Oncology, University Medical Center
      Hamburg-Eppendorf, Hamburg 20246, Germany.
FAU - Tabori, Uri
AU  - Tabori U
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G0A4, Canada; Division of Hematology/Oncology, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada; Program in Genetics & Genome Biology,
      Hospital for Sick Children, Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt
      Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON M5G1X8,
      Canada.
FAU - Lupien, Mathieu
AU  - Lupien M
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON M5G0A4,
      Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON
      M5G1L7, Canada.
FAU - Brudno, Michael
AU  - Brudno M
AD  - Department of Computer Science, University of Toronto, Toronto, ON M5G0A4,
      Canada; Program in Genetics & Genome Biology, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada.
FAU - Schuller, Ulrich
AU  - Schuller U
AD  - Department of Neuropathology, University Medical Center Hamburg-Eppendorf,
      Hamburg 20246, Germany.
FAU - Pietsch, Torsten
AU  - Pietsch T
AD  - Institute for Neuropathology, University of Bonn Medical Center, Bonn 53105,
      Germany.
FAU - Judkins, Alexander R
AU  - Judkins AR
AD  - Department of Pathology & Laboratory Medicine, Children's Hospital of Los
      Angeles, Los Angeles, CA 90027, USA.
FAU - Hawkins, Cynthia E
AU  - Hawkins CE
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G0A4, Canada; Division of Pathology, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour Research Centre,
      Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Bouffet, Eric
AU  - Bouffet E
AD  - Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G1X8, 
      Canada; Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada.
FAU - Kim, Seung-Ki
AU  - Kim SK
AD  - Division of Pediatric Neurosurgery, Seoul National University Children's
      Hospital, Seoul 03080, Korea.
FAU - Dirks, Peter B
AU  - Dirks PB
AD  - Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G1X8, Canada;
      Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G1X8, Canada;
      Program in Developmental & Stem Cell Biology, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour Research Centre,
      Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
FAU - Erdreich-Epstein, Anat
AU  - Erdreich-Epstein A
AD  - Department of Pediatrics, Children's Hospital Los Angeles, Keck School of
      Medicine, University of Southern California, Los Angeles, CA 90027, USA.
FAU - Arrowsmith, Cheryl H
AU  - Arrowsmith CH
AD  - Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1L7,
      Canada.
FAU - De Carvalho, Daniel D
AU  - De Carvalho DD
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON M5G0A4,
      Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON
      M5G1L7, Canada. Electronic address: ddecarv@uhnresearch.ca.
FAU - Rutka, James T
AU  - Rutka JT
AD  - Department of Surgery, University of Toronto, Toronto, ON M5G0A4, Canada;
      Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G1X8, Canada;
      Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, ON M5G1X8, Canada. Electronic address: james.rutka@sickkids.ca.
FAU - Jabado, Nada
AU  - Jabado N
AD  - Department of Pediatrics, McGill University, Montreal, QC H3Z2Z3, Canada;
      Department of Human Genetics, McGill University, Montreal, QC H3Z2Z3, Canada.
      Electronic address: nada.jabado@mcgill.ca.
FAU - Huang, Annie
AU  - Huang A
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5G0A4, Canada; Department of Paediatrics, University of Toronto,
      Toronto, ON M5G0A4, Canada; Division of Hematology/Oncology, Hospital for Sick
      Children, Toronto, ON M5G1X8, Canada; Arthur and Sonia Labatt Brain Tumour
      Research Centre, Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
      Electronic address: annie.huang@sickkids.ca.
LA  - eng
GR  - P41 GM103504/GM/NIGMS NIH HHS/United States
GR  - P41 HG004118/HG/NHGRI NIH HHS/United States
GR  - R01 GM070743/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3
      -ylpyrimidin-2-yl)amino)benzamide)
RN  - 0 (Chromatin)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (SMARCB1 Protein)
RN  - 0 (SMARCB1 protein, human)
RN  - EC 2.7.10.1 (PDGFRB protein, human)
RN  - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor beta)
RN  - RBZ1571X5H (Dasatinib)
RN  - Typical Teratoid Rhabdoid Tumor
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Central Nervous System Neoplasms/drug therapy/*genetics
MH  - Chromatin/*genetics
MH  - DNA Methylation
MH  - Dasatinib/pharmacology/therapeutic use
MH  - Epigenesis, Genetic/drug effects
MH  - Epigenomics/*methods
MH  - Humans
MH  - Mutation
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Pyrimidines/pharmacology/therapeutic use
MH  - Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors/*genetics
MH  - Rhabdoid Tumor/drug therapy/*genetics
MH  - SMARCB1 Protein/*genetics
MH  - Teratoma/drug therapy/*genetics
PMC - PMC5500911
MID - NIHMS870627
OTO - NOTNLM
OT  - *ATRT
OT  - *enhancer
OT  - *epigenomics
OT  - *genomics
OT  - *rhabdoid tumors
OT  - *subgroup-specific therapeutics
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/01/06 00:00 [received]
PHST- 2016/09/19 00:00 [revised]
PHST- 2016/10/31 00:00 [accepted]
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30509-8 [pii]
AID - 10.1016/j.ccell.2016.11.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.

PMID- 27960085
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis
      and Lysophosphatidic Acid Pathway Inhibition.
PG  - 879-890
LID - S1535-6108(16)30546-3 [pii]
LID - 10.1016/j.ccell.2016.11.004 [doi]
AB  - Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second
      most lethal cancer worldwide. HCC prediction and prevention in cirrhosis are key 
      unmet medical needs. Here we have established an HCC risk gene signature
      applicable to all major HCC etiologies: hepatitis B/C, alcohol, and non-alcoholic
      steatohepatitis. A transcriptome meta-analysis of >500 human cirrhotics revealed 
      global regulatory gene modules driving HCC risk and the lysophosphatidic acid
      pathway as a central chemoprevention target. Pharmacological inhibition of the
      pathway in vivo reduced tumors and reversed the gene signature, which was
      verified in organotypic ex vivo culture of patient-derived fibrotic liver
      tissues. These results demonstrate the utility of clinical organ transcriptome to
      enable a strategy, namely, reverse-engineering precision cancer prevention.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Nakagawa, Shigeki
AU  - Nakagawa S
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA; Department of
      Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto
      University, Kumamoto 860-8556, Japan.
FAU - Wei, Lan
AU  - Wei L
AD  - Division of Surgical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Song, Won Min
AU  - Song WM
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and
      Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029,
      USA.
FAU - Higashi, Takaaki
AU  - Higashi T
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA; Department of
      Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto
      University, Kumamoto 860-8556, Japan.
FAU - Ghoshal, Sarani
AU  - Ghoshal S
AD  - Division of Surgical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Kim, Rosa S
AU  - Kim RS
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Bian, C Billie
AU  - Bian CB
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Yamada, Suguru
AU  - Yamada S
AD  - Division of Surgical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Sun, Xiaochen
AU  - Sun X
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Venkatesh, Anu
AU  - Venkatesh A
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Goossens, Nicolas
AU  - Goossens N
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA; Division of Gastroenterology
      and Hepatology, Geneva University Hospital, 41205 Geneva, Switzerland.
FAU - Bain, Gretchen
AU  - Bain G
AD  - PharmAkea Therapeutics, San Diego, CA 92109, USA.
FAU - Lauwers, Gregory Y
AU  - Lauwers GY
AD  - Department of Pathology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Koh, Anna P
AU  - Koh AP
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - El-Abtah, Mohamed
AU  - El-Abtah M
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Ahmad, Noor B
AU  - Ahmad NB
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Hoshida, Hiroki
AU  - Hoshida H
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Erstad, Derek J
AU  - Erstad DJ
AD  - Division of Surgical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Gunasekaran, Ganesh
AU  - Gunasekaran G
AD  - Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY 10029, USA.
FAU - Lee, Youngmin
AU  - Lee Y
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Yu, Ming-Lung
AU  - Yu ML
AD  - Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center,
      Kaohsiung Medical University Hospital, and Faculty of Medicine, College of
      Medicine, and Center for Infectious Disease and Cancer Research, Kaohsiung
      Medical University, Kaohsiung 807, Taiwan; Institute of Biomedical Sciences,
      National Sun Yat-Sen University, Kaohsiung 804, Taiwan.
FAU - Chuang, Wan-Long
AU  - Chuang WL
AD  - Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center,
      Kaohsiung Medical University Hospital, and Faculty of Medicine, College of
      Medicine, and Center for Infectious Disease and Cancer Research, Kaohsiung
      Medical University, Kaohsiung 807, Taiwan.
FAU - Dai, Chia-Yen
AU  - Dai CY
AD  - Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center,
      Kaohsiung Medical University Hospital, and Faculty of Medicine, College of
      Medicine, and Center for Infectious Disease and Cancer Research, Kaohsiung
      Medical University, Kaohsiung 807, Taiwan.
FAU - Kobayashi, Masahiro
AU  - Kobayashi M
AD  - Department of Hepatology, Toranomon Hospital, Tokyo 105-0001, Japan.
FAU - Kumada, Hiromitsu
AU  - Kumada H
AD  - Department of Hepatology, Toranomon Hospital, Tokyo 105-0001, Japan.
FAU - Beppu, Toru
AU  - Beppu T
AD  - Department of Gastroenterological Surgery, Graduate School of Medical Sciences,
      Kumamoto University, Kumamoto 860-8556, Japan.
FAU - Baba, Hideo
AU  - Baba H
AD  - Department of Gastroenterological Surgery, Graduate School of Medical Sciences,
      Kumamoto University, Kumamoto 860-8556, Japan.
FAU - Mahajan, Milind
AU  - Mahajan M
AD  - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
      Sinai, New York, NY 10029, USA.
FAU - Nair, Venugopalan D
AU  - Nair VD
AD  - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Lanuti, Michael
AU  - Lanuti M
AD  - Division of Thoracic Surgery, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Villanueva, Augusto
AU  - Villanueva A
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Sangiovanni, Angelo
AU  - Sangiovanni A
AD  - M. & A. Migliavacca Center for Liver Disease and 1st Division of
      Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico,
      University of Milan, 20122 Milan, Italy.
FAU - Iavarone, Massimo
AU  - Iavarone M
AD  - M. & A. Migliavacca Center for Liver Disease and 1st Division of
      Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico,
      University of Milan, 20122 Milan, Italy.
FAU - Colombo, Massimo
AU  - Colombo M
AD  - M. & A. Migliavacca Center for Liver Disease and 1st Division of
      Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico,
      University of Milan, 20122 Milan, Italy.
FAU - Llovet, Josep M
AU  - Llovet JM
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA; Liver Cancer Translational
      Research Laboratory, Barcelona Clinic Liver Cancer Group, Liver Unit, Institut
      d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic,
      CIBERehd, Universitat de Barcelona, Institucio Catalana de Recerca i Estudis
      Avancats, Catalonia, 08036 Barcelona, Spain.
FAU - Subramanian, Aravind
AU  - Subramanian A
AD  - Cancer Program, Broad Institute of MIT and Harvard University, Cambridge, MA
      02142, USA.
FAU - Tager, Andrew M
AU  - Tager AM
AD  - Pulmonary and Critical Care Unit, Center for Immunology and Inflammatory
      Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
      02114, USA.
FAU - Friedman, Scott L
AU  - Friedman SL
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Baumert, Thomas F
AU  - Baumert TF
AD  - Institut National de la Sante et de la Recherche Medicale, U1110, Institut de
      Recherche sur les Maladies Virales et Hepatiques, Universite de Strasbourg, 67081
      Strasbourg, France; Institut Hospitalo-Universitaire, Pole hepato-digestif,
      Nouvel Hopital Civil, 67000 Strasbourg, France; Liver Center, Gastrointestinal
      Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Schwarz, Myron E
AU  - Schwarz ME
AD  - Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY 10029, USA.
FAU - Chung, Raymond T
AU  - Chung RT
AD  - Liver Center, Gastrointestinal Division, Department of Medicine, Massachusetts
      General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Tanabe, Kenneth K
AU  - Tanabe KK
AD  - Division of Surgical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
      Sinai, New York, NY 10029, USA.
FAU - Fuchs, Bryan C
AU  - Fuchs BC
AD  - Division of Surgical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, MA 02114, USA. Electronic address:
      bfuchs@mgh.harvard.edu.
FAU - Hoshida, Yujin
AU  - Hoshida Y
AD  - Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch
      Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of
      Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:
      yujin.hoshida@mssm.edu.
CN  - Precision Liver Cancer Prevention Consortium
LA  - eng
GR  - K24 DK078772/DK/NIDDK NIH HHS/United States
GR  - P30 DK043351/DK/NIDDK NIH HHS/United States
GR  - K01 CA140861/CA/NCI NIH HHS/United States
GR  - R01 DK104956/DK/NIDDK NIH HHS/United States
GR  - R01 DK098079/DK/NIDDK NIH HHS/United States
GR  - R01 DK099558/DK/NIDDK NIH HHS/United States
GR  - P30 CA196521/CA/NCI NIH HHS/United States
GR  - R56 DK098079/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Lysophospholipids)
RN  - PG6M3969SG (lysophosphatidic acid)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Carcinoma, Hepatocellular/genetics/*prevention & control
MH  - Cell Line, Tumor
MH  - Gene Expression Profiling/*methods
MH  - Gene Regulatory Networks
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Liver Cirrhosis/complications/*genetics
MH  - Liver Neoplasms/genetics/*prevention & control
MH  - Lysophospholipids/*biosynthesis
MH  - Rats
MH  - Risk Factors
MH  - Signal Transduction/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC5161110
MID - NIHMS830579
OTO - NOTNLM
OT  - *cancer chemoprevention
OT  - *gene signature
OT  - *hepatocellular carcinoma
OT  - *prognostic prediction
OT  - *transcriptome
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2015/12/04 00:00 [received]
PHST- 2016/09/28 00:00 [revised]
PHST- 2016/11/11 00:00 [accepted]
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30546-3 [pii]
AID - 10.1016/j.ccell.2016.11.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):879-890. doi: 10.1016/j.ccell.2016.11.004.

PMID- 27960084
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.
PG  - 836-848
LID - 10.1016/j.ccell.2016.10.009 [doi]
AB  - Tumor-secreted extracellular vesicles (EVs) are critical mediators of
      intercellular communication between tumor cells and stromal cells in local and
      distant microenvironments. Accordingly, EVs play an essential role in both
      primary tumor growth and metastatic evolution. EVs orchestrate multiple systemic 
      pathophysiological processes, such as coagulation, vascular leakiness, and
      reprogramming of stromal recipient cells to support pre-metastatic niche
      formation and subsequent metastasis. Clinically, EVs may be biomarkers and novel 
      therapeutic targets for cancer progression, particularly for predicting and
      preventing future metastatic development.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Becker, Annette
AU  - Becker A
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics,
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA.
FAU - Thakur, Basant Kumar
AU  - Thakur BK
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics,
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA.
AD  - Pediatric Clinic III, University Clinic of Essen, Hufelandstrasse-55, Essen
      45147, Germany.
FAU - Weiss, Joshua Mitchell
AU  - Weiss JM
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics,
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA.
FAU - Kim, Han Sang
AU  - Kim HS
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics,
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA.
AD  - Yonsei Cancer Center, Division of Medical Oncology, Departments of Internal
      Medicine, and Pharmacology, Yonsei University College of Medicine, Seoul 03722,
      Korea.
FAU - Peinado, Hector
AU  - Peinado H
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics,
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA.
AD  - Microenvironment and Metastasis Laboratory, Department of Molecular Oncology,
      Spanish National Cancer Research Center (CNIO), Madrid 28029, Spain.
FAU - Lyden, David
AU  - Lyden D
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics,
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA.
LA  - eng
GR  - R01 CA169416/CA/NCI NIH HHS/United States
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
GR  - U01 CA169538/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*secretion
MH  - Cell Communication
MH  - Exosomes
MH  - Extracellular Vesicles/*metabolism
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Neoplasms/*pathology/secretion
MH  - Prognosis
MH  - Tumor Microenvironment
PMC - PMC5157696
MID - NIHMS823488
OTO - NOTNLM
OT  - *cancer
OT  - *exosomes
OT  - *extracellular vesicles
OT  - *intercellular communication
OT  - *metastasis
OT  - *microvesicles
OT  - *pre-metastatic niche
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/04/16 00:00 [received]
PHST- 2016/08/05 00:00 [revised]
PHST- 2016/10/12 00:00 [accepted]
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - 10.1016/j.ccell.2016.10.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):836-848. doi: 10.1016/j.ccell.2016.10.009.

PMID- 27960083
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver.
PG  - 834-835
LID - S1535-6108(16)30559-1 [pii]
LID - 10.1016/j.ccell.2016.11.016 [doi]
AB  - A recent study reports a novel small molecule inhibitor of MCL-1 with efficacy in
      killing MCL-1-dependent cancer cells in vitro and in vivo. With the advent of
      S63845, the targeting of BCL-2, BCL-XL, and MCL-1 is now possible in vivo, but
      optimal clinical use is yet to be determined.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Letai, Anthony
AU  - Letai A
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
      Electronic address: anthony_letai@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MCL1 protein, human)
RN  - 0 (Myeloid Cell Leukemia Sequence 1 Protein)
RN  - 0 (Pyrimidines)
RN  - 0 (S63845)
RN  - 0 (Thiophenes)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Cell Survival/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Myeloid Cell Leukemia Sequence 1 Protein/*metabolism
MH  - Neoplasms/*drug therapy/metabolism
MH  - Pyrimidines/*pharmacology/therapeutic use
MH  - Thiophenes/*pharmacology/therapeutic use
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30559-1 [pii]
AID - 10.1016/j.ccell.2016.11.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):834-835. doi: 10.1016/j.ccell.2016.11.016.

PMID- 27960082
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Origins of Brain Tumor Macrophages.
PG  - 832-833
LID - S1535-6108(16)30558-X [pii]
LID - 10.1016/j.ccell.2016.11.015 [doi]
AB  - The ontogeny of brain-tumor-associated macrophages is poorly understood. New
      findings indicate that both resident microglia and blood-derived monocytes
      generate the pool of macrophages that infiltrate brain tumors of either primary
      or metastatic origin.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - De Palma, Michele
AU  - De Palma M
AD  - Swiss Institute for Experimental Cancer Research (ISREC), School of Life
      Sciences, Ecole Polytechnique Federale de Lausanne (EPFL), 1015 Lausanne,
      Switzerland. Electronic address: michele.depalma@epfl.ch.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Biomarkers, Tumor/metabolism
MH  - Brain Neoplasms/drug therapy/*immunology/pathology
MH  - Humans
MH  - Macrophages/drug effects/metabolism/*pathology
MH  - Microglia/drug effects/metabolism/*pathology
MH  - Monocytes/pathology
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30558-X [pii]
AID - 10.1016/j.ccell.2016.11.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):832-833. doi: 10.1016/j.ccell.2016.11.015.

PMID- 27960081
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - To PFKFB3 or Not to PFKFB3, That Is the Question.
PG  - 831
LID - S1535-6108(16)30550-5 [pii]
LID - 10.1016/j.ccell.2016.11.007 [doi]
AB  - In this issue of Cancer Cell, Cantelmo et al. describe how reduction of PFKFB3
      enzyme activity can promote vascular normalization. The authors show in turn how 
      this affects vascular permeability and can ultimately improve the efficacy of
      chemotherapeutic agents.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Branco, Cristina
AU  - Branco C
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK.
FAU - Johnson, Randall S
AU  - Johnson RS
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK; Department of Cell and Molecular Biology, The Karolinska
      Institute, Stockholm S-171 77, Sweden. Electronic address: rsj33@cam.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.105 (Phosphofructokinase-2)
SB  - IM
CON - Cancer Cell. 2016 Dec 12;30(6):968-985. PMID: 27866851
CIN - Cancer Cell. 2016 Dec 12;30(6):968-985. PMID: 27866851
MH  - *Antineoplastic Agents
MH  - Humans
MH  - *Phosphofructokinase-2
EDAT- 2016/12/14 06:00
MHDA- 2017/06/24 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(16)30550-5 [pii]
AID - 10.1016/j.ccell.2016.11.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):831. doi: 10.1016/j.ccell.2016.11.007.

PMID- 27960080
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - A Novel Link between Inflammation and Cancer.
PG  - 829-830
LID - S1535-6108(16)30556-6 [pii]
LID - 10.1016/j.ccell.2016.11.013 [doi]
AB  - Immune checkpoint-blockade treatments targeting PD-1/PD-L1 have revolutionized
      cancer therapy. Hence, understanding the regulation of PD-L1 expression has major
      clinical relevance. In this issue of Cancer Cell, Lim et al. report that
      inflammation-induced and NF-kappaB-driven expression of deubiquitinating enzyme
      CSN5 leads to PD-L1 stabilization and immune suppression in tumors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Grinberg-Bleyer, Yenkel
AU  - Grinberg-Bleyer Y
AD  - Department of Microbiology & Immunology, College of Physicians and Surgeons,
      Columbia University, New York, NY 10032, USA.
FAU - Ghosh, Sankar
AU  - Ghosh S
AD  - Department of Microbiology & Immunology, College of Physicians and Surgeons,
      Columbia University, New York, NY 10032, USA. Electronic address:
      sg2715@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (NF-kappa B)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - EC 3.4.-.- (COPS5 protein, human)
RN  - EC 3.4.19.12 (COP9 Signalosome Complex)
SB  - IM
MH  - B7-H1 Antigen/*metabolism
MH  - COP9 Signalosome Complex
MH  - Cell Cycle Checkpoints
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunity, Innate
MH  - Intracellular Signaling Peptides and Proteins/genetics/*metabolism
MH  - NF-kappa B/metabolism
MH  - Neoplasms/genetics/*immunology
MH  - Peptide Hydrolases/genetics/*metabolism
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30556-6 [pii]
AID - 10.1016/j.ccell.2016.11.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):829-830. doi: 10.1016/j.ccell.2016.11.013.

PMID- 27960079
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Liver Cancer Checks in When Bile Acid Clocks Out.
PG  - 827-828
LID - S1535-6108(16)30555-4 [pii]
LID - 10.1016/j.ccell.2016.11.012 [doi]
AB  - In this issue of Cancer Cell, Kettner et al. identify the disruption of normal
      circadian rhythmicity as an independent risk factor for hepatocellular carcinoma 
      (HCC) in experimental animals and reveal opposing roles for the nuclear receptors
      FXR and CAR in disease progression from non-alcoholic fatty liver disease (NAFLD)
      to HCC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Fu, Ting
AU  - Fu T
AD  - Gene Expression Laboratory, The Salk Institute for Biological Studies, 10010
      North Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Zhao, Xuan
AU  - Zhao X
AD  - Gene Expression Laboratory, The Salk Institute for Biological Studies, 10010
      North Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Evans, Ronald M
AU  - Evans RM
AD  - Gene Expression Laboratory, The Salk Institute for Biological Studies, 10010
      North Torrey Pines Road, La Jolla, CA 92037, USA; Howard Hughes Medical
      Institute, The Salk Institute for Biological Studies, 10010 North Torrey Pines
      Road, La Jolla, CA 92037, USA. Electronic address: evans@salk.edu.
LA  - eng
GR  - P01 HL088093/HL/NHLBI NIH HHS/United States
GR  - R01 HL105278/HL/NHLBI NIH HHS/United States
GR  - R24 DK090962/DK/NIDDK NIH HHS/United States
GR  - T32 CA009370/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - R37 DK057978/DK/NIDDK NIH HHS/United States
GR  - P30 CA014195/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Bile Acids and Salts)
SB  - IM
MH  - Animals
MH  - Bile Acids and Salts/*metabolism
MH  - Carcinoma, Hepatocellular/*epidemiology
MH  - Circadian Rhythm
MH  - Disease Progression
MH  - Humans
MH  - Incidence
MH  - Liver Neoplasms/*epidemiology
MH  - Non-alcoholic Fatty Liver Disease/*complications/metabolism
MH  - Risk Factors
PMC - PMC5439430
MID - NIHMS860582
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30555-4 [pii]
AID - 10.1016/j.ccell.2016.11.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):827-828. doi: 10.1016/j.ccell.2016.11.012.

PMID- 27960078
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Dormancy Stems the Tide of Chemotherapy.
PG  - 825-826
LID - S1535-6108(16)30557-8 [pii]
LID - 10.1016/j.ccell.2016.11.014 [doi]
AB  - In this issue of Cancer Cell, Ebinger et al. describe rare, non-cycling blasts in
      acute lymphoblastic leukemia that combine the phenotypes of dormancy, stemness,
      and chemo-resistance. This novel in vivo model for dormant blasts will facilitate
      the dissection of the niche and the development of therapies targeting the
      leukemic microenvironment.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Pal, Deepali
AU  - Pal D
AD  - Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research,
      Newcastle University, Level 6, Herschel Building, Brewery Lane, Newcastle upon
      Tyne NE1 7RU, UK.
FAU - Heidenreich, Olaf
AU  - Heidenreich O
AD  - Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research,
      Newcastle University, Level 6, Herschel Building, Brewery Lane, Newcastle upon
      Tyne NE1 7RU, UK.
FAU - Vormoor, Josef
AU  - Vormoor J
AD  - Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research,
      Newcastle University, Level 6, Herschel Building, Brewery Lane, Newcastle upon
      Tyne NE1 7RU, UK. Electronic address: josef.vormoor@ncl.ac.uk.
LA  - eng
GR  - 12788/Cancer Research UK/United Kingdom
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Mutation
MH  - Neoplastic Stem Cells/drug effects/*pathology
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/genetics/pathology
MH  - Tumor Microenvironment/drug effects
EDAT- 2016/12/14 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30557-8 [pii]
AID - 10.1016/j.ccell.2016.11.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):825-826. doi: 10.1016/j.ccell.2016.11.014.

PMID- 27916615
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute
      Lymphoblastic Leukemia.
PG  - 849-862
LID - S1535-6108(16)30508-6 [pii]
LID - 10.1016/j.ccell.2016.11.002 [doi]
AB  - Tumor relapse is associated with dismal prognosis, but responsible biological
      principles remain incompletely understood. To isolate and characterize
      relapse-inducing cells, we used genetic engineering and proliferation-sensitive
      dyes in patient-derived xenografts of acute lymphoblastic leukemia (ALL). We
      identified a rare subpopulation that resembled relapse-inducing cells with
      combined properties of long-term dormancy, treatment resistance, and stemness.
      Single-cell and bulk expression profiling revealed their similarity to primary
      ALL cells isolated from pediatric and adult patients at minimal residual disease 
      (MRD). Therapeutically adverse characteristics were reversible, as resistant,
      dormant cells became sensitive to treatment and started proliferating when
      dissociated from the in vivo environment. Our data suggest that ALL patients
      might profit from therapeutic strategies that release MRD cells from the niche.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Ebinger, Sarah
AU  - Ebinger S
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Center for
      Environmental Health (HMGU), 81377 Munich, Germany.
FAU - Ozdemir, Erbey Ziya
AU  - Ozdemir EZ
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Center for
      Environmental Health (HMGU), 81377 Munich, Germany.
FAU - Ziegenhain, Christoph
AU  - Ziegenhain C
AD  - Anthropology and Human Genomics, Department Biology II, Faculty of Biology,
      Ludwig-Maximilians-Universitat Munchen, 82152 Martinsried, Germany.
FAU - Tiedt, Sebastian
AU  - Tiedt S
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Center for
      Environmental Health (HMGU), 81377 Munich, Germany.
FAU - Castro Alves, Catarina
AU  - Castro Alves C
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Center for
      Environmental Health (HMGU), 81377 Munich, Germany.
FAU - Grunert, Michaela
AU  - Grunert M
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Center for
      Environmental Health (HMGU), 81377 Munich, Germany.
FAU - Dworzak, Michael
AU  - Dworzak M
AD  - Children's Cancer Research Institute and St. Anna Kinderspital, Department of
      Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.
FAU - Lutz, Christoph
AU  - Lutz C
AD  - Department of Medicine V, University of Heidelberg, 69120 Heidelberg, Germany.
FAU - Turati, Virginia A
AU  - Turati VA
AD  - University College London Cancer Institute, London WC1E, UK.
FAU - Enver, Tariq
AU  - Enver T
AD  - University College London Cancer Institute, London WC1E, UK.
FAU - Horny, Hans-Peter
AU  - Horny HP
AD  - Institute of Pathology, Ludwig-Maximilians-Universitat Munchen, 80337 Munich,
      Germany.
FAU - Sotlar, Karl
AU  - Sotlar K
AD  - Institute of Pathology, Ludwig-Maximilians-Universitat Munchen, 80337 Munich,
      Germany.
FAU - Parekh, Swati
AU  - Parekh S
AD  - Anthropology and Human Genomics, Department Biology II, Faculty of Biology,
      Ludwig-Maximilians-Universitat Munchen, 82152 Martinsried, Germany.
FAU - Spiekermann, Karsten
AU  - Spiekermann K
AD  - Department of Internal Medicine III, University Hospital Grosshadern,
      Ludwig-Maximilians-Universitat Munchen, 81377 Munich, Germany; German Consortium 
      for Translational Cancer Research (DKTK), Partnering Site, Munich, 81377 Munich, 
      Germany.
FAU - Hiddemann, Wolfgang
AU  - Hiddemann W
AD  - Department of Internal Medicine III, University Hospital Grosshadern,
      Ludwig-Maximilians-Universitat Munchen, 81377 Munich, Germany; German Consortium 
      for Translational Cancer Research (DKTK), Partnering Site, Munich, 81377 Munich, 
      Germany.
FAU - Schepers, Aloys
AU  - Schepers A
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Center for
      Environmental Health (HMGU), 81377 Munich, Germany.
FAU - Polzer, Bernhard
AU  - Polzer B
AD  - Project Group Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and
      Experimental Medicine ITEM, 93053 Regensburg, Germany.
FAU - Kirsch, Stefan
AU  - Kirsch S
AD  - Project Group Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and
      Experimental Medicine ITEM, 93053 Regensburg, Germany.
FAU - Hoffmann, Martin
AU  - Hoffmann M
AD  - Project Group Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and
      Experimental Medicine ITEM, 93053 Regensburg, Germany.
FAU - Knapp, Bettina
AU  - Knapp B
AD  - Institute of Computational Biology, Helmholtz Zentrum Munchen, German Center for 
      Environmental Health (HMGU), 85764 Neuherberg, Germany.
FAU - Hasenauer, Jan
AU  - Hasenauer J
AD  - Institute of Computational Biology, Helmholtz Zentrum Munchen, German Center for 
      Environmental Health (HMGU), 85764 Neuherberg, Germany; Department of
      Mathematics, Technische Universitat Munchen (TUM), 85748 Munich, Germany.
FAU - Pfeifer, Heike
AU  - Pfeifer H
AD  - Department of Medicine, Hematology and Oncology, Goethe University, 60590
      Frankfurt, Germany.
FAU - Panzer-Grumayer, Renate
AU  - Panzer-Grumayer R
AD  - Children's Cancer Research Institute and St. Anna Kinderspital, Department of
      Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.
FAU - Enard, Wolfgang
AU  - Enard W
AD  - Anthropology and Human Genomics, Department Biology II, Faculty of Biology,
      Ludwig-Maximilians-Universitat Munchen, 82152 Martinsried, Germany.
FAU - Gires, Olivier
AU  - Gires O
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical
      Center, Ludwig-Maximilians-Universitat Munchen, 81377 Munich, Germany.
FAU - Jeremias, Irmela
AU  - Jeremias I
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Center for
      Environmental Health (HMGU), 81377 Munich, Germany; German Consortium for
      Translational Cancer Research (DKTK), Partnering Site, Munich, 81377 Munich,
      Germany; Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig
      Maximilians University Munchen, 80337 Munich, Germany. Electronic address:
      irmela.jeremias@helmholtz-muenchen.de.
LA  - eng
PT  - Journal Article
DEP - 20161201
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Myc protein, mouse)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/metabolism/therapeutic use
MH  - Cell Proliferation
MH  - Child
MH  - Disease-Free Survival
MH  - *Drug Resistance, Neoplasm
MH  - Gene Expression Profiling/*methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Mice
MH  - Neoplasm Recurrence, Local/genetics/*pathology
MH  - Neoplasm Transplantation
MH  - Neoplasm, Residual/genetics/pathology
MH  - Neoplastic Stem Cells/*pathology
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/*pathology
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-myc/*genetics
MH  - Sequence Analysis, RNA/*methods
MH  - Single-Cell Analysis
MH  - Tumor Cells, Cultured
PMC - PMC5156313
OTO - NOTNLM
OT  - *Cancer stem cells
OT  - *RNA single-cell sequencing
OT  - *acute lymphoblastic leukemia
OT  - *dormant tumor cells
OT  - *minimal residual disease (MRD)
OT  - *patient-derived xenograft (PDX) cells
OT  - *primary patients' ALL MRD cells
OT  - *treatment resistance
EDAT- 2016/12/06 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/06 06:00
PHST- 2015/08/19 00:00 [received]
PHST- 2016/06/11 00:00 [revised]
PHST- 2016/10/31 00:00 [accepted]
PHST- 2016/12/06 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/12/06 06:00 [entrez]
AID - S1535-6108(16)30508-6 [pii]
AID - 10.1016/j.ccell.2016.11.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):849-862. doi: 10.1016/j.ccell.2016.11.002. Epub
      2016 Dec 1.

PMID- 27889186
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.
PG  - 909-924
LID - S1535-6108(16)30494-9 [pii]
LID - 10.1016/j.ccell.2016.10.007 [doi]
AB  - Chronic jet lag induces spontaneous hepatocellular carcinoma (HCC) in wild-type
      mice following a mechanism very similar to that observed in obese humans. The
      process initiates with non-alcoholic fatty liver disease (NAFLD) that progresses 
      to steatohepatitis and fibrosis before HCC detection. This pathophysiological
      pathway is driven by jet-lag-induced genome-wide gene deregulation and global
      liver metabolic dysfunction, with nuclear receptor-controlled cholesterol/bile
      acid and xenobiotic metabolism among the top deregulated pathways. Ablation of
      farnesoid X receptor dramatically increases enterohepatic bile acid levels and
      jet-lag-induced HCC, while loss of constitutive androstane receptor (CAR), a
      well-known liver tumor promoter that mediates toxic bile acid signaling, inhibits
      NAFLD-induced hepatocarcinogenesis. Circadian disruption activates CAR by
      promoting cholestasis, peripheral clock disruption, and sympathetic dysfunction.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kettner, Nicole M
AU  - Kettner NM
AD  - Department of Pediatrics/U.S. Department of Agriculture/Agricultural Research
      Service/Children's Nutrition Research Center, Baylor College of Medicine,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, Houston, TX 77030, USA.
FAU - Voicu, Horatio
AU  - Voicu H
AD  - Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Finegold, Milton J
AU  - Finegold MJ
AD  - Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; 
      Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Coarfa, Cristian
AU  - Coarfa C
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, 
      Houston, TX 77030, USA.
FAU - Sreekumar, Arun
AU  - Sreekumar A
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, 
      Houston, TX 77030, USA.
FAU - Putluri, Nagireddy
AU  - Putluri N
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, 
      Houston, TX 77030, USA.
FAU - Katchy, Chinenye A
AU  - Katchy CA
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Lee, Choogon
AU  - Lee C
AD  - Program in Neuroscience, Florida State University, College of Medicine,
      Tallahassee, FL 32306, USA.
FAU - Moore, David D
AU  - Moore DD
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, 
      Houston, TX 77030, USA. Electronic address: moore@bcm.edu.
FAU - Fu, Loning
AU  - Fu L
AD  - Department of Pediatrics/U.S. Department of Agriculture/Agricultural Research
      Service/Children's Nutrition Research Center, Baylor College of Medicine,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor 
      College of Medicine, Houston, TX 77030, USA. Electronic address: loningf@bcm.edu.
LA  - eng
GR  - R01 CA137019/CA/NCI NIH HHS/United States
GR  - R01 DK046546/DK/NIDDK NIH HHS/United States
GR  - T32 DK007696/DK/NIDDK NIH HHS/United States
GR  - P30 CA125123/CA/NCI NIH HHS/United States
GR  - P30 DK056338/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20161123
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (constitutive androstane receptor)
RN  - 0 (farnesoid X-activated receptor)
SB  - IM
CIN - Cell Metab. 2017 Jan 10;25(1):2-4. PMID: 28076761
CIN - Hepatology. 2017 Jun;65(6):2110-2112. PMID: 28198033
MH  - Animals
MH  - Carcinoma, Hepatocellular/*genetics/metabolism
MH  - *Circadian Clocks
MH  - Disease Models, Animal
MH  - Gene Expression Regulation
MH  - Genetic Predisposition to Disease
MH  - Homeostasis
MH  - Humans
MH  - Liver/metabolism
MH  - Liver Cirrhosis/*genetics/metabolism
MH  - Liver Neoplasms/*genetics/metabolism
MH  - Metabolome
MH  - Mice
MH  - Non-alcoholic Fatty Liver Disease/complications/*genetics/metabolism
MH  - Receptors, Cytoplasmic and Nuclear/genetics/*metabolism
PMC - PMC5695235
MID - NIHMS831356
OTO - NOTNLM
OT  - *cholestasis
OT  - *chronic circadian disruption
OT  - *constitutive androstane receptor (CAR)
OT  - *farnesoid X receptor (FXR)
OT  - *fibrosis
OT  - *hepatocarcinogenesis
OT  - *non-alcoholic fatty liver disease
OT  - *non-alcoholic steatohepatitis
OT  - *social jet lag
OT  - *sympathetic dysfunction
EDAT- 2016/11/28 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/28 06:00
PHST- 2016/02/24 00:00 [received]
PHST- 2016/07/31 00:00 [revised]
PHST- 2016/10/11 00:00 [accepted]
PHST- 2016/11/28 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/11/28 06:00 [entrez]
AID - S1535-6108(16)30494-9 [pii]
AID - 10.1016/j.ccell.2016.10.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):909-924. doi: 10.1016/j.ccell.2016.10.007. Epub
      2016 Nov 23.

PMID- 27889185
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive
      Leukemogenesis.
PG  - 863-878
LID - S1535-6108(16)30506-2 [pii]
LID - 10.1016/j.ccell.2016.10.019 [doi]
AB  - The nucleoporin 98 gene (NUP98) is fused to a variety of partner genes in
      multiple hematopoietic malignancies. Here, we demonstrate that NUP98 fusion
      proteins, including NUP98-HOXA9 (NHA9), NUP98-HOXD13 (NHD13), NUP98-NSD1,
      NUP98-PHF23, and NUP98-TOP1 physically interact with mixed lineage leukemia 1
      (MLL1) and the non-specific lethal (NSL) histone-modifying complexes. Chromatin
      immunoprecipitation sequencing illustrates that NHA9 and MLL1 co-localize on
      chromatin and are found associated with Hox gene promoter regions. Furthermore,
      MLL1 is required for the proliferation of NHA9 cells in vitro and in vivo.
      Inactivation of MLL1 leads to decreased expression of genes bound by NHA9 and
      MLL1 and reverses a gene expression signature found in NUP98-rearranged human
      leukemias. Our data reveal a molecular dependency on MLL1 function in
      NUP98-fusion-driven leukemogenesis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Xu, Haiming
AU  - Xu H
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer
      Institute, and Division of Hematology/Oncology, Boston Children's Hospital,
      Harvard Medical School, Boston, MA 02215, USA. Electronic address:
      haiming_xu@dfci.harvard.edu.
FAU - Valerio, Daria G
AU  - Valerio DG
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Eisold, Meghan E
AU  - Eisold ME
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Sinha, Amit
AU  - Sinha A
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Koche, Richard P
AU  - Koche RP
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Hu, Wenhuo
AU  - Hu W
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Chen, Chun-Wei
AU  - Chen CW
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer
      Institute, and Division of Hematology/Oncology, Boston Children's Hospital,
      Harvard Medical School, Boston, MA 02215, USA.
FAU - Chu, S Haihua
AU  - Chu SH
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer
      Institute, and Division of Hematology/Oncology, Boston Children's Hospital,
      Harvard Medical School, Boston, MA 02215, USA.
FAU - Brien, Gerard L
AU  - Brien GL
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer
      Institute, and Division of Hematology/Oncology, Boston Children's Hospital,
      Harvard Medical School, Boston, MA 02215, USA.
FAU - Park, Christopher Y
AU  - Park CY
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Hsieh, James J
AU  - Hsieh JJ
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ernst, Patricia
AU  - Ernst P
AD  - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO
      80045, USA.
FAU - Armstrong, Scott A
AU  - Armstrong SA
AD  - Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer
      Institute, and Division of Hematology/Oncology, Boston Children's Hospital,
      Harvard Medical School, Boston, MA 02215, USA. Electronic address:
      scott_armstrong@dfci.harvard.edu.
LA  - eng
GR  - R01 CA119008/CA/NCI NIH HHS/United States
GR  - R01 HL090036/HL/NHLBI NIH HHS/United States
GR  - R01 CA140575/CA/NCI NIH HHS/United States
GR  - R01 CA138505/CA/NCI NIH HHS/United States
GR  - P01 CA066996/CA/NCI NIH HHS/United States
GR  - R01 CA176745/CA/NCI NIH HHS/United States
GR  - K01 CA102594/CA/NCI NIH HHS/United States
GR  - U01 CA138505/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20161123
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromatin)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Nuclear Pore Complex Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (nuclear pore complex protein 98)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.1.1.43 (Mll protein, mouse)
SB  - IM
MH  - Animals
MH  - Cell Proliferation
MH  - Chromatin/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - HEK293 Cells
MH  - Histone-Lysine N-Methyltransferase/*metabolism
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - Leukemia/*metabolism
MH  - Mice
MH  - Myeloid-Lymphoid Leukemia Protein/*metabolism
MH  - Nuclear Pore Complex Proteins/*genetics/metabolism
MH  - Oncogene Proteins, Fusion/*metabolism
MH  - Promoter Regions, Genetic
MH  - Tumor Cells, Cultured
PMC - PMC5501282
MID - NIHMS827630
OTO - NOTNLM
OT  - *Hox gene
OT  - *NUP98 fusion
OT  - *leukemia
OT  - *mixed lineage leukemia 1
OT  - *non-specific lethal histone-modifying complexes
EDAT- 2016/11/28 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/28 06:00
PHST- 2015/12/22 00:00 [received]
PHST- 2016/07/29 00:00 [revised]
PHST- 2016/10/27 00:00 [accepted]
PHST- 2016/11/28 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/11/28 06:00 [entrez]
AID - S1535-6108(16)30506-2 [pii]
AID - 10.1016/j.ccell.2016.10.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):863-878. doi: 10.1016/j.ccell.2016.10.019. Epub
      2016 Nov 23.

PMID- 27866851
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel
      Normalization, Impairs Metastasis, and Improves Chemotherapy.
PG  - 968-985
LID - S1535-6108(16)30493-7 [pii]
LID - 10.1016/j.ccell.2016.10.006 [doi]
AB  - Abnormal tumor vessels promote metastasis and impair chemotherapy. Hence, tumor
      vessel normalization (TVN) is emerging as an anti-cancer treatment. Here, we show
      that tumor endothelial cells (ECs) have a hyper-glycolytic metabolism, shunting
      intermediates to nucleotide synthesis. EC haplo-deficiency or blockade of the
      glycolytic activator PFKFB3 did not affect tumor growth, but reduced cancer cell 
      invasion, intravasation, and metastasis by normalizing tumor vessels, which
      improved vessel maturation and perfusion. Mechanistically, PFKFB3 inhibition
      tightened the vascular barrier by reducing VE-cadherin endocytosis in ECs, and
      rendering pericytes more quiescent and adhesive (via upregulation of N-cadherin) 
      through glycolysis reduction; it also lowered the expression of cancer cell
      adhesion molecules in ECs by decreasing NF-kappaB signaling. PFKFB3-blockade
      treatment also improved chemotherapy of primary and metastatic tumors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Cantelmo, Anna Rita
AU  - Cantelmo AR
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Conradi, Lena-Christin
AU  - Conradi LC
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Brajic, Aleksandra
AU  - Brajic A
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Goveia, Jermaine
AU  - Goveia J
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Kalucka, Joanna
AU  - Kalucka J
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Pircher, Andreas
AU  - Pircher A
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Chaturvedi, Pallavi
AU  - Chaturvedi P
AD  - Department of Pharmacology, University of Illinois College of Medicine, Chicago, 
      IL 60612, USA.
FAU - Hol, Johanna
AU  - Hol J
AD  - Department of Pathology, K.G. Jebsen Inflammation Research Center, Oslo
      University Hospital, University of Oslo, Oslo 0424, Norway.
FAU - Thienpont, Bernard
AU  - Thienpont B
AD  - Laboratory for Translational Genetics, Vesalius Research Center, VIB, Leuven
      3000, Belgium; Laboratory for Translational Genetics, Department of Oncology, KU 
      Leuven, Leuven 3000, Belgium.
FAU - Teuwen, Laure-Anne
AU  - Teuwen LA
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Schoors, Sandra
AU  - Schoors S
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Boeckx, Bram
AU  - Boeckx B
AD  - Laboratory for Translational Genetics, Vesalius Research Center, VIB, Leuven
      3000, Belgium; Laboratory for Translational Genetics, Department of Oncology, KU 
      Leuven, Leuven 3000, Belgium.
FAU - Vriens, Joris
AU  - Vriens J
AD  - Laboratory of Ion Channel Research and TRP Research Platform Leuven (TRPLe), KU
      Leuven, Leuven 3000, Belgium.
FAU - Kuchnio, Anna
AU  - Kuchnio A
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Veys, Koen
AU  - Veys K
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Cruys, Bert
AU  - Cruys B
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Finotto, Lise
AU  - Finotto L
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Treps, Lucas
AU  - Treps L
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Stav-Noraas, Tor Espen
AU  - Stav-Noraas TE
AD  - Department of Pathology, K.G. Jebsen Inflammation Research Center, Oslo
      University Hospital, University of Oslo, Oslo 0424, Norway.
FAU - Bifari, Francesco
AU  - Bifari F
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Stapor, Peter
AU  - Stapor P
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Decimo, Ilaria
AU  - Decimo I
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Kampen, Kim
AU  - Kampen K
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - De Bock, Katrien
AU  - De Bock K
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Haraldsen, Guttorm
AU  - Haraldsen G
AD  - Department of Pathology, K.G. Jebsen Inflammation Research Center, Oslo
      University Hospital, University of Oslo, Oslo 0424, Norway.
FAU - Schoonjans, Luc
AU  - Schoonjans L
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Rabelink, Ton
AU  - Rabelink T
AD  - Department of Nephrology, Einthoven Laboratory for Vascular Medicine, LUMC,
      Leiden University Medical Center, Leiden 2300 RC, the Netherlands.
FAU - Eelen, Guy
AU  - Eelen G
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Ghesquiere, Bart
AU  - Ghesquiere B
AD  - Metabolomics Core Facility, Department of Oncology, KU Leuven, Leuven 3000,
      Belgium; Metabolomics Core Facility, Vesalius Research Center, VIB, Leuven 3000, 
      Belgium.
FAU - Rehman, Jalees
AU  - Rehman J
AD  - Department of Pharmacology, University of Illinois College of Medicine, Chicago, 
      IL 60612, USA; Section of Cardiology, Department of Medicine, University of
      Illinois College of Medicine, Chicago, IL 60612, USA.
FAU - Lambrechts, Diether
AU  - Lambrechts D
AD  - Laboratory for Translational Genetics, Vesalius Research Center, VIB, Leuven
      3000, Belgium; Laboratory for Translational Genetics, Department of Oncology, KU 
      Leuven, Leuven 3000, Belgium.
FAU - Malik, Asrar B
AU  - Malik AB
AD  - Department of Pharmacology, University of Illinois College of Medicine, Chicago, 
      IL 60612, USA.
FAU - Dewerchin, Mieke
AU  - Dewerchin M
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium.
FAU - Carmeliet, Peter
AU  - Carmeliet P
AD  - Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU
      Leuven, Leuven 3000, Belgium; Laboratory of Angiogenesis and Vascular Metabolism,
      Vesalius Research Center, VIB, Leuven 3000, Belgium. Electronic address:
      peter.carmeliet@vib-kuleuven.be.
LA  - eng
GR  - R01 HL090152/HL/NHLBI NIH HHS/United States
GR  - T32 HL007829/HL/NHLBI NIH HHS/United States
GR  - R01 GM094220/GM/NIGMS NIH HHS/United States
GR  - R01 HL118068/HL/NHLBI NIH HHS/United States
GR  - R01 HL045638/HL/NHLBI NIH HHS/United States
GR  - P01 HL060678/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Comment
DEP - 20161117
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cadherins)
RN  - 0 (Cdh2 protein, mouse)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - EC 2.7.1.105 (PFKFB3 protein, human)
RN  - EC 2.7.1.105 (Phosphofructokinase-2)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
CON - Cancer Cell. 2016 Dec 12;30(6):831. PMID: 27960081
CIN - Trends Mol Med. 2017 Mar;23 (3):197-200. PMID: 28173976
MH  - Animals
MH  - Cadherins/genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cisplatin/*administration & dosage/pharmacology
MH  - Drug Synergism
MH  - Drug Therapy
MH  - Epithelial Cells/*metabolism/pathology
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Glycolysis/drug effects
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Mice
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neoplasm Transplantation
MH  - Neoplasms/blood supply/drug therapy/*metabolism
MH  - Phosphofructokinase-2/*antagonists & inhibitors
MH  - Tamoxifen/*administration & dosage/pharmacology
PMC - PMC5675554
MID - NIHMS900017
OTO - NOTNLM
OT  - *angiogenesis
OT  - *chemotherapy
OT  - *glycolysis
OT  - *metastasis
OT  - *tumor endothelial cell metabolism
OT  - *tumor vessel normalization
EDAT- 2016/11/22 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/22 06:00
PHST- 2015/06/06 00:00 [received]
PHST- 2016/06/30 00:00 [revised]
PHST- 2016/10/04 00:00 [accepted]
PHST- 2016/11/22 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/11/22 06:00 [entrez]
AID - S1535-6108(16)30493-7 [pii]
AID - 10.1016/j.ccell.2016.10.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):968-985. doi: 10.1016/j.ccell.2016.10.006. Epub
      2016 Nov 17.

PMID- 27866850
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Dec 12
TI  - Deubiquitination and Stabilization of PD-L1 by CSN5.
PG  - 925-939
LID - S1535-6108(16)30497-4 [pii]
LID - 10.1016/j.ccell.2016.10.010 [doi]
AB  - Pro-inflammatory cytokines produced in the tumor microenvironment lead to
      eradication of anti-tumor immunity and enhanced tumor cell survival. In the
      current study, we identified tumor necrosis factor alpha (TNF-alpha) as a major
      factor triggering cancer cell immunosuppression against T cell surveillance via
      stabilization of programmed cell death-ligand 1 (PD-L1). We demonstrated that
      COP9 signalosome 5 (CSN5), induced by NF-kappaB p65, is required for
      TNF-alpha-mediated PD-L1 stabilization in cancer cells. CSN5 inhibits the
      ubiquitination and degradation of PD-L1. Inhibition of CSN5 by curcumin
      diminished cancer cell PD-L1 expression and sensitized cancer cells to anti-CTLA4
      therapy.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lim, Seung-Oe
AU  - Lim SO
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Li, Chia-Wei
AU  - Li CW
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Xia, Weiya
AU  - Xia W
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Cha, Jong-Ho
AU  - Cha JH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Tumor Microenvironment Global Core Research Center, College of Pharmacy,
      Seoul National University, Seoul 151-742, Korea.
FAU - Chan, Li-Chuan
AU  - Chan LC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center, Houston, TX 77030, USA.
FAU - Wu, Yun
AU  - Wu Y
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Chang, Shih-Shin
AU  - Chang SS
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center, Houston, TX 77030, USA.
FAU - Lin, Wan-Chi
AU  - Lin WC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Hsu, Jung-Mao
AU  - Hsu JM
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Hsu, Yi-Hsin
AU  - Hsu YH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Kim, Taewan
AU  - Kim T
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Chang, Wei-Chao
AU  - Chang WC
AD  - Center for Molecular Medicine and Graduate Institute of Cancer Biology, China
      Medical University, Taichung 404, Taiwan.
FAU - Hsu, Jennifer L
AU  - Hsu JL
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Center for Molecular Medicine and Graduate Institute of Cancer Biology,
      China Medical University, Taichung 404, Taiwan.
FAU - Yamaguchi, Hirohito
AU  - Yamaguchi H
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Ding, Qingqing
AU  - Ding Q
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Yang, Yi
AU  - Yang Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA.
FAU - Chen, Chung-Hsuan
AU  - Chen CH
AD  - Genomics Research Center, Academia Sinica, Nankang, 115 Taipei, Taiwan.
FAU - Sahin, Aysegul A
AU  - Sahin AA
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Yu, Dihua
AU  - Yu D
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center, Houston, TX 77030, USA.
FAU - Hortobagyi, Gabriel N
AU  - Hortobagyi GN
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA; Graduate School of Biomedical Sciences, The University of Texas Health
      Science Center, Houston, TX 77030, USA; Center for Molecular Medicine and
      Graduate Institute of Cancer Biology, China Medical University, Taichung 404,
      Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan.
      Electronic address: mhung@mdanderson.org.
LA  - eng
GR  - 27303C0140/ES/NIEHS NIH HHS/United States
GR  - P01 CA099031/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA109311/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20161117
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - EC 3.4.-.- (COPS5 protein, human)
RN  - EC 3.4.19.12 (COP9 Signalosome Complex)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - Animals
MH  - B7-H1 Antigen/chemistry/*metabolism
MH  - COP9 Signalosome Complex
MH  - Cell Line, Tumor
MH  - Curcumin/pharmacology
MH  - Female
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Mice
MH  - NF-kappa B/*metabolism
MH  - Neoplasm Transplantation
MH  - Neoplasms/*metabolism
MH  - Peptide Hydrolases/*metabolism
MH  - Protein Stability
MH  - Tumor Necrosis Factor-alpha/*metabolism
MH  - Ubiquitination
PMC - PMC5171205
MID - NIHMS834380
OTO - NOTNLM
OT  - *CSN5
OT  - *PD-L1
OT  - *TNF-alpha
OT  - *anti-CTLA4
OT  - *curcumin
OT  - *deubiquitination
EDAT- 2016/11/22 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/22 06:00
PHST- 2016/03/24 00:00 [received]
PHST- 2016/07/01 00:00 [revised]
PHST- 2016/10/24 00:00 [accepted]
PHST- 2016/11/22 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/11/22 06:00 [entrez]
AID - S1535-6108(16)30497-4 [pii]
AID - 10.1016/j.ccell.2016.10.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Dec 12;30(6):925-939. doi: 10.1016/j.ccell.2016.10.010. Epub
      2016 Nov 17.

PMID- 27908736
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of
      Acute Myelogenous Leukemia.
PG  - 792-805
LID - S1535-6108(16)30490-1 [pii]
LID - 10.1016/j.ccell.2016.10.003 [doi]
AB  - Acute myelogenous leukemia (AML) is an aggressive disease associated with drug
      resistance and relapse. To improve therapeutic strategies, it is critical to
      better understand the mechanisms that underlie AML progression. Here we show that
      the integrin binding glycoprotein CD98 plays a central role in AML. CD98 promotes
      AML propagation and lethality by driving engagement of leukemia cells with their 
      microenvironment and maintaining leukemic stem cells. Further, delivery of a
      humanized anti-CD98 antibody blocks growth of patient-derived AML, highlighting
      the importance of this pathway in human disease. These findings indicate that
      microenvironmental interactions are key regulators of AML and that disrupting
      these signals with targeted inhibitors such as CD98 antibodies may be a valuable 
      therapeutic approach for adults and children with this disease.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Bajaj, Jeevisha
AU  - Bajaj J
AD  - Department of Pharmacology, University of California San Diego School of
      Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, 
      La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego
      School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University
      of California San Diego School of Medicine, La Jolla, CA 92093, USA.
FAU - Konuma, Takaaki
AU  - Konuma T
AD  - Department of Pharmacology, University of California San Diego School of
      Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, 
      La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego
      School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University
      of California San Diego School of Medicine, La Jolla, CA 92093, USA.
FAU - Lytle, Nikki K
AU  - Lytle NK
AD  - Department of Pharmacology, University of California San Diego School of
      Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, 
      La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego
      School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University
      of California San Diego School of Medicine, La Jolla, CA 92093, USA.
FAU - Kwon, Hyog Young
AU  - Kwon HY
AD  - Department of Pharmacology, University of California San Diego School of
      Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, 
      La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego
      School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University
      of California San Diego School of Medicine, La Jolla, CA 92093, USA.
FAU - Ablack, Jailal N
AU  - Ablack JN
AD  - Department of Medicine, University of California San Diego School of Medicine, La
      Jolla, CA 92093, USA.
FAU - Cantor, Joseph M
AU  - Cantor JM
AD  - Department of Medicine, University of California San Diego School of Medicine, La
      Jolla, CA 92093, USA.
FAU - Rizzieri, David
AU  - Rizzieri D
AD  - Division of Cell Therapy, Department of Medicine, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Chuah, Charles
AU  - Chuah C
AD  - Department of Haematology, Singapore General Hospital, Cancer and Stem Cell
      Biology Program, Duke-NUS Graduate Medical School, Singapore 169857, Singapore.
FAU - Oehler, Vivian G
AU  - Oehler VG
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, WA 98109,
      USA.
FAU - Broome, Elizabeth H
AU  - Broome EH
AD  - Moores Cancer Center, University of California San Diego School of Medicine, La
      Jolla, CA 92093, USA; Department of Pathology, University of California San Diego
      School of Medicine, La Jolla, CA 92093, USA.
FAU - Ball, Edward D
AU  - Ball ED
AD  - Moores Cancer Center, University of California San Diego School of Medicine, La
      Jolla, CA 92093, USA; Department of Medicine, Blood and Marrow Transplantation
      Division, University of California San Diego School of Medicine, La Jolla, CA
      92093, USA.
FAU - van der Horst, Edward H
AU  - van der Horst EH
AD  - Igenica Biotherapeutics Inc., Burlingame, CA 94010, USA.
FAU - Ginsberg, Mark H
AU  - Ginsberg MH
AD  - Moores Cancer Center, University of California San Diego School of Medicine, La
      Jolla, CA 92093, USA; Department of Medicine, University of California San Diego 
      School of Medicine, La Jolla, CA 92093, USA. Electronic address:
      mhginsberg@ucsd.edu.
FAU - Reya, Tannishtha
AU  - Reya T
AD  - Department of Pharmacology, University of California San Diego School of
      Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, 
      La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego
      School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University
      of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic
      address: treya@ucsd.edu.
LA  - eng
GR  - R01 HL117807/HL/NHLBI NIH HHS/United States
GR  - T32 HL086344/HL/NHLBI NIH HHS/United States
GR  - DP1 CA174422/CA/NCI NIH HHS/United States
GR  - R01 HL097767/HL/NHLBI NIH HHS/United States
GR  - T32 GM007752/GM/NIGMS NIH HHS/United States
GR  - F31 CA206416/CA/NCI NIH HHS/United States
GR  - P01 HL078784/HL/NHLBI NIH HHS/United States
GR  - R01 DK099335/DK/NIDDK NIH HHS/United States
GR  - R35 CA197699/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
DEP - 20161027
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies)
RN  - 0 (Fusion Regulatory Protein-1)
SB  - IM
CON - Cancer Cell. 2017 Feb 13;31(2):159-161. PMID: 28196587
CIN - Cancer Cell. 2016 Nov 14;30(5):662-664. PMID: 27846387
MH  - Animals
MH  - Antibodies/*administration & dosage/pharmacology
MH  - Cell Adhesion
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Fusion Regulatory Protein-1/antagonists & inhibitors/*genetics
MH  - Gene Knockout Techniques
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/genetics/pathology
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Neoplastic Stem Cells/*pathology
PMC - PMC5137811
MID - NIHMS821676
OTO - NOTNLM
OT  - *CD98
OT  - *SLC3A2
OT  - *acute myelogenous leukemia
OT  - *adhesion
OT  - *cancer
OT  - *cancer stem cell
OT  - *imaging
OT  - *integrin
OT  - *leukemia
OT  - *microenvironment
EDAT- 2016/12/03 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/03 06:00
PHST- 2015/07/23 00:00 [received]
PHST- 2016/05/06 00:00 [revised]
PHST- 2016/10/03 00:00 [accepted]
PHST- 2016/12/03 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30490-1 [pii]
AID - 10.1016/j.ccell.2016.10.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):792-805. doi: 10.1016/j.ccell.2016.10.003. Epub
      2016 Oct 27.

PMID- 27908735
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and 
      Metastasis.
PG  - 694-707
LID - S1535-6108(16)30491-3 [pii]
LID - 10.1016/j.ccell.2016.10.004 [doi]
AB  - RNA binding proteins (RBPs) modulate cancer progression through poorly understood
      mechanisms. Here we show that the RBP UNR/CSDE1 is overexpressed in melanoma
      tumors and promotes invasion and metastasis. iCLIP sequencing, RNA sequencing,
      and ribosome profiling combined with in silico studies unveiled sets of
      pro-metastatic factors coordinately regulated by UNR as part of RNA regulons. In 
      addition to RNA steady-state levels, UNR was found to control many of its targets
      at the level of translation elongation/termination. Key pro-oncogenic targets of 
      UNR included VIM and RAC1, as validated by loss- and gain-of-function studies.
      Our results identify UNR as an oncogenic modulator of melanoma progression,
      unravel the underlying molecular mechanisms, and identify potential targets for
      this therapeutically challenging malignancy.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Wurth, Laurence
AU  - Wurth L
AD  - Gene Regulation, Stem Cells and Cancer Programme, Centre for Genomic Regulation
      (CRG), The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain;
      Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
FAU - Papasaikas, Panagiotis
AU  - Papasaikas P
AD  - Gene Regulation, Stem Cells and Cancer Programme, Centre for Genomic Regulation
      (CRG), The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain;
      Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
FAU - Olmeda, David
AU  - Olmeda D
AD  - Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO),
      28029 Madrid, Spain.
FAU - Bley, Nadine
AU  - Bley N
AD  - Section Molecular Cell Biology, Institute of Molecular Medicine (IMM),
      Martin-Luther-University (MLU), 06120 Halle, Germany.
FAU - Calvo, Guadalupe T
AU  - Calvo GT
AD  - Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO),
      28029 Madrid, Spain.
FAU - Guerrero, Santiago
AU  - Guerrero S
AD  - Gene Regulation, Stem Cells and Cancer Programme, Centre for Genomic Regulation
      (CRG), The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain;
      Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
FAU - Cerezo-Wallis, Daniela
AU  - Cerezo-Wallis D
AD  - Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO),
      28029 Madrid, Spain.
FAU - Martinez-Useros, Javier
AU  - Martinez-Useros J
AD  - Translational Oncology Division, Oncohealth Institute - Health Research Institute
      - University Hospital "Fundacion Jimenez Diaz", 28040 Madrid, Spain.
FAU - Garcia-Fernandez, Maria
AU  - Garcia-Fernandez M
AD  - Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO),
      28029 Madrid, Spain.
FAU - Huttelmaier, Stefan
AU  - Huttelmaier S
AD  - Section Molecular Cell Biology, Institute of Molecular Medicine (IMM),
      Martin-Luther-University (MLU), 06120 Halle, Germany.
FAU - Soengas, Maria S
AU  - Soengas MS
AD  - Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO),
      28029 Madrid, Spain.
FAU - Gebauer, Fatima
AU  - Gebauer F
AD  - Gene Regulation, Stem Cells and Cancer Programme, Centre for Genomic Regulation
      (CRG), The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain;
      Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain. Electronic address:
      fatima.gebauer@crg.eu.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20161027
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CSDE1 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (RAC1 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Vimentin)
RN  - EC 3.6.5.2 (rac1 GTP-Binding Protein)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):655-657. PMID: 27846383
CIN - Cancer Cell. 2016 Nov 14;30(5):655-657. PMID: 27846383
MH  - Animals
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Disease Progression
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Melanoma/genetics/metabolism/*pathology
MH  - Mice
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neoplasm Transplantation
MH  - RNA Processing, Post-Transcriptional
MH  - RNA-Binding Proteins/genetics/*metabolism
MH  - Ribosomes/genetics
MH  - Sequence Analysis, RNA/methods
MH  - *Up-Regulation
MH  - Vimentin/*genetics
MH  - rac1 GTP-Binding Protein/*genetics
OTO - NOTNLM
OT  - *CSDE1
OT  - *RAC1
OT  - *UNR
OT  - *Vimentin
OT  - *iCLIP
OT  - *melanoma
OT  - *metastasis
OT  - *ribosome profiling
OT  - *translation elongation
EDAT- 2016/12/03 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/12/03 06:00
PHST- 2015/09/07 00:00 [received]
PHST- 2016/06/13 00:00 [revised]
PHST- 2016/10/03 00:00 [accepted]
PHST- 2016/12/03 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30491-3 [pii]
AID - 10.1016/j.ccell.2016.10.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):694-707. doi: 10.1016/j.ccell.2016.10.004. Epub
      2016 Oct 27.

PMID- 27846394
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin
      B1/CDK1-Phosphorylated Nuclear iASPP.
PG  - 822-823
LID - S1535-6108(16)30454-8 [pii]
LID - 10.1016/j.ccell.2016.09.019 [doi]
FAU - Lu, Min
AU  - Lu M
FAU - Breyssens, Hilde
AU  - Breyssens H
FAU - Salter, Victoria
AU  - Salter V
FAU - Zhong, Shan
AU  - Zhong S
FAU - Hu, Ying
AU  - Hu Y
FAU - Baer, Caroline
AU  - Baer C
FAU - Ratnayaka, Indrika
AU  - Ratnayaka I
FAU - Sullivan, Alex
AU  - Sullivan A
FAU - Brown, Nicholas R
AU  - Brown NR
FAU - Endicott, Jane
AU  - Endicott J
FAU - Knapp, Stefan
AU  - Knapp S
FAU - Kessler, Benedikt M
AU  - Kessler BM
FAU - Middleton, Mark R
AU  - Middleton MR
FAU - Siebold, Christian
AU  - Siebold C
FAU - Jones, E Yvonne
AU  - Jones EY
FAU - Sviderskaya, Elena V
AU  - Sviderskaya EV
FAU - Cebon, Jonathan
AU  - Cebon J
FAU - John, Thomas
AU  - John T
FAU - Caballero, Otavia L
AU  - Caballero OL
FAU - Goding, Colin R
AU  - Goding CR
FAU - Lu, Xin
AU  - Lu X
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2013 May 13;23 (5):618-33. PMID: 23623661
EDAT- 2016/11/16 06:00
MHDA- 2016/11/16 06:01
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2016/11/16 06:01 [medline]
AID - S1535-6108(16)30454-8 [pii]
AID - 10.1016/j.ccell.2016.09.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):822-823. doi: 10.1016/j.ccell.2016.09.019.

PMID- 27846393
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180209
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B
      Cell Lineage.
PG  - 806-821
LID - S1535-6108(16)30449-4 [pii]
LID - 10.1016/j.ccell.2016.09.014 [doi]
AB  - We analyzed the in silico purified DNA methylation signatures of 82 mantle cell
      lymphomas (MCL) in comparison with cell subpopulations spanning the entire B cell
      lineage. We identified two MCL subgroups, respectively carrying epigenetic
      imprints of germinal-center-inexperienced and germinal-center-experienced B
      cells, and we found that DNA methylation profiles during lymphomagenesis are
      largely influenced by the methylation dynamics in normal B cells. An integrative 
      epigenomic approach revealed 10,504 differentially methylated regions in
      regulatory elements marked by H3K27ac in MCL primary cases, including a distant
      enhancer showing de novo looping to the MCL oncogene SOX11. Finally, we observed 
      that the magnitude of DNA methylation changes per case is highly variable and
      serves as an independent prognostic factor for MCL outcome.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Queiros, Ana C
AU  - Queiros AC
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain.
FAU - Beekman, Renee
AU  - Beekman R
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona
      08036, Spain.
FAU - Vilarrasa-Blasi, Roser
AU  - Vilarrasa-Blasi R
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain.
FAU - Duran-Ferrer, Marti
AU  - Duran-Ferrer M
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain.
FAU - Clot, Guillem
AU  - Clot G
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona
      08036, Spain.
FAU - Merkel, Angelika
AU  - Merkel A
AD  - Centro Nacional de Analisis Genomico, Parc Cientific de Barcelona, Barcelona
      08028, Spain.
FAU - Raineri, Emanuele
AU  - Raineri E
AD  - Centro Nacional de Analisis Genomico, Parc Cientific de Barcelona, Barcelona
      08028, Spain.
FAU - Russinol, Nuria
AU  - Russinol N
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS),
      Barcelona 08036, Spain.
FAU - Castellano, Giancarlo
AU  - Castellano G
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona
      08036, Spain.
FAU - Bea, Silvia
AU  - Bea S
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona
      08036, Spain.
FAU - Navarro, Alba
AU  - Navarro A
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona
      08036, Spain.
FAU - Kulis, Marta
AU  - Kulis M
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain.
FAU - Verdaguer-Dot, Nuria
AU  - Verdaguer-Dot N
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS),
      Barcelona 08036, Spain.
FAU - Jares, Pedro
AU  - Jares P
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain; Unidad de Genomica, IDIBAPS, Barcelona 08036, Spain.
FAU - Enjuanes, Anna
AU  - Enjuanes A
AD  - Unidad de Genomica, IDIBAPS, Barcelona 08036, Spain.
FAU - Calasanz, Maria Jose
AU  - Calasanz MJ
AD  - Department of Genetics, University of Navarra, Pamplona 31008, Spain.
FAU - Bergmann, Anke
AU  - Bergmann A
AD  - Institute of Human Genetics, Christian-Albrechts University, Kiel 24105, Germany;
      Department of Pediatrics, Christian-Albrechts University & University Hospital
      Schleswig-Holstein, Kiel 24105, Germany.
FAU - Vater, Inga
AU  - Vater I
AD  - Institute of Human Genetics, Christian-Albrechts University, Kiel 24105, Germany.
FAU - Salaverria, Itziar
AU  - Salaverria I
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona
      08036, Spain.
FAU - van de Werken, Harmen J G
AU  - van de Werken HJG
AD  - Department of Cell Biology, Erasmus MC, Rotterdam 3015 CN, the Netherlands;
      Cancer Computational Biology Center, Erasmus MC, Rotterdam 3015 CN, the
      Netherlands; Department of Urology, Erasmus MC, Rotterdam 3015 CN, the
      Netherlands.
FAU - Wilson, Wyndham H
AU  - Wilson WH
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Datta, Avik
AU  - Datta A
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute
      (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK.
FAU - Flicek, Paul
AU  - Flicek P
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute
      (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK.
FAU - Royo, Romina
AU  - Royo R
AD  - Joint Program on Computational Biology, Barcelona Supercomputing Center (BSC) and
      Institute of Research in Biomedicine (IRB), Barcelona Science Park, Barcelona
      08034, Spain.
FAU - Martens, Joost
AU  - Martens J
AD  - Molecular Biology, NCMLS, FNWI, Radboud University, Nijmegen 6500 HB, the
      Netherlands.
FAU - Gine, Eva
AU  - Gine E
AD  - Servicio de Hematologia, Hospital Clinic, IDIBAPS, Barcelona 08036, Spain.
FAU - Lopez-Guillermo, Armando
AU  - Lopez-Guillermo A
AD  - Servicio de Hematologia, Hospital Clinic, IDIBAPS, Barcelona 08036, Spain.
FAU - Stunnenberg, Hendrik G
AU  - Stunnenberg HG
AD  - Molecular Biology, NCMLS, FNWI, Radboud University, Nijmegen 6500 HB, the
      Netherlands.
FAU - Klapper, Wolfram
AU  - Klapper W
AD  - Hematopathology Section and Lymph Node Registry, Christian-Albrecht University,
      Kiel 24105, Germany.
FAU - Pott, Christiane
AU  - Pott C
AD  - Second Medical Department, University Hospital Schleswig-Holstein, Kiel 24116,
      Germany.
FAU - Heath, Simon
AU  - Heath S
AD  - Centro Nacional de Analisis Genomico, Parc Cientific de Barcelona, Barcelona
      08028, Spain.
FAU - Gut, Ivo G
AU  - Gut IG
AD  - Centro Nacional de Analisis Genomico, Parc Cientific de Barcelona, Barcelona
      08028, Spain.
FAU - Siebert, Reiner
AU  - Siebert R
AD  - Institute of Human Genetics, Christian-Albrechts University, Kiel 24105, Germany.
FAU - Campo, Elias
AU  - Campo E
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS),
      Barcelona 08036, Spain; Unidad de Hematopatologia, Servicio de Anatomia
      Patologica, Hospital Clinic, Barcelona 08036, Spain.
FAU - Martin-Subero, Jose I
AU  - Martin-Subero JI
AD  - Departamento de Fundamentos Clinicos, Universitat de Barcelona, Barcelona 08036, 
      Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS),
      Barcelona 08036, Spain. Electronic address: imartins@clinic.ub.es.
LA  - eng
GR  - 16-1285/Worldwide Cancer Research/United Kingdom
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (SOX11 protein, human)
RN  - 0 (SOXC Transcription Factors)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):665-667. PMID: 27846388
MH  - B-Lymphocytes/metabolism
MH  - Cell Line, Tumor
MH  - Cell Lineage
MH  - Computer Simulation
MH  - *DNA Methylation
MH  - *Enhancer Elements, Genetic
MH  - Epigenesis, Genetic
MH  - Epigenomics/*methods
MH  - Gene Expression Regulation, Neoplastic
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - Lymphoma, Mantle-Cell/*genetics
MH  - SOXC Transcription Factors/genetics
PMC - PMC5805090
MID - EMS75840
OTO - NOTNLM
OT  - *ChIP-seq
OT  - *DNA looping
OT  - *DNA methylation
OT  - *SOX11
OT  - *chromatin
OT  - *enhancer
OT  - *epigenomics
OT  - *lymphoma
OT  - *mantle cell lymphoma
OT  - *whole-genome bisulfite sequencing
EDAT- 2016/11/16 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/02/22 00:00 [received]
PHST- 2016/07/18 00:00 [revised]
PHST- 2016/09/19 00:00 [accepted]
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30449-4 [pii]
AID - 10.1016/j.ccell.2016.09.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):806-821. doi: 10.1016/j.ccell.2016.09.014.

PMID- 27846392
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy 
      in Blastic Plasmacytoid Dendritic Cell Neoplasm.
PG  - 764-778
LID - S1535-6108(16)30489-5 [pii]
LID - 10.1016/j.ccell.2016.10.002 [doi]
AB  - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and largely
      incurable hematologic malignancy originating from plasmacytoid dendritic cells
      (pDCs). Using RNAi screening, we identified the E-box transcription factor TCF4
      as a master regulator of the BPDCN oncogenic program. TCF4 served as a faithful
      diagnostic marker of BPDCN, and its downregulation caused the loss of the
      BPDCN-specific gene expression program and apoptosis. High-throughput drug
      screening revealed that bromodomain and extra-terminal domain inhibitors (BETis) 
      induced BPDCN apoptosis, which was attributable to disruption of a BPDCN-specific
      transcriptional network controlled by TCF4-dependent super-enhancers. BETis
      retarded the growth of BPDCN xenografts, supporting their clinical evaluation in 
      this recalcitrant malignancy.
CI  - Published by Elsevier Inc.
FAU - Ceribelli, Michele
AU  - Ceribelli M
AD  - Lymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892,
      USA; Division of Preclinical Innovation, National Center for Advancing
      Translational Sciences, NIH, Bethesda, MD 20892, USA.
FAU - Hou, Zhiying Esther
AU  - Hou ZE
AD  - Department of Microbiology and Immunology, Columbia University Medical Center,
      New York, NY 10032, USA.
FAU - Kelly, Priscilla N
AU  - Kelly PN
AD  - Lymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892,
      USA.
FAU - Huang, Da Wei
AU  - Huang DW
AD  - Lymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892,
      USA.
FAU - Wright, George
AU  - Wright G
AD  - Biometric Research Branch, National Cancer Institute, NIH, Bethesda, MD 20892,
      USA.
FAU - Ganapathi, Karthik
AU  - Ganapathi K
AD  - Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
FAU - Evbuomwan, Moses O
AU  - Evbuomwan MO
AD  - Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
FAU - Pittaluga, Stefania
AU  - Pittaluga S
AD  - Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
FAU - Shaffer, Arthur L
AU  - Shaffer AL
AD  - Lymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892,
      USA.
FAU - Marcucci, Guido
AU  - Marcucci G
AD  - Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
      National Medical Center, Duarte, CA 91010, USA.
FAU - Forman, Stephen J
AU  - Forman SJ
AD  - Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
      National Medical Center, Duarte, CA 91010, USA.
FAU - Xiao, Wenming
AU  - Xiao W
AD  - Division of Bioinformatics and Biostatistics, NCTR/FDA, Jefferson, AR 72079, USA.
FAU - Guha, Rajarshi
AU  - Guha R
AD  - Division of Preclinical Innovation, National Center for Advancing Translational
      Sciences, NIH, Bethesda, MD 20892, USA.
FAU - Zhang, Xiaohu
AU  - Zhang X
AD  - Division of Preclinical Innovation, National Center for Advancing Translational
      Sciences, NIH, Bethesda, MD 20892, USA.
FAU - Ferrer, Marc
AU  - Ferrer M
AD  - Division of Preclinical Innovation, National Center for Advancing Translational
      Sciences, NIH, Bethesda, MD 20892, USA.
FAU - Chaperot, Laurence
AU  - Chaperot L
AD  - R&D Laboratory, EFS Rhone-Alpes Grenoble, La Tronche 38701, France; Institute for
      Advanced Biosciences UGA, INSERM U1209, CNRS UMR 5309, Grenoble 38000, France.
FAU - Plumas, Joel
AU  - Plumas J
AD  - R&D Laboratory, EFS Rhone-Alpes Grenoble, La Tronche 38701, France; Institute for
      Advanced Biosciences UGA, INSERM U1209, CNRS UMR 5309, Grenoble 38000, France.
FAU - Jaffe, Elaine S
AU  - Jaffe ES
AD  - Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
FAU - Thomas, Craig J
AU  - Thomas CJ
AD  - Division of Preclinical Innovation, National Center for Advancing Translational
      Sciences, NIH, Bethesda, MD 20892, USA.
FAU - Reizis, Boris
AU  - Reizis B
AD  - Department of Microbiology and Immunology, Columbia University Medical Center,
      New York, NY 10032, USA; Department of Pathology, New York University School of
      Medicine, New York, NY 10016, USA. Electronic address: boris.reizis@nyumc.org.
FAU - Staudt, Louis M
AU  - Staudt LM
AD  - Lymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892,
      USA. Electronic address: lstaudt@mail.nih.gov.
LA  - eng
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - R01 AI072571/AI/NIAID NIH HHS/United States
GR  - U54 CA143930/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BRD4 protein, human)
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (TCF4 protein, human)
RN  - 0 (Transcription Factor 4)
RN  - 0 (Transcription Factors)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):659-660. PMID: 27846385
MH  - Animals
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/antagonists &
      inhibitors/*genetics
MH  - Cell Line, Tumor
MH  - Dendritic Cells/metabolism/*pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Regulatory Networks
MH  - HL-60 Cells
MH  - Hematologic Neoplasms/*drug therapy/genetics/pathology
MH  - Humans
MH  - Jurkat Cells
MH  - Mice
MH  - Nuclear Proteins/*genetics
MH  - RNA, Small Interfering/*administration & dosage/pharmacology
MH  - Small Molecule Libraries/*administration & dosage/pharmacology
MH  - Transcription Factor 4
MH  - Transcription Factors/antagonists & inhibitors/*genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC5175469
MID - NIHMS836217
OTO - NOTNLM
OT  - *BPDCN
OT  - *BRD4
OT  - *HTS
OT  - *TCF4
OT  - *super-enhancer
EDAT- 2016/11/16 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/02/05 00:00 [received]
PHST- 2016/07/27 00:00 [revised]
PHST- 2016/10/03 00:00 [accepted]
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30489-5 [pii]
AID - 10.1016/j.ccell.2016.10.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):764-778. doi: 10.1016/j.ccell.2016.10.002.

PMID- 27846391
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B
      Acute Lymphoblastic Leukemia.
PG  - 737-749
LID - S1535-6108(16)30495-0 [pii]
LID - 10.1016/j.ccell.2016.10.008 [doi]
AB  - The t(4;11)(q21;q23) fuses mixed-lineage leukemia (MLL) to AF4, the most common
      MLL-fusion partner. Here we show that MLL fused to murine Af4, highly conserved
      with human AF4, produces high-titer retrovirus permitting efficient transduction 
      of human CD34(+) cells, thereby generating a model of t(4;11) pro-B acute
      lymphoblastic leukemia (ALL) that fully recapitulates the immunophenotypic and
      molecular aspects of the disease. MLL-Af4 induces a B ALL distinct from MLL-AF9
      through differential genomic target binding of the fusion proteins leading to
      specific gene expression patterns. MLL-Af4 cells can assume a myeloid state under
      environmental pressure but retain lymphoid-lineage potential. Such incongruity
      was also observed in t(4;11) patients in whom leukemia evaded CD19-directed
      therapy by undergoing myeloid-lineage switch. Our model provides a valuable tool 
      to unravel the pathogenesis of MLL-AF4 leukemogenesis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lin, Shan
AU  - Lin S
AD  - Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH 45229, USA.
FAU - Luo, Roger T
AU  - Luo RT
AD  - Department of Medicine, Section of Hematology/Oncology, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Ptasinska, Anetta
AU  - Ptasinska A
AD  - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham
      B15 2TT, UK.
FAU - Kerry, Jon
AU  - Kerry J
AD  - MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, NIHR 
      Oxford Biomedical Research Centre Programme, University of Oxford, Oxford OX3
      9DS, UK.
FAU - Assi, Salam A
AU  - Assi SA
AD  - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham
      B15 2TT, UK.
FAU - Wunderlich, Mark
AU  - Wunderlich M
AD  - Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH 45229, USA.
FAU - Imamura, Toshihiko
AU  - Imamura T
AD  - Department of Medicine, Section of Hematology/Oncology, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Kaberlein, Joseph J
AU  - Kaberlein JJ
AD  - Department of Medicine, Section of Hematology/Oncology, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Rayes, Ahmad
AU  - Rayes A
AD  - Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH 45229, USA.
FAU - Althoff, Mark J
AU  - Althoff MJ
AD  - Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH 45229, USA.
FAU - Anastasi, John
AU  - Anastasi J
AD  - Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
FAU - O'Brien, Maureen M
AU  - O'Brien MM
AD  - Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH 45229, USA.
FAU - Meetei, Amom Ruhikanta
AU  - Meetei AR
AD  - Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH 45229, USA.
FAU - Milne, Thomas A
AU  - Milne TA
AD  - MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, NIHR 
      Oxford Biomedical Research Centre Programme, University of Oxford, Oxford OX3
      9DS, UK.
FAU - Bonifer, Constanze
AU  - Bonifer C
AD  - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham
      B15 2TT, UK.
FAU - Mulloy, James C
AU  - Mulloy JC
AD  - Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH 45229, USA. Electronic address: james.mulloy@cchmc.org.
FAU - Thirman, Michael J
AU  - Thirman MJ
AD  - Department of Medicine, Section of Hematology/Oncology, University of Chicago,
      Chicago, IL 60637, USA. Electronic address: mthirman@medicine.bsd.uchicago.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, CD34)
RN  - 0 (MLL protein, human)
RN  - 0 (MLL-AF4 fusion protein, human)
RN  - 0 (MLL-AF9 fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):657-658. PMID: 27846384
MH  - Animals
MH  - Antigens, CD34/*metabolism
MH  - Cell Lineage
MH  - Cell Transformation, Neoplastic/*genetics
MH  - Disease Models, Animal
MH  - Drug Resistance, Neoplasm
MH  - Histone-Lysine N-Methyltransferase/*genetics
MH  - Humans
MH  - Mice
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics/metabolism
MH  - Oncogene Proteins, Fusion/genetics/metabolism
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*genetics/metabolism
MH  - *Translocation, Genetic
OTO - NOTNLM
OT  - *MLL-AF4
OT  - *acquired resistance to targeted therapy
OT  - *acute lymphoblastic leukemia
OT  - *chimeric fusion proteins
OT  - *mouse models of cancer
OT  - *species specificity of oncogenes
EDAT- 2016/11/16 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/01/14 00:00 [received]
PHST- 2016/04/21 00:00 [revised]
PHST- 2016/10/12 00:00 [accepted]
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30495-0 [pii]
AID - 10.1016/j.ccell.2016.10.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):737-749. doi: 10.1016/j.ccell.2016.10.008.

PMID- 27846390
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5.
PG  - 723-736
LID - S1535-6108(16)30488-3 [pii]
LID - 10.1016/j.ccell.2016.10.001 [doi]
AB  - MicroRNAs (miRNA) are mostly downregulated in cancer. However, the mechanism
      underlying this phenomenon and the precise consequence in tumorigenesis remain
      obscure. Here we show that ERK suppresses pre-miRNA export from the nucleus
      through phosphorylation of exportin-5 (XPO5) at T345/S416/S497. After
      phosphorylation by ERK, conformation of XPO5 is altered by prolyl isomerase Pin1,
      resulting in reduction of pre-miRNA loading. In liver cancer, the ERK-mediated
      XPO5 suppression reduces miR-122, increases microtubule dynamics, and results in 
      tumor development and drug resistance. Analysis of clinical specimens further
      showed that XPO5 phosphorylation is associated with poor prognosis for liver
      cancer patients. Our study reveals a function of ERK in miRNA biogenesis and
      suggests that modulation of miRNA export has potential clinical implications.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Sun, Hui-Lung
AU  - Sun HL
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA; Pharmacological Institute, College of Medicine, National Taiwan
      University, Taipei 10051, Taiwan.
FAU - Cui, Ri
AU  - Cui R
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA.
FAU - Zhou, JianKang
AU  - Zhou J
AD  - Department of Thoracic Surgery, State Key Laboratory of Biotherapy/Collaborative 
      Innovation Center for Biotherapy, West China Hospital, Sichuan University,
      Chengdu 610041, PR China.
FAU - Teng, Kun-Yu
AU  - Teng KY
AD  - Department of Pathology, Ohio State University, Columbus, OH 43210, USA.
FAU - Hsiao, Yung-Hsuan
AU  - Hsiao YH
AD  - Department of Human Sciences, Human Nutrition Program, College of Education and
      Human Ecology, Ohio State University, Columbus, OH 43210, USA.
FAU - Nakanishi, Kotaro
AU  - Nakanishi K
AD  - Department of Chemistry and Biochemistry, Ohio State University, Columbus, OH
      43210, USA.
FAU - Fassan, Matteo
AU  - Fassan M
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA; ARC-NET Research Centre, University and Hospital Trust of Verona,
      Verona 37126, Italy.
FAU - Luo, Zhenghua
AU  - Luo Z
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA.
FAU - Shi, Guqin
AU  - Shi G
AD  - Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio
      State University, Columbus, OH 43210, USA.
FAU - Tili, Esmerina
AU  - Tili E
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA; Department of Anesthesiology, Ohio State University, Columbus, OH
      43210, USA.
FAU - Kutay, Huban
AU  - Kutay H
AD  - Department of Pathology, Ohio State University, Columbus, OH 43210, USA.
FAU - Lovat, Francesca
AU  - Lovat F
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA.
FAU - Vicentini, Caterina
AU  - Vicentini C
AD  - ARC-NET Research Centre, University and Hospital Trust of Verona, Verona 37126,
      Italy.
FAU - Huang, Han-Li
AU  - Huang HL
AD  - The Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical
      Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
FAU - Wang, Shih-Wei
AU  - Wang SW
AD  - Department of Medicine, Mackay Medical College, New Taipei City 25245, Taiwan.
FAU - Kim, Taewan
AU  - Kim T
AD  - Department of Molecular and Cellular Oncology, University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Zanesi, Nicola
AU  - Zanesi N
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA.
FAU - Jeon, Young-Jun
AU  - Jeon YJ
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA.
FAU - Lee, Tae Jin
AU  - Lee TJ
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA.
FAU - Guh, Jih-Hwa
AU  - Guh JH
AD  - School of Pharmacy, National Taiwan University, Taipei 10051, Taiwan.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA; Graduate Institute of Cancer Biology and
      Center for Molecular Medicine, China Medical University, Taichung 40402, Taiwan; 
      Department of Biotechnology, Asia University, Taichung 41354, Taiwan.
FAU - Ghoshal, Kalpana
AU  - Ghoshal K
AD  - Department of Pathology, Ohio State University, Columbus, OH 43210, USA.
FAU - Teng, Che-Ming
AU  - Teng CM
AD  - Pharmacological Institute, College of Medicine, National Taiwan University,
      Taipei 10051, Taiwan.
FAU - Peng, Yong
AU  - Peng Y
AD  - Department of Thoracic Surgery, State Key Laboratory of Biotherapy/Collaborative 
      Innovation Center for Biotherapy, West China Hospital, Sichuan University,
      Chengdu 610041, PR China. Electronic address: yongpeng@scu.edu.cn.
FAU - Croce, Carlo M
AU  - Croce CM
AD  - Department of Cancer Biology and Genetics, Ohio State University, Columbus, OH
      43210, USA. Electronic address: carlo.croce@osumc.edu.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA193244/CA/NCI NIH HHS/United States
GR  - R35 CA197706/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Karyopherins)
RN  - 0 (MIRN122 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NIMA-Interacting Peptidylprolyl Isomerase)
RN  - 0 (XPO5 protein, human)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 5.2.1.8 (PIN1 protein, human)
SB  - IM
MH  - Carcinoma, Hepatocellular/genetics/metabolism/*pathology
MH  - Down-Regulation
MH  - Drug Resistance, Neoplasm
MH  - Extracellular Signal-Regulated MAP Kinases/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Karyopherins/chemistry/*metabolism
MH  - Liver Neoplasms/genetics/metabolism/*pathology
MH  - MicroRNAs/*genetics
MH  - NIMA-Interacting Peptidylprolyl Isomerase/*metabolism
MH  - Phosphorylation
MH  - Prognosis
MH  - Protein Conformation
PMC - PMC5127275
MID - NIHMS821678
OTO - NOTNLM
OT  - *ERK
OT  - *Exportin-5
OT  - *Pin1
OT  - *drug resistance
OT  - *global downregulation
OT  - *liver cancer
OT  - *miR-122
OT  - *miRNA
OT  - *microtubule
OT  - *nuclear export
EDAT- 2016/11/16 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/16 06:00
PHST- 2015/07/24 00:00 [received]
PHST- 2016/04/01 00:00 [revised]
PHST- 2016/10/03 00:00 [accepted]
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30488-3 [pii]
AID - 10.1016/j.ccell.2016.10.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):723-736. doi: 10.1016/j.ccell.2016.10.001.

PMID- 27846389
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Characteristics and Significance of the Pre-metastatic Niche.
PG  - 668-681
LID - S1535-6108(16)30446-9 [pii]
LID - 10.1016/j.ccell.2016.09.011 [doi]
AB  - Primary tumors create a favorable microenvironment, namely, pre-metastatic niche,
      in secondary organs and tissue sites for subsequent metastases. The
      pre-metastatic niche can be primed and established through a complex interplay
      among primary tumor-derived factors, tumor-mobilized bone marrow-derived cells,
      and local stromal components. We review here our current understanding of the key
      components and underlying mechanisms for pre-metastatic niche formation. We
      propose six characteristics that define the pre-metastatic niche, which enable
      tumor cell colonization and promote metastasis, including immunosuppression,
      inflammation, angiogenesis/vascular permeability, lymphangiogenesis,
      organotropism, and reprogramming. We highlight the significance of the
      pre-metastatic niche, and discuss potential implications and future research
      directions.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Liu, Yang
AU  - Liu Y
AD  - National Key Laboratory of Medical Molecular Biology, Department of Immunology,
      Center for Immunotherapy, Institute of Basic Medical Sciences, Peking Union
      Medical College, Chinese Academy of Medical Sciences, Beijing 100005, China.
FAU - Cao, Xuetao
AU  - Cao X
AD  - National Key Laboratory of Medical Molecular Biology, Department of Immunology,
      Center for Immunotherapy, Institute of Basic Medical Sciences, Peking Union
      Medical College, Chinese Academy of Medical Sciences, Beijing 100005, China;
      National Key Laboratory of Medical Immunology & Institute of Immunology, Second
      Military Medical University, Shanghai 200433, China. Electronic address:
      caoxt@immunol.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Bone Marrow Cells/*pathology
MH  - Cellular Reprogramming
MH  - Disease Progression
MH  - Humans
MH  - Immune Tolerance
MH  - Neoplasm Metastasis
MH  - Neoplasms/*pathology
MH  - Stromal Cells/*pathology
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - *cancer intervention
OT  - *immunosuppression
OT  - *inflammation
OT  - *metastasis
OT  - *pre-metastatic niche
OT  - *tumor-host interaction
EDAT- 2016/11/16 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/05/30 00:00 [received]
PHST- 2016/07/22 00:00 [revised]
PHST- 2016/09/20 00:00 [accepted]
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - S1535-6108(16)30446-9 [pii]
AID - 10.1016/j.ccell.2016.09.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):668-681. doi: 10.1016/j.ccell.2016.09.011.

PMID- 27846388
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20180209
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Unraveling the DNA Methylome in Mantle Cell Lymphoma: New Insights into the
      Cellular Origin.
PG  - 665-667
LID - S1535-6108(16)30500-1 [pii]
LID - 10.1016/j.ccell.2016.10.013 [doi]
AB  - Our understanding of the DNA methylome and its impact on cancer evolution and
      disease progression is rapidly evolving. In this issue of Cancer Cell, Queiros et
      al. provide a detailed characterization of the DNA methylome in mantle cell
      lymphoma and reveal novel molecular subtypes, potentially with different cellular
      origins.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Mansouri, Larry
AU  - Mansouri L
AD  - Department of Immunology, Genetics and Pathology, Science for Life Laboratory,
      Uppsala University, 751 85 Uppsala, Sweden.
FAU - Rosenquist, Richard
AU  - Rosenquist R
AD  - Department of Immunology, Genetics and Pathology, Science for Life Laboratory,
      Uppsala University, 751 85 Uppsala, Sweden. Electronic address:
      richard.rosenquist@igp.uu.se.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):806-821. PMID: 27846393
CIN - Cancer Cell. 2016 Nov 14;30(5):806-821. PMID: 27846393
MH  - *Disease Progression
MH  - Humans
MH  - Lymphoma, Mantle-Cell/*genetics
EDAT- 2016/11/16 06:00
MHDA- 2017/06/24 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(16)30500-1 [pii]
AID - 10.1016/j.ccell.2016.10.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):665-667. doi: 10.1016/j.ccell.2016.10.013.

PMID- 27846387
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML.
PG  - 662-664
LID - S1535-6108(16)30501-3 [pii]
LID - 10.1016/j.ccell.2016.10.014 [doi]
AB  - In this issue of Cancer Cell, Bajaj and colleagues report that CD98, a
      heterodimeric protein highly expressed in acute myeloid leukemia (AML) and
      largely dispensable for basal hematopoiesis, plays an important role in
      facilitating leukemia stem cell adhesion to bone marrow vasculature and is a
      potential therapeutic target in AML.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Reinisch, Andreas
AU  - Reinisch A
AD  - Department of Medicine, Division of Hematology, Cancer Institute, and Institute
      for Stem Cell Biology and Regenerative Medicine, Stanford University School of
      Medicine, 265 Campus Drive, Stanford, CA 94305, USA.
FAU - Majeti, Ravindra
AU  - Majeti R
AD  - Department of Medicine, Division of Hematology, Cancer Institute, and Institute
      for Stem Cell Biology and Regenerative Medicine, Stanford University School of
      Medicine, 265 Campus Drive, Stanford, CA 94305, USA. Electronic address:
      rmajeti@stanford.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adhesives)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):792-805. PMID: 27908736
MH  - Adhesives/*metabolism
MH  - Bone Marrow/metabolism
MH  - Bone Marrow Cells/metabolism
MH  - Hematopoiesis
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy
EDAT- 2016/11/16 06:00
MHDA- 2017/07/01 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S1535-6108(16)30501-3 [pii]
AID - 10.1016/j.ccell.2016.10.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):662-664. doi: 10.1016/j.ccell.2016.10.014.

PMID- 27846386
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - An Alternative Sugar Fuels AML.
PG  - 660-662
LID - S1535-6108(16)30502-5 [pii]
LID - 10.1016/j.ccell.2016.10.015 [doi]
AB  - Although altered glucose metabolism is a well-studied feature of malignant cells,
      little is known about the direct metabolism of fructose. In this issue of Cancer 
      Cell, Chen et al. report that AML cells consume fructose and use it to maintain
      viability, especially when glucose is scarce.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Cairns, Rob A
AU  - Cairns RA
AD  - The Campbell Family Institute for Breast Cancer Research at Princess Margaret
      Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada. Electronic
      address: robc@uhnres.utoronto.ca.
FAU - Mak, Tak W
AU  - Mak TW
AD  - The Campbell Family Institute for Breast Cancer Research at Princess Margaret
      Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada. Electronic
      address: tmak@uhnresearch.ca.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 30237-26-4 (Fructose)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):779-791. PMID: 27746145
CIN - Cancer Cell. 2016 Nov 14;30(5):779-791. PMID: 27746145
MH  - Fructose/*metabolism
MH  - Glucose/*metabolism
MH  - Humans
EDAT- 2016/11/16 06:00
MHDA- 2017/06/24 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(16)30502-5 [pii]
AID - 10.1016/j.ccell.2016.10.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):660-662. doi: 10.1016/j.ccell.2016.10.015.

PMID- 27846385
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - An Unexpected Chink in the Transcriptional Armor of Plasmacytoid Dendritic
      Neoplasms.
PG  - 659-660
LID - S1535-6108(16)30503-7 [pii]
LID - 10.1016/j.ccell.2016.10.016 [doi]
AB  - In this issue of Cancer Cell, Ceribelli et al. use functional genomic and
      chemical screening to reveal the existence of a TCF4/BRD4-dependent oncogenic
      regulatory network in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and
      demonstrate that BPDCN cells are highly sensitive to therapeutic targeting of
      this novel dependency.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kleppe, Maria
AU  - Kleppe M
AD  - Human Oncology and Pathogenesis Program, Leukemia Service, Department of
      Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New
      York, NY 10065, USA.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Leukemia Service, Department of
      Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New
      York, NY 10065, USA. Electronic address: leviner@mskcc.org.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):764-778. PMID: 27846392
MH  - *Dendritic Cells
MH  - Hematologic Neoplasms/*drug therapy
MH  - Humans
MH  - Myeloproliferative Disorders
MH  - Skin Neoplasms
EDAT- 2016/11/16 06:00
MHDA- 2017/06/24 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(16)30503-7 [pii]
AID - 10.1016/j.ccell.2016.10.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):659-660. doi: 10.1016/j.ccell.2016.10.016.

PMID- 27846384
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - One Step Forward in the Challenging Arena of MLL-AF4 Leukemia.
PG  - 657-658
LID - S1535-6108(16)30504-9 [pii]
LID - 10.1016/j.ccell.2016.10.017 [doi]
AB  - MLL-AF4 leukemia is the predominant infant acute leukemia and has a poor
      prognosis. No current experimental models accurately reflect the human disease.
      Lin et al., in this issue of Cancer Cell, describe their model that recapitulates
      multiple key aspects of this aggressive disease, facilitating future mechanistic 
      and preclinical studies.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zeleznik-Le, Nancy J
AU  - Zeleznik-Le NJ
AD  - Oncology Research Institute and Department of Medicine, Loyola University
      Chicago, Maywood, IL 60153, USA. Electronic address: nzelezn@luc.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):737-749. PMID: 27846391
MH  - Humans
MH  - Leukemia
MH  - *Myeloid-Lymphoid Leukemia Protein
MH  - *Oncogene Proteins, Fusion
EDAT- 2016/11/16 06:00
MHDA- 2017/06/24 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(16)30504-9 [pii]
AID - 10.1016/j.ccell.2016.10.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):657-658. doi: 10.1016/j.ccell.2016.10.017.

PMID- 27846383
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - UNRelenting Translation UNRestrains Melanoma Migration.
PG  - 655-657
LID - S1535-6108(16)30499-8 [pii]
LID - 10.1016/j.ccell.2016.10.012 [doi]
AB  - The cytoplasmic RNA-binding protein UNR influences key developmental processes by
      controlling mRNA turnover and translation initiation. In this issue of Cancer
      Cell, Wurth et al. report that UNR is highly expressed in melanoma and enhances
      invasion and metastasis at least partly by inducing translation elongation of VIM
      and RAC1 mRNAs.
CI  - Published by Elsevier Inc.
FAU - Weeraratna, Ashani T
AU  - Weeraratna AT
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Gorospe, Myriam
AU  - Gorospe M
AD  - Laboratory of Genetics and Genomics, National Institute on Aging-IRP, National
      Institutes of Health, Baltimore, MD 21224, USA. Electronic address:
      myriam-gorospe@nih.gov.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA174746/CA/NCI NIH HHS/United States
GR  - ZIA AG000511-19/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):694-707. PMID: 27908735
MH  - DNA-Binding Proteins/*genetics
MH  - Humans
MH  - Melanoma
MH  - Protein Biosynthesis
MH  - RNA, Messenger/metabolism
MH  - RNA-Binding Proteins/*genetics
PMC - PMC5489341
MID - NIHMS874634
EDAT- 2016/11/16 06:00
MHDA- 2017/06/24 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(16)30499-8 [pii]
AID - 10.1016/j.ccell.2016.10.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):655-657. doi: 10.1016/j.ccell.2016.10.012.

PMID- 27846382
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Cholesterol: An Achilles' Heel for Glioblastoma?
PG  - 653-654
LID - S1535-6108(16)30498-6 [pii]
LID - 10.1016/j.ccell.2016.10.011 [doi]
AB  - In this issue of Cancer Cell, Villa et al. report that survival of glioblastoma
      cells is dependent on uptake of cholesterol. A synthetic agonist of the Liver X
      receptor depleted cholesterol in GBM cells, slowing growth of GBM xenografts.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - An, Zhenyi
AU  - An Z
AD  - Departments of Neurology, Pediatrics, and Neurosurgery, Brain Tumor Research
      Center, and Helen Diller Family Comprehensive Cancer Center, University of
      California, San Francisco, San Francisco, CA 94158, USA.
FAU - Weiss, William A
AU  - Weiss WA
AD  - Departments of Neurology, Pediatrics, and Neurosurgery, Brain Tumor Research
      Center, and Helen Diller Family Comprehensive Cancer Center, University of
      California, San Francisco, San Francisco, CA 94158, USA. Electronic address:
      waweiss@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):683-693. PMID: 27746144
CIN - Cancer Cell. 2016 Nov 14;30(5):683-693. PMID: 27746144
MH  - *Cholesterol
MH  - *Glioblastoma
MH  - Humans
EDAT- 2016/11/16 06:00
MHDA- 2017/06/24 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
AID - S1535-6108(16)30498-6 [pii]
AID - 10.1016/j.ccell.2016.10.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):653-654. doi: 10.1016/j.ccell.2016.10.011.

PMID- 27818134
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects
      in Chronic Lymphocytic Leukemia.
PG  - 750-763
LID - S1535-6108(16)30492-5 [pii]
LID - 10.1016/j.ccell.2016.10.005 [doi]
AB  - Mutations in SF3B1, which encodes a spliceosome component, are associated with
      poor outcome in chronic lymphocytic leukemia (CLL), but how these contribute to
      CLL progression remains poorly understood. We undertook a transcriptomic
      characterization of primary human CLL cells to identify transcripts and pathways 
      affected by SF3B1 mutation. Splicing alterations, identified in the analysis of
      bulk cells, were confirmed in single SF3B1-mutated CLL cells and also found in
      cell lines ectopically expressing mutant SF3B1. SF3B1 mutation was found to
      dysregulate multiple cellular functions including DNA damage response, telomere
      maintenance, and Notch signaling (mediated through KLF8 upregulation, increased
      TERC and TERT expression, or altered splicing of DVL2 transcript, respectively). 
      SF3B1 mutation leads to diverse changes in CLL-related pathways.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Wang, Lili
AU  - Wang L
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
FAU - Brooks, Angela N
AU  - Brooks AN
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 
      02141, USA; University of California, Santa Cruz, CA 95064, USA.
FAU - Fan, Jean
AU  - Fan J
AD  - Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115,
      USA.
FAU - Wan, Youzhong
AU  - Wan Y
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA; National Engineering Laboratory of AIDS Vaccine,
      School of Life Science, Jilin University, Changchun, Jilin, PRC.
FAU - Gambe, Rutendo
AU  - Gambe R
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA.
FAU - Li, Shuqiang
AU  - Li S
AD  - Fluidigm Corporation, South San Francisco, CA 94080, USA.
FAU - Hergert, Sarah
AU  - Hergert S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA.
FAU - Yin, Shanye
AU  - Yin S
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Freeman, Samuel S
AU  - Freeman SS
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
FAU - Levin, Joshua Z
AU  - Levin JZ
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
FAU - Fan, Lin
AU  - Fan L
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
FAU - Seiler, Michael
AU  - Seiler M
AD  - H3 Biomedicine, Cambridge, MA 02141, USA.
FAU - Buonamici, Silvia
AU  - Buonamici S
AD  - H3 Biomedicine, Cambridge, MA 02141, USA.
FAU - Smith, Peter G
AU  - Smith PG
AD  - H3 Biomedicine, Cambridge, MA 02141, USA.
FAU - Chau, Kevin F
AU  - Chau KF
AD  - Harvard Medical School, Boston, MA 02115, USA.
FAU - Cibulskis, Carrie L
AU  - Cibulskis CL
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
FAU - Zhang, Wandi
AU  - Zhang W
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA.
FAU - Rassenti, Laura Z
AU  - Rassenti LZ
AD  - Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093,
      USA.
FAU - Ghia, Emanuela M
AU  - Ghia EM
AD  - Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093,
      USA.
FAU - Kipps, Thomas J
AU  - Kipps TJ
AD  - Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093,
      USA.
FAU - Fernandes, Stacey
AU  - Fernandes S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA.
FAU - Bloch, Donald B
AU  - Bloch DB
AD  - Center for Immunology and Inflammatory Disease, Massachusetts General Hospital,
      Boston, MA 02115, USA.
FAU - Kotliar, Dylan
AU  - Kotliar D
AD  - Harvard Medical School, Boston, MA 02115, USA.
FAU - Landau, Dan A
AU  - Landau DA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
FAU - Shukla, Sachet A
AU  - Shukla SA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA.
FAU - Aster, Jon C
AU  - Aster JC
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Reed, Robin
AU  - Reed R
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - DeLuca, David S
AU  - DeLuca DS
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
FAU - Brown, Jennifer R
AU  - Brown JR
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's
      Hospital, Boston, MA 02115, USA.
FAU - Neuberg, Donna
AU  - Neuberg D
AD  - Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
      02115, USA.
FAU - Getz, Gad
AU  - Getz G
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
FAU - Livak, Kenneth J
AU  - Livak KJ
AD  - Fluidigm Corporation, South San Francisco, CA 94080, USA.
FAU - Meyerson, Matthew M
AU  - Meyerson MM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA.
FAU - Kharchenko, Peter V
AU  - Kharchenko PV
AD  - Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115,
      USA.
FAU - Wu, Catherine J
AU  - Wu CJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney
      Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 
      02141, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA
      02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:
      cwu@partners.org.
LA  - eng
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - R01 CA182461/CA/NCI NIH HHS/United States
GR  - F31 CA206236/CA/NCI NIH HHS/United States
GR  - R01 HL131768/HL/NHLBI NIH HHS/United States
GR  - R01 HL103532/HL/NHLBI NIH HHS/United States
GR  - T32 GM007753/GM/NIGMS NIH HHS/United States
GR  - R50 CA211482/CA/NCI NIH HHS/United States
GR  - P01 CA206978/CA/NCI NIH HHS/United States
GR  - P01 CA081534/CA/NCI NIH HHS/United States
GR  - R01 CA184922/CA/NCI NIH HHS/United States
GR  - R01 CA155010/CA/NCI NIH HHS/United States
GR  - R01 GM043375/GM/NIGMS NIH HHS/United States
GR  - R01 HL116452/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20161103
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DVL2 protein, human)
RN  - 0 (Dishevelled Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (RNA Splicing Factors)
RN  - 0 (Receptors, Notch)
RN  - 0 (SF3B1 protein, human)
SB  - IM
MH  - *Alternative Splicing
MH  - Cell Line, Tumor
MH  - Dishevelled Proteins/genetics
MH  - Gene Expression Profiling/*methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
MH  - *Mutation
MH  - Phosphoproteins/*genetics
MH  - RNA Splicing Factors/*genetics
MH  - Receptors, Notch/genetics
MH  - Signal Transduction
PMC - PMC5127278
MID - NIHMS822780
OTO - NOTNLM
OT  - *CLL
OT  - *Notch signaling
OT  - *RNA sequencing
OT  - *SF3B1
OT  - *alternative splicing
COIS- Michael Seiler, Silvia Buonamici, Peter G. Smith are employees and shareholders
      of H3 Biomedicine. Catherine J. Wu is co-founder and scientific advisory board
      member of Neon Therapeutics, Inc. All other authors have no conflicts of
      interest.
EDAT- 2016/11/08 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/11/08 06:00
PHST- 2015/11/12 00:00 [received]
PHST- 2016/09/01 00:00 [revised]
PHST- 2016/10/04 00:00 [accepted]
PHST- 2016/11/08 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/11/08 06:00 [entrez]
AID - S1535-6108(16)30492-5 [pii]
AID - 10.1016/j.ccell.2016.10.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):750-763. doi: 10.1016/j.ccell.2016.10.005. Epub
      2016 Nov 3.

PMID- 27773593
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic
      Response and Breast Cancer Carcinogenesis.
PG  - 708-722
LID - S1535-6108(16)30445-7 [pii]
LID - 10.1016/j.ccell.2016.09.010 [doi]
AB  - Although clinically associated with severe developmental defects, the biological 
      function of FOXK2 remains poorly explored. Here we report that FOXK2 interacts
      with transcription corepressor complexes NCoR/SMRT, SIN3A, NuRD, and REST/CoREST 
      to repress a cohort of genes including HIF1beta and EZH2 and to regulate several 
      signaling pathways including the hypoxic response. We show that FOXK2 inhibits
      the proliferation and invasion of breast cancer cells and suppresses the growth
      and metastasis of breast cancer. Interestingly, FOXK2 is transactivated by
      ERalpha and transrepressed via reciprocal successive feedback by HIF1beta/EZH2.
      Significantly, the expression of FOXK2 is progressively lost during breast cancer
      progression, and low FOXK2 expression is strongly correlated with higher
      histologic grades, positive lymph nodes, and ERalpha(-)/PR(-)/HER2(-) status, all
      indicators of poor prognosis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Shan, Lin
AU  - Shan L
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Zhou, Xing
AU  - Zhou X
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Liu, Xinhua
AU  - Liu X
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Su, Dongxue
AU  - Su D
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Hou, Yongqiang
AU  - Hou Y
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Yu, Na
AU  - Yu N
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Yang, Chao
AU  - Yang C
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Liu, Beibei
AU  - Liu B
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Gao, Jie
AU  - Gao J
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Duan, Yang
AU  - Duan Y
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Yang, Jianguo
AU  - Yang J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Department of Biochemistry and Molecular Biology, School of Basic
      Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
FAU - Li, Wanjin
AU  - Li W
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Department of Biochemistry and Molecular Biology, School of Basic
      Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
FAU - Liang, Jing
AU  - Liang J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Department of Biochemistry and Molecular Biology, School of Basic
      Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
FAU - Sun, Luyang
AU  - Sun L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Department of Biochemistry and Molecular Biology, School of Basic
      Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
FAU - Chen, Kexin
AU  - Chen K
AD  - Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer
      Institute and Hospital, Tianjin 300060, China.
FAU - Xuan, Chenghao
AU  - Xuan C
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China.
FAU - Shang, Yongfeng
AU  - Shang Y
AD  - Department of Biochemistry and Molecular Biology, 2011 Collaborative Innovation
      Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical
      Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 22
      Qixiangtai Road, Tianjin 300070, China; Key Laboratory of Carcinogenesis and
      Translational Research (Ministry of Education), Department of Biochemistry and
      Molecular Biology, School of Basic Medical Sciences, Peking University Health
      Science Center, Beijing 100191, China. Electronic address: yshang@hsc.pku.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20161020
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ARNT protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (estrogen receptor alpha, human)
RN  - 138391-32-9 (Aryl Hydrocarbon Receptor Nuclear Translocator)
RN  - 143298-33-3 (interleukin binding factor)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
SB  - IM
MH  - Animals
MH  - Aryl Hydrocarbon Receptor Nuclear Translocator/*genetics
MH  - Breast Neoplasms/genetics/metabolism/*pathology
MH  - Cell Hypoxia
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Down-Regulation
MH  - Enhancer of Zeste Homolog 2 Protein/*genetics
MH  - Estrogen Receptor alpha/*genetics
MH  - Female
MH  - Forkhead Transcription Factors/genetics/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Mice
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Signal Transduction
MH  - *Transcription, Genetic
EDAT- 2016/10/25 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/10/25 06:00
PHST- 2016/03/09 00:00 [received]
PHST- 2016/07/08 00:00 [revised]
PHST- 2016/09/20 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
AID - S1535-6108(16)30445-7 [pii]
AID - 10.1016/j.ccell.2016.09.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):708-722. doi: 10.1016/j.ccell.2016.09.010. Epub
      2016 Oct 20.

PMID- 27746145
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of
      Acute Myeloid Leukemia with Therapeutic Potential.
PG  - 779-791
LID - S1535-6108(16)30441-X [pii]
LID - 10.1016/j.ccell.2016.09.006 [doi]
AB  - Rapidly proliferating leukemic progenitor cells consume substantial glucose,
      which may lead to glucose insufficiency in bone marrow. We show that acute
      myeloid leukemia (AML) cells are prone to fructose utilization with an
      upregulated fructose transporter GLUT5, which compensates for glucose deficiency.
      Notably, AML patients with upregulated transcription of the GLUT5-encoding gene
      SLC2A5 or increased fructose utilization have poor outcomes. Pharmacological
      blockage of fructose uptake ameliorates leukemic phenotypes and potentiates the
      cytotoxicity of the antileukemic agent, Ara-C. In conclusion, this study
      highlights enhanced fructose utilization as a metabolic feature of AML and a
      potential therapeutic target.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Chen, Wen-Lian
AU  - Chen WL
AD  - State Key Laboratory of Medical Genomics, Department of Hematology, Shanghai
      Institute of Hematology, Rui Jin Hospital Affiliated with Shanghai Jiao Tong
      University School of Medicine, Shanghai 200025, China; Center for Translational
      Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital,
      Shanghai 200233, China; University of Hawaii Cancer Center, Honolulu, HI 96813,
      USA.
FAU - Wang, Yue-Ying
AU  - Wang YY
AD  - State Key Laboratory of Medical Genomics, Department of Hematology, Shanghai
      Institute of Hematology, Rui Jin Hospital Affiliated with Shanghai Jiao Tong
      University School of Medicine, Shanghai 200025, China.
FAU - Zhao, Aihua
AU  - Zhao A
AD  - Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai 200233, China.
FAU - Xia, Li
AU  - Xia L
AD  - State Key Laboratory of Medical Genomics, Department of Hematology, Shanghai
      Institute of Hematology, Rui Jin Hospital Affiliated with Shanghai Jiao Tong
      University School of Medicine, Shanghai 200025, China.
FAU - Xie, Guoxiang
AU  - Xie G
AD  - Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai 200233, China; University of Hawaii Cancer Center,
      Honolulu, HI 96813, USA.
FAU - Su, Mingming
AU  - Su M
AD  - Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai 200233, China; University of Hawaii Cancer Center,
      Honolulu, HI 96813, USA.
FAU - Zhao, Linjing
AU  - Zhao L
AD  - University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
FAU - Liu, Jiajian
AU  - Liu J
AD  - Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai 200233, China.
FAU - Qu, Chun
AU  - Qu C
AD  - Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai 200233, China.
FAU - Wei, Runmin
AU  - Wei R
AD  - University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
FAU - Rajani, Cynthia
AU  - Rajani C
AD  - University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
FAU - Ni, Yan
AU  - Ni Y
AD  - Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai 200233, China; University of Hawaii Cancer Center,
      Honolulu, HI 96813, USA.
FAU - Cheng, Zhen
AU  - Cheng Z
AD  - Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program,
      Canary Center at Stanford for Cancer Early Detection, School of Medicine,
      Stanford University, Stanford, CA 94305, USA.
FAU - Chen, Zhu
AU  - Chen Z
AD  - State Key Laboratory of Medical Genomics, Department of Hematology, Shanghai
      Institute of Hematology, Rui Jin Hospital Affiliated with Shanghai Jiao Tong
      University School of Medicine, Shanghai 200025, China.
FAU - Chen, Sai-Juan
AU  - Chen SJ
AD  - State Key Laboratory of Medical Genomics, Department of Hematology, Shanghai
      Institute of Hematology, Rui Jin Hospital Affiliated with Shanghai Jiao Tong
      University School of Medicine, Shanghai 200025, China. Electronic address:
      sjchen@stn.sh.cn.
FAU - Jia, Wei
AU  - Jia W
AD  - Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai 200233, China; University of Hawaii Cancer Center,
      Honolulu, HI 96813, USA. Electronic address: wjia@cc.hawaii.edu.
LA  - eng
GR  - P30 CA071789/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
DEP - 20161013
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Glucose Transporter Type 5)
RN  - 0 (SLC2A5 protein, human)
RN  - 04079A1RDZ (Cytarabine)
RN  - 30237-26-4 (Fructose)
RN  - 3OWL53L36A (Mannitol)
RN  - 41107-82-8 (2,5-anhydromannitol)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):660-662. PMID: 27846386
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cytarabine/*administration & dosage/pharmacology
MH  - Drug Synergism
MH  - Fructose/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques/methods
MH  - Glucose Transporter Type 5/*genetics/metabolism
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/genetics/metabolism
MH  - Mannitol/administration & dosage/*analogs & derivatives/pharmacology
MH  - Mice
MH  - Prognosis
MH  - Treatment Outcome
MH  - Up-Regulation
PMC - PMC5496656
MID - NIHMS820316
OTO - NOTNLM
OT  - *GLUT5
OT  - *SLC2A5
OT  - *acute myeloid leukemia
OT  - *fructose utilization
EDAT- 2016/10/18 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/10/18 06:00
PHST- 2015/11/17 00:00 [received]
PHST- 2016/04/08 00:00 [revised]
PHST- 2016/09/13 00:00 [accepted]
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/10/18 06:00 [entrez]
AID - S1535-6108(16)30441-X [pii]
AID - 10.1016/j.ccell.2016.09.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):779-791. doi: 10.1016/j.ccell.2016.09.006. Epub
      2016 Oct 13.

PMID- 27746144
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20180131
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Nov 14
TI  - An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.
PG  - 683-693
LID - S1535-6108(16)30443-3 [pii]
LID - 10.1016/j.ccell.2016.09.008 [doi]
AB  - Small-molecule inhibitors targeting growth factor receptors have failed to show
      efficacy for brain cancers, potentially due to their inability to achieve
      sufficient drug levels in the CNS. Targeting non-oncogene tumor co-dependencies
      provides an alternative approach, particularly if drugs with high brain
      penetration can be identified. Here we demonstrate that the highly lethal brain
      cancer glioblastoma (GBM) is remarkably dependent on cholesterol for survival,
      rendering these tumors sensitive to Liver X receptor (LXR) agonist-dependent cell
      death. We show that LXR-623, a clinically viable, highly brain-penetrant
      LXRalpha-partial/LXRbeta-full agonist selectively kills GBM cells in an LXRbeta- 
      and cholesterol-dependent fashion, causing tumor regression and prolonged
      survival in mouse models. Thus, a metabolic co-dependency provides a
      pharmacological means to kill growth factor-activated cancers in the CNS.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Villa, Genaro R
AU  - Villa GR
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, CA 90095, USA; Medical Scientist Training Program, David
      Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA; Ludwig Institute for 
      Cancer Research, University of California San Diego, La Jolla, CA 92093, USA.
FAU - Hulce, Jonathan J
AU  - Hulce JJ
AD  - Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The
      Scripps Research Institute, La Jolla, CA 92037, USA.
FAU - Zanca, Ciro
AU  - Zanca C
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Bi, Junfeng
AU  - Bi J
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Ikegami, Shiro
AU  - Ikegami S
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Cahill, Gabrielle L
AU  - Cahill GL
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Gu, Yuchao
AU  - Gu Y
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, CA 90095, USA; Ludwig Institute for Cancer Research,
      University of California San Diego, La Jolla, CA 92093, USA.
FAU - Lum, Kenneth M
AU  - Lum KM
AD  - Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The
      Scripps Research Institute, La Jolla, CA 92037, USA.
FAU - Masui, Kenta
AU  - Masui K
AD  - Department of Pathology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
FAU - Yang, Huijun
AU  - Yang H
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Rong, Xin
AU  - Rong X
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
FAU - Hong, Cynthia
AU  - Hong C
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
FAU - Turner, Kristen M
AU  - Turner KM
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Liu, Feng
AU  - Liu F
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Hon, Gary C
AU  - Hon GC
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Jenkins, David
AU  - Jenkins D
AD  - Small Molecule Discovery Program, Ludwig Institute for Cancer Research,
      University of California San Diego, La Jolla, CA 92093, USA.
FAU - Martini, Michael
AU  - Martini M
AD  - Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The
      Scripps Research Institute, La Jolla, CA 92037, USA.
FAU - Armando, Aaron M
AU  - Armando AM
AD  - Department of Pharmacology, UCSD School of Medicine, La Jolla, CA 92093, USA.
FAU - Quehenberger, Oswald
AU  - Quehenberger O
AD  - Department of Pharmacology, UCSD School of Medicine, La Jolla, CA 92093, USA;
      Department of Medicine, UCSD School of Medicine, La Jolla, CA 92093, USA.
FAU - Cloughesy, Timothy F
AU  - Cloughesy TF
AD  - Department of Neurology, David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Furnari, Frank B
AU  - Furnari FB
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA; Department of Pathology, UCSD School of Medicine, La Jolla,
      CA 92093, USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA 92093,
      USA.
FAU - Cavenee, Webster K
AU  - Cavenee WK
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA; Department of Medicine, UCSD School of Medicine, La Jolla, 
      CA 92093, USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA 92093,
      USA.
FAU - Tontonoz, Peter
AU  - Tontonoz P
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; Howard Hughes Medical Institute, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Gahman, Timothy C
AU  - Gahman TC
AD  - Small Molecule Discovery Program, Ludwig Institute for Cancer Research,
      University of California San Diego, La Jolla, CA 92093, USA.
FAU - Shiau, Andrew K
AU  - Shiau AK
AD  - Small Molecule Discovery Program, Ludwig Institute for Cancer Research,
      University of California San Diego, La Jolla, CA 92093, USA.
FAU - Cravatt, Benjamin F
AU  - Cravatt BF
AD  - Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The
      Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address:
      cravatt@scripps.edu.
FAU - Mischel, Paul S
AU  - Mischel PS
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA 92093, USA; Department of Pathology, UCSD School of Medicine, La Jolla,
      CA 92093, USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA 92093,
      USA. Electronic address: pmischel@ucsd.edu.
LA  - eng
GR  - F31 CA186668/CA/NCI NIH HHS/United States
GR  - R01 NS073831/NS/NINDS NIH HHS/United States
GR  - R01 NS080939/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Comment
DEP - 20161013
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole)
RN  - 0 (Indazoles)
RN  - 0 (Liver X Receptors)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
CON - Cancer Cell. 2016 Nov 14;30(5):653-654. PMID: 27846382
MH  - Animals
MH  - Brain Neoplasms/*drug therapy/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cholesterol/*metabolism
MH  - Female
MH  - Glioblastoma/*drug therapy/metabolism
MH  - Humans
MH  - Indazoles/*administration & dosage/pharmacology
MH  - Liver X Receptors/*metabolism
MH  - Mice
MH  - Treatment Outcome
PMC - PMC5479636
MID - NIHMS868604
OTO - NOTNLM
OT  - *brain cancer
OT  - *cholesterol
OT  - *glioblastoma
OT  - *liver X receptor
OT  - *metabolism
OT  - *oxysterols
EDAT- 2016/10/18 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/10/18 06:00
PHST- 2016/02/25 00:00 [received]
PHST- 2016/05/19 00:00 [revised]
PHST- 2016/09/17 00:00 [accepted]
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
PHST- 2016/10/18 06:00 [entrez]
AID - S1535-6108(16)30443-3 [pii]
AID - 10.1016/j.ccell.2016.09.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Nov 14;30(5):683-693. doi: 10.1016/j.ccell.2016.09.008. Epub
      2016 Oct 13.

PMID- 27728809
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and
      Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.
PG  - 651
LID - S1535-6108(16)30444-5 [pii]
LID - 10.1016/j.ccell.2016.09.009 [doi]
FAU - Marigo, Ilaria
AU  - Marigo I
FAU - Zilio, Serena
AU  - Zilio S
FAU - Desantis, Giacomo
AU  - Desantis G
FAU - Mlecnik, Bernhard
AU  - Mlecnik B
FAU - Agnellini, Andrielly H R
AU  - Agnellini AH
FAU - Ugel, Stefano
AU  - Ugel S
FAU - Sasso, Maria Stella
AU  - Sasso MS
FAU - Qualls, Joseph E
AU  - Qualls JE
FAU - Kratochvill, Franz
AU  - Kratochvill F
FAU - Zanovello, Paola
AU  - Zanovello P
FAU - Molon, Barbara
AU  - Molon B
FAU - Ries, Carola H
AU  - Ries CH
FAU - Runza, Valeria
AU  - Runza V
FAU - Hoves, Sabine
AU  - Hoves S
FAU - Bilocq, Amelie M
AU  - Bilocq AM
FAU - Bindea, Gabriela
AU  - Bindea G
FAU - Mazza, Emilia M C
AU  - Mazza EM
FAU - Bicciato, Silvio
AU  - Bicciato S
FAU - Galon, Jerome
AU  - Galon J
FAU - Murray, Peter J
AU  - Murray PJ
FAU - Bronte, Vincenzo
AU  - Bronte V
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Sep 12;30(3):377-390. PMID: 27622331
EDAT- 2016/10/12 06:00
MHDA- 2016/10/12 06:01
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2016/10/12 06:01 [medline]
AID - S1535-6108(16)30444-5 [pii]
AID - 10.1016/j.ccell.2016.09.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009.

PMID- 27728808
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180404
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents 
      - A Potential Therapy for Cancer.
PG  - 637-650
LID - S1535-6108(16)30437-8 [pii]
LID - 10.1016/j.ccell.2016.09.002 [doi]
AB  - Poly (ADP-ribose) polymerase inhibitors (PARPis) are clinically effective
      predominantly for BRCA-mutant tumors. We introduce a mechanism-based strategy to 
      enhance PARPi efficacy based on DNA damage-related binding between DNA
      methyltransferases (DNMTs) and PARP1. In acute myeloid leukemia (AML) and breast 
      cancer cells, DNMT inhibitors (DNMTis) alone covalently bind DNMTs into DNA and
      increase PARP1 tightly bound into chromatin. Low doses of DNMTis plus PARPis,
      versus each drug alone, increase PARPi efficacy, increasing amplitude and
      retention of PARP1 directly at laser-induced DNA damage sites. This correlates
      with increased DNA damage, synergistic tumor cytotoxicity, blunting of
      self-renewal, and strong anti-tumor responses, in vivo in unfavorable AML
      subtypes and BRCA wild-type breast cancer cells. Our combinatorial approach
      introduces a strategy to enhance efficacy of PARPis in treating cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Muvarak, Nidal E
AU  - Muvarak NE
AD  - Department of Radiation Oncology, University of Maryland, Baltimore, MD 21201,
      USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center,
      Baltimore, MD 21201, USA.
FAU - Chowdhury, Khadiza
AU  - Chowdhury K
AD  - Department of Radiation Oncology, University of Maryland, Baltimore, MD 21201,
      USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center,
      Baltimore, MD 21201, USA.
FAU - Xia, Limin
AU  - Xia L
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical
      Institutions, Baltimore, MD 21231, USA.
FAU - Robert, Carine
AU  - Robert C
AD  - Department of Radiation Oncology, University of Maryland, Baltimore, MD 21201,
      USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center,
      Baltimore, MD 21201, USA.
FAU - Choi, Eun Yong
AU  - Choi EY
AD  - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 
      21201, USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center, 
      Baltimore, MD 21201, USA.
FAU - Cai, Yi
AU  - Cai Y
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical
      Institutions, Baltimore, MD 21231, USA.
FAU - Bellani, Marina
AU  - Bellani M
AD  - Laboratory of Molecular Gerontology, National Institute on Aging, Baltimore, MD
      21224, USA.
FAU - Zou, Ying
AU  - Zou Y
AD  - Department of Pathology, University of Maryland School of Medicine, Baltimore, MD
      21201, USA.
FAU - Singh, Zeba N
AU  - Singh ZN
AD  - Department of Pathology, University of Maryland School of Medicine, Baltimore, MD
      21201, USA.
FAU - Duong, Vu H
AU  - Duong VH
AD  - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 
      21201, USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center, 
      Baltimore, MD 21201, USA.
FAU - Rutherford, Tyler
AU  - Rutherford T
AD  - Stevenson University, Stevenson, MD 21153, USA.
FAU - Nagaria, Pratik
AU  - Nagaria P
AD  - Department of Radiation Oncology, University of Maryland, Baltimore, MD 21201,
      USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center,
      Baltimore, MD 21201, USA.
FAU - Bentzen, Soren M
AU  - Bentzen SM
AD  - Department of Radiation Oncology, University of Maryland, Baltimore, MD 21201,
      USA; Department of Epidemiology and Public Health, University of Maryland School 
      of Medicine, Baltimore, MD 21201, USA.
FAU - Seidman, Michael M
AU  - Seidman MM
AD  - Laboratory of Molecular Gerontology, National Institute on Aging, Baltimore, MD
      21224, USA.
FAU - Baer, Maria R
AU  - Baer MR
AD  - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 
      21201, USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center, 
      Baltimore, MD 21201, USA; Veterans Affairs Medical Center, Baltimore, MD 21201,
      USA.
FAU - Lapidus, Rena G
AU  - Lapidus RG
AD  - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 
      21201, USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center, 
      Baltimore, MD 21201, USA.
FAU - Baylin, Stephen B
AU  - Baylin SB
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical
      Institutions, Baltimore, MD 21231, USA; Van Andel Research Institute, Grand
      Rapids, MI 49503.
FAU - Rassool, Feyruz V
AU  - Rassool FV
AD  - Department of Radiation Oncology, University of Maryland, Baltimore, MD 21201,
      USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center,
      Baltimore, MD 21201, USA. Electronic address: frassool@som.umaryland.edu.
LA  - eng
GR  - I01 BX002184/BX/BLRD VA/United States
GR  - Z01 AG000746/AG/NIA NIH HHS/United States
GR  - ZIA AG000746-08/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromatin)
RN  - 0 (Phthalazines)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 9QHX048FRV (talazoparib)
RN  - EC 2.4.2.30 (PARP1 protein, human)
RN  - EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1)
SB  - IM
CIN - Sci Transl Med. 2016 Nov 16;8(365):365ec182. PMID: 27856791
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Cell Line, Tumor
MH  - Chromatin/metabolism
MH  - DNA Breaks, Double-Stranded
MH  - DNA Methylation/*drug effects
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/genetics/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, Nude
MH  - Phthalazines/pharmacology
MH  - Poly (ADP-Ribose) Polymerase-1/antagonists & inhibitors/metabolism
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*pharmacology
MH  - Triple Negative Breast Neoplasms/*drug therapy/genetics/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5201166
MID - NIHMS816536
OTO - NOTNLM
OT  - *AML
OT  - *DNA damage
OT  - *DNA double-strand break
OT  - *DNA repair
OT  - *DNMT inhibitor
OT  - *DNMT1
OT  - *PARP
OT  - *PARP inhibitor
OT  - *PARP trapping
OT  - *breast cancer
COIS- DISCLOSURES C.R., F.V.R. and S.B.B. share co-inventor ship on US Provisional
      Patent Application Number: 61/929,680 for the concept of the combinatorial
      therapy.
EDAT- 2016/10/12 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/12 06:00
PHST- 2015/10/16 00:00 [received]
PHST- 2016/03/16 00:00 [revised]
PHST- 2016/09/08 00:00 [accepted]
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30437-8 [pii]
AID - 10.1016/j.ccell.2016.09.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):637-650. doi: 10.1016/j.ccell.2016.09.002.

PMID- 27728807
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of
      Chronic Lymphocytic Leukemia.
PG  - 610-622
LID - S1535-6108(16)30442-1 [pii]
LID - 10.1016/j.ccell.2016.09.007 [doi]
AB  - Survival of chronic lymphocytic leukemia (CLL) cells strictly depends on the
      support of an appropriate tumor microenvironment. Here, we demonstrate that LYN
      kinase is essential for CLL progression. Lyn deficiency results in a
      significantly reduced CLL burden in vivo. Loss of Lyn within leukemic cells
      reduces B cell receptor (BCR) signaling including BTK phosphorylation, but
      surprisingly does not affect leukemic cell expansion. Instead, syngeneic CLL
      transplantation of CLL cells into Lyn- or Btk-deficient recipients results in a
      strongly delayed leukemic progression and prolonged survival. Moreover, Lyn
      deficiency in macrophages hinders nursing functions for CLL cells, which is
      mediated by direct contact rather than secretion of soluble factors. Taken
      together, LYN and BTK seem essential for the formation of a microenvironment
      supporting leukemic growth.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Nguyen, Phuong-Hien
AU  - Nguyen PH
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany.
FAU - Fedorchenko, Oleg
AU  - Fedorchenko O
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany.
FAU - Rosen, Natascha
AU  - Rosen N
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany.
FAU - Koch, Maximilian
AU  - Koch M
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany.
FAU - Barthel, Romy
AU  - Barthel R
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany.
FAU - Winarski, Tomasz
AU  - Winarski T
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany.
FAU - Florin, Alexandra
AU  - Florin A
AD  - Institute of Pathology, University Hospital of Cologne, 50931 Cologne, Germany.
FAU - Wunderlich, F Thomas
AU  - Wunderlich FT
AD  - Max Planck Institute for Metabolism Research; Institute for Genetics, University 
      of Cologne, 50931 Cologne, Germany.
FAU - Reinart, Nina
AU  - Reinart N
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany.
FAU - Hallek, Michael
AU  - Hallek M
AD  - Department I of Internal Medicine, University Hospital of Cologne, Center for
      Integrated Oncology Cologne-Bonn, CECAD Center of Excellence on "Cellular Stress 
      Responses in Aging-Associated Diseases", University of Cologne, 50931 Cologne,
      Germany. Electronic address: michael.hallek@uni-koeln.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.10.2 (lyn protein-tyrosine kinase)
RN  - EC 2.7.10.2 (src-Family Kinases)
SB  - IM
CIN - Cancer Cell. 2016 Oct 10;30(4):511-512. PMID: 27728800
MH  - Animals
MH  - Cell Proliferation/physiology
MH  - Disease Progression
MH  - Gene Expression Regulation, Leukemic
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*enzymology/genetics/pathology
MH  - Mice
MH  - Signal Transduction
MH  - Tumor Microenvironment
MH  - src-Family Kinases/genetics/*metabolism
EDAT- 2016/10/12 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/12 06:00
PHST- 2015/12/04 00:00 [received]
PHST- 2016/05/16 00:00 [revised]
PHST- 2016/09/15 00:00 [accepted]
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30442-1 [pii]
AID - 10.1016/j.ccell.2016.09.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):610-622. doi: 10.1016/j.ccell.2016.09.007.

PMID- 27728806
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell
      Activity, Fibrosis, and Liver Cancer.
PG  - 595-609
LID - 10.1016/j.ccell.2016.09.004 [doi]
AB  - Hepatic stellate cells (HSCs) play critical roles in liver fibrosis and
      hepatocellular carcinoma (HCC). Vitamin D receptor (VDR) activation in HSCs
      inhibits liver inflammation and fibrosis. We found that p62/SQSTM1, a protein
      upregulated in liver parenchymal cells but downregulated in HCC-associated HSCs, 
      negatively controls HSC activation. Total body or HSC-specific p62 ablation
      potentiates HSCs and enhances inflammation, fibrosis, and HCC progression. p62
      directly interacts with VDR and RXR promoting their heterodimerization, which is 
      critical for VDR:RXR target gene recruitment. Loss of p62 in HSCs impairs the
      repression of fibrosis and inflammation by VDR agonists. This demonstrates that
      p62 is a negative regulator of liver inflammation and fibrosis through its
      ability to promote VDR signaling in HSCs, whose activation supports HCC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Duran, Angeles
AU  - Duran A
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Hernandez, Eloy D
AU  - Hernandez ED
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Reina-Campos, Miguel
AU  - Reina-Campos M
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
AD  - Sanford Burnham Prebys Graduate School of Biomedical Sciences, Sanford Burnham
      Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA
      92037, USA.
FAU - Castilla, Elias A
AU  - Castilla EA
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Subramaniam, Shankar
AU  - Subramaniam S
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine,
      Rochester, MN, USA.
FAU - Raghunandan, Sindhu
AU  - Raghunandan S
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine,
      Rochester, MN, USA.
FAU - Roberts, Lewis R
AU  - Roberts LR
AD  - Department of Bioengineering, Department of Cellular and Molecular Medicine, and 
      Department of Chemistry and Biochemistry, Departments of Pharmacology and
      Pathology, Moores Cancer Center, UCSD School of Medicine, La Jolla, CA
      92093-0723, USA.
FAU - Kisseleva, Tatiana
AU  - Kisseleva T
AD  - Department of Surgery, Departments of Pharmacology and Pathology, Moores Cancer
      Center, UCSD School of Medicine, La Jolla, CA 92093-0723, USA.
FAU - Karin, Michael
AU  - Karin M
AD  - Laboratory of Gene Regulation and Signal Transduction, Departments of
      Pharmacology and Pathology, Moores Cancer Center, UCSD School of Medicine, La
      Jolla, CA 92093-0723, USA.
FAU - Diaz-Meco, Maria T
AU  - Diaz-Meco MT
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Moscat, Jorge
AU  - Moscat J
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
LA  - eng
GR  - R01 DK108743/DK/NIDDK NIH HHS/United States
GR  - R01 CA192642/CA/NCI NIH HHS/United States
GR  - P01 DK098108/DK/NIDDK NIH HHS/United States
GR  - P42 ES010337/ES/NIEHS NIH HHS/United States
GR  - R01 CA172025/CA/NCI NIH HHS/United States
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - R01 DK099205/DK/NIDDK NIH HHS/United States
GR  - R01 CA118165/CA/NCI NIH HHS/United States
GR  - U01 AA022614/AA/NIAAA NIH HHS/United States
GR  - R01 CA163798/CA/NCI NIH HHS/United States
GR  - R01 DK101737/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptors, Calcitriol)
RN  - 0 (Retinoid X Receptors)
RN  - 0 (SQSTM1 protein, human)
RN  - 0 (Sequestosome-1 Protein)
RN  - 0 (Sqstm1 protein, mouse)
RN  - 0 (VDR protein, human)
SB  - IM
CIN - Cancer Cell. 2016 Oct 10;30(4):509-510. PMID: 27728799
MH  - Animals
MH  - HEK293 Cells
MH  - Hepatic Stellate Cells/*metabolism/pathology
MH  - Humans
MH  - Liver Cirrhosis/*metabolism/pathology
MH  - Liver Neoplasms/*metabolism/pathology
MH  - Mice
MH  - Mice, Knockout
MH  - Receptors, Calcitriol/*metabolism
MH  - Retinoid X Receptors/metabolism
MH  - Sequestosome-1 Protein/*metabolism
MH  - Signal Transduction
PMC - PMC5081228
MID - NIHMS817472
OTO - NOTNLM
OT  - *fibrosis
OT  - *hepatic stellate cells
OT  - *hepatocellular carcinoma
OT  - *inflammation
OT  - *liver cancer
OT  - *non-alcoholic steatohepatitis
OT  - *nuclear receptors
OT  - *p62
OT  - *sequestosome-1
OT  - *vitamin D receptor
EDAT- 2016/10/12 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/02/08 00:00 [received]
PHST- 2016/07/07 00:00 [revised]
PHST- 2016/09/12 00:00 [accepted]
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - 10.1016/j.ccell.2016.09.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):595-609. doi: 10.1016/j.ccell.2016.09.004.

PMID- 27728805
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine
      Prostate Cancer.
PG  - 563-577
LID - S1535-6108(16)30440-8 [pii]
LID - 10.1016/j.ccell.2016.09.005 [doi]
AB  - The transition from castration-resistant prostate adenocarcinoma (CRPC) to
      neuroendocrine prostate cancer (NEPC) has emerged as an important mechanism of
      treatment resistance. NEPC is associated with overexpression and gene
      amplification of MYCN (encoding N-Myc). N-Myc is an established oncogene in
      several rare pediatric tumors, but its role in prostate cancer progression is not
      well established. Integrating a genetically engineered mouse model and human
      prostate cancer transcriptome data, we show that N-Myc overexpression leads to
      the development of poorly differentiated, invasive prostate cancer that is
      molecularly similar to human NEPC. This includes an abrogation of androgen
      receptor signaling and induction of Polycomb Repressive Complex 2 signaling.
      Altogether, our data establishes N-Myc as an oncogenic driver of NEPC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Dardenne, Etienne
AU  - Dardenne E
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Beltran, Himisha
AU  - Beltran H
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Department 
      of Medicine, Weill Cornell Medicine, New York, NY 10065, USA; Englander Institute
      for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medicine,
      New York, NY 10065, USA.
FAU - Benelli, Matteo
AU  - Benelli M
AD  - Centre for Integrative Biology, University of Trento, Trento 38123, Italy.
FAU - Gayvert, Kaitlyn
AU  - Gayvert K
AD  - Department of Physiology and Biophysics, Institute for Computational Biomedicine,
      Weill Cornell Medicine, New York, NY 10065 USA; Tri-Institutional Training
      Program in Computational Biology and Medicine of Weill Cornell Medicine, Memorial
      Sloan Kettering Cancer Center, New York, NY 10065, and Cornell University,
      Ithaca, NY 14853, USA.
FAU - Berger, Adeline
AU  - Berger A
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Puca, Loredana
AU  - Puca L
AD  - Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill
      Cornell Medicine, New York, NY 10065, USA.
FAU - Cyrta, Joanna
AU  - Cyrta J
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine, New
      York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Sboner, Andrea
AU  - Sboner A
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine, New
      York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA;
      Department of Physiology and Biophysics, Institute for Computational Biomedicine,
      Weill Cornell Medicine, New York, NY 10065 USA; Tri-Institutional Training
      Program in Computational Biology and Medicine of Weill Cornell Medicine, Memorial
      Sloan Kettering Cancer Center, New York, NY 10065, and Cornell University,
      Ithaca, NY 14853, USA.
FAU - Noorzad, Zohal
AU  - Noorzad Z
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - MacDonald, Theresa
AU  - MacDonald T
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Cheung, Cynthia
AU  - Cheung C
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Yuen, Ka Shing
AU  - Yuen KS
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA.
FAU - Gao, Dong
AU  - Gao D
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Chen, Yu
AU  - Chen Y
AD  - Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA; Human
      Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Eilers, Martin
AU  - Eilers M
AD  - Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, 
      University of Wurzburg, Am Hubland, 97074 Wurzburg, Germany.
FAU - Mosquera, Juan-Miguel
AU  - Mosquera JM
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine, New
      York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Robinson, Brian D
AU  - Robinson BD
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Englander Institute for Precision Medicine, New
      York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Elemento, Olivier
AU  - Elemento O
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Englander
      Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell
      Medicine, New York, NY 10065, USA; Department of Physiology and Biophysics,
      Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY
      10065 USA.
FAU - Rubin, Mark A
AU  - Rubin MA
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA; Englander Institute for Precision Medicine, New York-Presbyterian
      Hospital, Weill Cornell Medicine, New York, NY 10065, USA; Department of
      Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell
      Medicine, New York, NY 10065 USA.
FAU - Demichelis, Francesca
AU  - Demichelis F
AD  - Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill
      Cornell Medicine, New York, NY 10065, USA; Centre for Integrative Biology,
      University of Trento, Trento 38123, Italy.
FAU - Rickman, David S
AU  - Rickman DS
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New
      York, NY 10065, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA; Englander Institute for Precision Medicine, New York-Presbyterian
      Hospital, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:
      dsr2005@med.cornell.edu.
LA  - eng
GR  - R01 CA179100/CA/NCI NIH HHS/United States
GR  - R01 CA193837/CA/NCI NIH HHS/United States
GR  - P50 CA092629/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - K08 CA140946/CA/NCI NIH HHS/United States
GR  - R01 CA116337/CA/NCI NIH HHS/United States
GR  - U01 CA111275/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Azepines)
RN  - 0 (MLN 8237)
RN  - 0 (MYCN protein, human)
RN  - 0 (MYCN protein, mouse)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Ezh2 protein, mouse)
SB  - IM
MH  - Animals
MH  - Azepines/pharmacology
MH  - Enhancer of Zeste Homolog 2 Protein/antagonists & inhibitors/*genetics/metabolism
MH  - Genes, myc
MH  - Heterografts
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - N-Myc Proto-Oncogene Protein/biosynthesis/*genetics/metabolism
MH  - Neuroendocrine Tumors/drug therapy/*genetics/metabolism/pathology
MH  - Prostatic Neoplasms/drug therapy/*genetics/metabolism/pathology
MH  - Prostatic Neoplasms, Castration-Resistant/drug
      therapy/genetics/metabolism/pathology
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Pyrimidines/pharmacology
MH  - Signal Transduction
MH  - Transcription, Genetic
PMC - PMC5540451
MID - NIHMS883202
OTO - NOTNLM
OT  - *Aurora kinase A
OT  - *EZH2
OT  - *N-Myc
OT  - *castration-resistant prostate adenocarcinoma
OT  - *genetically engineered mouse
OT  - *neuroendocrine prostate cancer
OT  - *prostate cancer organoid
EDAT- 2016/10/12 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/12 06:00
PHST- 2015/12/11 00:00 [received]
PHST- 2016/06/22 00:00 [revised]
PHST- 2016/09/13 00:00 [accepted]
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30440-8 [pii]
AID - 10.1016/j.ccell.2016.09.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005.

PMID- 27728804
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor
      Surveillance and Tumor Progression.
PG  - 533-547
LID - S1535-6108(16)30438-X [pii]
LID - 10.1016/j.ccell.2016.09.003 [doi]
AB  - Oncogene-induced senescence causes hepatocytes to secrete cytokines, which induce
      their immune-mediated clearance to prevent tumor initiation, a process termed
      "senescence surveillance." However, senescent hepatocytes give rise to
      hepatocellular carcinomas (HCCs), if the senescence program is bypassed or if
      senescent cells are not cleared. Here, we show context-specific roles for CCR2(+)
      myeloid cells in liver cancer. Senescence surveillance requires the recruitment
      and maturation of CCR2(+) myeloid cells, and CCR2 ablation caused outgrowth of
      HCC. In contrast, HCC cells block the maturation of recruited myeloid precursors,
      which, through NK cell inhibition, promote growth of murine HCC and worsen the
      prognosis and survival of human HCC patients. Thus, while senescent
      hepatocyte-secreted chemokines suppress liver cancer initiation, they may
      accelerate the growth of fully established HCC.
CI  - Published by Elsevier Inc.
FAU - Eggert, Tobias
AU  - Eggert T
AD  - Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology
      Branch, Center for Cancer Research, National Cancer Institute, National
      Institutes of Health, Bethesda, MD 20892, USA.
FAU - Wolter, Katharina
AU  - Wolter K
AD  - Division of Gastrointestinal Oncology, Department of Internal Medicine I,
      University of Tubingen, 72076 Tubingen, Germany.
FAU - Ji, Juling
AU  - Ji J
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Ma, Chi
AU  - Ma C
AD  - Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology
      Branch, Center for Cancer Research, National Cancer Institute, National
      Institutes of Health, Bethesda, MD 20892, USA.
FAU - Yevsa, Tetyana
AU  - Yevsa T
AD  - Division of Gastrointestinal Oncology, Department of Internal Medicine I,
      University of Tubingen, 72076 Tubingen, Germany.
FAU - Klotz, Sabrina
AU  - Klotz S
AD  - Division of Gastrointestinal Oncology, Department of Internal Medicine I,
      University of Tubingen, 72076 Tubingen, Germany.
FAU - Medina-Echeverz, Jose
AU  - Medina-Echeverz J
AD  - Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology
      Branch, Center for Cancer Research, National Cancer Institute, National
      Institutes of Health, Bethesda, MD 20892, USA.
FAU - Longerich, Thomas
AU  - Longerich T
AD  - Institute of Pathology, University Hospital RWTH Aachen, 52074 Aachen, Germany.
FAU - Forgues, Marshonna
AU  - Forgues M
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Reisinger, Florian
AU  - Reisinger F
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany; Division of Chronic Inflammation and Cancer,
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Heikenwalder, Mathias
AU  - Heikenwalder M
AD  - Institute of Virology, Technische Universitat Munchen and Helmholtz Zentrum
      Munchen, 81675 Munich, Germany; Division of Chronic Inflammation and Cancer,
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Wang, Xin Wei
AU  - Wang XW
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Zender, Lars
AU  - Zender L
AD  - Division of Gastrointestinal Oncology, Department of Internal Medicine I,
      University of Tubingen, 72076 Tubingen, Germany; Translational Gastrointestinal
      Oncology Group within the German Consortium for Translational Cancer Research
      (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
      Electronic address: lars.zender@med.uni-tuebingen.de.
FAU - Greten, Tim F
AU  - Greten TF
AD  - Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology
      Branch, Center for Cancer Research, National Cancer Institute, National
      Institutes of Health, Bethesda, MD 20892, USA. Electronic address:
      tim.greten@nih.gov.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CIN - Cancer Cell. 2016 Oct 10;30(4):507-508. PMID: 27728798
MH  - Animals
MH  - Carcinoma, Hepatocellular/*immunology/pathology
MH  - Cellular Senescence/immunology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Immunologic Surveillance
MH  - Liver Neoplasms/*immunology/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
OTO - NOTNLM
OT  - *CCL2
OT  - *CCR2
OT  - *HCC
OT  - *MDSC
OT  - *NK cells
OT  - *hepatocellular carcinoma
OT  - *liver cancer
OT  - *macrophages
OT  - *myeloid cells
OT  - *senescence
EDAT- 2016/10/12 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/12 06:00
PHST- 2015/06/15 00:00 [received]
PHST- 2016/03/28 00:00 [revised]
PHST- 2016/09/12 00:00 [accepted]
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30438-X [pii]
AID - 10.1016/j.ccell.2016.09.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):533-547. doi: 10.1016/j.ccell.2016.09.003.

PMID- 27728803
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell
      Carcinoma from Different Cells of Origin.
PG  - 519-532
LID - S1535-6108(16)30436-6 [pii]
LID - 10.1016/j.ccell.2016.09.001 [doi]
AB  - Lung squamous cell carcinoma (LSCC) is a devastating malignancy with no effective
      treatments, due to its complex genomic profile. Therefore, preclinical models
      mimicking its salient features are urgently needed. Here we describe mouse models
      bearing various combinations of genetic lesions predominantly found in human
      LSCC. We show that SOX2 but not FGFR1 overexpression in tracheobronchial basal
      cells combined with Cdkn2ab and Pten loss results in LSCC closely resembling the 
      human counterpart. Interestingly, Sox2;Pten;Cdkn2ab mice develop LSCC with a more
      peripheral location when Club or Alveolar type 2 (AT2) cells are targeted. Our
      model highlights the essential role of SOX2 in commanding the squamous cell fate 
      from different cells of origin and represents an invaluable tool for developing
      better intervention strategies.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Ferone, Giustina
AU  - Ferone G
AD  - Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan
      121, 1066 CX Amsterdam, the Netherlands.
FAU - Song, Ji-Ying
AU  - Song JY
AD  - Division of Experimental Animal Pathology, The Netherlands Cancer Institute,
      Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
FAU - Sutherland, Kate D
AU  - Sutherland KD
AD  - ACRF Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of
      Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, 
      The University of Melbourne, Parkville, VIC 3010, Australia.
FAU - Bhaskaran, Rajith
AU  - Bhaskaran R
AD  - Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan
      121, 1066 CX Amsterdam, the Netherlands; Skolkovo Institute of Science and
      Technology, Skolkovo Innovation Center, Building 5, Moscow 143026, Russia.
FAU - Monkhorst, Kim
AU  - Monkhorst K
AD  - Division of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX
      Amsterdam, the Netherlands.
FAU - Lambooij, Jan-Paul
AU  - Lambooij JP
AD  - Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan
      121, 1066 CX Amsterdam, the Netherlands.
FAU - Proost, Natalie
AU  - Proost N
AD  - Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan
      121, 1066 CX Amsterdam, the Netherlands.
FAU - Gargiulo, Gaetano
AU  - Gargiulo G
AD  - Department of Molecular Oncology, Max-Delbruck-Center for Molecular Medicine,
      Robert-Rossle-Strasse 10, 13092 Berlin, Germany.
FAU - Berns, Anton
AU  - Berns A
AD  - Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan
      121, 1066 CX Amsterdam, the Netherlands; Skolkovo Institute of Science and
      Technology, Skolkovo Innovation Center, Building 5, Moscow 143026, Russia.
      Electronic address: a.berns@nki.nl.
LA  - eng
GR  - 14-0433/Worldwide Cancer Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (SOX2 protein, human)
RN  - 0 (SOXB1 Transcription Factors)
RN  - 0 (Sox2 protein, mouse)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
SB  - IM
CIN - J Thorac Dis. 2017 Jan;9(1):E85-E86. PMID: 28203443
CIN - Cancer Cell. 2016 Oct 10;30(4):505-507. PMID: 27728797
MH  - Animals
MH  - Carcinoma, Squamous Cell/*genetics/metabolism/*pathology
MH  - Cell Proliferation/genetics
MH  - Disease Models, Animal
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/*genetics/metabolism/*pathology
MH  - Mice
MH  - Receptor, Fibroblast Growth Factor, Type 1/biosynthesis/genetics
MH  - SOXB1 Transcription Factors/*genetics
MH  - Transcription, Genetic
MH  - Tumor Microenvironment
PMC - PMC5065004
EDAT- 2016/10/12 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/03/03 00:00 [received]
PHST- 2016/07/05 00:00 [revised]
PHST- 2016/09/07 00:00 [accepted]
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30436-6 [pii]
AID - 10.1016/j.ccell.2016.09.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):519-532. doi: 10.1016/j.ccell.2016.09.001.

PMID- 27728802
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Targeting HIF2alpha in Clear-Cell Renal Cell Carcinoma.
PG  - 515-517
LID - S1535-6108(16)30451-2 [pii]
LID - 10.1016/j.ccell.2016.09.016 [doi]
AB  - In two recent studies, the HIF2alpha antagonist, PT2399, decreased
      HIF2alpha-dependent transcription and tumor growth in selected VHL-deficient
      clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2alpha 
      as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2alpha
      antagonism, and provide the foundation for predictive biomarker-driven clinical
      trials.
CI  - Published by Elsevier Inc.
FAU - Ricketts, Christopher J
AU  - Ricketts CJ
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892-1107, USA.
FAU - Crooks, Daniel R
AU  - Crooks DR
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892-1107, USA.
FAU - Linehan, W Marston
AU  - Linehan WM
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892-1107, USA. Electronic address: wml@nih.gov.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Indans)
RN  - 0 (PT2399)
RN  - 0 (Sulfones)
RN  - 0 (endothelial PAS domain-containing protein 1)
SB  - IM
CON - Nature. 2016 Nov 3;539(7627):112-117. PMID: 27595394
CON - Nature. 2016 Nov 3;539(7627):107-111. PMID: 27595393
MH  - Animals
MH  - Basic Helix-Loop-Helix Transcription Factors/*antagonists & inhibitors/*genetics
MH  - Carcinoma, Renal Cell/*drug therapy/genetics
MH  - Humans
MH  - Indans/*pharmacology
MH  - Kidney Neoplasms/*drug therapy
MH  - Mice
MH  - Mice, Nude
MH  - Molecular Targeted Therapy
MH  - Sulfones/*pharmacology
EDAT- 2016/10/12 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30451-2 [pii]
AID - 10.1016/j.ccell.2016.09.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):515-517. doi: 10.1016/j.ccell.2016.09.016.

PMID- 27728801
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Mdm2-RNA Interactions as a Target for Cancer Therapy: It's Not All About p53.
PG  - 513-514
LID - S1535-6108(16)30452-4 [pii]
LID - 10.1016/j.ccell.2016.09.017 [doi]
AB  - In this issue of Cancer Cell, Gu et al. characterize small molecules that inhibit
      the interaction of Mdm2 with the mRNA that encodes the anti-apoptotic XIAP,
      simultaneously decreasing expression of both proteins. This represents a novel
      approach that has relevance in tumor cells independent of p53 status.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Bohlman, Stephen
AU  - Bohlman S
AD  - Department of Oncological Sciences and The Graduate School of Biomedical
      Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Manfredi, James J
AU  - Manfredi JJ
AD  - Department of Oncological Sciences and The Graduate School of Biomedical
      Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
      Electronic address: james.manfredi@mssm.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 63231-63-0 (RNA)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
CON - Cancer Cell. 2016 Oct 10;30(4):623-636. PMID: 27666947
MH  - Apoptosis
MH  - Humans
MH  - Nuclear Proteins/genetics
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins c-mdm2/genetics
MH  - *RNA
MH  - RNA, Messenger/genetics
MH  - Tumor Suppressor Protein p53/*genetics
EDAT- 2016/10/12 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30452-4 [pii]
AID - 10.1016/j.ccell.2016.09.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):513-514. doi: 10.1016/j.ccell.2016.09.017.

PMID- 27728800
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - A New Role for Lyn in the CLL Microenvironment.
PG  - 511-512
LID - S1535-6108(16)30453-6 [pii]
LID - 10.1016/j.ccell.2016.09.018 [doi]
AB  - The role of Lyn, both a positive and a negative regulator of B and myeloid cells,
      in chronic lymphocytic leukemia (CLL) has not been well characterized. In this
      issue of Cancer Cell, Nguyen et al. demonstrated that Lyn in macrophages rather
      than in CLL cells is critical for the malignancy.
CI  - Copyright (c) 2016. Published by Elsevier Inc.
FAU - Dong, Shuai
AU  - Dong S
AD  - Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The 
      Ohio State University, Columbus, OH 43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center, The Ohio State University, Columbus, OH 43210, USA; Division of Medicinal
      Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210,
      USA. Electronic address: john.byrd@osumc.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.10.2 (src-Family Kinases)
SB  - IM
CON - Cancer Cell. 2016 Oct 10;30(4):610-622. PMID: 27728807
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell
MH  - Macrophages
MH  - Myeloid Cells
MH  - *src-Family Kinases
EDAT- 2016/10/12 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30453-6 [pii]
AID - 10.1016/j.ccell.2016.09.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):511-512. doi: 10.1016/j.ccell.2016.09.018.

PMID- 27728799
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - p62 in Liver Disease: Good Guy or Bad Guy?
PG  - 509-510
LID - S1535-6108(16)30448-2 [pii]
LID - 10.1016/j.ccell.2016.09.013 [doi]
AB  - The multidomain adaptor protein p62 has been suggested to exert pro-oncogenic
      functions in hepatocytes and other epithelial cells. In this issue of Cancer
      Cell, Duran et al. show that p62 acts as a non-cell-autonomous tumor suppressor
      in liver cancer by counteracting the activation of hepatic stellate cells.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hu, Zexi
AU  - Hu Z
AD  - Department of Internal Medicine VIII, University Hospital Tubingen, 72076
      Tubingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard 
      Karls University Tubingen, Otfried-Muller-Str. 14, 72076 Tubingen, Germany.
FAU - Zender, Lars
AU  - Zender L
AD  - Department of Internal Medicine VIII, University Hospital Tubingen, 72076
      Tubingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard 
      Karls University Tubingen, Otfried-Muller-Str. 14, 72076 Tubingen, Germany;
      Translational Gastrointestinal Oncology Group within the German Consortium for
      Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ),
      Heidelberg 69120, Germany. Electronic address: lars.zender@med.uni-tuebingen.de.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Oct 10;30(4):595-609. PMID: 27728806
MH  - Epithelial Cells
MH  - Genes, Tumor Suppressor
MH  - *Hepatocytes
MH  - Humans
MH  - *Liver Neoplasms
EDAT- 2016/10/12 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30448-2 [pii]
AID - 10.1016/j.ccell.2016.09.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):509-510. doi: 10.1016/j.ccell.2016.09.013.

PMID- 27728798
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Senescence and Cancer: In the Name of Immunosuppression.
PG  - 507-508
LID - S1535-6108(16)30450-0 [pii]
LID - 10.1016/j.ccell.2016.09.015 [doi]
AB  - Senescent cells and cancer cells recruit immunosuppressive myeloid cells. In this
      issue of Cancer Cell, Eggert et al. report that senescent cells recruit immature 
      myeloid cells (iMCs) through the secretion of the CCL2 cytokine and that these
      iMCs have pro- or anti-tumorigenic activities, depending on the cellular context.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Llanos, Susana
AU  - Llanos S
AD  - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. Electronic
      address: sllanos@cnio.es.
FAU - Serrano, Manuel
AU  - Serrano M
AD  - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. Electronic
      address: mserrano@cnio.es.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cytokines)
SB  - IM
CON - Cancer Cell. 2016 Oct 10;30(4):533-547. PMID: 27728804
MH  - Cellular Senescence
MH  - Cytokines
MH  - Humans
MH  - *Immune Tolerance
MH  - Myeloid Cells
MH  - *Neoplasms
EDAT- 2016/10/12 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30450-0 [pii]
AID - 10.1016/j.ccell.2016.09.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):507-508. doi: 10.1016/j.ccell.2016.09.015.

PMID- 27728797
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - SOX2 Determines Lineage Restriction: Modeling Lung Squamous Cell Carcinoma in the
      Mouse.
PG  - 505-507
LID - S1535-6108(16)30447-0 [pii]
LID - 10.1016/j.ccell.2016.09.012 [doi]
AB  - In this issue of Cancer Cell, Ferone et al. demonstrate that SOX2 not only drives
      lung tumor formation but also restricts tumor lineage to squamous cell carcinoma 
      (LSCC), regardless of cell of origin. This novel LSCC model should facilitate
      identification of key oncogenic drivers and treatment strategies for this lung
      cancer subtype.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Murray, Nicole R
AU  - Murray NR
AD  - Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL
      32224, USA.
FAU - Justilien, Verline
AU  - Justilien V
AD  - Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL
      32224, USA.
FAU - Fields, Alan P
AU  - Fields AP
AD  - Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL
      32224, USA. Electronic address: fields.alan@mayo.edu.
LA  - eng
GR  - R01 CA081436/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (SOXB1 Transcription Factors)
SB  - IM
CON - Cancer Cell. 2016 Oct 10;30(4):519-532. PMID: 27728803
MH  - Animals
MH  - Carcinoma, Non-Small-Cell Lung
MH  - Carcinoma, Squamous Cell/*genetics
MH  - Lung Neoplasms/genetics
MH  - Mice
MH  - Oncogenes
MH  - SOXB1 Transcription Factors/*genetics
EDAT- 2016/10/12 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30447-0 [pii]
AID - 10.1016/j.ccell.2016.09.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):505-507. doi: 10.1016/j.ccell.2016.09.012.

PMID- 27693047
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Expression of Idh1(R132H) in the Murine Subventricular Zone Stem Cell Niche
      Recapitulates Features of Early Gliomagenesis.
PG  - 578-594
LID - S1535-6108(16)30402-0 [pii]
LID - 10.1016/j.ccell.2016.08.017 [doi]
AB  - Isocitrate dehydrogenase 1 mutations drive human gliomagenesis, probably through 
      neomorphic enzyme activity that produces D-2-hydroxyglutarate. To model this
      disease, we conditionally expressed Idh1(R132H) in the subventricular zone (SVZ) 
      of the adult mouse brain. The mice developed hydrocephalus and grossly dilated
      lateral ventricles, with accumulation of 2-hydroxyglutarate and reduced
      alpha-ketoglutarate. Stem and transit amplifying/progenitor cell populations were
      expanded, and proliferation increased. Cells expressing SVZ markers infiltrated
      surrounding brain regions. SVZ cells also gave rise to proliferative
      subventricular nodules. DNA methylation was globally increased, while
      hydroxymethylation was decreased. Mutant SVZ cells overexpressed Wnt, cell-cycle 
      and stem cell genes, and shared an expression signature with human gliomas.
      Idh1(R132H) mutation in the major adult neurogenic stem cell niche causes a
      phenotype resembling gliomagenesis.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Bardella, Chiara
AU  - Bardella C
AD  - Molecular & Population Genetics Laboratory, Wellcome Trust Centre for Human
      Genetics, University of Oxford, Oxford OX3 7BN, UK.
FAU - Al-Dalahmah, Osama
AU  - Al-Dalahmah O
AD  - Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 
      3QX, UK.
FAU - Krell, Daniel
AU  - Krell D
AD  - Molecular & Population Genetics Laboratory, Wellcome Trust Centre for Human
      Genetics, University of Oxford, Oxford OX3 7BN, UK.
FAU - Brazauskas, Pijus
AU  - Brazauskas P
AD  - Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Al-Qahtani, Khalid
AU  - Al-Qahtani K
AD  - Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, UK.
FAU - Tomkova, Marketa
AU  - Tomkova M
AD  - Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Adam, Julie
AU  - Adam J
AD  - Hypoxia Biology Laboratory, Henry Wellcome Building for Molecular Physiology,
      University of Oxford, Oxford OX3 7BN, UK; Radcliffe Department of Medicine,
      OCDEM, Churchill Hospital, Oxford OX3 7LJ, UK.
FAU - Serres, Sebastien
AU  - Serres S
AD  - Department of Oncology, Cancer Research UK and MRC Oxford Institute for Radiation
      Oncology, University of Oxford, Oxford OX3 7LE, UK; School of Life Sciences, The 
      Medical School, University of Nottingham, Nottingham NG7 2UH, UK.
FAU - Lockstone, Helen
AU  - Lockstone H
AD  - Bioinformatics, Wellcome Trust Centre for Human Genetics, University of Oxford,
      Oxford OX3 7BN, UK.
FAU - Freeman-Mills, Luke
AU  - Freeman-Mills L
AD  - Molecular & Population Genetics Laboratory, Wellcome Trust Centre for Human
      Genetics, University of Oxford, Oxford OX3 7BN, UK.
FAU - Pfeffer, Inga
AU  - Pfeffer I
AD  - Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, UK.
FAU - Sibson, Nicola
AU  - Sibson N
AD  - Department of Oncology, Cancer Research UK and MRC Oxford Institute for Radiation
      Oncology, University of Oxford, Oxford OX3 7LE, UK.
FAU - Goldin, Robert
AU  - Goldin R
AD  - Centre for Pathology, St Mary's Hospital, Imperial College, London W2 1NY, UK.
FAU - Schuster-Boeckler, Benjamin
AU  - Schuster-Boeckler B
AD  - Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Pollard, Patrick J
AU  - Pollard PJ
AD  - Hypoxia Biology Laboratory, Henry Wellcome Building for Molecular Physiology,
      University of Oxford, Oxford OX3 7BN, UK; Department of Physiology, Institute of 
      Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, 405
      30 Gothenburg, Sweden.
FAU - Soga, Tomoyoshi
AU  - Soga T
AD  - Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji,
      Tsuruoka, Yamagata 997-0052, Japan.
FAU - McCullagh, James S
AU  - McCullagh JS
AD  - Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, UK.
FAU - Schofield, Christopher J
AU  - Schofield CJ
AD  - Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, UK.
FAU - Mulholland, Paul
AU  - Mulholland P
AD  - Department of Oncology, University College London Hospital, London NW1 2BU, UK.
FAU - Ansorge, Olaf
AU  - Ansorge O
AD  - Nuffield Department of Clinical Neurosciences, Department of Neuropathology, John
      Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK.
FAU - Kriaucionis, Skirmantas
AU  - Kriaucionis S
AD  - Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Ratcliffe, Peter J
AU  - Ratcliffe PJ
AD  - Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research,
      University of Oxford, Oxford OX3 7DQ, UK; Hypoxia Biology Laboratory, Henry
      Wellcome Building for Molecular Physiology, University of Oxford, Oxford OX3 7BN,
      UK.
FAU - Szele, Francis G
AU  - Szele FG
AD  - Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 
      3QX, UK. Electronic address: francis.szele@dpag.ox.ac.uk.
FAU - Tomlinson, Ian
AU  - Tomlinson I
AD  - Molecular & Population Genetics Laboratory, Wellcome Trust Centre for Human
      Genetics, University of Oxford, Oxford OX3 7BN, UK. Electronic address:
      iant@well.ox.ac.uk.
LA  - eng
GR  - A12055/Cancer Research UK/United Kingdom
GR  - C5255/A15935/Cancer Research UK/United Kingdom
GR  - 090532/Z/09/Z/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160929
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*enzymology/genetics/pathology
MH  - DNA Methylation
MH  - Glioma/*enzymology/genetics/pathology
MH  - Isocitrate Dehydrogenase/*biosynthesis/genetics
MH  - Lateral Ventricles/*enzymology/pathology
MH  - Mice
MH  - Mice, Transgenic
MH  - Mutation
MH  - Neoplastic Stem Cells/*enzymology/pathology
MH  - *Stem Cell Niche
MH  - Transcriptome
PMC - PMC5064912
OTO - NOTNLM
OT  - *DNA (hydroxy)methylation
OT  - *Wnt
OT  - *glioma
OT  - *hydroxyglutarate
OT  - *hydroxylase
OT  - *isocitrate dehydrogenase
OT  - *oncometabolite
OT  - *stem cell
OT  - *subventricular zone
OT  - *alpha-ketoglutarate
EDAT- 2016/10/04 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/04 06:00
PHST- 2015/12/29 00:00 [received]
PHST- 2016/06/22 00:00 [revised]
PHST- 2016/08/29 00:00 [accepted]
PHST- 2016/10/04 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
PHST- 2016/10/04 06:00 [entrez]
AID - S1535-6108(16)30402-0 [pii]
AID - 10.1016/j.ccell.2016.08.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):578-594. doi: 10.1016/j.ccell.2016.08.017. Epub
      2016 Sep 29.

PMID- 27693046
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through
      Glypican Release and Is a Marker of Clinical Outcome.
PG  - 548-562
LID - S1535-6108(16)30401-9 [pii]
LID - 10.1016/j.ccell.2016.08.016 [doi]
AB  - Neuroblastoma is a pediatric embryonal malignancy characterized by impaired
      neuronal differentiation. A better understanding of neuroblastoma differentiation
      is essential for developing new therapeutic approaches. GDE2 (encoded by GDPD5)
      is a six-transmembrane-domain glycerophosphodiesterase that promotes embryonic
      neurogenesis. We find that high GDPD5 expression is strongly associated with
      favorable outcome in neuroblastoma. GDE2 induces differentiation of neuroblastoma
      cells, suppresses cell motility, and opposes RhoA-driven neurite retraction. GDE2
      alters the Rac-RhoA activity balance and the expression of multiple
      differentiation-associated genes. Mechanistically, GDE2 acts by cleaving (in cis)
      and releasing glycosylphosphatidylinositol-anchored glypican-6, a putative
      co-receptor. A single point mutation in the ectodomain abolishes GDE2 function.
      Our results reveal GDE2 as a cell-autonomous inducer of neuroblastoma
      differentiation with prognostic significance and potential therapeutic value.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Matas-Rico, Elisa
AU  - Matas-Rico E
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - van Veen, Michiel
AU  - van Veen M
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Leyton-Puig, Daniela
AU  - Leyton-Puig D
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - van den Berg, Jeroen
AU  - van den Berg J
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Koster, Jan
AU  - Koster J
AD  - Department of Oncogenomics, Academic Medical Center, University of Amsterdam,
      1105 AZ Amsterdam, the Netherlands.
FAU - Kedziora, Katarzyna M
AU  - Kedziora KM
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Molenaar, Bas
AU  - Molenaar B
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Weerts, Marjolein J A
AU  - Weerts MJ
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - de Rink, Iris
AU  - de Rink I
AD  - Deep Sequencing Core Facility, The Netherlands Cancer Institute, 1066 CX
      Amsterdam, the Netherlands.
FAU - Medema, Rene H
AU  - Medema RH
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Giepmans, Ben N G
AU  - Giepmans BN
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Perrakis, Anastassis
AU  - Perrakis A
AD  - Division of Biochemistry, The Netherlands Cancer Institute, 1066 CX Amsterdam,
      the Netherlands.
FAU - Jalink, Kees
AU  - Jalink K
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Versteeg, Rogier
AU  - Versteeg R
AD  - Department of Oncogenomics, Academic Medical Center, University of Amsterdam,
      1105 AZ Amsterdam, the Netherlands.
FAU - Moolenaar, Wouter H
AU  - Moolenaar WH
AD  - Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands. Electronic address: w.moolenaar@nki.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160929
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (GPC6 protein, human)
RN  - 0 (Glycosylphosphatidylinositols)
RN  - 0 (Glypicans)
RN  - EC 3.1.4.- (Phosphoric Diester Hydrolases)
RN  - EC 3.1.4.46 (glycerophosphodiester phosphodiesterase)
SB  - IM
EIN - Cancer Cell. 2016 Dec 12;30(6):986. PMID: 27960089
MH  - Animals
MH  - Cell Differentiation/physiology
MH  - Chickens
MH  - Glycosylphosphatidylinositols/metabolism
MH  - Glypicans/*metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Neuroblastoma/*enzymology/*pathology
MH  - Phosphoric Diester Hydrolases/*metabolism
MH  - Prognosis
EDAT- 2016/10/04 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/10/04 06:00
PHST- 2015/11/09 00:00 [received]
PHST- 2016/06/06 00:00 [revised]
PHST- 2016/08/26 00:00 [accepted]
PHST- 2016/10/04 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
PHST- 2016/10/04 06:00 [entrez]
AID - S1535-6108(16)30401-9 [pii]
AID - 10.1016/j.ccell.2016.08.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):548-562. doi: 10.1016/j.ccell.2016.08.016. Epub
      2016 Sep 29.

PMID- 27666947
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Oct 10
TI  - Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.
PG  - 623-636
LID - S1535-6108(16)30400-7 [pii]
LID - 10.1016/j.ccell.2016.08.015 [doi]
AB  - MDM2 and XIAP are mutually regulated. Binding of MDM2 RING protein to the IRES
      region on XIAP mRNA results in MDM2 protein stabilization and enhanced XIAP
      translation. In this study, we developed a protein-RNA fluorescence polarization 
      (FP) assay for high-throughput screening (HTS) of chemical libraries. Our FP-HTS 
      identified eight inhibitors that blocked the MDM2 protein-XIAP RNA interaction,
      leading to MDM2 degradation. The compound-induced MDM2 downregulation resulted
      not only in inhibition of XIAP expression, but also in activation of p53, which
      contributed to cancer cell apoptosis in vitro and inhibition of cancer cell
      proliferation in vivo. Importantly, one of the MDM2/XIAP inhibitors, MX69, showed
      minimal inhibitory effect on normal human hematopoiesis in vitro and was very
      well tolerated in animal models.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Gu, Lubing
AU  - Gu L
AD  - Division of Hematology/Oncology, Department of Pediatrics, Aflac Cancer and Blood
      Disorders Center, Emory University School of Medicine, 1760 Haygood Drive,
      Atlanta, GA 30322, USA.
FAU - Zhang, Hailong
AU  - Zhang H
AD  - Division of Hematology/Oncology, Department of Pediatrics, Aflac Cancer and Blood
      Disorders Center, Emory University School of Medicine, 1760 Haygood Drive,
      Atlanta, GA 30322, USA.
FAU - Liu, Tao
AU  - Liu T
AD  - Division of Hematology/Oncology, Department of Pediatrics, Aflac Cancer and Blood
      Disorders Center, Emory University School of Medicine, 1760 Haygood Drive,
      Atlanta, GA 30322, USA.
FAU - Zhou, Sheng
AU  - Zhou S
AD  - Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan 430030, China.
FAU - Du, Yuhong
AU  - Du Y
AD  - Department of Pharmacology, Emory Chemical Biology Discovery Center, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Xiong, Jing
AU  - Xiong J
AD  - Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan 430030, China.
FAU - Yi, Sha
AU  - Yi S
AD  - Division of Hematology/Oncology, Department of Pediatrics, Aflac Cancer and Blood
      Disorders Center, Emory University School of Medicine, 1760 Haygood Drive,
      Atlanta, GA 30322, USA.
FAU - Qu, Cheng-Kui
AU  - Qu CK
AD  - Division of Hematology/Oncology, Department of Pediatrics, Aflac Cancer and Blood
      Disorders Center, Emory University School of Medicine, 1760 Haygood Drive,
      Atlanta, GA 30322, USA.
FAU - Fu, Haian
AU  - Fu H
AD  - Department of Pharmacology, Emory Chemical Biology Discovery Center, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Zhou, Muxiang
AU  - Zhou M
AD  - Division of Hematology/Oncology, Department of Pediatrics, Aflac Cancer and Blood
      Disorders Center, Emory University School of Medicine, 1760 Haygood Drive,
      Atlanta, GA 30322, USA. Electronic address: mzhou@emory.edu.
LA  - eng
GR  - R01 CA123490/CA/NCI NIH HHS/United States
GR  - R01 CA143107/CA/NCI NIH HHS/United States
GR  - R01 CA180519/CA/NCI NIH HHS/United States
GR  - U01 CA168449/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160922
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (X-Linked Inhibitor of Apoptosis Protein)
RN  - 0 (XIAP protein, human)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
CIN - Cancer Cell. 2016 Oct 10;30(4):513-514. PMID: 27728801
MH  - Animals
MH  - Cell Line, Tumor
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, SCID
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
MH  - Proto-Oncogene Proteins c-mdm2/*antagonists & inhibitors
MH  - X-Linked Inhibitor of Apoptosis Protein/*antagonists & inhibitors
MH  - Xenograft Model Antitumor Assays
PMC - PMC5079537
MID - NIHMS814272
EDAT- 2016/09/27 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/09/27 06:00
PHST- 2015/08/04 00:00 [received]
PHST- 2015/11/16 00:00 [revised]
PHST- 2016/08/26 00:00 [accepted]
PHST- 2016/09/27 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
PHST- 2016/09/27 06:00 [entrez]
AID - S1535-6108(16)30400-7 [pii]
AID - 10.1016/j.ccell.2016.08.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Oct 10;30(4):623-636. doi: 10.1016/j.ccell.2016.08.015. Epub
      2016 Sep 22.

PMID- 27622340
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against
      Oncogenic BRAF Signaling.
PG  - 501-503
LID - S1535-6108(16)30393-2 [pii]
LID - 10.1016/j.ccell.2016.08.008 [doi]
FAU - Karoulia, Zoi
AU  - Karoulia Z
FAU - Wu, Yang
AU  - Wu Y
FAU - Ahmed, Tamer A
AU  - Ahmed TA
FAU - Xin, Qisheng
AU  - Xin Q
FAU - Bollard, Julien
AU  - Bollard J
FAU - Krepler, Clemens
AU  - Krepler C
FAU - Wu, Xuewei
AU  - Wu X
FAU - Zhang, Chao
AU  - Zhang C
FAU - Bollag, Gideon
AU  - Bollag G
FAU - Herlyn, Meenhard
AU  - Herlyn M
FAU - Fagin, James A
AU  - Fagin JA
FAU - Lujambio, Amaia
AU  - Lujambio A
FAU - Gavathiotis, Evripidis
AU  - Gavathiotis E
FAU - Poulikakos, Poulikos I
AU  - Poulikakos PI
LA  - eng
GR  - R01 CA178394/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Published Erratum
DEP - 20160912
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Sep 12;30(3):485-498. PMID: 27523909
EDAT- 2016/09/14 06:00
MHDA- 2016/09/14 06:01
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2016/09/14 06:01 [medline]
PHST- 2016/09/14 06:00 [entrez]
AID - S1535-6108(16)30393-2 [pii]
AID - 10.1016/j.ccell.2016.08.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub
      2016 Sep 12.

PMID- 27622339
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - IDH1, Histone Methylation, and So Forth.
PG  - 501
LID - S1535-6108(16)30395-6 [pii]
LID - 10.1016/j.ccell.2016.08.010 [doi]
FAU - Penard-Lacronique, Virginie
AU  - Penard-Lacronique V
FAU - Bernard, Olivier A
AU  - Bernard OA
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160912
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Aug 8;30(2):192-194. PMID: 27505668
EDAT- 2016/09/14 06:00
MHDA- 2016/09/14 06:01
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2016/09/14 06:01 [medline]
PHST- 2016/09/14 06:00 [entrez]
AID - S1535-6108(16)30395-6 [pii]
AID - 10.1016/j.ccell.2016.08.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):501. doi: 10.1016/j.ccell.2016.08.010. Epub 2016
      Sep 12.

PMID- 27622338
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance
      to PD-L1 Blockade.
PG  - 500
LID - S1535-6108(16)30396-8 [pii]
LID - 10.1016/j.ccell.2016.08.011 [doi]
FAU - Tang, Haidong
AU  - Tang H
FAU - Wang, Yang
AU  - Wang Y
FAU - Chlewicki, Lukasz K
AU  - Chlewicki LK
FAU - Zhang, Yuan
AU  - Zhang Y
FAU - Guo, Jingya
AU  - Guo J
FAU - Liang, Wei
AU  - Liang W
FAU - Wang, Jieyi
AU  - Wang J
FAU - Wang, Xiaoxiao
AU  - Wang X
FAU - Fu, Yang-Xin
AU  - Fu YX
LA  - eng
GR  - R01 CA134563/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Published Erratum
DEP - 20160912
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Mar 14;29(3):285-96. PMID: 26977880
EDAT- 2016/09/14 06:00
MHDA- 2016/09/14 06:01
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2016/09/14 06:01 [medline]
PHST- 2016/09/14 06:00 [entrez]
AID - S1535-6108(16)30396-8 [pii]
AID - 10.1016/j.ccell.2016.08.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):500. doi: 10.1016/j.ccell.2016.08.011. Epub 2016
      Sep 12.

PMID- 27622337
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.
PG  - 499-500
LID - S1535-6108(16)30394-4 [pii]
LID - 10.1016/j.ccell.2016.08.009 [doi]
FAU - Lalaoui, Najoua
AU  - Lalaoui N
FAU - Hanggi, Kay
AU  - Hanggi K
FAU - Brumatti, Gabriela
AU  - Brumatti G
FAU - Chau, Diep
AU  - Chau D
FAU - Nguyen, Nhu-Y N
AU  - Nguyen NN
FAU - Vasilikos, Lazaros
AU  - Vasilikos L
FAU - Spilgies, Lisanne M
AU  - Spilgies LM
FAU - Heckmann, Denise A
AU  - Heckmann DA
FAU - Ma, Chunyan
AU  - Ma C
FAU - Ghisi, Margherita
AU  - Ghisi M
FAU - Salmon, Jessica M
AU  - Salmon JM
FAU - Matthews, Geoffrey M
AU  - Matthews GM
FAU - de Valle, Elisha
AU  - de Valle E
FAU - Moujalled, Donia M
AU  - Moujalled DM
FAU - Menon, Manoj B
AU  - Menon MB
FAU - Spall, Sukhdeep Kaur
AU  - Spall SK
FAU - Glaser, Stefan P
AU  - Glaser SP
FAU - Richmond, Jennifer
AU  - Richmond J
FAU - Lock, Richard B
AU  - Lock RB
FAU - Condon, Stephen M
AU  - Condon SM
FAU - Gugasyan, Raffi
AU  - Gugasyan R
FAU - Gaestel, Matthias
AU  - Gaestel M
FAU - Guthridge, Mark
AU  - Guthridge M
FAU - Johnstone, Ricky W
AU  - Johnstone RW
FAU - Munoz, Lenka
AU  - Munoz L
FAU - Wei, Andrew
AU  - Wei A
FAU - Ekert, Paul G
AU  - Ekert PG
FAU - Vaux, David L
AU  - Vaux DL
FAU - Wong, W Wei-Lynn
AU  - Wong WW
FAU - Silke, John
AU  - Silke J
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160912
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Feb 8;29(2):145-58. PMID: 26859455
EDAT- 2016/09/14 06:00
MHDA- 2016/09/14 06:01
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2016/09/14 06:01 [medline]
PHST- 2016/09/14 06:00 [entrez]
AID - S1535-6108(16)30394-4 [pii]
AID - 10.1016/j.ccell.2016.08.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):499-500. doi: 10.1016/j.ccell.2016.08.009. Epub
      2016 Sep 12.

PMID- 27622336
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
PG  - 474-484
LID - S1535-6108(16)30386-5 [pii]
LID - 10.1016/j.ccell.2016.08.003 [doi]
AB  - In the cytoplasm of virtually all clear-cell renal cell carcinoma (ccRCC),
      speckle-type POZ protein (SPOP) is overexpressed and misallocated, which may
      induce proliferation and promote kidney tumorigenesis. In normal cells, however, 
      SPOP is located in the nucleus and induces apoptosis. Here we show that a
      structure-based design and subsequent hit optimization yield small molecules that
      can inhibit the SPOP-substrate protein interaction and can suppress oncogenic
      SPOP-signaling pathways. These inhibitors kill human ccRCC cells that are
      dependent on oncogenic cytoplasmic SPOP. Notably, these inhibitors minimally
      affect the viability of other cells in which SPOP is not accumulated in the
      cytoplasm. Our findings validate the SPOP-substrate protein interaction as an
      attractive target specific to ccRCC that may yield novel drug discovery efforts.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Guo, Zhong-Qiang
AU  - Guo ZQ
AD  - CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of
      Genomics, Chinese Academy of Sciences, Beijing 100101, China; Department of
      Urology, Peking University First Hospital, Beijing 100034, China; Department of
      Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.
FAU - Zheng, Tong
AU  - Zheng T
AD  - Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;
      University of Chinese Academy of Sciences, Beijing 100049, China.
FAU - Chen, Baoen
AU  - Chen B
AD  - Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Luo, Cheng
AU  - Luo C
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Ouyang, Sisheng
AU  - Ouyang S
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Gong, Shouzhe
AU  - Gong S
AD  - Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Li, Jiafei
AU  - Li J
AD  - Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Mao, Liu-Liang
AU  - Mao LL
AD  - State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou
      730000, China.
FAU - Lian, Fulin
AU  - Lian F
AD  - Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese
      Academy of Sciences, Shanghai 201203, China.
FAU - Yang, Yong
AU  - Yang Y
AD  - State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
      Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Huang, Yue
AU  - Huang Y
AD  - Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;
      University of Chinese Academy of Sciences, Beijing 100049, China.
FAU - Li, Li
AU  - Li L
AD  - Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Lu, Jing
AU  - Lu J
AD  - Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia
      Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Zhang, Bidong
AU  - Zhang B
AD  - University of Chinese Academy of Sciences, Beijing 100049, China; Drug Discovery 
      and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of
      Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Zhou, Luming
AU  - Zhou L
AD  - Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of
      Education, and College of Life Sciences, Beijing Normal University, Beijing
      100875, China.
FAU - Ding, Hong
AU  - Ding H
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Gao, Zhiwei
AU  - Gao Z
AD  - State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
      Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Zhou, Liqun
AU  - Zhou L
AD  - Department of Urology, Peking University First Hospital, Beijing 100034, China.
FAU - Li, Guoqiang
AU  - Li G
AD  - CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of
      Genomics, Chinese Academy of Sciences, Beijing 100101, China.
FAU - Zhou, Ran
AU  - Zhou R
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Chen, Ke
AU  - Chen K
AD  - CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of
      Genomics, Chinese Academy of Sciences, Beijing 100101, China.
FAU - Liu, Jingqiu
AU  - Liu J
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Wen, Yi
AU  - Wen Y
AD  - Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese
      Academy of Sciences, Shanghai 201203, China.
FAU - Gong, Likun
AU  - Gong L
AD  - Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia
      Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Ke, Yuwen
AU  - Ke Y
AD  - CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of
      Genomics, Chinese Academy of Sciences, Beijing 100101, China.
FAU - Yang, Shang-Dong
AU  - Yang SD
AD  - State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou
      730000, China.
FAU - Qiu, Xiao-Bo
AU  - Qiu XB
AD  - Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of
      Education, and College of Life Sciences, Beijing Normal University, Beijing
      100875, China.
FAU - Zhang, Naixia
AU  - Zhang N
AD  - Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese
      Academy of Sciences, Shanghai 201203, China.
FAU - Ren, Jin
AU  - Ren J
AD  - Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia
      Medica, Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Zhong, Dafang
AU  - Zhong D
AD  - State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
      Chinese Academy of Sciences, Shanghai 201203, China.
FAU - Yang, Cai-Guang
AU  - Yang CG
AD  - Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
      Electronic address: yangcg@simm.ac.cn.
FAU - Liu, Jiang
AU  - Liu J
AD  - CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of
      Genomics, Chinese Academy of Sciences, Beijing 100101, China. Electronic address:
      liuj@big.ac.cn.
FAU - Jiang, Hualiang
AU  - Jiang H
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
      Electronic address: hljiang@simm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Repressor Proteins)
RN  - 0 (SPOP protein, human)
RN  - 0 (Small Molecule Libraries)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - Animals
MH  - Carcinoma, Renal Cell/*drug therapy/genetics/metabolism
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/genetics/metabolism
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred ICR
MH  - Molecular Targeted Therapy
MH  - Nuclear Proteins/*antagonists & inhibitors/genetics/metabolism
MH  - Repressor Proteins/*antagonists & inhibitors/genetics/metabolism
MH  - Signal Transduction
MH  - Small Molecule Libraries/*pharmacology
MH  - Ubiquitin-Protein Ligases/metabolism
MH  - Xenograft Model Antitumor Assays
EDAT- 2016/09/14 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/09/14 06:00
PHST- 2015/05/24 00:00 [received]
PHST- 2016/02/15 00:00 [revised]
PHST- 2016/08/08 00:00 [accepted]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30386-5 [pii]
AID - 10.1016/j.ccell.2016.08.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):474-484. doi: 10.1016/j.ccell.2016.08.003.

PMID- 27622335
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to
      Histone Deacetylase Inhibitors in Breast Cancer.
PG  - 459-473
LID - S1535-6108(16)30384-1 [pii]
LID - 10.1016/j.ccell.2016.08.001 [doi]
AB  - Histone deacetylase (HDAC) inhibitors have demonstrated clinical benefits in
      subtypes of hematological malignancies. However, the efficacy of HDAC inhibitors 
      in solid tumors remains uncertain. This study takes breast cancer as a model to
      understand mechanisms accounting for limited response of HDAC inhibitors in solid
      tumors and to seek combination solutions. We discover that feedback activation of
      leukemia inhibitory factor receptor (LIFR) signaling in breast cancer limits the 
      response to HDAC inhibition. Mechanistically, HDAC inhibition increases histone
      acetylation at the LIFR gene promoter, which recruits bromodomain protein BRD4,
      upregulates LIFR expression, and activates JAK1-STAT3 signaling. Importantly,
      JAK1 or BRD4 inhibition sensitizes breast cancer to HDAC inhibitors, implicating 
      combination inhibition of HDAC with JAK1 or BRD4 as potential therapies for
      breast cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zeng, Hanlin
AU  - Zeng H
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Qu, Jia
AU  - Qu J
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Jin, Nan
AU  - Jin N
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Xu, Jun
AU  - Xu J
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Lin, Chenchu
AU  - Lin C
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Chen, Yi
AU  - Chen Y
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Yang, Xinying
AU  - Yang X
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - He, Xiang
AU  - He X
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Tang, Shuai
AU  - Tang S
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Lan, Xiaojing
AU  - Lan X
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Yang, Xiaotong
AU  - Yang X
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Chen, Ziqi
AU  - Chen Z
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China.
FAU - Huang, Min
AU  - Huang M
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China. Electronic address: mhuang@simm.ac.cn.
FAU - Ding, Jian
AU  - Ding J
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China. Electronic address: jding@simm.ac.cn.
FAU - Geng, Meiyu
AU  - Geng M
AD  - Division of Antitumor Pharmacology, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
      201203, China. Electronic address: mygeng@simm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Receptors, OSM-LIF)
SB  - IM
CIN - Chin Clin Oncol. 2017 Feb;6(1):9. PMID: 28249539
MH  - Animals
MH  - Breast Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - HL-60 Cells
MH  - Histone Deacetylase Inhibitors/*pharmacology
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Receptors, OSM-LIF/genetics/*metabolism
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - *BET family proteins
OT  - *STAT3
OT  - *breast cancer
OT  - *histone deacetylases inhibitors
OT  - *leukemia inhibitory factor receptor
EDAT- 2016/09/14 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/09/14 06:00
PHST- 2016/01/26 00:00 [received]
PHST- 2016/06/02 00:00 [revised]
PHST- 2016/08/08 00:00 [accepted]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30384-1 [pii]
AID - 10.1016/j.ccell.2016.08.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):459-473. doi: 10.1016/j.ccell.2016.08.001.

PMID- 27622334
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer.
PG  - 418-431
LID - S1535-6108(16)30390-7 [pii]
LID - 10.1016/j.ccell.2016.08.005 [doi]
AB  - Metabolic adaptability is essential for tumor progression and includes
      cooperation between cancer cells with different metabolic phenotypes. Optimal
      glucose supply to glycolytic cancer cells occurs when oxidative cancer cells use 
      lactate preferentially to glucose. However, using lactate instead of glucose
      mimics glucose deprivation, and glucose starvation induces autophagy. We report
      that lactate sustains autophagy in cancer. In cancer cells preferentially to
      normal cells, lactate dehydrogenase B (LDHB), catalyzing the conversion of
      lactate and NAD(+) to pyruvate, NADH and H(+), controls lysosomal acidification, 
      vesicle maturation, and intracellular proteolysis. LDHB activity is necessary for
      basal autophagy and cancer cell proliferation not only in oxidative cancer cells 
      but also in glycolytic cancer cells.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Brisson, Lucie
AU  - Brisson L
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Banski, Piotr
AU  - Banski P
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Sboarina, Martina
AU  - Sboarina M
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Dethier, Coralie
AU  - Dethier C
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Danhier, Pierre
AU  - Danhier P
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium; Louvain Drug
      Research Institute (LDRI), Universite catholique de Louvain (UCL), 1200 Brussels,
      Belgium.
FAU - Fontenille, Marie-Josephine
AU  - Fontenille MJ
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Van Hee, Vincent F
AU  - Van Hee VF
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Vazeille, Thibaut
AU  - Vazeille T
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Tardy, Morgane
AU  - Tardy M
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Falces, Jorge
AU  - Falces J
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Bouzin, Caroline
AU  - Bouzin C
AD  - IREC Imaging Platform, Universite catholique de Louvain (UCL), 1200 Brussels,
      Belgium.
FAU - Porporato, Paolo E
AU  - Porporato PE
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Frederick, Raphael
AU  - Frederick R
AD  - Louvain Drug Research Institute (LDRI), Universite catholique de Louvain (UCL),
      1200 Brussels, Belgium.
FAU - Michiels, Carine
AU  - Michiels C
AD  - URBC-NARILIS, University of Namur, 5000 Namur, Belgium.
FAU - Copetti, Tamara
AU  - Copetti T
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium.
FAU - Sonveaux, Pierre
AU  - Sonveaux P
AD  - Institut de Recherche Experimentale et Clinique (IREC), Pole of Pharmacology,
      Universite catholique de Louvain (UCL), 1200 Brussels, Belgium. Electronic
      address: pierre.sonveaux@uclouvain.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Isoenzymes)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 1.1.1.27.- (lactate dehydrogenase 1)
SB  - IM
MH  - Animals
MH  - Autophagy/physiology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/physiology
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Isoenzymes/genetics/metabolism
MH  - L-Lactate Dehydrogenase/genetics/*metabolism
MH  - Lysosomes/*enzymology
MH  - Mice
MH  - Neoplasms/*enzymology/*pathology
EDAT- 2016/09/14 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/09/14 06:00
PHST- 2015/10/12 00:00 [received]
PHST- 2016/05/13 00:00 [revised]
PHST- 2016/08/10 00:00 [accepted]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30390-7 [pii]
AID - 10.1016/j.ccell.2016.08.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):418-431. doi: 10.1016/j.ccell.2016.08.005.

PMID- 27622333
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant
      Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
PG  - 404-417
LID - S1535-6108(16)30391-9 [pii]
LID - 10.1016/j.ccell.2016.08.006 [doi]
AB  - More than 80% of patients with the refractory anemia with ring sideroblasts
      subtype of myelodysplastic syndrome (MDS) have mutations in Splicing Factor 3B,
      Subunit 1 (SF3B1). We generated a conditional knockin mouse model of the most
      common SF3B1 mutation, Sf3b1(K700E). Sf3b1(K700E) mice develop macrocytic anemia 
      due to a terminal erythroid maturation defect, erythroid dysplasia, and long-term
      hematopoietic stem cell (LT-HSC) expansion. Sf3b1(K700E) myeloid progenitors and 
      SF3B1-mutant MDS patient samples demonstrate aberrant 3' splice-site selection
      associated with increased nonsense-mediated decay. Tet2 loss cooperates with
      Sf3b1(K700E) to cause a more severe erythroid and LT-HSC phenotype. Furthermore, 
      the spliceosome modulator, E7017, selectively kills SF3B1(K700E)-expressing
      cells. Thus, SF3B1(K700E) expression reflects the phenotype of the mutation in
      MDS and may be a therapeutic target in MDS.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Obeng, Esther A
AU  - Obeng EA
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115,
      USA; Division of Hematology/Oncology, Department of Medicine, Boston Children's
      Hospital, Boston, MA 02115, USA; Division of Hematology, Department of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
FAU - Chappell, Ryan J
AU  - Chappell RJ
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Seiler, Michael
AU  - Seiler M
AD  - H3 Biomedicine, Inc., Cambridge, MA 03129, USA.
FAU - Chen, Michelle C
AU  - Chen MC
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Campagna, Dean R
AU  - Campagna DR
AD  - Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
FAU - Schmidt, Paul J
AU  - Schmidt PJ
AD  - Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
FAU - Schneider, Rebekka K
AU  - Schneider RK
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Lord, Allegra M
AU  - Lord AM
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Wang, Lili
AU  - Wang L
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Gambe, Rutendo G
AU  - Gambe RG
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - McConkey, Marie E
AU  - McConkey ME
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Ali, Abdullah M
AU  - Ali AM
AD  - Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
      10027, USA.
FAU - Raza, Azra
AU  - Raza A
AD  - Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
      10027, USA.
FAU - Yu, Lihua
AU  - Yu L
AD  - H3 Biomedicine, Inc., Cambridge, MA 03129, USA.
FAU - Buonamici, Silvia
AU  - Buonamici S
AD  - H3 Biomedicine, Inc., Cambridge, MA 03129, USA.
FAU - Smith, Peter G
AU  - Smith PG
AD  - H3 Biomedicine, Inc., Cambridge, MA 03129, USA.
FAU - Mullally, Ann
AU  - Mullally A
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and
      Harvard, Cambridge, MA 02142, USA.
FAU - Wu, Catherine J
AU  - Wu CJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 
      02142, USA.
FAU - Fleming, Mark D
AU  - Fleming MD
AD  - Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
FAU - Ebert, Benjamin L
AU  - Ebert BL
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and
      Harvard, Cambridge, MA 02142, USA. Electronic address: bebert@partners.org.
LA  - eng
GR  - R24 DK099808/DK/NIDDK NIH HHS/United States
GR  - R01 HL082945/HL/NHLBI NIH HHS/United States
GR  - R24 DK094746/DK/NIDDK NIH HHS/United States
GR  - R01 CA184922/CA/NCI NIH HHS/United States
GR  - R01 DK087992/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA Splicing Factors)
RN  - 0 (SF3B1 protein, human)
RN  - 0 (Sf3b1 protein, mouse)
RN  - 0 (TET2 protein, human)
RN  - 0 (Tet2 protein, mouse)
SB  - IM
CIN - Cancer Cell. 2016 Sep 12;30(3):371-373. PMID: 27622329
MH  - Animals
MH  - DNA-Binding Proteins/genetics/metabolism
MH  - Erythropoiesis/genetics/*physiology
MH  - Hematopoietic Stem Cells/physiology
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Myelodysplastic Syndromes/genetics/metabolism
MH  - Phosphoproteins/deficiency/*genetics/metabolism
MH  - Point Mutation
MH  - Proto-Oncogene Proteins/genetics/metabolism
MH  - RNA Splicing
MH  - RNA Splicing Factors/deficiency/*genetics/metabolism
MH  - Spliceosomes/*physiology
PMC - PMC5023069
MID - NIHMS811914
EDAT- 2016/09/14 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/09/14 06:00
PHST- 2015/12/02 00:00 [received]
PHST- 2016/04/29 00:00 [revised]
PHST- 2016/08/16 00:00 [accepted]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30391-9 [pii]
AID - 10.1016/j.ccell.2016.08.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):404-417. doi: 10.1016/j.ccell.2016.08.006.

PMID- 27622332
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune
      Responses.
PG  - 391-403
LID - S1535-6108(16)30388-9 [pii]
LID - 10.1016/j.ccell.2016.06.025 [doi]
AB  - Preclinical studies targeting the adenosinergic pathway have gained much
      attention for their clinical potential in overcoming tumor-induced
      immunosuppression. Here, we have identified that co-blockade of the
      ectonucleotidase that generates adenosine CD73 and the A2A adenosine receptor
      (A2AR) that mediates adenosine signaling in leuokocytes, by using compound
      gene-targeted mice or therapeutics that target these molecules, limits tumor
      initiation, growth, and metastasis. This tumor control requires effector
      lymphocytes and interferon-gamma, while antibodies targeting CD73 promote an
      optimal therapeutic response in vivo when engaging activating Fc receptors. In a 
      two-way mixed leukocyte reaction using a fully human anti-CD73, we demonstrated
      that Fc receptor binding augmented the production of proinflammatory cytokines.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Young, Arabella
AU  - Young A
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, QLD 4006, Australia; School of Medicine,
      The University of Queensland, Herston, QLD 4006, Australia.
FAU - Ngiow, Shin Foong
AU  - Ngiow SF
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, QLD 4006, Australia; School of Medicine,
      The University of Queensland, Herston, QLD 4006, Australia.
FAU - Barkauskas, Deborah S
AU  - Barkauskas DS
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, QLD 4006, Australia.
FAU - Sult, Erin
AU  - Sult E
AD  - MedImmune, LLC., Gaithersburg, MD 20878, USA.
FAU - Hay, Carl
AU  - Hay C
AD  - MedImmune, LLC., Gaithersburg, MD 20878, USA.
FAU - Blake, Stephen J
AU  - Blake SJ
AD  - Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia.
FAU - Huang, Qihui
AU  - Huang Q
AD  - MedImmune, LLC., Gaithersburg, MD 20878, USA.
FAU - Liu, Jing
AU  - Liu J
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, QLD 4006, Australia; School of Medicine,
      The University of Queensland, Herston, QLD 4006, Australia; Cancer
      Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute,
      Herston, QLD 4006, Australia.
FAU - Takeda, Kazuyoshi
AU  - Takeda K
AD  - Division of Cell Biology, Biomedical Research Center, Graduate School of
      Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan.
FAU - Teng, Michele W L
AU  - Teng MWL
AD  - School of Medicine, The University of Queensland, Herston, QLD 4006, Australia;
      Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia.
FAU - Sachsenmeier, Kris
AU  - Sachsenmeier K
AD  - MedImmune, LLC., Gaithersburg, MD 20878, USA.
FAU - Smyth, Mark J
AU  - Smyth MJ
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, 300 Herston Road, Herston, QLD 4006, Australia; School of Medicine,
      The University of Queensland, Herston, QLD 4006, Australia. Electronic address:
      mark.smyth@qimrberghofer.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adenosine A2 Receptor Antagonists)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Receptor, Adenosine A2A)
RN  - EC 3.1.3.5 (5'-Nucleotidase)
SB  - IM
CIN - Cancer Cell. 2016 Sep 12;30(3):369-371. PMID: 27622328
MH  - 5'-Nucleotidase/*antagonists & inhibitors/immunology
MH  - Adenosine A2 Receptor Antagonists/*pharmacology
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/pharmacology
MH  - Female
MH  - Humans
MH  - Immune Tolerance/*immunology
MH  - Male
MH  - Mammary Neoplasms, Experimental/immunology/therapy
MH  - Melanoma, Experimental/immunology/therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neoplasms/*immunology/pathology/*therapy
MH  - Receptor, Adenosine A2A/immunology
MH  - Signal Transduction
OTO - NOTNLM
OT  - *CD73
OT  - *adenosine
OT  - *combination therapy
OT  - *immunotherapy
OT  - *tumor
EDAT- 2016/09/14 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/09/14 06:00
PHST- 2016/02/25 00:00 [received]
PHST- 2016/06/07 00:00 [revised]
PHST- 2016/08/05 00:00 [accepted]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30388-9 [pii]
AID - 10.1016/j.ccell.2016.06.025 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):391-403. doi: 10.1016/j.ccell.2016.06.025.

PMID- 27622331
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and
      Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.
PG  - 377-390
LID - S1535-6108(16)30389-0 [pii]
LID - 10.1016/j.ccell.2016.08.004 [doi]
AB  - Effective cancer immunotherapy requires overcoming immunosuppressive tumor
      microenvironments. We found that local nitric oxide (NO) production by
      tumor-infiltrating myeloid cells is important for adoptively transferred CD8(+)
      cytotoxic T cells to destroy tumors. These myeloid cells are phenotypically
      similar to inducible nitric oxide synthase (NOS2)- and tumor necrosis factor
      (TNF)-producing dendritic cells (DC), or Tip-DCs. Depletion of immunosuppressive,
      colony stimulating factor 1 receptor (CSF-1R)-dependent arginase 1(+) myeloid
      cells enhanced NO-dependent tumor killing. Tumor elimination via NOS2 required
      the CD40-CD40L pathway. We also uncovered a strong correlation between survival
      of colorectal cancer patients and NOS2, CD40, and TNF expression in their tumors.
      Our results identify a network of pro-tumor factors that can be targeted to boost
      cancer immunotherapies.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Marigo, Ilaria
AU  - Marigo I
AD  - Istituto Oncologico Veneto, IOV-IRCCS, 35128 Padova, Italy. Electronic address:
      ilaria.marigo@ioveneto.it.
FAU - Zilio, Serena
AU  - Zilio S
AD  - Oncology and Immunology Section, Department of Surgery, Oncology and
      Gastroenterology, University of Padova, 35128 Padova, Italy.
FAU - Desantis, Giacomo
AU  - Desantis G
AD  - Istituto Oncologico Veneto, IOV-IRCCS, 35128 Padova, Italy.
FAU - Mlecnik, Bernhard
AU  - Mlecnik B
AD  - INSERM UMRS1138, Laboratory of Integrative Cancer Immunology, Paris 75006,
      France; Universite Paris Descartes, Paris 75006, France; Cordeliers Research
      Centre, Universite Pierre et Marie Curie Paris 6, Paris 75006, France.
FAU - Agnellini, Andrielly H R
AU  - Agnellini AHR
AD  - Oncology and Immunology Section, Department of Surgery, Oncology and
      Gastroenterology, University of Padova, 35128 Padova, Italy.
FAU - Ugel, Stefano
AU  - Ugel S
AD  - Department of Medicine, Verona University Hospital, 37134 Verona, Italy.
FAU - Sasso, Maria Stella
AU  - Sasso MS
AD  - Oncology and Immunology Section, Department of Surgery, Oncology and
      Gastroenterology, University of Padova, 35128 Padova, Italy.
FAU - Qualls, Joseph E
AU  - Qualls JE
AD  - Departments of Infectious Diseases and Immunology, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Kratochvill, Franz
AU  - Kratochvill F
AD  - Departments of Infectious Diseases and Immunology, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Zanovello, Paola
AU  - Zanovello P
AD  - Istituto Oncologico Veneto, IOV-IRCCS, 35128 Padova, Italy; Oncology and
      Immunology Section, Department of Surgery, Oncology and Gastroenterology,
      University of Padova, 35128 Padova, Italy.
FAU - Molon, Barbara
AU  - Molon B
AD  - Istituto Oncologico Veneto, IOV-IRCCS, 35128 Padova, Italy.
FAU - Ries, Carola H
AU  - Ries CH
AD  - Roche Innovation Center Munich, Oncology Discovery, Pharma Research and Early
      Development, 82377 Penzberg, Germany.
FAU - Runza, Valeria
AU  - Runza V
AD  - Roche Innovation Center Munich, Oncology Discovery, Pharma Research and Early
      Development, 82377 Penzberg, Germany.
FAU - Hoves, Sabine
AU  - Hoves S
AD  - Roche Innovation Center Munich, Oncology Discovery, Pharma Research and Early
      Development, 82377 Penzberg, Germany.
FAU - Bilocq, Amelie M
AU  - Bilocq AM
AD  - INSERM UMRS1138, Laboratory of Integrative Cancer Immunology, Paris 75006,
      France; Universite Paris Descartes, Paris 75006, France; Cordeliers Research
      Centre, Universite Pierre et Marie Curie Paris 6, Paris 75006, France.
FAU - Bindea, Gabriela
AU  - Bindea G
AD  - INSERM UMRS1138, Laboratory of Integrative Cancer Immunology, Paris 75006,
      France; Universite Paris Descartes, Paris 75006, France; Cordeliers Research
      Centre, Universite Pierre et Marie Curie Paris 6, Paris 75006, France.
FAU - Mazza, Emilia M C
AU  - Mazza EMC
AD  - Department of Life Sciences, Center for Genome Research, University of Modena and
      Reggio Emilia, 41100 Modena, Italy.
FAU - Bicciato, Silvio
AU  - Bicciato S
AD  - Department of Life Sciences, Center for Genome Research, University of Modena and
      Reggio Emilia, 41100 Modena, Italy.
FAU - Galon, Jerome
AU  - Galon J
AD  - INSERM UMRS1138, Laboratory of Integrative Cancer Immunology, Paris 75006,
      France; Universite Paris Descartes, Paris 75006, France; Cordeliers Research
      Centre, Universite Pierre et Marie Curie Paris 6, Paris 75006, France.
FAU - Murray, Peter J
AU  - Murray PJ
AD  - Departments of Infectious Diseases and Immunology, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA. Electronic address: peter.murray@stjude.org.
FAU - Bronte, Vincenzo
AU  - Bronte V
AD  - Department of Medicine, Verona University Hospital, 37134 Verona, Italy.
      Electronic address: vincenzo.bronte@univr.it.
LA  - eng
GR  - F32 CA138064/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - R01 HL056067/HL/NHLBI NIH HHS/United States
GR  - R21 CA189990/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CD40 Antigens)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 147205-72-9 (CD40 Ligand)
RN  - EC 1.14.13.39 (NOS2 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 3.5.3.1 (Arginase)
SB  - IM
CIN - Cancer Cell. 2016 Sep 12;30(3):367-368. PMID: 27622327
EIN - Cancer Cell. 2016 Oct 10;30(4):651. PMID: 27728809
MH  - Animals
MH  - Arginase/biosynthesis/immunology
MH  - CD40 Antigens/immunology
MH  - CD40 Ligand/immunology
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neoplasms/*immunology/*therapy
MH  - Nitric Oxide Synthase Type II/biosynthesis/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Microenvironment
MH  - Tumor Necrosis Factor-alpha/biosynthesis/*immunology
PMC - PMC5023283
MID - NIHMS815017
EDAT- 2016/09/14 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/09/14 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2016/05/13 00:00 [revised]
PHST- 2016/08/09 00:00 [accepted]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30389-0 [pii]
AID - 10.1016/j.ccell.2016.08.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004.

PMID- 27622330
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Powering Tumor Metastasis with Recycled Fuel.
PG  - 374-375
LID - S1535-6108(16)30399-3 [pii]
LID - 10.1016/j.ccell.2016.08.014 [doi]
AB  - Receptor tyrosine kinase (RTK) recycling is of critical importance for RTK
      signaling and cancer, yet the process is poorly understood. In this issue, Ye et 
      al. identify GOLM1 as a cargo adaptor that drives hepatocellular carcinoma
      metastasis by promoting EGFR recycling and provide insights into how this process
      is regulated.
CI  - Copyright (c) 2016. Published by Elsevier Inc.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; Center for Molecular Medicine and
      Graduate Institute of Cancer Biology, China Medical University, Taichung 404,
      Taiwan. Electronic address: mhung@mdanderson.org.
FAU - Yang, Riyao
AU  - Yang R
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Sun, Yutong
AU  - Sun Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
CON - Cancer Cell. 2016 Sep 12;30(3):444-458. PMID: 27569582
MH  - *Carcinoma, Hepatocellular
MH  - Humans
MH  - Liver Neoplasms
MH  - *Receptor Protein-Tyrosine Kinases
MH  - Receptor, Epidermal Growth Factor
MH  - Signal Transduction
EDAT- 2016/09/14 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30399-3 [pii]
AID - 10.1016/j.ccell.2016.08.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):374-375. doi: 10.1016/j.ccell.2016.08.014.

PMID- 27622329
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities.
PG  - 371-373
LID - S1535-6108(16)30398-1 [pii]
LID - 10.1016/j.ccell.2016.08.013 [doi]
AB  - In this issue of Cancer Cell, Obeng et al. identify the consequences of
      expressing the most common mutation in the spliceosomal gene SF3B1 on
      hematopoiesis. The knockin mouse model described represents a valuable tool to
      dissect the effects of SF3B1 mutations on transformation, splicing, and less
      well-characterized functions of SF3B1.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Inoue, Daichi
AU  - Inoue D
AD  - Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
AD  - Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Leukemia Service, Department of
      Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
      Electronic address: abdelwao@mskcc.org.
LA  - eng
GR  - R01 CA201247/CA/NCI NIH HHS/United States
GR  - K08 CA160647/CA/NCI NIH HHS/United States
GR  - R01 HL128239/HL/NHLBI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30 CA006516/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Phosphoproteins)
RN  - 0 (RNA Splicing Factors)
SB  - IM
CON - Cancer Cell. 2016 Sep 12;30(3):404-417. PMID: 27622333
MH  - Animals
MH  - Mutation
MH  - Phosphoproteins/*genetics
MH  - RNA Splicing
MH  - *RNA Splicing Factors
MH  - Spliceosomes/genetics
PMC - PMC5569387
MID - NIHMS883341
EDAT- 2016/09/14 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30398-1 [pii]
AID - 10.1016/j.ccell.2016.08.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):371-373. doi: 10.1016/j.ccell.2016.08.013.

PMID- 27622328
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by
      Fc Receptor Engagement.
PG  - 369-371
LID - S1535-6108(16)30392-0 [pii]
LID - 10.1016/j.ccell.2016.08.007 [doi]
AB  - Targeting the signaling pathway of the immunosuppressive metabolite adenosine is 
      an emerging approach for cancer immunotherapy. In this issue of Cancer Cell,
      Young et al. describe that co-inhibition of the adenosingenic pathway through
      blockade of both CD73 and A2AR enhances antitumor efficacy through distinct
      mechanisms.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Dahan, Rony
AU  - Dahan R
AD  - Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New 
      York, NY 10065, USA.
FAU - Ravetch, Jeffrey V
AU  - Ravetch JV
AD  - Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New 
      York, NY 10065, USA. Electronic address: ravetch@rockefeller.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptor, Adenosine A2A)
RN  - 0 (Receptors, Fc)
RN  - K72T3FS567 (Adenosine)
SB  - IM
CON - Cancer Cell. 2016 Sep 12;30(3):391-403. PMID: 27622332
MH  - *Adenosine
MH  - Humans
MH  - Immunotherapy
MH  - *Receptor, Adenosine A2A
MH  - Receptors, Fc
MH  - Signal Transduction
EDAT- 2016/09/14 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30392-0 [pii]
AID - 10.1016/j.ccell.2016.08.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):369-371. doi: 10.1016/j.ccell.2016.08.007.

PMID- 27622327
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - Tipping the Balancing ACT.
PG  - 367-368
LID - S1535-6108(16)30397-X [pii]
LID - 10.1016/j.ccell.2016.08.012 [doi]
AB  - Adoptive cell transfer therapy has emerged as a powerful treatment for metastatic
      melanoma, but efficacy is limited by an inhospitable tumor microenvironment. In
      this issue of Cancer Cell, Marigo et al. demonstrate that therapy requires
      induced expression of nitric oxide synthase 2 in monocyte-derived dendritic
      cells.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Pilon-Thomas, Shari
AU  - Pilon-Thomas S
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      Tampa, FL 33612, USA; Department of Cutaneous Oncology, H. Lee Moffitt Cancer
      Center and Research Institute, Tampa, FL 33612, USA. Electronic address:
      shari.pilon-thomas@moffitt.org.
FAU - Ruffell, Brian
AU  - Ruffell B
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      Tampa, FL 33612, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center
      and Research Institute, Tampa, FL 33612, USA. Electronic address:
      brian.ruffell@moffitt.org.
LA  - eng
GR  - R00 CA185325/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
SB  - IM
CON - Cancer Cell. 2016 Sep 12;30(3):377-390. PMID: 27622331
MH  - Dendritic Cells
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - *Melanoma
MH  - Nitric Oxide Synthase Type II
MH  - Tumor Microenvironment
EDAT- 2016/09/14 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/09/14 06:00
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30397-X [pii]
AID - 10.1016/j.ccell.2016.08.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):367-368. doi: 10.1016/j.ccell.2016.08.012.

PMID- 27593345
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.
PG  - 432-443
LID - S1535-6108(16)30385-3 [pii]
LID - 10.1016/j.ccell.2016.08.002 [doi]
AB  - RhoGDI2 specifically suppresses bladder cancer metastasis but not primary tumor
      growth, which involves tumor-associated macrophages. We report that
      macrophage-secreted osteopontin binds to CD44s on the tumor cells and promotes
      invasion and clonal growth. These effects are RhoGDI2-sensitive and require CD44s
      binding to the Rac GEF TIAM1. Osteopontin expression correlates with tumor
      aggressiveness and poor clinical outcome in patients. Inhibiting this pathway
      potently blocked lung and lymph node metastasis; however, primary tumors and
      established metastasis were less sensitive. Osteopontin-CD44s-TIAM1 promotes
      clonal growth in vitro but not at high cell density. These data identify
      osteopontin-CD44-TIAM1-Rac1 axis as a RhoGDI2-sensitive pathway and potential
      therapeutic target in bladder cancer metastasis. They also elucidate the
      mechanism behind RhoGDI2 specificity for metastasis over established tumors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Ahmed, Mansoor
AU  - Ahmed M
AD  - Department of Internal Medicine (Cardiology), Yale Cardiovascular Research
      Center, Yale University, New Haven, CT 06520, USA. Electronic address:
      mansoornccs@gmail.com.
FAU - Sottnik, Joseph L
AU  - Sottnik JL
AD  - Department of Surgery, University of Colorado, Aurora, CO 80045, USA.
FAU - Dancik, Garrett M
AU  - Dancik GM
AD  - Mathematics and Computer Science Department, Eastern Connecticut State
      University, Willimantic, CT 06226, USA.
FAU - Sahu, Divya
AU  - Sahu D
AD  - Department of Pathology, University of California, San Diego, La Jolla, CA 92093,
      USA.
FAU - Hansel, Donna E
AU  - Hansel DE
AD  - Department of Pathology, University of California, San Diego, La Jolla, CA 92093,
      USA.
FAU - Theodorescu, Dan
AU  - Theodorescu D
AD  - Department of Surgery, University of Colorado, Aurora, CO 80045, USA; Department 
      of Pharmacology, University of Colorado, Aurora, CO 80045, USA; University of
      Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA. Electronic address: 
      dan.theodorescu@ucdenver.edu.
FAU - Schwartz, Martin A
AU  - Schwartz MA
AD  - Department of Internal Medicine (Cardiology), Yale Cardiovascular Research
      Center, Yale University, New Haven, CT 06520, USA; Departments of Cell Biology
      and Biomedical Engineering, Yale University, New Haven, CT 06520, USA. Electronic
      address: martin.schwartz@yale.edu.
LA  - eng
GR  - R01 CA143971/CA/NCI NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160901
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (rho Guanine Nucleotide Dissociation Inhibitor beta)
RN  - 106441-73-0 (Osteopontin)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Hyaluronan Receptors/*metabolism
MH  - Lung Neoplasms/pathology/*secondary
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Metastasis
MH  - Osteopontin/*metabolism
MH  - Urinary Bladder Neoplasms/metabolism/*pathology
MH  - rho Guanine Nucleotide Dissociation Inhibitor beta/*metabolism
PMC - PMC5154333
MID - NIHMS810001
EDAT- 2016/09/07 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/09/06 06:00
PHST- 2015/04/27 00:00 [received]
PHST- 2016/04/27 00:00 [revised]
PHST- 2016/08/08 00:00 [accepted]
PHST- 2016/09/06 06:00 [entrez]
PHST- 2016/09/07 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30385-3 [pii]
AID - 10.1016/j.ccell.2016.08.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):432-443. doi: 10.1016/j.ccell.2016.08.002. Epub
      2016 Sep 1.

PMID- 27569582
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma
      Metastasis.
PG  - 444-458
LID - S1535-6108(16)30351-8 [pii]
LID - 10.1016/j.ccell.2016.07.017 [doi]
AB  - The mechanism of cancer metastasis remains poorly understood. Using gene
      profiling of hepatocellular carcinoma (HCC) tissues, we have identified GOLM1 as 
      a leading gene relating to HCC metastasis. GOLM1 expression is correlated with
      early recurrence, metastasis, and poor survival of HCC patients. Both gain- and
      loss-of-function studies determine that GOLM1 acts as a key oncogene by promoting
      HCC growth and metastasis. It selectively interacts with epidermal growth factor 
      receptor (EGFR) and serves as a specific cargo adaptor to assist EGFR/RTK
      anchoring on the trans-Golgi network (TGN) and recycling back to the plasma
      membrane, leading to prolonged activation of the downstream kinases. These
      findings reveal the functional role of GOLM1, a Golgi-related protein, in
      EGFR/RTK recycling and metastatic progression of HCC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Ye, Qing-Hai
AU  - Ye QH
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China.
FAU - Zhu, Wen-Wei
AU  - Zhu WW
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China; Department of
      General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University,
      12 Urumqi Road (M), Shanghai 200040, China.
FAU - Zhang, Ju-Bo
AU  - Zhang JB
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China; Department of
      Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
FAU - Qin, Yi
AU  - Qin Y
AD  - Institutes of Biomedical Science, Fudan University, Shanghai 200032, China;
      Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai
      Cancer Center, Shanghai 200032, China.
FAU - Lu, Ming
AU  - Lu M
AD  - Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute,
      Fudan University, 12 Urumqi Road (M), Shanghai 200040, China.
FAU - Lin, Guo-Ling
AU  - Lin GL
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China.
FAU - Guo, Lei
AU  - Guo L
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China.
FAU - Lin, Zhen-Hai
AU  - Lin ZH
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China.
FAU - Roessler, Stephanie
AU  - Roessler S
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, NIH, Bethesda, MD 20892, USA; Institute of Pathology, University
      Hospital Heidelberg 69120 Heidelberg, Germany.
FAU - Forgues, Marshonna
AU  - Forgues M
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, NIH, Bethesda, MD 20892, USA.
FAU - Jia, Hu-Liang
AU  - Jia HL
AD  - Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute,
      Fudan University, 12 Urumqi Road (M), Shanghai 200040, China.
FAU - Lu, Lu
AU  - Lu L
AD  - Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute,
      Fudan University, 12 Urumqi Road (M), Shanghai 200040, China.
FAU - Zhang, Xiao-Fei
AU  - Zhang XF
AD  - Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute,
      Fudan University, 12 Urumqi Road (M), Shanghai 200040, China.
FAU - Lian, Bao-Feng
AU  - Lian BF
AD  - Shanghai Center for Bioinformatics Technology, Shanghai 201203, China.
FAU - Xie, Lu
AU  - Xie L
AD  - Shanghai Center for Bioinformatics Technology, Shanghai 201203, China.
FAU - Dong, Qiong-Zhu
AU  - Dong QZ
AD  - Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute,
      Fudan University, 12 Urumqi Road (M), Shanghai 200040, China; Institutes of
      Biomedical Science, Fudan University, Shanghai 200032, China.
FAU - Tang, Zhao-You
AU  - Tang ZY
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China; Department of
      General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University,
      12 Urumqi Road (M), Shanghai 200040, China.
FAU - Wang, Xin Wei
AU  - Wang XW
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer
      Institute, NIH, Bethesda, MD 20892, USA. Electronic address: xw3u@nih.gov.
FAU - Qin, Lun-Xiu
AU  - Qin LX
AD  - Liver Cancer Institute, Fudan University, Shanghai 200032, China; Department of
      General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University,
      12 Urumqi Road (M), Shanghai 200040, China; Institutes of Biomedical Science,
      Fudan University, Shanghai 200032, China. Electronic address: qinlx@fudan.edu.cn.
LA  - eng
GR  - Z01 BC010313/BC/NCI NIH HHS/United States
GR  - Z01 BC010877/BC/NCI NIH HHS/United States
GR  - ZIA BC010313-17/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC010877-08/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Intramural
DEP - 20160825
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (GOLM1 protein, human)
RN  - 0 (Membrane Proteins)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
CIN - Cancer Cell. 2016 Sep 12;30(3):374-375. PMID: 27622330
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Carcinoma, Hepatocellular/genetics/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Heterografts
MH  - Humans
MH  - Liver Neoplasms/genetics/*metabolism/pathology
MH  - Male
MH  - Membrane Proteins/biosynthesis/genetics/*metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Receptor, Epidermal Growth Factor/genetics/*metabolism
MH  - Transfection
MH  - Up-Regulation
MH  - Young Adult
PMC - PMC5021625
MID - NIHMS812717
COIS- The author(s) indicated no potential conflicts of interest.
EDAT- 2016/08/30 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/08/30 06:00
PHST- 2014/02/09 00:00 [received]
PHST- 2016/06/27 00:00 [revised]
PHST- 2016/07/26 00:00 [accepted]
PHST- 2016/08/30 06:00 [entrez]
PHST- 2016/08/30 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30351-8 [pii]
AID - 10.1016/j.ccell.2016.07.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):444-458. doi: 10.1016/j.ccell.2016.07.017. Epub
      2016 Aug 25.

PMID- 27523909
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Sep 12
TI  - An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against
      Oncogenic BRAF Signaling.
PG  - 485-498
LID - S1535-6108(16)30284-7 [pii]
LID - 10.1016/j.ccell.2016.06.024 [doi]
AB  - The complex biochemical effects of RAF inhibitors account for both the
      effectiveness and mechanisms of resistance to these drugs, but a unified
      mechanistic model has been lacking. Here we show that RAF inhibitors exert their 
      effects via two distinct allosteric mechanisms. Drug resistance due to
      dimerization is determined by the position of the alphaC helix stabilized by
      inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result 
      of inhibitor-induced formation of the RAF/RAS-GTP complex. The biochemical effect
      of RAF inhibitor in cells is the combined outcome of the two mechanisms.
      Therapeutic strategies including alphaC-helix-IN inhibitors are more effective in
      multiple mutant BRAF-driven tumor models, including colorectal and thyroid
      BRAF(V600E) cancers, in which first-generation RAF inhibitors have been
      ineffective.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Karoulia, Zoi
AU  - Karoulia Z
AD  - Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Wu, Yang
AU  - Wu Y
AD  - Department of Biochemistry, Department of Medicine, Albert Einstein Cancer
      Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of
      Medicine, Bronx, NY 10461, USA.
FAU - Ahmed, Tamer A
AU  - Ahmed TA
AD  - Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Xin, Qisheng
AU  - Xin Q
AD  - Department of Biochemistry, Department of Medicine, Albert Einstein Cancer
      Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of
      Medicine, Bronx, NY 10461, USA.
FAU - Bollard, Julien
AU  - Bollard J
AD  - Department of Oncological Sciences, Liver Cancer program, The Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Krepler, Clemens
AU  - Krepler C
AD  - Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis
      Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, PA
      19014, USA.
FAU - Wu, Xuewei
AU  - Wu X
AD  - Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Plexxikon Inc., Berkeley, CA 94710, USA.
FAU - Bollag, Gideon
AU  - Bollag G
AD  - Plexxikon Inc., Berkeley, CA 94710, USA.
FAU - Herlyn, Meenhard
AU  - Herlyn M
AD  - Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis
      Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, PA
      19014, USA.
FAU - Fagin, James A
AU  - Fagin JA
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Lujambio, Amaia
AU  - Lujambio A
AD  - Department of Oncological Sciences, Liver Cancer program, The Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Gavathiotis, Evripidis
AU  - Gavathiotis E
AD  - Department of Biochemistry, Department of Medicine, Albert Einstein Cancer
      Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of
      Medicine, Bronx, NY 10461, USA. Electronic address:
      evripidis.gavathiotis@einstein.yu.edu.
FAU - Poulikakos, Poulikos I
AU  - Poulikakos PI
AD  - Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
      Electronic address: poulikos.poulikakos@mssm.edu.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - P50 CA172012/CA/NCI NIH HHS/United States
GR  - R01 CA178394/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30 CA013330/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20160811
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
EIN - Cancer Cell. 2016 Sep 12;30(3):501-503. PMID: 27622340
MH  - Animals
MH  - Cell Line, Tumor
MH  - HEK293 Cells
MH  - Humans
MH  - Mice
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/genetics/metabolism
MH  - Signal Transduction/drug effects
PMC - PMC5021590
MID - NIHMS801002
COIS- C.Z. and G.B. are employees of Plexxikon Inc. All other authors declare no
      competing financial interests.
EDAT- 2016/08/16 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/08/16 06:00
PHST- 2015/09/01 00:00 [received]
PHST- 2016/05/10 00:00 [revised]
PHST- 2016/06/29 00:00 [accepted]
PHST- 2016/08/16 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - S1535-6108(16)30284-7 [pii]
AID - 10.1016/j.ccell.2016.06.024 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Sep 12;30(3):485-498. doi: 10.1016/j.ccell.2016.06.024. Epub
      2016 Aug 11.

PMID- 27505682
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - The Multifaceted Role of Perivascular Macrophages in Tumors.
PG  - 365
LID - S1535-6108(16)30343-9 [pii]
LID - 10.1016/j.ccell.2016.07.009 [doi]
FAU - Lewis, Claire E
AU  - Lewis CE
FAU - Harney, Allison S
AU  - Harney AS
FAU - Pollard, Jeffrey W
AU  - Pollard JW
LA  - eng
GR  - P01 CA100324/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Jul 11;30(1):18-25. PMID: 27411586
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30343-9 [pii]
AID - 10.1016/j.ccell.2016.07.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):365. doi: 10.1016/j.ccell.2016.07.009. Epub 2016
      Aug 8.

PMID- 27505681
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171222
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
PG  - 363
LID - S1535-6108(16)30347-6 [pii]
LID - 10.1016/j.ccell.2016.07.013 [doi]
FAU - Zheng, Siyuan
AU  - Zheng S
FAU - Cherniack, Andrew D
AU  - Cherniack AD
FAU - Dewal, Ninad
AU  - Dewal N
FAU - Moffitt, Richard A
AU  - Moffitt RA
FAU - Danilova, Ludmila
AU  - Danilova L
FAU - Murray, Bradley A
AU  - Murray BA
FAU - Lerario, Antonio M
AU  - Lerario AM
FAU - Else, Tobias
AU  - Else T
FAU - Knijnenburg, Theo A
AU  - Knijnenburg TA
FAU - Ciriello, Giovanni
AU  - Ciriello G
FAU - Kim, Seungchan
AU  - Kim S
FAU - Assie, Guillaume
AU  - Assie G
FAU - Morozova, Olena
AU  - Morozova O
FAU - Akbani, Rehan
AU  - Akbani R
FAU - Shih, Juliann
AU  - Shih J
FAU - Hoadley, Katherine A
AU  - Hoadley KA
FAU - Choueiri, Toni K
AU  - Choueiri TK
FAU - Waldmann, Jens
AU  - Waldmann J
FAU - Mete, Ozgur
AU  - Mete O
FAU - Robertson, A Gordon
AU  - Robertson AG
FAU - Wu, Hsin-Ta
AU  - Wu HT
FAU - Raphael, Benjamin J
AU  - Raphael BJ
FAU - Shao, Lina
AU  - Shao L
FAU - Meyerson, Matthew
AU  - Meyerson M
FAU - Demeure, Michael J
AU  - Demeure MJ
FAU - Beuschlein, Felix
AU  - Beuschlein F
FAU - Gill, Anthony J
AU  - Gill AJ
FAU - Sidhu, Stan B
AU  - Sidhu SB
FAU - Almeida, Madson Q
AU  - Almeida MQ
FAU - Fragoso, Maria C B V
AU  - Fragoso MCBV
FAU - Cope, Leslie M
AU  - Cope LM
FAU - Kebebew, Electron
AU  - Kebebew E
FAU - Habra, Mouhammed A
AU  - Habra MA
FAU - Whitsett, Timothy G
AU  - Whitsett TG
FAU - Bussey, Kimberly J
AU  - Bussey KJ
FAU - Rainey, William E
AU  - Rainey WE
FAU - Asa, Sylvia L
AU  - Asa SL
FAU - Bertherat, Jerome
AU  - Bertherat J
FAU - Fassnacht, Martin
AU  - Fassnacht M
FAU - Wheeler, David A
AU  - Wheeler DA
CN  - Cancer Genome Atlas Research Network
FAU - Hammer, Gary D
AU  - Hammer GD
FAU - Giordano, Thomas J
AU  - Giordano TJ
FAU - Verhaak, Roel G W
AU  - Verhaak RGW
LA  - eng
GR  - T32 CA009676/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 May 9;29(5):723-36. PMID: 27165744
IR  - Zheng S
FIR - Zheng, Siyuan
IR  - Verhaak RGW
FIR - Verhaak, Roel G W
IR  - Giordano TJ
FIR - Giordano, Thomas J
IR  - Hammer GD
FIR - Hammer, Gary D
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Dewal N
FIR - Dewal, Ninad
IR  - Moffitt RA
FIR - Moffitt, Richard A
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Murray BA
FIR - Murray, Bradley A
IR  - Lerario AM
FIR - Lerario, Antonio M
IR  - Else T
FIR - Else, Tobias
IR  - Knijnenburg TA
FIR - Knijnenburg, Theo A
IR  - Ciriello G
FIR - Ciriello, Giovanni
IR  - Kim S
FIR - Kim, Seungchan
IR  - Assie G
FIR - Assie, Guillaume
IR  - Morozova O
FIR - Morozova, Olena
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Shih J
FIR - Shih, Juliann
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Choueiri TK
FIR - Choueiri, Toni K
IR  - Waldmann J
FIR - Waldmann, Jens
IR  - Mete O
FIR - Mete, Ozgur
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Wu HT
FIR - Wu, Hsin-Tu
IR  - Raphael BJ
FIR - Raphael, Benjamin J
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Demeure MJ
FIR - Demeure, Michael J
IR  - Beuschlein F
FIR - Beuschlein, Felix
IR  - Gill AJ
FIR - Gill, Anthony J
IR  - Sidhu SB
FIR - Sidhu, Stan B
IR  - Almeida M
FIR - Almeida, Madson
IR  - Barisson Fragoso MC
FIR - Barisson Fragoso, Maria Candida
IR  - Cope LM
FIR - Cope, Leslie M
IR  - Kebebew E
FIR - Kebebew, Electron
IR  - Habra MA
FIR - Habra, Mouhammed Amir
IR  - Whitsett TG
FIR - Whitsett, Timothy G
IR  - Bussey KJ
FIR - Bussey, Kimberly J
IR  - Rainey WE
FIR - Rainey, William E
IR  - Asa SL
FIR - Asa, Sylvia L
IR  - Bertherat J
FIR - Bertherat, Jerome
IR  - Fassnacht M
FIR - Fassnacht, Martin
IR  - Wheeler DA
FIR - Wheeler, David A
IR  - Benz C
FIR - Benz, Christopher
IR  - Ally A
FIR - Ally, Adrian
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Brooks D
FIR - Brooks, Denise
IR  - Butterfield YSN
FIR - Butterfield, Yaron S N
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Guin R
FIR - Guin, Ranabir
IR  - Holt RA
FIR - Holt, Robert A
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Lee D
FIR - Lee, Darlene
IR  - Li HI
FIR - Li, Haiyan I
IR  - Lim L
FIR - Lim, Lynette
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Tam A
FIR - Tam, Angela
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Park PJ
FIR - Park, Peter J
IR  - Kroiss M
FIR - Kroiss, Matthias
IR  - Gao J
FIR - Gao, Jianjiong
IR  - Sander C
FIR - Sander, Chris
IR  - Schultz N
FIR - Schultz, Nikolaus
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Kucherlapati R
FIR - Kucherlapati, Raju
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Parker JS
FIR - Parker, Joel S
IR  - Perou CM
FIR - Perou, Charles M
IR  - Tan D
FIR - Tan, Donghui
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Ladanyi M
FIR - Ladanyi, Marc
IR  - Quinkler M
FIR - Quinkler, Marcus
IR  - Auman JT
FIR - Auman, J Todd
IR  - Latronico AC
FIR - Latronico, Ana Claudia
IR  - Mendonca BB
FIR - Mendonca, Berenice B
IR  - Sibony M
FIR - Sibony, Mathilde
IR  - Sanborn Z
FIR - Sanborn, Zack
IR  - Bellair M
FIR - Bellair, Michelle
IR  - Buhay C
FIR - Buhay, Christian
IR  - Covington K
FIR - Covington, Kyle
IR  - Dahdouli M
FIR - Dahdouli, Mahmoud
IR  - Dinh H
FIR - Dinh, Huyen
IR  - Doddapaneni H
FIR - Doddapaneni, Harsha
IR  - Downs B
FIR - Downs, Brittany
IR  - Drummond J
FIR - Drummond, Jennifer
IR  - Gibbs R
FIR - Gibbs, Richard
IR  - Hale W
FIR - Hale, Walker
IR  - Han Y
FIR - Han, Yi
IR  - Hawes A
FIR - Hawes, Alicia
IR  - Hu J
FIR - Hu, Jianhong
IR  - Kakkar N
FIR - Kakkar, Nipun
IR  - Kalra D
FIR - Kalra, Divya
IR  - Khan Z
FIR - Khan, Ziad
IR  - Kovar C
FIR - Kovar, Christine
IR  - Lee S
FIR - Lee, Sandy
IR  - Lewis L
FIR - Lewis, Lora
IR  - Morgan M
FIR - Morgan, Margaret
IR  - Morton D
FIR - Morton, Donna
IR  - Muzny D
FIR - Muzny, Donna
IR  - Santibanez J
FIR - Santibanez, Jireh
IR  - Xi L
FIR - Xi, Liu
IR  - Dousset B
FIR - Dousset, Bertrand
IR  - Groussin L
FIR - Groussin, Lionel
IR  - Libe R
FIR - Libe, Rossella
IR  - Chin L
FIR - Chin, Lynda
IR  - Reynolds S
FIR - Reynolds, Sheila
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Wu Y
FIR - Wu, Ye
IR  - Yeh JJ
FIR - Yeh, Jen Jen
IR  - Balu S
FIR - Balu, Saianand
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Meng S
FIR - Meng, Shaowu
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Shi Y
FIR - Shi, Yan
IR  - Simons JV
FIR - Simons, Janae V
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Wu J
FIR - Wu, Junyuan
IR  - Zhang W
FIR - Zhang, Wei
IR  - Mills Shaw KR
FIR - Mills Shaw, Kenna R
IR  - Demchok JA
FIR - Demchok, John A
IR  - Felau I
FIR - Felau, Ina
IR  - Sheth M
FIR - Sheth, Margi
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Wang Z
FIR - Wang, Zhining
IR  - Yang L
FIR - Yang, Liming
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Davidsen T
FIR - Davidsen, Tanja
IR  - Crawford C
FIR - Crawford, Catherine
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Bshara W
FIR - Bshara, Wiam
IR  - Gaudioso C
FIR - Gaudioso, Carmelo
IR  - Morrison C
FIR - Morrison, Carl
IR  - Soon P
FIR - Soon, Patsy
IR  - Alonso S
FIR - Alonso, Shelley
IR  - Baboud J
FIR - Baboud, Julien
IR  - Pihl T
FIR - Pihl, Todd
IR  - Raman R
FIR - Raman, Rohini
IR  - Sun Q
FIR - Sun, Qiang
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Arachchi H
FIR - Arachchi, Harindra
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Carter SL
FIR - Carter, Scott L
IR  - Cho J
FIR - Cho, Juok
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Getz G
FIR - Getz, Gad
IR  - Heiman DI
FIR - Heiman, David I
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lin P
FIR - Lin, Pei
IR  - Noble MS
FIR - Noble, Michael S
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Sougnez C
FIR - Sougnez, Carrie
IR  - Voet D
FIR - Voet, Doug
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Bowen J
FIR - Bowen, Jay
IR  - Coppens S
FIR - Coppens, Sara
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gerken M
FIR - Gerken, Mark
IR  - Helsel C
FIR - Helsel, Carmen
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Wise L
FIR - Wise, Lisa
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Baylin S
FIR - Baylin, Stephen
IR  - Herman JG
FIR - Herman, James G
IR  - LoBello J
FIR - LoBello, Janine
IR  - Watanabe A
FIR - Watanabe, Aprill
IR  - Haussler D
FIR - Haussler, David
IR  - Radenbaugh A
FIR - Radenbaugh, Amie
IR  - Rao A
FIR - Rao, Arjun
IR  - Zhu J
FIR - Zhu, Jingchun
IR  - Bartsch DK
FIR - Bartsch, Detlef K
IR  - Sbiera S
FIR - Sbiera, Silviu
IR  - Allolio B
FIR - Allolio, Bruno
IR  - Deutschbein T
FIR - Deutschbein, Timo
IR  - Ronchi C
FIR - Ronchi, Cristina
IR  - Raymond VM
FIR - Raymond, Victoria M
IR  - Vinco M
FIR - Vinco, Michelle
IR  - Shao L
FIR - Shao, Lina
IR  - Amble L
FIR - Amble, Linda
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Robinson B
FIR - Robinson, Bruce
IR  - Ju Z
FIR - Ju, Zhenlin
IR  - Kim H
FIR - Kim, Hoon
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu W
FIR - Liu, Wenbin
IR  - Lu Y
FIR - Lu, Yiling
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Sircar K
FIR - Sircar, Kanishka
IR  - Wang Q
FIR - Wang, Qianghu
IR  - Yoshihara K
FIR - Yoshihara, Kosuke
IR  - Laird PW
FIR - Laird, Peter W
IR  - Fan Y
FIR - Fan, Yu
IR  - Wang W
FIR - Wang, Wenyi
IR  - Shinbrot E
FIR - Shinbrot, Eve
IR  - Reincke M
FIR - Reincke, Martin
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Meier S
FIR - Meier, Sam
IR  - Defreitas T
FIR - Defreitas, Timothy
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30347-6 [pii]
AID - 10.1016/j.ccell.2016.07.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):363. doi: 10.1016/j.ccell.2016.07.013. Epub 2016
      Aug 8.

PMID- 27505680
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20180328
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias.
PG  - 363-365
LID - S1535-6108(16)30349-X [pii]
LID - 10.1016/j.ccell.2016.07.015 [doi]
FAU - Yang, Liubin
AU  - Yang L
FAU - Rodriguez, Benjamin
AU  - Rodriguez B
FAU - Mayle, Allison
AU  - Mayle A
FAU - Park, Hyun Jung
AU  - Park HJ
FAU - Lin, Xueqiu
AU  - Lin X
FAU - Luo, Min
AU  - Luo M
FAU - Jeong, Mira
AU  - Jeong M
FAU - Curry, Choladda V
AU  - Curry CV
FAU - Kim, Sang-Bae
AU  - Kim SB
FAU - Ruau, David
AU  - Ruau D
FAU - Zhang, Xiaotian
AU  - Zhang X
FAU - Zhou, Ting
AU  - Zhou T
FAU - Zhou, Michael
AU  - Zhou M
FAU - Rebel, Vivienne I
AU  - Rebel VI
FAU - Challen, Grant A
AU  - Challen GA
FAU - Gottgens, Berthold
AU  - Gottgens B
FAU - Lee, Ju-Seog
AU  - Lee JS
FAU - Rau, Rachel
AU  - Rau R
FAU - Li, Wei
AU  - Li W
FAU - Goodell, Margaret A
AU  - Goodell MA
LA  - eng
GR  - 12765/Cancer Research UK/United Kingdom
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P50 CA126752/CA/NCI NIH HHS/United States
GR  - R01 CA183252/CA/NCI NIH HHS/United States
GR  - MC_PC_12009/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Jun 13;29(6):922-934. PMID: 27300438
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30349-X [pii]
AID - 10.1016/j.ccell.2016.07.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):363-365. doi: 10.1016/j.ccell.2016.07.015. Epub
      2016 Aug 8.

PMID- 27505679
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Wip1 Controls Global Heterochromatin Silencing via ATM/BRCA1-Dependent DNA
      Methylation.
PG  - 361-362
LID - S1535-6108(16)30350-6 [pii]
LID - 10.1016/j.ccell.2016.07.016 [doi]
FAU - Filipponi, Doria
AU  - Filipponi D
FAU - Muller, Julius
AU  - Muller J
FAU - Emelyanov, Alexander
AU  - Emelyanov A
FAU - Bulavin, Dmitry V
AU  - Bulavin DV
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2013 Oct 14;24(4):528-41. PMID: 24135283
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30350-6 [pii]
AID - 10.1016/j.ccell.2016.07.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):361-362. doi: 10.1016/j.ccell.2016.07.016. Epub
      2016 Aug 8.

PMID- 27505678
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20180125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.
PG  - 359-360
LID - S1535-6108(16)30334-8 [pii]
LID - 10.1016/j.ccell.2016.07.003 [doi]
FAU - Kollmann, Karoline
AU  - Kollmann K
FAU - Heller, Gerwin
AU  - Heller G
FAU - Schneckenleithner, Christine
AU  - Schneckenleithner C
FAU - Warsch, Wolfgang
AU  - Warsch W
FAU - Scheicher, Ruth
AU  - Scheicher R
FAU - Ott, Rene G
AU  - Ott RG
FAU - Schafer, Markus
AU  - Schafer M
FAU - Fajmann, Sabine
AU  - Fajmann S
FAU - Schlederer, Michaela
AU  - Schlederer M
FAU - Schiefer, Ana-Iris
AU  - Schiefer AI
FAU - Reichart, Ursula
AU  - Reichart U
FAU - Mayerhofer, Matthias
AU  - Mayerhofer M
FAU - Hoeller, Christoph
AU  - Hoeller C
FAU - Zochbauer-Muller, Sabine
AU  - Zochbauer-Muller S
FAU - Kerjaschki, Dontscho
AU  - Kerjaschki D
FAU - Bock, Christoph
AU  - Bock C
FAU - Kenner, Lukas
AU  - Kenner L
FAU - Hoefler, Gerald
AU  - Hoefler G
FAU - Freissmuth, Michael
AU  - Freissmuth M
FAU - Green, Anthony R
AU  - Green AR
FAU - Moriggl, Richard
AU  - Moriggl R
FAU - Busslinger, Meinrad
AU  - Busslinger M
FAU - Malumbres, Marcos
AU  - Malumbres M
FAU - Sexl, Veronika
AU  - Sexl V
LA  - eng
GR  - 12765/Cancer Research UK/United Kingdom
GR  - 8961/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2013 Aug 12;24(2):167-81. PMID: 23948297
PMC - PMC5637299
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30334-8 [pii]
AID - 10.1016/j.ccell.2016.07.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):359-360. doi: 10.1016/j.ccell.2016.07.003. Epub
      2016 Aug 8.

PMID- 27505677
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in 
      Childhood Neuroblastoma.
PG  - 357-358
LID - S1535-6108(16)30333-6 [pii]
LID - 10.1016/j.ccell.2016.07.002 [doi]
FAU - Brockmann, Markus
AU  - Brockmann M
FAU - Poon, Evon
AU  - Poon E
FAU - Berry, Teeara
AU  - Berry T
FAU - Carstensen, Anne
AU  - Carstensen A
FAU - Deubzer, Hedwig E
AU  - Deubzer HE
FAU - Rycak, Lukas
AU  - Rycak L
FAU - Jamin, Yann
AU  - Jamin Y
FAU - Thway, Khin
AU  - Thway K
FAU - Robinson, Simon P
AU  - Robinson SP
FAU - Roels, Frederik
AU  - Roels F
FAU - Witt, Olaf
AU  - Witt O
FAU - Fischer, Matthias
AU  - Fischer M
FAU - Chesler, Louis
AU  - Chesler L
FAU - Eilers, Martin
AU  - Eilers M
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2013 Jul 8;24(1):75-89. PMID: 23792191
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30333-6 [pii]
AID - 10.1016/j.ccell.2016.07.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):357-358. doi: 10.1016/j.ccell.2016.07.002. Epub
      2016 Aug 8.

PMID- 27505676
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - A Critical Role for Notch Signaling in the Formation of Cholangiocellular
      Carcinomas.
PG  - 353-356
LID - S1535-6108(16)30336-1 [pii]
LID - 10.1016/j.ccell.2016.07.005 [doi]
FAU - Zender, Steffen
AU  - Zender S
FAU - Nickeleit, Irina
AU  - Nickeleit I
FAU - Wuestefeld, Torsten
AU  - Wuestefeld T
FAU - Sorensen, Inga
AU  - Sorensen I
FAU - Dauch, Daniel
AU  - Dauch D
FAU - Bozko, Przemyslaw
AU  - Bozko P
FAU - El-Khatib, Mona
AU  - El-Khatib M
FAU - Geffers, Robert
AU  - Geffers R
FAU - Bektas, Hueseyin
AU  - Bektas H
FAU - Manns, Michael P
AU  - Manns MP
FAU - Gossler, Achim
AU  - Gossler A
FAU - Wilkens, Ludwig
AU  - Wilkens L
FAU - Plentz, Ruben
AU  - Plentz R
FAU - Zender, Lars
AU  - Zender L
FAU - Malek, Nisar P
AU  - Malek NP
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2013 Jun 10;23(6):784-95. PMID: 23727022
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30336-1 [pii]
AID - 10.1016/j.ccell.2016.07.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):353-356. doi: 10.1016/j.ccell.2016.07.005. Epub
      2016 Aug 8.

PMID- 27505675
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Loss of the Par3 Polarity Protein Promotes Breast Tumorigenesis and Metastasis.
PG  - 351-352
LID - S1535-6108(16)30332-4 [pii]
LID - 10.1016/j.ccell.2016.07.001 [doi]
FAU - McCaffrey, Luke Martin
AU  - McCaffrey LM
FAU - Montalbano, JoAnne
AU  - Montalbano J
FAU - Mihai, Constantina
AU  - Mihai C
FAU - Macara, Ian G
AU  - Macara IG
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2012 Nov 13;22(5):601-14. PMID: 23153534
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30332-4 [pii]
AID - 10.1016/j.ccell.2016.07.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):351-352. doi: 10.1016/j.ccell.2016.07.001. Epub
      2016 Aug 8.

PMID- 27505674
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 
      Autoregulatory Loop in Multiple Myeloma Development.
PG  - 349-351
LID - S1535-6108(16)30341-5 [pii]
LID - 10.1016/j.ccell.2016.07.007 [doi]
FAU - Pichiorri, Flavia
AU  - Pichiorri F
FAU - Suh, Sung-Suk
AU  - Suh SS
FAU - Rocci, Alberto
AU  - Rocci A
FAU - De Luca, Luciana
AU  - De Luca L
FAU - Taccioli, Cristian
AU  - Taccioli C
FAU - Santhanam, Ramasamy
AU  - Santhanam R
FAU - Zhou, Wenchao
AU  - Zhou W
FAU - Benson, Don M Jr
AU  - Benson DM Jr
FAU - Hofmainster, Craig
AU  - Hofmainster C
FAU - Alder, Hansjuerg
AU  - Alder H
FAU - Garofalo, Michela
AU  - Garofalo M
FAU - Di Leva, Gianpiero
AU  - Di Leva G
FAU - Volinia, Stefano
AU  - Volinia S
FAU - Lin, Huey-Jen
AU  - Lin HJ
FAU - Perrotti, Danilo
AU  - Perrotti D
FAU - Kuehl, Michael
AU  - Kuehl M
FAU - Aqeilan, Rami I
AU  - Aqeilan RI
FAU - Palumbo, Antonio
AU  - Palumbo A
FAU - Croce, Carlo M
AU  - Croce CM
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160808
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2010 Oct 19;18(4):367-81. PMID: 20951946
EDAT- 2016/08/10 06:00
MHDA- 2016/08/10 06:01
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2016/08/10 06:01 [medline]
PHST- 2016/08/10 06:00 [entrez]
AID - S1535-6108(16)30341-5 [pii]
AID - 10.1016/j.ccell.2016.07.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):349-351. doi: 10.1016/j.ccell.2016.07.007. Epub
      2016 Aug 8.

PMID- 27505673
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Regulation of OGT by URI in Response to Glucose Confers c-MYC-Dependent Survival 
      Mechanisms.
PG  - 290-307
LID - S1535-6108(16)30283-5 [pii]
LID - 10.1016/j.ccell.2016.06.023 [doi]
AB  - Cancer cells can adapt and survive under low nutrient conditions, but underlying 
      mechanisms remain poorly explored. We demonstrate here that glucose maintains a
      functional complex between the co-chaperone URI, PP1gamma, and OGT, the enzyme
      catalyzing O-GlcNAcylation. Glucose deprivation induces the activation of PKA,
      which phosphorylates URI at Ser-371, resulting in PP1gamma release and
      URI-mediated OGT inhibition. Low OGT activity reduces O-GlcNAcylation and
      promotes c-MYC degradation to maintain cell survival. In the presence of glucose,
      PP1gamma-bound URI increases OGT and c-MYC levels. Accordingly, mice expressing
      non-phosphorylatable URI (S371A) in hepatocytes exhibit high OGT activity and
      c-MYC stabilization, accelerating liver tumorigenesis in agreement with c-MYC
      oncogenic functions. Our work uncovers that URI-regulated OGT confers
      c-MYC-dependent survival functions in response to glucose fluctuations.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Buren, Stefan
AU  - Buren S
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Gomes, Ana L
AU  - Gomes AL
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Teijeiro, Ana
AU  - Teijeiro A
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Fawal, Mohamad-Ali
AU  - Fawal MA
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Yilmaz, Mahmut
AU  - Yilmaz M
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Tummala, Krishna S
AU  - Tummala KS
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Perez, Manuel
AU  - Perez M
AD  - Biotechnology Programme, Confocal Microscopy Core Unit, Centro Nacional de
      Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Rodriguez-Justo, Manuel
AU  - Rodriguez-Justo M
AD  - Department of Research Pathology, Cancer Institute, University College London,
      London WC1E 6JJ, UK.
FAU - Campos-Olivas, Ramon
AU  - Campos-Olivas R
AD  - Structural Biology and Biocomputing Programme, Spectroscopy and Nuclear Magnetic 
      Resonance Unit, Centro Nacional de Investigaciones Oncologicas, CNIO, Madrid
      28029, Spain.
FAU - Megias, Diego
AU  - Megias D
AD  - Biotechnology Programme, Confocal Microscopy Core Unit, Centro Nacional de
      Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Djouder, Nabil
AU  - Djouder N
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain. Electronic
      address: ndjouder@cnio.es.
LA  - eng
GR  - 11-0242/Worldwide Cancer Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (MYC protein, human)
RN  - 0 (Myc protein, mouse)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (URI1 protein, human)
RN  - EC 2.4.1.- (N-Acetylglucosaminyltransferases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Glucose/administration & dosage/*metabolism
MH  - Glucose Tolerance Test
MH  - HEK293 Cells
MH  - HeLa Cells
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Liver Neoplasms/genetics/*metabolism
MH  - Mice
MH  - N-Acetylglucosaminyltransferases/*metabolism
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - RNA, Small Interfering/genetics/metabolism
MH  - Transfection
EDAT- 2016/08/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/10 06:00
PHST- 2014/12/18 00:00 [received]
PHST- 2015/08/01 00:00 [revised]
PHST- 2016/06/29 00:00 [accepted]
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30283-5 [pii]
AID - 10.1016/j.ccell.2016.06.023 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):290-307. doi: 10.1016/j.ccell.2016.06.023.

PMID- 27505672
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming.
PG  - 257-272
LID - S1535-6108(16)30335-X [pii]
LID - 10.1016/j.ccell.2016.07.004 [doi]
AB  - Hypoxia is a universal driver of aggressive tumor behavior, but the underlying
      mechanisms are not completely understood. Using a phosphoproteomics screen, we
      now show that active Akt accumulates in the mitochondria during hypoxia and
      phosphorylates pyruvate dehydrogenase kinase 1 (PDK1) on Thr346 to inactivate the
      pyruvate dehydrogenase complex. In turn, this pathway switches tumor metabolism
      toward glycolysis, antagonizes apoptosis and autophagy, dampens oxidative stress,
      and maintains tumor cell proliferation in the face of severe hypoxia.
      Mitochondrial Akt-PDK1 signaling correlates with unfavorable prognostic markers
      and shorter survival in glioma patients and may provide an "actionable"
      therapeutic target in cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Chae, Young Chan
AU  - Chae YC
AD  - Prostate Cancer Discovery and Development Program, Tumor Microenvironment and
      Metastasis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA
      19104, USA.
FAU - Vaira, Valentina
AU  - Vaira V
AD  - Istituto Nazionale Genetica Molecolare "Romeo and Enrica Invernizzi", Milan
      20122, Italy; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale
      Maggiore Policlinico, Milan 20122, Italy; Department of Pathophysiology and
      Transplantation, University of Milan, Milan 20122, Italy.
FAU - Caino, M Cecilia
AU  - Caino MC
AD  - Prostate Cancer Discovery and Development Program, Tumor Microenvironment and
      Metastasis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA
      19104, USA.
FAU - Tang, Hsin-Yao
AU  - Tang HY
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan
      20122, Italy.
FAU - Seo, Jae Ho
AU  - Seo JH
AD  - Prostate Cancer Discovery and Development Program, Tumor Microenvironment and
      Metastasis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA
      19104, USA.
FAU - Kossenkov, Andrew V
AU  - Kossenkov AV
AD  - Center for Systems and Computational Biology, The Wistar Institute, Philadelphia,
      PA 19104, USA.
FAU - Ottobrini, Luisa
AU  - Ottobrini L
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan
      20122, Italy; Institute for Molecular Bioimaging and Physiology (IBFM), National 
      Research Council (CNR), Milan 20090, Italy.
FAU - Martelli, Cristina
AU  - Martelli C
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan
      20122, Italy.
FAU - Lucignani, Giovanni
AU  - Lucignani G
AD  - Department of Health Sciences, University of Milan, Milan 20142, Italy;
      Department of Diagnostic Services, Unit of Nuclear Medicine, San Paolo Hospital, 
      Milan 20142, Italy.
FAU - Bertolini, Irene
AU  - Bertolini I
AD  - Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,
      Milan 20122, Italy; Department of Pathophysiology and Transplantation, University
      of Milan, Milan 20122, Italy.
FAU - Locatelli, Marco
AU  - Locatelli M
AD  - Division of Neurosurgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore
      Policlinico, Milan 20122, Italy.
FAU - Bryant, Kelly G
AU  - Bryant KG
AD  - Prostate Cancer Discovery and Development Program, Tumor Microenvironment and
      Metastasis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA
      19104, USA.
FAU - Ghosh, Jagadish C
AU  - Ghosh JC
AD  - Prostate Cancer Discovery and Development Program, Tumor Microenvironment and
      Metastasis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA
      19104, USA.
FAU - Lisanti, Sofia
AU  - Lisanti S
AD  - Prostate Cancer Discovery and Development Program, Tumor Microenvironment and
      Metastasis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA
      19104, USA.
FAU - Ku, Bonsu
AU  - Ku B
AD  - Functional Genomics Research Center, Korea Research Institute of Bioscience and
      Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Republic of Korea.
FAU - Bosari, Silvano
AU  - Bosari S
AD  - Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,
      Milan 20122, Italy; Department of Pathophysiology and Transplantation, University
      of Milan, Milan 20122, Italy.
FAU - Languino, Lucia R
AU  - Languino LR
AD  - Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 
      Philadelphia, PA 19107, USA.
FAU - Speicher, David W
AU  - Speicher DW
AD  - Center for Systems and Computational Biology, The Wistar Institute, Philadelphia,
      PA 19104, USA; Molecular and Cellular Oncogenesis Program, The Wistar Institute, 
      Philadelphia, PA 19104, USA.
FAU - Altieri, Dario C
AU  - Altieri DC
AD  - Prostate Cancer Discovery and Development Program, Tumor Microenvironment and
      Metastasis Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA
      19104, USA. Electronic address: daltieri@wistar.org.
LA  - eng
GR  - R01 CA078810/CA/NCI NIH HHS/United States
GR  - F32 CA177018/CA/NCI NIH HHS/United States
GR  - R01 CA089720/CA/NCI NIH HHS/United States
GR  - P01 CA140043/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R50 CA211199/CA/NCI NIH HHS/United States
GR  - R01 CA190027/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.2 (pyruvate dehydrogenase (acetyl-transferring) kinase)
SB  - IM
MH  - Animals
MH  - Cell Hypoxia/physiology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/physiology
MH  - Cellular Reprogramming/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, Nude
MH  - Mitochondria/*metabolism
MH  - Neoplasms/*metabolism/*pathology
MH  - Protein-Serine-Threonine Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction
PMC - PMC5131882
MID - NIHMS829253
OTO - NOTNLM
OT  - *Akt
OT  - *PDK1
OT  - *hypoxia
OT  - *metabolism
OT  - *mitochondria
OT  - *tumor cell proliferation
EDAT- 2016/08/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/10 06:00
PHST- 2015/08/19 00:00 [received]
PHST- 2016/03/04 00:00 [revised]
PHST- 2016/07/01 00:00 [accepted]
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30335-X [pii]
AID - 10.1016/j.ccell.2016.07.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):257-272. doi: 10.1016/j.ccell.2016.07.004.

PMID- 27505671
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating
      Alveolar Epithelial TLR3 to Recruit Neutrophils.
PG  - 243-256
LID - S1535-6108(16)30281-1 [pii]
LID - 10.1016/j.ccell.2016.06.021 [doi]
AB  - The pre-metastatic niche educated by primary tumor-derived elements contributes
      to cancer metastasis. However, the role of host stromal cells in metastatic niche
      formation and organ-specific metastatic tropism is not clearly defined. Here, we 
      demonstrate that lung epithelial cells are critical for initiating neutrophil
      recruitment and lung metastatic niche formation by sensing tumor exosomal RNAs
      via Toll-like receptor 3 (TLR3). TLR3-deficient mice show reduced lung metastasis
      in the spontaneous metastatic models. Mechanistically, primary tumor-derived
      exosomal RNAs, which are enriched in small nuclear RNAs, activate TLR3 in lung
      epithelial cells, consequently inducing chemokine secretion in the lung and
      promoting neutrophil recruitment. Identification of metastatic axis of tumor
      exosomal RNAs and host lung epithelial cell TLR3 activation provides potential
      targets to control cancer metastasis to the lung.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Liu, Yanfang
AU  - Liu Y
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second
      Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
FAU - Gu, Yan
AU  - Gu Y
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second
      Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
FAU - Han, Yanmei
AU  - Han Y
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second
      Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
FAU - Zhang, Qian
AU  - Zhang Q
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second
      Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
FAU - Jiang, Zhengping
AU  - Jiang Z
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second
      Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
FAU - Zhang, Xiang
AU  - Zhang X
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second
      Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
FAU - Huang, Bo
AU  - Huang B
AD  - National Key Laboratory of Medical Molecular Biology, Department of Immunology,
      Institute of Basic Medical Sciences, Peking Union Medical College, Chinese
      Academy of Medical Sciences, Beijing 100005, China.
FAU - Xu, Xiaoqing
AU  - Xu X
AD  - National Key Laboratory of Medical Molecular Biology, Department of Immunology,
      Institute of Basic Medical Sciences, Peking Union Medical College, Chinese
      Academy of Medical Sciences, Beijing 100005, China.
FAU - Zheng, Jianming
AU  - Zheng J
AD  - Department of Pathology, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Cao, Xuetao
AU  - Cao X
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second
      Military Medical University, 800 Xiangyin Road, Shanghai 200433, China; National 
      Key Laboratory of Medical Molecular Biology, Department of Immunology, Institute 
      of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of
      Medical Sciences, Beijing 100005, China. Electronic address: caoxt@immunol.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (RNA, Neoplasm)
RN  - 0 (RNA, Small Nuclear)
RN  - 0 (TLR3 protein, human)
RN  - 0 (TLR3 protein, mouse)
RN  - 0 (Toll-Like Receptor 3)
SB  - IM
CIN - J Thorac Dis. 2017 Apr;9(4):969-972. PMID: 28523150
CIN - Cancer Cell. 2016 Aug 8;30(2):189-191. PMID: 27505667
MH  - Animals
MH  - Base Sequence
MH  - Carcinoma, Lewis Lung/genetics/metabolism/pathology
MH  - Epithelial Cells/pathology
MH  - *Exosomes
MH  - Humans
MH  - Lung Neoplasms/*genetics/metabolism/pathology/*secondary
MH  - Melanoma, Experimental/genetics/metabolism/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neoplasm Metastasis
MH  - Neutrophil Infiltration/*genetics
MH  - RNA, Neoplasm/genetics/*metabolism
MH  - RNA, Small Nuclear/genetics/metabolism
MH  - Toll-Like Receptor 3/deficiency/*genetics/metabolism
OTO - NOTNLM
OT  - *TLR3
OT  - *alveolar epithelial cell
OT  - *exosomal RNA
OT  - *metastasis
OT  - *pre-metastatic niche
EDAT- 2016/08/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/10 06:00
PHST- 2016/01/27 00:00 [received]
PHST- 2016/05/01 00:00 [revised]
PHST- 2016/06/24 00:00 [accepted]
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30281-1 [pii]
AID - 10.1016/j.ccell.2016.06.021 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):243-256. doi: 10.1016/j.ccell.2016.06.021.

PMID- 27505670
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent
      Promoters, Mediate Germinal Center Formation and Lymphomagenesis.
PG  - 197-213
LID - S1535-6108(16)30337-3 [pii]
LID - 10.1016/j.ccell.2016.07.006 [doi]
AB  - The EZH2 histone methyltransferase mediates the humoral immune response and
      drives lymphomagenesis through formation of bivalent chromatin domains at
      critical germinal center (GC) B cell promoters. Herein we show that the actions
      of EZH2 in driving GC formation and lymphoma precursor lesions require
      site-specific binding by the BCL6 transcriptional repressor and the presence of a
      non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in
      GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable
      association of the complex and the resulting histone modifications. Moreover,
      oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma
      (DLBCL) development and combinatorial targeting of these repressors results in
      enhanced anti-lymphoma activity in DLBCLs.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Beguelin, Wendy
AU  - Beguelin W
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Teater, Matt
AU  - Teater M
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA;
      Institute for Computational Biomedicine, Weill Cornell Medical College, Cornell
      University, New York, NY 10021, USA.
FAU - Gearhart, Micah D
AU  - Gearhart MD
AD  - Department of Genetics, Cell Biology, and Development, Developmental Biology
      Center, Masonic Cancer Center, University of Minnesota, 6-160 Church Street SE,
      University of Minnesota, Minneapolis, MN 55455, USA.
FAU - Calvo Fernandez, Maria Teresa
AU  - Calvo Fernandez MT
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Goldstein, Rebecca L
AU  - Goldstein RL
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Cardenas, Mariano G
AU  - Cardenas MG
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Hatzi, Katerina
AU  - Hatzi K
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Rosen, Monica
AU  - Rosen M
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Shen, Hao
AU  - Shen H
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Corcoran, Connie M
AU  - Corcoran CM
AD  - Department of Genetics, Cell Biology, and Development, Developmental Biology
      Center, Masonic Cancer Center, University of Minnesota, 6-160 Church Street SE,
      University of Minnesota, Minneapolis, MN 55455, USA.
FAU - Hamline, Michelle Y
AU  - Hamline MY
AD  - Department of Genetics, Cell Biology, and Development, Developmental Biology
      Center, Masonic Cancer Center, University of Minnesota, 6-160 Church Street SE,
      University of Minnesota, Minneapolis, MN 55455, USA.
FAU - Gascoyne, Randy D
AU  - Gascoyne RD
AD  - Departments of Pathology and Lymphoid Cancer Research, Centre for Lymphoid
      Cancer, British Columbia Cancer Agency, British Columbia Cancer Research Centre, 
      Vancouver, BC, V5Z 1L3, Canada.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Licht, Jonathan D
AU  - Licht JD
AD  - Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center,
      Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
FAU - Shaknovich, Rita
AU  - Shaknovich R
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
FAU - Elemento, Olivier
AU  - Elemento O
AD  - Institute for Computational Biomedicine, Weill Cornell Medical College, Cornell
      University, New York, NY 10021, USA.
FAU - Bardwell, Vivian J
AU  - Bardwell VJ
AD  - Department of Genetics, Cell Biology, and Development, Developmental Biology
      Center, Masonic Cancer Center, University of Minnesota, 6-160 Church Street SE,
      University of Minnesota, Minneapolis, MN 55455, USA. Electronic address:
      bardw001@umn.edu.
FAU - Melnick, Ari M
AU  - Melnick AM
AD  - Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical
      College, Cornell University, 413 E 69(th) Street, New York, NY 10021, USA.
      Electronic address: amm2014@med.cornell.edu.
LA  - eng
GR  - R01 CA187109/CA/NCI NIH HHS/United States
GR  - R01 CA194547/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - F30 HL093996/HL/NHLBI NIH HHS/United States
GR  - T32 GM008244/GM/NIGMS NIH HHS/United States
GR  - R01 CA104348/CA/NCI NIH HHS/United States
GR  - R01 CA071540/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BCL6 protein, human)
RN  - 0 (BCOR protein, human)
RN  - 0 (Bcl6 protein, mouse)
RN  - 0 (Bcor protein, mouse)
RN  - 0 (CBX8 protein, human)
RN  - 0 (Cbx8 protein, mouse)
RN  - 0 (Mitochondrial Membrane Transport Proteins)
RN  - 0 (Polycomb-Group Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Repressor Proteins)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Ezh2 protein, mouse)
RN  - EC 2.3.2.27 (Polycomb Repressive Complex 1)
SB  - IM
CIN - Cancer Cell. 2016 Aug 8;30(2):185-187. PMID: 27505665
MH  - Animals
MH  - Enhancer of Zeste Homolog 2 Protein/*metabolism
MH  - Germinal Center/*metabolism/pathology
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/genetics/*metabolism/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Mitochondrial Membrane Transport Proteins
MH  - Polycomb Repressive Complex 1/*metabolism
MH  - Polycomb-Group Proteins/metabolism
MH  - Promoter Regions, Genetic
MH  - Proto-Oncogene Proteins/metabolism
MH  - Proto-Oncogene Proteins c-bcl-6/*metabolism
MH  - Repressor Proteins/*metabolism
MH  - Transcription, Genetic
PMC - PMC5000552
MID - NIHMS807257
EDAT- 2016/08/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/10 06:00
PHST- 2015/08/17 00:00 [received]
PHST- 2016/03/07 00:00 [revised]
PHST- 2016/07/13 00:00 [accepted]
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30337-3 [pii]
AID - 10.1016/j.ccell.2016.07.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):197-213. doi: 10.1016/j.ccell.2016.07.006.

PMID- 27505669
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Sticking It to Cancer with Molecular Glue for SHP2.
PG  - 194-196
LID - S1535-6108(16)30344-0 [pii]
LID - 10.1016/j.ccell.2016.07.010 [doi]
AB  - Much effort has been expended to develop inhibitors against protein-tyrosine
      phosphatases (PTPs), nearly all of it unsuccessful. A recent report, describing a
      highly specific, orally bioavailable inhibitor of the PTP oncoprotein SHP2 with
      in vivo activity, suggests that allostery might provide a way forward for PTP
      inhibitor development.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Ran, Hao
AU  - Ran H
AD  - Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical
      Center, New York, NY 10016, USA.
FAU - Tsutsumi, Ryouhei
AU  - Tsutsumi R
AD  - Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical
      Center, New York, NY 10016, USA.
FAU - Araki, Toshiyuki
AU  - Araki T
AD  - Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical
      Center, New York, NY 10016, USA.
FAU - Neel, Benjamin G
AU  - Neel BG
AD  - Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical
      Center, New York, NY 10016, USA. Electronic address: benjamin.neel@nyumc.org.
LA  - eng
GR  - R01 CA049152/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 11)
SB  - IM
CON - Nature. 2016 Jul 7;535(7610):148-52. PMID: 27362227
MH  - Animals
MH  - Humans
MH  - Mice
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy/enzymology/genetics
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists &
      inhibitors/genetics
PMC - PMC5558882
MID - NIHMS894159
EDAT- 2016/08/10 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30344-0 [pii]
AID - 10.1016/j.ccell.2016.07.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):194-196. doi: 10.1016/j.ccell.2016.07.010.

PMID- 27505668
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - IDH1, Histone Methylation, and So Forth.
PG  - 192-194
LID - S1535-6108(16)30342-7 [pii]
LID - 10.1016/j.ccell.2016.07.008 [doi]
AB  - IDH mutants cause aberrant DNA and histone methylation and contribute to
      hematological and neuronal malignancies. In this issue of Cancer Cell, Inoue et
      al. describe a potential specific effect of IDH1 mutations that reduces Atm
      expression via inhibition of H3K9 demethylases, which may represent a first step 
      toward cellular transformation.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Penard-Lacronique, Virginie
AU  - Penard-Lacronique V
AD  - INSERM U1170, 94805 Villejuif, France; Equipe Labellisee Ligue Nationale Contre
      le Cancer, Paris, France; Universite Paris Sud, Universite Paris-Saclay, 94720 Le
      Kremlin-Bicetre, France; Gustave Roussy, Universite Paris-Saclay, 94805
      Villejuif, France. Electronic address: virginie.penard-lacronique@inserm.fr.
FAU - Bernard, Olivier A
AU  - Bernard OA
AD  - INSERM U1170, 94805 Villejuif, France; Equipe Labellisee Ligue Nationale Contre
      le Cancer, Paris, France; Universite Paris Sud, Universite Paris-Saclay, 94720 Le
      Kremlin-Bicetre, France; Gustave Roussy, Universite Paris-Saclay, 94805
      Villejuif, France. Electronic address: olivier.bernard@inserm.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
SB  - IM
CON - Cancer Cell. 2016 Aug 8;30(2):337-348. PMID: 27424808
EIN - Cancer Cell. 2016 Sep 12;30(3):501. PMID: 27622339
MH  - DNA Methylation
MH  - Histones/*genetics
MH  - Humans
MH  - Isocitrate Dehydrogenase/*genetics
MH  - Methylation
MH  - Mutation
MH  - Neoplasms/genetics
EDAT- 2016/08/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30342-7 [pii]
AID - 10.1016/j.ccell.2016.07.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):192-194. doi: 10.1016/j.ccell.2016.07.008.

PMID- 27505667
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Pre-Metastatic Niche Formation Has Taken Its TOLL.
PG  - 189-191
LID - S1535-6108(16)30346-4 [pii]
LID - 10.1016/j.ccell.2016.07.012 [doi]
AB  - Pre-Metastatic Niches (PMNs) result from communications between primary tumors
      and the microenvironment of future distant metastasis via tumor-derived factors. 
      In this issue of Cancer Cell, Liu et al. show that TLR3 activation in lung
      epithelial cells by tumor exosomal RNAs triggers neutrophil recruitment, which
      contributes to PMN formation and metastasis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kenific, Candia M
AU  - Kenific CM
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
FAU - Nogues, Laura
AU  - Nogues L
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
FAU - Lyden, David
AU  - Lyden D
AD  - Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics
      and Cell and Developmental Biology, Drukier Institute for Children's Health,
      Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA; Department 
      of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
      Electronic address: dcl2001@med.cornell.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (RNA, Neoplasm)
SB  - IM
CON - Cancer Cell. 2016 Aug 8;30(2):243-256. PMID: 27505671
MH  - Epithelial Cells
MH  - Humans
MH  - Lung
MH  - Neoplasm Metastasis
MH  - *Neoplasms
MH  - RNA, Neoplasm
MH  - *Tumor Microenvironment
EDAT- 2016/08/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30346-4 [pii]
AID - 10.1016/j.ccell.2016.07.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):189-191. doi: 10.1016/j.ccell.2016.07.012.

PMID- 27505666
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Functionally Assessing Candidate Drivers Advances Precision Cancer Medicine.
PG  - 187-189
LID - S1535-6108(16)30345-2 [pii]
LID - 10.1016/j.ccell.2016.07.011 [doi]
AB  - The complexity of genomic alterations in cancer has made it difficult to identify
      oncogenic drivers for the development of targeted therapies. The study by Berger 
      et al. in this issue of Cancer Cell demonstrates that high-throughput functional 
      profiling can uncover impactful mutations and oncogenic driver alleles.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Scott, Kenneth L
AU  - Scott KL
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, One
      Baylor Plaza, Houston, TX 77030, USA.
FAU - Powers, Scott
AU  - Powers S
AD  - Department of Pathology, Stony Brook University, One Nichols Drive, Stony Brook, 
      NY 11794, USA. Electronic address: scott.powers@stonybrook.edu.
LA  - eng
GR  - P30 CA045508/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Aug 8;30(2):214-228. PMID: 27478040
MH  - Genomics
MH  - Humans
MH  - Mutation
MH  - *Neoplasms
MH  - *Precision Medicine
EDAT- 2016/08/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30345-2 [pii]
AID - 10.1016/j.ccell.2016.07.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):187-189. doi: 10.1016/j.ccell.2016.07.011.

PMID- 27505665
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Combinatorial Tethering: A Novel Mode to Recruit Non-canonical PRC1 for Normal
      and Malignant GC B Cell Development.
PG  - 185-187
LID - S1535-6108(16)30348-8 [pii]
LID - 10.1016/j.ccell.2016.07.014 [doi]
AB  - Polycomb repressive complexes (PRCs) are key to normal development and are
      frequently deregulated in human cancer. In this issue of Cancer Cell, Beguelin et
      al. report a mechanism of non-canonical PRC1 recruitment by BCL6 in collaboration
      with EZH2-mediated H3K27me3 for establishment of stable repressive complexes in
      germinal center B cells.
CI  - Copyright (c) 2016. Published by Elsevier Inc.
FAU - Zeisig, Bernd B
AU  - Zeisig BB
AD  - Division of Cancer Studies, Department of Haematological Medicine, Leukaemia and 
      Stem Cell Biology Group, King's College London, Denmark Hill, SE5 9NU London, UK.
FAU - So, Chi Wai Eric
AU  - So CWE
AD  - Division of Cancer Studies, Department of Haematological Medicine, Leukaemia and 
      Stem Cell Biology Group, King's College London, Denmark Hill, SE5 9NU London, UK.
      Electronic address: eric.so@kcl.ac.uk.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Polycomb-Group Proteins)
SB  - IM
CON - Cancer Cell. 2016 Aug 8;30(2):197-213. PMID: 27505670
MH  - B-Lymphocytes
MH  - *Germinal Center
MH  - Humans
MH  - *Polycomb-Group Proteins
EDAT- 2016/08/10 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/08/10 06:00
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - S1535-6108(16)30348-8 [pii]
AID - 10.1016/j.ccell.2016.07.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):185-187. doi: 10.1016/j.ccell.2016.07.014.

PMID- 27478041
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at
      the Adipocyte-Rich Metastatic Niche.
PG  - 273-289
LID - S1535-6108(16)30280-X [pii]
LID - 10.1016/j.ccell.2016.06.020 [doi]
AB  - The adipocyte-rich microenvironment forms a niche for ovarian cancer metastasis, 
      but the mechanisms driving this process are incompletely understood. Here we show
      that salt-inducible kinase 2 (SIK2) is overexpressed in adipocyte-rich metastatic
      deposits compared with ovarian primary lesions. Overexpression of SIK2 in ovarian
      cancer cells promotes abdominal metastasis while SIK2 depletion prevents
      metastasis in vivo. Importantly, adipocytes induce calcium-dependent activation
      and autophosphorylation of SIK2. Activated SIK2 plays a dual role in augmenting
      AMPK-induced phosphorylation of acetyl-CoA carboxylase and in activating the
      PI3K/AKT pathway through p85alpha-S154 phosphorylation. These findings identify
      SIK2 at the apex of the adipocyte-induced signaling cascades in cancer cells and 
      make a compelling case for targeting SIK2 for therapy in ovarian cancer.
CI  - Crown Copyright (c) 2016. Published by Elsevier Inc. All rights reserved.
FAU - Miranda, Fabrizio
AU  - Miranda F
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Mannion, David
AU  - Mannion D
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Liu, Shujuan
AU  - Liu S
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Zheng, Yiyan
AU  - Zheng Y
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Mangala, Lingegowda S
AU  - Mangala LS
AD  - Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515
      Holcombe Boulevard, Houston, TX 77030, USA; Center for RNAi and Non-Coding RNA,
      The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard,
      Houston, TX 77030, USA.
FAU - Redondo, Clara
AU  - Redondo C
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK; Structural Genomics Consortium, Nuffield Department
      of Medicine, University of Oxford, Old Road Campus Research Building, Oxford OX3 
      7DQ, UK.
FAU - Herrero-Gonzalez, Sandra
AU  - Herrero-Gonzalez S
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Xu, Ruoyan
AU  - Xu R
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Taylor, Charlotte
AU  - Taylor C
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Chedom, Donatien Fotso
AU  - Chedom DF
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Karaminejadranjbar, Mohammad
AU  - Karaminejadranjbar M
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Albukhari, Ashwag
AU  - Albukhari A
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK; Biochemistry Department, Faculty of Science, King
      Abdulaziz University, Jeddah 21551, Saudi Arabia.
FAU - Jiang, Dahai
AU  - Jiang D
AD  - Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515
      Holcombe Boulevard, Houston, TX 77030, USA; Center for RNAi and Non-Coding RNA,
      The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard,
      Houston, TX 77030, USA.
FAU - Pradeep, Sunila
AU  - Pradeep S
AD  - Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515
      Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Rodriguez-Aguayo, Cristian
AU  - Rodriguez-Aguayo C
AD  - Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer
      Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of
      Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Lopez-Berestein, Gabriel
AU  - Lopez-Berestein G
AD  - Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer
      Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of
      Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Salah, Eidarus
AU  - Salah E
AD  - Structural Genomics Consortium, Nuffield Department of Medicine, University of
      Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
FAU - Abdul Azeez, Kamal R
AU  - Abdul Azeez KR
AD  - Structural Genomics Consortium, Nuffield Department of Medicine, University of
      Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
FAU - Elkins, Jonathan M
AU  - Elkins JM
AD  - Structural Genomics Consortium, Nuffield Department of Medicine, University of
      Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
FAU - Campo, Leticia
AU  - Campo L
AD  - Department of Oncology, University of Oxford, Old Road Campus Research Building, 
      Roosevelt Drive, Oxford OX3 7DQ, UK.
FAU - Myers, Kevin A
AU  - Myers KA
AD  - Department of Oncology, University of Oxford, Old Road Campus Research Building, 
      Roosevelt Drive, Oxford OX3 7DQ, UK.
FAU - Klotz, Daniel
AU  - Klotz D
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Bivona, Serena
AU  - Bivona S
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK.
FAU - Dhar, Sunanda
AU  - Dhar S
AD  - Department of Histopathology, Oxford University Hospitals, Oxford OX3 9DU, UK.
FAU - Bast, Robert C Jr
AU  - Bast RC Jr
AD  - Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Saya, Hideyuki
AU  - Saya H
AD  - Division of Gene Regulation, Institute for Advanced Medical Research, School of
      Medicine, Keio University, Tokyo 160-8582, Japan.
FAU - Choi, Hwan Geun
AU  - Choi HG
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA; Department of Cancer Biology, Dana Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Gray, Nathanael S
AU  - Gray NS
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA; Department of Cancer Biology, Dana Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Fischer, Roman
AU  - Fischer R
AD  - Nuffield Department of Medicine, Target Discovery Institute, University of
      Oxford, Oxford OX3 7FZ, UK.
FAU - Kessler, Benedikt M
AU  - Kessler BM
AD  - Nuffield Department of Medicine, Target Discovery Institute, University of
      Oxford, Oxford OX3 7FZ, UK.
FAU - Yau, Christopher
AU  - Yau C
AD  - Wellcome Trust Centre for Human Genetics, NIHR Biomedical Research Centre,
      Roosevelt Drive, Oxford OX3 7BN, UK; Department of Statistics, University of
      Oxford, 1 South Parks Road, Oxford OX1 3TG, UK.
FAU - Sood, Anil K
AU  - Sood AK
AD  - Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515
      Holcombe Boulevard, Houston, TX 77030, USA; Center for RNAi and Non-Coding RNA,
      The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard,
      Houston, TX 77030, USA.
FAU - Motohara, Takeshi
AU  - Motohara T
AD  - Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto
      University, Kumamoto 860-8556, Japan.
FAU - Knapp, Stefan
AU  - Knapp S
AD  - Structural Genomics Consortium, Nuffield Department of Medicine, University of
      Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK; Nuffield
      Department of Medicine, Target Discovery Institute, University of Oxford, Oxford 
      OX3 7FZ, UK; Goethe-University Frankfurt, Institute for Pharmaceutical Chemistry 
      and Buchmann Institute for Life Sciences, Riedberg Campus, 60438 Frankfurt am
      Main, Germany.
FAU - Ahmed, Ahmed Ashour
AU  - Ahmed AA
AD  - Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine,
      University of Oxford, Headington, Oxford OX3 9DS, UK; Nuffield Department of
      Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe 
      Hospital, Oxford OX3 9DU, UK. Electronic address: ahmed.ahmed@obs-gyn.ox.ac.uk.
LA  - eng
GR  - G0902418/Medical Research Council/United Kingdom
GR  - Cancer Research UK/United Kingdom
GR  - MR/L001411/1/Medical Research Council/United Kingdom
GR  - 090532/Z/09/Z/Wellcome Trust/United Kingdom
GR  - UH3 TR000943/TR/NCATS NIH HHS/United States
GR  - 092809/Z/10/Z/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20160728
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.- (salt-inducible kinase-2, human)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - EC 6.4.1.2 (Acetyl-CoA Carboxylase)
SB  - IM
MH  - AMP-Activated Protein Kinases/metabolism
MH  - Acetyl-CoA Carboxylase/metabolism
MH  - Adipocytes/enzymology/metabolism/pathology
MH  - Animals
MH  - Female
MH  - Heterografts
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Nude
MH  - Neoplasm Metastasis
MH  - Oncogene Protein v-akt/metabolism
MH  - Ovarian Neoplasms/enzymology/*genetics/*metabolism/pathology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein-Serine-Threonine Kinases/*metabolism
MH  - Signal Transduction
EDAT- 2016/08/02 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/02 06:00
PHST- 2014/12/08 00:00 [received]
PHST- 2015/12/24 00:00 [revised]
PHST- 2016/06/23 00:00 [accepted]
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30280-X [pii]
AID - 10.1016/j.ccell.2016.06.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):273-289. doi: 10.1016/j.ccell.2016.06.020. Epub
      2016 Jul 28.

PMID- 27478040
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - High-throughput Phenotyping of Lung Cancer Somatic Mutations.
PG  - 214-228
LID - 10.1016/j.ccell.2016.06.022 [doi]
AB  - Recent genome sequencing efforts have identified millions of somatic mutations in
      cancer. However, the functional impact of most variants is poorly understood.
      Here we characterize 194 somatic mutations identified in primary lung
      adenocarcinomas. We present an expression-based variant-impact phenotyping (eVIP)
      method that uses gene expression changes to distinguish impactful from neutral
      somatic mutations. eVIP identified 69% of mutations analyzed as impactful and 31%
      as functionally neutral. A subset of the impactful mutations induces xenograft
      tumor formation in mice and/or confers resistance to cellular EGFR inhibition.
      Among these impactful variants are rare somatic, clinically actionable variants
      including EGFR S645C, ARAF S214C and S214F, ERBB2 S418T, and multiple BRAF
      variants, demonstrating that rare mutations can be functionally important in
      cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Berger, Alice H
AU  - Berger AH
AD  - Dana-Farber Cancer Institute, Boston, MA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
AD  - Harvard Medical School, Boston, MA.
FAU - Brooks, Angela N
AU  - Brooks AN
AD  - Dana-Farber Cancer Institute, Boston, MA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
AD  - Harvard Medical School, Boston, MA.
FAU - Wu, Xiaoyun
AU  - Wu X
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Shrestha, Yashaswi
AU  - Shrestha Y
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Chouinard, Candace
AU  - Chouinard C
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Piccioni, Federica
AU  - Piccioni F
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Bagul, Mukta
AU  - Bagul M
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Kamburov, Atanas
AU  - Kamburov A
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
AD  - Harvard Medical School, Boston, MA.
AD  - Department of Pathology and Cancer Center, Massachusetts General Hospital,
      Boston, MA.
FAU - Imielinski, Marcin
AU  - Imielinski M
AD  - Dana-Farber Cancer Institute, Boston, MA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
AD  - Harvard Medical School, Boston, MA.
FAU - Hogstrom, Larson
AU  - Hogstrom L
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Zhu, Cong
AU  - Zhu C
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Yang, Xiaoping
AU  - Yang X
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Pantel, Sasha
AU  - Pantel S
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Sakai, Ryo
AU  - Sakai R
AD  - KU Leuven, Leuven, Belgium.
FAU - Watson, Jacqueline
AU  - Watson J
AD  - Dana-Farber Cancer Institute, Boston, MA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Kaplan, Nathan
AU  - Kaplan N
AD  - Dana-Farber Cancer Institute, Boston, MA.
FAU - Campbell, Joshua D
AU  - Campbell JD
AD  - Dana-Farber Cancer Institute, Boston, MA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
AD  - Harvard Medical School, Boston, MA.
FAU - Singh, Shantanu
AU  - Singh S
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Root, David E
AU  - Root DE
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Narayan, Rajiv
AU  - Narayan R
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Natoli, Ted
AU  - Natoli T
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Lahr, David L
AU  - Lahr DL
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Tirosh, Itay
AU  - Tirosh I
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Tamayo, Pablo
AU  - Tamayo P
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Getz, Gad
AU  - Getz G
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
AD  - Harvard Medical School, Boston, MA.
AD  - Department of Pathology and Cancer Center, Massachusetts General Hospital,
      Boston, MA.
FAU - Wong, Bang
AU  - Wong B
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Doench, John
AU  - Doench J
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Subramanian, Aravind
AU  - Subramanian A
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Golub, Todd R
AU  - Golub TR
AD  - Dana-Farber Cancer Institute, Boston, MA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
FAU - Meyerson, Matthew
AU  - Meyerson M
AD  - Dana-Farber Cancer Institute, Boston, MA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
AD  - Harvard Medical School, Boston, MA.
FAU - Boehm, Jesse S
AU  - Boehm JS
AD  - Broad Institute of MIT and Harvard, Cambridge, MA.
LA  - eng
GR  - K99 CA197762/CA/NCI NIH HHS/United States
GR  - U24 CA194107/CA/NCI NIH HHS/United States
GR  - P30 CA023100/CA/NCI NIH HHS/United States
GR  - R35 CA197568/CA/NCI NIH HHS/United States
GR  - R01 CA154480/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160728
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - Adenocarcinoma of lung
SB  - IM
CIN - Cancer Cell. 2016 Aug 8;30(2):187-189. PMID: 27505666
CIN - Nat Rev Clin Oncol. 2016 Aug 19;13(9):527. PMID: 27538976
EIN - Cancer Cell. 2017 Dec 11;32(6):884. PMID: 29232558
MH  - Adenocarcinoma/*genetics
MH  - Animals
MH  - Cell Line, Tumor
MH  - Gene Expression Profiling
MH  - Heterografts
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - Lung Neoplasms/*genetics
MH  - Mice
MH  - *Mutation
MH  - Oncogenes
MH  - Phenotype
PMC - PMC5003022
MID - NIHMS801008
EDAT- 2016/08/02 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/02 06:00
PHST- 2015/11/05 00:00 [received]
PHST- 2016/04/27 00:00 [revised]
PHST- 2016/06/29 00:00 [accepted]
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - 10.1016/j.ccell.2016.06.022 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):214-228. doi: 10.1016/j.ccell.2016.06.022. Epub
      2016 Jul 28.

PMID- 27478039
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular
      Carcinoma Development.
PG  - 308-323
LID - S1535-6108(16)30269-0 [pii]
LID - 10.1016/j.ccell.2016.06.009 [doi]
AB  - Hepatocellular carcinoma (HCC) represents a classic example of
      inflammation-linked cancer. To characterize the role of the immune system in
      hepatic injury and tumor development, we comparatively studied the extent of
      liver disease and hepatocarcinogenesis in immunocompromised versus
      immunocompetent Fah-deficient mice. Strikingly, chronic liver injury and tumor
      development were markedly suppressed in alymphoid Fah(-/-) mice despite an
      overall increased mortality. Mechanistically, we show that CD8(+) T cells and
      lymphotoxin beta are central mediators of HCC formation. Antibody-mediated
      depletion of CD8(+) T cells as well as pharmacological inhibition of the
      lymphotoxin-beta receptor markedly delays tumor development in mice with chronic 
      liver injury. Thus, our study unveils distinct functions of the immune system,
      which are required for liver regeneration, survival, and hepatocarcinogenesis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Endig, Jessica
AU  - Endig J
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany.
FAU - Buitrago-Molina, Laura Elisa
AU  - Buitrago-Molina LE
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany.
FAU - Marhenke, Silke
AU  - Marhenke S
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany.
FAU - Reisinger, Florian
AU  - Reisinger F
AD  - Institute of Virology, Technische Universitat Munchen, Helmholtz Zentrum
      Muenchen, 85764 Munich, Germany.
FAU - Saborowski, Anna
AU  - Saborowski A
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany.
FAU - Schutt, Jutta
AU  - Schutt J
AD  - Department of Cardiology, Philipps University Marburg, 35037 Marburg, Germany.
FAU - Limbourg, Florian
AU  - Limbourg F
AD  - Department of Nephrology and Hypertension, Hannover Medical School, 30625
      Hannover, Germany.
FAU - Konecke, Christian
AU  - Konecke C
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation,
      Hannover Medical School, 30625 Hannover, Germany.
FAU - Schreder, Alina
AU  - Schreder A
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation,
      Hannover Medical School, 30625 Hannover, Germany.
FAU - Michael, Alina
AU  - Michael A
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany.
FAU - Misslitz, Ana Clara
AU  - Misslitz AC
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany.
FAU - Healy, Marc Eammonn
AU  - Healy ME
AD  - Institute of Surgical Pathology, University Hospital Zurich, 8091 Zurich,
      Switzerland.
FAU - Geffers, Robert
AU  - Geffers R
AD  - Department of Cell Biology, Helmholtz Centre for Infection Research, 38124
      Braunschweig, Germany.
FAU - Clavel, Thomas
AU  - Clavel T
AD  - ZIEL Institute for Food and Health, Technische Universitat Munchen, 85764 Munich,
      Germany.
FAU - Haller, Dirk
AU  - Haller D
AD  - ZIEL Institute for Food and Health, Technische Universitat Munchen, 85764 Munich,
      Germany.
FAU - Unger, Kristian
AU  - Unger K
AD  - Research Unit Radiation Cytogenetics, Helmholtz Zentrum Munchen, 85764 Munich,
      Germany.
FAU - Finegold, Milton
AU  - Finegold M
AD  - Department of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.
FAU - Weber, Achim
AU  - Weber A
AD  - Institute of Surgical Pathology, University Hospital Zurich, 8091 Zurich,
      Switzerland.
FAU - Manns, Michael P
AU  - Manns MP
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany.
FAU - Longerich, Thomas
AU  - Longerich T
AD  - Institute of Pathology, Aachen University Hospital, 52074 Aachen, Germany.
FAU - Heikenwalder, Mathias
AU  - Heikenwalder M
AD  - Department of Cardiology, Philipps University Marburg, 35037 Marburg, Germany;
      Division of Chronic Inflammation and Cancer, German Cancer Research Center
      Heidelberg, 69121 Heidelberg, Germany.
FAU - Vogel, Arndt
AU  - Vogel A
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
      School, 30625 Hannover, Germany. Electronic address: vogel.arndt@mh-hannover.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160728
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (LTB protein, human)
RN  - 0 (Ltb protein, mouse)
RN  - 0 (Lymphotoxin-beta)
RN  - EC 3.- (Hydrolases)
RN  - EC 3.7.1.2 (fumarylacetoacetase)
SB  - IM
MH  - Adaptive Immunity
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/immunology/pathology
MH  - Carcinogenesis/immunology
MH  - Carcinoma, Hepatocellular/*immunology/pathology
MH  - Humans
MH  - Hydrolases/immunology
MH  - Liver Diseases/*immunology/pathology
MH  - Liver Neoplasms/*immunology/pathology
MH  - Liver Regeneration/immunology
MH  - Lymphotoxin-beta/immunology
MH  - Mice
EDAT- 2016/08/02 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/08/02 06:00
PHST- 2015/05/13 00:00 [received]
PHST- 2016/03/09 00:00 [revised]
PHST- 2016/06/16 00:00 [accepted]
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30269-0 [pii]
AID - 10.1016/j.ccell.2016.06.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):308-323. doi: 10.1016/j.ccell.2016.06.009. Epub
      2016 Jul 28.

PMID- 27451907
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers
      Resistance to PI3Kalpha Inhibition.
PG  - 229-242
LID - S1535-6108(16)30264-1 [pii]
LID - 10.1016/j.ccell.2016.06.004 [doi]
AB  - PIK3CA, which encodes the p110alpha subunit of PI3K, is frequently mutated and
      oncogenic in breast cancer. PI3Kalpha inhibitors are in clinical development and 
      despite promising early clinical activity, intrinsic resistance is frequent among
      patients. We have previously reported that residual downstream mTORC1 activity
      upon treatment with PI3Kalpha inhibitors drives resistance to these agents.
      However, the mechanism underlying this phenotype is not fully understood. Here we
      show that in cancer cells resistant to PI3Kalpha inhibition, PDK1 blockade
      restores sensitivity to these therapies. SGK1, which is activated by PDK1,
      contributes to the maintenance of residual mTORC1 activity through direct
      phosphorylation and inhibition of TSC2. Targeting either PDK1 or SGK1 prevents
      mTORC1 activation, restoring the antitumoral effects of PI3Kalpha inhibition in
      resistant cells.
CI  - Copyright (c) 2016 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Castel, Pau
AU  - Castel P
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Ellis, Haley
AU  - Ellis H
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Bago, Ruzica
AU  - Bago R
AD  - MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences,
      University of Dundee, Dow Street, Dundee DD1 5EH, Scotland.
FAU - Toska, Eneda
AU  - Toska E
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Razavi, Pedram
AU  - Razavi P
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of
      Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, Suite
      M2015, New York, NY 10065, USA.
FAU - Carmona, F Javier
AU  - Carmona FJ
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Kannan, Srinivasaraghavan
AU  - Kannan S
AD  - Bioinformatics Institute (A( *)STAR), 30 Biopolis Street, #07-01 Matrix,
      Singapore 138671, Singapore.
FAU - Verma, Chandra S
AU  - Verma CS
AD  - Bioinformatics Institute (A( *)STAR), 30 Biopolis Street, #07-01 Matrix,
      Singapore 138671, Singapore; School of Biological Sciences, Nanyang Technological
      University, 60 Nanyang Drive, Singapore 637551, Singapore; Department of
      Biological Sciences, National University of Singapore, 14 Science Drive 4,
      Singapore 117543, Singapore.
FAU - Dickler, Maura
AU  - Dickler M
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue,
      Box 20, Suite M2015, New York, NY 10065, USA.
FAU - Chandarlapaty, Sarat
AU  - Chandarlapaty S
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of
      Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, Suite
      M2015, New York, NY 10065, USA.
FAU - Brogi, Edi
AU  - Brogi E
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York
      Avenue, Box 20, New York, NY 10065, USA.
FAU - Alessi, Dario R
AU  - Alessi DR
AD  - MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences,
      University of Dundee, Dow Street, Dundee DD1 5EH, Scotland.
FAU - Baselga, Jose
AU  - Baselga J
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of
      Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, Suite
      M2015, New York, NY 10065, USA. Electronic address: baselgaj@mskcc.org.
FAU - Scaltriti, Maurizio
AU  - Scaltriti M
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of
      Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New 
      York, NY 10065, USA. Electronic address: scaltrim@mskcc.org.
LA  - eng
GR  - MC_UU_12016/2/Medical Research Council/United Kingdom
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA190642/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20160721
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Immediate-Early Proteins)
RN  - 0 (Multiprotein Complexes)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (serum-glucocorticoid regulated kinase)
RN  - EC 2.7.11.2 (pyruvate dehydrogenase (acetyl-transferring) kinase)
SB  - IM
MH  - Animals
MH  - Class I Phosphatidylinositol 3-Kinases
MH  - Humans
MH  - Immediate-Early Proteins/*metabolism
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - Multiprotein Complexes/*metabolism
MH  - Phosphatidylinositol 3-Kinases/*antagonists & inhibitors/metabolism
MH  - Protein-Serine-Threonine Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC4982440
EDAT- 2016/07/28 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/07/26 06:00
PHST- 2015/07/24 00:00 [received]
PHST- 2016/01/27 00:00 [revised]
PHST- 2016/06/09 00:00 [accepted]
PHST- 2016/07/26 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30264-1 [pii]
AID - 10.1016/j.ccell.2016.06.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):229-242. doi: 10.1016/j.ccell.2016.06.004. Epub
      2016 Jul 21.

PMID- 27424808
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage
      Independent of TET2.
PG  - 337-348
LID - S1535-6108(16)30223-9 [pii]
LID - 10.1016/j.ccell.2016.05.018 [doi]
AB  - Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common drivers of
      acute myeloid leukemia (AML) but their mechanism is not fully understood. It is
      thought that IDH1 mutants act by inhibiting TET2 to alter DNA methylation, but
      there are significant unexplained clinical differences between IDH1- and
      TET2-mutant diseases. We have discovered that mice expressing endogenous mutant
      IDH1 have reduced numbers of hematopoietic stem cells (HSCs), in contrast to Tet2
      knockout (TET2-KO) mice. Mutant IDH1 downregulates the DNA damage (DD) sensor ATM
      by altering histone methylation, leading to impaired DNA repair, increased
      sensitivity to DD, and reduced HSC self-renewal, independent of TET2. ATM
      expression is also decreased in human IDH1-mutated AML. These findings may have
      implications for treatment of IDH-mutant leukemia.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Inoue, Satoshi
AU  - Inoue S
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Li, Wanda Y
AU  - Li WY
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Tseng, Alan
AU  - Tseng A
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada;
      Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7,
      Canada.
FAU - Beerman, Isabel
AU  - Beerman I
AD  - Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston,
      MA 00133, USA; Department of Stem Cell and Regenerative Biology, Harvard
      University, Cambridge, MA 02138, USA.
FAU - Elia, Andrew J
AU  - Elia AJ
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Bendall, Sean C
AU  - Bendall SC
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Lemonnier, Francois
AU  - Lemonnier F
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Kron, Ken J
AU  - Kron KJ
AD  - The Princess Margaret Cancer Centre and Ontario Cancer Institute, University
      Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Cescon, David W
AU  - Cescon DW
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Hao, Zhenyue
AU  - Hao Z
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Lind, Evan F
AU  - Lind EF
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Takayama, Naoya
AU  - Takayama N
AD  - The Princess Margaret Cancer Centre and Ontario Cancer Institute, University
      Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Planello, Aline C
AU  - Planello AC
AD  - The Princess Margaret Cancer Centre and Ontario Cancer Institute, University
      Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics,
      University of Toronto, Toronto, ON M5G 1L7, Canada; Department of Morphology,
      Piracicaba Dental School, UNICAMP, Piracicaba, SP 13414-903, Brazil.
FAU - Shen, Shu Yi
AU  - Shen SY
AD  - The Princess Margaret Cancer Centre and Ontario Cancer Institute, University
      Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Shih, Alan H
AU  - Shih AH
AD  - Human Oncology and Pathogenesis Program, Leukemia Service, Department of
      Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Larsen, Dana M
AU  - Larsen DM
AD  - Mbed Pathology, Toronto, ON M5J 2H2, Canada.
FAU - Li, Qinxi
AU  - Li Q
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Snow, Bryan E
AU  - Snow BE
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Wakeham, Andrew
AU  - Wakeham A
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Haight, Jillian
AU  - Haight J
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Gorrini, Chiara
AU  - Gorrini C
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Bassi, Christian
AU  - Bassi C
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Thu, Kelsie L
AU  - Thu KL
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Murakami, Kiichi
AU  - Murakami K
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Elford, Alisha R
AU  - Elford AR
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Ueda, Takeshi
AU  - Ueda T
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; Department of Disease Model Research
      Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima
      734-8553, Japan.
FAU - Straley, Kimberly
AU  - Straley K
AD  - Agios Pharmaceuticals, Cambridge, MA 02139, USA.
FAU - Yen, Katharine E
AU  - Yen KE
AD  - Agios Pharmaceuticals, Cambridge, MA 02139, USA.
FAU - Melino, Gerry
AU  - Melino G
AD  - Medical Research Council, Toxicology Unit, Leicester LE1 9HN, UK; Department of
      Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome 00133, 
      Italy.
FAU - Cimmino, Luisa
AU  - Cimmino L
AD  - Department of Pathology, Howard Hughes Medical Institute, New York University
      School of Medicine, New York, NY 10016, USA.
FAU - Aifantis, Iannis
AU  - Aifantis I
AD  - Department of Pathology, Howard Hughes Medical Institute, New York University
      School of Medicine, New York, NY 10016, USA.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Leukemia Service, Department of
      Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - De Carvalho, Daniel D
AU  - De Carvalho DD
AD  - The Princess Margaret Cancer Centre and Ontario Cancer Institute, University
      Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Lupien, Mathieu
AU  - Lupien M
AD  - The Princess Margaret Cancer Centre and Ontario Cancer Institute, University
      Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Rossi, Derrick J
AU  - Rossi DJ
AD  - Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston,
      MA 00133, USA.
FAU - Nolan, Garry P
AU  - Nolan GP
AD  - The Baxter Laboratory for Stem Cell Biology, Department of Microbiology and
      Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Cairns, Rob A
AU  - Cairns RA
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Mak, Tak W
AU  - Mak TW
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and
      Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada;
      Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7,
      Canada. Electronic address: tmak@uhnres.utoronto.ca.
LA  - eng
GR  - R01 CA173636/CA/NCI NIH HHS/United States
GR  - UC4 DK104218/DK/NIDDK NIH HHS/United States
GR  - MC_U132670600/Medical Research Council/United Kingdom
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA169784/CA/NCI NIH HHS/United States
GR  - U10 CA180827/CA/NCI NIH HHS/United States
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160714
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (TET2 protein, human)
RN  - 0 (Tet2 protein, mouse)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - EC 2.7.11.1 (ATM protein, human)
RN  - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
RN  - EC 2.7.11.1 (Atm protein, mouse)
SB  - IM
CIN - Cancer Cell. 2016 Aug 8;30(2):192-194. PMID: 27505668
MH  - Animals
MH  - Ataxia Telangiectasia Mutated Proteins/*genetics/metabolism
MH  - *DNA Damage
MH  - *DNA Repair
MH  - DNA-Binding Proteins/*genetics/metabolism
MH  - Down-Regulation
MH  - Hematopoietic Stem Cells/cytology/*enzymology
MH  - Humans
MH  - Isocitrate Dehydrogenase/*genetics/metabolism
MH  - Mice
MH  - Mutation
MH  - Proto-Oncogene Proteins/*genetics/metabolism
PMC - PMC5022794
MID - NIHMS814063
COIS- Other authors declare that no conflicts of interest exist.
EDAT- 2016/07/19 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/07/19 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2016/04/01 00:00 [revised]
PHST- 2016/05/31 00:00 [accepted]
PHST- 2016/07/19 06:00 [entrez]
PHST- 2016/07/19 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30223-9 [pii]
AID - 10.1016/j.ccell.2016.05.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):337-348. doi: 10.1016/j.ccell.2016.05.018. Epub
      2016 Jul 14.

PMID- 27424807
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 2
DP  - 2016 Aug 8
TI  - Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor
      Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
PG  - 324-336
LID - S1535-6108(16)30263-X [pii]
LID - 10.1016/j.ccell.2016.06.003 [doi]
AB  - Intratumoral dendritic cells (DC) bearing CD103 in mice or CD141 in humans drive 
      intratumoral CD8(+) T cell activation. Using multiple strategies, we identified a
      critical role for these DC in trafficking tumor antigen to lymph nodes (LN),
      resulting in both direct CD8(+) T cell stimulation and antigen hand-off to
      resident myeloid cells. These effects all required CCR7. Live imaging
      demonstrated direct presentation to T cells in LN, and CCR7 loss specifically in 
      these cells resulted in defective LN T cell priming and increased tumor
      outgrowth. CCR7 expression levels in human tumors correlate with signatures of
      CD141(+) DC, intratumoral T cells, and better clinical outcomes. This work
      identifies an ongoing pathway to T cell priming, which should be harnessed for
      tumor therapies.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Roberts, Edward W
AU  - Roberts EW
AD  - Department of Pathology, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, CA 94143-0511, USA.
FAU - Broz, Miranda L
AU  - Broz ML
AD  - Department of Pathology, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, CA 94143-0511, USA.
FAU - Binnewies, Mikhail
AU  - Binnewies M
AD  - Department of Pathology, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, CA 94143-0511, USA.
FAU - Headley, Mark B
AU  - Headley MB
AD  - Department of Pathology, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, CA 94143-0511, USA.
FAU - Nelson, Amanda E
AU  - Nelson AE
AD  - Department of Pathology, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, CA 94143-0511, USA.
FAU - Wolf, Denise M
AU  - Wolf DM
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Kaisho, Tsuneyasu
AU  - Kaisho T
AD  - Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509,
      Japan.
FAU - Bogunovic, Dusan
AU  - Bogunovic D
AD  - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Bhardwaj, Nina
AU  - Bhardwaj N
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Krummel, Matthew F
AU  - Krummel MF
AD  - Department of Pathology, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, CA 94143-0511, USA. Electronic address:
      matthew.krummel@ucsf.edu.
LA  - eng
GR  - R21 CA191428/CA/NCI NIH HHS/United States
GR  - T32 AI007334/AI/NIAID NIH HHS/United States
GR  - T32 HD007470/HD/NICHD NIH HHS/United States
GR  - U54 CA163123/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20160714
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antigens, Surface)
RN  - 0 (CCR7 protein, human)
RN  - 0 (Ccr7 protein, mouse)
RN  - 0 (Integrin alpha Chains)
RN  - 0 (Receptors, CCR7)
RN  - 0 (alpha E integrins)
RN  - 0 (blood dendritic cell antigen 3, human)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Antigens, CD/immunology
MH  - Antigens, Neoplasm/immunology
MH  - Antigens, Surface/immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Movement/immunology
MH  - Dendritic Cells/*immunology/pathology
MH  - Humans
MH  - Integrin alpha Chains/immunology
MH  - Lymph Nodes/immunology/pathology
MH  - Melanoma/*immunology/pathology
MH  - Melanoma, Experimental/immunology/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Receptors, CCR7/*immunology
PMC - PMC5374862
MID - NIHMS852268
OTO - NOTNLM
OT  - *2-photon imaging
OT  - *anti-tumor T cell priming
OT  - *antigen presentation
OT  - *antigen trafficking
OT  - *dendritic cells
OT  - *draining lymph node
OT  - *melanoma
OT  - *tumor
OT  - *tumor immune response
EDAT- 2016/07/19 06:00
MHDA- 2017/08/22 06:00
CRDT- 2016/07/19 06:00
PHST- 2015/08/21 00:00 [received]
PHST- 2016/02/08 00:00 [revised]
PHST- 2016/06/04 00:00 [accepted]
PHST- 2016/07/19 06:00 [entrez]
PHST- 2016/07/19 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S1535-6108(16)30263-X [pii]
AID - 10.1016/j.ccell.2016.06.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Aug 8;30(2):324-336. doi: 10.1016/j.ccell.2016.06.003. Epub
      2016 Jul 14.

PMID- 27479035
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF
      Inhibitor Resistance.
PG  - 183
LID - S1535-6108(16)30267-7 [pii]
LID - 10.1016/j.ccell.2016.06.007 [doi]
FAU - Cerezo, Michael
AU  - Cerezo M
FAU - Lehraiki, Abdelali
AU  - Lehraiki A
FAU - Millet, Antoine
AU  - Millet A
FAU - Rouaud, Florian
AU  - Rouaud F
FAU - Plaisant, Magali
AU  - Plaisant M
FAU - Jaune, Emilie
AU  - Jaune E
FAU - Botton, Thomas
AU  - Botton T
FAU - Ronco, Cyril
AU  - Ronco C
FAU - Abbe, Patricia
AU  - Abbe P
FAU - Amdouni, Hella
AU  - Amdouni H
FAU - Passeron, Thierry
AU  - Passeron T
FAU - Hofman, Veronique
AU  - Hofman V
FAU - Mograbi, Baharia
AU  - Mograbi B
FAU - Dabert-Gay, Anne-Sophie
AU  - Dabert-Gay AS
FAU - Debayle, Delphine
AU  - Debayle D
FAU - Alcor, Damien
AU  - Alcor D
FAU - Rabhi, Nabil
AU  - Rabhi N
FAU - Annicotte, Jean-Sebastien
AU  - Annicotte JS
FAU - Heliot, Laurent
AU  - Heliot L
FAU - Gonzalez-Pisfil, Mariano
AU  - Gonzalez-Pisfil M
FAU - Robert, Caroline
AU  - Robert C
FAU - Morera, Solange
AU  - Morera S
FAU - Vigouroux, Armelle
AU  - Vigouroux A
FAU - Gual, Philippe
AU  - Gual P
FAU - Ali, Maruf M U
AU  - Ali MMU
FAU - Bertolotto, Corine
AU  - Bertolotto C
FAU - Hofman, Paul
AU  - Hofman P
FAU - Ballotti, Robert
AU  - Ballotti R
FAU - Benhida, Rachid
AU  - Benhida R
FAU - Rocchi, Stephane
AU  - Rocchi S
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160711
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Jun 13;29(6):805-19. Intlekoffer, Andrew M corrected to
      Intlekofer, Andrew M; LaBoeuf, Nicole corrected to LeBoeuf, Nicole R. PMID:
      27238082
EDAT- 2016/08/02 06:00
MHDA- 2016/08/02 06:01
CRDT- 2016/08/02 06:00
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2016/08/02 06:01 [medline]
AID - S1535-6108(16)30267-7 [pii]
AID - 10.1016/j.ccell.2016.06.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.007. Epub 2016
      Jul 11.

PMID- 27479034
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170930
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - The Public Repository of Xenografts Enables Discovery and Randomized Phase
      II-like Trials in Mice.
PG  - 183
LID - S1535-6108(16)30268-9 [pii]
LID - 10.1016/j.ccell.2016.06.008 [doi]
FAU - Townsend, Elizabeth C
AU  - Townsend EC
FAU - Murakami, Mark A
AU  - Murakami MA
FAU - Christodoulou, Alexandra
AU  - Christodoulou A
FAU - Christie, Amanda L
AU  - Christie AL
FAU - Koster, Johannes
AU  - Koster J
FAU - DeSouza, Tiffany A
AU  - DeSouza TA
FAU - Morgan, Elizabeth A
AU  - Morgan EA
FAU - Kallgren, Scott P
AU  - Kallgren SP
FAU - Liu, Huiyun
AU  - Liu H
FAU - Wu, Shuo-Chieh
AU  - Wu SC
FAU - Plana, Olivia
AU  - Plana O
FAU - Montero, Joan
AU  - Montero J
FAU - Stevenson, Kristen E
AU  - Stevenson KE
FAU - Rao, Prakash
AU  - Rao P
FAU - Vadhi, Raga
AU  - Vadhi R
FAU - Andreeff, Michael
AU  - Andreeff M
FAU - Armand, Philippe
AU  - Armand P
FAU - Ballen, Karen K
AU  - Ballen KK
FAU - Barzaghi-Rinaudo, Patrizia
AU  - Barzaghi-Rinaudo P
FAU - Cahill, Sarah
AU  - Cahill S
FAU - Clark, Rachael A
AU  - Clark RA
FAU - Cooke, Vesselina G
AU  - Cooke VG
FAU - Davids, Matthew S
AU  - Davids MS
FAU - DeAngelo, Daniel J
AU  - DeAngelo DJ
FAU - Dorfman, David M
AU  - Dorfman DM
FAU - Eaton, Hilary
AU  - Eaton H
FAU - Ebert, Benjamin L
AU  - Ebert BL
FAU - Etchin, Julia
AU  - Etchin J
FAU - Firestone, Brant
AU  - Firestone B
FAU - Fisher, David C
AU  - Fisher DC
FAU - Freedman, Arnold S
AU  - Freedman AS
FAU - Galinsky, Ilene A
AU  - Galinsky IA
FAU - Gao, Hui
AU  - Gao H
FAU - Garcia, Jacqueline S
AU  - Garcia JS
FAU - Garnache-Ottou, Francine
AU  - Garnache-Ottou F
FAU - Graubert, Timothy A
AU  - Graubert TA
FAU - Gutierrez, Alejandro
AU  - Gutierrez A
FAU - Halilovic, Ensar
AU  - Halilovic E
FAU - Harris, Marian H
AU  - Harris MH
FAU - Herbert, Zachary T
AU  - Herbert ZT
FAU - Horwitz, Steven M
AU  - Horwitz SM
FAU - Inghirami, Giorgio
AU  - Inghirami G
FAU - Intlekofer, Andrew M
AU  - Intlekofer AM
FAU - Ito, Moriko
AU  - Ito M
FAU - Izraeli, Shai
AU  - Izraeli S
FAU - Jacobsen, Eric D
AU  - Jacobsen ED
FAU - Jacobson, Caron A
AU  - Jacobson CA
FAU - Jeay, Sebastien
AU  - Jeay S
FAU - Jeremias, Irmela
AU  - Jeremias I
FAU - Kelliher, Michelle A
AU  - Kelliher MA
FAU - Koch, Raphael
AU  - Koch R
FAU - Konopleva, Marina
AU  - Konopleva M
FAU - Kopp, Nadja
AU  - Kopp N
FAU - Kornblau, Steven M
AU  - Kornblau SM
FAU - Kung, Andrew L
AU  - Kung AL
FAU - Kupper, Thomas S
AU  - Kupper TS
FAU - LeBoeuf, Nicole R
AU  - LeBoeuf NR
FAU - LaCasce, Ann S
AU  - LaCasce AS
FAU - Lees, Emma
AU  - Lees E
FAU - Li, Loretta S
AU  - Li LS
FAU - Look, A Thomas
AU  - Look AT
FAU - Murakami, Masato
AU  - Murakami M
FAU - Muschen, Markus
AU  - Muschen M
FAU - Neuberg, Donna
AU  - Neuberg D
FAU - Ng, Samuel Y
AU  - Ng SY
FAU - Odejide, Oreofe O
AU  - Odejide OO
FAU - Orkin, Stuart H
AU  - Orkin SH
FAU - Paquette, Rachel R
AU  - Paquette RR
FAU - Place, Andrew E
AU  - Place AE
FAU - Roderick, Justine E
AU  - Roderick JE
FAU - Ryan, Jeremy A
AU  - Ryan JA
FAU - Sallan, Stephen E
AU  - Sallan SE
FAU - Shoji, Brent
AU  - Shoji B
FAU - Silverman, Lewis B
AU  - Silverman LB
FAU - Soiffer, Robert J
AU  - Soiffer RJ
FAU - Steensma, David P
AU  - Steensma DP
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
FAU - Stone, Richard M
AU  - Stone RM
FAU - Tamburini, Jerome
AU  - Tamburini J
FAU - Thorner, Aaron R
AU  - Thorner AR
FAU - van Hummelen, Paul
AU  - van Hummelen P
FAU - Wadleigh, Martha
AU  - Wadleigh M
FAU - Wiesmann, Marion
AU  - Wiesmann M
FAU - Weng, Andrew P
AU  - Weng AP
FAU - Wuerthner, Jens U
AU  - Wuerthner JU
FAU - Williams, David A
AU  - Williams DA
FAU - Wollison, Bruce M
AU  - Wollison BM
FAU - Lane, Andrew A
AU  - Lane AA
FAU - Letai, Anthony
AU  - Letai A
FAU - Bertagnolli, Monica M
AU  - Bertagnolli MM
FAU - Ritz, Jerome
AU  - Ritz J
FAU - Brown, Myles
AU  - Brown M
FAU - Long, Henry
AU  - Long H
FAU - Aster, Jon C
AU  - Aster JC
FAU - Shipp, Margaret A
AU  - Shipp MA
FAU - Griffin, James D
AU  - Griffin JD
FAU - Weinstock, David M
AU  - Weinstock DM
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160711
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Apr 11;29(4):574-86. Intlekoffer, Andrew M corrected to
      Intlekofer, Andrew M; LaBoeuf, Nicole corrected to LeBoeuf, Nicole R. PMID:
      27070704
EDAT- 2016/08/02 06:00
MHDA- 2016/08/02 06:01
CRDT- 2016/08/02 06:00
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2016/08/02 06:01 [medline]
AID - S1535-6108(16)30268-9 [pii]
AID - 10.1016/j.ccell.2016.06.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016
      Jul 11.

PMID- 27479033
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Rab1A Is an mTORC1 Activator and a Colorectal Oncogene.
PG  - 181-182
LID - S1535-6108(16)30274-4 [pii]
LID - 10.1016/j.ccell.2016.06.014 [doi]
FAU - Thomas, Janice D
AU  - Thomas JD
FAU - Zhang, Yan-Jie
AU  - Zhang YJ
FAU - Wei, Yue-Hua
AU  - Wei YH
FAU - Cho, Jun-Hung
AU  - Cho JH
FAU - Morris, Laura E
AU  - Morris LE
FAU - Wang, Hui-Yun
AU  - Wang HY
FAU - Zheng, X F Steven
AU  - Zheng XFS
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160711
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2014 Nov 10;26(5):754-69. PMID: 25446900
EDAT- 2016/08/02 06:00
MHDA- 2016/08/02 06:01
CRDT- 2016/08/02 06:00
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2016/08/02 06:01 [medline]
AID - S1535-6108(16)30274-4 [pii]
AID - 10.1016/j.ccell.2016.06.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):181-182. doi: 10.1016/j.ccell.2016.06.014. Epub
      2016 Jul 11.

PMID- 27479032
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression 
      and Metastasis.
PG  - 179-180
LID - S1535-6108(16)30273-2 [pii]
LID - 10.1016/j.ccell.2016.06.013 [doi]
FAU - Wang, Lu
AU  - Wang L
FAU - Zhao, Zibo
AU  - Zhao Z
FAU - Meyer, Mark B
AU  - Meyer MB
FAU - Saha, Sandeep
AU  - Saha S
FAU - Yu, Menggang
AU  - Yu M
FAU - Guo, Ailan
AU  - Guo A
FAU - Wisinski, Kari B
AU  - Wisinski KB
FAU - Huang, Wei
AU  - Huang W
FAU - Cai, Weibo
AU  - Cai W
FAU - Pike, J Wesley
AU  - Pike JW
FAU - Yuan, Ming
AU  - Yuan M
FAU - Ahlquist, Paul
AU  - Ahlquist P
FAU - Xu, Wei
AU  - Xu W
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160711
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2014 Jan 13;25(1):21-36. PMID: 24434208
EDAT- 2016/08/02 06:00
MHDA- 2016/08/02 06:01
CRDT- 2016/08/02 06:00
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2016/08/02 06:01 [medline]
AID - S1535-6108(16)30273-2 [pii]
AID - 10.1016/j.ccell.2016.06.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):179-180. doi: 10.1016/j.ccell.2016.06.013. Epub
      2016 Jul 11.

PMID- 27479031
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule,
      Allosteric Inhibitor of FGF Receptor Signaling.
PG  - 176-178
LID - S1535-6108(16)30275-6 [pii]
LID - 10.1016/j.ccell.2016.06.015 [doi]
FAU - Herbert, Corentin
AU  - Herbert C
FAU - Schieborr, Ulrich
AU  - Schieborr U
FAU - Saxena, Krishna
AU  - Saxena K
FAU - Juraszek, Jarek
AU  - Juraszek J
FAU - De Smet, Frederik
AU  - De Smet F
FAU - Alcouffe, Chantal
AU  - Alcouffe C
FAU - Bianciotto, Marc
AU  - Bianciotto M
FAU - Saladino, Giorgio
AU  - Saladino G
FAU - Sibrac, David
AU  - Sibrac D
FAU - Kudlinzki, Denis
AU  - Kudlinzki D
FAU - Sreeramulu, Sridhar
AU  - Sreeramulu S
FAU - Brown, Alan
AU  - Brown A
FAU - Rigon, Patrice
AU  - Rigon P
FAU - Herault, Jean-Pascal
AU  - Herault JP
FAU - Lassalle, Gilbert
AU  - Lassalle G
FAU - Blundell, Tom L
AU  - Blundell TL
FAU - Rousseau, Frederic
AU  - Rousseau F
FAU - Gils, Ann
AU  - Gils A
FAU - Schymkowitz, Joost
AU  - Schymkowitz J
FAU - Tompa, Peter
AU  - Tompa P
FAU - Herbert, Jean-Marc
AU  - Herbert JM
FAU - Carmeliet, Peter
AU  - Carmeliet P
FAU - Gervasio, Francesco Luigi
AU  - Gervasio FL
FAU - Schwalbe, Harald
AU  - Schwalbe H
FAU - Bono, Francoise
AU  - Bono F
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160711
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2013 Apr 15;23(4):489-501. PMID: 23597563
EDAT- 2016/08/02 06:00
MHDA- 2016/08/02 06:01
CRDT- 2016/08/02 06:00
PHST- 2016/08/02 06:00 [entrez]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2016/08/02 06:01 [medline]
AID - S1535-6108(16)30275-6 [pii]
AID - 10.1016/j.ccell.2016.06.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):176-178. doi: 10.1016/j.ccell.2016.06.015. Epub
      2016 Jul 11.

PMID- 27411590
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20180121
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and
      Hepatocellular Carcinoma.
PG  - 161-175
LID - S1535-6108(16)30225-2 [pii]
LID - 10.1016/j.ccell.2016.05.020 [doi]
AB  - Obesity increases hepatocellular carcinoma (HCC) risks via unknown mediators. We 
      report that hepatic unconventional prefoldin RPB5 interactor (URI) couples
      nutrient surpluses to inflammation and non-alcoholic steatohepatitis (NASH), a
      common cause of HCC. URI-induced DNA damage in hepatocytes triggers inflammation 
      via T helper 17 (Th17) lymphocytes and interleukin 17A (IL-17A). This induces
      white adipose tissue neutrophil infiltration mediating insulin resistance (IR)
      and fatty acid release, stored in liver as triglycerides, causing NASH. NASH and 
      subsequently HCC are prevented by pharmacological suppression of Th17 cell
      differentiation, IL-17A blocking antibodies, and genetic ablation of the IL-17A
      receptor in myeloid cells. Human hepatitis, fatty liver, and viral
      hepatitis-associated HCC exhibit increased IL-17A correlating positively with
      steatosis. IL-17A blockers may prevent IR, NASH, and HCC in high-risk patients.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Gomes, Ana L
AU  - Gomes AL
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Teijeiro, Ana
AU  - Teijeiro A
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Buren, Stefan
AU  - Buren S
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Tummala, Krishna S
AU  - Tummala KS
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Yilmaz, Mahmut
AU  - Yilmaz M
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain.
FAU - Waisman, Ari
AU  - Waisman A
AD  - Institute for Molecular Medicine, University Medical Center, Johannes Gutenberg
      University of Mainz, Mainz 55131, Germany.
FAU - Theurillat, Jean-Philippe
AU  - Theurillat JP
AD  - Functional Cancer Genomics Group, Institute of Oncology Research (IOR),
      Bellinzona 6500, Switzerland.
FAU - Perna, Cristian
AU  - Perna C
AD  - Department of Pathology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid
      28034, Spain.
FAU - Djouder, Nabil
AU  - Djouder N
AD  - Cancer Cell Biology Programme, Growth Factors, Nutrients and Cancer Group, Centro
      Nacional de Investigaciones Oncologicas, CNIO, Madrid 28029, Spain. Electronic
      address: ndjouder@cnio.es.
LA  - eng
GR  - 11-0242/Worldwide Cancer Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (IL17A protein, human)
RN  - 0 (Interleukin-17)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (URI1 protein, human)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):15-7. PMID: 27411585
CIN - Hepatology. 2017 Feb;65(2):739-741. PMID: 28012256
MH  - Animals
MH  - Carcinoma, Hepatocellular/etiology/genetics/*immunology
MH  - DNA Damage
MH  - Diet, High-Fat/*adverse effects
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Interleukin-17/*metabolism
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Liver Neoplasms/etiology/genetics/*immunology
MH  - Male
MH  - Mice
MH  - Neutrophil Infiltration
MH  - Non-alcoholic Fatty Liver Disease/etiology/genetics/*immunology
MH  - Th17 Cells/immunology
EDAT- 2016/07/15 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/15 06:00
PHST- 2015/05/12 00:00 [received]
PHST- 2016/05/15 00:00 [revised]
PHST- 2016/05/28 00:00 [accepted]
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30225-2 [pii]
AID - 10.1016/j.ccell.2016.05.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):161-175. doi: 10.1016/j.ccell.2016.05.020.

PMID- 27411589
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20171207
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.
PG  - 147-160
LID - S1535-6108(16)30221-5 [pii]
LID - 10.1016/j.ccell.2016.05.016 [doi]
AB  - Caloric restriction mimetics (CRMs) mimic the biochemical effects of nutrient
      deprivation by reducing lysine acetylation of cellular proteins, thus triggering 
      autophagy. Treatment with the CRM hydroxycitrate, an inhibitor of ATP citrate
      lyase, induced the depletion of regulatory T cells (which dampen anticancer
      immunity) from autophagy-competent, but not autophagy-deficient, mutant
      KRAS-induced lung cancers in mice, thereby improving anticancer
      immunosurveillance and reducing tumor mass. Short-term fasting or treatment with 
      several chemically unrelated autophagy-inducing CRMs, including hydroxycitrate
      and spermidine, improved the inhibition of tumor growth by chemotherapy in vivo. 
      This effect was only observed for autophagy-competent tumors, depended on the
      presence of T lymphocytes, and was accompanied by the depletion of regulatory T
      cells from the tumor bed.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Pietrocola, Federico
AU  - Pietrocola F
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France.
FAU - Pol, Jonathan
AU  - Pol J
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite Paris
      Descartes/Paris V, Sorbonne Paris Cite, 75006 Paris, France.
FAU - Vacchelli, Erika
AU  - Vacchelli E
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France.
FAU - Rao, Shuan
AU  - Rao S
AD  - Institute for Molecular Biotechnology of the Austrian Academy of Sciences, 1030
      Vienna, Austria.
FAU - Enot, David P
AU  - Enot DP
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; Metabolomics and Cell
      Biology Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
FAU - Baracco, Elisa E
AU  - Baracco EE
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France.
FAU - Levesque, Sarah
AU  - Levesque S
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France.
FAU - Castoldi, Francesca
AU  - Castoldi F
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France; Sotio
      a.c., 17000 Prague, Czech Republic.
FAU - Jacquelot, Nicolas
AU  - Jacquelot N
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France;
      INSERM U1015, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Center of
      Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, 94800 Villejuif, 
      France.
FAU - Yamazaki, Takahiro
AU  - Yamazaki T
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France;
      INSERM U1015, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Center of
      Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, 94800 Villejuif, 
      France.
FAU - Senovilla, Laura
AU  - Senovilla L
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite Paris
      Descartes/Paris V, Sorbonne Paris Cite, 75006 Paris, France.
FAU - Marino, Guillermo
AU  - Marino G
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France.
FAU - Aranda, Fernando
AU  - Aranda F
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France.
FAU - Durand, Sylvere
AU  - Durand S
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; Metabolomics and Cell
      Biology Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
FAU - Sica, Valentina
AU  - Sica V
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France.
FAU - Chery, Alexis
AU  - Chery A
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; Metabolomics and Cell
      Biology Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
FAU - Lachkar, Sylvie
AU  - Lachkar S
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France.
FAU - Sigl, Verena
AU  - Sigl V
AD  - Institute for Molecular Biotechnology of the Austrian Academy of Sciences, 1030
      Vienna, Austria.
FAU - Bloy, Norma
AU  - Bloy N
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France.
FAU - Buque, Aitziber
AU  - Buque A
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France.
FAU - Falzoni, Simonetta
AU  - Falzoni S
AD  - Department of Morphology, Surgery and Experimental Medicine University of
      Ferrara, 44121 Ferrara, Italy.
FAU - Ryffel, Bernhard
AU  - Ryffel B
AD  - UMR7355, CNRS and University, 45067 Orleans, France; Institute of Infectious
      Disease and Molecular Medicine, University of Cape Town, 7925 Cape Town, South
      Africa.
FAU - Apetoh, Lionel
AU  - Apetoh L
AD  - INSERM, U866, 21078 Dijon, France; Faculte de Medecine, Universite de Bourgogne, 
      21078 Dijon, France; Centre Georges Francois Leclerc, 21000 Dijon, France.
FAU - Di Virgilio, Francesco
AU  - Di Virgilio F
AD  - Department of Morphology, Surgery and Experimental Medicine University of
      Ferrara, 44121 Ferrara, Italy.
FAU - Madeo, Frank
AU  - Madeo F
AD  - Institute of Molecular Biosciences, NAWI Graz, University of Graz,
      Humboldtstrasse 50, 8010 Graz, Austria; BioTechMed-Graz, Humboldtstrasse 50, 8010
      Graz, Austria.
FAU - Maiuri, Maria Chiara
AU  - Maiuri MC
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; Universite
      Paris-Sud/Paris-Saclay, Faculte de Medecine, 94276 Kremlin-Bicetre, France;
      INSERM U1015, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Center of
      Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, 94800 Villejuif, 
      France.
FAU - Levine, Beth
AU  - Levine B
AD  - Department of Internal Medicine, Center for Autophagy Research, Howard Hughes
      Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX
      73590, USA.
FAU - Penninger, Josef M
AU  - Penninger JM
AD  - Institute for Molecular Biotechnology of the Austrian Academy of Sciences, 1030
      Vienna, Austria.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - Gustave Roussy Cancer Campus, 94800 Villejuif, France; INSERM, U1138, 75006
      Paris, France; Equipe 11 labellisee par la Ligue Nationale contre le Cancer,
      Centre de Recherche des Cordeliers, 75006 Paris, France; Universite Paris
      Descartes/Paris V, Sorbonne Paris Cite, 75006 Paris, France; Metabolomics and
      Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France;
      Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, 75015 Paris, France; 
      Department of Women's and Children's Health, Karolinska Institute, Karolinska
      University Hospital, Stockholm, Sweden; INSERM U1138, Centre de Recherche des
      Cordeliers, 75006 Paris, France. Electronic address: kroemer@orange.fr.
LA  - eng
GR  - R01 CA109618/CA/NCI NIH HHS/United States
GR  - U19 AI109725/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Atg5 protein, mouse)
RN  - 0 (Autophagy-Related Protein 5)
RN  - 0 (Citrates)
RN  - 8W94T9026R (hydroxycitric acid)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - U87FK77H25 (Spermidine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):13-5. PMID: 27411584
MH  - Animals
MH  - Autophagy
MH  - Autophagy-Related Protein 5/genetics
MH  - Caloric Restriction/methods
MH  - Cell Line, Tumor
MH  - Citrates/*administration & dosage/pharmacology
MH  - Humans
MH  - Methotrexate/administration & dosage/pharmacology
MH  - Mice
MH  - Monitoring, Immunologic
MH  - Mutation
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/*diet therapy/*drug therapy/immunology
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Spermidine/*administration & dosage/pharmacology
MH  - T-Lymphocytes, Regulatory/*drug effects
PMC - PMC5715805
MID - NIHMS921177
OTO - NOTNLM
OT  - *cancer
OT  - *chemotherapy
OT  - *immunosurveillance
OT  - *regulatory T cell
EDAT- 2016/07/15 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/15 06:00
PHST- 2015/06/16 00:00 [received]
PHST- 2016/02/06 00:00 [revised]
PHST- 2016/05/26 00:00 [accepted]
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30221-5 [pii]
AID - 10.1016/j.ccell.2016.05.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.

PMID- 27411588
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20180315
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor
      Cytotoxicity.
PG  - 136-146
LID - 10.1016/j.ccell.2016.06.005 [doi]
AB  - Immune-based interventions are promising strategies to achieve long-term
      cancer-free survival. Fasting was previously shown to differentially sensitize
      tumors to chemotherapy while protecting normal cells, including hematopoietic
      stem and immune cells, from its toxic side effects. Here, we show that the
      combination of chemotherapy and a fasting-mimicking diet (FMD) increases the
      levels of bone marrow common lymphoid progenitor cells and cytotoxic CD8(+)
      tumor-infiltrating lymphocytes (TILs), leading to a major delay in breast cancer 
      and melanoma progression. In breast tumors, this effect is partially mediated by 
      the downregulation of the stress-responsive enzyme heme oxygenase-1 (HO-1). These
      data indicate that FMD cycles combined with chemotherapy can enhance T
      cell-dependent targeted killing of cancer cells both by stimulating the
      hematopoietic system and by enhancing CD8(+)-dependent tumor cytotoxicity.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Di Biase, Stefano
AU  - Di Biase S
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Lee, Changhan
AU  - Lee C
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Brandhorst, Sebastian
AU  - Brandhorst S
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Manes, Brianna
AU  - Manes B
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Buono, Roberta
AU  - Buono R
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Cheng, Chia-Wei
AU  - Cheng CW
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Cacciottolo, Mafalda
AU  - Cacciottolo M
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Martin-Montalvo, Alejandro
AU  - Martin-Montalvo A
AD  - Translational Gerontology Branch, National Institute on Aging, National
      Institutes of Health, Baltimore, MD 21224, USA.
FAU - de Cabo, Rafael
AU  - de Cabo R
AD  - Translational Gerontology Branch, National Institute on Aging, National
      Institutes of Health, Baltimore, MD 21224, USA.
FAU - Wei, Min
AU  - Wei M
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Morgan, Todd E
AU  - Morgan TE
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
FAU - Longo, Valter D
AU  - Longo VD
AD  - Longevity Institute, Leonard Davis School of Gerontology and Department of
      Biological Sciences, University of Southern California, Los Angeles, CA 90089,
      USA.
AD  - IFOM, FIRC Institute of Molecular Oncology, Milano, Italy.
LA  - eng
GR  - HHSN261201200051C/CA/NCI NIH HHS/United States
GR  - P01 AG034906/AG/NIA NIH HHS/United States
GR  - R01 AG020642/AG/NIA NIH HHS/United States
GR  - R01 AG052558/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 80168379AG (Doxorubicin)
RN  - EC 1.14.14.18 (HMOX1 protein, human)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
SB  - IM
CON - Front Oncol. 2017 Jun 02;7:116. PMID: 28626728
CIN - Cancer Cell. 2016 Jul 11;30(1):13-5. PMID: 27411584
CIN - Front Oncol. 2017 Jun 02;7:116. PMID: 28626728
MH  - Animals
MH  - Breast Neoplasms/*diet therapy/*drug therapy/immunology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Combined Modality Therapy
MH  - Disease Progression
MH  - Down-Regulation
MH  - Doxorubicin/*administration & dosage/pharmacology
MH  - Fasting
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Heme Oxygenase-1/*metabolism
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/drug effects/*immunology
MH  - MCF-7 Cells
MH  - Mice
MH  - Neoplasm Transplantation
MH  - T-Lymphocytes, Cytotoxic/drug effects/*immunology
PMC - PMC5388544
MID - NIHMS796105
EDAT- 2016/07/15 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/15 06:00
PHST- 2015/06/15 00:00 [received]
PHST- 2016/01/30 00:00 [revised]
PHST- 2016/06/10 00:00 [accepted]
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - 10.1016/j.ccell.2016.06.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):136-146. doi: 10.1016/j.ccell.2016.06.005.

PMID- 27411587
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and
      Differentiation of Leukemia Initiating Cells.
PG  - 75-91
LID - S1535-6108(16)30227-6 [pii]
LID - 10.1016/j.ccell.2016.06.002 [doi]
AB  - Since acute myeloid leukemia (AML) is characterized by the blockade of
      hematopoietic differentiation and cell death, we interrogated RIPK3 signaling in 
      AML development. Genetic loss of Ripk3 converted murine FLT3-ITD-driven
      myeloproliferation into an overt AML by enhancing the accumulation of
      leukemia-initiating cells (LIC). Failed inflammasome activation and cell death
      mediated by tumor necrosis factor receptor caused this accumulation of LIC
      exemplified by accelerated leukemia onset in Il1r1(-/-), Pycard(-/-), and
      Tnfr1/2(-/-) mice. RIPK3 signaling was partly mediated by mixed lineage kinase
      domain-like. This link between suppression of RIPK3, failed interleukin-1beta
      release, and blocked cell death was supported by significantly reduced RIPK3 in
      primary AML patient cohorts. Our data identify RIPK3 and the inflammasome as key 
      tumor suppressors in AML.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hockendorf, Ulrike
AU  - Hockendorf U
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Yabal, Monica
AU  - Yabal M
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Herold, Tobias
AU  - Herold T
AD  - Department of Internal Medicine 3, University Hospital Grosshadern,
      Ludwig-Maximilians-Universitat (LMU), 81377 Munchen, Germany.
FAU - Munkhbaatar, Enkhtsetseg
AU  - Munkhbaatar E
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Rott, Stephanie
AU  - Rott S
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Jilg, Stefanie
AU  - Jilg S
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Kauschinger, Johanna
AU  - Kauschinger J
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Magnani, Giovanni
AU  - Magnani G
AD  - Institute of Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, 
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Reisinger, Florian
AU  - Reisinger F
AD  - Institute of Virology, Helmholtz Zentrum Munchen fur Gesundheit und Umwelt
      (HMGU), 85764 Neuherberg, Germany.
FAU - Heuser, Michael
AU  - Heuser M
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation,
      Hannover Medical School, 30625 Hannover, Germany.
FAU - Kreipe, Hans
AU  - Kreipe H
AD  - Institute of Pathology, Hannover Medical School, 30625 Hannover, Germany.
FAU - Sotlar, Karl
AU  - Sotlar K
AD  - Institute of Pathology, Ludwig-Maximilians-University (LMU), 80337 Munchen,
      Germany.
FAU - Engleitner, Thomas
AU  - Engleitner T
AD  - II. Medical Department for Gastroentreology, Klinikum rechts der Isar, Technische
      Universitat Munchen, 81675 Munchen, Germany; German Cancer Consortium (DKTK),
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Rad, Roland
AU  - Rad R
AD  - II. Medical Department for Gastroentreology, Klinikum rechts der Isar, Technische
      Universitat Munchen, 81675 Munchen, Germany; German Cancer Consortium (DKTK),
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Weichert, Wilko
AU  - Weichert W
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; Institute of Pathology, Klinikum rechts der Isar, Technische
      Universitat Munchen, 81675 Munchen, Germany.
FAU - Peschel, Christian
AU  - Peschel C
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany; German Cancer Consortium 
      (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Ruland, Jurgen
AU  - Ruland J
AD  - Institute of Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, 
      Technische Universitat Munchen, 81675 Munchen, Germany; German Cancer Consortium 
      (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Heikenwalder, Mathias
AU  - Heikenwalder M
AD  - Institute of Virology, Helmholtz Zentrum Munchen fur Gesundheit und Umwelt
      (HMGU), 85764 Neuherberg, Germany; Division of Chronic Inflammation and Cancer,
      German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Spiekermann, Karsten
AU  - Spiekermann K
AD  - Department of Internal Medicine 3, University Hospital Grosshadern,
      Ludwig-Maximilians-Universitat (LMU), 81377 Munchen, Germany; German Cancer
      Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg,
      Germany.
FAU - Slotta-Huspenina, Julia
AU  - Slotta-Huspenina J
AD  - Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen,
      81675 Munchen, Germany.
FAU - Gross, Olaf
AU  - Gross O
AD  - Institute of Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, 
      Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Jost, Philipp J
AU  - Jost PJ
AD  - III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany; German Cancer Consortium 
      (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
      Electronic address: philipp.jost@tum.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Inflammasomes)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - EC 2.7.11.1 (RIPK3 protein, human)
RN  - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Ripk3 protein, mouse)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):7-9. PMID: 27411581
MH  - Animals
MH  - Apoptosis
MH  - Cell Differentiation
MH  - Down-Regulation
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Leukemic
MH  - Humans
MH  - Inflammasomes/metabolism
MH  - Leukemia, Myeloid, Acute/genetics/metabolism/*pathology
MH  - Mice
MH  - Neoplasms, Experimental
MH  - Neoplastic Stem Cells/*cytology
MH  - Receptor-Interacting Protein Serine-Threonine Kinases/genetics/*metabolism
MH  - Receptors, Tumor Necrosis Factor/metabolism
MH  - Tumor Cells, Cultured
EDAT- 2016/07/15 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/15 06:00
PHST- 2015/09/29 00:00 [received]
PHST- 2016/03/04 00:00 [revised]
PHST- 2016/06/01 00:00 [accepted]
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30227-6 [pii]
AID - 10.1016/j.ccell.2016.06.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):75-91. doi: 10.1016/j.ccell.2016.06.002.

PMID- 27411586
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - The Multifaceted Role of Perivascular Macrophages in Tumors.
PG  - 18-25
LID - S1535-6108(16)30222-7 [pii]
LID - 10.1016/j.ccell.2016.05.017 [doi]
AB  - Evidence has emerged for macrophages in the perivascular niche of tumors
      regulating important processes like angiogenesis, various steps in the metastatic
      cascade, the recruitment and activity of other tumor-promoting leukocytes, and
      tumor responses to frontline therapies like irradiation and chemotherapy.
      Understanding the mechanisms controlling the recruitment, retention, and function
      of these cells could identify important targets for anti-cancer therapeutics.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lewis, Claire E
AU  - Lewis CE
AD  - Department of Oncology and Metabolism, University of Sheffield Medical School,
      Sheffield S10 2RX, UK. Electronic address: claire.lewis@sheffield.ac.uk.
FAU - Harney, Allison S
AU  - Harney AS
AD  - Departments of Anatomy and Structural Biology, Developmental and Molecular
      Biology, Albert Einstein College of Medicine, New York 10461, USA.
FAU - Pollard, Jeffrey W
AU  - Pollard JW
AD  - Departments of Anatomy and Structural Biology, Developmental and Molecular
      Biology, Albert Einstein College of Medicine, New York 10461, USA; MRC Centre for
      Reproductive Health, Queen's Medical Research Institute, University of Edinburgh,
      Edinburgh EH16 4TJ, UK. Electronic address: jeff.pollard@ed.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - G1002033/Medical Research Council/United Kingdom
GR  - P01 CA100324/CA/NCI NIH HHS/United States
GR  - R01 CA172451/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
EIN - Cancer Cell. 2016 Aug 8;30(2):365. PMID: 27505682
MH  - Animals
MH  - Biomarkers, Tumor/*metabolism
MH  - Disease Progression
MH  - Humans
MH  - Macrophages/*metabolism/*pathology
MH  - Neoplasm Metastasis
MH  - Neoplasms/blood supply/metabolism/pathology/*therapy
MH  - Neovascularization, Pathologic
MH  - Treatment Outcome
MH  - Tumor Microenvironment
PMC - PMC5024543
MID - NIHMS813193
EDAT- 2016/07/15 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/03/08 00:00 [received]
PHST- 2016/05/18 00:00 [revised]
PHST- 2016/05/28 00:00 [accepted]
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30222-7 [pii]
AID - 10.1016/j.ccell.2016.05.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):18-25. doi: 10.1016/j.ccell.2016.05.017.

PMID- 27411585
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - P(URI)fying Novel Drivers of NASH and HCC: A Feedforward Loop of IL17A via White 
      Adipose Tissue.
PG  - 15-17
LID - S1535-6108(16)30270-7 [pii]
LID - 10.1016/j.ccell.2016.06.010 [doi]
AB  - How obesity and metabolic syndrome trigger non-alcoholic steatohepatitis (NASH)
      and hepatocellular carcinoma (HCC) remains elusive. In this issue, Gomes and
      colleagues describe that nutrient surplus induces hepatic URI expression,
      triggering genotoxicity and IL17A expression, thus leading to insulin resistance,
      NASH, and HCC. IL17A signaling blockers might become a readily translatable
      therapy.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Weber, Achim
AU  - Weber A
AD  - Institute of Surgical Pathology, University and University Hospital Zurich,
      Zurich 8091, Switzerland.
FAU - Heikenwalder, Mathias
AU  - Heikenwalder M
AD  - Institute of Virology, Technische Universitat Munchen/Helmholtz Zentrum Munchen, 
      Munich 81675, Germany; Division of Chronic Inflammation and Cancer, German Cancer
      Research Center (DKFZ), Heidelberg 69120, Germany. Electronic address:
      m.heikenwaelder@dkfz.de.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):161-75. PMID: 27411590
MH  - Adipose Tissue, White/metabolism
MH  - Carcinoma, Hepatocellular/*metabolism
MH  - Fatty Liver
MH  - Humans
MH  - Liver Neoplasms/*metabolism
MH  - Non-alcoholic Fatty Liver Disease/metabolism
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30270-7 [pii]
AID - 10.1016/j.ccell.2016.06.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):15-17. doi: 10.1016/j.ccell.2016.06.010.

PMID- 27411584
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20171206
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Hunger Pains: Stimulating the Appetite of the Immune System for Cancer.
PG  - 13-15
LID - S1535-6108(16)30279-3 [pii]
LID - 10.1016/j.ccell.2016.06.019 [doi]
AB  - In this issue, Pietrocola et al. and Di Biase et al. independently demonstrate
      that caloric restriction from fasting and pharmacologic inhibition results in an 
      enhanced immunogenic response leading to reduced tumor growth. These two studies 
      provide an exciting connection between the emerging fields of cancer and immune
      metabolism.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Englert, Judson M
AU  - Englert JM
AD  - Department of Oncology, Sidney-Kimmel Comprehensive Cancer Research Center, Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Powell, Jonathan D
AU  - Powell JD
AD  - Department of Oncology, Sidney-Kimmel Comprehensive Cancer Research Center, Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic
      address: poweljo@jhmi.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):147-60. PMID: 27411589
CON - Cancer Cell. 2016 Jul 11;30(1):136-46. PMID: 27411588
MH  - *Appetite
MH  - Fasting
MH  - Humans
MH  - *Hunger
MH  - Immune System
MH  - Neoplasms
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30279-3 [pii]
AID - 10.1016/j.ccell.2016.06.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):13-15. doi: 10.1016/j.ccell.2016.06.019.

PMID- 27411583
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Tumor-Associated Neutrophils Show Phenotypic and Functional Divergence in Human
      Lung Cancer.
PG  - 11-13
LID - S1535-6108(16)30276-8 [pii]
LID - 10.1016/j.ccell.2016.06.016 [doi]
AB  - Studies in murine cancer models have demonstrated the phenotypic and functional
      divergence of neutrophils; however, their role in pro- or anti-tumor responses in
      human remains elusive. In this issue of Cancer Cell, Singhal et al. report the
      existence of specialized subsets of neutrophils in human lung cancer with
      diverging functions.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Saha, Shilpi
AU  - Saha S
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology & Research
      (A( *)STAR), #04-06 Immunos, 8A Biomedical Grove, Singapore 138648, Singapore.
FAU - Biswas, Subhra K
AU  - Biswas SK
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology & Research
      (A( *)STAR), #04-06 Immunos, 8A Biomedical Grove, Singapore 138648, Singapore.
      Electronic address: subhra_biswas@immunol.a-star.edu.sg.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):120-35. PMID: 27374224
MH  - Animals
MH  - Humans
MH  - *Lung Neoplasms
MH  - *Neutrophils
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30276-8 [pii]
AID - 10.1016/j.ccell.2016.06.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):11-13. doi: 10.1016/j.ccell.2016.06.016.

PMID- 27411582
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Modeling the Epigenetic Chain Reaction Downstream of DNMT3A(R882H).
PG  - 9-10
LID - S1535-6108(16)30278-1 [pii]
LID - 10.1016/j.ccell.2016.06.018 [doi]
AB  - In this issue of Cancer Cell, Lu et al. use a mouse model of
      DNMT3A(R882H)/NRAS(G12D) acute myeloid leukemia to define a cascade of chromatin 
      changes that emanate from DNMT3A-bound enhancers to initiate disease. The authors
      also reveal a chemical strategy to interrupt this process.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Somerville, Tim D D
AU  - Somerville TDD
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
FAU - Vakoc, Christopher R
AU  - Vakoc CR
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
      Electronic address: vakoc@cshl.edu.
LA  - eng
GR  - P30 CA045508/CA/NCI NIH HHS/United States
GR  - R01 CA174793/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):92-107. PMID: 27344947
MH  - Animals
MH  - DNA (Cytosine-5-)-Methyltransferases/*genetics
MH  - Epigenomics
MH  - *Leukemia, Myeloid, Acute
MH  - Mutation
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30278-1 [pii]
AID - 10.1016/j.ccell.2016.06.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):9-10. doi: 10.1016/j.ccell.2016.06.018.

PMID- 27411581
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - RIPK3 Slams the Brake on Leukemogenesis.
PG  - 7-9
LID - S1535-6108(16)30277-X [pii]
LID - 10.1016/j.ccell.2016.06.017 [doi]
AB  - Evasion of cell death is a key hallmark of cancers. In this issue of Cancer Cell,
      Hockendorf and colleagues identified RIPK3, an essential kinase for necroptosis, 
      as having a key role in inhibiting acute myeloid leukemia development.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Chan, Francis Ka-Ming
AU  - Chan FK
AD  - Department of Pathology, Immunology and Microbiology Program, University of
      Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
      Electronic address: francis.chan@umassmed.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):75-91. PMID: 27411587
MH  - Apoptosis/*drug effects
MH  - Cell Death/drug effects
MH  - Humans
MH  - Leukemia
MH  - *Necrosis
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30277-X [pii]
AID - 10.1016/j.ccell.2016.06.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):7-9. doi: 10.1016/j.ccell.2016.06.017.

PMID- 27411580
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Antagonizing Self-Renewal in Acute Myeloid Leukemia: ID2 Takes the Stage.
PG  - 5-7
LID - S1535-6108(16)30266-5 [pii]
LID - 10.1016/j.ccell.2016.06.006 [doi]
AB  - E proteins and their functional antagonists, the ID proteins, have significant
      roles in normal hematopoiesis. In this issue of Cancer Cell, Ghisi et al. show
      that high ID2 levels antagonize self-renewal and promote differentiation of
      leukemic stem cells in the MLL-translocated molecular subtype of acute myeloid
      leukemia.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Deb, Gauri
AU  - Deb G
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Somervaille, Tim C P
AU  - Somervaille TCP
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK. Electronic address:
      tim.somervaille@cruk.manchester.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Transcription Factors)
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):59-74. PMID: 27374225
MH  - *Cell Differentiation
MH  - Hematopoietic Stem Cells/metabolism
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Transcription Factors
MH  - Translocation, Genetic
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30266-5 [pii]
AID - 10.1016/j.ccell.2016.06.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):5-7. doi: 10.1016/j.ccell.2016.06.006.

PMID- 27411579
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20171025
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Context, Context, Context: New Gene Programs Linked to Bad Behavior in
      MLL-AF9-Initiated Leukemia.
PG  - 3-5
LID - S1535-6108(16)30271-9 [pii]
LID - 10.1016/j.ccell.2016.06.011 [doi]
AB  - In this issue of Cancer Cell, Stavropoulou et al. report that expression of the
      MLL-AF9 fusion results in acute myelogenous leukemia (AML) with different
      behaviors depending on cell context, which leads them to identify a
      transcriptional signature surprisingly resembling that of the
      epithelial-to-mesenchymal (EMT) transition, correlating with aggressiveness of
      disease.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Watanabe, Tatsuro
AU  - Watanabe T
AD  - Division of Hematology, Oncology and Bone Marrow Transplant, Department of
      Pediatrics, University of Colorado, Denver/Anschutz Medical Campus, 12800 East
      19th Avenue, MS #8302, Aurora, CO 80045, USA.
FAU - Ernst, Patricia
AU  - Ernst P
AD  - Division of Hematology, Oncology and Bone Marrow Transplant, Department of
      Pediatrics, University of Colorado, Denver/Anschutz Medical Campus, 12800 East
      19th Avenue, MS #8302, Aurora, CO 80045, USA. Electronic address:
      patricia.ernst@ucdenver.edu.
LA  - eng
GR  - R01 HL090036/HL/NHLBI NIH HHS/United States
GR  - R21 OD019716/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):43-58. PMID: 27344946
MH  - Humans
MH  - Leukemia, Myeloid, Acute/genetics
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics
MH  - Oncogene Proteins, Fusion/*genetics
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30271-9 [pii]
AID - 10.1016/j.ccell.2016.06.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):3-5. doi: 10.1016/j.ccell.2016.06.011.

PMID- 27411578
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Molecular Subtypes of Non-muscle Invasive Bladder Cancer.
PG  - 1-3
LID - S1535-6108(16)30272-0 [pii]
LID - 10.1016/j.ccell.2016.06.012 [doi]
AB  - In this issue of Cancer Cell, Hedegaard et al. report a comprehensive
      multi-center transcriptional analysis of non-muscle invasive urothelial bladder
      cancer. They describe three molecular subtypes similar to those seen in other
      cohorts, as well as a unique CIS signature associated with risk of progression to
      muscle invasive cancer.
CI  - Copyright (c) 2016. Published by Elsevier Inc.
FAU - Lerner, Seth P
AU  - Lerner SP
AD  - Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of
      Medicine, Houston, TX 77030, USA. Electronic address: slerner@bcm.edu.
FAU - Robertson, A Gordon
AU  - Robertson AG
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Jul 11;30(1):27-42. PMID: 27321955
MH  - Disease Progression
MH  - Humans
MH  - *Neoplasm Invasiveness
MH  - *Urinary Bladder Neoplasms
EDAT- 2016/07/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30272-0 [pii]
AID - 10.1016/j.ccell.2016.06.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):1-3. doi: 10.1016/j.ccell.2016.06.012.

PMID- 27374225
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged
      Acute Myeloid Leukemia.
PG  - 59-74
LID - S1535-6108(16)30224-0 [pii]
LID - 10.1016/j.ccell.2016.05.019 [doi]
AB  - E proteins and their antagonists, the Id proteins, are transcriptional regulators
      important for normal hematopoiesis. We found that Id2 acts as a key regulator of 
      leukemia stem cell (LSC) potential in MLL-rearranged acute myeloid leukemia
      (AML). Low endogenous Id2 expression is associated with LSC enrichment while Id2 
      overexpression impairs MLL-AF9-leukemia initiation and growth. Importantly,
      MLL-AF9 itself controls the E-protein pathway by suppressing Id2 while directly
      activating E2-2 expression, and E2-2 depletion phenocopies Id2 overexpression in 
      MLL-AF9-AML cells. Remarkably, Id2 tumor-suppressive function is conserved in
      t(8;21) AML. Low expression of Id2 and its associated gene signature are
      associated with poor prognosis in MLL-rearranged and t(8;21) AML patients,
      identifying the Id2/E-protein axis as a promising new therapeutic target in AML.
CI  - Crown Copyright (c) 2016. Published by Elsevier Inc. All rights reserved.
FAU - Ghisi, Margherita
AU  - Ghisi M
AD  - Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia; Australian Centre for Blood Diseases, Monash
      University, Melbourne, 3004 VIC, Australia. Electronic address:
      margherita.ghisi@monash.edu.
FAU - Kats, Lev
AU  - Kats L
AD  - Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia; The Sir Peter MacCallum Department of
      Oncology, University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Masson, Frederick
AU  - Masson F
AD  - Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute and 
      La Trobe University School of Cancer Medicine, Heidelberg, 3084 VIC, Australia;
      Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical
      Research, Parkville, 3052 VIC, Australia; Department of Medical Biology, The
      University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Li, Jason
AU  - Li J
AD  - The Sir Peter MacCallum Department of Oncology, University of Melbourne,
      Parkville, 3010 VIC, Australia; Bioinformatics Core, Peter MacCallum Cancer
      Centre, St. Andrews Place, East Melbourne, 3002 VIC, Australia.
FAU - Kratina, Tobias
AU  - Kratina T
AD  - Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical
      Research, Parkville, 3052 VIC, Australia; Department of Medical Biology, The
      University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Vidacs, Eva
AU  - Vidacs E
AD  - Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia.
FAU - Gilan, Omer
AU  - Gilan O
AD  - Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia; The Sir Peter MacCallum Department of
      Oncology, University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Doyle, Maria A
AU  - Doyle MA
AD  - Research Computing Facility, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia.
FAU - Newbold, Andrea
AU  - Newbold A
AD  - Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia; The Sir Peter MacCallum Department of
      Oncology, University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Bolden, Jessica E
AU  - Bolden JE
AD  - Department of Medical Biology, The University of Melbourne, Parkville, 3010 VIC, 
      Australia; Molecular Medicine Division, The Walter and Eliza Hall Institute of
      Medical Research, 1G Royal Parade, Parkville, 3052 VIC, Australia.
FAU - Fairfax, Kirsten A
AU  - Fairfax KA
AD  - Department of Medical Biology, The University of Melbourne, Parkville, 3010 VIC, 
      Australia; Molecular Medicine Division, The Walter and Eliza Hall Institute of
      Medical Research, 1G Royal Parade, Parkville, 3052 VIC, Australia.
FAU - de Graaf, Carolyn A
AU  - de Graaf CA
AD  - Department of Medical Biology, The University of Melbourne, Parkville, 3010 VIC, 
      Australia; Molecular Medicine Division, The Walter and Eliza Hall Institute of
      Medical Research, 1G Royal Parade, Parkville, 3052 VIC, Australia.
FAU - Firth, Matthew
AU  - Firth M
AD  - Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical
      Research, Parkville, 3052 VIC, Australia; Department of Medical Biology, The
      University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Zuber, Johannes
AU  - Zuber J
AD  - Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Dr.
      Bohr-Gasse 7, 1030 Vienna, Austria.
FAU - Dickins, Ross A
AU  - Dickins RA
AD  - Australian Centre for Blood Diseases, Monash University, Melbourne, 3004 VIC,
      Australia.
FAU - Corcoran, Lynn M
AU  - Corcoran LM
AD  - Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical
      Research, Parkville, 3052 VIC, Australia; Department of Medical Biology, The
      University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Dawson, Mark A
AU  - Dawson MA
AD  - Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia; The Sir Peter MacCallum Department of
      Oncology, University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Belz, Gabrielle T
AU  - Belz GT
AD  - Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical
      Research, Parkville, 3052 VIC, Australia; Department of Medical Biology, The
      University of Melbourne, Parkville, 3010 VIC, Australia.
FAU - Johnstone, Ricky W
AU  - Johnstone RW
AD  - Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place,
      East Melbourne, 3002 VIC, Australia; The Sir Peter MacCallum Department of
      Oncology, University of Melbourne, Parkville, 3010 VIC, Australia. Electronic
      address: ricky.johnstone@petermac.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160630
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ID2 protein, human)
RN  - 0 (Inhibitor of Differentiation Protein 2)
RN  - 0 (MLL-AF9 fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TCF7L2 protein, human)
RN  - 0 (Transcription Factor 7-Like 2 Protein)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):5-7. PMID: 27411580
MH  - Animals
MH  - Cell Proliferation
MH  - Chromosomes, Human, Pair 21/genetics
MH  - Chromosomes, Human, Pair 8/genetics
MH  - Gene Expression Regulation, Leukemic
MH  - Humans
MH  - Inhibitor of Differentiation Protein 2/*genetics/metabolism
MH  - Leukemia, Myeloid, Acute/*genetics/metabolism/*pathology
MH  - Mice
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics/metabolism
MH  - Neoplasms, Experimental
MH  - Oncogene Proteins, Fusion/*genetics/metabolism
MH  - Prognosis
MH  - Stem Cells/cytology/metabolism
MH  - Survival Analysis
MH  - Transcription Factor 7-Like 2 Protein/*genetics/metabolism
MH  - *Translocation, Genetic
EDAT- 2016/07/05 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/05 06:00
PHST- 2015/07/11 00:00 [received]
PHST- 2016/02/29 00:00 [revised]
PHST- 2016/05/31 00:00 [accepted]
PHST- 2016/07/05 06:00 [entrez]
PHST- 2016/07/05 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30224-0 [pii]
AID - 10.1016/j.ccell.2016.05.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):59-74. doi: 10.1016/j.ccell.2016.05.019. Epub 2016
      Jun 30.

PMID- 27374224
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20171111
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Origin and Role of a Subset of Tumor-Associated Neutrophils with
      Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.
PG  - 120-135
LID - S1535-6108(16)30226-4 [pii]
LID - 10.1016/j.ccell.2016.06.001 [doi]
AB  - Based on studies in mouse tumor models, granulocytes appear to play a
      tumor-promoting role. However, there are limited data about the phenotype and
      function of tumor-associated neutrophils (TANs) in humans. Here, we identify a
      subset of TANs that exhibited characteristics of both neutrophils and
      antigen-presenting cells (APCs) in early-stage human lung cancer. These APC-like 
      "hybrid neutrophils," which originate from CD11b(+)CD15(hi)CD10(-)CD16(low)
      immature progenitors, are able to cross-present antigens, as well as trigger and 
      augment anti-tumor T cell responses. Interferon-gamma and granulocyte-macrophage 
      colony-stimulating factor are requisite factors in the tumor that, working
      through the Ikaros transcription factor, synergistically exert their
      APC-promoting effects on the progenitors. Overall, these data demonstrate the
      existence of a specialized TAN subset with anti-tumor capabilities in human
      cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Singhal, Sunil
AU  - Singhal S
AD  - Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine 
      at the University of Pennsylvania, Philadelphia, PA 19104, USA; Division of
      Thoracic Surgery, Department of Surgery, Philadelphia VA Medical Center,
      Philadelphia, PA 19104, USA.
FAU - Bhojnagarwala, Pratik S
AU  - Bhojnagarwala PS
AD  - Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine 
      at the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - O'Brien, Shaun
AU  - O'Brien S
AD  - Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Moon, Edmund K
AU  - Moon EK
AD  - Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Garfall, Alfred L
AU  - Garfall AL
AD  - Division of Hematology/Oncology, Department of Medicine, Perelman School of
      Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Rao, Abhishek S
AU  - Rao AS
AD  - Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine 
      at the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Quatromoni, Jon G
AU  - Quatromoni JG
AD  - Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine 
      at the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Stephen, Tom Li
AU  - Stephen TL
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Litzky, Leslie
AU  - Litzky L
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Deshpande, Charuhas
AU  - Deshpande C
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Feldman, Michael D
AU  - Feldman MD
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Hancock, Wayne W
AU  - Hancock WW
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA; Department of
      Pathology and Laboratory Medicine, Children's Hospital of Philadelphia,
      Philadelphia, PA 19104, USA.
FAU - Conejo-Garcia, Jose R
AU  - Conejo-Garcia JR
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Albelda, Steven M
AU  - Albelda SM
AD  - Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Eruslanov, Evgeniy B
AU  - Eruslanov EB
AD  - Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine 
      at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic
      address: evgeniy.eruslanov@uphs.upenn.edu.
LA  - eng
GR  - R01 CA187392/CA/NCI NIH HHS/United States
GR  - R01 CA193556/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - K12 CA076931/CA/NCI NIH HHS/United States
GR  - P30 ES013508/ES/NIEHS NIH HHS/United States
GR  - R01 CA124515/CA/NCI NIH HHS/United States
GR  - R01 CA178687/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20160630
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 148971-36-2 (Ikaros Transcription Factor)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):11-3. PMID: 27411583
MH  - Antigen-Presenting Cells/*immunology
MH  - Gene Expression Regulation, Neoplastic
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/immunology
MH  - Humans
MH  - Ikaros Transcription Factor/metabolism
MH  - Interferon-gamma/immunology
MH  - Lung Neoplasms/*immunology
MH  - Neoplasm Staging
MH  - Neutrophils/cytology/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
PMC - PMC4945447
MID - NIHMS793568
EDAT- 2016/07/05 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/05 06:00
PHST- 2016/01/05 00:00 [received]
PHST- 2016/04/08 00:00 [revised]
PHST- 2016/06/01 00:00 [accepted]
PHST- 2016/07/05 06:00 [entrez]
PHST- 2016/07/05 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30226-4 [pii]
AID - 10.1016/j.ccell.2016.06.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):120-135. doi: 10.1016/j.ccell.2016.06.001. Epub
      2016 Jun 30.

PMID- 27374223
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status 
      and Sensitizes Established and Resistant Tumors to Immunotherapy.
PG  - 108-119
LID - S1535-6108(16)30217-3 [pii]
LID - 10.1016/j.ccell.2016.05.012 [doi]
AB  - Immunotherapies are highly promising cancer treatments, but understanding the
      factors mediating their resistance remains critical. Successes in randomized
      clinical testing have supported the growing appreciation that oncolytic
      virotherapies primarily act as immunotherapies. Here we identified prostaglandin 
      E2 (PGE2) in the tumor as a key mediator of resistance to immunotherapies,
      including oncolytic vaccinia virotherapy. Elevated levels of PGE2 coupled to
      suppressive chemokine profiles and high levels of granulocytic myeloid-derived
      suppressor cells resulted in loss of immunotherapeutic potential. Viral vectors
      engineered to target PGE2 were capable of overcoming localized immunosuppression 
      leading to profound changes in the tumor's immune status. This allowed the viral 
      vectors to raise robust anti-tumor adaptive immune responses and sensitized
      established and previously resistant tumors to immunotherapies.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hou, Weizhou
AU  - Hou W
AD  - Department of Cell Biology, University of Pittsburgh Cancer Institute, University
      of Pittsburgh, Pittsburgh, PA 15213, USA.
FAU - Sampath, Padma
AU  - Sampath P
AD  - Department of Cell Biology, University of Pittsburgh Cancer Institute, University
      of Pittsburgh, Pittsburgh, PA 15213, USA.
FAU - Rojas, Juan J
AU  - Rojas JJ
AD  - Department of Cell Biology, University of Pittsburgh Cancer Institute, University
      of Pittsburgh, Pittsburgh, PA 15213, USA.
FAU - Thorne, Steve H
AU  - Thorne SH
AD  - Department of Cell Biology, University of Pittsburgh Cancer Institute, University
      of Pittsburgh, Pittsburgh, PA 15213, USA; Department of Immunology, G17a, Hillman
      Cancer Center, University of Pittsburgh, 5117 Center Avenue, Pittsburgh, PA
      15213, USA. Electronic address: thornesh@upmc.edu.
LA  - eng
GR  - P30 CA047904/CA/NCI NIH HHS/United States
GR  - R01 CA140215/CA/NCI NIH HHS/United States
GR  - R01 CA178766/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160630
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cancer Vaccines)
RN  - 0 (Chemokines)
RN  - EC 1.1.1.- (Hydroxyprostaglandin Dehydrogenases)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cell Survival
MH  - Chemokines/*metabolism
MH  - Dinoprostone/*antagonists & inhibitors
MH  - Drug Resistance, Neoplasm
MH  - Gene Targeting/*methods
MH  - Genetic Vectors/administration & dosage
MH  - Hydroxyprostaglandin Dehydrogenases/*genetics/pharmacology
MH  - Immunotherapy
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/immunology/*therapy
MH  - Oncolytic Virotherapy/*methods
MH  - Oncolytic Viruses/genetics/immunology
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vaccinia virus/genetics
PMC - PMC4962335
MID - NIHMS801006
OTO - NOTNLM
OT  - *COX-2
OT  - *MDSC
OT  - *PGE(2)
OT  - *immune suppression
OT  - *oncolytic virus
EDAT- 2016/07/05 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/05 06:00
PHST- 2015/07/16 00:00 [received]
PHST- 2016/02/26 00:00 [revised]
PHST- 2016/05/23 00:00 [accepted]
PHST- 2016/07/05 06:00 [entrez]
PHST- 2016/07/05 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30217-3 [pii]
AID - 10.1016/j.ccell.2016.05.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):108-119. doi: 10.1016/j.ccell.2016.05.012. Epub
      2016 Jun 30.

PMID- 27344947
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20180201
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell
      Gene-Expression Program and Acute Leukemia Development.
PG  - 92-107
LID - S1535-6108(16)30213-6 [pii]
LID - 10.1016/j.ccell.2016.05.008 [doi]
AB  - DNA methyltransferase 3A (DNMT3A) is frequently mutated in hematological cancers;
      however, the underlying oncogenic mechanism remains elusive. Here, we report that
      the DNMT3A mutational hotspot at Arg882 (DNMT3A(R882H)) cooperates with NRAS
      mutation to transform hematopoietic stem/progenitor cells and induce acute
      leukemia development. Mechanistically, DNMT3A(R882H) directly binds to and
      potentiates transactivation of stemness genes critical for leukemogenicity
      including Meis1, Mn1, and Hoxa gene cluster. DNMT3A(R882H) induces focal
      epigenetic alterations, including CpG hypomethylation and concurrent gain of
      active histone modifications, at cis-regulatory elements such as enhancers to
      facilitate gene transcription. CRISPR/Cas9-mediated ablation of a putative Meis1 
      enhancer carrying DNMT3A(R882H)-induced DNA hypomethylation impairs Meis1
      expression. Importantly, DNMT3A(R882H)-induced gene-expression programs can be
      repressed through Dot1l inhibition, providing an attractive therapeutic strategy 
      for DNMT3A-mutated leukemias.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lu, Rui
AU  - Lu R
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina School of
      Medicine, Chapel Hill, NC 27599, USA; Department of Biochemistry and Biophysics, 
      University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
FAU - Wang, Ping
AU  - Wang P
AD  - Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA.
FAU - Parton, Trevor
AU  - Parton T
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Zhou, Yang
AU  - Zhou Y
AD  - Department of Pathology and Laboratory Medicine, McAllister Heart Institute,
      University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
FAU - Chrysovergis, Kaliopi
AU  - Chrysovergis K
AD  - Laboratory of Molecular Carcinogenesis, National Institute of Environmental
      Health Sciences, National Institute of Health, Research Triangle Park, NC 27709, 
      USA.
FAU - Rockowitz, Shira
AU  - Rockowitz S
AD  - Departments of Genetics and Neuroscience, Albert Einstein College of Medicine,
      Bronx, NY 10461, USA.
FAU - Chen, Wei-Yi
AU  - Chen WY
AD  - Institute of Biochemistry and Molecular Biology, National Yang-Ming University,
      Taipei 11221, Taiwan.
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Wade, Paul A
AU  - Wade PA
AD  - Laboratory of Molecular Carcinogenesis, National Institute of Environmental
      Health Sciences, National Institute of Health, Research Triangle Park, NC 27709, 
      USA.
FAU - Zheng, Deyou
AU  - Zheng D
AD  - Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA; Departments of Genetics and Neuroscience, Albert Einstein College of
      Medicine, Bronx, NY 10461, USA. Electronic address: deyou.zheng@einstein.yu.edu.
FAU - Wang, Gang Greg
AU  - Wang GG
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina School of
      Medicine, Chapel Hill, NC 27599, USA; Department of Biochemistry and Biophysics, 
      University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA;
      Curriculum in Genetics and Molecular Biology, University of North Carolina at
      Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address:
      greg_wang@med.unc.edu.
LA  - eng
GR  - R01 CA215284/CA/NCI NIH HHS/United States
GR  - P30 CA016086/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - K99 CA151683/CA/NCI NIH HHS/United States
GR  - R00 CA151683/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160623
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Homeodomain Proteins)
RN  - 0 (MEIS1 protein, human)
RN  - 0 (Meis1 protein, mouse)
RN  - 0 (Myeloid Ecotropic Viral Integration Site 1 Protein)
RN  - 0 (Neoplasm Proteins)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 2.1.1.- (Methyltransferases)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
RN  - EC 2.1.1.37 (DNA methyltransferase 3A)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):9-10. PMID: 27411582
MH  - Animals
MH  - Arginine/*genetics
MH  - DNA (Cytosine-5-)-Methyltransferases/*genetics
MH  - DNA Methylation
MH  - Epigenesis, Genetic
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Leukemic
MH  - Genes, ras
MH  - Homeodomain Proteins/genetics
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics/pathology
MH  - Methyltransferases/antagonists & inhibitors
MH  - Mice
MH  - Mutation
MH  - Myeloid Ecotropic Viral Integration Site 1 Protein
MH  - Neoplasm Proteins/genetics
MH  - Neoplasms, Experimental
MH  - Promoter Regions, Genetic
MH  - Stem Cells/cytology/*pathology
MH  - Tumor Cells, Cultured
PMC - PMC4945461
MID - NIHMS790754
EDAT- 2016/06/28 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/06/28 06:00
PHST- 2015/07/21 00:00 [received]
PHST- 2016/03/03 00:00 [revised]
PHST- 2016/05/19 00:00 [accepted]
PHST- 2016/06/28 06:00 [entrez]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30213-6 [pii]
AID - 10.1016/j.ccell.2016.05.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):92-107. doi: 10.1016/j.ccell.2016.05.008. Epub
      2016 Jun 23.

PMID- 27344946
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML
      Expressing EMT-Related Genes Linked to Poor Outcome.
PG  - 43-58
LID - S1535-6108(16)30216-1 [pii]
LID - 10.1016/j.ccell.2016.05.011 [doi]
AB  - To address the impact of cellular origin on acute myeloid leukemia (AML), we
      generated an inducible transgenic mouse model for MLL-AF9-driven leukemia.
      MLL-AF9 expression in long-term hematopoietic stem cells (LT-HSC) in vitro
      resulted in dispersed clonogenic growth and expression of genes involved in
      migration and invasion. In vivo, 20% LT-HSC-derived AML were particularly
      aggressive with extensive tissue infiltration, chemoresistance, and expressed
      genes related to epithelial-mesenchymal transition (EMT) in solid cancers.
      Knockdown of the EMT regulator ZEB1 significantly reduced leukemic blast
      invasion. By classifying mouse and human leukemias according to Evi1/EVI1 and
      Erg/ERG expression, reflecting aggressiveness and cell of origin, and performing 
      comparative transcriptomics, we identified several EMT-related genes that were
      significantly associated with poor overall survival of AML patients.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Stavropoulou, Vaia
AU  - Stavropoulou V
AD  - Department of Biomedicine, University Children's Hospital (UKBB), University of
      Basel, 4031 Basel, Switzerland.
FAU - Kaspar, Susanne
AU  - Kaspar S
AD  - Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse 66,
      4058 Basel, Switzerland; Faculty of Sciences, University of Basel, 4031 Basel,
      Switzerland.
FAU - Brault, Laurent
AU  - Brault L
AD  - Department of Biomedicine, University Children's Hospital (UKBB), University of
      Basel, 4031 Basel, Switzerland.
FAU - Sanders, Mathijs A
AU  - Sanders MA
AD  - Department of Hematology, Erasmus University Medical Center, 3015 CE Rotterdam,
      the Netherlands.
FAU - Juge, Sabine
AU  - Juge S
AD  - Department of Biomedicine, University Children's Hospital (UKBB), University of
      Basel, 4031 Basel, Switzerland.
FAU - Morettini, Stefano
AU  - Morettini S
AD  - Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse 66,
      4058 Basel, Switzerland.
FAU - Tzankov, Alexandar
AU  - Tzankov A
AD  - Institute for Pathology, University Hospital Basel, 4031 Basel, Switzerland.
FAU - Iacovino, Michelina
AU  - Iacovino M
AD  - Department of Pediatrics, LA Biomedical Research Institute, Torrance, CA 90502,
      USA.
FAU - Lau, I-Jun
AU  - Lau IJ
AD  - MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, NIHR 
      Oxford Biomedical Research Centre Programme, University of Oxford, Oxford OX3
      9DS, UK.
FAU - Milne, Thomas A
AU  - Milne TA
AD  - MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, NIHR 
      Oxford Biomedical Research Centre Programme, University of Oxford, Oxford OX3
      9DS, UK.
FAU - Royo, Helene
AU  - Royo H
AD  - Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse 66,
      4058 Basel, Switzerland.
FAU - Kyba, Michael
AU  - Kyba M
AD  - Department of Pediatrics, Lillehei Heart Institute, University of Minnesota,
      Minneapolis, MN 55455, USA.
FAU - Valk, Peter J M
AU  - Valk PJM
AD  - Department of Hematology, Erasmus University Medical Center, 3015 CE Rotterdam,
      the Netherlands.
FAU - Peters, Antoine H F M
AU  - Peters AHFM
AD  - Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse 66,
      4058 Basel, Switzerland; Faculty of Sciences, University of Basel, 4031 Basel,
      Switzerland. Electronic address: antoine.peters@fmi.ch.
FAU - Schwaller, Juerg
AU  - Schwaller J
AD  - Department of Biomedicine, University Children's Hospital (UKBB), University of
      Basel, 4031 Basel, Switzerland. Electronic address: j.schwaller@unibas.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160623
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MLL-AF9 fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (ZEB1 protein, human)
RN  - 0 (ZEB1 protein, mouse)
RN  - 0 (Zinc Finger E-box-Binding Homeobox 1)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):3-5. PMID: 27411579
MH  - Animals
MH  - Drug Resistance, Neoplasm
MH  - *Epithelial-Mesenchymal Transition
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Leukemic
MH  - Hematopoietic Stem Cell Transplantation
MH  - Hematopoietic Stem Cells/*cytology/metabolism
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics/metabolism/*pathology
MH  - Mice
MH  - Mice, Transgenic
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics/*metabolism
MH  - Neoplasm Invasiveness
MH  - Neoplasms, Experimental
MH  - Oncogene Proteins, Fusion/*genetics/*metabolism
MH  - Prognosis
MH  - Tumor Cells, Cultured
MH  - Zinc Finger E-box-Binding Homeobox 1/genetics
OTO - NOTNLM
OT  - *EMT
OT  - *MLL-AF9
OT  - *acute myeloid leukemia
OT  - *invasion
OT  - *poor overall survival
OT  - *stem cell
EDAT- 2016/06/28 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/06/28 06:00
PHST- 2015/03/30 00:00 [received]
PHST- 2016/03/22 00:00 [revised]
PHST- 2016/05/23 00:00 [accepted]
PHST- 2016/06/28 06:00 [entrez]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30216-1 [pii]
AID - 10.1016/j.ccell.2016.05.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):43-58. doi: 10.1016/j.ccell.2016.05.011. Epub 2016
      Jun 23.

PMID- 27321955
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20180128
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 30
IP  - 1
DP  - 2016 Jul 11
TI  - Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
PG  - 27-42
LID - S1535-6108(16)30209-4 [pii]
LID - 10.1016/j.ccell.2016.05.004 [doi]
AB  - Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely
      different outcomes. We performed a comprehensive transcriptional analysis of 460 
      early-stage urothelial carcinomas and showed that NMIBC can be subgrouped into
      three major classes with basal- and luminal-like characteristics and different
      clinical outcomes. Large differences in biological processes such as the cell
      cycle, epithelial-mesenchymal transition, and differentiation were observed.
      Analysis of transcript variants revealed frequent mutations in genes encoding
      proteins involved in chromatin organization and cytoskeletal functions.
      Furthermore, mutations in well-known cancer driver genes (e.g., TP53 and ERBB2)
      were primarily found in high-risk tumors, together with APOBEC-related mutational
      signatures. The identification of subclasses in NMIBC may offer better
      prognostication and treatment selection based on subclass assignment.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hedegaard, Jakob
AU  - Hedegaard J
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Lamy, Philippe
AU  - Lamy P
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Nordentoft, Iver
AU  - Nordentoft I
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Algaba, Ferran
AU  - Algaba F
AD  - Section of Pathology, Fundacio Puigvert, University Autonoma de Barcelona,
      Barcelona 08025, Spain.
FAU - Hoyer, Soren
AU  - Hoyer S
AD  - Department of Pathology, Aarhus University Hospital, Aarhus 8000, Denmark.
FAU - Ulhoi, Benedicte Parm
AU  - Ulhoi BP
AD  - Department of Pathology, Aarhus University Hospital, Aarhus 8000, Denmark.
FAU - Vang, Soren
AU  - Vang S
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Reinert, Thomas
AU  - Reinert T
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Hermann, Gregers G
AU  - Hermann GG
AD  - Department of Urology, Frederiksberg Hospital, Frederiksberg 2000, Denmark.
FAU - Mogensen, Karin
AU  - Mogensen K
AD  - Department of Urology, Frederiksberg Hospital, Frederiksberg 2000, Denmark.
FAU - Thomsen, Mathilde Borg Houlberg
AU  - Thomsen MBH
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Nielsen, Morten Muhlig
AU  - Nielsen MM
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Marquez, Mirari
AU  - Marquez M
AD  - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
FAU - Segersten, Ulrika
AU  - Segersten U
AD  - Department of Surgical Sciences, Uppsala University, Uppsala 75185, Sweden.
FAU - Aine, Mattias
AU  - Aine M
AD  - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund
      University, Lund 22100, Sweden.
FAU - Hoglund, Mattias
AU  - Hoglund M
AD  - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund
      University, Lund 22100, Sweden.
FAU - Birkenkamp-Demtroder, Karin
AU  - Birkenkamp-Demtroder K
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Fristrup, Niels
AU  - Fristrup N
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Borre, Michael
AU  - Borre M
AD  - Department of Urology, Aarhus University Hospital, Aarhus 8200, Denmark.
FAU - Hartmann, Arndt
AU  - Hartmann A
AD  - Institute of Pathology, University Hospital Erlangen, Friedrich
      Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany.
FAU - Stohr, Robert
AU  - Stohr R
AD  - Institute of Pathology, University Hospital Erlangen, Friedrich
      Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany.
FAU - Wach, Sven
AU  - Wach S
AD  - Department of Urology, University Hospital Erlangen, Friedrich
      Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany.
FAU - Keck, Bastian
AU  - Keck B
AD  - Department of Urology, University Hospital Erlangen, Friedrich
      Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany.
FAU - Seitz, Anna Katharina
AU  - Seitz AK
AD  - Department of Urology, Klinikum rechts der Isar der Technischen Universitat
      Munchen, Munich 81675, Germany.
FAU - Nawroth, Roman
AU  - Nawroth R
AD  - Department of Urology, Klinikum rechts der Isar der Technischen Universitat
      Munchen, Munich 81675, Germany.
FAU - Maurer, Tobias
AU  - Maurer T
AD  - Department of Urology, Klinikum rechts der Isar der Technischen Universitat
      Munchen, Munich 81675, Germany.
FAU - Tulic, Cane
AU  - Tulic C
AD  - Faculty of Medicine, Clinic of Urology, Clinical Centre of Serbia, University of 
      Belgrade, 11000 Belgrade, Serbia.
FAU - Simic, Tatjana
AU  - Simic T
AD  - Faculty of Medicine, Institute of Medical and Clinical Biochemistry, University
      of Belgrade, 11000 Belgrade, Serbia.
FAU - Junker, Kerstin
AU  - Junker K
AD  - Department of Urology, Saarland University, Homburg 66421, Germany.
FAU - Horstmann, Marcus
AU  - Horstmann M
AD  - Department of Urology, Friedrich-Schiller-University Jena, Jena 07737, Germany.
FAU - Harving, Niels
AU  - Harving N
AD  - Department of Urology, Aalborg University Hospital, Aalborg 9000, Denmark.
FAU - Petersen, Astrid Christine
AU  - Petersen AC
AD  - Department of Pathology, Aalborg University Hospital, Aalborg 9000, Denmark.
FAU - Calle, M Luz
AU  - Calle ML
AD  - Systems Biology Department, University of Vic, Vic, Barcelona 08500, Spain.
FAU - Steyerberg, Ewout W
AU  - Steyerberg EW
AD  - Department of Public Health, Erasmus Medical Centre, 3015 CE Rotterdam, the
      Netherlands.
FAU - Beukers, Willemien
AU  - Beukers W
AD  - Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the
      Netherlands.
FAU - van Kessel, Kim E M
AU  - van Kessel KEM
AD  - Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the
      Netherlands.
FAU - Jensen, Jorgen Bjerggaard
AU  - Jensen JB
AD  - Department of Urology, Aarhus University Hospital, Aarhus 8200, Denmark.
FAU - Pedersen, Jakob Skou
AU  - Pedersen JS
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Malmstrom, Per-Uno
AU  - Malmstrom PU
AD  - Department of Surgical Sciences, Uppsala University, Uppsala 75185, Sweden.
FAU - Malats, Nuria
AU  - Malats N
AD  - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
FAU - Real, Francisco X
AU  - Real FX
AD  - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain; Departament 
      de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona
      08003, Spain.
FAU - Zwarthoff, Ellen C
AU  - Zwarthoff EC
AD  - Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the
      Netherlands.
FAU - Orntoft, Torben Falck
AU  - Orntoft TF
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark.
FAU - Dyrskjot, Lars
AU  - Dyrskjot L
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200,
      Denmark. Electronic address: lars@clin.au.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160616
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 3.5.4.5 (APOBEC Deaminases)
SB  - IM
CIN - Cancer Cell. 2016 Jul 11;30(1):1-3. PMID: 27411578
CIN - Eur Urol. 2016 Dec;70(6):1076. PMID: 27567209
MH  - APOBEC Deaminases/genetics
MH  - Biomarkers, Tumor/*genetics
MH  - Cluster Analysis
MH  - Female
MH  - Gene Expression Profiling/*methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - *Mutation
MH  - Neoplasm Staging
MH  - RNA, Long Noncoding/genetics
MH  - Sequence Analysis, RNA/*methods
MH  - Survival Analysis
MH  - Urinary Bladder Neoplasms/*genetics/*pathology
EDAT- 2016/06/21 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/06/21 06:00
PHST- 2015/11/26 00:00 [received]
PHST- 2016/02/18 00:00 [revised]
PHST- 2016/05/13 00:00 [accepted]
PHST- 2016/06/21 06:00 [entrez]
PHST- 2016/06/21 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - S1535-6108(16)30209-4 [pii]
AID - 10.1016/j.ccell.2016.05.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016
      Jun 16.

PMID- 27300438
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias.
PG  - 922-934
LID - 10.1016/j.ccell.2016.05.003 [doi]
AB  - DNMT3A, the gene encoding the de novo DNA methyltransferase 3A, is among the most
      frequently mutated genes in hematologic malignancies. However, the mechanisms
      through which DNMT3A normally suppresses malignancy development are unknown.
      Here, we show that DNMT3A loss synergizes with the FLT3 internal tandem
      duplication in a dose-influenced fashion to generate rapid lethal lymphoid or
      myeloid leukemias similar to their human counterparts. Loss of DNMT3A leads to
      reduced DNA methylation, predominantly at hematopoietic enhancer regions in both 
      mouse and human samples. Myeloid and lymphoid diseases arise from transformed
      murine hematopoietic stem cells. Broadly, our findings support a role for DNMT3A 
      as a guardian of the epigenetic state at enhancer regions, critical for
      inhibition of leukemic transformation.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Yang, Liubin
AU  - Yang L
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      Texas 77030, USA.
AD  - Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston,
      Texas 77030, USA.
FAU - Rodriguez, Benjamin
AU  - Rodriguez B
AD  - Dan L. Duncan Cancer Center and Department of Molecular and Cellular Biology,
      Baylor College of Medicine, Houston, Texas 77030, USA.
FAU - Mayle, Allison
AU  - Mayle A
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      Texas 77030, USA.
AD  - Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston,
      Texas 77030, USA.
FAU - Park, Hyun Jung
AU  - Park HJ
AD  - Dan L. Duncan Cancer Center and Department of Molecular and Cellular Biology,
      Baylor College of Medicine, Houston, Texas 77030, USA.
FAU - Lin, Xueqiu
AU  - Lin X
AD  - Dan L. Duncan Cancer Center and Department of Molecular and Cellular Biology,
      Baylor College of Medicine, Houston, Texas 77030, USA.
AD  - Department of Bioinformatics, School of Life sciences and Technology, Tongji
      University, Shanghai 20092, China.
FAU - Luo, Min
AU  - Luo M
AD  - Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston,
      Texas 77030, USA.
FAU - Jeong, Mira
AU  - Jeong M
AD  - Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston,
      Texas 77030, USA.
FAU - Curry, Choladda V
AU  - Curry CV
AD  - Department of Pathology and Immunology, Texas Children's Hospital, Baylor College
      of Medicine, Houston, Texas 77030, USA.
FAU - Kim, Sang-Bae
AU  - Kim SB
AD  - Department of Systems Biology, Division of Cancer Medicine, University of Texas
      MD Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Ruau, David
AU  - Ruau D
AD  - Wellcome Trust/MRC Stem Cell Institute, Cambridge CB2 0XY, UK.
FAU - Zhang, Xiaotian
AU  - Zhang X
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      Texas 77030, USA.
AD  - Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston,
      Texas 77030, USA.
FAU - Zhou, Ting
AU  - Zhou T
AD  - Greehey Children's Cancer Research Institute and Department of Cellular and
      Structural Biology, University of Texas Health Science Center at San Antonio, San
      Antonio, TX 78229, USA.
FAU - Zhou, Michael
AU  - Zhou M
AD  - Rice University, Houston, Texas 77030, USA.
FAU - Rebel, Vivienne I
AU  - Rebel VI
AD  - Greehey Children's Cancer Research Institute and Department of Cellular and
      Structural Biology, University of Texas Health Science Center at San Antonio, San
      Antonio, TX 78229, USA.
FAU - Challen, Grant A
AU  - Challen GA
AD  - Division of Oncology, Washington University School of Medicine, St. Louis,
      Missouri 63110, USA.
FAU - Gottgens, Berthold
AU  - Gottgens B
AD  - Wellcome Trust/MRC Stem Cell Institute, Cambridge CB2 0XY, UK.
FAU - Lee, Ju-Seog
AU  - Lee JS
AD  - Department of Systems Biology, Division of Cancer Medicine, University of Texas
      MD Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Rau, Rachel
AU  - Rau R
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA.
FAU - Li, Wei
AU  - Li W
AD  - Dan L. Duncan Cancer Center and Department of Molecular and Cellular Biology,
      Baylor College of Medicine, Houston, Texas 77030, USA.
FAU - Goodell, Margaret A
AU  - Goodell MA
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      Texas 77030, USA.
AD  - Dan L. Duncan Cancer Center and Department of Molecular and Cellular Biology,
      Baylor College of Medicine, Houston, Texas 77030, USA.
AD  - Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston,
      Texas 77030, USA.
AD  - Department of Systems Biology, Division of Cancer Medicine, University of Texas
      MD Anderson Cancer Center, Houston, Texas 77030, USA.
LA  - eng
GR  - R01 CA193466/CA/NCI NIH HHS/United States
GR  - R56 DK092883/DK/NIDDK NIH HHS/United States
GR  - 12765/Cancer Research UK/United Kingdom
GR  - P50 CA126752/CA/NCI NIH HHS/United States
GR  - P30 CA125123/CA/NCI NIH HHS/United States
GR  - P30 AI036211/AI/NIAID NIH HHS/United States
GR  - K12 CA090433/CA/NCI NIH HHS/United States
GR  - S10 RR024574/RR/NCRR NIH HHS/United States
GR  - T32 DK060445/DK/NIDDK NIH HHS/United States
GR  - R01 CA183252/CA/NCI NIH HHS/United States
GR  - R01 HG007538/HG/NHGRI NIH HHS/United States
GR  - MC_PC_12009/Medical Research Council/United Kingdom
GR  - R01 DK092883/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
RN  - EC 2.1.1.37 (DNA methyltransferase 3A)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
EIN - Cancer Cell. 2016 Aug 8;30(2):363-365. PMID: 27505680
MH  - Animals
MH  - DNA (Cytosine-5-)-Methyltransferases/*genetics
MH  - *DNA Methylation
MH  - Enhancer Elements, Genetic
MH  - Epigenesis, Genetic
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockout Techniques
MH  - Humans
MH  - Leukemia/*genetics
MH  - Mice
MH  - Mutation
MH  - Neoplasms, Experimental
MH  - fms-Like Tyrosine Kinase 3/*genetics
PMC - PMC4908977
MID - NIHMS787337
EDAT- 2016/06/15 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/15 06:00
PHST- 2015/03/23 00:00 [received]
PHST- 2016/02/29 00:00 [revised]
PHST- 2016/05/10 00:00 [accepted]
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - 10.1016/j.ccell.2016.05.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):922-934. doi: 10.1016/j.ccell.2016.05.003.

PMID- 27300437
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - miRNA-126 Orchestrates an Oncogenic Program in B Cell Precursor Acute
      Lymphoblastic Leukemia.
PG  - 905-921
LID - S1535-6108(16)30212-4 [pii]
LID - 10.1016/j.ccell.2016.05.007 [doi]
AB  - MicroRNA (miRNA)-126 is a known regulator of hematopoietic stem cell quiescence. 
      We engineered murine hematopoiesis to express miRNA-126 across all
      differentiation stages. Thirty percent of mice developed monoclonal B cell
      leukemia, which was prevented or regressed when a tetracycline-repressible
      miRNA-126 cassette was switched off. Regression was accompanied by upregulation
      of cell-cycle regulators and B cell differentiation genes, and downregulation of 
      oncogenic signaling pathways. Expression of dominant-negative p53 delayed blast
      clearance upon miRNA-126 switch-off, highlighting the relevance of p53 inhibition
      in miRNA-126 addiction. Forced miRNA-126 expression in mouse and human
      progenitors reduced p53 transcriptional activity through regulation of multiple
      p53-related targets. miRNA-126 is highly expressed in a subset of human B-ALL,
      and antagonizing miRNA-126 in ALL xenograft models triggered apoptosis and
      reduced disease burden.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Nucera, Silvia
AU  - Nucera S
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy.
FAU - Giustacchini, Alice
AU  - Giustacchini A
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy; Vita Salute
      San Raffaele University, 20132 Milan, Italy.
FAU - Boccalatte, Francesco
AU  - Boccalatte F
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy; Vita Salute
      San Raffaele University, 20132 Milan, Italy.
FAU - Calabria, Andrea
AU  - Calabria A
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy.
FAU - Fanciullo, Cristiana
AU  - Fanciullo C
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy; Vita Salute
      San Raffaele University, 20132 Milan, Italy.
FAU - Plati, Tiziana
AU  - Plati T
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy.
FAU - Ranghetti, Anna
AU  - Ranghetti A
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy.
FAU - Garcia-Manteiga, Jose
AU  - Garcia-Manteiga J
AD  - Centre for Translational Genomics and Bioinformatics, IRCSS Ospedale San
      Raffaele, 20132 Milan, Italy.
FAU - Cittaro, Davide
AU  - Cittaro D
AD  - Centre for Translational Genomics and Bioinformatics, IRCSS Ospedale San
      Raffaele, 20132 Milan, Italy.
FAU - Benedicenti, Fabrizio
AU  - Benedicenti F
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy.
FAU - Lechman, Eric R
AU  - Lechman ER
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, 
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Dick, John E
AU  - Dick JE
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, 
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Ponzoni, Maurilio
AU  - Ponzoni M
AD  - Vita Salute San Raffaele University, 20132 Milan, Italy; Pathology Unit, IRCSS
      Ospedale San Raffaele, 20132 Milan, Italy.
FAU - Ciceri, Fabio
AU  - Ciceri F
AD  - Vita Salute San Raffaele University, 20132 Milan, Italy; Hematology and Bone
      Marrow Transplantation Unit, IRCSS Ospedale San Raffaele, 20132 Milan, Italy.
FAU - Montini, Eugenio
AU  - Montini E
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy.
FAU - Gentner, Bernhard
AU  - Gentner B
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy; Hematology 
      and Bone Marrow Transplantation Unit, IRCSS Ospedale San Raffaele, 20132 Milan,
      Italy. Electronic address: gentner.bernhard@hsr.it.
FAU - Naldini, Luigi
AU  - Naldini L
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy; Vita Salute
      San Raffaele University, 20132 Milan, Italy. Electronic address:
      naldini.luigi@hsr.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MIRN126 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Cell Cycle
MH  - Cell Differentiation
MH  - Gene Expression Regulation, Neoplastic
MH  - Hematopoietic Stem Cell Transplantation
MH  - Hematopoietic Stem Cells/*metabolism
MH  - Humans
MH  - Mice
MH  - MicroRNAs/*genetics/metabolism
MH  - Neoplasms, Experimental
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*genetics/metabolism/*pathology
MH  - Signal Transduction
MH  - Tumor Suppressor Protein p53/*genetics
MH  - Up-Regulation
EDAT- 2016/06/15 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/15 06:00
PHST- 2015/05/29 00:00 [received]
PHST- 2016/01/12 00:00 [revised]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30212-4 [pii]
AID - 10.1016/j.ccell.2016.05.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):905-921. doi: 10.1016/j.ccell.2016.05.007.

PMID- 27300436
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - DeltaNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC
      Inhibitors in Cancer.
PG  - 874-888
LID - S1535-6108(16)30206-9 [pii]
LID - 10.1016/j.ccell.2016.04.016 [doi]
AB  - DeltaNp63 is an oncogenic member of the p53 family and acts to inhibit the
      tumor-suppressive activities of the p53 family. By performing a chemical library 
      screen, we identified histone deacetylase inhibitors (HDACi) as agents reducing
      DeltaNp63 protein stability through the E3 ubiquitin ligase, Fbw7. DeltaNp63
      inhibition decreases the levels of its transcriptional target, DGCR8, and the
      maturation of let-7d and miR-128, which we found to be critical for HDACi
      function in vitro and in vivo. Our work identified Fbw7 as a predictive marker
      for HDACi response in squamous cell carcinomas and lymphomas, and unveiled let-7d
      and miR-128 as specific targets to bypass tumor resistance to HDACi treatment.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Napoli, Marco
AU  - Napoli M
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Venkatanarayan, Avinashnarayan
AU  - Venkatanarayan A
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate
      School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Raulji, Payal
AU  - Raulji P
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Meyers, Brooke A
AU  - Meyers BA
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Norton, William
AU  - Norton W
AD  - Department of Veterinary Medicine and Surgery, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Mangala, Lingegowda S
AU  - Mangala LS
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Center for RNA Interference and Non-Coding RNA, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Sood, Anil K
AU  - Sood AK
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Center for RNA Interference and Non-Coding RNA, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Rodriguez-Aguayo, Cristian
AU  - Rodriguez-Aguayo C
AD  - Center for RNA Interference and Non-Coding RNA, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Lopez-Berestein, Gabriel
AU  - Lopez-Berestein G
AD  - Center for RNA Interference and Non-Coding RNA, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Vin, Harina
AU  - Vin H
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Duvic, Madeleine
AU  - Duvic M
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Tetzlaff, Michael B
AU  - Tetzlaff MB
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Pathology, The
      University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 
      TX 77030, USA.
FAU - Curry, Jonathan L
AU  - Curry JL
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Pathology, The
      University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 
      TX 77030, USA.
FAU - Rook, Alain H
AU  - Rook AH
AD  - Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104,
      USA.
FAU - Abbas, Hussein A
AU  - Abbas HA
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Coarfa, Cristian
AU  - Coarfa C
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine, 1
      Baylor Plaza, Houston, TX 77030, USA.
FAU - Gunaratne, Preethi H
AU  - Gunaratne PH
AD  - Department of Biology and Biochemistry, University of Houston, Houston, TX 77204,
      USA.
FAU - Tsai, Kenneth Y
AU  - Tsai KY
AD  - Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate
      School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Dermatology, The
      University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 
      TX 77030, USA.
FAU - Flores, Elsa R
AU  - Flores ER
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate
      School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA; Center for RNA Interference and 
      Non-Coding RNA, The University of Texas MD Anderson Cancer Center, 1515 Holcombe 
      Boulevard, Houston, TX 77030, USA. Electronic address: elsaflores@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA136411/CA/NCI NIH HHS/United States
GR  - R01 CA160394/CA/NCI NIH HHS/United States
GR  - R35 CA197452/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DGCR8 protein, human)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (MIRN128 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (TP53 protein, human)
RN  - 0 (TP63 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (mirnlet7 microRNA, human)
SB  - IM
MH  - Animals
MH  - Carcinoma, Squamous Cell/*drug therapy/genetics
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm
MH  - Gene Expression Regulation, Neoplastic
MH  - Histone Deacetylase Inhibitors/*administration & dosage/pharmacology
MH  - Humans
MH  - Lymphoma/*drug therapy/genetics
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Small Molecule Libraries/administration & dosage/pharmacology
MH  - Transcription Factors/*genetics
MH  - Tumor Suppressor Protein p53/*genetics
MH  - Tumor Suppressor Proteins/*genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC4908836
MID - NIHMS785717
EDAT- 2016/06/15 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/15 06:00
PHST- 2015/05/27 00:00 [received]
PHST- 2015/12/04 00:00 [revised]
PHST- 2016/04/29 00:00 [accepted]
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30206-9 [pii]
AID - 10.1016/j.ccell.2016.04.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):874-888. doi: 10.1016/j.ccell.2016.04.016.

PMID- 27300435
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and
      Survival of Glioblastoma Stem Cells.
PG  - 859-873
LID - S1535-6108(16)30207-0 [pii]
LID - 10.1016/j.ccell.2016.05.002 [doi]
AB  - Glioblastomas (GBM) grow in a rich neurochemical milieu, but the impact of
      neurochemicals on GBM growth is largely unexplored. We interrogated 680
      neurochemical compounds in patient-derived GBM neural stem cells (GNS) to
      determine the effects on proliferation and survival. Compounds that modulate
      dopaminergic, serotonergic, and cholinergic signaling pathways selectively
      affected GNS growth. In particular, dopamine receptor D4 (DRD4) antagonists
      selectively inhibited GNS growth and promoted differentiation of normal neural
      stem cells. DRD4 antagonists inhibited the downstream effectors PDGFRbeta,
      ERK1/2, and mTOR and disrupted the autophagy-lysosomal pathway, leading to
      accumulation of autophagic vacuoles followed by G0/G1 arrest and apoptosis. These
      results demonstrate a role for neurochemical pathways in governing GBM stem cell 
      proliferation and suggest therapeutic approaches for GBM.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Dolma, Sonam
AU  - Dolma S
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada; Department of Laboratory Medicine and Pathobiology, University of
      Toronto, Toronto, ON M5S 1A8, Canada.
FAU - Selvadurai, Hayden J
AU  - Selvadurai HJ
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Lan, Xiaoyang
AU  - Lan X
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada.
FAU - Lee, Lilian
AU  - Lee L
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Kushida, Michelle
AU  - Kushida M
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Voisin, Veronique
AU  - Voisin V
AD  - Donnelly Center for Cellular and Biomedical Research, University of Toronto,
      Toronto M5S3E1, Canada.
FAU - Whetstone, Heather
AU  - Whetstone H
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - So, Milly
AU  - So M
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Aviv, Tzvi
AU  - Aviv T
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Park, Nicole
AU  - Park N
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada.
FAU - Zhu, Xueming
AU  - Zhu X
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Xu, ChangJiang
AU  - Xu C
AD  - Donnelly Center for Cellular and Biomedical Research, University of Toronto,
      Toronto M5S3E1, Canada.
FAU - Head, Renee
AU  - Head R
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Rowland, Katherine J
AU  - Rowland KJ
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada.
FAU - Bernstein, Mark
AU  - Bernstein M
AD  - Division of Neurosurgery, Toronto Western Hospital, University of Toronto,
      Toronto, ON M5T 2S8, Canada.
FAU - Clarke, Ian D
AU  - Clarke ID
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada; School of Interdisciplinary Studies, OCAD University, Toronto, ON M5T
      1W1, Canada.
FAU - Bader, Gary
AU  - Bader G
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8,
      Canada; Donnelly Center for Cellular and Biomedical Research, University of
      Toronto, Toronto M5S3E1, Canada.
FAU - Harrington, Lea
AU  - Harrington L
AD  - Department of Medicine, Institute for Research in Immunology and Cancer,
      Universite de Montreal, Montreal, QC H3T 1J4, Canada.
FAU - Brumell, John H
AU  - Brumell JH
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8,
      Canada; Cell Biology Program, SickKids, Toronto, ON M5G 0A4, Canada.
FAU - Tyers, Mike
AU  - Tyers M
AD  - Department of Medicine, Institute for Research in Immunology and Cancer,
      Universite de Montreal, Montreal, QC H3T 1J4, Canada.
FAU - Dirks, Peter B
AU  - Dirks PB
AD  - Arthur and Sonia Labatt Brain Tumor Research Center and Developmental and Stem
      Cell Biology, The Hospital for Sick Children (SickKids), Toronto, ON M5G 0A4,
      Canada; Department of Laboratory Medicine and Pathobiology, University of
      Toronto, Toronto, ON M5S 1A8, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5S 1A8, Canada; Division of Neurosurgery,
      SickKids, Toronto, ON M5G 1X8, Canada. Electronic address:
      peter.dirks@sickkids.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DRD4 protein, human)
RN  - 0 (Small Molecule Libraries)
RN  - 137750-34-6 (Receptors, Dopamine D4)
SB  - IM
CIN - Cancer Cell. 2016 Jun 13;29(6):778-80. PMID: 27300432
MH  - Animals
MH  - Autophagy
MH  - Brain Neoplasms/*drug therapy/metabolism
MH  - Cell Differentiation/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Glioblastoma/*drug therapy/metabolism
MH  - Humans
MH  - Mice
MH  - Neoplastic Stem Cells/cytology/drug effects
MH  - Neural Stem Cells/cytology/*drug effects/pathology
MH  - Receptors, Dopamine D4/antagonists & inhibitors/*metabolism
MH  - Signal Transduction/drug effects
MH  - Small Molecule Libraries/*administration & dosage/pharmacology
MH  - Survival Analysis
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
EDAT- 2016/06/15 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/15 06:00
PHST- 2014/10/31 00:00 [received]
PHST- 2016/03/18 00:00 [revised]
PHST- 2016/05/04 00:00 [accepted]
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30207-0 [pii]
AID - 10.1016/j.ccell.2016.05.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):859-873. doi: 10.1016/j.ccell.2016.05.002.

PMID- 27300434
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - YAP/TAZ at the Roots of Cancer.
PG  - 783-803
LID - S1535-6108(16)30210-0 [pii]
LID - 10.1016/j.ccell.2016.05.005 [doi]
AB  - YAP and TAZ are highly related transcriptional regulators pervasively activated
      in human malignancies. Recent work indicates that, remarkably, YAP/TAZ are
      essential for cancer initiation or growth of most solid tumors. Their activation 
      induces cancer stem cell attributes, proliferation, chemoresistance, and
      metastasis. YAP/TAZ are sensors of the structural and mechanical features of the 
      cell microenvironment. A number of cancer-associated extrinsic and intrinsic cues
      conspire to overrule the YAP-inhibiting microenvironment of normal tissues,
      including changes in mechanotransduction, inflammation, oncogenic signaling, and 
      regulation of the Hippo pathway. Addiction to YAP/TAZ thus potentially represents
      a central cancer vulnerability that may be exploited therapeutically.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zanconato, Francesca
AU  - Zanconato F
AD  - Department of Molecular Medicine, University of Padua School of Medicine, viale
      Colombo 3, 35126 Padua, Italy.
FAU - Cordenonsi, Michelangelo
AU  - Cordenonsi M
AD  - Department of Molecular Medicine, University of Padua School of Medicine, viale
      Colombo 3, 35126 Padua, Italy. Electronic address:
      michelangelo.cordenonsi@unipd.it.
FAU - Piccolo, Stefano
AU  - Piccolo S
AD  - Department of Molecular Medicine, University of Padua School of Medicine, viale
      Colombo 3, 35126 Padua, Italy. Electronic address: piccolo@bio.unipd.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Phosphoproteins)
RN  - 0 (TAZ protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - EC 2.7.11.1 (Hippo protein, human)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Animals
MH  - Cell Proliferation
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Mechanotransduction, Cellular
MH  - Neoplasms/*metabolism/*pathology/therapy
MH  - Neoplastic Stem Cells/metabolism
MH  - Phosphoproteins/*metabolism
MH  - Protein-Serine-Threonine Kinases/metabolism
MH  - Signal Transduction
MH  - Transcription Factors/*metabolism
MH  - Tumor Microenvironment
EDAT- 2016/06/15 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/01/25 00:00 [received]
PHST- 2016/04/26 00:00 [revised]
PHST- 2016/05/16 00:00 [accepted]
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30210-0 [pii]
AID - 10.1016/j.ccell.2016.05.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):783-803. doi: 10.1016/j.ccell.2016.05.005.

PMID- 27300433
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Tension and Transformation in Pancreas Cancer: Can Phenotype Break Free from the 
      Chrysalis of Genotype?
PG  - 780-782
LID - S1535-6108(16)30220-3 [pii]
LID - 10.1016/j.ccell.2016.05.015 [doi]
AB  - A recent study finds that impaired TGFbeta signaling can initiate a positive
      feedback loop between increasing ECM stiffness and epithelial cell contractility 
      in pancreas cancer. Even more surprising is the possibility that this phenotype
      can liberate the epithelium from dependence on the genetic events that
      transformed it.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - DuFort, Christopher C
AU  - DuFort CC
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Hingorani, Sunil R
AU  - Hingorani SR
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Public Health Sciences Division, Fred Hutchinson Cancer Research
      Center, Seattle, WA 98109, USA; Division of Medical Oncology, University of
      Washington School of Medicine, Seattle, WA 98195, USA. Electronic address:
      srh@fhcrc.org.
LA  - eng
GR  - R01 CA161112/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Animals
MH  - Epithelial Cells/*pathology
MH  - Epithelial-Mesenchymal Transition
MH  - Extracellular Matrix/*metabolism
MH  - Genotype
MH  - Humans
MH  - Pancreatic Neoplasms/genetics/metabolism/*pathology
MH  - Phenotype
MH  - Signal Transduction
MH  - Transforming Growth Factor beta/*metabolism
EDAT- 2016/06/15 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30220-3 [pii]
AID - 10.1016/j.ccell.2016.05.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):780-782. doi: 10.1016/j.ccell.2016.05.015.

PMID- 27300432
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Gliomas "Dope Up" for Growth.
PG  - 778-780
LID - S1535-6108(16)30215-X [pii]
LID - 10.1016/j.ccell.2016.05.010 [doi]
AB  - An emerging body of data highlights trophic functions of neurotransmitters on
      proliferation and differentiation of normal neural progenitors. In this issue of 
      Cancer Cell, Dolma et al. document pro-survival functions of a neurotransmitter
      receptor in glioma progenitor cells, with practical overtones for therapy.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Paolella, Brenton R
AU  - Paolella BR
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Stiles, Charles D
AU  - Stiles CD
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA. Electronic address: charles_stiles@dfci.harvard.edu.
LA  - eng
GR  - F32 CA180653/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Jun 13;29(6):859-73. PMID: 27300435
MH  - Brain Neoplasms
MH  - Cell Differentiation
MH  - Glioma/*therapy
MH  - Humans
MH  - *Stem Cells
EDAT- 2016/06/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30215-X [pii]
AID - 10.1016/j.ccell.2016.05.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):778-780. doi: 10.1016/j.ccell.2016.05.010.

PMID- 27300431
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170930
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - TRIM-ing Ligand Dependence in Castration-Resistant Prostate Cancer.
PG  - 776-778
LID - S1535-6108(16)30219-7 [pii]
LID - 10.1016/j.ccell.2016.05.014 [doi]
AB  - Prostate cancer is lethal when tumors evolve to activate androgen receptor
      signaling, which circumvents ligand-deprivation therapy. In this issue of Cancer 
      Cell, Groner et al. show that histone reader and transcription co-regulator
      TRIM24 occupies a central role in this evolution, nominating inhibitors of
      TRIM24's bromodomain as a new therapeutic avenue.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Patel, Lalit R
AU  - Patel LR
AD  - Department of Epigenetics and Molecular Carcinogenesis, Center for Cancer
      Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX
      77030, USA; University of Texas Graduate School of Biomedical Sciences at
      Houston, Houston, TX 77030, USA.
FAU - Barton, Michelle C
AU  - Barton MC
AD  - Department of Epigenetics and Molecular Carcinogenesis, Center for Cancer
      Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX
      77030, USA; University of Texas Graduate School of Biomedical Sciences at
      Houston, Houston, TX 77030, USA. Electronic address: mbarton@mdanderson.org.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Ligands)
RN  - 0 (Receptors, Androgen)
SB  - IM
CON - Cancer Cell. 2016 Jun 13;29(6):846-58. PMID: 27238081
MH  - Humans
MH  - Ligands
MH  - Male
MH  - Prostatic Neoplasms/drug therapy
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy
MH  - Receptors, Androgen/*genetics
MH  - Signal Transduction
MH  - Transcription, Genetic
EDAT- 2016/06/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30219-7 [pii]
AID - 10.1016/j.ccell.2016.05.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):776-778. doi: 10.1016/j.ccell.2016.05.014.

PMID- 27300430
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Pancreatic Cancer: Planning Ahead for Metastatic Spread.
PG  - 774-776
LID - S1535-6108(16)30218-5 [pii]
LID - 10.1016/j.ccell.2016.05.013 [doi]
AB  - Metastasis and therapy resistance are cardinal features of pancreatic ductal
      adenocarcinoma, a commonly lethal malignancy. In this issue of Cancer Cell,
      Steele et al. show that CXCR2 expression and neutrophils are required for
      metastasis. In mice treated with advanced disease, inhibiting both CXCR2 and PD1 
      cooperatively but not individually prolongs survival.
CI  - Copyright (c) 2016. Published by Elsevier Inc.
FAU - Stromnes, Ingunn M
AU  - Stromnes IM
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Program in Immunology, Fred Hutchinson Cancer Research Center,
      Seattle, WA 98109, USA. Electronic address: istromne@fredhutch.org.
FAU - Greenberg, Philip D
AU  - Greenberg PD
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Program in Immunology, Fred Hutchinson Cancer Research Center,
      Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington
      School of Medicine, Seattle, WA 98195, USA; Department of Immunology, University 
      of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address:
      pgreen@uw.edu.
LA  - eng
GR  - R01 CA033084/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Jun 13;29(6):832-45. PMID: 27265504
MH  - Adenocarcinoma
MH  - Animals
MH  - Carcinoma, Pancreatic Ductal/*metabolism
MH  - Pancreatic Neoplasms/*metabolism
EDAT- 2016/06/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30218-5 [pii]
AID - 10.1016/j.ccell.2016.05.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):774-776. doi: 10.1016/j.ccell.2016.05.013.

PMID- 27300429
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40
      Immunomodulatory mAb Efficacy.
PG  - 771-773
LID - S1535-6108(16)30214-8 [pii]
LID - 10.1016/j.ccell.2016.05.009 [doi]
AB  - In this issue of Cancer Cell, Dahan and colleagues demonstrate that modified Fc
      regions of agonistic anti-human CD40 mAbs can drastically increase their
      efficiency in a mouse pre-clinical model expressing human CD40 and IgG receptors.
      This study also highlights the fine balance between increased treatment efficacy 
      and secondary side effects.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Bruhns, Pierre
AU  - Bruhns P
AD  - Unit of Antibodies in Therapy and Pathology, Department of Immunology, Institut
      Pasteur, Paris 75015, France; INSERM, U1222, Paris 75015, France. Electronic
      address: bruhns@pasteur.fr.
FAU - Teillaud, Jean-Luc
AU  - Teillaud JL
AD  - Cordeliers Research Center-INSERM UMR-S 1138, "Cancer, Immune Control and Escape"
      Laboratory, Paris 75006, France; Paris Descartes-Paris 5 University, UMR-S 1138, 
      Paris 75006, France; Pierre et Marie Curie-Paris 6 University, UMR-S 1138, Paris 
      75006, France.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD40 Antigens)
RN  - 0 (Receptors, IgG)
SB  - IM
CON - Cancer Cell. 2016 Jun 13;29(6):820-31. PMID: 27265505
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology
MH  - *CD40 Antigens
MH  - Humans
MH  - *Receptors, IgG
EDAT- 2016/06/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30214-8 [pii]
AID - 10.1016/j.ccell.2016.05.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):771-773. doi: 10.1016/j.ccell.2016.05.009.

PMID- 27300428
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Gr(i)p the ER to Stress Out Melanoma.
PG  - 769-771
LID - S1535-6108(16)30211-2 [pii]
LID - 10.1016/j.ccell.2016.05.006 [doi]
AB  - Because of their elevated steady-state stress level, cancer cells are
      particularly sensitive to perturbation of mechanisms regulating protein
      homeostasis. In this issue, Cerezo and colleagues show that pharmacologic
      modulation of GRP78, master regulator of the unfolded protein response in the
      endoplasmic reticulum, can be exploited for cancer treatment.
CI  - Published by Elsevier Inc.
FAU - Xu, Wanping
AU  - Xu W
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      9000 Rockville Pike, Bethesda, MD 20892, USA.
FAU - Neckers, Len
AU  - Neckers L
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address:
      neckers@nih.gov.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Heat-Shock Proteins)
SB  - IM
CON - Cancer Cell. 2016 Jun 13;29(6):805-19. PMID: 27238082
MH  - Animals
MH  - Endoplasmic Reticulum/metabolism
MH  - *Endoplasmic Reticulum Stress
MH  - Heat-Shock Proteins/genetics
MH  - Homeostasis
MH  - Humans
MH  - Melanoma/metabolism
MH  - *Unfolded Protein Response
EDAT- 2016/06/15 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30211-2 [pii]
AID - 10.1016/j.ccell.2016.05.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):769-771. doi: 10.1016/j.ccell.2016.05.006.

PMID- 27265506
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20180213
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal
      Melanoma.
PG  - 889-904
LID - S1535-6108(16)30205-7 [pii]
LID - 10.1016/j.ccell.2016.04.015 [doi]
AB  - Activating mutations in Galphaq proteins, which form the alpha subunit of certain
      heterotrimeric G proteins, drive uveal melanoma oncogenesis by triggering
      multiple downstream signaling pathways, including PLC/PKC, Rho/Rac, and YAP. Here
      we show that the small GTPase ARF6 acts as a proximal node of oncogenic Galphaq
      signaling to induce all of these downstream pathways as well as beta-catenin
      signaling. ARF6 activates these diverse pathways through a common mechanism: the 
      trafficking of GNAQ and beta-catenin from the plasma membrane to cytoplasmic
      vesicles and the nucleus, respectively. Blocking ARF6 with a small-molecule
      inhibitor reduces uveal melanoma cell proliferation and tumorigenesis in a mouse 
      model, confirming the functional relevance of this pathway and suggesting a
      therapeutic strategy for Galpha-mediated diseases.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Yoo, Jae Hyuk
AU  - Yoo JH
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Department of Oncological
      Sciences, University of Utah, Salt Lake City, UT 84112, USA.
FAU - Shi, Dallas S
AU  - Shi DS
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Department of Human Genetics,
      University of Utah, Salt Lake City, UT 84112, USA.
FAU - Grossmann, Allie H
AU  - Grossmann AH
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Department of Pathology,
      University of Utah, Salt Lake City, UT 84112, USA; ARUP Laboratories, University 
      of Utah, Salt Lake City, UT 84112, USA.
FAU - Sorensen, Lise K
AU  - Sorensen LK
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA.
FAU - Tong, ZongZhong
AU  - Tong Z
AD  - Navigen Inc., 383 Colorow Drive, Salt Lake City, UT 84108, USA; Key Laboratory
      for Human Disease Gene Study, Sichuan Academy of Medical Sciences and Sichuan
      Provincial People's Hospital, Chengdu 610072, China.
FAU - Mleynek, Tara M
AU  - Mleynek TM
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA.
FAU - Rogers, Aaron
AU  - Rogers A
AD  - Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
FAU - Zhu, Weiquan
AU  - Zhu W
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Division of Cardiovascular
      Medicine, Department of Medicine, University of Utah, Salt Lake City, UT 84112,
      USA.
FAU - Richards, Jackson R
AU  - Richards JR
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Department of Oncological
      Sciences, University of Utah, Salt Lake City, UT 84112, USA.
FAU - Winter, Jacob M
AU  - Winter JM
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA.
FAU - Zhu, Jie
AU  - Zhu J
AD  - Department of Ophthalmology and Shiley Eye Institute, University of California,
      San Diego, La Jolla, CA 92093, USA.
FAU - Dunn, Christine
AU  - Dunn C
AD  - Navigen Inc., 383 Colorow Drive, Salt Lake City, UT 84108, USA.
FAU - Bajji, Ashok
AU  - Bajji A
AD  - Navigen Inc., 383 Colorow Drive, Salt Lake City, UT 84108, USA; VioGen
      Biosciences LLC, Salt Lake City, UT 84119, USA.
FAU - Shenderovich, Mark
AU  - Shenderovich M
AD  - Navigen Inc., 383 Colorow Drive, Salt Lake City, UT 84108, USA; Mol3D Research
      LLC, Salt Lake City, UT 84124, USA.
FAU - Mueller, Alan L
AU  - Mueller AL
AD  - Navigen Inc., 383 Colorow Drive, Salt Lake City, UT 84108, USA.
FAU - Woodman, Scott E
AU  - Woodman SE
AD  - Department of Melanoma Medical Oncology, Department of Systems Biology,
      University of Texas, MD Anderson Cancer Center, Houston, TX 77054, USA.
FAU - Harbour, J William
AU  - Harbour JW
AD  - Ocular Oncology Service, Bascom Palmer Eye Institute and Sylvester Comprehensive 
      Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136,
      USA.
FAU - Thomas, Kirk R
AU  - Thomas KR
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Division of Hematology,
      Department of Medicine, University of Utah, Salt Lake City, UT 84112, USA.
FAU - Odelberg, Shannon J
AU  - Odelberg SJ
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Division of Cardiovascular
      Medicine, Department of Medicine, University of Utah, Salt Lake City, UT 84112,
      USA; Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, 
      UT 84112, USA.
FAU - Ostanin, Kirill
AU  - Ostanin K
AD  - Navigen Inc., 383 Colorow Drive, Salt Lake City, UT 84108, USA. Electronic
      address: kostanin@nvgn.com.
FAU - Li, Dean Y
AU  - Li DY
AD  - Department of Medicine, Program in Molecular Medicine, University of Utah, 15
      North 2030 East, Salt Lake City, UT 84112, USA; Department of Oncological
      Sciences, University of Utah, Salt Lake City, UT 84112, USA; Department of Human 
      Genetics, University of Utah, Salt Lake City, UT 84112, USA; ARUP Laboratories,
      University of Utah, Salt Lake City, UT 84112, USA; Key Laboratory for Human
      Disease Gene Study, Sichuan Academy of Medical Sciences and Sichuan Provincial
      People's Hospital, Chengdu 610072, China; Division of Cardiovascular Medicine,
      Department of Medicine, University of Utah, Salt Lake City, UT 84112, USA;
      Department of Cardiology, VA Salt Lake City Health Care System, Salt Lake City,
      UT 84112, USA. Electronic address: dean.li@u2m2.utah.edu.
LA  - eng
GR  - R43 EY022516/EY/NEI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U54 HL112311/HL/NHLBI NIH HHS/United States
GR  - R01 CA163970/CA/NCI NIH HHS/United States
GR  - R43 AR063509/AR/NIAMS NIH HHS/United States
GR  - R01 AR064788/AR/NIAMS NIH HHS/United States
GR  - U01 NS083573/NS/NINDS NIH HHS/United States
GR  - R01 CA202778/CA/NCI NIH HHS/United States
GR  - R01 EY025342/EY/NEI NIH HHS/United States
GR  - R01 CA125970/CA/NCI NIH HHS/United States
GR  - UL1 TR000105/TR/NCATS NIH HHS/United States
GR  - R01 HL077671/HL/NHLBI NIH HHS/United States
GR  - R01 NS080893/NS/NINDS NIH HHS/United States
GR  - T32 HL007576/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001067/TR/NCATS NIH HHS/United States
GR  - R01 HL084516/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160602
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (GNAQ protein, human)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (beta Catenin)
RN  - EC 3.6.5.1 (GTP-Binding Protein alpha Subunits, Gq-G11)
RN  - EC 3.6.5.2 (ADP-Ribosylation Factors)
RN  - EC 3.6.5.2 (ADP-ribosylation factor 6)
RN  - Uveal melanoma
SB  - IM
MH  - ADP-Ribosylation Factors/antagonists & inhibitors/genetics/*metabolism
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Membrane/metabolism
MH  - Cell Nucleus/metabolism
MH  - Cell Proliferation/drug effects
MH  - Cytoplasm/metabolism
MH  - GTP-Binding Protein alpha Subunits, Gq-G11/*genetics/metabolism
MH  - Humans
MH  - Melanoma/*drug therapy/genetics/metabolism
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Protein Transport/drug effects
MH  - Signal Transduction/drug effects
MH  - Small Molecule Libraries/*administration & dosage/pharmacology
MH  - Uveal Neoplasms/*drug therapy/genetics/metabolism
MH  - beta Catenin/*metabolism
PMC - PMC5027844
MID - NIHMS784997
EDAT- 2016/06/07 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/07 06:00
PHST- 2015/04/19 00:00 [received]
PHST- 2015/10/16 00:00 [revised]
PHST- 2016/04/29 00:00 [accepted]
PHST- 2016/06/07 06:00 [entrez]
PHST- 2016/06/07 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30205-7 [pii]
AID - 10.1016/j.ccell.2016.04.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):889-904. doi: 10.1016/j.ccell.2016.04.015. Epub
      2016 Jun 2.

PMID- 27265505
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires
      Selective FcgammaR Engagement.
PG  - 820-831
LID - S1535-6108(16)30204-5 [pii]
LID - 10.1016/j.ccell.2016.05.001 [doi]
AB  - While engagement of the inhibitory Fcgamma-receptor (FcgammaR) IIB is an absolute
      requirement for in vivo antitumor activity of agonistic mouse anti-CD40
      monoclonal antibodies (mAbs), a similar requirement for human mAbs has been
      disputed. By using a mouse model humanized for its FcgammaRs and CD40, we
      revealed that FcgammaRIIB engagement is essential for the activity of human CD40 
      mAbs, while engagement of the activating FcgammaRIIA inhibits this activity. By
      engineering Fc variants with selective enhanced binding to FcgammaRIIB, but not
      to FcgammaRIIA, significantly improved antitumor immunity was observed. These
      findings highlight the necessity of optimizing the Fc domain for this class of
      therapeutic antibodies by using appropriate preclinical models that accurately
      reflect the unique affinities and cellular expression of human FcgammaR.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Dahan, Rony
AU  - Dahan R
AD  - Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230
      York Avenue, New York, NY 10021-6399, USA.
FAU - Barnhart, Bryan C
AU  - Barnhart BC
AD  - Bristol-Myers Squibb, Biologics Discovery California, 700 Bay Road, Redwood City,
      CA 94063, USA.
FAU - Li, Fubin
AU  - Li F
AD  - Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230
      York Avenue, New York, NY 10021-6399, USA.
FAU - Yamniuk, Aaron P
AU  - Yamniuk AP
AD  - Bristol-Myers Squibb, Department of Molecular Discovery Technologies, Princeton, 
      NJ 08543, USA.
FAU - Korman, Alan J
AU  - Korman AJ
AD  - Bristol-Myers Squibb, Biologics Discovery California, 700 Bay Road, Redwood City,
      CA 94063, USA.
FAU - Ravetch, Jeffrey V
AU  - Ravetch JV
AD  - Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230
      York Avenue, New York, NY 10021-6399, USA. Electronic address:
      ravetch@rockefeller.edu.
LA  - eng
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - R01 CA080757/CA/NCI NIH HHS/United States
GR  - R35 CA196620/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160602
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (CD40 Antigens)
RN  - 0 (Fc gamma receptor IIA)
RN  - 0 (Fc gamma receptor IIB)
RN  - 0 (Receptors, IgG)
SB  - IM
CIN - Cancer Cell. 2016 Jun 13;29(6):771-3. PMID: 27300429
MH  - Animals
MH  - Antibodies, Monoclonal/*administration & dosage/immunology
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/immunology
MH  - CD40 Antigens/*agonists
MH  - Cell Line, Tumor
MH  - Humans
MH  - Immunotherapy
MH  - Mice
MH  - Neoplasms/*drug therapy/immunology
MH  - Receptors, IgG/*immunology
MH  - Xenograft Model Antitumor Assays
PMC - PMC4975533
MID - NIHMS790808
EDAT- 2016/06/07 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/07 06:00
PHST- 2015/11/12 00:00 [received]
PHST- 2016/02/29 00:00 [revised]
PHST- 2016/05/02 00:00 [accepted]
PHST- 2016/06/07 06:00 [entrez]
PHST- 2016/06/07 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30204-5 [pii]
AID - 10.1016/j.ccell.2016.05.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):820-831. doi: 10.1016/j.ccell.2016.05.001. Epub
      2016 Jun 2.

PMID- 27265504
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in
      Pancreatic Ductal Adenocarcinoma.
PG  - 832-845
LID - S1535-6108(16)30203-3 [pii]
LID - 10.1016/j.ccell.2016.04.014 [doi]
AB  - CXCR2 has been suggested to have both tumor-promoting and tumor-suppressive
      properties. Here we show that CXCR2 signaling is upregulated in human pancreatic 
      cancer, predominantly in neutrophil/myeloid-derived suppressor cells, but rarely 
      in tumor cells. Genetic ablation or inhibition of CXCR2 abrogated metastasis, but
      only inhibition slowed tumorigenesis. Depletion of neutrophils/myeloid-derived
      suppressor cells also suppressed metastasis suggesting a key role for CXCR2 in
      establishing and maintaining the metastatic niche. Importantly, loss or
      inhibition of CXCR2 improved T cell entry, and combined inhibition of CXCR2 and
      PD1 in mice with established disease significantly extended survival. We show
      that CXCR2 signaling in the myeloid compartment can promote pancreatic
      tumorigenesis and is required for pancreatic cancer metastasis, making it an
      excellent therapeutic target.
CI  - Copyright (c) 2016 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Steele, Colin W
AU  - Steele CW
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - Karim, Saadia A
AU  - Karim SA
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - Leach, Joshua D G
AU  - Leach JDG
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - Bailey, Peter
AU  - Bailey P
AD  - Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
FAU - Upstill-Goddard, Rosanna
AU  - Upstill-Goddard R
AD  - Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
FAU - Rishi, Loveena
AU  - Rishi L
AD  - Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
FAU - Foth, Mona
AU  - Foth M
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - Bryson, Sheila
AU  - Bryson S
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - McDaid, Karen
AU  - McDaid K
AD  - Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK.
FAU - Wilson, Zena
AU  - Wilson Z
AD  - Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK.
FAU - Eberlein, Catherine
AU  - Eberlein C
AD  - Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK.
FAU - Candido, Juliana B
AU  - Candido JB
AD  - Centre for Cancer and Inflammation, Barts Cancer Institute, London EC1M 6BQ, UK.
FAU - Clarke, Mairi
AU  - Clarke M
AD  - Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
      G12 8QQ UK.
FAU - Nixon, Colin
AU  - Nixon C
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - Connelly, John
AU  - Connelly J
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - Jamieson, Nigel
AU  - Jamieson N
AD  - Department of Surgery, Glasgow Royal Infirmary, Glasgow G4 0SF, UK.
FAU - Carter, C Ross
AU  - Carter CR
AD  - Department of Surgery, Glasgow Royal Infirmary, Glasgow G4 0SF, UK.
FAU - Balkwill, Frances
AU  - Balkwill F
AD  - Centre for Cancer and Inflammation, Barts Cancer Institute, London EC1M 6BQ, UK.
FAU - Chang, David K
AU  - Chang DK
AD  - Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
FAU - Evans, T R Jeffry
AU  - Evans TRJ
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61
      1BD, UK.
FAU - Strathdee, Douglas
AU  - Strathdee D
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK.
FAU - Biankin, Andrew V
AU  - Biankin AV
AD  - Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
FAU - Nibbs, Robert J B
AU  - Nibbs RJB
AD  - Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
      G12 8QQ UK.
FAU - Barry, Simon T
AU  - Barry ST
AD  - Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK.
FAU - Sansom, Owen J
AU  - Sansom OJ
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61
      1BD, UK. Electronic address: o.sansom@beatson.gla.ac.uk.
FAU - Morton, Jennifer P
AU  - Morton JP
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow
      G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61
      1BD, UK.
LA  - eng
GR  - 11650/Cancer Research UK/United Kingdom
GR  - G0900992/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160602
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Receptors, Interleukin-8B)
RN  - 0 (Small Molecule Libraries)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 52CMI0WC3Y (atezolizumab)
RN  - B76N6SBZ8R (gemcitabine)
SB  - IM
CIN - Cancer Cell. 2016 Jun 13;29(6):774-6. PMID: 27300430
MH  - Animals
MH  - Antibodies, Monoclonal/*administration & dosage/pharmacology
MH  - Carcinoma, Pancreatic Ductal/*drug therapy/genetics/pathology
MH  - Cell Line, Tumor
MH  - Deoxycytidine/administration & dosage/analogs & derivatives/pharmacology
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Immunotherapy
MH  - Mice
MH  - Neoplasm Metastasis
MH  - Pancreatic Neoplasms/*drug therapy/genetics/pathology
MH  - Prognosis
MH  - Receptors, Interleukin-8B/antagonists & inhibitors/*genetics
MH  - Signal Transduction
MH  - Small Molecule Libraries/administration & dosage/pharmacology
MH  - Survival Analysis
MH  - Up-Regulation
MH  - Xenograft Model Antitumor Assays
PMC - PMC4912354
EDAT- 2016/06/07 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/06/07 06:00
PHST- 2015/08/22 00:00 [received]
PHST- 2016/02/09 00:00 [revised]
PHST- 2016/04/29 00:00 [accepted]
PHST- 2016/06/07 06:00 [entrez]
PHST- 2016/06/07 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30203-3 [pii]
AID - 10.1016/j.ccell.2016.04.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub
      2016 Jun 2.

PMID- 27238082
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF
      Inhibitor Resistance.
PG  - 805-819
LID - S1535-6108(16)30171-4 [pii]
LID - 10.1016/j.ccell.2016.04.013 [doi]
AB  - We have discovered and developed a series of molecules (thiazole
      benzenesulfonamides). HA15, the lead compound of this series, displayed
      anti-cancerous activity on all melanoma cells tested, including cells isolated
      from patients and cells that developed resistance to BRAF inhibitors. Our
      molecule displayed activity against other liquid and solid tumors. HA15 also
      exhibited strong efficacy in xenograft mouse models with melanoma cells either
      sensitive or resistant to BRAF inhibitors. Transcriptomic, proteomic, and
      biochemical studies identified the chaperone BiP/GRP78/HSPA5 as the specific
      target of HA15 and demonstrated that the interaction increases ER stress, leading
      to melanoma cell death by concomitant induction of autophagic and apoptotic
      mechanisms.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Cerezo, Michael
AU  - Cerezo M
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Lehraiki, Abdelali
AU  - Lehraiki A
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Millet, Antoine
AU  - Millet A
AD  - Institut de Chimie de Nice UMR UNS-CNRS 7272, Universite Nice Sophia Antipolis,
      Parc Valrose, 06108 Nice cedex 2, France.
FAU - Rouaud, Florian
AU  - Rouaud F
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Plaisant, Magali
AU  - Plaisant M
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Jaune, Emilie
AU  - Jaune E
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Botton, Thomas
AU  - Botton T
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Ronco, Cyril
AU  - Ronco C
AD  - Institut de Chimie de Nice UMR UNS-CNRS 7272, Universite Nice Sophia Antipolis,
      Parc Valrose, 06108 Nice cedex 2, France.
FAU - Abbe, Patricia
AU  - Abbe P
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Amdouni, Hella
AU  - Amdouni H
AD  - Institut de Chimie de Nice UMR UNS-CNRS 7272, Universite Nice Sophia Antipolis,
      Parc Valrose, 06108 Nice cedex 2, France.
FAU - Passeron, Thierry
AU  - Passeron T
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France; Service de Dermatologie, Hopital Archet II, CHU, 06204 Nice,
      France.
FAU - Hofman, Veronique
AU  - Hofman V
AD  - UFR de Medecine, Universite de Nice Sophia Antipolis, 06000 Nice, France;
      Institute of Research on Cancer and Ageing of Nice (IRCAN), INSERM U1081, CNRS
      UMR7284, Nice 06107, France; Laboratoire de pathologie clinique et experimentale 
      et Hospital-related biobank (BB-0033-00025), Hopital Pasteur, 06002 Nice, France.
FAU - Mograbi, Baharia
AU  - Mograbi B
AD  - UFR de Medecine, Universite de Nice Sophia Antipolis, 06000 Nice, France;
      Institute of Research on Cancer and Ageing of Nice (IRCAN), INSERM U1081, CNRS
      UMR7284, Nice 06107, France.
FAU - Dabert-Gay, Anne-Sophie
AU  - Dabert-Gay AS
AD  - UFR de Medecine, Universite de Nice Sophia Antipolis, 06000 Nice, France; CNRS
      UMR 7275, Institut de Pharmacologie Moleculaire et Cellulaire (IPMC), 06560
      Sophia Antipolis, France.
FAU - Debayle, Delphine
AU  - Debayle D
AD  - UFR de Medecine, Universite de Nice Sophia Antipolis, 06000 Nice, France; CNRS
      UMR 7275, Institut de Pharmacologie Moleculaire et Cellulaire (IPMC), 06560
      Sophia Antipolis, France.
FAU - Alcor, Damien
AU  - Alcor D
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France.
FAU - Rabhi, Nabil
AU  - Rabhi N
AD  - University Lille, CNRS, Institut Pasteur de Lille, UMR 8199 - EGID, 59000 Lille, 
      France.
FAU - Annicotte, Jean-Sebastien
AU  - Annicotte JS
AD  - University Lille, CNRS, Institut Pasteur de Lille, UMR 8199 - EGID, 59000 Lille, 
      France.
FAU - Heliot, Laurent
AU  - Heliot L
AD  - Equipe Biophotonique Cellulaire Fonctionnelle, Laboratoire de Physique des
      Lasers, Atomes et Molecules (PhLAM) GDR 2588, 59658 Villeneuve d'Ascq, France.
FAU - Gonzalez-Pisfil, Mariano
AU  - Gonzalez-Pisfil M
AD  - Equipe Biophotonique Cellulaire Fonctionnelle, Laboratoire de Physique des
      Lasers, Atomes et Molecules (PhLAM) GDR 2588, 59658 Villeneuve d'Ascq, France.
FAU - Robert, Caroline
AU  - Robert C
AD  - Department of Dermatology, Cancer Campus, Gustave Roussy Institute, 114, rue
      Edouard-Vaillant, 94805 Villejuif, France.
FAU - Morera, Solange
AU  - Morera S
AD  - Institute for Integrative Biology of the Cell (I2BC), CNRS CEA University
      Paris-Sud, Universite Paris-Saclay, Gif-sur-Yvette 91198, France.
FAU - Vigouroux, Armelle
AU  - Vigouroux A
AD  - Institute for Integrative Biology of the Cell (I2BC), CNRS CEA University
      Paris-Sud, Universite Paris-Saclay, Gif-sur-Yvette 91198, France.
FAU - Gual, Philippe
AU  - Gual P
AD  - INSERM, U1065, Team 8, Centre Mediterraneen de Medecine Moleculaire (C3M), 151
      route de Saint Antoine de Ginestiere, 06204 Nice cedex 3, France.
FAU - Ali, Maruf M U
AU  - Ali MMU
AD  - Department of Life Sciences, Imperial College London, South Kensington Campus,
      London SW7 2AZ, UK.
FAU - Bertolotto, Corine
AU  - Bertolotto C
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France; Service de Dermatologie, Hopital Archet II, CHU, 06204 Nice,
      France.
FAU - Hofman, Paul
AU  - Hofman P
AD  - UFR de Medecine, Universite de Nice Sophia Antipolis, 06000 Nice, France;
      Institute of Research on Cancer and Ageing of Nice (IRCAN), INSERM U1081, CNRS
      UMR7284, Nice 06107, France; Laboratoire de pathologie clinique et experimentale 
      et Hospital-related biobank (BB-0033-00025), Hopital Pasteur, 06002 Nice, France.
FAU - Ballotti, Robert
AU  - Ballotti R
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France; Service de Dermatologie, Hopital Archet II, CHU, 06204 Nice,
      France.
FAU - Benhida, Rachid
AU  - Benhida R
AD  - Institut de Chimie de Nice UMR UNS-CNRS 7272, Universite Nice Sophia Antipolis,
      Parc Valrose, 06108 Nice cedex 2, France. Electronic address: benhida@unice.fr.
FAU - Rocchi, Stephane
AU  - Rocchi S
AD  - INSERM, U1065, Equipe Biologie et Pathologie des cellules melanocytaire: de la
      pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire
      (C3M), Batiment ARCHIMED, 151 route de Saint Antoine de Ginestiere, 06204 Nice
      cedex 3, France; UFR de Medecine, Universite de Nice Sophia Antipolis, 06000
      Nice, France; Service de Dermatologie, Hopital Archet II, CHU, 06204 Nice,
      France. Electronic address: srocchi@unice.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160526
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Sulfonamides)
RN  - 0 (molecular chaperone GRP78)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CIN - Cancer Cell. 2016 Jun 13;29(6):769-71. PMID: 27300428
EIN - Cancer Cell. 2016 Jul 11;30(1):183. PMID: 27479035
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Endoplasmic Reticulum Stress/*drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Heat-Shock Proteins/genetics/metabolism
MH  - Humans
MH  - Melanoma/*drug therapy/metabolism
MH  - Mice
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors
MH  - Sulfonamides/*administration & dosage/pharmacology
MH  - Xenograft Model Antitumor Assays
EDAT- 2016/05/31 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/05/31 06:00
PHST- 2015/07/23 00:00 [received]
PHST- 2016/02/15 00:00 [revised]
PHST- 2016/04/27 00:00 [accepted]
PHST- 2016/05/31 06:00 [entrez]
PHST- 2016/05/31 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30171-4 [pii]
AID - 10.1016/j.ccell.2016.04.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):805-819. doi: 10.1016/j.ccell.2016.04.013. Epub
      2016 May 26.

PMID- 27238081
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170811
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
PG  - 846-858
LID - S1535-6108(16)30170-2 [pii]
LID - 10.1016/j.ccell.2016.04.012 [doi]
AB  - Androgen receptor (AR) signaling is a key driver of prostate cancer (PC). While
      androgen-deprivation therapy is transiently effective in advanced disease, tumors
      often progress to a lethal castration-resistant state (CRPC). We show that
      recurrent PC-driver mutations in speckle-type POZ protein (SPOP) stabilize the
      TRIM24 protein, which promotes proliferation under low androgen conditions.
      TRIM24 augments AR signaling, and AR and TRIM24 co-activated genes are
      significantly upregulated in CRPC. Expression of TRIM24 protein increases from
      primary PC to CRPC, and both TRIM24 protein levels and the AR/TRIM24 gene
      signature predict disease recurrence. Analyses in CRPC cells reveal that the
      TRIM24 bromodomain and the AR-interacting motif are essential to support
      proliferation. These data provide a rationale for therapeutic TRIM24 targeting in
      SPOP mutant and CRPC patients.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Groner, Anna C
AU  - Groner AC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Cato, Laura
AU  - Cato L
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - de Tribolet-Hardy, Jonas
AU  - de Tribolet-Hardy J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Bernasocchi, Tiziano
AU  - Bernasocchi T
AD  - Institute of Oncology Research, Bellinzona 6500, Switzerland.
FAU - Janouskova, Hana
AU  - Janouskova H
AD  - Institute of Oncology Research, Bellinzona 6500, Switzerland.
FAU - Melchers, Diana
AU  - Melchers D
AD  - PamGene International, Den Bosch 521HH, the Netherlands.
FAU - Houtman, Rene
AU  - Houtman R
AD  - PamGene International, Den Bosch 521HH, the Netherlands.
FAU - Cato, Andrew C B
AU  - Cato ACB
AD  - Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76344
      Eggenstein-Leopoldshafen, Germany.
FAU - Tschopp, Patrick
AU  - Tschopp P
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02215, USA.
FAU - Gu, Lei
AU  - Gu L
AD  - Division of Newborn Medicine, Children's Hospital Boston and Department of Cell
      Biology, Harvard Medical School, Boston, MA 02215, USA.
FAU - Corsinotti, Andrea
AU  - Corsinotti A
AD  - MRC Centre for Regenerative Medicine, Institute for Stem Cell Research, School of
      Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory 
      Animal Resource Center, Department of Anatomy and Embryology, Faculty of
      Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575,
      Japan.
FAU - Zhong, Qing
AU  - Zhong Q
AD  - Institute of Surgical Pathology, University Hospital Zurich, Zurich 8091,
      Switzerland.
FAU - Fankhauser, Christian
AU  - Fankhauser C
AD  - Institute of Surgical Pathology, University Hospital Zurich, Zurich 8091,
      Switzerland; Department of Urology, University Hospital Zurich, Zurich 8091,
      Switzerland.
FAU - Fritz, Christine
AU  - Fritz C
AD  - Institute of Surgical Pathology, University Hospital Zurich, Zurich 8091,
      Switzerland.
FAU - Poyet, Cedric
AU  - Poyet C
AD  - Department of Urology, University Hospital Zurich, Zurich 8091, Switzerland.
FAU - Wagner, Ulrich
AU  - Wagner U
AD  - Institute of Surgical Pathology, University Hospital Zurich, Zurich 8091,
      Switzerland.
FAU - Guo, Tiannan
AU  - Guo T
AD  - Department of Biology, Institute of Molecular Systems Biology, Eidgenossische
      Technische Hochschule (ETH) Zurich, Zurich 8093, Switzerland.
FAU - Aebersold, Ruedi
AU  - Aebersold R
AD  - Department of Biology, Institute of Molecular Systems Biology, Eidgenossische
      Technische Hochschule (ETH) Zurich, Zurich 8093, Switzerland; Faculty of Science,
      University of Zurich, Zurich 8057, Switzerland.
FAU - Garraway, Levi A
AU  - Garraway LA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; The Broad Institute of Harvard and MIT, Cambridge,
      MA 02142, USA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, 
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Wild, Peter J
AU  - Wild PJ
AD  - Institute of Surgical Pathology, University Hospital Zurich, Zurich 8091,
      Switzerland.
FAU - Theurillat, Jean-Philippe
AU  - Theurillat JP
AD  - Institute of Oncology Research, Bellinzona 6500, Switzerland; The Broad Institute
      of Harvard and MIT, Cambridge, MA 02142, USA; Centre Hospitalier Universitaire
      Vaudois, University of Lausanne, Lausanne 1011, Switzerland. Electronic address: 
      jeanp_theurillat@ior.iosi.ch.
FAU - Brown, Myles
AU  - Brown M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
      Electronic address: myles_brown@dfci.harvard.edu.
LA  - eng
GR  - P01 CA163227/CA/NCI NIH HHS/United States
GR  - P50 CA090381/CA/NCI NIH HHS/United States
GR  - T32 CA009172/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160526
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (AR protein, human)
RN  - 0 (Carrier Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Repressor Proteins)
RN  - 0 (SPOP protein, human)
RN  - 0 (TRIM24 protein, human)
SB  - IM
CIN - Cancer Cell. 2016 Jun 13;29(6):776-8. PMID: 27300431
MH  - Animals
MH  - Carrier Proteins/chemistry/*genetics/metabolism
MH  - Cell Proliferation
MH  - Disease Progression
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Neoplasm Transplantation
MH  - Nuclear Proteins/*genetics
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology
MH  - Prostatic Neoplasms, Castration-Resistant/*genetics/metabolism/pathology
MH  - Receptors, Androgen/chemistry/*genetics/metabolism
MH  - Repressor Proteins/*genetics
MH  - Signal Transduction
PMC - PMC5124371
MID - NIHMS783994
EDAT- 2016/05/31 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/05/31 06:00
PHST- 2015/06/11 00:00 [received]
PHST- 2015/12/15 00:00 [revised]
PHST- 2016/04/27 00:00 [accepted]
PHST- 2016/05/31 06:00 [entrez]
PHST- 2016/05/31 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30170-2 [pii]
AID - 10.1016/j.ccell.2016.04.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):846-858. doi: 10.1016/j.ccell.2016.04.012. Epub
      2016 May 26.

PMID- 27211490
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20171214
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 6
DP  - 2016 Jun 13
TI  - p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by
      Maintaining Survival of Stressed HCC-Initiating Cells.
PG  - 935-948
LID - S1535-6108(16)30164-7 [pii]
LID - 10.1016/j.ccell.2016.04.006 [doi]
AB  - p62 is a ubiquitin-binding autophagy receptor and signaling protein that
      accumulates in premalignant liver diseases and most hepatocellular carcinomas
      (HCCs). Although p62 was proposed to participate in the formation of benign
      adenomas in autophagy-deficient livers, its role in HCC initiation was not
      explored. Here we show that p62 is necessary and sufficient for HCC induction in 
      mice and that its high expression in non-tumor human liver predicts rapid HCC
      recurrence after curative ablation. High p62 expression is needed for activation 
      of NRF2 and mTORC1, induction of c-Myc, and protection of HCC-initiating cells
      from oxidative stress-induced death.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Umemura, Atsushi
AU  - Umemura A
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA; Department of Molecular Gastroenterology and Hepatology, Graduate
      School of Medical Science, Kyoto Prefectural University of Medicine, 465
      Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - He, Feng
AU  - He F
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA.
FAU - Taniguchi, Koji
AU  - Taniguchi K
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA; Department of Surgery and Science, Graduate School of Medical
      Sciences, Kyushu University, Fukuoka 812-8582, Japan; Department of Microbiology 
      and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan.
FAU - Nakagawa, Hayato
AU  - Nakagawa H
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA; Department of Gastroenterology, Graduate School of Medicine,
      University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
FAU - Yamachika, Shinichiro
AU  - Yamachika S
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA.
FAU - Font-Burgada, Joan
AU  - Font-Burgada J
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA.
FAU - Zhong, Zhenyu
AU  - Zhong Z
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA.
FAU - Subramaniam, Shankar
AU  - Subramaniam S
AD  - Departments of Bioengineering, Cellular and Molecular Medicine, and Chemistry and
      Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA.
FAU - Raghunandan, Sindhu
AU  - Raghunandan S
AD  - Departments of Bioengineering, Cellular and Molecular Medicine, and Chemistry and
      Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA.
FAU - Duran, Angeles
AU  - Duran A
AD  - Cancer Metabolism and Signaling Networks Program, Sanford-Burnham-Prebys Medical 
      Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Linares, Juan F
AU  - Linares JF
AD  - Cancer Metabolism and Signaling Networks Program, Sanford-Burnham-Prebys Medical 
      Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Reina-Campos, Miguel
AU  - Reina-Campos M
AD  - Cancer Metabolism and Signaling Networks Program, Sanford-Burnham-Prebys Medical 
      Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Umemura, Shiori
AU  - Umemura S
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA; Department of Obstetrics and Gynecology, Graduate School of Medical
      Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho,
      Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - Valasek, Mark A
AU  - Valasek MA
AD  - Department of Pathology, University of California San Diego, 9500 Gilman Drive,
      La Jolla, CA 92093, USA.
FAU - Seki, Ekihiro
AU  - Seki E
AD  - Department of Medicine, University of California San Diego, 9500 Gilman Drive, La
      Jolla, CA 92093, USA; Division of Gastroenterology, Department of Medicine,
      Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
FAU - Yamaguchi, Kanji
AU  - Yamaguchi K
AD  - Department of Molecular Gastroenterology and Hepatology, Graduate School of
      Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho,
      Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - Koike, Kazuhiko
AU  - Koike K
AD  - Department of Gastroenterology, Graduate School of Medicine, University of Tokyo,
      7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
FAU - Itoh, Yoshito
AU  - Itoh Y
AD  - Department of Molecular Gastroenterology and Hepatology, Graduate School of
      Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho,
      Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - Diaz-Meco, Maria T
AU  - Diaz-Meco MT
AD  - Cancer Metabolism and Signaling Networks Program, Sanford-Burnham-Prebys Medical 
      Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Moscat, Jorge
AU  - Moscat J
AD  - Cancer Metabolism and Signaling Networks Program, Sanford-Burnham-Prebys Medical 
      Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
      Electronic address: jmoscat@sbpdiscovery.org.
FAU - Karin, Michael
AU  - Karin M
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA
      92093, USA; Department of Pathology, University of California San Diego, 9500
      Gilman Drive, La Jolla, CA 92093, USA. Electronic address: karinoffice@ucsd.edu.
LA  - eng
GR  - R01 DK108743/DK/NIDDK NIH HHS/United States
GR  - R01 CA192642/CA/NCI NIH HHS/United States
GR  - P01 DK098108/DK/NIDDK NIH HHS/United States
GR  - P42 ES010337/ES/NIEHS NIH HHS/United States
GR  - R01 CA172025/CA/NCI NIH HHS/United States
GR  - R01 CA211794/CA/NCI NIH HHS/United States
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - P30 CA023100/CA/NCI NIH HHS/United States
GR  - R01 CA118165/CA/NCI NIH HHS/United States
GR  - R01 CA163798/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160519
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MYC protein, human)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (SQSTM1 protein, human)
RN  - 0 (Sequestosome-1 Protein)
RN  - 0 (Sqstm1 protein, mouse)
RN  - 3IQ78TTX1A (Diethylnitrosamine)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
SB  - IM
MH  - Animals
MH  - Carcinoma, Hepatocellular/*genetics/pathology
MH  - Cell Survival
MH  - Diethylnitrosamine/adverse effects
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Liver Neoplasms/*genetics/pathology
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mice
MH  - Mice, Transgenic
MH  - Multiprotein Complexes/genetics
MH  - NF-E2-Related Factor 2/genetics
MH  - Neoplasms, Experimental
MH  - Neoplastic Stem Cells/*cytology/drug effects
MH  - Proto-Oncogene Proteins c-myc/genetics
MH  - Sequestosome-1 Protein/*genetics
MH  - TOR Serine-Threonine Kinases/genetics
MH  - *Up-Regulation
PMC - PMC4907799
MID - NIHMS781453
EDAT- 2016/05/24 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/05/24 06:00
PHST- 2015/12/10 00:00 [received]
PHST- 2016/02/01 00:00 [revised]
PHST- 2016/04/18 00:00 [accepted]
PHST- 2016/05/24 06:00 [entrez]
PHST- 2016/05/24 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
AID - S1535-6108(16)30164-7 [pii]
AID - 10.1016/j.ccell.2016.04.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jun 13;29(6):935-948. doi: 10.1016/j.ccell.2016.04.006. Epub
      2016 May 19.

PMID- 27165747
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits
      Broad Anticancer Activity.
PG  - 767-768
LID - S1535-6108(16)30163-5 [pii]
LID - 10.1016/j.ccell.2016.04.005 [doi]
FAU - Jing, Hui
AU  - Jing H
FAU - Hu, Jing
AU  - Hu J
FAU - He, Bin
AU  - He B
FAU - Negron Abril, Yashira L
AU  - Negron Abril YL
FAU - Stupinski, Jack
AU  - Stupinski J
FAU - Weiser, Keren
AU  - Weiser K
FAU - Carbonaro, Marisa
AU  - Carbonaro M
FAU - Chiang, Ying-Ling
AU  - Chiang YL
FAU - Southard, Teresa
AU  - Southard T
FAU - Giannakakou, Paraskevi
AU  - Giannakakou P
FAU - Weiss, Robert S
AU  - Weiss RS
FAU - Lin, Hening
AU  - Lin H
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20160509
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Mar 14;29(3):297-310. PMID: 26977881
EDAT- 2016/05/12 06:00
MHDA- 2016/05/12 06:01
CRDT- 2016/05/12 06:00
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2016/05/12 06:01 [medline]
PHST- 2016/05/12 06:00 [entrez]
AID - S1535-6108(16)30163-5 [pii]
AID - 10.1016/j.ccell.2016.04.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):767-768. doi: 10.1016/j.ccell.2016.04.005. Epub
      2016 May 9.

PMID- 27165746
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering
      Lipid Metabolism.
PG  - 751-766
LID - S1535-6108(16)30161-1 [pii]
LID - 10.1016/j.ccell.2016.04.003 [doi]
AB  - Large-scale heterozygous deletions are a hallmark of cancer genomes. The
      concomitant loss of multiple genes creates vulnerabilities that are impossible to
      reveal through the study of individual genes. To delineate the functional outcome
      of chromosome 8p loss of heterozygosity (LOH), a common aberration in breast
      cancer, we modeled 8p LOH using TALEN-based genomic engineering. 8p LOH alters
      fatty acid and ceramide metabolism. The shift in lipid metabolism triggers
      invasiveness and confers tumor growth under stress conditions due to increased
      autophagy. The resistance of 8p-deleted cells to chemotherapeutic drugs concurs
      with poorer survival rates of breast cancer patients harboring an 8p LOH. The
      autophagy dependency of 8p-deleted cells provides the rational basis for
      treatment of 8p LOH tumors with autophagy inhibitors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Cai, Yanyan
AU  - Cai Y
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium.
FAU - Crowther, Jonathan
AU  - Crowther J
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium.
FAU - Pastor, Tibor
AU  - Pastor T
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium.
FAU - Abbasi Asbagh, Layka
AU  - Abbasi Asbagh L
AD  - Department of Oncology, KU Leuven, Leuven 3000, Belgium.
FAU - Baietti, Maria Francesca
AU  - Baietti MF
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium.
FAU - De Troyer, Magdalena
AU  - De Troyer M
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium.
FAU - Vazquez, Iria
AU  - Vazquez I
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium.
FAU - Talebi, Ali
AU  - Talebi A
AD  - Department of Oncology, KU Leuven, Leuven 3000, Belgium.
FAU - Renzi, Fabrizio
AU  - Renzi F
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium.
FAU - Dehairs, Jonas
AU  - Dehairs J
AD  - Department of Oncology, KU Leuven, Leuven 3000, Belgium.
FAU - Swinnen, Johannes V
AU  - Swinnen JV
AD  - Department of Oncology, KU Leuven, Leuven 3000, Belgium.
FAU - Sablina, Anna A
AU  - Sablina AA
AD  - VIB Center for the Biology of Disease, VIB, Leuven 3000, Belgium; Department of
      Human Genetics, KU Leuven, Leuven 3000, Belgium. Electronic address:
      anna.sablina@cme.vib-kuleuven.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
SB  - IM
CIN - Cancer Cell. 2016 May 9;29(5):617-9. PMID: 27165739
MH  - Antineoplastic Agents/pharmacology
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Cell Hypoxia
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects/genetics
MH  - Cell Survival/drug effects/genetics
MH  - Cell Transformation, Neoplastic/drug effects/genetics
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 8/*genetics
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Kaplan-Meier Estimate
MH  - Lipid Metabolism/drug effects/*genetics
MH  - Multivariate Analysis
MH  - Prognosis
MH  - RNA Interference
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Spheroids, Cellular/drug effects/metabolism
EDAT- 2016/05/12 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/12 06:00
PHST- 2015/07/28 00:00 [received]
PHST- 2015/11/22 00:00 [revised]
PHST- 2016/04/06 00:00 [accepted]
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30161-1 [pii]
AID - 10.1016/j.ccell.2016.04.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):751-766. doi: 10.1016/j.ccell.2016.04.003.

PMID- 27165745
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy
      Number Alterations.
PG  - 737-750
LID - S1535-6108(16)30108-8 [pii]
LID - 10.1016/j.ccell.2016.03.025 [doi]
AB  - The identification of driver loci underlying arm-level somatic copy number
      alterations (SCNAs) in cancer has remained challenging and incomplete. Here, we
      assess the relative impact and present a detailed landscape of arm-level SCNAs in
      10,985 patient samples across 33 cancer types from The Cancer Genome Atlas
      (TCGA). Furthermore, using chromosome 9p loss in lower grade glioma (LGG) as a
      model, we employ a unique multi-tiered genomic dissection strategy using 540
      patients from three independent LGG datasets to identify genetic loci that govern
      tumor aggressiveness and poor survival. This comprehensive approach uncovered
      several 9p loss-specific prognostic markers, validated existing ones, and
      redefined the impact of CDKN2A loss in LGG.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Roy, David M
AU  - Roy DM
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Weill Cornell/Rockefeller/Sloan Kettering
      Tri-Institutional MD-PhD Program, New York, NY 10065, USA.
FAU - Walsh, Logan A
AU  - Walsh LA
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Desrichard, Alexis
AU  - Desrichard A
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Huse, Jason T
AU  - Huse JT
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Brain Tumor Center, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA; Department of Pathology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Wu, Wei
AU  - Wu W
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Gao, JianJiong
AU  - Gao J
AD  - Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, 
      NY 10065, USA.
FAU - Bose, Promita
AU  - Bose P
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Lee, William
AU  - Lee W
AD  - Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, 
      NY 10065, USA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer 
      Center, New York, NY 10065, USA.
FAU - Chan, Timothy A
AU  - Chan TA
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Brain Tumor Center, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA; Department of Radiation Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Cellular and Developmental
      Biology, Weill Cornell Medical College, New York, NY 10065, USA. Electronic
      address: chant@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA154767/CA/NCI NIH HHS/United States
GR  - R01 CA177828/CA/NCI NIH HHS/United States
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p18)
SB  - IM
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 9/genetics
MH  - Cyclin-Dependent Kinase Inhibitor p18/genetics
MH  - *DNA Copy Number Variations
MH  - DNA Methylation
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genome, Human/*genetics
MH  - Genomics/*methods
MH  - Glioma/genetics/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasms/*genetics/pathology
MH  - Prognosis
MH  - Survival Analysis
PMC - PMC4864611
MID - NIHMS774317
EDAT- 2016/05/12 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/12 06:00
PHST- 2015/05/07 00:00 [received]
PHST- 2015/12/22 00:00 [revised]
PHST- 2016/03/24 00:00 [accepted]
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30108-8 [pii]
AID - 10.1016/j.ccell.2016.03.025 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):737-750. doi: 10.1016/j.ccell.2016.03.025.

PMID- 27165744
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20171124
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
PG  - 723-736
LID - S1535-6108(16)30160-X [pii]
LID - 10.1016/j.ccell.2016.04.002 [doi]
AB  - We describe a comprehensive genomic characterization of adrenocortical carcinoma 
      (ACC). Using this dataset, we expand the catalogue of known ACC driver genes to
      include PRKAR1A, RPL22, TERF2, CCNE1, and NF1. Genome wide DNA copy-number
      analysis revealed frequent occurrence of massive DNA loss followed by
      whole-genome doubling (WGD), which was associated with aggressive clinical
      course, suggesting WGD is a hallmark of disease progression. Corroborating this
      hypothesis were increased TERT expression, decreased telomere length, and
      activation of cell-cycle programs. Integrated subtype analysis identified three
      ACC subtypes with distinct clinical outcome and molecular alterations which could
      be captured by a 68-CpG probe DNA-methylation signature, proposing a strategy for
      clinical stratification of patients based on molecular markers.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zheng, Siyuan
AU  - Zheng S
AD  - Departments of Genomic Medicine, Bioinformatics, and Computational Biology,
      Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Cherniack, Andrew D
AU  - Cherniack AD
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
FAU - Dewal, Ninad
AU  - Dewal N
AD  - Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030,
      USA.
FAU - Moffitt, Richard A
AU  - Moffitt RA
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Danilova, Ludmila
AU  - Danilova L
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
      Baltimore, MD 21287, USA.
FAU - Murray, Bradley A
AU  - Murray BA
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
FAU - Lerario, Antonio M
AU  - Lerario AM
AD  - Unidade de Suprarrenal, Laboratorio de Hormonios e Genetica Molecular LIM42,
      Servico de Endocrinologia e Metabologia, Hospital das Clinicas, Faculdade de
      Medicina da Universidade de Sao Paulo, Sao Paulo 05403-900, Brazil; Departments
      of Cell & Developmental Biology, Pathology, Molecular & Integrative Physiology,
      Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; University
      of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
      48109, USA.
FAU - Else, Tobias
AU  - Else T
AD  - Departments of Cell & Developmental Biology, Pathology, Molecular & Integrative
      Physiology, Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; 
      University of Michigan Comprehensive Cancer Center, University of Michigan, Ann
      Arbor, MI 48109, USA.
FAU - Knijnenburg, Theo A
AU  - Knijnenburg TA
AD  - Institute for Systems Biology, Seattle, WA 98109, USA.
FAU - Ciriello, Giovanni
AU  - Ciriello G
AD  - Department of Computational Biology, University of Lausanne, Rue du Bugnon 27,
      1005 Lausanne, Switzerland; Computational Biology Center, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Kim, Seungchan
AU  - Kim S
AD  - Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
FAU - Assie, Guillaume
AU  - Assie G
AD  - Inserm U1016, CNRS UMR 8104, Institut Cochin, 75014 Paris, France; Faculte de
      Medecine Paris Descartes, Universite Paris Descartes, Sorbonne Paris Cite, 75006 
      Paris, France; Department of Endocrinology, Referral Center for Rare Adrenal
      Diseases, Assistance Publique Hopitaux de Paris, Hopital Cochin, 75014 Paris,
      France; European Network for the Study of Adrenal Tumors, 75014 Paris, France.
FAU - Morozova, Olena
AU  - Morozova O
AD  - University of California Santa Cruz Genomics Institute, University California
      Santa Cruz, Santa Cruz, CA 95064, USA.
FAU - Akbani, Rehan
AU  - Akbani R
AD  - Departments of Genomic Medicine, Bioinformatics, and Computational Biology,
      Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Shih, Juliann
AU  - Shih J
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
FAU - Hoadley, Katherine A
AU  - Hoadley KA
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's
      Hospital, Boston, MA 02115, USA.
FAU - Waldmann, Jens
AU  - Waldmann J
AD  - European Network for the Study of Adrenal Tumors, 75014 Paris, France; Department
      of Visceral, Thoracic and Vascular Surgery, University Hospital Giessen and
      Marburg, Campus Marburg, General Surgery, Endocrine Center, 34501 Marburg,
      Germany.
FAU - Mete, Ozgur
AU  - Mete O
AD  - Department of Laboratory Medicine and Pathobiology, University Health Network,
      Toronto, ON M5G 2C4, Canada.
FAU - Robertson, A Gordon
AU  - Robertson AG
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC
      V5Z 4S6, Canada.
FAU - Wu, Hsin-Ta
AU  - Wu HT
AD  - Department of Computer Science, Brown University, Providence, RI 02906, USA.
FAU - Raphael, Benjamin J
AU  - Raphael BJ
AD  - Department of Computer Science, Brown University, Providence, RI 02906, USA.
FAU - Shao, Lina
AU  - Shao L
AD  - Departments of Cell & Developmental Biology, Pathology, Molecular & Integrative
      Physiology, Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Meyerson, Matthew
AU  - Meyerson M
AD  - The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology
      and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA;
      Department of Pathology, Harvard Medical School, Boston, MA 02215, USA.
FAU - Demeure, Michael J
AU  - Demeure MJ
AD  - Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
FAU - Beuschlein, Felix
AU  - Beuschlein F
AD  - European Network for the Study of Adrenal Tumors, 75014 Paris, France; Endocrine 
      Research Unit, Medizinische Klinik und Poliklinik IV, Klinikum der Universitat
      Munchen, 80336 Munich, Germany.
FAU - Gill, Anthony J
AU  - Gill AJ
AD  - Cancer Diagnosis and Pathology Group and Cancer Genetics Laboratory, Kolling
      Institute of Medical Research, University of Sydney, Sydney, NSW 2006, Australia;
      Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW 
      2065, Australia.
FAU - Sidhu, Stan B
AU  - Sidhu SB
AD  - Cancer Diagnosis and Pathology Group and Cancer Genetics Laboratory, Kolling
      Institute of Medical Research, University of Sydney, Sydney, NSW 2006, Australia;
      Endocrine Surgical Unit, Royal North Shore Hospital, St Leonards, NSW 2065,
      Australia.
FAU - Almeida, Madson Q
AU  - Almeida MQ
AD  - Unidade de Suprarrenal, Laboratorio de Hormonios e Genetica Molecular LIM42,
      Servico de Endocrinologia e Metabologia, Hospital das Clinicas, Faculdade de
      Medicina da Universidade de Sao Paulo, Sao Paulo 05403-900, Brazil; Instituto do 
      Cancer do Estado de Sao Paulo (ICESP), Faculdade de Medicina da Universidade de
      Sao Paulo, Sao Paulo 05403-900, Brazil.
FAU - Fragoso, Maria C B V
AU  - Fragoso MCBV
AD  - Unidade de Suprarrenal, Laboratorio de Hormonios e Genetica Molecular LIM42,
      Servico de Endocrinologia e Metabologia, Hospital das Clinicas, Faculdade de
      Medicina da Universidade de Sao Paulo, Sao Paulo 05403-900, Brazil; Instituto do 
      Cancer do Estado de Sao Paulo (ICESP), Faculdade de Medicina da Universidade de
      Sao Paulo, Sao Paulo 05403-900, Brazil.
FAU - Cope, Leslie M
AU  - Cope LM
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
      Baltimore, MD 21287, USA.
FAU - Kebebew, Electron
AU  - Kebebew E
AD  - Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Habra, Mouhammed A
AU  - Habra MA
AD  - Departments of Genomic Medicine, Bioinformatics, and Computational Biology,
      Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Whitsett, Timothy G
AU  - Whitsett TG
AD  - Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
FAU - Bussey, Kimberly J
AU  - Bussey KJ
AD  - Translational Genomics Research Institute, Phoenix, AZ 85004, USA; NantOmics,
      LLC, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-5001,
      USA.
FAU - Rainey, William E
AU  - Rainey WE
AD  - Departments of Cell & Developmental Biology, Pathology, Molecular & Integrative
      Physiology, Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; 
      University of Michigan Comprehensive Cancer Center, University of Michigan, Ann
      Arbor, MI 48109, USA.
FAU - Asa, Sylvia L
AU  - Asa SL
AD  - Department of Laboratory Medicine and Pathobiology, University Health Network,
      Toronto, ON M5G 2C4, Canada.
FAU - Bertherat, Jerome
AU  - Bertherat J
AD  - Inserm U1016, CNRS UMR 8104, Institut Cochin, 75014 Paris, France; Faculte de
      Medecine Paris Descartes, Universite Paris Descartes, Sorbonne Paris Cite, 75006 
      Paris, France; Department of Endocrinology, Referral Center for Rare Adrenal
      Diseases, Assistance Publique Hopitaux de Paris, Hopital Cochin, 75014 Paris,
      France; European Network for the Study of Adrenal Tumors, 75014 Paris, France.
FAU - Fassnacht, Martin
AU  - Fassnacht M
AD  - European Network for the Study of Adrenal Tumors, 75014 Paris, France; Endocrine 
      and Diabetes Unit, Department of Internal Medicine I, University Hospital
      Wurzburg, 97080 Wurzburg, Germany; Comprehensive Cancer Center Mainfranken,
      University of Wurzburg, 97080 Wurzburg, Germany.
FAU - Wheeler, David A
AU  - Wheeler DA
AD  - Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030,
      USA.
CN  - Cancer Genome Atlas Research Network
FAU - Hammer, Gary D
AU  - Hammer GD
AD  - Departments of Cell & Developmental Biology, Pathology, Molecular & Integrative
      Physiology, Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; 
      University of Michigan Comprehensive Cancer Center, University of Michigan, Ann
      Arbor, MI 48109, USA.
FAU - Giordano, Thomas J
AU  - Giordano TJ
AD  - Departments of Cell & Developmental Biology, Pathology, Molecular & Integrative
      Physiology, Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; 
      University of Michigan Comprehensive Cancer Center, University of Michigan, Ann
      Arbor, MI 48109, USA. Electronic address: giordano@med.umich.edu.
FAU - Verhaak, Roel G W
AU  - Verhaak RGW
AD  - Departments of Genomic Medicine, Bioinformatics, and Computational Biology,
      Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA. Electronic address:
      rverhaak@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U24 CA143882/CA/NCI NIH HHS/United States
GR  - U54 HG003067/HG/NHGRI NIH HHS/United States
GR  - U24 CA143835/CA/NCI NIH HHS/United States
GR  - P30 CA046592/CA/NCI NIH HHS/United States
GR  - U24 CA143866/CA/NCI NIH HHS/United States
GR  - U24 CA143845/CA/NCI NIH HHS/United States
GR  - U24 CA143799/CA/NCI NIH HHS/United States
GR  - U54 HG003273/HG/NHGRI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U24 CA144025/CA/NCI NIH HHS/United States
GR  - U24 CA180951/CA/NCI NIH HHS/United States
GR  - U24 CA143840/CA/NCI NIH HHS/United States
GR  - U24 CA143843/CA/NCI NIH HHS/United States
GR  - U24 CA210974/CA/NCI NIH HHS/United States
GR  - U24 CA143858/CA/NCI NIH HHS/United States
GR  - U24 CA143848/CA/NCI NIH HHS/United States
GR  - U54 HG003079/HG/NHGRI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - U24 CA143867/CA/NCI NIH HHS/United States
GR  - U24 CA199461/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CIN - Nat Rev Endocrinol. 2016 Aug;12 (8):433. PMID: 27259178
EIN - Cancer Cell. 2016 Aug 8;30(2):363. PMID: 27505681
MH  - Adolescent
MH  - Adrenal Cortex Neoplasms/*genetics/pathology/therapy
MH  - Adrenocortical Carcinoma/*genetics/pathology/therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - DNA Methylation
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease/genetics
MH  - Genome, Human/*genetics
MH  - Genomics/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Outcome Assessment (Health Care)
MH  - Prognosis
MH  - Young Adult
PMC - PMC4864952
MID - NIHMS777121
IR  - Zheng S
FIR - Zheng, Siyuan
IR  - Verhaak RGW
FIR - Verhaak, Roel G W
IR  - Giordano TJ
FIR - Giordano, Thomas J
IR  - Hammer GD
FIR - Hammer, Gary D
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Dewal N
FIR - Dewal, Ninad
IR  - Moffitt RA
FIR - Moffitt, Richard A
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Murray BA
FIR - Murray, Bradley A
IR  - Lerario AM
FIR - Lerario, Antonio M
IR  - Else T
FIR - Else, Tobias
IR  - Knijnenburg TA
FIR - Knijnenburg, Theo A
IR  - Ciriello G
FIR - Ciriello, Giovanni
IR  - Kim S
FIR - Kim, Seungchan
IR  - Assie G
FIR - Assie, Guillaume
IR  - Morozova O
FIR - Morozova, Olena
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Shih J
FIR - Shih, Juliann
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Choueiri TK
FIR - Choueiri, Toni K
IR  - Waldmann J
FIR - Waldmann, Jens
IR  - Mete O
FIR - Mete, Ozgur
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Wu HT
FIR - Wu, Hsin-Tu
IR  - Raphael BJ
FIR - Raphael, Benjamin J
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Demeure MJ
FIR - Demeure, Michael J
IR  - Beuschlein F
FIR - Beuschlein, Felix
IR  - Gill AJ
FIR - Gill, Anthony J
IR  - Sidhu SB
FIR - Sidhu, Stan B
IR  - Almeida M
FIR - Almeida, Madson
IR  - Barisson Fragoso MC
FIR - Barisson Fragoso, Maria Candida
IR  - Cope LM
FIR - Cope, Leslie M
IR  - Kebebew E
FIR - Kebebew, Electron
IR  - Habra MA
FIR - Habra, Mouhammed Amir
IR  - Whitsett TG
FIR - Whitsett, Timothy G
IR  - Bussey KJ
FIR - Bussey, Kimberly J
IR  - Rainey WE
FIR - Rainey, William E
IR  - Asa SL
FIR - Asa, Sylvia L
IR  - Bertherat J
FIR - Bertherat, Jerome
IR  - Fassnacht M
FIR - Fassnacht, Martin
IR  - Wheeler DA
FIR - Wheeler, David A
IR  - Benz C
FIR - Benz, Christopher
IR  - Ally A
FIR - Ally, Adrian
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Brooks D
FIR - Brooks, Denise
IR  - Butterfield YSN
FIR - Butterfield, Yaron S N
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Guin R
FIR - Guin, Ranabir
IR  - Holt RA
FIR - Holt, Robert A
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Lee D
FIR - Lee, Darlene
IR  - Li HI
FIR - Li, Haiyan I
IR  - Lim L
FIR - Lim, Lynette
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Marra MA
FIR - Marra, Marco A
IR  - Mayo M
FIR - Mayo, Michael
IR  - Moore RA
FIR - Moore, Richard A
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Tam A
FIR - Tam, Angela
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Park PJ
FIR - Park, Peter J
IR  - Kroiss M
FIR - Kroiss, Matthias
IR  - Gao J
FIR - Gao, Jianjiong
IR  - Sander C
FIR - Sander, Chris
IR  - Schultz N
FIR - Schultz, Nikolaus
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Kucherlapati R
FIR - Kucherlapati, Raju
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Parker JS
FIR - Parker, Joel S
IR  - Perou CM
FIR - Perou, Charles M
IR  - Tan D
FIR - Tan, Donghui
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Ladanyi M
FIR - Ladanyi, Marc
IR  - Quinkler M
FIR - Quinkler, Marcus
IR  - Auman JT
FIR - Auman, J Todd
IR  - Latronico AC
FIR - Latronico, Ana Claudia
IR  - Mendonca BB
FIR - Mendonca, Berenice B
IR  - Sibony M
FIR - Sibony, Mathilde
IR  - Sanborn Z
FIR - Sanborn, Zack
IR  - Bellair M
FIR - Bellair, Michelle
IR  - Buhay C
FIR - Buhay, Christian
IR  - Covington K
FIR - Covington, Kyle
IR  - Dahdouli M
FIR - Dahdouli, Mahmoud
IR  - Dinh H
FIR - Dinh, Huyen
IR  - Doddapaneni H
FIR - Doddapaneni, Harsha
IR  - Downs B
FIR - Downs, Brittany
IR  - Drummond J
FIR - Drummond, Jennifer
IR  - Gibbs R
FIR - Gibbs, Richard
IR  - Hale W
FIR - Hale, Walker
IR  - Han Y
FIR - Han, Yi
IR  - Hawes A
FIR - Hawes, Alicia
IR  - Hu J
FIR - Hu, Jianhong
IR  - Kakkar N
FIR - Kakkar, Nipun
IR  - Kalra D
FIR - Kalra, Divya
IR  - Khan Z
FIR - Khan, Ziad
IR  - Kovar C
FIR - Kovar, Christine
IR  - Lee S
FIR - Lee, Sandy
IR  - Lewis L
FIR - Lewis, Lora
IR  - Morgan M
FIR - Morgan, Margaret
IR  - Morton D
FIR - Morton, Donna
IR  - Muzny D
FIR - Muzny, Donna
IR  - Santibanez J
FIR - Santibanez, Jireh
IR  - Xi L
FIR - Xi, Liu
IR  - Dousset B
FIR - Dousset, Bertrand
IR  - Groussin L
FIR - Groussin, Lionel
IR  - Libe R
FIR - Libe, Rossella
IR  - Chin L
FIR - Chin, Lynda
IR  - Reynolds S
FIR - Reynolds, Sheila
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Liu J
FIR - Liu, Jia
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Wu Y
FIR - Wu, Ye
IR  - Yeh JJ
FIR - Yeh, Jen Jen
IR  - Balu S
FIR - Balu, Saianand
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Meng S
FIR - Meng, Shaowu
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Shi Y
FIR - Shi, Yan
IR  - Simons JV
FIR - Simons, Janae V
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Wu J
FIR - Wu, Junyuan
IR  - Zhang W
FIR - Zhang, Wei
IR  - Mills Shaw KR
FIR - Mills Shaw, Kenna R
IR  - Demchok JA
FIR - Demchok, John A
IR  - Felau I
FIR - Felau, Ina
IR  - Sheth M
FIR - Sheth, Margi
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Wang Z
FIR - Wang, Zhining
IR  - Yang L
FIR - Yang, Liming
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Davidsen T
FIR - Davidsen, Tanja
IR  - Crawford C
FIR - Crawford, Catherine
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Bshara W
FIR - Bshara, Wiam
IR  - Gaudioso C
FIR - Gaudioso, Carmelo
IR  - Morrison C
FIR - Morrison, Carl
IR  - Soon P
FIR - Soon, Patsy
IR  - Alonso S
FIR - Alonso, Shelley
IR  - Baboud J
FIR - Baboud, Julien
IR  - Pihl T
FIR - Pihl, Todd
IR  - Raman R
FIR - Raman, Rohini
IR  - Sun Q
FIR - Sun, Qiang
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Arachchi H
FIR - Arachchi, Harindra
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Carter SL
FIR - Carter, Scott L
IR  - Cho J
FIR - Cho, Juok
IR  - Frazer S
FIR - Frazer, Scott
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Getz G
FIR - Getz, Gad
IR  - Heiman DI
FIR - Heiman, David I
IR  - Kim J
FIR - Kim, Jaegil
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lin P
FIR - Lin, Pei
IR  - Noble MS
FIR - Noble, Michael S
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Sougnez C
FIR - Sougnez, Carrie
IR  - Voet D
FIR - Voet, Doug
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Bowen J
FIR - Bowen, Jay
IR  - Coppens S
FIR - Coppens, Sara
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gerken M
FIR - Gerken, Mark
IR  - Helsel C
FIR - Helsel, Carmen
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Wise L
FIR - Wise, Lisa
IR  - Zmuda E
FIR - Zmuda, Erik
IR  - Baylin S
FIR - Baylin, Stephen
IR  - Herman JG
FIR - Herman, James G
IR  - LoBello J
FIR - LoBello, Janine
IR  - Watanabe A
FIR - Watanabe, Aprill
IR  - Haussler D
FIR - Haussler, David
IR  - Radenbaugh A
FIR - Radenbaugh, Amie
IR  - Rao A
FIR - Rao, Arjun
IR  - Zhu J
FIR - Zhu, Jingchun
IR  - Bartsch DK
FIR - Bartsch, Detlef K
IR  - Sbiera S
FIR - Sbiera, Silviu
IR  - Allolio B
FIR - Allolio, Bruno
IR  - Deutschbein T
FIR - Deutschbein, Timo
IR  - Ronchi C
FIR - Ronchi, Cristina
IR  - Raymond VM
FIR - Raymond, Victoria M
IR  - Vinco M
FIR - Vinco, Michelle
IR  - Shao L
FIR - Shao, Lina
IR  - Amble L
FIR - Amble, Linda
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Robinson B
FIR - Robinson, Bruce
IR  - Ju Z
FIR - Ju, Zhenlin
IR  - Kim H
FIR - Kim, Hoon
IR  - Ling S
FIR - Ling, Shiyun
IR  - Liu W
FIR - Liu, Wenbin
IR  - Lu Y
FIR - Lu, Yiling
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Sircar K
FIR - Sircar, Kanishka
IR  - Wang Q
FIR - Wang, Qianghu
IR  - Yoshihara K
FIR - Yoshihara, Kosuke
IR  - Laird PW
FIR - Laird, Peter W
IR  - Fan Y
FIR - Fan, Yu
IR  - Wang W
FIR - Wang, Wenyi
IR  - Shinbrot E
FIR - Shinbrot, Eve
IR  - Reincke M
FIR - Reincke, Martin
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Meier S
FIR - Meier, Sam
IR  - Defreitas T
FIR - Defreitas, Timothy
EDAT- 2016/05/12 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/12 06:00
PHST- 2015/08/11 00:00 [received]
PHST- 2015/12/08 00:00 [revised]
PHST- 2016/04/05 00:00 [accepted]
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30160-X [pii]
AID - 10.1016/j.ccell.2016.04.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):723-736. doi: 10.1016/j.ccell.2016.04.002.

PMID- 27165743
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Comprehensive Characterization of Molecular Differences in Cancer between Male
      and Female Patients.
PG  - 711-722
LID - S1535-6108(16)30111-8 [pii]
LID - 10.1016/j.ccell.2016.04.001 [doi]
AB  - An individual's sex has been long recognized as a key factor affecting cancer
      incidence, prognosis, and treatment responses. However, the molecular basis for
      sex disparities in cancer remains poorly understood. We performed a comprehensive
      analysis of molecular differences between male and female patients in 13 cancer
      types of The Cancer Genome Atlas and revealed two sex-effect groups associated
      with distinct incidence and mortality profiles. One group contains a small number
      of sex-affected genes, whereas the other shows much more extensive sex-biased
      molecular signatures. Importantly, 53% of clinically actionable genes (60/114)
      show sex-biased signatures. Our study provides a systematic molecular-level
      understanding of sex effects in diverse cancers and suggests a pressing need to
      develop sex-specific therapeutic strategies in certain cancer types.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Liu, Lingxiang
AU  - Liu L
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Oncology, The
      First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029,
      China.
FAU - Chen, Hu
AU  - Chen H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Program in Structural
      and Computational Biology and Molecular Biophysics, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Wang, Yumeng
AU  - Wang Y
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Program in Structural
      and Computational Biology and Molecular Biophysics, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Xu, Yanxun
AU  - Xu Y
AD  - Department of Applied Mathematics and Statistics, Johns Hopkins University,
      Baltimore, MD 21218, USA.
FAU - Mao, Huzhang
AU  - Mao H
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Department of Biostatistics, The University of Texas
      Health Science Center at Houston, Houston, TX 77030, USA.
FAU - Li, Jun
AU  - Li J
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Shu, Yongqian
AU  - Shu Y
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, Jiangsu 210029, China.
FAU - Li, Liang
AU  - Li L
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Program in Structural
      and Computational Biology and Molecular Biophysics, Baylor College of Medicine,
      Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:
      hliang1@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA175486/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MicroRNAs)
SB  - IM
CIN - Trends Cancer. 2016 Jul;2(7):325-326. PMID: 28741533
MH  - DNA Copy Number Variations
MH  - DNA Methylation
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Genome, Human/*genetics
MH  - Genomics/*methods
MH  - Humans
MH  - Male
MH  - MicroRNAs/genetics
MH  - Mutation
MH  - Neoplasms/classification/*genetics/*metabolism
MH  - Proteomics/*methods
MH  - Sex Factors
PMC - PMC4864951
MID - NIHMS776587
EDAT- 2016/05/12 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/12 06:00
PHST- 2015/11/07 00:00 [received]
PHST- 2016/02/15 00:00 [revised]
PHST- 2016/04/01 00:00 [accepted]
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30111-8 [pii]
AID - 10.1016/j.ccell.2016.04.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):711-722. doi: 10.1016/j.ccell.2016.04.001.

PMID- 27165742
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates
      Tumor Phenotype and Mitotic Growth in Malignant Glioma.
PG  - 669-683
LID - S1535-6108(16)30110-6 [pii]
LID - 10.1016/j.ccell.2016.03.027 [doi]
AB  - Malignant gliomas exhibit extensive heterogeneity and poor prognosis. Here we
      identify mitotic Olig2-expressing cells as tumor-propagating cells in proneural
      gliomas, elimination of which blocks tumor initiation and progression.
      Intriguingly, deletion of Olig2 resulted in tumors that grow, albeit at a
      decelerated rate. Genome occupancy and expression profiling analyses reveal that 
      Olig2 directly activates cell-proliferation machinery to promote tumorigenesis.
      Olig2 deletion causes a tumor phenotypic shift from an oligodendrocyte
      precursor-correlated proneural toward an astroglia-associated gene expression
      pattern, manifest in downregulation of platelet-derived growth factor
      receptor-alpha and reciprocal upregulation of epidermal growth factor receptor
      (EGFR). Olig2 deletion further sensitizes glioma cells to EGFR inhibitors and
      extends the lifespan of animals. Thus, Olig2-orchestrated receptor signaling
      drives mitotic growth and regulates glioma phenotypic plasticity. Targeting Olig2
      may circumvent resistance to EGFR-targeted drugs.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lu, Fanghui
AU  - Lu F
AD  - Laboratory of Pathology, State Key Laboratory of Biotherapy, West China Hospital,
      Sichuan University and National Collaborative Innovation Center, Chengdu 610041, 
      China; Department of Pediatrics, Division of Experimental Hematology and Cancer
      Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH 25229, USA.
FAU - Chen, Ying
AU  - Chen Y
AD  - School of Life Sciences, Xiamen University, Fujian 361102, China.
FAU - Zhao, Chuntao
AU  - Zhao C
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Wang, Haibo
AU  - Wang H
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - He, Danyang
AU  - He D
AD  - Department of Pathology & Integrative Biology Program, University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Xu, Lingli
AU  - Xu L
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Wang, Jincheng
AU  - Wang J
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - He, Xuelian
AU  - He X
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Deng, Yaqi
AU  - Deng Y
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Lu, Ellen E
AU  - Lu EE
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Liu, Xue
AU  - Liu X
AD  - School of Life Sciences, Xiamen University, Fujian 361102, China.
FAU - Verma, Ravinder
AU  - Verma R
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Bu, Hong
AU  - Bu H
AD  - Laboratory of Pathology, State Key Laboratory of Biotherapy, West China Hospital,
      Sichuan University and National Collaborative Innovation Center, Chengdu 610041, 
      China.
FAU - Drissi, Rachid
AU  - Drissi R
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Fouladi, Maryam
AU  - Fouladi M
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Stemmer-Rachamimov, Anat O
AU  - Stemmer-Rachamimov AO
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA 02114, USA.
FAU - Burns, Dennis
AU  - Burns D
AD  - Department of Pathology & Integrative Biology Program, University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Xin, Mei
AU  - Xin M
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA.
FAU - Rubin, Joshua B
AU  - Rubin JB
AD  - Departments of Pediatrics and Anatomy and Neurobiology, Washington University
      School of Medicine, St Louis, MO 63110, USA.
FAU - Bahassi, El Mustapha
AU  - Bahassi EM
AD  - Department of Internal Medicine, UC Brain Tumor Center, University of Cincinnati,
      Cincinnati, OH 45267, USA.
FAU - Canoll, Peter
AU  - Canoll P
AD  - Department of Pathology & Cellular Biology, Columbia University Medical Center,
      New York, NY 10032, USA.
FAU - Holland, Eric C
AU  - Holland EC
AD  - Division of Human Biology and Solid Tumor Translational Research, Fred Hutchinson
      Cancer Research Center, Alvord Brain Tumor Center, University of Washington,
      Seattle, WA 98109, USA.
FAU - Lu, Q Richard
AU  - Lu QR
AD  - Department of Pediatrics, Division of Experimental Hematology and Cancer Biology,
      Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
      25229, USA; Key Laboratory of Birth Defects, Children's Hospital of Fudan
      University, Shanghai 201102, China. Electronic address: richard.lu@cchmc.org.
LA  - eng
GR  - R01 NS072427/NS/NINDS NIH HHS/United States
GR  - R01 NS078092/NS/NINDS NIH HHS/United States
GR  - R01 NS075243/NS/NINDS NIH HHS/United States
GR  - R01 HL132211/HL/NHLBI NIH HHS/United States
GR  - R37 NS096359/NS/NINDS NIH HHS/United States
GR  - UL1 TR001425/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Nerve Tissue Proteins)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor)
SB  - IM
CIN - Cancer Cell. 2016 May 9;29(5):613-5. PMID: 27165737
MH  - Animals
MH  - Astrocytes/metabolism
MH  - Basic Helix-Loop-Helix Transcription Factors/*genetics/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*genetics
MH  - Cell Transformation, Neoplastic/genetics
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Glioma/*genetics/metabolism/pathology
MH  - Humans
MH  - Mice, 129 Strain
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Nerve Tissue Proteins/*genetics/metabolism
MH  - Oligodendroglia/metabolism
MH  - Phenotype
MH  - Receptor, Epidermal Growth Factor/*genetics/metabolism
MH  - Receptors, Platelet-Derived Growth Factor/*genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/genetics
MH  - Spheroids, Cellular/metabolism
MH  - Survival Analysis
PMC - PMC4946168
MID - NIHMS774896
EDAT- 2016/05/12 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/12 06:00
PHST- 2015/08/03 00:00 [received]
PHST- 2016/01/05 00:00 [revised]
PHST- 2016/03/31 00:00 [accepted]
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30110-6 [pii]
AID - 10.1016/j.ccell.2016.03.027 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):669-683. doi: 10.1016/j.ccell.2016.03.027.

PMID- 27165741
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Squamous Cell Cancers: A Unified Perspective on Biology and Genetics.
PG  - 622-637
LID - S1535-6108(16)30162-3 [pii]
LID - 10.1016/j.ccell.2016.04.004 [doi]
AB  - Squamous cell carcinomas (SCCs) represent the most frequent human solid tumors
      and are a major cause of cancer mortality. These highly heterogeneous tumors
      arise from closely interconnected epithelial cell populations with intrinsic
      self-renewal potential inversely related to the stratified differentiation
      program. SCCs can also originate from simple or pseudo-stratified epithelia
      through activation of quiescent cells and/or a switch in cell-fate determination.
      Here, we focus on specific determinants implicated in the development of SCCs by 
      recent large-scale genomic, genetic, and epigenetic studies, and complementary
      functional analysis. The evidence indicates that SCCs from various body sites,
      while clinically treated as separate entities, have common determinants, pointing
      to a unified perspective of the disease and potential new avenues for prevention 
      and treatment.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Dotto, G Paolo
AU  - Dotto GP
AD  - Department of Biochemistry, University of Lausanne, Epalinges 1066, Switzerland; 
      Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown,
      MA 02129, USA. Electronic address: paolo.dotto@unil.ch.
FAU - Rustgi, Anil K
AU  - Rustgi AK
AD  - Division of Gastroenterology, Departments of Medicine and Genetics, Abramson
      Cancer Center, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, PA 19104, USA. Electronic address: anil2@mail.med.upenn.edu.
LA  - eng
GR  - P30 DK050306/DK/NIDDK NIH HHS/United States
GR  - R01 AR064786/AR/NIAMS NIH HHS/United States
GR  - R01 AR039190/AR/NIAMS NIH HHS/United States
GR  - P01 CA098101/CA/NCI NIH HHS/United States
GR  - P30 CA016520/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Alcohol Drinking/adverse effects
MH  - Carcinoma, Squamous Cell/etiology/*genetics/therapy
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease/*genetics
MH  - Humans
MH  - Infection/complications
MH  - Models, Genetic
MH  - *Mutation
MH  - Smoking/adverse effects
MH  - Ultraviolet Rays/adverse effects
PMC - PMC4870309
MID - NIHMS783650
EDAT- 2016/05/12 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/12 06:00
PHST- 2015/09/28 00:00 [received]
PHST- 2016/01/20 00:00 [revised]
PHST- 2016/04/07 00:00 [accepted]
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30162-3 [pii]
AID - 10.1016/j.ccell.2016.04.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):622-637. doi: 10.1016/j.ccell.2016.04.004.

PMID- 27165740
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Targeting the lncRNA SAMMSON Reveals Metabolic Vulnerability in Melanoma.
PG  - 619-621
LID - S1535-6108(16)30168-4 [pii]
LID - 10.1016/j.ccell.2016.04.010 [doi]
AB  - In a recent study, Leucci et al. report a role for the long non-coding RNA
      SAMMSON in driving mitochondrial function in melanoma. Targeting SAMMSON, the
      gene of which is frequently co-amplified with MITF, highlights a new
      cell-type-specific therapeutic vulnerability in melanoma irrespective of BRAF,
      NRAS, or p53 status.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Goding, Colin R
AU  - Goding CR
AD  - Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University
      of Oxford, Headington, Oxford OX3 7DQ, UK. Electronic address:
      colin.goding@ludwig.ox.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (RNA, Long Noncoding)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CON - Nature. 2016 Mar 24;531(7595):518-22. PMID: 27008969
MH  - Humans
MH  - Melanoma/genetics
MH  - Mitochondria/genetics
MH  - Mutation
MH  - Proto-Oncogene Proteins B-raf/*genetics
MH  - *RNA, Long Noncoding
EDAT- 2016/05/12 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/05/12 06:00
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30168-4 [pii]
AID - 10.1016/j.ccell.2016.04.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):619-621. doi: 10.1016/j.ccell.2016.04.010.

PMID- 27165739
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Coordinated Tumor Suppression by Chromosome 8p.
PG  - 617-619
LID - S1535-6108(16)30169-6 [pii]
LID - 10.1016/j.ccell.2016.04.011 [doi]
AB  - In this issue of Cancer Cell, Cai et al. use genome editing to study 8p deletions
      in a mammary epithelial cell model and show that 8p loss of heterozygosity (LOH) 
      attenuates the action of several genes that collectively promote cell invasion
      and enhance cellular sensitivity to autophagy inhibitors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Tschaharganeh, Darjus F
AU  - Tschaharganeh DF
AD  - Department of Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Bosbach, Benedikt
AU  - Bosbach B
AD  - Department of Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Lowe, Scott W
AU  - Lowe SW
AD  - Department of Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Howard Hughes Medical Institute, New York, NY 10065,
      USA. Electronic address: lowes@mskcc.org.
LA  - eng
GR  - Howard Hughes Medical Institute/United States
GR  - P01 CA013106/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 May 9;29(5):751-66. PMID: 27165746
MH  - *Chromosome Deletion
MH  - Chromosome Mapping
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - *Loss of Heterozygosity
MH  - Neoplasms/genetics
PMC - PMC5120649
MID - NIHMS829567
EDAT- 2016/05/12 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/05/12 06:00
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30169-6 [pii]
AID - 10.1016/j.ccell.2016.04.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):617-619. doi: 10.1016/j.ccell.2016.04.011.

PMID- 27165738
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Multifaceted Role of IRAK-M in the Promotion of Colon Carcinogenesis via Barrier 
      Dysfunction and STAT3 Oncoprotein Stabilization in Tumors.
PG  - 615-617
LID - S1535-6108(16)30166-0 [pii]
LID - 10.1016/j.ccell.2016.04.008 [doi]
AB  - Dysregulated interactions between the host immune system and gut microbiota can
      underpin inflammation, leading to colorectal cancer (CRC). In this issue of
      Cancer Cell, Kesselring et al. reveal a bimodal role of the TLR/IL-1R-signaling
      negative regulator, IRAK-M, in promoting tumoral microbial colonization and STAT3
      oncoprotein stabilization during CRC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Jenkins, Brendan J
AU  - Jenkins BJ
AD  - Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical
      Research, 27-31 Wright Street, Clayton, VIC 3168, Australia; Department of
      Molecular Translational Science, Faculty of Medicine, Nursing and Health
      Sciences, Monash University, Clayton, VIC 3800, Australia. Electronic address:
      brendan.jenkins@hudson.org.au.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Oncogene Proteins)
RN  - 0 (STAT3 Transcription Factor)
RN  - EC 2.7.11.1 (Interleukin-1 Receptor-Associated Kinases)
SB  - IM
CON - Cancer Cell. 2016 May 9;29(5):684-96. PMID: 27150039
MH  - Carcinogenesis
MH  - Humans
MH  - Interleukin-1 Receptor-Associated Kinases/*metabolism
MH  - Oncogene Proteins
MH  - STAT3 Transcription Factor/*metabolism
MH  - Signal Transduction
EDAT- 2016/05/12 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/05/12 06:00
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30166-0 [pii]
AID - 10.1016/j.ccell.2016.04.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):615-617. doi: 10.1016/j.ccell.2016.04.008.

PMID- 27165737
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Head of the Class: OLIG2 and Glioblastoma Phenotype.
PG  - 613-615
LID - S1535-6108(16)30165-9 [pii]
LID - 10.1016/j.ccell.2016.04.007 [doi]
AB  - Genomic mapping has driven the classification of glioblastoma into distinct
      molecular subclasses, but mechanisms that regulate tumor subclass phenotypes are 
      only now emerging. In this issue of Cancer Cell, Lu et al. describe a phenotypic 
      switch from PDGFRA-enriched "proneural" to EGFR-enriched "classical" features in 
      glioblastoma upon ablation of Olig2.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Leelatian, Nalin
AU  - Leelatian N
AD  - Department of Cancer Biology, Vanderbilt University School of Medicine, 761B
      Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232-6840, USA.
FAU - Ihrie, Rebecca A
AU  - Ihrie RA
AD  - Department of Cancer Biology, Vanderbilt University School of Medicine, 761B
      Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232-6840, USA;
      Department of Neurological Surgery, Vanderbilt University School of Medicine,
      761B Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232-6840,
      USA. Electronic address: rebecca.ihrie@vanderbilt.edu.
LA  - eng
GR  - R01 NS096238/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Transcription Factors)
SB  - IM
CON - Cancer Cell. 2016 May 9;29(5):669-83. PMID: 27165742
MH  - Brain Neoplasms/*genetics
MH  - Glioblastoma/*genetics
MH  - Humans
MH  - Phenotype
MH  - Transcription Factors/genetics
EDAT- 2016/05/12 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/05/12 06:00
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30165-9 [pii]
AID - 10.1016/j.ccell.2016.04.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):613-615. doi: 10.1016/j.ccell.2016.04.007.

PMID- 27165736
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and
      Myeloma Pathophysiology.
PG  - 611-612
LID - S1535-6108(16)30167-2 [pii]
LID - 10.1016/j.ccell.2016.04.009 [doi]
AB  - In this issue of Cancer Cell, Zhang et al. report that TJP1 suppresses
      EGFR/JAK1/STAT3-mediated signaling and increases the proteasome inhibitor
      sensitivity of myeloma cells by altering the cellular proteasome capacity versus 
      proteasome load of undegraded intracellular proteins.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Mitsiades, Constantine S
AU  - Mitsiades CS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute and Department of
      Medicine, Harvard Medical School, Boston, MA 02215, USA. Electronic address:
      constantine_mitsiades@dfci.harvard.edu.
LA  - eng
GR  - R01 CA050947/CA/NCI NIH HHS/United States
GR  - R01 CA179483/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Boronic Acids)
RN  - 0 (Proteasome Inhibitors)
RN  - 0 (Zonula Occludens-1 Protein)
RN  - 69G8BD63PP (Bortezomib)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
SB  - IM
CON - Cancer Cell. 2016 May 9;29(5):639-52. PMID: 27132469
MH  - Boronic Acids
MH  - Bortezomib
MH  - Cell Line, Tumor
MH  - Humans
MH  - Multiple Myeloma/metabolism
MH  - Proteasome Endopeptidase Complex/metabolism
MH  - Proteasome Inhibitors/*pharmacology
MH  - *Zonula Occludens-1 Protein
EDAT- 2016/05/12 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/05/12 06:00
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - S1535-6108(16)30167-2 [pii]
AID - 10.1016/j.ccell.2016.04.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):611-612. doi: 10.1016/j.ccell.2016.04.009.

PMID- 27150039
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - IRAK-M Expression in Tumor Cells Supports Colorectal Cancer Progression through
      Reduction of Antimicrobial Defense and Stabilization of STAT3.
PG  - 684-696
LID - S1535-6108(16)30097-6 [pii]
LID - 10.1016/j.ccell.2016.03.014 [doi]
AB  - Colorectal cancer (CRC) is associated with loss of epithelial barrier integrity, 
      which facilitates the interaction of the immunological microenvironment with the 
      luminal microbiome, eliciting tumor-supportive inflammation. An important
      regulator of intestinal inflammatory responses is IRAK-M, a negative regulator of
      TLR signaling. Here we investigate the compartment-specific impact of IRAK-M on
      colorectal carcinogenesis using a mouse model. We demonstrate that IRAK-M is
      expressed in tumor cells due to combined TLR and Wnt activation. Tumor
      cell-intrinsic IRAK-M is responsible for regulation of microbial colonization of 
      tumors and STAT3 protein stability in tumor cells, leading to tumor cell
      proliferation. IRAK-M expression in human CRCs is associated with poor prognosis.
      These results suggest that IRAK-M may be a potential therapeutic target for CRC
      treatment.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kesselring, Rebecca
AU  - Kesselring R
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Glaesner, Joachim
AU  - Glaesner J
AD  - Institute of Microbiology and Hygiene, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Hiergeist, Andreas
AU  - Hiergeist A
AD  - Institute of Microbiology and Hygiene, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Naschberger, Elisabeth
AU  - Naschberger E
AD  - Department of Surgery, University Medical Center Erlangen, Schwabachanlage 12,
      91054 Erlangen, Germany.
FAU - Neumann, Helmut
AU  - Neumann H
AD  - Department of Internal Medicine, University Medical Center Erlangen, Ulmenweg 18,
      91054 Erlangen, Germany.
FAU - Brunner, Stefan M
AU  - Brunner SM
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Wege, Anja K
AU  - Wege AK
AD  - Clinic of Gynecology and Obstetrics, Caritas Hospital St. Josef, University of
      Regensburg, 93053 Regensburg, Germany.
FAU - Seebauer, Caroline
AU  - Seebauer C
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Kohl, Gudrun
AU  - Kohl G
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Merkl, Susanne
AU  - Merkl S
AD  - Department of Surgery, University Medical Center Erlangen, Schwabachanlage 12,
      91054 Erlangen, Germany.
FAU - Croner, Roland S
AU  - Croner RS
AD  - Department of Surgery, University Medical Center Erlangen, Schwabachanlage 12,
      91054 Erlangen, Germany.
FAU - Hackl, Christina
AU  - Hackl C
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Sturzl, Michael
AU  - Sturzl M
AD  - Department of Surgery, University Medical Center Erlangen, Schwabachanlage 12,
      91054 Erlangen, Germany.
FAU - Neurath, Markus F
AU  - Neurath MF
AD  - Department of Internal Medicine, University Medical Center Erlangen, Ulmenweg 18,
      91054 Erlangen, Germany.
FAU - Gessner, Andre
AU  - Gessner A
AD  - Institute of Microbiology and Hygiene, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Schlitt, Hans-Juergen
AU  - Schlitt HJ
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Geissler, Edward K
AU  - Geissler EK
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
FAU - Fichtner-Feigl, Stefan
AU  - Fichtner-Feigl S
AD  - Department of Surgery, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; Regensburg Center for
      Interventional Immunology, University Medical Center Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. Electronic address:
      stefan.fichtner@ukr.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160414
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (Toll-Like Receptors)
RN  - EC 2.7.11.1 (IRAK3 protein, human)
RN  - EC 2.7.11.1 (Interleukin-1 Receptor-Associated Kinases)
RN  - EC 2.7.11.1 (Irak3 protein, mouse)
SB  - IM
CIN - Cancer Cell. 2016 May 9;29(5):615-7. PMID: 27165738
MH  - Animals
MH  - Cell Proliferation
MH  - Colitis/immunology
MH  - Colorectal Neoplasms/genetics/*immunology/*microbiology
MH  - Disease Progression
MH  - Host-Pathogen Interactions/immunology
MH  - Humans
MH  - Immunoblotting
MH  - Immunohistochemistry
MH  - Interleukin-1 Receptor-Associated Kinases/genetics/*immunology/metabolism
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - Microbiota/*immunology
MH  - Phosphorylation/immunology
MH  - Prognosis
MH  - Protein Stability
MH  - STAT3 Transcription Factor/*immunology/metabolism
MH  - Survival Analysis
MH  - Toll-Like Receptors/immunology/metabolism
MH  - Wnt Signaling Pathway/immunology
OTO - NOTNLM
OT  - *IRAK-M
OT  - *STAT3
OT  - *Toll-like receptors
OT  - *Wnt signaling
OT  - *colorectal cancer
OT  - *microbiome
EDAT- 2016/05/07 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/07 06:00
PHST- 2015/02/23 00:00 [received]
PHST- 2015/08/12 00:00 [revised]
PHST- 2016/03/18 00:00 [accepted]
PHST- 2016/05/07 06:00 [entrez]
PHST- 2016/05/07 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30097-6 [pii]
AID - 10.1016/j.ccell.2016.03.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):684-696. doi: 10.1016/j.ccell.2016.03.014. Epub
      2016 Apr 14.

PMID- 27150038
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic
      Self-Sufficiency.
PG  - 697-710
LID - S1535-6108(16)30085-X [pii]
LID - 10.1016/j.ccell.2016.03.003 [doi]
AB  - The ability of cancer cells to establish lethal metastatic lesions requires the
      survival and expansion of single cancer cells at distant sites. The factors
      controlling the clonal growth ability of individual cancer cells remain poorly
      understood. Here, we show that high expression of the transcription factor ARNTL2
      predicts poor lung adenocarcinoma patient outcome. Arntl2 is required for
      metastatic ability in vivo and clonal growth in cell culture. Arntl2 drives
      metastatic self-sufficiency by orchestrating the expression of a complex
      pro-metastatic secretome. We identify Clock as an Arntl2 partner and functionally
      validate the matricellular protein Smoc2 as a pro-metastatic secreted factor.
      These findings shed light on the molecular mechanisms that enable single cancer
      cells to form allochthonous tumors in foreign tissue environments.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Brady, Jennifer J
AU  - Brady JJ
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Chuang, Chen-Hua
AU  - Chuang CH
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Greenside, Peyton G
AU  - Greenside PG
AD  - Biomedical Informatics Training Program, Stanford University School of Medicine, 
      Stanford, CA 94305, USA.
FAU - Rogers, Zoe N
AU  - Rogers ZN
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Murray, Christopher W
AU  - Murray CW
AD  - Cancer Biology Program, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Caswell, Deborah R
AU  - Caswell DR
AD  - Cancer Biology Program, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Hartmann, Ursula
AU  - Hartmann U
AD  - Center for Biochemistry, University of Cologne, 50931 Cologne, Germany.
FAU - Connolly, Andrew J
AU  - Connolly AJ
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Sweet-Cordero, E Alejandro
AU  - Sweet-Cordero EA
AD  - Cancer Biology Program, Stanford University School of Medicine, Stanford, CA
      94305, USA; Stanford Cancer Institute, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Department of Pediatrics, Stanford University School of 
      Medicine, Stanford, CA 94305, USA.
FAU - Kundaje, Anshul
AU  - Kundaje A
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA
      94305, USA; Department of Computer Science, Stanford University, Stanford, CA
      94305, USA.
FAU - Winslow, Monte M
AU  - Winslow MM
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA
      94305, USA; Department of Pathology, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Cancer Biology Program, Stanford University School of
      Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University
      School of Medicine, Stanford, CA 94305, USA. Electronic address:
      mwinslow@stanford.edu.
LA  - eng
GR  - T32 CA009302/CA/NCI NIH HHS/United States
GR  - F32 CA189659/CA/NCI NIH HHS/United States
GR  - R01 CA175336/CA/NCI NIH HHS/United States
GR  - T15 LM007033/LM/NLM NIH HHS/United States
GR  - R01 CA157510/CA/NCI NIH HHS/United States
GR  - T32 GM007790/GM/NIGMS NIH HHS/United States
GR  - R01 CA204620/CA/NCI NIH HHS/United States
GR  - P30 CA124435/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160414
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ARNTL Transcription Factors)
RN  - 0 (ARNTL2 protein, human)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (SMOC2 protein, human)
RN  - EC 2.3.1.48 (CLOCK Proteins)
SB  - IM
MH  - ARNTL Transcription Factors/*genetics/secretion
MH  - Adenocarcinoma/*genetics/pathology/secretion
MH  - Animals
MH  - Blotting, Western
MH  - CLOCK Proteins/genetics/secretion
MH  - Calcium-Binding Proteins/genetics/secretion
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology/secretion
MH  - Mice, 129 Strain
MH  - Mice, Inbred NOD
MH  - Mice, Knockout
MH  - Mice, SCID
MH  - Neoplasm Metastasis
MH  - RNA Interference
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Analysis
PMC - PMC4864124
MID - NIHMS767960
EDAT- 2016/05/07 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/07 06:00
PHST- 2015/09/20 00:00 [received]
PHST- 2016/01/23 00:00 [revised]
PHST- 2016/03/05 00:00 [accepted]
PHST- 2016/05/07 06:00 [entrez]
PHST- 2016/05/07 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30085-X [pii]
AID - 10.1016/j.ccell.2016.03.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):697-710. doi: 10.1016/j.ccell.2016.03.003. Epub
      2016 Apr 14.

PMID- 27132469
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor
      Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
PG  - 639-652
LID - S1535-6108(16)30109-X [pii]
LID - 10.1016/j.ccell.2016.03.026 [doi]
AB  - Proteasome inhibitors have revolutionized outcomes in multiple myeloma, but they 
      are used empirically, and primary and secondary resistance are emerging problems.
      We have identified TJP1 as a determinant of plasma cell proteasome inhibitor
      susceptibility. TJP1 suppressed expression of the catalytically active
      immunoproteasome subunits LMP7 and LMP2, decreased proteasome activity, and
      enhanced proteasome inhibitor sensitivity in vitro and in vivo. This occurred
      through TJP1-mediated suppression of EGFR/JAK1/STAT3 signaling, which modulated
      LMP7 and LMP2 levels. In the clinic, high TJP1 expression in patient myeloma
      cells was associated with a significantly higher likelihood of responding to
      bortezomib and a longer response duration, supporting the use of TJP1 as a
      biomarker to identify patients most likely to benefit from proteasome inhibitors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zhang, Xing-Ding
AU  - Zhang XD
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Cyrus Tang Hematology Center, Soochow University,
      Suzhou, Jiangsu 215123, China; Xi'an Jiaotong University Suzhou Academy, Suzhou, 
      Jiangsu 215123, China.
FAU - Baladandayuthapani, Veerabhadran
AU  - Baladandayuthapani V
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Lin, Heather
AU  - Lin H
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Mulligan, George
AU  - Mulligan G
AD  - Millennium: The Takeda Oncology Company, Cambridge, MA 02139, USA.
FAU - Li, Bin
AU  - Li B
AD  - Millennium: The Takeda Oncology Company, Cambridge, MA 02139, USA.
FAU - Esseltine, Dixie-Lee W
AU  - Esseltine DW
AD  - Millennium: The Takeda Oncology Company, Cambridge, MA 02139, USA.
FAU - Qi, Lin
AU  - Qi L
AD  - Xi'an Jiaotong University Suzhou Academy, Suzhou, Jiangsu 215123, China.
FAU - Xu, Jianliang
AU  - Xu J
AD  - Institute of Molecular and Cell Biology, Singapore 138673, Republic of Singapore.
FAU - Hunziker, Walter
AU  - Hunziker W
AD  - Institute of Molecular and Cell Biology, Singapore 138673, Republic of Singapore.
FAU - Barlogie, Bart
AU  - Barlogie B
AD  - Myeloma Institute for Research and Therapy, University of Arkansas for Medical
      Sciences, Little Rock, AR 72205, USA.
FAU - Usmani, Saad Z
AU  - Usmani SZ
AD  - Myeloma Institute for Research and Therapy, University of Arkansas for Medical
      Sciences, Little Rock, AR 72205, USA; Department of Hematologic Oncology, Levine 
      Cancer Institute, Carolinas Healthcare System, Charlotte, NC 28204, USA.
FAU - Zhang, Qing
AU  - Zhang Q
AD  - Myeloma Institute for Research and Therapy, University of Arkansas for Medical
      Sciences, Little Rock, AR 72205, USA; Department of Hematologic Oncology, Levine 
      Cancer Institute, Carolinas Healthcare System, Charlotte, NC 28204, USA.
FAU - Crowley, John
AU  - Crowley J
AD  - Cancer Research and Biostatistics, Seattle, WA 98101, USA.
FAU - Hoering, Antje
AU  - Hoering A
AD  - Cancer Research and Biostatistics, Seattle, WA 98101, USA.
FAU - Shah, Jatin J
AU  - Shah JJ
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Weber, Donna M
AU  - Weber DM
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Manasanch, Elisabet E
AU  - Manasanch EE
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Thomas, Sheeba K
AU  - Thomas SK
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Li, Bing-Zong
AU  - Li BZ
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Wang, Hui-Han
AU  - Wang HH
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Zhang, Jiexin
AU  - Zhang J
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Kuiatse, Isere
AU  - Kuiatse I
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Tang, Jin-Le
AU  - Tang JL
AD  - Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China.
FAU - Wang, Hua
AU  - Wang H
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - He, Jin
AU  - He J
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Milan, Enrico
AU  - Milan E
AD  - Division of Genetics and Cell Biology, San Raffaele Scientific Institute,
      Universita Vita-Salute San Raffaele, Milan 20132, Italy.
FAU - Cenci, Simone
AU  - Cenci S
AD  - Division of Genetics and Cell Biology, San Raffaele Scientific Institute,
      Universita Vita-Salute San Raffaele, Milan 20132, Italy.
FAU - Ma, Wen-Cai
AU  - Ma WC
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Wang, Zhi-Qiang
AU  - Wang ZQ
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Davis, Richard Eric
AU  - Davis RE
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Yang, Lin
AU  - Yang L
AD  - Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China; 
      Xi'an Jiaotong University Suzhou Academy, Suzhou, Jiangsu 215123, China.
      Electronic address: yanglin@suda.edu.cn.
FAU - Orlowski, Robert Z
AU  - Orlowski RZ
AD  - Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Experimental Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic
      address: rorlowsk@mdanderson.org.
LA  - eng
GR  - R01 CA194264/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA142509/CA/NCI NIH HHS/United States
GR  - U10 CA032102/CA/NCI NIH HHS/United States
GR  - R01 CA184464/CA/NCI NIH HHS/United States
GR  - P01 CA055819/CA/NCI NIH HHS/United States
GR  - U10 CA180888/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160428
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proteasome Inhibitors)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (TJP1 protein, human)
RN  - 0 (Zonula Occludens-1 Protein)
RN  - 144416-78-4 (LMP-2 protein)
RN  - 69G8BD63PP (Bortezomib)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.10.2 (JAK1 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 1)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
RN  - EC 3.4.25.1 (LMP7 protein)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
SB  - IM
CIN - Cancer Cell. 2016 May 9;29(5):611-2. PMID: 27165736
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Blotting, Western
MH  - Bortezomib/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Cysteine Endopeptidases/metabolism
MH  - Disease-Free Survival
MH  - Erlotinib Hydrochloride/pharmacology/therapeutic use
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Janus Kinase 1/*metabolism
MH  - Mice, SCID
MH  - Multiple Myeloma/*drug therapy/genetics/metabolism
MH  - Proteasome Endopeptidase Complex/*metabolism
MH  - Proteasome Inhibitors/pharmacology/*therapeutic use
MH  - RNA Interference
MH  - Receptor, Epidermal Growth Factor/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - STAT3 Transcription Factor/*metabolism
MH  - Signal Transduction/drug effects
MH  - Xenograft Model Antitumor Assays/methods
MH  - Zonula Occludens-1 Protein/genetics/*metabolism
PMC - PMC4983190
MID - NIHMS774502
EDAT- 2016/05/03 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/05/03 06:00
PHST- 2013/11/21 00:00 [received]
PHST- 2015/12/26 00:00 [revised]
PHST- 2016/03/25 00:00 [accepted]
PHST- 2016/05/03 06:00 [entrez]
PHST- 2016/05/03 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30109-X [pii]
AID - 10.1016/j.ccell.2016.03.026 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub
      2016 Apr 28.

PMID- 27117758
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20170907
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 5
DP  - 2016 May 9
TI  - Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by
      Acting as a Competing Endogenous RNA.
PG  - 653-668
LID - S1535-6108(16)30086-1 [pii]
LID - 10.1016/j.ccell.2016.03.004 [doi]
AB  - Sunitinib resistance is a major challenge for advanced renal cell carcinoma
      (RCC). Understanding the underlying mechanisms and developing effective
      strategies against sunitinib resistance are highly desired in the clinic. Here we
      identified an lncRNA, named lncARSR (lncRNA Activated in RCC with Sunitinib
      Resistance), which correlated with clinically poor sunitinib response. lncARSR
      promoted sunitinib resistance via competitively binding miR-34/miR-449 to
      facilitate AXL and c-MET expression in RCC cells. Furthermore, bioactive lncARSR 
      could be incorporated into exosomes and transmitted to sensitive cells, thus
      disseminating sunitinib resistance. Treatment of sunitinib-resistant RCC with
      locked nucleic acids targeting lncARSR or an AXL/c-MET inhibitor restored
      sunitinib response. Therefore, lncARSR may serve as a predictor and a potential
      therapeutic target for sunitinib resistance.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Qu, Le
AU  - Qu L
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Ding, Jin
AU  - Ding J
AD  - The International Cooperation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
      200433, China.
FAU - Chen, Cheng
AU  - Chen C
AD  - The International Cooperation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
      200433, China; Department of Medical Oncology, Jinling Hospital, Nanjing
      University Clinical School of Medicine, Nanjing 210002, China.
FAU - Wu, Zhen-Jie
AU  - Wu ZJ
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Liu, Bing
AU  - Liu B
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Gao, Yi
AU  - Gao Y
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Liu, Feng
AU  - Liu F
AD  - Department of Medical Genetics, College of Basic Medicine, Second Military
      Medical University, Shanghai 200433, China.
FAU - Sun, Wen
AU  - Sun W
AD  - The International Cooperation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
      200433, China.
FAU - Li, Xiao-Feng
AU  - Li XF
AD  - The International Cooperation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
      200433, China.
FAU - Wang, Xue
AU  - Wang X
AD  - The International Cooperation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
      200433, China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Histology and Embryology, College of Basic Medicine, Second
      Military Medical University, Shanghai 200433, China.
FAU - Xu, Zhen-Yu
AU  - Xu ZY
AD  - Department of Histology and Embryology, College of Basic Medicine, Second
      Military Medical University, Shanghai 200433, China.
FAU - Gao, Li
AU  - Gao L
AD  - Department of Pathology, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Yang, Qing
AU  - Yang Q
AD  - Department of Urology, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Xu, Bin
AU  - Xu B
AD  - Department of Urology, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Li, Yao-Ming
AU  - Li YM
AD  - Department of Urology, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Fang, Zi-Yu
AU  - Fang ZY
AD  - Department of Urology, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Xu, Zhi-Peng
AU  - Xu ZP
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Bao, Yi
AU  - Bao Y
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Wu, Deng-Shuang
AU  - Wu DS
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China.
FAU - Miao, Xiong
AU  - Miao X
AD  - Department of Orthopedics, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Sun, Hai-Yang
AU  - Sun HY
AD  - Department of Orthopedics, Second Affiliated Hospital, School of Medicine,
      Zhejiang University, Hangzhou, Zhejiang 310009, China.
FAU - Sun, Ying-Hao
AU  - Sun YH
AD  - Department of Urology, Changhai Hospital, Second Military Medical University,
      Shanghai 200433, China.
FAU - Wang, Hong-Yang
AU  - Wang HY
AD  - The International Cooperation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
      200433, China. Electronic address: hywangk@vip.sina.com.
FAU - Wang, Lin-Hui
AU  - Wang LH
AD  - Department of Urology, Changzheng Hospital, Second Military Medical University,
      Shanghai 200003, China. Electronic address: wanglinhuicz@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160421
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (MIRN34 microRNA, human)
RN  - 0 (MIRN449 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Pyrroles)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (long noncoding RNA ARSR, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (axl receptor tyrosine kinase)
RN  - V99T50803M (sunitinib)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Blotting, Northern
MH  - Carcinoma, Renal Cell/blood/*drug therapy/genetics
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Disease-Free Survival
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Exosomes/*genetics
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Indoles/*pharmacology
MH  - Kidney Neoplasms/blood/*drug therapy/genetics
MH  - Mice, Nude
MH  - MicroRNAs/genetics/metabolism
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins c-met/genetics
MH  - Pyrroles/*pharmacology
MH  - RNA, Long Noncoding/blood/*genetics/metabolism
MH  - RNA, Neoplasm/genetics/metabolism
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/genetics
MH  - Treatment Outcome
MH  - Xenograft Model Antitumor Assays/methods
EDAT- 2016/04/28 06:00
MHDA- 2017/04/01 06:00
CRDT- 2016/04/28 06:00
PHST- 2015/06/29 00:00 [received]
PHST- 2015/11/08 00:00 [revised]
PHST- 2016/03/04 00:00 [accepted]
PHST- 2016/04/28 06:00 [entrez]
PHST- 2016/04/28 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - S1535-6108(16)30086-1 [pii]
AID - 10.1016/j.ccell.2016.03.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 May 9;29(5):653-668. doi: 10.1016/j.ccell.2016.03.004. Epub
      2016 Apr 21.

PMID- 27070709
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - SnapShot: Renal Cell Carcinoma.
PG  - 610-610.e1
LID - S1535-6108(16)30104-0 [pii]
LID - 10.1016/j.ccell.2016.03.021 [doi]
AB  - Renal cell carcinoma (RCC) is a heterogeneous disease made up of a number of
      different cancer types, with distinct histologies, clinical courses, therapeutic 
      responses, and genetic drivers. Germline mutations in 14 genes have been
      associated with increased risk of RCC and can result in HIF pathway activation,
      chromatin dysregulation, and altered metabolism. Knowledge of these pathway
      alterations can inform the development of targeted therapeutic approaches. To
      view this SnapShot, open or download the PDF.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Ricketts, Christopher J
AU  - Ricketts CJ
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892, USA.
FAU - Crooks, Daniel R
AU  - Crooks DR
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892, USA.
FAU - Sourbier, Carole
AU  - Sourbier C
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892, USA.
FAU - Schmidt, Laura S
AU  - Schmidt LS
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892, USA.
FAU - Srinivasan, Ramaprasad
AU  - Srinivasan R
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892, USA.
FAU - Linehan, W Marston
AU  - Linehan WM
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      Bethesda, MD 20892, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Lipids)
RN  - 0 (Neoplasm Proteins)
RN  - 0RH81L854J (Glutamine)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Carcinoma, Renal Cell/classification/genetics/metabolism
MH  - Energy Metabolism
MH  - Genes, Neoplasm
MH  - Glucose/metabolism
MH  - Glutamine/metabolism
MH  - Glycolysis
MH  - Humans
MH  - *Kidney Neoplasms/classification/genetics/metabolism
MH  - Lipids/biosynthesis
MH  - Neoplasm Proteins/genetics
MH  - Neoplastic Syndromes, Hereditary/genetics
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30104-0 [pii]
AID - 10.1016/j.ccell.2016.03.021 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):610-610.e1. doi: 10.1016/j.ccell.2016.03.021.

PMID- 27070708
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160817
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits
      Broad Anticancer Activity.
PG  - 607
LID - S1535-6108(16)30093-9 [pii]
LID - 10.1016/j.ccell.2016.03.011 [doi]
FAU - Jing, Hui
AU  - Jing H
FAU - Hu, Jing
AU  - Hu J
FAU - He, Bin
AU  - He B
FAU - Negron Abril, Yashira L
AU  - Negron Abril YL
FAU - Stupinski, Jack
AU  - Stupinski J
FAU - Weiser, Keren
AU  - Weiser K
FAU - Carbonaro, Marisa
AU  - Carbonaro M
FAU - Chiang, Ying-Ling
AU  - Chiang YL
FAU - Southard, Teresa
AU  - Southard T
FAU - Giannakakou, Paraskevi
AU  - Giannakakou P
FAU - Weiss, Robert S
AU  - Weiss RS
FAU - Lin, Hening
AU  - Lin H
LA  - eng
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Mar 14;29(3):297-310. Giannakakou, Paraszkevi [corrected to
      Giannakakou, Paraskevi]. PMID: 26977881
EDAT- 2016/04/14 06:00
MHDA- 2016/04/14 06:01
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/04/14 06:01 [medline]
AID - S1535-6108(16)30093-9 [pii]
AID - 10.1016/j.ccell.2016.03.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):607. doi: 10.1016/j.ccell.2016.03.011.

PMID- 27070707
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160817
LR  - 20170930
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1
      Oncogene Expression.
PG  - 607-608
LID - S1535-6108(16)30096-4 [pii]
LID - 10.1016/j.ccell.2016.03.013 [doi]
FAU - Bueno, Maria J
AU  - Bueno MJ
FAU - Perez de Castro, Ignacio
AU  - Perez de Castro I
FAU - Gomez de Cedron, Marta
AU  - Gomez de Cedron M
FAU - Santos, Javier
AU  - Santos J
FAU - Calin, George A
AU  - Calin GA
FAU - Cigudosa, Juan C
AU  - Cigudosa JC
FAU - Croce, Carlo M
AU  - Croce CM
FAU - Fernandez-Piqueras, Jose
AU  - Fernandez-Piqueras J
FAU - Malumbres, Marcos
AU  - Malumbres M
LA  - eng
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2008 Jun;13(6):496-506. PMID: 18538733
EDAT- 2016/04/14 06:00
MHDA- 2016/04/14 06:01
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/04/14 06:01 [medline]
AID - S1535-6108(16)30096-4 [pii]
AID - 10.1016/j.ccell.2016.03.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):607-608. doi: 10.1016/j.ccell.2016.03.013.

PMID- 27070706
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160817
LR  - 20171013
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant
      Hematopoietic Stem Cells.
PG  - 602-606
LID - S1535-6108(16)30098-8 [pii]
LID - 10.1016/j.ccell.2016.03.015 [doi]
FAU - Lechman, Eric R
AU  - Lechman ER
FAU - Gentner, Bernhard
AU  - Gentner B
FAU - Ng, Stanley W K
AU  - Ng SWK
FAU - Schoof, Erwin M
AU  - Schoof EM
FAU - van Galen, Peter
AU  - van Galen P
FAU - Kennedy, James A
AU  - Kennedy JA
FAU - Nucera, Silvia
AU  - Nucera S
FAU - Ciceri, Fabio
AU  - Ciceri F
FAU - Kaufmann, Kerstin B
AU  - Kaufmann KB
FAU - Takayama, Naoya
AU  - Takayama N
FAU - Dobson, Stephanie M
AU  - Dobson SM
FAU - Trotman-Grant, Aaron
AU  - Trotman-Grant A
FAU - Krivdova, Gabriela
AU  - Krivdova G
FAU - Elzinga, Janneke
AU  - Elzinga J
FAU - Mitchell, Amanda
AU  - Mitchell A
FAU - Nilsson, Bjorn
AU  - Nilsson B
FAU - Hermans, Karin G
AU  - Hermans KG
FAU - Eppert, Kolja
AU  - Eppert K
FAU - Marke, Rene
AU  - Marke R
FAU - Isserlin, Ruth
AU  - Isserlin R
FAU - Voisin, Veronique
AU  - Voisin V
FAU - Bader, Gary D
AU  - Bader GD
FAU - Zandstra, Peter W
AU  - Zandstra PW
FAU - Golub, Todd R
AU  - Golub TR
FAU - Ebert, Benjamin L
AU  - Ebert BL
FAU - Lu, Jun
AU  - Lu J
FAU - Minden, Mark
AU  - Minden M
FAU - Wang, Jean C Y
AU  - Wang JCY
FAU - Naldini, Luigi
AU  - Naldini L
FAU - Dick, John E
AU  - Dick JE
LA  - eng
PT  - Published Erratum
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EFR - Cancer Cell. 2016 Feb 8;29(2):214-28. PMID: 26832662
PMC - PMC5628169
EDAT- 2016/04/14 06:00
MHDA- 2016/04/14 06:01
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/04/14 06:01 [medline]
AID - S1535-6108(16)30098-8 [pii]
AID - 10.1016/j.ccell.2016.03.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):602-606. doi: 10.1016/j.ccell.2016.03.015.

PMID- 27070705
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted 
      Effectively by Anti-CCR5 Therapy in Cancer Patients.
PG  - 587-601
LID - S1535-6108(16)30087-3 [pii]
LID - 10.1016/j.ccell.2016.03.005 [doi]
AB  - The immune response influences the clinical course of colorectal cancer (CRC).
      Analyzing the invasive margin of human CRC liver metastases, we identified a
      mechanism of immune cell exploitation by tumor cells. While two distinct subsets 
      of myeloid cells induce an influx of T cells into the invasive margin via
      CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral
      effects via CCR5. CCR5 blockade in patient-derived functional in vitro
      organotypic culture models showed a macrophage repolarization with anti-tumoral
      effects. These anti-tumoral effects were then confirmed in a phase I trial with a
      CCR5 antagonist in patients with liver metastases of advanced refractory CRC.
      Mitigation of tumor-promoting inflammation within the tumor tissue and objective 
      tumor responses in CRC were observed.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Halama, Niels
AU  - Halama N
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis
      Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg,
      69120 Heidelberg, Germany; Institute for Immunology, University Hospital
      Heidelberg, 69120 Heidelberg, Germany. Electronic address:
      niels.halama@nct-heidelberg.de.
FAU - Zoernig, Inka
AU  - Zoernig I
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Berthel, Anna
AU  - Berthel A
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis
      Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg,
      69120 Heidelberg, Germany.
FAU - Kahlert, Christoph
AU  - Kahlert C
AD  - Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany;
      Department of Surgery, University Hospital Dresden, 01307 Dresden, Germany.
FAU - Klupp, Fee
AU  - Klupp F
AD  - Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Suarez-Carmona, Meggy
AU  - Suarez-Carmona M
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Suetterlin, Thomas
AU  - Suetterlin T
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis
      Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg,
      69120 Heidelberg, Germany.
FAU - Brand, Karsten
AU  - Brand K
AD  - Institute for Pathology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany.
FAU - Krauss, Juergen
AU  - Krauss J
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Lasitschka, Felix
AU  - Lasitschka F
AD  - Institute for Pathology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany.
FAU - Lerchl, Tina
AU  - Lerchl T
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis
      Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg,
      69120 Heidelberg, Germany.
FAU - Luckner-Minden, Claudia
AU  - Luckner-Minden C
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Ulrich, Alexis
AU  - Ulrich A
AD  - Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Koch, Moritz
AU  - Koch M
AD  - Department of Surgery, University Hospital Dresden, 01307 Dresden, Germany.
FAU - Weitz, Juergen
AU  - Weitz J
AD  - Department of Surgery, University Hospital Dresden, 01307 Dresden, Germany.
FAU - Schneider, Martin
AU  - Schneider M
AD  - Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Buechler, Markus W
AU  - Buechler MW
AD  - Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AD  - INSERM U1015, Institut Gustave Roussy (IGR), 94805 Villejuif, France.
FAU - Herrmann, Thomas
AU  - Herrmann T
AD  - Department of Internal Medicine I, Klinikum Idar-Oberstein, 55743 Idar Oberstein,
      Germany.
FAU - Benner, Axel
AU  - Benner A
AD  - Division of Biostatistics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Kunz, Christina
AU  - Kunz C
AD  - Division of Biostatistics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Luecke, Stephan
AU  - Luecke S
AD  - Division of Biostatistics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Springfeld, Christoph
AU  - Springfeld C
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Grabe, Niels
AU  - Grabe N
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis
      Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg,
      69120 Heidelberg, Germany.
FAU - Falk, Christine S
AU  - Falk CS
AD  - Institute of Transplant Immunology, Integrated Research and Treatment Center
      Transplantation, Hannover Medical School, 30625 Hannover, Germany.
FAU - Jaeger, Dirk
AU  - Jaeger D
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University
      Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis
      Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg,
      69120 Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CCL5 protein, human)
RN  - 0 (CCR5 protein, human)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Chemokines)
RN  - 0 (Cyclohexanes)
RN  - 0 (Interferon-alpha)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, CCR5)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - 0 (Triazoles)
RN  - 0813BZ6866 (Clodronic Acid)
RN  - 24T2A1DOYB (regorafenib)
RN  - MD6P741W8A (maraviroc)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
CIN - Cancer Cell. 2016 Apr 11;29(4):437-9. PMID: 27070698
MH  - Adenocarcinoma/drug therapy/immunology/*secondary
MH  - Apoptosis/drug effects
MH  - Chemokine CCL5/*antagonists & inhibitors/biosynthesis/secretion
MH  - Chemokines/physiology
MH  - Chemotaxis
MH  - Clinical Trials, Phase I as Topic
MH  - Clodronic Acid/pharmacology
MH  - Colorectal Neoplasms/*immunology
MH  - Cyclohexanes/pharmacology/therapeutic use
MH  - Humans
MH  - Interferon-alpha/secretion
MH  - Liver Neoplasms/drug therapy/immunology/*secondary/secretion
MH  - Lung Neoplasms/drug therapy/secondary
MH  - Lymphocytes, Tumor-Infiltrating/immunology/secretion
MH  - Macrophages/drug effects/secretion
MH  - *Molecular Targeted Therapy
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Neoplasm Invasiveness
MH  - Neoplasm Proteins/*antagonists & inhibitors/physiology
MH  - Phenylurea Compounds/therapeutic use
MH  - Pilot Projects
MH  - Pyridines/therapeutic use
MH  - Receptors, CCR5/*drug effects/metabolism
MH  - STAT3 Transcription Factor/physiology
MH  - Survival Analysis
MH  - Triazoles/pharmacology/therapeutic use
MH  - Tumor Cells, Cultured
MH  - Tumor Microenvironment/drug effects
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2015/07/17 00:00 [received]
PHST- 2016/01/27 00:00 [revised]
PHST- 2016/03/11 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30087-3 [pii]
AID - 10.1016/j.ccell.2016.03.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005.

PMID- 27070704
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20171215
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - The Public Repository of Xenografts Enables Discovery and Randomized Phase
      II-like Trials in Mice.
PG  - 574-586
LID - S1535-6108(16)30090-3 [pii]
LID - 10.1016/j.ccell.2016.03.008 [doi]
AB  - More than 90% of drugs with preclinical activity fail in human trials, largely
      due to insufficient efficacy. We hypothesized that adequately powered trials of
      patient-derived xenografts (PDX) in mice could efficiently define therapeutic
      activity across heterogeneous tumors. To address this hypothesis, we established 
      a large, publicly available repository of well-characterized leukemia and
      lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository
      of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to
      the primary specimens and the PDXs derived from them. Using this repository, we
      demonstrate that large studies of acute leukemia PDXs that mimic human randomized
      clinical trials can characterize drug efficacy and generate transcriptional,
      functional, and proteomic biomarkers in both treatment-naive and
      relapsed/refractory disease.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Townsend, Elizabeth C
AU  - Townsend EC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Murakami, Mark A
AU  - Murakami MA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Christodoulou, Alexandra
AU  - Christodoulou A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Christie, Amanda L
AU  - Christie AL
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Koster, Johannes
AU  - Koster J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA; Center for Functional Cancer
      Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - DeSouza, Tiffany A
AU  - DeSouza TA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Morgan, Elizabeth A
AU  - Morgan EA
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Kallgren, Scott P
AU  - Kallgren SP
AD  - Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115,
      USA.
FAU - Liu, Huiyun
AU  - Liu H
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Wu, Shuo-Chieh
AU  - Wu SC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Plana, Olivia
AU  - Plana O
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Montero, Joan
AU  - Montero J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Stevenson, Kristen E
AU  - Stevenson KE
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Rao, Prakash
AU  - Rao P
AD  - Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston,
      MA 02215, USA.
FAU - Vadhi, Raga
AU  - Vadhi R
AD  - Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston,
      MA 02215, USA.
FAU - Andreeff, Michael
AU  - Andreeff M
AD  - Leukemia Division, MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Armand, Philippe
AU  - Armand P
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Ballen, Karen K
AU  - Ballen KK
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Barzaghi-Rinaudo, Patrizia
AU  - Barzaghi-Rinaudo P
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Cahill, Sarah
AU  - Cahill S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Clark, Rachael A
AU  - Clark RA
AD  - Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Cooke, Vesselina G
AU  - Cooke VG
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Davids, Matthew S
AU  - Davids MS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - DeAngelo, Daniel J
AU  - DeAngelo DJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Dorfman, David M
AU  - Dorfman DM
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Eaton, Hilary
AU  - Eaton H
AD  - Office of Research and Technology Ventures, Dana-Farber Cancer Institute, Boston,
      MA 02215, USA.
FAU - Ebert, Benjamin L
AU  - Ebert BL
AD  - Department of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Etchin, Julia
AU  - Etchin J
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Firestone, Brant
AU  - Firestone B
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Fisher, David C
AU  - Fisher DC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Freedman, Arnold S
AU  - Freedman AS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Galinsky, Ilene A
AU  - Galinsky IA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Gao, Hui
AU  - Gao H
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Garcia, Jacqueline S
AU  - Garcia JS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Garnache-Ottou, Francine
AU  - Garnache-Ottou F
AD  - EFS Bourgogne Franche Comte, INSERM UMR1098, 25020 Besancon, France.
FAU - Graubert, Timothy A
AU  - Graubert TA
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Gutierrez, Alejandro
AU  - Gutierrez A
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215,
      USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - Halilovic, Ensar
AU  - Halilovic E
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Harris, Marian H
AU  - Harris MH
AD  - Department of Pathology, Boston Children's Hospital, Boston, MA 02215, USA.
FAU - Herbert, Zachary T
AU  - Herbert ZT
AD  - Molecular Biology Core Facility, Dana-Farber Cancer Institute, Boston, MA 02215, 
      USA.
FAU - Horwitz, Steven M
AU  - Horwitz SM
AD  - Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Inghirami, Giorgio
AU  - Inghirami G
AD  - Department of Pathology, Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Intlekofer, Andrew M
AU  - Intlekofer AM
AD  - Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Ito, Moriko
AU  - Ito M
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Izraeli, Shai
AU  - Izraeli S
AD  - Functional Genomics and Leukemia Research, Sheba Medical Center, Tel Hashomer and
      Tel Aviv University, Ramat Gan, 52621, Israel.
FAU - Jacobsen, Eric D
AU  - Jacobsen ED
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Jacobson, Caron A
AU  - Jacobson CA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Jeay, Sebastien
AU  - Jeay S
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Jeremias, Irmela
AU  - Jeremias I
AD  - Department of Gene Vectors, Helmholtz Zentrum Munchen, German Research Center for
      Environmental Health, Marchioninistrasse 25, 81377 Munich, Germany; Department of
      Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilians University,
      Lindwurmstrasse 4, 80337 Munich, Germany.
FAU - Kelliher, Michelle A
AU  - Kelliher MA
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA 01655, USA.
FAU - Koch, Raphael
AU  - Koch R
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Konopleva, Marina
AU  - Konopleva M
AD  - Leukemia Division, MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kopp, Nadja
AU  - Kopp N
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Kornblau, Steven M
AU  - Kornblau SM
AD  - Leukemia Division, MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kung, Andrew L
AU  - Kung AL
AD  - Department of Pediatrics, Columbia University Medical Center, New York, NY 10032,
      USA.
FAU - Kupper, Thomas S
AU  - Kupper TS
AD  - Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - LeBoeuf, Nicole R
AU  - LeBoeuf NR
AD  - Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - LaCasce, Ann S
AU  - LaCasce AS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Lees, Emma
AU  - Lees E
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Li, Loretta S
AU  - Li LS
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Look, A Thomas
AU  - Look AT
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Murakami, Masato
AU  - Murakami M
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Muschen, Markus
AU  - Muschen M
AD  - Department of Laboratory Medicine, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Neuberg, Donna
AU  - Neuberg D
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Ng, Samuel Y
AU  - Ng SY
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Odejide, Oreofe O
AU  - Odejide OO
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Orkin, Stuart H
AU  - Orkin SH
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Paquette, Rachel R
AU  - Paquette RR
AD  - Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - Place, Andrew E
AU  - Place AE
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Roderick, Justine E
AU  - Roderick JE
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA 01655, USA.
FAU - Ryan, Jeremy A
AU  - Ryan JA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Sallan, Stephen E
AU  - Sallan SE
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Shoji, Brent
AU  - Shoji B
AD  - Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Silverman, Lewis B
AU  - Silverman LB
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Soiffer, Robert J
AU  - Soiffer RJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Steensma, David P
AU  - Steensma DP
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Tamburini, Jerome
AU  - Tamburini J
AD  - Universite Paris Descartes, Faculte de Medecine Sorbonne Paris Cite, 75005 Paris,
      France.
FAU - Thorner, Aaron R
AU  - Thorner AR
AD  - Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - van Hummelen, Paul
AU  - van Hummelen P
AD  - Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - Wadleigh, Martha
AU  - Wadleigh M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Wiesmann, Marion
AU  - Wiesmann M
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Weng, Andrew P
AU  - Weng AP
AD  - Department of Pathology, British Columbia Cancer Research Center, Vancouver V5Z
      1H8, Canada.
FAU - Wuerthner, Jens U
AU  - Wuerthner JU
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis
      Institutes for Biomedical Research, 4056 Basel, Switzerland.
FAU - Williams, David A
AU  - Williams DA
AD  - Department of Pediatrics, Columbia University Medical Center, New York, NY 10032,
      USA.
FAU - Wollison, Bruce M
AU  - Wollison BM
AD  - Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - Lane, Andrew A
AU  - Lane AA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Letai, Anthony
AU  - Letai A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Bertagnolli, Monica M
AU  - Bertagnolli MM
AD  - Department of Laboratory Medicine, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Ritz, Jerome
AU  - Ritz J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Brown, Myles
AU  - Brown M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA; Center for Functional Cancer
      Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Long, Henry
AU  - Long H
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA; Center for Functional Cancer
      Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Aster, Jon C
AU  - Aster JC
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Shipp, Margaret A
AU  - Shipp MA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Griffin, James D
AU  - Griffin JD
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA.
FAU - Weinstock, David M
AU  - Weinstock DM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450
      Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT,
      Cambridge, MA 02142, USA. Electronic address: dweinstock@partners.org.
LA  - eng
GR  - P30 AR069625/AR/NIAMS NIH HHS/United States
GR  - R01 CA193651/CA/NCI NIH HHS/United States
GR  - T32 HL116324/HL/NHLBI NIH HHS/United States
GR  - P01 CA066996/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA157644/CA/NCI NIH HHS/United States
GR  - R01 CA203721/CA/NCI NIH HHS/United States
GR  - R01 AR063962/AR/NIAMS NIH HHS/United States
GR  - R01 CA172387/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Isoquinolines)
RN  - 0 (NVP-CGM097)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Piperazines)
RN  - 0 (Proteome)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
EIN - Cancer Cell. 2016 Jul 11;30(1):183. PMID: 27479034
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Biomarkers, Tumor
MH  - Cell Lineage
MH  - Female
MH  - Gene Expression Profiling
MH  - Genes, p53
MH  - *Heterografts
MH  - Humans
MH  - Internet
MH  - Isoquinolines/pharmacology/therapeutic use
MH  - Leukemia/metabolism/*pathology
MH  - Leukemia, Experimental/drug therapy
MH  - Lymphoma/metabolism/*pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Molecular Targeted Therapy
MH  - Neoplasm Proteins/antagonists & inhibitors
MH  - Neoplasm Transplantation
MH  - Phenotype
MH  - Piperazines/pharmacology/therapeutic use
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/pathology
MH  - Proteome
MH  - Proto-Oncogene Proteins c-mdm2/antagonists & inhibitors
MH  - Random Allocation
MH  - Randomized Controlled Trials as Topic/methods
MH  - Research Design
MH  - *Tissue Banks
MH  - Transcriptome
MH  - *Xenograft Model Antitumor Assays
PMC - PMC5177991
MID - NIHMS794414
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2015/12/14 00:00 [received]
PHST- 2016/01/25 00:00 [revised]
PHST- 2016/03/11 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30090-3 [pii]
AID - 10.1016/j.ccell.2016.03.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008.

PMID- 27070703
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs
      Targeted Combination Therapy in Glioblastoma.
PG  - 563-573
LID - S1535-6108(16)30094-0 [pii]
LID - 10.1016/j.ccell.2016.03.012 [doi]
AB  - Intratumoral heterogeneity of signaling networks may contribute to targeted
      cancer therapy resistance, including in the highly lethal brain cancer
      glioblastoma (GBM). We performed single-cell phosphoproteomics on a
      patient-derived in vivo GBM model of mTOR kinase inhibitor resistance and coupled
      it to an analytical approach for detecting changes in signaling coordination.
      Alterations in the protein signaling coordination were resolved as early as 2.5
      days after treatment, anticipating drug resistance long before it was clinically 
      manifest. Combination therapies were identified that resulted in complete and
      sustained tumor suppression in vivo. This approach may identify actionable
      alterations in signal coordination that underlie adaptive resistance, which can
      be suppressed through combination drug therapy, including non-obvious drug
      combinations.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Wei, Wei
AU  - Wei W
AD  - Division of Chemistry and Chemical Engineering, NanoSystems Biology Cancer
      Center, California Institute of Technology, Pasadena, CA 91125, USA; Department
      of Applied Physics and Materials Science, California Institute of Technology,
      Pasadena, CA 91125, USA; Department of Molecular and Medical Pharmacology,
      University of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Shin, Young Shik
AU  - Shin YS
AD  - Division of Chemistry and Chemical Engineering, NanoSystems Biology Cancer
      Center, California Institute of Technology, Pasadena, CA 91125, USA; Department
      of Molecular and Medical Pharmacology, University of California, Los Angeles, Los
      Angeles, CA 90095, USA.
FAU - Xue, Min
AU  - Xue M
AD  - Division of Chemistry and Chemical Engineering, NanoSystems Biology Cancer
      Center, California Institute of Technology, Pasadena, CA 91125, USA.
FAU - Matsutani, Tomoo
AU  - Matsutani T
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA.
FAU - Masui, Kenta
AU  - Masui K
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA.
FAU - Yang, Huijun
AU  - Yang H
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA.
FAU - Ikegami, Shiro
AU  - Ikegami S
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA.
FAU - Gu, Yuchao
AU  - Gu Y
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA.
FAU - Herrmann, Ken
AU  - Herrmann K
AD  - Department of Molecular and Medical Pharmacology, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
FAU - Johnson, Dazy
AU  - Johnson D
AD  - Department of Molecular and Medical Pharmacology, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
FAU - Ding, Xiangming
AU  - Ding X
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
FAU - Hwang, Kiwook
AU  - Hwang K
AD  - Division of Chemistry and Chemical Engineering, NanoSystems Biology Cancer
      Center, California Institute of Technology, Pasadena, CA 91125, USA.
FAU - Kim, Jungwoo
AU  - Kim J
AD  - Division of Chemistry and Chemical Engineering, NanoSystems Biology Cancer
      Center, California Institute of Technology, Pasadena, CA 91125, USA.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
FAU - Su, Yapeng
AU  - Su Y
AD  - Division of Chemistry and Chemical Engineering, NanoSystems Biology Cancer
      Center, California Institute of Technology, Pasadena, CA 91125, USA.
FAU - Li, Xinmin
AU  - Li X
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
FAU - Bonetti, Bruno
AU  - Bonetti B
AD  - Department of Neurological and Movement Sciences, University of Verona, Verona,
      37134, Italy.
FAU - Chopra, Rajesh
AU  - Chopra R
AD  - Celgene Corporation, San Diego, CA 92121, USA.
FAU - James, C David
AU  - James CD
AD  - Department of Neurological Surgery, Northwestern University Feinberg School of
      Medicine, Chicago, IL 60611, USA.
FAU - Cavenee, Webster K
AU  - Cavenee WK
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA.
FAU - Cloughesy, Timothy F
AU  - Cloughesy TF
AD  - Department of Neurology, University of California, Los Angeles, Los Angeles, CA
      90095, USA.
FAU - Mischel, Paul S
AU  - Mischel PS
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA. Electronic address: pmischel@ucsd.edu.
FAU - Heath, James R
AU  - Heath JR
AD  - Division of Chemistry and Chemical Engineering, NanoSystems Biology Cancer
      Center, California Institute of Technology, Pasadena, CA 91125, USA; Department
      of Molecular and Medical Pharmacology, University of California, Los Angeles, Los
      Angeles, CA 90095, USA. Electronic address: heath@caltech.edu.
FAU - Gini, Beatrice
AU  - Gini B
AD  - Ludwig Institute for Cancer Research, University of California, San Diego, La
      Jolla, CA 92093, USA.
LA  - eng
GR  - R01 NS073831/NS/NINDS NIH HHS/United States
GR  - U54 CA151819/CA/NCI NIH HHS/United States
GR  - U54 CA199090/CA/NCI NIH HHS/United States
GR  - P30 CA060553/CA/NCI NIH HHS/United States
GR  - P30 CA016042/CA/NCI NIH HHS/United States
GR  - P30 CA023100/CA/NCI NIH HHS/United States
GR  - NS73831/NS/NINDS NIH HHS/United States
GR  - 5U54CA 151819/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Butadienes)
RN  - 0 (CC214-2)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nitriles)
RN  - 0 (Phosphoproteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazines)
RN  - 0 (U 0126)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
CIN - Cancer Cell. 2016 Apr 11;29(4):435-6. PMID: 27070697
MH  - Adaptation, Physiological
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use
MH  - Brain Neoplasms/drug therapy/*metabolism/pathology
MH  - Butadienes/administration & dosage
MH  - Dasatinib/administration & dosage
MH  - Drug Resistance, Neoplasm
MH  - Drug Synergism
MH  - Gene Expression Profiling
MH  - Genes, erbB-1
MH  - Glioblastoma/drug therapy/*metabolism/pathology
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mechanistic Target of Rapamycin Complex 2
MH  - Mice
MH  - Models, Biological
MH  - *Molecular Targeted Therapy
MH  - Multiprotein Complexes/antagonists & inhibitors/physiology
MH  - Mutation
MH  - Neoplasm Proteins/antagonists & inhibitors/genetics/*metabolism
MH  - Nitriles/administration & dosage
MH  - Phosphoproteins/*metabolism
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Proteomics/*methods
MH  - Pyrazines/administration & dosage
MH  - Receptor, Epidermal Growth Factor/antagonists & inhibitors/physiology
MH  - Selection, Genetic
MH  - Signal Transduction/drug effects
MH  - Single-Cell Analysis/*methods
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/physiology
MH  - Xenograft Model Antitumor Assays
PMC - PMC4831071
MID - NIHMS771139
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2015/08/02 00:00 [received]
PHST- 2015/11/25 00:00 [revised]
PHST- 2016/03/15 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30094-0 [pii]
AID - 10.1016/j.ccell.2016.03.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):563-573. doi: 10.1016/j.ccell.2016.03.012.

PMID- 27070702
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse
      Large B Cell Lymphoma.
PG  - 494-507
LID - S1535-6108(16)30088-5 [pii]
LID - 10.1016/j.ccell.2016.03.006 [doi]
AB  - Chronic active B cell receptor (BCR) signaling, a hallmark of the activated B
      cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), engages the
      CARD11-MALT1-BCL10 (CBM) adapter complex to activate IkappaB kinase (IKK) and the
      classical NF-kappaB pathway. Here we show that the CBM complex includes the E3
      ubiquitin ligases cIAP1 and cIAP2, which are essential mediators of BCR-dependent
      NF-kappaB activity in ABC DLBCL. cIAP1/2 attach K63-linked polyubiquitin chains
      on themselves and on BCL10, resulting in the recruitment of IKK and the linear
      ubiquitin chain ligase LUBAC, which is essential for IKK activation. SMAC
      mimetics target cIAP1/2 for destruction, and consequently suppress NF-kappaB and 
      selectively kill BCR-dependent ABC DLBCL lines, supporting their clinical
      evaluation in patients with ABC DLBCL.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Yang, Yibin
AU  - Yang Y
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Kelly, Priscilla
AU  - Kelly P
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Shaffer, Arthur L 3rd
AU  - Shaffer AL 3rd
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Schmitz, Roland
AU  - Schmitz R
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Yoo, Hee Min
AU  - Yoo HM
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Liu, Xinyue
AU  - Liu X
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Huang, Da Wei
AU  - Huang DW
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Webster, Daniel
AU  - Webster D
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Young, Ryan M
AU  - Young RM
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Nakagawa, Masao
AU  - Nakagawa M
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Ceribelli, Michele
AU  - Ceribelli M
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Wright, George W
AU  - Wright GW
AD  - Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National
      Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Yang, Yandan
AU  - Yang Y
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Zhao, Hong
AU  - Zhao H
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Yu, Xin
AU  - Yu X
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Xu, Weihong
AU  - Xu W
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA.
FAU - Chan, Wing C
AU  - Chan WC
AD  - Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, 
      USA.
FAU - Jaffe, Elaine S
AU  - Jaffe ES
AD  - Laboratory of Pathology, Center for Cancer Research, National Cancer Institute,
      Bethesda, MD 20892, USA.
FAU - Gascoyne, Randy D
AU  - Gascoyne RD
AD  - British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
FAU - Campo, Elias
AU  - Campo E
AD  - Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
FAU - Rosenwald, Andreas
AU  - Rosenwald A
AD  - Department of Pathology, University of Wurzburg, 97080 Wurzburg, Germany.
FAU - Ott, German
AU  - Ott G
AD  - Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Dr. Margarete
      Fischer-Bosch Institute for Clinical Pharmacology, 70376 Stuttgart, Germany.
FAU - Delabie, Jan
AU  - Delabie J
AD  - Department of Pathology, University Health Network, Toronto, Ontario M5G 2C4,
      Canada.
FAU - Rimsza, Lisa
AU  - Rimsza L
AD  - Department of Pathology, University of Arizona, Tucson, AZ 85724, USA.
FAU - Staudt, Louis M
AU  - Staudt LM
AD  - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 
      4N115, Bethesda, MD 20892, USA. Electronic address: lstaudt@mail.nih.gov.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (B-Cell CLL-Lymphoma 10 Protein)
RN  - 0 (BCL10 protein, human)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (CARD Signaling Adaptor Proteins)
RN  - 0 (DIABLO protein, human)
RN  - 0 (Dipeptides)
RN  - 0 (Indoles)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (NF-kappa B)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, Antigen, B-Cell)
RN  - 0 (SM 164)
RN  - 0 (Triazoles)
RN  - 6O4Z07B57R (birinapant)
RN  - EC 2.3.2.27 (BIRC2 protein, human)
RN  - EC 2.3.2.27 (BIRC3 protein, human)
RN  - EC 2.3.2.27 (Baculoviral IAP Repeat-Containing 3 Protein)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.7.11.10 (I-kappa B Kinase)
RN  - EC 3.4.22.- (Caspases)
RN  - EC 3.4.22.- (MALT1 protein, human)
RN  - EC 3.4.22.- (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein)
RN  - EC 4.6.1.2 (CARD11 protein, human)
RN  - EC 4.6.1.2 (Guanylate Cyclase)
SB  - IM
CIN - Cancer Cell. 2016 Apr 11;29(4):425-7. PMID: 27070692
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Animals
MH  - B-Cell CLL-Lymphoma 10 Protein
MH  - B-Lymphocytes/*drug effects/metabolism
MH  - Baculoviral IAP Repeat-Containing 3 Protein
MH  - Bridged Bicyclo Compounds, Heterocyclic/pharmacology/*therapeutic use
MH  - CARD Signaling Adaptor Proteins/metabolism
MH  - CRISPR-Cas Systems
MH  - Caspases/metabolism
MH  - Cell Line, Tumor
MH  - Dipeptides/pharmacology/*therapeutic use
MH  - Enzyme Activation
MH  - Gene Dosage
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Guanylate Cyclase/metabolism
MH  - Humans
MH  - I-kappa B Kinase/metabolism
MH  - Indoles/pharmacology/*therapeutic use
MH  - Inhibitor of Apoptosis Proteins/antagonists & inhibitors/genetics/*physiology
MH  - Intracellular Signaling Peptides and Proteins/chemistry
MH  - Lymphoma, Large B-Cell, Diffuse/classification/*drug therapy/metabolism
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Mitochondrial Proteins/chemistry
MH  - Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein
MH  - Multiprotein Complexes/metabolism
MH  - NF-kappa B/antagonists & inhibitors/metabolism
MH  - Neoplasm Proteins/antagonists & inhibitors/genetics/metabolism/*physiology
MH  - Protein Processing, Post-Translational/*drug effects
MH  - Receptors, Antigen, B-Cell/metabolism
MH  - Triazoles/pharmacology/*therapeutic use
MH  - Ubiquitin-Protein Ligases/antagonists & inhibitors/genetics/*physiology
MH  - Ubiquitination/drug effects
MH  - Xenograft Model Antitumor Assays
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2015/09/22 00:00 [received]
PHST- 2016/01/27 00:00 [revised]
PHST- 2016/03/11 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30088-5 [pii]
AID - 10.1016/j.ccell.2016.03.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):494-507. doi: 10.1016/j.ccell.2016.03.006.

PMID- 27070701
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.
PG  - 464-476
LID - S1535-6108(16)30089-7 [pii]
LID - 10.1016/j.ccell.2016.03.007 [doi]
AB  - The epigenome is a key determinant of transcriptional output. Perturbations
      within the epigenome are thought to be a key feature of many, perhaps all
      cancers, and it is now clear that epigenetic changes are instrumental in cancer
      development. The inherent reversibility of these changes makes them attractive
      targets for therapeutic manipulation, and a number of small molecules targeting
      chromatin-based mechanisms are currently in clinical trials. In this perspective 
      we discuss how understanding the cancer epigenome is providing insights into
      disease pathogenesis and informing drug development. We also highlight additional
      opportunities to further unlock the therapeutic potential within the cancer
      epigenome.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Brien, Gerard L
AU  - Brien GL
AD  - The Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New 
      York, NY 10065, USA; Cancer Biology and Genetics Program, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Valerio, Daria G
AU  - Valerio DG
AD  - The Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New 
      York, NY 10065, USA; Cancer Biology and Genetics Program, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Armstrong, Scott A
AU  - Armstrong SA
AD  - The Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New 
      York, NY 10065, USA; Cancer Biology and Genetics Program, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Department of Pediatrics,
      Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic
      address: armstros@mskcc.org.
LA  - eng
GR  - CA66996/CA/NCI NIH HHS/United States
GR  - CA140575/CA/NCI NIH HHS/United States
GR  - R01 CA140575/CA/NCI NIH HHS/United States
GR  - CA176745/CA/NCI NIH HHS/United States
GR  - P01 CA066996/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA176745/CA/NCI NIH HHS/United States
GR  - P30CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chromatin)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Histones)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oncogene Proteins)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacokinetics
MH  - Cell Transformation, Neoplastic/*genetics
MH  - Chromatin/drug effects/genetics
MH  - Chromosome Aberrations
MH  - Clinical Trials as Topic
MH  - DNA Methylation/drug effects
MH  - DNA, Neoplasm/drug effects/genetics
MH  - Drug Resistance, Neoplasm/drug effects/genetics
MH  - Epigenesis, Genetic/drug effects/genetics
MH  - *Epigenomics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Histone Code/drug effects
MH  - Histone Deacetylase Inhibitors/therapeutic use
MH  - Histones/metabolism
MH  - Humans
MH  - Mice
MH  - Models, Genetic
MH  - *Molecular Targeted Therapy
MH  - Mutation
MH  - Neoplasm Proteins/metabolism
MH  - Neoplasms/*genetics/prevention & control/therapy
MH  - Oncogene Proteins/metabolism
MH  - Protein Processing, Post-Translational/drug effects
MH  - *Therapies, Investigational
MH  - Transcription, Genetic/drug effects
PMC - PMC4889129
MID - NIHMS776239
OTO - NOTNLM
OT  - Cancer
OT  - chromatin
OT  - epigenome
OT  - histone modification
OT  - targeted therapy
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/02/15 00:00 [received]
PHST- 2016/03/09 00:00 [revised]
PHST- 2016/03/11 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30089-7 [pii]
AID - 10.1016/j.ccell.2016.03.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):464-476. doi: 10.1016/j.ccell.2016.03.007.

PMID- 27070700
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Long Noncoding RNAs in Cancer Pathways.
PG  - 452-463
LID - S1535-6108(16)30092-7 [pii]
LID - 10.1016/j.ccell.2016.03.010 [doi]
AB  - Genome-wide cancer mutation analyses are revealing an extensive landscape of
      functional mutations within the noncoding genome, with profound effects on the
      expression of long noncoding RNAs (lncRNAs). While the exquisite regulation of
      lncRNA transcription can provide signals of malignant transformation, we now
      understand that lncRNAs drive many important cancer phenotypes through their
      interactions with other cellular macromolecules including DNA, protein, and RNA. 
      Recent advancements in surveying lncRNA molecular mechanisms are now providing
      the tools to functionally annotate these cancer-associated transcripts, making
      these molecules attractive targets for therapeutic intervention in the fight
      against cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Schmitt, Adam M
AU  - Schmitt AM
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA. Electronic address: schmitta@mskcc.org.
FAU - Chang, Howard Y
AU  - Chang HY
AD  - Center for Personal Dynamic Regulomes, Stanford University School of Medicine,
      Stanford, CA 94305, USA. Electronic address: howchang@stanford.edu.
LA  - eng
GR  - R01-ES023168/ES/NIEHS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01-CA118750/CA/NCI NIH HHS/United States
GR  - R01 ES023168/ES/NIEHS NIH HHS/United States
GR  - R01 CA118750/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chromatin)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Animals
MH  - Biomarkers, Tumor
MH  - Cell Compartmentation
MH  - Cell Division/genetics
MH  - Cell Movement/genetics
MH  - Cellular Senescence/genetics
MH  - Chromatin/ultrastructure
MH  - Disease Progression
MH  - Forecasting
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Humans
MH  - Mice
MH  - Models, Genetic
MH  - Mutation
MH  - Neoplasm Metastasis
MH  - Neoplasm Proteins/metabolism
MH  - Neoplasms/diagnosis/*genetics
MH  - Prognosis
MH  - RNA, Long Noncoding/analysis/*genetics
MH  - RNA, Messenger/metabolism
MH  - RNA, Neoplasm/analysis/*genetics
MH  - RNA-Binding Proteins/metabolism
MH  - Transcription, Genetic
MH  - Transcriptome
MH  - Treatment Outcome
PMC - PMC4831138
MID - NIHMS770680
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/01/13 00:00 [received]
PHST- 2016/03/01 00:00 [revised]
PHST- 2016/03/14 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30092-7 [pii]
AID - 10.1016/j.ccell.2016.03.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):452-463. doi: 10.1016/j.ccell.2016.03.010.

PMID- 27070699
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20170718
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Intratumoral Heterogeneity of the Epigenome.
PG  - 440-451
LID - 10.1016/j.ccell.2016.03.009 [doi]
AB  - Investigation into intratumoral heterogeneity (ITH) of the epigenome is in a
      formative stage. The patterns of tumor evolution inferred from epigenetic ITH and
      genetic ITH are remarkably similar, suggesting widespread co-dependency of these 
      disparate mechanisms. The biological and clinical relevance of epigenetic ITH are
      becoming more apparent. Rare tumor cells with unique and reversible epigenetic
      states may drive drug resistance, and the degree of epigenetic ITH at diagnosis
      may predict patient outcome. This perspective presents these current concepts and
      clinical implications of epigenetic ITH, and the experimental and computational
      techniques at the forefront of ITH exploration.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Mazor, Tali
AU  - Mazor T
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Pankov, Aleksandr
AU  - Pankov A
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco, San Francisco, CA 94158, USA.
FAU - Song, Jun S
AU  - Song JS
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco, San Francisco, CA 94158, USA.
AD  - Department of Bioengineering, University of Illinois at Urbana-Champaign,
      Champaign, IL 61801, USA.
AD  - Department of Physics, University of Illinois at Urbana-Champaign, Champaign, IL 
      61801, USA.
AD  - Institute for Genomic Biology, University of Illinois at Urbana-Champaign,
      Champaign, IL 61801, USA.
FAU - Costello, Joseph F
AU  - Costello JF
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
LA  - eng
GR  - T32 GM067547/GM/NIGMS NIH HHS/United States
GR  - P01 CA118816/CA/NCI NIH HHS/United States
GR  - R01 CA169316/CA/NCI NIH HHS/United States
GR  - R01 CA163336/CA/NCI NIH HHS/United States
GR  - R01CA169316/CA/NCI NIH HHS/United States
GR  - P50 CA097257/CA/NCI NIH HHS/United States
GR  - P50CA097257/CA/NCI NIH HHS/United States
GR  - T32 GM008568/GM/NIGMS NIH HHS/United States
GR  - R01CA163336/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Cell Transformation, Neoplastic/*genetics
MH  - CpG Islands/genetics
MH  - DNA Methylation
MH  - DNA, Neoplasm/chemistry/genetics
MH  - Disease Progression
MH  - *Epigenesis, Genetic
MH  - *Epigenomics
MH  - Forecasting
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Genetic Heterogeneity
MH  - Humans
MH  - Mutation
MH  - Neoplasms/*genetics/pathology
MH  - Neoplastic Stem Cells/metabolism
MH  - Promoter Regions, Genetic/genetics
PMC - PMC4852161
MID - NIHMS776244
EDAT- 2016/04/14 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/01/31 00:00 [received]
PHST- 2016/03/11 00:00 [revised]
PHST- 2016/03/14 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - 10.1016/j.ccell.2016.03.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):440-451. doi: 10.1016/j.ccell.2016.03.009.

PMID- 27070698
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Interfering with CCL5/CCR5 at the Tumor-Stroma Interface.
PG  - 437-439
LID - S1535-6108(16)30102-7 [pii]
LID - 10.1016/j.ccell.2016.03.019 [doi]
AB  - In this issue of Cancer Cell, Halama et al. (2016) further advance chemokine
      interference as a therapeutic option for cancer by demonstrating the effect of
      CCR5 blockade in reshaping macrophage polarization toward an anti-tumor
      functional state in patient-derived tumor models and liver metastases of
      colorectal cancer patients.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Bronte, Vincenzo
AU  - Bronte V
AD  - Immunology, Department of Medicine, Verona University Hospital, Verona 37134,
      Italy. Electronic address: vincenzo.bronte@univr.it.
FAU - Bria, Emilio
AU  - Bria E
AD  - Medical Oncology, Department of Medicine, Verona University Hospital, Verona
      37134, Italy.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chemokine CCL5)
RN  - 0 (Receptors, CCR5)
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):587-601. PMID: 27070705
MH  - *Chemokine CCL5
MH  - Colorectal Neoplasms
MH  - Humans
MH  - *Receptors, CCR5
MH  - Soft Tissue Neoplasms
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30102-7 [pii]
AID - 10.1016/j.ccell.2016.03.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):437-439. doi: 10.1016/j.ccell.2016.03.019.

PMID- 27070697
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can
      Explain Treatment Resistance in Glioma.
PG  - 435-436
LID - S1535-6108(16)30105-2 [pii]
LID - 10.1016/j.ccell.2016.03.022 [doi]
AB  - In this issue of Cancer Cell, Wei et al. (2016) identify adaptive re-wiring of
      signaling nodes in glioma as major mechanisms of treatment resistance without
      genome-wide mutations. Targeting these nodes before treatment blocks resistance
      and underscores the importance of single-cell phosphoproteomics and network
      re-wiring in predicting cancer treatment responses.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lam, Fred C
AU  - Lam FC
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Yaffe, Michael B
AU  - Yaffe MB
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA; Departments of Biological Engineering
      and Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA;
      Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215, USA. Electronic address: myaffe@mit.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):563-73. PMID: 27070703
MH  - Genomics
MH  - Glioma/*genetics
MH  - Humans
MH  - *Mutation
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30105-2 [pii]
AID - 10.1016/j.ccell.2016.03.022 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):435-436. doi: 10.1016/j.ccell.2016.03.022.

PMID- 27070696
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Glycoholics Anonymous: Cancer Sobers Up with mTORC1.
PG  - 432-434
LID - S1535-6108(16)30099-X [pii]
LID - 10.1016/j.ccell.2016.03.016 [doi]
AB  - In this issue of Cancer Cell, Pusapati et al. (2016) reveal that mTORC1
      orchestrates the metabolic reprogramming of cancer cells in response to
      glycolytic inhibitors, bypassing glycolysis by increasing glutamine uptake and
      pentose phosphate flux to generate energy and biomass.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Fu, Vivian
AU  - Fu V
AD  - Department of Pharmacology and Moores Cancer Center, University of California,
      San Diego, La Jolla, CA 92093, USA.
FAU - Moroishi, Toshiro
AU  - Moroishi T
AD  - Department of Pharmacology and Moores Cancer Center, University of California,
      San Diego, La Jolla, CA 92093, USA.
FAU - Guan, Kun-Liang
AU  - Guan KL
AD  - Department of Pharmacology and Moores Cancer Center, University of California,
      San Diego, La Jolla, CA 92093, USA. Electronic address: kuguan@ucsd.edu.
LA  - eng
GR  - R01 GM051586/GM/NIGMS NIH HHS/United States
GR  - CA196878/CA/NCI NIH HHS/United States
GR  - GM51586/GM/NIGMS NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0RH81L854J (Glutamine)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):548-62. PMID: 27052953
MH  - Glucose/*metabolism
MH  - Glutamine/metabolism
MH  - Glycolysis
MH  - Humans
MH  - Neoplasms
MH  - *Pentose Phosphate Pathway
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30099-X [pii]
AID - 10.1016/j.ccell.2016.03.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):432-434. doi: 10.1016/j.ccell.2016.03.016.

PMID- 27070695
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer.
PG  - 431-432
LID - S1535-6108(16)30106-4 [pii]
LID - 10.1016/j.ccell.2016.03.023 [doi]
AB  - In this issue of Cancer Cell, Lee and colleagues (2016) define the biologic role 
      of MYCN in promoting prostate tumorigenesis and development of a neuroendocrine
      phenotype. This has important implications for the clinical management of
      neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc
      destabilization progress in the clinic.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Carver, Brett S
AU  - Carver BS
AD  - Department of Surgery, Division of Urology, Human Oncology and Pathogenesis
      Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
      Electronic address: carverb@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA182503/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.11.1 (Aurora Kinase A)
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):536-47. PMID: 27050099
MH  - Aurora Kinase A
MH  - *Carcinoma, Neuroendocrine
MH  - Cell Line, Tumor
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*genetics
PMC - PMC5550814
MID - NIHMS892787
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30106-4 [pii]
AID - 10.1016/j.ccell.2016.03.023 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):431-432. doi: 10.1016/j.ccell.2016.03.023.

PMID- 27070694
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs.
PG  - 429-431
LID - S1535-6108(16)30103-9 [pii]
LID - 10.1016/j.ccell.2016.03.020 [doi]
AB  - AKT inhibitors represent promising therapeutics for cancers with PI3K-AKT pathway
      hyperactivation. In this issue of Cancer Cell, Wang et al. (2016) report the
      unexpected finding that ablation of AKT signaling in hepatocytes leads to
      hepatocellular carcinoma and enhances the incidence of lung metastases in a
      toxin-induced liver cancer model.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Fortin, Jerome
AU  - Fortin J
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada.
FAU - Mak, Tak W
AU  - Mak TW
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada; Department of
      Medical Biophysics, University of Toronto, University Health Network, 610
      University Avenue, Toronto, ON M5G 2C1, Canada; Ontario Cancer Institute,
      University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada.
      Electronic address: tmak@uhnresearch.ca.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):523-35. PMID: 26996309
MH  - Humans
MH  - Liver Neoplasms
MH  - Lung Neoplasms
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30103-9 [pii]
AID - 10.1016/j.ccell.2016.03.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):429-431. doi: 10.1016/j.ccell.2016.03.020.

PMID- 27070693
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Blood-Brain Barrier Breakdown Determines Differential Therapeutic Outcome in
      Genetically Diverse Forms of Medulloblastoma.
PG  - 427-429
LID - S1535-6108(16)30107-6 [pii]
LID - 10.1016/j.ccell.2016.03.024 [doi]
AB  - Medulloblastoma driven by Wnt/beta-catenin and Sonic hedgehog pathway mutations
      show favorable and poor patient survival upon treatment, respectively. In this
      Cancer Cell issue, Phoenix and colleagues (2016) report disruption of the
      blood-brain barrier by Wif1 specifically in Wnt-driven medulloblastoma, resulting
      in increased treatment response and survival in mouse models.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Guerit, Sylvaine
AU  - Guerit S
AD  - Institute of Neurology (Edinger-Institute), Johann Wolfgang Goethe-University
      Frankfurt Medical School, Heinrich-Hoffmann-Strasse 7, 60528 Frankfurt, Germany.
FAU - Liebner, Stefan
AU  - Liebner S
AD  - Institute of Neurology (Edinger-Institute), Johann Wolfgang Goethe-University
      Frankfurt Medical School, Heinrich-Hoffmann-Strasse 7, 60528 Frankfurt, Germany. 
      Electronic address: stefan.liebner@kgu.de.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Hedgehog Proteins)
RN  - 0 (beta Catenin)
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):508-22. PMID: 27050100
MH  - Animals
MH  - *Blood-Brain Barrier
MH  - Cerebellar Neoplasms/drug therapy
MH  - Hedgehog Proteins/metabolism
MH  - Humans
MH  - Medulloblastoma/*drug therapy
MH  - Signal Transduction
MH  - beta Catenin/metabolism
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30107-6 [pii]
AID - 10.1016/j.ccell.2016.03.024 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):427-429. doi: 10.1016/j.ccell.2016.03.024.

PMID- 27070692
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Killing Lymphoma with Smac-Mimetics: As Easy as ABC?
PG  - 425-427
LID - S1535-6108(16)30101-5 [pii]
LID - 10.1016/j.ccell.2016.03.018 [doi]
AB  - Smac-mimetics are compounds that target cellular Inhibitor of APoptosis (cIAP)
      proteins and induce tumor cell death. In this issue of Cancer Cell, Yang and
      colleagues (2016) identify cIAPs at the CARD11-MALT1-BCL10 complex in the ABC
      subtype of diffuse large B cell lymphoma (DLBCL), making this malignancy a prime 
      target for these drugs.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Nachbur, Ueli
AU  - Nachbur U
AD  - The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade,
      Parkville, VIC 3052, Australia; Department of Medical Biology, University of
      Melbourne, Melbourne, VIC 3010, Australia. Electronic address:
      nachbur@wehi.edu.au.
FAU - Silke, John
AU  - Silke J
AD  - The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade,
      Parkville, VIC 3052, Australia; Department of Medical Biology, University of
      Melbourne, Melbourne, VIC 3010, Australia.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (NF-kappa B)
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):494-507. PMID: 27070702
MH  - *Cell Line, Tumor
MH  - Humans
MH  - *Inhibitor of Apoptosis Proteins
MH  - Lymphoma, Large B-Cell, Diffuse
MH  - NF-kappa B/metabolism
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30101-5 [pii]
AID - 10.1016/j.ccell.2016.03.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):425-427. doi: 10.1016/j.ccell.2016.03.018.

PMID- 27070691
OWN - NLM
STAT- MEDLINE
DCOM- 20160824
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Deletion Mutations Keep Kinase Inhibitors in the Loop.
PG  - 423-425
LID - S1535-6108(16)30100-3 [pii]
LID - 10.1016/j.ccell.2016.03.017 [doi]
AB  - Effective clinical application of conformationally selective kinase inhibitors
      requires tailoring drug choice to the tumor's activating mutation(s). In this
      issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in
      BRAF, EGFR, and HER2 cause primary resistance to common inhibitors, suggesting
      strategies for improved inhibitor selection.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Freed, Daniel M
AU  - Freed DM
AD  - Department of Pharmacology, Yale University School of Medicine, New Haven, CT
      06520, USA; Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
FAU - Park, Jin H
AU  - Park JH
AD  - Department of Pharmacology, Yale University School of Medicine, New Haven, CT
      06520, USA; Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
FAU - Radhakrishnan, Ravi
AU  - Radhakrishnan R
AD  - Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104,
      USA.
FAU - Lemmon, Mark A
AU  - Lemmon MA
AD  - Department of Pharmacology, Yale University School of Medicine, New Haven, CT
      06520, USA; Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
      Electronic address: mark.lemmon@yale.edu.
LA  - eng
GR  - U54 CA193417/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
CON - Cancer Cell. 2016 Apr 11;29(4):477-93. PMID: 26996308
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Drug Resistance, Neoplasm/genetics
MH  - Humans
MH  - Lung Neoplasms/genetics
MH  - *Mutation
MH  - Neoplasms/*genetics
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Receptor, Epidermal Growth Factor/genetics
MH  - Sequence Deletion
PMC - PMC5028821
MID - NIHMS816765
EDAT- 2016/04/14 06:00
MHDA- 2016/08/25 06:00
CRDT- 2016/04/13 06:00
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/08/25 06:00 [medline]
AID - S1535-6108(16)30100-3 [pii]
AID - 10.1016/j.ccell.2016.03.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):423-425. doi: 10.1016/j.ccell.2016.03.017.

PMID- 27052953
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis
      Addiction in Cancer Cells.
PG  - 548-562
LID - S1535-6108(16)30052-6 [pii]
LID - 10.1016/j.ccell.2016.02.018 [doi]
AB  - Although glycolysis is substantially elevated in many tumors, therapeutic
      targeting of glycolysis in cancer patients has not yet been successful,
      potentially reflecting the metabolic plasticity of tumor cells. In various cancer
      cells exposed to a continuous glycolytic block, we identified a recurrent
      reprogramming mechanism involving sustained mTORC1 signaling that underlies
      escape from glycolytic addiction. Active mTORC1 directs increased glucose flux
      via the pentose phosphate pathway back into glycolysis, thereby circumventing a
      glycolysis block and ensuring adequate ATP and biomass production. Combined
      inhibition of glycolysis and mTORC1 signaling disrupted metabolic reprogramming
      in tumor cells and inhibited their growth in vitro and in vivo. These findings
      reveal novel combinatorial therapeutic strategies to realize the potential
      benefit from targeting the Warburg effect.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Pusapati, Raju V
AU  - Pusapati RV
AD  - Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080,
      USA.
FAU - Daemen, Anneleen
AU  - Daemen A
AD  - Department of Bioinformatics and Computational Biology, Genentech Inc, South San 
      Francisco, CA 94080, USA.
FAU - Wilson, Catherine
AU  - Wilson C
AD  - Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080,
      USA.
FAU - Sandoval, Wendy
AU  - Sandoval W
AD  - Department of Protein Chemistry, Genentech Inc, South San Francisco, CA 94080,
      USA.
FAU - Gao, Min
AU  - Gao M
AD  - Department of Translational Oncology, Genentech Inc, South San Francisco, CA
      94080, USA.
FAU - Haley, Benjamin
AU  - Haley B
AD  - Department of Molecular Biology, Genentech Inc, South San Francisco, CA 94080,
      USA.
FAU - Baudy, Andreas R
AU  - Baudy AR
AD  - Department of Biomedical Imaging, Genentech Inc, South San Francisco, CA 94080,
      USA.
FAU - Hatzivassiliou, Georgia
AU  - Hatzivassiliou G
AD  - Department of Translational Oncology, Genentech Inc, South San Francisco, CA
      94080, USA.
FAU - Evangelista, Marie
AU  - Evangelista M
AD  - Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080,
      USA. Electronic address: evangelista.marie@gene.com.
FAU - Settleman, Jeff
AU  - Settleman J
AD  - Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080,
      USA. Electronic address: settleman@calicolabs.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20160324
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cytokines)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - 0RH81L854J (Glutamine)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (ribosomal protein S6 kinase, 70kD, polypeptide 1)
RN  - EC 3.5.1.2 (Glutaminase)
RN  - EC 5.3.1.9 (GPI protein, human)
RN  - EC 5.3.1.9 (Glucose-6-Phosphate Isomerase)
SB  - IM
CON - Cancer Discov. 2016 May;6(5):469. PMID: 27056835
CIN - Cancer Cell. 2016 Apr 11;29(4):432-4. PMID: 27070696
MH  - Adenosine Triphosphate/biosynthesis
MH  - Animals
MH  - Carcinoma/pathology
MH  - Cell Line, Tumor
MH  - Citric Acid Cycle
MH  - Combined Modality Therapy
MH  - Cytokines/antagonists & inhibitors/genetics
MH  - Deoxyglucose/pharmacology/therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Drug Synergism
MH  - Energy Metabolism/drug effects
MH  - Everolimus/pharmacology/therapeutic use
MH  - Female
MH  - Glucose-6-Phosphate Isomerase/antagonists & inhibitors/genetics
MH  - Glutaminase/antagonists & inhibitors/physiology
MH  - Glutamine/metabolism
MH  - *Glycolysis/drug effects
MH  - Hep G2 Cells
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Metabolomics
MH  - Mice
MH  - Mice, Nude
MH  - *Molecular Targeted Therapy
MH  - Multiprotein Complexes/antagonists & inhibitors/*physiology
MH  - Neoplasm Proteins/antagonists & inhibitors/*physiology
MH  - Neoplasms/drug therapy/*metabolism
MH  - Ovarian Neoplasms/pathology
MH  - Pentose Phosphate Pathway/drug effects/physiology
MH  - RNA Interference
MH  - RNA, Small Interfering/therapeutic use
MH  - Ribosomal Protein S6 Kinases, 70-kDa/antagonists & inhibitors/physiology
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*physiology
MH  - Tumor Stem Cell Assay
MH  - Xenograft Model Antitumor Assays
EDAT- 2016/04/08 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/08 06:00
PHST- 2015/08/31 00:00 [received]
PHST- 2016/01/05 00:00 [revised]
PHST- 2016/02/23 00:00 [accepted]
PHST- 2016/04/08 06:00 [entrez]
PHST- 2016/04/08 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30052-6 [pii]
AID - 10.1016/j.ccell.2016.02.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):548-562. doi: 10.1016/j.ccell.2016.02.018. Epub
      2016 Mar 24.

PMID- 27050100
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20171113
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.
PG  - 508-522
LID - S1535-6108(16)30055-1 [pii]
LID - 10.1016/j.ccell.2016.03.002 [doi]
AB  - The childhood brain tumor, medulloblastoma, includes four subtypes with very
      different prognoses. Here, we show that paracrine signals driven by mutant
      beta-catenin in WNT-medulloblastoma, an essentially curable form of the disease, 
      induce an aberrant fenestrated vasculature that permits the accumulation of high 
      levels of intra-tumoral chemotherapy and a robust therapeutic response. In
      contrast, SHH-medulloblastoma, a less curable disease subtype, contains an intact
      blood brain barrier, rendering this tumor impermeable and resistant to
      chemotherapy. The medulloblastoma-endothelial cell paracrine axis can be
      manipulated in vivo, altering chemotherapy permeability and clinical response.
      Thus, medulloblastoma genotype dictates tumor vessel phenotype, explaining in
      part the disparate prognoses among medulloblastoma subtypes and suggesting an
      approach to enhance the chemoresponsiveness of other brain tumors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Phoenix, Timothy N
AU  - Phoenix TN
AD  - Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 
      262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Patmore, Deanna M
AU  - Patmore DM
AD  - Li Ka Shing Centre, CRUK Cambridge Institute, University of Cambridge, Robinson
      Way, Cambridge CB2 0RE, England.
FAU - Boop, Scott
AU  - Boop S
AD  - Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 
      262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Boulos, Nidal
AU  - Boulos N
AD  - Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 
      262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Jacus, Megan O
AU  - Jacus MO
AD  - Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Patel, Yogesh T
AU  - Patel YT
AD  - Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Roussel, Martine F
AU  - Roussel MF
AD  - Department of Tumor Cell Biology, St. Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Finkelstein, David
AU  - Finkelstein D
AD  - Department of Computational Biology, St. Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Goumnerova, Liliana
AU  - Goumnerova L
AD  - Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA.
FAU - Perreault, Sebastien
AU  - Perreault S
AD  - Department of Neurology and Neurological Sciences, Stanford University Medical
      Center, 1201 Welch Road, Stanford, CA 94305, USA.
FAU - Wadhwa, Elizabeth
AU  - Wadhwa E
AD  - Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA.
FAU - Cho, Yoon-Jae
AU  - Cho YJ
AD  - Department of Neurology and Neurological Sciences, Stanford University Medical
      Center, 1201 Welch Road, Stanford, CA 94305, USA; Department of Neurosurgery,
      Stanford University Medical Center, 1201 Welch Road, Stanford, CA 94305, USA.
FAU - Stewart, Clinton F
AU  - Stewart CF
AD  - Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Gilbertson, Richard J
AU  - Gilbertson RJ
AD  - Li Ka Shing Centre, CRUK Cambridge Institute, University of Cambridge, Robinson
      Way, Cambridge CB2 0RE, England. Electronic address:
      richard.gilbertson@cruk.cam.ac.uk.
LA  - eng
GR  - R01 CA129541/CA/NCI NIH HHS/United States
GR  - R25 CA023944/CA/NCI NIH HHS/United States
GR  - P01CA96832/CA/NCI NIH HHS/United States
GR  - P30CA021765/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - P01 CA096832/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160331
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Carrier Proteins)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Glucose Transporter Type 1)
RN  - 0 (Membrane Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (PLVAP protein, human)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (SLC2A1 protein, human)
RN  - 0 (WNT7A protein, human)
RN  - 0 (Wnt Proteins)
RN  - 5J49Q6B70F (Vincristine)
SB  - IM
CIN - Cancer Cell. 2016 Apr 11;29(4):427-9. PMID: 27070693
CIN - Nat Rev Clin Oncol. 2016 Jun;13(6):330. PMID: 27092953
MH  - Animals
MH  - Antineoplastic Agents/pharmacokinetics
MH  - *Blood-Brain Barrier
MH  - Carrier Proteins/physiology
MH  - Cerebellar Neoplasms/blood supply/classification/drug therapy/*genetics/secretion
MH  - Culture Media, Conditioned/pharmacology
MH  - Disease Models, Animal
MH  - Drug Resistance, Neoplasm/physiology
MH  - Endothelium, Vascular/metabolism/ultrastructure
MH  - Genetic Association Studies
MH  - Genetic Vectors/therapeutic use
MH  - Genotype
MH  - Glucose Transporter Type 1/physiology
MH  - Humans
MH  - Medulloblastoma/blood supply/classification/drug therapy/*genetics/secretion
MH  - Membrane Proteins/physiology
MH  - Mice
MH  - Mice, Transgenic
MH  - Neoplasm Proteins/physiology
MH  - Paracrine Communication/drug effects
MH  - Pericytes/pathology
MH  - Recombinant Fusion Proteins/metabolism
MH  - Tight Junctions/ultrastructure
MH  - Transduction, Genetic
MH  - Vincristine/pharmacokinetics/therapeutic use
MH  - Wnt Proteins/genetics/physiology
MH  - Wnt Signaling Pathway/drug effects
PMC - PMC4829447
MID - NIHMS771329
EDAT- 2016/04/07 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/07 06:00
PHST- 2015/10/04 00:00 [received]
PHST- 2015/12/23 00:00 [revised]
PHST- 2016/03/01 00:00 [accepted]
PHST- 2016/04/07 06:00 [entrez]
PHST- 2016/04/07 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30055-1 [pii]
AID - 10.1016/j.ccell.2016.03.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):508-522. doi: 10.1016/j.ccell.2016.03.002. Epub
      2016 Mar 31.

PMID- 27050099
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate
      Epithelial Cells.
PG  - 536-547
LID - S1535-6108(16)30054-X [pii]
LID - 10.1016/j.ccell.2016.03.001 [doi]
AB  - MYCN amplification and overexpression are common in neuroendocrine prostate
      cancer (NEPC). However, the impact of aberrant N-Myc expression in prostate
      tumorigenesis and the cellular origin of NEPC have not been established. We
      define N-Myc and activated AKT1 as oncogenic components sufficient to transform
      human prostate epithelial cells to prostate adenocarcinoma and NEPC with
      phenotypic and molecular features of aggressive, late-stage human disease. We
      directly show that prostate adenocarcinoma and NEPC can arise from a common
      epithelial clone. Further, N-Myc is required for tumor maintenance, and
      destabilization of N-Myc through Aurora A kinase inhibition reduces tumor burden.
      Our findings establish N-Myc as a driver of NEPC and a target for therapeutic
      intervention.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lee, John K
AU  - Lee JK
AD  - Division of Hematology and Oncology, Department of Medicine, University of
      California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute,
      University of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Phillips, John W
AU  - Phillips JW
AD  - Department of Microbiology, Immunology, and Medical Genetics, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Smith, Bryan A
AU  - Smith BA
AD  - Department of Microbiology, Immunology, and Medical Genetics, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Park, Jung Wook
AU  - Park JW
AD  - Department of Microbiology, Immunology, and Medical Genetics, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Stoyanova, Tanya
AU  - Stoyanova T
AD  - Department of Microbiology, Immunology, and Medical Genetics, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - McCaffrey, Erin F
AU  - McCaffrey EF
AD  - Department of Microbiology, Immunology, and Medical Genetics, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Baertsch, Robert
AU  - Baertsch R
AD  - Center for Biomolecular Science and Engineering, Jack Baskin School of
      Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
FAU - Sokolov, Artem
AU  - Sokolov A
AD  - Center for Biomolecular Science and Engineering, Jack Baskin School of
      Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
FAU - Meyerowitz, Justin G
AU  - Meyerowitz JG
AD  - Helen Diller Family Comprehensive Cancer Center, University of California, San
      Francisco, San Francisco, CA 94158, USA; Departments of Neurology and
      Neurological Surgery, University of California, San Francisco, San Francisco, CA 
      94158, USA; Department of Cellular and Molecular Pharmacology, University of
      California, San Francisco, San Francisco, CA 94158, USA.
FAU - Mathis, Colleen
AU  - Mathis C
AD  - Department of Microbiology, Immunology, and Medical Genetics, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Cheng, Donghui
AU  - Cheng D
AD  - Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research,
      University of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Stuart, Joshua M
AU  - Stuart JM
AD  - Center for Biomolecular Science and Engineering, Jack Baskin School of
      Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
FAU - Shokat, Kevan M
AU  - Shokat KM
AD  - Helen Diller Family Comprehensive Cancer Center, University of California, San
      Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular
      Pharmacology, University of California, San Francisco, San Francisco, CA 94158,
      USA; Howard Hughes Medical Institute, University of California, Los Angeles, Los 
      Angeles, CA 90095, USA.
FAU - Gustafson, W Clay
AU  - Gustafson WC
AD  - Helen Diller Family Comprehensive Cancer Center, University of California, San
      Francisco, San Francisco, CA 94158, USA; Department of Pediatrics, UCSF Benioff
      Children's Hospital, University of California, San Francisco, San Francisco, CA
      94158, USA.
FAU - Huang, Jiaoti
AU  - Huang J
AD  - Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research,
      University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of 
      Pathology and Laboratory Medicine, University of California, Los Angeles, Los
      Angeles, CA 90095, USA.
FAU - Witte, Owen N
AU  - Witte ON
AD  - Department of Microbiology, Immunology, and Medical Genetics, University of
      California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center 
      of Regenerative Medicine and Stem Cell Research, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical
      Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; 
      Howard Hughes Medical Institute, University of California, Los Angeles, Los
      Angeles, CA 90095, USA. Electronic address: owenwitte@mednet.ucla.edu.
LA  - eng
GR  - R01 CA195505/CA/NCI NIH HHS/United States
GR  - K08 NS079485/NS/NINDS NIH HHS/United States
GR  - R01 CA181242/CA/NCI NIH HHS/United States
GR  - U54 HG006097/HG/NHGRI NIH HHS/United States
GR  - T32 GM007618/GM/NIGMS NIH HHS/United States
GR  - R01 GM109031/GM/NIGMS NIH HHS/United States
GR  - U01 CA164188/CA/NCI NIH HHS/United States
GR  - K99 CA184397/CA/NCI NIH HHS/United States
GR  - P50 CA092131/CA/NCI NIH HHS/United States
GR  - P30 CA016042/CA/NCI NIH HHS/United States
GR  - T32 CA009120/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - R00 CA184397/CA/NCI NIH HHS/United States
GR  - T32 CA009056/CA/NCI NIH HHS/United States
GR  - R01 CA180778/CA/NCI NIH HHS/United States
GR  - R01 CA172603/CA/NCI NIH HHS/United States
GR  - U54 HL127365/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160331
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Azepines)
RN  - 0 (CD532 compound)
RN  - 0 (MLN 8237)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Pyrimidines)
RN  - 0 (Recombinant Fusion Proteins)
RN  - EC 2.7.11.1 (AKT1 protein, human)
RN  - EC 2.7.11.1 (AURKA protein, human)
RN  - EC 2.7.11.1 (Aurora Kinase A)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
CIN - Cancer Cell. 2016 Apr 11;29(4):431-2. PMID: 27070695
MH  - Adenocarcinoma/*genetics/pathology
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Aurora Kinase A/antagonists & inhibitors/physiology
MH  - Azepines/therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Transformation, Neoplastic/*genetics
MH  - Enzyme Activation
MH  - Epithelial Cells/metabolism/*pathology
MH  - Exome
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, myc
MH  - Humans
MH  - Laser Capture Microdissection
MH  - Male
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Molecular Targeted Therapy
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neoplasm Proteins/genetics/*physiology
MH  - Neoplastic Stem Cells/metabolism/pathology
MH  - Neuroendocrine Tumors/*genetics/pathology
MH  - Orchiectomy
MH  - Phenylurea Compounds/therapeutic use
MH  - Prostatic Neoplasms/*genetics/pathology
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Proto-Oncogene Proteins c-akt/physiology
MH  - Proto-Oncogene Proteins c-myc/*physiology
MH  - Pyrimidines/therapeutic use
MH  - Recombinant Fusion Proteins/metabolism
MH  - Transduction, Genetic
MH  - Xenograft Model Antitumor Assays
PMC - PMC4829466
MID - NIHMS766191
EDAT- 2016/04/07 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/04/07 06:00
PHST- 2015/09/21 00:00 [received]
PHST- 2015/12/15 00:00 [revised]
PHST- 2016/03/01 00:00 [accepted]
PHST- 2016/04/07 06:00 [entrez]
PHST- 2016/04/07 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30054-X [pii]
AID - 10.1016/j.ccell.2016.03.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):536-547. doi: 10.1016/j.ccell.2016.03.001. Epub
      2016 Mar 31.

PMID- 26996309
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20180119
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms.
PG  - 523-535
LID - S1535-6108(16)30042-3 [pii]
LID - 10.1016/j.ccell.2016.02.008 [doi]
AB  - Akt is frequently hyperactivated in human cancers and is targeted for cancer
      therapy. However, the physiological consequences of systemic Akt isoform
      inhibition were not fully explored. We showed that while combined Akt1 and Akt3
      deletion in adult mice is tolerated, combined Akt1 and Akt2 deletion induced
      rapid mortality. Akt2(-/-) mice survived hepatic Akt1 deletion but all developed 
      spontaneous hepatocellular carcinoma (HCC), which is associated with
      FoxO-dependent liver injury and inflammation. The gene expression signature of
      HCC-bearing livers is similar to aggressive human HCC. Consistently, neither
      Akt1(-/-) nor Akt2(-/-) mice are resistant to diethylnitrosamine-induced
      hepatocarcinogenesis, and Akt2(-/-) mice display a high incidence of lung
      metastasis. Thus, in contrast to other cancers, hepatic Akt inhibition induces
      liver injury that could promote HCC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Biochemistry and Molecular Genetics, College of Medicine,
      University of Illinois at Chicago, Chicago, IL 60607, USA.
FAU - Yu, Wan-Ni
AU  - Yu WN
AD  - Department of Biochemistry and Molecular Genetics, College of Medicine,
      University of Illinois at Chicago, Chicago, IL 60607, USA.
FAU - Chen, Xinyu
AU  - Chen X
AD  - Department of Biochemistry and Molecular Genetics, College of Medicine,
      University of Illinois at Chicago, Chicago, IL 60607, USA.
FAU - Peng, Xiao-Ding
AU  - Peng XD
AD  - Department of Biochemistry and Molecular Genetics, College of Medicine,
      University of Illinois at Chicago, Chicago, IL 60607, USA.
FAU - Jeon, Sang-Min
AU  - Jeon SM
AD  - Department of Biochemistry and Molecular Genetics, College of Medicine,
      University of Illinois at Chicago, Chicago, IL 60607, USA.
FAU - Birnbaum, Morris J
AU  - Birnbaum MJ
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
      Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Guzman, Grace
AU  - Guzman G
AD  - Department of Pathology, College of Medicine, Cancer Center, University of
      Illinois Hospital and Health Science Chicago, Chicago, IL 60612, USA.
FAU - Hay, Nissim
AU  - Hay N
AD  - Department of Biochemistry and Molecular Genetics, College of Medicine,
      University of Illinois at Chicago, Chicago, IL 60607, USA; Research & Development
      Section, Jesse Brown VA Medical Center, Chicago, IL 60612, USA. Electronic
      address: nhay@uic.edu.
LA  - eng
GR  - R01AG016927/AG/NIA NIH HHS/United States
GR  - R01 DK056886/DK/NIDDK NIH HHS/United States
GR  - I01 BX000733/BX/BLRD VA/United States
GR  - R01 DK56886/DK/NIDDK NIH HHS/United States
GR  - R01 AG016927/AG/NIA NIH HHS/United States
GR  - R01 CA090764/CA/NCI NIH HHS/United States
GR  - R01CA090764/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20160317
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acids)
RN  - 0 (Forkhead Box Protein O1)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Foxo1 protein, mouse)
RN  - 0 (Insulin)
RN  - 0 (Interleukin-6)
RN  - 0 (Protein Isoforms)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (interleukin-6, mouse)
RN  - EC 2.7.11.1 (Akt1 protein, mouse)
RN  - EC 2.7.11.1 (Akt2 protein, mouse)
RN  - EC 2.7.11.1 (Akt3 protein, mouse)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
CON - Cancer Discov. 2016 May;6(5):473. PMID: 27034381
CIN - Cancer Cell. 2016 Apr 11;29(4):429-31. PMID: 27070694
CIN - Hepatology. 2016 Oct;64(4):1358-61. PMID: 27515381
MH  - Age Factors
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Energy Metabolism/genetics
MH  - Fatty Acids/metabolism
MH  - Female
MH  - Forkhead Box Protein O1
MH  - Forkhead Transcription Factors/physiology
MH  - Growth Disorders/genetics
MH  - Hepatitis/genetics
MH  - Hypoglycemia/genetics
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Interleukin-6/blood
MH  - Liver Neoplasms, Experimental/chemically induced/*genetics
MH  - Lung Neoplasms/secondary
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Promoter Regions, Genetic/drug effects
MH  - Protein Isoforms/physiology
MH  - Proto-Oncogene Proteins c-akt/*deficiency/genetics/physiology
MH  - Recombinant Fusion Proteins/metabolism
PMC - PMC4921241
MID - NIHMS761990
EDAT- 2016/03/22 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/03/22 06:00
PHST- 2015/08/04 00:00 [received]
PHST- 2015/12/12 00:00 [revised]
PHST- 2016/02/16 00:00 [accepted]
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30042-3 [pii]
AID - 10.1016/j.ccell.2016.02.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):523-535. doi: 10.1016/j.ccell.2016.02.008. Epub
      2016 Mar 17.

PMID- 26996308
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 4
DP  - 2016 Apr 11
TI  - Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.
PG  - 477-493
LID - S1535-6108(16)30044-7 [pii]
LID - 10.1016/j.ccell.2016.02.010 [doi]
AB  - Activating mutations in protein kinases drive many cancers. While how recurring
      point mutations affect kinase activity has been described, the effect of in-frame
      deletions is not well understood. We show that oncogenic deletions within the
      beta3-alphaC loop of HER2 and BRAF are analogous to the recurrent EGFR exon 19
      deletions. We identify pancreatic carcinomas with BRAF deletions mutually
      exclusive with KRAS mutations. Crystal structures of BRAF deletions reveal the
      truncated loop restrains alphaC in an active "in" conformation, imparting
      resistance to inhibitors like vemurafenib that bind the alphaC "out"
      conformation. Characterization of loop length explains the prevalence of five
      amino acid deletions in BRAF, EGFR, and HER2 and highlights the importance of
      this region for kinase activity and inhibitor efficacy.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Foster, Scott A
AU  - Foster SA
AD  - Department of Discovery Oncology, Genentech Inc., 1 DNA Way, South San Francisco,
      CA 94080, USA.
FAU - Whalen, Daniel M
AU  - Whalen DM
AD  - Department of Protein Chemistry & Structural Biology, Genentech Inc., 1 DNA Way, 
      South San Francisco, CA 94080, USA.
FAU - Ozen, Aysegul
AU  - Ozen A
AD  - Department of Discovery Chemistry, Genentech Inc., 1 DNA Way, South San
      Francisco, CA 94080, USA; Department of Early Discovery Biochemistry, Genentech
      Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
FAU - Wongchenko, Matthew J
AU  - Wongchenko MJ
AD  - Department of Oncology Biomarker Development, Genentech Inc., 1 DNA Way, South
      San Francisco, CA 94080, USA.
FAU - Yin, JianPing
AU  - Yin J
AD  - Department of Protein Chemistry & Structural Biology, Genentech Inc., 1 DNA Way, 
      South San Francisco, CA 94080, USA.
FAU - Yen, Ivana
AU  - Yen I
AD  - Department of Discovery Oncology, Genentech Inc., 1 DNA Way, South San Francisco,
      CA 94080, USA.
FAU - Schaefer, Gabriele
AU  - Schaefer G
AD  - Department of Translational Oncology, Genentech Inc., 1 DNA Way, South San
      Francisco, CA 94080, USA.
FAU - Mayfield, John D
AU  - Mayfield JD
AD  - Foundation Medicine, 150 Second Street, Cambridge, MA 02141, USA.
FAU - Chmielecki, Juliann
AU  - Chmielecki J
AD  - Foundation Medicine, 150 Second Street, Cambridge, MA 02141, USA.
FAU - Stephens, Philip J
AU  - Stephens PJ
AD  - Foundation Medicine, 150 Second Street, Cambridge, MA 02141, USA.
FAU - Albacker, Lee A
AU  - Albacker LA
AD  - Foundation Medicine, 150 Second Street, Cambridge, MA 02141, USA.
FAU - Yan, Yibing
AU  - Yan Y
AD  - Department of Oncology Biomarker Development, Genentech Inc., 1 DNA Way, South
      San Francisco, CA 94080, USA.
FAU - Song, Kyung
AU  - Song K
AD  - Department of Translational Oncology, Genentech Inc., 1 DNA Way, South San
      Francisco, CA 94080, USA.
FAU - Hatzivassiliou, Georgia
AU  - Hatzivassiliou G
AD  - Department of Cancer Immunology, Genentech Inc., 1 DNA Way, South San Francisco, 
      CA 94080, USA.
FAU - Eigenbrot, Charles
AU  - Eigenbrot C
AD  - Department of Protein Chemistry & Structural Biology, Genentech Inc., 1 DNA Way, 
      South San Francisco, CA 94080, USA.
FAU - Yu, Christine
AU  - Yu C
AD  - Department of Protein Chemistry & Structural Biology, Genentech Inc., 1 DNA Way, 
      South San Francisco, CA 94080, USA.
FAU - Shaw, Andrey S
AU  - Shaw AS
AD  - Department of Discovery Oncology, Genentech Inc., 1 DNA Way, South San Francisco,
      CA 94080, USA.
FAU - Manning, Gerard
AU  - Manning G
AD  - Department of Bioinformatics & Computational Biology, Genentech Inc., 1 DNA Way, 
      South San Francisco, CA 94080, USA.
FAU - Skelton, Nicholas J
AU  - Skelton NJ
AD  - Department of Discovery Chemistry, Genentech Inc., 1 DNA Way, South San
      Francisco, CA 94080, USA.
FAU - Hymowitz, Sarah G
AU  - Hymowitz SG
AD  - Department of Protein Chemistry & Structural Biology, Genentech Inc., 1 DNA Way, 
      South San Francisco, CA 94080, USA.
FAU - Malek, Shiva
AU  - Malek S
AD  - Department of Discovery Oncology, Genentech Inc., 1 DNA Way, South San Francisco,
      CA 94080, USA. Electronic address: shivam@gene.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160317
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CIN - Cancer Cell. 2016 Apr 11;29(4):423-5. PMID: 27070691
MH  - Amino Acid Sequence
MH  - Amino Acid Substitution
MH  - Antineoplastic Agents/pharmacology
MH  - Base Pairing/genetics
MH  - Conserved Sequence
MH  - Dimerization
MH  - Drug Resistance, Neoplasm/genetics
MH  - Enzyme Activation/genetics
MH  - *Genes, erbB-1
MH  - *Genes, erbB-2
MH  - Humans
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - *Mutation
MH  - Neoplasm Proteins/antagonists & inhibitors/*genetics/metabolism
MH  - Neoplasms/enzymology/*genetics
MH  - Protein Conformation
MH  - Protein Interaction Mapping
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Protein Structure, Secondary
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors/*genetics/metabolism
MH  - Receptor, Epidermal Growth Factor/metabolism
MH  - Receptor, ErbB-2/antagonists & inhibitors/metabolism
MH  - Sequence Alignment
MH  - Sequence Homology, Amino Acid
MH  - Structure-Activity Relationship
EDAT- 2016/03/22 06:00
MHDA- 2016/09/09 06:00
CRDT- 2016/03/22 06:00
PHST- 2015/11/20 00:00 [received]
PHST- 2016/01/11 00:00 [revised]
PHST- 2016/02/13 00:00 [accepted]
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - S1535-6108(16)30044-7 [pii]
AID - 10.1016/j.ccell.2016.02.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Apr 11;29(4):477-493. doi: 10.1016/j.ccell.2016.02.010. Epub
      2016 Mar 17.

PMID- 26977886
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170526
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal
      Heterogeneity and Dysregulated Developmental Pathways.
PG  - 394-406
LID - 10.1016/j.ccell.2016.02.009 [doi]
LID - S1535-6108(16)30043-5 [pii]
AB  - Malignant rhabdoid tumors (MRTs) are rare lethal tumors of childhood that most
      commonly occur in the kidney and brain. MRTs are driven by SMARCB1 loss, but the 
      molecular consequences of SMARCB1 loss in extra-cranial tumors have not been
      comprehensively described and genomic resources for analyses of extra-cranial MRT
      are limited. To provide such data, we used whole-genome sequencing, whole-genome 
      bisulfite sequencing, whole transcriptome (RNA-seq) and microRNA sequencing
      (miRNA-seq), and histone modification profiling to characterize extra-cranial
      MRTs. Our analyses revealed gene expression and methylation subgroups and focused
      on dysregulated pathways, including those involved in neural crest development.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Chun, Hye-Jung E
AU  - Chun HJ
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Lim, Emilia L
AU  - Lim EL
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Heravi-Moussavi, Alireza
AU  - Heravi-Moussavi A
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Saberi, Saeed
AU  - Saberi S
AD  - Department of Microbiology and Immunology, University of British Columbia,
      Vancouver, BC V6T 1Z4, Canada.
FAU - Mungall, Karen L
AU  - Mungall KL
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Bilenky, Mikhail
AU  - Bilenky M
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Carles, Annaick
AU  - Carles A
AD  - Department of Microbiology and Immunology, University of British Columbia,
      Vancouver, BC V6T 1Z4, Canada.
FAU - Tse, Kane
AU  - Tse K
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Shlafman, Inna
AU  - Shlafman I
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Zhu, Kelsey
AU  - Zhu K
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Qian, Jenny Q
AU  - Qian JQ
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Palmquist, Diana L
AU  - Palmquist DL
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - He, An
AU  - He A
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Long, William
AU  - Long W
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Goya, Rodrigo
AU  - Goya R
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Ng, Michelle
AU  - Ng M
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - LeBlanc, Veronique G
AU  - LeBlanc VG
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Pleasance, Erin
AU  - Pleasance E
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Thiessen, Nina
AU  - Thiessen N
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Wong, Tina
AU  - Wong T
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Chuah, Eric
AU  - Chuah E
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Zhao, Yong-Jun
AU  - Zhao YJ
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Schein, Jacquie E
AU  - Schein JE
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Gerhard, Daniela S
AU  - Gerhard DS
AD  - Office of Cancer Genomics, National Cancer Institute, US National Institutes of
      Health, Bethesda, MD 20892, USA.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick
      Children, Toronto, ON M5G 1X8, Canada.
FAU - Mungall, Andrew J
AU  - Mungall AJ
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Moore, Richard A
AU  - Moore RA
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Ma, Yussanne
AU  - Ma Y
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Jones, Steven J M
AU  - Jones SJ
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada; Department of Molecular Biology and Biochemistry, 
      Simon Fraser University, Burnaby, BC V5A 1S6, Canada; Department of Medical
      Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
FAU - Perlman, Elizabeth J
AU  - Perlman EJ
AD  - Department of Pathology and Laboratory Medicine, Lurie Children's Hospital,
      Northwestern University's Feinberg School of Medicine and Robert H. Lurie Cancer 
      Center, Chicago, IL 60611, USA.
FAU - Hirst, Martin
AU  - Hirst M
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada; Department of Microbiology and Immunology,
      University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
FAU - Marra, Marco A
AU  - Marra MA
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 1L3, Canada; Department of Medical Genetics, University of
      British Columbia, Vancouver, BC V6H 3N1, Canada. Electronic address:
      mmarra@bcgsc.ca.
LA  - eng
GR  - P30 CA060553/CA/NCI NIH HHS/United States
GR  - HHSN261200800001E/PHS HHS/United States
GR  - CIHR-262119/Canadian Institutes of Health Research/Canada
GR  - N01CO12400/CA/NCI NIH HHS/United States
GR  - FDN-143288/Canadian Institutes of Health Research/Canada
GR  - N01-CO-12400/CO/NCI NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromosomal Proteins, Non-Histone)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Histones)
RN  - 0 (MicroRNAs)
RN  - 0 (SMARCB1 Protein)
RN  - 0 (SMARCB1 protein, human)
RN  - 0 (Transcription Factors)
SB  - IM
CIN - Trends Cancer. 2016 May;2(5):217-218. PMID: 27672680
MH  - Cell Line, Tumor
MH  - Chromosomal Proteins, Non-Histone/genetics
MH  - DNA Methylation/genetics
MH  - DNA-Binding Proteins/genetics
MH  - Gene Expression/genetics
MH  - Gene Expression Regulation, Developmental/*genetics
MH  - Histones/genetics
MH  - Humans
MH  - MicroRNAs/genetics
MH  - Rhabdoid Tumor/*genetics
MH  - SMARCB1 Protein
MH  - Transcription Factors/genetics
MH  - Transcriptome/genetics
PMC - PMC5094835
MID - NIHMS821050
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2015/07/17 00:00 [received]
PHST- 2016/01/05 00:00 [revised]
PHST- 2016/02/16 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30043-5 [pii]
AID - 10.1016/j.ccell.2016.02.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):394-406. doi: 10.1016/j.ccell.2016.02.009.

PMID- 26977885
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170419
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Protein Kinase Ciota Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS
      Lung Adenocarcinoma.
PG  - 367-78
LID - 10.1016/j.ccell.2016.02.012 [doi]
LID - S1535-6108(16)30046-0 [pii]
AB  - We report that the protein kinase Ciota (PKCiota) oncogene controls expression of
      NOTCH3, a key driver of stemness, in KRAS-mediated lung adenocarcinoma (LADC).
      PKCiota activates NOTCH3 expression by phosphorylating the ELF3 transcription
      factor and driving ELF3 occupancy on the NOTCH3 promoter. PKCiota-ELF3-NOTCH3
      signaling controls the tumor-initiating cell phenotype by regulating asymmetric
      cell division, a process necessary for tumor initiation and maintenance. Primary 
      LADC tumors exhibit PKCiota-ELF3-NOTCH3 signaling, and combined pharmacologic
      blockade of PKCiota and NOTCH synergistically inhibits tumorigenic behavior in
      vitro and LADC growth in vivo demonstrating the therapeutic potential of
      PKCiota-ELF3-NOTCH3 signal inhibition to more effectively treat KRAS LADC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Ali, Syed A
AU  - Ali SA
AD  - Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, 
      USA.
FAU - Justilien, Verline
AU  - Justilien V
AD  - Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, 
      USA.
FAU - Jamieson, Lee
AU  - Jamieson L
AD  - Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, 
      USA.
FAU - Murray, Nicole R
AU  - Murray NR
AD  - Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, 
      USA.
FAU - Fields, Alan P
AU  - Fields AP
AD  - Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, 
      USA. Electronic address: fields.alan@mayo.edu.
LA  - eng
GR  - R01 CA14090-05/CA/NCI NIH HHS/United States
GR  - R01 CA081436/CA/NCI NIH HHS/United States
GR  - R01 CA206367/CA/NCI NIH HHS/United States
GR  - R01 CA081436-18/CA/NCI NIH HHS/United States
GR  - P30 CA015083/CA/NCI NIH HHS/United States
GR  - R21 CA151250-02/CA/NCI NIH HHS/United States
GR  - R21 CA151250/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (ELF3 protein, human)
RN  - 0 (KRAS protein, human)
RN  - 0 (NOTCH3 protein, human)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Receptor, Notch3)
RN  - 0 (Receptors, Notch)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - Adenocarcinoma of lung
SB  - IM
MH  - Adenocarcinoma/*genetics/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Transformation, Neoplastic/genetics/*metabolism
MH  - DNA-Binding Proteins/metabolism
MH  - Humans
MH  - Lung Neoplasms/*genetics/*metabolism
MH  - Mutation/genetics
MH  - Neoplastic Stem Cells/metabolism
MH  - Phenotype
MH  - Promoter Regions, Genetic/genetics
MH  - Protein Kinase C/*metabolism
MH  - Proto-Oncogene Proteins c-ets/metabolism
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Receptor, Notch3
MH  - Receptors, Notch/*metabolism
MH  - Signal Transduction/genetics
MH  - Stem Cells/*metabolism
MH  - Transcription Factors/metabolism
PMC - PMC4795153
MID - NIHMS761777
OTO - NOTNLM
OT  - ELF3
OT  - KRAS-driven lung adenocarcinoma
OT  - NOTCH signaling
OT  - protein kinase Ciota
OT  - therapeutic intervention
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2015/02/23 00:00 [received]
PHST- 2015/08/21 00:00 [revised]
PHST- 2016/02/17 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30046-0 [pii]
AID - 10.1016/j.ccell.2016.02.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):367-78. doi: 10.1016/j.ccell.2016.02.012.

PMID- 26977884
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - PITPNC1 Recruits RAB1B to the Golgi Network to Drive Malignant Secretion.
PG  - 339-53
LID - 10.1016/j.ccell.2016.02.013 [doi]
LID - S1535-6108(16)30047-2 [pii]
AB  - Enhanced secretion of tumorigenic effector proteins is a feature of malignant
      cells. The molecular mechanisms underlying this feature are poorly defined. We
      identify PITPNC1 as a gene amplified in a large fraction of human breast cancer
      and overexpressed in metastatic breast, melanoma, and colon cancers. Biochemical,
      molecular, and cell-biological studies reveal that PITPNC1 promotes malignant
      secretion by binding Golgi-resident PI4P and localizing RAB1B to the Golgi. RAB1B
      localization to the Golgi allows for the recruitment of GOLPH3, which facilitates
      Golgi extension and enhanced vesicular release. PITPNC1-mediated vesicular
      release drives metastasis by increasing the secretion of pro-invasive and
      pro-angiogenic mediators HTRA1, MMP1, FAM3C, PDGFA, and ADAM10. We establish
      PITPNC1 as a PI4P-binding protein that enhances vesicular secretion capacity in
      malignancy.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Halberg, Nils
AU  - Halberg N
AD  - Laboratory of Systems Cancer Biology, Rockefeller University, Box 16, 1230 York
      Avenue, New York, NY 10065, USA; Department of Biomedicine, University of Bergen,
      Jonas Liesvej 91, 5020 Bergen, Norway. Electronic address: nils.halberg@uib.no.
FAU - Sengelaub, Caitlin A
AU  - Sengelaub CA
AD  - Laboratory of Systems Cancer Biology, Rockefeller University, Box 16, 1230 York
      Avenue, New York, NY 10065, USA.
FAU - Navrazhina, Kristina
AU  - Navrazhina K
AD  - Laboratory of Systems Cancer Biology, Rockefeller University, Box 16, 1230 York
      Avenue, New York, NY 10065, USA.
FAU - Molina, Henrik
AU  - Molina H
AD  - Laboratory of Systems Cancer Biology, Rockefeller University, Box 16, 1230 York
      Avenue, New York, NY 10065, USA.
FAU - Uryu, Kunihiro
AU  - Uryu K
AD  - Laboratory of Systems Cancer Biology, Rockefeller University, Box 16, 1230 York
      Avenue, New York, NY 10065, USA.
FAU - Tavazoie, Sohail F
AU  - Tavazoie SF
AD  - Laboratory of Systems Cancer Biology, Rockefeller University, Box 16, 1230 York
      Avenue, New York, NY 10065, USA. Electronic address: stavazoie@rockefeller.edu.
LA  - eng
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
GR  - T32GM007739/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (PITPNC1 protein, human)
RN  - EC 3.6.1.- (Rab1B protein, human)
RN  - EC 3.6.5.2 (rab1 GTP-Binding Proteins)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/metabolism
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/metabolism
MH  - Female
MH  - Golgi Apparatus/*metabolism
MH  - Humans
MH  - Melanoma/metabolism
MH  - Membrane Transport Proteins/*metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - rab1 GTP-Binding Proteins/*metabolism
PMC - PMC5300038
MID - NIHMS845580
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2014/12/22 00:00 [received]
PHST- 2015/08/19 00:00 [revised]
PHST- 2016/02/18 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30047-2 [pii]
AID - 10.1016/j.ccell.2016.02.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):339-53. doi: 10.1016/j.ccell.2016.02.013.

PMID- 26977883
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170421
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal 
      Reprogramming during Early Pancreatic Carcinogenesis.
PG  - 324-38
LID - 10.1016/j.ccell.2016.02.005 [doi]
LID - S1535-6108(16)30039-3 [pii]
AB  - Understanding the molecular mechanisms of tumor initiation has significant impact
      on early cancer detection and intervention. To define the role of KLF4 in
      pancreatic ductal adenocarcinoma (PDA) initiation, we used molecular biological
      analyses and mouse models of klf4 gain- and loss-of-function and mutant Kras.
      KLF4 is upregulated in and required for acinar-to-ductal metaplasia. Klf4
      ablation drastically attenuates the formation of pancreatic intraepithelial
      neoplasia induced by mutant Kras(G12D), whereas upregulation of KLF4 does the
      opposite. Mutant KRAS and cellular injuries induce KLF4 expression, and ectopic
      expression of KLF4 in acinar cells reduces acinar lineage- and induces ductal
      lineage-related marker expression. These results demonstrate that KLF4 induces
      ductal identity in PanIN initiation and may be a potential target for prevention 
      of PDA initiation.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Wei, Daoyan
AU  - Wei D
AD  - Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Wang, Liang
AU  - Wang L
AD  - Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Yan, Yongmin
AU  - Yan Y
AD  - Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Jia, Zhiliang
AU  - Jia Z
AD  - Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Gagea, Mihai
AU  - Gagea M
AD  - Department of Veterinary Medicine & Surgery, The University of Texas MD Anderson 
      Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Li, Zhiwei
AU  - Li Z
AD  - Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Zuo, Xiangsheng
AU  - Zuo X
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD
      Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Kong, Xiangyu
AU  - Kong X
AD  - Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Huang, Suyun
AU  - Huang S
AD  - Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Xie, Keping
AU  - Xie K
AD  - Department of Gastroenterology, Hepatology & Nutrition, The University of Texas
      MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
      Department of Gastroenterology, Hepatology & Nutrition, Unit 1644, The University
      of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030,
      USA. Electronic address: kepxie@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA195651/CA/NCI NIH HHS/United States
GR  - R01 CA129956/CA/NCI NIH HHS/United States
GR  - R01 CA148954/CA/NCI NIH HHS/United States
GR  - R01CA129956/CA/NCI NIH HHS/United States
GR  - R01CA195651/CA/NCI NIH HHS/United States
GR  - R01 CA198090/CA/NCI NIH HHS/United States
GR  - R01CA172233/CA/NCI NIH HHS/United States
GR  - R01 CA172233/CA/NCI NIH HHS/United States
GR  - R03CA124523/CA/NCI NIH HHS/United States
GR  - R01CA148954/CA/NCI NIH HHS/United States
GR  - R01 CA152309/CA/NCI NIH HHS/United States
GR  - R01CA152309/CA/NCI NIH HHS/United States
GR  - R03 CA124523/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (GKLF protein)
RN  - 0 (Kruppel-Like Transcription Factors)
SB  - IM
CIN - Cancer Cell. 2016 Mar 14;29(3):247-8. PMID: 26977875
MH  - Acinar Cells/metabolism/*pathology
MH  - Animals
MH  - Carcinogenesis/*genetics/metabolism/*pathology
MH  - Carcinoma, Pancreatic Ductal/genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Transformation, Neoplastic/genetics/metabolism/pathology
MH  - Genes, ras/genetics
MH  - Humans
MH  - Kruppel-Like Transcription Factors/*metabolism
MH  - Mice
MH  - Pancreas/metabolism/*pathology
MH  - Pancreatic Ducts/metabolism/*pathology
MH  - Precancerous Conditions/*genetics/metabolism/pathology
MH  - Up-Regulation/genetics
PMC - PMC4794756
MID - NIHMS760224
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2015/09/08 00:00 [received]
PHST- 2015/11/12 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30039-3 [pii]
AID - 10.1016/j.ccell.2016.02.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):324-38. doi: 10.1016/j.ccell.2016.02.005.

PMID- 26977882
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170622
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven
      Medulloblastoma.
PG  - 311-23
LID - 10.1016/j.ccell.2016.02.011 [doi]
LID - S1535-6108(16)30045-9 [pii]
AB  - Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite
      aggressive therapy, many patients succumb to the disease, and survivors
      experience severe side effects from treatment. MYC-driven MB has a particularly
      poor prognosis and would greatly benefit from more effective therapies. We used
      an animal model of MYC-driven MB to screen for drugs that decrease viability of
      tumor cells. Among the most effective compounds were histone deacetylase
      inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in
      vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs 
      also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor
      growth in vivo. These studies identify an effective combination therapy for the
      most aggressive form of MB.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Pei, Yanxin
AU  - Pei Y
AD  - Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Cancer and
      Immunology Department, Brain Tumor Institute, Children's National Medical Center,
      Washington, DC 20010, USA.
FAU - Liu, Kun-Wei
AU  - Liu KW
AD  - Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
FAU - Wang, Jun
AU  - Wang J
AD  - Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
FAU - Garancher, Alexandra
AU  - Garancher A
AD  - Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
FAU - Tao, Ran
AU  - Tao R
AD  - Cancer and Immunology Department, Brain Tumor Institute, Children's National
      Medical Center, Washington, DC 20010, USA.
FAU - Esparza, Lourdes A
AU  - Esparza LA
AD  - Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
FAU - Maier, Donna L
AU  - Maier DL
AD  - Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
FAU - Udaka, Yoko T
AU  - Udaka YT
AD  - Department of Pediatrics, University of California San Diego - Rady Children's
      Hospital, San Diego, CA 92123, USA.
FAU - Murad, Najiba
AU  - Murad N
AD  - Cancer and Immunology Department, Brain Tumor Institute, Children's National
      Medical Center, Washington, DC 20010, USA.
FAU - Morrissy, Sorana
AU  - Morrissy S
AD  - Program in Developmental and Stem Cell Biology, Division of Neurosurgery,
      Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.
FAU - Seker-Cin, Huriye
AU  - Seker-Cin H
AD  - Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg,
      Germany.
FAU - Brabetz, Sebastian
AU  - Brabetz S
AD  - Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg,
      Germany.
FAU - Qi, Lin
AU  - Qi L
AD  - Brain Tumor Program, Department of Pediatrics, Texas Children's Cancer Center,
      Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Kogiso, Mari
AU  - Kogiso M
AD  - Brain Tumor Program, Department of Pediatrics, Texas Children's Cancer Center,
      Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Schubert, Simone
AU  - Schubert S
AD  - Department of Neurology and Neurological Sciences, Stanford University School of 
      Medicine, Stanford, CA 94305, USA.
FAU - Olson, James M
AU  - Olson JM
AD  - Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, Seattle, WA 
      98109, USA.
FAU - Cho, Yoon-Jae
AU  - Cho YJ
AD  - Department of Neurology and Neurological Sciences, Stanford University School of 
      Medicine, Stanford, CA 94305, USA.
FAU - Li, Xiao-Nan
AU  - Li XN
AD  - Brain Tumor Program, Department of Pediatrics, Texas Children's Cancer Center,
      Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Crawford, John R
AU  - Crawford JR
AD  - Department of Pediatrics, University of California San Diego - Rady Children's
      Hospital, San Diego, CA 92123, USA; Department of Neurosciences, University of
      California San Diego - Rady Children's Hospital, San Diego, CA 92123, USA.
FAU - Levy, Michael L
AU  - Levy ML
AD  - Department of Neurosurgery, University of California San Diego - Rady Children's 
      Hospital, San Diego, CA 92123, USA.
FAU - Kool, Marcel
AU  - Kool M
AD  - Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg,
      Germany.
FAU - Pfister, Stefan M
AU  - Pfister SM
AD  - Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg,
      Germany.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Program in Developmental and Stem Cell Biology, Division of Neurosurgery,
      Hospital for Sick Children, Toronto, ON M5G 0A4, Canada; Division of
      Neurosurgery, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Wechsler-Reya, Robert J
AU  - Wechsler-Reya RJ
AD  - Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. Electronic
      address: rwreya@sbpdiscovery.org.
LA  - eng
GR  - CA159859/CA/NCI NIH HHS/United States
GR  - CA030199/CA/NCI NIH HHS/United States
GR  - R01 CA135491/CA/NCI NIH HHS/United States
GR  - R01 CA159859/CA/NCI NIH HHS/United States
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - P30 CA023100/CA/NCI NIH HHS/United States
GR  - R01 CA122759/CA/NCI NIH HHS/United States
GR  - CA122759/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 3.5.1.98 (Histone Deacetylases)
SB  - IM
CON - Cancer Discov. 2016 May;6(5):OF10. PMID: 27012830
MH  - Animals
MH  - Cell Proliferation/*drug effects
MH  - Disease Models, Animal
MH  - Forkhead Transcription Factors/metabolism
MH  - Genes, Tumor Suppressor/drug effects
MH  - Histone Deacetylase Inhibitors/*pharmacology
MH  - Histone Deacetylases/*metabolism
MH  - Humans
MH  - Medulloblastoma/*drug therapy/*metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
MH  - Proto-Oncogene Proteins c-myc/*metabolism
PMC - PMC4794752
MID - NIHMS762083
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2013/11/06 00:00 [received]
PHST- 2015/12/28 00:00 [revised]
PHST- 2016/02/14 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30045-9 [pii]
AID - 10.1016/j.ccell.2016.02.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):311-23. doi: 10.1016/j.ccell.2016.02.011.

PMID- 26977881
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170317
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits
      Broad Anticancer Activity.
PG  - 297-310
LID - 10.1016/j.ccell.2016.02.007 [doi]
LID - S1535-6108(16)30041-1 [pii]
AB  - Targeting sirtuins for cancer treatment has been a topic of debate due to
      conflicting reports and lack of potent and specific inhibitors. We have developed
      a thiomyristoyl lysine compound, TM, as a potent SIRT2-specific inhibitor with a 
      broad anticancer effect in various human cancer cells and mouse models of breast 
      cancer. Mechanistically, SIRT2 inhibition promotes c-Myc ubiquitination and
      degradation. The anticancer effect of TM correlates with its ability to decrease 
      c-Myc level. TM had limited effects on non-cancerous cells and tumor-free mice,
      suggesting that cancer cells have an increased dependency on SIRT2 that can be
      exploited for therapeutic benefit. Our studies demonstrate that SIRT2-selective
      inhibitors are promising anticancer agents and may represent a general strategy
      to target certain c-Myc-driven cancers.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Jing, Hui
AU  - Jing H
AD  - Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY
      14853, USA.
FAU - Hu, Jing
AU  - Hu J
AD  - Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY
      14853, USA.
FAU - He, Bin
AU  - He B
AD  - Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY
      14853, USA.
FAU - Negron Abril, Yashira L
AU  - Negron Abril YL
AD  - Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853, USA.
FAU - Stupinski, Jack
AU  - Stupinski J
AD  - Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853, USA.
FAU - Weiser, Keren
AU  - Weiser K
AD  - Division of Hematology & Medical Oncology, Weill Medical College of Cornell
      University, 1300 York Avenue, C610C, New York, NY 10065-4896, USA.
FAU - Carbonaro, Marisa
AU  - Carbonaro M
AD  - Division of Hematology & Medical Oncology, Weill Medical College of Cornell
      University, 1300 York Avenue, C610C, New York, NY 10065-4896, USA.
FAU - Chiang, Ying-Ling
AU  - Chiang YL
AD  - Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY
      14853, USA.
FAU - Southard, Teresa
AU  - Southard T
AD  - Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853, USA.
FAU - Giannakakou, Paraskevi
AU  - Giannakakou P
AD  - Division of Hematology & Medical Oncology, Weill Medical College of Cornell
      University, 1300 York Avenue, C610C, New York, NY 10065-4896, USA.
FAU - Weiss, Robert S
AU  - Weiss RS
AD  - Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853, USA.
FAU - Lin, Hening
AU  - Lin H
AD  - Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY
      14853, USA; Howard Hughes Medical Institute, Department of Chemistry and Chemical
      Biology, Cornell University, Ithaca, NY 14853, USA. Electronic address:
      hl379@cornell.edu.
LA  - eng
GR  - R01 CA163255/CA/NCI NIH HHS/United States
GR  - T32 GM008500/GM/NIGMS NIH HHS/United States
GR  - 5T32GM008500/GM/NIGMS NIH HHS/United States
GR  - CA163255/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 3.5.1.- (Sirtuin 2)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
EIN - Cancer Cell. 2016 Apr 11;29(4):607. Giannakakou, Paraszkevi [corrected to
      Giannakakou, Paraskevi]. PMID: 27070708
EIN - Cancer Cell. 2016 May 9;29(5):767-768. PMID: 27165747
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Breast Neoplasms/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Female
MH  - HeLa Cells
MH  - Humans
MH  - Lysine/metabolism
MH  - MCF-7 Cells
MH  - Mice
MH  - Oncogene Proteins/*metabolism
MH  - Proteolysis/*drug effects
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Sirtuin 2/*antagonists & inhibitors/metabolism
MH  - Ubiquitination/drug effects
PMC - PMC4811675
MID - NIHMS767207
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2015/02/13 00:00 [received]
PHST- 2015/07/03 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30041-1 [pii]
AID - 10.1016/j.ccell.2016.02.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):297-310. doi: 10.1016/j.ccell.2016.02.007.

PMID- 26977880
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance
      to PD-L1 Blockade.
PG  - 285-96
LID - 10.1016/j.ccell.2016.02.004 [doi]
LID - S1535-6108(16)30038-1 [pii]
AB  - Immune checkpoint blockade therapies fail to induce responses in the majority of 
      cancer patients, so how to increase the objective response rate becomes an urgent
      challenge. Here, we demonstrate that sufficient T cell infiltration in tumor
      tissues is a prerequisite for response to PD-L1 blockade. Targeting tumors with
      tumor necrosis factor superfamily member LIGHT activates lymphotoxin
      beta-receptor signaling, leading to the production of chemokines that recruit
      massive numbers of T cells. Furthermore, targeting non-T cell-inflamed tumor
      tissues by antibody-guided LIGHT creates a T cell-inflamed microenvironment and
      overcomes tumor resistance to checkpoint blockade. Our data indicate that
      targeting LIGHT might be a potent strategy to increase the responses to
      checkpoint blockades and other immunotherapies in non-T cell-inflamed tumors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Tang, Haidong
AU  - Tang H
AD  - Department of Pathology and Committee on Immunology, University of Chicago,
      Chicago, IL 60637, USA; Department of Pathology, University of Texas Southwestern
      Medical Center, Dallas, TX 75235, USA.
FAU - Wang, Yang
AU  - Wang Y
AD  - Department of Pathology and Committee on Immunology, University of Chicago,
      Chicago, IL 60637, USA; Department of Pathology, University of Texas Southwestern
      Medical Center, Dallas, TX 75235, USA.
FAU - Chlewicki, Lukasz K
AU  - Chlewicki LK
AD  - Department of Pathology and Committee on Immunology, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Zhang, Yuan
AU  - Zhang Y
AD  - Department of Pathology and Committee on Immunology, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Guo, Jingya
AU  - Guo J
AD  - Chinese Academy of Science Key Laboratory for Infection and Immunity, IBP-UTSW
      Joint Immunotherapy Group, Institute of Biophysics, Chinese Academy of Sciences, 
      Beijing 100101, China.
FAU - Liang, Wei
AU  - Liang W
AD  - Chinese Academy of Science Key Laboratory for Infection and Immunity, IBP-UTSW
      Joint Immunotherapy Group, Institute of Biophysics, Chinese Academy of Sciences, 
      Beijing 100101, China.
FAU - Wang, Jieyi
AU  - Wang J
AD  - Oncology Biologics, AbbVie Biotherapeutics Research (ABR), 1500 Seaport
      Boulevard, Redwood City, CA 94063, USA.
FAU - Wang, Xiaoxiao
AU  - Wang X
AD  - Alphamab Co. Ltd., Suzhou, Jiangsu 215125, China.
FAU - Fu, Yang-Xin
AU  - Fu YX
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas,
      TX 75235, USA; Chinese Academy of Science Key Laboratory for Infection and
      Immunity, IBP-UTSW Joint Immunotherapy Group, Institute of Biophysics, Chinese
      Academy of Sciences, Beijing 100101, China. Electronic address:
      yang-xin.fu@utsouthwestern.edu.
LA  - eng
GR  - R01 CA134563/CA/NCI NIH HHS/United States
GR  - R01 CA141975/CA/NCI NIH HHS/United States
GR  - CA141975/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Lymphotoxin beta Receptor)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
EIN - Cancer Cell. 2016 Sep 12;30(3):500. PMID: 27622338
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antineoplastic Agents/*immunology
MH  - B7-H1 Antigen/*immunology
MH  - Drug Resistance, Neoplasm/immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Lymphotoxin beta Receptor/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Signal Transduction/drug effects/immunology
MH  - T-Lymphocytes/drug effects/*immunology
MH  - Tumor Microenvironment/drug effects/*immunology
MH  - Tumor Necrosis Factor-alpha/immunology
PMC - PMC4794755
MID - NIHMS759865
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2015/08/24 00:00 [received]
PHST- 2015/12/30 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30038-1 [pii]
AID - 10.1016/j.ccell.2016.02.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):285-96. doi: 10.1016/j.ccell.2016.02.004.

PMID- 26977879
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170622
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for
      Targeted Melanoma Therapy.
PG  - 270-84
LID - 10.1016/j.ccell.2016.02.003 [doi]
LID - S1535-6108(16)30037-X [pii]
AB  - Once melanomas have progressed with acquired resistance to mitogen-activated
      protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major
      challenge. We therefore examined the therapy phase before acquired resistance had
      developed and discovered the melanoma survival oncogene MITF as a driver of an
      early non-mutational and reversible drug-tolerance state, which is induced by
      PAX3-mediated upregulation of MITF. A drug-repositioning screen identified the
      HIV1-protease inhibitor nelfinavir as potent suppressor of PAX3 and MITF
      expression. Nelfinavir profoundly sensitizes BRAF and NRAS mutant melanoma cells 
      to MAPK-pathway inhibitors. Moreover, nelfinavir is effective in BRAF and NRAS
      mutant melanoma cells isolated from patients progressed on MAPK inhibitor (MAPKi)
      therapy and in BRAF/NRAS/PTEN mutant tumors. We demonstrate that inhibiting a
      driver of MAPKi-induced drug tolerance could improve current approaches of
      targeted melanoma therapy.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Smith, Michael P
AU  - Smith MP
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK.
FAU - Brunton, Holly
AU  - Brunton H
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK.
FAU - Rowling, Emily J
AU  - Rowling EJ
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK.
FAU - Ferguson, Jennifer
AU  - Ferguson J
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK.
FAU - Arozarena, Imanol
AU  - Arozarena I
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK.
FAU - Miskolczi, Zsofia
AU  - Miskolczi Z
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK.
FAU - Lee, Jessica L
AU  - Lee JL
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK.
FAU - Girotti, Maria R
AU  - Girotti MR
AD  - Molecular Oncology Group, CRUK Manchester Institute for Cancer Research,
      Manchester Cancer Research Centre, Wilmslow Road, Manchester, M20 4BX, UK.
FAU - Marais, Richard
AU  - Marais R
AD  - Molecular Oncology Group, CRUK Manchester Institute for Cancer Research,
      Manchester Cancer Research Centre, Wilmslow Road, Manchester, M20 4BX, UK.
FAU - Levesque, Mitchell P
AU  - Levesque MP
AD  - Department of Dermatology, UniversitatsSpital Zurich, University of Zurich,
      Gloriastrasse 31, 8091 Zurich, Switzerland.
FAU - Dummer, Reinhard
AU  - Dummer R
AD  - Department of Dermatology, UniversitatsSpital Zurich, University of Zurich,
      Gloriastrasse 31, 8091 Zurich, Switzerland.
FAU - Frederick, Dennie T
AU  - Frederick DT
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit
      Street, Boston, MA 02114-2696, USA.
FAU - Flaherty, Keith T
AU  - Flaherty KT
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit
      Street, Boston, MA 02114-2696, USA.
FAU - Cooper, Zachary A
AU  - Cooper ZA
AD  - Divison of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400
      Pressler Street, Houston, TX 77030, USA.
FAU - Wargo, Jennifer A
AU  - Wargo JA
AD  - Divison of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400
      Pressler Street, Houston, TX 77030, USA.
FAU - Wellbrock, Claudia
AU  - Wellbrock C
AD  - Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix
      Research, The University of Manchester, Michael Smith Building, Oxford Road,
      Manchester, M13 9PT, UK. Electronic address: claudia.wellbrock@manchester.ac.uk.
LA  - eng
GR  - U54 CA163125/CA/NCI NIH HHS/United States
GR  - A12985/Cancer Research UK/United Kingdom
GR  - K08CA160692/CA/NCI NIH HHS/United States
GR  - C5759/A20971/Cancer Research UK/United Kingdom
GR  - 12-0235/Worldwide Cancer Research/United Kingdom
GR  - C11591/A16416/Cancer Research UK/United Kingdom
GR  - C5759/A12328/Cancer Research UK/United Kingdom
GR  - Wellcome Trust/United Kingdom
GR  - K08 CA160692/CA/NCI NIH HHS/United States
GR  - U54CA163125/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (HIV Protease Inhibitors)
RN  - 0 (Membrane Proteins)
RN  - 0 (PAX3 Transcription Factor)
RN  - 0 (PAX3 protein, human)
RN  - 0 (Paired Box Transcription Factors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 3.6.1.- (GTP Phosphohydrolases)
RN  - EC 3.6.1.- (NRAS protein, human)
RN  - HO3OGH5D7I (Nelfinavir)
SB  - IM
CON - Cancer Discov. 2016 May;6(5):OF11. PMID: 27012829
CIN - Cancer Cell. 2016 Mar 14;29(3):245-6. PMID: 26977874
CIN - Pigment Cell Melanoma Res. 2016 May;29(3):263-5. PMID: 26999069
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/drug effects/genetics
MH  - Drug Tolerance/*genetics
MH  - GTP Phosphohydrolases/genetics
MH  - HIV Protease Inhibitors/pharmacology
MH  - Humans
MH  - Melanoma/*drug therapy/*genetics
MH  - Membrane Proteins/genetics
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Mutation/*drug effects/*genetics
MH  - Nelfinavir/pharmacology
MH  - PAX3 Transcription Factor
MH  - Paired Box Transcription Factors/genetics
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Up-Regulation/drug effects/genetics
PMC - PMC4796027
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2015/07/03 00:00 [received]
PHST- 2015/12/18 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30037-X [pii]
AID - 10.1016/j.ccell.2016.02.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):270-84. doi: 10.1016/j.ccell.2016.02.003.

PMID- 26977878
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6
      Inhibitors.
PG  - 255-69
LID - 10.1016/j.ccell.2016.02.006 [doi]
LID - S1535-6108(16)30040-X [pii]
AB  - Using transgenic mouse models, cell line-based functional studies, and clinical
      specimens, we show that cyclin D1/CDK4 mediate resistance to targeted therapy for
      HER2-positive breast cancer. This is overcome using CDK4/6 inhibitors. Inhibition
      of CDK4/6 not only suppresses Rb phosphorylation, but also reduces TSC2
      phosphorylation and thus partially attenuates mTORC1 activity. This relieves
      feedback inhibition of upstream EGFR family kinases, resensitizing tumors to
      EGFR/HER2 blockade. Consequently, dual inhibition of EGFR/HER2 and CDK4/6 invokes
      a more potent suppression of TSC2 phosphorylation and hence mTORC1/S6K/S6RP
      activity. The suppression of both Rb and S6RP enhances G1 arrest and a phenotype 
      resembling cellular senescence. In vivo, CDK4/6 inhibitors sensitize
      patient-derived xenograft tumors to HER2-targeted therapies and delay tumor
      recurrence in a transgenic model of HER2-positive breast cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Goel, Shom
AU  - Goel S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA. Electronic address: shom_goel@dfci.harvard.edu.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Watt, April C
AU  - Watt AC
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Tolaney, Sara M
AU  - Tolaney SM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Dillon, Deborah A
AU  - Dillon DA
AD  - Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Li, Wei
AU  - Li W
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Harvard School of Public Health, Boston, MA 02215, USA; Center for
      Functional Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Ramm, Susanne
AU  - Ramm S
AD  - Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science,
      Harvard Medical School, Boston, MA 02115, USA; Renal Division, Department of
      Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Palmer, Adam C
AU  - Palmer AC
AD  - Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science,
      Harvard Medical School, Boston, MA 02115, USA; Department of Systems Biology,
      Harvard Medical School, Boston, MA 02115, USA; School of Biotechnology and
      Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052,
      Australia.
FAU - Yuzugullu, Haluk
AU  - Yuzugullu H
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Varadan, Vinay
AU  - Varadan V
AD  - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 
      44106, USA.
FAU - Tuck, David
AU  - Tuck D
AD  - Department of Pathology, Yale University, New Haven, CT 06520, USA.
FAU - Harris, Lyndsay N
AU  - Harris LN
AD  - Case Western Reserve School of Medicine, Cleveland, OH 44106, USA.
FAU - Wong, Kwok-Kin
AU  - Wong KK
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Liu, X Shirley
AU  - Liu XS
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Harvard School of Public Health, Boston, MA 02215, USA; Center for
      Functional Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Sicinski, Piotr
AU  - Sicinski P
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Winer, Eric P
AU  - Winer EP
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Krop, Ian E
AU  - Krop IE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Zhao, Jean J
AU  - Zhao JJ
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard
      Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard,
      Cambridge, MA 02142, USA. Electronic address: jean_zhao@dfci.harvard.edu.
LA  - eng
GR  - R01 CA083688/CA/NCI NIH HHS/United States
GR  - U01 CA180980/CA/NCI NIH HHS/United States
GR  - P01 CA080111/CA/NCI NIH HHS/United States
GR  - R01 CA172461/CA/NCI NIH HHS/United States
GR  - R25 CA094186/CA/NCI NIH HHS/United States
GR  - P50 CA168504/CA/NCI NIH HHS/United States
GR  - U01CA180980/CA/NCI NIH HHS/United States
GR  - CA172461/CA/NCI NIH HHS/United States
GR  - P50 CA165962/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
SB  - IM
CON - Cancer Discov. 2016 May;6(5):OF4. PMID: 27012828
CIN - Cancer Cell. 2016 Mar 14;29(3):243-4. PMID: 26977873
MH  - Animals
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Cell Line, Tumor
MH  - Cyclin-Dependent Kinase 4/*antagonists & inhibitors/metabolism
MH  - Cyclin-Dependent Kinase 6/*antagonists & inhibitors/metabolism
MH  - Disease Models, Animal
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mice
MH  - Mice, Nude
MH  - Mice, Transgenic
MH  - Multiprotein Complexes/metabolism
MH  - Neoplasm Recurrence, Local/mortality
MH  - Phosphorylation/drug effects
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Receptor, Epidermal Growth Factor/metabolism
MH  - Receptor, ErbB-2/*metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Tumor Suppressor Proteins/metabolism
PMC - PMC4794996
MID - NIHMS760115
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2015/07/14 00:00 [received]
PHST- 2015/10/22 00:00 [revised]
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30040-X [pii]
AID - 10.1016/j.ccell.2016.02.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):255-69. doi: 10.1016/j.ccell.2016.02.006.

PMID- 26977877
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down.
PG  - 251-3
LID - 10.1016/j.ccell.2016.02.015 [doi]
LID - S1535-6108(16)30049-6 [pii]
AB  - Two recent studies evaluated a small molecule that specifically binds to and
      inactivates the KRAS G12C mutant. The new findings argue that the perception that
      mutant KRAS is persistently frozen in its active GTP-bound form may not be
      accurate.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hobbs, G Aaron
AU  - Hobbs GA
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Wittinghofer, Alfred
AU  - Wittinghofer A
AD  - Department of Structural Biology, Max Planck Institute of Molecular Physiology,
      44227 Dortmund, Germany.
FAU - Der, Channing J
AU  - Der CJ
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA. Electronic address: cjder@med.unc.edu.
LA  - eng
GR  - F32 CA200313/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (ARS853)
RN  - 0 (Azetidines)
RN  - 0 (KRAS protein, human)
RN  - 0 (Piperazines)
RN  - 146-91-8 (Guanosine Diphosphate)
RN  - 86-01-1 (Guanosine Triphosphate)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Azetidines
MH  - Guanosine Diphosphate/metabolism
MH  - Guanosine Triphosphate/metabolism
MH  - Humans
MH  - Mutation/*genetics
MH  - Piperazines
MH  - Proto-Oncogene Proteins p21(ras)/*genetics/metabolism
EDAT- 2016/03/16 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/16 06:00
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30049-6 [pii]
AID - 10.1016/j.ccell.2016.02.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):251-3. doi: 10.1016/j.ccell.2016.02.015.

PMID- 26977876
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen
      Signaling in ER(+) Breast Cancer.
PG  - 249-50
LID - 10.1016/j.ccell.2016.02.017 [doi]
LID - S1535-6108(16)30051-4 [pii]
AB  - In this issue of Cancer Cell, Sflomos et al. (2016) describe a robust preclinical
      animal model of ER(+) breast cancer. The authors identify the critical role of
      the breast microenvironment in determining hormone response of ER(+) breast
      cancer cells and in driving the luminal phenotype of breast cancer.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Haricharan, Svasti
AU  - Haricharan S
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Lei, Jonathan
AU  - Lei J
AD  - Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor
      College of Medicine, Houston, TX 77030, USA.
FAU - Ellis, Matthew
AU  - Ellis M
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA;
      Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor
      College of Medicine, Houston, TX 77030, USA. Electronic address:
      matthew.ellis@bcm.edu.
LA  - eng
GR  - T32 GM088129/GM/NIGMS NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Estrogen Receptor alpha)
SB  - IM
CON - Cancer Cell. 2016 Mar 14;29(3):407-22. PMID: 26947176
MH  - Animals
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Estrogen Receptor alpha/*genetics
MH  - Female
MH  - Humans
MH  - Mammary Glands, Human/*pathology
MH  - Tumor Microenvironment/*genetics
PMC - PMC5047062
MID - NIHMS819047
EDAT- 2016/03/16 06:00
MHDA- 2016/07/29 06:00
CRDT- 2016/03/16 06:00
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
AID - S1535-6108(16)30051-4 [pii]
AID - 10.1016/j.ccell.2016.02.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):249-50. doi: 10.1016/j.ccell.2016.02.017.

PMID- 26977875
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20171209
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - KLF4 Initiates Acinar Cell Reprogramming and Is Essential for the Early Stages of
      Pancreatic Carcinogenesis.
PG  - 247-8
LID - 10.1016/j.ccell.2016.02.019 [doi]
LID - S1535-6108(16)30053-8 [pii]
AB  - Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and is minimally
      responsive to current chemotherapies. In this issue of Cancer Cell, Xie et al.
      (2016) identify the transcription factor KLF4 as essential for the early stages
      of pancreatic carcinogenesis, expanding the repertoire of targets for early
      intervention strategies.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Maddipati, Ravikanth
AU  - Maddipati R
AD  - Division of Gastroenterology, Department of Medicine, University of Pennsylvania 
      Perelman School of Medicine, Philadelphia, PA 19104-4863, USA.
FAU - Katz, Jonathan P
AU  - Katz JP
AD  - Division of Gastroenterology, Department of Medicine, University of Pennsylvania 
      Perelman School of Medicine, Philadelphia, PA 19104-4863, USA. Electronic
      address: jpkatz@mail.med.upenn.edu.
LA  - eng
GR  - R01 DK069984/DK/NIDDK NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Kruppel-Like Transcription Factors)
SB  - IM
CON - Cancer Cell. 2016 Mar 14;29(3):324-38. PMID: 26977883
MH  - Acinar Cells/*pathology
MH  - Animals
MH  - Carcinogenesis/*genetics/*pathology
MH  - Humans
MH  - Kruppel-Like Transcription Factors/*metabolism
MH  - Pancreas/*pathology
MH  - Pancreatic Ducts/*pathology
MH  - Precancerous Conditions/*genetics
EDAT- 2016/03/16 06:00
MHDA- 2016/07/29 06:00
CRDT- 2016/03/16 06:00
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
AID - S1535-6108(16)30053-8 [pii]
AID - 10.1016/j.ccell.2016.02.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):247-8. doi: 10.1016/j.ccell.2016.02.019.

PMID- 26977874
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20160316
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - HIV Drug to Aid Melanoma Therapies?
PG  - 245-6
LID - 10.1016/j.ccell.2016.02.014 [doi]
LID - S1535-6108(16)30048-4 [pii]
AB  - The HIV1 protease inhibitor nelfinavir is being investigated as a cancer
      therapeutic. In this issue of Cancer Cell, Smith et al. (2016) report that
      nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in
      melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS
      mutations to MEK inhibitors.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kim, Hyungsoo
AU  - Kim H
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys
      Medical Discovery Institute, La Jolla, CA 92037, USA.
FAU - Ronai, Ze'ev A
AU  - Ronai ZA
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys
      Medical Discovery Institute, La Jolla, CA 92037, USA. Electronic address:
      zeev@ronailab.net.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
CON - Cancer Cell. 2016 Mar 14;29(3):270-84. PMID: 26977879
MH  - Drug Tolerance/*genetics
MH  - Humans
MH  - Melanoma/*drug therapy/*genetics
MH  - Mutation/*drug effects/*genetics
MH  - Protein Kinase Inhibitors/*pharmacology
EDAT- 2016/03/16 06:00
MHDA- 2016/07/29 06:00
CRDT- 2016/03/16 06:00
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
AID - S1535-6108(16)30048-4 [pii]
AID - 10.1016/j.ccell.2016.02.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):245-6. doi: 10.1016/j.ccell.2016.02.014.

PMID- 26977873
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20160316
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER(2)(+) Breast Cancer.
PG  - 243-4
LID - 10.1016/j.ccell.2016.02.016 [doi]
LID - S1535-6108(16)30050-2 [pii]
AB  - CDK4/6 inhibitors have received approval for treating hormone-positive breast
      tumors, but whether other aggressive cancers respond to these molecules is not
      yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected 
      activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing
      HER2-positive cancers to EGFR/HER2 blockade.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Malumbres, Marcos
AU  - Malumbres M
AD  - Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncologicas
      (CNIO), Melchor Fernandez Almagro 3, E-28029 Madrid, Spain. Electronic address:
      malumbres@cnio.es.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
SB  - IM
CON - Cancer Cell. 2016 Mar 14;29(3):255-69. PMID: 26977878
MH  - Animals
MH  - Breast Neoplasms/*drug therapy
MH  - Cyclin-Dependent Kinase 4/*antagonists & inhibitors
MH  - Cyclin-Dependent Kinase 6/*antagonists & inhibitors
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Humans
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Receptor, ErbB-2/*metabolism
EDAT- 2016/03/16 06:00
MHDA- 2016/07/29 06:00
CRDT- 2016/03/16 06:00
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
AID - S1535-6108(16)30050-2 [pii]
AID - 10.1016/j.ccell.2016.02.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):243-4. doi: 10.1016/j.ccell.2016.02.016.

PMID- 26947176
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170622
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - A Preclinical Model for ERalpha-Positive Breast Cancer Points to the Epithelial
      Microenvironment as Determinant of Luminal Phenotype and Hormone Response.
PG  - 407-22
LID - 10.1016/j.ccell.2016.02.002 [doi]
LID - S1535-6108(16)30036-8 [pii]
AB  - Seventy-five percent of breast cancers are estrogen receptor alpha positive
      (ER(+)). Research on these tumors is hampered by lack of adequate in vivo models;
      cell line xenografts require non-physiological hormone supplements, and
      patient-derived xenografts (PDXs) are hard to establish. We show that the
      traditional grafting of ER(+) tumor cells into mammary fat pads induces
      TGFbeta/SLUG signaling and basal differentiation when they require low SLUG
      levels to grow in vivo. Grafting into the milk ducts suppresses SLUG; ER(+) tumor
      cells develop, like their clinical counterparts, in the presence of physiological
      hormone levels. Intraductal ER(+) PDXs are retransplantable, predictive, and
      appear genomically stable. The model provides opportunities for translational
      research and the study of physiologically relevant hormone action in breast
      carcinogenesis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Sflomos, George
AU  - Sflomos G
AD  - ISREC - Swiss Institute for Experimental Cancer Research, School of Life
      Sciences, Ecole polytechnique federale de Lausanne (EPFL), SV2.832 Station 19,
      1015 Lausanne, Switzerland.
FAU - Dormoy, Valerian
AU  - Dormoy V
AD  - ISREC - Swiss Institute for Experimental Cancer Research, School of Life
      Sciences, Ecole polytechnique federale de Lausanne (EPFL), SV2.832 Station 19,
      1015 Lausanne, Switzerland.
FAU - Metsalu, Tauno
AU  - Metsalu T
AD  - Institute of Computer Science, University of Tartu, Liivi 2, Tartu 50409,
      Estonia.
FAU - Jeitziner, Rachel
AU  - Jeitziner R
AD  - ISREC - Swiss Institute for Experimental Cancer Research, School of Life
      Sciences, Ecole polytechnique federale de Lausanne (EPFL), SV2.832 Station 19,
      1015 Lausanne, Switzerland.
FAU - Battista, Laura
AU  - Battista L
AD  - ISREC - Swiss Institute for Experimental Cancer Research, School of Life
      Sciences, Ecole polytechnique federale de Lausanne (EPFL), SV2.832 Station 19,
      1015 Lausanne, Switzerland.
FAU - Scabia, Valentina
AU  - Scabia V
AD  - ISREC - Swiss Institute for Experimental Cancer Research, School of Life
      Sciences, Ecole polytechnique federale de Lausanne (EPFL), SV2.832 Station 19,
      1015 Lausanne, Switzerland.
FAU - Raffoul, Wassim
AU  - Raffoul W
AD  - Lausanne University Hospital, 1011 Lausanne, Switzerland.
FAU - Delaloye, Jean-Francois
AU  - Delaloye JF
AD  - Lausanne University Hospital, 1011 Lausanne, Switzerland.
FAU - Treboux, Assya
AU  - Treboux A
AD  - Lausanne University Hospital, 1011 Lausanne, Switzerland.
FAU - Fiche, Maryse
AU  - Fiche M
AD  - Lausanne University Hospital, 1011 Lausanne, Switzerland.
FAU - Vilo, Jaak
AU  - Vilo J
AD  - Institute of Computer Science, University of Tartu, Liivi 2, Tartu 50409,
      Estonia.
FAU - Ayyanan, Ayyakkannu
AU  - Ayyanan A
AD  - ISREC - Swiss Institute for Experimental Cancer Research, School of Life
      Sciences, Ecole polytechnique federale de Lausanne (EPFL), SV2.832 Station 19,
      1015 Lausanne, Switzerland.
FAU - Brisken, Cathrin
AU  - Brisken C
AD  - ISREC - Swiss Institute for Experimental Cancer Research, School of Life
      Sciences, Ecole polytechnique federale de Lausanne (EPFL), SV2.832 Station 19,
      1015 Lausanne, Switzerland. Electronic address: cathrin.brisken@epfl.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20160303
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (SNAI1 protein, human)
RN  - 0 (Snai2 protein, mouse)
RN  - 0 (Snail Family Transcription Factors)
RN  - 0 (Transcription Factors)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (estrogen receptor alpha, human)
SB  - IM
CON - Cancer Discov. 2016 May;6(5):OF6. PMID: 26988668
CIN - Cancer Cell. 2016 Mar 14;29(3):249-50. PMID: 26977876
MH  - Animals
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Cell Line, Tumor
MH  - Estrogen Receptor alpha/*genetics
MH  - Female
MH  - Humans
MH  - MCF-7 Cells
MH  - Mammary Glands, Human/*pathology
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Signal Transduction/genetics
MH  - Snail Family Transcription Factors
MH  - Transcription Factors/genetics
MH  - Transforming Growth Factor beta/genetics
MH  - Tumor Microenvironment/*genetics
EDAT- 2016/03/08 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/08 06:00
PHST- 2015/05/04 00:00 [received]
PHST- 2015/11/16 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/03/08 06:00 [entrez]
PHST- 2016/03/08 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30036-8 [pii]
AID - 10.1016/j.ccell.2016.02.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):407-22. doi: 10.1016/j.ccell.2016.02.002. Epub
      2016 Mar 3.

PMID- 26923874
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170215
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups
      with Distinct Enhancer Landscapes.
PG  - 379-93
LID - 10.1016/j.ccell.2016.02.001 [doi]
LID - S1535-6108(16)30035-6 [pii]
AB  - Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in
      infants. Although the prognosis of ATRT patients is poor, some patients respond
      favorably to current treatments, suggesting molecular inter-tumor heterogeneity. 
      To investigate this further, we genetically and epigenetically analyzed 192
      ATRTs. Three distinct molecular subgroups of ATRTs, associated with differences
      in demographics, tumor location, and type of SMARCB1 alterations, were
      identified. Whole-genome DNA and RNA sequencing found no recurrent mutations in
      addition to SMARCB1 that would explain the differences between subgroups.
      Whole-genome bisulfite sequencing and H3K27Ac chromatin-immunoprecipitation
      sequencing of primary tumors, however, revealed clear differences, leading to the
      identification of subgroup-specific regulatory networks and potential therapeutic
      targets.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Johann, Pascal D
AU  - Johann PD
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany; Department of Pediatric
      Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany.
FAU - Erkek, Serap
AU  - Erkek S
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany; European Molecular Biology
      Laboratory, Genome Biology Unit, 69117 Heidelberg, Germany.
FAU - Zapatka, Marc
AU  - Zapatka M
AD  - German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg,
      Germany; Division of Molecular Genetics, German Cancer Research Center, 69120
      Heidelberg, Germany.
FAU - Kerl, Kornelius
AU  - Kerl K
AD  - Department of Pediatric Hematology and Oncology, University Children's Hospital
      Muenster, 48149 Munster, Germany.
FAU - Buchhalter, Ivo
AU  - Buchhalter I
AD  - Division of Theoretical Bioinformatics, German Cancer Research Center, 69120
      Heidelberg, Germany.
FAU - Hovestadt, Volker
AU  - Hovestadt V
AD  - German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg,
      Germany; Division of Molecular Genetics, German Cancer Research Center, 69120
      Heidelberg, Germany.
FAU - Jones, David T W
AU  - Jones DT
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany.
FAU - Sturm, Dominik
AU  - Sturm D
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany; Department of Pediatric
      Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany.
FAU - Hermann, Carl
AU  - Hermann C
AD  - Division of Theoretical Bioinformatics, German Cancer Research Center, 69120
      Heidelberg, Germany.
FAU - Segura Wang, Maia
AU  - Segura Wang M
AD  - European Molecular Biology Laboratory, Genome Biology Unit, 69117 Heidelberg,
      Germany.
FAU - Korshunov, Andrey
AU  - Korshunov A
AD  - Department of Neuropathology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center,
      69120 Heidelberg, Germany.
FAU - Rhyzova, Marina
AU  - Rhyzova M
AD  - Department of Neuropathology, Burdenko Neurosurgical Institute, 125047 Moscow,
      Russia.
FAU - Grobner, Susanne
AU  - Grobner S
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany.
FAU - Brabetz, Sebastian
AU  - Brabetz S
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany.
FAU - Chavez, Lukas
AU  - Chavez L
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany.
FAU - Bens, Susanne
AU  - Bens S
AD  - Institute for Human Genetics, 24105 Kiel, Germany.
FAU - Groschel, Stefan
AU  - Groschel S
AD  - Division of Translational Oncology, Nationales Centrum fur Tumorerkrankungen NCT,
      69120 Heidelberg, Germany.
FAU - Kratochwil, Fabian
AU  - Kratochwil F
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany.
FAU - Wittmann, Andrea
AU  - Wittmann A
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany.
FAU - Sieber, Laura
AU  - Sieber L
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany.
FAU - Georg, Christina
AU  - Georg C
AD  - Division of Translational Oncology, Nationales Centrum fur Tumorerkrankungen NCT,
      69120 Heidelberg, Germany.
FAU - Wolf, Stefan
AU  - Wolf S
AD  - Genomics and Proteomics Core Facility, German Cancer Research Center, 69120
      Heidelberg, Germany.
FAU - Beck, Katja
AU  - Beck K
AD  - German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg,
      Germany; Division of Molecular Genetics, German Cancer Research Center, 69120
      Heidelberg, Germany.
FAU - Oyen, Florian
AU  - Oyen F
AD  - Department of Pediatric Hematology and Oncology, University Hospital
      Hamburg-Eppendorf, 20246 Hamburg, Germany.
FAU - Capper, David
AU  - Capper D
AD  - Department of Neuropathology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center,
      69120 Heidelberg, Germany.
FAU - van Sluis, Peter
AU  - van Sluis P
AD  - Department of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the
      Netherlands.
FAU - Volckmann, Richard
AU  - Volckmann R
AD  - Department of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the
      Netherlands.
FAU - Koster, Jan
AU  - Koster J
AD  - Department of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the
      Netherlands.
FAU - Versteeg, Rogier
AU  - Versteeg R
AD  - Department of Oncogenomics, Academic Medical Center, 1105 AZ Amsterdam, the
      Netherlands.
FAU - von Deimling, Andreas
AU  - von Deimling A
AD  - Department of Neuropathology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center,
      69120 Heidelberg, Germany.
FAU - Milde, Till
AU  - Milde T
AD  - Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, 
      69120 Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German
      Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Witt, Olaf
AU  - Witt O
AD  - Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, 
      69120 Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German
      Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Kulozik, Andreas E
AU  - Kulozik AE
AD  - Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, 
      69120 Heidelberg, Germany.
FAU - Ebinger, Martin
AU  - Ebinger M
AD  - Department of General Pediatrics, Hematology and Oncology, University of
      Tubingen, 72076 Tubingen, Germany.
FAU - Shalaby, Tarek
AU  - Shalaby T
AD  - Department of Neuro-Oncology, Children's Research Center, University Children's
      Hospital, 8032 Zurich, Switzerland.
FAU - Grotzer, Michael
AU  - Grotzer M
AD  - Department of Neuro-Oncology, Children's Research Center, University Children's
      Hospital, 8032 Zurich, Switzerland.
FAU - Sumerauer, David
AU  - Sumerauer D
AD  - Department of Pediatric Hematology and Oncology, Charles University and
      University Hospital Motol, 15006 Prague, Czech Republic.
FAU - Zamecnik, Josef
AU  - Zamecnik J
AD  - Deptartment of Pathology and Molecular Medicine, Charles University, 2nd Medical 
      Faculty, University Hospital Motol, 15006 Prague, Czech Republic.
FAU - Mora, Jaume
AU  - Mora J
AD  - Department of Hematology and Oncology, Children's Hospital, Hospital San Joan de 
      Deu, 08950 Barcelona, Spain.
FAU - Jabado, Nada
AU  - Jabado N
AD  - Departments of Pediatrics and Human Genetics, McGill University Health Center
      Research Institute, Montreal, QC H3A 1A4, Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, 
      University of Toronto, Toronto, ON M5G0A4, Canada.
FAU - Huang, Annie
AU  - Huang A
AD  - Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, 
      University of Toronto, Toronto, ON M5G0A4, Canada.
FAU - Aronica, Eleonora
AU  - Aronica E
AD  - Department of Neuropathology, Academic Medical Center, 20246 Amsterdam, the
      Netherlands.
FAU - Bertoni, Anna
AU  - Bertoni A
AD  - Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, 
      Germany.
FAU - Radlwimmer, Bernhard
AU  - Radlwimmer B
AD  - Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, 
      Germany.
FAU - Pietsch, Torsten
AU  - Pietsch T
AD  - Department of Neuropathology, University of Bonn, 53127 Bonn, Germany.
FAU - Schuller, Ulrich
AU  - Schuller U
AD  - Center of Neuropathology, Ludwig-Maximilians-Universitat, 81377 Munich, Germany.
FAU - Schneppenheim, Reinhard
AU  - Schneppenheim R
AD  - Department of Pediatric Hematology and Oncology, University Hospital
      Hamburg-Eppendorf, 20246 Hamburg, Germany.
FAU - Northcott, Paul A
AU  - Northcott PA
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany.
FAU - Korbel, Jan O
AU  - Korbel JO
AD  - European Molecular Biology Laboratory, Genome Biology Unit, 69117 Heidelberg,
      Germany.
FAU - Siebert, Reiner
AU  - Siebert R
AD  - Institute for Human Genetics, 24105 Kiel, Germany.
FAU - Fruhwald, Michael C
AU  - Fruhwald MC
AD  - Swabian Childrens' Cancer Center, Children's Hospital Augsburg, 86156 Augsburg,
      Germany; EU-RHAB registry Center, 86156 Augsburg, Germany.
FAU - Lichter, Peter
AU  - Lichter P
AD  - German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg,
      Germany; Division of Molecular Genetics, German Cancer Research Center, 69120
      Heidelberg, Germany; Heidelberg Center for Personalized Oncology, DKFZ-HIPO,
      DKFZ, 69120 Heidelberg, Germany.
FAU - Eils, Roland
AU  - Eils R
AD  - Division of Theoretical Bioinformatics, German Cancer Research Center, 69120
      Heidelberg, Germany; Heidelberg Center for Personalized Oncology, DKFZ-HIPO,
      DKFZ, 69120 Heidelberg, Germany.
FAU - Gajjar, Amar
AU  - Gajjar A
AD  - St Jude Children's Research Hospital, Memphis, TN 38105, USA.
FAU - Hasselblatt, Martin
AU  - Hasselblatt M
AD  - Institute of Neuropathology, University Hospital Munster, 48149 Munster, Germany.
FAU - Pfister, Stefan M
AU  - Pfister SM
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany; Department of Pediatric
      Hematology and Oncology, University Hospital Heidelberg, 69120 Heidelberg,
      Germany.
FAU - Kool, Marcel
AU  - Kool M
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im
      Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK),
      Core Center Heidelberg, 69120 Heidelberg, Germany. Electronic address:
      m.kool@dkfz.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160225
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromosomal Proteins, Non-Histone)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (SMARCB1 Protein)
RN  - 0 (SMARCB1 protein, human)
RN  - 0 (Transcription Factors)
RN  - Teratoid Tumor, Atypical
SB  - IM
CIN - Trends Cancer. 2016 May;2(5):217-218. PMID: 27672680
MH  - Brain Neoplasms/genetics
MH  - Chromosomal Proteins, Non-Histone/genetics
MH  - DNA-Binding Proteins/genetics
MH  - Epigenesis, Genetic/*genetics
MH  - Humans
MH  - Mutation/genetics
MH  - Rhabdoid Tumor/*genetics
MH  - SMARCB1 Protein
MH  - Teratoma/*genetics
MH  - Transcription Factors/genetics
EDAT- 2016/03/01 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/03/01 06:00
PHST- 2015/08/14 00:00 [received]
PHST- 2015/12/22 00:00 [revised]
PHST- 2016/02/01 00:00 [accepted]
PHST- 2016/03/01 06:00 [entrez]
PHST- 2016/03/01 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30035-6 [pii]
AID - 10.1016/j.ccell.2016.02.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):379-93. doi: 10.1016/j.ccell.2016.02.001. Epub
      2016 Feb 25.

PMID- 26908355
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 3
DP  - 2016 Mar 14
TI  - Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and
      Required for Liver and Colon Cancer Development.
PG  - 354-66
LID - 10.1016/j.ccell.2016.01.013 [doi]
LID - S1535-6108(16)30007-1 [pii]
AB  - Smyd3 is a protein methyltransferase implicated in cancer development. Here we
      show that Smyd3 expression in mice is required for chemically induced liver and
      colon cancer formation. In these organs Smyd3 functions in the nucleus,
      stimulating the transcription of several key regulators involved in cell
      proliferation, epithelial-mesenchymal transition, the JAK/Stat3 oncogenic
      pathway, as well as the Myc and Ctnnb1 oncogenes. Smyd3 interacts with
      H3K4Me3-modified histone tails, which facilitates its recruitment to the core
      promoter regions of most active genes. Smyd3 binding density on target genes
      positively correlates with increased RNA polymerase-II density and
      transcriptional outputs. Despite its widespread distribution, the
      transcription-potentiating function of Smyd3 is restricted to a particular set of
      genes, whose expression is induced specifically during carcinogenesis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Sarris, Michalis E
AU  - Sarris ME
AD  - Biomedical Sciences Research Center Alexander Fleming, 16672 Vari, Greece; School
      of Medicine, University of Crete, 71003 Herakleion, Crete, Greece.
FAU - Moulos, Panagiotis
AU  - Moulos P
AD  - Biomedical Sciences Research Center Alexander Fleming, 16672 Vari, Greece.
FAU - Haroniti, Anna
AU  - Haroniti A
AD  - Biomedical Sciences Research Center Alexander Fleming, 16672 Vari, Greece.
FAU - Giakountis, Antonis
AU  - Giakountis A
AD  - Biomedical Sciences Research Center Alexander Fleming, 16672 Vari, Greece.
FAU - Talianidis, Iannis
AU  - Talianidis I
AD  - Biomedical Sciences Research Center Alexander Fleming, 16672 Vari, Greece.
      Electronic address: talianidis@fleming.gr.
LA  - eng
GR  - 09-0586/Worldwide Cancer Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160218
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CTNNB1 protein, mouse)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (beta Catenin)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.1.1.43 (Smyd3 protein, mouse)
RN  - EC 2.7.10.2 (Janus Kinases)
RN  - EC 2.7.7.- (RNA Polymerase II)
SB  - IM
MH  - Animals
MH  - Carcinogenesis/genetics
MH  - Cell Proliferation/genetics
MH  - Colonic Neoplasms/*genetics
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Histone-Lysine N-Methyltransferase/*genetics
MH  - Janus Kinases/genetics
MH  - Liver Neoplasms/*genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Proto-Oncogene Proteins c-myc/genetics
MH  - RNA Polymerase II/genetics
MH  - STAT3 Transcription Factor/genetics
MH  - Transcription, Genetic/*genetics
MH  - Transcriptional Activation/genetics
MH  - beta Catenin/genetics
EDAT- 2016/02/26 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/02/25 06:00
PHST- 2015/04/14 00:00 [received]
PHST- 2015/10/21 00:00 [revised]
PHST- 2016/01/22 00:00 [accepted]
PHST- 2016/02/25 06:00 [entrez]
PHST- 2016/02/26 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S1535-6108(16)30007-1 [pii]
AID - 10.1016/j.ccell.2016.01.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Mar 14;29(3):354-66. doi: 10.1016/j.ccell.2016.01.013. Epub
      2016 Feb 18.

PMID- 26859459
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20180112
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells
      in an NF-kappaB-dependent Manner.
PG  - 201-13
LID - 10.1016/j.ccell.2016.01.005 [doi]
LID - S1535-6108(16)00034-9 [pii]
AB  - Activation of nuclear factor kappaB (NF-kappaB) induces mesenchymal (MES)
      transdifferentiation and radioresistance in glioma stem cells (GSCs), but
      molecular mechanisms for NF-kappaB activation in GSCs are currently unknown.
      Here, we report that mixed lineage kinase 4 (MLK4) is overexpressed in MES but
      not proneural (PN) GSCs. Silencing MLK4 suppresses self-renewal, motility,
      tumorigenesis, and radioresistance of MES GSCs via a loss of the MES signature.
      MLK4 binds and phosphorylates the NF-kappaB regulator IKKalpha, leading to
      activation of NF-kappaB signaling in GSCs. MLK4 expression is inversely
      correlated with patient prognosis in MES, but not PN high-grade gliomas.
      Collectively, our results uncover MLK4 as an upstream regulator of NF-kappaB
      signaling and a potential molecular target for the MES subtype of glioblastomas.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kim, Sung-Hak
AU  - Kim SH
AD  - Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL
      35294, USA.
FAU - Ezhilarasan, Ravesanker
AU  - Ezhilarasan R
AD  - Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Phillips, Emma
AU  - Phillips E
AD  - Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, 
      Germany.
FAU - Gallego-Perez, Daniel
AU  - Gallego-Perez D
AD  - Department of Surgery, The Ohio State University, Columbus, OH 43210, USA;
      Department of Biomedical Engineering, The Ohio State University, Columbus, OH
      43210, USA; Center for Affordable Nanoengineering of Polymeric Biomedical
      Devices, The Ohio State University, Columbus, OH 43210, USA; Center for
      Regenerative Medicine and Cell-Based Therapies, The Ohio State University,
      Columbus, OH 43210, USA.
FAU - Sparks, Amanda
AU  - Sparks A
AD  - Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State
      University, Columbus, OH 43210, USA.
FAU - Taylor, David
AU  - Taylor D
AD  - Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State
      University, Columbus, OH 43210, USA.
FAU - Ladner, Katherine
AU  - Ladner K
AD  - Human Cancer Genetics Program, Department of Molecular Virology, Immunology and
      Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.
FAU - Furuta, Takuya
AU  - Furuta T
AD  - Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan.
FAU - Sabit, Hemragul
AU  - Sabit H
AD  - Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan.
FAU - Chhipa, Rishi
AU  - Chhipa R
AD  - Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, 
      OH 45242, USA.
FAU - Cho, Ju Hwan
AU  - Cho JH
AD  - Department of Radiation Oncology, Comprehensive Cancer Center, The Ohio State
      University, Columbus, OH 43210, USA.
FAU - Mohyeldin, Ahmed
AU  - Mohyeldin A
AD  - Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State
      University, Columbus, OH 43210, USA.
FAU - Beck, Samuel
AU  - Beck S
AD  - Department of Molecular Biosciences, Institute for Cellular and Molecular
      Biology, Center for Systems and Synthetic Biology, The University of Texas at
      Austin, Austin, TX 78712, USA.
FAU - Kurozumi, Kazuhiko
AU  - Kurozumi K
AD  - Department of Neurological Surgery, Okayama University Graduate School of
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
FAU - Kuroiwa, Toshihiko
AU  - Kuroiwa T
AD  - Department of Neurosurgery, Osaka Medical College, Osaka 569-8686, Japan.
FAU - Iwata, Ryoichi
AU  - Iwata R
AD  - Department of Neurosurgery, Kansai Medical University, Osaka 573-1191, Japan.
FAU - Asai, Akio
AU  - Asai A
AD  - Department of Neurosurgery, Kansai Medical University, Osaka 573-1191, Japan.
FAU - Kim, Jonghwan
AU  - Kim J
AD  - Department of Molecular Biosciences, Institute for Cellular and Molecular
      Biology, Center for Systems and Synthetic Biology, The University of Texas at
      Austin, Austin, TX 78712, USA.
FAU - Sulman, Erik P
AU  - Sulman EP
AD  - Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Cheng, Shi-Yuan
AU  - Cheng SY
AD  - The Ken & Ruth Davee Department of Neurology & Northwestern Brain Tumor
      Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer 
      Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611,
      USA.
FAU - Lee, L James
AU  - Lee LJ
AD  - Center for Affordable Nanoengineering of Polymeric Biomedical Devices, The Ohio
      State University, Columbus, OH 43210, USA; Center for Regenerative Medicine and
      Cell-Based Therapies, The Ohio State University, Columbus, OH 43210, USA;
      Department of Chemical and Biomolecular Engineering, The Ohio State University,
      Columbus, OH 43210, USA.
FAU - Nakada, Mitsutoshi
AU  - Nakada M
AD  - Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan.
FAU - Guttridge, Denis
AU  - Guttridge D
AD  - Human Cancer Genetics Program, Department of Molecular Virology, Immunology and
      Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.
FAU - DasGupta, Biplab
AU  - DasGupta B
AD  - Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, 
      OH 45242, USA.
FAU - Goidts, Violaine
AU  - Goidts V
AD  - Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, 
      Germany.
FAU - Bhat, Krishna P
AU  - Bhat KP
AD  - Department of Translational Molecular Pathology, The University of Texas, M.D.
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Nakano, Ichiro
AU  - Nakano I
AD  - Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL
      35294, USA; UAB Comprehensive Cancer Center, University of Alabama at Birmingham,
      Birmingham, AL 35294, USA. Electronic address: inakano@uabmc.edu.
LA  - eng
GR  - R01 NS083767/NS/NINDS NIH HHS/United States
GR  - NIH/NINDSR01 NS083767/NS/NINDS NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - NIH/NINDS 1R01NS0 75291-01/NS/NINDS NIH HHS/United States
GR  - NS093843/NS/NINDS NIH HHS/United States
GR  - R01 NS095634/NS/NINDS NIH HHS/United States
GR  - R21 CA175875/CA/NCI NIH HHS/United States
GR  - R01 CA201402/CA/NCI NIH HHS/United States
GR  - NS095634/NS/NINDS NIH HHS/United States
GR  - 2P50CA1270011/CA/NCI NIH HHS/United States
GR  - R01 CA183991/CA/NCI NIH HHS/United States
GR  - P30 CA060553/CA/NCI NIH HHS/United States
GR  - NIH/NCI P01 CA163205/CA/NCI NIH HHS/United States
GR  - R01 CA159811/CA/NCI NIH HHS/United States
GR  - R01 NS093843/NS/NINDS NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - UL1 TR001425/TR/NCATS NIH HHS/United States
GR  - R01 NS087913/NS/NINDS NIH HHS/United States
GR  - P50 CA127001/CA/NCI NIH HHS/United States
GR  - P01 CA163205/CA/NCI NIH HHS/United States
GR  - R25 GM089571/GM/NIGMS NIH HHS/United States
GR  - NIH R01CA158911/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (NF-kappa B)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 2.7.11.25 (mitogen-activated protein kinase kinase kinase MLK4, human)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Brain Neoplasms/*enzymology/pathology
MH  - Gene Silencing
MH  - Glioma/*enzymology/pathology
MH  - Humans
MH  - MAP Kinase Kinase Kinases/genetics/*metabolism
MH  - Mesenchymal Stromal Cells/*enzymology/pathology
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Neoplastic Stem Cells/*enzymology/pathology
MH  - Phosphorylation
MH  - Signal Transduction
PMC - PMC4837946
MID - NIHMS751843
OTO - NOTNLM
OT  - cancer stem cell
OT  - epithelial-to-mesenchymal transition
OT  - glioblastoma
OT  - proneural-mesenchymal transition
EDAT- 2016/02/10 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/02/10 06:00
PHST- 2014/08/27 00:00 [received]
PHST- 2015/06/26 00:00 [revised]
PHST- 2016/01/11 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(16)00034-9 [pii]
AID - 10.1016/j.ccell.2016.01.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):201-13. doi: 10.1016/j.ccell.2016.01.005.

PMID- 26859458
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20170208
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic
      Leukemia.
PG  - 186-200
LID - 10.1016/j.ccell.2015.12.013 [doi]
LID - S1535-6108(15)00477-8 [pii]
AB  - Chromosomal rearrangements are a hallmark of acute lymphoblastic leukemia (ALL)
      and are important ALL initiating events. We describe four different
      rearrangements of the erythropoietin receptor gene EPOR in Philadelphia
      chromosome-like (Ph-like) ALL. All of these rearrangements result in truncation
      of the cytoplasmic tail of EPOR at residues similar to those mutated in primary
      familial congenital polycythemia, with preservation of the proximal tyrosine
      essential for receptor activation and loss of distal regulatory residues. This
      resulted in deregulated EPOR expression, hypersensitivity to erythropoietin
      stimulation, and heightened JAK-STAT activation. Expression of truncated EPOR in 
      mouse B cell progenitors induced ALL in vivo. Human leukemic cells with EPOR
      rearrangements were sensitive to JAK-STAT inhibition, suggesting a therapeutic
      option in high-risk ALL.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Iacobucci, Ilaria
AU  - Iacobucci I
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Li, Yongjin
AU  - Li Y
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Roberts, Kathryn G
AU  - Roberts KG
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Dobson, Stephanie M
AU  - Dobson SM
AD  - Princess Margaret Cancer Centre, University Health Network and Department of
      Molecular Genetics, University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Kim, Jaeseung C
AU  - Kim JC
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9,
      Canada; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
FAU - Payne-Turner, Debbie
AU  - Payne-Turner D
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Harvey, Richard C
AU  - Harvey RC
AD  - University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM
      87106, USA.
FAU - Valentine, Marcus
AU  - Valentine M
AD  - Cytogenetics Shared Resource, St. Jude Children's Research Hospital, Memphis, TN 
      38105, USA.
FAU - McCastlain, Kelly
AU  - McCastlain K
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Easton, John
AU  - Easton J
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Yergeau, Donald
AU  - Yergeau D
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Janke, Laura J
AU  - Janke LJ
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Shao, Ying
AU  - Shao Y
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA; Department of Computational Biology, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Chen, I-Ming L
AU  - Chen IM
AD  - University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM
      87106, USA.
FAU - Rusch, Michael
AU  - Rusch M
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Zandi, Sasan
AU  - Zandi S
AD  - Princess Margaret Cancer Centre, University Health Network and Department of
      Molecular Genetics, University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Kornblau, Steven M
AU  - Kornblau SM
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Konopleva, Marina
AU  - Konopleva M
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Jabbour, Elias
AU  - Jabbour E
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Paietta, Elisabeth M
AU  - Paietta EM
AD  - Montefiore Medical Center, Bronx, NY 10467, USA.
FAU - Rowe, Jacob M
AU  - Rowe JM
AD  - Department of Hematology, Shaare Zedek Medicak Center, Jerusalem 910310, Israel.
FAU - Pui, Ching-Hon
AU  - Pui CH
AD  - Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105,
      USA.
FAU - Gastier-Foster, Julie
AU  - Gastier-Foster J
AD  - The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205,
      USA.
FAU - Gu, Zhaohui
AU  - Gu Z
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Reshmi, Shalini
AU  - Reshmi S
AD  - The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205,
      USA.
FAU - Loh, Mignon L
AU  - Loh ML
AD  - Department of Pediatrics and the Helen Diller Family Cancer Center, University of
      California, San Francisco, CA 94115, USA.
FAU - Racevskis, Janis
AU  - Racevskis J
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Tallman, Martin S
AU  - Tallman MS
AD  - Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center,
      New York, NY 10065, USA.
FAU - Wiernik, Peter H
AU  - Wiernik PH
AD  - Cancer Research Foundation of New York, Bronx, NY 10514, USA.
FAU - Litzow, Mark R
AU  - Litzow MR
AD  - Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Willman, Cheryl L
AU  - Willman CL
AD  - University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM
      87106, USA.
FAU - McPherson, John D
AU  - McPherson JD
AD  - Department of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer 
      Center, Sacramento, CA 95817, USA.
FAU - Downing, James R
AU  - Downing JR
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Zhang, Jinghui
AU  - Zhang J
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Dick, John E
AU  - Dick JE
AD  - Princess Margaret Cancer Centre, University Health Network and Department of
      Molecular Genetics, University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Hunger, Stephen P
AU  - Hunger SP
AD  - Department of Pediatrics and Center for Childhood Cancer Research, The Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Mullighan, Charles G
AU  - Mullighan CG
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA. Electronic address: charles.mullighan@stjude.org.
LA  - eng
GR  - U24 CA196173/CA/NCI NIH HHS/United States
GR  - U10 CA98413/CA/NCI NIH HHS/United States
GR  - U10 CA021115/CA/NCI NIH HHS/United States
GR  - U24 CA196172/CA/NCI NIH HHS/United States
GR  - CA145707/CA/NCI NIH HHS/United States
GR  - U10 CA098413/CA/NCI NIH HHS/United States
GR  - U24 CA114766/CA/NCI NIH HHS/United States
GR  - CA21765/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U10 CA180791/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - CA180827/CA/NCI NIH HHS/United States
GR  - U01 CA157937/CA/NCI NIH HHS/United States
GR  - U10 CA098543/CA/NCI NIH HHS/United States
GR  - RC1 CA145707/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - U10 CA180794/CA/NCI NIH HHS/United States
GR  - U24 CA114737/CA/NCI NIH HHS/United States
GR  - U10 CA98543/CA/NCI NIH HHS/United States
GR  - U10 CA180827/CA/NCI NIH HHS/United States
GR  - P50 GM115279/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Erythropoietin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antineoplastic Agents/therapeutic use
MH  - Base Sequence
MH  - *Gene Order
MH  - Humans
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/*genetics
MH  - Receptors, Erythropoietin/*genetics
PMC - PMC4750652
MID - NIHMS755084
EDAT- 2016/02/10 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/02/10 06:00
PHST- 2015/10/18 00:00 [received]
PHST- 2015/11/17 00:00 [revised]
PHST- 2015/12/23 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(15)00477-8 [pii]
AID - 10.1016/j.ccell.2015.12.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):186-200. doi: 10.1016/j.ccell.2015.12.013.

PMID- 26859457
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical
      Implications in Cancers.
PG  - 173-85
LID - 10.1016/j.ccell.2016.01.001 [doi]
LID - S1535-6108(16)00029-5 [pii]
AB  - Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a
      mechanism to allow these tumors to escape the pro-apoptotic activity of some of
      its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the
      V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2
      domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts
      the interaction between netrin-1 and UNC5H2 and triggers death of
      netrin-1-expressing tumor cells in vitro. We also present evidence that combining
      the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in
      treating tumors showing no or modest netrin-1 expression. These results support
      that this antibody is a promising drug candidate.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Grandin, Melodie
AU  - Grandin M
AD  - Apoptosis, Cancer and Development Laboratory, Equipe labellisee 'La Ligue', LabEx
      DEVweCAN, Centre de Recherche en Cancerologie de Lyon, INSERM U1052-CNRS UMR5286,
      Universite de Lyon, Centre Leon Berard, 69008 Lyon, France.
FAU - Meier, Markus
AU  - Meier M
AD  - Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, MB
      RT3 2N2, Canada.
FAU - Delcros, Jean Guy
AU  - Delcros JG
AD  - Apoptosis, Cancer and Development Laboratory, Equipe labellisee 'La Ligue', LabEx
      DEVweCAN, Centre de Recherche en Cancerologie de Lyon, INSERM U1052-CNRS UMR5286,
      Universite de Lyon, Centre Leon Berard, 69008 Lyon, France.
FAU - Nikodemus, Denise
AU  - Nikodemus D
AD  - Center for Biochemistry, Institute for Dental Research and Oral Musculoskeletal
      Research, University of Cologne, 50931 Cologne, Germany; Centre for Ecology,
      Evolution and Environmental Changes, Faculdade de Ciencias, Universidade de
      Lisboa, Lisbon 1749-016, Portugal.
FAU - Reuten, Raphael
AU  - Reuten R
AD  - Center for Biochemistry, Institute for Dental Research and Oral Musculoskeletal
      Research, University of Cologne, 50931 Cologne, Germany.
FAU - Patel, Trushar R
AU  - Patel TR
AD  - Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, MB
      RT3 2N2, Canada; Department of Microbiology, University of Manitoba, 144 Dysart
      Road, Winnipeg, MB RT3 2N2, Canada.
FAU - Goldschneider, David
AU  - Goldschneider D
AD  - Apoptosis, Cancer and Development Laboratory, Equipe labellisee 'La Ligue', LabEx
      DEVweCAN, Centre de Recherche en Cancerologie de Lyon, INSERM U1052-CNRS UMR5286,
      Universite de Lyon, Centre Leon Berard, 69008 Lyon, France; Netris Pharma, Centre
      Leon Berard, 69008 Lyon, France.
FAU - Orriss, George
AU  - Orriss G
AD  - Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, MB
      RT3 2N2, Canada.
FAU - Krahn, Natalie
AU  - Krahn N
AD  - Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, MB
      RT3 2N2, Canada.
FAU - Boussouar, Amina
AU  - Boussouar A
AD  - Apoptosis, Cancer and Development Laboratory, Equipe labellisee 'La Ligue', LabEx
      DEVweCAN, Centre de Recherche en Cancerologie de Lyon, INSERM U1052-CNRS UMR5286,
      Universite de Lyon, Centre Leon Berard, 69008 Lyon, France.
FAU - Abes, Riad
AU  - Abes R
AD  - Netris Pharma, Centre Leon Berard, 69008 Lyon, France.
FAU - Dean, Yann
AU  - Dean Y
AD  - Netris Pharma, Centre Leon Berard, 69008 Lyon, France.
FAU - Neves, David
AU  - Neves D
AD  - Netris Pharma, Centre Leon Berard, 69008 Lyon, France.
FAU - Bernet, Agnes
AU  - Bernet A
AD  - Apoptosis, Cancer and Development Laboratory, Equipe labellisee 'La Ligue', LabEx
      DEVweCAN, Centre de Recherche en Cancerologie de Lyon, INSERM U1052-CNRS UMR5286,
      Universite de Lyon, Centre Leon Berard, 69008 Lyon, France; Netris Pharma, Centre
      Leon Berard, 69008 Lyon, France.
FAU - Depil, Stephane
AU  - Depil S
AD  - Netris Pharma, Centre Leon Berard, 69008 Lyon, France.
FAU - Schneiders, Fiona
AU  - Schneiders F
AD  - Center for Biochemistry, Institute for Dental Research and Oral Musculoskeletal
      Research, University of Cologne, 50931 Cologne, Germany.
FAU - Poole, Kate
AU  - Poole K
AD  - Department of Neuroscience, Max-Delbruck Center for Molecular Medicine,
      Robert-Rossle Strabetae 10, Berlin 13092, Germany.
FAU - Dante, Robert
AU  - Dante R
AD  - Apoptosis, Cancer and Development Laboratory, Equipe labellisee 'La Ligue', LabEx
      DEVweCAN, Centre de Recherche en Cancerologie de Lyon, INSERM U1052-CNRS UMR5286,
      Universite de Lyon, Centre Leon Berard, 69008 Lyon, France.
FAU - Koch, Manuel
AU  - Koch M
AD  - Center for Biochemistry, Institute for Dental Research and Oral Musculoskeletal
      Research, University of Cologne, 50931 Cologne, Germany; Centre for Ecology,
      Evolution and Environmental Changes, Faculdade de Ciencias, Universidade de
      Lisboa, Lisbon 1749-016, Portugal.
FAU - Mehlen, Patrick
AU  - Mehlen P
AD  - Apoptosis, Cancer and Development Laboratory, Equipe labellisee 'La Ligue', LabEx
      DEVweCAN, Centre de Recherche en Cancerologie de Lyon, INSERM U1052-CNRS UMR5286,
      Universite de Lyon, Centre Leon Berard, 69008 Lyon, France. Electronic address:
      patrick.mehlen@lyon.unicancer.fr.
FAU - Stetefeld, Jorg
AU  - Stetefeld J
AD  - Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, MB
      RT3 2N2, Canada. Electronic address: jorg.stetefeld@ad.manitoba.ca.
LA  - eng
GR  - RPA-109759/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (NTN1 protein, human)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Netrin Receptors)
RN  - 0 (Ntn1 protein, mouse)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (UNC5C protein, human)
RN  - 158651-98-0 (Netrin-1)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Models, Molecular
MH  - Neoplasms/metabolism/pathology/*therapy
MH  - Nerve Growth Factors/immunology/*metabolism
MH  - Netrin Receptors
MH  - Netrin-1
MH  - Protein Binding
MH  - Receptors, Cell Surface/*metabolism
MH  - Tumor Suppressor Proteins/immunology/*metabolism
EDAT- 2016/02/10 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/02/10 06:00
PHST- 2015/05/22 00:00 [received]
PHST- 2015/09/02 00:00 [revised]
PHST- 2016/01/05 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(16)00029-5 [pii]
AID - 10.1016/j.ccell.2016.01.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):173-85. doi: 10.1016/j.ccell.2016.01.001.

PMID- 26859456
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20161126
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to
      Develop a Potent and Specific Targeted Therapy Combination.
PG  - 159-72
LID - 10.1016/j.ccell.2016.01.002 [doi]
LID - S1535-6108(16)00031-3 [pii]
AB  - Fewer than half of children with high-risk neuroblastoma survive. Many of these
      tumors harbor high-level amplification of MYCN, which correlates with poor
      disease outcome. Using data from our large drug screen we predicted, and
      subsequently demonstrated, that MYCN-amplified neuroblastomas are sensitive to
      the BCL-2 inhibitor ABT-199. This sensitivity occurs in part through low
      anti-apoptotic BCL-xL expression, high pro-apoptotic NOXA expression, and
      paradoxical, MYCN-driven upregulation of NOXA. Screening for enhancers of ABT-199
      sensitivity in MYCN-amplified neuroblastomas, we demonstrate that the Aurora
      Kinase A inhibitor MLN8237 combines with ABT-199 to induce widespread apoptosis. 
      In diverse models of MYCN-amplified neuroblastoma, including a patient-derived
      xenograft model, this combination uniformly induced tumor shrinkage, and in
      multiple instances led to complete tumor regression.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Ham, Jungoh
AU  - Ham J
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Costa, Carlotta
AU  - Costa C
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Sano, Renata
AU  - Sano R
AD  - Division of Oncology and Center for Childhood Cancer Research, The Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Lochmann, Timothy L
AU  - Lochmann TL
AD  - Department of Microbiology and Immunology, Massey Cancer Center, Richmond, VA
      23298, USA.
FAU - Sennott, Erin M
AU  - Sennott EM
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Patel, Neha U
AU  - Patel NU
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Dastur, Anahita
AU  - Dastur A
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Gomez-Caraballo, Maria
AU  - Gomez-Caraballo M
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Krytska, Kateryna
AU  - Krytska K
AD  - Division of Oncology and Center for Childhood Cancer Research, The Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Hata, Aaron N
AU  - Hata AN
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Floros, Konstantinos V
AU  - Floros KV
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Hughes, Mark T
AU  - Hughes MT
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Jakubik, Charles T
AU  - Jakubik CT
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Heisey, Daniel A R
AU  - Heisey DA
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Ferrell, Justin T
AU  - Ferrell JT
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Bristol, Molly L
AU  - Bristol ML
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - March, Ryan J
AU  - March RJ
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Yates, Craig
AU  - Yates C
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Hicks, Mark A
AU  - Hicks MA
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Nakajima, Wataru
AU  - Nakajima W
AD  - Department of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon
      Medical School, Kawasaki 211-8533, Japan.
FAU - Gowda, Madhu
AU  - Gowda M
AD  - Department of Pediatrics, Children's Hospital of Richmond, VCU, Richmond, VA
      23298, USA.
FAU - Windle, Brad E
AU  - Windle BE
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Dozmorov, Mikhail G
AU  - Dozmorov MG
AD  - Department of Biostatistics, Virginia Commonwealth University, Richmond, VA
      23298, USA.
FAU - Garnett, Mathew J
AU  - Garnett MJ
AD  - Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - McDermott, Ultan
AU  - McDermott U
AD  - Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Harada, Hisashi
AU  - Harada H
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Taylor, Shirley M
AU  - Taylor SM
AD  - Department of Microbiology and Immunology, Massey Cancer Center, Richmond, VA
      23298, USA.
FAU - Morgan, Iain M
AU  - Morgan IM
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA.
FAU - Benes, Cyril H
AU  - Benes CH
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Engelman, Jeffrey A
AU  - Engelman JA
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; Department
      of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Mosse, Yael P
AU  - Mosse YP
AD  - Division of Oncology and Center for Childhood Cancer Research, The Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, 
      University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104,
      USA.
FAU - Faber, Anthony C
AU  - Faber AC
AD  - Philips Institute for Oral Health Research, VCU School of Dentistry and Massey
      Cancer Center, Virginia Commonwealth University, Perkinson Building, Richmond, VA
      23298, USA. Electronic address: acfaber@vcu.edu.
LA  - eng
GR  - 102696/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Sulfonamides)
RN  - XKJ5VVK2WD (navitoclax)
SB  - IM
MH  - Aniline Compounds/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Apoptosis/*genetics
MH  - Cell Line, Tumor
MH  - Humans
MH  - N-Myc Proto-Oncogene Protein
MH  - Neuroblastoma/*drug therapy/genetics/pathology
MH  - Nuclear Proteins
MH  - Oncogene Proteins
MH  - Sulfonamides/therapeutic use
PMC - PMC4749542
EDAT- 2016/02/10 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/02/10 06:00
PHST- 2015/06/18 00:00 [received]
PHST- 2015/11/14 00:00 [revised]
PHST- 2016/01/07 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(16)00031-3 [pii]
AID - 10.1016/j.ccell.2016.01.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.

PMID- 26859455
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20171024
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.
PG  - 145-58
LID - 10.1016/j.ccell.2016.01.006 [doi]
LID - S1535-6108(16)00035-0 [pii]
AB  - Birinapant is a smac-mimetic (SM) in clinical trials for treating cancer. SM
      antagonize inhibitor of apoptosis (IAP) proteins and simultaneously induce tumor 
      necrosis factor (TNF) secretion to render cancers sensitive to TNF-induced
      killing. To enhance SM efficacy, we screened kinase inhibitors for their ability 
      to increase TNF production of SM-treated cells. We showed that p38 inhibitors
      increased TNF induced by SM. Unexpectedly, even though p38 is required for
      Toll-like receptors to induce TNF, loss of p38 or its downstream kinase MK2
      increased induction of TNF by SM. Hence, we show that the p38/MK2 axis can
      inhibit or promote TNF production, depending on the stimulus. Importantly,
      clinical p38 inhibitors overcame resistance of primary acute myeloid leukemia to 
      birinapant.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Lalaoui, Najoua
AU  - Lalaoui N
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Hanggi, Kay
AU  - Hanggi K
AD  - Institute of Experimental Immunology, University of Zurich, Zurich 8057,
      Switzerland.
FAU - Brumatti, Gabriela
AU  - Brumatti G
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Chau, Diep
AU  - Chau D
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Nguyen, Nhu-Y N
AU  - Nguyen NY
AD  - Department of Clinical Hematology, The Alfred Hospital and Monash University,
      Melbourne, VIC 3004, Australia; Australian Centre for Blood Diseases, Monash
      University, Melbourne, VIC 3004, Australia.
FAU - Vasilikos, Lazaros
AU  - Vasilikos L
AD  - Institute of Experimental Immunology, University of Zurich, Zurich 8057,
      Switzerland.
FAU - Spilgies, Lisanne M
AU  - Spilgies LM
AD  - Institute of Experimental Immunology, University of Zurich, Zurich 8057,
      Switzerland.
FAU - Heckmann, Denise A
AU  - Heckmann DA
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Ma, Chunyan
AU  - Ma C
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Ghisi, Margherita
AU  - Ghisi M
AD  - Gene Regulation Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer
      Centre, East Melbourne, VIC 3002, Australia; The Sir Peter MacCallum Department
      of Oncology, University of Melbourne, Parkville, VIC 3050, Australia.
FAU - Salmon, Jessica M
AU  - Salmon JM
AD  - Gene Regulation Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer
      Centre, East Melbourne, VIC 3002, Australia; The Sir Peter MacCallum Department
      of Oncology, University of Melbourne, Parkville, VIC 3050, Australia.
FAU - Matthews, Geoffrey M
AU  - Matthews GM
AD  - Gene Regulation Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer
      Centre, East Melbourne, VIC 3002, Australia; The Sir Peter MacCallum Department
      of Oncology, University of Melbourne, Parkville, VIC 3050, Australia.
FAU - de Valle, Elisha
AU  - de Valle E
AD  - Immunomonitoring Facility and Centre for Biomedical Research, The Burnet
      Institute, Melbourne, VIC 3004, Australia; Department of Immunology, Central
      Clinical School, Monash University, Melbourne, VIC 3181, Australia.
FAU - Moujalled, Donia M
AU  - Moujalled DM
AD  - Department of Clinical Hematology, The Alfred Hospital and Monash University,
      Melbourne, VIC 3004, Australia; Australian Centre for Blood Diseases, Monash
      University, Melbourne, VIC 3004, Australia.
FAU - Menon, Manoj B
AU  - Menon MB
AD  - Institute of Physiological Chemistry, Hannover Medical School,
      Carl-Neuberg-Street 1, 30625 Hannover, Germany.
FAU - Spall, Sukhdeep Kaur
AU  - Spall SK
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Glaser, Stefan P
AU  - Glaser SP
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Richmond, Jennifer
AU  - Richmond J
AD  - Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW,
      Randwick, NSW 2031, Australia.
FAU - Lock, Richard B
AU  - Lock RB
AD  - Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW,
      Randwick, NSW 2031, Australia.
FAU - Condon, Stephen M
AU  - Condon SM
AD  - TetraLogic Pharmaceuticals Corporation, 343 Phoenixville Pike, Malvern, PA 19355,
      USA.
FAU - Gugasyan, Raffi
AU  - Gugasyan R
AD  - Immunomonitoring Facility and Centre for Biomedical Research, The Burnet
      Institute, Melbourne, VIC 3004, Australia; Department of Immunology, Central
      Clinical School, Monash University, Melbourne, VIC 3181, Australia.
FAU - Gaestel, Matthias
AU  - Gaestel M
AD  - Institute of Physiological Chemistry, Hannover Medical School,
      Carl-Neuberg-Street 1, 30625 Hannover, Germany.
FAU - Guthridge, Mark
AU  - Guthridge M
AD  - Department of Clinical Hematology, The Alfred Hospital and Monash University,
      Melbourne, VIC 3004, Australia; Australian Centre for Blood Diseases, Monash
      University, Melbourne, VIC 3004, Australia.
FAU - Johnstone, Ricky W
AU  - Johnstone RW
AD  - Gene Regulation Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer
      Centre, East Melbourne, VIC 3002, Australia; The Sir Peter MacCallum Department
      of Oncology, University of Melbourne, Parkville, VIC 3050, Australia.
FAU - Munoz, Lenka
AU  - Munoz L
AD  - Department of Pathology, School of Medical Sciences, University of Sydney,
      Sydney, NSW 2006, Australia.
FAU - Wei, Andrew
AU  - Wei A
AD  - Department of Clinical Hematology, The Alfred Hospital and Monash University,
      Melbourne, VIC 3004, Australia; Australian Centre for Blood Diseases, Monash
      University, Melbourne, VIC 3004, Australia.
FAU - Ekert, Paul G
AU  - Ekert PG
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Pediatrics, University of Melbourne, Parkville, VIC 3050,
      Australia; Murdoch Children's Research Institute, Royal Children's Hospital,
      Parkville, VIC 3052, Australia.
FAU - Vaux, David L
AU  - Vaux DL
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia.
FAU - Wong, W Wei-Lynn
AU  - Wong WW
AD  - Institute of Experimental Immunology, University of Zurich, Zurich 8057,
      Switzerland.
FAU - Silke, John
AU  - Silke J
AD  - Cell Signaling & Cell Death and Cancer & Hematology Divisions, The Walter and
      Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia;
      Department of Medical Biology, University of Melbourne, Parkville, VIC 3050,
      Australia. Electronic address: silke@wehi.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DIABLO protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 2.7.1.- (MAP-kinase-activated kinase 2)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
CIN - Cancer Cell. 2016 Feb 8;29(2):131-3. PMID: 26859448
EIN - Cancer Cell. 2016 Sep 12;30(3):499-500. PMID: 27622337
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*antagonists &
      inhibitors/*physiology
MH  - Leukemia/*drug therapy
MH  - Mice
MH  - Mitochondrial Proteins/*physiology
MH  - *Molecular Mimicry
MH  - Protein-Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Tumor Necrosis Factor-alpha/biosynthesis
MH  - p38 Mitogen-Activated Protein Kinases/*antagonists & inhibitors
EDAT- 2016/02/10 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/02/10 06:00
PHST- 2015/04/08 00:00 [received]
PHST- 2015/09/17 00:00 [revised]
PHST- 2016/01/11 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(16)00035-0 [pii]
AID - 10.1016/j.ccell.2016.01.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):145-58. doi: 10.1016/j.ccell.2016.01.006.

PMID- 26859454
OWN - NLM
STAT- MEDLINE
DCOM- 20160608
LR  - 20160210
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Re: a Word of Caution on New and Revolutionary Diagnostic Tests.
PG  - 143-4
LID - 10.1016/j.ccell.2016.01.004 [doi]
LID - S1535-6108(16)00033-7 [pii]
FAU - Best, Myron G
AU  - Best MG
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Sol, Nik
AU  - Sol N
AD  - Department of Neurology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Tannous, Bakhos A
AU  - Tannous BA
AD  - Department of Neurology, Massachusetts General Hospital and Neuroscience Program,
      Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
FAU - Wesseling, Pieter
AU  - Wesseling P
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Pathology,
      Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands.
FAU - Wurdinger, Thomas
AU  - Wurdinger T
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard
      Medical School, 149 13th Street, Charlestown, MA 02129, USA; thromboDx B.V., 1098
      EA Amsterdam, the Netherlands. Electronic address: t.wurdinger@vumc.nl.
LA  - eng
PT  - Comment
PT  - Letter
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
CON - Cancer Cell. 2016 Feb 8;29(2):141-2. PMID: 26859453
CON - Cancer Cell. 2015 Nov 9;28(5):666-76. PMID: 26525104
MH  - Biomarkers, Tumor/*genetics
MH  - Blood Platelets/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/*genetics
MH  - Signal Transduction/*genetics
EDAT- 2016/02/10 06:00
MHDA- 2016/06/09 06:00
CRDT- 2016/02/10 06:00
PHST- 2015/12/09 00:00 [received]
PHST- 2016/01/11 00:00 [revised]
PHST- 2016/01/11 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - S1535-6108(16)00033-7 [pii]
AID - 10.1016/j.ccell.2016.01.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):143-4. doi: 10.1016/j.ccell.2016.01.004.

PMID- 26859453
OWN - NLM
STAT- MEDLINE
DCOM- 20160608
LR  - 20160210
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - A Word of Caution on New and Revolutionary Diagnostic Tests.
PG  - 141-2
LID - 10.1016/j.ccell.2016.01.003 [doi]
LID - S1535-6108(16)00032-5 [pii]
FAU - Diamandis, Eleftherios P
AU  - Diamandis EP
AD  - Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Suite
      L6-201, 60 Murray Street, Toronto, ON M5T 3L9, Canada; Department of Clinical
      Biochemistry, University Health Network, 200 Elizabeth Street, Toronto, ON M5T
      2C4, Canada; Department of Laboratory Medicine and Pathobiology, University of
      Toronto, 1 King's College Circle, Room 6231, Toronto, ON M5S 1A8, Canada.
      Electronic address: ediamandis@mtsinai.on.ca.
LA  - eng
PT  - Comment
PT  - Letter
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
CON - Cancer Cell. 2015 Nov 9;28(5):666-76. PMID: 26525104
CIN - Cancer Cell. 2016 Feb 8;29(2):143-4. PMID: 26859454
MH  - Biomarkers, Tumor/*genetics
MH  - Blood Platelets/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/*genetics
MH  - Signal Transduction/*genetics
EDAT- 2016/02/10 06:00
MHDA- 2016/06/09 06:00
CRDT- 2016/02/10 06:00
PHST- 2015/11/23 00:00 [received]
PHST- 2016/01/11 00:00 [revised]
PHST- 2016/01/11 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - S1535-6108(16)00032-5 [pii]
AID - 10.1016/j.ccell.2016.01.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):141-2. doi: 10.1016/j.ccell.2016.01.003.

PMID- 26859452
OWN - NLM
STAT- MEDLINE
DCOM- 20160608
LR  - 20160210
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Bringing IDH into the Fold.
PG  - 139-40
LID - 10.1016/j.ccell.2016.01.010 [doi]
LID - S1535-6108(16)30004-6 [pii]
AB  - Glioma-associated mutations in IDH1 or IDH2 lead to aberrant DNA methylation. A
      recent paper shows that loss of methylation-sensitive CTCF binding in IDH mutant 
      cells leads to disruption of enhancer boundary function, which results in
      aberrant activation of PDGFRA expression via an enhancer associated with an
      adjacent gene.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zadeh, Gelareh
AU  - Zadeh G
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, 
      Canada; Division of Neurosurgery, University Health Network, Toronto, ON M5T 2S8,
      Canada. Electronic address: gelareh.zadeh@uhn.ca.
FAU - Aldape, Kenneth
AU  - Aldape K
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, 
      Canada; Department of Laboratory Medicine and Pathology, University of Toronto,
      Toronto, ON M5T 2S8, Canada.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
SB  - IM
CON - Nature. 2016 Jan 7;529(7584):110-4. PMID: 26700815
MH  - *Gene Expression Regulation, Neoplastic
MH  - Glioma/*enzymology/*genetics
MH  - Humans
MH  - Insulator Elements/*genetics
MH  - Isocitrate Dehydrogenase/*genetics
MH  - Mutation/*genetics
MH  - Oncogenes/*genetics
EDAT- 2016/02/10 06:00
MHDA- 2016/06/09 06:00
CRDT- 2016/02/10 06:00
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - S1535-6108(16)30004-6 [pii]
AID - 10.1016/j.ccell.2016.01.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):139-40. doi: 10.1016/j.ccell.2016.01.010.

PMID- 26859451
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20160210
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Fall of the Optical Wall: Freedom from the Tyranny of the Microscope Improves
      Glioma Risk Stratification.
PG  - 137-8
LID - 10.1016/j.ccell.2016.01.009 [doi]
LID - S1535-6108(16)30003-4 [pii]
AB  - A recent study uses an integrated genomic approach to identify biologically
      defined subgroups of adult diffuse glioma. These results further lay the
      foundation for a pathological classification scheme for gliomas that incorporates
      both histology and molecular biomarkers, which appears far more robust than the
      current scheme, based solely on morphology.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON M5G
      1X8, Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G 1X8,
      Canada. Electronic address: mdtaylor@sickkids.ca.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Brain Neoplasms/classification/metabolism/*pathology
MH  - Glioma/classification/metabolism/*pathology
MH  - Humans
EDAT- 2016/02/10 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/02/10 06:00
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(16)30003-4 [pii]
AID - 10.1016/j.ccell.2016.01.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):137-8. doi: 10.1016/j.ccell.2016.01.009.

PMID- 26859450
OWN - NLM
STAT- MEDLINE
DCOM- 20160623
LR  - 20170714
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Defining the Molecular Alterations of Ampullary Carcinoma.
PG  - 135-6
LID - 10.1016/j.ccell.2016.01.011 [doi]
LID - S1535-6108(16)30005-8 [pii]
AB  - Ampullary carcinomas represent a group of heterogeneous tumors that can be
      histologically divided into two subtypes with distinct pathogenic and clinical
      characteristics. Yachida et al. (2016) and Gingras et al. (2016) now report the
      genomic landscape of ampullary carcinoma, providing insights into molecular
      drivers with clinical implications for diagnosis and therapeutics.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Tan, Jing
AU  - Tan J
AD  - Laboratory of Cancer Epigenome, National Cancer Centre Singapore, 11 Hospital
      Drive, Singapore 169610, Singapore; Division of Cancer and Stem Cell Biology,
      Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore.
FAU - Tan, Patrick
AU  - Tan P
AD  - Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 8
      College Road, Singapore 169857, Singapore.
FAU - Teh, Bin Tean
AU  - Teh BT
AD  - Laboratory of Cancer Epigenome, National Cancer Centre Singapore, 11 Hospital
      Drive, Singapore 169610, Singapore; Division of Cancer and Stem Cell Biology,
      Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore.
      Electronic address: teh.bin.tean@singhealth.com.sg.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Transcription Factors)
SB  - IM
CON - Cancer Cell. 2016 Feb 8;29(2):229-40. PMID: 26806338
CON - Cell Rep. 2016 Feb 2;14(4):907-19. PMID: 26804919
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Pancreatic Neoplasms/*genetics
MH  - Proto-Oncogene Proteins c-ets/*genetics
MH  - Transcription Factors/*genetics
EDAT- 2016/02/10 06:00
MHDA- 2016/06/24 06:00
CRDT- 2016/02/10 06:00
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/24 06:00 [medline]
AID - S1535-6108(16)30005-8 [pii]
AID - 10.1016/j.ccell.2016.01.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):135-6. doi: 10.1016/j.ccell.2016.01.011.

PMID- 26859449
OWN - NLM
STAT- MEDLINE
DCOM- 20160623
LR  - 20160210
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - miR-126 Drives Quiescence and Self-Renewal in Leukemic Stem Cells.
PG  - 133-5
LID - 10.1016/j.ccell.2016.01.007 [doi]
LID - S1535-6108(16)30001-0 [pii]
AB  - Leukemic stem cells (LSCs) are resistant to conventional chemotherapy and promote
      acute myeloid leukemia (AML) progression and recurrence. In this issue of Cancer 
      Cell, Lechman and colleagues (2016) identify the microRNA miR-126 as a regulator 
      of PI3K-AKT-mTOR and CDK3 signaling driving LSC self-renewal and chemotherapy
      resistance.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Raffel, Simon
AU  - Raffel S
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany; Division of Stem Cells and Cancer, Deutsches
      Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany.
FAU - Trumpp, Andreas
AU  - Trumpp A
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany; Division of Stem Cells and Cancer, Deutsches
      Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany. Electronic address:
      a.trumpp@dkfz.de.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MicroRNAs)
SB  - IM
CON - Cancer Cell. 2016 Feb 8;29(2):214-28. PMID: 26832662
MH  - Animals
MH  - Hematopoietic Stem Cells/*pathology
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*pathology
MH  - MicroRNAs/*physiology
EDAT- 2016/02/10 06:00
MHDA- 2016/06/24 06:00
CRDT- 2016/02/10 06:00
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/24 06:00 [medline]
AID - S1535-6108(16)30001-0 [pii]
AID - 10.1016/j.ccell.2016.01.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):133-5. doi: 10.1016/j.ccell.2016.01.007.

PMID- 26859448
OWN - NLM
STAT- MEDLINE
DCOM- 20160623
LR  - 20170125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - TNFalpha-Mediated Cytotoxic Responses to IAP Inhibition Are Limited by the
      p38alpha MAPK Pathway.
PG  - 131-3
LID - 10.1016/j.ccell.2016.01.008 [doi]
LID - S1535-6108(16)30002-2 [pii]
AB  - Smac mimetics (SMs), a class of drugs that can promote tumor cell death,
      represent a potential therapeutic strategy for the treatment of cancer. In this
      issue of Cancer Cell, Lalaoui et al. (2016) report that SM efficacy can be
      potently increased by inhibition of the p38alpha MAPK/MK2 signaling pathway.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Girnius, Nomeda
AU  - Girnius N
AD  - Program in Molecular Medicine, University of Massachusetts Medical School,
      Worcester, MA 01605, USA.
FAU - Davis, Roger J
AU  - Davis RJ
AD  - Program in Molecular Medicine, University of Massachusetts Medical School,
      Worcester, MA 01605, USA; Howard Hughes Medical Institute. Electronic address:
      roger.davis@umassmed.edu.
LA  - eng
GR  - R01 DK107220/DK/NIDDK NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Mitochondrial Proteins)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
CON - Cancer Cell. 2016 Feb 8;29(2):145-58. PMID: 26859455
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*antagonists &
      inhibitors/*physiology
MH  - Leukemia/*drug therapy
MH  - Mitochondrial Proteins/*physiology
MH  - *Molecular Mimicry
MH  - Protein-Serine-Threonine Kinases/*antagonists & inhibitors
MH  - p38 Mitogen-Activated Protein Kinases/*antagonists & inhibitors
EDAT- 2016/02/10 06:00
MHDA- 2016/06/24 06:00
CRDT- 2016/02/10 06:00
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/06/24 06:00 [medline]
AID - S1535-6108(16)30002-2 [pii]
AID - 10.1016/j.ccell.2016.01.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):131-3. doi: 10.1016/j.ccell.2016.01.008.

PMID- 26832662
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20171004
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant
      Hematopoietic Stem Cells.
PG  - 214-28
LID - 10.1016/j.ccell.2015.12.011 [doi]
LID - S1535-6108(15)00475-4 [pii]
AB  - To investigate miRNA function in human acute myeloid leukemia (AML) stem cells
      (LSC), we generated a prognostic LSC-associated miRNA signature derived from
      functionally validated subpopulations of AML samples. For one signature miRNA,
      miR-126, high bioactivity aggregated all in vivo patient sample LSC activity into
      a single sorted population, tightly coupling miR-126 expression to LSC function. 
      Through functional studies, miR-126 was found to restrain cell cycle progression,
      prevent differentiation, and increase self-renewal of primary LSC in vivo.
      Compared with prior results showing miR-126 regulation of normal hematopoietic
      stem cell (HSC) cycling, these functional stem effects are opposite between LSC
      and HSC. Combined transcriptome and proteome analysis demonstrates that miR-126
      targets the PI3K/AKT/MTOR signaling pathway, preserving LSC quiescence and
      promoting chemotherapy resistance.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Lechman, Eric R
AU  - Lechman ER
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Gentner, Bernhard
AU  - Gentner B
AD  - San Raffaele Telethon Institute for Gene Therapy, San Raffaele Hospital, Milan
      20132, Italy; Vita Salute San Raffaele University, San Raffaele Scientific
      Institute, San Raffaele Hospital, Milan 20132, Italy; Hematology and Bone Marrow 
      Transplantation Unit, San Raffaele Hospital, Milan 20132, Italy.
FAU - Ng, Stanley W K
AU  - Ng SW
AD  - Department of Chemical Engineering and Applied Chemistry, Institute of
      Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5G
      2M9, Canada; The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1,
      Canada.
FAU - Schoof, Erwin M
AU  - Schoof EM
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - van Galen, Peter
AU  - van Galen P
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Kennedy, James A
AU  - Kennedy JA
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Medicine, University of
      Toronto, Toronto, ON M5G 2M9, Canada.
FAU - Nucera, Silvia
AU  - Nucera S
AD  - San Raffaele Telethon Institute for Gene Therapy, San Raffaele Hospital, Milan
      20132, Italy; Vita Salute San Raffaele University, San Raffaele Scientific
      Institute, San Raffaele Hospital, Milan 20132, Italy.
FAU - Ciceri, Fabio
AU  - Ciceri F
AD  - Vita Salute San Raffaele University, San Raffaele Scientific Institute, San
      Raffaele Hospital, Milan 20132, Italy; Hematology and Bone Marrow Transplantation
      Unit, San Raffaele Hospital, Milan 20132, Italy.
FAU - Kaufmann, Kerstin B
AU  - Kaufmann KB
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Takayama, Naoya
AU  - Takayama N
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Dobson, Stephanie M
AU  - Dobson SM
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Trotman-Grant, Aaron
AU  - Trotman-Grant A
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Krivdova, Gabriela
AU  - Krivdova G
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Elzinga, Janneke
AU  - Elzinga J
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Mitchell, Amanda
AU  - Mitchell A
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Nilsson, Bjorn
AU  - Nilsson B
AD  - Department of Hematology and Transfusion Medicine, Lund University Hospital, Lund
      221 84, Sweden.
FAU - Hermans, Karin G
AU  - Hermans KG
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada.
FAU - Eppert, Kolja
AU  - Eppert K
AD  - Department of Pediatrics, McGill University and The Research Institute of the
      McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
FAU - Marke, Rene
AU  - Marke R
AD  - Laboratory of Pediatric Oncology, Radboud University Medical Center, Nijmegen,
      6500 HB, Netherlands.
FAU - Isserlin, Ruth
AU  - Isserlin R
AD  - The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada.
FAU - Voisin, Veronique
AU  - Voisin V
AD  - The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada.
FAU - Bader, Gary D
AU  - Bader GD
AD  - The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada.
FAU - Zandstra, Peter W
AU  - Zandstra PW
AD  - Department of Chemical Engineering and Applied Chemistry, Institute of
      Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5G
      2M9, Canada; The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1,
      Canada.
FAU - Golub, Todd R
AU  - Golub TR
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, 44 Binney Street,
      Boston, MA 02115, USA.
FAU - Ebert, Benjamin L
AU  - Ebert BL
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Lu, Jun
AU  - Lu J
AD  - Yale Stem Cell Center, Yale Cancer Center, Yale University School of Medicine,
      New Haven, CT 06520, USA.
FAU - Minden, Mark
AU  - Minden M
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Medicine, University of
      Toronto, Toronto, ON M5G 2M9, Canada.
FAU - Wang, Jean C Y
AU  - Wang JC
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Medicine, University of
      Toronto, Toronto, ON M5G 2M9, Canada.
FAU - Naldini, Luigi
AU  - Naldini L
AD  - San Raffaele Telethon Institute for Gene Therapy, San Raffaele Hospital, Milan
      20132, Italy; Vita Salute San Raffaele University, San Raffaele Scientific
      Institute, San Raffaele Hospital, Milan 20132, Italy.
FAU - Dick, John E
AU  - Dick JE
AD  - Princess Margaret Cancer Centre, University Health Network, University of
      Toronto, Toronto, ON M5G 1L7, Canada; Department of Molecular Genetics,
      University of Toronto, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer
      Research Tower, Room 8-301, 101 College Street, Toronto M5G 1L7, Canada.
      Electronic address: jdick@uhnresearch.ca.
LA  - eng
GR  - R01 CA121941/CA/NCI NIH HHS/United States
GR  - U24 CA194107/CA/NCI NIH HHS/United States
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160128
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MIRN126 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
CIN - Cancer Cell. 2016 Feb 8;29(2):133-5. PMID: 26859449
EIN - Cancer Cell. 2016 Apr 11;29(4):602-6. PMID: 27070706
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Cell Line, Tumor
MH  - Gene Knockdown Techniques
MH  - Hematopoietic Stem Cells/*pathology
MH  - Heterografts
MH  - Humans
MH  - Leukemia, Myeloid, Acute/genetics/*pathology
MH  - Mice
MH  - Mice, SCID
MH  - MicroRNAs/genetics/*physiology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
PMC - PMC4749543
EDAT- 2016/02/03 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/02/03 06:00
PHST- 2014/03/17 00:00 [received]
PHST- 2015/07/13 00:00 [revised]
PHST- 2015/12/21 00:00 [accepted]
PHST- 2016/02/03 06:00 [entrez]
PHST- 2016/02/03 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(15)00475-4 [pii]
AID - 10.1016/j.ccell.2015.12.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):214-28. doi: 10.1016/j.ccell.2015.12.011. Epub 2016
      Jan 28.

PMID- 26806338
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20170714
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 2
DP  - 2016 Feb 8
TI  - Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma.
PG  - 229-40
LID - 10.1016/j.ccell.2015.12.012 [doi]
LID - S1535-6108(15)00476-6 [pii]
AB  - Ampullary carcinomas are highly malignant neoplasms that can have either
      intestinal or pancreatobiliary differentiation. To characterize somatic
      alterations in ampullary carcinomas, we performed whole-exome sequencing and DNA 
      copy-number analysis on 60 ampullary carcinomas resected from clinically
      well-characterized Japanese and American patients. We next selected 92 genes and 
      performed targeted sequencing to validate significantly mutated genes in an
      additional 112 cancers. The prevalence of driver gene mutations in carcinomas
      with the intestinal phenotype is different from those with the pancreatobiliary
      phenotype. We identified a characteristic significantly mutated driver gene
      (ELF3) as well as previously known driver genes (TP53, KRAS, APC, and others).
      Functional studies demonstrated that ELF3 silencing in normal human epithelial
      cells enhances their motility and invasion.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Yachida, Shinichi
AU  - Yachida S
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan; Division of Cancer Genomics, National Cancer Center Research
      Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 1040045, Japan. Electronic address:
      syachida@ncc.go.jp.
FAU - Wood, Laura D
AU  - Wood LD
AD  - Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The
      Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Suzuki, Masami
AU  - Suzuki M
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Takai, Erina
AU  - Takai E
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Totoki, Yasushi
AU  - Totoki Y
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Kato, Mamoru
AU  - Kato M
AD  - Department of Bioinformatics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Luchini, Claudio
AU  - Luchini C
AD  - Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The
      Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Arai, Yasuhito
AU  - Arai Y
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Nakamura, Hiromi
AU  - Nakamura H
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Hama, Natsuko
AU  - Hama N
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Elzawahry, Asmaa
AU  - Elzawahry A
AD  - Department of Bioinformatics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Hosoda, Fumie
AU  - Hosoda F
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Shirota, Tomoki
AU  - Shirota T
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan.
FAU - Morimoto, Nobuhiko
AU  - Morimoto N
AD  - Division of Medical Elemental Technology Development, Department of Advanced
      Analysis Technology, R&D Group, Olympus Corporation, Tokyo 1630914, Japan.
FAU - Hori, Kunio
AU  - Hori K
AD  - Division of Medical Elemental Technology Development, Department of Advanced
      Analysis Technology, R&D Group, Olympus Corporation, Tokyo 1630914, Japan.
FAU - Funazaki, Jun
AU  - Funazaki J
AD  - Division of Medical Elemental Technology Development, Department of Advanced
      Analysis Technology, R&D Group, Olympus Corporation, Tokyo 1630914, Japan.
FAU - Tanaka, Hikaru
AU  - Tanaka H
AD  - Division of Virology, National Cancer Center Research Institute, Tokyo 1040045,
      Japan.
FAU - Morizane, Chigusa
AU  - Morizane C
AD  - Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center
      Hospital, Tokyo 1040045, Japan.
FAU - Okusaka, Takuji
AU  - Okusaka T
AD  - Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center
      Hospital, Tokyo 1040045, Japan.
FAU - Nara, Satoshi
AU  - Nara S
AD  - Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital,
      Tokyo 1040045, Japan.
FAU - Shimada, Kazuaki
AU  - Shimada K
AD  - Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital,
      Tokyo 1040045, Japan.
FAU - Hiraoka, Nobuyoshi
AU  - Hiraoka N
AD  - Department of Pathology and Clinical Laboratories, National Cancer Center
      Hospital, Tokyo 1040045, Japan.
FAU - Taniguchi, Hirokazu
AU  - Taniguchi H
AD  - Department of Pathology and Clinical Laboratories, National Cancer Center
      Hospital, Tokyo 1040045, Japan.
FAU - Higuchi, Ryota
AU  - Higuchi R
AD  - Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical
      University, Tokyo 1628666, Japan.
FAU - Oshima, Minoru
AU  - Oshima M
AD  - Department of Gastroenterological Surgery, Kagawa University, Kagawa 7610793,
      Japan.
FAU - Okano, Keiichi
AU  - Okano K
AD  - Department of Gastroenterological Surgery, Kagawa University, Kagawa 7610793,
      Japan.
FAU - Hirono, Seiko
AU  - Hirono S
AD  - Second Department of Surgery, Wakayama Medical University, Wakayama 6418509,
      Japan.
FAU - Mizuma, Masamichi
AU  - Mizuma M
AD  - Department of Surgery, Tohoku University Graduate School of Medicine, Sendai
      Miyagi 9808575, Japan.
FAU - Arihiro, Koji
AU  - Arihiro K
AD  - Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima
      7348551, Japan.
FAU - Yamamoto, Masakazu
AU  - Yamamoto M
AD  - Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical
      University, Tokyo 1628666, Japan.
FAU - Unno, Michiaki
AU  - Unno M
AD  - Department of Surgery, Tohoku University Graduate School of Medicine, Sendai
      Miyagi 9808575, Japan.
FAU - Yamaue, Hiroki
AU  - Yamaue H
AD  - Second Department of Surgery, Wakayama Medical University, Wakayama 6418509,
      Japan.
FAU - Weiss, Matthew J
AU  - Weiss MJ
AD  - Department of Surgery, The Johns Hopkins University School of Medicine,
      Baltimore, MD 21287, USA.
FAU - Wolfgang, Christopher L
AU  - Wolfgang CL
AD  - Department of Surgery, The Johns Hopkins University School of Medicine,
      Baltimore, MD 21287, USA.
FAU - Furukawa, Toru
AU  - Furukawa T
AD  - Institute for Integrated Medical Science, Tokyo Women's Medical University, Tokyo
      1628666, Japan.
FAU - Nakagama, Hitoshi
AU  - Nakagama H
AD  - Division of Carcinogenesis and Cancer Prevention, National Cancer Center Research
      Institute, Tokyo 1040045, Japan.
FAU - Vogelstein, Bert
AU  - Vogelstein B
AD  - Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The
      Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; The Ludwig
      Center and The Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer
      Center, Baltimore, MD 21287, USA.
FAU - Kiyono, Tohru
AU  - Kiyono T
AD  - Division of Carcinogenesis and Cancer Prevention, National Cancer Center Research
      Institute, Tokyo 1040045, Japan.
FAU - Hruban, Ralph H
AU  - Hruban RH
AD  - Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The
      Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department
      of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins
      University School of Medicine, Baltimore, MD 21231, USA.
FAU - Shibata, Tatsuhiro
AU  - Shibata T
AD  - Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
      1040045, Japan; Laboratory of Molecular Medicine, Human Genome Center, The
      Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan.
LA  - eng
GR  - K08 DK107781/DK/NIDDK NIH HHS/United States
GR  - P50 CA062924/CA/NCI NIH HHS/United States
GR  - CA62924/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160121
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (ELF3 protein, human)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Transcription Factors)
RN  - Pancreatic Carcinoma
SB  - IM
CIN - Cancer Cell. 2016 Feb 8;29(2):135-6. PMID: 26859450
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - DNA-Binding Proteins/*genetics
MH  - Exome
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*genetics
MH  - Proto-Oncogene Proteins c-ets/*genetics
MH  - Transcription Factors/*genetics
MH  - Young Adult
PMC - PMC5503303
MID - NIHMS868704
EDAT- 2016/01/26 06:00
MHDA- 2016/06/23 06:00
CRDT- 2016/01/26 06:00
PHST- 2015/04/10 00:00 [received]
PHST- 2015/09/16 00:00 [revised]
PHST- 2015/12/21 00:00 [accepted]
PHST- 2016/01/26 06:00 [entrez]
PHST- 2016/01/26 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - S1535-6108(15)00476-6 [pii]
AID - 10.1016/j.ccell.2015.12.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Feb 8;29(2):229-40. doi: 10.1016/j.ccell.2015.12.012. Epub 2016
      Jan 21.

PMID- 26766593
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20160115
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in 
      Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
PG  - 117-29
LID - 10.1016/j.ccell.2015.12.008 [doi]
LID - S1535-6108(15)00472-9 [pii]
AB  - Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into
      targeted cells through internalization and lysosomal trafficking has emerged as
      an effective cancer therapy. We show that a bivalent biparatopic antibody
      targeting two non-overlapping epitopes on HER2 can induce HER2 receptor
      clustering, which in turn promotes robust internalization, lysosomal trafficking,
      and degradation. When conjugated with a tubulysin-based microtubule inhibitor,
      the biparatopic ADC demonstrates superior anti-tumor activity over
      ado-trastuzumab emtansine (T-DM1) in tumor models representing various patient
      subpopulations, including T-DM1 eligible, T-DM1 ineligible, and T-DM1
      relapsed/refractory. Our findings indicate that this biparatopic ADC has
      promising potential as an effective therapy for metastatic breast cancer and a
      broader patient population may benefit from this unique HER2-targeting ADC.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Li, John Y
AU  - Li JY
AD  - Biosuperiors, MedImmune LLC, Gaithersburg, MD 20878, USA. Electronic address:
      lij@medimmune.com.
FAU - Perry, Samuel R
AU  - Perry SR
AD  - Biosuperiors, MedImmune LLC, Gaithersburg, MD 20878, USA.
FAU - Muniz-Medina, Vanessa
AU  - Muniz-Medina V
AD  - Biosuperiors, MedImmune LLC, Gaithersburg, MD 20878, USA.
FAU - Wang, Xinzhong
AU  - Wang X
AD  - Biosuperiors, MedImmune LLC, Gaithersburg, MD 20878, USA.
FAU - Wetzel, Leslie K
AU  - Wetzel LK
AD  - Oncology, MedImmune LLC, Gaithersburg, MD 20878, USA.
FAU - Rebelatto, Marlon C
AU  - Rebelatto MC
AD  - Biologics Safety Assessment, MedImmune LLC, Gaithersburg, MD 20878, USA.
FAU - Hinrichs, Mary Jane Masson
AU  - Hinrichs MJ
AD  - Biologics Safety Assessment, MedImmune LLC, Gaithersburg, MD 20878, USA.
FAU - Bezabeh, Binyam Z
AU  - Bezabeh BZ
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Fleming, Ryan L
AU  - Fleming RL
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Dimasi, Nazzareno
AU  - Dimasi N
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Feng, Hui
AU  - Feng H
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Toader, Dorin
AU  - Toader D
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Yuan, Andy Q
AU  - Yuan AQ
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Xu, Lan
AU  - Xu L
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Lin, Jia
AU  - Lin J
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Gao, Changshou
AU  - Gao C
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Wu, Herren
AU  - Wu H
AD  - Antibody Discovery & Protein Engineering, MedImmune LLC, Gaithersburg, MD 20878, 
      USA.
FAU - Dixit, Rakesh
AU  - Dixit R
AD  - Biologics Safety Assessment, MedImmune LLC, Gaithersburg, MD 20878, USA.
FAU - Osbourn, Jane K
AU  - Osbourn JK
AD  - Biosuperiors, MedImmune LLC, Gaithersburg, MD 20878, USA; MedImmune Ltd, Granta
      Park, Cambridge CB21 6GH, UK.
FAU - Coats, Steven R
AU  - Coats SR
AD  - Biosuperiors, MedImmune LLC, Gaithersburg, MD 20878, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunotoxins)
RN  - 14083FR882 (Maytansine)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - SE2KH7T06F (ado-trastuzumab emtansine)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/immunology
MH  - Female
MH  - Humans
MH  - Immunotoxins/*therapeutic use
MH  - Maytansine/*analogs & derivatives/therapeutic use
MH  - Mice
MH  - Receptor, ErbB-2/*immunology
MH  - Trastuzumab/*therapeutic use
MH  - Treatment Outcome
EDAT- 2016/01/15 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/03/31 00:00 [received]
PHST- 2015/09/18 00:00 [revised]
PHST- 2015/12/15 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - S1535-6108(15)00472-9 [pii]
AID - 10.1016/j.ccell.2015.12.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008.

PMID- 26766592
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20170718
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.
PG  - 104-116
LID - 10.1016/j.ccell.2015.12.004 [doi]
AB  - Dysregulated metabolism is a hallmark of cancer, manifested through alterations
      in metabolites. We performed metabolomic profiling on 138 matched clear cell
      renal cell carcinoma (ccRCC)/normal tissue pairs and found that ccRCC is
      characterized by broad shifts in central carbon metabolism, one-carbon
      metabolism, and antioxidant response. Tumor progression and metastasis were
      associated with metabolite increases in glutathione and cysteine/methionine
      metabolism pathways. We develop an analytic pipeline and visualization tool
      (metabolograms) to bridge the gap between TCGA transcriptomic profiling and our
      metabolomic data, which enables us to assemble an integrated pathway-level
      metabolic atlas and to demonstrate discordance between transcriptome and
      metabolome. Lastly, expression profiling was performed on a high-glutathione
      cluster, which corresponds to a poor-survival subgroup in the ccRCC TCGA cohort.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hakimi, A Ari
AU  - Hakimi AA
FAU - Reznik, Ed
AU  - Reznik E
FAU - Lee, Chung-Han
AU  - Lee CH
FAU - Creighton, Chad J
AU  - Creighton CJ
FAU - Brannon, A Rose
AU  - Brannon AR
FAU - Luna, Augustin
AU  - Luna A
FAU - Aksoy, B Arman
AU  - Aksoy BA
FAU - Liu, Eric Minwei
AU  - Liu EM
FAU - Shen, Ronglai
AU  - Shen R
FAU - Lee, William
AU  - Lee W
FAU - Chen, Yang
AU  - Chen Y
FAU - Stirdivant, Steve M
AU  - Stirdivant SM
FAU - Russo, Paul
AU  - Russo P
FAU - Chen, Ying Bei
AU  - Chen YB
FAU - Tickoo, Satish K
AU  - Tickoo SK
FAU - Reuter, Victor E
AU  - Reuter VE
FAU - Cheng, Emily H
AU  - Cheng EH
FAU - Sander, Chris
AU  - Sander C
FAU - Hsieh, James J
AU  - Hsieh JJ
LA  - eng
GR  - T32 CA160001/CA/NCI NIH HHS/United States
GR  - 5U24CA143843/CA/NCI NIH HHS/United States
GR  - R01 CA138505/CA/NCI NIH HHS/United States
GR  - P30CA125123/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U24 CA143840/CA/NCI NIH HHS/United States
GR  - P30 CA125123/CA/NCI NIH HHS/United States
GR  - 5T32CA160001/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
CIN - Nat Rev Urol. 2016 Mar;13(3):126. PMID: 26813954
CIN - Transl Androl Urol. 2016 Oct;5(5):801-803. PMID: 27785441
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Renal Cell/*diagnosis/*genetics
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Genetic Predisposition to Disease/genetics
MH  - Humans
MH  - Kidney Neoplasms/*diagnosis/*genetics
MH  - Metabolomics/methods
MH  - Neoplasm Staging
MH  - Prognosis
PMC - PMC4809063
MID - NIHMS746037
EDAT- 2016/01/15 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/04/26 00:00 [received]
PHST- 2015/08/27 00:00 [revised]
PHST- 2015/12/11 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - 10.1016/j.ccell.2015.12.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):104-116. doi: 10.1016/j.ccell.2015.12.004.

PMID- 26766591
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20161126
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that 
      Is Predictive of Clinical Outcomes of Human Acute Leukemia.
PG  - 61-74
LID - 10.1016/j.ccell.2015.11.012 [doi]
LID - S1535-6108(15)00434-1 [pii]
AB  - Initial pathway alternations required for pathogenesis of human acute myeloid
      leukemia (AML) are poorly understood. Here we reveal that removal of glycogen
      synthase kinase-3alpha (GSK-3alpha) and GSK-3beta dependency leads to aggressive 
      AML. Although GSK-3alpha deletion alone has no effect, GSK-3beta deletion in
      hematopoietic stem cells (HSCs) resulted in a pre-neoplastic state consistent
      with human myelodysplastic syndromes (MDSs). Transcriptome and functional studies
      reveal that each GSK-3beta and GSK-3alpha uniquely contributes to AML by
      affecting Wnt/Akt/mTOR signaling and metabolism, respectively. The molecular
      signature of HSCs deleted for GSK-3beta provided a prognostic tool for disease
      progression and survival of MDS patients. Our study reveals that GSK-3alpha- and 
      GSK-3beta-regulated pathways can be responsible for stepwise transition to MDS
      and subsequent AML, thereby providing potential therapeutic targets of disease
      evolution.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Guezguez, Borhane
AU  - Guezguez B
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada.
FAU - Almakadi, Mohammed
AU  - Almakadi M
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical
      Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada; Department of
      Oncology, Juravinski Cancer Center, Faculty of Health Sciences, McMaster
      University, Hamilton, ON L8N 3Z5, Canada.
FAU - Benoit, Yannick D
AU  - Benoit YD
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada.
FAU - Shapovalova, Zoya
AU  - Shapovalova Z
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada.
FAU - Rahmig, Susann
AU  - Rahmig S
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada.
FAU - Fiebig-Comyn, Aline
AU  - Fiebig-Comyn A
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada.
FAU - Casado, Fanny L
AU  - Casado FL
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada.
FAU - Tanasijevic, Borko
AU  - Tanasijevic B
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada.
FAU - Bresolin, Silvia
AU  - Bresolin S
AD  - Department of Women's and Children's Health, University of Padova, Padua, Italy.
FAU - Masetti, Riccardo
AU  - Masetti R
AD  - Department of Pediatric Oncology and Hematology, University of Bologna, Bologna, 
      Italy.
FAU - Doble, Bradley W
AU  - Doble BW
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical
      Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada.
FAU - Bhatia, Mickie
AU  - Bhatia M
AD  - McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of
      Medicine, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical
      Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada; McMaster Stem Cell
      and Cancer Research Institute (SCC-RI), Michael G. DeGroote School of Medicine,
      McMaster University, 1280 Main Street West, MDCL 5029, Hamilton, ON L8S 4K1,
      Canada. Electronic address: mbhatia@mcmaster.ca.
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.11.1 (GSK3B protein, human)
RN  - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
RN  - EC 2.7.11.1 (Gsk3b protein, mouse)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.26 (Glycogen Synthase Kinase 3)
RN  - EC 2.7.11.26 (glycogen synthase kinase 3 alpha)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Glycogen Synthase Kinase 3/deficiency/*metabolism
MH  - Glycogen Synthase Kinase 3 beta
MH  - Hematopoietic Stem Cells/*enzymology
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*enzymology/genetics/therapy
MH  - Mice, Transgenic
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/physiology
EDAT- 2016/01/15 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/15 06:00
PHST- 2014/07/03 00:00 [received]
PHST- 2015/04/23 00:00 [revised]
PHST- 2015/11/17 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - S1535-6108(15)00434-1 [pii]
AID - 10.1016/j.ccell.2015.11.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):61-74. doi: 10.1016/j.ccell.2015.11.012.

PMID- 26766590
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20180316
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates
      Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.
PG  - 49-60
LID - 10.1016/j.ccell.2015.12.005 [doi]
LID - S1535-6108(15)00469-9 [pii]
AB  - The hypoxic tumor microenvironment serves as a niche for maintaining the
      glioma-initiating cells (GICs) that are critical for glioblastoma (GBM)
      occurrence and recurrence. Here, we report that hypoxia-induced miR-215 is vital 
      for reprograming GICs to fit the hypoxic microenvironment via suppressing the
      expression of an epigenetic regulator KDM1B and modulating activities of multiple
      pathways. Interestingly, biogenesis of miR-215 and several miRNAs is accelerated 
      post-transcriptionally by hypoxia-inducible factors (HIFs) through HIF-Drosha
      interaction. Moreover, miR-215 expression correlates inversely with KDM1B while
      correlating positively with HIF1alpha and GBM progression in patients. These
      findings reveal a direct role of HIF in regulating miRNA biogenesis and
      consequently activating the miR-215-KDM1B-mediated signaling required for GIC
      adaptation to hypoxia.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hu, Jing
AU  - Hu J
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Sun, Tao
AU  - Sun T
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Chen, Zhengxin
AU  - Chen Z
AD  - Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, Jiangsu Province 210029, China.
FAU - Wang, Shuai
AU  - Wang S
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, Jiangsu Province 210029, China.
FAU - Yuan, Lifeng
AU  - Yuan L
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Liu, Tingyu
AU  - Liu T
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Li, Hai-Ri
AU  - Li HR
AD  - Department of Cellular & Molecular Medicine, University of California, San Diego,
      La Jolla, CA 92093, USA.
FAU - Wang, Pingping
AU  - Wang P
AD  - Department of Cellular & Molecular Medicine, University of California, San Diego,
      La Jolla, CA 92093, USA.
FAU - Feng, Yukuan
AU  - Feng Y
AD  - Department of Cellular & Molecular Medicine, University of California, San Diego,
      La Jolla, CA 92093, USA; Department of Anatomy, Mudanjiang Medical College,
      Mudanjiang, Heilongjiang Province 157011, China.
FAU - Wang, Qinhong
AU  - Wang Q
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - McLendon, Roger E
AU  - McLendon RE
AD  - The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Friedman, Allan H
AU  - Friedman AH
AD  - The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Keir, Stephen T
AU  - Keir ST
AD  - The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Bigner, Darell D
AU  - Bigner DD
AD  - The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Rathmell, Jeff
AU  - Rathmell J
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Fu, Xiang-Dong
AU  - Fu XD
AD  - Department of Cellular & Molecular Medicine, University of California, San Diego,
      La Jolla, CA 92093, USA.
FAU - Li, Qi-Jing
AU  - Li QJ
AD  - Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA.
FAU - Wang, Huibo
AU  - Wang H
AD  - Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, Jiangsu Province 210029, China.
FAU - Wang, Xiao-Fan
AU  - Wang XF
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center,
      Durham, NC 27710, USA. Electronic address: xiao.fan.wang@duke.edu.
LA  - eng
GR  - AI091878/AI/NIAID NIH HHS/United States
GR  - P50 CA190991/CA/NCI NIH HHS/United States
GR  - R56 AI091878/AI/NIAID NIH HHS/United States
GR  - T32 GM007184/GM/NIGMS NIH HHS/United States
GR  - R01 AI091878/AI/NIAID NIH HHS/United States
GR  - R01 CA154586/CA/NCI NIH HHS/United States
GR  - CA164791/CA/NCI NIH HHS/United States
GR  - R01 CA164791/CA/NCI NIH HHS/United States
GR  - R01 GM049369/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MIRN215 microRNA, human)
RN  - 0 (MIRN215 microRNA, mouse)
RN  - 0 (MicroRNAs)
RN  - EC 1.5.- (Oxidoreductases, N-Demethylating)
RN  - EC 1.5.- (kdm1b protein, mouse)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/genetics/pathology
MH  - Cell Hypoxia
MH  - Cell Line, Tumor
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Glioma/*genetics
MH  - Humans
MH  - Mice, Nude
MH  - MicroRNAs/*genetics
MH  - Neoplasm Recurrence, Local/genetics
MH  - Oxidoreductases, N-Demethylating/*genetics
MH  - Tumor Microenvironment/*genetics
PMC - PMC4871949
MID - NIHMS746294
EDAT- 2016/01/15 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/01/29 00:00 [received]
PHST- 2015/09/30 00:00 [revised]
PHST- 2015/12/14 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - S1535-6108(15)00469-9 [pii]
AID - 10.1016/j.ccell.2015.12.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):49-60. doi: 10.1016/j.ccell.2015.12.005.

PMID- 26766589
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute
      Myeloid Leukemia.
PG  - 32-48
LID - 10.1016/j.ccell.2015.12.007 [doi]
LID - S1535-6108(15)00471-7 [pii]
AB  - Transcriptional deregulation plays a major role in acute myeloid leukemia, and
      therefore identification of epigenetic modifying enzymes essential for the
      maintenance of oncogenic transcription programs holds the key to better
      understanding of the biology and designing effective therapeutic strategies for
      the disease. Here we provide experimental evidence for the functional involvement
      and therapeutic potential of targeting PRMT1, an H4R3 methyltransferase, in
      various MLL and non-MLL leukemias. PRMT1 is necessary but not sufficient for
      leukemic transformation, which requires co-recruitment of KDM4C, an H3K9
      demethylase, by chimeric transcription factors to mediate epigenetic
      reprogramming. Pharmacological inhibition of KDM4C/PRMT1 suppresses transcription
      and transformation ability of MLL fusions and MOZ-TIF2, revealing a tractable
      aberrant epigenetic circuitry mediated by KDM4C and PRMT1 in acute leukemia.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Cheung, Ngai
AU  - Cheung N
AD  - Leukemia and Stem Cell Biology Group, Division of Cancer Studies, Department of
      Haematological Medicine, King's College London, Denmark Hill Campus, London SE5
      9NU, UK.
FAU - Fung, Tsz Kan
AU  - Fung TK
AD  - Leukemia and Stem Cell Biology Group, Division of Cancer Studies, Department of
      Haematological Medicine, King's College London, Denmark Hill Campus, London SE5
      9NU, UK.
FAU - Zeisig, Bernd B
AU  - Zeisig BB
AD  - Leukemia and Stem Cell Biology Group, Division of Cancer Studies, Department of
      Haematological Medicine, King's College London, Denmark Hill Campus, London SE5
      9NU, UK.
FAU - Holmes, Katie
AU  - Holmes K
AD  - Leukemia and Stem Cell Biology Group, Division of Cancer Studies, Department of
      Haematological Medicine, King's College London, Denmark Hill Campus, London SE5
      9NU, UK.
FAU - Rane, Jayant K
AU  - Rane JK
AD  - Leukemia and Stem Cell Biology Group, Division of Cancer Studies, Department of
      Haematological Medicine, King's College London, Denmark Hill Campus, London SE5
      9NU, UK.
FAU - Mowen, Kerri A
AU  - Mowen KA
AD  - Department of Chemical Physiology and Immunology & Microbial Sciences, The
      Scripps Research Institute, La Jolla, CA 92037, USA.
FAU - Finn, Michael G
AU  - Finn MG
AD  - School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta,
      GA 30332, USA.
FAU - Lenhard, Boris
AU  - Lenhard B
AD  - Department of Molecular Sciences, Institute of Clinical Sciences, Faculty of
      Medicine, Imperial College London and MRC Clinical Sciences Centre, Du Cane Road,
      London W12 0NN, UK.
FAU - Chan, Li Chong
AU  - Chan LC
AD  - Department of Pathology, The University of Hong Kong, Pokfulam Road, Hong Kong.
FAU - So, Chi Wai Eric
AU  - So CW
AD  - Leukemia and Stem Cell Biology Group, Division of Cancer Studies, Department of
      Haematological Medicine, King's College London, Denmark Hill Campus, London SE5
      9NU, UK. Electronic address: eric.so@kcl.ac.uk.
LA  - eng
GR  - G0800892/Medical Research Council/United Kingdom
GR  - MC_UP_1102/1/Medical Research Council/United Kingdom
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (KDM4C protein, human)
RN  - 0 (Repressor Proteins)
RN  - 0 (Transcription Factors)
RN  - EC 1.14.11.- (Jmjd2c protein, mouse)
RN  - EC 1.14.11.- (Jumonji Domain-Containing Histone Demethylases)
RN  - EC 1.5.- (Oxidoreductases, N-Demethylating)
RN  - EC 2.1.1.319 (PRMT1 protein, human)
RN  - EC 2.1.1.319 (Prmt1 protein, mouse)
RN  - EC 2.1.1.319 (Protein-Arginine N-Methyltransferases)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Transformation, Neoplastic/genetics/metabolism
MH  - Epigenesis, Genetic/genetics
MH  - Gene Expression Regulation, Leukemic/*genetics
MH  - Humans
MH  - Jumonji Domain-Containing Histone Demethylases/genetics/*metabolism
MH  - Leukemia, Myeloid, Acute/*genetics/metabolism
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Oxidoreductases, N-Demethylating/genetics/*metabolism
MH  - Protein-Arginine N-Methyltransferases/genetics/*metabolism
MH  - Repressor Proteins/genetics/*metabolism
MH  - Transcription Factors/genetics
PMC - PMC4712026
OTO - NOTNLM
OT  - AML
OT  - KDM
OT  - KDM4C
OT  - KMT
OT  - MLL fusions
OT  - MOZ-TIF2
OT  - PMT
OT  - PRMT1
OT  - acute myeloid leukemia
OT  - histone demethylase
OT  - histone methyltransferase
OT  - leukemia epigenetics
EDAT- 2016/01/15 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/02/13 00:00 [received]
PHST- 2015/07/31 00:00 [revised]
PHST- 2015/12/15 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - S1535-6108(15)00471-7 [pii]
AID - 10.1016/j.ccell.2015.12.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):32-48. doi: 10.1016/j.ccell.2015.12.007.

PMID- 26766588
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20161126
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and
      Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.
PG  - 17-31
LID - 10.1016/j.ccell.2015.12.006 [doi]
LID - S1535-6108(15)00470-5 [pii]
AB  - Polycomb repressive complexes (PRC) are frequently implicated in human cancer,
      acting either as oncogenes or tumor suppressors. Here, we show that PRC2 is a
      critical regulator of KRAS-driven non-small cell lung cancer progression.
      Modulation of PRC2 by either Ezh2 overexpression or Eed deletion enhances
      KRAS-driven adenomagenesis and inflammation, respectively. Eed-loss-driven
      inflammation leads to massive macrophage recruitment and marked decline in tissue
      function. Additional Trp53 inactivation activates a cell-autonomous
      epithelial-to-mesenchymal transition program leading to an invasive mucinous
      adenocarcinoma. A switch between methylated/acetylated chromatin underlies the
      tumor phenotypic evolution, prominently involving genes controlled by Hippo/Wnt
      signaling. Our observations in the mouse models were conserved in human cells.
      Importantly, PRC2 inactivation results in context-dependent phenotypic
      alterations, with implications for its therapeutic application.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Serresi, Michela
AU  - Serresi M
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands.
FAU - Gargiulo, Gaetano
AU  - Gargiulo G
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address:
      g.gargiulo@nki.nl.
FAU - Proost, Natalie
AU  - Proost N
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands.
FAU - Siteur, Bjorn
AU  - Siteur B
AD  - Mouse Clinic Intervention Unit, The Netherlands Cancer Institute, 1066 CX
      Amsterdam, the Netherlands.
FAU - Cesaroni, Matteo
AU  - Cesaroni M
AD  - The Fels Institute, Temple University School of Medicine, Philadelphia, PA 19140,
      USA.
FAU - Koppens, Martijn
AU  - Koppens M
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands.
FAU - Xie, Huafeng
AU  - Xie H
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of
      Hematology/Oncology, Boston Children's Hospital, Harvard Stem Cell Institute,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Sutherland, Kate D
AU  - Sutherland KD
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands.
FAU - Hulsman, Danielle
AU  - Hulsman D
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands.
FAU - Citterio, Elisabetta
AU  - Citterio E
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands.
FAU - Orkin, Stuart
AU  - Orkin S
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of
      Hematology/Oncology, Boston Children's Hospital, Harvard Stem Cell Institute,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Berns, Anton
AU  - Berns A
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands.
FAU - van Lohuizen, Maarten
AU  - van Lohuizen M
AD  - Division of Molecular Genetics, Centre for Biomedical Genetics, The Netherlands
      Cancer Institute, 1066 CX Amsterdam, the Netherlands; Cancer Genomics Centre
      (CGC.nl), Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic
      address: m.v.lohuizen@nki.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - 0 (KRAS protein, human)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Ezh2 protein, mouse)
RN  - EC 2.1.1.43 (Polycomb Repressive Complex 2)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
EIN - Cancer Cell. 2016 Feb 8;29(2):241
MH  - Acetylation
MH  - Animals
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*metabolism
MH  - Cell Proliferation/genetics/physiology
MH  - Disease Models, Animal
MH  - Enhancer of Zeste Homolog 2 Protein
MH  - Epithelial-Mesenchymal Transition/*genetics
MH  - Histones/metabolism
MH  - Humans
MH  - Inflammation/genetics/metabolism
MH  - Mice, Transgenic
MH  - Polycomb Repressive Complex 2/genetics/*metabolism
MH  - Proto-Oncogene Proteins p21(ras)/genetics/*metabolism
EDAT- 2016/01/15 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/03/12 00:00 [received]
PHST- 2015/09/07 00:00 [revised]
PHST- 2015/12/14 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - S1535-6108(15)00470-5 [pii]
AID - 10.1016/j.ccell.2015.12.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):17-31. doi: 10.1016/j.ccell.2015.12.006.

PMID- 26766587
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20170718
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.
PG  - 5-16
LID - 10.1016/j.ccell.2015.12.003 [doi]
AB  - Four distinct subgroups of cerebellar medulloblastomas (MBs) differ in their
      histopathology, molecular profiles, and prognosis. c-Myc (Myc) or MycN
      overexpression in granule neuron progenitors (GNPs) induces Group 3 (G3) or Sonic
      Hedgehog (SHH) MBs, respectively. Differences in Myc and MycN transcriptional
      profiles depend, in part, on their interaction with Miz1, which binds strongly to
      Myc but not MycN, to target sites on chromatin. Myc suppresses ciliogenesis and
      reprograms the transcriptome of SHH-dependent GNPs through Miz1-dependent gene
      repression to maintain stemness. Genetic disruption of the Myc/Miz1 interaction
      inhibited G3 MB development. Target genes of Myc/Miz1 are repressed in human G3
      MBs but not in other subgroups. Therefore, the Myc/Miz1 interaction is a defining
      hallmark of G3 MB development.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Vo, BaoHan T
AU  - Vo BT
AD  - Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis,
      262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Wolf, Elmar
AU  - Wolf E
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany.
FAU - Kawauchi, Daisuke
AU  - Kawauchi D
AD  - Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis,
      262 Danny Thomas Place, Memphis, TN 38105, USA.
AD  - German Cancer Research Center (DKFZ), Division of Pediatric Neurooncology (B062) 
      Im Neuenheimer Feld 580, 69120 Heidelberg, Germany.
FAU - Gebhardt, Anneli
AU  - Gebhardt A
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany.
FAU - Rehg, Jerold E
AU  - Rehg JE
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Finkelstein, David
AU  - Finkelstein D
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, 262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Walz, Susanne
AU  - Walz S
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany.
AD  - Comprehensive Cancer Center Mainfranken, University of Wurzburg,
      Josef-Schneider-Str.6, 97080 Wurzburg, Germany.
FAU - Murphy, Brian L
AU  - Murphy BL
AD  - Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis,
      262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Youn, Yong Ha
AU  - Youn YH
AD  - Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 
      Memphis, 262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Han, Young-Goo
AU  - Han YG
AD  - Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 
      Memphis, 262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Eilers, Martin
AU  - Eilers M
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany.
AD  - Comprehensive Cancer Center Mainfranken, University of Wurzburg,
      Josef-Schneider-Str.6, 97080 Wurzburg, Germany.
FAU - Roussel, Martine F
AU  - Roussel MF
AD  - Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis,
      262 Danny Thomas Place, Memphis, TN 38105, USA.
LA  - eng
GR  - CA021765/CA/NCI NIH HHS/United States
GR  - CA-21765/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - P01 CA096832/CA/NCI NIH HHS/United States
GR  - CA-096832/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Hedgehog Proteins)
RN  - 0 (Miz1 protein, mouse)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Protein Inhibitors of Activated STAT)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
CIN - Cancer Cell. 2016 Jan 11;29(1):1-2. PMID: 26766585
MH  - Animals
MH  - Cerebellar Neoplasms/*metabolism/*pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - Hedgehog Proteins/genetics
MH  - Medulloblastoma/*metabolism
MH  - Mice
MH  - Neurons/*metabolism
MH  - Nuclear Proteins/*metabolism
MH  - Protein Inhibitors of Activated STAT/*metabolism
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Signal Transduction/genetics
PMC - PMC4714043
MID - NIHMS745210
EDAT- 2016/01/15 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/03/15 00:00 [received]
PHST- 2015/10/25 00:00 [revised]
PHST- 2015/12/09 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - 10.1016/j.ccell.2015.12.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):5-16. doi: 10.1016/j.ccell.2015.12.003.

PMID- 26766586
OWN - NLM
STAT- MEDLINE
DCOM- 20160511
LR  - 20160115
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver.
PG  - 3-4
LID - 10.1016/j.ccell.2015.12.010 [doi]
LID - S1535-6108(15)00474-2 [pii]
AB  - Inhibitors of B cell receptor signaling substantially changed the treatment of
      chronic lymphocytic leukemia as the first targeted agents to enter routine
      clinical practice. A recent paper by Roberts and colleagues describes an
      additional therapeutic target by reporting encouraging clinical results with
      venetoclax, an inhibitor of the antiapoptotic protein BCL2.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - Division of Hematology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, The Ohio State University, Columbus, OH 43210, USA.
      Electronic address: john.byrd@osumc.edu.
LA  - eng
GR  - K23CA178183/CA/NCI NIH HHS/United States
GR  - P01 CA095426/CA/NCI NIH HHS/United States
GR  - R01 CA169162/CA/NCI NIH HHS/United States
GR  - R01 CA177292/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - T32 CA09338/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Sulfonamides)
SB  - IM
CON - J Clin Oncol. 2012 Feb 10;30(5):488-96. PMID: 22184378
MH  - Aniline Compounds/*administration & dosage/*pharmacology
MH  - Antineoplastic Agents/*administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
MH  - Male
MH  - Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors/*metabolism
MH  - Sulfonamides/*administration & dosage/*pharmacology
EDAT- 2016/01/15 06:00
MHDA- 2016/05/12 06:00
CRDT- 2016/01/15 06:00
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/12 06:00 [medline]
AID - S1535-6108(15)00474-2 [pii]
AID - 10.1016/j.ccell.2015.12.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):3-4. doi: 10.1016/j.ccell.2015.12.010.

PMID- 26766585
OWN - NLM
STAT- MEDLINE
DCOM- 20160526
LR  - 20160115
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - Parsing Myc Paralogs in Oncogenesis.
PG  - 1-2
LID - 10.1016/j.ccell.2015.12.009 [doi]
LID - S1535-6108(15)00473-0 [pii]
AB  - Myc and its paralog MycN are thought to be functionally redundant, but Myc- and
      MycN-driven medulloblastomas exhibit distinct phenotypes. In this issue of Cancer
      Cell, Vo and colleagues (2016) show that this phenotypic difference stems from
      the preferential ability of Myc, relative to MycN, to bind Miz1 and repress
      transcription.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Mathsyaraja, Haritha
AU  - Mathsyaraja H
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Eisenman, Robert N
AU  - Eisenman RN
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA. Electronic address: eisenman@fhcrc.org.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Protein Inhibitors of Activated STAT)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
CON - Cancer Cell. 2016 Jan 11;29(1):5-16. PMID: 26766587
MH  - Animals
MH  - Cerebellar Neoplasms/*metabolism/*pathology
MH  - Medulloblastoma/*metabolism
MH  - Neurons/*metabolism
MH  - Nuclear Proteins/*metabolism
MH  - Protein Inhibitors of Activated STAT/*metabolism
MH  - Proto-Oncogene Proteins c-myc/*metabolism
EDAT- 2016/01/15 06:00
MHDA- 2016/05/27 06:00
CRDT- 2016/01/15 06:00
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/05/27 06:00 [medline]
AID - S1535-6108(15)00473-0 [pii]
AID - 10.1016/j.ccell.2015.12.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):1-2. doi: 10.1016/j.ccell.2015.12.009.

PMID- 26748848
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20170930
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian 
      Carcinomas.
PG  - 90-103
LID - 10.1016/j.ccell.2015.12.002 [doi]
LID - S1535-6108(15)00466-3 [pii]
AB  - Half of all human cancers lose p53 function by missense mutations, with an
      unknown fraction of these containing p53 in a self-aggregated amyloid-like state.
      Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53
      amyloid formation, rescues p53 function in cancer cell lines and in organoids
      derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer
      characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its
      wild-type counterpart in regulating target genes, reducing cell proliferation and
      increasing cell death. Intraperitoneal administration decreases tumor
      proliferation and shrinks xenografts in vivo. Our data show the effectiveness of 
      targeting a specific aggregation defect of p53 and its potential applicability to
      HGSOCs.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Soragni, Alice
AU  - Soragni A
AD  - Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE
      Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570,
      USA.
FAU - Janzen, Deanna M
AU  - Janzen DM
AD  - Department of Obstetrics and Gynecology, David Geffen School of Medicine,
      University of California Los Angeles, Los Angeles, CA 90095, USA.
FAU - Johnson, Lisa M
AU  - Johnson LM
AD  - Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE
      Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570,
      USA.
FAU - Lindgren, Anne G
AU  - Lindgren AG
AD  - Department of Obstetrics and Gynecology, David Geffen School of Medicine,
      University of California Los Angeles, Los Angeles, CA 90095, USA.
FAU - Thai-Quynh Nguyen, Anh
AU  - Thai-Quynh Nguyen A
AD  - Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE
      Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570,
      USA.
FAU - Tiourin, Ekaterina
AU  - Tiourin E
AD  - Department of Obstetrics and Gynecology, David Geffen School of Medicine,
      University of California Los Angeles, Los Angeles, CA 90095, USA.
FAU - Soriaga, Angela B
AU  - Soriaga AB
AD  - Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE
      Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570,
      USA.
FAU - Lu, Jing
AU  - Lu J
AD  - Molecular, Cell and Developmental Biology, University of California Los Angeles, 
      Los Angeles, CA 90095, USA.
FAU - Jiang, Lin
AU  - Jiang L
AD  - Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE
      Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570,
      USA.
FAU - Faull, Kym F
AU  - Faull KF
AD  - Pasarow Mass Spectrometry Laboratory, Semel Institute, 405 Hilgard Avenue, Los
      Angeles, CA 90095, USA.
FAU - Pellegrini, Matteo
AU  - Pellegrini M
AD  - Molecular, Cell and Developmental Biology, University of California Los Angeles, 
      Los Angeles, CA 90095, USA.
FAU - Memarzadeh, Sanaz
AU  - Memarzadeh S
AD  - Department of Obstetrics and Gynecology, David Geffen School of Medicine,
      University of California Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe 
      Broad Center of Regenerative Medicine and Stem Cell Research, University of
      California Los Angles, Los Angeles, CA 90095, USA; The VA Greater Los Angeles
      Health Care System, Los Angeles, CA 90073, USA. Electronic address:
      smemarzadeh@mednet.ucla.edu.
FAU - Eisenberg, David S
AU  - Eisenberg DS
AD  - Departments of Biological Chemistry and Chemistry and Biochemistry, UCLA-DOE
      Institute, HHMI, 611 South Charles E. Young Drive, Los Angeles, CA 90095-1570,
      USA. Electronic address: david@mbi.ucla.edu.
LA  - eng
GR  - R01 AG029430/AG/NIA NIH HHS/United States
GR  - UL1TR000124/TR/NCATS NIH HHS/United States
GR  - IK2 BX001305/BX/BLRD VA/United States
GR  - R01 CA183877/CA/NCI NIH HHS/United States
GR  - AG-029430/AG/NIA NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
GR  - S10 RR023718/RR/NCRR NIH HHS/United States
GR  - P30 CA016042/CA/NCI NIH HHS/United States
GR  - 1S10RR023718-01A2/RR/NCRR NIH HHS/United States
GR  - R01CA183877/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20151231
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
CIN - Nat Rev Drug Discov. 2016 Feb;15(2):85. PMID: 26837589
MH  - Animals
MH  - Cell Line
MH  - Cell Proliferation/*genetics
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Mice, Transgenic
MH  - Ovarian Neoplasms/genetics/*metabolism/pathology
MH  - Tumor Suppressor Protein p53/genetics/*metabolism
PMC - PMC4733364
MID - NIHMS745211
EDAT- 2016/01/11 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/11 06:00
PHST- 2015/02/02 00:00 [received]
PHST- 2015/06/24 00:00 [revised]
PHST- 2015/12/09 00:00 [accepted]
PHST- 2016/01/11 06:00 [entrez]
PHST- 2016/01/11 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - S1535-6108(15)00466-3 [pii]
AID - 10.1016/j.ccell.2015.12.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):90-103. doi: 10.1016/j.ccell.2015.12.002. Epub
      2015 Dec 31.

PMID- 26725216
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20170111
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Jan 11
TI  - Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC 
      Degradation and Senescence-like Growth Suppression.
PG  - 75-89
LID - 10.1016/j.ccell.2015.11.011 [doi]
LID - S1535-6108(15)00433-X [pii]
AB  - Induction of compensatory mechanisms and ERK reactivation has limited the
      effectiveness of Raf and MEK inhibitors in RAS-mutant cancers. We determined that
      direct pharmacologic inhibition of ERK suppressed the growth of a subset of
      KRAS-mutant pancreatic cancer cell lines and that concurrent phosphatidylinositol
      3-kinase (PI3K) inhibition caused synergistic cell death. Additional combinations
      that enhanced ERK inhibitor action were also identified. Unexpectedly, long-term 
      treatment of sensitive cell lines caused senescence, mediated in part by MYC
      degradation and p16 reactivation. Enhanced basal PI3K-AKT-mTOR signaling was
      associated with de novo resistance to ERK inhibitor, as were other protein
      kinases identified by kinome-wide siRNA screening and a genetic gain-of-function 
      screen. Our findings reveal distinct consequences of inhibiting this kinase
      cascade at the level of ERK.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Hayes, Tikvah K
AU  - Hayes TK
AD  - Curriculum in Genetics and Molecular Biology, University of North Carolina at
      Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, 
      University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Neel, Nicole F
AU  - Neel NF
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Hu, Chaoxin
AU  - Hu C
AD  - Departments of Pathology and Translational Molecular Pathology, University of
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Gautam, Prson
AU  - Gautam P
AD  - Institute for Molecular Medicine Finland, University of Helsinki, 00290 Helsinki,
      Finland.
FAU - Chenard, Melissa
AU  - Chenard M
AD  - Merck Research Laboratories, Boston, MA 02115, USA.
FAU - Long, Brian
AU  - Long B
AD  - Merck Research Laboratories, Boston, MA 02115, USA.
FAU - Aziz, Meraj
AU  - Aziz M
AD  - Departments of Cancer and Cell Biology, Translational Genomics Research
      Institute, Phoenix, AZ 85004, USA.
FAU - Kassner, Michelle
AU  - Kassner M
AD  - Departments of Cancer and Cell Biology, Translational Genomics Research
      Institute, Phoenix, AZ 85004, USA.
FAU - Bryant, Kirsten L
AU  - Bryant KL
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Pierobon, Mariaelena
AU  - Pierobon M
AD  - Center for Applied Proteomics and Molecular Medicine, George Mason University,
      Manassas, VA 20110, USA.
FAU - Marayati, Raoud
AU  - Marayati R
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Kher, Swapnil
AU  - Kher S
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - George, Samuel D
AU  - George SD
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, NC 27599, USA.
FAU - Xu, Mai
AU  - Xu M
AD  - Divisions of Oncology, Department of Internal Medicine, Washington University
      School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA; Division of
      Medical Oncology, Alvin J. Siteman Cancer Center, Washington University School of
      Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.
FAU - Wang-Gillam, Andrea
AU  - Wang-Gillam A
AD  - Divisions of Oncology, Department of Internal Medicine, Washington University
      School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA; Division of
      Medical Oncology, Alvin J. Siteman Cancer Center, Washington University School of
      Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.
FAU - Samatar, Ahmed A
AU  - Samatar AA
AD  - Merck Research Laboratories, Boston, MA 02115, USA.
FAU - Maitra, Anirban
AU  - Maitra A
AD  - Departments of Pathology and Translational Molecular Pathology, University of
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Wennerberg, Krister
AU  - Wennerberg K
AD  - Institute for Molecular Medicine Finland, University of Helsinki, 00290 Helsinki,
      Finland.
FAU - Petricoin, Emanuel F 3rd
AU  - Petricoin EF 3rd
AD  - Center for Applied Proteomics and Molecular Medicine, George Mason University,
      Manassas, VA 20110, USA.
FAU - Yin, Hongwei H
AU  - Yin HH
AD  - Departments of Cancer and Cell Biology, Translational Genomics Research
      Institute, Phoenix, AZ 85004, USA.
FAU - Nelkin, Barry
AU  - Nelkin B
AD  - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore,
      MD 21287, USA.
FAU - Cox, Adrienne D
AU  - Cox AD
AD  - Curriculum in Genetics and Molecular Biology, University of North Carolina at
      Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, 
      University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA;
      Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel
      Hill, NC 27599, USA; Department of Radiation Oncology, University of North
      Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Yeh, Jen Jen
AU  - Yeh JJ
AD  - Curriculum in Genetics and Molecular Biology, University of North Carolina at
      Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, 
      University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA;
      Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel
      Hill, NC 27599, USA; Department of Surgery, University of North Carolina at
      Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Der, Channing J
AU  - Der CJ
AD  - Curriculum in Genetics and Molecular Biology, University of North Carolina at
      Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, 
      University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA;
      Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel
      Hill, NC 27599, USA. Electronic address: cjder@med.unc.edu.
LA  - eng
GR  - R21 CA179193/CA/NCI NIH HHS/United States
GR  - R01 CA042978/CA/NCI NIH HHS/United States
GR  - P30 CA016086/CA/NCI NIH HHS/United States
GR  - R01 CA175747/CA/NCI NIH HHS/United States
GR  - CA179193/CA/NCI NIH HHS/United States
GR  - T32 CA071341/CA/NCI NIH HHS/United States
GR  - CA42978/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151224
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Myc protein, mouse)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Extracellular Signal-Regulated MAP Kinases/genetics/*metabolism
MH  - MAP Kinase Signaling System/*genetics
MH  - Mice
MH  - Mitogen-Activated Protein Kinase Kinases/genetics/metabolism
MH  - Pancreatic Neoplasms/*genetics/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Proto-Oncogene Proteins c-myc/*genetics/metabolism
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Time
PMC - PMC4816652
MID - NIHMS744014
EDAT- 2016/01/05 06:00
MHDA- 2016/05/26 06:00
CRDT- 2016/01/04 06:00
PHST- 2014/03/28 00:00 [received]
PHST- 2015/04/06 00:00 [revised]
PHST- 2015/11/18 00:00 [accepted]
PHST- 2016/01/04 06:00 [entrez]
PHST- 2016/01/05 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - S1535-6108(15)00433-X [pii]
AID - 10.1016/j.ccell.2015.11.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015
      Dec 24.

PMID- 26777415
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development
      and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling.
PG  - 758-772
LID - S1535-6108(15)00381-5 [pii]
LID - 10.1016/j.ccell.2015.10.004 [doi]
AB  - Angiosarcoma/lymphangiosarcoma is a rare malignancy with poor prognosis. We
      generated a mouse model with inducible endothelial-cell-specific deletion of Tsc1
      to examine mTORC1 signaling in lymphangiosarcoma. Tsc1 loss increased retinal
      angiogenesis in neonates and led to endothelial proliferative lesions from
      vascular malformations to vascular tumors in adult mice. Sustained mTORC1
      signaling was required for lymphangiosarcoma development and maintenance.
      Increased VEGF expression in tumor cells was seen, and blocking autocrine VEGF
      signaling abolished vascular tumor development and growth. We also found
      significant correlations between mTORC1 activation and VEGF, HIF1alpha, and c-Myc
      expression in human angiosarcoma samples. These studies demonstrated critical
      mechanisms of aberrant mTORC1 activation in lymphangiosarcoma and validate the
      mice as a valuable model for further study.
FAU - Sun, Shaogang
AU  - Sun S
AD  - Department of Cancer Biology, College of Medicine, University of Cincinnati,
      Cincinnati, OH 45267, USA.
FAU - Chen, Song
AU  - Chen S
AD  - Department of Cancer Biology, College of Medicine, University of Cincinnati,
      Cincinnati, OH 45267, USA.
FAU - Liu, Fei
AU  - Liu F
AD  - Department of Biologic and Materials Sciences, University of Michigan, Ann Arbor,
      MI 48109, USA.
FAU - Wu, Haige
AU  - Wu H
AD  - Department of Cancer Biology, College of Medicine, University of Cincinnati,
      Cincinnati, OH 45267, USA.
FAU - McHugh, Jonathan
AU  - McHugh J
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Bergin, Ingrid L
AU  - Bergin IL
AD  - Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI 48109,
      USA.
FAU - Gupta, Anita
AU  - Gupta A
AD  - Department of Pathology, Cincinnati Children's Hospital Medical Center, College
      of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
FAU - Adams, Denise
AU  - Adams D
AD  - Department of Pediatrics, College of Medicine, University of Cincinnati,
      Cincinnati, OH 45267, USA.
FAU - Guan, Jun-Lin
AU  - Guan JL
AD  - Department of Cancer Biology, College of Medicine, University of Cincinnati,
      Cincinnati, OH 45267, USA. Electronic address: guanjl@uc.edu.
LA  - eng
GR  - R03 DE021718/DE/NIDCR NIH HHS/United States
GR  - R01 HL073394/HL/NHLBI NIH HHS/United States
GR  - HL073394/HL/NHLBI NIH HHS/United States
GR  - R01 AR062030/AR/NIAMS NIH HHS/United States
GR  - R01 CA150926/CA/NCI NIH HHS/United States
GR  - CA163493/CA/NCI NIH HHS/United States
GR  - R01 CA163493/CA/NCI NIH HHS/United States
GR  - AR062030/AR/NIAMS NIH HHS/United States
GR  - CA150926/CA/NCI NIH HHS/United States
GR  - DE021718/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hif1a protein, mouse)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (MYC protein, human)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Myc protein, mouse)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (tuberous sclerosis complex 1 protein)
RN  - 0 (vascular endothelial growth factor A, mouse)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology
MH  - Animals
MH  - *Autocrine Communication/drug effects
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic/genetics/*metabolism/pathology
MH  - Cells, Cultured
MH  - Endothelial Cells/drug effects/*enzymology/pathology
MH  - Enzyme Activation
MH  - Genotype
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/analysis/genetics/metabolism
MH  - Lymphangiosarcoma/drug therapy/genetics/*metabolism/pathology
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - Multiprotein Complexes/antagonists & inhibitors/*metabolism
MH  - Neoplasm Invasiveness
MH  - *Neovascularization, Pathologic
MH  - Phenotype
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins c-myc/analysis/genetics/metabolism
MH  - RNA Interference
MH  - Receptors, Vascular Endothelial Growth Factor/metabolism
MH  - Retinal Neovascularization/genetics/metabolism/pathology
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
MH  - Transfection
MH  - Tumor Burden
MH  - Tumor Suppressor Proteins/genetics/metabolism
MH  - Vascular Endothelial Growth Factor A/analysis/antagonists &
      inhibitors/*metabolism
PMC - PMC4828306
MID - NIHMS730887
EDAT- 2016/01/19 06:00
MHDA- 2016/04/19 06:00
CRDT- 2016/01/19 06:00
PHST- 2014/09/22 00:00 [received]
PHST- 2015/07/16 00:00 [revised]
PHST- 2015/10/08 00:00 [accepted]
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00381-5 [pii]
AID - 10.1016/j.ccell.2015.10.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):758-772. doi: 10.1016/j.ccell.2015.10.004.

PMID- 26678341
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal
      Cancer.
PG  - 815-829
LID - S1535-6108(15)00422-5 [pii]
LID - 10.1016/j.ccell.2015.11.001 [doi]
AB  - Hierarchical organization of tissues relies on stem cells, which either
      self-renew or produce committed progenitors predestined for lineage
      differentiation. Here we identify HOXA5 as an important repressor of intestinal
      stem cell fate in vivo and identify a reciprocal feedback between HOXA5 and Wnt
      signaling. HOXA5 is suppressed by the Wnt pathway to maintain stemness and
      becomes active only outside the intestinal crypt where it inhibits Wnt signaling 
      to enforce differentiation. In colon cancer, HOXA5 is downregulated, and its
      re-expression induces loss of the cancer stem cell phenotype, preventing tumor
      progression and metastasis. Tumor regression by HOXA5 induction can be triggered 
      by retinoids, which represent tangible means to treat colon cancer by eliminating
      cancer stem cells.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ordonez-Moran, Paloma
AU  - Ordonez-Moran P
AD  - Ecole Polytechnique Federale de Lausanne (EPFL), ISREC (Swiss Institute for
      Experimental Cancer Research), Lausanne 1015, Switzerland.
FAU - Dafflon, Caroline
AU  - Dafflon C
AD  - Ecole Polytechnique Federale de Lausanne (EPFL), ISREC (Swiss Institute for
      Experimental Cancer Research), Lausanne 1015, Switzerland.
FAU - Imajo, Masamichi
AU  - Imajo M
AD  - Laboratory of Bioimaging and Cell Signaling, Graduate School of Biostudies, Kyoto
      University, Sakyo-ku, Kyoto 606-8501, Japan; Department of Cell and Developmental
      Biology, Graduate School of Biostudies, Kyoto University, Sakyo-ku, Kyoto
      606-8502, Japan; JST, CREST, Chiyoda-ku, Tokyo 102-0075, Japan.
FAU - Nishida, Eisuke
AU  - Nishida E
AD  - Department of Cell and Developmental Biology, Graduate School of Biostudies,
      Kyoto University, Sakyo-ku, Kyoto 606-8502, Japan; JST, CREST, Chiyoda-ku, Tokyo 
      102-0075, Japan.
FAU - Huelsken, Joerg
AU  - Huelsken J
AD  - Ecole Polytechnique Federale de Lausanne (EPFL), ISREC (Swiss Institute for
      Experimental Cancer Research), Lausanne 1015, Switzerland. Electronic address:
      joerg.huelsken@epfl.ch.
LA  - eng
SI  - GEO/GSE74862
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HOXA5 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Hoxa5 protein, mouse)
RN  - 0 (Phosphoproteins)
RN  - 0 (Retinoids)
SB  - IM
CIN - Cancer Cell. 2015 Dec 14;28(6):683-5. PMID: 26678334
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Caco-2 Cells
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic/genetics/metabolism/pathology
MH  - Colorectal Neoplasms/drug therapy/genetics/*metabolism/pathology
MH  - Feedback, Physiological
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - HCT116 Cells
MH  - HT29 Cells
MH  - Homeodomain Proteins/genetics/*metabolism
MH  - Humans
MH  - Intestinal Mucosa/*metabolism/pathology
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplastic Stem Cells/drug effects/*metabolism/pathology
MH  - Phenotype
MH  - Phosphoproteins/genetics/*metabolism
MH  - RNA Interference
MH  - Retinoids/pharmacology
MH  - Time Factors
MH  - Tissue Culture Techniques
MH  - Transfection
MH  - Tumor Cells, Cultured
MH  - *Wnt Signaling Pathway/drug effects
OTO - NOTNLM
OT  - MYC
OT  - cancer stem cells
OT  - retinoids
OT  - beta-catenin
EDAT- 2015/12/19 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/12/19 06:00
PHST- 2014/04/15 00:00 [received]
PHST- 2015/08/11 00:00 [revised]
PHST- 2015/11/05 00:00 [accepted]
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00422-5 [pii]
AID - 10.1016/j.ccell.2015.11.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):815-829. doi: 10.1016/j.ccell.2015.11.001.

PMID- 26678340
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic
      Tumor Cells.
PG  - 785-799
LID - S1535-6108(15)00426-2 [pii]
LID - 10.1016/j.ccell.2015.11.005 [doi]
AB  - Polymorphonuclear neutrophils (PMNs) are largely considered to foster cancer
      development despite wielding an arsenal of cytotoxic agents. Using a mouse model 
      of PTEN-deficient uterine cancer, we describe a surprising inhibitory role for
      PMNs in epithelial carcinogenesis. By inducing tumor cell detachment from the
      basement membrane, PMNs impeded early-stage tumor growth and retarded malignant
      progression. Unexpectedly, PMN recruitment and tumor growth control occurred
      independently of lymphocytes and cellular senescence and instead ensued as part
      of the tumor's intrinsic inflammatory response to hypoxia. In humans, a PMN gene 
      signature correlated with improved survival in several cancer subtypes, including
      PTEN-deficient uterine cancer. These findings provide insight into
      tumor-associated PMNs and reveal a context-specific capacity for PMNs to directly
      combat tumorigenesis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Blaisdell, Adam
AU  - Blaisdell A
AD  - Department of Pathology, NYU School of Medicine, New York, NY 10016, USA.
FAU - Crequer, Amandine
AU  - Crequer A
AD  - Department of Pathology, NYU School of Medicine, New York, NY 10016, USA.
FAU - Columbus, Devin
AU  - Columbus D
AD  - Department of Pathology, NYU School of Medicine, New York, NY 10016, USA.
FAU - Daikoku, Takiko
AU  - Daikoku T
AD  - Division of Reproductive Sciences, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH 45229, USA.
FAU - Mittal, Khush
AU  - Mittal K
AD  - Department of Pathology, NYU School of Medicine, New York, NY 10016, USA.
FAU - Dey, Sudhansu K
AU  - Dey SK
AD  - Division of Reproductive Sciences, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH 45229, USA.
FAU - Erlebacher, Adrian
AU  - Erlebacher A
AD  - Department of Pathology, NYU School of Medicine, New York, NY 10016, USA; NYU
      Cancer Institute, NYU Langone Medical Center, New York, NY 10016, USA. Electronic
      address: adrian.erlebacher@nyumc.org.
LA  - eng
SI  - GEO/GSE73541
GR  - R01CA168755/CA/NCI NIH HHS/United States
GR  - P30 CA016087/CA/NCI NIH HHS/United States
GR  - P01CA7783/CA/NCI NIH HHS/United States
GR  - F30 CA165385/CA/NCI NIH HHS/United States
GR  - P01 CA077839/CA/NCI NIH HHS/United States
GR  - R01 HD068524/HD/NICHD NIH HHS/United States
GR  - F30CA165385/CA/NCI NIH HHS/United States
GR  - R01 CA168755/CA/NCI NIH HHS/United States
GR  - HD068524/HD/NICHD NIH HHS/United States
GR  - P30CA016087/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Inflammation Mediators)
RN  - 0 (Myd88 protein, mouse)
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (Receptors, Colony-Stimulating Factor)
RN  - 0 (Receptors, Interleukin-8B)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (Pten protein, mouse)
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation
MH  - Carcinoma,
      Endometrioid/enzymology/genetics/immunology/mortality/pathology/*prevention &
      control
MH  - Cell Adhesion
MH  - Cell Hypoxia
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Chemotaxis
MH  - Computational Biology
MH  - Databases, Genetic
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Transfer Techniques
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Myeloid Differentiation Factor 88/deficiency/genetics
MH  - Neoplasm Staging
MH  - Neutrophil Activation
MH  - Neutrophil Infiltration
MH  - Neutrophils/*immunology/metabolism
MH  - Ovarian Neoplasms/enzymology/genetics/immunology/mortality/pathology/*prevention 
      & control
MH  - Ovariectomy
MH  - PTEN Phosphohydrolase/deficiency/genetics
MH  - *Phagocytosis
MH  - Receptors, Colony-Stimulating Factor/deficiency/genetics
MH  - Receptors, Interleukin-8B/genetics/metabolism
MH  - Survival Analysis
MH  - Time Factors
MH  - Tumor Burden
MH  - *Tumor Microenvironment
MH  - Uterus/enzymology/*immunology/pathology
PMC - PMC4698345
MID - NIHMS743428
EDAT- 2015/12/19 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/03/11 00:00 [received]
PHST- 2015/08/20 00:00 [revised]
PHST- 2015/11/17 00:00 [accepted]
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00426-2 [pii]
AID - 10.1016/j.ccell.2015.11.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):785-799. doi: 10.1016/j.ccell.2015.11.005.

PMID- 26678339
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
PG  - 773-784
LID - S1535-6108(15)00427-4 [pii]
LID - 10.1016/j.ccell.2015.11.006 [doi]
AB  - Heterozygous mutation of IDH1 in cancers modifies IDH1 enzymatic activity,
      reprogramming metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG).
      Here, we found that 2-HG depletion did not inhibit growth of several IDH1 mutant 
      solid cancer types. To identify other metabolic therapeutic targets, we
      systematically profiled metabolites in endogenous IDH1 mutant cancer cells after 
      mutant IDH1 inhibition and discovered a profound vulnerability to depletion of
      the coenzyme NAD+. Mutant IDH1 lowered NAD+ levels by downregulating the NAD+
      salvage pathway enzyme nicotinate phosphoribosyltransferase (Naprt1), sensitizing
      to NAD+ depletion via concomitant nicotinamide phosphoribosyltransferase (NAMPT) 
      inhibition. NAD+ depletion activated the intracellular energy sensor AMPK,
      triggered autophagy, and resulted in cytotoxicity. Thus, we identify NAD+
      depletion as a metabolic susceptibility of IDH1 mutant cancers.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Tateishi, Kensuke
AU  - Tateishi K
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Wakimoto, Hiroaki
AU  - Wakimoto H
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Iafrate, A John
AU  - Iafrate AJ
AD  - Department of Pathology, Translational Neuro-Oncology Laboratory, Massachusetts
      General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Tanaka, Shota
AU  - Tanaka S
AD  - Divisions of Neuro-Oncology and Hematology/Oncology, Department of Neurology,
      Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard 
      Medical School, Boston, MA 02114, USA.
FAU - Loebel, Franziska
AU  - Loebel F
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Lelic, Nina
AU  - Lelic N
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Wiederschain, Dmitri
AU  - Wiederschain D
AD  - Sanofi Oncology, Cambridge, MA 02139, USA.
FAU - Bedel, Olivier
AU  - Bedel O
AD  - Sanofi Oncology, Cambridge, MA 02139, USA.
FAU - Deng, Gejing
AU  - Deng G
AD  - Sanofi Oncology, Cambridge, MA 02139, USA.
FAU - Zhang, Bailin
AU  - Zhang B
AD  - Sanofi Oncology, Cambridge, MA 02139, USA.
FAU - He, Timothy
AU  - He T
AD  - Sanofi Oncology, Cambridge, MA 02139, USA.
FAU - Shi, Xu
AU  - Shi X
AD  - Cardiovascular Research Center, Cardiology Division, Department of Medicine,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Gerszten, Robert E
AU  - Gerszten RE
AD  - Cardiovascular Research Center, Cardiology Division, Department of Medicine,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Zhang, Yiyun
AU  - Zhang Y
AD  - Cardiovascular Research Center, Cardiology Division, Department of Medicine,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Yeh, Jing-Ruey J
AU  - Yeh JJ
AD  - Cardiovascular Research Center, Cardiology Division, Department of Medicine,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Curry, William T
AU  - Curry WT
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Zhao, Dan
AU  - Zhao D
AD  - Divisions of Neuro-Oncology and Hematology/Oncology, Department of Neurology,
      Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard 
      Medical School, Boston, MA 02114, USA.
FAU - Sundaram, Sudhandra
AU  - Sundaram S
AD  - Divisions of Neuro-Oncology and Hematology/Oncology, Department of Neurology,
      Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard 
      Medical School, Boston, MA 02114, USA.
FAU - Nigim, Fares
AU  - Nigim F
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Koerner, Mara V A
AU  - Koerner MVA
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Ho, Quan
AU  - Ho Q
AD  - Department of Pathology, Translational Neuro-Oncology Laboratory, Massachusetts
      General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Fisher, David E
AU  - Fisher DE
AD  - Department of Dermatology, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Roider, Elisabeth M
AU  - Roider EM
AD  - Department of Dermatology, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Kemeny, Lajos V
AU  - Kemeny LV
AD  - Department of Dermatology, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Samuels, Yardena
AU  - Samuels Y
AD  - Weizmann Institute of Science, Rehovot 7610001, Israel.
FAU - Flaherty, Keith T
AU  - Flaherty KT
AD  - Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical 
      School, Boston, MA 02114, USA.
FAU - Batchelor, Tracy T
AU  - Batchelor TT
AD  - Divisions of Neuro-Oncology and Hematology/Oncology, Department of Neurology,
      Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard 
      Medical School, Boston, MA 02114, USA.
FAU - Chi, Andrew S
AU  - Chi AS
AD  - Divisions of Neuro-Oncology and Hematology/Oncology, Department of Neurology,
      Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard 
      Medical School, Boston, MA 02114, USA. Electronic address: chia01@nyumc.org.
FAU - Cahill, Daniel P
AU  - Cahill DP
AD  - Department of Neurosurgery, Translational Neuro-Oncology Laboratory,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
      Electronic address: cahill@mgh.harvard.edu.
LA  - eng
SI  - GEO/GSE73270
GR  - R01 CA140188/CA/NCI NIH HHS/United States
GR  - K24 CA125440/CA/NCI NIH HHS/United States
GR  - NIH K24 CA125440-06/CA/NCI NIH HHS/United States
GR  - R01 AR043369/AR/NIAMS NIH HHS/United States
GR  - NIHP50CA165962-01A1/CA/NCI NIH HHS/United States
GR  - NIH R01CA140188/CA/NCI NIH HHS/United States
GR  - P50 CA165962/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cytokines)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Glutarates)
RN  - 0U46U6E8UK (NAD)
RN  - 2889-31-8 (alpha-hydroxyglutarate)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - EC 2.4.2.- (Pentosyltransferases)
RN  - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
RN  - EC 2.4.2.12 (nicotinamide phosphoribosyltransferase, human)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - EC 6.3.4.21 (nicotinate phosphoribosyltransferase)
SB  - IM
CIN - Nat Rev Cancer. 2016 Feb;16(2):70. PMID: 26743031
MH  - AMP-Activated Protein Kinases/metabolism
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Autophagy/drug effects
MH  - Brain Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Cell Proliferation/drug effects
MH  - Cytokines/*antagonists & inhibitors/metabolism
MH  - Energy Metabolism/drug effects
MH  - Enzyme Activation
MH  - Enzyme Inhibitors/*pharmacology
MH  - Female
MH  - Glioblastoma/*drug therapy/enzymology/genetics/pathology
MH  - Glutarates/metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Isocitrate Dehydrogenase/antagonists & inhibitors/*genetics/metabolism
MH  - Metabolomics/methods
MH  - Mice, SCID
MH  - Molecular Targeted Therapy
MH  - *Mutation
MH  - NAD/*deficiency
MH  - Nicotinamide Phosphoribosyltransferase/*antagonists & inhibitors/metabolism
MH  - Pentosyltransferases/metabolism
MH  - Signal Transduction/drug effects
MH  - Spheroids, Cellular
MH  - Time Factors
MH  - Transfection
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC4684594
MID - NIHMS740445
EDAT- 2015/12/19 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/02/25 00:00 [received]
PHST- 2015/07/09 00:00 [revised]
PHST- 2015/11/14 00:00 [accepted]
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00427-4 [pii]
AID - 10.1016/j.ccell.2015.11.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):773-784. doi: 10.1016/j.ccell.2015.11.006.

PMID- 26678338
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary 
      Epithelial Cells and Breast Cancer.
PG  - 743-757
LID - S1535-6108(15)00390-6 [pii]
LID - 10.1016/j.ccell.2015.10.013 [doi]
AB  - In several developmental lineages, an increase in MYC expression drives the
      transition from quiescent stem cells to transit-amplifying cells. We show that
      MYC activates a stereotypic transcriptional program of genes involved in cell
      growth in mammary epithelial cells. This change in gene expression indirectly
      inhibits the YAP/TAZ co-activators, which maintain the clonogenic potential of
      these cells. We identify a phospholipase of the mitochondrial outer membrane,
      PLD6, as the mediator of MYC activity. MYC-dependent growth strains cellular
      energy resources and stimulates AMP-activated kinase (AMPK). PLD6 alters
      mitochondrial fusion and fission dynamics downstream of MYC. This change
      activates AMPK, which in turn inhibits YAP/TAZ. Mouse models and human
      pathological data show that MYC enhances AMPK and suppresses YAP/TAZ activity in 
      mammary tumors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - von Eyss, Bjorn
AU  - von Eyss B
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany.
FAU - Jaenicke, Laura A
AU  - Jaenicke LA
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany.
FAU - Kortlever, Roderik M
AU  - Kortlever RM
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK; Department of Pathology and Helen Diller Family
      Comprehensive Cancer Center, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Royla, Nadine
AU  - Royla N
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine, Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
FAU - Wiese, Katrin E
AU  - Wiese KE
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany.
FAU - Letschert, Sebastian
AU  - Letschert S
AD  - Department of Biotechnology and Biophysics, Biocenter, University of Wurzburg, Am
      Hubland, 97074 Wurzburg, Germany.
FAU - McDuffus, Leigh-Anne
AU  - McDuffus LA
AD  - Histopathology and ISH Core Facility, Cancer Research UK Cambridge Research
      Institute, Cambridge CB2 0RE, UK.
FAU - Sauer, Markus
AU  - Sauer M
AD  - Department of Biotechnology and Biophysics, Biocenter, University of Wurzburg, Am
      Hubland, 97074 Wurzburg, Germany.
FAU - Rosenwald, Andreas
AU  - Rosenwald A
AD  - Institute of Pathology, University of Wurzburg, Josef-Schneider-Strasse 2, 97080 
      Wurzburg, Germany; Comprehensive Cancer Center Mainfranken, University of
      Wurzburg, Josef-Schneider-Strasse 6, 97080 Wurzburg, Germany.
FAU - Evan, Gerard I
AU  - Evan GI
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK; Department of Pathology and Helen Diller Family
      Comprehensive Cancer Center, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Kempa, Stefan
AU  - Kempa S
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine, Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
FAU - Eilers, Martin
AU  - Eilers M
AD  - Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074
      Wurzburg, Germany; Comprehensive Cancer Center Mainfranken, University of
      Wurzburg, Josef-Schneider-Strasse 6, 97080 Wurzburg, Germany. Electronic address:
      martin.eilers@biozentrum.uni-wuerzburg.de.
LA  - eng
SI  - GEO/GSE66263
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (MYC protein, human)
RN  - 0 (Phosphoproteins)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (WWTR1 protein, human)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - EC 3.1.4.4 (Phospholipase D)
SB  - IM
MH  - AMP-Activated Protein Kinases/metabolism
MH  - Adaptor Proteins, Signal Transducing/genetics/*metabolism
MH  - Animals
MH  - Breast Neoplasms/genetics/*metabolism/pathology
MH  - Cell Line
MH  - Cell Lineage
MH  - Computational Biology
MH  - Databases, Genetic
MH  - Enzyme Activation
MH  - Enzyme Induction
MH  - Epithelial Cells/*metabolism/pathology
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Mammary Glands, Human/*metabolism/pathology
MH  - Mice, Transgenic
MH  - Mitochondria/*metabolism/pathology
MH  - *Mitochondrial Dynamics
MH  - Phenotype
MH  - Phospholipase D/biosynthesis/genetics
MH  - Phosphoproteins/genetics/*metabolism
MH  - Phosphorylation
MH  - Proto-Oncogene Proteins c-myc/genetics/*metabolism
MH  - RNA Interference
MH  - Signal Transduction
MH  - Time Factors
MH  - Transfection
EDAT- 2015/12/19 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/06/08 00:00 [received]
PHST- 2015/08/31 00:00 [revised]
PHST- 2015/10/20 00:00 [accepted]
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00390-6 [pii]
AID - 10.1016/j.ccell.2015.10.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):743-757. doi: 10.1016/j.ccell.2015.10.013.

PMID- 26678337
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Immunological Effects of Conventional Chemotherapy and Targeted Anticancer
      Agents.
PG  - 690-714
LID - S1535-6108(15)00389-X [pii]
LID - 10.1016/j.ccell.2015.10.012 [doi]
AB  - The tremendous clinical success of checkpoint blockers illustrates the potential 
      of reestablishing latent immunosurveillance for cancer therapy. Although largely 
      neglected in the clinical practice, accumulating evidence indicates that the
      efficacy of conventional and targeted anticancer agents does not only involve
      direct cytostatic/cytotoxic effects, but also relies on the (re)activation of
      tumor-targeting immune responses. Chemotherapy can promote such responses by
      increasing the immunogenicity of malignant cells, or by inhibiting
      immunosuppressive circuitries that are established by developing neoplasms. These
      immunological "side" effects of chemotherapy are desirable, and their in-depth
      comprehension will facilitate the design of novel combinatorial regimens with
      improved clinical efficacy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Galluzzi, Lorenzo
AU  - Galluzzi L
AD  - Equipe 11 Labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      75006 Paris, France; INSERM, U1138, 75006 Paris, France; Universite Paris
      Descartes/Paris V, Sorbonne Paris Cite, 75006 Paris, France; Universite Pierre et
      Marie Curie/Paris VI, 75006 Paris, France; Gustave Roussy Comprehensive Cancer
      Institute, 94805 Villejuif, France.
FAU - Buque, Aitziber
AU  - Buque A
AD  - Equipe 11 Labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      75006 Paris, France; INSERM, U1138, 75006 Paris, France; Universite Paris
      Descartes/Paris V, Sorbonne Paris Cite, 75006 Paris, France; Universite Pierre et
      Marie Curie/Paris VI, 75006 Paris, France; Gustave Roussy Comprehensive Cancer
      Institute, 94805 Villejuif, France.
FAU - Kepp, Oliver
AU  - Kepp O
AD  - Equipe 11 Labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      75006 Paris, France; INSERM, U1138, 75006 Paris, France; Universite Paris
      Descartes/Paris V, Sorbonne Paris Cite, 75006 Paris, France; Universite Pierre et
      Marie Curie/Paris VI, 75006 Paris, France; Metabolomics and Cell Biology
      Platforms, Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif,
      France.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AD  - Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France; INSERM,
      U1015, 94805 Villejuif, France; Center of Clinical Investigations in Biotherapies
      of Cancer (CICBT) 507, 94805 Villejuif, France; Universite Paris Sud/Paris XI,
      94270 Le Kremlin-Bicetre, France. Electronic address:
      laurence.zitvogel@gustaveroussy.fr.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - Equipe 11 Labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      75006 Paris, France; INSERM, U1138, 75006 Paris, France; Universite Paris
      Descartes/Paris V, Sorbonne Paris Cite, 75006 Paris, France; Universite Pierre et
      Marie Curie/Paris VI, 75006 Paris, France; Metabolomics and Cell Biology
      Platforms, Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif,
      France; Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, 75015 Paris, 
      France; Karolinska Institute, Department of Women's and Children's Health,
      Karolinska University Hospital, 17176 Stockholm, Sweden. Electronic address:
      kroemer@orange.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Immunologic Factors/adverse effects/*therapeutic use
MH  - Lymphocytes, Tumor-Infiltrating/drug effects/immunology/metabolism
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy/immunology/metabolism/pathology
MH  - Signal Transduction/drug effects
MH  - Treatment Outcome
MH  - Tumor Escape/drug effects
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - checkpoint blockade
OT  - immune contexture
OT  - immunogenic cell death
OT  - natural killer cells
OT  - tumor-associated macrophages
OT  - tumor-infiltrating lymphocytes
EDAT- 2015/12/19 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/07/28 00:00 [received]
PHST- 2015/10/05 00:00 [revised]
PHST- 2015/10/23 00:00 [accepted]
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00389-X [pii]
AID - 10.1016/j.ccell.2015.10.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):690-714. doi: 10.1016/j.ccell.2015.10.012.

PMID- 26678336
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Immunotherapy Not Working? Check Your Microbiota.
PG  - 687-689
LID - S1535-6108(15)00431-6 [pii]
LID - 10.1016/j.ccell.2015.11.010 [doi]
AB  - Gut microbes have ascended to prominence as key modulators of host immunity,
      raising the possibility that they could influence the outcome of cancer
      immunotherapy. Two recent studies address this question by identifying specific
      gut-resident bacteria as drivers of checkpoint blockade immunotherapy in
      pre-clinical tumor models.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - West, Nathan R
AU  - West NR
AD  - Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7LF, UK.
FAU - Powrie, Fiona
AU  - Powrie F
AD  - Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7LF, UK;
      Translational Gastroenterology Unit, Experimental Medicine Division, University
      of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. Electronic address:
      fiona.powrie@kennedy.ox.ac.uk.
LA  - eng
GR  - 095688/Wellcome Trust/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Anthracyclines)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Receptors, Retinoic Acid)
SB  - IM
CON - Nat Genet. 2015 Sep;47(9):1079-84. PMID: 26237429
CON - Science. 2015 Nov 27;350(6264):1084-9. PMID: 26541606
MH  - Animals
MH  - Anthracyclines/*adverse effects
MH  - Antibiotics, Antineoplastic/*adverse effects
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - B7-H1 Antigen/*immunology
MH  - Bifidobacterium/*immunology
MH  - Gastrointestinal Microbiome/*immunology
MH  - Humans
MH  - Melanoma/*immunology/*therapy
MH  - Receptors, Retinoic Acid/*genetics
MH  - Skin Neoplasms/*immunology/*therapy
MH  - Ventricular Dysfunction, Left/*genetics
EDAT- 2015/12/19 06:00
MHDA- 2016/04/09 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
AID - S1535-6108(15)00431-6 [pii]
AID - 10.1016/j.ccell.2015.11.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):687-689. doi: 10.1016/j.ccell.2015.11.010.

PMID- 26678335
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Getting Tumor Dendritic Cells to Engage the Dead.
PG  - 685-687
LID - S1535-6108(15)00430-4 [pii]
LID - 10.1016/j.ccell.2015.11.009 [doi]
AB  - The immunogenic effects of chemotherapy rely on effective activation of dendritic
      cells to present antigen to tumor-specific T cells. However, the signals that
      govern how dendritic cells seek out dying cancer cells to initiate this process
      are poorly understood. A recent study by Vacchelli et al. provides important
      insight.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Cucolo, Lisa
AU  - Cucolo L
AD  - Abramson Family Cancer Research Institute, Department of Radiation Oncology,
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, 
      USA.
FAU - Minn, Andy J
AU  - Minn AJ
AD  - Abramson Family Cancer Research Institute, Department of Radiation Oncology,
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, 
      USA. Electronic address: andyminn@mail.med.upenn.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Anthracyclines)
RN  - 0 (Receptors, Formyl Peptide)
SB  - IM
CON - Science. 2015 Nov 20;350(6263):972-8. PMID: 26516201
MH  - Animals
MH  - Anthracyclines/*therapeutic use
MH  - Female
MH  - Humans
MH  - Neoplasms/*drug therapy/*immunology
MH  - Receptors, Formyl Peptide/*physiology
EDAT- 2015/12/19 06:00
MHDA- 2016/04/09 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
AID - S1535-6108(15)00430-4 [pii]
AID - 10.1016/j.ccell.2015.11.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):685-687. doi: 10.1016/j.ccell.2015.11.009.

PMID- 26678334
OWN - NLM
STAT- MEDLINE
DCOM- 20160419
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Stemming Colorectal Cancer Growth and Metastasis: HOXA5 Forces Cancer Stem Cells 
      to Differentiate.
PG  - 683-685
LID - S1535-6108(15)00425-0 [pii]
LID - 10.1016/j.ccell.2015.11.004 [doi]
AB  - Wnt signaling drives colorectal cancer stem cells, but effective therapeutics
      targeting these cells and their signaling pathways are lacking. In this issue of 
      Cancer Cell, Ordonez-Moran and colleagues describe a promising therapeutic
      intervention for colorectal cancers that selectively induces cancer stem cell
      differentiation through HOXA5 expression and Wnt signaling inhibition.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Tan, Si Hui
AU  - Tan SH
AD  - Institute of Medical Biology, 8A Biomedical Grove, 06-06 Immunos, 138648
      Singapore, Singapore.
FAU - Barker, Nick
AU  - Barker N
AD  - Institute of Medical Biology, 8A Biomedical Grove, 06-06 Immunos, 138648
      Singapore, Singapore; MRC Centre for Regenerative Medicine, The University of
      Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK; Department of
      Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 
      117596 Singapore, Singapore. Electronic address:
      nicholas.barker@imb.a-star.edu.sg.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Phosphoproteins)
SB  - IM
CON - Cancer Cell. 2015 Dec 14;28(6):815-29. PMID: 26678341
MH  - Animals
MH  - Colorectal Neoplasms/*metabolism
MH  - Female
MH  - Homeodomain Proteins/*metabolism
MH  - Humans
MH  - Intestinal Mucosa/*metabolism
MH  - Male
MH  - Neoplastic Stem Cells/*metabolism
MH  - Phosphoproteins/*metabolism
MH  - *Wnt Signaling Pathway
EDAT- 2015/12/19 06:00
MHDA- 2016/04/20 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/20 06:00 [medline]
AID - S1535-6108(15)00425-0 [pii]
AID - 10.1016/j.ccell.2015.11.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):683-685. doi: 10.1016/j.ccell.2015.11.004.

PMID- 26678333
OWN - NLM
STAT- MEDLINE
DCOM- 20160419
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Take It Down a NOTCH in Forebrain Tumors.
PG  - 681-682
LID - S1535-6108(15)00429-8 [pii]
LID - 10.1016/j.ccell.2015.11.008 [doi]
AB  - In this issue of Cancer Cell, Giachino and colleagues, employing various
      approaches, describe a tumor suppressor function for Notch signaling in forebrain
      tumors and suggest that decreased Notch activity could be a key molecular event
      in supratentorial primitive neuroectodermal tumors (sPNET).
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Oldrini, Barbara
AU  - Oldrini B
AD  - Cancer Cell Biology Programme, Seve Ballesteros Foundation Brain Tumor Group,
      Centro Nacional de Investigaciones Oncologicas, CNIO, 28029 Madrid, Spain.
FAU - Schuhmacher, Alberto J
AU  - Schuhmacher AJ
AD  - Cancer Cell Biology Programme, Seve Ballesteros Foundation Brain Tumor Group,
      Centro Nacional de Investigaciones Oncologicas, CNIO, 28029 Madrid, Spain.
FAU - Squatrito, Massimo
AU  - Squatrito M
AD  - Cancer Cell Biology Programme, Seve Ballesteros Foundation Brain Tumor Group,
      Centro Nacional de Investigaciones Oncologicas, CNIO, 28029 Madrid, Spain.
      Electronic address: msquatrito@cnio.es.
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptors, Notch)
RN  - 0 (Tumor Suppressor Proteins)
SB  - IM
CON - Cancer Cell. 2015 Dec 14;28(6):730-42. PMID: 26669487
MH  - Animals
MH  - Brain Neoplasms/*metabolism
MH  - Glioma/*metabolism
MH  - Humans
MH  - Neoplastic Stem Cells/*metabolism
MH  - Neural Stem Cells/*metabolism
MH  - Prosencephalon/*metabolism
MH  - Receptors, Notch/*metabolism
MH  - *Signal Transduction
MH  - Tumor Suppressor Proteins/*metabolism
EDAT- 2015/12/19 06:00
MHDA- 2016/04/20 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/20 06:00 [medline]
AID - S1535-6108(15)00429-8 [pii]
AID - 10.1016/j.ccell.2015.11.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):681-682. doi: 10.1016/j.ccell.2015.11.008.

PMID- 26678332
OWN - NLM
STAT- MEDLINE
DCOM- 20160419
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Glioma Stem-like Cells Keep Their H3.3 Variant Levels at Bay.
PG  - 679-680
LID - S1535-6108(15)00432-8 [pii]
LID - 10.1016/j.ccell.2015.12.001 [doi]
AB  - Pediatric glioblastomas (GBMs) commonly harbor mutations in histone variant H3.3,
      while adult GBMs do not. In this issue of Cancer Cell, Gallo and colleagues
      demonstrate that adult GBM stem-like cells repress H3.3 expression to maintain
      self-renewal properties.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Becher, Oren J
AU  - Becher OJ
AD  - Division of Pediatric Hematology-Oncology, Duke University Medical Center,
      Durham, NC 27710, USA; Preston Robert Tisch Brain Tumor Center, Duke University
      Medical Center, Durham, NC 27710, USA. Electronic address: oren.becher@duke.edu.
FAU - Holland, Eric C
AU  - Holland EC
AD  - Division of Human Biology, Solid Tumor and Translational Research, Fred
      Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Alvord Brain Tumor
      Center, University of Washington, Seattle, WA 98104, USA. Electronic address:
      eholland@fhcrc.org.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Histones)
SB  - IM
CON - Cancer Cell. 2015 Dec 14;28(6):715-29. PMID: 26626085
MH  - Animals
MH  - Brain Neoplasms/*metabolism
MH  - *Cell Self Renewal
MH  - *Chromatin Assembly and Disassembly
MH  - DNA-Binding Proteins/*metabolism
MH  - Glioblastoma/*metabolism
MH  - Histones/*metabolism
MH  - Humans
MH  - Neoplastic Stem Cells/*metabolism
EDAT- 2015/12/19 06:00
MHDA- 2016/04/20 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/04/20 06:00 [medline]
AID - S1535-6108(15)00432-8 [pii]
AID - 10.1016/j.ccell.2015.12.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):679-680. doi: 10.1016/j.ccell.2015.12.001.

PMID- 26669487
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes.
PG  - 730-742
LID - S1535-6108(15)00385-2 [pii]
LID - 10.1016/j.ccell.2015.10.008 [doi]
AB  - In the brain, Notch signaling maintains normal neural stem cells, but also brain 
      cancer stem cells, indicating an oncogenic role. Here, we identify an unexpected 
      tumor suppressor function for Notch in forebrain tumor subtypes. Genetic
      inactivation of RBP-Jkappa, a key Notch mediator, or Notch1 and Notch2 receptors 
      accelerates PDGF-driven glioma growth in mice. Conversely, genetic activation of 
      the Notch pathway reduces glioma growth and increases survival. In humans, high
      Notch activity strongly correlates with distinct glioma subtypes, increased
      patient survival, and lower tumor grade. Additionally, simultaneous inactivation 
      of RBP-Jkappa and p53 induces primitive neuroectodermal-like tumors in mice.
      Hence, Notch signaling cooperates with p53 to restrict cell proliferation and
      tumor growth in mouse models of human brain tumors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Giachino, Claudio
AU  - Giachino C
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel,
      Switzerland. Electronic address: claudio.giachino@unibas.ch.
FAU - Boulay, Jean-Louis
AU  - Boulay JL
AD  - Department of Biomedicine, University Hospital Basel, Spitalstrasse 21, 4031
      Basel, Switzerland.
FAU - Ivanek, Robert
AU  - Ivanek R
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel,
      Switzerland.
FAU - Alvarado, Alvaro
AU  - Alvarado A
AD  - Department of Cellular and Molecular Medicine, Lerner Research Institute,
      Cleveland Clinic, 9500 Euclid Avenue, NC 10, Cleveland, OH 44195, USA.
FAU - Tostado, Cristobal
AU  - Tostado C
AD  - Department of Biomedicine, University Hospital Basel, Spitalstrasse 21, 4031
      Basel, Switzerland.
FAU - Lugert, Sebastian
AU  - Lugert S
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel,
      Switzerland.
FAU - Tchorz, Jan
AU  - Tchorz J
AD  - Department of Biomedicine, University of Basel, Kingelbergstrasse 50-70, 4056
      Basel, Switzerland.
FAU - Coban, Mustafa
AU  - Coban M
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel,
      Switzerland.
FAU - Mariani, Luigi
AU  - Mariani L
AD  - Department of Biomedicine, University Hospital Basel, Spitalstrasse 21, 4031
      Basel, Switzerland.
FAU - Bettler, Bernhard
AU  - Bettler B
AD  - Department of Biomedicine, University of Basel, Kingelbergstrasse 50-70, 4056
      Basel, Switzerland.
FAU - Lathia, Justin
AU  - Lathia J
AD  - Department of Cellular and Molecular Medicine, Lerner Research Institute,
      Cleveland Clinic, 9500 Euclid Avenue, NC 10, Cleveland, OH 44195, USA.
FAU - Frank, Stephan
AU  - Frank S
AD  - Division of Neuropathology, Institute of Pathology, University of Basel,
      Schoenbeinstrasse 40, 4031 Basel, Switzerland.
FAU - Pfister, Stefan
AU  - Pfister S
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69121 
      Heidelberg, Germany.
FAU - Kool, Marcel
AU  - Kool M
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69121 
      Heidelberg, Germany.
FAU - Taylor, Verdon
AU  - Taylor V
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel,
      Switzerland. Electronic address: verdon.taylor@unibas.ch.
LA  - eng
SI  - GEO/GSE64230
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151205
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Hes5 protein, mouse)
RN  - 0 (Immunoglobulin J Recombination Signal Sequence-Binding Protein)
RN  - 0 (Notch1 protein, mouse)
RN  - 0 (Notch2 protein, mouse)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (Proto-Oncogene Proteins c-sis)
RN  - 0 (Rbpj protein, mouse)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Receptor, Notch2)
RN  - 0 (Receptors, Notch)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Repressor Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (platelet-derived growth factor A)
SB  - IM
CIN - Cancer Cell. 2015 Dec 14;28(6):681-2. PMID: 26678333
MH  - Animals
MH  - Basic Helix-Loop-Helix Transcription Factors/genetics/metabolism
MH  - Brain Neoplasms/genetics/*metabolism/mortality/pathology
MH  - Cell Proliferation
MH  - Databases, Genetic
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Transfer Techniques
MH  - Glioma/genetics/*metabolism/mortality/pathology
MH  - Humans
MH  - Immunoglobulin J Recombination Signal Sequence-Binding
      Protein/genetics/metabolism
MH  - Infusions, Intraventricular
MH  - Kaplan-Meier Estimate
MH  - Mice, Knockout
MH  - Neoplasm Grading
MH  - Neoplastic Stem Cells/*metabolism/pathology
MH  - Neural Stem Cells/*metabolism/pathology
MH  - Phenotype
MH  - Platelet-Derived Growth Factor/administration & dosage
MH  - Prosencephalon/*metabolism/pathology
MH  - Proto-Oncogene Proteins c-sis/genetics/metabolism
MH  - Receptor, Notch1/genetics/metabolism
MH  - Receptor, Notch2/genetics/metabolism
MH  - Receptors, Notch/genetics/*metabolism
MH  - Recombinant Proteins/administration & dosage
MH  - Repressor Proteins/genetics/metabolism
MH  - *Signal Transduction
MH  - Time Factors
MH  - Tumor Burden
MH  - Tumor Suppressor Protein p53/genetics/metabolism
MH  - Tumor Suppressor Proteins/genetics/*metabolism
OTO - NOTNLM
OT  - Hes5
OT  - Notch signaling
OT  - brain tumor
OT  - glioma
OT  - primitive neuroectodermal tumor
EDAT- 2015/12/17 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/12/17 06:00
PHST- 2015/04/27 00:00 [received]
PHST- 2015/08/06 00:00 [revised]
PHST- 2015/10/16 00:00 [accepted]
PHST- 2015/12/17 06:00 [entrez]
PHST- 2015/12/17 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00385-2 [pii]
AID - 10.1016/j.ccell.2015.10.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):730-742. doi: 10.1016/j.ccell.2015.10.008. Epub
      2015 Dec 5.

PMID- 28843280
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to
      Drive Resistance of p53-Defective Tumors to Chemotherapy.
PG  - 831
LID - S1535-6108(15)00424-9 [pii]
LID - 10.1016/j.ccell.2015.11.003 [doi]
FAU - Cannell, Ian G
AU  - Cannell IG
FAU - Merrick, Karl A
AU  - Merrick KA
FAU - Morandell, Sandra
AU  - Morandell S
FAU - Zhu, Chang-Qi
AU  - Zhu CQ
FAU - Braun, Christian J
AU  - Braun CJ
FAU - Grant, Robert A
AU  - Grant RA
FAU - Cameron, Eleanor R
AU  - Cameron ER
FAU - Tsao, Ming-Sound
AU  - Tsao MS
FAU - Hemann, Michael T
AU  - Hemann MT
FAU - Yaffe, Michael B
AU  - Yaffe MB
LA  - eng
PT  - Published Erratum
DEP - 20151214
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2015/12/14 00:00
MHDA- 2015/12/14 00:01
CRDT- 2017/08/28 06:00
PHST- 2017/08/28 06:00 [entrez]
PHST- 2015/12/14 00:00 [pubmed]
PHST- 2015/12/14 00:01 [medline]
AID - S1535-6108(15)00424-9 [pii]
AID - 10.1016/j.ccell.2015.11.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):831. doi: 10.1016/j.ccell.2015.11.003. Epub 2015
      Dec 14.

PMID- 28843279
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces
      Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.
PG  - 831-833
LID - S1535-6108(15)00423-7 [pii]
LID - 10.1016/j.ccell.2015.11.002 [doi]
FAU - Ozdemir, Berna C
AU  - Ozdemir BC
FAU - Pentcheva-Hoang, Tsvetelina
AU  - Pentcheva-Hoang T
FAU - Carstens, Julienne L
AU  - Carstens JL
FAU - Zheng, Xiaofeng
AU  - Zheng X
FAU - Wu, Chia-Chin
AU  - Wu CC
FAU - Simpson, Tyler R
AU  - Simpson TR
FAU - Laklai, Hanane
AU  - Laklai H
FAU - Sugimoto, Hikaru
AU  - Sugimoto H
FAU - Kahlert, Christoph
AU  - Kahlert C
FAU - Novitskiy, Sergey V
AU  - Novitskiy SV
FAU - De Jesus-Acosta, Ana
AU  - De Jesus-Acosta A
FAU - Sharma, Padmanee
AU  - Sharma P
FAU - Heidari, Pedram
AU  - Heidari P
FAU - Mahmood, Umar
AU  - Mahmood U
FAU - Chin, Lynda
AU  - Chin L
FAU - Moses, Harold L
AU  - Moses HL
FAU - Weaver, Valerie M
AU  - Weaver VM
FAU - Maitra, Anirban
AU  - Maitra A
FAU - Allison, James P
AU  - Allison JP
FAU - LeBleu, Valerie S
AU  - LeBleu VS
FAU - Kalluri, Raghu
AU  - Kalluri R
LA  - eng
PT  - Published Erratum
DEP - 20151214
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2015/12/14 00:00
MHDA- 2015/12/14 00:01
CRDT- 2017/08/28 06:00
PHST- 2017/08/28 06:00 [entrez]
PHST- 2015/12/14 00:00 [pubmed]
PHST- 2015/12/14 00:01 [medline]
AID - S1535-6108(15)00423-7 [pii]
AID - 10.1016/j.ccell.2015.11.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):831-833. doi: 10.1016/j.ccell.2015.11.002. Epub
      2015 Dec 14.

PMID- 28843278
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171013
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1
      Kinase Activity-Mediated Hepatocyte Apoptosis.
PG  - 830
LID - S1535-6108(15)00428-6 [pii]
LID - 10.1016/j.ccell.2015.11.007 [doi]
FAU - Kondylis, Vangelis
AU  - Kondylis V
FAU - Polykratis, Apostolos
AU  - Polykratis A
FAU - Ehlken, Hanno
AU  - Ehlken H
FAU - Ochoa-Callejero, Laura
AU  - Ochoa-Callejero L
FAU - Straub, Beate Katharina
AU  - Straub BK
FAU - Krishna-Subramanian, Santosh
AU  - Krishna-Subramanian S
FAU - Van, Trieu-My
AU  - Van TM
FAU - Curth, Harald-Morten
AU  - Curth HM
FAU - Heise, Nicole
AU  - Heise N
FAU - Weih, Falk
AU  - Weih F
FAU - Klein, Ulf
AU  - Klein U
FAU - Schirmacher, Peter
AU  - Schirmacher P
FAU - Kelliher, Michelle
AU  - Kelliher M
FAU - Pasparakis, Manolis
AU  - Pasparakis M
LA  - eng
PT  - Published Erratum
DEP - 20151214
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5628166
EDAT- 2015/12/14 00:00
MHDA- 2015/12/14 00:01
CRDT- 2017/08/28 06:00
PHST- 2017/08/28 06:00 [entrez]
PHST- 2015/12/14 00:00 [pubmed]
PHST- 2015/12/14 00:01 [medline]
AID - S1535-6108(15)00428-6 [pii]
AID - 10.1016/j.ccell.2015.11.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):830. doi: 10.1016/j.ccell.2015.11.007. Epub 2015
      Dec 14.

PMID- 26626085
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20170827
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant
      H3.3 and Globally Reorganizing Chromatin.
PG  - 715-729
LID - S1535-6108(15)00382-7 [pii]
LID - 10.1016/j.ccell.2015.10.005 [doi]
AB  - Mutations in the histone 3 variant H3.3 have been identified in one-third of
      pediatric glioblastomas (GBMs), but not in adult tumors. Here we show that H3.3
      is a dynamic determinant of functional properties in adult GBM. H3.3 is repressed
      by mixed lineage leukemia 5 (MLL5) in self-renewing GBM cells. MLL5 is a global
      epigenetic repressor that orchestrates reorganization of chromatin structure by
      punctuating chromosomes with foci of compacted chromatin, favoring tumorigenic
      and self-renewing properties. Conversely, H3.3 antagonizes self-renewal and
      promotes differentiation. We exploited these epigenetic states to rationally
      identify two small molecules that effectively curb cancer stem cell properties in
      a preclinical model. Our work uncovers a role for MLL5 and H3.3 in maintaining
      self-renewal hierarchies in adult GBM.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Gallo, Marco
AU  - Gallo M
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada.
FAU - Coutinho, Fiona J
AU  - Coutinho FJ
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada.
FAU - Vanner, Robert J
AU  - Vanner RJ
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada.
FAU - Gayden, Tenzin
AU  - Gayden T
AD  - Departments of Pediatrics and Human Genetics, McGill University and McGill
      University Health Centre Research Institute, Montreal, QC H3H 1P4, Canada.
FAU - Mack, Stephen C
AU  - Mack SC
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada; Department of Stem Cell Biology and Regenerative Medicine, Lerner
      Research Institute, Cleveland, OH 44195, USA; Laboratory Medicine and
      Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
FAU - Murison, Alex
AU  - Murison A
AD  - Ontario Institute for Cancer Research and Princess Margaret Cancer
      Centre-University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Remke, Marc
AU  - Remke M
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada.
FAU - Li, Ren
AU  - Li R
AD  - Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON 
      M5G 0A4, Canada.
FAU - Takayama, Naoya
AU  - Takayama N
AD  - Ontario Institute for Cancer Research and Princess Margaret Cancer
      Centre-University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Desai, Kinjal
AU  - Desai K
AD  - Department of Genetics, Norris Cotton Cancer Center, Dartmouth Medical School,
      Lebanon, NH 03755, USA.
FAU - Lee, Lilian
AU  - Lee L
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada.
FAU - Lan, Xiaoyang
AU  - Lan X
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada.
FAU - Park, Nicole I
AU  - Park NI
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada.
FAU - Barsyte-Lovejoy, Dalia
AU  - Barsyte-Lovejoy D
AD  - Ontario Institute for Cancer Research and Princess Margaret Cancer
      Centre-University Health Network, Toronto, ON M5G 1L7, Canada; Structural
      Genomics Consortium, Toronto, ON M5G 1L7, Canada.
FAU - Smil, David
AU  - Smil D
AD  - Ontario Institute for Cancer Research and Princess Margaret Cancer
      Centre-University Health Network, Toronto, ON M5G 1L7, Canada; Structural
      Genomics Consortium, Toronto, ON M5G 1L7, Canada.
FAU - Sturm, Dominik
AU  - Sturm D
AD  - Division of Pediatric Neurooncology, German Cancer Research Centre (DKFZ),
      Heidelberg 69120, Germany.
FAU - Kushida, Michelle M
AU  - Kushida MM
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada.
FAU - Head, Renee
AU  - Head R
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada.
FAU - Cusimano, Michael D
AU  - Cusimano MD
AD  - Division of Neurosurgery, University of Toronto, Toronto, ON M5S 1A8, Canada; St.
      Michael's Hospital, Toronto, ON M5B 1W8, Canada.
FAU - Bernstein, Mark
AU  - Bernstein M
AD  - Division of Neurosurgery, University of Toronto, Toronto, ON M5S 1A8, Canada;
      Toronto Western Hospital, Toronto, ON M5T 2S8, Canada.
FAU - Clarke, Ian D
AU  - Clarke ID
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada.
FAU - Dick, John E
AU  - Dick JE
AD  - Ontario Institute for Cancer Research and Princess Margaret Cancer
      Centre-University Health Network, Toronto, ON M5G 1L7, Canada.
FAU - Pfister, Stefan M
AU  - Pfister SM
AD  - Division of Pediatric Neurooncology, German Cancer Research Centre (DKFZ),
      Heidelberg 69120, Germany.
FAU - Rich, Jeremy N
AU  - Rich JN
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland, OH 44195, USA.
FAU - Arrowsmith, Cheryl H
AU  - Arrowsmith CH
AD  - Ontario Institute for Cancer Research and Princess Margaret Cancer
      Centre-University Health Network, Toronto, ON M5G 1L7, Canada; Structural
      Genomics Consortium, Toronto, ON M5G 1L7, Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada; Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON 
      M5S 1A8, Canada; Division of Neurosurgery, University of Toronto, Toronto, ON M5S
      1A8, Canada.
FAU - Jabado, Nada
AU  - Jabado N
AD  - Departments of Pediatrics and Human Genetics, McGill University and McGill
      University Health Centre Research Institute, Montreal, QC H3H 1P4, Canada.
FAU - Bazett-Jones, David P
AU  - Bazett-Jones DP
AD  - Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON 
      M5G 0A4, Canada.
FAU - Lupien, Mathieu
AU  - Lupien M
AD  - Ontario Institute for Cancer Research and Princess Margaret Cancer
      Centre-University Health Network, Toronto, ON M5G 1L7, Canada; Department of
      Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
      Electronic address: mlupien@uhnres.utoronto.ca.
FAU - Dirks, Peter B
AU  - Dirks PB
AD  - Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain
      Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4,
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 
      1A8, Canada; Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, ON M5S 1A8, Canada; Division of Neurosurgery, University of Toronto,
      Toronto, ON M5S 1A8, Canada. Electronic address: peter.dirks@sickkids.ca.
LA  - eng
SI  - GEO/GSE63267
SI  - GEO/GSE63296
SI  - GEO/GSE67633
GR  - Canadian Institutes of Health Research/Canada
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151125
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Histones)
RN  - 0 (MLL5 protein, human)
SB  - IM
CIN - Cancer Cell. 2015 Dec 14;28(6):679-80. PMID: 26678332
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Brain Neoplasms/drug therapy/genetics/*metabolism/mortality/pathology
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - *Cell Self Renewal/drug effects
MH  - Child
MH  - Child, Preschool
MH  - *Chromatin Assembly and Disassembly/drug effects
MH  - DNA Methylation
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Drug Design
MH  - Epigenesis, Genetic
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Glioblastoma/drug therapy/genetics/*metabolism/mortality/pathology
MH  - Histones/genetics/*metabolism
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Molecular Targeted Therapy
MH  - Mutation
MH  - Neoplastic Stem Cells/drug effects/*metabolism/pathology
MH  - Prognosis
MH  - RNA Interference
MH  - Signal Transduction
MH  - Time Factors
MH  - Transfection
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
MH  - Young Adult
EDAT- 2015/12/03 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/12/03 06:00
PHST- 2015/06/04 00:00 [received]
PHST- 2015/08/13 00:00 [revised]
PHST- 2015/10/12 00:00 [accepted]
PHST- 2015/12/03 06:00 [entrez]
PHST- 2015/12/03 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00382-7 [pii]
AID - 10.1016/j.ccell.2015.10.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):715-729. doi: 10.1016/j.ccell.2015.10.005. Epub
      2015 Nov 25.

PMID- 26585400
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 6
DP  - 2015 Dec 14
TI  - Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric
      Epithelium and Are Supported by a Perivascular Stem Cell Niche.
PG  - 800-814
LID - S1535-6108(15)00380-3 [pii]
LID - 10.1016/j.ccell.2015.10.003 [doi]
AB  - The regulation and stem cell origin of normal and neoplastic gastric glands are
      uncertain. Here, we show that Mist1 expression marks quiescent stem cells in the 
      gastric corpus isthmus. Mist1(+) stem cells serve as a cell-of-origin for
      intestinal-type cancer with the combination of Kras and Apc mutation and for
      diffuse-type cancer with the loss of E-cadherin. Diffuse-type cancer development 
      is dependent on inflammation mediated by Cxcl12(+) endothelial cells and Cxcr4(+)
      gastric innate lymphoid cells (ILCs). These cells form the perivascular gastric
      stem cell niche, and Wnt5a produced from ILCs activates RhoA to inhibit anoikis
      in the E-cadherin-depleted cells. Targeting Cxcr4, ILCs, or Wnt5a inhibits
      diffuse-type gastric carcinogenesis, providing targets within the neoplastic
      gastric stem cell niche.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Hayakawa, Yoku
AU  - Hayakawa Y
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Ariyama, Hiroshi
AU  - Ariyama H
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Stancikova, Jitka
AU  - Stancikova J
AD  - Department of Cell and Developmental Biology, Institute of Molecular Genetics,
      Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.
FAU - Sakitani, Kosuke
AU  - Sakitani K
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Asfaha, Samuel
AU  - Asfaha S
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Renz, Bernhard W
AU  - Renz BW
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA;
      Department of General, Visceral, Transplantation, Vascular, and Thoracic Surgery,
      Hospital of the University of Munich, Munich 81377, Germany.
FAU - Dubeykovskaya, Zinaida A
AU  - Dubeykovskaya ZA
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Shibata, Wataru
AU  - Shibata W
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Wang, Hongshan
AU  - Wang H
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Westphalen, Christoph B
AU  - Westphalen CB
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Chen, Xiaowei
AU  - Chen X
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Takemoto, Yoshihiro
AU  - Takemoto Y
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Kim, Woosook
AU  - Kim W
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Khurana, Shradha S
AU  - Khurana SS
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Tailor, Yagnesh
AU  - Tailor Y
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Nagar, Karan
AU  - Nagar K
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Tomita, Hiroyuki
AU  - Tomita H
AD  - Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu 
      501-1194, Japan.
FAU - Hara, Akira
AU  - Hara A
AD  - Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu 
      501-1194, Japan.
FAU - Sepulveda, Antonia R
AU  - Sepulveda AR
AD  - Division of Clinical Pathology and Cell Biology, Department of Pathology,
      Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Setlik, Wanda
AU  - Setlik W
AD  - Department of Pathology and Cell Biology, Columbia University College of
      Physicians and Surgeons, New York, NY 10032, USA.
FAU - Gershon, Michael D
AU  - Gershon MD
AD  - Department of Pathology and Cell Biology, Columbia University College of
      Physicians and Surgeons, New York, NY 10032, USA.
FAU - Saha, Subhrajit
AU  - Saha S
AD  - Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY 
      10461, USA.
FAU - Ding, Lei
AU  - Ding L
AD  - Departments of Rehabilitation and Regenerative Medicine and Microbiology and
      Immunology, Columbia University College of Physicians and Surgeons, New York, NY 
      10032, USA.
FAU - Shen, Zeli
AU  - Shen Z
AD  - Division of Comparative Medicine, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA.
FAU - Fox, James G
AU  - Fox JG
AD  - Division of Comparative Medicine, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA.
FAU - Friedman, Richard A
AU  - Friedman RA
AD  - Herbert Irving Comprehensive Cancer Center Biomedical Informatics Shared Resource
      and Department of Biomedical Informatics, Columbia University College of
      Physicians and Surgeons, New York, NY 10032, USA.
FAU - Konieczny, Stephen F
AU  - Konieczny SF
AD  - Department of Biological Sciences and the Purdue Center for Cancer Research,
      Purdue University, West Lafayette, IN 47907, USA.
FAU - Worthley, Daniel L
AU  - Worthley DL
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
FAU - Korinek, Vladimir
AU  - Korinek V
AD  - Department of Cell and Developmental Biology, Institute of Molecular Genetics,
      Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.
FAU - Wang, Timothy C
AU  - Wang TC
AD  - Division of Digestive and Liver Disease, Department of Medicine, Columbia
      University College of Physicians and Surgeons, New York, NY 10032, USA.
      Electronic address: tcw21@columbia.edu.
LA  - eng
GR  - R01 CA093405/CA/NCI NIH HHS/United States
GR  - R01 NS015547/NS/NINDS NIH HHS/United States
GR  - R01CA093405/CA/NCI NIH HHS/United States
GR  - U54 CA126513/CA/NCI NIH HHS/United States
GR  - R01CA120979/CA/NCI NIH HHS/United States
GR  - U54CA126513/CA/NCI NIH HHS/United States
GR  - R01 DK055489/DK/NIDDK NIH HHS/United States
GR  - R01 CA120979/CA/NCI NIH HHS/United States
GR  - R01 CA124586/CA/NCI NIH HHS/United States
GR  - R01 DK052778/DK/NIDDK NIH HHS/United States
GR  - R01DK052778/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151112
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (CXCR4 protein, mouse)
RN  - 0 (Cadherins)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Cxcl12 protein, mouse)
RN  - 0 (MIST1 protein, human)
RN  - 0 (Mist1 protein, mouse)
RN  - 0 (Receptors, CXCR4)
RN  - 0 (Wnt Proteins)
RN  - 0 (Wnt-5a Protein)
RN  - 0 (Wnt5a protein, mouse)
RN  - EC 3.6.5.2 (RhoA protein, mouse)
RN  - EC 3.6.5.2 (rho GTP-Binding Proteins)
SB  - IM
CIN - Cell Stem Cell. 2016 Jan 7;18(1):7-9. PMID: 26748749
MH  - Animals
MH  - Anoikis
MH  - Antineoplastic Agents/pharmacology
MH  - Basic Helix-Loop-Helix Transcription Factors/genetics/*metabolism
MH  - Bone Marrow Transplantation
MH  - Cadherins/metabolism
MH  - Cell Communication
MH  - Cell Line, Tumor
MH  - Cell Lineage
MH  - Cell Transformation, Neoplastic/genetics/metabolism/pathology
MH  - Cellular Senescence
MH  - Chemokine CXCL12/metabolism
MH  - Endothelial Cells/metabolism/pathology
MH  - Epithelial Cells/drug effects/*metabolism/pathology
MH  - Gastric Mucosa/drug effects/*metabolism/pathology
MH  - Humans
MH  - Lymphocytes/metabolism/pathology
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Neoplastic Stem Cells/drug effects/*metabolism/pathology
MH  - Receptors, CXCR4/metabolism
MH  - Signal Transduction
MH  - *Stem Cell Niche
MH  - Stomach Neoplasms/drug therapy/genetics/*metabolism/pathology
MH  - Time Factors
MH  - *Tumor Microenvironment
MH  - Wnt Proteins/metabolism
MH  - Wnt Signaling Pathway
MH  - Wnt-5a Protein
MH  - rho GTP-Binding Proteins/metabolism
PMC - PMC4684751
MID - NIHMS737666
EDAT- 2015/11/21 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/11/21 06:00
PHST- 2015/05/26 00:00 [received]
PHST- 2015/08/26 00:00 [revised]
PHST- 2015/10/08 00:00 [accepted]
PHST- 2015/11/21 06:00 [entrez]
PHST- 2015/11/21 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - S1535-6108(15)00380-3 [pii]
AID - 10.1016/j.ccell.2015.10.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Dec 14;28(6):800-814. doi: 10.1016/j.ccell.2015.10.003. Epub
      2015 Nov 12.

PMID- 26602816
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170718
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to
      Drive Resistance of p53-Defective Tumors to Chemotherapy.
PG  - 623-637
LID - 10.1016/j.ccell.2015.09.009 [doi]
AB  - In normal cells, p53 is activated by DNA damage checkpoint kinases to
      simultaneously control the G1/S and G2/M cell cycle checkpoints through
      transcriptional induction of p21(cip1) and Gadd45alpha. In p53-mutant tumors,
      cell cycle checkpoints are rewired, leading to dependency on the p38/MK2 pathway 
      to survive DNA-damaging chemotherapy. Here we show that the RNA binding protein
      hnRNPA0 is the "successor" to p53 for checkpoint control. Like p53, hnRNPA0 is
      activated by a checkpoint kinase (MK2) and simultaneously controls both cell
      cycle checkpoints through distinct target mRNAs, but unlike p53, this is through 
      the post-transcriptional stabilization of p27(Kip1) and Gadd45alpha mRNAs. This
      pathway drives cisplatin resistance in lung cancer, demonstrating the importance 
      of post-transcriptional RNA control to chemotherapy response.
FAU - Cannell, Ian G
AU  - Cannell IG
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Merrick, Karl A
AU  - Merrick KA
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Morandell, Sandra
AU  - Morandell S
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Zhu, Chang-Qi
AU  - Zhu CQ
AD  - Princess Margaret Cancer Centre, University Health Network and University of
      Toronto, Canada.
FAU - Braun, Christian J
AU  - Braun CJ
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Grant, Robert A
AU  - Grant RA
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Cameron, Eleanor R
AU  - Cameron ER
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Tsao, Ming-Sound
AU  - Tsao MS
AD  - Princess Margaret Cancer Centre, University Health Network and University of
      Toronto, Canada.
FAU - Hemann, Michael T
AU  - Hemann MT
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Yaffe, Michael B
AU  - Yaffe MB
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
AD  - Department of Biology, Massachusetts Institute of Technology, Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA.
AD  - Department of Biological Engineering, Massachusetts Institute of Technology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215 USA.
LA  - eng
GR  - ES015339/ES/NIEHS NIH HHS/United States
GR  - ES-002109/ES/NIEHS NIH HHS/United States
GR  - R01 ES015339/ES/NIEHS NIH HHS/United States
GR  - R01 GM059281/GM/NIGMS NIH HHS/United States
GR  - P30 CA014051/CA/NCI NIH HHS/United States
GR  - R01 GM060594/GM/NIGMS NIH HHS/United States
GR  - P30-CA14051/CA/NCI NIH HHS/United States
GR  - U54 CA112967/CA/NCI NIH HHS/United States
GR  - CA112967/CA/NCI NIH HHS/United States
GR  - GM60594/GM/NIGMS NIH HHS/United States
GR  - R01 GM104047/GM/NIGMS NIH HHS/United States
GR  - P30 ES002109/ES/NIEHS NIH HHS/United States
GR  - GM59281/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (GADD45A protein, human)
RN  - 0 (HNRNPA0 protein, human)
RN  - 0 (Heterogeneous-Nuclear Ribonucleoproteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
EIN - Cancer Cell. 2015 Dec 14;28(6):831
MH  - Aged
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Cell Cycle Checkpoints/*genetics
MH  - Cell Cycle Proteins/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Cisplatin/therapeutic use
MH  - Cyclin-Dependent Kinase Inhibitor p21/genetics/metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p27/genetics/metabolism
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Pleiotropy
MH  - HEK293 Cells
MH  - Heterogeneous-Nuclear Ribonucleoproteins/*genetics/metabolism
MH  - Humans
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasms/drug therapy/*genetics/metabolism
MH  - Nuclear Proteins/genetics/metabolism
MH  - RNA Interference
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Analysis
MH  - Tumor Suppressor Protein p53/*genetics
PMC - PMC4830093
MID - NIHMS726139
EDAT- 2015/11/26 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/26 06:00
PHST- 2013/11/01 00:00 [received]
PHST- 2014/12/24 00:00 [revised]
PHST- 2015/09/18 00:00 [accepted]
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.1016/j.ccell.2015.09.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):623-637. doi: 10.1016/j.ccell.2015.09.009.

PMID- 26602815
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP
      Starvation.
PG  - 557-568
LID - S1535-6108(15)00346-3 [pii]
LID - 10.1016/j.ccell.2015.09.015 [doi]
AB  - Histone H3K36 trimethylation (H3K36me3) is frequently lost in multiple cancer
      types, identifying it as an important therapeutic target. Here we identify a
      synthetic lethal interaction in which H3K36me3-deficient cancers are acutely
      sensitive to WEE1 inhibition. We show that RRM2, a ribonucleotide reductase
      subunit, is the target of this synthetic lethal interaction. RRM2 is regulated by
      two pathways here: first, H3K36me3 facilitates RRM2 expression through
      transcription initiation factor recruitment; second, WEE1 inhibition degrades
      RRM2 through untimely CDK activation. Therefore, WEE1 inhibition in
      H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion,
      S-phase arrest, and apoptosis. Accordingly, this synthetic lethality is
      suppressed by increasing RRM2 expression or inhibiting RRM2 degradation. Finally,
      we demonstrate that WEE1 inhibitor AZD1775 regresses H3K36me3-deficient tumor
      xenografts.
FAU - Pfister, Sophia X
AU  - Pfister SX
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Markkanen, Enni
AU  - Markkanen E
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK; Institute of Pharmacology and
      Toxicology, Vetsuisse Faculty, Winterthurerstrasse 260, 8057 Zurich, Switzerland.
FAU - Jiang, Yanyan
AU  - Jiang Y
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Sarkar, Sovan
AU  - Sarkar S
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Woodcock, Mick
AU  - Woodcock M
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Orlando, Giulia
AU  - Orlando G
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Mavrommati, Ioanna
AU  - Mavrommati I
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Pai, Chen-Chun
AU  - Pai CC
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Zalmas, Lykourgos-Panagiotis
AU  - Zalmas LP
AD  - Department of Oncology, University of Oxford, Old Road Campus Research Building, 
      Oxford OX3 7DQ, UK.
FAU - Drobnitzky, Neele
AU  - Drobnitzky N
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Dianov, Grigory L
AU  - Dianov GL
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK; Institute of Cytology and Genetics RAS,
      Novosibirsk 630090, Russia.
FAU - Verrill, Clare
AU  - Verrill C
AD  - Department of Cellular Pathology, Oxford University Hospitals NHS Trust, John
      Radcliffe Hospital, Oxford OX3 9DU, UK.
FAU - Macaulay, Valentine M
AU  - Macaulay VM
AD  - Department of Oncology, University of Oxford, Old Road Campus Research Building, 
      Oxford OX3 7DQ, UK; Oxford Cancer and Haematology Centre, Oxford University
      Hospitals NHS Trust, Churchill Hospital, Oxford OX3 7LJ, UK.
FAU - Ying, Songmin
AU  - Ying S
AD  - Department of Respiratory and Critical Care Medicine of the Second Affiliated
      Hospital and Department of Pharmacology, Zhejiang University School of Medicine, 
      Hangzhou 310058, China.
FAU - La Thangue, Nicholas B
AU  - La Thangue NB
AD  - Department of Oncology, University of Oxford, Old Road Campus Research Building, 
      Oxford OX3 7DQ, UK.
FAU - D'Angiolella, Vincenzo
AU  - D'Angiolella V
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Ryan, Anderson J
AU  - Ryan AJ
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK.
FAU - Humphrey, Timothy C
AU  - Humphrey TC
AD  - CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Oxford OX3 7DQ, UK. Electronic address:
      timothy.humphrey@oncology.ox.ac.uk.
LA  - eng
GR  - MC_PC_12002/Medical Research Council/United Kingdom
GR  - MC_PC_12003/Medical Research Council/United Kingdom
GR  - G1000807/Medical Research Council/United Kingdom
GR  - MC_PC_12006/Medical Research Council/United Kingdom
GR  - MC_PC_12001/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Histones)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Nucleotides)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - EC 1.17.4.- (ribonucleotide reductase M2)
RN  - EC 1.17.4.1 (Ribonucleoside Diphosphate Reductase)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.1.1.43 (Set2 protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (WEE1 protein, human)
RN  - K2T6HJX3I3 (MK-1775)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
CIN - Cancer Cell. 2015 Nov 9;28(5):545-7. PMID: 26555168
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Blotting, Western
MH  - Cell Cycle Proteins/antagonists & inhibitors/genetics/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects/genetics
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Histone-Lysine N-Methyltransferase/genetics/metabolism
MH  - Histones/genetics/*metabolism
MH  - Humans
MH  - Lysine/genetics/metabolism
MH  - Methylation/drug effects
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Molecular Sequence Data
MH  - Neoplasms/genetics/*metabolism/prevention & control
MH  - Nuclear Proteins/antagonists & inhibitors/genetics/*metabolism
MH  - Nucleotides/genetics/*metabolism
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors/genetics/*metabolism
MH  - Pyrazoles/pharmacology
MH  - Pyrimidines/pharmacology
MH  - RNA Interference
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Ribonucleoside Diphosphate Reductase/genetics/metabolism
MH  - Sequence Homology, Amino Acid
MH  - Sequence Homology, Nucleic Acid
MH  - Xenograft Model Antitumor Assays
PMC - PMC4643307
EDAT- 2015/11/26 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/26 06:00
PHST- 2015/04/03 00:00 [received]
PHST- 2015/07/28 00:00 [revised]
PHST- 2015/09/22 00:00 [accepted]
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00346-3 [pii]
AID - 10.1016/j.ccell.2015.09.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):557-568. doi: 10.1016/j.ccell.2015.09.015.

PMID- 26555176
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - SnapShot: Multiple Myeloma.
PG  - 678-678.e1
LID - S1535-6108(15)00391-8 [pii]
LID - 10.1016/j.ccell.2015.10.014 [doi]
AB  - Multiple myeloma (MM) is a plasma cell malignancy characterized by a
      heterogeneous clinical presentation. Genetic abnormalities are not only key
      events in the origin and progression of the disease but are also useful tools for
      prognosis, risk stratification, and therapeutic decision making. Although still
      incurable, a revolution in the treatment of MM is currently ongoing, leading to a
      significant improvement of clinical outcome and survival. To view this SnapShot, 
      open or download the PDF.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Braggio, Esteban
AU  - Braggio E
AD  - Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.
FAU - Kortum, K Martin
AU  - Kortum KM
AD  - Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.
FAU - Stewart, A Keith
AU  - Stewart AK
AD  - Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.
LA  - eng
GR  - P50 CA186781/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - *Chromosome Aberrations
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Male
MH  - Multiple Myeloma/diagnosis/drug therapy/*genetics
MH  - *Mutation
MH  - Plasma Cells/drug effects/*metabolism/pathology
MH  - Prognosis
MH  - Signal Transduction/genetics
MH  - Survival Analysis
PMC - PMC4864595
MID - NIHMS783874
EDAT- 2015/11/12 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00391-8 [pii]
AID - 10.1016/j.ccell.2015.10.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):678-678.e1. doi: 10.1016/j.ccell.2015.10.014.

PMID- 26555175
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of
      Protein Homeostasis.
PG  - 653-665
LID - S1535-6108(15)00379-7 [pii]
LID - 10.1016/j.ccell.2015.10.002 [doi]
AB  - p97 is a AAA-ATPase with multiple cellular functions, one of which is critical
      regulation of protein homeostasis pathways. We describe the characterization of
      CB-5083, a potent, selective, and orally bioavailable inhibitor of p97. Treatment
      of tumor cells with CB-5083 leads to accumulation of poly-ubiquitinated proteins,
      retention of endoplasmic reticulum-associated degradation (ERAD) substrates, and 
      generation of irresolvable proteotoxic stress, leading to activation of the
      apoptotic arm of the unfolded protein response. In xenograft models, CB-5083
      causes modulation of key p97-related pathways, induces apoptosis, and has
      antitumor activity in a broad range of both hematological and solid tumor models.
      Molecular determinants of CB-5083 activity include expression of genes in the
      ERAD pathway, providing a potential strategy for patient selection.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Anderson, Daniel J
AU  - Anderson DJ
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA. Electronic address:
      danderson@cleavebio.com.
FAU - Le Moigne, Ronan
AU  - Le Moigne R
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Djakovic, Stevan
AU  - Djakovic S
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Kumar, Brajesh
AU  - Kumar B
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Rice, Julie
AU  - Rice J
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Wong, Steve
AU  - Wong S
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Wang, Jinhai
AU  - Wang J
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Yao, Bing
AU  - Yao B
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Valle, Eduardo
AU  - Valle E
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Kiss von Soly, Szerenke
AU  - Kiss von Soly S
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Madriaga, Antonett
AU  - Madriaga A
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Soriano, Ferdie
AU  - Soriano F
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Menon, Mary-Kamala
AU  - Menon MK
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Wu, Zhi Yong
AU  - Wu ZY
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Kampmann, Martin
AU  - Kampmann M
AD  - Department of Cellular and Molecular Pharmacology and Howard Hughes Medical
      Institute, University of California, San Francisco, San Francisco, CA 94158, USA.
FAU - Chen, Yuwen
AU  - Chen Y
AD  - Department of Cellular and Molecular Pharmacology and Howard Hughes Medical
      Institute, University of California, San Francisco, San Francisco, CA 94158, USA.
FAU - Weissman, Jonathan S
AU  - Weissman JS
AD  - Department of Cellular and Molecular Pharmacology and Howard Hughes Medical
      Institute, University of California, San Francisco, San Francisco, CA 94158, USA.
FAU - Aftab, Blake T
AU  - Aftab BT
AD  - Division of Hematology & Oncology, Department of Medicine, Helen Diller Family
      Cancer Center, University of California, San Francisco, San Francisco, CA 94158, 
      USA.
FAU - Yakes, F Michael
AU  - Yakes FM
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Shawver, Laura
AU  - Shawver L
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Zhou, Han-Jie
AU  - Zhou HJ
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Wustrow, David
AU  - Wustrow D
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
FAU - Rolfe, Mark
AU  - Rolfe M
AD  - Cleave Biosciences, Inc., Burlingame, CA 94010, USA.
LA  - eng
SI  - GEO/GSE73588
GR  - K99 CA181494/CA/NCI NIH HHS/United States
GR  - R00 CA181494/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CB-5083)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Pyrimidines)
RN  - 0 (Ubiquitinated Proteins)
RN  - EC 3.6.1.- (Adenosine Triphosphatases)
RN  - EC 3.6.1.- (p97 ATPase)
SB  - IM
CIN - Cancer Cell. 2015 Nov 9;28(5):550-2. PMID: 26555170
MH  - Adenosine Triphosphatases/*antagonists & inhibitors/genetics/metabolism
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Blotting, Western
MH  - CRISPR-Cas Systems
MH  - Cell Line, Tumor
MH  - Endoplasmic Reticulum-Associated Degradation/drug effects
MH  - Enzyme Inhibitors/chemistry/*pharmacology
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - HCT116 Cells
MH  - HEK293 Cells
MH  - Homeostasis/*drug effects
MH  - Humans
MH  - Indoles/chemistry/pharmacology
MH  - K562 Cells
MH  - Mice, Nude
MH  - Mice, SCID
MH  - Molecular Structure
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasms/*drug therapy/genetics/metabolism
MH  - Nuclear Proteins/*antagonists & inhibitors/genetics/metabolism
MH  - Pyrimidines/chemistry/pharmacology
MH  - RNA Interference
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Ubiquitinated Proteins/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC4941640
MID - NIHMS793552
EDAT- 2015/11/12 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/04/02 00:00 [received]
PHST- 2015/08/04 00:00 [revised]
PHST- 2015/10/06 00:00 [accepted]
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00379-7 [pii]
AID - 10.1016/j.ccell.2015.10.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):653-665. doi: 10.1016/j.ccell.2015.10.002.

PMID- 26555174
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1
      Kinase Activity-Mediated Hepatocyte Apoptosis.
PG  - 582-598
LID - S1535-6108(15)00378-5 [pii]
LID - 10.1016/j.ccell.2015.10.001 [doi]
AB  - IkappaB kinase/nuclear [corrected] factor kappaB (IKK/NF-kappaB) signaling
      exhibits important yet opposing functions in hepatocarcinogenesis. Mice lacking
      NEMO in liver parenchymal cells (LPC) spontaneously develop steatohepatitis and
      hepatocellular carcinoma (HCC) suggesting that NF-kappaB prevents liver disease
      and cancer. Here, we show that complete NF-kappaB inhibition by combined
      LPC-specific ablation of RelA, c-Rel, and RelB did not phenocopy NEMO deficiency,
      but constitutively active IKK2-mediated NF-kappaB activation prevented
      hepatocellular damage and HCC in NEMO(LPC-KO) mice. Knock-in expression of kinase
      inactive receptor-interacting protein kinase 1 (RIPK1) prevented hepatocyte
      apoptosis and HCC, while RIPK1 ablation induced TNFR1-associated death domain
      protein (TRADD)-dependent hepatocyte apoptosis and liver tumors in NEMO(LPC-KO)
      mice, revealing distinct kinase-dependent and scaffolding functions of RIPK1.
      Collectively, these results show that NEMO prevents hepatocarcinogenesis by
      inhibiting RIPK1 kinase activity-driven hepatocyte apoptosis through
      NF-kappaB-dependent and -independent functions.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Kondylis, Vangelis
AU  - Kondylis V
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany.
FAU - Polykratis, Apostolos
AU  - Polykratis A
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany.
FAU - Ehlken, Hanno
AU  - Ehlken H
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany.
FAU - Ochoa-Callejero, Laura
AU  - Ochoa-Callejero L
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany.
FAU - Straub, Beate Katharina
AU  - Straub BK
AD  - Institute of Pathology, University Hospital Heidelberg, INF 224, 69120
      Heidelberg, Germany.
FAU - Krishna-Subramanian, Santosh
AU  - Krishna-Subramanian S
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany.
FAU - Van, Trieu-My
AU  - Van TM
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany.
FAU - Curth, Harald-Morten
AU  - Curth HM
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany.
FAU - Heise, Nicole
AU  - Heise N
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
      10032, USA.
FAU - Weih, Falk
AU  - Weih F
AD  - Leibniz-Institute for Age Research-Fritz-Lipmann-Institute, 07745 Jena, Germany.
FAU - Klein, Ulf
AU  - Klein U
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
      10032, USA; Department of Pathology and Cell Biology, Columbia University, New
      York, NY 10032, USA; Department of Microbiology and Immunology, Columbia
      University, New York, NY 10032, USA.
FAU - Schirmacher, Peter
AU  - Schirmacher P
AD  - Institute of Pathology, University Hospital Heidelberg, INF 224, 69120
      Heidelberg, Germany.
FAU - Kelliher, Michelle
AU  - Kelliher M
AD  - Department of Molecular, Cellular and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA 01605, USA.
FAU - Pasparakis, Manolis
AU  - Pasparakis M
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany; Cologne
      Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
      (CECAD), University of Cologne, 50931 Cologne, Germany; Center for Molecular
      Medicine (CMMC), University of Cologne, 50931, Cologne, Germany. Electronic
      address: pasparakis@uni-koeln.de.
LA  - eng
GR  - 15-0228/Worldwide Cancer Research/United Kingdom
GR  - 323040/European Research Council/International
GR  - R01 AI075118/AI/NIAID NIH HHS/United States
GR  - R01AI075118/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (NEMO protein, mouse)
RN  - 0 (NF-kappa B)
RN  - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Ripk1 protein, mouse)
RN  - EC 2.7.11.10 (I-kappa B Kinase)
RN  - EC 2.7.11.10 (Ikbkb protein, mouse)
SB  - IM
EIN - Cancer Cell. 2015 Dec 14;28(6):830
MH  - Animals
MH  - Apoptosis/genetics
MH  - Carcinoma, Hepatocellular/genetics/*metabolism
MH  - Cells, Cultured
MH  - Fatty Liver/genetics/*metabolism
MH  - Gene Expression
MH  - Hepatocytes/*metabolism
MH  - I-kappa B Kinase/genetics/metabolism
MH  - Immunoblotting
MH  - Immunohistochemistry
MH  - Intracellular Signaling Peptides and Proteins/genetics/*metabolism
MH  - Liver/metabolism/pathology
MH  - Liver Neoplasms/genetics/*metabolism
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - NF-kappa B/genetics/metabolism
MH  - Receptor-Interacting Protein Serine-Threonine Kinases/genetics/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/genetics
PMC - PMC4644221
EDAT- 2015/11/12 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/12 06:00
PHST- 2014/03/24 00:00 [received]
PHST- 2015/06/02 00:00 [revised]
PHST- 2015/10/06 00:00 [accepted]
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00378-5 [pii]
AID - 10.1016/j.ccell.2015.10.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):582-598. doi: 10.1016/j.ccell.2015.10.001.

PMID- 26555173
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and 
      Tumor Growth.
PG  - 569-581
LID - S1535-6108(15)00352-9 [pii]
LID - 10.1016/j.ccell.2015.09.021 [doi]
AB  - Tumorigenesis is associated with increased glucose consumption and lipogenesis,
      but how these pathways are interlinked is unclear. Here, we delineate a pathway
      in which EGFR signaling, by increasing glucose uptake, promotes N-glycosylation
      of sterol regulatory element-binding protein (SREBP) cleavage-activating protein 
      (SCAP) and consequent activation of SREBP-1, an ER-bound transcription factor
      with central roles in lipid metabolism. Glycosylation stabilizes SCAP and reduces
      its association with Insig-1, allowing movement of SCAP/SREBP to the Golgi and
      consequent proteolytic activation of SREBP. Xenograft studies reveal that
      blocking SCAP N-glycosylation ameliorates EGFRvIII-driven glioblastoma growth.
      Thus, SCAP acts as key glucose-responsive protein linking oncogenic signaling and
      fuel availability to SREBP-dependent lipogenesis. Targeting SCAP N-glycosylation 
      may provide a promising means of treating malignancies and metabolic diseases.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Cheng, Chunming
AU  - Cheng C
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Ru, Peng
AU  - Ru P
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Geng, Feng
AU  - Geng F
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Liu, Junfeng
AU  - Liu J
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA; College of Life Science and Technology, Beijing 
      University of Chemical Technology, Beijing 100029, PR China.
FAU - Yoo, Ji Young
AU  - Yoo JY
AD  - Department of Neurosurgery, The Ohio State University Comprehensive Cancer
      Center, Columbus, OH 43210, USA.
FAU - Wu, Xiaoning
AU  - Wu X
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Cheng, Xiang
AU  - Cheng X
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Euthine, Vanessa
AU  - Euthine V
AD  - CarMeN Laboratory, INSERM U1060, INRA 1397, Faculte de Medecine Lyon Sud BP 12,
      Universite de Lyon, 69921 Oullins Cedex, France.
FAU - Hu, Peng
AU  - Hu P
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Guo, Jeffrey Yunhua
AU  - Guo JY
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Lefai, Etienne
AU  - Lefai E
AD  - CarMeN Laboratory, INSERM U1060, INRA 1397, Faculte de Medecine Lyon Sud BP 12,
      Universite de Lyon, 69921 Oullins Cedex, France.
FAU - Kaur, Balveen
AU  - Kaur B
AD  - Department of Neurosurgery, The Ohio State University Comprehensive Cancer
      Center, Columbus, OH 43210, USA.
FAU - Nohturfft, Axel
AU  - Nohturfft A
AD  - Vascular Biology Research Centre, St. George's University of London, London SW17 
      0RE, UK.
FAU - Ma, Jianjie
AU  - Ma J
AD  - Department of Surgery, Davis Heart and Lung Research Institute, The Ohio State
      University Medical Center, Columbus, OH 43210, USA.
FAU - Chakravarti, Arnab
AU  - Chakravarti A
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
FAU - Guo, Deliang
AU  - Guo D
AD  - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH 43210, USA. Electronic address: deliang.guo@osumc.edu.
LA  - eng
GR  - R01 CA150153/CA/NCI NIH HHS/United States
GR  - R21 NS072838/NS/NINDS NIH HHS/United States
GR  - R01 DK106394/DK/NIDDK NIH HHS/United States
GR  - R01 NS064607/NS/NINDS NIH HHS/United States
GR  - P30 NS038526/NS/NINDS NIH HHS/United States
GR  - R01 NS079701/NS/NINDS NIH HHS/United States
GR  - R01 AG028614/AG/NIA NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - NS072838/NS/NINDS NIH HHS/United States
GR  - P01 CA163205/CA/NCI NIH HHS/United States
GR  - AG28614/AG/NIA NIH HHS/United States
GR  - NS079701/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (INSIG1 protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (SREBF1 protein, human)
RN  - 0 (SREBP cleavage-activating protein)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
CIN - Cancer Cell. 2015 Nov 9;28(5):548-9. PMID: 26555169
MH  - Animals
MH  - Blotting, Western
MH  - Cell Line
MH  - Female
MH  - Glucose/metabolism/pharmacology
MH  - Glycosylation/drug effects
MH  - Golgi Apparatus/metabolism
MH  - HEK293 Cells
MH  - Hep G2 Cells
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/genetics/*metabolism
MH  - MCF-7 Cells
MH  - Membrane Proteins/genetics/*metabolism
MH  - Mice, Nude
MH  - Microscopy, Confocal
MH  - Neoplasms/genetics/*metabolism/pathology
MH  - Protein Binding
MH  - RNA Interference
MH  - Sterol Regulatory Element Binding Protein 1/genetics/*metabolism
MH  - Survival Analysis
MH  - Transplantation, Heterologous
MH  - Tumor Burden/genetics
PMC - PMC4643405
MID - NIHMS728998
OTO - NOTNLM
OT  - EGFR signaling
OT  - Insig-1
OT  - N-glycosylation
OT  - SCAP
OT  - SREBP-1
OT  - glioblastoma
EDAT- 2015/11/12 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/03/12 00:00 [received]
PHST- 2015/08/04 00:00 [revised]
PHST- 2015/09/27 00:00 [accepted]
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00352-9 [pii]
AID - 10.1016/j.ccell.2015.09.021 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):569-581. doi: 10.1016/j.ccell.2015.09.021.

PMID- 26555172
OWN - NLM
STAT- MEDLINE
DCOM- 20160211
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Welcoming Treat: Astrocyte-Derived Exosomes Induce PTEN Suppression to Foster
      Brain Metastasis.
PG  - 554-556
LID - S1535-6108(15)00387-6 [pii]
LID - 10.1016/j.ccell.2015.10.010 [doi]
AB  - Metastasis to distant organs depends on pathological crosstalk between tumor
      cells and various tissue-specific stromal components. Zhang and colleagues
      recently demonstrated that astrocyte-derived exosomal miR-19a reversibly
      downregulated PTEN expression in cancer cells, thereby increasing their CCL2
      secretion and recruitment of myeloid cell to promote brain metastasis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Aleckovic, Masa
AU  - Aleckovic M
AD  - Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
FAU - Kang, Yibin
AU  - Kang Y
AD  - Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA. 
      Electronic address: ykang@princeton.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MicroRNAs)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
CON - Nature. 2015 Nov 5;527(7576):100-4. PMID: 26479035
MH  - Animals
MH  - Brain Neoplasms/*pathology/*secondary
MH  - Exosomes/*genetics
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Gene Silencing
MH  - Humans
MH  - Male
MH  - MicroRNAs/*genetics
MH  - PTEN Phosphohydrolase/*deficiency
MH  - *Tumor Microenvironment
EDAT- 2015/11/12 06:00
MHDA- 2016/02/13 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
AID - S1535-6108(15)00387-6 [pii]
AID - 10.1016/j.ccell.2015.10.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):554-556. doi: 10.1016/j.ccell.2015.10.010.

PMID- 26555171
OWN - NLM
STAT- MEDLINE
DCOM- 20160405
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients.
PG  - 552-554
LID - S1535-6108(15)00384-0 [pii]
LID - 10.1016/j.ccell.2015.10.007 [doi]
AB  - Real-time monitoring of changes in cells or cell products released from malignant
      lesions into the blood has opened new diagnostic avenues ("liquid biopsy"). In
      this issue of Cancer Cell, Best and colleagues describe that tumor-associated
      blood platelets provide specific information on the location and molecular
      composition of the primary tumor.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Joosse, Simon A
AU  - Joosse SA
AD  - Department of Tumor Biology, Center of Experimental Medicine, University Medical 
      Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
FAU - Pantel, Klaus
AU  - Pantel K
AD  - Department of Tumor Biology, Center of Experimental Medicine, University Medical 
      Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Electronic
      address: pantel@uke.de.
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
CON - Cancer Cell. 2015 Nov 9;28(5):666-76. PMID: 26525104
MH  - Biomarkers, Tumor/*genetics
MH  - Blood Platelets/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/*genetics
MH  - Signal Transduction/*genetics
EDAT- 2015/11/12 06:00
MHDA- 2016/04/06 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/06 06:00 [medline]
AID - S1535-6108(15)00384-0 [pii]
AID - 10.1016/j.ccell.2015.10.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):552-554. doi: 10.1016/j.ccell.2015.10.007.

PMID- 26555170
OWN - NLM
STAT- MEDLINE
DCOM- 20160405
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - In Search of a Cure for Proteostasis-Addicted Cancer: A AAA Target Revealed.
PG  - 550-552
LID - S1535-6108(15)00383-9 [pii]
LID - 10.1016/j.ccell.2015.10.006 [doi]
AB  - Tumorigenesis is often associated with an unbalanced protein homeostasis
      (proteostasis) network, which sensitizes cancer cells to drugs targeting protein 
      quality control (PQC) regulators. In this issue of Cancer Cell, Anderson and
      colleagues investigated the anti-cancer activity of a new class of inhibitor
      against a multi-functional ATPase essential for proteostasis maintenance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Xia, Di
AU  - Xia D
AD  - Laboratory of Cell Biology, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic
      address: xiad@mail.nih.gov.
FAU - Ye, Yihong
AU  - Ye Y
AD  - Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and
      Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
      Electronic address: yihongy@mail.nih.gov.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Nuclear Proteins)
RN  - EC 3.6.1.- (Adenosine Triphosphatases)
SB  - IM
CON - Cancer Cell. 2015 Nov 9;28(5):653-65. PMID: 26555175
MH  - Adenosine Triphosphatases/*antagonists & inhibitors
MH  - Animals
MH  - Enzyme Inhibitors/*pharmacology
MH  - Homeostasis/*drug effects
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Nuclear Proteins/*antagonists & inhibitors
EDAT- 2015/11/12 06:00
MHDA- 2016/04/06 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/06 06:00 [medline]
AID - S1535-6108(15)00383-9 [pii]
AID - 10.1016/j.ccell.2015.10.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):550-552. doi: 10.1016/j.ccell.2015.10.006.

PMID- 26555169
OWN - NLM
STAT- MEDLINE
DCOM- 20160405
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Sugar Makes Fat by Talking to SCAP.
PG  - 548-549
LID - S1535-6108(15)00388-8 [pii]
LID - 10.1016/j.ccell.2015.10.011 [doi]
AB  - Elevated blood glucose promotes lipogenesis via activating SREBP transcription
      factors. Tumors exhibit increased glucose uptake and lipogenesis, but the
      mechanisms controlling this are poorly understood. In this issue of Cancer Cell, 
      Cheng and colleagues find that glucose activates SREBP by stabilizing SCAP, a
      central regulator of the SREBP pathway.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Shao, Wei
AU  - Shao W
AD  - Department of Cell Biology, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
FAU - Espenshade, Peter J
AU  - Espenshade PJ
AD  - Department of Cell Biology, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA. Electronic address: peter.espenshade@jhmi.edu.
LA  - eng
GR  - R01 HL077588/HL/NHLBI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
SB  - IM
CON - Cancer Cell. 2015 Nov 9;28(5):569-81. PMID: 26555173
MH  - Animals
MH  - Female
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Membrane Proteins/*metabolism
MH  - Neoplasms/*metabolism
MH  - Sterol Regulatory Element Binding Protein 1/*metabolism
PMC - PMC4772404
MID - NIHMS761092
EDAT- 2015/11/12 06:00
MHDA- 2016/04/06 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/06 06:00 [medline]
AID - S1535-6108(15)00388-8 [pii]
AID - 10.1016/j.ccell.2015.10.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):548-549. doi: 10.1016/j.ccell.2015.10.011.

PMID- 26555168
OWN - NLM
STAT- MEDLINE
DCOM- 20160405
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Epigenetic Deficiencies and Replicative Stress: Driving Cancer Cells to an Early 
      Grave.
PG  - 545-547
LID - S1535-6108(15)00386-4 [pii]
LID - 10.1016/j.ccell.2015.10.009 [doi]
AB  - Cancer cell-specific synthetic lethal interactions entail promising therapeutic
      possibilities. In this issue of Cancer Cell, Pfister et al. describe a synthetic 
      lethal interaction where cancer cells deficient in H3K36me3 owing to SETD2
      loss-of-function mutation are strongly sensitized to inhibition of WEE1, a cell
      cycle controlling kinase.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Shoaib, Muhammad
AU  - Shoaib M
AD  - Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Ole
      Maaloes Vej 5, 2200 Copenhagen N, Denmark.
FAU - Sorensen, Claus Storgaard
AU  - Sorensen CS
AD  - Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Ole
      Maaloes Vej 5, 2200 Copenhagen N, Denmark. Electronic address:
      claus.storgaard@bric.ku.dk.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Histones)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Nucleotides)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
CON - Cancer Cell. 2015 Nov 9;28(5):557-68. PMID: 26602815
MH  - Animals
MH  - Cell Cycle Proteins/*metabolism
MH  - Histones/*metabolism
MH  - Humans
MH  - Neoplasms/*metabolism
MH  - Nuclear Proteins/*metabolism
MH  - Nucleotides/*metabolism
MH  - Protein-Tyrosine Kinases/*metabolism
EDAT- 2015/11/12 06:00
MHDA- 2016/04/06 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/04/06 06:00 [medline]
AID - S1535-6108(15)00386-4 [pii]
AID - 10.1016/j.ccell.2015.10.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):545-547. doi: 10.1016/j.ccell.2015.10.009.

PMID- 26525104
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass,
      and Molecular Pathway Cancer Diagnostics.
PG  - 666-676
LID - S1535-6108(15)00349-9 [pii]
LID - 10.1016/j.ccell.2015.09.018 [doi]
AB  - Tumor-educated blood platelets (TEPs) are implicated as central players in the
      systemic and local responses to tumor growth, thereby altering their RNA profile.
      We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet
      samples. We distinguished 228 patients with localized and metastasized tumors
      from 55 healthy individuals with 96% accuracy. Across six different tumor types, 
      the location of the primary tumor was correctly identified with 71% accuracy.
      Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were
      accurately distinguished using surrogate TEP mRNA profiles. Our results indicate 
      that blood platelets provide a valuable platform for pan-cancer, multiclass
      cancer, and companion diagnostics, possibly enabling clinical advances in
      blood-based "liquid biopsies".
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Best, Myron G
AU  - Best MG
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Sol, Nik
AU  - Sol N
AD  - Department of Neurology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Kooi, Irsan
AU  - Kooi I
AD  - Department of Clinical Genetics, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Tannous, Jihane
AU  - Tannous J
AD  - Department of Neurology, Massachusetts General Hospital and Neuroscience Program,
      Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
FAU - Westerman, Bart A
AU  - Westerman BA
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Rustenburg, Francois
AU  - Rustenburg F
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan
      1117, 1081 HV Amsterdam, the Netherlands.
FAU - Schellen, Pepijn
AU  - Schellen P
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V.,
      1098 EA Amsterdam, the Netherlands.
FAU - Verschueren, Heleen
AU  - Verschueren H
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V.,
      1098 EA Amsterdam, the Netherlands.
FAU - Post, Edward
AU  - Post E
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V.,
      1098 EA Amsterdam, the Netherlands.
FAU - Koster, Jan
AU  - Koster J
AD  - Department of Oncogenomics, Academic Medical Center, Meibergdreef 9, 1105 AZ
      Amsterdam, the Netherlands.
FAU - Ylstra, Bauke
AU  - Ylstra B
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Ameziane, Najim
AU  - Ameziane N
AD  - Department of Clinical Genetics, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Dorsman, Josephine
AU  - Dorsman J
AD  - Department of Clinical Genetics, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Smit, Egbert F
AU  - Smit EF
AD  - Department of Pulmonary Diseases, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Verheul, Henk M
AU  - Verheul HM
AD  - Department of Medical Oncology, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Noske, David P
AU  - Noske DP
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Reijneveld, Jaap C
AU  - Reijneveld JC
AD  - Department of Neurology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
FAU - Nilsson, R Jonas A
AU  - Nilsson RJA
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V.,
      1098 EA Amsterdam, the Netherlands; Department of Radiation Sciences, Oncology,
      Umea University, 90185 Umea, Sweden.
FAU - Tannous, Bakhos A
AU  - Tannous BA
AD  - Department of Neurology, Massachusetts General Hospital and Neuroscience Program,
      Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
FAU - Wesseling, Pieter
AU  - Wesseling P
AD  - Department of Pathology, VU University Medical Center, Cancer Center Amsterdam,
      De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Pathology,
      Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands.
FAU - Wurdinger, Thomas
AU  - Wurdinger T
AD  - Department of Neurosurgery, VU University Medical Center, Cancer Center
      Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of
      Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard
      Medical School, 149 13th Street, Charlestown, MA 02129, USA; thromboDx B.V., 1098
      EA Amsterdam, the Netherlands. Electronic address: t.wurdinger@vumc.nl.
LA  - eng
SI  - GEO/GSE68086
GR  - P01 CA069246/CA/NCI NIH HHS/United States
GR  - R21 CA176359/CA/NCI NIH HHS/United States
GR  - CA069246/CA/NCI NIH HHS/United States
GR  - NIH/NCI CA176359/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151029
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KRAS protein, human)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
CIN - Nat Rev Genet. 2015 Dec;16(12):688. PMID: 26553328
CIN - Cancer Cell. 2015 Nov 9;28(5):552-4. PMID: 26555171
CIN - Nat Rev Cancer. 2015 Dec;15(12):696-7. PMID: 26563465
CIN - Cancer Cell. 2016 Feb 8;29(2):143-4. PMID: 26859454
CIN - Cancer Cell. 2016 Feb 8;29(2):141-2. PMID: 26859453
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/blood/*genetics
MH  - Blood Platelets/*metabolism
MH  - Class I Phosphatidylinositol 3-Kinases
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Ontology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasms/blood/diagnosis/*genetics
MH  - Pathology, Molecular/methods
MH  - Phosphatidylinositol 3-Kinases/genetics
MH  - Proto-Oncogene Proteins c-met/genetics
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Receptor, Epidermal Growth Factor/genetics
MH  - Receptor, ErbB-2/genetics
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Sequence Analysis, RNA/methods
MH  - Signal Transduction/*genetics
MH  - Support Vector Machine
MH  - Young Adult
PMC - PMC4644263
EDAT- 2015/11/04 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/04 06:00
PHST- 2015/03/23 00:00 [received]
PHST- 2015/07/02 00:00 [revised]
PHST- 2015/09/25 00:00 [accepted]
PHST- 2015/11/04 06:00 [entrez]
PHST- 2015/11/04 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00349-9 [pii]
AID - 10.1016/j.ccell.2015.09.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):666-676. doi: 10.1016/j.ccell.2015.09.018. Epub
      2015 Oct 29.

PMID- 26525103
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170718
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical
      Barriers to Treat Pancreatic Ductal Adenocarcinoma.
PG  - 638-652
LID - 10.1016/j.ccell.2015.09.022 [doi]
AB  - Pancreatic ductal adenocarcinomas (PDAs) erect physical barriers to chemotherapy 
      and induce multiple mechanisms of immune suppression, creating a sanctuary for
      unimpeded growth. We tested the ability of T cells engineered to express an
      affinity-enhanced T cell receptor (TCR) against a native antigen to overcome
      these barriers in a genetically engineered model of autochthonous PDA. Engineered
      T cells preferentially accumulate in PDA and induce tumor cell death and stromal 
      remodeling. However, tumor-infiltrating T cells become progressively
      dysfunctional, a limitation successfully overcome by serial T cell infusions that
      resulted in a near-doubling of survival without overt toxicities. Similarly
      engineered human T cells lyse PDA cells in vitro, further supporting clinical
      advancement of this TCR-based strategy for the treatment of PDA.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Stromnes, Ingunn M
AU  - Stromnes IM
AD  - Clinical Research Division, Seattle, WA, 98109.
AD  - Department of Immunology, University of Washington School of Medicine, Seattle,
      WA, 98195.
FAU - Schmitt, Thomas M
AU  - Schmitt TM
AD  - Clinical Research Division, Seattle, WA, 98109.
FAU - Hulbert, Ayaka
AU  - Hulbert A
AD  - Clinical Research Division, Seattle, WA, 98109.
FAU - Brockenbrough, J Scott
AU  - Brockenbrough JS
AD  - Clinical Research Division, Seattle, WA, 98109.
FAU - Nguyen, Hieu
AU  - Nguyen H
AD  - Clinical Research Division, Seattle, WA, 98109.
FAU - Cuevas, Carlos
AU  - Cuevas C
AD  - Department of Radiology, University of Washington School of Medicine, Seattle,
      WA, 98195.
FAU - Dotson, Ashley M
AU  - Dotson AM
AD  - Clinical Research Division, Seattle, WA, 98109.
FAU - Tan, Xiaoxia
AU  - Tan X
AD  - Department of Immunology, University of Washington School of Medicine, Seattle,
      WA, 98195.
FAU - Hotes, Jennifer L
AU  - Hotes JL
AD  - Clinical Research Division, Seattle, WA, 98109.
FAU - Greenberg, Philip D
AU  - Greenberg PD
AD  - Clinical Research Division, Seattle, WA, 98109.
AD  - Department of Immunology, University of Washington School of Medicine, Seattle,
      WA, 98195.
AD  - Division of Medical Oncology, University of Washington School of Medicine,
      Seattle, WA, 98195.
FAU - Hingorani, Sunil R
AU  - Hingorani SR
AD  - Clinical Research Division, Seattle, WA, 98109.
AD  - Public Health Sciences Division of the Fred Hutchinson Cancer Research Center,
      Seattle, WA, 98109.
AD  - Division of Medical Oncology, University of Washington School of Medicine,
      Seattle, WA, 98195.
LA  - eng
GR  - CA015704/CA/NCI NIH HHS/United States
GR  - CA161112/CA/NCI NIH HHS/United States
GR  - R01 CA161112/CA/NCI NIH HHS/United States
GR  - CA033084/CA/NCI NIH HHS/United States
GR  - P01 CA018029/CA/NCI NIH HHS/United States
GR  - P30 CA015704/CA/NCI NIH HHS/United States
GR  - R37 CA033084/CA/NCI NIH HHS/United States
GR  - CA018029/CA/NCI NIH HHS/United States
GR  - R01 CA033084/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151029
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (mesothelin)
SB  - IM
CIN - Nat Rev Drug Discov. 2016 Jan;15(1):16-7. PMID: 26718277
MH  - Animals
MH  - Antigens/*immunology
MH  - Carcinoma, Pancreatic Ductal/*immunology/pathology/therapy
MH  - Cell Line, Tumor
MH  - GPI-Linked Proteins/genetics/immunology/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - HEK293 Cells
MH  - Humans
MH  - Immunoblotting
MH  - Immunotherapy, Adoptive/methods
MH  - Jurkat Cells
MH  - Kaplan-Meier Estimate
MH  - Mice, 129 Strain
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Pancreatic Neoplasms/*immunology/pathology/therapy
MH  - Protein Engineering/methods
MH  - Receptors, Antigen, T-Cell/genetics/immunology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - T-Lymphocytes/*immunology/metabolism/transplantation
MH  - Transfection
MH  - Tumor Cells, Cultured
PMC - PMC4724422
MID - NIHMS734222
EDAT- 2015/11/04 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/04 06:00
PHST- 2015/03/21 00:00 [received]
PHST- 2015/08/18 00:00 [revised]
PHST- 2015/09/30 00:00 [accepted]
PHST- 2015/11/04 06:00 [entrez]
PHST- 2015/11/04 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.1016/j.ccell.2015.09.022 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):638-652. doi: 10.1016/j.ccell.2015.09.022. Epub
      2015 Oct 29.

PMID- 26481148
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - Erythropoietin Stimulates Tumor Growth via EphB4.
PG  - 610-622
LID - S1535-6108(15)00339-6 [pii]
LID - 10.1016/j.ccell.2015.09.008 [doi]
AB  - While recombinant human erythropoietin (rhEpo) has been widely used to treat
      anemia in cancer patients, concerns about its adverse effects on patient survival
      have emerged. A lack of correlation between expression of the canonical EpoR and 
      rhEpo's effects on cancer cells prompted us to consider the existence of an
      alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that
      triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth
      and progression. In human ovarian and breast cancer samples, expression of EphB4 
      rather than the canonical EpoR correlated with decreased disease-specific
      survival in rhEpo-treated patients. These results identify EphB4 as a critical
      mediator of erythropoietin-induced tumor progression and further provide
      clinically significant dimension to the biology of erythropoietin.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Pradeep, Sunila
AU  - Pradeep S
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Huang, Jie
AU  - Huang J
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Mora, Edna M
AU  - Mora EM
AD  - Department of Surgery, University of Puerto Rico, San Juan 00936, Puerto Rico;
      University of Puerto Rico Comprehensive Cancer Center, San Juan 00936, Puerto
      Rico; Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Nick, Alpa M
AU  - Nick AM
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Cho, Min Soon
AU  - Cho MS
AD  - Department of Benign Hematology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Wu, Sherry Y
AU  - Wu SY
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Noh, Kyunghee
AU  - Noh K
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Pecot, Chad V
AU  - Pecot CV
AD  - Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC
      27599, USA.
FAU - Rupaimoole, Rajesha
AU  - Rupaimoole R
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Stein, Martin A
AU  - Stein MA
AD  - Molecular Health, GmbH, Heidelberg 69115, Germany.
FAU - Brock, Stephan
AU  - Brock S
AD  - Molecular Health, GmbH, Heidelberg 69115, Germany.
FAU - Wen, Yunfei
AU  - Wen Y
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Xiong, Chiyi
AU  - Xiong C
AD  - Department of Experimental Diagnostic Imaging, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Gharpure, Kshipra
AU  - Gharpure K
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Hansen, Jean M
AU  - Hansen JM
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Nagaraja, Archana S
AU  - Nagaraja AS
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Previs, Rebecca A
AU  - Previs RA
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Vivas-Mejia, Pablo
AU  - Vivas-Mejia P
AD  - Department of Surgery, University of Puerto Rico, San Juan 00936, Puerto Rico.
FAU - Han, Hee Dong
AU  - Han HD
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA; Center for RNA Interference and Non-coding RNA,
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hu, Wei
AU  - Hu W
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Mangala, Lingegowda S
AU  - Mangala LS
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA; Center for RNA Interference and Non-coding RNA,
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zand, Behrouz
AU  - Zand B
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Stagg, Loren J
AU  - Stagg LJ
AD  - Department of Biochemistry and Molecular Biology and Center for Biomolecular
      Structure and Function, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ladbury, John E
AU  - Ladbury JE
AD  - Department of Biochemistry and Molecular Biology and Center for Biomolecular
      Structure and Function, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ozpolat, Bulent
AU  - Ozpolat B
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Alpay, S Neslihan
AU  - Alpay SN
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Nishimura, Masato
AU  - Nishimura M
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Stone, Rebecca L
AU  - Stone RL
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Matsuo, Koji
AU  - Matsuo K
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Armaiz-Pena, Guillermo N
AU  - Armaiz-Pena GN
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Dalton, Heather J
AU  - Dalton HJ
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Danes, Christopher
AU  - Danes C
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Goodman, Blake
AU  - Goodman B
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Rodriguez-Aguayo, Cristian
AU  - Rodriguez-Aguayo C
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Kruger, Carola
AU  - Kruger C
AD  - Molecular Neurology, Sygnis AG, Heidelberg 69120, Germany.
FAU - Schneider, Armin
AU  - Schneider A
AD  - Molecular Neurology, Sygnis AG, Heidelberg 69120, Germany.
FAU - Haghpeykar, Shyon
AU  - Haghpeykar S
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Jaladurgam, Padmavathi
AU  - Jaladurgam P
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Center for Molecular Medicine and Graduate Institute of
      Cancer Biology, China Medical University, Taichung 402, Taiwan.
FAU - Coleman, Robert L
AU  - Coleman RL
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA.
FAU - Liu, Jinsong
AU  - Liu J
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Li, Chun
AU  - Li C
AD  - Department of Biochemistry and Molecular Biology and Center for Biomolecular
      Structure and Function, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Urbauer, Diana
AU  - Urbauer D
AD  - Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
      77030, USA.
FAU - Lopez-Berestein, Gabriel
AU  - Lopez-Berestein G
AD  - Center for RNA Interference and Non-coding RNA, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; Department of Experimental
      Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
      77030, USA.
FAU - Jackson, David B
AU  - Jackson DB
AD  - Molecular Health, GmbH, Heidelberg 69115, Germany.
FAU - Sood, Anil K
AU  - Sood AK
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77584, USA; Center for RNA Interference and Non-coding RNA,
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Cancer
      Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030,
      USA. Electronic address: asood@mdanderson.org.
LA  - eng
GR  - U54 CA 096300/CA/NCI NIH HHS/United States
GR  - T32 CA101642/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - UH2 TR000943/TR/NCATS NIH HHS/United States
GR  - CA 177909/CA/NCI NIH HHS/United States
GR  - R01 CA177909/CA/NCI NIH HHS/United States
GR  - UH3 TR000943/TR/NCATS NIH HHS/United States
GR  - R01 CA109298/CA/NCI NIH HHS/United States
GR  - P50 CA098258/CA/NCI NIH HHS/United States
GR  - U54 CA151668/CA/NCI NIH HHS/United States
GR  - U54CA151668/CA/NCI NIH HHS/United States
GR  - U54 CA096300/CA/NCI NIH HHS/United States
GR  - CA 16672/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
GR  - R01 CA128797/CA/NCI NIH HHS/United States
GR  - CA 109298/CA/NCI NIH HHS/United States
GR  - K12 HD050128/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20151017
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptors, Erythropoietin)
RN  - 0 (Recombinant Proteins)
RN  - 0 (STAT3 Transcription Factor)
RN  - 11096-26-7 (Erythropoietin)
RN  - EC 2.7.10.1 (Receptor, EphB4)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Blotting, Western
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Disease Progression
MH  - Erythropoietin/genetics/*pharmacology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - MCF-7 Cells
MH  - Mice, Inbred C57BL
MH  - Mice, Nude
MH  - Middle Aged
MH  - Ovarian Neoplasms/*genetics/metabolism/pathology
MH  - Protein Binding/drug effects
MH  - Receptor, EphB4/*genetics/metabolism
MH  - Receptors, Erythropoietin/genetics/metabolism
MH  - Recombinant Proteins/pharmacology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - STAT3 Transcription Factor/genetics/metabolism
MH  - Young Adult
PMC - PMC4643364
MID - NIHMS725533
EDAT- 2015/10/21 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/10/21 06:00
PHST- 2014/06/06 00:00 [received]
PHST- 2014/11/05 00:00 [revised]
PHST- 2015/09/16 00:00 [accepted]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00339-6 [pii]
AID - 10.1016/j.ccell.2015.09.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):610-622. doi: 10.1016/j.ccell.2015.09.008. Epub
      2015 Oct 17.

PMID- 26481147
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 5
DP  - 2015 Nov 9
TI  - A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
PG  - 599-609
LID - S1535-6108(15)00343-8 [pii]
LID - 10.1016/j.ccell.2015.09.012 [doi]
AB  - A more complete understanding of aberrant oncogenic signaling in neuroblastoma, a
      malignancy of the developing sympathetic nervous system, is paramount to
      improving patient outcomes. Recently, we identified LIN28B as an oncogenic driver
      in high-risk neuroblastoma. Here, we identify the oncogene RAN as a LIN28B target
      and show regional gain of chromosome 12q24 as an additional somatic alteration
      resulting in increased RAN expression. We show that LIN28B influences RAN
      expression by promoting RAN Binding Protein 2 expression and by directly binding 
      RAN mRNA. Further, we demonstrate a convergence of LIN28B and RAN signaling on
      Aurora kinase A activity. Collectively, these findings demonstrate that
      LIN28B-RAN-AURKA signaling drives neuroblastoma oncogenesis, suggesting that this
      pathway may be amenable to therapeutic targeting.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Schnepp, Robert W
AU  - Schnepp RW
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Khurana, Priya
AU  - Khurana P
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Attiyeh, Edward F
AU  - Attiyeh EF
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, 
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, 
      USA.
FAU - Raman, Pichai
AU  - Raman P
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Biomedical
      and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA
      19104, USA.
FAU - Chodosh, Sara E
AU  - Chodosh SE
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Oldridge, Derek A
AU  - Oldridge DA
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Gagliardi, Maria E
AU  - Gagliardi ME
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Conkrite, Karina L
AU  - Conkrite KL
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Asgharzadeh, Shahab
AU  - Asgharzadeh S
AD  - Division of Hematology, Oncology, and Blood and Marrow Transplantation,
      Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA 90027,
      USA.
FAU - Seeger, Robert C
AU  - Seeger RC
AD  - Division of Hematology, Oncology, and Blood and Marrow Transplantation,
      Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA 90027,
      USA.
FAU - Madison, Blair B
AU  - Madison BB
AD  - Division of Gastroenterology, Washington University School of Medicine in St.
      Louis, St. Louis, MO 63110, USA.
FAU - Rustgi, Anil K
AU  - Rustgi AK
AD  - Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 
      Philadelphia, PA 19104, USA; Division of Gastroenterology, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of 
      Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      PA 19104, USA; Department of Genetics, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Maris, John M
AU  - Maris JM
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, 
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, 
      USA; Abramson Family Cancer Research Institute, Perelman School of Medicine at
      University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
      maris@email.chop.edu.
FAU - Diskin, Sharon J
AU  - Diskin SJ
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, 
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, 
      USA; Abramson Family Cancer Research Institute, Perelman School of Medicine at
      University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
      diskin@email.chop.edu.
LA  - eng
GR  - R01-CA124709/CA/NCI NIH HHS/United States
GR  - R01 CA124709/CA/NCI NIH HHS/United States
GR  - F30 CA192831/CA/NCI NIH HHS/United States
GR  - RC1 MD004418/MD/NIMHD NIH HHS/United States
GR  - R01 DK056645/DK/NIDDK NIH HHS/United States
GR  - K01 DK093885/DK/NIDDK NIH HHS/United States
GR  - 1RC1MD004418-01/MD/NIMHD NIH HHS/United States
GR  - R00-CA151869/CA/NCI NIH HHS/United States
GR  - K12 HD043245/HD/NICHD NIH HHS/United States
GR  - K12 HD04324/HD/NICHD NIH HHS/United States
GR  - T32 CA009615/CA/NCI NIH HHS/United States
GR  - T32 HG000046/HG/NHGRI NIH HHS/United States
GR  - R00 CA151869/CA/NCI NIH HHS/United States
GR  - R01-DK056645/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151017
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (LIN28B protein, human)
RN  - 0 (MYCN protein, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Molecular Chaperones)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Nuclear Pore Complex Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins)
RN  - 0 (RAN protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (mirnlet7 microRNA, human)
RN  - 0 (ran-binding protein 2)
RN  - EC 2.7.11.1 (AURKA protein, human)
RN  - EC 2.7.11.1 (Aurora Kinase A)
RN  - EC 3.6.5.2 (ran GTP-Binding Protein)
SB  - IM
MH  - Aurora Kinase A/*genetics/metabolism
MH  - Blotting, Western
MH  - Carcinogenesis/genetics
MH  - Cell Line, Tumor
MH  - Child
MH  - Chromosomes, Human, Pair 12/genetics
MH  - DNA Copy Number Variations
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - MicroRNAs/genetics
MH  - Molecular Chaperones/genetics/metabolism
MH  - N-Myc Proto-Oncogene Protein
MH  - Neuroblastoma/*genetics/metabolism/pathology
MH  - Nuclear Pore Complex Proteins/genetics/metabolism
MH  - Nuclear Proteins/genetics/metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - Oncogene Proteins/genetics/metabolism
MH  - RNA-Binding Proteins/*genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/*genetics
MH  - ran GTP-Binding Protein/*genetics/metabolism
PMC - PMC4643330
MID - NIHMS728949
EDAT- 2015/10/21 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/02/14 00:00 [received]
PHST- 2015/06/18 00:00 [revised]
PHST- 2015/09/22 00:00 [accepted]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1535-6108(15)00343-8 [pii]
AID - 10.1016/j.ccell.2015.09.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Nov 9;28(5):599-609. doi: 10.1016/j.ccell.2015.09.012. Epub
      2015 Oct 17.

PMID- 26461095
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Comprehensive Genomic Characterization of Long Non-coding RNAs across Human
      Cancers.
PG  - 529-540
LID - S1535-6108(15)00337-2 [pii]
LID - 10.1016/j.ccell.2015.09.006 [doi]
AB  - The discovery of long non-coding RNA (lncRNA) has dramatically altered our
      understanding of cancer. Here, we describe a comprehensive analysis of lncRNA
      alterations at transcriptional, genomic, and epigenetic levels in 5,037 human
      tumor specimens across 13 cancer types from The Cancer Genome Atlas. Our results 
      suggest that the expression and dysregulation of lncRNAs are highly cancer type
      specific compared with protein-coding genes. Using the integrative data generated
      by this analysis, we present a clinically guided small interfering RNA screening 
      strategy and a co-expression analysis approach to identify cancer driver lncRNAs 
      and predict their functions. This provides a resource for investigating lncRNAs
      in cancer and lays the groundwork for the development of new diagnostics and
      treatments.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Yan, Xiaohui
AU  - Yan X
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Shanghai Key
      Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and
      Gynecology Hospital, Fudan University, Shanghai 200011, China.
FAU - Hu, Zhongyi
AU  - Hu Z
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Feng, Yi
AU  - Feng Y
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson
      Family Cancer Research Institute, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Hu, Xiaowen
AU  - Hu X
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Yuan, Jiao
AU  - Yuan J
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Zhao, Sihai D
AU  - Zhao SD
AD  - Department of Statistics, University of Illinois at Urbana-Champaign, Champaign, 
      IL 61820, USA.
FAU - Zhang, Youyou
AU  - Zhang Y
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Yang, Lu
AU  - Yang L
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; West China
      Medical School, Sichuan University, Chengdu 610041, China.
FAU - Shan, Weiwei
AU  - Shan W
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Shanghai Key
      Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and
      Gynecology Hospital, Fudan University, Shanghai 200011, China.
FAU - He, Qun
AU  - He Q
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Fan, Lingling
AU  - Fan L
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Shanghai Key
      Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and
      Gynecology Hospital, Fudan University, Shanghai 200011, China.
FAU - Kandalaft, Lana E
AU  - Kandalaft LE
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Ludwig Center 
      for Cancer Research and Department of Oncology, University of Lausanne, Lausanne 
      1007, Switzerland.
FAU - Tanyi, Janos L
AU  - Tanyi JL
AD  - Department of Obstetrics and Gynecology, Perelman School of Medicine, University 
      of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Li, Chunsheng
AU  - Li C
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of 
      Obstetrics and Gynecology, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Yuan, Chao-Xing
AU  - Yuan CX
AD  - Department of Pharmacology, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Zhang, Dongmei
AU  - Zhang D
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; West China
      Medical School, Sichuan University, Chengdu 610041, China.
FAU - Yuan, Huiqing
AU  - Yuan H
AD  - Department of Biochemistry and Molecular Biology, School of Medicine, Shandong
      University, Jinan 250012, China.
FAU - Hua, Keqin
AU  - Hua K
AD  - Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases,
      Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
FAU - Lu, Yiling
AU  - Lu Y
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77054, USA.
FAU - Katsaros, Dionyssios
AU  - Katsaros D
AD  - Department of Surgical Sciences, Gynecologic Oncology, Azienda Ospedaliero -
      Universitaria Citta della Salute, Turin 10126, Italy.
FAU - Huang, Qihong
AU  - Huang Q
AD  - Wistar Institute, Philadelphia, PA 19104, USA.
FAU - Montone, Kathleen
AU  - Montone K
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Fan, Yi
AU  - Fan Y
AD  - Department of Radiation Oncology, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Coukos, George
AU  - Coukos G
AD  - Ludwig Center for Cancer Research and Department of Oncology, University of
      Lausanne, Lausanne 1007, Switzerland.
FAU - Boyd, Jeff
AU  - Boyd J
AD  - Cancer Genome Institute, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
FAU - Sood, Anil K
AU  - Sood AK
AD  - Department of Gynecologic Oncology, University of Texas MD Anderson Cancer
      Center, Houston, TX 77054, USA; Center for RNA Interference and Non-Coding RNA,
      University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
FAU - Rebbeck, Timothy
AU  - Rebbeck T
AD  - Department of Biostatistics and Epidemiology, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77054, USA.
FAU - Dang, Chi V
AU  - Dang CV
AD  - Abramson Family Cancer Research Institute, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Medicine, 
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, 
      USA. Electronic address: dangvchi@exchange.upenn.edu.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Center for Research on Reproduction & Women's Health, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of 
      Obstetrics and Gynecology, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
      linzhang@mail.med.upenn.edu.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50CA098258/CA/NCI NIH HHS/United States
GR  - R01 CA057341/CA/NCI NIH HHS/United States
GR  - P50CA174523/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA142776/CA/NCI NIH HHS/United States
GR  - CA016672/CA/NCI NIH HHS/United States
GR  - P01CA099031/CA/NCI NIH HHS/United States
GR  - P50 CA098258/CA/NCI NIH HHS/United States
GR  - R01 CA148759/CA/NCI NIH HHS/United States
GR  - U24CA143883/CA/NCI NIH HHS/United States
GR  - R01CA148759/CA/NCI NIH HHS/United States
GR  - P50 CA174523/CA/NCI NIH HHS/United States
GR  - R01 CA051497/CA/NCI NIH HHS/United States
GR  - R01CA142776/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
GR  - P50CA083638/CA/NCI NIH HHS/United States
GR  - P30 CA016520/CA/NCI NIH HHS/United States
GR  - R01 CA190415/CA/NCI NIH HHS/United States
GR  - P50 CA083638/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - P01 CA099031/CA/NCI NIH HHS/United States
GR  - P50CA083639/CA/NCI NIH HHS/United States
GR  - R01CA190415/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Cell Line, Tumor
MH  - Computational Biology/methods
MH  - Epigenesis, Genetic
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Genetic Variation
MH  - Genome, Human
MH  - Humans
MH  - Neoplasms/*genetics
MH  - RNA, Long Noncoding/*genetics
MH  - Transcription, Genetic
PMC - PMC4777353
MID - NIHMS726531
EDAT- 2015/10/16 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/03/07 00:00 [received]
PHST- 2015/07/23 00:00 [revised]
PHST- 2015/09/15 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00337-2 [pii]
AID - 10.1016/j.ccell.2015.09.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):529-540. doi: 10.1016/j.ccell.2015.09.006.

PMID- 26461094
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.
PG  - 500-514
LID - S1535-6108(15)00334-7 [pii]
LID - 10.1016/j.ccell.2015.09.003 [doi]
AB  - Plasmodium falciparum engineer infected erythrocytes to present the malarial
      protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS)
      exclusively expressed in the placenta. Here, we show that the same CS
      modification is present on a high proportion of malignant cells and that it can
      be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors,
      placental-like CS chains are linked to a limited repertoire of cancer-associated 
      proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in 
      vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds 
      strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate 
      how an evolutionarily refined parasite-derived protein can be exploited to target
      a common, but complex, malignancy-associated glycosaminoglycan modification.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Salanti, Ali
AU  - Salanti A
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark. Electronic
      address: salanti@sund.ku.dk.
FAU - Clausen, Thomas M
AU  - Clausen TM
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark; Vancouver
      Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, 
      University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Department of
      Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z
      1L3, Canada.
FAU - Agerbaek, Mette O
AU  - Agerbaek MO
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark; Vancouver
      Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, 
      University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
FAU - Al Nakouzi, Nader
AU  - Al Nakouzi N
AD  - Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic 
      Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
FAU - Dahlback, Madeleine
AU  - Dahlback M
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Oo, Htoo Z
AU  - Oo HZ
AD  - Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic 
      Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
FAU - Lee, Sherry
AU  - Lee S
AD  - Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
FAU - Gustavsson, Tobias
AU  - Gustavsson T
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Rich, Jamie R
AU  - Rich JR
AD  - Kairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug
      Research and Development, Vancouver, BC V6T 1Z3, Canada.
FAU - Hedberg, Bradley J
AU  - Hedberg BJ
AD  - Kairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug
      Research and Development, Vancouver, BC V6T 1Z3, Canada.
FAU - Mao, Yang
AU  - Mao Y
AD  - Department of Biochemistry, Boston University School of Medicine, Boston, MA
      02118, USA.
FAU - Barington, Line
AU  - Barington L
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Pereira, Marina A
AU  - Pereira MA
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - LoBello, Janine
AU  - LoBello J
AD  - Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
FAU - Endo, Makoto
AU  - Endo M
AD  - Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver,
      BC V6H 3Z6, Canada; Department of Pathology and Laboratory Medicine, University
      of British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Anatomic
      Pathology, Kyushu University, Fukuoka 812-8582, Japan; Department of Orthopaedic 
      Surgery, Kyushu University, Fukuoka 819-0395, Japan.
FAU - Fazli, Ladan
AU  - Fazli L
AD  - Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
FAU - Soden, Jo
AU  - Soden J
AD  - Retrogenix Ltd., Crown House, Bingswood Estate, Whaley Bridge, High Peak SK23
      7LY, UK.
FAU - Wang, Chris K
AU  - Wang CK
AD  - Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
FAU - Sander, Adam F
AU  - Sander AF
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Dagil, Robert
AU  - Dagil R
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Thrane, Susan
AU  - Thrane S
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Holst, Peter J
AU  - Holst PJ
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Meng, Le
AU  - Meng L
AD  - Department of Biochemistry, Boston University School of Medicine, Boston, MA
      02118, USA.
FAU - Favero, Francesco
AU  - Favero F
AD  - Centre for Biological Sequence Analysis, Technical University of Denmark, Lyngby 
      2800, Denmark.
FAU - Weiss, Glen J
AU  - Weiss GJ
AD  - Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA; Cancer 
      Treatment Centers of America, Goodyear, AZ 85338, USA.
FAU - Nielsen, Morten A
AU  - Nielsen MA
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Freeth, Jim
AU  - Freeth J
AD  - Retrogenix Ltd., Crown House, Bingswood Estate, Whaley Bridge, High Peak SK23
      7LY, UK.
FAU - Nielsen, Torsten O
AU  - Nielsen TO
AD  - Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver,
      BC V6H 3Z6, Canada; Department of Pathology and Laboratory Medicine, University
      of British Columbia, Vancouver, BC V6T 2B5, Canada.
FAU - Zaia, Joseph
AU  - Zaia J
AD  - Department of Biochemistry, Boston University School of Medicine, Boston, MA
      02118, USA.
FAU - Tran, Nhan L
AU  - Tran NL
AD  - Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
FAU - Trent, Jeff
AU  - Trent J
AD  - Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
FAU - Babcook, John S
AU  - Babcook JS
AD  - Kairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug
      Research and Development, Vancouver, BC V6T 1Z3, Canada.
FAU - Theander, Thor G
AU  - Theander TG
AD  - Department of Immunology and Microbiology, Centre for Medical Parasitology,
      University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious
      Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
FAU - Sorensen, Poul H
AU  - Sorensen PH
AD  - Department of Molecular Oncology, British Columbia Cancer Research Centre,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Daugaard, Mads
AU  - Daugaard M
AD  - Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic 
      Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
      Electronic address: mads.daugaard@ubc.ca.
LA  - eng
GR  - P41 GM104603/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, Protozoan)
RN  - 0 (CD44 protein, human)
RN  - 0 (CSPG4 protein, human)
RN  - 0 (Chondroitin Sulfate Proteoglycans)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Membrane Proteins)
RN  - 0 (Oligopeptides)
RN  - 0 (Recombinant Proteins)
RN  - 0 (VAR2CSA protein, Plasmodium falciparum)
RN  - 6S0T7U2I3F (hemiasterlin)
RN  - 9007-28-7 (Chondroitin Sulfates)
SB  - IM
MH  - Animals
MH  - Antigens, Protozoan/*genetics/metabolism
MH  - Cell Line, Tumor
MH  - Chondroitin Sulfate Proteoglycans/metabolism
MH  - Chondroitin Sulfates/*metabolism
MH  - Female
MH  - HEK293 Cells
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Hyaluronan Receptors/metabolism
MH  - Melanoma, Experimental/metabolism/*therapy
MH  - Membrane Proteins/metabolism
MH  - Mice
MH  - Molecular Targeted Therapy
MH  - Oligopeptides/genetics/metabolism
MH  - Organ Specificity
MH  - Placenta/*metabolism
MH  - Pregnancy
MH  - Recombinant Proteins/*administration & dosage/pharmacology
MH  - Skin Neoplasms/metabolism/*therapy
PMC - PMC4790448
MID - NIHMS764950
EDAT- 2015/10/16 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/06/12 00:00 [received]
PHST- 2015/07/31 00:00 [revised]
PHST- 2015/09/08 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00334-7 [pii]
AID - 10.1016/j.ccell.2015.09.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):500-514. doi: 10.1016/j.ccell.2015.09.003.

PMID- 26461093
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2
      Inhibition via FOXO/c-Myc Axis.
PG  - 472-485
LID - S1535-6108(15)00336-0 [pii]
LID - 10.1016/j.ccell.2015.09.005 [doi]
AB  - Human epidermal growth factor receptor 2 (HER2) is upregulated in a subset of
      human breast cancers. However, the cancer cells often quickly develop an adaptive
      response to HER2 kinase inhibitors. We found that an epigenetic pathway involving
      MLL2 is crucial for growth of HER2(+) cells and MLL2 reduces sensitivity of the
      cancer cells to a HER2 inhibitor, lapatinib. Lapatinib-induced FOXO transcription
      factors, normally tumor-suppressing, paradoxically upregulate c-Myc
      epigenetically in concert with a cascade of MLL2-associating epigenetic
      regulators to dampen sensitivity of the cancer cells to lapatinib. An epigenetic 
      inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth
      in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically
      regulated FOXO/c-Myc axis as a potential target to improve therapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Matkar, Smita
AU  - Matkar S
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Sharma, Paras
AU  - Sharma P
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Gao, Shubin
AU  - Gao S
AD  - Xiamen University College of Medicine, Xiangan District, Xiamen 361006, PR China.
FAU - Gurung, Buddha
AU  - Gurung B
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Katona, Bryson W
AU  - Katona BW
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Liao, Jennifer
AU  - Liao J
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Muhammad, Abdul Bari
AU  - Muhammad AB
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Kong, Xiang-Cheng
AU  - Kong XC
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA; Department of Urology, Renmin Hospital of Wuhan University, Wuhan
      430060, PR China.
FAU - Jin, Guanghui
AU  - Jin G
AD  - Xiamen University College of Medicine, Xiangan District, Xiamen 361006, PR China.
FAU - Dang, Chi V
AU  - Dang CV
AD  - Department of Medicine, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA.
FAU - Hua, Xianxin
AU  - Hua X
AD  - Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson
      Cancer Center, University of Pennsylvania, 412 Curie Boulevard, Philadelphia, PA 
      19104, USA. Electronic address: huax@mail.med.upenn.edu.
LA  - eng
GR  - 1-R01-CA-178856/CA/NCI NIH HHS/United States
GR  - P30 DK050306/DK/NIDDK NIH HHS/United States
GR  - R01-DK085121/DK/NIDDK NIH HHS/United States
GR  - R01 DK097555/DK/NIDDK NIH HHS/United States
GR  - R01 DK085121/DK/NIDDK NIH HHS/United States
GR  - R01 CA178856/CA/NCI NIH HHS/United States
GR  - P30DK050306/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (GSK525762A)
RN  - 0 (MLL2 protein, human)
RN  - 0 (MYC protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Quinazolines)
RN  - 0VUA21238F (lapatinib)
RN  - 12794-10-4 (Benzodiazepines)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - Benzodiazepines/administration & dosage/pharmacology
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/*genetics/metabolism
MH  - Drug Resistance, Neoplasm
MH  - Drug Synergism
MH  - *Epigenesis, Genetic/drug effects
MH  - Female
MH  - Forkhead Transcription Factors/*genetics/metabolism
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Mice
MH  - Neoplasm Proteins/*genetics/metabolism
MH  - Protein Kinase Inhibitors/administration & dosage/pharmacology
MH  - Proto-Oncogene Proteins c-myc/*genetics/metabolism
MH  - Quinazolines/administration & dosage/pharmacology
MH  - Receptor, ErbB-2/*antagonists & inhibitors/genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC4748715
MID - NIHMS751692
EDAT- 2015/10/16 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/10/14 06:00
PHST- 2014/06/30 00:00 [received]
PHST- 2015/05/26 00:00 [revised]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00336-0 [pii]
AID - 10.1016/j.ccell.2015.09.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):472-485. doi: 10.1016/j.ccell.2015.09.005.

PMID- 26461092
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20180125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells.
PG  - 441-455
LID - S1535-6108(15)00333-5 [pii]
LID - 10.1016/j.ccell.2015.09.002 [doi]
AB  - Glioblastomas display hierarchies with self-renewing cancer stem-like cells
      (CSCs). RNA sequencing and enhancer mapping revealed regulatory programs unique
      to CSCs causing upregulation of the iron transporter transferrin, the top
      differentially expressed gene compared with tissue-specific progenitors. Direct
      interrogation of iron uptake demonstrated that CSCs potently extract iron from
      the microenvironment more effectively than other tumor cells. Systematic
      interrogation of iron flux determined that CSCs preferentially require
      transferrin receptor and ferritin, two core iron regulators, to propagate and
      form tumors in vivo. Depleting ferritin disrupted CSC mitotic progression,
      through the STAT3-FoxM1 regulatory axis, revealing an iron-regulated CSC pathway.
      Iron is a unique, primordial metal fundamental for earliest life forms, on which 
      CSCs have an epigenetically programmed, targetable dependence.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Schonberg, David L
AU  - Schonberg DL
AD  - Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Miller, Tyler E
AU  - Miller TE
AD  - Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Wu, Qiulian
AU  - Wu Q
AD  - Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Flavahan, William A
AU  - Flavahan WA
AD  - Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Das, Nupur K
AU  - Das NK
AD  - Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
      44195, USA.
FAU - Hale, James S
AU  - Hale JS
AD  - Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
      44195, USA.
FAU - Hubert, Christopher G
AU  - Hubert CG
AD  - Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Mack, Stephen C
AU  - Mack SC
AD  - Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Jarrar, Awad M
AU  - Jarrar AM
AD  - Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
      44195, USA.
FAU - Karl, Robert T
AU  - Karl RT
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University
      School of Medicine, Cleveland, OH 44106, USA.
FAU - Rosager, Ann Mari
AU  - Rosager AM
AD  - Department of Clinical Pathology, Odense University Hospital, 5000 Odense,
      Denmark.
FAU - Nixon, Anne M
AU  - Nixon AM
AD  - Department of Neurosurgery, Penn State College of Medicine, Hershey, PA 17033,
      USA.
FAU - Tesar, Paul J
AU  - Tesar PJ
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University
      School of Medicine, Cleveland, OH 44106, USA.
FAU - Hamerlik, Petra
AU  - Hamerlik P
AD  - Brain Tumor Biology Group, Danish Cancer Society Research Center, 2100
      Copenhagen, Denmark.
FAU - Kristensen, Bjarne W
AU  - Kristensen BW
AD  - Department of Clinical Pathology, Odense University Hospital, 5000 Odense,
      Denmark.
FAU - Horbinski, Craig
AU  - Horbinski C
AD  - Division of Neuropathology, Department of Pathology, University of Kentucky,
      Lexington, KY 40536, USA.
FAU - Connor, James R
AU  - Connor JR
AD  - Department of Neurosurgery, Penn State College of Medicine, Hershey, PA 17033,
      USA.
FAU - Fox, Paul L
AU  - Fox PL
AD  - Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
      44195, USA.
FAU - Lathia, Justin D
AU  - Lathia JD
AD  - Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
      44195, USA.
FAU - Rich, Jeremy N
AU  - Rich JN
AD  - Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic,
      Cleveland, OH 44195, USA. Electronic address: richj@ccf.org.
LA  - eng
SI  - GEO/GSE72204
GR  - R01 CA169117/CA/NCI NIH HHS/United States
GR  - P30CA177558/CA/NCI NIH HHS/United States
GR  - K99/R00 CA157948/CA/NCI NIH HHS/United States
GR  - P20 RR020171/RR/NCRR NIH HHS/United States
GR  - R01 NS083629/NS/NINDS NIH HHS/United States
GR  - R21 CA198254/CA/NCI NIH HHS/United States
GR  - P01 HL076491/HL/NHLBI NIH HHS/United States
GR  - R01 DK083359/DK/NIDDK NIH HHS/United States
GR  - Canadian Institutes of Health Research/Canada
GR  - T32 GM008056/GM/NIGMS NIH HHS/United States
GR  - P30 CA177558/CA/NCI NIH HHS/United States
GR  - K08 CA155764/CA/NCI NIH HHS/United States
GR  - R01 CA171652/CA/NCI NIH HHS/United States
GR  - R01 NS089272/NS/NINDS NIH HHS/United States
GR  - F32 CA189647/CA/NCI NIH HHS/United States
GR  - R21 CA191263/CA/NCI NIH HHS/United States
GR  - R01 NS087913/NS/NINDS NIH HHS/United States
GR  - T32 TRN508838/PHS HHS/United States
GR  - F30 CA183510/CA/NCI NIH HHS/United States
GR  - 2P20 RR020171/RR/NCRR NIH HHS/United States
GR  - T32 GM007250/GM/NIGMS NIH HHS/United States
GR  - R01 CA154130/CA/NCI NIH HHS/United States
GR  - P01 HL029582/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Receptors, Transferrin)
RN  - 0 (Transferrin)
RN  - 9007-73-2 (Ferritins)
RN  - E1UOL152H7 (Iron)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/genetics/metabolism/*pathology
MH  - Cells, Cultured
MH  - Embryonic Stem Cells
MH  - Epigenesis, Genetic
MH  - Ferritins/genetics/*metabolism
MH  - Forkhead Transcription Factors/genetics/metabolism
MH  - Gene Expression Profiling
MH  - Glioblastoma/genetics/metabolism/*pathology
MH  - Humans
MH  - Iron/*metabolism
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Neoplastic Stem Cells/*metabolism/pathology
MH  - Receptors, Transferrin/genetics/*metabolism
MH  - Sequence Analysis, RNA
MH  - Signal Transduction
MH  - Transferrin/metabolism
PMC - PMC4646058
MID - NIHMS727501
EDAT- 2015/10/16 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/10/14 06:00
PHST- 2014/09/16 00:00 [received]
PHST- 2015/05/31 00:00 [revised]
PHST- 2015/09/09 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00333-5 [pii]
AID - 10.1016/j.ccell.2015.09.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):441-455. doi: 10.1016/j.ccell.2015.09.002.

PMID- 26461091
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes.
PG  - 429-440
LID - S1535-6108(15)00338-4 [pii]
LID - 10.1016/j.ccell.2015.09.007 [doi]
AB  - A central question in glioblastoma multiforme (GBM) research is the identity of
      the tumor-initiating cell, and its contribution to the malignant phenotype and
      genomic state. We examine the potential of adult lineage-restricted progenitors
      to induce fully penetrant GBM using CNS progenitor-specific inducible Cre mice to
      mutate Nf1, Trp53, and Pten. We identify two phenotypically and molecularly
      distinct GBM subtypes governed by identical driver mutations. We demonstrate that
      the two subtypes arise from functionally independent pools of adult CNS
      progenitors. Despite histologic identity as GBM, these tumor types are separable 
      based on the lineage of the tumor-initiating cell. These studies point to the
      cell of origin as a major determinant of GBM subtype diversity.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Alcantara Llaguno, Sheila R
AU  - Alcantara Llaguno SR
AD  - Department of Developmental Biology, The University of Texas Southwestern Medical
      Center at Dallas, Dallas, TX 75390, USA. Electronic address: alcantas@mskcc.org.
FAU - Wang, Zilai
AU  - Wang Z
AD  - Department of Developmental Biology, The University of Texas Southwestern Medical
      Center at Dallas, Dallas, TX 75390, USA.
FAU - Sun, Daochun
AU  - Sun D
AD  - Department of Developmental Biology, The University of Texas Southwestern Medical
      Center at Dallas, Dallas, TX 75390, USA.
FAU - Chen, Jian
AU  - Chen J
AD  - Department of Developmental Biology, The University of Texas Southwestern Medical
      Center at Dallas, Dallas, TX 75390, USA.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Developmental Biology, The University of Texas Southwestern Medical
      Center at Dallas, Dallas, TX 75390, USA.
FAU - Kim, Euiseok
AU  - Kim E
AD  - Department of Neuroscience, The University of Texas Southwestern Medical Center
      at Dallas, Dallas, TX 75390, USA.
FAU - Hatanpaa, Kimmo J
AU  - Hatanpaa KJ
AD  - Department of Pathology, The University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX 75390, USA.
FAU - Raisanen, Jack M
AU  - Raisanen JM
AD  - Department of Pathology, The University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX 75390, USA.
FAU - Burns, Dennis K
AU  - Burns DK
AD  - Department of Pathology, The University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX 75390, USA.
FAU - Johnson, Jane E
AU  - Johnson JE
AD  - Department of Neuroscience, The University of Texas Southwestern Medical Center
      at Dallas, Dallas, TX 75390, USA.
FAU - Parada, Luis F
AU  - Parada LF
AD  - Department of Developmental Biology, The University of Texas Southwestern Medical
      Center at Dallas, Dallas, TX 75390, USA. Electronic address: paradal@mskcc.org.
LA  - eng
SI  - GEO/GSE57036
SI  - GEO/GSE57038
GR  - R01 CA131313/CA/NCI NIH HHS/United States
GR  - T32 CA124334/CA/NCI NIH HHS/United States
GR  - 2T32CA124334-06/CA/NCI NIH HHS/United States
GR  - CA131313-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Neurofibromin 1)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (Pten protein, mouse)
SB  - IM
CIN - Cancer Cell. 2015 Oct 12;28(4):403-4. PMID: 26461085
MH  - Adult Stem Cells/metabolism/*pathology
MH  - Animals
MH  - Brain Neoplasms/*genetics/*pathology
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Central Nervous System/*cytology
MH  - Glioblastoma/*genetics/*pathology
MH  - Humans
MH  - Mice
MH  - Mutation
MH  - Neoplastic Stem Cells/metabolism/pathology
MH  - Neurofibromin 1/genetics
MH  - PTEN Phosphohydrolase/genetics
MH  - Tumor Suppressor Protein p53/genetics
PMC - PMC4607935
MID - NIHMS727493
EDAT- 2015/10/16 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/10/14 06:00
PHST- 2014/05/05 00:00 [received]
PHST- 2015/07/08 00:00 [revised]
PHST- 2015/09/16 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00338-4 [pii]
AID - 10.1016/j.ccell.2015.09.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):429-440. doi: 10.1016/j.ccell.2015.09.007.

PMID- 26461090
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics
      and Persistence of CAR T Cells.
PG  - 415-428
LID - S1535-6108(15)00335-9 [pii]
LID - 10.1016/j.ccell.2015.09.004 [doi]
AB  - T cell engineering is a powerful means to rapidly generate anti-tumor T cells.
      The costimulatory properties of second-generation chimeric antigen receptors
      (CARs) determine the overall potency of adoptively transferred T cells. Using an 
      in vivo "stress test" to challenge CD19-targeted T cells, we studied the
      functionality and persistence imparted by seven different CAR structures
      providing CD28 and/or 4-1BB costimulation. One configuration, which uses two
      signaling domains (CD28 and CD3zeta) and the 4-1BB ligand, provided the highest
      therapeutic efficacy, showing balanced tumoricidal function and increased T cell 
      persistence accompanied by an elevated CD8/CD4 ratio and decreased exhaustion.
      Remarkably, induction of the IRF7/IFNbeta pathway was required for optimal
      anti-tumor activity. Thus, 1928z-41BBL T cells possess strikingly potent
      intrinsic and immunomodulatory qualities.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Zhao, Zeguo
AU  - Zhao Z
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA.
FAU - Condomines, Maud
AU  - Condomines M
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA.
FAU - van der Stegen, Sjoukje J C
AU  - van der Stegen SJC
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA.
FAU - Perna, Fabiana
AU  - Perna F
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA.
FAU - Kloss, Christopher C
AU  - Kloss CC
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA.
FAU - Gunset, Gertrude
AU  - Gunset G
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA.
FAU - Plotkin, Jason
AU  - Plotkin J
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA.
FAU - Sadelain, Michel
AU  - Sadelain M
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Immunology Program, Sloan Kettering Institute, New York, NY 10065,
      USA. Electronic address: m-sadelain@ski.mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, CD19)
RN  - 0 (CD28 Antigens)
RN  - 0 (Interferon Regulatory Factor-7)
RN  - 0 (Receptors, Antigen)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor Receptor Superfamily, Member 9)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
CIN - Cancer Cell. 2015 Oct 12;28(4):401-2. PMID: 26461084
MH  - Antigens, CD19/immunology/metabolism
MH  - CD28 Antigens/biosynthesis/genetics/*immunology
MH  - Hematologic Neoplasms/*immunology/pathology/therapy
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Interferon Regulatory Factor-7/metabolism
MH  - Interferon-gamma/metabolism
MH  - Kinetics
MH  - Lymphocyte Activation/immunology
MH  - Receptors, Antigen/genetics/*immunology
MH  - Recombinant Proteins/genetics/immunology
MH  - Signal Transduction
MH  - T-Lymphocytes/*immunology/pathology
MH  - Tumor Necrosis Factor Receptor Superfamily, Member
      9/biosynthesis/genetics/*immunology
PMC - PMC5003056
MID - NIHMS810637
EDAT- 2015/10/16 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/03/27 00:00 [received]
PHST- 2015/07/17 00:00 [revised]
PHST- 2015/09/09 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00335-9 [pii]
AID - 10.1016/j.ccell.2015.09.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):415-428. doi: 10.1016/j.ccell.2015.09.004.

PMID- 26461089
OWN - NLM
STAT- MEDLINE
DCOM- 20160111
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Subtyping Pancreatic Cancer.
PG  - 411-413
LID - S1535-6108(15)00351-7 [pii]
LID - 10.1016/j.ccell.2015.09.020 [doi]
AB  - The complex tumor microenvironment can make molecularly subtyping cancer using
      mRNA expression challenging, particularly for cancers with low epithelial
      content, such as pancreatic cancer. In a recent edition of Nature Genetics,
      Moffitt and colleagues show that subtracting normal epithelial transcripts can
      provide insights into the molecular pathology of pancreatic cancer.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Biankin, Andrew V
AU  - Biankin AV
AD  - Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of 
      Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, Scotland G61 1BD,
      UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow G31 2ER,
      UK; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical
      Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; South
      Western Sydney Clinical School, Faculty of Medicine, University of NSW,
      Liverpool, NSW 2170, Australia. Electronic address: andrew.biankin@glasgow.ac.uk.
FAU - Maitra, Anirban
AU  - Maitra A
AD  - Pathology and Translational Molecular Pathology, Sheikh Ahmed Center for
      Pancreatic Cancer Research, University of Texas, MD Anderson Cancer Center, 1515 
      Holcombe Boulevard, Houston, TX 77030 USA.
LA  - eng
GR  - 103721/Wellcome Trust/United Kingdom
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Nat Genet. 2015 Oct;47(10):1168-78. PMID: 26343385
MH  - Adenocarcinoma/*pathology
MH  - Animals
MH  - Carcinoma, Pancreatic Ductal/*pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Pancreatic Neoplasms/*pathology
MH  - Stromal Cells/*pathology
EDAT- 2015/10/16 06:00
MHDA- 2016/01/12 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/12 06:00 [medline]
AID - S1535-6108(15)00351-7 [pii]
AID - 10.1016/j.ccell.2015.09.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):411-413. doi: 10.1016/j.ccell.2015.09.020.

PMID- 26461088
OWN - NLM
STAT- MEDLINE
DCOM- 20160111
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - PPARgamma: Welcoming the New Kid on the CML Stem Cell Block.
PG  - 409-411
LID - S1535-6108(15)00348-7 [pii]
LID - 10.1016/j.ccell.2015.09.017 [doi]
AB  - Recently, chronic myeloid leukemia (CML) patients already responding to treatment
      showed improved molecular responses with pioglitazone, presumably through
      PPARgamma activation and CML stem cell eradication. Given data demonstrating
      deepening responses and successful treatment discontinuation with current
      therapy, the necessity for new therapies targeting CML stem cells to achieve cure
      is unclear.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Apsel Winger, Beth
AU  - Apsel Winger B
AD  - Department of Pediatric Hematology/Oncology, University of California, San
      Francisco, San Francisco, CA 94143, USA.
FAU - Shah, Neil P
AU  - Shah NP
AD  - Division of Hematology/Oncology, Department of Medicine, University of
      California, San Francisco, San Francisco, CA 94143, USA. Electronic address:
      neil.shah@ucsf.edu.
LA  - eng
GR  - T32 CA128583/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Benzamides)
RN  - 0 (PPAR gamma)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (Thiazolidinediones)
SB  - IM
CON - Nature. 2015 Sep 17;525(7569):380-3. PMID: 26331539
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology/*therapeutic use
MH  - Benzamides/*administration & dosage
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/*pathology
MH  - Neoplastic Stem Cells/*drug effects
MH  - PPAR gamma/*agonists
MH  - Piperazines/*administration & dosage
MH  - Pyrimidines/*administration & dosage
MH  - Thiazolidinediones/*administration & dosage
EDAT- 2015/10/16 06:00
MHDA- 2016/01/12 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/12 06:00 [medline]
AID - S1535-6108(15)00348-7 [pii]
AID - 10.1016/j.ccell.2015.09.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):409-411. doi: 10.1016/j.ccell.2015.09.017.

PMID- 26461087
OWN - NLM
STAT- MEDLINE
DCOM- 20160111
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
PG  - 407-408
LID - S1535-6108(15)00350-5 [pii]
LID - 10.1016/j.ccell.2015.09.019 [doi]
AB  - Mutations in the TP53 gene not only inactivate its tumor suppressor function but 
      also confer this transcription factor with gain-of-function oncogenic properties.
      A recent paper by Zhu and colleagues reveals a novel molecular pathway driven by 
      mutant p53 and the COMPASS chromatin-modifying complex that is amenable to
      pharmacological inhibition.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Abraham, Christopher G
AU  - Abraham CG
AD  - Linda Crnic Institute for Down Syndrome, University of Colorado Denver School Of 
      Medicine, Aurora, CO 80045, USA; Department of Pharmacology, University of
      Colorado Denver School Of Medicine, Aurora, CO 80045, USA.
FAU - Espinosa, Joaquin M
AU  - Espinosa JM
AD  - Linda Crnic Institute for Down Syndrome, University of Colorado Denver School Of 
      Medicine, Aurora, CO 80045, USA; Department of Pharmacology, University of
      Colorado Denver School Of Medicine, Aurora, CO 80045, USA. Electronic address:
      joaquin.espinosa@ucdenver.edu.
LA  - eng
GR  - R01 CA117907/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chromatin)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
CON - Nature. 2015 Sep 10;525(7568):206-11. PMID: 26331536
MH  - Animals
MH  - Chromatin/*genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Mutation/*genetics
MH  - Neoplasms/*genetics/*pathology
MH  - Tumor Suppressor Protein p53/*genetics/*metabolism
EDAT- 2015/10/16 06:00
MHDA- 2016/01/12 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/12 06:00 [medline]
AID - S1535-6108(15)00350-5 [pii]
AID - 10.1016/j.ccell.2015.09.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):407-408. doi: 10.1016/j.ccell.2015.09.019.

PMID- 26461086
OWN - NLM
STAT- MEDLINE
DCOM- 20160111
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Splicing and Dicing MYC-Mediated Synthetic Lethality.
PG  - 405-406
LID - S1535-6108(15)00347-5 [pii]
LID - 10.1016/j.ccell.2015.09.016 [doi]
AB  - In a recent issue of Nature, Hsu and colleagues report that oncogenic MYC
      activation is synthetic lethal with inhibition of the core spliceosome, because
      MYC-driven growth and increased transcription leave tumors dependent on pre-mRNA 
      processing for survival. As direct targeting of MYC has remained elusive,
      synthetic lethal strategies are attractive.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Stine, Zachary E
AU  - Stine ZE
AD  - Abramson Family Cancer Research Institute, Abramson Cancer Center, University of 
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Dang, Chi V
AU  - Dang CV
AD  - Abramson Family Cancer Research Institute, Abramson Cancer Center, University of 
      Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
      dangvchi@exchange.upenn.edu.
LA  - eng
GR  - F32 CA174148/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Nature. 2015 Sep 17;525(7569):384-8. PMID: 26331541
MH  - Animals
MH  - Breast Neoplasms/*drug therapy/*genetics
MH  - Female
MH  - Genes, myc/*genetics
MH  - Humans
MH  - Spliceosomes/*drug effects/*metabolism
EDAT- 2015/10/16 06:00
MHDA- 2016/01/12 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/12 06:00 [medline]
AID - S1535-6108(15)00347-5 [pii]
AID - 10.1016/j.ccell.2015.09.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):405-406. doi: 10.1016/j.ccell.2015.09.016.

PMID- 26461085
OWN - NLM
STAT- MEDLINE
DCOM- 20160119
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Of Brains and Blood: Developmental Origins of Glioma Diversity?
PG  - 403-404
LID - S1535-6108(15)00344-X [pii]
LID - 10.1016/j.ccell.2015.09.013 [doi]
AB  - The multiple cell types of brain and blood arise from pluripotent stem cells via 
      progressively more committed downstream progenitors. In this issue of Cancer
      Cell, Alcantara Llaguno and colleagues show that identical genetic drivers give
      rise to distinct glioma subtypes within differentially committed neural
      progenitors-a paradigm well established for leukemias.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Filbin, Mariella G
AU  - Filbin MG
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Stiles, Charles D
AU  - Stiles CD
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA. Electronic address: charles_stiles@dfci.harvard.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2015 Oct 12;28(4):429-40. PMID: 26461091
MH  - Adult Stem Cells/*pathology
MH  - Animals
MH  - Brain Neoplasms/*genetics/*pathology
MH  - Central Nervous System/*cytology
MH  - Glioblastoma/*genetics/*pathology
MH  - Humans
EDAT- 2015/10/16 06:00
MHDA- 2016/01/20 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/20 06:00 [medline]
AID - S1535-6108(15)00344-X [pii]
AID - 10.1016/j.ccell.2015.09.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):403-404. doi: 10.1016/j.ccell.2015.09.013.

PMID- 26461084
OWN - NLM
STAT- MEDLINE
DCOM- 20160119
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Shifting the Evolving CAR T Cell Platform into Higher Gear.
PG  - 401-402
LID - S1535-6108(15)00345-1 [pii]
LID - 10.1016/j.ccell.2015.09.014 [doi]
AB  - In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen
      receptor (CAR) T cells to show that CD28-CD3zeta CAR T cells that constitutively 
      express 4-1BBL promote T cell expansion and tumor eradication while reducing
      exhaustion. The results have important implications for the development of
      effective CAR T cell therapies in cancer patients.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Holohan, Daniel R
AU  - Holohan DR
AD  - UCSF Diabetes Center and Department of Medicine, University of California, San
      Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA.
FAU - Lee, James C
AU  - Lee JC
AD  - UCSF Diabetes Center and Department of Medicine, University of California, San
      Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA.
FAU - Bluestone, Jeffrey A
AU  - Bluestone JA
AD  - UCSF Diabetes Center and Department of Medicine, University of California, San
      Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA.
      Electronic address: jeff.bluestone@ucsf.edu.
LA  - eng
GR  - R01 AI046643/AI/NIAID NIH HHS/United States
GR  - T32 AI007090/AI/NIAID NIH HHS/United States
GR  - T32 AI007334/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CD28 Antigens)
RN  - 0 (Receptors, Antigen)
RN  - 0 (Tumor Necrosis Factor Receptor Superfamily, Member 9)
SB  - IM
CON - Cancer Cell. 2015 Oct 12;28(4):415-28. PMID: 26461090
MH  - CD28 Antigens/*immunology
MH  - Hematologic Neoplasms/*immunology
MH  - Humans
MH  - Receptors, Antigen/*immunology
MH  - T-Lymphocytes/*immunology
MH  - Tumor Necrosis Factor Receptor Superfamily, Member 9/*immunology
EDAT- 2015/10/16 06:00
MHDA- 2016/01/20 06:00
CRDT- 2015/10/14 06:00
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/01/20 06:00 [medline]
AID - S1535-6108(15)00345-1 [pii]
AID - 10.1016/j.ccell.2015.09.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):401-402. doi: 10.1016/j.ccell.2015.09.014.

PMID- 28854351
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - FcgammaRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1
      Axis.
PG  - 543
LID - S1535-6108(15)00342-6 [pii]
LID - 10.1016/j.ccell.2015.09.011 [doi]
FAU - Dahan, Rony
AU  - Dahan R
FAU - Sega, Emanuela
AU  - Sega E
FAU - Engelhardt, John
AU  - Engelhardt J
FAU - Selby, Mark
AU  - Selby M
FAU - Korman, Alan J
AU  - Korman AJ
FAU - Ravetch, Jeffrey V
AU  - Ravetch JV
LA  - eng
PT  - Published Erratum
DEP - 20151012
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2015/10/12 00:00
MHDA- 2015/10/12 00:01
CRDT- 2017/08/31 06:00
PHST- 2017/08/31 06:00 [entrez]
PHST- 2015/10/12 00:00 [pubmed]
PHST- 2015/10/12 00:01 [medline]
AID - S1535-6108(15)00342-6 [pii]
AID - 10.1016/j.ccell.2015.09.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):543. doi: 10.1016/j.ccell.2015.09.011. Epub 2015
      Oct 12.

PMID- 28854350
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome 
      Inhibitor Resistance in Multiple Myeloma.
PG  - 541-542
LID - S1535-6108(15)00341-4 [pii]
LID - 10.1016/j.ccell.2015.09.010 [doi]
FAU - Leung-Hagesteijn, Chungyee
AU  - Leung-Hagesteijn C
FAU - Erdmann, Natalie
AU  - Erdmann N
FAU - Cheung, Grace
AU  - Cheung G
FAU - Keats, Jonathan J
AU  - Keats JJ
FAU - Stewart, A Keith
AU  - Stewart AK
FAU - Reece, Donna E
AU  - Reece DE
FAU - Chung, Kim Chan
AU  - Chung KC
FAU - Tiedemann, Rodger E
AU  - Tiedemann RE
LA  - eng
PT  - Published Erratum
DEP - 20151012
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
EDAT- 2015/10/12 00:00
MHDA- 2015/10/12 00:01
CRDT- 2017/08/31 06:00
PHST- 2017/08/31 06:00 [entrez]
PHST- 2015/10/12 00:00 [pubmed]
PHST- 2015/10/12 00:01 [medline]
AID - S1535-6108(15)00341-4 [pii]
AID - 10.1016/j.ccell.2015.09.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):541-542. doi: 10.1016/j.ccell.2015.09.010. Epub
      2015 Oct 12.

PMID- 26439496
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20171228
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human
      Cancers.
PG  - 515-528
LID - S1535-6108(15)00304-9 [pii]
LID - 10.1016/j.ccell.2015.08.013 [doi]
AB  - Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transcriptional
      mechanism, but its genomic landscape and clinical relevance in cancer have not
      been investigated systematically. We characterized the global A-to-I RNA editing 
      profiles of 6,236 patient samples of 17 cancer types from The Cancer Genome Atlas
      and revealed a striking diversity of altered RNA-editing patterns in tumors
      relative to normal tissues. We identified an appreciable number of clinically
      relevant editing events, many of which are in noncoding regions. We
      experimentally demonstrated the effects of several cross-tumor nonsynonymous RNA 
      editing events on cell viability and provide the evidence that RNA editing could 
      selectively affect drug sensitivity. These results highlight RNA editing as an
      exciting theme for investigating cancer mechanisms, biomarkers, and treatments.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Han, Leng
AU  - Han L
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Diao, Lixia
AU  - Diao L
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yu, Shuangxing
AU  - Yu S
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Xu, Xiaoyan
AU  - Xu X
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Pathophysiology,
      College of Basic Medicine, China Medical University, Shenyang City, Liaoning
      Province 110001, China.
FAU - Li, Jie
AU  - Li J
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Zhang, Rui
AU  - Zhang R
AD  - Department of Genetics, Stanford University, Stanford, CA 94305, USA.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Division of Biostatistics, The
      University of Texas Health Science Center at Houston, School of Public Health,
      Houston TX 77030, USA.
FAU - Werner, Henrica M J
AU  - Werner HMJ
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Women's Department, Haukeland University Hospital, Jonas 
      Liesvei 72, 5053 Bergen, Norway.
FAU - Eterovic, A Karina
AU  - Eterovic AK
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Li, Jun
AU  - Li J
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Nair, Nikitha
AU  - Nair N
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Minelli, Rosalba
AU  - Minelli R
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Tsang, Yiu Huen
AU  - Tsang YH
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Cheung, Lydia W T
AU  - Cheung LWT
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Jeong, Kang Jin
AU  - Jeong KJ
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Roszik, Jason
AU  - Roszik J
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Ju, Zhenlin
AU  - Ju Z
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Woodman, Scott E
AU  - Woodman SE
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Lu, Yiling
AU  - Lu Y
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Scott, Kenneth L
AU  - Scott KL
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Li, Jin Billy
AU  - Li JB
AD  - Department of Genetics, Stanford University, Stanford, CA 94305, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA. Electronic address: gmills@mdanderson.org.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology,
      The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
      Electronic address: hliang1@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01GM102484/GM/NIGMS NIH HHS/United States
GR  - CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA098258/CA/NCI NIH HHS/United States
GR  - U01 CA168394/CA/NCI NIH HHS/United States
GR  - U24CA143883/CA/NCI NIH HHS/United States
GR  - CA098258/CA/NCI NIH HHS/United States
GR  - R01CA175486/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
GR  - R01 GM102484/GM/NIGMS NIH HHS/United States
GR  - R01 CA175486/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - CA168394/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151001
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 5A614L51CT (Inosine)
RN  - K72T3FS567 (Adenosine)
SB  - IM
CIN - Nat Rev Cancer. 2015 Dec;15(12):698. PMID: 26511457
CIN - Trends Cancer. 2015 Dec;1(4):211-212. PMID: 27695712
MH  - Adenosine/*metabolism
MH  - Antineoplastic Agents/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Survival
MH  - Genome, Human
MH  - Humans
MH  - Inosine/*metabolism
MH  - Neoplasms/*genetics/pathology
MH  - *RNA Editing
PMC - PMC4605878
MID - NIHMS721165
EDAT- 2015/10/07 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/10/07 06:00
PHST- 2014/12/26 00:00 [received]
PHST- 2015/06/16 00:00 [revised]
PHST- 2015/08/28 00:00 [accepted]
PHST- 2015/10/07 06:00 [entrez]
PHST- 2015/10/07 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00304-9 [pii]
AID - 10.1016/j.ccell.2015.08.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):515-528. doi: 10.1016/j.ccell.2015.08.013. Epub
      2015 Oct 1.

PMID- 26412325
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20170830
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed 
      Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit.
PG  - 456-471
LID - S1535-6108(15)00303-7 [pii]
LID - 10.1016/j.ccell.2015.08.012 [doi]
AB  - The associations of tricyclic antidepressants (TCAs) with reduced incidence of
      gliomas and elevated autophagy in glioma cells motivated investigation in mouse
      models of gliomagenesis. First, we established that imipramine, a TCA, increased 
      autophagy and conveyed modest therapeutic benefit in tumor-bearing animals. Then 
      we screened clinically approved agents suggested to affect autophagy for their
      ability to enhance imipramine-induced autophagy-associated cell death. The
      anticoagulant ticlopidine, which inhibits the purinergic receptor P2Y12,
      potentiated imipramine, elevating cAMP, a modulator of autophagy, reducing cell
      viability in culture, and increasing survival in glioma-bearing mice. Efficacy of
      the combination was obviated by knockdown of the autophagic regulatory gene ATG7,
      implicating cell-lethal autophagy. This seemingly innocuous combination of TCAs
      and P2Y12 inhibitors may have applicability for treating glioma.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Shchors, Ksenya
AU  - Shchors K
AD  - Swiss Institute for Experimental Cancer Research, Swiss Federal Institute of
      Technology, Lausanne 1015, Switzerland.
FAU - Massaras, Aristea
AU  - Massaras A
AD  - Swiss Institute for Experimental Cancer Research, Swiss Federal Institute of
      Technology, Lausanne 1015, Switzerland.
FAU - Hanahan, Douglas
AU  - Hanahan D
AD  - Swiss Institute for Experimental Cancer Research, Swiss Federal Institute of
      Technology, Lausanne 1015, Switzerland. Electronic address:
      douglas.hanahan@epfl.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150924
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Anticoagulants)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Atg7 protein, mouse)
RN  - 0 (Microtubule-Associated Proteins)
RN  - EC 6.2.1.45 (Autophagy-Related Protein 7)
RN  - OGG85SX4E4 (Imipramine)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
CIN - Nat Rev Cancer. 2015 Nov;15(11):636. PMID: 26469144
MH  - Animals
MH  - Anticoagulants/administration & dosage/pharmacology
MH  - Antidepressive Agents, Tricyclic/administration & dosage/pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration &
      dosage/pharmacology
MH  - Autophagy/drug effects
MH  - Autophagy-Related Protein 7
MH  - Brain Neoplasms/*drug therapy/mortality/pathology
MH  - Cell Survival/drug effects
MH  - Drug Repositioning
MH  - Drug Synergism
MH  - Gene Knockdown Techniques
MH  - Glioma/*drug therapy/mortality/pathology
MH  - Imipramine/*administration & dosage/pharmacology
MH  - Mice
MH  - Microtubule-Associated Proteins/genetics
MH  - Survival Analysis
MH  - Ticlopidine/*administration & dosage/pharmacology
MH  - Xenograft Model Antitumor Assays
EDAT- 2015/09/29 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/09/29 06:00
PHST- 2014/11/10 00:00 [received]
PHST- 2015/04/13 00:00 [revised]
PHST- 2015/08/31 00:00 [accepted]
PHST- 2015/09/29 06:00 [entrez]
PHST- 2015/09/29 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00303-7 [pii]
AID - 10.1016/j.ccell.2015.08.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):456-471. doi: 10.1016/j.ccell.2015.08.012. Epub
      2015 Sep 24.

PMID- 26412324
OWN - NLM
STAT- MEDLINE
DCOM- 20160118
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Oct 12
TI  - hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and 
      Differentiation Programs in Hematologic Malignancies.
PG  - 486-499
LID - S1535-6108(15)00305-0 [pii]
LID - 10.1016/j.ccell.2015.09.001 [doi]
AB  - hnRNP K regulates cellular programs, and changes in its expression and mutational
      status have been implicated in neoplastic malignancies. To directly examine its
      role in tumorigenesis, we generated a mouse model harboring an Hnrnpk knockout
      allele (Hnrnpk(+/-)). Hnrnpk haploinsufficiency resulted in reduced survival,
      increased tumor formation, genomic instability, and the development of
      transplantable hematopoietic neoplasms with myeloproliferation. Reduced hnRNP K
      expression attenuated p21 activation, downregulated C/EBP levels, and activated
      STAT3 signaling. Additionally, analysis of samples from primary acute myeloid
      leukemia patients harboring a partial deletion of chromosome 9 revealed a
      significant decrease in HNRNPK expression. Together, these data implicate hnRNP K
      in the development of hematological disorders and suggest hnRNP K acts as a tumor
      suppressor.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Gallardo, Miguel
AU  - Gallardo M
AD  - Department of Leukemia, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Lee, Hun Ju
AU  - Lee HJ
AD  - Department of Lymphoma & Myeloma, The University of Texas, MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Zhang, Xiaorui
AU  - Zhang X
AD  - Department of Leukemia, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Bueso-Ramos, Carlos
AU  - Bueso-Ramos C
AD  - Department of Histopathology, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Pageon, Laura R
AU  - Pageon LR
AD  - Department of Veterinary Medicine & Surgery, The University of Texas, MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - McArthur, Mark
AU  - McArthur M
AD  - Department of Veterinary Medicine & Surgery, The University of Texas, MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Multani, Asha
AU  - Multani A
AD  - Department of Genetics, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Nazha, Aziz
AU  - Nazha A
AD  - Department of Leukemia, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Manshouri, Taghi
AU  - Manshouri T
AD  - Department of Leukemia, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Parker-Thornburg, Jan
AU  - Parker-Thornburg J
AD  - Department of Genetics, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Rapado, Inmaculada
AU  - Rapado I
AD  - Department of Hematology, Hospital Universitario 12 de Octubre and CNIO, Madrid
      28041, Spain.
FAU - Quintas-Cardama, Alfonso
AU  - Quintas-Cardama A
AD  - Department of Leukemia, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Kornblau, Steven M
AU  - Kornblau SM
AD  - Department of Leukemia, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Martinez-Lopez, Joaquin
AU  - Martinez-Lopez J
AD  - Department of Hematology, Hospital Universitario 12 de Octubre and CNIO, Madrid
      28041, Spain.
FAU - Post, Sean M
AU  - Post SM
AD  - Department of Leukemia, The University of Texas, MD Anderson Cancer Center,
      Houston, TX 77030, USA. Electronic address: spost@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA100632/CA/NCI NIH HHS/United States
GR  - CA16672/CA/NCI NIH HHS/United States
GR  - P50 CA1000632-09/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150924
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (HNRNPK protein, mouse)
RN  - 0 (Heterogeneous-Nuclear Ribonucleoprotein K)
RN  - 0 (Ribonucleoproteins)
RN  - 146410-60-8 (HNRNPK protein, human)
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Chromosomal Instability
MH  - Chromosomes, Human, Pair 9/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockout Techniques
MH  - *Haploinsufficiency
MH  - Hematologic Neoplasms/genetics/metabolism/*pathology
MH  - Heterogeneous-Nuclear Ribonucleoprotein K
MH  - Humans
MH  - Mice
MH  - Ribonucleoproteins/*genetics/*metabolism
MH  - Signal Transduction
MH  - Survival Analysis
PMC - PMC4652598
MID - NIHMS734287
EDAT- 2015/09/29 06:00
MHDA- 2016/01/19 06:00
CRDT- 2015/09/29 06:00
PHST- 2014/08/18 00:00 [received]
PHST- 2015/04/14 00:00 [revised]
PHST- 2015/09/01 00:00 [accepted]
PHST- 2015/09/29 06:00 [entrez]
PHST- 2015/09/29 06:00 [pubmed]
PHST- 2016/01/19 06:00 [medline]
AID - S1535-6108(15)00305-0 [pii]
AID - 10.1016/j.ccell.2015.09.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Oct 12;28(4):486-499. doi: 10.1016/j.ccell.2015.09.001. Epub
      2015 Sep 24.

PMID- 26373281
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination 
      in ALT Cancer Cells.
PG  - 357-69
LID - 10.1016/j.ccell.2015.08.003 [doi]
LID - S1535-6108(15)00294-9 [pii]
AB  - The chromatin-remodeler ATRX is frequently lost in cancer cells that use ALT
      (alternative lengthening of telomeres) for telomere maintenance, but its function
      in telomere recombination is unknown. Here we show that loss of ATRX suppresses
      the timely resolution of sister telomere cohesion that normally occurs prior to
      mitosis. In the absence of ATRX, the histone variant macroH2A1.1 binds to the
      poly(ADP-ribose) polymerase tankyrase 1, preventing it from localizing to
      telomeres and resolving cohesion. The resulting persistent telomere cohesion
      promotes recombination between sister telomeres, while it suppresses
      inappropriate recombination between non-sisters. Forced resolution of sister
      telomere cohesion induces excessive recombination between non-homologs, genomic
      instability, and impaired cell growth, indicating the ATRX-macroH2A1.1-tankyrase 
      axis as a potential therapeutic target in ALT tumors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ramamoorthy, Mahesh
AU  - Ramamoorthy M
AD  - Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular 
      Medicine, Department of Pathology, NYU Langone Medical Center and School of
      Medicine, New York, NY 10016, USA.
FAU - Smith, Susan
AU  - Smith S
AD  - Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular 
      Medicine, Department of Pathology, NYU Langone Medical Center and School of
      Medicine, New York, NY 10016, USA. Electronic address: susan.smith@med.nyu.edu.
LA  - eng
GR  - R01 CA116352/CA/NCI NIH HHS/United States
GR  - R01CA116352/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - 0 (Nuclear Proteins)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
RN  - EC 2.7.7.49 (Telomerase)
RN  - EC 3.6.4.- (DNA Helicases)
RN  - EC 3.6.4.12 (ATRX protein, human)
RN  - EC 3.6.4.12 (X-linked Nuclear Protein)
SB  - IM
CIN - Cancer Cell. 2015 Sep 14;28(3):277-9. PMID: 26373274
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Chromatin Assembly and Disassembly/genetics
MH  - DNA Helicases/*genetics
MH  - Genomic Instability/genetics
MH  - HEK293 Cells
MH  - HeLa Cells
MH  - Histones/genetics
MH  - Humans
MH  - Nuclear Proteins/*genetics
MH  - Poly(ADP-ribose) Polymerases/genetics
MH  - Recombination, Genetic/*genetics
MH  - Telomerase/genetics
MH  - Telomere/*genetics
MH  - Telomere Homeostasis/genetics
MH  - X-linked Nuclear Protein
PMC - PMC4573400
MID - NIHMS714077
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2014/12/23 00:00 [received]
PHST- 2015/04/08 00:00 [revised]
PHST- 2015/08/03 00:00 [accepted]
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00294-9 [pii]
AID - 10.1016/j.ccell.2015.08.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):357-69. doi: 10.1016/j.ccell.2015.08.003.

PMID- 26373280
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20150916
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute
      Myeloid Leukemia.
PG  - 329-42
LID - 10.1016/j.ccell.2015.07.017 [doi]
LID - S1535-6108(15)00269-X [pii]
AB  - Through in silico and other analyses, we identified FOXC1 as expressed in at
      least 20% of human AML cases, but not in normal hematopoietic populations. FOXC1 
      expression in AML was almost exclusively associated with expression of the HOXA/B
      locus. Functional experiments demonstrated that FOXC1 contributes to a block in
      monocyte/macrophage differentiation and enhances clonogenic potential. In in vivo
      analyses, FOXC1 collaborates with HOXA9 to accelerate significantly the onset of 
      symptomatic leukemia. A FOXC1-repressed gene set identified in murine leukemia
      exhibited quantitative repression in human AML in accordance with FOXC1
      expression, and FOXC1(high) human AML cases exhibited reduced morphologic
      monocytic differentiation and inferior survival. Thus, FOXC1 is frequently
      derepressed to functional effect in human AML.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Somerville, Tim D D
AU  - Somerville TD
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Wiseman, Daniel H
AU  - Wiseman DH
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Spencer, Gary J
AU  - Spencer GJ
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Huang, Xu
AU  - Huang X
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Lynch, James T
AU  - Lynch JT
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Leong, Hui Sun
AU  - Leong HS
AD  - Computational Biology Support Group, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Williams, Emma L
AU  - Williams EL
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK.
FAU - Cheesman, Edmund
AU  - Cheesman E
AD  - Department of Diagnostic Paediatric Pathology, Royal Manchester Children's
      Hospital, Manchester M13 9WL, UK.
FAU - Somervaille, Tim C P
AU  - Somervaille TC
AD  - Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The
      University of Manchester, Manchester M20 4BX, UK. Electronic address:
      tim.somervaille@cruk.manchester.ac.uk.
LA  - eng
SI  - GEO/GSE66256
GR  - C5759/A02901/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (homeobox protein HOXA9)
SB  - IM
MH  - Animals
MH  - Cell Differentiation/genetics
MH  - Forkhead Transcription Factors/*genetics/metabolism
MH  - Hematopoiesis/genetics
MH  - Homeodomain Proteins/metabolism
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics/metabolism
MH  - Macrophages/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Middle Aged
MH  - Monocytes/metabolism
MH  - Neoplasm Proteins/genetics/metabolism
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/02/19 00:00 [received]
PHST- 2015/06/01 00:00 [revised]
PHST- 2015/07/30 00:00 [accepted]
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00269-X [pii]
AID - 10.1016/j.ccell.2015.07.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):329-42. doi: 10.1016/j.ccell.2015.07.017.

PMID- 26373279
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Spatiotemporal Evolution of the Primary Glioblastoma Genome.
PG  - 318-28
LID - 10.1016/j.ccell.2015.07.013 [doi]
LID - S1535-6108(15)00265-2 [pii]
AB  - Tumor recurrence following treatment is the major cause of mortality for
      glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary
      process at recurrence are critical for improved patient care. Here, we describe
      our genomic analyses of the initial and recurrent tumor specimens from each of 38
      GBM patients. A substantial divergence in the landscape of driver alterations was
      associated with distant appearance of a recurrent tumor from the initial tumor,
      suggesting that the genomic profile of the initial tumor can mislead targeted
      therapies for the distally recurred tumor. In addition, in contrast to
      IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation 
      following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced
      hypermutation for these tumors under the standard regimen.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Kim, Jinkuk
AU  - Kim J
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea; Samsung Advanced Institute of Technology, Samsung Electronics Co., Ltd.,
      Seoul 06351, Korea.
FAU - Lee, In-Hee
AU  - Lee IH
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea; Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
FAU - Cho, Hee Jin
AU  - Cho HJ
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351,
      Korea.
FAU - Park, Chul-Kee
AU  - Park CK
AD  - Department of Neurosurgery, Seoul National University Hospital, Seoul National
      University College of Medicine, Seoul 06351, Korea.
FAU - Jung, Yang-Soon
AU  - Jung YS
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University
      School of Medicine, Seoul 06351, Korea.
FAU - Kim, Yanghee
AU  - Kim Y
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea.
FAU - Nam, So Hee
AU  - Nam SH
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea.
FAU - Kim, Byung Sup
AU  - Kim BS
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University
      School of Medicine, Seoul 06351, Korea.
FAU - Johnson, Mark D
AU  - Johnson MD
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Kong, Doo-Sik
AU  - Kong DS
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University
      School of Medicine, Seoul 06351, Korea.
FAU - Seol, Ho Jun
AU  - Seol HJ
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University
      School of Medicine, Seoul 06351, Korea.
FAU - Lee, Jung-Il
AU  - Lee JI
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University
      School of Medicine, Seoul 06351, Korea.
FAU - Joo, Kyeung Min
AU  - Joo KM
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351,
      Korea; Department of Anatomy and Cell Biology, Sungkyunkwan University School of 
      Medicine, Seoul 06351, Korea.
FAU - Yoon, Yeup
AU  - Yoon Y
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351,
      Korea.
FAU - Park, Woong-Yang
AU  - Park WY
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea; Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea;
      Department of Health Sciences and Technology, Samsung Advanced Institute for
      Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351,
      Korea.
FAU - Lee, Jeongwu
AU  - Lee J
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Park, Peter J
AU  - Park PJ
AD  - Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA;
      Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115,
      USA. Electronic address: peter_park@harvard.edu.
FAU - Nam, Do-Hyun
AU  - Nam DH
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351,
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351,
      Korea; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan
      University School of Medicine, Seoul 06351, Korea. Electronic address:
      nsnam@skku.edu.
LA  - eng
SI  - GEO/GSE63035
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - YF1K15M17Y (temozolomide)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Brain Neoplasms/drug therapy
MH  - Dacarbazine/analogs & derivatives/therapeutic use
MH  - Glioblastoma/drug therapy/*genetics
MH  - Glioma/genetics
MH  - Humans
MH  - Isocitrate Dehydrogenase/genetics
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy/*genetics
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2014/11/07 00:00 [received]
PHST- 2015/06/10 00:00 [revised]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00265-2 [pii]
AID - 10.1016/j.ccell.2015.07.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):318-28. doi: 10.1016/j.ccell.2015.07.013.

PMID- 26373278
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20170930
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define
      Similar Evolutionary Histories in Brain Tumors.
PG  - 307-317
LID - 10.1016/j.ccell.2015.07.012 [doi]
AB  - The evolutionary history of tumor cell populations can be reconstructed from
      patterns of genetic alterations. In contrast to stable genetic events, epigenetic
      states are reversible and sensitive to the microenvironment, prompting the
      question whether epigenetic information can similarly be used to discover tumor
      phylogeny. We examined the spatial and temporal dynamics of DNA methylation in a 
      cohort of low-grade gliomas and their patient-matched recurrences. Genes
      transcriptionally upregulated through promoter hypomethylation during malignant
      progression to high-grade glioblastoma were enriched in cell cycle function,
      evolving in parallel with genetic alterations that deregulate the G1/S cell cycle
      checkpoint. Moreover, phyloepigenetic relationships robustly recapitulated
      phylogenetic patterns inferred from somatic mutations. These findings highlight
      widespread co-dependency of genetic and epigenetic events throughout brain tumor 
      evolution.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Mazor, Tali
AU  - Mazor T
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Pankov, Aleksandr
AU  - Pankov A
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco, San Francisco, CA 94158, USA.
FAU - Johnson, Brett E
AU  - Johnson BE
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Hong, Chibo
AU  - Hong C
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Hamilton, Emily G
AU  - Hamilton EG
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Bell, Robert J A
AU  - Bell RJA
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Smirnov, Ivan V
AU  - Smirnov IV
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Reis, Gerald F
AU  - Reis GF
AD  - Department of Pathology, University of California San Francisco, San Francisco,
      CA 94158, USA.
FAU - Phillips, Joanna J
AU  - Phillips JJ
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
AD  - Department of Pathology, University of California San Francisco, San Francisco,
      CA 94158, USA.
FAU - Barnes, Michael J
AU  - Barnes MJ
AD  - Department of Pathology, University of California San Francisco, San Francisco,
      CA 94158, USA.
FAU - Idbaih, Ahmed
AU  - Idbaih A
AD  - Inserm U 1127, CNRS UMR 7225, Sorbonne Universites, UPMC Univ Paris 06 UMR S
      1127, Institut du Cerveau et de la Moelle epiniere, ICM, F-75013, Paris, France.
AD  - AP-HP, Hopital de la Pitie Salpetriere, Service de Neurologie 2-Mazarin, F-75013,
      Paris, France.
FAU - Alentorn, Agusti
AU  - Alentorn A
AD  - Inserm U 1127, CNRS UMR 7225, Sorbonne Universites, UPMC Univ Paris 06 UMR S
      1127, Institut du Cerveau et de la Moelle epiniere, ICM, F-75013, Paris, France.
AD  - AP-HP, Hopital de la Pitie Salpetriere, Service de Neurologie 2-Mazarin, F-75013,
      Paris, France.
FAU - Kloezeman, Jenneke J
AU  - Kloezeman JJ
AD  - Department of Neurosurgery, Brain Tumor Center, Erasmus Medical Center,
      Rotterdam, The Netherlands.
FAU - Lamfers, Martine L M
AU  - Lamfers MLM
AD  - Department of Neurosurgery, Brain Tumor Center, Erasmus Medical Center,
      Rotterdam, The Netherlands.
FAU - Bollen, Andrew W
AU  - Bollen AW
AD  - Department of Pathology, University of California San Francisco, San Francisco,
      CA 94158, USA.
FAU - Taylor, Barry S
AU  - Taylor BS
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
AD  - Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 
      NY 10065, USA.
FAU - Molinaro, Annette M
AU  - Molinaro AM
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco, San Francisco, CA 94158, USA.
FAU - Olshen, Adam B
AU  - Olshen AB
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco, San Francisco, CA 94158, USA.
AD  - Helen Diller Family Comprehensive Cancer Center, University of California San
      Francisco, San Francisco, CA 94158, USA.
FAU - Chang, Susan M
AU  - Chang SM
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
FAU - Song, Jun S
AU  - Song JS
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco, San Francisco, CA 94158, USA.
AD  - Department of Bioengineering, University of Illinois at Urbana-Champaign,
      Champaign, IL 61801, USA.
AD  - Department of Physics, University of Illinois at Urbana-Champaign, Champaign, IL 
      61801, USA.
AD  - Institute for Genomic Biology, University of Illinois at Urbana-Champaign,
      Champaign, IL 61801, USA.
FAU - Costello, Joseph F
AU  - Costello JF
AD  - Department of Neurological Surgery, University of California San Francisco, San
      Francisco, CA 94158, USA.
LA  - eng
GR  - T32 GM067547/GM/NIGMS NIH HHS/United States
GR  - P01 CA118816/CA/NCI NIH HHS/United States
GR  - R01 CA169316/CA/NCI NIH HHS/United States
GR  - T32GM008568/GM/NIGMS NIH HHS/United States
GR  - R25 NS070680/NS/NINDS NIH HHS/United States
GR  - R01 CA163336/CA/NCI NIH HHS/United States
GR  - R25NS070680/NS/NINDS NIH HHS/United States
GR  - P30 CA082103/CA/NCI NIH HHS/United States
GR  - T32GM067547/GM/NIGMS NIH HHS/United States
GR  - R01CA169316/CA/NCI NIH HHS/United States
GR  - P50 CA097257/CA/NCI NIH HHS/United States
GR  - P50CA097257/CA/NCI NIH HHS/United States
GR  - T32 GM008568/GM/NIGMS NIH HHS/United States
GR  - R21 NS093654/NS/NINDS NIH HHS/United States
GR  - R01CA163336/CA/NCI NIH HHS/United States
GR  - P30CA82103/CA/NCI NIH HHS/United States
GR  - 1T32CA15102201/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CIN - Cancer Cell. 2015 Sep 14;28(3):275-7. PMID: 26373273
MH  - Brain Neoplasms/*genetics
MH  - DNA Methylation/*genetics
MH  - Epigenesis, Genetic/genetics
MH  - G1 Phase Cell Cycle Checkpoints/*genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Glioblastoma/genetics
MH  - Glioma/genetics
MH  - Humans
MH  - Mutation/*genetics
MH  - Phylogeny
MH  - Promoter Regions, Genetic/genetics
MH  - Transcription, Genetic/genetics
MH  - Up-Regulation/genetics
PMC - PMC4573399
MID - NIHMS716840
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/03/20 00:00 [received]
PHST- 2015/05/21 00:00 [revised]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1016/j.ccell.2015.07.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):307-317. doi: 10.1016/j.ccell.2015.07.012.

PMID- 26373277
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - FcgammaRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1
      Axis.
PG  - 285-95
LID - 10.1016/j.ccell.2015.08.004 [doi]
LID - S1535-6108(15)00295-0 [pii]
AB  - Immune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway 
      by monoclonal antibodies (Abs) has shown promising clinical benefit in the
      treatment of multiple cancer types. We elucidated the contribution of the
      fragment crystallizable (Fc) domains of anti-PD-1 and anti-PD-ligand 1 (L1) Abs
      for their optimal anti-tumor activity. We revealed that distinct Fcgamma receptor
      (FcgammaRs) dependency and mechanisms account for the in vivo activity of
      anti-PD-1 versus anti-PD-L1 Abs. Anti-PD-1 Abs were found to be FcgammaR
      independent in vivo; the presence of FcgammaR-binding capacity compromises their 
      anti-tumor activity. In contrast, the anti-PD-L1 Abs show augmented anti-tumor
      activity when activating FcgammaR binding is introduced into the molecules,
      altering myeloid subsets within the tumor microenvironment.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Dahan, Rony
AU  - Dahan R
AD  - Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New 
      York, NY 10065, USA.
FAU - Sega, Emanuela
AU  - Sega E
AD  - Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063,
      USA.
FAU - Engelhardt, John
AU  - Engelhardt J
AD  - Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063,
      USA.
FAU - Selby, Mark
AU  - Selby M
AD  - Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063,
      USA.
FAU - Korman, Alan J
AU  - Korman AJ
AD  - Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063,
      USA.
FAU - Ravetch, Jeffrey V
AU  - Ravetch JV
AD  - Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New 
      York, NY 10065, USA. Electronic address: ravetch@rockefeller.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Cd274 protein, mouse)
RN  - 0 (Ligands)
RN  - 0 (Pdcd1 protein, mouse)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Receptors, IgG)
SB  - IM
CIN - Cancer Cell. 2015 Sep 14;28(3):273-5. PMID: 26373272
EIN - Cancer Cell. 2015 Oct 12;28(4):543
MH  - Animals
MH  - Antibodies/*immunology
MH  - B7-H1 Antigen/*immunology
MH  - Cell Line, Tumor
MH  - Ligands
MH  - Mice
MH  - Neoplasms/*immunology
MH  - Programmed Cell Death 1 Receptor/*immunology
MH  - Receptors, IgG/*immunology
MH  - Tumor Microenvironment/immunology
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/03/17 00:00 [received]
PHST- 2015/06/29 00:00 [revised]
PHST- 2015/08/12 00:00 [accepted]
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00295-0 [pii]
AID - 10.1016/j.ccell.2015.08.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):285-95. doi: 10.1016/j.ccell.2015.08.004.

PMID- 26373276
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20150916
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T
      Cells.
PG  - 281-3
LID - 10.1016/j.ccell.2015.08.009 [doi]
LID - S1535-6108(15)00300-1 [pii]
AB  - NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work 
      supports their use in multiple myeloma by showing that ex vivo antigen-specific
      expanded T cells traffic to and persist in bone marrow, are well tolerated, and
      produce promising response rates when infused after stem cell transplantation.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - San Miguel, Jesus F
AU  - San Miguel JF
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA),
      IDISNA, 31008 Pamplona, Spain. Electronic address: sanmiguel@unav.es.
FAU - Paiva, Bruno
AU  - Paiva B
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA),
      IDISNA, 31008 Pamplona, Spain.
FAU - Lasarte, Juan-Jose
AU  - Lasarte JJ
AD  - Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA),
      IDISNA, 31008 Pamplona, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Bone Marrow/immunology
MH  - Cell Engineering/methods
MH  - Humans
MH  - Multiple Myeloma/*immunology
MH  - Receptors, Antigen, T-Cell/*immunology
MH  - T-Lymphocytes/*immunology
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00300-1 [pii]
AID - 10.1016/j.ccell.2015.08.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):281-3. doi: 10.1016/j.ccell.2015.08.009.

PMID- 26373275
OWN - NLM
STAT- MEDLINE
DCOM- 20151207
LR  - 20150916
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Path Forward for RAF Therapies: Inhibition of Monomers and Dimers.
PG  - 279-81
LID - 10.1016/j.ccell.2015.08.006 [doi]
LID - S1535-6108(15)00297-4 [pii]
AB  - Current BRAF inhibitors block signaling from monomeric BRAF(V600E), but not from 
      oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao
      and colleagues investigate why current drugs are ineffective against RAF dimers, 
      while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric
      and dimeric RAF.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Kortum, Robert L
AU  - Kortum RL
AD  - Department of Pharmacology and Molecular Therapeutics, Uniformed Services
      University for the Health Sciences, Bethesda, MD 20814, USA; Laboratory of Cell
      and Developmental Signaling, National Cancer Institute at Frederick, Frederick,
      MD 21702, USA.
FAU - Morrison, Deborah K
AU  - Morrison DK
AD  - Laboratory of Cell and Developmental Signaling, National Cancer Institute at
      Frederick, Frederick, MD 21702, USA. Electronic address: morrisod@mail.nih.gov.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CON - Cancer Cell. 2015 Sep 14;28(3):370-83. PMID: 26343582
MH  - Humans
MH  - MAP Kinase Signaling System/*drug effects/*genetics
MH  - Mutation/*genetics
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/*genetics
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00297-4 [pii]
AID - 10.1016/j.ccell.2015.08.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):279-81. doi: 10.1016/j.ccell.2015.08.006.

PMID- 26373274
OWN - NLM
STAT- MEDLINE
DCOM- 20151207
LR  - 20150916
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Keeping It in the Family: ATRX Loss Promotes Persistent Sister Telomere Cohesion 
      in ALT Cancer Cells.
PG  - 277-9
LID - 10.1016/j.ccell.2015.08.005 [doi]
LID - S1535-6108(15)00296-2 [pii]
AB  - In this issue of Cancer Cell, Ramamoorthy and Smith report that cancer cells that
      maintain their chromosome ends through alternative lengthening of telomeres (ALT)
      display persistent sister telomere cohesion. This delayed resolution of sister
      telomere cohesion depends upon the loss of ATRX and its histone-sequestering
      function and is associated with increased recombination between sister telomeres.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Roake, Caitlin M
AU  - Roake CM
AD  - Cancer Biology Program, Stanford University School of Medicine, Stanford, CA
      94305, USA; Department of Medicine, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Artandi, Steven E
AU  - Artandi SE
AD  - Cancer Biology Program, Stanford University School of Medicine, Stanford, CA
      94305, USA; Department of Medicine, Stanford University School of Medicine,
      Stanford, CA 94305, USA; Department of Biochemistry, Stanford University School
      of Medicine, Stanford, CA 94305, USA. Electronic address: sartandi@stanford.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - EC 3.6.4.- (DNA Helicases)
SB  - IM
CON - Cancer Cell. 2015 Sep 14;28(3):357-69. PMID: 26373281
MH  - DNA Helicases/*genetics
MH  - Humans
MH  - Nuclear Proteins/*genetics
MH  - Recombination, Genetic/*genetics
MH  - Telomere/*genetics
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00296-2 [pii]
AID - 10.1016/j.ccell.2015.08.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):277-9. doi: 10.1016/j.ccell.2015.08.005.

PMID- 26373273
OWN - NLM
STAT- MEDLINE
DCOM- 20151207
LR  - 20150916
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - The Amazing and Deadly Glioma Race.
PG  - 275-7
LID - 10.1016/j.ccell.2015.08.010 [doi]
LID - S1535-6108(15)00301-3 [pii]
AB  - In this issue of Cancer Cell, studies from Mazor and colleagues and Kim and
      colleagues use a combination of epigenetic and genetic approaches to reveal a
      complex evolutionary process underlying two of the biggest challenges facing
      neuro-oncology, specifically glioblastoma malignant progression and treatment
      resistance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON M5G
      1X8, Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumor Research Center, Hospital for Sick Children,
      Toronto, ON M5G 1X8, Canada. Electronic address: mdtaylor@sickkids.ca.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2015 Sep 14;28(3):307-17. PMID: 26373278
MH  - Brain Neoplasms/*genetics
MH  - DNA Methylation/*genetics
MH  - G1 Phase Cell Cycle Checkpoints/*genetics
MH  - Humans
MH  - Mutation/*genetics
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00301-3 [pii]
AID - 10.1016/j.ccell.2015.08.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):275-7. doi: 10.1016/j.ccell.2015.08.010.

PMID- 26373272
OWN - NLM
STAT- MEDLINE
DCOM- 20151207
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy
      through Optimization of the IgG Framework.
PG  - 273-5
LID - 10.1016/j.ccell.2015.08.008 [doi]
LID - S1535-6108(15)00299-8 [pii]
AB  - In this issue of Cancer Cell, Dahan and colleagues demonstrate that the Fc region
      has a significant impact on the therapeutic capacity of checkpoint inhibitor
      antibodies targeting the PD-1/PD-L1 axis in pre-clinical tumor models. This work 
      provides important insights with respect to the further clinical development of
      checkpoint inhibitors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Offringa, Rienk
AU  - Offringa R
AD  - Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research
      Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Electronic address:
      r.offringa@dkfz.de.
FAU - Glennie, Martin J
AU  - Glennie MJ
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Receptors, IgG)
SB  - IM
CON - Cancer Cell. 2015 Sep 14;28(3):285-95. PMID: 26373277
MH  - Animals
MH  - Antibodies/*immunology
MH  - B7-H1 Antigen/*immunology
MH  - Neoplasms/*immunology
MH  - Programmed Cell Death 1 Receptor/*immunology
MH  - Receptors, IgG/*immunology
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00299-8 [pii]
AID - 10.1016/j.ccell.2015.08.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):273-5. doi: 10.1016/j.ccell.2015.08.008.

PMID- 26343583
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20150916
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor
      Activities in RAS or BRAF Mutant Cancers.
PG  - 384-98
LID - 10.1016/j.ccell.2015.08.002 [doi]
LID - S1535-6108(15)00293-7 [pii]
AB  - LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and
      occupies both protomers in RAF dimers. Biochemical and cellular analyses revealed
      that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity,
      while vemurafenib or dabrafenib have little or modest CRAF activity compared to
      their BRAF activities. LY3009120 induces BRAF-CRAF dimerization but inhibits the 
      phosphorylation of downstream MEK and ERK, suggesting that it effectively
      inhibits the kinase activity of BRAF-CRAF heterodimers. Further analyses
      demonstrated that LY3009120 also inhibits various forms of RAF dimers including
      BRAF or CRAF homodimers. Due to these unique properties, LY3009120 demonstrates
      minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits
      anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF
      mutation.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Peng, Sheng-Bin
AU  - Peng SB
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA. Electronic address:
      peng_sheng-bin@lilly.com.
FAU - Henry, James R
AU  - Henry JR
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Kaufman, Michael D
AU  - Kaufman MD
AD  - Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
FAU - Lu, Wei-Ping
AU  - Lu WP
AD  - Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
FAU - Smith, Bryan D
AU  - Smith BD
AD  - Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
FAU - Vogeti, Subha
AU  - Vogeti S
AD  - Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
FAU - Rutkoski, Thomas J
AU  - Rutkoski TJ
AD  - Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
FAU - Wise, Scott
AU  - Wise S
AD  - Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
FAU - Chun, Lawrence
AU  - Chun L
AD  - Emerald Biostructures, Bainbridge Island, WA 98110, USA.
FAU - Zhang, Youyan
AU  - Zhang Y
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Van Horn, Robert D
AU  - Van Horn RD
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Yin, Tinggui
AU  - Yin T
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Zhang, Xiaoyi
AU  - Zhang X
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Yadav, Vipin
AU  - Yadav V
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Chen, Shih-Hsun
AU  - Chen SH
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Gong, Xueqian
AU  - Gong X
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Ma, Xiwen
AU  - Ma X
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Webster, Yue
AU  - Webster Y
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Buchanan, Sean
AU  - Buchanan S
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Mochalkin, Igor
AU  - Mochalkin I
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Huber, Lysiane
AU  - Huber L
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Kays, Lisa
AU  - Kays L
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Donoho, Gregory P
AU  - Donoho GP
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Walgren, Jennie
AU  - Walgren J
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - McCann, Denis
AU  - McCann D
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Patel, Phenil
AU  - Patel P
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Conti, Ilaria
AU  - Conti I
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Plowman, Gregory D
AU  - Plowman GD
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Starling, James J
AU  - Starling JJ
AD  - Eli Lilly and Company, Indianapolis, IN 46285, USA.
FAU - Flynn, Daniel L
AU  - Flynn DL
AD  - Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150903
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (LY3009120)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Isoforms)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-raf)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Line, Tumor
MH  - Dimerization
MH  - Humans
MH  - MAP Kinase Signaling System/drug effects/genetics
MH  - Mitogen-Activated Protein Kinases/genetics
MH  - Mutation/drug effects/genetics
MH  - Neoplasms/*drug therapy/genetics
MH  - Phenylurea Compounds/*pharmacology
MH  - Phosphorylation/drug effects/genetics
MH  - Protein Isoforms/*antagonists & inhibitors/genetics
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/*genetics
MH  - Proto-Oncogene Proteins c-raf/genetics
MH  - Pyrimidines/*pharmacology
MH  - Signal Transduction/drug effects/genetics
MH  - ras Proteins/*genetics
EDAT- 2015/09/08 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/08 06:00
PHST- 2015/02/28 00:00 [received]
PHST- 2015/06/29 00:00 [revised]
PHST- 2015/08/03 00:00 [accepted]
PHST- 2015/09/08 06:00 [entrez]
PHST- 2015/09/08 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00293-7 [pii]
AID - 10.1016/j.ccell.2015.08.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002. Epub
      2015 Sep 3.

PMID- 26343582
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine 
      Their Sensitivity to Pharmacologic Inhibition.
PG  - 370-83
LID - 10.1016/j.ccell.2015.08.001 [doi]
LID - S1535-6108(15)00292-5 [pii]
AB  - ERK signaling requires RAS-induced RAF dimerization and is limited by feedback.
      Activated BRAF mutants evade feedback inhibition of RAS by either of two
      mechanisms. BRAF V600 mutants are activated monomers when RAS activity is low;
      all other activating BRAF mutants function as constitutive RAS-independent
      dimers. RAF inhibitors effectively inhibit mutant monomers, but not dimers; their
      binding to one site in the dimer significantly reduces their affinity for the
      second. Tumors with non-V600E BRAF mutants are insensitive to these drugs, and
      increased expression of BRAF V600E dimers causes acquired resistance. A compound 
      that equally inhibits both sites of mutant RAF dimers inhibits tumors driven by
      either class of mutants or those BRAF V600E tumors with dimer-dependent acquired 
      resistance to monomer-specific inhibitors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Yao, Zhan
AU  - Yao Z
AD  - Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Torres, Neilawattie M
AU  - Torres NM
AD  - Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Tao, Anthony
AU  - Tao A
AD  - College of Arts and Sciences, New York University, New York, NY 10003, USA.
FAU - Gao, Yijun
AU  - Gao Y
AD  - Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Luo, Lusong
AU  - Luo L
AD  - BeiGene (Beijing) Co., Ltd., No. 30 Science Park Road, Zhong-Guan-Cun Life
      Science Park, Changping District, Beijing 102206, China.
FAU - Li, Qi
AU  - Li Q
AD  - Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - de Stanchina, Elisa
AU  - de Stanchina E
AD  - Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Solit, David B
AU  - Solit DB
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA; Center for Molecular Oncology, Memorial
      Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Poulikakos, Poulikos I
AU  - Poulikakos PI
AD  - Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Rosen, Neal
AU  - Rosen N
AD  - Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA; Center for Mechanism Based Therapeutics,
      Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic
      address: rosenn@mskcc.org.
LA  - eng
GR  - R01 CA169351/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P01CA129243/CA/NCI NIH HHS/United States
GR  - R01CA169351/CA/NCI NIH HHS/United States
GR  - P01 CA129243/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150903
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
CIN - Cancer Cell. 2015 Sep 14;28(3):279-81. PMID: 26373275
MH  - Cell Line, Tumor
MH  - Dimerization
MH  - Drug Resistance, Neoplasm/drug effects/genetics
MH  - Humans
MH  - MAP Kinase Signaling System/*drug effects/*genetics
MH  - Mutation/*genetics
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/*genetics
MH  - ras Proteins/genetics
PMC - PMC4894664
MID - NIHMS714070
EDAT- 2015/09/08 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/08 06:00
PHST- 2014/12/10 00:00 [received]
PHST- 2015/07/21 00:00 [revised]
PHST- 2015/08/03 00:00 [accepted]
PHST- 2015/09/08 06:00 [entrez]
PHST- 2015/09/08 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00292-5 [pii]
AID - 10.1016/j.ccell.2015.08.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):370-83. doi: 10.1016/j.ccell.2015.08.001. Epub
      2015 Sep 3.

PMID- 26321222
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - IL-36gamma Transforms the Tumor Microenvironment and Promotes Type 1
      Lymphocyte-Mediated Antitumor Immune Responses.
PG  - 296-306
LID - 10.1016/j.ccell.2015.07.014 [doi]
LID - S1535-6108(15)00266-4 [pii]
AB  - Cytokines play a pivotal role in regulating tumor immunogenicity and antitumor
      immunity. IL-36gamma is important for the IL-23/IL-17-dominated inflammation and 
      anti-BCG Th1 immune responses. However, the impact of IL-36gamma on tumor
      immunity is unknown. Here we found that IL-36gamma stimulated CD8(+) T cells, NK 
      cells, and gammadelta T cells synergistically with TCR signaling and/or IL-12.
      Importantly, IL-36gamma exerted profound antitumor effects in vivo and
      transformed the tumor microenvironment in favor of tumor eradication.
      Furthermore, IL-36gamma strongly increased the efficacy of tumor vaccination.
      Moreover, IL-36gamma expression inversely correlated with the progression of
      human melanoma and lung cancer. Our study establishes a role of IL-36gamma in
      promoting antitumor immune responses and suggests its potential clinical
      translation into cancer immunotherapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wang, Xuefeng
AU  - Wang X
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of Biochemistry and
      Molecular Biology, School of Biology and Basic Medical Sciences, Soochow
      University, Suzhou 215123, China; Department of Immunology, Institute of Medical 
      Biotechnology, School of Biology and Basic Medical Sciences, Soochow University, 
      Suzhou 215123, China.
FAU - Zhao, Xin
AU  - Zhao X
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of General Surgery, The
      First Affiliated Hospital of Soochow University, Suzhou 215006, China.
FAU - Feng, Chao
AU  - Feng C
AD  - Department of Immunology, Institute of Medical Biotechnology, School of Biology
      and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
FAU - Weinstein, Aliyah
AU  - Weinstein A
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of Dermatology, University 
      of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
FAU - Xia, Rui
AU  - Xia R
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of Immunology, Institute of
      Medical Biotechnology, School of Biology and Basic Medical Sciences, Soochow
      University, Suzhou 215123, China.
FAU - Wen, Wen
AU  - Wen W
AD  - Department of Immunology, Institute of Medical Biotechnology, School of Biology
      and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
FAU - Lv, Quansheng
AU  - Lv Q
AD  - Department of Immunology, Institute of Medical Biotechnology, School of Biology
      and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
FAU - Zuo, Shuting
AU  - Zuo S
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of Surgery, The Second
      Hospital of Jilin University, Changchun 130041, China.
FAU - Tang, Peijun
AU  - Tang P
AD  - Department of Pulmonary Tuberculosis, The Affiliated Hospital for Infectious
      Diseases of Soochow University, Suzhou 215007, China.
FAU - Yang, Xi
AU  - Yang X
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; School of Medicine, Tsinghua
      University, Peking 100084, China.
FAU - Chen, Xiaojuan
AU  - Chen X
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of Gastroenterology, The
      First Affiliated Hospital of Soochow University, Suzhou 215006, China.
FAU - Wang, Hongrui
AU  - Wang H
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell
      Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102,
      China.
FAU - Zang, Shayang
AU  - Zang S
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of Immunology, Institute of
      Medical Biotechnology, School of Biology and Basic Medical Sciences, Soochow
      University, Suzhou 215123, China.
FAU - Stollings, Lindsay
AU  - Stollings L
AD  - Department of Anesthesiology, University of Pittsburgh Medical Center, 3471 Fifth
      Avenue, Pittsburgh, PA 15213, USA.
FAU - Denning, Timothy L
AU  - Denning TL
AD  - Center for Inflammation, Immunity, and Infection, Institute for Biomedical
      Sciences, Georgia State University, Atlanta, GA 30303, USA.
FAU - Jiang, Jingting
AU  - Jiang J
AD  - Department of Tumor Biotherapy, The Third Affiliated Hospital of Soochow
      University, Changzhou 213003, China.
FAU - Fan, Jie
AU  - Fan J
AD  - Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh,
      PA 15213, USA; Research and Development, Veterans Affairs Pittsburgh Healthcare
      System, Pittsburgh PA 15240, USA.
FAU - Zhang, Guangbo
AU  - Zhang G
AD  - Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of
      Soochow University, Suzhou 215006, China.
FAU - Zhang, Xueguang
AU  - Zhang X
AD  - Department of Immunology, Institute of Medical Biotechnology, School of Biology
      and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
FAU - Zhu, Yibei
AU  - Zhu Y
AD  - Department of Immunology, Institute of Medical Biotechnology, School of Biology
      and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
FAU - Storkus, Walter
AU  - Storkus W
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; Department of Dermatology, University 
      of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
FAU - Lu, Binfeng
AU  - Lu B
AD  - Department of Immunology, University of Pittsburgh School of Medicine, 200
      Lothrop Street, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer
      Institute, Pittsburgh, PA 15261, USA. Electronic address: binfeng@pitt.edu.
LA  - eng
GR  - 1P50 CA097190/CA/NCI NIH HHS/United States
GR  - UL1 TR000005/TR/NCATS NIH HHS/United States
GR  - P50 CA159981/CA/NCI NIH HHS/United States
GR  - UL1 RR024153/RR/NCRR NIH HHS/United States
GR  - R21CA167229/CA/NCI NIH HHS/United States
GR  - T32 GM075770/GM/NIGMS NIH HHS/United States
GR  - P50CA159981/CA/NCI NIH HHS/United States
GR  - UL1TR000005/TR/NCATS NIH HHS/United States
GR  - R21 CA167229/CA/NCI NIH HHS/United States
GR  - P50 CA097190/CA/NCI NIH HHS/United States
GR  - T32 AI089443/AI/NIAID NIH HHS/United States
GR  - T32GM075770/GM/NIGMS NIH HHS/United States
GR  - R01 CA169118/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150827
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (IL36G protein, human)
RN  - 0 (Interleukin-1)
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cancer Vaccines/immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Interleukin-1/*immunology
MH  - Interleukin-12/immunology
MH  - Killer Cells, Natural/*immunology
MH  - Lung Neoplasms/immunology
MH  - Melanoma, Experimental/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Receptors, Antigen, T-Cell, gamma-delta/immunology
MH  - Tumor Cells, Cultured
MH  - Tumor Microenvironment/*immunology
PMC - PMC4573903
MID - NIHMS712563
EDAT- 2015/09/01 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/01 06:00
PHST- 2014/07/28 00:00 [received]
PHST- 2015/01/11 00:00 [revised]
PHST- 2015/07/27 00:00 [accepted]
PHST- 2015/09/01 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00266-4 [pii]
AID - 10.1016/j.ccell.2015.07.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):296-306. doi: 10.1016/j.ccell.2015.07.014. Epub
      2015 Aug 27.

PMID- 26321221
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20171222
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.
PG  - 343-56
LID - 10.1016/j.ccell.2015.07.016 [doi]
LID - S1535-6108(15)00268-8 [pii]
AB  - Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a
      hallmark of high-risk acute lymphoblastic leukemia (ALL), however the role of
      IKZF1 alterations in ALL pathogenesis is poorly understood. Here, we show that in
      mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically
      promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations
      result in acquisition of stem cell-like features, including self-renewal and
      increased bone marrow stromal adhesion. Retinoid receptor agonists reversed this 
      phenotype, partly by inducing expression of IKZF1, resulting in abrogation of
      adhesion and self-renewal, cell cycle arrest, and attenuation of proliferation
      without direct cytotoxicity. Retinoids potentiated the activity of dasatinib in
      mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in
      IKZF1-mutated ALL.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Churchman, Michelle L
AU  - Churchman ML
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Low, Jonathan
AU  - Low J
AD  - Department of Chemical Biology and Therapeutics, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Qu, Chunxu
AU  - Qu C
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Paietta, Elisabeth M
AU  - Paietta EM
AD  - Department of Medicine, Montefiore Medical Center, North Division, Bronx, NY
      10466, USA.
FAU - Kasper, Lawryn H
AU  - Kasper LH
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Chang, Yunchao
AU  - Chang Y
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Payne-Turner, Debbie
AU  - Payne-Turner D
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Althoff, Mark J
AU  - Althoff MJ
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Song, Guangchun
AU  - Song G
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Chen, Shann-Ching
AU  - Chen SC
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Rusch, Michael
AU  - Rusch M
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - McGoldrick, Dan
AU  - McGoldrick D
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Edmonson, Michael
AU  - Edmonson M
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Gupta, Pankaj
AU  - Gupta P
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Wang, Yong-Dong
AU  - Wang YD
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Caufield, William
AU  - Caufield W
AD  - Preclinical Pharmacokinetics Shared Resource, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Freeman, Burgess
AU  - Freeman B
AD  - Preclinical Pharmacokinetics Shared Resource, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Li, Lie
AU  - Li L
AD  - Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Panetta, John C
AU  - Panetta JC
AD  - Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Baker, Sharyn
AU  - Baker S
AD  - Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Yang, Yung-Li
AU  - Yang YL
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Roberts, Kathryn G
AU  - Roberts KG
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - McCastlain, Kelly
AU  - McCastlain K
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Iacobucci, Ilaria
AU  - Iacobucci I
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Peters, Jennifer L
AU  - Peters JL
AD  - Department of Cellular Imaging Shared Resource, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Centonze, Victoria E
AU  - Centonze VE
AD  - Department of Cellular Imaging Shared Resource, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Notta, Faiyaz
AU  - Notta F
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, 
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Dobson, Stephanie M
AU  - Dobson SM
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, 
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Zandi, Sasan
AU  - Zandi S
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, 
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Dick, John E
AU  - Dick JE
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, 
      Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 
      1L7, Canada.
FAU - Janke, Laura
AU  - Janke L
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Peng, Junmin
AU  - Peng J
AD  - Departments of Structural Biology and Developmental Neurobiology, St. Jude
      Children's Research Hospital, Memphis, TN 38105, USA; St. Jude Proteomics
      Facility, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
FAU - Kodali, Kiran
AU  - Kodali K
AD  - St. Jude Proteomics Facility, St. Jude Children's Research Hospital, Memphis, TN 
      38105, USA.
FAU - Pagala, Vishwajeeth
AU  - Pagala V
AD  - St. Jude Proteomics Facility, St. Jude Children's Research Hospital, Memphis, TN 
      38105, USA.
FAU - Min, Jaeki
AU  - Min J
AD  - Department of Chemical Biology and Therapeutics, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Mayasundari, Anand
AU  - Mayasundari A
AD  - Department of Chemical Biology and Therapeutics, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Williams, Richard T
AU  - Williams RT
AD  - Puma Biotechnology, Los Angeles, CA 90024, USA.
FAU - Willman, Cheryl L
AU  - Willman CL
AD  - Department of Pathology, University of New Mexico Cancer Center, Albuquerque, NM 
      87131, USA.
FAU - Rowe, Jacob
AU  - Rowe J
AD  - Hematology, Shaare Zedek Medical Center, 9103102 Jerusalem, Israel.
FAU - Luger, Selina
AU  - Luger S
AD  - Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - Dickins, Ross A
AU  - Dickins RA
AD  - The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052,
      Australia.
FAU - Guy, R Kiplin
AU  - Guy RK
AD  - Department of Chemical Biology and Therapeutics, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Chen, Taosheng
AU  - Chen T
AD  - Department of Chemical Biology and Therapeutics, St. Jude Children's Research
      Hospital, Memphis, TN 38105, USA.
FAU - Mullighan, Charles G
AU  - Mullighan CG
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA. Electronic address: charles.mullighan@stjude.org.
LA  - eng
SI  - GEO/GSE54821
SI  - GEO/GSE68391
GR  - U24-CA114737/CA/NCI NIH HHS/United States
GR  - U10 CA021115/CA/NCI NIH HHS/United States
GR  - R25 CA023944/CA/NCI NIH HHS/United States
GR  - U24 CA196172/CA/NCI NIH HHS/United States
GR  - U10 CA21115/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - U01 CA157937/CA/NCI NIH HHS/United States
GR  - RC1 CA145707/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - U24 CA114737/CA/NCI NIH HHS/United States
GR  - R25 CA23944/CA/NCI NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - U10 CA180827/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150827
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoids)
RN  - 148971-36-2 (Ikaros Transcription Factor)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Animals
MH  - Cell Cycle Checkpoints/genetics
MH  - Fusion Proteins, bcr-abl/*genetics
MH  - Humans
MH  - Ikaros Transcription Factor/*genetics
MH  - Mice
MH  - Mutation/*genetics
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics/metabolism
MH  - Receptors, Retinoic Acid/metabolism
MH  - Retinoids/*metabolism
PMC - PMC4573904
MID - NIHMS712753
EDAT- 2015/09/01 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/01 06:00
PHST- 2014/11/04 00:00 [received]
PHST- 2015/04/07 00:00 [revised]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/09/01 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00268-8 [pii]
AID - 10.1016/j.ccell.2015.07.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):343-56. doi: 10.1016/j.ccell.2015.07.016. Epub
      2015 Aug 27.

PMID- 26267538
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20150813
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis.
PG  - 253-69
LID - 10.1016/j.ccell.2015.07.006 [doi]
LID - S1535-6108(15)00258-5 [pii]
AB  - Cancer-driven granulo-monocytopoiesis stimulates expansion of tumor promoting
      myeloid populations, mostly myeloid-derived suppressor cells (MDSCs) and
      tumor-associated macrophages (TAMs). We identified subsets of MDSCs and TAMs
      based on the expression of retinoic-acid-related orphan receptor (RORC1/RORgamma)
      in human and mouse tumor bearers. RORC1 orchestrates myelopoiesis by suppressing 
      negative (Socs3 and Bcl3) and promoting positive (C/EBPbeta) regulators of
      granulopoiesis, as well as the key transcriptional mediators of myeloid
      progenitor commitment and differentiation to the monocytic/macrophage lineage
      (IRF8 and PU.1). RORC1 supported tumor-promoting innate immunity by protecting
      MDSCs from apoptosis, mediating TAM differentiation and M2 polarization, and
      limiting tumor infiltration by mature neutrophils. Accordingly, ablation of RORC1
      in the hematopoietic compartment prevented cancer-driven myelopoiesis, resulting 
      in inhibition of tumor growth and metastasis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Strauss, Laura
AU  - Strauss L
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy.
FAU - Sangaletti, Sabina
AU  - Sangaletti S
AD  - Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan,
      Italy.
FAU - Consonni, Francesca Maria
AU  - Consonni FM
AD  - Department of Pharmaceutical Sciences, Universita del Piemonte Orientale "Amedeo 
      Avogadro," Via Bovio 6, 28100 Novara, Italy.
FAU - Szebeni, Gabor
AU  - Szebeni G
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy.
FAU - Morlacchi, Sara
AU  - Morlacchi S
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy.
FAU - Totaro, Maria Grazia
AU  - Totaro MG
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy.
FAU - Porta, Chiara
AU  - Porta C
AD  - Department of Pharmaceutical Sciences, Universita del Piemonte Orientale "Amedeo 
      Avogadro," Via Bovio 6, 28100 Novara, Italy.
FAU - Anselmo, Achille
AU  - Anselmo A
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy.
FAU - Tartari, Silvia
AU  - Tartari S
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy.
FAU - Doni, Andrea
AU  - Doni A
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy.
FAU - Zitelli, Francesco
AU  - Zitelli F
AD  - Department of Pharmaceutical Sciences, Universita del Piemonte Orientale "Amedeo 
      Avogadro," Via Bovio 6, 28100 Novara, Italy.
FAU - Tripodo, Claudio
AU  - Tripodo C
AD  - Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Via 
      del Vespro 129, 90127 Palermo, Italy.
FAU - Colombo, Mario P
AU  - Colombo MP
AD  - Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan,
      Italy.
FAU - Sica, Antonio
AU  - Sica A
AD  - Department of Inflammation and Immunology, Humanitas Clinical and Research
      Center, 20089 Rozzano, Milan, Italy; Department of Pharmaceutical Sciences,
      Universita del Piemonte Orientale "Amedeo Avogadro," Via Bovio 6, 28100 Novara,
      Italy. Electronic address: antonio.sica@humanitasresearch.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cytokines)
RN  - 0 (Nuclear Receptor Subfamily 1, Group F, Member 3)
SB  - IM
CIN - Cancer Cell. 2015 Aug 10;28(2):147-9. PMID: 26267530
MH  - Animals
MH  - Apoptosis/genetics
MH  - Cell Differentiation/genetics
MH  - Cell Line, Tumor
MH  - Cytokines/genetics/metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Granulocytes/*metabolism/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Macrophages/metabolism/pathology
MH  - Male
MH  - Mice, 129 Strain
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Microscopy, Confocal
MH  - Monocytes/*metabolism/pathology
MH  - Myeloid Cells/metabolism/pathology
MH  - Myelopoiesis/*genetics
MH  - Neoplasms, Experimental/*genetics/metabolism/pathology
MH  - Neutrophils/metabolism
MH  - Nuclear Receptor Subfamily 1, Group F, Member 3/*genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Burden/genetics
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2014/09/30 00:00 [received]
PHST- 2015/04/09 00:00 [revised]
PHST- 2015/07/21 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00258-5 [pii]
AID - 10.1016/j.ccell.2015.07.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):253-69. doi: 10.1016/j.ccell.2015.07.006.

PMID- 26267537
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that
      Overstimulates Cancer Cells and Leads to Cell Stress and Death.
PG  - 240-52
LID - 10.1016/j.ccell.2015.07.005 [doi]
LID - S1535-6108(15)00257-3 [pii]
AB  - By integrating growth pathways on which cancer cells rely, steroid receptor
      coactivators (SRC-1, SRC-2, and SRC-3) represent emerging targets in cancer
      therapeutics. High-throughput screening for SRC small molecule inhibitors (SMIs) 
      uncovered MCB-613 as a potent SRC small molecule "stimulator" (SMS). We
      demonstrate that MCB-613 can super-stimulate SRCs' transcriptional activity.
      Further investigation revealed that MCB-613 increases SRCs' interactions with
      other coactivators and markedly induces ER stress coupled to the generation of
      reactive oxygen species (ROS). Because cancer cells overexpress SRCs and rely on 
      them for growth, we show that we can exploit MCB-613 to selectively induce
      excessive stress in cancer cells. This suggests that over-stimulating the SRC
      oncogenic program can be an effective strategy to kill cancer cells.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Yu, Yang
AU  - Yu Y
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Chow, Dar-Chone
AU  - Chow DC
AD  - Department of Pharmacology, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Yan, Fei
AU  - Yan F
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Hsu, Chih-Chao
AU  - Hsu CC
AD  - Department of Epigenetics and Molecular Carcinogenesis, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Stossi, Fabio
AU  - Stossi F
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Mancini, Michael A
AU  - Mancini MA
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Palzkill, Timothy
AU  - Palzkill T
AD  - Department of Pharmacology, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Liao, Lan
AU  - Liao L
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Zhou, Suoling
AU  - Zhou S
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Xu, Jianming
AU  - Xu J
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Lonard, David M
AU  - Lonard DM
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA. Electronic address: dlonard@bcm.edu.
FAU - O'Malley, Bert W
AU  - O'Malley BW
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine,
      Houston, TX 77030, USA. Electronic address: berto@bcm.edu.
LA  - eng
GR  - HD076596/HD/NICHD NIH HHS/United States
GR  - R01 CA193455/CA/NCI NIH HHS/United States
GR  - DK059820/DK/NIDDK NIH HHS/United States
GR  - P01 DK059820/DK/NIDDK NIH HHS/United States
GR  - R01 HD007857/HD/NICHD NIH HHS/United States
GR  - U01 HD076596/HD/NICHD NIH HHS/United States
GR  - CA112403/CA/NCI NIH HHS/United States
GR  - R01 HD008188/HD/NICHD NIH HHS/United States
GR  - R01 CA112403/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (4-ethyl-2,6-bispyridin-3-ylmethylenecyclohexanone)
RN  - 0 (Cyclohexanones)
RN  - 0 (Nuclear Receptor Coactivator 2)
RN  - 0 (Pyridines)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Small Molecule Libraries)
RN  - EC 2.3.1.48 (Nuclear Receptor Coactivator 1)
RN  - EC 2.3.1.48 (Nuclear Receptor Coactivator 3)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Cyclohexanones/chemistry/metabolism/pharmacology
MH  - Drug Screening Assays, Antitumor/methods
MH  - Endoplasmic Reticulum Stress/drug effects
MH  - HEK293 Cells
MH  - HeLa Cells
MH  - Humans
MH  - Immunoblotting
MH  - MCF-7 Cells
MH  - Molecular Structure
MH  - Mutation
MH  - Neoplasms/genetics/metabolism/*prevention & control
MH  - Nuclear Receptor Coactivator 1/genetics/*metabolism
MH  - Nuclear Receptor Coactivator 2/genetics/*metabolism
MH  - Nuclear Receptor Coactivator 3/genetics/*metabolism
MH  - Oxidative Stress/drug effects
MH  - Protein Binding/drug effects
MH  - Pyridines/chemistry/metabolism/pharmacology
MH  - RNA Interference
MH  - Reactive Oxygen Species/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Small Molecule Libraries/chemistry/metabolism/*pharmacology
MH  - Tumor Burden/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC4536575
MID - NIHMS709579
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2014/09/23 00:00 [received]
PHST- 2015/03/12 00:00 [revised]
PHST- 2015/07/10 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00257-3 [pii]
AID - 10.1016/j.ccell.2015.07.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):240-52. doi: 10.1016/j.ccell.2015.07.005.

PMID- 26267536
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20151223
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
PG  - 225-39
LID - 10.1016/j.ccell.2015.07.002 [doi]
LID - S1535-6108(15)00254-8 [pii]
AB  - The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial
      role in cancer by affecting tumor growth, angiogenesis, drug resistance, and
      escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The 
      soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF 
      antagonist. Here we demonstrate that human PTX3 overexpression in transgenic mice
      driven by the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis
      in heterotopic, orthotopic, and autochthonous FGF-dependent tumor models. Using
      pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding
      pentapeptide with FGF2, we identified a small-molecule chemical (NSC12) that acts
      as an extracellular FGF trap with significant implications in cancer therapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ronca, Roberto
AU  - Ronca R
AD  - Department of Molecular and Translational Medicine, University of Brescia, 25123 
      Brescia, Italy. Electronic address: roberto.ronca@unibs.it.
FAU - Giacomini, Arianna
AU  - Giacomini A
AD  - Department of Molecular and Translational Medicine, University of Brescia, 25123 
      Brescia, Italy.
FAU - Di Salle, Emanuela
AU  - Di Salle E
AD  - Department of Molecular and Translational Medicine, University of Brescia, 25123 
      Brescia, Italy.
FAU - Coltrini, Daniela
AU  - Coltrini D
AD  - Department of Molecular and Translational Medicine, University of Brescia, 25123 
      Brescia, Italy.
FAU - Pagano, Katiuscia
AU  - Pagano K
AD  - NMR Laboratory, Istituto per lo Studio delle Macromolecole, CNR, 20133 Milan,
      Italy.
FAU - Ragona, Laura
AU  - Ragona L
AD  - NMR Laboratory, Istituto per lo Studio delle Macromolecole, CNR, 20133 Milan,
      Italy.
FAU - Matarazzo, Sara
AU  - Matarazzo S
AD  - Department of Molecular and Translational Medicine, University of Brescia, 25123 
      Brescia, Italy.
FAU - Rezzola, Sara
AU  - Rezzola S
AD  - Department of Molecular and Translational Medicine, University of Brescia, 25123 
      Brescia, Italy.
FAU - Maiolo, Daniele
AU  - Maiolo D
AD  - Chemistry for Technologies Laboratory and INSTM, School of Engineering,
      University of Brescia, 25123 Brescia, Italy.
FAU - Torrella, Rubben
AU  - Torrella R
AD  - Istituto di Chimica del Riconoscimento Molecolare, CNR, 20133 Milan, Italy.
FAU - Moroni, Elisabetta
AU  - Moroni E
AD  - Istituto di Chimica del Riconoscimento Molecolare, CNR, 20133 Milan, Italy.
FAU - Mazzieri, Roberta
AU  - Mazzieri R
AD  - University of Queensland Diamantina Institute, Translational Research Institute, 
      Brisbane, QLD 4102, Australia.
FAU - Escobar, Giulia
AU  - Escobar G
AD  - San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy; Vita Salute
      San Raffaele University, 20132 Milan, Italy.
FAU - Mor, Marco
AU  - Mor M
AD  - Department of Pharmacy, University of Parma, 43121 Parma, Italy.
FAU - Colombo, Giorgio
AU  - Colombo G
AD  - Istituto di Chimica del Riconoscimento Molecolare, CNR, 20133 Milan, Italy.
FAU - Presta, Marco
AU  - Presta M
AD  - Department of Molecular and Translational Medicine, University of Brescia, 25123 
      Brescia, Italy. Electronic address: marco.presta@unibs.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Serum Amyloid P-Component)
RN  - 0 (Small Molecule Libraries)
RN  - 148591-49-5 (PTX3 protein)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
CIN - Nat Rev Drug Discov. 2015 Oct;14(10):680. PMID: 26424356
MH  - Animals
MH  - Blotting, Western
MH  - C-Reactive Protein/*genetics/metabolism
MH  - Cell Cycle/drug effects/genetics
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects/genetics
MH  - Cells, Cultured
MH  - Female
MH  - Fibroblast Growth Factors/*genetics/metabolism/pharmacology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Nude
MH  - Mice, Transgenic
MH  - Molecular Structure
MH  - Neoplasms/*genetics/metabolism/therapy
MH  - Neovascularization, Pathologic/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Serum Amyloid P-Component/*genetics/metabolism
MH  - Small Molecule Libraries/chemistry/pharmacology
MH  - Tumor Burden/drug effects/genetics
MH  - Xenograft Model Antitumor Assays/methods
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2014/07/31 00:00 [received]
PHST- 2015/04/10 00:00 [revised]
PHST- 2015/07/10 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00254-8 [pii]
AID - 10.1016/j.ccell.2015.07.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):225-39. doi: 10.1016/j.ccell.2015.07.002.

PMID- 26267535
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer
      Development.
PG  - 183-97
LID - 10.1016/j.ccell.2015.07.004 [doi]
LID - S1535-6108(15)00256-1 [pii]
AB  - Biomarkers for predicting prognosis are critical to treating colorectal cancer
      (CRC) patients. We found that CSN6, a subunit of COP9 signalosome, is
      overexpressed in CRC samples and that CSN6 overexpression is correlated with poor
      patient survival. Mechanistic studies revealed that CSN6 is deregulated by
      epidermal growth factor receptor (EGFR) signaling, in which ERK2 binds directly
      to CSN6 Leu163/Val165 and phosphorylates CSN6 at Ser148. Furthermore, CSN6
      regulated beta-Trcp and stabilized beta-catenin expression by blocking the
      ubiquitin-proteasome pathway, thereby promoting CRC development. High CSN6
      expression was positively correlated with ERK2 activation and beta-catenin
      overexpression in CRC samples, and inhibiting CSN6 stability with cetuximab
      reduced colon cancer growth. Taken together, our study's findings indicate that
      the deregulation of beta-catenin by ERK2-activated CSN6 is important for CRC
      development.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Fang, Lekun
AU  - Fang L
AD  - Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen
      University, Guangzhou 510655, China; Guangdong Provincial Key Laboratory of
      Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-sen
      University, Guangzhou 510655, China; Department of Molecular and Cellular
      Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030,
      USA.
FAU - Lu, Weisi
AU  - Lu W
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou 510060, China; Key Laboratory of Gene Engineering of the
      Ministry of Education, School of Life Sciences, Sun Yat-sen University, Guangzhou
      510275, China; Program in Genes and Development, The University of Texas Graduate
      School of Biomedical Sciences at Houston, Houston, TX 77030, USA.
FAU - Choi, Hyun Ho
AU  - Choi HH
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yeung, Sai-Ching J
AU  - Yeung SC
AD  - Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Tung, Jung-Yu
AU  - Tung JY
AD  - Institute of Molecular Biology, Academia Sinica, Taipei 11529, Taiwan.
FAU - Hsiao, Chwan-Deng
AU  - Hsiao CD
AD  - Institute of Molecular Biology, Academia Sinica, Taipei 11529, Taiwan.
FAU - Fuentes-Mattei, Enrique
AU  - Fuentes-Mattei E
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Menter, David
AU  - Menter D
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Chen, Chuangqi
AU  - Chen C
AD  - Department of Surgery, The First Affiliated Hospital of Sun Yat-sen University,
      Guangzhou 510080, China.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen
      University, Guangzhou 510655, China; Guangdong Provincial Key Laboratory of
      Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-sen
      University, Guangzhou 510655, China.
FAU - Wang, Jianping
AU  - Wang J
AD  - Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen
      University, Guangzhou 510655, China; Guangdong Provincial Key Laboratory of
      Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-sen
      University, Guangzhou 510655, China. Electronic address: wangjpgz@163.com.
FAU - Lee, Mong-Hong
AU  - Lee MH
AD  - Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The
      Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China;
      Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; Program in Cancer Biology, The
      University of Texas Graduate School of Biomedical Sciences at Houston, Houston,
      TX 77030, USA; Program in Genes and Development, The University of Texas Graduate
      School of Biomedical Sciences at Houston, Houston, TX 77030, USA. Electronic
      address: mhlee@mdanderson.org.
LA  - eng
SI  - GEO/GSE60697
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - CA16672/CA/NCI NIH HHS/United States
GR  - L30 CA199587/CA/NCI NIH HHS/United States
GR  - R01CA089266/CA/NCI NIH HHS/United States
GR  - R01 CA089266/CA/NCI NIH HHS/United States
GR  - KG081048/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (COPS6 protein, human)
RN  - 0 (beta Catenin)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 3.4.19.12 (COP9 Signalosome Complex)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/genetics/*metabolism
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Blotting, Western
MH  - COP9 Signalosome Complex
MH  - Cell Line, Tumor
MH  - Cetuximab/pharmacology
MH  - Colorectal Neoplasms/drug therapy/genetics/*metabolism
MH  - Female
MH  - Gene Expression Profiling
MH  - HCT116 Cells
MH  - Humans
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Middle Aged
MH  - Mitogen-Activated Protein Kinase 1/genetics/*metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - Phosphorylation
MH  - RNA Interference
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/drug effects/genetics
MH  - Tumor Burden/drug effects/genetics
MH  - Ubiquitination
MH  - Xenograft Model Antitumor Assays/methods
MH  - beta Catenin/genetics/*metabolism
PMC - PMC4560098
MID - NIHMS711265
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2014/08/25 00:00 [received]
PHST- 2015/01/17 00:00 [revised]
PHST- 2015/07/10 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00256-1 [pii]
AID - 10.1016/j.ccell.2015.07.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):183-97. doi: 10.1016/j.ccell.2015.07.004.

PMID- 26267534
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20151214
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK
      Pathway Oncogenes.
PG  - 170-82
LID - 10.1016/j.ccell.2015.07.001 [doi]
LID - S1535-6108(15)00253-6 [pii]
AB  - Nearly 50% of human malignancies exhibit unregulated RAS-ERK signaling;
      inhibiting it is a valid strategy for antineoplastic intervention. Upon
      activation, ERK dimerize, which is essential for ERK extranuclear, but not for
      nuclear, signaling. Here, we describe a small molecule inhibitor for ERK
      dimerization that, without affecting ERK phosphorylation, forestalls
      tumorigenesis driven by RAS-ERK pathway oncogenes. This compound is unaffected by
      resistance mechanisms that hamper classical RAS-ERK pathway inhibitors. Thus, ERK
      dimerization inhibitors provide the proof of principle for two understudied
      concepts in cancer therapy: (1) the blockade of sub-localization-specific
      sub-signals, rather than total signals, as a means of impeding oncogenic RAS-ERK 
      signaling and (2) targeting regulatory protein-protein interactions, rather than 
      catalytic activities, as an approach for producing effective antitumor agents.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Herrero, Ana
AU  - Herrero A
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain.
FAU - Pinto, Adan
AU  - Pinto A
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain.
FAU - Colon-Bolea, Paula
AU  - Colon-Bolea P
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain.
FAU - Casar, Berta
AU  - Casar B
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain.
FAU - Jones, Mary
AU  - Jones M
AD  - Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK.
FAU - Agudo-Ibanez, Lorena
AU  - Agudo-Ibanez L
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain.
FAU - Vidal, Rebeca
AU  - Vidal R
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain; Departamento de Fisiologia y Farmacologia, Centro de Investigacion
      Biomedica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III
      Universidad de Cantabria, Santander 39011, Spain.
FAU - Tenbaum, Stephan P
AU  - Tenbaum SP
AD  - Stem Cells and Cancer Laboratory, Translational Research Program, Vall d'Hebron
      Institute of Oncology (VHIO), Barcelona 08035, Spain.
FAU - Nuciforo, Paolo
AU  - Nuciforo P
AD  - Stem Cells and Cancer Laboratory, Translational Research Program, Vall d'Hebron
      Institute of Oncology (VHIO), Barcelona 08035, Spain.
FAU - Valdizan, Elsa M
AU  - Valdizan EM
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain; Departamento de Fisiologia y Farmacologia, Centro de Investigacion
      Biomedica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III
      Universidad de Cantabria, Santander 39011, Spain.
FAU - Horvath, Zoltan
AU  - Horvath Z
AD  - Vichem Chemie Research Ltd., 1022 Budapest, Hungary.
FAU - Orfi, Laszlo
AU  - Orfi L
AD  - Vichem Chemie Research Ltd., 1022 Budapest, Hungary; Department of Pharmaceutical
      Chemistry, Semmelweis University, 1092 Budapest, Hungary.
FAU - Pineda-Lucena, Antonio
AU  - Pineda-Lucena A
AD  - Centro de Investigacion Principe Felipe, 46012 Valencia, Spain.
FAU - Bony, Emilie
AU  - Bony E
AD  - Pharmacognosy Research Group, Louvain Drug Research Institute, Universite
      Catholique de Louvain, 1200 Bruxelles, Belgium.
FAU - Keri, Gyorgy
AU  - Keri G
AD  - Vichem Chemie Research Ltd., 1022 Budapest, Hungary; MTA-SE Pathobiochemistry
      Research Group, Department of Medical Chemistry, Semmelweis University, 1092
      Budapest, Hungary.
FAU - Rivas, German
AU  - Rivas G
AD  - Centro de Investigaciones Biologicas, Consejo Superior de Investigaciones
      Cientificas, 28040 Madrid, Spain.
FAU - Pazos, Angel
AU  - Pazos A
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain; Departamento de Fisiologia y Farmacologia, Centro de Investigacion
      Biomedica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III
      Universidad de Cantabria, Santander 39011, Spain.
FAU - Gozalbes, Rafael
AU  - Gozalbes R
AD  - ProtoQSAR S.L., 46008 Valencia, Spain.
FAU - Palmer, Hector G
AU  - Palmer HG
AD  - Stem Cells and Cancer Laboratory, Translational Research Program, Vall d'Hebron
      Institute of Oncology (VHIO), Barcelona 08035, Spain.
FAU - Hurlstone, Adam
AU  - Hurlstone A
AD  - Departamento de Fisiologia y Farmacologia, Centro de Investigacion Biomedica en
      Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III Universidad de
      Cantabria, Santander 39011, Spain.
FAU - Crespo, Piero
AU  - Crespo P
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC), Consejo Superior 
      de Investigaciones Cientificas (CSIC), Universidad de Cantabria, Santander 39011,
      Spain. Electronic address: crespop@unican.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DEL-22379)
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Small Molecule Libraries)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
CIN - Nat Rev Cancer. 2015 Oct;15(10):574-5. PMID: 26355243
CIN - Cancer Cell. 2015 Aug 10;28(2):145-7. PMID: 26267529
MH  - Animals
MH  - Carcinogenesis/*drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Chick Embryo
MH  - Female
MH  - HEK293 Cells
MH  - Humans
MH  - Immunoblotting
MH  - Indoles/chemistry/metabolism/pharmacology
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, Nude
MH  - Mice, SCID
MH  - Mitogen-Activated Protein Kinase 1/*antagonists & inhibitors/chemistry/metabolism
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Protein Binding/drug effects
MH  - Protein Kinase Inhibitors/chemistry/metabolism/pharmacology
MH  - Protein Multimerization/*drug effects
MH  - Protein Structure, Tertiary
MH  - Signal Transduction/*drug effects
MH  - Small Molecule Libraries/chemistry/metabolism/*pharmacology
MH  - Xenograft Model Antitumor Assays/methods
MH  - Zebrafish
MH  - ras Proteins/*metabolism
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2014/09/03 00:00 [received]
PHST- 2015/04/30 00:00 [revised]
PHST- 2015/07/08 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00253-6 [pii]
AID - 10.1016/j.ccell.2015.07.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):170-82. doi: 10.1016/j.ccell.2015.07.001.

PMID- 26267533
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast
      Cancer Growth and Metastasis.
PG  - 155-69
LID - 10.1016/j.ccell.2015.07.003 [doi]
LID - S1535-6108(15)00255-X [pii]
AB  - Metastasis is the major cause of breast cancer mortality. Phosphoinositide
      3-kinase (PI3K) generated PtdIns(3,4,5)P3 activates AKT, which promotes breast
      cancer cell proliferation and regulates migration. To date, none of the inositol 
      polyphosphate 5-phosphatases that inhibit PI3K/AKT signaling have been reported
      as tumor suppressors in breast cancer. Here, we show depletion of the inositol
      polyphosphate 5-phosphatase PIPP (INPP5J) increases breast cancer cell
      transformation, but reduces cell migration and invasion. Pipp ablation
      accelerates oncogene-driven breast cancer tumor growth in vivo, but paradoxically
      reduces metastasis by regulating AKT1-dependent tumor cell migration. PIPP mRNA
      expression is reduced in human ER-negative breast cancers associated with reduced
      long-term outcome. Collectively, our findings identify PIPP as a suppressor of
      oncogenic PI3K/AKT signaling in breast cancer.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ooms, Lisa M
AU  - Ooms LM
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Binge, Lauren C
AU  - Binge LC
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Davies, Elizabeth M
AU  - Davies EM
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Rahman, Parvin
AU  - Rahman P
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Conway, James R W
AU  - Conway JR
AD  - Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Faculty of
      Medicine, St Vincent's Clinical School, University of NSW, Darlinghurst, NSW
      2010, Australia.
FAU - Gurung, Rajendra
AU  - Gurung R
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Ferguson, Daniel T
AU  - Ferguson DT
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Papa, Antonella
AU  - Papa A
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Fedele, Clare G
AU  - Fedele CG
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Vieusseux, Jessica L
AU  - Vieusseux JL
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Chai, Ryan C
AU  - Chai RC
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Koentgen, Frank
AU  - Koentgen F
AD  - Ozgene Pty Ltd, Bentley DC, WA 6983, Australia.
FAU - Price, John T
AU  - Price JT
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Tiganis, Tony
AU  - Tiganis T
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia.
FAU - Timpson, Paul
AU  - Timpson P
AD  - Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Faculty of
      Medicine, St Vincent's Clinical School, University of NSW, Darlinghurst, NSW
      2010, Australia.
FAU - McLean, Catriona A
AU  - McLean CA
AD  - Department of Anatomical Pathology, Alfred Hospital, Prahran, VIC 3181,
      Australia.
FAU - Mitchell, Christina A
AU  - Mitchell CA
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC
      3800, Australia. Electronic address: christina.mitchell@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
RN  - EC 3.1.3.56 (Inositol Polyphosphate 5-Phosphatases)
SB  - IM
CIN - Cancer Cell. 2015 Aug 10;28(2):143-5. PMID: 26267528
MH  - Animals
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/*genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Inositol Polyphosphate 5-Phosphatases
MH  - Kaplan-Meier Estimate
MH  - Mice, Inbred BALB C
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - Neoplasm Metastasis
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - Phosphoric Monoester Hydrolases/*genetics/metabolism
MH  - Proto-Oncogene Proteins c-akt/*genetics/metabolism
MH  - RNA Interference
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/genetics
MH  - Tumor Burden/genetics
MH  - Xenograft Model Antitumor Assays/methods
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2014/12/21 00:00 [received]
PHST- 2015/06/03 00:00 [revised]
PHST- 2015/07/10 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00255-X [pii]
AID - 10.1016/j.ccell.2015.07.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):155-69. doi: 10.1016/j.ccell.2015.07.003.

PMID- 26267532
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20161025
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy.
PG  - 151-3
LID - 10.1016/j.ccell.2015.07.015 [doi]
LID - S1535-6108(15)00267-6 [pii]
AB  - In clinical oncology, detecting and treating disease as early as possible is the 
      brass ring to be grasped. Does a new test based on circulating exosomes bring it 
      closer for patients with pancreas cancer?
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Hingorani, Sunil R
AU  - Hingorani SR
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Public Health Sciences Division, Fred Hutchinson Cancer Research
      Center, Seattle, WA 98109, USA; Division of Medical Oncology, University of
      Washington School of Medicine, Seattle, WA 98195, USA. Electronic address:
      srh@fhcrc.org.
LA  - eng
GR  - R01 CA129357/CA/NCI NIH HHS/United States
GR  - R01 CA161112/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Glypicans)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Animals
MH  - Biomarkers, Tumor/blood/*metabolism
MH  - Exosomes/genetics/*metabolism
MH  - Flow Cytometry
MH  - Glypicans/blood/*metabolism
MH  - Humans
MH  - Mice
MH  - Mutation
MH  - Pancreatic Neoplasms/blood/*diagnosis/genetics
MH  - ras Proteins/genetics/metabolism
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00267-6 [pii]
AID - 10.1016/j.ccell.2015.07.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):151-3. doi: 10.1016/j.ccell.2015.07.015.

PMID- 26267531
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20150813
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?
PG  - 149-50
LID - 10.1016/j.ccell.2015.07.011 [doi]
LID - S1535-6108(15)00263-9 [pii]
AB  - Molecular studies of intra-tumor heterogeneity (ITH) are revealing a large amount
      of DNA-based variation in many individual tumors. In a recent publication by
      Yates and colleagues, the ITH of breast tumors was examined and shown to have
      important implications for the development of resistant disease, metastasis, and 
      clinical sequencing efforts.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Parker, Joel S
AU  - Parker JS
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel
      Hill, NC 27599, USA; Department of Genetics, University of North Carolina, Chapel
      Hill, NC 27599, USA.
FAU - Perou, Charles M
AU  - Perou CM
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel
      Hill, NC 27599, USA; Department of Genetics, University of North Carolina, Chapel
      Hill, NC 27599, USA. Electronic address: cperou@med.unc.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Breast Neoplasms/drug therapy/genetics/pathology
MH  - *DNA Copy Number Variations
MH  - Female
MH  - *Genetic Heterogeneity
MH  - Genetic Predisposition to Disease/genetics
MH  - *Genetic Variation
MH  - Humans
MH  - Mutation
MH  - Neoplasm, Residual/drug therapy/genetics/pathology
MH  - Neoplasms/drug therapy/*genetics/pathology
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00263-9 [pii]
AID - 10.1016/j.ccell.2015.07.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):149-50. doi: 10.1016/j.ccell.2015.07.011.

PMID- 26267530
OWN - NLM
STAT- MEDLINE
DCOM- 20151125
LR  - 20161025
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells.
PG  - 147-9
LID - 10.1016/j.ccell.2015.07.007 [doi]
LID - S1535-6108(15)00259-7 [pii]
AB  - Myeloid-derived suppressor cells (MDSCs) play a major role in cancer. MDSC
      expansion is closely associated with tumor progression, but molecular mechanisms 
      of this expansion remain poorly understood. In this issue of Cancer Cell, Strauss
      and colleagues describe the roles of the nuclear receptor ROR1C in the regulation
      of MDSC differentiation and expansion.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Gabrilovich, Dmitry
AU  - Gabrilovich D
AD  - The Wistar Institute, 3601 Spruce Street, Room 180, Philadelphia, PA, 19104, USA.
      Electronic address: dgabrilovich@wistar.org.
FAU - Nefedova, Yulia
AU  - Nefedova Y
AD  - The Wistar Institute, 3601 Spruce Street, Room 180, Philadelphia, PA, 19104, USA.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA084488/CA/NCI NIH HHS/United States
GR  - R01 CA141438/CA/NCI NIH HHS/United States
GR  - R01 CA177646/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Receptor Subfamily 1, Group F, Member 3)
SB  - IM
CON - Cancer Cell. 2015 Aug 10;28(2):253-69. PMID: 26267538
MH  - Animals
MH  - Female
MH  - Granulocytes/*metabolism
MH  - Humans
MH  - Male
MH  - Monocytes/*metabolism
MH  - Myelopoiesis/*genetics
MH  - Neoplasms, Experimental/*genetics
MH  - Nuclear Receptor Subfamily 1, Group F, Member 3/*genetics
PMC - PMC4669045
MID - NIHMS740714
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00259-7 [pii]
AID - 10.1016/j.ccell.2015.07.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):147-9. doi: 10.1016/j.ccell.2015.07.007.

PMID- 26267529
OWN - NLM
STAT- MEDLINE
DCOM- 20151125
LR  - 20180222
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - A Kinase Divided.
PG  - 145-7
LID - 10.1016/j.ccell.2015.07.008 [doi]
LID - S1535-6108(15)00260-3 [pii]
AB  - In this issue of Cancer Cell, Herrero and colleagues identify an anti-tumorigenic
      small molecule that blocks ERK dimerization, but neither its catalytic activity
      nor its phosphorylation by MEK. These findings demonstrate that targeting protein
      dimerization could be a therapeutic avenue for inhibiting kinase signaling
      pathways associated with lower drug resistance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Karra, Aroon S
AU  - Karra AS
AD  - Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390,
      USA.
FAU - Taylor, Clinton A 4th
AU  - Taylor CA 4th
AD  - Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390,
      USA.
FAU - Thorne, Curtis A
AU  - Thorne CA
AD  - Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390,
      USA.
FAU - Cobb, Melanie H
AU  - Cobb MH
AD  - Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390,
      USA. Electronic address: melanie.cobb@utsouthwestern.edu.
LA  - eng
GR  - K99 DK103126/DK/NIDDK NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Small Molecule Libraries)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
CON - Cancer Cell. 2015 Aug 10;28(2):170-82. PMID: 26267534
MH  - Animals
MH  - Carcinogenesis/*drug effects
MH  - Female
MH  - Humans
MH  - Mitogen-Activated Protein Kinase 1/*antagonists & inhibitors
MH  - Protein Multimerization/*drug effects
MH  - Signal Transduction/*drug effects
MH  - Small Molecule Libraries/*pharmacology
MH  - ras Proteins/*metabolism
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00260-3 [pii]
AID - 10.1016/j.ccell.2015.07.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):145-7. doi: 10.1016/j.ccell.2015.07.008.

PMID- 26267528
OWN - NLM
STAT- MEDLINE
DCOM- 20151125
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K?
PG  - 143-5
LID - 10.1016/j.ccell.2015.07.010 [doi]
LID - S1535-6108(15)00262-7 [pii]
AB  - In this issue of Cancer Cell, Ooms and colleagues show that the lipid phosphatase
      PIPP/INPP5J, frequently inactivated in triple-negative breast cancers, functions 
      as a tumor suppressor by specifically modulating the activity of AKT1 in the
      context of oncogenic PI3K signaling, leading to inhibition of metastatic
      dissemination.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Toker, Alex
AU  - Toker A
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, 330 Brookline Avenue, Boston, MA, 02215, USA. Electronic address:
      atoker@bidmc.harvard.edu.
FAU - Rameh, Lucia
AU  - Rameh L
AD  - Department of Medicine, Boston University School of Medicine, 650 Albany Street, 
      Boston, MA, 02118, USA. Electronic address: rameh@bu.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
SB  - IM
CON - Cancer Cell. 2015 Aug 10;28(2):155-69. PMID: 26267533
MH  - Animals
MH  - Breast Neoplasms/*genetics
MH  - Cell Proliferation/*genetics
MH  - Humans
MH  - Phosphoric Monoester Hydrolases/*genetics
MH  - Proto-Oncogene Proteins c-akt/*genetics
EDAT- 2015/08/13 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00262-7 [pii]
AID - 10.1016/j.ccell.2015.07.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):143-5. doi: 10.1016/j.ccell.2015.07.010.

PMID- 26212250
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor
      Vasculature to Oncolytic Virus Infection.
PG  - 210-24
LID - 10.1016/j.ccell.2015.06.009 [doi]
LID - S1535-6108(15)00219-6 [pii]
AB  - Oncolytic viruses designed to attack malignant cells can in addition infect and
      destroy tumor vascular endothelial cells. We show here that this expanded tropism
      of oncolytic vaccinia virus to the endothelial compartment is a consequence of
      VEGF-mediated suppression of the intrinsic antiviral response. VEGF/VEGFR2
      signaling through Erk1/2 and Stat3 leads to upregulation, nuclear localization,
      and activation of the transcription repressor PRD1-BF1/Blimp1. PRD1-BF1 does not 
      contribute to the mitogenic effects of VEGF, but directly represses genes
      involved in type I interferon (IFN)-mediated antiviral signaling. In vivo
      suppression of VEGF signaling diminishes PRD1-BF1/Blimp1 expression in tumor
      vasculature and inhibits intravenously administered oncolytic vaccinia delivery
      to and consequent spread within the tumor.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Arulanandam, Rozanne
AU  - Arulanandam R
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Batenchuk, Cory
AU  - Batenchuk C
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Angarita, Fernando A
AU  - Angarita FA
AD  - Toronto General Research Institute (TGRI), University Health Network, Toronto, ON
      M5G 2M9, Canada.
FAU - Ottolino-Perry, Kathryn
AU  - Ottolino-Perry K
AD  - Toronto General Research Institute (TGRI), University Health Network, Toronto, ON
      M5G 2M9, Canada.
FAU - Cousineau, Sophie
AU  - Cousineau S
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Mottashed, Amelia
AU  - Mottashed A
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Burgess, Emma
AU  - Burgess E
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Falls, Theresa J
AU  - Falls TJ
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - De Silva, Naomi
AU  - De Silva N
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Tsang, Jovian
AU  - Tsang J
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Howe, Grant A
AU  - Howe GA
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Bourgeois-Daigneault, Marie-Claude
AU  - Bourgeois-Daigneault MC
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Conrad, David P
AU  - Conrad DP
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Daneshmand, Manijeh
AU  - Daneshmand M
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Breitbach, Caroline J
AU  - Breitbach CJ
AD  - SillaJen Biotherapeutics, San Francisco, CA 94111-3380, USA.
FAU - Kirn, David H
AU  - Kirn DH
AD  - SillaJen Biotherapeutics, San Francisco, CA 94111-3380, USA.
FAU - Raptis, Leda
AU  - Raptis L
AD  - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON
      K7L 3N6, Canada.
FAU - Sad, Subash
AU  - Sad S
AD  - Department of Biochemistry, Microbiology and Immunology, University of Ottawa,
      Ottawa, ON K1H 8M5, Canada.
FAU - Atkins, Harold
AU  - Atkins H
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Huh, Michael S
AU  - Huh MS
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Diallo, Jean-Simon
AU  - Diallo JS
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Lichty, Brian D
AU  - Lichty BD
AD  - McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4K1,
      Canada.
FAU - Ilkow, Carolina S
AU  - Ilkow CS
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Le Boeuf, Fabrice
AU  - Le Boeuf F
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - Addison, Christina L
AU  - Addison CL
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada.
FAU - McCart, J Andrea
AU  - McCart JA
AD  - Toronto General Research Institute (TGRI), University Health Network, Toronto, ON
      M5G 2M9, Canada; Department of Surgery, Mount Sinai Hospital, University of
      Toronto, Toronto, ON M5G 1X5, Canada.
FAU - Bell, John C
AU  - Bell JC
AD  - Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute,
      Ottawa, ON K1H 8L6, Canada. Electronic address: jbell@ohri.ca.
LA  - eng
PT  - Journal Article
DEP - 20150723
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Prdm1 protein, mouse)
RN  - 0 (Repressor Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 138415-26-6 (PRDM1 protein, human)
RN  - EC 2.1.1.- (Positive Regulatory Domain I-Binding Factor 1)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Animals
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Gene Expression/drug effects
MH  - Gene Expression Profiling
MH  - Host-Pathogen Interactions
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism/virology
MH  - Humans
MH  - Mice, Inbred C57BL
MH  - Microscopy, Fluorescence
MH  - Neoplasms/blood supply/therapy/*virology
MH  - Neovascularization, Pathologic/genetics/metabolism/virology
MH  - Oncolytic Viruses/*physiology
MH  - Positive Regulatory Domain I-Binding Factor 1
MH  - RNA Interference
MH  - Receptors, Vascular Endothelial Growth Factor/genetics/metabolism
MH  - Repressor Proteins/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transcription Factors/genetics/*metabolism
MH  - Transcriptional Activation/drug effects
MH  - Vaccinia virus/physiology
MH  - Vascular Endothelial Growth Factor A/*pharmacology
EDAT- 2015/07/28 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/07/28 06:00
PHST- 2014/09/10 00:00 [received]
PHST- 2015/03/30 00:00 [revised]
PHST- 2015/06/23 00:00 [accepted]
PHST- 2015/07/28 06:00 [entrez]
PHST- 2015/07/28 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00219-6 [pii]
AID - 10.1016/j.ccell.2015.06.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub
      2015 Jul 23.

PMID- 26190263
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 2
DP  - 2015 Aug 10
TI  - The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.
PG  - 198-209
LID - 10.1016/j.ccell.2015.06.003 [doi]
LID - S1535-6108(15)00213-5 [pii]
AB  - The genetic programs that maintain leukemia stem cell (LSC) self-renewal and
      oncogenic potential have been well defined; however, the comprehensive epigenetic
      landscape that sustains LSC cellular identity and functionality is less well
      established. We report that LSCs in MLL-associated leukemia reside in an
      epigenetic state of relative genome-wide high-level H3K4me3 and low-level
      H3K79me2. LSC differentiation is associated with reversal of these broad
      epigenetic profiles, with concomitant downregulation of crucial MLL target genes 
      and the LSC maintenance transcriptional program that is driven by the loss of
      H3K4me3, but not H3K79me2. The H3K4-specific demethylase KDM5B negatively
      regulates leukemogenesis in murine and human MLL-rearranged AML cells,
      demonstrating a crucial role for the H3K4 global methylome in determining LSC
      fate.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wong, Stephen H K
AU  - Wong SH
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Goode, David L
AU  - Goode DL
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA
      94305, USA; Peter MacCallum Cancer Centre and University of Melbourne, Melbourne,
      VIC 3010, Australia.
FAU - Iwasaki, Masayuki
AU  - Iwasaki M
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Wei, Michael C
AU  - Wei MC
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Kuo, Hsu-Ping
AU  - Kuo HP
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Zhu, Li
AU  - Zhu L
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Schneidawind, Dominik
AU  - Schneidawind D
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Duque-Afonso, Jesus
AU  - Duque-Afonso J
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Weng, Ziming
AU  - Weng Z
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Cleary, Michael L
AU  - Cleary ML
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA
      94305, USA. Electronic address: mcleary@stanford.edu.
LA  - eng
SI  - GEO/GSE60193
GR  - R01 CA116606/CA/NCI NIH HHS/United States
GR  - T32 CA009151/CA/NCI NIH HHS/United States
GR  - T32 CA009302/CA/NCI NIH HHS/United States
GR  - CA116606/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150716
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - 0 (Il2rg protein, mouse)
RN  - 0 (Interleukin Receptor Common gamma Subunit)
RN  - 0 (MLL protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Repressor Proteins)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 1.14.11.- (Jumonji Domain-Containing Histone Demethylases)
RN  - EC 1.14.11.- (KDM5B protein, human)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Transformation, Neoplastic/genetics/*metabolism
MH  - Cells, Cultured
MH  - *Epigenesis, Genetic
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Leukemic
MH  - HEK293 Cells
MH  - Histone-Lysine N-Methyltransferase/genetics/metabolism
MH  - Histones/*metabolism
MH  - Humans
MH  - Interleukin Receptor Common gamma Subunit/deficiency/genetics
MH  - Jumonji Domain-Containing Histone Demethylases/genetics/metabolism
MH  - Leukemia/genetics/*metabolism/pathology
MH  - Lysine/metabolism
MH  - Methylation
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, Knockout
MH  - Mice, SCID
MH  - Myeloid-Lymphoid Leukemia Protein/genetics/metabolism
MH  - Neoplastic Stem Cells/*metabolism
MH  - Nuclear Proteins/genetics/metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - RNA Interference
MH  - Repressor Proteins/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transplantation, Heterologous
PMC - PMC4536132
MID - NIHMS704994
EDAT- 2015/07/21 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/07/21 06:00
PHST- 2014/12/24 00:00 [received]
PHST- 2015/03/30 00:00 [revised]
PHST- 2015/06/10 00:00 [accepted]
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00213-5 [pii]
AID - 10.1016/j.ccell.2015.06.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Aug 10;28(2):198-209. doi: 10.1016/j.ccell.2015.06.003. Epub
      2015 Jul 16.

PMID- 26175417
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - MYC Is a Major Determinant of Mitotic Cell Fate.
PG  - 129-40
LID - 10.1016/j.ccell.2015.06.001 [doi]
LID - S1535-6108(15)00211-1 [pii]
AB  - Taxol and other antimitotic agents are frontline chemotherapy agents but the
      mechanisms responsible for patient benefit remain unclear. Following a
      genome-wide siRNA screen, we identified the oncogenic transcription factor Myc as
      a taxol sensitizer. Using time-lapse imaging to correlate mitotic behavior with
      cell fate, we show that Myc sensitizes cells to mitotic blockers and agents that 
      accelerate mitotic progression. Myc achieves this by upregulating a cluster of
      redundant pro-apoptotic BH3-only proteins and suppressing pro-survival Bcl-xL.
      Gene expression analysis of breast cancers indicates that taxane responses
      correlate positively with Myc and negatively with Bcl-xL. Accordingly,
      pharmacological inhibition of Bcl-xL restores apoptosis in Myc-deficient cells.
      These results open up opportunities for biomarkers and combination therapies that
      could enhance traditional and second-generation antimitotic agents.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Topham, Caroline
AU  - Topham C
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK.
FAU - Tighe, Anthony
AU  - Tighe A
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK.
FAU - Ly, Peter
AU  - Ly P
AD  - Ludwig Institute for Cancer Research and Department of Cellular and Molecular
      Medicine, University of California at San Diego, La Jolla, CA 92093, USA.
FAU - Bennett, Ailsa
AU  - Bennett A
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK.
FAU - Sloss, Olivia
AU  - Sloss O
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK.
FAU - Nelson, Louisa
AU  - Nelson L
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK.
FAU - Ridgway, Rachel A
AU  - Ridgway RA
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61BD, UK.
FAU - Huels, David
AU  - Huels D
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61BD, UK.
FAU - Littler, Samantha
AU  - Littler S
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK.
FAU - Schandl, Claudia
AU  - Schandl C
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK.
FAU - Sun, Ying
AU  - Sun Y
AD  - Ludwig Institute for Cancer Research and Department of Cellular and Molecular
      Medicine, University of California at San Diego, La Jolla, CA 92093, USA.
FAU - Bechi, Beatrice
AU  - Bechi B
AD  - School of Chemistry, University of Manchester, Oxford Road, Manchester M13 9PL,
      UK.
FAU - Procter, David J
AU  - Procter DJ
AD  - School of Chemistry, University of Manchester, Oxford Road, Manchester M13 9PL,
      UK.
FAU - Sansom, Owen J
AU  - Sansom OJ
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61BD, UK.
FAU - Cleveland, Don W
AU  - Cleveland DW
AD  - Ludwig Institute for Cancer Research and Department of Cellular and Molecular
      Medicine, University of California at San Diego, La Jolla, CA 92093, USA.
FAU - Taylor, Stephen S
AU  - Taylor SS
AD  - Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester M13
      9PT, UK. Electronic address: stephen.taylor@manchester.ac.uk.
LA  - eng
SI  - GEO/GSE68219
GR  - R01 GM029513/GM/NIGMS NIH HHS/United States
GR  - Cancer Research UK/United Kingdom
GR  - Medical Research Council/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antimitotic Agents)
RN  - 0 (BCL2L1 protein, human)
RN  - 0 (C22orf29 protein, human)
RN  - 0 (EGR1 protein, human)
RN  - 0 (Early Growth Response Protein 1)
RN  - 0 (MYC protein, human)
RN  - 0 (Myc protein, mouse)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (bcl-X Protein)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Animals
MH  - Antimitotic Agents/pharmacology
MH  - Apoptosis/drug effects
MH  - Breast Neoplasms/genetics/pathology
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/genetics/pathology
MH  - Early Growth Response Protein 1/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Lung Neoplasms/genetics/pathology
MH  - Mice
MH  - Mitosis/drug effects
MH  - Molecular Sequence Data
MH  - Neoplasms/*genetics/pathology
MH  - Ovarian Neoplasms/genetics/pathology
MH  - Paclitaxel/pharmacology
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - Proto-Oncogene Proteins c-myc/*genetics
MH  - bcl-X Protein/*genetics
PMC - PMC4518499
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2014/10/10 00:00 [received]
PHST- 2015/03/04 00:00 [revised]
PHST- 2015/06/08 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00211-1 [pii]
AID - 10.1016/j.ccell.2015.06.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):129-40. doi: 10.1016/j.ccell.2015.06.001.

PMID- 26175416
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20161215
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression
      and Metastasis.
PG  - 97-113
LID - 10.1016/j.ccell.2015.06.004 [doi]
LID - S1535-6108(15)00214-7 [pii]
AB  - Emerging evidence demonstrates that the DNA repair kinase DNA-PKcs exerts
      divergent roles in transcriptional regulation of unsolved consequence. Here, in
      vitro and in vivo interrogation demonstrate that DNA-PKcs functions as a
      selective modulator of transcriptional networks that induce cell migration,
      invasion, and metastasis. Accordingly, suppression of DNA-PKcs inhibits tumor
      metastases. Clinical assessment revealed that DNA-PKcs is significantly elevated 
      in advanced disease and independently predicts for metastases, recurrence, and
      reduced overall survival. Further investigation demonstrated that DNA-PKcs in
      advanced tumors is highly activated, independent of DNA damage indicators.
      Combined, these findings reveal unexpected DNA-PKcs functions, identify DNA-PKcs 
      as a potent driver of tumor progression and metastases, and nominate DNA-PKcs as 
      a therapeutic target for advanced malignancies.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Goodwin, Jonathan F
AU  - Goodwin JF
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA.
FAU - Kothari, Vishal
AU  - Kothari V
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109,
      USA.
FAU - Drake, Justin M
AU  - Drake JM
AD  - Departments of Microbiology, Immunology, & Molecular Genetics, UCLA, Los Angeles,
      CA 90095, USA.
FAU - Zhao, Shuang
AU  - Zhao S
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109,
      USA.
FAU - Dylgjeri, Emanuela
AU  - Dylgjeri E
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA.
FAU - Dean, Jeffry L
AU  - Dean JL
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA.
FAU - Schiewer, Matthew J
AU  - Schiewer MJ
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA.
FAU - McNair, Christopher
AU  - McNair C
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA.
FAU - Jones, Jennifer K
AU  - Jones JK
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA.
FAU - Aytes, Alvaro
AU  - Aytes A
AD  - Departments of Urology, Pathology & Cell Biology, Systems Biology, Institute for 
      Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University 
      Medical Center, New York, NY 10032, USA.
FAU - Magee, Michael S
AU  - Magee MS
AD  - Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson
      University, Philadelphia, PA 19107, USA.
FAU - Snook, Adam E
AU  - Snook AE
AD  - Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson
      University, Philadelphia, PA 19107, USA.
FAU - Zhu, Ziqi
AU  - Zhu Z
AD  - Department of Cancer Biology, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Den, Robert B
AU  - Den RB
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA; Department of Radiation Oncology, Thomas Jefferson University,
      Philadelphia, PA 19107, USA; Kimmel Cancer Center, Thomas Jefferson University,
      Philadelphia, PA 19107, USA.
FAU - Birbe, Ruth C
AU  - Birbe RC
AD  - Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107,
      USA.
FAU - Gomella, Leonard G
AU  - Gomella LG
AD  - Department of Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
FAU - Graham, Nicholas A
AU  - Graham NA
AD  - Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA;
      Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.
FAU - Vashisht, Ajay A
AU  - Vashisht AA
AD  - Department of Biological Chemistry, UCLA, Los Angeles, CA 90095, USA.
FAU - Wohlschlegel, James A
AU  - Wohlschlegel JA
AD  - Department of Biological Chemistry, UCLA, Los Angeles, CA 90095, USA.
FAU - Graeber, Thomas G
AU  - Graeber TG
AD  - Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA;
      Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA;
      Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA; California
      NanoSystems Institute, UCLA, Los Angeles, CA 90095, USA.
FAU - Karnes, R Jeffrey
AU  - Karnes RJ
AD  - Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.
FAU - Takhar, Mandeep
AU  - Takhar M
AD  - GenomeDx Biosciences, San Diego, CA 92121, USA.
FAU - Davicioni, Elai
AU  - Davicioni E
AD  - GenomeDx Biosciences, San Diego, CA 92121, USA.
FAU - Tomlins, Scott A
AU  - Tomlins SA
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI
      48109, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
      48109, USA.
FAU - Abate-Shen, Cory
AU  - Abate-Shen C
AD  - Departments of Urology, Pathology & Cell Biology, Systems Biology, Institute for 
      Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University 
      Medical Center, New York, NY 10032, USA.
FAU - Sharifi, Nima
AU  - Sharifi N
AD  - Department of Cancer Biology, Cleveland Clinic, Cleveland, OH 44195, USA;
      Department of Urology, Cleveland Clinic, Cleveland, OH 44195, USA; Solid Tumor
      Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Witte, Owen N
AU  - Witte ON
AD  - Departments of Microbiology, Immunology, & Molecular Genetics, UCLA, Los Angeles,
      CA 90095, USA; Department of Molecular & Medical Pharmacology, UCLA, Los Angeles,
      CA 90095, USA; Howard Hughes Medical Institute, UCLA, Los Angeles, CA 90095, USA;
      Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, 
      Los Angeles, CA 90095, USA.
FAU - Feng, Felix Y
AU  - Feng FY
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI 48109, USA; Department of Radiation Oncology, University of Michigan, Ann
      Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, Ann
      Arbor, MI 48109, USA.
FAU - Knudsen, Karen E
AU  - Knudsen KE
AD  - Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
      19107, USA; Department of Urology, Thomas Jefferson University, Philadelphia, PA 
      19107, USA; Department of Radiation Oncology, Thomas Jefferson University,
      Philadelphia, PA 19107, USA; Kimmel Cancer Center, Thomas Jefferson University,
      Philadelphia, PA 19107, USA. Electronic address: karen.knudsen@jefferson.edu.
LA  - eng
SI  - GEO/GSE63480
GR  - CA173481/CA/NCI NIH HHS/United States
GR  - CA183929/CA/NCI NIH HHS/United States
GR  - R25 CA098010/CA/NCI NIH HHS/United States
GR  - CA176401/CA/NCI NIH HHS/United States
GR  - UL1TR000124/TR/NCATS NIH HHS/United States
GR  - R01 CA173481/CA/NCI NIH HHS/United States
GR  - CA168585/CA/NCI NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
GR  - R01 CA159945/CA/NCI NIH HHS/United States
GR  - R25T CA098010/CA/NCI NIH HHS/United States
GR  - CA159945/CA/NCI NIH HHS/United States
GR  - GM089778/GM/NIGMS NIH HHS/United States
GR  - R01 CA176401/CA/NCI NIH HHS/United States
GR  - P01 CA168585/CA/NCI NIH HHS/United States
GR  - R01 GM089778/GM/NIGMS NIH HHS/United States
GR  - P30 CA056036/CA/NCI NIH HHS/United States
GR  - R01 CA183929/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (AR protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Receptors, Androgen)
RN  - EC 2.7.11.1 (DNA-Activated Protein Kinase)
RN  - EC 2.7.11.1 (Prkdc protein, mouse)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - DNA-Activated Protein Kinase/*genetics/*metabolism
MH  - DNA-Binding Proteins/*genetics/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Regulatory Networks
MH  - Humans
MH  - Male
MH  - Mice
MH  - Molecular Sequence Data
MH  - Neoplasm Invasiveness
MH  - Neoplasm Transplantation
MH  - Nuclear Proteins/*genetics/*metabolism
MH  - Prostatic Neoplasms/genetics/metabolism/*pathology
MH  - Receptors, Androgen/genetics/metabolism
PMC - PMC4531387
MID - NIHMS704948
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2014/12/01 00:00 [received]
PHST- 2015/04/02 00:00 [revised]
PHST- 2015/06/12 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00214-7 [pii]
AID - 10.1016/j.ccell.2015.06.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):97-113. doi: 10.1016/j.ccell.2015.06.004.

PMID- 26175415
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20170714
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in
      SCLC.
PG  - 57-69
LID - 10.1016/j.ccell.2015.06.002 [doi]
LID - S1535-6108(15)00212-3 [pii]
AB  - Epigenetic dysregulation has emerged as an important mechanism in cancer.
      Alterations in epigenetic machinery have become a major focus for targeted
      therapies. The current report describes the discovery and biological activity of 
      a cyclopropylamine containing inhibitor of Lysine Demethylase 1 (LSD1),
      GSK2879552. This small molecule is a potent, selective, orally bioavailable,
      mechanism-based irreversible inactivator of LSD1. A proliferation screen of cell 
      lines representing a number of tumor types indicated that small cell lung
      carcinoma (SCLC) is sensitive to LSD1 inhibition. The subset of SCLC lines and
      primary samples that undergo growth inhibition in response to GSK2879552 exhibit 
      DNA hypomethylation of a signature set of probes, suggesting this may be used as 
      a predictive biomarker of activity.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Mohammad, Helai P
AU  - Mohammad HP
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Smitheman, Kimberly N
AU  - Smitheman KN
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Kamat, Chandrashekhar D
AU  - Kamat CD
AD  - Oncology Department, Johns Hopkins University, Baltimore, MD 21231, USA.
FAU - Soong, David
AU  - Soong D
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Federowicz, Kelly E
AU  - Federowicz KE
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Van Aller, Glenn S
AU  - Van Aller GS
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Schneck, Jess L
AU  - Schneck JL
AD  - Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Carson, Jeffrey D
AU  - Carson JD
AD  - Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Liu, Yan
AU  - Liu Y
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Butticello, Michael
AU  - Butticello M
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Bonnette, William G
AU  - Bonnette WG
AD  - Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Gorman, Shelby A
AU  - Gorman SA
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Degenhardt, Yan
AU  - Degenhardt Y
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Bai, Yuchen
AU  - Bai Y
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - McCabe, Michael T
AU  - McCabe MT
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Pappalardi, Melissa B
AU  - Pappalardi MB
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Kasparec, Jiri
AU  - Kasparec J
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Tian, Xinrong
AU  - Tian X
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - McNulty, Kenneth C
AU  - McNulty KC
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Rouse, Meagan
AU  - Rouse M
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - McDevitt, Patrick
AU  - McDevitt P
AD  - Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Ho, Thau
AU  - Ho T
AD  - Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Crouthamel, Michelle
AU  - Crouthamel M
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Hart, Timothy K
AU  - Hart TK
AD  - Safety Assessment Department, GlaxoSmithKline, Upper Merion, PA 19406, USA.
FAU - Concha, Nestor O
AU  - Concha NO
AD  - Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - McHugh, Charles F
AU  - McHugh CF
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Miller, William H
AU  - Miller WH
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Dhanak, Dashyant
AU  - Dhanak D
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Tummino, Peter J
AU  - Tummino PJ
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Carpenter, Christopher L
AU  - Carpenter CL
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Johnson, Neil W
AU  - Johnson NW
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Hann, Christine L
AU  - Hann CL
AD  - Oncology Department, Johns Hopkins University, Baltimore, MD 21231, USA.
FAU - Kruger, Ryan G
AU  - Kruger RG
AD  - Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA.
      Electronic address: ryan.g.kruger@gsk.com.
LA  - eng
SI  - GEO/GSE66298
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzoates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (GSK2879552)
RN  - EC 1.14.11.- (Histone Demethylases)
RN  - EC 1.5.- (KDM1A protein, human)
SB  - IM
CIN - Cancer Cell. 2015 Jul 13;28(1):4-6. PMID: 26175409
MH  - Administration, Oral
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacology
MH  - Benzoates/*administration & dosage/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cyclopropanes/*administration & dosage/pharmacology
MH  - DNA Methylation/*drug effects
MH  - Enzyme Inhibitors/*administration & dosage/pharmacology
MH  - Epigenesis, Genetic/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Histone Demethylases/*antagonists & inhibitors/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/pathology
MH  - Mice
MH  - Molecular Sequence Data
MH  - Small Cell Lung Carcinoma/*drug therapy/genetics/pathology
MH  - Xenograft Model Antitumor Assays
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/02/04 00:00 [received]
PHST- 2015/05/04 00:00 [revised]
PHST- 2015/06/09 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00212-3 [pii]
AID - 10.1016/j.ccell.2015.06.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):57-69. doi: 10.1016/j.ccell.2015.06.002.

PMID- 26175414
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic
      Leukemia.
PG  - 29-41
LID - 10.1016/j.ccell.2015.06.005 [doi]
LID - S1535-6108(15)00215-9 [pii]
AB  - A variety of cancers depend on JAK2 signaling, including the high-risk subset of 
      B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements. Type I
      JAK2 inhibitors induce paradoxical JAK2 hyperphosphorylation in these leukemias
      and have limited activity. To improve the efficacy of JAK2 inhibition in B-ALL,
      we developed the type II inhibitor CHZ868, which stabilizes JAK2 in an inactive
      conformation. CHZ868 potently suppressed the growth of CRLF2-rearranged human
      B-ALL cells, abrogated JAK2 signaling, and improved survival in mice with human
      or murine B-ALL. CHZ868 and dexamethasone synergistically induced apoptosis in
      JAK2-dependent B-ALLs and further improved in vivo survival compared to CHZ868
      alone. These data support the testing of type II JAK2 inhibition in patients with
      JAK2-dependent leukemias and other disorders.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wu, Shuo-Chieh
AU  - Wu SC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Li, Loretta S
AU  - Li LS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
      02215, USA.
FAU - Kopp, Nadja
AU  - Kopp N
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Montero, Joan
AU  - Montero J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Chapuy, Bjoern
AU  - Chapuy B
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Yoda, Akinori
AU  - Yoda A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Christie, Amanda L
AU  - Christie AL
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Liu, Huiyun
AU  - Liu H
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Christodoulou, Alexandra
AU  - Christodoulou A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - van Bodegom, Diederik
AU  - van Bodegom D
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - van der Zwet, Jordy
AU  - van der Zwet J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Layer, Jacob V
AU  - Layer JV
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Tivey, Trevor
AU  - Tivey T
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Lane, Andrew A
AU  - Lane AA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Ryan, Jeremy A
AU  - Ryan JA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Ng, Samuel Y
AU  - Ng SY
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - DeAngelo, Daniel J
AU  - DeAngelo DJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Steensma, David
AU  - Steensma D
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Wadleigh, Martha
AU  - Wadleigh M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Harris, Marian
AU  - Harris M
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Mandon, Emeline
AU  - Mandon E
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Ebel, Nicolas
AU  - Ebel N
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Andraos, Rita
AU  - Andraos R
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Romanet, Vincent
AU  - Romanet V
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Dolemeyer, Arno
AU  - Dolemeyer A
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Sterker, Dario
AU  - Sterker D
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Zender, Michael
AU  - Zender M
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Rodig, Scott J
AU  - Rodig SJ
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Murakami, Masato
AU  - Murakami M
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Hofmann, Francesco
AU  - Hofmann F
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Kuo, Frank
AU  - Kuo F
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Eck, Michael J
AU  - Eck MJ
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Silverman, Lewis B
AU  - Silverman LB
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Sallan, Stephen E
AU  - Sallan SE
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Letai, Anthony
AU  - Letai A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Baffert, Fabienne
AU  - Baffert F
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Vangrevelinghe, Eric
AU  - Vangrevelinghe E
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Radimerski, Thomas
AU  - Radimerski T
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
FAU - Gaul, Christoph
AU  - Gaul C
AD  - Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. Electronic 
      address: christoph.gaul@novartis.com.
FAU - Weinstock, David M
AU  - Weinstock DM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Broad Institute, Cambridge, MA 02142, USA. Electronic address:
      dweinstock@partners.org.
LA  - eng
SI  - GEO/GSE61696
GR  - T32 CA136432/CA/NCI NIH HHS/United States
GR  - R01 CA151898/CA/NCI NIH HHS/United States
GR  - T32 HL116324/HL/NHLBI NIH HHS/United States
GR  - T32 CA009172/CA/NCI NIH HHS/United States
GR  - K08 CA181340/CA/NCI NIH HHS/United States
GR  - R01CA151898-01/CA/NCI NIH HHS/United States
GR  - R01 GM110352/GM/NIGMS NIH HHS/United States
GR  - R01 CA172387/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Aminopyridines)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (CHZ868)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
CIN - Cancer Cell. 2015 Jul 13;28(1):1-2. PMID: 26175407
MH  - Aminopyridines/*administration & dosage/pharmacology
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Apoptosis
MH  - Benzimidazoles/*administration & dosage/pharmacology
MH  - Cell Line, Tumor
MH  - Cytoprotection/drug effects
MH  - Dexamethasone/*administration & dosage
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Drug Synergism
MH  - Humans
MH  - Janus Kinase 2/*antagonists & inhibitors/chemistry/genetics
MH  - Mice
MH  - Mutation
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/genetics
MH  - Protein Kinase Inhibitors/*administration & dosage/pharmacology
MH  - Signal Transduction/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC4505625
MID - NIHMS705060
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2014/11/03 00:00 [received]
PHST- 2015/05/01 00:00 [revised]
PHST- 2015/06/14 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00215-9 [pii]
AID - 10.1016/j.ccell.2015.06.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):29-41. doi: 10.1016/j.ccell.2015.06.005.

PMID- 26175413
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and
      Demonstrates Efficacy in Myeloproliferative Neoplasms.
PG  - 15-28
LID - 10.1016/j.ccell.2015.06.006 [doi]
LID - S1535-6108(15)00216-0 [pii]
AB  - Although clinically tested JAK inhibitors reduce splenomegaly and systemic
      symptoms, molecular responses are not observed in most myeloproliferative
      neoplasm (MPN) patients. We previously demonstrated that MPN cells become
      persistent to type I JAK inhibitors that bind the active conformation of JAK2. We
      investigated whether CHZ868, a type II JAK inhibitor, would demonstrate activity 
      in JAK inhibitor persistent cells, murine MPN models, and MPN patient samples.
      JAK2 and MPL mutant cell lines were sensitive to CHZ868, including type I JAK
      inhibitor persistent cells. CHZ868 showed significant activity in murine MPN
      models and induced reductions in mutant allele burden not observed with type I
      JAK inhibitors. These data demonstrate that type II JAK inhibition is a viable
      therapeutic approach for MPN patients.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Meyer, Sara C
AU  - Meyer SC
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Keller, Matthew D
AU  - Keller MD
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Chiu, Sophia
AU  - Chiu S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Koppikar, Priya
AU  - Koppikar P
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Guryanova, Olga A
AU  - Guryanova OA
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Rapaport, Franck
AU  - Rapaport F
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Xu, Ke
AU  - Xu K
AD  - Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Manova, Katia
AU  - Manova K
AD  - Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Pankov, Dmitry
AU  - Pankov D
AD  - Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - O'Reilly, Richard J
AU  - O'Reilly RJ
AD  - Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Kleppe, Maria
AU  - Kleppe M
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - McKenney, Anna Sophia
AU  - McKenney AS
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Shih, Alan H
AU  - Shih AH
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Shank, Kaitlyn
AU  - Shank K
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ahn, Jihae
AU  - Ahn J
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Papalexi, Eftymia
AU  - Papalexi E
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Spitzer, Barbara
AU  - Spitzer B
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Socci, Nick
AU  - Socci N
AD  - Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 
      NY 10065, USA.
FAU - Viale, Agnes
AU  - Viale A
AD  - Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, 
      NY 10065, USA.
FAU - Mandon, Emeline
AU  - Mandon E
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Ebel, Nicolas
AU  - Ebel N
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Andraos, Rita
AU  - Andraos R
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Rubert, Joelle
AU  - Rubert J
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Dammassa, Ernesta
AU  - Dammassa E
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Romanet, Vincent
AU  - Romanet V
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Dolemeyer, Arno
AU  - Dolemeyer A
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Zender, Michael
AU  - Zender M
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Heinlein, Melanie
AU  - Heinlein M
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Rampal, Raajit
AU  - Rampal R
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Leukemia Service, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Weinberg, Rona Singer
AU  - Weinberg RS
AD  - New York Blood Center, New York, NY 10065, USA.
FAU - Hoffman, Ronald
AU  - Hoffman R
AD  - Department of Medicine, Mount Sinai Hospital, New York, NY 10029, USA.
FAU - Sellers, William R
AU  - Sellers WR
AD  - Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
FAU - Hofmann, Francesco
AU  - Hofmann F
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Murakami, Masato
AU  - Murakami M
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Baffert, Fabienne
AU  - Baffert F
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Gaul, Christoph
AU  - Gaul C
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
FAU - Radimerski, Thomas
AU  - Radimerski T
AD  - Novartis Institutes for Biomedical Research, Basel 4056, Switzerland. Electronic 
      address: thomas.radimerski@novartis.com.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Leukemia Service, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA. Electronic address:
      leviner@mskcc.org.
LA  - eng
SI  - GEO/GSE69827
GR  - 1K99CA178191/CA/NCI NIH HHS/United States
GR  - 5F30CA183497/CA/NCI NIH HHS/United States
GR  - P01 CA108671/CA/NCI NIH HHS/United States
GR  - T32GM007739/GM/NIGMS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - K08 CA188529/CA/NCI NIH HHS/United States
GR  - R01 CA151949/CA/NCI NIH HHS/United States
GR  - 1R01CA151949-01/CA/NCI NIH HHS/United States
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
GR  - K99 CA178191/CA/NCI NIH HHS/United States
GR  - F30 CA183497/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Thrombopoietin)
RN  - 143641-95-6 (MPL protein, human)
RN  - 6O01GMS00P
      (N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide)
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
CIN - Cancer Cell. 2015 Jul 13;28(1):1-2. PMID: 26175407
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacology
MH  - Benzamides/administration & dosage
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Janus Kinase 2/*antagonists & inhibitors/*genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Myeloproliferative Disorders/*drug therapy/genetics/metabolism
MH  - Protein Kinase Inhibitors/*administration & dosage/pharmacology
MH  - Pyrimidines/administration & dosage
MH  - Receptors, Thrombopoietin/genetics/metabolism
MH  - Sequence Analysis, RNA
MH  - Signal Transduction/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC4503933
MID - NIHMS705062
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2014/11/03 00:00 [received]
PHST- 2015/05/05 00:00 [revised]
PHST- 2015/06/14 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00216-0 [pii]
AID - 10.1016/j.ccell.2015.06.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006.

PMID- 26175412
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20150715
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.
PG  - 11-3
LID - 10.1016/j.ccell.2015.06.012 [doi]
LID - S1535-6108(15)00222-6 [pii]
AB  - Immune checkpoint-blocking therapies have yielded positive clinical data in a
      series of human malignancies. Recent work from Le and colleagues strongly
      supports the use of these therapies for mismatch repair-deficient tumors,
      independent of underlying tumor type. These data suggest the importance of
      sensing the consequences of DNA damage in cancer immunotherapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Kelderman, Sander
AU  - Kelderman S
AD  - Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Schumacher, Ton N
AU  - Schumacher TN
AD  - Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands.
FAU - Kvistborg, Pia
AU  - Kvistborg P
AD  - Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066
      CX Amsterdam, the Netherlands. Electronic address: p.kvistborg@nki.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - DNA Mismatch Repair
MH  - Humans
MH  - Neoplasms/*drug therapy/metabolism
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Tumor Microenvironment/drug effects
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00222-6 [pii]
AID - 10.1016/j.ccell.2015.06.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):11-3. doi: 10.1016/j.ccell.2015.06.012.

PMID- 26175411
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20151119
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Genetic Classification of Gliomas: Refining Histopathology.
PG  - 9-11
LID - 10.1016/j.ccell.2015.06.014 [doi]
LID - S1535-6108(15)00224-X [pii]
AB  - Newly published studies validate prior reports that specific combinations of
      genetic alternations in IDH1/2, ATRX, TERT, TP53, and co-deletion of 1p/19q have 
      the ability to reclassify gliomas into rational subsets, defining a glioma's
      biological and clinical behavior more accurately than stratifications based
      solely on histopathology.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Foote, Michael B
AU  - Foote MB
AD  - The Swim Across America Laboratory at Johns Hopkins, Baltimore, MD 21287, USA;
      The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
      21287, USA; The Ludwig Center for Cancer Genetics and Therapeutic at Johns
      Hopkins, Baltimore, MD 21287, USA.
FAU - Papadopoulos, Nickolas
AU  - Papadopoulos N
AD  - The Swim Across America Laboratory at Johns Hopkins, Baltimore, MD 21287, USA;
      The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
      21287, USA; The Ludwig Center for Cancer Genetics and Therapeutic at Johns
      Hopkins, Baltimore, MD 21287, USA.
FAU - Diaz, Luis A Jr
AU  - Diaz LA Jr
AD  - The Swim Across America Laboratory at Johns Hopkins, Baltimore, MD 21287, USA;
      The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
      21287, USA; The Ludwig Center for Cancer Genetics and Therapeutic at Johns
      Hopkins, Baltimore, MD 21287, USA. Electronic address: ldiaz1@jhmi.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Brain Neoplasms/genetics/*pathology
MH  - Genomic Instability
MH  - Glioma/genetics/*pathology
MH  - Humans
MH  - Prognosis
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00224-X [pii]
AID - 10.1016/j.ccell.2015.06.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):9-11. doi: 10.1016/j.ccell.2015.06.014.

PMID- 26175410
OWN - NLM
STAT- MEDLINE
DCOM- 20151014
LR  - 20151119
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.
PG  - 7-9
LID - 10.1016/j.ccell.2015.06.008 [doi]
LID - S1535-6108(15)00218-4 [pii]
AB  - Adaptive chemoresistance and consequent tumor recurrence present major obstacles 
      to the improvement of the prognosis and quality-of-life of patients with
      advanced-stage ovarian cancer. In this issue of Cancer Cell, Yu and colleagues
      describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel
      resistance by modulating the stability of microtubules.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wei, Wei
AU  - Wei W
AD  - Center for Cancer Research, The Gillette Center for Gynecologic Oncology,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Birrer, Michael J
AU  - Birrer MJ
AD  - Center for Cancer Research, The Gillette Center for Gynecologic Oncology,
      Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
      Electronic address: mbirrer@partners.org.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Oxazines)
RN  - 0 (Pyridines)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
CON - Cancer Cell. 2015 Jul 13;28(1):82-96. PMID: 26096845
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*antagonists & inhibitors
MH  - Microtubules/*drug effects
MH  - Ovarian Neoplasms/*drug therapy
MH  - Oxazines/*administration & dosage
MH  - Paclitaxel/*administration & dosage
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Pyridines/*administration & dosage
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00218-4 [pii]
AID - 10.1016/j.ccell.2015.06.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):7-9. doi: 10.1016/j.ccell.2015.06.008.

PMID- 26175409
OWN - NLM
STAT- MEDLINE
DCOM- 20151014
LR  - 20170714
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via
      LSD1 Inhibition.
PG  - 4-6
LID - 10.1016/j.ccell.2015.06.011 [doi]
LID - S1535-6108(15)00221-4 [pii]
AB  - In this issue of Cancer Cell, Mohammad et al. describe LSD1, a histone
      demethylase, as a therapeutic target in SCLC with a unique epigenetic signature
      to predict drug sensitivity. Inhibition of LSD1 reduces cell proliferation and
      stem cell maintenance while promoting cell differentiation and reducing tumor
      growth in preclinical models.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Stewart, C Allison
AU  - Stewart CA
AD  - Department of Thoracic and Head and Neck Medical Oncology, MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Byers, Lauren Averett
AU  - Byers LA
AD  - Department of Thoracic and Head and Neck Medical Oncology, MD Anderson Cancer
      Center, Houston, TX 77030, USA. Electronic address: lbyers@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA070907/CA/NCI NIH HHS/United States
GR  - 5P50 CA070907/CA/NCI NIH HHS/United States
GR  - P30CA016672/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzoates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Enzyme Inhibitors)
RN  - EC 1.14.11.- (Histone Demethylases)
SB  - IM
CON - Cancer Cell. 2015 Jul 13;28(1):57-69. PMID: 26175415
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage
MH  - Benzoates/*administration & dosage
MH  - Cyclopropanes/*administration & dosage
MH  - DNA Methylation/*drug effects
MH  - Enzyme Inhibitors/*administration & dosage
MH  - Histone Demethylases/*antagonists & inhibitors
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Small Cell Lung Carcinoma/*drug therapy
PMC - PMC5497474
MID - NIHMS865162
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00221-4 [pii]
AID - 10.1016/j.ccell.2015.06.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):4-6. doi: 10.1016/j.ccell.2015.06.011.

PMID- 26175408
OWN - NLM
STAT- MEDLINE
DCOM- 20151014
LR  - 20150715
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Are Synthetic Compounds that Silence the Liver-X-Receptor the Next Generation of 
      Anti-cancer Drugs?
PG  - 3-4
LID - 10.1016/j.ccell.2015.06.013 [doi]
LID - S1535-6108(15)00223-8 [pii]
AB  - Glycolytic and lipogenic inhibitors have proven unsuccessful in cancer treatment 
      strategies. In this issue of Cancer Cell, Flaveny and colleagues target the
      liver-X-receptor with an inverse agonist and show that key glycolytic and
      lipogenic genes are suppressed, leading to apoptosis of tumor cells without an
      effect on non-malignant cells.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Steffensen, Knut R
AU  - Steffensen KR
AD  - Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska
      Institutet, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.
      Electronic address: knut.steffensen@ki.se.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Orphan Nuclear Receptors)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (Sulfonamides)
SB  - IM
CON - Cancer Cell. 2015 Jul 13;28(1):42-56. PMID: 26120082
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage
MH  - Humans
MH  - Lipogenesis/*drug effects
MH  - Neoplasms/*drug therapy
MH  - Orphan Nuclear Receptors/*agonists
MH  - Small Molecule Libraries/*administration & dosage
MH  - Sulfonamides/*administration & dosage
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00223-8 [pii]
AID - 10.1016/j.ccell.2015.06.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):3-4. doi: 10.1016/j.ccell.2015.06.013.

PMID- 26175407
OWN - NLM
STAT- MEDLINE
DCOM- 20151014
LR  - 20150715
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Targeting the Inactive Conformation of JAK2 in Hematological Malignancies.
PG  - 1-2
LID - 10.1016/j.ccell.2015.06.010 [doi]
LID - S1535-6108(15)00220-2 [pii]
AB  - Activating JAK2 mutants cause hematological malignancies. Current clinical type I
      JAK2 inhibitors effectively relieve symptoms but fail to resolve the disease. In 
      this issue of Cancer Cell, two articles by Wu and colleagues and Meyer and
      colleagues characterize a type II JAK2 inhibitor that is effective in preclinical
      models of JAK2-dependent myeloproliferative neoplasms and B cell acute
      lymphoblastic leukemia.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Silvennoinen, Olli
AU  - Silvennoinen O
AD  - School of Medicine, University of Tampere, Biokatu 8, 33014 Tampere, Finland;
      Clinical Hematology, Department of Internal Medicine, Tampere University
      Hospital, Medisiinarinkatu 3, 33520 Tampere, Finland. Electronic address:
      olli.silvennoinen@uta.fi.
FAU - Hubbard, Stevan R
AU  - Hubbard SR
AD  - Kimmel Center for Biology and Medicine at the Skirball Institute and Department
      of Biochemistry and Molecular Pharmacology, New York University School of
      Medicine, 540 First Avenue, New York, NY 10016, USA.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Aminopyridines)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
CON - Cancer Cell. 2015 Jul 13;28(1):29-41. PMID: 26175414
CON - Cancer Cell. 2015 Jul 13;28(1):15-28. PMID: 26175413
MH  - Aminopyridines/*administration & dosage
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage
MH  - Benzimidazoles/*administration & dosage
MH  - Dexamethasone/*administration & dosage
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Humans
MH  - Janus Kinase 2/*antagonists & inhibitors/*genetics
MH  - Myeloproliferative Disorders/*drug therapy
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
MH  - Protein Kinase Inhibitors/*administration & dosage
EDAT- 2015/07/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00220-2 [pii]
AID - 10.1016/j.ccell.2015.06.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):1-2. doi: 10.1016/j.ccell.2015.06.010.

PMID- 26144315
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20161215
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second
      Generation ALK Inhibitors in Preclinical Models.
PG  - 70-81
LID - 10.1016/j.ccell.2015.05.010 [doi]
LID - S1535-6108(15)00186-5 [pii]
AB  - We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
      ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors,
      PF-06463922 displayed superior potency against all known clinically acquired ALK 
      mutations, including the highly resistant G1202R mutant. Furthermore, PF-06463922
      treatment led to regression of EML4-ALK-driven brain metastases, leading to
      prolonged mouse survival, in a superior manner. Finally, PF-06463922 demonstrated
      high selectivity and safety margins in a variety of preclinical studies. These
      results suggest that PF-06463922 will be highly effective for the treatment of
      patients with ALK-driven lung cancers, including those who relapsed on clinically
      available ALK inhibitors because of secondary ALK kinase domain mutations and/or 
      brain metastases.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Zou, Helen Y
AU  - Zou HY
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Friboulet, Luc
AU  - Friboulet L
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard
      Medical School, Boston, MA 02114, USA.
FAU - Kodack, David P
AU  - Kodack DP
AD  - Department of Radiation Oncology, Edwin L. Steele Laboratory, Massachusetts
      General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Engstrom, Lars D
AU  - Engstrom LD
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Li, Qiuhua
AU  - Li Q
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - West, Melissa
AU  - West M
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Tang, Ruth W
AU  - Tang RW
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Wang, Hui
AU  - Wang H
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Tsaparikos, Konstantinos
AU  - Tsaparikos K
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Wang, Jinwei
AU  - Wang J
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Timofeevski, Sergei
AU  - Timofeevski S
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Katayama, Ryohei
AU  - Katayama R
AD  - Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo
      135-8550, Japan.
FAU - Dinh, Dac M
AU  - Dinh DM
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Lam, Hieu
AU  - Lam H
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Lam, Justine L
AU  - Lam JL
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Yamazaki, Shinji
AU  - Yamazaki S
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Hu, Wenyue
AU  - Hu W
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Patel, Bhushankumar
AU  - Patel B
AD  - Department of Radiation Oncology, Edwin L. Steele Laboratory, Massachusetts
      General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Bezwada, Divya
AU  - Bezwada D
AD  - Department of Radiation Oncology, Edwin L. Steele Laboratory, Massachusetts
      General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Frias, Rosa L
AU  - Frias RL
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard
      Medical School, Boston, MA 02114, USA.
FAU - Lifshits, Eugene
AU  - Lifshits E
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard
      Medical School, Boston, MA 02114, USA.
FAU - Mahmood, Sidra
AU  - Mahmood S
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard
      Medical School, Boston, MA 02114, USA.
FAU - Gainor, Justin F
AU  - Gainor JF
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard
      Medical School, Boston, MA 02114, USA.
FAU - Affolter, Timothy
AU  - Affolter T
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Lappin, Patrick B
AU  - Lappin PB
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Gukasyan, Hovhannes
AU  - Gukasyan H
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Lee, Nathan
AU  - Lee N
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Deng, Shibing
AU  - Deng S
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Jain, Rakesh K
AU  - Jain RK
AD  - Department of Radiation Oncology, Edwin L. Steele Laboratory, Massachusetts
      General Hospital, Harvard Medical School, Boston, MA 02114, USA.
FAU - Johnson, Ted W
AU  - Johnson TW
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Shaw, Alice T
AU  - Shaw AT
AD  - Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard
      Medical School, Boston, MA 02114, USA.
FAU - Fantin, Valeria R
AU  - Fantin VR
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA.
FAU - Smeal, Tod
AU  - Smeal T
AD  - Pfizer World Wide Research and Development, 10724 Science Center Drive, San
      Diego, CA 92121, USA. Electronic address: tod.smeal@pfizer.com.
LA  - eng
GR  - P01 CA080124/CA/NCI NIH HHS/United States
GR  - R01 CA164273/CA/NCI NIH HHS/United States
GR  - 5R01CA164273-02/CA/NCI NIH HHS/United States
GR  - P01-CA080124/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150702
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(methen
      o)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Lactams, Macrocyclic)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (anaplastic lymphoma kinase)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacology
MH  - Brain Neoplasms/*drug therapy/genetics/*secondary
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Humans
MH  - Lactams, Macrocyclic/*administration & dosage/pharmacology
MH  - Mice
MH  - Mutation
MH  - NIH 3T3 Cells
MH  - Neoplasms/*drug therapy/genetics
MH  - Protein Kinase Inhibitors/administration & dosage/pharmacology
MH  - Receptor Protein-Tyrosine Kinases/antagonists & inhibitors/*genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC4504786
MID - NIHMS695856
EDAT- 2015/07/07 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/07 06:00
PHST- 2014/12/05 00:00 [received]
PHST- 2015/03/16 00:00 [revised]
PHST- 2015/05/18 00:00 [accepted]
PHST- 2015/07/07 06:00 [entrez]
PHST- 2015/07/07 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00186-5 [pii]
AID - 10.1016/j.ccell.2015.05.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):70-81. doi: 10.1016/j.ccell.2015.05.010. Epub 2015
      Jul 2.

PMID- 26120082
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the
      Warburg Effect and Lipogenesis.
PG  - 42-56
LID - 10.1016/j.ccell.2015.05.007 [doi]
LID - S1535-6108(15)00183-X [pii]
AB  - Malignant cells exhibit aerobic glycolysis (the Warburg effect) and become
      dependent on de novo lipogenesis, which sustains rapid proliferation and
      resistance to cellular stress. The nuclear receptor liver-X-receptor (LXR)
      directly regulates expression of key glycolytic and lipogenic genes. To disrupt
      these oncogenic metabolism pathways, we designed an LXR inverse agonist SR9243
      that induces LXR-corepressor interaction. In cancer cells, SR9243 significantly
      inhibited the Warburg effect and lipogenesis by reducing glycolytic and lipogenic
      gene expression. SR9243 induced apoptosis in tumors without inducing weight loss,
      hepatotoxicity, or inflammation. Our results suggest that LXR inverse agonists
      may be an effective cancer treatment approach.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Flaveny, Colin A
AU  - Flaveny CA
AD  - Department of Pharmacological & Physiological Science, Saint Louis University
      School of Medicine, St. Louis, MO 63104, USA. Electronic address:
      flavenyca@slu.edu.
FAU - Griffett, Kristine
AU  - Griffett K
AD  - Department of Pharmacological & Physiological Science, Saint Louis University
      School of Medicine, St. Louis, MO 63104, USA.
FAU - El-Gendy, Bahaa El-Dien M
AU  - El-Gendy Bel-D
AD  - Chemistry Department, Faculty of Science, Benha University, Benha 13518, Egypt.
FAU - Kazantzis, Melissa
AU  - Kazantzis M
AD  - Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL
      33458, USA.
FAU - Sengupta, Monideepa
AU  - Sengupta M
AD  - Department of Pharmacological & Physiological Science, Saint Louis University
      School of Medicine, St. Louis, MO 63104, USA.
FAU - Amelio, Antonio L
AU  - Amelio AL
AD  - Lineberger Comprehensive Cancer Center, Biomedical Research Imaging Center,
      University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Chatterjee, Arindam
AU  - Chatterjee A
AD  - Department of Pharmacological & Physiological Science, Saint Louis University
      School of Medicine, St. Louis, MO 63104, USA.
FAU - Walker, John
AU  - Walker J
AD  - Department of Pharmacological & Physiological Science, Saint Louis University
      School of Medicine, St. Louis, MO 63104, USA.
FAU - Solt, Laura A
AU  - Solt LA
AD  - Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL
      33458, USA.
FAU - Kamenecka, Theodore M
AU  - Kamenecka TM
AD  - Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL
      33458, USA.
FAU - Burris, Thomas P
AU  - Burris TP
AD  - Department of Pharmacological & Physiological Science, Saint Louis University
      School of Medicine, St. Louis, MO 63104, USA; Siteman Cancer Center, Washington
      University School of Medicine, St. Louis, MO 63310, USA. Electronic address:
      burristp@slu.edu.
LA  - eng
GR  - R00 CA157954/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20150625
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Liver X Receptors)
RN  - 0 (Orphan Nuclear Receptors)
RN  - 0 (SR9243)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (Sulfonamides)
SB  - IM
CIN - Cancer Cell. 2015 Jul 13;28(1):3-4. PMID: 26175408
CIN - Nat Rev Drug Discov. 2015 Sep;14(9):602. PMID: 26323542
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacology
MH  - Cell Line, Tumor
MH  - Glycolysis/drug effects
MH  - HT29 Cells
MH  - Hep G2 Cells
MH  - Humans
MH  - Lipogenesis/*drug effects
MH  - Liver X Receptors
MH  - Mice
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy/pathology
MH  - Organ Specificity
MH  - Orphan Nuclear Receptors/*agonists
MH  - Small Molecule Libraries/*administration & dosage/pharmacology
MH  - Sulfonamides/*administration & dosage/pharmacology
MH  - Weight Loss/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC4965273
MID - NIHMS803649
EDAT- 2015/06/30 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/06/30 06:00
PHST- 2014/11/12 00:00 [received]
PHST- 2015/03/27 00:00 [revised]
PHST- 2015/05/12 00:00 [accepted]
PHST- 2015/06/30 06:00 [entrez]
PHST- 2015/06/30 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00183-X [pii]
AID - 10.1016/j.ccell.2015.05.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):42-56. doi: 10.1016/j.ccell.2015.05.007. Epub 2015
      Jun 25.

PMID- 26096845
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity 
      in Ovarian Cancer Cells by Stabilizing Microtubules.
PG  - 82-96
LID - 10.1016/j.ccell.2015.05.009 [doi]
LID - S1535-6108(15)00185-3 [pii]
AB  - Resistance to chemotherapy represents a major obstacle for long-term remission,
      and effective strategies to overcome drug resistance would have significant
      clinical impact. We report that recurrent ovarian carcinomas after
      paclitaxel/carboplatin treatment have higher levels of spleen tyrosine kinase
      (SYK) and phospho-SYK. In vitro, paclitaxel-resistant cells expressed higher SYK,
      and the ratio of phospho-SYK/SYK positively associated with paclitaxel resistance
      in ovarian cancer cells. Inactivation of SYK by inhibitors or gene knockdown
      sensitized paclitaxel cytotoxicity in vitro and in vivo. Analysis of the
      phosphotyrosine proteome in paclitaxel-resistant tumor cells revealed that SYK
      phosphorylates tubulins and microtubule-associated proteins. Inhibition of SYK
      enhanced microtubule stability in paclitaxel-resistant tumor cells that were
      otherwise insensitive. Thus, targeting SYK pathway is a promising strategy to
      enhance paclitaxel response.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Yu, Yu
AU  - Yu Y
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA.
FAU - Gaillard, Stephanie
AU  - Gaillard S
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA.
FAU - Phillip, Jude M
AU  - Phillip JM
AD  - Department of Chemical and Biomolecular Engineering, Physical Sciences-Oncology
      Center, and Institute for NanoBioTechology, Johns Hopkins University, Baltimore, 
      MD 21218, USA.
FAU - Huang, Tai-Chung
AU  - Huang TC
AD  - Department of Biological Chemistry and Oncology, Johns Hopkins Medical
      Institutions, Baltimore, MD 21205, USA.
FAU - Pinto, Sneha M
AU  - Pinto SM
AD  - Department of Biological Chemistry and Oncology, Johns Hopkins Medical
      Institutions, Baltimore, MD 21205, USA.
FAU - Tessarollo, Nayara G
AU  - Tessarollo NG
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA; Biotechnology
      Program/Renorbio, Health Science Center, Federal University of Espirito Santo,
      Vitoria 29075-910, Brazil.
FAU - Zhang, Zhen
AU  - Zhang Z
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA.
FAU - Pandey, Akhilesh
AU  - Pandey A
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA; Department of Biological 
      Chemistry and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, 
      USA.
FAU - Wirtz, Denis
AU  - Wirtz D
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA; Department of Chemical
      and Biomolecular Engineering, Physical Sciences-Oncology Center, and Institute
      for NanoBioTechology, Johns Hopkins University, Baltimore, MD 21218, USA.
FAU - Ayhan, Ayse
AU  - Ayhan A
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA; Department of Pathology, 
      Seirei Mikatahara Hospital and Hamamatsu University School of Medicine, Hamamatsu
      431-3192, Japan.
FAU - Davidson, Ben
AU  - Davidson B
AD  - Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital,
      0310 Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine,
      University of Oslo, 0316 Oslo, Norway.
FAU - Wang, Tian-Li
AU  - Wang TL
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA. Electronic address:
      tlw@jhmi.edu.
FAU - Shih, Ie-Ming
AU  - Shih IeM
AD  - Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns
      Hopkins Medical Institutions, Baltimore, MD 21205, USA; Department of Gynecology 
      and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
      Electronic address: ishih@jhmi.edu.
LA  - eng
GR  - R21 CA187512/CA/NCI NIH HHS/United States
GR  - P30 CA006973/CA/NCI NIH HHS/United States
GR  - R01 CA148826/CA/NCI NIH HHS/United States
GR  - R01CA148826/CA/NCI NIH HHS/United States
GR  - U24CA160036/CA/NCI NIH HHS/United States
GR  - R21CA187512/CA/NCI NIH HHS/United States
GR  - U54CA143868/CA/NCI NIH HHS/United States
GR  - R01CA174388/CA/NCI NIH HHS/United States
GR  - R01 CA103937/CA/NCI NIH HHS/United States
GR  - R01CA103937/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150618
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0
      (N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyph
      enyl)-2,4-pyrimidinediamine)
RN  - 0 (Oxazines)
RN  - 0 (Pyridines)
RN  - 0 (Tubulin)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (SYK protein, human)
RN  - EC 2.7.10.2 (Syk Kinase)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
CIN - Cancer Cell. 2015 Jul 13;28(1):7-9. PMID: 26175410
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Drug Synergism
MH  - Female
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*antagonists &
      inhibitors/genetics/metabolism
MH  - Microtubule-Associated Proteins/metabolism
MH  - Microtubules/*drug effects
MH  - Ovarian Neoplasms/*drug therapy/metabolism/pathology
MH  - Oxazines/*administration & dosage/pharmacology
MH  - Paclitaxel/*administration & dosage/pharmacology
MH  - Phosphorylation/drug effects
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors/genetics/metabolism
MH  - Pyridines/*administration & dosage/pharmacology
MH  - Syk Kinase
MH  - Tubulin/metabolism
MH  - Up-Regulation
MH  - Xenograft Model Antitumor Assays
PMC - PMC5257279
MID - NIHMS691639
EDAT- 2015/06/23 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/06/23 06:00
PHST- 2014/11/06 00:00 [received]
PHST- 2015/03/11 00:00 [revised]
PHST- 2015/05/12 00:00 [accepted]
PHST- 2015/06/23 06:00 [entrez]
PHST- 2015/06/23 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00185-3 [pii]
AID - 10.1016/j.ccell.2015.05.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):82-96. doi: 10.1016/j.ccell.2015.05.009. Epub 2015
      Jun 18.

PMID- 26073130
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jul 13
TI  - Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a 
      Therapeutic Target in Acute Lymphoblastic Leukemia.
PG  - 114-28
LID - 10.1016/j.ccell.2015.05.008 [doi]
LID - S1535-6108(15)00184-1 [pii]
AB  - Studying mechanisms of malignant transformation of human pre-B cells, we found
      that acute activation of oncogenes induced immediate cell death in the vast
      majority of cells. Few surviving pre-B cell clones had acquired permissiveness to
      oncogenic signaling by strong activation of negative feedback regulation of Erk
      signaling. Studying negative feedback regulation of Erk in genetic experiments at
      three different levels, we found that Spry2, Dusp6, and Etv5 were essential for
      oncogenic transformation in mouse models for pre-B acute lymphoblastic leukemia
      (ALL). Interestingly, a small molecule inhibitor of DUSP6 selectively induced
      cell death in patient-derived pre-B ALL cells and overcame conventional
      mechanisms of drug-resistance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Shojaee, Seyedmehdi
AU  - Shojaee S
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Caeser, Rebecca
AU  - Caeser R
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA; Department of Haematology, University of Cambridge,
      Cambridge CB2 0AH, UK.
FAU - Buchner, Maike
AU  - Buchner M
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Park, Eugene
AU  - Park E
AD  - Department of Haematology, University of Cambridge, Cambridge CB2 0AH, UK.
FAU - Swaminathan, Srividya
AU  - Swaminathan S
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Hurtz, Christian
AU  - Hurtz C
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Geng, Huimin
AU  - Geng H
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Chan, Lai N
AU  - Chan LN
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Klemm, Lars
AU  - Klemm L
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA.
FAU - Hofmann, Wolf-Karsten
AU  - Hofmann WK
AD  - III. Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg,
      Heidelberg 68167, Germany.
FAU - Qiu, Yi Hua
AU  - Qiu YH
AD  - Department of Leukemia, The University of Texas M.D. Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Zhang, Nianxiang
AU  - Zhang N
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      M.D. Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Coombes, Kevin R
AU  - Coombes KR
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      M.D. Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Paietta, Elisabeth
AU  - Paietta E
AD  - Albert Einstein College of Medicine, Bronx, NY 10466, USA.
FAU - Molkentin, Jeffery
AU  - Molkentin J
AD  - Howard Hughes Medical Institute and Cincinnati Children's Hospital, University of
      Cincinnati, Cincinnati, OH 45247, USA.
FAU - Koeffler, H Phillip
AU  - Koeffler HP
AD  - Division of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA
      90095, USA; Cancer Science Institute of Singapore, National University of
      Singapore, Singapore 117599, Singapore.
FAU - Willman, Cheryl L
AU  - Willman CL
AD  - Department of Pathology, University of New Mexico Cancer Center, Albuquerque, NM 
      87102, USA.
FAU - Hunger, Stephen P
AU  - Hunger SP
AD  - Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
      19104, USA.
FAU - Melnick, Ari
AU  - Melnick A
AD  - Departments of Medicine and Pharmacology, Weill Cornell Medical College, New
      York, NY 10065, USA.
FAU - Kornblau, Steven M
AU  - Kornblau SM
AD  - Department of Leukemia, The University of Texas M.D. Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Muschen, Markus
AU  - Muschen M
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA 94143, USA. Electronic address: markus.muschen@ucsf.edu.
LA  - eng
SI  - GEO/GSE21664
SI  - GEO/GSE23743
SI  - GEO/GSE34832
SI  - GEO/GSE34833
SI  - GEO/GSE34834
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - 101880/Wellcome Trust/United Kingdom
GR  - U10 CA021115/CA/NCI NIH HHS/United States
GR  - UG1 CA189859/CA/NCI NIH HHS/United States
GR  - U24 CA196172/CA/NCI NIH HHS/United States
GR  - R01 CA157644/CA/NCI NIH HHS/United States
GR  - R01 CA172558/CA/NCI NIH HHS/United States
GR  - R01 CA169458/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - R01 CA139032/CA/NCI NIH HHS/United States
GR  - U10 CA180794/CA/NCI NIH HHS/United States
GR  - U10 CA180827/CA/NCI NIH HHS/United States
GR  - R01 CA137060/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20150611
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Etv5 protein, mouse)
RN  - 0 (Host Cell Factor C1)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (Spry2 protein, mouse)
RN  - 0 (Transcription Factors)
RN  - EC 3.1.3.48 (Dual Specificity Phosphatase 6)
RN  - EC 3.1.3.48 (Dusp6 protein, mouse)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Cell Transformation, Neoplastic/*genetics/metabolism/pathology
MH  - DNA-Binding Proteins/genetics/metabolism
MH  - Dual Specificity Phosphatase 6/genetics/metabolism
MH  - Host Cell Factor C1
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/antagonists &
      inhibitors/genetics/metabolism
MH  - *MAP Kinase Signaling System/drug effects
MH  - Membrane Proteins/antagonists & inhibitors/genetics/metabolism
MH  - Mice
MH  - Mice, Transgenic
MH  - Molecular Sequence Data
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics/metabolism/*pathology
MH  - Prognosis
MH  - Small Molecule Libraries/pharmacology
MH  - Transcription Factors/genetics/metabolism
PMC - PMC4565502
MID - NIHMS711710
EDAT- 2015/06/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/06/16 06:00
PHST- 2014/07/03 00:00 [received]
PHST- 2015/02/05 00:00 [revised]
PHST- 2015/05/12 00:00 [accepted]
PHST- 2015/06/16 06:00 [entrez]
PHST- 2015/06/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S1535-6108(15)00184-1 [pii]
AID - 10.1016/j.ccell.2015.05.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jul 13;28(1):114-28. doi: 10.1016/j.ccell.2015.05.008. Epub
      2015 Jun 11.

PMID- 26058080
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20170421
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human
      Acute Myeloid Leukemia.
PG  - 864-76
LID - 10.1016/j.ccell.2015.05.004 [doi]
LID - S1535-6108(15)00180-4 [pii]
AB  - From an shRNA screen, we identified ClpP as a member of the mitochondrial
      proteome whose knockdown reduced the viability of K562 leukemic cells. Expression
      of this mitochondrial protease that has structural similarity to the cytoplasmic 
      proteosome is increased in leukemic cells from approximately half of all patients
      with AML. Genetic or chemical inhibition of ClpP killed cells from both human AML
      cell lines and primary samples in which the cells showed elevated ClpP expression
      but did not affect their normal counterparts. Importantly, Clpp knockout mice
      were viable with normal hematopoiesis. Mechanistically, we found that ClpP
      interacts with mitochondrial respiratory chain proteins and metabolic enzymes,
      and knockdown of ClpP in leukemic cells inhibited oxidative phosphorylation and
      mitochondrial metabolism.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Cole, Alicia
AU  - Cole A
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Wang, Zezhou
AU  - Wang Z
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Coyaud, Etienne
AU  - Coyaud E
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Voisin, Veronique
AU  - Voisin V
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8,
      Canada.
FAU - Gronda, Marcela
AU  - Gronda M
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Jitkova, Yulia
AU  - Jitkova Y
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Mattson, Rachel
AU  - Mattson R
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Hurren, Rose
AU  - Hurren R
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Babovic, Sonja
AU  - Babovic S
AD  - Terry Fox Laboratory, British Columbia Cancer Agency and University of British
      Columbia, Vancouver, BC V5Z 1L3, Canada.
FAU - Maclean, Neil
AU  - Maclean N
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Restall, Ian
AU  - Restall I
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Wang, Xiaoming
AU  - Wang X
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Jeyaraju, Danny V
AU  - Jeyaraju DV
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Sukhai, Mahadeo A
AU  - Sukhai MA
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Prabha, Swayam
AU  - Prabha S
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Bashir, Shaheena
AU  - Bashir S
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8,
      Canada.
FAU - Ramakrishnan, Ashwin
AU  - Ramakrishnan A
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Leung, Elisa
AU  - Leung E
AD  - Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada.
FAU - Qia, Yi Hua
AU  - Qia YH
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Zhang, Nianxian
AU  - Zhang N
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Combes, Kevin R
AU  - Combes KR
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ketela, Troy
AU  - Ketela T
AD  - Department of Molecular Genetics, Donnelly Centre for Cellular and Biomolecular
      Research, Toronto, ON M5S 3E1, Canada.
FAU - Lin, Fengshu
AU  - Lin F
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Houry, Walid A
AU  - Houry WA
AD  - Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada.
FAU - Aman, Ahmed
AU  - Aman A
AD  - Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G
      0A3, Canada.
FAU - Al-Awar, Rima
AU  - Al-Awar R
AD  - Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G
      0A3, Canada; Department of Pharmacology and Toxicology, University of Toronto,
      Toronto, ON M5S 1A8, Canada.
FAU - Zheng, Wei
AU  - Zheng W
AD  - National Center for Advancing Translational Sciences, National Institutes of
      Health, Bethesda, MD 20892, USA.
FAU - Wienholds, Erno
AU  - Wienholds E
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada; Department of
      Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada.
FAU - Xu, Chang Jiang
AU  - Xu CJ
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8,
      Canada.
FAU - Dick, John
AU  - Dick J
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada; Department of
      Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada.
FAU - Wang, Jean C Y
AU  - Wang JC
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada; Department of
      Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada.
FAU - Moffat, Jason
AU  - Moffat J
AD  - Department of Molecular Genetics, Donnelly Centre for Cellular and Biomolecular
      Research, Toronto, ON M5S 3E1, Canada.
FAU - Minden, Mark D
AU  - Minden MD
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada; Department of
      Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada.
FAU - Eaves, Connie J
AU  - Eaves CJ
AD  - Terry Fox Laboratory, British Columbia Cancer Agency and University of British
      Columbia, Vancouver, BC V5Z 1L3, Canada.
FAU - Bader, Gary D
AU  - Bader GD
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8,
      Canada.
FAU - Hao, Zhenyue
AU  - Hao Z
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Kornblau, Steven M
AU  - Kornblau SM
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Raught, Brian
AU  - Raught B
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
FAU - Schimmer, Aaron D
AU  - Schimmer AD
AD  - Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada; Department of
      Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada. Electronic address:
      aaron.schimmer@utoronto.ca.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA157456/CA/NCI NIH HHS/United States
GR  - NCI 1R01CA157456/CA/NCI NIH HHS/United States
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (RNA, Small Interfering)
RN  - EC 3.4.21.92 (ClpP protein, human)
RN  - EC 3.4.21.92 (Endopeptidase Clp)
SB  - IM
CIN - Cancer Cell. 2015 Jun 8;27(6):747-9. PMID: 26058072
MH  - Animals
MH  - Endopeptidase Clp/*antagonists & inhibitors/metabolism
MH  - Enzyme Inhibitors/*pharmacology
MH  - Heterografts
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/*enzymology
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, SCID
MH  - RNA, Small Interfering/genetics
PMC - PMC4461837
MID - NIHMS690556
EDAT- 2015/06/10 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/10 06:00
PHST- 2014/11/04 00:00 [received]
PHST- 2015/02/06 00:00 [revised]
PHST- 2015/05/07 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00180-4 [pii]
AID - 10.1016/j.ccell.2015.05.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):864-76. doi: 10.1016/j.ccell.2015.05.004.

PMID- 26058079
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and
      Overcome Resistance to Therapy.
PG  - 837-51
LID - 10.1016/j.ccell.2015.05.006 [doi]
LID - S1535-6108(15)00182-8 [pii]
AB  - Unsustained enzyme inhibition is a barrier to targeted therapy for cancer. Here, 
      resistance to a class I PI3K inhibitor in a model of metastatic breast cancer
      driven by PI3K and MYC was associated with feedback activation of tyrosine kinase
      receptors (RTKs), AKT, mTOR, and MYC. Inhibitors of bromodomain and extra
      terminal domain (BET) proteins also failed to affect tumor growth. Interestingly,
      BET inhibitors lowered PI3K signaling and dissociated BRD4 from chromatin at
      regulatory regions of insulin receptor and EGFR family RTKs to reduce their
      expression. Combined PI3K and BET inhibition induced cell death, tumor
      regression, and clamped inhibition of PI3K signaling in a broad range of tumor
      cell lines to provide a strategy to overcome resistance to kinase inhibitor
      therapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Stratikopoulos, Elias E
AU  - Stratikopoulos EE
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1470
      Madison Avenue, New York, NY 10029, USA.
FAU - Dendy, Meaghan
AU  - Dendy M
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1470
      Madison Avenue, New York, NY 10029, USA.
FAU - Szabolcs, Matthias
AU  - Szabolcs M
AD  - Department of Pathology, Columbia University Medical Center, New York, NY 10032, 
      USA.
FAU - Khaykin, Alan J
AU  - Khaykin AJ
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1470
      Madison Avenue, New York, NY 10029, USA.
FAU - Lefebvre, Celine
AU  - Lefebvre C
AD  - Inserm U981, Institut Gustave Roussy, 94805 Villejuif, France.
FAU - Zhou, Ming-Ming
AU  - Zhou MM
AD  - Department of Structural and Chemical Biology, Icahn School of Medicine at Mount 
      Sinai, 1470 Madison Avenue, New York, NY 10029, USA.
FAU - Parsons, Ramon
AU  - Parsons R
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1470
      Madison Avenue, New York, NY 10029, USA. Electronic address:
      ramon.parsons@mssm.edu.
LA  - eng
GR  - R01 CA082783/CA/NCI NIH HHS/United States
GR  - R01 CA129432/CA/NCI NIH HHS/United States
GR  - BC087596/BC/NCI NIH HHS/United States
GR  - NCI R01 CA129432/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BRD4 protein, human)
RN  - 0 (Brd4 protein, mouse)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - EC 2.7.1.137 (Pik3ca protein, mouse)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Breast Neoplasms/*drug therapy/genetics/metabolism
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Class I Phosphatidylinositol 3-Kinases
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Mammary Neoplasms, Experimental/drug therapy/genetics/metabolism
MH  - Mice
MH  - Mice, Transgenic
MH  - Nuclear Proteins/*antagonists & inhibitors/genetics/metabolism
MH  - Phosphatidylinositol 3-Kinases/*antagonists & inhibitors/genetics/metabolism
MH  - Protein Interaction Domains and Motifs
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Random Allocation
MH  - Signal Transduction
MH  - Transcription Factors/*antagonists & inhibitors/genetics/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC4918409
MID - NIHMS785771
EDAT- 2015/06/10 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/10 06:00
PHST- 2014/09/23 00:00 [received]
PHST- 2015/04/14 00:00 [revised]
PHST- 2015/05/07 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00182-8 [pii]
AID - 10.1016/j.ccell.2015.05.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):837-51. doi: 10.1016/j.ccell.2015.05.006.

PMID- 26058078
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - ERG Activates the YAP1 Transcriptional Program and Induces the Development of
      Age-Related Prostate Tumors.
PG  - 797-808
LID - 10.1016/j.ccell.2015.05.005 [doi]
LID - S1535-6108(15)00181-6 [pii]
AB  - The significance of ERG in human prostate cancer is unclear because mouse
      prostate is resistant to ERG-mediated transformation. We determined that ERG
      activates the transcriptional program regulated by YAP1 of the Hippo signaling
      pathway and found that prostate-specific activation of either ERG or YAP1 in mice
      induces similar transcriptional changes and results in age-related prostate
      tumors. ERG binds to chromatin regions occupied by TEAD/YAP1 and transactivates
      Hippo target genes. In addition, in human luminal-type prostate cancer cells, ERG
      binds to the promoter of YAP1 and is necessary for YAP1 expression. These results
      provide direct genetic evidence of a causal role for ERG in prostate cancer and
      reveal a connection between ERG and the Hippo signaling pathway.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Nguyen, Liem T
AU  - Nguyen LT
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Tretiakova, Maria S
AU  - Tretiakova MS
AD  - Department of Pathology, University of Washington, Seattle, WA 98195, USA.
FAU - Silvis, Mark R
AU  - Silvis MR
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Lucas, Jared
AU  - Lucas J
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Klezovitch, Olga
AU  - Klezovitch O
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Coleman, Ilsa
AU  - Coleman I
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Bolouri, Hamid
AU  - Bolouri H
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Kutyavin, Vassily I
AU  - Kutyavin VI
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Morrissey, Colm
AU  - Morrissey C
AD  - Department of Urology, University of Washington, Seattle, WA 98195, USA.
FAU - True, Lawrence D
AU  - True LD
AD  - Department of Pathology, University of Washington, Seattle, WA 98195, USA;
      Institute for Stem Cell and Regenerative Medicine, University of Washington,
      Seattle, WA 98195, USA.
FAU - Nelson, Peter S
AU  - Nelson PS
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Department of Urology, University of Washington, Seattle, WA 98195,
      USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA;
      Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA; 
      Department of Pathology, University of Washington, Seattle, WA 98195, USA.
FAU - Vasioukhin, Valeri
AU  - Vasioukhin V
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Department of Pathology, University of Washington, Seattle, WA 98195,
      USA; Institute for Stem Cell and Regenerative Medicine, University of Washington,
      Seattle, WA 98195, USA. Electronic address: vvasiouk@fhcrc.org.
LA  - eng
SI  - SRA/SRP041840
GR  - R01 CA176844/CA/NCI NIH HHS/United States
GR  - R01CA176844/CA/NCI NIH HHS/United States
GR  - P50 CA097186/CA/NCI NIH HHS/United States
GR  - P50CA097186/CA/NCI NIH HHS/United States
GR  - P01 CA085859/CA/NCI NIH HHS/United States
GR  - P01CA085859/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (ERG protein, human)
RN  - 0 (ERG protein, mouse)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (Porphyrins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - 0 (Transcriptional Regulator ERG)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - 0 (Yap protein, mouse)
RN  - 0X9PA28K43 (verteporfin)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/antagonists &
      inhibitors/*genetics/metabolism
MH  - Age Factors
MH  - Animals
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Oncogene Proteins/*genetics/metabolism
MH  - Phosphoproteins/antagonists & inhibitors/*genetics/metabolism
MH  - Porphyrins/pharmacology
MH  - Prostatic Neoplasms/drug therapy/*genetics/metabolism/pathology
MH  - Random Allocation
MH  - Signal Transduction
MH  - Trans-Activators/*genetics/metabolism
MH  - Transcription Factors/*genetics/metabolism
MH  - Transcriptional Activation
MH  - Transcriptional Regulator ERG
MH  - Translocation, Genetic
MH  - Up-Regulation
MH  - Xenograft Model Antitumor Assays
PMC - PMC4461839
MID - NIHMS690705
EDAT- 2015/06/10 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/10 06:00
PHST- 2014/08/11 00:00 [received]
PHST- 2014/11/17 00:00 [revised]
PHST- 2015/05/07 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00181-6 [pii]
AID - 10.1016/j.ccell.2015.05.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):797-808. doi: 10.1016/j.ccell.2015.05.005.

PMID- 26058077
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer
      Pain.
PG  - 780-96
LID - 10.1016/j.ccell.2015.04.017 [doi]
LID - S1535-6108(15)00150-6 [pii]
AB  - Cancer pain is a debilitating disorder and a primary determinant of the poor
      quality of life. Here, we report a non-vascular role for ligands of the Vascular 
      Endothelial Growth Factor (VEGF) family in cancer pain. Tumor-derived VEGF-A,
      PLGF-2, and VEGF-B augment pain sensitivity through selective activation of VEGF 
      receptor 1 (VEGFR1) expressed in sensory neurons in human cancer and mouse
      models. Sensory-neuron-specific genetic deletion/silencing or local or systemic
      blockade of VEGFR1 prevented tumor-induced nerve remodeling and attenuated cancer
      pain in diverse mouse models in vivo. These findings identify a therapeutic
      potential for VEGFR1-modifying drugs in cancer pain and suggest a palliative
      effect for VEGF/VEGFR1-targeting anti-angiogenic tumor therapies.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Selvaraj, Deepitha
AU  - Selvaraj D
AD  - Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120
      Heidelberg, Germany.
FAU - Gangadharan, Vijayan
AU  - Gangadharan V
AD  - Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120
      Heidelberg, Germany.
FAU - Michalski, Christoph W
AU  - Michalski CW
AD  - Department of Surgery, Heidelberg University, Im Neuenheimer Feld 110, 69120
      Heidelberg, Germany.
FAU - Kurejova, Martina
AU  - Kurejova M
AD  - Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120
      Heidelberg, Germany.
FAU - Stosser, Sebastian
AU  - Stosser S
AD  - Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120
      Heidelberg, Germany.
FAU - Srivastava, Kshitij
AU  - Srivastava K
AD  - Division of Vascular Oncology and Metastasis, German Cancer Research Center
      (DKFZ-ZMBH Alliance), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
FAU - Schweizerhof, Matthias
AU  - Schweizerhof M
AD  - Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120
      Heidelberg, Germany.
FAU - Waltenberger, Johannes
AU  - Waltenberger J
AD  - Department of Cardiovascular Medicine, University Hospital Munster, 48149
      Munster, Germany; Cells-in-Motion Cluster of Excellence (EXC 1003-CiM),
      University of Munster, 48149 Munster, Germany.
FAU - Ferrara, Napoleone
AU  - Ferrara N
AD  - University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA
      92093, USA.
FAU - Heppenstall, Paul
AU  - Heppenstall P
AD  - European Molecular Biology Laboratory, Adriano Buzzati-Traverso Campus, Via
      Ramarini 32, 00015 Monterotondo, Italy; Molecular Medicine Partnership Unit, Otto
      Meyerhof Center, Im Neuenheimer Feld, 69120 Heidelberg, Germany.
FAU - Shibuya, Masabumi
AU  - Shibuya M
AD  - Department of Molecular Oncology, Graduate School of Medicine and Dentistry,
      Tokyo Dental and Medical University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8519,
      Japan.
FAU - Augustin, Hellmut G
AU  - Augustin HG
AD  - Division of Vascular Oncology and Metastasis, German Cancer Research Center
      (DKFZ-ZMBH Alliance), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany;
      Department of Vascular Biology and Tumor Angiogenesis, Medical Faculty Mannheim
      (CBTM), Heidelberg University, Ludolph-Krehl-Strasse 14, 68167 Mannheim, Germany.
FAU - Kuner, Rohini
AU  - Kuner R
AD  - Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120
      Heidelberg, Germany; Molecular Medicine Partnership Unit, Otto Meyerhof Center,
      Im Neuenheimer Feld, 69120 Heidelberg, Germany. Electronic address:
      rohini.kuner@pharma.uni-heidelberg.de.
LA  - eng
GR  - 294293/European Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Angiogenesis Inhibitors)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
SB  - IM
EIN - Cancer Cell. 2015 Aug 10;28(2):270
MH  - Angiogenesis Inhibitors/pharmacology
MH  - Animals
MH  - Disease Models, Animal
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasms/metabolism/*pathology
MH  - Pain/drug therapy/*metabolism/pathology
MH  - Sensory Receptor Cells/drug effects/*metabolism/pathology
MH  - Up-Regulation
MH  - Vascular Endothelial Growth Factor Receptor-1/antagonists &
      inhibitors/*biosynthesis
PMC - PMC4469373
EDAT- 2015/06/10 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/10 06:00
PHST- 2014/06/23 00:00 [received]
PHST- 2015/01/28 00:00 [revised]
PHST- 2015/04/29 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00150-6 [pii]
AID - 10.1016/j.ccell.2015.04.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):780-96. doi: 10.1016/j.ccell.2015.04.017.

PMID- 26058076
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20150610
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute
      Lymphoblastic Leukemia.
PG  - 769-79
LID - 10.1016/j.ccell.2015.05.003 [doi]
LID - S1535-6108(15)00179-8 [pii]
AB  - Impaired cell migration has been demonstrated in T cell acute lymphoblastic
      leukemia (T-ALL) cells upon calcineurin inactivation, among other phenotypic
      traits including increased apoptosis, inhibition of cell proliferation, and
      ultimately inhibition of leukemia-initiating cell (LIC) activity. Herein we
      demonstrate that the chemokine receptor CXCR4 is essential to the LIC activity of
      T-ALL leukemic cells both in NOTCH-induced mouse T-ALL and human T-ALL xenograft 
      models. We further demonstrate that calcineurin regulates CXCR4 cell-surface
      expression in a cortactin-dependent manner, a mechanism essential to the
      migratory properties of T-ALL cells. Because 20%-25% of pediatric and over 50% of
      adult patients with T-ALL do not achieve complete remission and relapse, our
      results call for clinical trials incorporating CXCR4 antagonists in T-ALL
      treatment.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Passaro, Diana
AU  - Passaro D
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France. Electronic address: diana.passaro@crick.ac.uk.
FAU - Irigoyen, Marta
AU  - Irigoyen M
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France.
FAU - Catherinet, Claire
AU  - Catherinet C
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France.
FAU - Gachet, Stephanie
AU  - Gachet S
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France.
FAU - Da Costa De Jesus, Cindy
AU  - Da Costa De Jesus C
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France.
FAU - Lasgi, Charlene
AU  - Lasgi C
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France.
FAU - Tran Quang, Christine
AU  - Tran Quang C
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France.
FAU - Ghysdael, Jacques
AU  - Ghysdael J
AD  - Institut Curie, Centre Universitaire, Bat 110, 91405 Orsay, France; Centre
      National de la Recherche Scientifique, Unite Mixte de Recherche 3306, Centre
      Universitaire, Bat 110, 91405 Orsay, France; Institut National de la Sante et de 
      la Recherche Medicale, Unite 1005, Centre Universitaire, Bat 110, 91405 Orsay,
      France. Electronic address: jacques.ghysdael@curie.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CXCR4 protein, human)
RN  - 0 (CXCR4 protein, mouse)
RN  - 0 (NOTCH1 protein, human)
RN  - 0 (Notch1 protein, mouse)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Receptors, CXCR4)
RN  - EC 3.1.3.16 (Calcineurin)
SB  - IM
CIN - Cancer Cell. 2015 Jun 8;27(6):745-6. PMID: 26058071
MH  - Animals
MH  - Apoptosis/physiology
MH  - Calcineurin/metabolism
MH  - Cell Movement/physiology
MH  - Cell Proliferation/physiology
MH  - Heterografts
MH  - Humans
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics/*metabolism/*pathology
MH  - Receptor, Notch1/genetics/metabolism
MH  - Receptors, CXCR4/biosynthesis/genetics/*metabolism
MH  - Signal Transduction
EDAT- 2015/06/10 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/10 06:00
PHST- 2014/10/22 00:00 [received]
PHST- 2015/04/05 00:00 [revised]
PHST- 2015/05/07 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00179-8 [pii]
AID - 10.1016/j.ccell.2015.05.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):769-79. doi: 10.1016/j.ccell.2015.05.003.

PMID- 26058075
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia
      Maintenance.
PG  - 755-68
LID - 10.1016/j.ccell.2015.05.002 [doi]
LID - S1535-6108(15)00178-6 [pii]
AB  - The role of the microenvironment in T cell acute lymphoblastic leukemia (T-ALL), 
      or any acute leukemia, is poorly understood. Here we demonstrate that T-ALL cells
      are in direct, stable contact with CXCL12-producing bone marrow stroma. Cxcl12
      deletion from vascular endothelial, but not perivascular, cells impeded tumor
      growth, suggesting a vascular niche for T-ALL. Moreover, genetic targeting of
      Cxcr4 in murine T-ALL after disease onset led to rapid, sustained disease
      remission, and CXCR4 antagonism suppressed human T-ALL in primary xenografts.
      Loss of CXCR4 targeted key T-ALL regulators, including the MYC pathway, and
      decreased leukemia initiating cell activity in vivo. Our data identify a T-ALL
      niche and suggest targeting CXCL12/CXCR4 signaling as a powerful therapeutic
      approach for T-ALL.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Pitt, Lauren A
AU  - Pitt LA
AD  - Skirball Institute of Biomolecular Medicine, New York University School of
      Medicine, 540 First Avenue, New York, NY 10016, USA; Department of Pathology, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
FAU - Tikhonova, Anastasia N
AU  - Tikhonova AN
AD  - Howard Hughes Medical Institute and Laura and Isaac Perlmutter Cancer Center, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA;
      Department of Pathology, New York University School of Medicine, 550 First
      Avenue, New York, NY 10016, USA.
FAU - Hu, Hai
AU  - Hu H
AD  - Howard Hughes Medical Institute and Laura and Isaac Perlmutter Cancer Center, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA;
      Department of Pathology, New York University School of Medicine, 550 First
      Avenue, New York, NY 10016, USA.
FAU - Trimarchi, Thomas
AU  - Trimarchi T
AD  - Howard Hughes Medical Institute and Laura and Isaac Perlmutter Cancer Center, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA;
      Department of Pathology, New York University School of Medicine, 550 First
      Avenue, New York, NY 10016, USA.
FAU - King, Bryan
AU  - King B
AD  - Howard Hughes Medical Institute and Laura and Isaac Perlmutter Cancer Center, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA;
      Department of Pathology, New York University School of Medicine, 550 First
      Avenue, New York, NY 10016, USA.
FAU - Gong, Yixiao
AU  - Gong Y
AD  - Howard Hughes Medical Institute and Laura and Isaac Perlmutter Cancer Center, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA;
      Department of Pathology, New York University School of Medicine, 550 First
      Avenue, New York, NY 10016, USA.
FAU - Sanchez-Martin, Marta
AU  - Sanchez-Martin M
AD  - Institute for Cancer Genetics, Department of Pathology and Department of
      Pediatrics, Columbia University, 1130 Saint Nicholas Avenue, New York, NY 10032, 
      USA.
FAU - Tsirigos, Aris
AU  - Tsirigos A
AD  - Howard Hughes Medical Institute and Laura and Isaac Perlmutter Cancer Center, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA;
      Department of Pathology, New York University School of Medicine, 550 First
      Avenue, New York, NY 10016, USA.
FAU - Littman, Dan R
AU  - Littman DR
AD  - Howard Hughes Medical Institute and Skirball Institute of Biomolecular Medicine, 
      New York University School of Medicine, 540 First Avenue, New York, NY 10016,
      USA.
FAU - Ferrando, Adolfo A
AU  - Ferrando AA
AD  - Institute for Cancer Genetics, Department of Pathology and Department of
      Pediatrics, Columbia University, 1130 Saint Nicholas Avenue, New York, NY 10032, 
      USA.
FAU - Morrison, Sean J
AU  - Morrison SJ
AD  - Howard Hughes Medical Institute and Children's Research Institute and Department 
      of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390,
      USA.
FAU - Fooksman, David R
AU  - Fooksman DR
AD  - Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park
      Avenue, Forchheimer Building, Room 131, Bronx, NY 10461, USA.
FAU - Aifantis, Iannis
AU  - Aifantis I
AD  - Howard Hughes Medical Institute and Laura and Isaac Perlmutter Cancer Center, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA;
      Department of Pathology, New York University School of Medicine, 550 First
      Avenue, New York, NY 10016, USA. Electronic address: iannis.aifantis@nyumc.org.
FAU - Schwab, Susan R
AU  - Schwab SR
AD  - Skirball Institute of Biomolecular Medicine, New York University School of
      Medicine, 540 First Avenue, New York, NY 10016, USA; Department of Pathology, New
      York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
      Electronic address: susan.schwab@med.nyu.edu.
LA  - eng
SI  - GEO/GSE60367
GR  - P30CA013330/CA/NCI NIH HHS/United States
GR  - R01 CA173636/CA/NCI NIH HHS/United States
GR  - T32 CA009161/CA/NCI NIH HHS/United States
GR  - 5R01CA169784/CA/NCI NIH HHS/United States
GR  - P30 CA016087/CA/NCI NIH HHS/United States
GR  - R01 CA133379/CA/NCI NIH HHS/United States
GR  - R01 AI085166/AI/NIAID NIH HHS/United States
GR  - R01 CA194923/CA/NCI NIH HHS/United States
GR  - 1R01GM088847/GM/NIGMS NIH HHS/United States
GR  - P30CA016087-30/CA/NCI NIH HHS/United States
GR  - R01 CA149655/CA/NCI NIH HHS/United States
GR  - R01 CA105129/CA/NCI NIH HHS/United States
GR  - 5R01CA173636/CA/NCI NIH HHS/United States
GR  - 1R01CA133379/CA/NCI NIH HHS/United States
GR  - 1R01CA149655/CA/NCI NIH HHS/United States
GR  - R01 AI072529/AI/NIAID NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - 5T32CA009161-37/CA/NCI NIH HHS/United States
GR  - R01 CA169784/CA/NCI NIH HHS/United States
GR  - 1R01CA105129/CA/NCI NIH HHS/United States
GR  - 5R01AI085166/AI/NIAID NIH HHS/United States
GR  - P30 CA013330/CA/NCI NIH HHS/United States
GR  - P30CA016087/CA/NCI NIH HHS/United States
GR  - R01 GM088847/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CXCL12 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Cxcl12 protein, mouse)
RN  - 0 (N-(1,4,8,11-
      tetraazacyclotetradecanyl-1,4-phenylenebis(methylene))-2-(aminomethyl)- pyridine)
RN  - 0 (Pyridines)
SB  - IM
CIN - Cancer Cell. 2015 Jun 8;27(6):745-6. PMID: 26058071
CIN - Trends Immunol. 2015 Sep;36(9):504-6. PMID: 26282886
MH  - Animals
MH  - Bone Marrow Cells/metabolism/pathology
MH  - Chemokine CXCL12/*antagonists & inhibitors/*biosynthesis/genetics
MH  - Endothelium, Vascular/*metabolism/pathology
MH  - Female
MH  - Gene Deletion
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Mice, Transgenic
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*drug
      therapy/genetics/*metabolism/pathology
MH  - Pyridines/*pharmacology
MH  - Stromal Cells/metabolism/pathology
MH  - Xenograft Model Antitumor Assays
PMC - PMC4461838
MID - NIHMS692782
EDAT- 2015/06/10 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/10 06:00
PHST- 2014/10/21 00:00 [received]
PHST- 2015/03/01 00:00 [revised]
PHST- 2015/05/04 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00178-6 [pii]
AID - 10.1016/j.ccell.2015.05.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):755-68. doi: 10.1016/j.ccell.2015.05.002.

PMID- 26058074
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20150610
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.
PG  - 751-3
LID - 10.1016/j.ccell.2015.05.012 [doi]
LID - S1535-6108(15)00188-9 [pii]
AB  - The T790M mutation in EGFR accounts for approximately half of all lung cancer
      cases with acquired resistance to the current clinical EGFR tyrosine kinase
      inhibitors. In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and
      AZD9291 are highly active when T790M is present and modestly active when T790M is
      absent.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Politi, Katerina
AU  - Politi K
AD  - Department of Pathology, Yale University School of Medicine, New Haven, CT 06510,
      USA; Section of Medical Oncology, Department of Medicine, Yale University School 
      of Medicine, New Haven, CT 06510, USA; Yale Comprehensive Cancer Center, Yale
      University School of Medicine, New Haven, CT 06510, USA. Electronic address:
      katerina.politi@yale.edu.
FAU - Ayeni, Deborah
AU  - Ayeni D
AD  - Department of Pathology, Yale University School of Medicine, New Haven, CT 06510,
      USA.
FAU - Lynch, Thomas
AU  - Lynch T
AD  - Section of Medical Oncology, Department of Medicine, Yale University School of
      Medicine, New Haven, CT 06510, USA; Yale Comprehensive Cancer Center, Yale
      University School of Medicine, New Haven, CT 06510, USA. Electronic address:
      thomas.lynch@yale.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics/pathology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Mutation
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Receptor, Epidermal Growth Factor/*antagonists & inhibitors/genetics/metabolism
EDAT- 2015/06/10 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/10 06:00
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00188-9 [pii]
AID - 10.1016/j.ccell.2015.05.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):751-3. doi: 10.1016/j.ccell.2015.05.012.

PMID- 26058073
OWN - NLM
STAT- MEDLINE
DCOM- 20150810
LR  - 20150610
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - Excluding T Cells: Is beta-Catenin the Full Story?
PG  - 749-50
LID - 10.1016/j.ccell.2015.05.014 [doi]
LID - S1535-6108(15)00190-7 [pii]
AB  - Spranger and colleagues reported recently in Nature an inverse relationship
      between melanoma intrinsic beta-catenin signaling and intratumoral T cell
      infiltration, providing an explanation for potential mechanisms of T cell
      exclusion. Further insights are needed into the mechanisms leading to a lack of T
      cell infiltration of cancers and primary immune resistance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Hu-Lieskovan, Siwen
AU  - Hu-Lieskovan S
AD  - Division of Hematology-Oncology, Department of Medicine, University of California
      Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer
      Center (JCCC) at UCLA, Los Angeles, CA 90095, USA.
FAU - Homet Moreno, Blanca
AU  - Homet Moreno B
AD  - Division of Hematology-Oncology, Department of Medicine, University of California
      Los Angeles (UCLA), Los Angeles, CA 90095, USA.
FAU - Ribas, Antoni
AU  - Ribas A
AD  - Division of Hematology-Oncology, Department of Medicine, University of California
      Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Surgery, University
      of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of
      Medical and Molecular Pharmacology, University of California Los Angeles (UCLA), 
      Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC) at UCLA,
      Los Angeles, CA 90095, USA. Electronic address: aribas@mednet.ucla.edu.
LA  - eng
GR  - CA199205/CA/NCI NIH HHS/United States
GR  - P01 CA132681/CA/NCI NIH HHS/United States
GR  - P01 CA168585/CA/NCI NIH HHS/United States
GR  - R01 CA170689/CA/NCI NIH HHS/United States
GR  - U54 CA119347/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (beta Catenin)
SB  - IM
CON - Nature. 2015 Jul 9;523(7559):231-5. PMID: 25970248
MH  - Animals
MH  - Humans
MH  - Melanoma/*immunology/*physiopathology
MH  - *Signal Transduction
MH  - T-Lymphocytes/*immunology
MH  - Tumor Microenvironment/*immunology
MH  - beta Catenin/*immunology
EDAT- 2015/06/10 06:00
MHDA- 2015/08/11 06:00
CRDT- 2015/06/10 06:00
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/08/11 06:00 [medline]
AID - S1535-6108(15)00190-7 [pii]
AID - 10.1016/j.ccell.2015.05.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):749-50. doi: 10.1016/j.ccell.2015.05.014.

PMID- 26058072
OWN - NLM
STAT- MEDLINE
DCOM- 20150904
LR  - 20150610
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - Antagonizing ClpP: A New Power Play in Targeted Therapy for AML.
PG  - 747-9
LID - 10.1016/j.ccell.2015.05.013 [doi]
LID - S1535-6108(15)00189-0 [pii]
AB  - In this issue of Cancer Cell, Cole and colleagues report a non-mutant
      mitochondrial protein (ClpP) that is overexpressed in a wide range of acute
      myeloid leukemia (AML) cases, but not in normal hematopoietic precursors. This
      finding suggests a potentially unique therapeutic targeting opportunity for this 
      difficult-to-treat disease.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, Department of Medicine, The Ohio State University,
      Columbus, OH 43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Medicine, The Ohio State University,
      Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, 
      B302 Starling-Loving Hall, 320 West 10(th) Avenue, Columbus, OH 43210, USA.
      Electronic address: john.byrd@osumc.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Enzyme Inhibitors)
RN  - EC 3.4.21.92 (Endopeptidase Clp)
SB  - IM
CON - Cancer Cell. 2015 Jun 8;27(6):864-76. PMID: 26058080
MH  - Animals
MH  - Endopeptidase Clp/*antagonists & inhibitors
MH  - Enzyme Inhibitors/*pharmacology
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/*enzymology
MH  - Male
EDAT- 2015/06/10 06:00
MHDA- 2015/09/05 06:00
CRDT- 2015/06/10 06:00
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/05 06:00 [medline]
AID - S1535-6108(15)00189-0 [pii]
AID - 10.1016/j.ccell.2015.05.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):747-9. doi: 10.1016/j.ccell.2015.05.013.

PMID- 26058071
OWN - NLM
STAT- MEDLINE
DCOM- 20150904
LR  - 20150610
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - T-ALL: Home Is where the CXCL12 Is.
PG  - 745-6
LID - 10.1016/j.ccell.2015.05.011 [doi]
LID - S1535-6108(15)00187-7 [pii]
AB  - T cell acute lymphoblastic leukemia (T-ALL) is caused by mutations affecting cell
      survival, proliferation, and differentiation. In addition to requiring these
      mutations, Passaro and colleagues and Pitt and colleagues in this issue of Cancer
      Cell demonstrate that T-ALL initiating cells residing in bone marrow depend on
      the CXCR4/CXCL12 signaling axis for disease maintenance and progression.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - de Bock, Charles E
AU  - de Bock CE
AD  - VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; KU Leuven
      Center for Human Genetics, 3000 Leuven, Belgium. Electronic address:
      charles.debock@cme.vib-kuleuven.be.
FAU - Cools, Jan
AU  - Cools J
AD  - VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; KU Leuven
      Center for Human Genetics, 3000 Leuven, Belgium. Electronic address:
      jan.cools@cme.vib-kuleuven.be.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, CXCR4)
SB  - IM
CON - Cancer Cell. 2015 Jun 8;27(6):769-79. PMID: 26058076
CON - Cancer Cell. 2015 Jun 8;27(6):755-68. PMID: 26058075
MH  - Animals
MH  - Chemokine CXCL12/*antagonists & inhibitors/*biosynthesis
MH  - Endothelium, Vascular/*metabolism
MH  - Female
MH  - Humans
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*drug
      therapy/*metabolism/*pathology
MH  - Pyridines/*pharmacology
MH  - Receptors, CXCR4/*metabolism
EDAT- 2015/06/10 06:00
MHDA- 2015/09/05 06:00
CRDT- 2015/06/10 06:00
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2015/09/05 06:00 [medline]
AID - S1535-6108(15)00187-7 [pii]
AID - 10.1016/j.ccell.2015.05.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):745-6. doi: 10.1016/j.ccell.2015.05.011.

PMID- 26028330
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated
      Repression Programs Contributes to Breast Cancer Metastasis.
PG  - 822-36
LID - 10.1016/j.ccell.2015.04.011 [doi]
LID - S1535-6108(15)00144-0 [pii]
AB  - How loss-of-function of GATA3 contributes to the development of breast cancer is 
      poorly understood. Here, we report that GATA3 nucleates a transcription
      repression program composed of G9A and MTA3-, but not MTA1- or MTA2-, constituted
      NuRD complex. Genome-wide analysis of the GATA3/G9A/NuRD(MTA3) targets identified
      a cohort of genes including ZEB2 that are critically involved in
      epithelial-to-mesenchymal transition and cell invasion. We demonstrate that the
      GATA3/G9A/NuRD(MTA3) complex inhibits the invasive potential of breast cancer
      cells in vitro and suppresses breast cancer metastasis in vivo. Strikingly, the
      expression of GATA3, G9A, and MTA3 is concurrently downregulated during breast
      cancer progression, leading to an elevated expression of ZEB2, which, in turn,
      represses the expression of G9A and MTA3 through the recruitment of
      G9A/NuRD(MTA1).
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Si, Wenzhe
AU  - Si W
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Huang, Wei
AU  - Huang W
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Zheng, Yu
AU  - Zheng Y
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Yang, Yang
AU  - Yang Y
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Liu, Xujun
AU  - Liu X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Shan, Lin
AU  - Shan L
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Zhou, Xing
AU  - Zhou X
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Wang, Yue
AU  - Wang Y
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Su, Dongxue
AU  - Su D
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Gao, Jie
AU  - Gao J
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Yan, Ruorong
AU  - Yan R
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Han, Xiao
AU  - Han X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Li, Wanjin
AU  - Li W
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - He, Lin
AU  - He L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Shi, Lei
AU  - Shi L
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Xuan, Chenghao
AU  - Xuan C
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China.
FAU - Liang, Jing
AU  - Liang J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Sun, Luyang
AU  - Sun L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin 
      Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular
      Biology, Tianjin Medical University, Tianjin 300070, China. Electronic address:
      yanwang@tmu.edu.cn.
FAU - Shang, Yongfeng
AU  - Shang Y
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of
      Education), Beijing Key Laboratory of Protein Posttranslational Modifications and
      Cell Function, Department of Biochemistry and Molecular Biology, Peking
      University Health Science Center, Beijing 100191, China; 2011 Collaborative
      Innovation Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of
      Medical Epigenetics, Department of Biochemistry and Molecular Biology, Tianjin
      Medical University, Tianjin 300070, China. Electronic address:
      yshang@hsc.pku.edu.cn.
LA  - eng
SI  - GEO/GSE67206
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150528
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Repressor Proteins)
RN  - 0 (ZEB2 protein, human)
RN  - 0 (Zinc Finger E-box Binding Homeobox 2)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/genetics/*metabolism/*pathology
MH  - Epithelial-Mesenchymal Transition
MH  - Female
MH  - GATA3 Transcription Factor/genetics/*metabolism
MH  - Heterografts
MH  - Homeodomain Proteins/genetics/*metabolism
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice
MH  - Mice, Nude
MH  - Mice, SCID
MH  - Neoplasm Metastasis
MH  - Repressor Proteins/genetics/*metabolism
MH  - Transfection
MH  - Zinc Finger E-box Binding Homeobox 2
EDAT- 2015/06/02 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/06/02 06:00
PHST- 2014/10/13 00:00 [received]
PHST- 2015/02/17 00:00 [revised]
PHST- 2015/04/17 00:00 [accepted]
PHST- 2015/06/02 06:00 [entrez]
PHST- 2015/06/02 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00144-0 [pii]
AID - 10.1016/j.ccell.2015.04.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):822-36. doi: 10.1016/j.ccell.2015.04.011. Epub 2015
      May 28.

PMID- 26004684
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
PG  - 852-63
LID - 10.1016/j.ccell.2015.04.010 [doi]
LID - S1535-6108(15)00143-9 [pii]
AB  - The BH4 domain of Bcl2 is required for its antiapoptotic function, thus
      constituting a promising anticancer target. We identified a small-molecule
      Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and
      selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that
      abrogates its antiapoptotic function, converting it from a survival molecule to a
      cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived
      from cell lines and patient without significant normal tissue toxicity at
      effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor 
      tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment
      exhibits strong synergy against lung cancer in vivo. Development of this Bcl2-BH4
      antagonist may provide a strategy to improve lung cancer outcome.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Han, Bingshe
AU  - Han B
AD  - Department of Radiation Oncology, Emory University School of Medicine and Winship
      Cancer Institute of Emory University, Atlanta, GA 30322, USA.
FAU - Park, Dongkyoo
AU  - Park D
AD  - Department of Radiation Oncology, Emory University School of Medicine and Winship
      Cancer Institute of Emory University, Atlanta, GA 30322, USA.
FAU - Li, Rui
AU  - Li R
AD  - Department of Radiation Oncology, Emory University School of Medicine and Winship
      Cancer Institute of Emory University, Atlanta, GA 30322, USA.
FAU - Xie, Maohua
AU  - Xie M
AD  - Department of Radiation Oncology, Emory University School of Medicine and Winship
      Cancer Institute of Emory University, Atlanta, GA 30322, USA.
FAU - Owonikoko, Taofeek K
AU  - Owonikoko TK
AD  - Department of Hematology and Medical Oncology, Emory University School of
      Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322,
      USA.
FAU - Zhang, Guojing
AU  - Zhang G
AD  - Department of Hematology and Medical Oncology, Emory University School of
      Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322,
      USA.
FAU - Sica, Gabriel L
AU  - Sica GL
AD  - Department of Pathology, Emory University School of Medicine and Winship Cancer
      Institute of Emory University, Atlanta, GA 30322, USA.
FAU - Ding, Chunyong
AU  - Ding C
AD  - Chemical Biology Program, Department of Pharmacology and Toxicology, University
      of Texas Medical Branch, Galveston, TX 77555, USA.
FAU - Zhou, Jia
AU  - Zhou J
AD  - Chemical Biology Program, Department of Pharmacology and Toxicology, University
      of Texas Medical Branch, Galveston, TX 77555, USA.
FAU - Magis, Andrew T
AU  - Magis AT
AD  - Institute for Systems Biology, Seattle, WA 98109, USA.
FAU - Chen, Zhuo G
AU  - Chen ZG
AD  - Department of Hematology and Medical Oncology, Emory University School of
      Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322,
      USA.
FAU - Shin, Dong M
AU  - Shin DM
AD  - Department of Hematology and Medical Oncology, Emory University School of
      Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322,
      USA.
FAU - Ramalingam, Suresh S
AU  - Ramalingam SS
AD  - Department of Hematology and Medical Oncology, Emory University School of
      Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322,
      USA.
FAU - Khuri, Fadlo R
AU  - Khuri FR
AD  - Department of Hematology and Medical Oncology, Emory University School of
      Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322,
      USA.
FAU - Curran, Walter J
AU  - Curran WJ
AD  - Department of Radiation Oncology, Emory University School of Medicine and Winship
      Cancer Institute of Emory University, Atlanta, GA 30322, USA.
FAU - Deng, Xingming
AU  - Deng X
AD  - Department of Radiation Oncology, Emory University School of Medicine and Winship
      Cancer Institute of Emory University, Atlanta, GA 30322, USA. Electronic address:
      xdeng4@emory.edu.
LA  - eng
GR  - R01 CA136534/CA/NCI NIH HHS/United States
GR  - R01CA136534/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150521
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BCL2 protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Small Molecule Libraries)
RN  - 114100-40-2 (Bcl2 protein, mouse)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism/pathology
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Protein Structure, Tertiary
MH  - Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors/metabolism
MH  - Signal Transduction
MH  - Small Molecule Libraries/*pharmacology
MH  - Xenograft Model Antitumor Assays
PMC - PMC4470473
MID - NIHMS695854
EDAT- 2015/05/26 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/05/26 06:00
PHST- 2014/03/12 00:00 [received]
PHST- 2014/10/06 00:00 [revised]
PHST- 2015/04/17 00:00 [accepted]
PHST- 2015/05/26 06:00 [entrez]
PHST- 2015/05/26 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00143-9 [pii]
AID - 10.1016/j.ccell.2015.04.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):852-63. doi: 10.1016/j.ccell.2015.04.010. Epub 2015
      May 21.

PMID- 25982816
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 6
DP  - 2015 Jun 8
TI  - The TGF-beta Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to 
      Bone.
PG  - 809-21
LID - 10.1016/j.ccell.2015.04.009 [doi]
LID - S1535-6108(15)00142-7 [pii]
AB  - Transforming growth factor-beta (TGF-beta) regulates the expression of genes
      supporting breast cancer cells in bone, but little is known about prostate cancer
      bone metastases and TGF-beta. Our study reveals that the TGFBR1 inhibitor SD208
      effectively reduces prostate cancer bone metastases. TGF-beta upregulates in
      prostate cancer cells a set of genes associated with cancer aggressiveness and
      bone metastases, and the most upregulated gene was PMEPA1. In patients, PMEPA1
      expression decreased in metastatic prostate cancer and low Pmepa1 correlated with
      decreased metastasis-free survival. Only membrane-anchored isoforms of PMEPA1
      interacted with R-SMADs and ubiquitin ligases, blocking TGF-beta signaling
      independently of the proteasome. Interrupting this negative feedback loop by
      PMEPA1 knockdown increased prometastatic gene expression and bone metastases in a
      mouse prostate cancer model.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Fournier, Pierrick G J
AU  - Fournier PG
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA; Division of Endocrinology, University of Virginia School of
      Medicine, Charlottesville, VA 22903, USA.
FAU - Juarez, Patricia
AU  - Juarez P
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA; Division of Endocrinology, University of Virginia School of
      Medicine, Charlottesville, VA 22903, USA.
FAU - Jiang, Guanglong
AU  - Jiang G
AD  - Center for Computational Biology and Bioinformatics, Indiana University,
      Indianapolis, IN 46202, USA.
FAU - Clines, Gregory A
AU  - Clines GA
AD  - Division of Endocrinology, University of Virginia School of Medicine,
      Charlottesville, VA 22903, USA; Division of Metabolism, Endocrinology and
      Diabetes, University of Michigan, Ann Arbor, MI 48105, USA.
FAU - Niewolna, Maria
AU  - Niewolna M
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA; Division of Endocrinology, University of Virginia School of
      Medicine, Charlottesville, VA 22903, USA.
FAU - Kim, Hun Soo
AU  - Kim HS
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA.
FAU - Walton, Holly W
AU  - Walton HW
AD  - Division of Endocrinology, University of Virginia School of Medicine,
      Charlottesville, VA 22903, USA.
FAU - Peng, Xiang Hong
AU  - Peng XH
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA; Division of Endocrinology, University of Virginia School of
      Medicine, Charlottesville, VA 22903, USA.
FAU - Liu, Yunlong
AU  - Liu Y
AD  - Center for Computational Biology and Bioinformatics, Indiana University,
      Indianapolis, IN 46202, USA.
FAU - Mohammad, Khalid S
AU  - Mohammad KS
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA; Division of Endocrinology, University of Virginia School of
      Medicine, Charlottesville, VA 22903, USA.
FAU - Wells, Clark D
AU  - Wells CD
AD  - Department of Biochemistry and Molecular Biology, Indiana University School of
      Medicine, Indianapolis, IN 46202, USA.
FAU - Chirgwin, John M
AU  - Chirgwin JM
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA; Division of Endocrinology, University of Virginia School of
      Medicine, Charlottesville, VA 22903, USA; Richard L. Roudebush VA Medical Center,
      Indianapolis, IN 46202, USA.
FAU - Guise, Theresa A
AU  - Guise TA
AD  - Division of Endocrinology, Indiana University School of Medicine, Indianapolis,
      IN 46202, USA; Division of Endocrinology, University of Virginia School of
      Medicine, Charlottesville, VA 22903, USA. Electronic address: tguise@iu.edu.
LA  - eng
SI  - GEO/GSE58698
GR  - R29 CA069158/CA/NCI NIH HHS/United States
GR  - R01 CA069158/CA/NCI NIH HHS/United States
GR  - U01 CA143057/CA/NCI NIH HHS/United States
GR  - R01CA069158/CA/NCI NIH HHS/United States
GR  - U01CA143057/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20150514
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Membrane Proteins)
RN  - 0 (PMEPA1 protein, human)
RN  - 0 (Pteridines)
RN  - 0 (SD-208)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
CIN - Nat Rev Urol. 2015 Jul;12(7):362. PMID: 26057060
MH  - Animals
MH  - Bone Neoplasms/genetics/metabolism/prevention & control/*secondary
MH  - COS Cells
MH  - Cell Line, Tumor
MH  - Cercopithecus aethiops
MH  - Disease Models, Animal
MH  - Gene Knockdown Techniques
MH  - Hep G2 Cells
MH  - Humans
MH  - Male
MH  - Membrane Proteins/genetics/*metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Prostatic Neoplasms/drug therapy/genetics/metabolism/*pathology
MH  - Pteridines/pharmacology
MH  - Signal Transduction
MH  - Transforming Growth Factor beta/antagonists & inhibitors/*metabolism
PMC - PMC4464909
MID - NIHMS683662
EDAT- 2015/05/20 06:00
MHDA- 2015/09/04 06:00
CRDT- 2015/05/19 06:00
PHST- 2014/07/03 00:00 [received]
PHST- 2014/11/11 00:00 [revised]
PHST- 2015/04/14 00:00 [accepted]
PHST- 2015/05/19 06:00 [entrez]
PHST- 2015/05/20 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1535-6108(15)00142-7 [pii]
AID - 10.1016/j.ccell.2015.04.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jun 8;27(6):809-21. doi: 10.1016/j.ccell.2015.04.009. Epub 2015
      May 14.

PMID- 25965575
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Molecular Classification of Ependymal Tumors across All CNS Compartments,
      Histopathological Grades, and Age Groups.
PG  - 728-43
LID - 10.1016/j.ccell.2015.04.002 [doi]
LID - S1535-6108(15)00135-X [pii]
AB  - Ependymal tumors across age groups are currently classified and graded solely by 
      histopathology. It is, however, commonly accepted that this classification scheme
      has limited clinical utility based on its lack of reproducibility in predicting
      patients' outcome. We aimed at establishing a uniform molecular classification
      using DNA methylation profiling. Nine molecular subgroups were identified in a
      large cohort of 500 tumors, 3 in each anatomical compartment of the CNS, spine,
      posterior fossa, supratentorial. Two supratentorial subgroups are characterized
      by prototypic fusion genes involving RELA and YAP1, respectively. Regarding
      clinical associations, the molecular classification proposed herein outperforms
      the current histopathological classification and thus might serve as a basis for 
      the next World Health Organization classification of CNS tumors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Pajtler, Kristian W
AU  - Pajtler KW
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany; Department of Pediatric Oncology and Hematology, University 
      Children's Hospital Essen, 45147 Essen, Germany.
FAU - Witt, Hendrik
AU  - Witt H
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology,
      University Hospital, 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 
      69120 Heidelberg, Germany.
FAU - Sill, Martin
AU  - Sill M
AD  - Division of Biostatistics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Jones, David T W
AU  - Jones DT
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany.
FAU - Hovestadt, Volker
AU  - Hovestadt V
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Kratochwil, Fabian
AU  - Kratochwil F
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany.
FAU - Wani, Khalida
AU  - Wani K
AD  - Department of Translational Molecular Pathology, University of Texas MD Anderson 
      Cancer Center, Houston, TX 77030, USA.
FAU - Tatevossian, Ruth
AU  - Tatevossian R
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Punchihewa, Chandanamali
AU  - Punchihewa C
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Johann, Pascal
AU  - Johann P
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany.
FAU - Reimand, Juri
AU  - Reimand J
AD  - The Donnelly Center, University of Toronto, Toronto, ON M5S 3E1, Canada.
FAU - Warnatz, Hans-Jorg
AU  - Warnatz HJ
AD  - Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics,
      14195 Berlin, Germany.
FAU - Ryzhova, Marina
AU  - Ryzhova M
AD  - Department of Neuropathology, NN Burdenko Neurosurgical Institute, 125047 Moscow,
      Russia.
FAU - Mack, Steve
AU  - Mack S
AD  - Division of Neurosurgery, Arthur & Sonia Labatt Brain Tumour Research Centre, The
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - Division of Neurosurgery, Arthur & Sonia Labatt Brain Tumour Research Centre, The
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of
      Hematology/Oncology, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Capper, David
AU  - Capper D
AD  - Department of Neuropathology, University of Heidelberg, 69120 Heidelberg,
      Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center 
      (DKFZ), 69120 Heidelberg, Germany.
FAU - Schweizer, Leonille
AU  - Schweizer L
AD  - Department of Neuropathology, University of Heidelberg, 69120 Heidelberg,
      Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center 
      (DKFZ), 69120 Heidelberg, Germany.
FAU - Sieber, Laura
AU  - Sieber L
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany.
FAU - Wittmann, Andrea
AU  - Wittmann A
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany.
FAU - Huang, Zhiqin
AU  - Huang Z
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - van Sluis, Peter
AU  - van Sluis P
AD  - Department of Oncogenomics, Academic Medical Center, 1105AZ Amsterdam, the
      Netherlands.
FAU - Volckmann, Richard
AU  - Volckmann R
AD  - Department of Oncogenomics, Academic Medical Center, 1105AZ Amsterdam, the
      Netherlands.
FAU - Koster, Jan
AU  - Koster J
AD  - Department of Oncogenomics, Academic Medical Center, 1105AZ Amsterdam, the
      Netherlands.
FAU - Versteeg, Rogier
AU  - Versteeg R
AD  - Department of Oncogenomics, Academic Medical Center, 1105AZ Amsterdam, the
      Netherlands.
FAU - Fults, Daniel
AU  - Fults D
AD  - University of Utah, Salt Lake City, UT 84132, USA.
FAU - Toledano, Helen
AU  - Toledano H
AD  - Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel,
      49202 Petah Tikva, Israel.
FAU - Avigad, Smadar
AU  - Avigad S
AD  - Department of Molecular Oncology, Schneider Children's Medical Center of Israel, 
      Tel Aviv University, 49202 Tel Aviv, Israel.
FAU - Hoffman, Lindsey M
AU  - Hoffman LM
AD  - Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA.
FAU - Donson, Andrew M
AU  - Donson AM
AD  - Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA.
FAU - Foreman, Nicholas
AU  - Foreman N
AD  - Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA.
FAU - Hewer, Ekkehard
AU  - Hewer E
AD  - Department of Pathology, University of Bern, 3010 Bern, Switzerland.
FAU - Zitterbart, Karel
AU  - Zitterbart K
AD  - Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno
      and Masaryk University, 61300 Brno, Czech Republic; Regional Centre for Applied
      Molecular Oncology, Masaryk Memorial Cancer Institute, 65653 Brno, Czech
      Republic.
FAU - Gilbert, Mark
AU  - Gilbert M
AD  - Division of Cancer Medicine, Department of Neuro-Oncology, The University of
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Armstrong, Terri S
AU  - Armstrong TS
AD  - Division of Cancer Medicine, Department of Neuro-Oncology, The University of
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Family
      Health, University of Texas Health Science Center-SON, Houston, TX 77030, USA.
FAU - Gupta, Nalin
AU  - Gupta N
AD  - Department of Neurological Surgery, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Allen, Jeffrey C
AU  - Allen JC
AD  - Departments of Pediatrics and Neurology, NYU Langone Medical Center, New York, NY
      10016, USA.
FAU - Karajannis, Matthias A
AU  - Karajannis MA
AD  - Division of Pediatric Hematology and Oncology, Departments of Pediatrics and
      Otolaryngology, NYU Langone Medical Center, New York, NY 10016, USA.
FAU - Zagzag, David
AU  - Zagzag D
AD  - Department of Pathology, NYU Langone Medical Center, New York, NY 10016, USA.
FAU - Hasselblatt, Martin
AU  - Hasselblatt M
AD  - Institute for Neuropathology, University Hospital Munster, 48149 Munster,
      Germany.
FAU - Kulozik, Andreas E
AU  - Kulozik AE
AD  - Department of Pediatric Oncology, Hematology and Immunology, University Hospital,
      69120 Heidelberg, Germany.
FAU - Witt, Olaf
AU  - Witt O
AD  - Department of Pediatric Oncology, Hematology and Immunology, University Hospital,
      69120 Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German
      Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Collins, V Peter
AU  - Collins VP
AD  - Department of Pathology, University of Cambridge, Cambridge CB2 1TN, UK.
FAU - von Hoff, Katja
AU  - von Hoff K
AD  - Department of Pediatric Hematology and Oncology, University Medical Center
      Hamburg-Eppendorf, 20246 Hamburg, Germany.
FAU - Rutkowski, Stefan
AU  - Rutkowski S
AD  - Department of Pediatric Hematology and Oncology, University Medical Center
      Hamburg-Eppendorf, 20246 Hamburg, Germany.
FAU - Pietsch, Torsten
AU  - Pietsch T
AD  - Department of Neuropathology, University of Bonn, 53127 Bonn, Germany.
FAU - Bader, Gary
AU  - Bader G
AD  - The Donnelly Center, University of Toronto, Toronto, ON M5S 3E1, Canada.
FAU - Yaspo, Marie-Laure
AU  - Yaspo ML
AD  - Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics,
      14195 Berlin, Germany.
FAU - von Deimling, Andreas
AU  - von Deimling A
AD  - Department of Neuropathology, University of Heidelberg, 69120 Heidelberg,
      Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center 
      (DKFZ), 69120 Heidelberg, Germany.
FAU - Lichter, Peter
AU  - Lichter P
AD  - German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; Division of Molecular
      Genetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Division of Neurosurgery, Arthur & Sonia Labatt Brain Tumour Research Centre, The
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Gilbertson, Richard
AU  - Gilbertson R
AD  - Department of Developmental Neurobiology, St Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Ellison, David W
AU  - Ellison DW
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Aldape, Kenneth
AU  - Aldape K
AD  - Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5G 1L7,
      Canada.
FAU - Korshunov, Andrey
AU  - Korshunov A
AD  - Department of Neuropathology, University of Heidelberg, 69120 Heidelberg,
      Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center 
      (DKFZ), 69120 Heidelberg, Germany.
FAU - Kool, Marcel
AU  - Kool M
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany. Electronic address: m.kool@dkfz.de.
FAU - Pfister, Stefan M
AU  - Pfister SM
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology,
      University Hospital, 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 
      69120 Heidelberg, Germany. Electronic address: s.pfister@dkfz.de.
LA  - eng
SI  - GEO/GSE64415
SI  - GEO/GSE65362
GR  - UL1 TR001445/TR/NCATS NIH HHS/United States
GR  - R01 CA129541/CA/NCI NIH HHS/United States
GR  - P30 CA016087/CA/NCI NIH HHS/United States
GR  - UL 1 TR000038/TR/NCATS NIH HHS/United States
GR  - R01 CA121941/CA/NCI NIH HHS/United States
GR  - P30CA016087/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Phosphoproteins)
RN  - 0 (YAP1 (Yes-associated) protein, human)
SB  - IM
CIN - Cancer Cell. 2015 May 11;27(5):613-5. PMID: 25965568
MH  - Adaptor Proteins, Signal Transducing/genetics
MH  - Adolescent
MH  - Adult
MH  - *Age Factors
MH  - Aged
MH  - Central Nervous System Neoplasms/classification/genetics/*pathology
MH  - Child
MH  - Child, Preschool
MH  - DNA Methylation
MH  - Ependymoma/classification/genetics/*pathology
MH  - Female
MH  - Gene Dosage
MH  - Gene Expression Profiling
MH  - Gene Fusion
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Phosphoproteins/genetics
MH  - Transcription, Genetic
MH  - Young Adult
PMC - PMC4712639
MID - NIHMS745680
EDAT- 2015/05/13 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/13 06:00
PHST- 2014/12/24 00:00 [received]
PHST- 2015/02/26 00:00 [revised]
PHST- 2015/04/08 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00135-X [pii]
AID - 10.1016/j.ccell.2015.04.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):728-43. doi: 10.1016/j.ccell.2015.04.002.

PMID- 25965574
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus
      Carcinoma Oncogenes.
PG  - 712-27
LID - 10.1016/j.ccell.2015.04.005 [doi]
LID - S1535-6108(15)00138-5 [pii]
AB  - Choroid plexus carcinomas (CPCs) are poorly understood and frequently lethal
      brain tumors with few treatment options. Using a mouse model of the disease and a
      large cohort of human CPCs, we performed a cross-species, genome-wide search for 
      oncogenes within syntenic regions of chromosome gain. TAF12, NFYC, and RAD54L
      co-located on human chromosome 1p32-35.3 and mouse chromosome 4qD1-D3 were
      identified as oncogenes that are gained in tumors in both species and required
      for disease initiation and progression. TAF12 and NFYC are transcription factors 
      that regulate the epigenome, whereas RAD54L plays a central role in DNA repair.
      Our data identify a group of concurrently gained oncogenes that cooperate in the 
      formation of CPC and reveal potential avenues for therapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Tong, Yiai
AU  - Tong Y
AD  - Department of Developmental Neurobiology, St Jude Children's Research Hospital,
      262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Merino, Diana
AU  - Merino D
AD  - Genetics and Genome Biology Program, The Hospital for Sick Children, Department
      of Medical Biophysics, University of Toronto, Toronto, ON M5G 1X8, Canada.
FAU - Nimmervoll, Birgit
AU  - Nimmervoll B
AD  - Department of Developmental Neurobiology, St Jude Children's Research Hospital,
      262 Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Gupta, Kirti
AU  - Gupta K
AD  - Department of Pathology, St Jude Children's Research Hospital, 262 Danny Thomas
      Place, Memphis, TN 38105, USA.
FAU - Wang, Yong-Dong
AU  - Wang YD
AD  - Department of Computational Biology, St Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Finkelstein, David
AU  - Finkelstein D
AD  - Department of Computational Biology, St Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Dalton, James
AU  - Dalton J
AD  - Department of Pathology, St Jude Children's Research Hospital, 262 Danny Thomas
      Place, Memphis, TN 38105, USA.
FAU - Ellison, David W
AU  - Ellison DW
AD  - Department of Pathology, St Jude Children's Research Hospital, 262 Danny Thomas
      Place, Memphis, TN 38105, USA.
FAU - Ma, Xiaotu
AU  - Ma X
AD  - Department of Computational Biology, St Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Zhang, Jinghui
AU  - Zhang J
AD  - Department of Computational Biology, St Jude Children's Research Hospital, 262
      Danny Thomas Place, Memphis, TN 38105, USA.
FAU - Malkin, David
AU  - Malkin D
AD  - Genetics and Genome Biology Program, The Hospital for Sick Children, Department
      of Medical Biophysics, University of Toronto, Toronto, ON M5G 1X8, Canada;
      Division of Hematology/Oncology, The Hospital for Sick Children, Department of
      Medical Biophysics, University of Toronto, Toronto, ON M5G 1X8, Canada.
FAU - Gilbertson, Richard J
AU  - Gilbertson RJ
AD  - Department of Developmental Neurobiology, St Jude Children's Research Hospital,
      262 Danny Thomas Place, Memphis, TN 38105, USA; Department of Oncology, St Jude
      Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
      Electronic address: richard.gilbertson@stjude.org.
LA  - eng
SI  - GEO/GSE60899
GR  - R01 CA129541/CA/NCI NIH HHS/United States
GR  - R01CA129541/CA/NCI NIH HHS/United States
GR  - P01CA96832/CA/NCI NIH HHS/United States
GR  - P30CA021765/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - P01 CA096832/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (CCAAT-Binding Factor)
RN  - 0 (DNA Primers)
RN  - 0 (NFYC protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RAD54L protein, human)
RN  - 0 (TAF12 protein, human)
RN  - 0 (TATA-Binding Protein Associated Factors)
RN  - EC 3.6.4.- (DNA Helicases)
RN  - Choroid Plexus Carcinoma
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - CCAAT-Binding Factor/*genetics
MH  - Carcinoma/*genetics/pathology
MH  - Cell Proliferation/genetics
MH  - Choroid Plexus Neoplasms/*genetics/pathology
MH  - Chromosome Mapping
MH  - DNA Helicases/*genetics
MH  - DNA Primers
MH  - *Genomics
MH  - Humans
MH  - Mice
MH  - Nuclear Proteins/*genetics
MH  - Oligonucleotide Array Sequence Analysis
MH  - *Oncogenes
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Species Specificity
MH  - TATA-Binding Protein Associated Factors/*genetics
PMC - PMC4458854
MID - NIHMS686190
EDAT- 2015/05/13 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/13 06:00
PHST- 2014/09/19 00:00 [received]
PHST- 2014/11/16 00:00 [revised]
PHST- 2015/04/10 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00138-5 [pii]
AID - 10.1016/j.ccell.2015.04.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):712-27. doi: 10.1016/j.ccell.2015.04.005.

PMID- 25965573
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Translational Activation of HIF1alpha by YB-1 Promotes Sarcoma Metastasis.
PG  - 682-97
LID - 10.1016/j.ccell.2015.04.003 [doi]
LID - S1535-6108(15)00136-1 [pii]
AB  - Metastatic dissemination is the leading cause of death in cancer patients, which 
      is particularly evident for high-risk sarcomas such as Ewing sarcoma,
      osteosarcoma, and rhabdomyosarcoma. Previous research identified a crucial role
      for YB-1 in the epithelial-to-mesenchymal transition (EMT) and metastasis of
      epithelial malignancies. Based on clinical data and two distinct animal models,
      we now report that YB-1 is also a major metastatic driver in high-risk sarcomas. 
      Our data establish YB-1 as a critical regulator of hypoxia-inducible factor
      1alpha (HIF1alpha) expression in sarcoma cells. YB-1 enhances HIF1alpha protein
      expression by directly binding to and activating translation of HIF1A messages.
      This leads to HIF1alpha-mediated sarcoma cell invasion and enhanced metastatic
      capacity in vivo, highlighting a translationally regulated YB-1-HIF1alpha axis in
      sarcoma metastasis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - El-Naggar, Amal M
AU  - El-Naggar AM
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, BC V6T 2B5, Canada; Department of Molecular Oncology, British Columbia
      Cancer Research Center, Vancouver, BC V5Z 1L3, Canada.
FAU - Veinotte, Chansey J
AU  - Veinotte CJ
AD  - Department of Pediatrics, IWK Health Centre, Halifax, NS B3K 6R8, Canada.
FAU - Cheng, Hongwei
AU  - Cheng H
AD  - Department of Urologic Sciences, University of British Columbia, Vancouver, BC
      V5Z 1M9, Canada.
FAU - Grunewald, Thomas G P
AU  - Grunewald TG
AD  - Laboratory for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich,
      Thalkirchner Strasse 36, 80337 Munich, Germany.
FAU - Negri, Gian Luca
AU  - Negri GL
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, BC V6T 2B5, Canada; Department of Molecular Oncology, British Columbia
      Cancer Research Center, Vancouver, BC V5Z 1L3, Canada.
FAU - Somasekharan, Syam Prakash
AU  - Somasekharan SP
AD  - Department of Molecular Oncology, British Columbia Cancer Research Center,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Corkery, Dale P
AU  - Corkery DP
AD  - Department of Pediatrics, IWK Health Centre, Halifax, NS B3K 6R8, Canada.
FAU - Tirode, Franck
AU  - Tirode F
AD  - INSERM U830, Laboratoire de genetique et biologie des cancers, Institut Curie,
      75248 Paris, France.
FAU - Mathers, Joan
AU  - Mathers J
AD  - Department of Molecular Oncology, British Columbia Cancer Research Center,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Khan, Debjit
AU  - Khan D
AD  - Department of Molecular Oncology, British Columbia Cancer Research Center,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Kyle, Alastair H
AU  - Kyle AH
AD  - Department of Integrative Oncology, Radiation Biology Unit, British Columbia
      Cancer Research Center, Vancouver, BC V5Z 1L3, Canada.
FAU - Baker, Jennifer H
AU  - Baker JH
AD  - Department of Integrative Oncology, Radiation Biology Unit, British Columbia
      Cancer Research Center, Vancouver, BC V5Z 1L3, Canada.
FAU - LePard, Nancy E
AU  - LePard NE
AD  - Department of Integrative Oncology, Radiation Biology Unit, British Columbia
      Cancer Research Center, Vancouver, BC V5Z 1L3, Canada.
FAU - McKinney, Steven
AU  - McKinney S
AD  - Department of Molecular Oncology, British Columbia Cancer Research Center,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Hajee, Shamil
AU  - Hajee S
AD  - Department of Molecular Oncology, British Columbia Cancer Research Center,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Bosiljcic, Momir
AU  - Bosiljcic M
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, BC V6T 2B5, Canada; Department of Integrative Oncology, Radiation
      Biology Unit, British Columbia Cancer Research Center, Vancouver, BC V5Z 1L3,
      Canada.
FAU - Leprivier, Gabriel
AU  - Leprivier G
AD  - Department of Molecular Oncology, British Columbia Cancer Research Center,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Tognon, Cristina E
AU  - Tognon CE
AD  - Department of Molecular Oncology, British Columbia Cancer Research Center,
      Vancouver, BC V5Z 1L3, Canada.
FAU - Minchinton, Andrew I
AU  - Minchinton AI
AD  - Department of Integrative Oncology, Radiation Biology Unit, British Columbia
      Cancer Research Center, Vancouver, BC V5Z 1L3, Canada.
FAU - Bennewith, Kevin L
AU  - Bennewith KL
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, BC V6T 2B5, Canada; Department of Integrative Oncology, Radiation
      Biology Unit, British Columbia Cancer Research Center, Vancouver, BC V5Z 1L3,
      Canada.
FAU - Delattre, Olivier
AU  - Delattre O
AD  - INSERM U830, Laboratoire de genetique et biologie des cancers, Institut Curie,
      75248 Paris, France.
FAU - Wang, Yuzhuo
AU  - Wang Y
AD  - Department of Urologic Sciences, University of British Columbia, Vancouver, BC
      V5Z 1M9, Canada.
FAU - Dellaire, Graham
AU  - Dellaire G
AD  - Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
FAU - Berman, Jason N
AU  - Berman JN
AD  - Department of Pediatrics, IWK Health Centre, Halifax, NS B3K 6R8, Canada;
      Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada;
      Department of Pediatrics, Dalhousie University, Halifax, NS B3H 4R2, Canada.
FAU - Sorensen, Poul H
AU  - Sorensen PH
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, BC V6T 2B5, Canada; Department of Molecular Oncology, British Columbia
      Cancer Research Center, Vancouver, BC V5Z 1L3, Canada. Electronic address:
      psor@mail.ubc.ca.
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Y-Box-Binding Protein 1)
RN  - 0 (YBX1 protein, human)
RN  - EC 2.3.2.27 (Von Hippel-Lindau Tumor Suppressor Protein)
RN  - EC 6.3.2.- (VHL protein, human)
SB  - IM
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*physiology
MH  - Neoplasm Invasiveness
MH  - *Neoplasm Metastasis
MH  - *Protein Biosynthesis
MH  - Sarcoma/genetics/*pathology
MH  - Von Hippel-Lindau Tumor Suppressor Protein/physiology
MH  - Y-Box-Binding Protein 1/*physiology
EDAT- 2015/05/13 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/13 06:00
PHST- 2014/03/07 00:00 [received]
PHST- 2015/02/28 00:00 [revised]
PHST- 2015/04/10 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00136-1 [pii]
AID - 10.1016/j.ccell.2015.04.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):682-97. doi: 10.1016/j.ccell.2015.04.003.

PMID- 25965572
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Treatment of chronic myelogenous leukemia by blocking cytokine alterations found 
      in normal stem and progenitor cells.
PG  - 671-81
LID - 10.1016/j.ccell.2015.04.004 [doi]
LID - S1535-6108(15)00137-3 [pii]
AB  - Leukemic cells disrupt normal patterns of blood cell formation, but little is
      understood about the mechanism. We investigated whether leukemic cells alter
      functions of normal hematopoietic stem and progenitor cells. Exposure to chronic 
      myelogenous leukemia (CML) caused normal mouse hematopoietic progenitor cells to 
      divide more readily, altered their differentiation, and reduced their
      reconstitution and self-renewal potential. Interestingly, the normal bystander
      cells acquired gene expression patterns resembling their malignant counterparts. 
      Therefore, much of the leukemia signature is mediated by extrinsic factors.
      Indeed, IL-6 was responsible for most of these changes. Compatible results were
      obtained when human CML were cultured with normal human hematopoietic progenitor 
      cells. Furthermore, neutralization of IL-6 prevented these changes and treated
      the disease.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Welner, Robert S
AU  - Welner RS
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Amabile, Giovanni
AU  - Amabile G
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Bararia, Deepak
AU  - Bararia D
AD  - Cancer Science Institute, National University of Singapore, Singapore 119077,
      Singapore.
FAU - Czibere, Akos
AU  - Czibere A
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Yang, Henry
AU  - Yang H
AD  - Cancer Science Institute, National University of Singapore, Singapore 119077,
      Singapore.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Pontes, Lorena Lobo De Figueiredo
AU  - Pontes LL
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Ye, Min
AU  - Ye M
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Levantini, Elena
AU  - Levantini E
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA;
      Institute of Biomedical Technologies, National Research Council (CNR), Pisa
      56124, Italy.
FAU - Di Ruscio, Annalisa
AU  - Di Ruscio A
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Martinelli, Giovanni
AU  - Martinelli G
AD  - Department of Specialized Medicine, University of Bologna, Bologna 40126, Italy.
FAU - Tenen, Daniel G
AU  - Tenen DG
AD  - Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA;
      Cancer Science Institute, National University of Singapore, Singapore 119077,
      Singapore. Electronic address: daniel.tenen@nus.edu.sg.
LA  - eng
SI  - GEO/GSE59337
GR  - CA66996/CA/NCI NIH HHS/United States
GR  - P01 CA066996/CA/NCI NIH HHS/United States
GR  - HL112719/HL/NHLBI NIH HHS/United States
GR  - R01 DK103858/DK/NIDDK NIH HHS/United States
GR  - 1K99CA188595-01/CA/NCI NIH HHS/United States
GR  - K99 CA188595/CA/NCI NIH HHS/United States
GR  - R01 HL112719/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-6)
SB  - IM
CIN - Cancer Cell. 2015 May 11;27(5):611-3. PMID: 25965567
MH  - Animals
MH  - Coculture Techniques
MH  - Cytokines/*antagonists & inhibitors/metabolism
MH  - Hematopoietic Stem Cells/*cytology
MH  - Humans
MH  - Interleukin-6/pharmacology/therapeutic use
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
MH  - Mice
MH  - Tumor Cells, Cultured
PMC - PMC4447336
MID - NIHMS684935
EDAT- 2015/05/13 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/13 06:00
PHST- 2014/12/04 00:00 [received]
PHST- 2015/02/24 00:00 [revised]
PHST- 2015/04/10 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00137-3 [pii]
AID - 10.1016/j.ccell.2015.04.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):671-81. doi: 10.1016/j.ccell.2015.04.004.

PMID- 25965571
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Telomere dysfunction drives aberrant hematopoietic differentiation and
      myelodysplastic syndrome.
PG  - 644-57
LID - 10.1016/j.ccell.2015.04.007 [doi]
LID - S1535-6108(15)00140-3 [pii]
AB  - Myelodysplastic syndrome (MDS) risk correlates with advancing age,
      therapy-induced DNA damage, and/or shorter telomeres, but whether telomere
      erosion directly induces MDS is unknown. Here, we provide the genetic evidence
      that telomere dysfunction-induced DNA damage drives classical MDS phenotypes and 
      alters common myeloid progenitor (CMP) differentiation by repressing the
      expression of mRNA splicing/processing genes, including SRSF2. RNA-seq analyses
      of telomere dysfunctional CMP identified aberrantly spliced transcripts linked to
      pathways relevant to MDS pathogenesis such as genome stability, DNA repair,
      chromatin remodeling, and histone modification, which are also enriched in mouse 
      CMP haploinsufficient for SRSF2 and in CD34(+) CMML patient cells harboring SRSF2
      mutation. Together, our studies establish an intimate link across telomere
      biology, aberrant RNA splicing, and myeloid progenitor differentiation.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Colla, Simona
AU  - Colla S
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA. Electronic address: scolla@mdanderson.org.
FAU - Ong, Derrick Sek Tong
AU  - Ong DS
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ogoti, Yamini
AU  - Ogoti Y
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Marchesini, Matteo
AU  - Marchesini M
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Mistry, Nipun A
AU  - Mistry NA
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Clise-Dwyer, Karen
AU  - Clise-Dwyer K
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ang, Sonny A
AU  - Ang SA
AD  - Department of Pediatric Research, University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Storti, Paola
AU  - Storti P
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA; Hematology, Department of Clinical and Experimental
      Medicine, University of Parma, 43126 Parma, Italy.
FAU - Viale, Andrea
AU  - Viale A
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Giuliani, Nicola
AU  - Giuliani N
AD  - Hematology, Department of Clinical and Experimental Medicine, University of
      Parma, 43126 Parma, Italy.
FAU - Ruisaard, Kathryn
AU  - Ruisaard K
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas
      MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ganan Gomez, Irene
AU  - Ganan Gomez I
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Bristow, Christopher A
AU  - Bristow CA
AD  - Institute for Applied Cancer Science, University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Estecio, Marcos
AU  - Estecio M
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA; Department of Molecular Carcinogenesis, University of Texas MD
      Anderson Cancer Center, Smithville, TX 78957, USA.
FAU - Weksberg, David C
AU  - Weksberg DC
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ho, Yan Wing
AU  - Ho YW
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Hu, Baoli
AU  - Hu B
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Genovese, Giannicola
AU  - Genovese G
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Pettazzoni, Piergiorgio
AU  - Pettazzoni P
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Multani, Asha S
AU  - Multani AS
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Jiang, Shan
AU  - Jiang S
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Hua, Sujun
AU  - Hua S
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Ryan, Michael C
AU  - Ryan MC
AD  - In Silico Solutions, Falls Church, VA 22043, USA.
FAU - Carugo, Alessandro
AU  - Carugo A
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Nezi, Luigi
AU  - Nezi L
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Wei, Yue
AU  - Wei Y
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Yang, Hui
AU  - Yang H
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - D'Anca, Marianna
AU  - D'Anca M
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Gaddis, Sarah
AU  - Gaddis S
AD  - Department of Molecular Carcinogenesis, University of Texas MD Anderson Cancer
      Center, Smithville, TX 78957, USA.
FAU - Gong, Ting
AU  - Gong T
AD  - Department of Molecular Carcinogenesis, University of Texas MD Anderson Cancer
      Center, Smithville, TX 78957, USA.
FAU - Horner, James W
AU  - Horner JW
AD  - Institute for Applied Cancer Science, University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Heffernan, Timothy P
AU  - Heffernan TP
AD  - Institute for Applied Cancer Science, University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Jones, Philip
AU  - Jones P
AD  - Institute for Applied Cancer Science, University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Cooper, Laurence J N
AU  - Cooper LJ
AD  - Department of Pediatric Research, University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Bioinformatics and Computational Biology, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kantarjian, Hagop
AU  - Kantarjian H
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Wang, Y Alan
AU  - Wang YA
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Chin, Lynda
AU  - Chin L
AD  - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Bueso-Ramos, Carlos
AU  - Bueso-Ramos C
AD  - Department of Hematopathology, University of Texas MD Cancer Center, Houston, TX 
      77030, USA.
FAU - Garcia-Manero, Guillermo
AU  - Garcia-Manero G
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - DePinho, Ronald A
AU  - DePinho RA
AD  - Department of Cancer Biology, University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA. Electronic address: rdepinho@mdanderson.org.
LA  - eng
SI  - GEO/GSE62393
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - CA143883/CA/NCI NIH HHS/United States
GR  - P30 CA16672/CA/NCI NIH HHS/United States
GR  - R01 CA084628/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Ribonucleoproteins)
RN  - 147153-65-9 (SRSF2 protein, human)
RN  - 170974-22-8 (Serine-Arginine Splicing Factors)
SB  - IM
CIN - Cancer Cell. 2015 May 11;27(5):607-9. PMID: 25965565
MH  - Animals
MH  - Cell Differentiation/*genetics
MH  - Haploinsufficiency
MH  - Hematopoiesis/*genetics
MH  - Humans
MH  - Mice
MH  - Myelodysplastic Syndromes/*genetics/pathology
MH  - Nuclear Proteins/genetics
MH  - RNA Splicing
MH  - Ribonucleoproteins/genetics
MH  - Serine-Arginine Splicing Factors
MH  - *Telomere
PMC - PMC4596059
MID - NIHMS684850
EDAT- 2015/05/13 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/13 06:00
PHST- 2014/12/23 00:00 [received]
PHST- 2015/01/31 00:00 [revised]
PHST- 2015/04/13 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00140-3 [pii]
AID - 10.1016/j.ccell.2015.04.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):644-57. doi: 10.1016/j.ccell.2015.04.007.

PMID- 25965570
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
PG  - 631-43
LID - 10.1016/j.ccell.2015.04.008 [doi]
LID - S1535-6108(15)00141-5 [pii]
AB  - Heterozygous somatic mutations in the spliceosome gene U2AF1 occur in
      approximately 11% of patients with myelodysplastic syndromes (MDS), the most
      common adult myeloid malignancy. It is unclear how these mutations contribute to 
      disease. We examined in vivo hematopoietic consequences of the most common U2AF1 
      mutation using a doxycycline-inducible transgenic mouse model. Mice expressing
      mutant U2AF1(S34F) display altered hematopoiesis and changes in pre-mRNA splicing
      in hematopoietic progenitor cells by whole transcriptome analysis (RNA-seq).
      Integration with human RNA-seq datasets determined that common mutant
      U2AF1-induced splicing alterations are enriched in RNA processing genes,
      ribosomal genes, and recurrently mutated MDS and acute myeloid
      leukemia-associated genes. These findings support the hypothesis that mutant
      U2AF1 alters downstream gene isoform expression, thereby contributing to abnormal
      hematopoiesis in patients with MDS.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Shirai, Cara Lunn
AU  - Shirai CL
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Ley, James N
AU  - Ley JN
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - White, Brian S
AU  - White BS
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA; The Genome Institute, Washington University, St. Louis, MO 63110, 
      USA.
FAU - Kim, Sanghyun
AU  - Kim S
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Tibbitts, Justin
AU  - Tibbitts J
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Shao, Jin
AU  - Shao J
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Ndonwi, Matthew
AU  - Ndonwi M
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Wadugu, Brian
AU  - Wadugu B
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Duncavage, Eric J
AU  - Duncavage EJ
AD  - Department of Pathology and Immunology, Washington University, St. Louis, MO
      63110, USA.
FAU - Okeyo-Owuor, Theresa
AU  - Okeyo-Owuor T
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Liu, Tuoen
AU  - Liu T
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA.
FAU - Griffith, Malachi
AU  - Griffith M
AD  - The Genome Institute, Washington University, St. Louis, MO 63110, USA.
FAU - McGrath, Sean
AU  - McGrath S
AD  - The Genome Institute, Washington University, St. Louis, MO 63110, USA.
FAU - Magrini, Vincent
AU  - Magrini V
AD  - The Genome Institute, Washington University, St. Louis, MO 63110, USA.
FAU - Fulton, Robert S
AU  - Fulton RS
AD  - The Genome Institute, Washington University, St. Louis, MO 63110, USA.
FAU - Fronick, Catrina
AU  - Fronick C
AD  - The Genome Institute, Washington University, St. Louis, MO 63110, USA.
FAU - O'Laughlin, Michelle
AU  - O'Laughlin M
AD  - The Genome Institute, Washington University, St. Louis, MO 63110, USA.
FAU - Graubert, Timothy A
AU  - Graubert TA
AD  - Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USA.
FAU - Walter, Matthew J
AU  - Walter MJ
AD  - Division of Oncology, Department of Medicine, Washington University, St. Louis,
      MO 63110, USA. Electronic address: mjwalter@dom.wustl.edu.
LA  - eng
SI  - GEO/GSE66793
GR  - T32 CA113275/CA/NCI NIH HHS/United States
GR  - P50CA171963/CA/NCI NIH HHS/United States
GR  - P50 CA171963/CA/NCI NIH HHS/United States
GR  - T32HL007088/HL/NHLBI NIH HHS/United States
GR  - K12 CA167540/CA/NCI NIH HHS/United States
GR  - P30 CA091842/CA/NCI NIH HHS/United States
GR  - P30CA91842/CA/NCI NIH HHS/United States
GR  - UL1 TR000448/TR/NCATS NIH HHS/United States
GR  - K12CA167540/CA/NCI NIH HHS/United States
GR  - T32 HL007088/HL/NHLBI NIH HHS/United States
GR  - K12 HL087107/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Ribonucleoproteins)
RN  - 0 (Splicing Factor U2AF)
RN  - 0 (U2AF1 protein, human)
SB  - IM
CIN - Cancer Cell. 2015 May 11;27(5):607-9. PMID: 25965565
MH  - Animals
MH  - Hematopoiesis/*genetics
MH  - Humans
MH  - Leukemia, Myeloid, Acute/genetics
MH  - Mice, Transgenic
MH  - *Mutation
MH  - Myelodysplastic Syndromes/genetics
MH  - Nuclear Proteins/*genetics
MH  - RNA Precursors/*genetics
MH  - RNA Splicing/*genetics
MH  - RNA, Messenger/*genetics
MH  - Ribonucleoproteins/*genetics
MH  - Splicing Factor U2AF
PMC - PMC4430854
MID - NIHMS682360
EDAT- 2015/05/13 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/13 06:00
PHST- 2014/12/24 00:00 [received]
PHST- 2015/03/16 00:00 [revised]
PHST- 2015/04/13 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00141-5 [pii]
AID - 10.1016/j.ccell.2015.04.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):631-43. doi: 10.1016/j.ccell.2015.04.008.

PMID- 25965569
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon
      Recognition.
PG  - 617-30
LID - 10.1016/j.ccell.2015.04.006 [doi]
LID - S1535-6108(15)00139-7 [pii]
AB  - Mutations affecting spliceosomal proteins are the most common mutations in
      patients with myelodysplastic syndromes (MDS), but their role in MDS pathogenesis
      has not been delineated. Here we report that mutations affecting the splicing
      factor SRSF2 directly impair hematopoietic differentiation in vivo, which is not 
      due to SRSF2 loss of function. By contrast, SRSF2 mutations alter SRSF2's normal 
      sequence-specific RNA binding activity, thereby altering the recognition of
      specific exonic splicing enhancer motifs to drive recurrent mis-splicing of key
      hematopoietic regulators. This includes SRSF2 mutation-dependent splicing of
      EZH2, which triggers nonsense-mediated decay, which, in turn, results in impaired
      hematopoietic differentiation. These data provide a mechanistic link between a
      mutant spliceosomal protein, alterations in the splicing of key regulators, and
      impaired hematopoiesis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Kim, Eunhee
AU  - Kim E
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ilagan, Janine O
AU  - Ilagan JO
AD  - Computational Biology Program, Public Health Sciences Division, Fred Hutchinson
      Cancer Research Center, Seattle, WA 98109, USA; Basic Sciences Division, Fred
      Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
FAU - Liang, Yang
AU  - Liang Y
AD  - Hematology, Yale Comprehensive Cancer Center and Department of Internal Medicine,
      Yale University School of Medicine, New Haven, CT 06520, USA.
FAU - Daubner, Gerrit M
AU  - Daubner GM
AD  - Institute for Molecular Biology and Biophysics, ETH, 8093 Zurich, Switzerland.
FAU - Lee, Stanley C-W
AU  - Lee SC
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ramakrishnan, Aravind
AU  - Ramakrishnan A
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Division of Medical Oncology, School of Medicine, University of
      Washington, Seattle, WA 98109, USA.
FAU - Li, Yue
AU  - Li Y
AD  - Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, 
      CT 06520, USA.
FAU - Chung, Young Rock
AU  - Chung YR
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Micol, Jean-Baptiste
AU  - Micol JB
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Murphy, Michele E
AU  - Murphy ME
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA.
FAU - Cho, Hana
AU  - Cho H
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Kim, Min-Kyung
AU  - Kim MK
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Zebari, Ahmad S
AU  - Zebari AS
AD  - Computational Biology Program, Public Health Sciences Division, Fred Hutchinson
      Cancer Research Center, Seattle, WA 98109, USA; Basic Sciences Division, Fred
      Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
FAU - Aumann, Shlomzion
AU  - Aumann S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Park, Christopher Y
AU  - Park CY
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Department of Pathology, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Buonamici, Silvia
AU  - Buonamici S
AD  - H3 Biomedicine, Cambridge, MA 03129, USA.
FAU - Smith, Peter G
AU  - Smith PG
AD  - H3 Biomedicine, Cambridge, MA 03129, USA.
FAU - Deeg, H Joachim
AU  - Deeg HJ
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
      98109, USA; Division of Medical Oncology, School of Medicine, University of
      Washington, Seattle, WA 98109, USA.
FAU - Lobry, Camille
AU  - Lobry C
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1009,
      Institut Gustave Roussy, 94805 Villejuif, France; Universite Paris-Sud, 91400
      Orsay, France.
FAU - Aifantis, Iannis
AU  - Aifantis I
AD  - Howard Hughes Medical Institute and Department of Pathology, New York University 
      School of Medicine, New York, NY 10016, USA.
FAU - Modis, Yorgo
AU  - Modis Y
AD  - Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, 
      CT 06520, USA; Department of Medicine, University of Cambridge, MRC Laboratory of
      Molecular Biology, Cambridge CB2 0QH, UK.
FAU - Allain, Frederic H-T
AU  - Allain FH
AD  - Institute for Molecular Biology and Biophysics, ETH, 8093 Zurich, Switzerland.
FAU - Halene, Stephanie
AU  - Halene S
AD  - Hematology, Yale Comprehensive Cancer Center and Department of Internal Medicine,
      Yale University School of Medicine, New Haven, CT 06520, USA.
FAU - Bradley, Robert K
AU  - Bradley RK
AD  - Computational Biology Program, Public Health Sciences Division, Fred Hutchinson
      Cancer Research Center, Seattle, WA 98109, USA; Basic Sciences Division, Fred
      Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address:
      rbradley@fhcrc.org.
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Leukemia Service, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA. Electronic address:
      abdelwao@mskcc.org.
LA  - eng
GR  - R25 CA020449/CA/NCI NIH HHS/United States
GR  - 15-0399/Worldwide Cancer Research/United Kingdom
GR  - P30 CA015704/CA/NCI NIH HHS/United States
GR  - K08 CA160647/CA/NCI NIH HHS/United States
GR  - R56 DK103854/DK/NIDDK NIH HHS/United States
GR  - 101908/Z/13/Z/Wellcome Trust/United Kingdom
GR  - P30 DK056465/DK/NIDDK NIH HHS/United States
GR  - R01 CA169784/CA/NCI NIH HHS/United States
GR  - T32 CA009657/CA/NCI NIH HHS/United States
GR  - U01 HL099993/HL/NHLBI NIH HHS/United States
GR  - P30 CA016359/CA/NCI NIH HHS/United States
GR  - R01 GM102869/GM/NIGMS NIH HHS/United States
GR  - 1K08CA160647-01/CA/NCI NIH HHS/United States
GR  - 101908/Wellcome Trust/United Kingdom
GR  - K08 DK082783/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Ribonucleoproteins)
RN  - 0 (Sfrs2 protein, mouse)
RN  - 170974-22-8 (Serine-Arginine Splicing Factors)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Ezh2 protein, mouse)
RN  - EC 2.1.1.43 (Polycomb Repressive Complex 2)
SB  - IM
CIN - Cancer Cell. 2015 May 11;27(5):607-9. PMID: 25965565
MH  - Animals
MH  - Enhancer of Zeste Homolog 2 Protein
MH  - *Exons
MH  - Gene Expression
MH  - Mice
MH  - Mice, Mutant Strains
MH  - *Mutation
MH  - Myelodysplastic Syndromes/*genetics
MH  - Nuclear Proteins/*genetics
MH  - Polycomb Repressive Complex 2/genetics/metabolism
MH  - Proteolysis
MH  - RNA Splicing
MH  - Ribonucleoproteins/*genetics
MH  - Serine-Arginine Splicing Factors
PMC - PMC4429920
MID - NIHMS680914
EDAT- 2015/05/13 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/13 06:00
PHST- 2014/12/02 00:00 [received]
PHST- 2015/02/19 00:00 [revised]
PHST- 2015/04/10 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00139-7 [pii]
AID - 10.1016/j.ccell.2015.04.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):617-30. doi: 10.1016/j.ccell.2015.04.006.

PMID- 25965568
OWN - NLM
STAT- MEDLINE
DCOM- 20150721
LR  - 20150513
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Defining the molecular landscape of ependymomas.
PG  - 613-5
LID - 10.1016/j.ccell.2015.04.015 [doi]
LID - S1535-6108(15)00148-8 [pii]
AB  - Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and 
      colleagues identify nine subgroups of ependymoma using DNA methylation profiles. 
      Two subgroups, predominately pediatric, are responsible for most of the
      mortality, with all others having nearly 100% overall survival after 5 years.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Archer, Tenley C
AU  - Archer TC
AD  - Department of Neurology, Boston Children's Hospital, Harvard Medical School,
      Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard,
      Harvard University, Cambridge, MA 02138, USA.
FAU - Pomeroy, Scott L
AU  - Pomeroy SL
AD  - Department of Neurology, Boston Children's Hospital, Harvard Medical School,
      Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard,
      Harvard University, Cambridge, MA 02138, USA. Electronic address:
      scott.pomeroy@childrens.harvard.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2015 May 11;27(5):728-43. PMID: 25965575
MH  - *Age Factors
MH  - Central Nervous System Neoplasms/*pathology
MH  - Ependymoma/*pathology
MH  - Female
MH  - Humans
MH  - Male
EDAT- 2015/05/13 06:00
MHDA- 2015/07/22 06:00
CRDT- 2015/05/13 06:00
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/22 06:00 [medline]
AID - S1535-6108(15)00148-8 [pii]
AID - 10.1016/j.ccell.2015.04.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):613-5. doi: 10.1016/j.ccell.2015.04.015.

PMID- 25965567
OWN - NLM
STAT- MEDLINE
DCOM- 20150721
LR  - 20150513
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Convert and conquer: the strategy of chronic myelogenous leukemic cells.
PG  - 611-3
LID - 10.1016/j.ccell.2015.04.012 [doi]
LID - S1535-6108(15)00145-2 [pii]
AB  - Emerging evidence is contributing to explain how leukemias disrupt normal blood
      cell production. In this issue of Cancer Cell, Welner and colleagues show that,
      during the development of chronic myeloid leukemia, mutated cells transform
      normal hematopoietic progenitors into "leukemic like" cells through IL-6
      secretion, proposing a new cellular target.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Mendez-Ferrer, Simon
AU  - Mendez-Ferrer S
AD  - Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones
      Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; Stem Cell Institute and 
      Department of Haematology, University of Cambridge and National Health Service
      Blood and Transplant, Cambridge Biomedical Campus, CB2 0PT Cambridge, UK.
      Electronic address: sm2116@cam.ac.uk.
FAU - Garcia-Fernandez, Maria
AU  - Garcia-Fernandez M
AD  - Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones
      Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain.
FAU - de Castillejo, Carlos L F
AU  - de Castillejo CL
AD  - Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones
      Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cytokines)
SB  - IM
CON - Cancer Cell. 2015 May 11;27(5):671-81. PMID: 25965572
MH  - Animals
MH  - Cytokines/*antagonists & inhibitors
MH  - Hematopoietic Stem Cells/*cytology
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
EDAT- 2015/05/13 06:00
MHDA- 2015/07/22 06:00
CRDT- 2015/05/13 06:00
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/22 06:00 [medline]
AID - S1535-6108(15)00145-2 [pii]
AID - 10.1016/j.ccell.2015.04.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):611-3. doi: 10.1016/j.ccell.2015.04.012.

PMID- 25965566
OWN - NLM
STAT- MEDLINE
DCOM- 20150721
LR  - 20150513
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Functionally relevant RNA helicase mutations in familial and sporadic myeloid
      malignancies.
PG  - 609-11
LID - 10.1016/j.ccell.2015.04.013 [doi]
LID - S1535-6108(15)00146-4 [pii]
AB  - In this issue of Cancer Cell, Polprasert and colleagues identified recurrent
      mutations in the DEAD/H-box RNA helicase gene DDX41 in familial and acquired
      cases of myelodsyplasia and acute myeloid leukemia. These mutations induce
      defects in RNA splicing and represent a new class of mutations in myeloid
      malignancies.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Antony-Debre, Ileana
AU  - Antony-Debre I
AD  - Department of Cell Biology and Department of Medicine (Oncology), Albert Einstein
      College of Medicine/Montefiore Medical Center, New York, NY 10461, USA.
FAU - Steidl, Ulrich
AU  - Steidl U
AD  - Department of Cell Biology and Department of Medicine (Oncology), Albert Einstein
      College of Medicine/Montefiore Medical Center, New York, NY 10461, USA.
      Electronic address: ulrich.steidl@einstein.yu.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 3.6.4.13 (DEAD-box RNA Helicases)
SB  - IM
CON - Cancer Cell. 2015 May 11;27(5):658-70. PMID: 25920683
MH  - Animals
MH  - DEAD-box RNA Helicases/*genetics
MH  - Female
MH  - *Germ-Line Mutation
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
EDAT- 2015/05/13 06:00
MHDA- 2015/07/22 06:00
CRDT- 2015/05/13 06:00
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/22 06:00 [medline]
AID - S1535-6108(15)00146-4 [pii]
AID - 10.1016/j.ccell.2015.04.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):609-11. doi: 10.1016/j.ccell.2015.04.013.

PMID- 25965565
OWN - NLM
STAT- MEDLINE
DCOM- 20150721
LR  - 20150513
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Charting the "Splice" Routes to MDS.
PG  - 607-9
LID - 10.1016/j.ccell.2015.04.016 [doi]
LID - S1535-6108(15)00149-X [pii]
AB  - Mutations in components of the 3' mRNA splicing machinery are found in almost 50%
      of myelodysplastic syndrome (MDS) cases. In this issue of Cancer Cell, Kim and
      colleagues, Colla and colleagues, and Shirai and colleagues report on the impact 
      of mutated or dysregulated splicing factors to hematopoiesis, mRNA splicing, and 
      MDS pathogenesis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Obeng, Esther A
AU  - Obeng EA
AD  - Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA;
      Dana-Farber Cancer Institute, Boston, MA 02115, USA; Division of
      Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
FAU - Ebert, Benjamin L
AU  - Ebert BL
AD  - Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA;
      Dana-Farber Cancer Institute, Boston, MA 02115, USA. Electronic address:
      bebert@partners.org.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Ribonucleoproteins)
SB  - IM
CON - Cancer Cell. 2015 May 11;27(5):617-30. PMID: 25965569
CON - Cancer Cell. 2015 May 11;27(5):644-57. PMID: 25965571
CON - Cancer Cell. 2015 May 11;27(5):631-43. PMID: 25965570
MH  - Animals
MH  - Cell Differentiation/*genetics
MH  - *Exons
MH  - Hematopoiesis/*genetics
MH  - Humans
MH  - *Mutation
MH  - Myelodysplastic Syndromes/*genetics
MH  - Nuclear Proteins/*genetics
MH  - RNA Precursors/*genetics
MH  - RNA Splicing/*genetics
MH  - RNA, Messenger/*genetics
MH  - Ribonucleoproteins/*genetics
MH  - *Telomere
EDAT- 2015/05/13 06:00
MHDA- 2015/07/22 06:00
CRDT- 2015/05/13 06:00
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/07/22 06:00 [medline]
AID - S1535-6108(15)00149-X [pii]
AID - 10.1016/j.ccell.2015.04.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):607-9. doi: 10.1016/j.ccell.2015.04.016.

PMID- 25936644
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung
      Cancer Plasticity and Therapeutic Response.
PG  - 698-711
LID - 10.1016/j.ccell.2015.04.001 [doi]
LID - S1535-6108(15)00134-8 [pii]
AB  - LKB1 regulates both cell growth and energy metabolism. It remains unclear how
      LKB1 inactivation coordinates tumor progression with metabolic adaptation in
      non-small cell lung cancer (NSCLC). Here in Kras(G12D);Lkb1(lox/lox) (KL) mouse
      model, we reveal differential reactive oxygen species (ROS) levels in lung
      adenocarcinoma (ADC) and squamous cell carcinoma (SCC). ROS can modulate
      ADC-to-SCC transdifferentiation (AST). Further, pentose phosphate pathway
      deregulation and impaired fatty acid oxidation collectively contribute to the
      redox imbalance and functionally affect AST. Similar tumor and redox
      heterogeneity also exist in human NSCLC with LKB1 inactivation. In preclinical
      trials toward metabolic stress, certain KL ADC can develop drug resistance
      through squamous transdifferentiation. This study uncovers critical redox control
      of tumor plasticity that may affect therapeutic response in NSCLC.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Li, Fuming
AU  - Li F
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Han, Xiangkun
AU  - Han X
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Li, Fei
AU  - Li F
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Wang, Rui
AU  - Wang R
AD  - Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
      200032, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China.
FAU - Gao, Yijun
AU  - Gao Y
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Wang, Xujun
AU  - Wang X
AD  - Department of Bioinformatics, School of Life Science and Technology, Tongji
      University, Shanghai 200092, China.
FAU - Fang, Zhaoyuan
AU  - Fang Z
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Zhang, Wenjing
AU  - Zhang W
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Yao, Shun
AU  - Yao S
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Tong, Xinyuan
AU  - Tong X
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Wang, Yuetong
AU  - Wang Y
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Feng, Yan
AU  - Feng Y
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China.
FAU - Sun, Yihua
AU  - Sun Y
AD  - Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
      200032, China.
FAU - Li, Yuan
AU  - Li Y
AD  - Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
      200032, China.
FAU - Wong, Kwok-Kin
AU  - Wong KK
AD  - Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Zhai, Qiwei
AU  - Zhai Q
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China.
FAU - Chen, Haiquan
AU  - Chen H
AD  - Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
      200032, China. Electronic address: hqchen1@yahoo.com.
FAU - Ji, Hongbin
AU  - Ji H
AD  - Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai 200031, China; Innovation Center for Cell Signaling Network, Institute
      of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai 200031, China. Electronic address:
      hbji@sibcb.ac.cn.
LA  - eng
GR  - R01 CA140594/CA/NCI NIH HHS/United States
GR  - R01 CA163896/CA/NCI NIH HHS/United States
GR  - R01 CA166480/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150430
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Reactive Oxygen Species)
RN  - EC 2.7.1.- (Stk11 protein, mouse)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism/pathology/therapy
MH  - Cell Differentiation
MH  - Disease Models, Animal
MH  - Humans
MH  - Lung Neoplasms/*metabolism/pathology/therapy
MH  - Mice
MH  - Oxidation-Reduction
MH  - Pentose Phosphate Pathway
MH  - Protein-Serine-Threonine Kinases/*antagonists & inhibitors/genetics
MH  - Reactive Oxygen Species/metabolism
PMC - PMC4746728
MID - NIHMS753242
EDAT- 2015/05/06 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/05/05 06:00
PHST- 2014/04/18 00:00 [received]
PHST- 2015/02/21 00:00 [revised]
PHST- 2015/04/06 00:00 [accepted]
PHST- 2015/05/05 06:00 [entrez]
PHST- 2015/05/06 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00134-8 [pii]
AID - 10.1016/j.ccell.2015.04.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):698-711. doi: 10.1016/j.ccell.2015.04.001. Epub
      2015 Apr 30.

PMID- 25920683
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20180222
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 5
DP  - 2015 May 11
TI  - Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.
PG  - 658-70
LID - 10.1016/j.ccell.2015.03.017 [doi]
LID - S1535-6108(15)00105-1 [pii]
AB  - Most cases of adult myeloid neoplasms are routinely assumed to be sporadic. Here,
      we describe an adult familial acute myeloid leukemia (AML) syndrome caused by
      germline mutations in the DEAD/H-box helicase gene DDX41. DDX41 was also found to
      be affected by somatic mutations in sporadic cases of myeloid neoplasms as well
      as in a biallelic fashion in 50% of patients with germline DDX41 mutations.
      Moreover, corresponding deletions on 5q35.3 present in 6% of cases led to
      haploinsufficient DDX41 expression. DDX41 lesions caused altered pre-mRNA
      splicing and RNA processing. DDX41 is exemplary of other RNA helicase genes also 
      affected by somatic mutations, suggesting that they constitute a family of tumor 
      suppressor genes.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Polprasert, Chantana
AU  - Polprasert C
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA; Department of Medicine, Chulalongkorn
      University, Bangkok 10330, Thailand.
FAU - Schulze, Isabell
AU  - Schulze I
AD  - Department of Hematology and Oncology, University of Halle, Halle 06108, Germany;
      Department of Hematology and Oncology, University of Muenster, Muenster 48149,
      Germany.
FAU - Sekeres, Mikkael A
AU  - Sekeres MA
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA; Leukemia Program, Cleveland Clinic, Taussig 
      Cancer Institute, Cleveland, OH 44195, USA.
FAU - Makishima, Hideki
AU  - Makishima H
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Przychodzen, Bartlomiej
AU  - Przychodzen B
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Hosono, Naoko
AU  - Hosono N
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA; First Department of Internal Medicine,
      Faculty of Medical Sciences, University of Fukui, Fukui 910-8507, Japan.
FAU - Singh, Jarnail
AU  - Singh J
AD  - Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Padgett, Richard A
AU  - Padgett RA
AD  - Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic,
      Cleveland, OH 44195, USA.
FAU - Gu, Xiaorong
AU  - Gu X
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Phillips, James G
AU  - Phillips JG
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Clemente, Michael
AU  - Clemente M
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Parker, Yvonne
AU  - Parker Y
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Lindner, Daniel
AU  - Lindner D
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Dienes, Brittney
AU  - Dienes B
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Jankowsky, Eckhard
AU  - Jankowsky E
AD  - Department of Biochemistry, Case Western Reserve University, Cleveland, OH 44106,
      USA.
FAU - Saunthararajah, Yogen
AU  - Saunthararajah Y
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA.
FAU - Du, Yang
AU  - Du Y
AD  - Department of Pediatrics, Uniformed Services University of the Health Sciences,
      Bethesda, MD 20814, USA.
FAU - Oakley, Kevin
AU  - Oakley K
AD  - Department of Pediatrics, Uniformed Services University of the Health Sciences,
      Bethesda, MD 20814, USA.
FAU - Nguyen, Nhu
AU  - Nguyen N
AD  - Department of Pediatrics, Uniformed Services University of the Health Sciences,
      Bethesda, MD 20814, USA.
FAU - Mukherjee, Sudipto
AU  - Mukherjee S
AD  - Leukemia Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
      44195, USA.
FAU - Pabst, Caroline
AU  - Pabst C
AD  - Department of Hematology and Oncology, University of Halle, Halle 06108, Germany.
FAU - Godley, Lucy A
AU  - Godley LA
AD  - Department of Medicine, Comprehensive Cancer Center and Center for Clinical
      Cancer Genetics, University of Chicago, Chicago, IL 60637, USA.
FAU - Churpek, Jane E
AU  - Churpek JE
AD  - Department of Medicine, Comprehensive Cancer Center and Center for Clinical
      Cancer Genetics, University of Chicago, Chicago, IL 60637, USA.
FAU - Pollyea, Daniel A
AU  - Pollyea DA
AD  - University of Colorado School of Medicine and University of Colorado Cancer
      Center, Aurora, CO 80045, USA.
FAU - Krug, Utz
AU  - Krug U
AD  - Department of Hematology and Oncology, University of Muenster, Muenster 48149,
      Germany.
FAU - Berdel, Wolfgang E
AU  - Berdel WE
AD  - Department of Hematology and Oncology, University of Muenster, Muenster 48149,
      Germany.
FAU - Klein, Hans-Ulrich
AU  - Klein HU
AD  - Institute of Medical Informatics, University of Muenster, Muenster 48149,
      Germany.
FAU - Dugas, Martin
AU  - Dugas M
AD  - Institute of Medical Informatics, University of Muenster, Muenster 48149,
      Germany.
FAU - Shiraishi, Yuichi
AU  - Shiraishi Y
AD  - Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo
      113-8654, Japan.
FAU - Chiba, Kenichi
AU  - Chiba K
AD  - Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo
      113-8654, Japan.
FAU - Tanaka, Hiroko
AU  - Tanaka H
AD  - Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo
      113-8654, Japan.
FAU - Miyano, Satoru
AU  - Miyano S
AD  - Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo
      113-8654, Japan.
FAU - Yoshida, Kenichi
AU  - Yoshida K
AD  - Department of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501,
      Japan.
FAU - Ogawa, Seishi
AU  - Ogawa S
AD  - Department of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501,
      Japan.
FAU - Muller-Tidow, Carsten
AU  - Muller-Tidow C
AD  - Department of Hematology and Oncology, University of Halle, Halle 06108, Germany;
      Department of Hematology and Oncology, University of Muenster, Muenster 48149,
      Germany. Electronic address: carsten.mueller-tidow@uk-halle.de.
FAU - Maciejewski, Jaroslaw P
AU  - Maciejewski JP
AD  - Department of Translational Hematology and Oncology Research, Taussig Cancer
      Institute, Cleveland, OH 44195, USA; Leukemia Program, Cleveland Clinic, Taussig 
      Cancer Institute, Cleveland, OH 44195, USA. Electronic address: maciejj@ccf.org.
LA  - eng
SI  - GEO/GSE66668
SI  - SRA/PRJNA275985
GR  - R01HL118281/HL/NHLBI NIH HHS/United States
GR  - R01 CA143193/CA/NCI NIH HHS/United States
GR  - R01 HL118281/HL/NHLBI NIH HHS/United States
GR  - K24 HL077522/HL/NHLBI NIH HHS/United States
GR  - R01CA143193/CA/NCI NIH HHS/United States
GR  - 2K24HL077522/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150423
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 3.6.1.- (DDX41 protein, human)
RN  - EC 3.6.4.13 (DEAD-box RNA Helicases)
SB  - IM
CIN - Cancer Cell. 2015 May 11;27(5):609-11. PMID: 25965566
MH  - Aged
MH  - Aged, 80 and over
MH  - Amino Acid Sequence
MH  - Animals
MH  - DEAD-box RNA Helicases/chemistry/*genetics
MH  - Female
MH  - *Germ-Line Mutation
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Pedigree
MH  - RNA Splicing
MH  - Sequence Homology, Amino Acid
EDAT- 2015/04/30 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/04/30 06:00
PHST- 2014/07/16 00:00 [received]
PHST- 2015/02/09 00:00 [revised]
PHST- 2015/03/30 00:00 [accepted]
PHST- 2015/04/30 06:00 [entrez]
PHST- 2015/04/30 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - S1535-6108(15)00105-1 [pii]
AID - 10.1016/j.ccell.2015.03.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 May 11;27(5):658-70. doi: 10.1016/j.ccell.2015.03.017. Epub
      2015 Apr 23.

PMID- 25873177
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Intravital imaging reveals how BRAF inhibition generates drug-tolerant
      microenvironments with high integrin beta1/FAK signaling.
PG  - 574-88
LID - 10.1016/j.ccell.2015.03.008 [doi]
LID - S1535-6108(15)00096-3 [pii]
AB  - Intravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor
      reveals how the tumor microenvironment affects response to BRAF inhibition by
      PLX4720. Initially, melanoma cells respond to PLX4720, but rapid reactivation of 
      ERK/MAPK is observed in areas of high stromal density. This is linked to
      "paradoxical" activation of melanoma-associated fibroblasts by PLX4720 and the
      promotion of matrix production and remodeling leading to elevated integrin
      beta1/FAK/Src signaling in melanoma cells. Fibronectin-rich matrices with 3-12
      kPa elastic modulus are sufficient to provide PLX4720 tolerance. Co-inhibition of
      BRAF and FAK abolished ERK reactivation and led to more effective control of
      BRAF-mutant melanoma. We propose that paradoxically activated MAFs provide a
      "safe haven" for melanoma cells to tolerate BRAF inhibition.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Hirata, Eishu
AU  - Hirata E
AD  - Tumor Cell Biology Laboratory, Cancer Research UK London Research Institute,
      London WC2A 3LY, UK.
FAU - Girotti, Maria Romina
AU  - Girotti MR
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Wilmslow Road,
      Manchester M20 4BX, UK.
FAU - Viros, Amaya
AU  - Viros A
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Wilmslow Road,
      Manchester M20 4BX, UK.
FAU - Hooper, Steven
AU  - Hooper S
AD  - Tumor Cell Biology Laboratory, Cancer Research UK London Research Institute,
      London WC2A 3LY, UK.
FAU - Spencer-Dene, Bradley
AU  - Spencer-Dene B
AD  - Experimental Histopathology Laboratory, Cancer Research UK London Research
      Institute, London WC2A 3LY, UK.
FAU - Matsuda, Michiyuki
AU  - Matsuda M
AD  - Laboratory of Bioimaging and Cell Signalling, Kyoto University Graduate School of
      Biostudies, Kyoto 606-8315, Japan.
FAU - Larkin, James
AU  - Larkin J
AD  - Department of Medical Oncology, Royal Marsden NHS Trust, Fulham Road, London SW3 
      6JJ, UK.
FAU - Marais, Richard
AU  - Marais R
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Wilmslow Road,
      Manchester M20 4BX, UK.
FAU - Sahai, Erik
AU  - Sahai E
AD  - Tumor Cell Biology Laboratory, Cancer Research UK London Research Institute,
      London WC2A 3LY, UK. Electronic address: erik.sahai@crick.ac.uk.
LA  - eng
SI  - GEO/GSE63160
GR  - 100282/Wellcome Trust/United Kingdom
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Indoles)
RN  - 0 (Integrin beta1)
RN  - 0 (PLX 4720)
RN  - 0 (Sulfonamides)
RN  - EC 2.7.10.2 (Focal Adhesion Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CIN - Nat Rev Cancer. 2015 Jun;15(6):318-9. PMID: 25998706
CIN - Cancer Cell. 2015 Apr 13;27(4):429-31. PMID: 25873166
CIN - Intravital. 2015 Jul 30;4(2):e1074788. PMID: 28244506
MH  - Animals
MH  - Cell Line, Tumor
MH  - *Drug Resistance, Neoplasm
MH  - Focal Adhesion Protein-Tyrosine Kinases/*metabolism
MH  - Humans
MH  - Indoles/pharmacology/therapeutic use
MH  - Integrin beta1/*metabolism
MH  - Melanoma/drug therapy/genetics/*metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/genetics
MH  - Signal Transduction/drug effects
MH  - Sulfonamides/pharmacology/therapeutic use
MH  - *Tumor Microenvironment
PMC - PMC4402404
EDAT- 2015/04/16 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/03/23 00:00 [received]
PHST- 2015/02/16 00:00 [revised]
PHST- 2015/03/16 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00096-3 [pii]
AID - 10.1016/j.ccell.2015.03.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):574-88. doi: 10.1016/j.ccell.2015.03.008.

PMID- 25873176
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - TGIF governs a feed-forward network that empowers Wnt signaling to drive mammary 
      tumorigenesis.
PG  - 547-60
LID - 10.1016/j.ccell.2015.03.002 [doi]
LID - S1535-6108(15)00090-2 [pii]
AB  - Many types of human cancers having hyperactivated Wnt signaling display no
      causative alterations in known effectors of this pathway. Here, we report a
      function of TGIF in Wnt signaling. TGIF associates with and diverts Axin1 and
      Axin2 from the beta-catenin destruction complex, therefore allowing beta-catenin 
      accrual. Intriguingly, activation of Wnt signaling induces the expression of
      TGIF, which unveils a feed-forward loop that ensures effective integration of Wnt
      signaling. In triple-negative breast cancers (TNBC), elevated levels of TGIF
      correlate with high Wnt signaling and poor survival of patients. Moreover,
      genetic experiments revealed that Tgif1 ablation impeded mammary tumor
      development in MMTV-Wnt1 mice, further underscoring a requirement of TGIF for
      oncogenic Wnt signaling.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Zhang, Ming-Zhu
AU  - Zhang MZ
AD  - Department of Oral Medicine, Infection and Immunity, Harvard School of Dental
      Medicine, 188 Longwood Avenue, Boston, MA 02115, USA; Department of Orthopaedics,
      Tongji University School of Medicine, Shanghai 200065, China.
FAU - Ferrigno, Olivier
AU  - Ferrigno O
AD  - Laboratory of Cell Signaling and Carcinogenesis, INSERM UMRS938, 184 Rue du
      Faubourg St-Antoine, 75571 Paris, France.
FAU - Wang, Zhe
AU  - Wang Z
AD  - Department of Biochemistry, University of Mississippi Medical Center, 2500 North 
      State Street, Jackson, MS 39216, USA.
FAU - Ohnishi, Mutsuko
AU  - Ohnishi M
AD  - Department of Oral Medicine, Infection and Immunity, Harvard School of Dental
      Medicine, 188 Longwood Avenue, Boston, MA 02115, USA.
FAU - Prunier, Celine
AU  - Prunier C
AD  - Laboratory of Cell Signaling and Carcinogenesis, INSERM UMRS938, 184 Rue du
      Faubourg St-Antoine, 75571 Paris, France.
FAU - Levy, Laurence
AU  - Levy L
AD  - Laboratory of Cell Signaling and Carcinogenesis, INSERM UMRS938, 184 Rue du
      Faubourg St-Antoine, 75571 Paris, France.
FAU - Razzaque, Mohammed
AU  - Razzaque M
AD  - Department of Oral Medicine, Infection and Immunity, Harvard School of Dental
      Medicine, 188 Longwood Avenue, Boston, MA 02115, USA.
FAU - Horne, Williams C
AU  - Horne WC
AD  - Department of Oral Medicine, Infection and Immunity, Harvard School of Dental
      Medicine, 188 Longwood Avenue, Boston, MA 02115, USA.
FAU - Romero, Damian
AU  - Romero D
AD  - Department of Biochemistry, University of Mississippi Medical Center, 2500 North 
      State Street, Jackson, MS 39216, USA.
FAU - Tzivion, Guri
AU  - Tzivion G
AD  - Department of Biochemistry, University of Mississippi Medical Center, 2500 North 
      State Street, Jackson, MS 39216, USA.
FAU - Colland, Frederic
AU  - Colland F
AD  - Hybrigenics, 3-5 impasse Reille, 75014 Paris, France.
FAU - Baron, Roland
AU  - Baron R
AD  - Department of Oral Medicine, Infection and Immunity, Harvard School of Dental
      Medicine, 188 Longwood Avenue, Boston, MA 02115, USA.
FAU - Atfi, Azeddine
AU  - Atfi A
AD  - Laboratory of Cell Signaling and Carcinogenesis, INSERM UMRS938, 184 Rue du
      Faubourg St-Antoine, 75571 Paris, France; Department of Biochemistry, University 
      of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
      Electronic address: azeddine.atfi@inserm.fr.
LA  - eng
GR  - R01 AR048218/AR/NIAMS NIH HHS/United States
GR  - R01 AR059070/AR/NIAMS NIH HHS/United States
GR  - R01-AR059070/AR/NIAMS NIH HHS/United States
GR  - R01-AR48218/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Axin Protein)
RN  - 0 (Axin1 protein, mouse)
RN  - 0 (Axin2 protein, mouse)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Repressor Proteins)
RN  - 0 (Tgif protein, mouse)
RN  - 0 (beta Catenin)
SB  - IM
MH  - Active Transport, Cell Nucleus
MH  - Animals
MH  - Axin Protein/metabolism
MH  - Homeodomain Proteins/metabolism/*physiology
MH  - Humans
MH  - Mammary Neoplasms, Experimental/*metabolism
MH  - Mice
MH  - Models, Biological
MH  - Repressor Proteins/metabolism/*physiology
MH  - *Wnt Signaling Pathway
MH  - beta Catenin/metabolism
PMC - PMC4398914
MID - NIHMS670729
EDAT- 2015/04/16 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/06/17 00:00 [received]
PHST- 2014/12/10 00:00 [revised]
PHST- 2015/03/02 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00090-2 [pii]
AID - 10.1016/j.ccell.2015.03.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):547-60. doi: 10.1016/j.ccell.2015.03.002.

PMID- 25873175
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR
      axis in head and neck and esophageal squamous cell carcinomas.
PG  - 533-46
LID - 10.1016/j.ccell.2015.03.010 [doi]
LID - S1535-6108(15)00098-7 [pii]
AB  - Phosphoinositide-3-kinase (PI3K)-alpha inhibitors have shown clinical activity in
      squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations
      or amplification. Studying models of therapeutic resistance, we have observed
      that SCC cells that become refractory to PI3Kalpha inhibition maintain
      PI3K-independent activation of the mammalian target of rapamycin (mTOR). This
      persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. AXL
      is overexpressed in resistant tumors from both laboratory models and patients
      treated with the PI3Kalpha inhibitor BYL719. AXL dimerizes with and
      phosphorylates epidermal growth factor receptor (EGFR), resulting in activation
      of phospholipase Cgamma (PLCgamma)-protein kinase C (PKC), which, in turn,
      activates mTOR. Combined treatment with PI3Kalpha and either EGFR, AXL, or PKC
      inhibitors reverts this resistance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Elkabets, Moshe
AU  - Elkabets M
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Pazarentzos, Evangelos
AU  - Pazarentzos E
AD  - Division of Hematology and Oncology, Department of Medicine, Helen Diller
      Comprehensive Cancer Center, University of California, San Francisco, 600 16th
      Street, San Francisco, CA 94158, USA.
FAU - Juric, Dejan
AU  - Juric D
AD  - Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, 
      USA.
FAU - Sheng, Qing
AU  - Sheng Q
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Pelossof, Raphael A
AU  - Pelossof RA
AD  - Computation Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York
      Avenue, Box 20, New York, NY 10065, USA.
FAU - Brook, Samuel
AU  - Brook S
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Benzaken, Ana Oaknin
AU  - Benzaken AO
AD  - Medical Oncology, Vall d'Hebron Institute of Oncology, Pg Vall d'Hebron, 119-129,
      Barcelona 08035, Spain.
FAU - Rodon, Jordi
AU  - Rodon J
AD  - Medical Oncology, Vall d'Hebron Institute of Oncology, Pg Vall d'Hebron, 119-129,
      Barcelona 08035, Spain.
FAU - Morse, Natasha
AU  - Morse N
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
FAU - Yan, Jenny Jiacheng
AU  - Yan JJ
AD  - Division of Hematology and Oncology, Department of Medicine, Helen Diller
      Comprehensive Cancer Center, University of California, San Francisco, 600 16th
      Street, San Francisco, CA 94158, USA.
FAU - Liu, Manway
AU  - Liu M
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Das, Rita
AU  - Das R
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Chen, Yan
AU  - Chen Y
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Tam, Angela
AU  - Tam A
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Wang, Huiqin
AU  - Wang H
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Liang, Jinsheng
AU  - Liang J
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Gurski, Joseph M
AU  - Gurski JM
AD  - Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, 
      USA.
FAU - Kerr, Darcy A
AU  - Kerr DA
AD  - Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, 
      USA.
FAU - Rosell, Rafael
AU  - Rosell R
AD  - Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet s/n,
      08916 Badalona, Spain; Pangaea Biotech SL, Laboratorio de Oncologia, Hospital
      Universitario Quiron Dexeus, C/ Sabino Arana 5-19, 08028 Barcelona, Spain.
FAU - Teixido, Cristina
AU  - Teixido C
AD  - Pangaea Biotech SL, Laboratorio de Oncologia, Hospital Universitario Quiron
      Dexeus, C/ Sabino Arana 5-19, 08028 Barcelona, Spain.
FAU - Huang, Alan
AU  - Huang A
AD  - Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100
      Technology Square, Cambridge, MA 02139, USA.
FAU - Ghossein, Ronald A
AU  - Ghossein RA
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Rosen, Neal
AU  - Rosen N
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Molecular Pharmacology
      Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Bivona, Trever G
AU  - Bivona TG
AD  - Division of Hematology and Oncology, Department of Medicine, Helen Diller
      Comprehensive Cancer Center, University of California, San Francisco, 600 16th
      Street, San Francisco, CA 94158, USA.
FAU - Scaltriti, Maurizio
AU  - Scaltriti M
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address:
      scaltrim@mskcc.org.
FAU - Baselga, Jose
AU  - Baselga J
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of
      Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New
      York, NY 10065, USA. Electronic address: baselgaj@mskcc.org.
LA  - eng
SI  - GEO/GSE61515
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - DP2 CA174497/CA/NCI NIH HHS/United States
GR  - K12 CA087723/CA/NCI NIH HHS/United States
GR  - R01 CA169338/CA/NCI NIH HHS/United States
GR  - T32 CA071345/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (NVP-BYL719)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Thiazoles)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (axl receptor tyrosine kinase)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - PQX0D8J21J (Cetuximab)
RN  - Esophageal Squamous Cell Carcinoma
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Humanized/pharmacology
MH  - Carcinoma, Squamous Cell/*metabolism
MH  - Cell Line, Tumor
MH  - Cetuximab
MH  - Class I Phosphatidylinositol 3-Kinases
MH  - Drug Resistance, Neoplasm
MH  - Esophageal Neoplasms/*metabolism
MH  - Head and Neck Neoplasms/*metabolism
MH  - Humans
MH  - Mice
MH  - Phosphatidylinositol 3-Kinases/antagonists & inhibitors/genetics/metabolism
MH  - Protein Kinase C/metabolism
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins/genetics/metabolism/*physiology
MH  - Receptor Protein-Tyrosine Kinases/genetics/metabolism/*physiology
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Thiazoles/pharmacology
MH  - Xenograft Model Antitumor Assays
PMC - PMC4398915
MID - NIHMS677397
EDAT- 2015/04/16 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/08/31 00:00 [received]
PHST- 2015/01/11 00:00 [revised]
PHST- 2015/03/16 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00098-7 [pii]
AID - 10.1016/j.ccell.2015.03.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.

PMID- 25873174
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20180313
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in
      anaplastic large cell lymphoma.
PG  - 516-32
LID - 10.1016/j.ccell.2015.03.006 [doi]
LID - S1535-6108(15)00094-X [pii]
AB  - A systematic characterization of the genetic alterations driving ALCLs has not
      been performed. By integrating massive sequencing strategies, we provide a
      comprehensive characterization of driver genetic alterations (somatic point
      mutations, copy number alterations, and gene fusions) in ALK(-) ALCLs. We
      identified activating mutations of JAK1 and/or STAT3 genes in approximately 20%
      of 88 [corrected] ALK(-) ALCLs and demonstrated that 38% of systemic ALK(-) ALCLs
      displayed double lesions. Recurrent chimeras combining a transcription factor
      (NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT
      JAK1/STAT3 ALK(-) ALCL. All these aberrations lead to the constitutive activation
      of the JAK/STAT3 pathway, which was proved oncogenic. Consistently, JAK/STAT3
      pathway inhibition impaired cell growth in vitro and in vivo.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Crescenzo, Ramona
AU  - Crescenzo R
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical
      College, New York, NY 10021, USA.
FAU - Abate, Francesco
AU  - Abate F
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Control and Computer Engineering, Politecnico di Torino,
      10129 Torino, Italy; Department of Biomedical Informatics and Department of
      Systems Biology, Center for Computational Biology and Bioinformatics, Columbia
      University, New York, NY 10027, USA.
FAU - Lasorsa, Elena
AU  - Lasorsa E
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy.
FAU - Tabbo', Fabrizio
AU  - Tabbo' F
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical
      College, New York, NY 10021, USA.
FAU - Gaudiano, Marcello
AU  - Gaudiano M
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical
      College, New York, NY 10021, USA.
FAU - Chiesa, Nicoletta
AU  - Chiesa N
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy.
FAU - Di Giacomo, Filomena
AU  - Di Giacomo F
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy.
FAU - Spaccarotella, Elisa
AU  - Spaccarotella E
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy.
FAU - Barbarossa, Luigi
AU  - Barbarossa L
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy.
FAU - Ercole, Elisabetta
AU  - Ercole E
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy.
FAU - Todaro, Maria
AU  - Todaro M
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical
      College, New York, NY 10021, USA.
FAU - Boi, Michela
AU  - Boi M
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical
      College, New York, NY 10021, USA.
FAU - Acquaviva, Andrea
AU  - Acquaviva A
AD  - Department of Control and Computer Engineering, Politecnico di Torino, 10129
      Torino, Italy.
FAU - Ficarra, Elisa
AU  - Ficarra E
AD  - Department of Control and Computer Engineering, Politecnico di Torino, 10129
      Torino, Italy.
FAU - Novero, Domenico
AU  - Novero D
AD  - Department of Pathology, A.O. Citta della Salute e della Scienza (Molinette),
      10126 Torino, Italy.
FAU - Rinaldi, Andrea
AU  - Rinaldi A
AD  - Lymphoma and Genomics Research Program, Institute of Oncology Research, 6500
      Bellinzona, Switzerland.
FAU - Tousseyn, Thomas
AU  - Tousseyn T
AD  - Translational Cell and Tissue Research Lab, KU Leuven, 3000 Leuven, Belgium.
FAU - Rosenwald, Andreas
AU  - Rosenwald A
AD  - Institute of Pathology, University of Wurzburg and Comprehensive Cancer Center
      Mainfranken, 97080 Wurzburg, Germany.
FAU - Kenner, Lukas
AU  - Kenner L
AD  - Ludwing Boltzmann Institute for Cancer Research, 1090 Vienna, Austria.
FAU - Cerroni, Lorenzo
AU  - Cerroni L
AD  - Research Unit Dermatopathology of the Medical University of Graz, 8036 Graz,
      Austria.
FAU - Tzankov, Alexander
AU  - Tzankov A
AD  - Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland.
FAU - Ponzoni, Maurilio
AU  - Ponzoni M
AD  - Pathology & Lymphoid Malignancies Units, San Raffaele Scientific Institute, 20132
      Milan, Italy.
FAU - Paulli, Marco
AU  - Paulli M
AD  - Department of Human Pathology, University of Pavia and Scientific Institute
      Fondazione Policlinico San Matteo, 27100 Pavia, Italy.
FAU - Weisenburger, Dennis
AU  - Weisenburger D
AD  - Department of Pathology, City of Hope Medical Center, Duarte, CA 91010, USA.
FAU - Chan, Wing C
AU  - Chan WC
AD  - Department of Pathology, City of Hope Medical Center, Duarte, CA 91010, USA.
FAU - Iqbal, Javeed
AU  - Iqbal J
AD  - Department of Pathology and Microbiology, University of Nebraska Medical Center, 
      Omaha, NE 68198, USA.
FAU - Piris, Miguel A
AU  - Piris MA
AD  - Cancer Genomics, Instituto de Formacion e Investigacion Marques de Valdecilla and
      Department of Pathology, Hospital Universitario Marques de Valdecilla, 39008
      Santander, Spain.
FAU - Zamo', Alberto
AU  - Zamo' A
AD  - Department of Pathology and Diagnostics, University of Verona, 37134 Verona,
      Italy.
FAU - Ciardullo, Carmela
AU  - Ciardullo C
AD  - Division of Hematology, Department of Translational Medicine, Amedeo Avogadro
      University of Eastern Piedmont, 28100 Novara, Italy.
FAU - Rossi, Davide
AU  - Rossi D
AD  - Division of Hematology, Department of Translational Medicine, Amedeo Avogadro
      University of Eastern Piedmont, 28100 Novara, Italy.
FAU - Gaidano, Gianluca
AU  - Gaidano G
AD  - Division of Hematology, Department of Translational Medicine, Amedeo Avogadro
      University of Eastern Piedmont, 28100 Novara, Italy.
FAU - Pileri, Stefano
AU  - Pileri S
AD  - European Institute of Oncology, 20141 Milano, Italy; Bologna University School of
      Medicine, 40126 Bologna, Italy.
FAU - Tiacci, Enrico
AU  - Tiacci E
AD  - Institute of Hematology-Centro di Ricerche Onco-Ematologiche (CREO), Ospedale S. 
      Maria della Misericordia, University of Perugia, 06100 Perugia, Italy.
FAU - Falini, Brunangelo
AU  - Falini B
AD  - Institute of Hematology-Centro di Ricerche Onco-Ematologiche (CREO), Ospedale S. 
      Maria della Misericordia, University of Perugia, 06100 Perugia, Italy.
FAU - Shultz, Leonard D
AU  - Shultz LD
AD  - The Jackson Laboratory, Bar Harbor, ME 04609, USA.
FAU - Mevellec, Laurence
AU  - Mevellec L
AD  - Janssen Research & Development, a Division of Janssen-Cilag, Campus de
      Maigremont, CS10615, 27106 Val-de-Reuil Cedex, France.
FAU - Vialard, Jorge E
AU  - Vialard JE
AD  - Janssen Research & Development, a Division of Janssen Pharmaceutica NV,
      Turnhoutseweg 30, 2340 Beerse, Belgium.
FAU - Piva, Roberto
AU  - Piva R
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Pathology and NYU Cancer Center, New York University School 
      of Medicine, New York, NY 10016, USA.
FAU - Bertoni, Francesco
AU  - Bertoni F
AD  - Lymphoma and Genomics Research Program, Institute of Oncology Research, 6500
      Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, 6500
      Bellinzona, Switzerland.
FAU - Rabadan, Raul
AU  - Rabadan R
AD  - Department of Biomedical Informatics and Department of Systems Biology, Center
      for Computational Biology and Bioinformatics, Columbia University, New York, NY
      10027, USA. Electronic address: rr2579@cumc.columbia.edu.
FAU - Inghirami, Giorgio
AU  - Inghirami G
AD  - Department of Molecular Biotechnology and Health Science and Center for
      Experimental Research and Medical Studies, University of Torino, 10126 Torino,
      Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical
      College, New York, NY 10021, USA; Department of Pathology and NYU Cancer Center, 
      New York University School of Medicine, New York, NY 10016, USA. Electronic
      address: ggi9001@med.cornell.edu.
CN  - European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of
      Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium 
      "Genetics-Driven Targeted Management of Lymphoid Malignancies"
LA  - eng
GR  - R01 CA179044/CA/NCI NIH HHS/United States
GR  - R01 CA185486/CA/NCI NIH HHS/United States
GR  - U54 CA121852/CA/NCI NIH HHS/United States
GR  - R01CA185486/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Activating Transcription Factor 3)
RN  - 0 (Atf3 protein, mouse)
RN  - 0 (Mutant Chimeric Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (Stat3 protein, mouse)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Ros1 protein, mouse)
RN  - EC 2.7.10.2 (Jak1 protein, mouse)
RN  - EC 2.7.10.2 (Janus Kinase 1)
RN  - EC 2.7.10.2 (TYK2 Kinase)
RN  - EC 2.7.10.2 (Tyk2 protein, mouse)
SB  - IM
EIN - Cancer Cell. 2015 May 11;27(5):744
MH  - Activating Transcription Factor 3/genetics/metabolism
MH  - Animals
MH  - Cell Line, Tumor
MH  - *Gene Expression Regulation, Neoplastic
MH  - HEK293 Cells
MH  - Humans
MH  - Janus Kinase 1/genetics
MH  - Lymphoma, Large-Cell, Anaplastic/*genetics
MH  - Mice
MH  - Mutant Chimeric Proteins/genetics/metabolism
MH  - NF-kappa B/genetics
MH  - Phosphorylation
MH  - Proto-Oncogene Proteins/genetics
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - STAT3 Transcription Factor/genetics/*metabolism
MH  - Signal Transduction
MH  - TYK2 Kinase/genetics
EDAT- 2015/04/16 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/07/10 00:00 [received]
PHST- 2014/11/14 00:00 [revised]
PHST- 2015/03/10 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00094-X [pii]
AID - 10.1016/j.ccell.2015.03.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):516-32. doi: 10.1016/j.ccell.2015.03.006.

PMID- 25873173
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Mutational cooperativity linked to combinatorial epigenetic gain of function in
      acute myeloid leukemia.
PG  - 502-15
LID - 10.1016/j.ccell.2015.03.009 [doi]
LID - S1535-6108(15)00097-5 [pii]
AB  - Specific combinations of acute myeloid leukemia (AML) disease alleles, including 
      FLT3 and TET2 mutations, confer distinct biologic features and adverse outcome.
      We generated mice with mutations in Tet2 and Flt3, which resulted in fully
      penetrant, lethal AML. Multipotent Tet2(-/-);Flt3(ITD) progenitors (LSK
      CD48(+)CD150(-)) propagate disease in secondary recipients and were refractory to
      standard AML chemotherapy and FLT3-targeted therapy. Flt3(ITD) mutations and Tet2
      loss cooperatively remodeled DNA methylation and gene expression to an extent not
      seen with either mutant allele alone, including at the Gata2 locus. Re-expression
      of Gata2 induced differentiation in AML stem cells and attenuated leukemogenesis.
      TET2 and FLT3 mutations cooperatively induce AML, with a defined leukemia stem
      cell population characterized by site-specific changes in DNA methylation and
      gene expression.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Shih, Alan H
AU  - Shih AH
AD  - Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Jiang, Yanwen
AU  - Jiang Y
AD  - Institute for Computational Biomedicine and Department of Physiology and
      Biophysics, Weill Cornell Medical College, New York, NY 10065, USA; Department of
      Medicine/Hematology-Oncology and Department of Pharmacology, Weill Cornell
      Medical College, New York, NY 10065, USA.
FAU - Meydan, Cem
AU  - Meydan C
AD  - Institute for Computational Biomedicine and Department of Physiology and
      Biophysics, Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Shank, Kaitlyn
AU  - Shank K
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Pandey, Suveg
AU  - Pandey S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Barreyro, Laura
AU  - Barreyro L
AD  - Department of Cell Biology and Division of Hematologic Malignancies, Department
      of Medicine (Oncology), Albert Einstein College of Medicine, New York, NY 10461, 
      USA.
FAU - Antony-Debre, Ileana
AU  - Antony-Debre I
AD  - Department of Cell Biology and Division of Hematologic Malignancies, Department
      of Medicine (Oncology), Albert Einstein College of Medicine, New York, NY 10461, 
      USA.
FAU - Viale, Agnes
AU  - Viale A
AD  - Genomics Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Socci, Nicholas
AU  - Socci N
AD  - Bioinformatics Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, 
      USA.
FAU - Sun, Yongming
AU  - Sun Y
AD  - Life Technologies, South San Francisco, CA 94080, USA.
FAU - Robertson, Alexander
AU  - Robertson A
AD  - Life Technologies, South San Francisco, CA 94080, USA.
FAU - Cavatore, Magali
AU  - Cavatore M
AD  - Genomics Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - de Stanchina, Elisa
AU  - de Stanchina E
AD  - Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Hricik, Todd
AU  - Hricik T
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Rapaport, Franck
AU  - Rapaport F
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Woods, Brittany
AU  - Woods B
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Wei, Chen
AU  - Wei C
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Hatlen, Megan
AU  - Hatlen M
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Baljevic, Muhamed
AU  - Baljevic M
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Nimer, Stephen D
AU  - Nimer SD
AD  - Sylvester Cancer Center, University of Miami, Miami, FL 33136, USA.
FAU - Tallman, Martin
AU  - Tallman M
AD  - Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Paietta, Elisabeth
AU  - Paietta E
AD  - Department of Oncology, Montefiore Hospital, Bronx, NY 10467, USA.
FAU - Cimmino, Luisa
AU  - Cimmino L
AD  - Department of Pathology and Howard Hughes Medical Institute, NYU School of
      Medicine, New York, NY 10016, USA.
FAU - Aifantis, Iannis
AU  - Aifantis I
AD  - Department of Pathology and Howard Hughes Medical Institute, NYU School of
      Medicine, New York, NY 10016, USA.
FAU - Steidl, Ulrich
AU  - Steidl U
AD  - Department of Cell Biology and Division of Hematologic Malignancies, Department
      of Medicine (Oncology), Albert Einstein College of Medicine, New York, NY 10461, 
      USA.
FAU - Mason, Chris
AU  - Mason C
AD  - Institute for Computational Biomedicine and Department of Physiology and
      Biophysics, Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Melnick, Ari
AU  - Melnick A
AD  - Department of Medicine/Hematology-Oncology and Department of Pharmacology, Weill 
      Cornell Medical College, New York, NY 10065, USA; Weill Cornell Medical College, 
      Cornell University, 413 E 69th Street, BB-1462, New York, NY 10021, USA.
      Electronic address: amm2014@med.cornell.edu.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA; Memorial Sloan Kettering Cancer Center, 1275
      York Avenue, Box 20, New York, NY 10065, USA. Electronic address:
      leviner@mskcc.org.
LA  - eng
GR  - R01 CA173636/CA/NCI NIH HHS/United States
GR  - R01 CA166835/CA/NCI NIH HHS/United States
GR  - R01 CA166429/CA/NCI NIH HHS/United States
GR  - R01CA166835/CA/NCI NIH HHS/United States
GR  - U10 CA021115/CA/NCI NIH HHS/United States
GR  - U24 CA196172/CA/NCI NIH HHS/United States
GR  - R01NS076465/NS/NINDS NIH HHS/United States
GR  - R01HG006798/HG/NHGRI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 HG006798/HG/NHGRI NIH HHS/United States
GR  - R01 CA169784/CA/NCI NIH HHS/United States
GR  - CA172636-01/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - R01 NS076465/NS/NINDS NIH HHS/United States
GR  - P30 CA013330/CA/NCI NIH HHS/United States
GR  - U10 CA180827/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (GATA2 Transcription Factor)
RN  - 0 (Gata2 protein, mouse)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Tet2 protein, mouse)
RN  - 04079A1RDZ (Cytarabine)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.10.1 (Flt3 protein, mouse)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Cell Differentiation/genetics
MH  - Cytarabine/therapeutic use
MH  - DNA Methylation
MH  - DNA-Binding Proteins/*genetics/metabolism
MH  - Doxorubicin/therapeutic use
MH  - *Epigenesis, Genetic
MH  - GATA2 Transcription Factor/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Silencing
MH  - Haploinsufficiency
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Mutation
MH  - Proto-Oncogene Proteins/*genetics/metabolism
MH  - fms-Like Tyrosine Kinase 3/*genetics/metabolism
PMC - PMC4518555
MID - NIHMS673840
EDAT- 2015/04/16 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/07/02 00:00 [received]
PHST- 2014/12/24 00:00 [revised]
PHST- 2015/03/16 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00097-5 [pii]
AID - 10.1016/j.ccell.2015.03.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):502-15. doi: 10.1016/j.ccell.2015.03.009.

PMID- 25873172
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20171110
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Synergistic innate and adaptive immune response to combination immunotherapy with
      anti-tumor antigen antibodies and extended serum half-life IL-2.
PG  - 489-501
LID - 10.1016/j.ccell.2015.03.004 [doi]
LID - S1535-6108(15)00092-6 [pii]
AB  - Cancer immunotherapies under development have generally focused on either
      stimulating T cell immunity or driving antibody-directed effector functions of
      the innate immune system such as antibody-dependent cell-mediated cytotoxicity
      (ADCC). We find that a combination of an anti-tumor antigen antibody and an
      untargeted IL-2 fusion protein with delayed systemic clearance induces
      significant tumor control in aggressive isogenic tumor models via a concerted
      innate and adaptive response involving neutrophils, NK cells, macrophages, and
      CD8(+) T cells. This combination therapy induces an intratumoral "cytokine storm"
      and extensive lymphocyte infiltration. Adoptive transfer of anti-tumor T cells
      together with this combination therapy leads to robust cures of established
      tumors and development of immunological memory.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Zhu, Eric F
AU  - Zhu EF
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Gai, Shuning A
AU  - Gai SA
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Opel, Cary F
AU  - Opel CF
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Kwan, Byron H
AU  - Kwan BH
AD  - Department of Biological Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Surana, Rishi
AU  - Surana R
AD  - Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,
      Washington, DC 20057, USA.
FAU - Mihm, Martin C
AU  - Mihm MC
AD  - Department of Pathology, Harvard Medical School, Boston, MA 02115, USA;
      Department of Pathology, Massachusetts General Hospital, Boston, MA 02214, USA.
FAU - Kauke, Monique J
AU  - Kauke MJ
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Moynihan, Kelly D
AU  - Moynihan KD
AD  - Department of Biological Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Angelini, Alessandro
AU  - Angelini A
AD  - Koch Institute for Integrative Cancer Research, Massachusetts Institute of
      Technology, Cambridge, MA 02139, USA.
FAU - Williams, Robert T
AU  - Williams RT
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA
      02139, USA.
FAU - Stephan, Matthias T
AU  - Stephan MT
AD  - Department of Materials Science and Engineering, Massachusetts Institute of
      Technology, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer
      Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Kim, Jacob S
AU  - Kim JS
AD  - Koch Institute for Integrative Cancer Research, Massachusetts Institute of
      Technology, Cambridge, MA 02139, USA.
FAU - Yaffe, Michael B
AU  - Yaffe MB
AD  - Department of Biological Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of
      Technology, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer
      Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Irvine, Darrell J
AU  - Irvine DJ
AD  - Department of Biological Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Department of Materials Science and Engineering,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Koch Institute
      for Integrative Cancer Research, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Ragon Institute of Massachusetts General Hospital,
      Massachusetts Institute of Technology and Harvard University, Boston, MA 02129,
      USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
FAU - Weiner, Louis M
AU  - Weiner LM
AD  - Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,
      Washington, DC 20057, USA.
FAU - Dranoff, Glenn
AU  - Dranoff G
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Wittrup, K Dane
AU  - Wittrup KD
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA; Koch Institute for Integrative
      Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
      Electronic address: wittrup@mit.edu.
LA  - eng
GR  - P30 CA014051/CA/NCI NIH HHS/United States
GR  - R01 CA050633/CA/NCI NIH HHS/United States
GR  - T32 GM008334/GM/NIGMS NIH HHS/United States
GR  - R01 CA174795/CA/NCI NIH HHS/United States
GR  - Intramural NIH HHS/United States
GR  - T32 CA009686/CA/NCI NIH HHS/United States
GR  - CA174795/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Adaptive Immunity
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/drug effects/immunology
MH  - Drug Synergism
MH  - Half-Life
MH  - Immunity, Innate
MH  - Immunotherapy
MH  - Interleukin-2/metabolism/pharmacokinetics/pharmacology
MH  - Killer Cells, Natural/drug effects/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasms/immunology/*therapy
PMC - PMC4398916
MID - NIHMS672386
EDAT- 2015/04/16 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2013/11/21 00:00 [received]
PHST- 2014/10/19 00:00 [revised]
PHST- 2015/03/09 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00092-6 [pii]
AID - 10.1016/j.ccell.2015.03.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):489-501. doi: 10.1016/j.ccell.2015.03.004.

PMID- 25873171
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20151119
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and
      overcome resistance to antibody therapy in vivo.
PG  - 473-88
LID - 10.1016/j.ccell.2015.03.005 [doi]
LID - S1535-6108(15)00093-8 [pii]
AB  - Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of
      action by engaging the immune system. Unfortunately, cures rarely occur and
      patients display intrinsic or acquired resistance. Here, we demonstrate the
      therapeutic potential of targeting human (h) FcgammaRIIB (CD32B), a receptor
      implicated in immune cell desensitization and tumor cell resistance.
      FcgammaRIIB-blocking antibodies prevented internalization of the CD20-specific
      antibody rituximab, thereby maximizing cell surface accessibility and immune
      effector cell mediated antitumor activity. In hFcgammaRIIB-transgenic (Tg) mice, 
      FcgammaRIIB-blocking antibodies effectively deleted target cells in combination
      with rituximab, and other therapeutic antibodies, from resistance-prone stromal
      compartments. Similar efficacy was seen in primary human tumor xenografts,
      including with cells from patients with relapsed/refractory disease. These data
      support the further development of hFcgammaRIIB antibodies for clinical
      assessment.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Roghanian, Ali
AU  - Roghanian A
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Teige, Ingrid
AU  - Teige I
AD  - BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Martensson, Linda
AU  - Martensson L
AD  - BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Cox, Kerry L
AU  - Cox KL
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Kovacek, Mathilda
AU  - Kovacek M
AD  - BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Ljungars, Anne
AU  - Ljungars A
AD  - BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Mattson, Jenny
AU  - Mattson J
AD  - BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Sundberg, Annika
AU  - Sundberg A
AD  - BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Vaughan, Andrew T
AU  - Vaughan AT
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Shah, Vallari
AU  - Shah V
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Smyth, Neil R
AU  - Smyth NR
AD  - Centre for Biological Sciences, University of Southampton, Southampton SO16 6YD, 
      UK.
FAU - Sheth, Bhavwanti
AU  - Sheth B
AD  - Centre for Biological Sciences, University of Southampton, Southampton SO16 6YD, 
      UK.
FAU - Chan, H T Claude
AU  - Chan HT
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Li, Zhan-Chun
AU  - Li ZC
AD  - BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Williams, Emily L
AU  - Williams EL
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Manfredi, Giusi
AU  - Manfredi G
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Oldham, Robert J
AU  - Oldham RJ
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Mockridge, C Ian
AU  - Mockridge CI
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - James, Sonya A
AU  - James SA
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Dahal, Lekh N
AU  - Dahal LN
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Hussain, Khiyam
AU  - Hussain K
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Nilsson, Bjorn
AU  - Nilsson B
AD  - Division of Hematology and Transfusion Medicine, Department of Laboratory
      Medicine, Lund University, 221 85 Lund, Sweden.
FAU - Verbeek, J Sjef
AU  - Verbeek JS
AD  - Department of Human Genetics, Leiden University Medical Centre, Albinusdreef 2,
      2333 ZA Leiden, the Netherlands.
FAU - Juliusson, Gunnar
AU  - Juliusson G
AD  - Skane University Hospital, Lund University, 221 84 Lund, Sweden.
FAU - Hansson, Markus
AU  - Hansson M
AD  - Skane University Hospital, Lund University, 221 84 Lund, Sweden.
FAU - Jerkeman, Mats
AU  - Jerkeman M
AD  - Skane University Hospital, Lund University, 221 84 Lund, Sweden.
FAU - Johnson, Peter W M
AU  - Johnson PW
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Davies, Andrew
AU  - Davies A
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Beers, Stephen A
AU  - Beers SA
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Glennie, Martin J
AU  - Glennie MJ
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
FAU - Frendeus, Bjorn
AU  - Frendeus B
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; BioInvent
      International AB, Solvegatan 41, 22370 Lund, Sweden.
FAU - Cragg, Mark S
AU  - Cragg MS
AD  - Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University
      of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
      Electronic address: msc@soton.ac.uk.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (FCGR2B protein, human)
RN  - 0 (Receptors, IgG)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
CIN - Cancer Cell. 2015 Apr 13;27(4):427-8. PMID: 25873165
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived/metabolism/pharmacology/*therapeutic use
MH  - Drug Synergism
MH  - Humans
MH  - Mice
MH  - Neoplasms/drug therapy/immunology
MH  - Receptors, IgG/*antagonists & inhibitors/physiology
MH  - Rituximab
EDAT- 2015/04/16 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/06/27 00:00 [received]
PHST- 2014/11/19 00:00 [revised]
PHST- 2015/03/10 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00093-8 [pii]
AID - 10.1016/j.ccell.2015.03.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.

PMID- 25873170
OWN - NLM
STAT- MEDLINE
DCOM- 20151001
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Radiotherapy complements immune checkpoint blockade.
PG  - 437-8
LID - 10.1016/j.ccell.2015.03.015 [doi]
LID - S1535-6108(15)00103-8 [pii]
AB  - Adaptive immune resistance ablates effective anti-tumor immune responses. In a
      recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats
      adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The
      superior activity of radiation and dual immune checkpoint blockade is mediated by
      non-redundant immune mechanisms in cancer.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ngiow, Shin Foong
AU  - Ngiow SF
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia; School of Medicine, University of
      Queensland, Herston, QLD 4006, Australia.
FAU - McArthur, Grant A
AU  - McArthur GA
AD  - Cancer Therapeutics Programs, Trescowthick Laboratories, Peter MacCallum Cancer
      Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia; Sir Peter
      MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010,
      Australia.
FAU - Smyth, Mark J
AU  - Smyth MJ
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia; School of Medicine, University of
      Queensland, Herston, QLD 4006, Australia. Electronic address:
      mark.smyth@qimrberghofer.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CTLA-4 Antigen)
SB  - IM
CON - Nature. 2015 Apr 16;520(7547):373-7. PMID: 25754329
MH  - Animals
MH  - B7-H1 Antigen/*antagonists & inhibitors
MH  - CTLA-4 Antigen/*antagonists & inhibitors
MH  - Cell Cycle Checkpoints/*drug effects
MH  - Female
MH  - Humans
MH  - Melanoma/*drug therapy/*immunology/*radiotherapy
MH  - T-Lymphocytes/*drug effects/*radiation effects
EDAT- 2015/04/16 06:00
MHDA- 2015/10/02 06:00
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/10/02 06:00 [medline]
AID - S1535-6108(15)00103-8 [pii]
AID - 10.1016/j.ccell.2015.03.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):437-8. doi: 10.1016/j.ccell.2015.03.015.

PMID- 25873169
OWN - NLM
STAT- MEDLINE
DCOM- 20160114
LR  - 20161025
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Something in the air: hyperoxic conditioning of the tumor microenvironment for
      enhanced immunotherapy.
PG  - 435-6
LID - 10.1016/j.ccell.2015.03.014 [doi]
LID - S1535-6108(15)00102-6 [pii]
AB  - Recent clinical trials in cancer therapy have demonstrated unprecedented
      responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a
      provocative recent paper in Science Translational Medicine, Hatfield and
      colleagues demonstrate the ability of supplemental oxygen to act as a novel
      immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Leone, Robert D
AU  - Leone RD
AD  - Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Horton, Maureen R
AU  - Horton MR
AD  - Pulmonary Division, Department of Medicine, Johns Hopkins University School of
      Medicine, Baltimore, MD 21287, USA.
FAU - Powell, Jonathan D
AU  - Powell JD
AD  - Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic
      address: poweljo@jhmi.edu.
LA  - eng
GR  - P30 CA006973/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - S88TT14065 (Oxygen)
SB  - IM
CON - Sci Transl Med. 2015 Mar 4;7(277):277ra30. PMID: 25739764
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Female
MH  - Humans
MH  - Neoplasms/*drug therapy/*immunology
MH  - Oxygen/*therapeutic use
PMC - PMC4696011
MID - NIHMS737458
EDAT- 2015/04/16 06:00
MHDA- 2016/01/15 06:00
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2016/01/15 06:00 [medline]
AID - S1535-6108(15)00102-6 [pii]
AID - 10.1016/j.ccell.2015.03.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):435-6. doi: 10.1016/j.ccell.2015.03.014.

PMID- 25873168
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - When one mutation is all it takes.
PG  - 433-4
LID - 10.1016/j.ccell.2015.03.016 [doi]
LID - S1535-6108(15)00104-X [pii]
AB  - In a recent issue of Nature Genetics, Andersson and colleagues report that MLL
      fusion alone may be sufficient to spawn an aggressive leukemia in infants. Some
      other pediatric cancers may share a similar, single, "big-hit" origin, possibly
      reflecting a critical developmental window of stem cell vulnerability.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Greaves, Mel
AU  - Greaves M
AD  - Centre for Evolution and Cancer, The Institute of Cancer Research, London,
      Brookes Lawley Building, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. Electronic
      address: mel.greaves@icr.ac.uk.
LA  - eng
GR  - 105104/Wellcome Trust/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
CON - Nat Genet. 2015 Apr;47(4):330-7. PMID: 25730765
MH  - Humans
MH  - *Mutation
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics
EDAT- 2015/04/16 06:00
MHDA- 2015/06/16 06:00
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - S1535-6108(15)00104-X [pii]
AID - 10.1016/j.ccell.2015.03.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):433-4. doi: 10.1016/j.ccell.2015.03.016.

PMID- 25873167
OWN - NLM
STAT- MEDLINE
DCOM- 20150624
LR  - 20150415
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia.
PG  - 431-3
LID - 10.1016/j.ccell.2015.03.012 [doi]
LID - S1535-6108(15)00100-2 [pii]
AB  - The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion
      proteins is required for leukemic transformation and may represent a therapeutic 
      opportunity. In this issue of Cancer Cell, Borkin and colleagues describe the
      development of highly potent small-molecule inhibitors of this interaction that
      reverse the leukemic phenotype and prolong survival in murine models of
      MLL-rearranged leukemia.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Kuhn, Michael W M
AU  - Kuhn MW
AD  - Cancer Biology and Genetics Program and Department of Pediatrics, Memorial Sloan 
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Armstrong, Scott A
AU  - Armstrong SA
AD  - Cancer Biology and Genetics Program and Department of Pediatrics, Memorial Sloan 
      Kettering Cancer Center, New York, NY 10065, USA. Electronic address:
      armstros@mskcc.org.
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Proto-Oncogene Proteins)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
CON - Cancer Cell. 2015 Apr 13;27(4):589-602. PMID: 25817203
MH  - Animals
MH  - Female
MH  - Humans
MH  - Myeloid-Lymphoid Leukemia Protein/*metabolism
MH  - Proto-Oncogene Proteins/*metabolism
EDAT- 2015/04/16 06:00
MHDA- 2015/06/25 06:00
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/25 06:00 [medline]
AID - S1535-6108(15)00100-2 [pii]
AID - 10.1016/j.ccell.2015.03.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):431-3. doi: 10.1016/j.ccell.2015.03.012.

PMID- 25873166
OWN - NLM
STAT- MEDLINE
DCOM- 20150624
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - FAK to the rescue: activated stroma promotes a "safe haven" for BRAF-mutant
      melanoma cells by inducing FAK signaling.
PG  - 429-31
LID - 10.1016/j.ccell.2015.03.013 [doi]
LID - S1535-6108(15)00101-4 [pii]
AB  - Perhaps the most pressing need in cancer therapeutics is to understand drug
      resistance. In this issue of Cancer Cell, Hirata and colleagues show that
      melanoma-associated fibroblasts can drive resistance to the BRAF inhibitor
      PLX4720 by stimulating matrix production/remodeling, and, consequently, survival 
      signaling in melanoma cells via beta1-integrin, Src, and FAK.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Frame, Margaret C
AU  - Frame MC
AD  - Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular
      Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK.
      Electronic address: m.frame@ed.ac.uk.
FAU - Serrels, Alan
AU  - Serrels A
AD  - Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular
      Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Integrin beta1)
RN  - EC 2.7.10.2 (Focal Adhesion Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CON - Cancer Cell. 2015 Apr 13;27(4):574-88. PMID: 25873177
MH  - Animals
MH  - *Drug Resistance, Neoplasm
MH  - Focal Adhesion Protein-Tyrosine Kinases/*metabolism
MH  - Humans
MH  - Integrin beta1/*metabolism
MH  - Melanoma/*metabolism
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
MH  - *Tumor Microenvironment
EDAT- 2015/04/16 06:00
MHDA- 2015/06/25 06:00
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/25 06:00 [medline]
AID - S1535-6108(15)00101-4 [pii]
AID - 10.1016/j.ccell.2015.03.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):429-31. doi: 10.1016/j.ccell.2015.03.013.

PMID- 25873165
OWN - NLM
STAT- MEDLINE
DCOM- 20150624
LR  - 20150415
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Releasing the brakes: targeting FcgammaRIIB on B cells to enhance
      antibody-dependent lymphoma immunotherapy.
PG  - 427-8
LID - 10.1016/j.ccell.2015.03.011 [doi]
LID - S1535-6108(15)00099-9 [pii]
AB  - The inhibitory Fcgamma receptor modulates therapeutic antibody activity by
      setting a threshold for effector cell activation and removing antibodies from the
      tumor cell surface. In this issue of Cancer Cell, Roghanian and colleagues
      demonstrate that antibodies blocking inhibitory Fcgamma receptor function can
      enhance therapeutic antibody activity to allow optimal tumor cell depletion.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Seeling, Michaela
AU  - Seeling M
AD  - Institute of Genetics, Department of Biology, University of Erlangen-Nurnberg,
      Erwin-Rommelstrasse 3, 91058 Erlangen, Germany.
FAU - Nimmerjahn, Falk
AU  - Nimmerjahn F
AD  - Institute of Genetics, Department of Biology, University of Erlangen-Nurnberg,
      Erwin-Rommelstrasse 3, 91058 Erlangen, Germany. Electronic address:
      falk.nimmerjahn@fau.de.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Receptors, IgG)
SB  - IM
CON - Cancer Cell. 2015 Apr 13;27(4):473-88. PMID: 25873171
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived/*therapeutic use
MH  - Humans
MH  - Receptors, IgG/*antagonists & inhibitors
EDAT- 2015/04/16 06:00
MHDA- 2015/06/25 06:00
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/06/25 06:00 [medline]
AID - S1535-6108(15)00099-9 [pii]
AID - 10.1016/j.ccell.2015.03.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):427-8. doi: 10.1016/j.ccell.2015.03.011.

PMID- 25858805
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Macrophages and therapeutic resistance in cancer.
PG  - 462-72
LID - 10.1016/j.ccell.2015.02.015 [doi]
LID - S1535-6108(15)00065-3 [pii]
AB  - How neoplastic cells respond to therapy is not solely dependent on the complexity
      of the genomic aberrations they harbor but is also regulated by numerous dynamic 
      properties of the tumor microenvironment. Identifying and targeting critical
      pathways that improve therapeutic efficacy by bolstering anti-tumor immune
      responses holds great potential for improving outcomes and impacting long-term
      patient survival. Macrophages are key regulators of homeostatic tissue and tumor 
      microenvironments. Therefore, therapeutics impacting macrophage presence and/or
      bioactivity have shown promise in preclinical models and are now being evaluated 
      in the clinic. This review discusses the molecular/cellular pathways identified
      so far whereby macrophages mediate therapeutic responses.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ruffell, Brian
AU  - Ruffell B
AD  - Department of Cell, Developmental, and Cancer Biology and Knight Cancer
      Institute, Oregon Health and Science University, Portland, OR 97034.
FAU - Coussens, Lisa M
AU  - Coussens LM
AD  - Department of Cell, Developmental, and Cancer Biology and Knight Cancer
      Institute, Oregon Health and Science University, Portland, OR 97034. Electronic
      address: coussenl@ohsu.edu.
LA  - eng
GR  - R00 CA185325/CA/NCI NIH HHS/United States
GR  - R01 CA155331/CA/NCI NIH HHS/United States
GR  - U54 CA163123/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20150406
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - Animals
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunotherapy
MH  - Macrophages/drug effects/*immunology
MH  - Mice
MH  - Models, Immunological
MH  - Neoplasm Metastasis/immunology/therapy
MH  - Neoplasms/immunology/pathology/*therapy
MH  - Neovascularization, Pathologic/immunology/therapy
MH  - *Tumor Microenvironment
PMC - PMC4400235
MID - NIHMS669318
EDAT- 2015/04/11 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/01/18 00:00 [received]
PHST- 2015/02/18 00:00 [revised]
PHST- 2015/02/26 00:00 [accepted]
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00065-3 [pii]
AID - 10.1016/j.ccell.2015.02.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):462-72. doi: 10.1016/j.ccell.2015.02.015. Epub
      2015 Apr 6.

PMID- 25858804
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Immune checkpoint blockade: a common denominator approach to cancer therapy.
PG  - 450-61
LID - 10.1016/j.ccell.2015.03.001 [doi]
LID - S1535-6108(15)00089-6 [pii]
AB  - The immune system recognizes and is poised to eliminate cancer but is held in
      check by inhibitory receptors and ligands. These immune checkpoint pathways,
      which normally maintain self-tolerance and limit collateral tissue damage during 
      anti-microbial immune responses, can be co-opted by cancer to evade immune
      destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4,
      anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor
      immunity and mediate durable cancer regressions. The complex biology of immune
      checkpoint pathways still contains many mysteries, and the full activity spectrum
      of checkpoint-blocking drugs, used alone or in combination, is currently the
      subject of intense study.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Topalian, Suzanne L
AU  - Topalian SL
AD  - Department of Surgery, Sidney Kimmel Comprehensive Cancer Center and Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic
      address: stopali1@jhmi.edu.
FAU - Drake, Charles G
AU  - Drake CG
AD  - The Brady Urological Institute, Sidney Kimmel Comprehensive Cancer Center and
      Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department
      of Oncology, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins
      University School of Medicine, Baltimore, MD 21287, USA.
FAU - Pardoll, Drew M
AU  - Pardoll DM
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
LA  - eng
GR  - R01 CA142779/CA/NCI NIH HHS/United States
GR  - R01 CA154555/CA/NCI NIH HHS/United States
GR  - R01CA142779/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150406
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CD28 Antigens)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - CD28 Antigens/antagonists & inhibitors/immunology/physiology
MH  - CTLA-4 Antigen/antagonists & inhibitors/immunology/physiology
MH  - Humans
MH  - Immunotherapy
MH  - *Models, Immunological
MH  - Neoplasms/*immunology
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology/physiology
PMC - PMC4400238
MID - NIHMS670602
EDAT- 2015/04/11 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/01/09 00:00 [received]
PHST- 2015/02/17 00:00 [revised]
PHST- 2015/03/03 00:00 [accepted]
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00089-6 [pii]
AID - 10.1016/j.ccell.2015.03.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub
      2015 Apr 6.

PMID- 25858803
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20171011
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - The journey from discoveries in fundamental immunology to cancer immunotherapy.
PG  - 439-49
LID - 10.1016/j.ccell.2015.03.007 [doi]
LID - S1535-6108(15)00095-1 [pii]
AB  - Recent advances in cancer immunotherapy have directly built on 50 years of
      fundamental and technological advances that made checkpoint blockade and T cell
      engineering possible. In this review, we intend to show that research, not
      specifically designed to bring relief or cure to any particular disease, can,
      when creatively exploited, lead to spectacular results in the management of
      cancer. The discovery of thymus immune function, T cells, and immune surveillance
      bore the seeds for today's targeted immune interventions and chimeric antigen
      receptors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Miller, Jacques F A P
AU  - Miller JF
AD  - The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3050,
      Australia. Electronic address: miller@wehi.edu.au.
FAU - Sadelain, Michel
AU  - Sadelain M
AD  - The Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA. Electronic address: m-sadelain@ski.mskcc.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150406
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - *Allergy and Immunology
MH  - Animals
MH  - B-Lymphocytes/physiology
MH  - Cancer Vaccines/therapeutic use
MH  - Humans
MH  - Immunologic Surveillance
MH  - Immunotherapy/*trends
MH  - Mice
MH  - Neoplasms/immunology/*therapy
MH  - *Research
MH  - T-Lymphocytes/physiology
MH  - Thymus Gland/immunology
EDAT- 2015/04/11 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/01/27 00:00 [received]
PHST- 2015/03/01 00:00 [revised]
PHST- 2015/03/16 00:00 [accepted]
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00095-1 [pii]
AID - 10.1016/j.ccell.2015.03.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):439-49. doi: 10.1016/j.ccell.2015.03.007. Epub
      2015 Apr 6.

PMID- 25843002
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression,
      invasion, and metastasis.
PG  - 561-73
LID - 10.1016/j.ccell.2015.02.014 [doi]
LID - S1535-6108(15)00064-1 [pii]
AB  - Many cancers harbor oncogenic mutations of KRAS. Effectors mediating cancer
      progression, invasion, and metastasis in KRAS-mutated cancers are only
      incompletely understood. Here we identify cancer cell-expressed murine TRAIL-R,
      whose main function ascribed so far has been the induction of apoptosis as a
      crucial mediator of KRAS-driven cancer progression, invasion, and metastasis and 
      in vivo Rac-1 activation. Cancer cell-restricted genetic ablation of murine
      TRAIL-R in autochthonous KRAS-driven models of non-small-cell lung cancer (NSCLC)
      and pancreatic ductal adenocarcinoma (PDAC) reduces tumor growth, blunts
      metastasis, and prolongs survival by inhibiting cancer cell-autonomous migration,
      proliferation, and invasion. Consistent with this, high TRAIL-R2 expression
      correlates with invasion of human PDAC into lymph vessels and with shortened
      metastasis-free survival of KRAS-mutated colorectal cancer patients.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - von Karstedt, Silvia
AU  - von Karstedt S
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, 72 Huntley Street, London WC1E 6DD, UK.
FAU - Conti, Annalisa
AU  - Conti A
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, 72 Huntley Street, London WC1E 6DD, UK; Department of
      Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale
      dei Tumori, 20133 Milan, Italy.
FAU - Nobis, Max
AU  - Nobis M
AD  - Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61
      1BD, UK.
FAU - Montinaro, Antonella
AU  - Montinaro A
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, 72 Huntley Street, London WC1E 6DD, UK.
FAU - Hartwig, Torsten
AU  - Hartwig T
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, 72 Huntley Street, London WC1E 6DD, UK.
FAU - Lemke, Johannes
AU  - Lemke J
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, 72 Huntley Street, London WC1E 6DD, UK.
FAU - Legler, Karen
AU  - Legler K
AD  - Division of Molecular Oncology, Institute for Experimental Cancer Research,
      University of Kiel, 24105 Kiel, Germany.
FAU - Annewanter, Franka
AU  - Annewanter F
AD  - Division of Molecular Oncology, Institute for Experimental Cancer Research,
      University of Kiel, 24105 Kiel, Germany.
FAU - Campbell, Andrew D
AU  - Campbell AD
AD  - Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61
      1BD, UK.
FAU - Taraborrelli, Lucia
AU  - Taraborrelli L
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, 72 Huntley Street, London WC1E 6DD, UK.
FAU - Grosse-Wilde, Anne
AU  - Grosse-Wilde A
AD  - German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, 
      Germany; Institute for Systems Biology, 401 Terry Avenue N, Seattle, WA 98109,
      USA.
FAU - Coy, Johannes F
AU  - Coy JF
AD  - German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, 
      Germany; TAVARLIN AG, Biotechpark Pfungstadt, Reissstrasse 1a, 64319 Pfungstadt, 
      Germany.
FAU - El-Bahrawy, Mona A
AU  - El-Bahrawy MA
AD  - Department of Histopathology, Imperial College London, Du Cane Road, London W12
      0NN, UK.
FAU - Bergmann, Frank
AU  - Bergmann F
AD  - Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 
      69120 Heidelberg, Germany.
FAU - Koschny, Ronald
AU  - Koschny R
AD  - Department of Gastroenterology, University Hospital Heidelberg, Im Neuenheimer
      Feld 410, 69120 Heidelberg, Germany.
FAU - Werner, Jens
AU  - Werner J
AD  - Department of Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 110,
      69120 Heidelberg, Germany.
FAU - Ganten, Tom M
AU  - Ganten TM
AD  - Department of Gastroenterology, University Hospital Heidelberg, Im Neuenheimer
      Feld 410, 69120 Heidelberg, Germany.
FAU - Schweiger, Thomas
AU  - Schweiger T
AD  - Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 
      18-20, 1090 Vienna, Austria; Christian Doppler Laboratory for Cardiac and
      Thoracic Diagnosis and Regeneration, Medical University of Vienna, Waehringer
      Guertel 18-20, 1090 Vienna, Austria.
FAU - Hoetzenecker, Konrad
AU  - Hoetzenecker K
AD  - Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration,
      Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
FAU - Kenessey, Istvan
AU  - Kenessey I
AD  - 2nd Department of Pathology, Semmelweis University Budapest, Ulloi ut 93, 1091
      Budapest, Hungary.
FAU - Hegedus, Balazs
AU  - Hegedus B
AD  - Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 
      18-20, 1090 Vienna, Austria; Molecular Oncology Research Group, Hungarian Academy
      of Sciences-Semmelweis University, 1091 Budapest, Hungary.
FAU - Bergmann, Michael
AU  - Bergmann M
AD  - Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 
      18-20, 1090 Vienna, Austria.
FAU - Hauser, Charlotte
AU  - Hauser C
AD  - Department of General Surgery, Visceral, Thoracic, Transplantation and Pediatric 
      Surgery, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
FAU - Egberts, Jan-Hendrik
AU  - Egberts JH
AD  - Department of General Surgery, Visceral, Thoracic, Transplantation and Pediatric 
      Surgery, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
FAU - Becker, Thomas
AU  - Becker T
AD  - Department of General Surgery, Visceral, Thoracic, Transplantation and Pediatric 
      Surgery, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
FAU - Rocken, Christoph
AU  - Rocken C
AD  - Department of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
FAU - Kalthoff, Holger
AU  - Kalthoff H
AD  - Division of Molecular Oncology, Institute for Experimental Cancer Research,
      University of Kiel, 24105 Kiel, Germany.
FAU - Trauzold, Anna
AU  - Trauzold A
AD  - Division of Molecular Oncology, Institute for Experimental Cancer Research,
      University of Kiel, 24105 Kiel, Germany; Department of General Surgery, Visceral,
      Thoracic, Transplantation and Pediatric Surgery, University Hospital
      Schleswig-Holstein, 24105 Kiel, Germany.
FAU - Anderson, Kurt I
AU  - Anderson KI
AD  - Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61
      1BD, UK.
FAU - Sansom, Owen J
AU  - Sansom OJ
AD  - Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61
      1BD, UK.
FAU - Walczak, Henning
AU  - Walczak H
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, 72 Huntley Street, London WC1E 6DD, UK. Electronic address:
      h.walczak@ucl.ac.uk.
LA  - eng
GR  - 096831/Wellcome Trust/United Kingdom
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150402
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Animals
MH  - Apoptosis/genetics
MH  - Carcinoma, Pancreatic Ductal/genetics/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, SCID
MH  - Models, Biological
MH  - Neoplasm Invasiveness/genetics
MH  - Prognosis
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism/*physiology
EDAT- 2015/04/07 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/04/07 06:00
PHST- 2014/04/04 00:00 [received]
PHST- 2015/02/02 00:00 [revised]
PHST- 2015/02/26 00:00 [accepted]
PHST- 2015/04/07 06:00 [entrez]
PHST- 2015/04/07 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00064-1 [pii]
AID - 10.1016/j.ccell.2015.02.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):561-73. doi: 10.1016/j.ccell.2015.02.014. Epub
      2015 Apr 2.

PMID- 25817203
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 4
DP  - 2015 Apr 13
TI  - Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL
      leukemia in vivo.
PG  - 589-602
LID - 10.1016/j.ccell.2015.02.016 [doi]
LID - S1535-6108(15)00066-5 [pii]
AB  - Chromosomal translocations affecting mixed lineage leukemia gene (MLL) result in 
      acute leukemias resistant to therapy. The leukemogenic activity of MLL fusion
      proteins is dependent on their interaction with menin, providing basis for
      therapeutic intervention. Here we report the development of highly potent and
      orally bioavailable small-molecule inhibitors of the menin-MLL interaction,
      MI-463 and MI-503, and show their profound effects in MLL leukemia cells and
      substantial survival benefit in mouse models of MLL leukemia. Finally, we
      demonstrate the efficacy of these compounds in primary samples derived from MLL
      leukemia patients. Overall, we demonstrate that pharmacologic inhibition of the
      menin-MLL interaction represents an effective treatment for MLL leukemias in vivo
      and provide advanced molecular scaffold for clinical lead identification.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Borkin, Dmitry
AU  - Borkin D
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - He, Shihan
AU  - He S
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Miao, Hongzhi
AU  - Miao H
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Kempinska, Katarzyna
AU  - Kempinska K
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Pollock, Jonathan
AU  - Pollock J
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA;
      Graduate Program in Molecular and Cellular Pathology, University of Michigan, Ann
      Arbor, MI 48109, USA.
FAU - Chase, Jennifer
AU  - Chase J
AD  - Center for Stem Cell Biology, Life Sciences Institute, University of Michigan,
      Ann Arbor, MI 48109, USA; Graduate Program in Cellular and Molecular Biology,
      University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Purohit, Trupta
AU  - Purohit T
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Malik, Bhavna
AU  - Malik B
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Zhao, Ting
AU  - Zhao T
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Wang, Jingya
AU  - Wang J
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Wen, Bo
AU  - Wen B
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Zong, Hongliang
AU  - Zong H
AD  - Department of Medicine, Weill Medical College of Cornell University, New York, NY
      10065, USA.
FAU - Jones, Morgan
AU  - Jones M
AD  - Center for Stem Cell Biology, Life Sciences Institute, University of Michigan,
      Ann Arbor, MI 48109, USA; Graduate Program in Cellular and Molecular Biology,
      University of Michigan, Ann Arbor, MI 48109, USA; Medical Scientist Training
      Program, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Danet-Desnoyers, Gwenn
AU  - Danet-Desnoyers G
AD  - Department of Medicine, Division of Hematology-Oncology, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Guzman, Monica L
AU  - Guzman ML
AD  - Department of Medicine, Weill Medical College of Cornell University, New York, NY
      10065, USA.
FAU - Talpaz, Moshe
AU  - Talpaz M
AD  - Division of Hematology-Oncology, Department of Internal Medicine, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Bixby, Dale L
AU  - Bixby DL
AD  - Division of Hematology-Oncology, Department of Internal Medicine, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Sun, Duxin
AU  - Sun D
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Hess, Jay L
AU  - Hess JL
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; School
      of Medicine, Indiana University, Indianapolis, IN 46202, USA.
FAU - Muntean, Andrew G
AU  - Muntean AG
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Maillard, Ivan
AU  - Maillard I
AD  - Center for Stem Cell Biology, Life Sciences Institute, University of Michigan,
      Ann Arbor, MI 48109, USA; Division of Hematology-Oncology, Department of Internal
      Medicine, University of Michigan, Ann Arbor, MI 48109, USA; Department of Cell
      and Developmental Biology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Cierpicki, Tomasz
AU  - Cierpicki T
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Grembecka, Jolanta
AU  - Grembecka J
AD  - Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
      Electronic address: jolantag@umich.edu.
LA  - eng
SI  - GEO/GSE60673
SI  - PDB/4X5Y
SI  - PDB/4X5Z
GR  - R01 CA151425/CA/NCI NIH HHS/United States
GR  - P30 CA046592/CA/NCI NIH HHS/United States
GR  - R01 CA160467/CA/NCI NIH HHS/United States
GR  - 1R01CA160467/CA/NCI NIH HHS/United States
GR  - R01 AI091627/AI/NIAID NIH HHS/United States
GR  - T32 HD007505/HD/NICHD NIH HHS/United States
GR  - HD007505/HD/NICHD NIH HHS/United States
GR  - GM007315/GM/NIGMS NIH HHS/United States
GR  - T32 GM007315/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150326
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MEN1 protein, human)
RN  - 0 (MLL protein, human)
RN  - 0 (Men1 protein, mouse)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.1.1.43 (Mll protein, mouse)
SB  - IM
CIN - Cancer Cell. 2015 Apr 13;27(4):431-3. PMID: 25873167
CIN - Nat Rev Cancer. 2015 May;15(5):256-7. PMID: 25877330
MH  - Animals
MH  - Antineoplastic Agents/chemistry/pharmacology/therapeutic use
MH  - Disease Progression
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Hematopoiesis/drug effects
MH  - Histone-Lysine N-Methyltransferase/genetics/metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Myeloid-Lymphoid Leukemia Protein/chemistry/genetics/*metabolism
MH  - Oncogene Proteins, Fusion/antagonists & inhibitors/genetics
MH  - Proto-Oncogene Proteins/genetics/*metabolism
MH  - Tumor Cells, Cultured
PMC - PMC4415852
MID - NIHMS675650
EDAT- 2015/03/31 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/03/31 06:00
PHST- 2014/08/15 00:00 [received]
PHST- 2014/12/11 00:00 [revised]
PHST- 2015/02/27 00:00 [accepted]
PHST- 2015/03/31 06:00 [entrez]
PHST- 2015/03/31 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S1535-6108(15)00066-5 [pii]
AID - 10.1016/j.ccell.2015.02.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub
      2015 Mar 26.

PMID- 25759025
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20180130
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling
      defines a distinct subtype of acute lymphoblastic leukemia.
PG  - 409-25
LID - 10.1016/j.ccell.2015.02.003 [doi]
LID - S1535-6108(15)00053-7 [pii]
AB  - Studying 830 pre-B ALL cases from four clinical trials, we found that human ALL
      can be divided into two fundamentally distinct subtypes based on pre-BCR
      function. While absent in the majority of ALL cases, tonic pre-BCR signaling was 
      found in 112 cases (13.5%). In these cases, tonic pre-BCR signaling induced
      activation of BCL6, which in turn increased pre-BCR signaling output at the
      transcriptional level. Interestingly, inhibition of pre-BCR-related tyrosine
      kinases reduced constitutive BCL6 expression and selectively killed
      patient-derived pre-BCR(+) ALL cells. These findings identify a genetically and
      phenotypically distinct subset of human ALL that critically depends on tonic
      pre-BCR signaling. In vivo treatment studies suggested that pre-BCR tyrosine
      kinase inhibitors are useful for the treatment of patients with pre-BCR(+) ALL.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Geng, Huimin
AU  - Geng H
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Hurtz, Christian
AU  - Hurtz C
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Lenz, Kyle B
AU  - Lenz KB
AD  - Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon
      Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute,
      Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Chen, Zhengshan
AU  - Chen Z
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Baumjohann, Dirk
AU  - Baumjohann D
AD  - Microbiology and Immunology, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Thompson, Sarah
AU  - Thompson S
AD  - Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon
      Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute,
      Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Goloviznina, Natalya A
AU  - Goloviznina NA
AD  - Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon
      Health & Science University, Portland, OR 97239, USA; Pape Family Pediatric
      Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Chen, Wei-Yi
AU  - Chen WY
AD  - Laboratory of Biochemistry and Molecular Biology, Rockefeller University, New
      York, NY 10065, USA; Institute of Biochemistry and Molecular Biology, National
      Yang-Ming University, Taipei 11221, Taiwan.
FAU - Huan, Jianya
AU  - Huan J
AD  - Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon
      Health & Science University, Portland, OR 97239, USA; Pape Family Pediatric
      Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.
FAU - LaTocha, Dorian
AU  - LaTocha D
AD  - Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, 
      USA.
FAU - Ballabio, Erica
AU  - Ballabio E
AD  - MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
FAU - Xiao, Gang
AU  - Xiao G
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Lee, Jae-Woong
AU  - Lee JW
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Deucher, Anne
AU  - Deucher A
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Qi, Zhongxia
AU  - Qi Z
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Park, Eugene
AU  - Park E
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Huang, Chuanxin
AU  - Huang C
AD  - Departments of Medicine and Pharmacology, Weill Cornell Medical College, New
      York, NY 10065, USA.
FAU - Nahar, Rahul
AU  - Nahar R
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Kweon, Soo-Mi
AU  - Kweon SM
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Shojaee, Seyedmehdi
AU  - Shojaee S
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Chan, Lai N
AU  - Chan LN
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Yu, Jingwei
AU  - Yu J
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA.
FAU - Kornblau, Steven M
AU  - Kornblau SM
AD  - Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Bijl, Janetta J
AU  - Bijl JJ
AD  - Hopital Maisonneuve-Rosemont, Montreal, QC H1T 2M4, Canada.
FAU - Ye, B Hilda
AU  - Ye BH
AD  - Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA.
FAU - Ansel, K Mark
AU  - Ansel KM
AD  - Microbiology and Immunology, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Paietta, Elisabeth
AU  - Paietta E
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461,
      USA.
FAU - Melnick, Ari
AU  - Melnick A
AD  - Departments of Medicine and Pharmacology, Weill Cornell Medical College, New
      York, NY 10065, USA.
FAU - Hunger, Stephen P
AU  - Hunger SP
AD  - Division of Pediatric Oncology and Center for Childhood Cancer Research,
      Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
FAU - Kurre, Peter
AU  - Kurre P
AD  - Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon
      Health & Science University, Portland, OR 97239, USA; Pape Family Pediatric
      Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Tyner, Jeffrey W
AU  - Tyner JW
AD  - Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, 
      USA; Department of Cell & Developmental Biology, Oregon Health & Science
      University, Portland, OR 97239, USA.
FAU - Loh, Mignon L
AU  - Loh ML
AD  - Pediatric Hematology-Oncology, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Roeder, Robert G
AU  - Roeder RG
AD  - Laboratory of Biochemistry and Molecular Biology, Rockefeller University, New
      York, NY 10065, USA.
FAU - Druker, Brian J
AU  - Druker BJ
AD  - Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, 
      USA; Howard Hughes Medical Institute, Portland, OR 97239, USA.
FAU - Burger, Jan A
AU  - Burger JA
AD  - Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston,
      TX 77030, USA.
FAU - Milne, Thomas A
AU  - Milne TA
AD  - MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
FAU - Chang, Bill H
AU  - Chang BH
AD  - Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon
      Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute,
      Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Muschen, Markus
AU  - Muschen M
AD  - Departments of Laboratory Medicine, University of California, San Francisco, San 
      Francisco, CA 94143, USA. Electronic address: markus.muschen@ucsf.edu.
LA  - eng
SI  - GEO/GSE59332
SI  - GEO/GSE59538
GR  - R01 CA178765/CA/NCI NIH HHS/United States
GR  - U10 CA98413/CA/NCI NIH HHS/United States
GR  - R01CA183947/CA/NCI NIH HHS/United States
GR  - 101880/Wellcome Trust/United Kingdom
GR  - U10 CA021115/CA/NCI NIH HHS/United States
GR  - U24 CA196172/CA/NCI NIH HHS/United States
GR  - Medical Research Council/United Kingdom
GR  - U10 CA098413/CA/NCI NIH HHS/United States
GR  - U24 CA114766/CA/NCI NIH HHS/United States
GR  - R01 CA157644/CA/NCI NIH HHS/United States
GR  - R00 CA151457/CA/NCI NIH HHS/United States
GR  - R01 CA172558/CA/NCI NIH HHS/United States
GR  - R01CA137060/CA/NCI NIH HHS/United States
GR  - R01 CA169458/CA/NCI NIH HHS/United States
GR  - CA178765/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - R01 CA163086/CA/NCI NIH HHS/United States
GR  - CA163068/CA/NCI NIH HHS/United States
GR  - R01CA169458/CA/NCI NIH HHS/United States
GR  - U10 CA098543/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - R01 CA139032/CA/NCI NIH HHS/United States
GR  - R01CA157644/CA/NCI NIH HHS/United States
GR  - R00CA151457/CA/NCI NIH HHS/United States
GR  - R01CA172558/CA/NCI NIH HHS/United States
GR  - U10 CA98543/CA/NCI NIH HHS/United States
GR  - R01CA139032/CA/NCI NIH HHS/United States
GR  - P30 CA069533/CA/NCI NIH HHS/United States
GR  - MC_UU_12009/6/Medical Research Council/United Kingdom
GR  - U10 CA180827/CA/NCI NIH HHS/United States
GR  - R01 CA137060/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BCL6 protein, human)
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Pre-B-Cell Leukemia Transcription Factor 1)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (TCF3 protein, human)
RN  - 0 (pbx1 protein, human)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (SYK protein, human)
RN  - EC 2.7.10.2 (Syk Kinase)
RN  - EC 2.7.10.2 (src-Family Kinases)
SB  - IM
CIN - Cancer Cell. 2015 Mar 9;27(3):321-3. PMID: 25759017
CIN - Cancer Discov. 2015 May;5(5):OF15. PMID: 25790981
MH  - Basic Helix-Loop-Helix Transcription Factors/metabolism/physiology
MH  - Clinical Trials as Topic
MH  - DNA-Binding Proteins/genetics/metabolism/*physiology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/metabolism
MH  - Molecular Sequence Data
MH  - Phosphatidylinositol 3-Kinase/metabolism
MH  - Pre-B-Cell Leukemia Transcription Factor 1
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics/*metabolism/pathology
MH  - Precursor Cells, B-Lymphoid/*metabolism
MH  - Protein-Tyrosine Kinases/metabolism
MH  - Proto-Oncogene Proteins/metabolism/physiology
MH  - Proto-Oncogene Proteins c-bcl-6
MH  - Signal Transduction
MH  - Syk Kinase
MH  - Up-Regulation
MH  - src-Family Kinases/metabolism
PMC - PMC4618684
MID - NIHMS664649
EDAT- 2015/03/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/09/02 00:00 [received]
PHST- 2014/12/22 00:00 [revised]
PHST- 2015/02/10 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1535-6108(15)00053-7 [pii]
AID - 10.1016/j.ccell.2015.02.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):409-25. doi: 10.1016/j.ccell.2015.02.003.

PMID- 25759024
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - A functional landscape of resistance to ALK inhibition in lung cancer.
PG  - 397-408
LID - 10.1016/j.ccell.2015.02.005 [doi]
LID - S1535-6108(15)00055-0 [pii]
AB  - We conducted a large-scale functional genetic study to characterize mechanisms of
      resistance to ALK inhibition in ALK-dependent lung cancer cells. We identify
      members of known resistance pathways and additional putative resistance drivers. 
      Among the latter were members of the P2Y purinergic receptor family of
      G-protein-coupled receptors (P2Y1, P2Y2, and P2Y6). P2Y receptors mediated
      resistance in part through a protein-kinase-C (PKC)-dependent mechanism.
      Moreover, PKC activation alone was sufficient to confer resistance to ALK
      inhibitors, whereas combined ALK and PKC inhibition restored sensitivity. We
      observed enrichment of gene signatures associated with several resistance drivers
      (including P2Y receptors) in crizotinib-resistant ALK-rearranged lung tumors
      compared to treatment-naive controls, supporting a role for these identified
      mechanisms in clinical ALK inhibitor resistance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wilson, Frederick H
AU  - Wilson FH
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA.
FAU - Johannessen, Cory M
AU  - Johannessen CM
AD  - The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Piccioni, Federica
AU  - Piccioni F
AD  - The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Tamayo, Pablo
AU  - Tamayo P
AD  - The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Kim, Jong Wook
AU  - Kim JW
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA.
FAU - Van Allen, Eliezer M
AU  - Van Allen EM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA.
FAU - Corsello, Steven M
AU  - Corsello SM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA.
FAU - Capelletti, Marzia
AU  - Capelletti M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Calles, Antonio
AU  - Calles A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Butaney, Mohit
AU  - Butaney M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Sharifnia, Tanaz
AU  - Sharifnia T
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA.
FAU - Gabriel, Stacey B
AU  - Gabriel SB
AD  - The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Mesirov, Jill P
AU  - Mesirov JP
AD  - The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Hahn, William C
AU  - Hahn WC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA.
FAU - Engelman, Jeffrey A
AU  - Engelman JA
AD  - Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.
FAU - Meyerson, Matthew
AU  - Meyerson M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA; Department of Pathology, Brigham and Women's Hospital, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Root, David E
AU  - Root DE
AD  - The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Janne, Pasi A
AU  - Janne PA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; Belfer Institute for Applied Cancer Science,
      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
FAU - Garraway, Levi A
AU  - Garraway LA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge,
      MA 02142, USA. Electronic address: levi_garraway@dfci.harvard.edu.
LA  - eng
SI  - dbGaP/PHS000855.V1.P1
GR  - NIH R01 CA154480/CA/NCI NIH HHS/United States
GR  - R01 GM074024/GM/NIGMS NIH HHS/United States
GR  - U54 HG003067/HG/NHGRI NIH HHS/United States
GR  - #5U54HG003067-11/HG/NHGRI NIH HHS/United States
GR  - GM074024/GM/NIGMS NIH HHS/United States
GR  - U54 HG006093/HG/NHGRI NIH HHS/United States
GR  - NIH R01 CA136851/CA/NCI NIH HHS/United States
GR  - T32 CA009172/CA/NCI NIH HHS/United States
GR  - P01 CA154303/CA/NCI NIH HHS/United States
GR  - U01 CA176058/CA/NCI NIH HHS/United States
GR  - DP2 0D002750/DP/NCCDPHP CDC HHS/United States
GR  - R33 CA155554/CA/NCI NIH HHS/United States
GR  - R01 CA154480/CA/NCI NIH HHS/United States
GR  - U54 CA112962/CA/NCI NIH HHS/United States
GR  - NIH 5R33CA155554-03/CA/NCI NIH HHS/United States
GR  - R01 CA121941/CA/NCI NIH HHS/United States
GR  - R01 CA136851/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Purinergic P2Y)
RN  - 53AH36668S (crizotinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (anaplastic lymphoma kinase)
SB  - IM
CIN - Cancer Discov. 2015 May;5(5):OF10. PMID: 25790980
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*genetics/pathology
MH  - Pyrazoles/*pharmacology/therapeutic use
MH  - Pyridines/*pharmacology/therapeutic use
MH  - Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/genetics/metabolism
MH  - Receptor, Epidermal Growth Factor/genetics
MH  - Receptor, ErbB-2/genetics
MH  - Receptors, Purinergic P2Y/genetics
MH  - Signal Transduction/drug effects/genetics
PMC - PMC4398996
MID - NIHMS669094
EDAT- 2015/03/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/09/24 00:00 [received]
PHST- 2014/12/15 00:00 [revised]
PHST- 2015/02/10 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1535-6108(15)00055-0 [pii]
AID - 10.1016/j.ccell.2015.02.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):397-408. doi: 10.1016/j.ccell.2015.02.005.

PMID- 25759023
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20160601
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals
      targeting opportunities.
PG  - 382-96
LID - 10.1016/j.ccell.2015.02.007 [doi]
LID - S1535-6108(15)00057-4 [pii]
AB  - Large efforts dedicated to detect somatic alterations across tumor genomes/exomes
      are expected to produce significant improvements in precision cancer medicine.
      However, high inter-tumor heterogeneity is a major obstacle to developing and
      applying therapeutic targeted agents to treat most cancer patients. Here, we
      offer a comprehensive assessment of the scope of targeted therapeutic agents in a
      large pan-cancer cohort. We developed an in silico prescription strategy based on
      identification of the driver alterations in each tumor and their druggability
      options. Although relatively few tumors are tractable by approved agents
      following clinical guidelines (5.9%), up to 40.2% could benefit from different
      repurposing options, and up to 73.3% considering treatments currently under
      clinical investigation. We also identified 80 therapeutically targetable cancer
      genes.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Rubio-Perez, Carlota
AU  - Rubio-Perez C
AD  - Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM
      Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor 
      Aiguader 88, 08003 Barcelona, Catalonia, Spain.
FAU - Tamborero, David
AU  - Tamborero D
AD  - Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM
      Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor 
      Aiguader 88, 08003 Barcelona, Catalonia, Spain.
FAU - Schroeder, Michael P
AU  - Schroeder MP
AD  - Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM
      Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor 
      Aiguader 88, 08003 Barcelona, Catalonia, Spain.
FAU - Antolin, Albert A
AU  - Antolin AA
AD  - Systems Pharmacology, Research Program on Biomedical Informatics, IMIM Hospital
      del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor Aiguader 
      88, 08003 Barcelona, Catalonia, Spain.
FAU - Deu-Pons, Jordi
AU  - Deu-Pons J
AD  - Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM
      Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor 
      Aiguader 88, 08003 Barcelona, Catalonia, Spain.
FAU - Perez-Llamas, Christian
AU  - Perez-Llamas C
AD  - Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM
      Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor 
      Aiguader 88, 08003 Barcelona, Catalonia, Spain.
FAU - Mestres, Jordi
AU  - Mestres J
AD  - Systems Pharmacology, Research Program on Biomedical Informatics, IMIM Hospital
      del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor Aiguader 
      88, 08003 Barcelona, Catalonia, Spain.
FAU - Gonzalez-Perez, Abel
AU  - Gonzalez-Perez A
AD  - Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM
      Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor 
      Aiguader 88, 08003 Barcelona, Catalonia, Spain.
FAU - Lopez-Bigas, Nuria
AU  - Lopez-Bigas N
AD  - Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM
      Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor 
      Aiguader 88, 08003 Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i 
      Estudis Avancats (ICREA), Passeig Lluis Companys 23, 08010 Barcelona, Spain.
      Electronic address: nuria.lopez@upf.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
SB  - IM
CIN - Nat Rev Drug Discov. 2015 May;14(5):311. PMID: 25907342
CIN - Cancer Cell. 2015 Mar 9;27(3):319-21. PMID: 25759016
CIN - Cancer Discov. 2015 May;5(5):OF16. PMID: 25813349
MH  - Antineoplastic Agents
MH  - Carcinogenesis/*genetics
MH  - Clinical Protocols
MH  - Clinical Trials as Topic
MH  - Cohort Studies
MH  - Computational Biology
MH  - DNA Mutational Analysis
MH  - *Decision Making, Computer-Assisted
MH  - Drug Repositioning
MH  - Humans
MH  - Neoplasms/drug therapy/*genetics
MH  - Precision Medicine/*methods
EDAT- 2015/03/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/05/23 00:00 [received]
PHST- 2014/10/21 00:00 [revised]
PHST- 2015/02/17 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1535-6108(15)00057-4 [pii]
AID - 10.1016/j.ccell.2015.02.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):382-96. doi: 10.1016/j.ccell.2015.02.007.

PMID- 25759022
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20150311
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB
      phosphorylation and suppresses breast cancer metastasis.
PG  - 370-81
LID - 10.1016/j.ccell.2015.02.004 [doi]
LID - S1535-6108(15)00054-9 [pii]
AB  - NF-kappaB is a critical link between inflammation and cancer, but whether long
      non-coding RNAs (lncRNAs) regulate its activation remains unknown. Here, we
      identify an NF-KappaB Interacting LncRNA (NKILA), which is upregulated by
      NF-kappaB, binds to NF-kappaB/IkappaB, and directly masks phosphorylation motifs 
      of IkappaB, thereby inhibiting IKK-induced IkappaB phosphorylation and NF-kappaB 
      activation. Unlike DNA that is dissociated from NF-kappaB by IkappaB, NKILA
      interacts with NF-kappaB/IkappaB to form a stable complex. Importantly, NKILA is 
      essential to prevent over-activation of NF-kappaB pathway in
      inflammation-stimulated breast epithelial cells. Furthermore, low NKILA
      expression is associated with breast cancer metastasis and poor patient
      prognosis. Therefore, lncRNAs can directly interact with functional domains of
      signaling proteins, serving as a class of NF-kappaB modulators to suppress cancer
      metastasis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Liu, Bodu
AU  - Liu B
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China; Key Laboratory of Gene
      Engineering of Ministry of Education, State Key Laboratory of Biocontrol, School 
      of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.
FAU - Sun, Lijuan
AU  - Sun L
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China; Key Laboratory of Gene
      Engineering of Ministry of Education, State Key Laboratory of Biocontrol, School 
      of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.
FAU - Liu, Qiang
AU  - Liu Q
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China.
FAU - Gong, Chang
AU  - Gong C
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China.
FAU - Yao, Yandan
AU  - Yao Y
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China.
FAU - Lv, Xiaobin
AU  - Lv X
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China.
FAU - Lin, Ling
AU  - Lin L
AD  - Department of Internal Medicine, The First Affiliated Hospital, Shantou
      University Medical College, Shantou 515041, China.
FAU - Yao, Herui
AU  - Yao H
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China.
FAU - Su, Fengxi
AU  - Su F
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China.
FAU - Li, Dangsheng
AU  - Li D
AD  - Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320
      Yueyang Road, Shanghai 200031, China.
FAU - Zeng, Musheng
AU  - Zeng M
AD  - State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen
      University, Guangzhou 510060, China.
FAU - Song, Erwei
AU  - Song E
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou 510120, China; Key Laboratory of Malignant Tumor Gene Regulation and
      Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial
      Hospital, Sun Yat-sen University, Guangzhou 510120, China; Key Laboratory of Gene
      Engineering of Ministry of Education, State Key Laboratory of Biocontrol, School 
      of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China. Electronic
      address: songew@mail.sysu.edu.cn.
LA  - eng
SI  - GEO/GSE57539
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (I-kappa B Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Female
MH  - Humans
MH  - I-kappa B Proteins/chemistry/metabolism/physiology
MH  - NF-kappa B/chemistry/*metabolism/physiology
MH  - Neoplasm Metastasis/*genetics
MH  - Phosphorylation
MH  - Prognosis
MH  - Protein Structure, Tertiary
MH  - RNA, Long Noncoding/*physiology
MH  - Signal Transduction
MH  - Up-Regulation
EDAT- 2015/03/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/03/12 06:00
PHST- 2013/02/25 00:00 [received]
PHST- 2014/12/19 00:00 [revised]
PHST- 2015/02/10 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1535-6108(15)00054-9 [pii]
AID - 10.1016/j.ccell.2015.02.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):370-81. doi: 10.1016/j.ccell.2015.02.004.

PMID- 25759021
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20170930
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - Regulation of glutamine carrier proteins by RNF5 determines breast cancer
      response to ER stress-inducing chemotherapies.
PG  - 354-69
LID - 10.1016/j.ccell.2015.02.006 [doi]
LID - S1535-6108(15)00056-2 [pii]
AB  - Many tumor cells are fueled by altered metabolism and increased glutamine (Gln)
      dependence. We identify regulation of the L-glutamine carrier proteins SLC1A5 and
      SLC38A2 (SLC1A5/38A2) by the ubiquitin ligase RNF5. Paclitaxel-induced ER stress 
      to breast cancer (BCa) cells promotes RNF5 association, ubiquitination, and
      degradation of SLC1A5/38A2. This decreases Gln uptake, levels of TCA cycle
      components, mTOR signaling, and proliferation while increasing autophagy and cell
      death. Rnf5-deficient MMTV-PyMT mammary tumors were less differentiated and
      showed elevated SLC1A5 expression. Whereas RNF5 depletion in MDA-MB-231 cells
      promoted tumorigenesis and abolished paclitaxel responsiveness, SLC1A5/38A2
      knockdown elicited opposing effects. Inverse RNF5(hi)/SLC1A5/38A2(lo) expression 
      was associated with positive prognosis in BCa. Thus, RNF5 control of Gln uptake
      underlies BCa response to chemotherapies.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Jeon, Young Joo
AU  - Jeon YJ
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Khelifa, Sihem
AU  - Khelifa S
AD  - Department of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Ratnikov, Boris
AU  - Ratnikov B
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Scott, David A
AU  - Scott DA
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Feng, Yongmei
AU  - Feng Y
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Parisi, Fabio
AU  - Parisi F
AD  - Department of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Ruller, Chelsea
AU  - Ruller C
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Lau, Eric
AU  - Lau E
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Kim, Hyungsoo
AU  - Kim H
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Brill, Laurence M
AU  - Brill LM
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Jiang, Tingting
AU  - Jiang T
AD  - Department of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Rimm, David L
AU  - Rimm DL
AD  - Department of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Cardiff, Robert D
AU  - Cardiff RD
AD  - Department of Pathology, University of California, Davis, Davis, CA 95616, USA.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - Department of Systems Biology, MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Smith, Jeffrey W
AU  - Smith JW
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Osterman, Andrei L
AU  - Osterman AL
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA.
FAU - Kluger, Yuval
AU  - Kluger Y
AD  - Department of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Ronai, Ze'ev A
AU  - Ronai ZA
AD  - Tumor Initiation and Maintenance Program, Cancer Center, Sanford-Burnham Medical 
      Research Institute, La Jolla, CA 92037, USA. Electronic address: ronai@sbmri.org.
LA  - eng
GR  - R01 CA188372/CA/NCI NIH HHS/United States
GR  - P01 CA128814/CA/NCI NIH HHS/United States
GR  - R01 CA097105/CA/NCI NIH HHS/United States
GR  - CA128814/CA/NCI NIH HHS/United States
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - R25 CA174664/CA/NCI NIH HHS/United States
GR  - CA097105/CA/NCI NIH HHS/United States
GR  - P30CA30199/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Amino Acid Transport System A)
RN  - 0 (Amino Acid Transport System ASC)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 0 (SLC1A5 protein, human)
RN  - 0 (SLC38A2 protein, human)
RN  - EC 2.3.2.27 (RNF5 protein, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
CIN - Cancer Cell. 2015 Mar 9;27(3):317-9. PMID: 25759015
MH  - Amino Acid Transport System A/genetics/*metabolism
MH  - Amino Acid Transport System ASC/genetics/*metabolism
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Apoptosis/drug effects
MH  - Autophagy/drug effects
MH  - Breast Neoplasms/drug therapy/genetics/*metabolism
MH  - Citric Acid Cycle/drug effects
MH  - DNA-Binding Proteins/genetics/metabolism/*physiology
MH  - Endoplasmic Reticulum/drug effects
MH  - Endoplasmic Reticulum Stress/*drug effects/genetics
MH  - Female
MH  - Humans
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Nude
MH  - Minor Histocompatibility Antigens
MH  - Paclitaxel/*pharmacology/therapeutic use
MH  - Proteolysis/drug effects
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Ubiquitin-Protein Ligases/genetics/metabolism/*physiology
MH  - Ubiquitination
PMC - PMC4356903
MID - NIHMS664650
EDAT- 2015/03/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/04/29 00:00 [received]
PHST- 2014/10/28 00:00 [revised]
PHST- 2015/02/05 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1535-6108(15)00056-2 [pii]
AID - 10.1016/j.ccell.2015.02.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):354-69. doi: 10.1016/j.ccell.2015.02.006.

PMID- 25759020
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - Smoothened variants explain the majority of drug resistance in basal cell
      carcinoma.
PG  - 342-53
LID - 10.1016/j.ccell.2015.02.002 [doi]
LID - S1535-6108(15)00052-5 [pii]
AB  - Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened
      (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in
      50% (22 of 44) of resistant BCCs and show that these mutations maintain Hedgehog 
      signaling in the presence of SMO inhibitors. Alterations include four ligand
      binding pocket mutations defining sites of inhibitor binding and four variants
      conferring constitutive activity and inhibitor resistance, illuminating pivotal
      residues that ensure receptor autoinhibition. In the presence of a SMO inhibitor,
      tumor cells containing either class of SMO mutants effectively outcompete cells
      containing the wild-type SMO. Finally, we show that both classes of SMO variants 
      respond to aPKC-iota/lambda or GLI2 inhibitors that operate downstream of SMO,
      setting the stage for the clinical use of GLI antagonists.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Atwood, Scott X
AU  - Atwood SX
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Sarin, Kavita Y
AU  - Sarin KY
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Whitson, Ramon J
AU  - Whitson RJ
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Li, Jiang R
AU  - Li JR
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Kim, Geurim
AU  - Kim G
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Rezaee, Melika
AU  - Rezaee M
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Ally, Mina S
AU  - Ally MS
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Kim, Jinah
AU  - Kim J
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Yao, Catherine
AU  - Yao C
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Chang, Anne Lynn S
AU  - Chang AL
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA.
FAU - Oro, Anthony E
AU  - Oro AE
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA. Electronic address:
      oro@stanford.edu.
FAU - Tang, Jean Y
AU  - Tang JY
AD  - Program in Epithelial Biology and Department of Dermatology, Stanford University 
      School of Medicine, Stanford, CA 94305, USA. Electronic address:
      tangy@stanford.edu.
LA  - eng
SI  - GEO/GSE58377
GR  - 2AR046786/AR/NIAMS NIH HHS/United States
GR  - 1K99CA176847/CA/NCI NIH HHS/United States
GR  - R01 AR054780/AR/NIAMS NIH HHS/United States
GR  - R00 CA176847/CA/NCI NIH HHS/United States
GR  - R01 AR046786/AR/NIAMS NIH HHS/United States
GR  - K99 CA176847/CA/NCI NIH HHS/United States
GR  - R01 CA157895/CA/NCI NIH HHS/United States
GR  - 5ARO54780/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Anilides)
RN  - 0 (Hedgehog Proteins)
RN  - 0 (HhAntag691)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (SMO protein, human)
RN  - 0 (Smoothened Receptor)
SB  - IM
CIN - Cancer Discov. 2015 May;5(5):OF9. PMID: 25813347
CIN - Cancer Cell. 2015 Mar 9;27(3):315-6. PMID: 25759014
MH  - Anilides/chemistry/*therapeutic use
MH  - Binding Sites
MH  - Carcinoma, Basal Cell/*drug therapy/genetics/pathology
MH  - DNA Mutational Analysis
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Exome
MH  - Hedgehog Proteins/genetics/metabolism
MH  - Humans
MH  - Models, Molecular
MH  - Mutation
MH  - Protein Structure, Tertiary
MH  - Pyridines/chemistry/*therapeutic use
MH  - Receptors, G-Protein-Coupled/chemistry/*genetics
MH  - Sequence Analysis, DNA
MH  - Signal Transduction
MH  - Skin Neoplasms/*drug therapy/genetics/pathology
MH  - Smoothened Receptor
PMC - PMC4357167
MID - NIHMS666270
EDAT- 2015/03/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/05/20 00:00 [received]
PHST- 2014/11/11 00:00 [revised]
PHST- 2015/02/04 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1535-6108(15)00052-5 [pii]
AID - 10.1016/j.ccell.2015.02.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):342-53. doi: 10.1016/j.ccell.2015.02.002.

PMID- 25759019
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
PG  - 327-41
LID - 10.1016/j.ccell.2015.02.001 [doi]
LID - S1535-6108(15)00051-3 [pii]
AB  - Smoothened (SMO) inhibitors are under clinical investigation for the treatment of
      several cancers. Vismodegib is approved for the treatment of locally advanced and
      metastatic basal cell carcinoma (BCC). Most BCC patients experience significant
      clinical benefit on vismodegib, but some develop resistance. Genomic analysis of 
      tumor biopsies revealed that vismodegib resistance is associated with Hedgehog
      (Hh) pathway reactivation, predominantly through mutation of the drug target SMO 
      and to a lesser extent through concurrent copy number changes in SUFU and GLI2.
      SMO mutations either directly impaired drug binding or activated SMO to varying
      levels. Furthermore, we found evidence for intra-tumor heterogeneity, suggesting 
      that a combination of therapies targeting components at multiple levels of the Hh
      pathway is required to overcome resistance.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Sharpe, Hayley J
AU  - Sharpe HJ
AD  - Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080,
      USA.
FAU - Pau, Gregoire
AU  - Pau G
AD  - Department of Bioinformatics and Computational Biology, Genentech, Inc., South
      San Francisco, CA 94080, USA.
FAU - Dijkgraaf, Gerrit J
AU  - Dijkgraaf GJ
AD  - Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080,
      USA.
FAU - Basset-Seguin, Nicole
AU  - Basset-Seguin N
AD  - Paris 7 Hopital Saint-Louis, Paris 75010, France.
FAU - Modrusan, Zora
AU  - Modrusan Z
AD  - Department of Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, 
      USA.
FAU - Januario, Thomas
AU  - Januario T
AD  - Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080,
      USA.
FAU - Tsui, Vickie
AU  - Tsui V
AD  - Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
      94080, USA.
FAU - Durham, Alison B
AU  - Durham AB
AD  - Department of Dermatology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Dlugosz, Andrzej A
AU  - Dlugosz AA
AD  - Department of Dermatology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Haverty, Peter M
AU  - Haverty PM
AD  - Department of Bioinformatics and Computational Biology, Genentech, Inc., South
      San Francisco, CA 94080, USA.
FAU - Bourgon, Richard
AU  - Bourgon R
AD  - Department of Bioinformatics and Computational Biology, Genentech, Inc., South
      San Francisco, CA 94080, USA.
FAU - Tang, Jean Y
AU  - Tang JY
AD  - Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Sarin, Kavita Y
AU  - Sarin KY
AD  - Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Dirix, Luc
AU  - Dirix L
AD  - Sint-Augustinus Cancer Center, Antwerp University Hospital, University of
      Antwerp, Antwerp 2610, Belgium.
FAU - Fisher, David C
AU  - Fisher DC
AD  - Dana-Farber Cancer Institute, Boston, MA 02215, USA.
FAU - Rudin, Charles M
AU  - Rudin CM
AD  - Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Sofen, Howard
AU  - Sofen H
AD  - Department of Medicine/Dermatology, UCLA School of Medicine, Los Angeles, CA
      90095, USA.
FAU - Migden, Michael R
AU  - Migden MR
AD  - MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yauch, Robert L
AU  - Yauch RL
AD  - Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080,
      USA.
FAU - de Sauvage, Frederic J
AU  - de Sauvage FJ
AD  - Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080,
      USA. Electronic address: sauvage@gene.com.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30 CA046592/CA/NCI NIH HHS/United States
GR  - R01 CA087837/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Anilides)
RN  - 0 (GLI2 protein, human)
RN  - 0 (Hedgehog Proteins)
RN  - 0 (HhAntag691)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Patched Receptors)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Repressor Proteins)
RN  - 0 (SMO protein, human)
RN  - 0 (SUFU protein, human)
RN  - 0 (Smoothened Receptor)
RN  - 0 (Zinc Finger Protein Gli2)
SB  - IM
CIN - Cancer Discov. 2015 May;5(5):OF9. PMID: 25813347
CIN - Cancer Cell. 2015 Mar 9;27(3):315-6. PMID: 25759014
MH  - Anilides/chemistry/*therapeutic use
MH  - Binding Sites
MH  - Carcinoma, Basal Cell/drug therapy/*genetics
MH  - DNA Copy Number Variations
MH  - DNA Mutational Analysis
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Exome
MH  - Hedgehog Proteins/genetics
MH  - Humans
MH  - Kruppel-Like Transcription Factors/genetics
MH  - Models, Molecular
MH  - Mutation
MH  - Nuclear Proteins/genetics
MH  - Patched Receptors
MH  - Protein Structure, Tertiary
MH  - Pyridines/chemistry/*therapeutic use
MH  - Receptors, Cell Surface/genetics
MH  - Receptors, G-Protein-Coupled/chemistry/*genetics
MH  - Repressor Proteins/genetics
MH  - Sequence Analysis, DNA
MH  - Skin Neoplasms/drug therapy/*genetics
MH  - Smoothened Receptor
MH  - Zinc Finger Protein Gli2
PMC - PMC5675004
MID - NIHMS916562
EDAT- 2015/03/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/05/16 00:00 [received]
PHST- 2014/11/12 00:00 [revised]
PHST- 2015/02/05 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1535-6108(15)00051-3 [pii]
AID - 10.1016/j.ccell.2015.02.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):327-41. doi: 10.1016/j.ccell.2015.02.001.

PMID- 25759018
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.
PG  - 323-5
LID - 10.1016/j.ccell.2015.02.013 [doi]
LID - S1535-6108(15)00063-X [pii]
AB  - There is a pressing need to develop novel, mechanism-based therapeutic approaches
      that can be used to improve therapies for genetically defined tumor subtypes.
      Chan and colleagues have demonstrated recently that BCL-2 inhibitors can target
      IDH1/2 mutant cancers through a mutant-specific dependency in metabolic
      regulation.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Pronier, Elodie
AU  - Pronier E
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Leukemia Service, Memorial Sloan Kettering Cancer
      Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address:
      leviner@mskcc.org.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Sulfonamides)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
SB  - IM
CON - Nat Med. 2015 Feb;21(2):178-84. PMID: 25599133
MH  - Antineoplastic Agents/*pharmacology
MH  - Bridged Bicyclo Compounds, Heterocyclic/*pharmacology
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Humans
MH  - Isocitrate Dehydrogenase/*genetics
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors
MH  - Sulfonamides/*pharmacology
EDAT- 2015/03/12 06:00
MHDA- 2015/05/12 06:00
CRDT- 2015/03/12 06:00
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - S1535-6108(15)00063-X [pii]
AID - 10.1016/j.ccell.2015.02.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):323-5. doi: 10.1016/j.ccell.2015.02.013.

PMID- 25759017
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - The pre-BCR to the rescue: therapeutic targeting of pre-B cell ALL.
PG  - 321-3
LID - 10.1016/j.ccell.2015.02.012 [doi]
LID - S1535-6108(15)00062-8 [pii]
AB  - Pre B-ALL is an aggressive cancer of the blood for which treatment of patients
      with relapsed and refractory disease remains a challenge. In this issue of Cancer
      Cell, Geng and colleagues surveyed the activation status of the pre-B cell
      receptor and comprehensively investigated downstream signaling mechanisms
      currently targetable with small molecule inhibitors.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Trimarchi, Thomas
AU  - Trimarchi T
AD  - Department of Pathology and Howard Hughes Medical Institute, NYU School of
      Medicine New York, NY 10016, USA.
FAU - Aifantis, Iannis
AU  - Aifantis I
AD  - Department of Pathology and Howard Hughes Medical Institute, NYU School of
      Medicine New York, NY 10016, USA. Electronic address: iannis.aifantis@nyumc.org.
LA  - eng
GR  - R01 CA173636/CA/NCI NIH HHS/United States
GR  - T32 CA009161/CA/NCI NIH HHS/United States
GR  - 5R01CA169784/CA/NCI NIH HHS/United States
GR  - R01 CA133379/CA/NCI NIH HHS/United States
GR  - 1R01GM088847/GM/NIGMS NIH HHS/United States
GR  - R01 CA149655/CA/NCI NIH HHS/United States
GR  - R01 CA105129/CA/NCI NIH HHS/United States
GR  - 5R01CA173636/CA/NCI NIH HHS/United States
GR  - 1R01CA133379/CA/NCI NIH HHS/United States
GR  - 1R01CA149655/CA/NCI NIH HHS/United States
GR  - 5T32CA009161-37/CA/NCI NIH HHS/United States
GR  - R01 CA169784/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - 1R01CA105129/CA/NCI NIH HHS/United States
GR  - R01 GM088847/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (BCL6 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
SB  - IM
CON - Cancer Cell. 2015 Mar 9;27(3):409-25. PMID: 25759025
MH  - DNA-Binding Proteins/*physiology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*metabolism
MH  - Precursor Cells, B-Lymphoid/*metabolism
MH  - Proto-Oncogene Proteins c-bcl-6
PMC - PMC4532279
MID - NIHMS713508
EDAT- 2015/03/12 06:00
MHDA- 2015/05/12 06:00
CRDT- 2015/03/12 06:00
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - S1535-6108(15)00062-8 [pii]
AID - 10.1016/j.ccell.2015.02.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):321-3. doi: 10.1016/j.ccell.2015.02.012.

PMID- 25759016
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - Seek and destroy: relating cancer drivers to therapies.
PG  - 319-21
LID - 10.1016/j.ccell.2015.02.011 [doi]
LID - S1535-6108(15)00061-6 [pii]
AB  - In this issue of Cancer Cell, Rubio-Perez and colleagues present an in silico
      prescription strategy based on identifying somatic driver alterations and
      druggability options. Although relatively few patients were found treatable
      following current clinical guidelines, many more could benefit from drug
      repurposing, considering compounds at various stages of (pre-)clinical
      investigation.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Martinez-Ledesma, Emmanuel
AU  - Martinez-Ledesma E
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - de Groot, John F
AU  - de Groot JF
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030, USA.
FAU - Verhaak, Roel G W
AU  - Verhaak RG
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational
      Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030,
      USA. Electronic address: rverhaak@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA190121/CA/NCI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - P50 CA127001/CA/NCI NIH HHS/United States
GR  - P01 CA085878/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2015 Mar 9;27(3):382-96. PMID: 25759023
MH  - Carcinogenesis/*genetics
MH  - *Decision Making, Computer-Assisted
MH  - Humans
MH  - Neoplasms/*genetics
MH  - Precision Medicine/*methods
EDAT- 2015/03/12 06:00
MHDA- 2015/05/12 06:00
CRDT- 2015/03/12 06:00
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - S1535-6108(15)00061-6 [pii]
AID - 10.1016/j.ccell.2015.02.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):319-21. doi: 10.1016/j.ccell.2015.02.011.

PMID- 25759015
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20161125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - The GLU that holds cancer together: targeting GLUtamine transporters in breast
      cancer.
PG  - 317-9
LID - 10.1016/j.ccell.2015.02.010 [doi]
LID - S1535-6108(15)00060-4 [pii]
AB  - Many cancer cells require exogenous glutamine for proliferation, supply of TCA
      cycle intermediates, lipid synthesis, mTOR activity, and neutralization of
      reactive oxygen species. In this issue of Cancer Cell, Jeon and colleagues
      identify chemotherapy-induced endoplasmic reticulum stress as a novel strategy to
      target glutamine dependence.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Moses, Michael A
AU  - Moses MA
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      9000 Rockville Pike, Bethesda, MD 20892, USA.
FAU - Neckers, Len
AU  - Neckers L
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address:
      neckersl@mail.nih.gov.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Amino Acid Transport System A)
RN  - 0 (Amino Acid Transport System ASC)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 0 (SLC1A5 protein, human)
RN  - 0 (SLC38A2 protein, human)
RN  - EC 2.3.2.27 (RNF5 protein, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
CON - Cancer Cell. 2015 Mar 9;27(3):354-69. PMID: 25759021
MH  - Amino Acid Transport System A/*metabolism
MH  - Amino Acid Transport System ASC/*metabolism
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Breast Neoplasms/*metabolism
MH  - DNA-Binding Proteins/*physiology
MH  - Endoplasmic Reticulum Stress/*drug effects
MH  - Female
MH  - Humans
MH  - Minor Histocompatibility Antigens
MH  - Paclitaxel/*pharmacology
MH  - Ubiquitin-Protein Ligases/*physiology
EDAT- 2015/03/12 06:00
MHDA- 2015/05/12 06:00
CRDT- 2015/03/12 06:00
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - S1535-6108(15)00060-4 [pii]
AID - 10.1016/j.ccell.2015.02.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):317-9. doi: 10.1016/j.ccell.2015.02.010.

PMID- 25759014
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20171108
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Mar 9
TI  - Vismodegib resistance in basal cell carcinoma: not a smooth fit.
PG  - 315-6
LID - 10.1016/j.ccell.2015.02.009 [doi]
LID - S1535-6108(15)00059-8 [pii]
AB  - In this issue of Cancer Cell, two complementary papers by Atwood and colleagues
      and Sharpe and colleagues show that basal cell carcinomas resistant to the
      Smoothened (SMO) inhibitor vismodegib frequently harbor SMO mutations that limit 
      drug binding, with mutations at some sites also increasing basal SMO activity.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Ridky, Todd W
AU  - Ridky TW
AD  - Department of Dermatology, Perelman School of Medicine, University of
      Pennsylvania, BRB 1053, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
FAU - Cotsarelis, George
AU  - Cotsarelis G
AD  - Department of Dermatology, Perelman School of Medicine, University of
      Pennsylvania, BRB 1053, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
      Electronic address: cotsarel@mail.med.upenn.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Anilides)
RN  - 0 (HhAntag691)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (SMO protein, human)
RN  - 0 (Smoothened Receptor)
SB  - IM
CON - Cancer Cell. 2015 Mar 9;27(3):342-53. PMID: 25759020
CON - Cancer Cell. 2015 Mar 9;27(3):327-41. PMID: 25759019
MH  - Anilides/*therapeutic use
MH  - Carcinoma, Basal Cell/*drug therapy/*genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Humans
MH  - Pyridines/*therapeutic use
MH  - Receptors, G-Protein-Coupled/*genetics
MH  - Skin Neoplasms/*drug therapy/*genetics
MH  - Smoothened Receptor
EDAT- 2015/03/12 06:00
MHDA- 2015/05/12 06:00
CRDT- 2015/03/12 06:00
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - S1535-6108(15)00059-8 [pii]
AID - 10.1016/j.ccell.2015.02.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Mar 9;27(3):315-6. doi: 10.1016/j.ccell.2015.02.009.

PMID- 25670083
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20150211
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex
      underlie high-risk blastemal type Wilms tumors.
PG  - 298-311
LID - 10.1016/j.ccell.2015.01.002 [doi]
LID - S1535-6108(15)00017-3 [pii]
AB  - Blastemal histology in chemotherapy-treated pediatric Wilms tumors
      (nephroblastoma) is associated with adverse prognosis. To uncover the underlying 
      tumor biology and find therapeutic leads for this subgroup, we analyzed 58
      blastemal type Wilms tumors by exome and transcriptome sequencing and validated
      our findings in a large replication cohort. Recurrent mutations included a
      hotspot mutation (Q177R) in the homeo-domain of SIX1 and SIX2 in tumors with high
      proliferative potential (18.1% of blastemal cases); mutations in the DROSHA/DGCR8
      microprocessor genes (18.2% of blastemal cases); mutations in DICER1 and DIS3L2; 
      and alterations in IGF2, MYCN, and TP53, the latter being strongly associated
      with dismal outcome. DROSHA and DGCR8 mutations strongly altered miRNA expression
      patterns in tumors, which was functionally validated in cell lines expressing
      mutant DROSHA.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wegert, Jenny
AU  - Wegert J
AD  - Theodor-Boveri-Institute/Biocenter, Developmental Biochemistry, and Comprehensive
      Cancer Center Mainfranken, Wuerzburg University, 97074 Wuerzburg, Germany.
FAU - Ishaque, Naveed
AU  - Ishaque N
AD  - Division of Theoretical Bioinformatics (B080), German Cancer Research Center
      (DKFZ), 69121 Heidelberg, Germany; Heidelberg Center for Personalised Oncology
      (DKFZ-HIPO), German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany.
FAU - Vardapour, Romina
AU  - Vardapour R
AD  - Theodor-Boveri-Institute/Biocenter, Developmental Biochemistry, and Comprehensive
      Cancer Center Mainfranken, Wuerzburg University, 97074 Wuerzburg, Germany.
FAU - Georg, Christina
AU  - Georg C
AD  - Heidelberg Center for Personalised Oncology (DKFZ-HIPO), German Cancer Research
      Center (DKFZ), 69121 Heidelberg, Germany.
FAU - Gu, Zuguang
AU  - Gu Z
AD  - Division of Theoretical Bioinformatics (B080), German Cancer Research Center
      (DKFZ), 69121 Heidelberg, Germany; Heidelberg Center for Personalised Oncology
      (DKFZ-HIPO), German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany.
FAU - Bieg, Matthias
AU  - Bieg M
AD  - Division of Theoretical Bioinformatics (B080), German Cancer Research Center
      (DKFZ), 69121 Heidelberg, Germany; Heidelberg Center for Personalised Oncology
      (DKFZ-HIPO), German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany.
FAU - Ziegler, Barbara
AU  - Ziegler B
AD  - Theodor-Boveri-Institute/Biocenter, Developmental Biochemistry, and Comprehensive
      Cancer Center Mainfranken, Wuerzburg University, 97074 Wuerzburg, Germany.
FAU - Bausenwein, Sabrina
AU  - Bausenwein S
AD  - Theodor-Boveri-Institute/Biocenter, Developmental Biochemistry, and Comprehensive
      Cancer Center Mainfranken, Wuerzburg University, 97074 Wuerzburg, Germany.
FAU - Nourkami, Nasenien
AU  - Nourkami N
AD  - Department of Pediatric Oncology and Hematology, Saarland University Hospital,
      66421 Homburg, Germany.
FAU - Ludwig, Nicole
AU  - Ludwig N
AD  - Department of Human Genetics, Saarland University, 66421 Homburg, Germany.
FAU - Keller, Andreas
AU  - Keller A
AD  - Department of Human Genetics, Saarland University, 66421 Homburg, Germany.
FAU - Grimm, Clemens
AU  - Grimm C
AD  - Theodor-Boveri-Institute/Biocenter, Biochemistry, Wuerzburg University, 97074
      Wuerzburg, Germany.
FAU - Kneitz, Susanne
AU  - Kneitz S
AD  - Theodor-Boveri-Institute/Biocenter, Physiological Chemistry, Wuerzburg
      University, 97074 Wuerzburg, Germany.
FAU - Williams, Richard D
AU  - Williams RD
AD  - UCL Institute of Child Health, London WC1N 1EH, UK.
FAU - Chagtai, Tas
AU  - Chagtai T
AD  - UCL Institute of Child Health, London WC1N 1EH, UK.
FAU - Pritchard-Jones, Kathy
AU  - Pritchard-Jones K
AD  - UCL Institute of Child Health, London WC1N 1EH, UK.
FAU - van Sluis, Peter
AU  - van Sluis P
AD  - Department of Oncogenomics, Academic Medical Center, University of Amsterdam,
      1007 MB Amsterdam, the Netherlands.
FAU - Volckmann, Richard
AU  - Volckmann R
AD  - Department of Oncogenomics, Academic Medical Center, University of Amsterdam,
      1007 MB Amsterdam, the Netherlands.
FAU - Koster, Jan
AU  - Koster J
AD  - Department of Oncogenomics, Academic Medical Center, University of Amsterdam,
      1007 MB Amsterdam, the Netherlands.
FAU - Versteeg, Rogier
AU  - Versteeg R
AD  - Department of Oncogenomics, Academic Medical Center, University of Amsterdam,
      1007 MB Amsterdam, the Netherlands.
FAU - Acha, Tomas
AU  - Acha T
AD  - Unidad de Oncologia Pediatrica, Hospital Materno-Infantil de Malaga, 29011
      Malaga, Spain.
FAU - O'Sullivan, Maureen J
AU  - O'Sullivan MJ
AD  - National Children's Research Centre, Our Lady's Children's Hospital, Crumlin, and
      Trinity College, Dublin 12, Ireland.
FAU - Bode, Peter K
AU  - Bode PK
AD  - Department of Pediatric Hematology and Oncology, Children's University Hospital, 
      8032 Zurich, Switzerland.
FAU - Niggli, Felix
AU  - Niggli F
AD  - Department of Pediatric Hematology and Oncology, Children's University Hospital, 
      8032 Zurich, Switzerland.
FAU - Tytgat, Godelieve A
AU  - Tytgat GA
AD  - Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical
      Center, University of Amsterdam, 1007 MB Amsterdam, the Netherlands.
FAU - van Tinteren, Harm
AU  - van Tinteren H
AD  - Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical
      Center, University of Amsterdam, 1007 MB Amsterdam, the Netherlands.
FAU - van den Heuvel-Eibrink, Marry M
AU  - van den Heuvel-Eibrink MM
AD  - Department of Pediatric Oncology, Erasmus MC-University Medical Center Rotterdam,
      3000 CA Rotterdam, the Netherlands.
FAU - Meese, Eckart
AU  - Meese E
AD  - Department of Human Genetics, Saarland University, 66421 Homburg, Germany.
FAU - Vokuhl, Christian
AU  - Vokuhl C
AD  - Kiel Paediatric Cancer Registry, Christian Albrechts University, 24105 Kiel,
      Germany.
FAU - Leuschner, Ivo
AU  - Leuschner I
AD  - Kiel Paediatric Cancer Registry, Christian Albrechts University, 24105 Kiel,
      Germany.
FAU - Graf, Norbert
AU  - Graf N
AD  - Department of Pediatric Oncology and Hematology, Saarland University Hospital,
      66421 Homburg, Germany.
FAU - Eils, Roland
AU  - Eils R
AD  - Division of Theoretical Bioinformatics (B080), German Cancer Research Center
      (DKFZ), 69121 Heidelberg, Germany; Heidelberg Center for Personalised Oncology
      (DKFZ-HIPO), German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany;
      Department for Bioinformatics and Functional Genomics, Institute for Pharmacy and
      Molecular Biotechnology (IPMB) and BioQuant, Heidelberg University, 69121
      Heidelberg, Germany.
FAU - Pfister, Stefan M
AU  - Pfister SM
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany.
FAU - Kool, Marcel
AU  - Kool M
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany.
FAU - Gessler, Manfred
AU  - Gessler M
AD  - Theodor-Boveri-Institute/Biocenter, Developmental Biochemistry, and Comprehensive
      Cancer Center Mainfranken, Wuerzburg University, 97074 Wuerzburg, Germany.
      Electronic address: gessler@biozentrum.uni-wuerzburg.de.
LA  - eng
SI  - GEO/GSE53224
SI  - GEO/GSE57370
SI  - GEO/GSE60081
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DGCR8 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (MicroRNAs)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (SIX1 protein, human)
RN  - 0 (SIX2 protein, human)
RN  - EC 3.1.26.3 (DROSHA protein, human)
RN  - EC 3.1.26.3 (Ribonuclease III)
SB  - IM
MH  - Gene Expression Regulation, Neoplastic
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - MicroRNAs/biosynthesis
MH  - Mutation
MH  - Neoplasm Proteins/biosynthesis
MH  - Nerve Tissue Proteins/*genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Ribonuclease III/*genetics
MH  - Transcriptome
MH  - Wilms Tumor/*genetics/pathology
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2014/08/11 00:00 [received]
PHST- 2014/11/24 00:00 [revised]
PHST- 2015/01/09 00:00 [accepted]
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00017-3 [pii]
AID - 10.1016/j.ccell.2015.01.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):298-311. doi: 10.1016/j.ccell.2015.01.002.

PMID- 25670082
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20170930
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology
      Wilms tumors.
PG  - 286-97
LID - 10.1016/j.ccell.2015.01.003 [doi]
LID - S1535-6108(15)00018-5 [pii]
AB  - We report the most common single-nucleotide substitution/deletion mutations in
      favorable histology Wilms tumors (FHWTs) to occur within SIX1/2 (7% of 534
      tumors) and microRNA processing genes (miRNAPGs) DGCR8 and DROSHA (15% of 534
      tumors). Comprehensive analysis of 77 FHWTs indicates that tumors with SIX1/2
      and/or miRNAPG mutations show a pre-induction metanephric mesenchyme gene
      expression pattern and are significantly associated with both perilobar
      nephrogenic rests and 11p15 imprinting aberrations. Significantly decreased
      expression of mature Let-7a and the miR-200 family (responsible for
      mesenchymal-to-epithelial transition) in miRNAPG mutant tumors is associated with
      an undifferentiated blastemal histology. The combination of SIX and miRNAPG
      mutations in the same tumor is associated with evidence of RAS activation and a
      higher rate of relapse and death.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Walz, Amy L
AU  - Walz AL
AD  - Division of Hematology-Oncology and Transplantation, Ann and Robert H. Lurie
      Children's Hospital of Chicago, Northwestern University's Feinberg School of
      Medicine, Chicago, IL 60611, USA.
FAU - Ooms, Ariadne
AU  - Ooms A
AD  - Department of Pathology, Josephine Nefkens Institute, Erasmus Medical Center,
      Rotterdam CA 3000, the Netherlands.
FAU - Gadd, Samantha
AU  - Gadd S
AD  - Department of Pathology and Laboratory Medicine, Lurie Children's Hospital,
      Northwestern University's Feinberg School of Medicine and Robert H. Lurie Cancer 
      Center, Chicago, IL 60611, USA.
FAU - Gerhard, Daniela S
AU  - Gerhard DS
AD  - Office of Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
FAU - Smith, Malcolm A
AU  - Smith MA
AD  - Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892,
      USA.
FAU - Guidry Auvil, Jaime M
AU  - Guidry Auvil JM
AD  - Office of Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
FAU - Meerzaman, Daoud
AU  - Meerzaman D
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Chen, Qing-Rong
AU  - Chen QR
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Hsu, Chih Hao
AU  - Hsu CH
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Yan, Chunhua
AU  - Yan C
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Nguyen, Cu
AU  - Nguyen C
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Hu, Ying
AU  - Hu Y
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, Bethesda, MD 20892, USA.
FAU - Bowlby, Reanne
AU  - Bowlby R
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 4S6, Canada.
FAU - Brooks, Denise
AU  - Brooks D
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 4S6, Canada.
FAU - Ma, Yussanne
AU  - Ma Y
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 4S6, Canada.
FAU - Mungall, Andrew J
AU  - Mungall AJ
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 4S6, Canada.
FAU - Moore, Richard A
AU  - Moore RA
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 4S6, Canada.
FAU - Schein, Jacqueline
AU  - Schein J
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 4S6, Canada.
FAU - Marra, Marco A
AU  - Marra MA
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, BC V5Z 4S6, Canada; Department of Medical Genetics, University of
      British Columbia, Vancouver, BC V6H 3N1, Canada.
FAU - Huff, Vicki
AU  - Huff V
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Dome, Jeffrey S
AU  - Dome JS
AD  - Division of Pediatric Hematology/Oncology, Children's National Medical Center,
      Washington, DC 20010, USA.
FAU - Chi, Yueh-Yun
AU  - Chi YY
AD  - Department of Biostatistics, University of Florida, Gainesville, FL 32610, USA.
FAU - Mullighan, Charles G
AU  - Mullighan CG
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Wheeler, David A
AU  - Wheeler DA
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Hampton, Oliver A
AU  - Hampton OA
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Jafari, Nadereh
AU  - Jafari N
AD  - Center for Genetic Medicine, Northwestern University, Chicago, IL 60611, USA.
FAU - Ross, Nicole
AU  - Ross N
AD  - Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, 
      Ohio State University College of Medicine, Columbus, OH 43205, USA.
FAU - Gastier-Foster, Julie M
AU  - Gastier-Foster JM
AD  - Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, 
      Ohio State University College of Medicine, Columbus, OH 43205, USA.
FAU - Perlman, Elizabeth J
AU  - Perlman EJ
AD  - Department of Pathology and Laboratory Medicine, Lurie Children's Hospital,
      Northwestern University's Feinberg School of Medicine and Robert H. Lurie Cancer 
      Center, Chicago, IL 60611, USA. Electronic address: eperlman@luriechildrens.org.
LA  - eng
GR  - T32 CA079447/CA/NCI NIH HHS/United States
GR  - U10CA98543/CA/NCI NIH HHS/United States
GR  - U24 CA114766/CA/NCI NIH HHS/United States
GR  - U10CA42326/CA/NCI NIH HHS/United States
GR  - U01 CA088131/CA/NCI NIH HHS/United States
GR  - U10 CA098543/CA/NCI NIH HHS/United States
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - UO1CA88131/CA/NCI NIH HHS/United States
GR  - U10 CA180886/CA/NCI NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - U10 CA98543/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DGCR8 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (MicroRNAs)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (SIX1 protein, human)
RN  - 0 (SIX2 protein, human)
RN  - 0 (mirnlet7 microRNA, human)
RN  - EC 3.1.26.3 (DROSHA protein, human)
RN  - EC 3.1.26.3 (Ribonuclease III)
SB  - IM
EIN - Cancer Cell. 2015 Mar 9;27(3):426. Guidry Auvil, Jamie M [corrected to Guidry
      Auvil, Jaime M]
MH  - Gene Expression Regulation, Neoplastic
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - Loss of Heterozygosity/genetics
MH  - MicroRNAs/genetics
MH  - Mutation
MH  - Neoplasm Recurrence, Local/genetics/pathology
MH  - Nerve Tissue Proteins/*genetics
MH  - Polymorphism, Single Nucleotide
MH  - RNA-Binding Proteins/*genetics
MH  - Ribonuclease III/*genetics
MH  - Wilms Tumor/*genetics/pathology
PMC - PMC4800737
MID - NIHMS656238
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2014/08/28 00:00 [received]
PHST- 2014/11/28 00:00 [revised]
PHST- 2015/01/12 00:00 [accepted]
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00018-5 [pii]
AID - 10.1016/j.ccell.2015.01.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):286-97. doi: 10.1016/j.ccell.2015.01.003.

PMID- 25670081
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to
      regulate redox homeostasis and tumor growth.
PG  - 257-70
LID - 10.1016/j.ccell.2014.12.006 [doi]
LID - S1535-6108(14)00515-7 [pii]
AB  - How mitochondrial glutaminolysis contributes to redox homeostasis in cancer cells
      remains unclear. Here we report that the mitochondrial enzyme glutamate
      dehydrogenase 1 (GDH1) is commonly upregulated in human cancers. GDH1 is
      important for redox homeostasis in cancer cells by controlling the intracellular 
      levels of its product alpha-ketoglutarate and subsequent metabolite fumarate.
      Mechanistically, fumarate binds to and activates a reactive oxygen species
      scavenging enzyme glutathione peroxidase 1. Targeting GDH1 by shRNA or a small
      molecule inhibitor R162 resulted in imbalanced redox homeostasis, leading to
      attenuated cancer cell proliferation and tumor growth.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Jin, Lingtao
AU  - Jin L
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Li, Dan
AU  - Li D
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Alesi, Gina N
AU  - Alesi GN
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Fan, Jun
AU  - Fan J
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Kang, Hee-Bum
AU  - Kang HB
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Lu, Zhou
AU  - Lu Z
AD  - Department of Chemistry and Institute for Biophysical Dynamics, The University of
      Chicago, Chicago, IL 60637, USA.
FAU - Boggon, Titus J
AU  - Boggon TJ
AD  - Department of Pharmacology, Yale University, New Haven, CT 06520, USA.
FAU - Jin, Peng
AU  - Jin P
AD  - Department of Human Genetics, Emory University, Atlanta, GA 30322, USA.
FAU - Yi, Hong
AU  - Yi H
AD  - Robert P. Apkarian Integrated Electron Microscopy Core, Emory University,
      Atlanta, GA 30322, USA.
FAU - Wright, Elizabeth R
AU  - Wright ER
AD  - Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322,
      USA.
FAU - Duong, Duc
AU  - Duong D
AD  - Department of Biochemistry, Emory University School of Medicine, Atlanta, GA
      30322, USA.
FAU - Seyfried, Nicholas T
AU  - Seyfried NT
AD  - Department of Biochemistry, Emory University School of Medicine, Atlanta, GA
      30322, USA.
FAU - Egnatchik, Robert
AU  - Egnatchik R
AD  - UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - DeBerardinis, Ralph J
AU  - DeBerardinis RJ
AD  - UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Magliocca, Kelly R
AU  - Magliocca KR
AD  - Department of Pathology & Laboratory Medicine, Emory University School of
      Medicine, Atlanta, GA 30322, USA.
FAU - He, Chuan
AU  - He C
AD  - Department of Chemistry and Institute for Biophysical Dynamics, The University of
      Chicago, Chicago, IL 60637, USA.
FAU - Arellano, Martha L
AU  - Arellano ML
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Khoury, Hanna J
AU  - Khoury HJ
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Shin, Dong M
AU  - Shin DM
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Khuri, Fadlo R
AU  - Khuri FR
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Kang, Sumin
AU  - Kang S
AD  - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory
      University School of Medicine, Atlanta, GA 30322, USA. Electronic address:
      smkang@emory.edu.
LA  - eng
GR  - R01 CA157996/CA/NCI NIH HHS/United States
GR  - P30 CA138292/CA/NCI NIH HHS/United States
GR  - R01 CA174786/CA/NCI NIH HHS/United States
GR  - S10 RR025679-01/RR/NCRR NIH HHS/United States
GR  - R01 CA140515/CA/NCI NIH HHS/United States
GR  - S10 RR025679/RR/NCRR NIH HHS/United States
GR  - R01 CA175316/CA/NCI NIH HHS/United States
GR  - R01 CA183594/CA/NCI NIH HHS/United States
GR  - F31 CA183365/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antioxidants)
RN  - 0 (Fumarates)
RN  - 0 (Ketoglutaric Acids)
RN  - 0 (Reactive Oxygen Species)
RN  - 8ID597Z82X (alpha-ketoglutaric acid)
RN  - EC 1.11.1.- (glutathione peroxidase GPX1)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.4.1.2 (Glutamate Dehydrogenase)
RN  - EC 1.4.1.3 (GLUD1 protein, human)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
MH  - Antioxidants/metabolism
MH  - Carcinogenesis
MH  - Fumarates/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Glutamate Dehydrogenase/antagonists & inhibitors/*biosynthesis/genetics
MH  - Glutathione/*metabolism
MH  - Glutathione Peroxidase/*biosynthesis/genetics
MH  - Humans
MH  - Ketoglutaric Acids/metabolism
MH  - Leukemia/enzymology/*genetics/pathology
MH  - Mitochondria/*enzymology/pathology
MH  - Oxidation-Reduction
MH  - Primary Cell Culture
MH  - Reactive Oxygen Species/metabolism
MH  - Signal Transduction/genetics
PMC - PMC4325424
MID - NIHMS660472
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2014/06/16 00:00 [received]
PHST- 2014/09/29 00:00 [revised]
PHST- 2014/12/15 00:00 [accepted]
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(14)00515-7 [pii]
AID - 10.1016/j.ccell.2014.12.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):257-70. doi: 10.1016/j.ccell.2014.12.006.

PMID- 25670080
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
PG  - 223-39
LID - 10.1016/j.ccell.2014.11.013 [doi]
LID - S1535-6108(14)00464-4 [pii]
AB  - Elucidating the determinants of aggressiveness in lethal prostate cancer may
      stimulate therapeutic strategies that improve clinical outcomes. We used
      experimental models and clinical databases to identify GATA2 as a regulator of
      chemotherapy resistance and tumorigenicity in this context. Mechanistically,
      direct upregulation of the growth hormone IGF2 emerged as a mediator of the
      aggressive properties regulated by GATA2. IGF2 in turn activated IGF1R and INSR
      as well as a downstream polykinase program. The characterization of this axis
      prompted a combination strategy whereby dual IGF1R/INSR inhibition restored the
      efficacy of chemotherapy and improved survival in preclinical models. These
      studies reveal a GATA2-IGF2 aggressiveness axis in lethal prostate cancer and
      identify a therapeutic opportunity in this challenging disease.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Vidal, Samuel J
AU  - Vidal SJ
AD  - College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA;
      Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Rodriguez-Bravo, Veronica
AU  - Rodriguez-Bravo V
AD  - Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Quinn, S Aidan
AU  - Quinn SA
AD  - Department of Pathology and Cell Biology, Columbia University, New York, NY, USA 
      10032, USA.
FAU - Rodriguez-Barrueco, Ruth
AU  - Rodriguez-Barrueco R
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Lujambio, Amaia
AU  - Lujambio A
AD  - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Williams, Estrelania
AU  - Williams E
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Sun, Xiaochen
AU  - Sun X
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - de la Iglesia-Vicente, Janis
AU  - de la Iglesia-Vicente J
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Lee, Albert
AU  - Lee A
AD  - Department of Biomedical Informatics, Center for Computational Biology and
      Bioinformatics, Columbia University, New York, NY 10031, USA.
FAU - Readhead, Ben
AU  - Readhead B
AD  - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
      Sinai, New York, NY 10029, USA.
FAU - Chen, Xintong
AU  - Chen X
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Galsky, Matthew
AU  - Galsky M
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Esteve, Berta
AU  - Esteve B
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Petrylak, Daniel P
AU  - Petrylak DP
AD  - Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT 06510,
      USA.
FAU - Dudley, Joel T
AU  - Dudley JT
AD  - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
      Sinai, New York, NY 10029, USA.
FAU - Rabadan, Raul
AU  - Rabadan R
AD  - Department of Biomedical Informatics, Center for Computational Biology and
      Bioinformatics, Columbia University, New York, NY 10031, USA.
FAU - Silva, Jose M
AU  - Silva JM
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Hoshida, Yujin
AU  - Hoshida Y
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA.
FAU - Lowe, Scott W
AU  - Lowe SW
AD  - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New 
      York, NY 10065, USA.
FAU - Cordon-Cardo, Carlos
AU  - Cordon-Cardo C
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA. Electronic address: carlos.cordon-cardo@mssm.edu.
FAU - Domingo-Domenech, Josep
AU  - Domingo-Domenech J
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
      10029, USA. Electronic address: josep.domingo-domenech@mssm.edu.
LA  - eng
SI  - GEO/GSE58966
GR  - T32 GM082797/GM/NIGMS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - P01 CA087497/CA/NCI NIH HHS/United States
GR  - U01 CA168409/CA/NCI NIH HHS/United States
GR  - R01 DK099558/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antigens, CD)
RN  - 0 (GATA2 Transcription Factor)
RN  - 0 (GATA2 protein, human)
RN  - 0 (IGF2 protein, human)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - EC 2.7.10.1 (INSR protein, human)
RN  - EC 2.7.10.1 (Receptor, Insulin)
SB  - IM
CIN - Cancer Cell. 2015 Feb 9;27(2):158-9. PMID: 25670076
MH  - Animals
MH  - Antigens, CD/genetics
MH  - Cell Proliferation
MH  - Drug Resistance, Neoplasm/genetics
MH  - GATA2 Transcription Factor/*genetics
MH  - Humans
MH  - Insulin-Like Growth Factor II/genetics
MH  - Male
MH  - Mice
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy/*genetics/pathology
MH  - Receptor, Insulin/genetics
MH  - Signal Transduction
MH  - Xenograft Model Antitumor Assays
PMC - PMC4356948
MID - NIHMS665302
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2014/07/09 00:00 [received]
PHST- 2014/10/07 00:00 [revised]
PHST- 2014/11/13 00:00 [accepted]
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(14)00464-4 [pii]
AID - 10.1016/j.ccell.2014.11.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):223-39. doi: 10.1016/j.ccell.2014.11.013.

PMID- 25670079
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - 14-3-3zeta turns TGF-beta's function from tumor suppressor to metastasis promoter
      in breast cancer by contextual changes of Smad partners from p53 to Gli2.
PG  - 177-92
LID - 10.1016/j.ccell.2014.11.025 [doi]
LID - S1535-6108(14)00476-0 [pii]
AB  - Transforming growth factor beta (TGF-beta) functions as a tumor suppressor in
      premalignant cells but as a metastasis promoter in cancer cells. The dichotomous 
      functions of TGF-beta are proposed to be dictated by different partners of its
      downstream effector Smads. However, the mechanism for the contextual changes of
      Smad partners remained undefined. Here, we demonstrate that 14-3-3zeta
      destabilizes p53, a Smad partner in premalignant mammary epithelial cells, by
      downregulating 14-3-3sigma, thus turning off TGF-beta's tumor suppression
      function. Conversely, 14-3-3zeta stabilizes Gli2 in breast cancer cells, and Gli2
      partners with Smads to activate PTHrP and promote TGF-beta-induced bone
      metastasis. The 14-3-3zeta-driven contextual changes of Smad partners from p53 to
      Gli2 may serve as biomarkers and therapeutic targets of TGF-beta-mediated cancer 
      progression.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Xu, Jia
AU  - Xu J
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Acharya, Sunil
AU  - Acharya S
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas Graduate 
      School of Biomedical Sciences, Houston, TX 77030, USA.
FAU - Sahin, Ozgur
AU  - Sahin O
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zhang, Qingling
AU  - Zhang Q
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Saito, Yohei
AU  - Saito Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Yao, Jun
AU  - Yao J
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Wang, Hai
AU  - Wang H
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Li, Ping
AU  - Li P
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas Graduate 
      School of Biomedical Sciences, Houston, TX 77030, USA.
FAU - Lowery, Frank J
AU  - Lowery FJ
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas Graduate 
      School of Biomedical Sciences, Houston, TX 77030, USA.
FAU - Kuo, Wen-Ling
AU  - Kuo WL
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Xiao, Yi
AU  - Xiao Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ensor, Joe
AU  - Ensor J
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Sahin, Aysegul A
AU  - Sahin AA
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Zhang, Xiang H-F
AU  - Zhang XH
AD  - Lester and Sue Smith Breast Center and Department of Molecular and Cellular
      Biology, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas Graduate 
      School of Biomedical Sciences, Houston, TX 77030, USA; Center for Molecular
      Medicine and Graduate Institute of Cancer Biology, China Medical University,
      Taichung 404, Taiwan.
FAU - Zhang, Jitao David
AU  - Zhang JD
AD  - Pharmaceutical Research and Early Development, F. Hoffmann-La Roche, Ltd., 4070
      Basel, Switzerland.
FAU - Yu, Dihua
AU  - Yu D
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas Graduate 
      School of Biomedical Sciences, Houston, TX 77030, USA. Electronic address:
      dyu@mdanderson.org.
LA  - eng
SI  - GEO/GSE52032
SI  - GEO/GSE52066
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01-CA112567-07/CA/NCI NIH HHS/United States
GR  - P01 CA099031/CA/NCI NIH HHS/United States
GR  - R01 CA112567/CA/NCI NIH HHS/United States
GR  - P30-CA 16672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (14-3-3 Proteins)
RN  - 0 (GLI2 protein, human)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Smad Proteins)
RN  - 0 (TP53 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (YWHAZ protein, human)
RN  - 0 (Zinc Finger Protein Gli2)
SB  - IM
CIN - Breast Cancer Res. 2015;17:92. PMID: 26160166
CIN - Cancer Cell. 2015 Feb 9;27(2):151-3. PMID: 25670073
MH  - 14-3-3 Proteins/*genetics
MH  - Bone Neoplasms/*genetics/pathology/secondary
MH  - Breast Neoplasms/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Female
MH  - Humans
MH  - Kruppel-Like Transcription Factors/*genetics
MH  - Molecular Targeted Therapy
MH  - Neoplasm Metastasis
MH  - Nuclear Proteins/*genetics
MH  - Promoter Regions, Genetic
MH  - Smad Proteins/genetics
MH  - Transforming Growth Factor beta/*genetics
MH  - Tumor Suppressor Protein p53/*genetics
MH  - Zinc Finger Protein Gli2
PMC - PMC4325275
MID - NIHMS645738
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2014/05/06 00:00 [received]
PHST- 2014/09/10 00:00 [revised]
PHST- 2014/11/24 00:00 [accepted]
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(14)00476-0 [pii]
AID - 10.1016/j.ccell.2014.11.025 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):177-92. doi: 10.1016/j.ccell.2014.11.025.

PMID- 25670078
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Emerging strategies for treating brain metastases from breast cancer.
PG  - 163-75
LID - 10.1016/j.ccell.2015.01.001 [doi]
LID - S1535-6108(15)00016-1 [pii]
AB  - Brain metastasis is an end stage in breast cancer progression. Traditional
      treatment options have minimal efficacy, and overall survival is on the order of 
      months. The incidence of brain metastatic disease is increasing with the improved
      management of systemic disease and prolongation of survival. Unfortunately, the
      targeted therapies that control systemic disease have diminished efficacy against
      brain lesions. There are reasons to be optimistic, however, as emerging therapies
      have shown promise in preclinical and early clinical settings. This review
      discusses recent advances in breast cancer brain metastasis therapy and potential
      approaches for successful treatment.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Kodack, David P
AU  - Kodack DP
AD  - Edwin L. Steele Laboratory, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Askoxylakis, Vasileios
AU  - Askoxylakis V
AD  - Edwin L. Steele Laboratory, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Ferraro, Gino B
AU  - Ferraro GB
AD  - Edwin L. Steele Laboratory, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Fukumura, Dai
AU  - Fukumura D
AD  - Edwin L. Steele Laboratory, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Jain, Rakesh K
AU  - Jain RK
AD  - Edwin L. Steele Laboratory, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA. Electronic address: jain@steele.mgh.harvard.edu.
LA  - eng
GR  - R01 CA126642/CA/NCI NIH HHS/United States
GR  - P41 EB015903/EB/NIBIB NIH HHS/United States
GR  - P50 CA098131/CA/NCI NIH HHS/United States
GR  - P01 CA080124/CA/NCI NIH HHS/United States
GR  - R01-CA126642/CA/NCI NIH HHS/United States
GR  - R01-CA096915/CA/NCI NIH HHS/United States
GR  - R01 CA096915/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Brain Neoplasms/*drug therapy/*genetics/pathology/secondary
MH  - Breast Neoplasms/*drug therapy/genetics/pathology
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Pathology, Molecular
MH  - Receptor, ErbB-2/genetics
PMC - PMC4325273
MID - NIHMS654963
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2014/07/17 00:00 [received]
PHST- 2014/10/25 00:00 [revised]
PHST- 2015/01/06 00:00 [accepted]
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00016-1 [pii]
AID - 10.1016/j.ccell.2015.01.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):163-75. doi: 10.1016/j.ccell.2015.01.001.

PMID- 25670077
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20150211
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Web of the extended Myc network captures metabolism for tumorigenesis.
PG  - 160-2
LID - 10.1016/j.ccell.2015.01.004 [doi]
LID - S1535-6108(15)00019-7 [pii]
AB  - In this issue of Cancer Cell, Carroll and colleagues describe the role of MondoA,
      a member of the Myc-Max-Mxd-Mxl transcription factor network (termed the extended
      Myc network herein), in Myc-mediated alterations in cancer cell metabolism and
      tumorigenesis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Dang, Chi V
AU  - Dang CV
AD  - Abramson Cancer Center, Abramson Family Cancer Research Institute, University of 
      Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
      dangvchi@exchange.upenn.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (MONDOA protein, human)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
CON - Cancer Cell. 2015 Feb 9;27(2):271-85. PMID: 25640402
MH  - Animals
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/*genetics
MH  - Humans
MH  - Neuroblastoma/*genetics
MH  - Proto-Oncogene Proteins c-myc/*genetics
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00019-7 [pii]
AID - 10.1016/j.ccell.2015.01.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):160-2. doi: 10.1016/j.ccell.2015.01.004.

PMID- 25670076
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20150211
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation 
      of IGF2.
PG  - 158-9
LID - 10.1016/j.ccell.2015.01.008 [doi]
LID - S1535-6108(15)00023-9 [pii]
AB  - GATA2 has been well-characterized as a critical pioneer transcription factor for 
      androgen receptor (AR) in prostate cancer. In this issue of Cancer Cell, Vidal
      and colleagues identify increased GATA2 and its AR-independent transactivation of
      IGF2 as a mechanism that can mediate taxane resistance through activation of
      IGF1/insulin receptor signaling.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Plymate, Stephen R
AU  - Plymate SR
AD  - Department of Medicine, University of Washington and GRECC-VAPSHCS, Seattle, WA
      98104, USA.
FAU - Bhatt, Rupal S
AU  - Bhatt RS
AD  - Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess
      Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School,
      Boston, MA 02215, USA.
FAU - Balk, Steven P
AU  - Balk SP
AD  - Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess
      Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School,
      Boston, MA 02215, USA. Electronic address: sbalk@bidmc.harvard.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (GATA2 Transcription Factor)
RN  - 0 (GATA2 protein, human)
SB  - IM
CON - Cancer Cell. 2015 Feb 9;27(2):223-39. PMID: 25670080
MH  - Animals
MH  - GATA2 Transcription Factor/*genetics
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy/*genetics
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00023-9 [pii]
AID - 10.1016/j.ccell.2015.01.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):158-9. doi: 10.1016/j.ccell.2015.01.008.

PMID- 25670075
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20150211
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Reactive oxygen species in cancer: a dance with the devil.
PG  - 156-7
LID - 10.1016/j.ccell.2015.01.007 [doi]
LID - S1535-6108(15)00022-7 [pii]
AB  - Reactive oxygen species (ROS) can initiate cancer, but oxidant generation in
      tumors leaves them vulnerable to further stresses. In this issue of Cancer Cell, 
      Harris and colleagues show that augmenting oxidant stress in normal cells limits 
      tumor initiation and progression. Hence, strategic targeting of antioxidant
      systems may undermine survival of new tumor cells.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Schumacker, Paul T
AU  - Schumacker PT
AD  - Department of Pediatrics, Northwestern University Feinberg School of Medicine,
      Chicago, IL 60611, USA. Electronic address: p-schumacker@northwestern.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antioxidants)
RN  - EC 6.3.2.2 (Glutamate-Cysteine Ligase)
SB  - IM
CON - Cancer Cell. 2015 Feb 9;27(2):211-22. PMID: 25620030
MH  - Animals
MH  - Antioxidants/*metabolism
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Glutamate-Cysteine Ligase/*genetics
MH  - Humans
MH  - Mammary Neoplasms, Animal/*genetics
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00022-7 [pii]
AID - 10.1016/j.ccell.2015.01.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):156-7. doi: 10.1016/j.ccell.2015.01.007.

PMID- 25670074
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20150211
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Cradle of evil: osteogenic niche for early bone metastasis.
PG  - 153-5
LID - 10.1016/j.ccell.2015.01.006 [doi]
LID - S1535-6108(15)00021-5 [pii]
AB  - Bone metastasis often emerges long after the initial dissemination of cancer
      cells. In this issue of Cancer Cell, Wang and colleagues demonstrate that
      disseminated breast cancer cells engage osteogenic niches in the bone through
      heterotypic adherins junctions. This interaction activates mTOR signaling in
      cancer cells and supports their expansion to micrometastases.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Zheng, Hanqiu
AU  - Zheng H
AD  - Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
FAU - Kang, Yibin
AU  - Kang Y
AD  - Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA. 
      Electronic address: ykang@princeton.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
CON - Cancer Cell. 2015 Feb 9;27(2):193-210. PMID: 25600338
MH  - Bone Neoplasms/*genetics
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Humans
MH  - Osteogenesis/*genetics
MH  - Tumor Microenvironment/*genetics
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00021-5 [pii]
AID - 10.1016/j.ccell.2015.01.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):153-5. doi: 10.1016/j.ccell.2015.01.006.

PMID- 25670073
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - 14-3-3zeta turns TGF-beta to the dark side.
PG  - 151-3
LID - 10.1016/j.ccell.2015.01.005 [doi]
LID - S1535-6108(15)00020-3 [pii]
AB  - TGF-beta/SMAD signaling has long been known to exhibit a dual role in cancer,
      questioning what determines its context-dependent functions. In this issue of
      Cancer Cell, Xu and colleagues describe a critical role of the adaptor protein
      14-3-3zeta in modulating SMAD activities by changing its interaction partners
      during breast cancer progression.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - ten Dijke, Peter
AU  - ten Dijke P
AD  - Department of Molecular Cell Biology, Cancer Genomics Centre Netherlands, Leiden 
      University Medical Center, Postbus 9600, 2300 RC Leiden, the Netherlands; Ludwig 
      Institute for Cancer Research, Science for Life Laboratory, Uppsala University,
      Box 595, 75124 Uppsala, Sweden. Electronic address: p.ten_dijke@lumc.nl.
FAU - van Dam, Hans
AU  - van Dam H
AD  - Department of Molecular Cell Biology, Cancer Genomics Centre Netherlands, Leiden 
      University Medical Center, Postbus 9600, 2300 RC Leiden, the Netherlands; Ludwig 
      Institute for Cancer Research, Science for Life Laboratory, Uppsala University,
      Box 595, 75124 Uppsala, Sweden.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (14-3-3 Proteins)
RN  - 0 (GLI2 protein, human)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (Nuclear Proteins)
RN  - 0 (TP53 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (YWHAZ protein, human)
RN  - 0 (Zinc Finger Protein Gli2)
SB  - IM
CON - Cancer Cell. 2015 Feb 9;27(2):177-92. PMID: 25670079
MH  - 14-3-3 Proteins/*genetics
MH  - Bone Neoplasms/*genetics
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Humans
MH  - Kruppel-Like Transcription Factors/*genetics
MH  - Nuclear Proteins/*genetics
MH  - Transforming Growth Factor beta/*genetics
MH  - Tumor Suppressor Protein p53/*genetics
MH  - Zinc Finger Protein Gli2
EDAT- 2015/02/12 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/12 06:00
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(15)00020-3 [pii]
AID - 10.1016/j.ccell.2015.01.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):151-3. doi: 10.1016/j.ccell.2015.01.005.

PMID- 25640402
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and
      tumorigenesis.
PG  - 271-85
LID - 10.1016/j.ccell.2014.11.024 [doi]
LID - S1535-6108(14)00475-9 [pii]
AB  - Deregulated Myc transcriptionally reprograms cell metabolism to promote
      neoplasia. Here we show that oncogenic Myc requires the Myc superfamily member
      MondoA, a nutrient-sensing transcription factor, for tumorigenesis. Knockdown of 
      MondoA, or its dimerization partner Mlx, blocks Myc-induced reprogramming of
      multiple metabolic pathways, resulting in apoptosis. Identification and knockdown
      of genes coregulated by Myc and MondoA have allowed us to define metabolic
      functions required by deregulated Myc and demonstrate a critical role for lipid
      biosynthesis in survival of Myc-driven cancer. Furthermore, overexpression of a
      subset of Myc and MondoA coregulated genes correlates with poor outcome of
      patients with diverse cancers. Coregulation of cancer metabolism by Myc and
      MondoA provides the potential for therapeutics aimed at inhibiting MondoA and its
      target genes.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Carroll, Patrick A
AU  - Carroll PA
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, MS A2-025,
      P.O. Box 19024, Seattle, WA 98109-1024, USA.
FAU - Diolaiti, Daniel
AU  - Diolaiti D
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, MS A2-025,
      P.O. Box 19024, Seattle, WA 98109-1024, USA.
FAU - McFerrin, Lisa
AU  - McFerrin L
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, MS A2-025,
      P.O. Box 19024, Seattle, WA 98109-1024, USA.
FAU - Gu, Haiwei
AU  - Gu H
AD  - Northwest Metabolomics Research Center, Department of Anesthesiology and Pain
      Medicine, University of Washington, 850 Republican Street, Room S148, P.O. Box
      358057, Seattle, WA 98109-8057, USA.
FAU - Djukovic, Danijel
AU  - Djukovic D
AD  - Northwest Metabolomics Research Center, Department of Anesthesiology and Pain
      Medicine, University of Washington, 850 Republican Street, Room S148, P.O. Box
      358057, Seattle, WA 98109-8057, USA.
FAU - Du, Jianhai
AU  - Du J
AD  - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
FAU - Cheng, Pei Feng
AU  - Cheng PF
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, MS A2-025,
      P.O. Box 19024, Seattle, WA 98109-1024, USA.
FAU - Anderson, Sarah
AU  - Anderson S
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, MS A2-025,
      P.O. Box 19024, Seattle, WA 98109-1024, USA.
FAU - Ulrich, Michelle
AU  - Ulrich M
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, MS A2-025,
      P.O. Box 19024, Seattle, WA 98109-1024, USA.
FAU - Hurley, James B
AU  - Hurley JB
AD  - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA;
      Department of Ophthalmology, University of Washington, Seattle, WA 98195, USA.
FAU - Raftery, Daniel
AU  - Raftery D
AD  - Northwest Metabolomics Research Center, Department of Anesthesiology and Pain
      Medicine, University of Washington, 850 Republican Street, Room S148, P.O. Box
      358057, Seattle, WA 98109-8057, USA; Division of Public Health Sciences, Fred
      Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109,
      USA.
FAU - Ayer, Donald E
AU  - Ayer DE
AD  - Department of Oncological Sciences, Huntsman Cancer Institute, University of
      Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
FAU - Eisenman, Robert N
AU  - Eisenman RN
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, MS A2-025,
      P.O. Box 19024, Seattle, WA 98109-1024, USA. Electronic address:
      eisenman@fhcrc.org.
LA  - eng
GR  - R01 EY006641/EY/NEI NIH HHS/United States
GR  - R37 CA057138/CA/NCI NIH HHS/United States
GR  - R01 CA057138/CA/NCI NIH HHS/United States
GR  - R37CA57138/CA/NCI NIH HHS/United States
GR  - P30 EY001730/EY/NEI NIH HHS/United States
GR  - UL1RR025014/RR/NCRR NIH HHS/United States
GR  - R01-GM055668/GM/NIGMS NIH HHS/United States
GR  - R01 GM055668/GM/NIGMS NIH HHS/United States
GR  - UL1 RR025014/RR/NCRR NIH HHS/United States
GR  - R01 EY017863/EY/NEI NIH HHS/United States
GR  - T32 CA009657/CA/NCI NIH HHS/United States
GR  - R01 EY06641/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150129
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (MONDOA protein, human)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
CIN - Cancer Cell. 2015 Feb 9;27(2):160-2. PMID: 25670077
MH  - Animals
MH  - Apoptosis/genetics
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/chemistry/*genetics
MH  - Carcinogenesis/genetics
MH  - Cellular Reprogramming/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Mice
MH  - Neuroblastoma/*genetics/metabolism/pathology
MH  - Protein Multimerization
MH  - Proto-Oncogene Proteins c-myc/biosynthesis/*genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC4326605
MID - NIHMS645735
EDAT- 2015/02/03 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/02/03 06:00
PHST- 2014/02/18 00:00 [received]
PHST- 2014/09/02 00:00 [revised]
PHST- 2014/11/21 00:00 [accepted]
PHST- 2015/02/03 06:00 [entrez]
PHST- 2015/02/03 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(14)00475-9 [pii]
AID - 10.1016/j.ccell.2014.11.024 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):271-85. doi: 10.1016/j.ccell.2014.11.024. Epub 2015
      Jan 29.

PMID- 25620030
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20150211
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Glutathione and thioredoxin antioxidant pathways synergize to drive cancer
      initiation and progression.
PG  - 211-22
LID - 10.1016/j.ccell.2014.11.019 [doi]
LID - S1535-6108(14)00470-X [pii]
AB  - Controversy over the role of antioxidants in cancer has persisted for decades.
      Here, we demonstrate that synthesis of the antioxidant glutathione (GSH), driven 
      by GCLM, is required for cancer initiation. Genetic loss of Gclm prevents a
      tumor's ability to drive malignant transformation. Intriguingly, these findings
      can be replicated using an inhibitor of GSH synthesis, but only if delivered
      prior to cancer onset, suggesting that at later stages of tumor progression GSH
      becomes dispensable potentially due to compensation from alternative antioxidant 
      pathways. Remarkably, combined inhibition of GSH and thioredoxin antioxidant
      pathways leads to a synergistic cancer cell death in vitro and in vivo,
      demonstrating the importance of these two antioxidants to tumor progression and
      as potential targets for therapeutic intervention.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Harris, Isaac S
AU  - Harris IS
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Department of
      Medical Biophysics, University Health Network, 620 University Avenue, Toronto, ON
      M5G 2M9, Canada.
FAU - Treloar, Aislinn E
AU  - Treloar AE
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Department of
      Medical Biophysics, University Health Network, 620 University Avenue, Toronto, ON
      M5G 2M9, Canada.
FAU - Inoue, Satoshi
AU  - Inoue S
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Sasaki, Masato
AU  - Sasaki M
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Department of
      Infection and Host Defense, Tohoku Pharmaceutical University, 4-4-1 Komatsushima,
      Aoba-ku, Sendai, Miyagi 981-8558, Japan.
FAU - Gorrini, Chiara
AU  - Gorrini C
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Lee, Kim Chung
AU  - Lee KC
AD  - Department of Pathology, The University of Hong Kong, Hong Kong, China.
FAU - Yung, Ka Yi
AU  - Yung KY
AD  - Department of Pathology, The University of Hong Kong, Hong Kong, China.
FAU - Brenner, Dirk
AU  - Brenner D
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Department of
      Infection and Immunity, Luxembourg Institute of Health, 84, Val Fleuri, 1526
      Luxembourg, Luxembourg.
FAU - Knobbe-Thomsen, Christiane B
AU  - Knobbe-Thomsen CB
AD  - Department of Neuropathology, Heinrich Heine University, 40225 Dusseldorf,
      Germany.
FAU - Cox, Maureen A
AU  - Cox MA
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Elia, Andrew
AU  - Elia A
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Berger, Thorsten
AU  - Berger T
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Cescon, David W
AU  - Cescon DW
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Department of
      Medical Biophysics, University Health Network, 620 University Avenue, Toronto, ON
      M5G 2M9, Canada.
FAU - Adeoye, Adewunmi
AU  - Adeoye A
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Laboratory Medicine 
      Program, University Health Network, 620 University Avenue, Toronto, ON M5G 2M9,
      Canada; Department of Laboratory Medicine and Pathobiology, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Brustle, Anne
AU  - Brustle A
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Molyneux, Sam D
AU  - Molyneux SD
AD  - Department of Medical Biophysics, University Health Network, 620 University
      Avenue, Toronto, ON M5G 2M9, Canada; Ontario Cancer Institute, University Health 
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Mason, Jacqueline M
AU  - Mason JM
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Li, Wanda Y
AU  - Li WY
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Yamamoto, Kazuo
AU  - Yamamoto K
AD  - Division of Cell Function Research Support, Biomedical Research Support Center,
      Nagasaki University School of Medical Sciences, 1-12-4 Sakamoto, Nagasaki
      852-8523, Japan.
FAU - Wakeham, Andrew
AU  - Wakeham A
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Berman, Hal K
AU  - Berman HK
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Laboratory Medicine 
      Program, University Health Network, 620 University Avenue, Toronto, ON M5G 2M9,
      Canada; Department of Laboratory Medicine and Pathobiology, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Khokha, Rama
AU  - Khokha R
AD  - Department of Medical Biophysics, University Health Network, 620 University
      Avenue, Toronto, ON M5G 2M9, Canada; Ontario Cancer Institute, University Health 
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Done, Susan J
AU  - Done SJ
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Laboratory Medicine 
      Program, University Health Network, 620 University Avenue, Toronto, ON M5G 2M9,
      Canada; Department of Laboratory Medicine and Pathobiology, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
FAU - Kavanagh, Terrance J
AU  - Kavanagh TJ
AD  - Department of Environmental and Occupational Health Sciences, University of
      Washington, Seattle, WA 98195, USA.
FAU - Lam, Ching-Wan
AU  - Lam CW
AD  - Department of Pathology, The University of Hong Kong, Hong Kong, China.
FAU - Mak, Tak W
AU  - Mak TW
AD  - The Campbell Family Institute for Breast Cancer Research, University Health
      Network, 620 University Avenue, Toronto, ON M5G 2M9, Canada; Department of
      Medical Biophysics, University Health Network, 620 University Avenue, Toronto, ON
      M5G 2M9, Canada. Electronic address: tmak@uhnres.utoronto.ca.
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150122
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antioxidants)
RN  - 52500-60-4 (Thioredoxins)
RN  - EC 6.3.2.2 (Glutamate-Cysteine Ligase)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
CIN - Cancer Cell. 2015 Feb 9;27(2):156-7. PMID: 25670075
EIN - Cancer Cell. 2015 Feb 9;27(2):314
MH  - Animals
MH  - Antioxidants/*metabolism
MH  - Breast Neoplasms/*genetics/pathology
MH  - Carcinogenesis
MH  - Female
MH  - Glutamate-Cysteine Ligase/*genetics/metabolism
MH  - Glutathione/genetics
MH  - Humans
MH  - Mammary Neoplasms, Animal/drug therapy/*genetics/pathology
MH  - Mice
MH  - Mice, Transgenic
MH  - Thioredoxins/metabolism
EDAT- 2015/01/27 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/01/27 06:00
PHST- 2013/03/18 00:00 [received]
PHST- 2014/07/15 00:00 [revised]
PHST- 2014/11/18 00:00 [accepted]
PHST- 2015/01/27 06:00 [entrez]
PHST- 2015/01/27 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(14)00470-X [pii]
AID - 10.1016/j.ccell.2014.11.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):211-22. doi: 10.1016/j.ccell.2014.11.019. Epub 2015
      Jan 22.

PMID- 25600339
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of
      BRAF/MEK cotargeting but result in melanoma drug addiction.
PG  - 240-56
LID - 10.1016/j.ccell.2014.11.018 [doi]
LID - S1535-6108(14)00469-3 [pii]
AB  - Combined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi)
      therapy but is still beset by acquired resistance. We show that melanomas acquire
      resistance to combined BRAF and MEK inhibition by augmenting or combining
      mechanisms of single-agent BRAFi resistance. These double-drug
      resistance-associated genetic configurations significantly altered molecular
      interactions underlying MAPK pathway reactivation. (V600E)BRAF, expressed at
      supraphysiological levels because of (V600E)BRAF ultra-amplification, dimerized
      with and activated CRAF. In addition, MEK mutants enhanced interaction with
      overexpressed (V600E)BRAF via a regulatory interface at R662 of (V600E)BRAF.
      Importantly, melanoma cell lines selected for resistance to BRAFi+MEKi, but not
      those to BRAFi alone, displayed robust drug addiction, providing a potentially
      exploitable therapeutic opportunity.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Moriceau, Gatien
AU  - Moriceau G
AD  - Division of Dermatology, Department of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Hugo, Willy
AU  - Hugo W
AD  - Division of Dermatology, Department of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Hong, Aayoung
AU  - Hong A
AD  - Division of Dermatology, Department of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical
      Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; 
      David Geffen School of Medicine, University of California, Los Angeles, Los
      Angeles, CA 90095, USA.
FAU - Shi, Hubing
AU  - Shi H
AD  - Division of Dermatology, Department of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Kong, Xiangju
AU  - Kong X
AD  - Division of Dermatology, Department of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Yu, Clarissa C
AU  - Yu CC
AD  - Division of Dermatology, Department of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Koya, Richard C
AU  - Koya RC
AD  - Division of Oncology, Department of Medicine, Roswell Park Cancer Institute,
      Buffalo, NY 14263, USA.
FAU - Samatar, Ahmed A
AU  - Samatar AA
AD  - Discovery Oncology, Merck Research Laboratories, Boston, MA 02115, USA.
FAU - Khanlou, Negar
AU  - Khanlou N
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Braun, Jonathan
AU  - Braun J
AD  - Department of Pathology and Laboratory Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center,
      University of California, Los Angeles, Los Angeles, CA 90095, USA; David Geffen
      School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095,
      USA.
FAU - Ruchalski, Kathleen
AU  - Ruchalski K
AD  - Department of Radiological Sciences, University of California, Los Angeles, Los
      Angeles, CA 90095, USA; David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Seifert, Heike
AU  - Seifert H
AD  - Department of Medicine, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Larkin, James
AU  - Larkin J
AD  - Department of Medicine, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
FAU - Dahlman, Kimberly B
AU  - Dahlman KB
AD  - Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA;
      Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA.
FAU - Johnson, Douglas B
AU  - Johnson DB
AD  - Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA;
      Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA.
FAU - Algazi, Alain
AU  - Algazi A
AD  - Division of Hematology and Oncology, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Sosman, Jeffrey A
AU  - Sosman JA
AD  - Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA;
      Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA.
FAU - Ribas, Antoni
AU  - Ribas A
AD  - Department of Molecular and Medical Pharmacology, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; Division of Hematology and Oncology,
      Department of Medicine, University of California, Los Angeles, Los Angeles, CA
      90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA 90095, USA.
FAU - Lo, Roger S
AU  - Lo RS
AD  - Division of Dermatology, Department of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical
      Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; 
      Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los
      Angeles, CA 90095, USA; David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:
      rlo@mednet.ucla.edu.
LA  - eng
SI  - SRA/SRP049746
GR  - 5K24CA097588-09/CA/NCI NIH HHS/United States
GR  - K12 CA090625/CA/NCI NIH HHS/United States
GR  - 1R01CA176111/CA/NCI NIH HHS/United States
GR  - R01 CA176111/CA/NCI NIH HHS/United States
GR  - 1P01CA168585/CA/NCI NIH HHS/United States
GR  - K24 CA097588/CA/NCI NIH HHS/United States
GR  - P30 CA016042/CA/NCI NIH HHS/United States
GR  - P01 CA168585/CA/NCI NIH HHS/United States
GR  - K22 CA151638/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150115
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CIN - Nat Rev Clin Oncol. 2015 Apr;12(4):189. PMID: 25687909
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Humans
MH  - MAP Kinase Signaling System/genetics
MH  - Melanoma/*drug therapy/*genetics/pathology
MH  - Molecular Targeted Therapy
MH  - Mutation
MH  - Protein Kinase Inhibitors/administration & dosage
MH  - Proto-Oncogene Proteins B-raf/*genetics
PMC - PMC4326539
MID - NIHMS644596
EDAT- 2015/01/21 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/01/21 06:00
PHST- 2014/04/22 00:00 [received]
PHST- 2014/09/01 00:00 [revised]
PHST- 2014/11/19 00:00 [accepted]
PHST- 2015/01/21 06:00 [entrez]
PHST- 2015/01/21 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(14)00469-3 [pii]
AID - 10.1016/j.ccell.2014.11.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015
      Jan 15.

PMID- 25600338
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20180328
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Feb 9
TI  - The osteogenic niche promotes early-stage bone colonization of disseminated
      breast cancer cells.
PG  - 193-210
LID - 10.1016/j.ccell.2014.11.017 [doi]
LID - S1535-6108(14)00468-1 [pii]
AB  - Breast cancer bone micrometastases can remain asymptomatic for years before
      progressing into overt lesions. The biology of this process, including the
      microenvironment niche and supporting pathways, is unclear. We find that bone
      micrometastases predominantly reside in a niche that exhibits features of
      osteogenesis. Niche interactions are mediated by heterotypic adherens junctions
      (hAJs) involving cancer-derived E-cadherin and osteogenic N-cadherin, the
      disruption of which abolishes niche-conferred advantages. We elucidate that hAJ
      activates the mTOR pathway in cancer cells, which drives the progression from
      single cells to micrometastases. Human data set analyses support the roles of AJ 
      and the mTOR pathway in bone colonization. Our study illuminates the initiation
      of bone colonization, and provides potential therapeutic targets to block
      progression toward osteolytic metastases.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wang, Hai
AU  - Wang H
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Yu, Cuijuan
AU  - Yu C
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Gao, Xia
AU  - Gao X
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Welte, Thomas
AU  - Welte T
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Muscarella, Aaron M
AU  - Muscarella AM
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Integrative Molecular and Biomedical Sciences Graduate
      Program, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Tian, Lin
AU  - Tian L
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, 
      One Baylor Plaza, Houston, TX 77030, USA; Verna and Marrs McLean Department of
      Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA.
FAU - Zhao, Hong
AU  - Zhao H
AD  - NCI Center for Modeling Cancer Development, Weill Cornell Medical College, 6670
      Bertner Avenue, Houston, TX 77030, USA; Department of Systems Medicine and
      Bioengineering, The Methodist Hospital Research Institute, Weill Cornell Medical 
      College, 6670 Bertner Avenue, Houston, TX 77030, USA.
FAU - Zhao, Zhen
AU  - Zhao Z
AD  - NCI Center for Modeling Cancer Development, Weill Cornell Medical College, 6670
      Bertner Avenue, Houston, TX 77030, USA; Department of Systems Medicine and
      Bioengineering, The Methodist Hospital Research Institute, Weill Cornell Medical 
      College, 6670 Bertner Avenue, Houston, TX 77030, USA; Department of Radiology,
      Southeast University School of Medicine, Nanjing 210018, China.
FAU - Du, Shiyu
AU  - Du S
AD  - Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, 
      China.
FAU - Tao, Jianning
AU  - Tao J
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, One
      Baylor Plaza, Houston, TX 77030, USA.
FAU - Lee, Brendan
AU  - Lee B
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, One
      Baylor Plaza, Houston, TX 77030, USA.
FAU - Westbrook, Thomas F
AU  - Westbrook TF
AD  - Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor
      College of Medicine, One Baylor Plaza, Houston, TX 77030, USA; Verna and Marrs
      McLean Department of Biochemistry and Molecular Biology, Baylor College of
      Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Wong, Stephen T C
AU  - Wong ST
AD  - Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, One Baylor Plaza, Houston, TX 77030, USA; NCI Center for
      Modeling Cancer Development, Weill Cornell Medical College, 6670 Bertner Avenue, 
      Houston, TX 77030, USA; Department of Systems Medicine and Bioengineering, The
      Methodist Hospital Research Institute, Weill Cornell Medical College, 6670
      Bertner Avenue, Houston, TX 77030, USA; Department of Radiology, Houston
      Methodist Hospital, 6565 Fannin Street, Houston, TX 77459, USA.
FAU - Jin, Xin
AU  - Jin X
AD  - Cancer Program, the Eli and Edythe L. Broad Institute, 415 Main Street,
      Cambridge, MA 02142, USA.
FAU - Rosen, Jeffrey M
AU  - Rosen JM
AD  - Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor
      College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Osborne, C Kent
AU  - Osborne CK
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, 
      One Baylor Plaza, Houston, TX 77030, USA; Department of Molecular and Cellular
      Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Zhang, Xiang H-F
AU  - Zhang XH
AD  - Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza,
      Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, 
      One Baylor Plaza, Houston, TX 77030, USA; Department of Molecular and Cellular
      Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA;
      McNair Medical Institute, Baylor College of Medicine, One Baylor Plaza, Houston, 
      TX 77030, USA. Electronic address: xiangz@bcm.edu.
LA  - eng
GR  - CA151293/CA/NCI NIH HHS/United States
GR  - K99 CA151293/CA/NCI NIH HHS/United States
GR  - R01 CA148761/CA/NCI NIH HHS/United States
GR  - CA149196-04/CA/NCI NIH HHS/United States
GR  - U54CA149196/CA/NCI NIH HHS/United States
GR  - R01 CA183878/CA/NCI NIH HHS/United States
GR  - U54 CA149196/CA/NCI NIH HHS/United States
GR  - CA148761/CA/NCI NIH HHS/United States
GR  - CA183878/CA/NCI NIH HHS/United States
GR  - R00 CA151293/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20150115
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cadherins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
SB  - IM
CIN - Cancer Cell. 2015 Feb 9;27(2):153-5. PMID: 25670074
MH  - Bone Neoplasms/*genetics/pathology/secondary
MH  - Breast Neoplasms/*genetics/pathology
MH  - Cadherins/genetics
MH  - Cell Line, Tumor
MH  - Female
MH  - Humans
MH  - Neoplasm Staging
MH  - Osteogenesis/*genetics
MH  - TOR Serine-Threonine Kinases/genetics
MH  - Tumor Microenvironment/*genetics
PMC - PMC4326554
MID - NIHMS644614
EDAT- 2015/01/21 06:00
MHDA- 2015/04/25 06:00
CRDT- 2015/01/21 06:00
PHST- 2014/05/13 00:00 [received]
PHST- 2014/09/24 00:00 [revised]
PHST- 2014/11/18 00:00 [accepted]
PHST- 2015/01/21 06:00 [entrez]
PHST- 2015/01/21 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S1535-6108(14)00468-1 [pii]
AID - 10.1016/j.ccell.2014.11.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Feb 9;27(2):193-210. doi: 10.1016/j.ccell.2014.11.017. Epub
      2015 Jan 15.

PMID- 25584895
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20171110
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Dual-action combination therapy enhances angiogenesis while reducing tumor growth
      and spread.
PG  - 123-37
LID - 10.1016/j.ccell.2014.10.015 [doi]
LID - S1535-6108(14)00419-X [pii]
AB  - Increasing chemotherapy delivery to tumors, while enhancing drug uptake and
      reducing side effects, is a primary goal of cancer research. In mouse and human
      cancer models in vivo, we show that coadministration of low-dose Cilengitide and 
      Verapamil increases tumor angiogenesis, leakiness, blood flow, and Gemcitabine
      delivery. This approach reduces tumor growth, metastasis, and minimizes side
      effects while extending survival. At a molecular level, this strategy alters
      Gemcitabine transporter and metabolizing enzyme expression levels, enhancing the 
      potency of Gemcitabine within tumor cells in vivo and in vitro. Thus, the dual
      action of low-dose Cilengitide, in vessels and tumor cells, improves chemotherapy
      efficacy. Overall, our data demonstrate that vascular promotion therapy is a
      means to improve cancer treatment.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Wong, Ping-Pui
AU  - Wong PP
AD  - Centre for Tumor Biology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK.
FAU - Demircioglu, Fevzi
AU  - Demircioglu F
AD  - Centre for Tumor Biology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK.
FAU - Ghazaly, Essam
AU  - Ghazaly E
AD  - Centre for Haemato-Oncology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK.
FAU - Alrawashdeh, Wasfi
AU  - Alrawashdeh W
AD  - Centre for Molecular Oncology, Barts Cancer Institute-a CR-UK Centre of
      Excellence, Queen Mary University of London, John Vane Science Centre,
      Charterhouse Square, London EC1M 6BQ, UK.
FAU - Stratford, Michael R L
AU  - Stratford MR
AD  - CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology,
      University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
FAU - Scudamore, Cheryl L
AU  - Scudamore CL
AD  - Mary Lyon Centre, MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire
      OX11 0RD, UK.
FAU - Cereser, Biancastella
AU  - Cereser B
AD  - Centre for Tumor Biology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK.
FAU - Crnogorac-Jurcevic, Tatjana
AU  - Crnogorac-Jurcevic T
AD  - Centre for Molecular Oncology, Barts Cancer Institute-a CR-UK Centre of
      Excellence, Queen Mary University of London, John Vane Science Centre,
      Charterhouse Square, London EC1M 6BQ, UK.
FAU - McDonald, Stuart
AU  - McDonald S
AD  - Centre for Tumor Biology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK.
FAU - Elia, George
AU  - Elia G
AD  - Centre for Tumor Biology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK.
FAU - Hagemann, Thorsten
AU  - Hagemann T
AD  - Centre for Cancer Inflammation, Barts Cancer Institute-a CR-UK Centre of
      Excellence, Queen Mary University of London, John Vane Science Centre,
      Charterhouse Square, London EC1M 6BQ, UK; Barts and the London HPB Centre, The
      Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK.
FAU - Kocher, Hemant M
AU  - Kocher HM
AD  - Centre for Tumor Biology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK; Barts and the London HPB Centre, The Royal London Hospital, 
      Barts Health NHS Trust, London E1 1BB, UK.
FAU - Hodivala-Dilke, Kairbaan M
AU  - Hodivala-Dilke KM
AD  - Centre for Tumor Biology, Barts Cancer Institute-a CR-UK Centre of Excellence,
      Queen Mary University of London, John Vane Science Centre, Charterhouse Square,
      London EC1M 6BQ, UK. Electronic address: k.hodivala-dilke@qmul.ac.uk.
LA  - eng
GR  - 12007/Cancer Research UK/United Kingdom
GR  - C82181/A12007/Cancer Research UK/United Kingdom
GR  - C18270/A14355/Cancer Research UK/United Kingdom
GR  - G0901338/Medical Research Council/United Kingdom
GR  - G0901609/Medical Research Council/United Kingdom
GR  - C18270/A12888/Cancer Research UK/United Kingdom
GR  - 12-1068/Worldwide Cancer Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Snake Venoms)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 4EDF46E4GI (Cilengitide)
RN  - B76N6SBZ8R (gemcitabine)
RN  - CJ0O37KU29 (Verapamil)
SB  - IM
CIN - Cancer Cell. 2015 Jan 12;27(1):7-9. PMID: 25584889
CIN - Nat Rev Cancer. 2015 Mar;15(3):135. PMID: 25652345
MH  - Animals
MH  - Antimetabolites, Antineoplastic/*administration & dosage/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Carcinoma, Lewis Lung/*drug therapy/*pathology
MH  - Cell Line, Tumor
MH  - Deoxycytidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Drug Synergism
MH  - Humans
MH  - Lung/blood supply/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Neovascularization, Pathologic/drug therapy
MH  - Pancreas/blood supply/pathology
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Snake Venoms/*administration & dosage/therapeutic use
MH  - Verapamil/*administration & dosage/therapeutic use
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2014/02/24 00:00 [received]
PHST- 2014/08/12 00:00 [revised]
PHST- 2014/10/27 00:00 [accepted]
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00419-X [pii]
AID - 10.1016/j.ccell.2014.10.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):123-37. doi: 10.1016/j.ccell.2014.10.015.

PMID- 25584894
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20180125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell
      growth under metabolic stress.
PG  - 57-71
LID - 10.1016/j.ccell.2014.12.002 [doi]
LID - S1535-6108(14)00511-X [pii]
AB  - A functional genomics study revealed that the activity of acetyl-CoA synthetase 2
      (ACSS2) contributes to cancer cell growth under low-oxygen and lipid-depleted
      conditions. Comparative metabolomics and lipidomics demonstrated that acetate is 
      used as a nutritional source by cancer cells in an ACSS2-dependent manner, and
      supplied a significant fraction of the carbon within the fatty acid and
      phospholipid pools. ACSS2 expression is upregulated under metabolically stressed 
      conditions and ACSS2 silencing reduced the growth of tumor xenografts. ACSS2
      exhibits copy-number gain in human breast tumors, and ACSS2 expression correlates
      with disease progression. These results signify a critical role for acetate
      consumption in the production of lipid biomass within the harsh tumor
      microenvironment.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Schug, Zachary T
AU  - Schug ZT
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Peck, Barrie
AU  - Peck B
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Jones, Dylan T
AU  - Jones DT
AD  - Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine,
      University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
FAU - Zhang, Qifeng
AU  - Zhang Q
AD  - Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.
FAU - Grosskurth, Shaun
AU  - Grosskurth S
AD  - AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
FAU - Alam, Israt S
AU  - Alam IS
AD  - Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, 
      Du Cane Road, London W12 0NN, UK.
FAU - Goodwin, Louise M
AU  - Goodwin LM
AD  - AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
FAU - Smethurst, Elizabeth
AU  - Smethurst E
AD  - Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.
FAU - Mason, Susan
AU  - Mason S
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Blyth, Karen
AU  - Blyth K
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - McGarry, Lynn
AU  - McGarry L
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - James, Daniel
AU  - James D
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Shanks, Emma
AU  - Shanks E
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Kalna, Gabriela
AU  - Kalna G
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Saunders, Rebecca E
AU  - Saunders RE
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Jiang, Ming
AU  - Jiang M
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Howell, Michael
AU  - Howell M
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Lassailly, Francois
AU  - Lassailly F
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Thin, May Zaw
AU  - Thin MZ
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Spencer-Dene, Bradley
AU  - Spencer-Dene B
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Stamp, Gordon
AU  - Stamp G
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - van den Broek, Niels J F
AU  - van den Broek NJ
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Mackay, Gillian
AU  - Mackay G
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Bulusu, Vinay
AU  - Bulusu V
AD  - Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback 
      Road, Glasgow G61 1BD, UK.
FAU - Kamphorst, Jurre J
AU  - Kamphorst JJ
AD  - Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback 
      Road, Glasgow G61 1BD, UK.
FAU - Tardito, Saverio
AU  - Tardito S
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Strachan, David
AU  - Strachan D
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK.
FAU - Harris, Adrian L
AU  - Harris AL
AD  - Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine,
      University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
FAU - Aboagye, Eric O
AU  - Aboagye EO
AD  - Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, 
      Du Cane Road, London W12 0NN, UK.
FAU - Critchlow, Susan E
AU  - Critchlow SE
AD  - AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
FAU - Wakelam, Michael J O
AU  - Wakelam MJ
AD  - Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.
FAU - Schulze, Almut
AU  - Schulze A
AD  - Cancer Research UK, London Institute, 44 Lincoln's Inn Fields, London WC2A 3LY,
      UK.
FAU - Gottlieb, Eyal
AU  - Gottlieb E
AD  - Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow 
      G61 1BD, UK. Electronic address: e.gottlieb@beatson.gla.ac.uk.
LA  - eng
GR  - BBS/E/B/000C0413/Biotechnology and Biological Sciences Research Council/United
      Kingdom
GR  - NIHR/CS/009/009/Department of Health/United Kingdom
GR  - G0700915/Medical Research Council/United Kingdom
GR  - 11359/Cancer Research UK/United Kingdom
GR  - 10337/Cancer Research UK/United Kingdom
GR  - Biotechnology and Biological Sciences Research Council/United Kingdom
GR  - Cancer Research UK/United Kingdom
GR  - BBS/E/B/000C0415/Biotechnology and Biological Sciences Research Council/United
      Kingdom
GR  - MR/J007986/1/Medical Research Council/United Kingdom
GR  - EME/13/122/01/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Fatty Acids)
RN  - EC 6.2.1.1 (ACSS2 protein, human)
RN  - EC 6.2.1.1 (ACSS2 protein, mouse)
RN  - EC 6.2.1.1 (Acetate-CoA Ligase)
SB  - IM
MH  - Acetate-CoA Ligase/*genetics/*metabolism
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Disease Progression
MH  - Fatty Acids/*metabolism
MH  - Gene Dosage
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Hypoxia
MH  - MCF-7 Cells
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Neoplasms/genetics/metabolism/*pathology
MH  - Stress, Physiological
PMC - PMC4297291
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2014/11/06 00:00 [received]
PHST- 2014/12/05 00:00 [revised]
PHST- 2014/12/09 00:00 [accepted]
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00511-X [pii]
AID - 10.1016/j.ccell.2014.12.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):57-71. doi: 10.1016/j.ccell.2014.12.002.

PMID- 25584893
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for 
      melanoma formation.
PG  - 41-56
LID - 10.1016/j.ccell.2014.11.014 [doi]
LID - S1535-6108(14)00465-6 [pii]
AB  - Braf(V600E) induces benign, growth-arrested melanocytic nevus development, but
      also drives melanoma formation. Cdkn2a loss in Braf(V600E) melanocytes in mice
      results in rare progression to melanoma, but only after stable growth arrest as
      nevi. Immediate progression to melanoma is prevented by upregulation of
      miR-99/100, which downregulates mTOR and IGF1R signaling. mTORC1 activation
      through Stk11 (Lkb1) loss abrogates growth arrest of Braf(V600E) melanocytic
      nevi, but is insufficient for complete progression to melanoma. Cdkn2a loss is
      associated with mTORC2 and Akt activation in human and murine melanocytic
      neoplasms. Simultaneous Cdkn2a and Lkb1 inactivation in Braf(V600E) melanocytes
      results in activation of both mTORC1 and mTORC2/Akt, inducing rapid melanoma
      formation in mice. In this model, activation of both mTORC1/2 is required for
      Braf-induced melanomagenesis.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Damsky, William
AU  - Damsky W
AD  - Department of Dermatology, Yale University, New Haven, CT 06510, USA. Electronic 
      address: william.damsky@gmail.com.
FAU - Micevic, Goran
AU  - Micevic G
AD  - Department of Dermatology, Yale University, New Haven, CT 06510, USA; Department 
      of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Meeth, Katrina
AU  - Meeth K
AD  - Department of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Muthusamy, Viswanathan
AU  - Muthusamy V
AD  - Department of Chemistry, Yale University, New Haven, CT 06510, USA.
FAU - Curley, David P
AU  - Curley DP
AD  - Department of Emergency Medicine, The Warren Alpert Medical School of Brown
      University, Providence, RI 02912, USA.
FAU - Santhanakrishnan, Manjula
AU  - Santhanakrishnan M
AD  - Department of Laboratory Medicine, Yale University School of Medicine, New Haven,
      CT 06510, USA.
FAU - Erdelyi, Ildiko
AU  - Erdelyi I
AD  - Section of Comparative Medicine, Yale University School of Medicine, New Haven,
      CT 06510, USA.
FAU - Platt, James T
AU  - Platt JT
AD  - Department of Dermatology, Yale University, New Haven, CT 06510, USA.
FAU - Huang, Laura
AU  - Huang L
AD  - Department of Dermatology, Yale University, New Haven, CT 06510, USA.
FAU - Theodosakis, Nicholas
AU  - Theodosakis N
AD  - Department of Pathology, Yale University, New Haven, CT 06510, USA.
FAU - Zaidi, M Raza
AU  - Zaidi MR
AD  - Fels Institute for Cancer Research and Molecular Biology, Temple University
      School of Medicine, Philadelphia, PA 19140, USA.
FAU - Tighe, Scott
AU  - Tighe S
AD  - NextGen Sequencing Facility, Vermont Cancer Center, University of Vermont,
      College of Medicine, Burlington, VT 05405, USA.
FAU - Davies, Michael A
AU  - Davies MA
AD  - Department of Melanoma Medical Oncology, Division of Cancer Medicine, The
      University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Dankort, David
AU  - Dankort D
AD  - Department of Biology, McGill University, Montreal, QC H3G OB1, Canada.
FAU - McMahon, Martin
AU  - McMahon M
AD  - Helen Diller Family Comprehensive Cancer Center and Department of Cellular and
      Molecular Pharmacology, University of California, San Francisco, San Francisco,
      CA 94158, USA.
FAU - Merlino, Glenn
AU  - Merlino G
AD  - Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda,
      MD 20892, USA.
FAU - Bardeesy, Nabeel
AU  - Bardeesy N
AD  - Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard 
      Medical School, Boston, MA 02114, USA.
FAU - Bosenberg, Marcus
AU  - Bosenberg M
AD  - Department of Dermatology, Yale University, New Haven, CT 06510, USA; Department 
      of Pathology, Yale University, New Haven, CT 06510, USA. Electronic address:
      marcus.bosenberg@yale.edu.
LA  - eng
SI  - GEO/GSE61750
GR  - CA-16672/CA/NCI NIH HHS/United States
GR  - P20 GM103449/GM/NIGMS NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P01 CA128814/CA/NCI NIH HHS/United States
GR  - R01 CA176839/CA/NCI NIH HHS/United States
GR  - T32 GM007205/GM/NIGMS NIH HHS/United States
GR  - P50 CA121974/CA/NCI NIH HHS/United States
GR  - R01 CA112054/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cdkn2a protein, mouse)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (MicroRNAs)
RN  - 0 (Mirn100 microRNA, mouse)
RN  - 0 (Mirn99 microRNA, mouse)
RN  - 0 (Multiprotein Complexes)
RN  - EC 2.7.1.- (Stk11 protein, mouse)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Braf protein, mouse)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CIN - Cancer Cell. 2015 Jan 12;27(1):3-5. PMID: 25584887
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics/metabolism
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mechanistic Target of Rapamycin Complex 2
MH  - Melanocytes/metabolism
MH  - Melanoma, Experimental/metabolism/*pathology
MH  - Mice
MH  - MicroRNAs/metabolism
MH  - Molecular Sequence Data
MH  - Multiprotein Complexes/*metabolism
MH  - Mutation
MH  - Nevus/*metabolism/pathology
MH  - Protein-Serine-Threonine Kinases/genetics/*metabolism
MH  - Proto-Oncogene Proteins B-raf/*metabolism
MH  - Signal Transduction
MH  - Skin Neoplasms/*metabolism/pathology
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC4295062
MID - NIHMS643850
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2011/12/21 00:00 [received]
PHST- 2014/09/04 00:00 [revised]
PHST- 2014/11/14 00:00 [accepted]
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00465-6 [pii]
AID - 10.1016/j.ccell.2014.11.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):41-56. doi: 10.1016/j.ccell.2014.11.014.

PMID- 25584892
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20150921
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Biological and therapeutic impact of intratumor heterogeneity in cancer
      evolution.
PG  - 15-26
LID - 10.1016/j.ccell.2014.12.001 [doi]
LID - S1535-6108(14)00510-8 [pii]
AB  - Precision medicine requires an understanding of cancer genes and mutational
      processes, as well as an appreciation of the extent to which these are found
      heterogeneously in cancer cells during tumor evolution. Here, we explore the
      processes shaping the cancer genome, placing these within the context of tumor
      evolution and their impact on intratumor heterogeneity and drug development. We
      review evidence for constraints and contingencies to tumor evolution and
      highlight the clinical implications of diversity within tumors. We outline the
      limitations of genome-driven targeted therapies and explore future strategies,
      including immune and adaptive approaches, to address this therapeutic challenge.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - McGranahan, Nicholas
AU  - McGranahan N
AD  - Cancer Research UK London Research Institute, London WC2A 3LY, UK; Centre for
      Mathematics & Physics in the Life Science & Experimental Biology (CoMPLEX),
      University College London, London WC1E 6BT, UK.
FAU - Swanton, Charles
AU  - Swanton C
AD  - Cancer Research UK London Research Institute, London WC2A 3LY, UK; UCL Cancer
      Institute, Paul O'Gorman Building, Huntley Street, London WC1E 6DD, UK.
      Electronic address: charles.swanton@cancer.org.uk.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
EIN - Cancer Cell. 2015 Jul 13;28(1):141
MH  - Evolution, Molecular
MH  - *Genes, Neoplasm
MH  - Genetic Heterogeneity
MH  - Genomics
MH  - Humans
MH  - Mutation
MH  - Neoplasms/*genetics/*pathology
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2014/10/01 00:00 [received]
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00510-8 [pii]
AID - 10.1016/j.ccell.2014.12.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):15-26. doi: 10.1016/j.ccell.2014.12.001.

PMID- 25584891
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20151119
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Biomarkers in cancer immunotherapy.
PG  - 12-4
LID - 10.1016/j.ccell.2014.12.004 [doi]
LID - S1535-6108(14)00513-3 [pii]
AB  - Antibodies against T cell checkpoint molecules have started to revolutionize
      cancer treatment. Nevertheless, less than half of all patients respond to these
      immunotherapies. Recent work supports the potential value of biomarkers that
      predict therapy outcome and inspires the development of assay systems that
      interrogate other aspects of the cancer-immunity cycle.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Schumacher, Ton N
AU  - Schumacher TN
AD  - Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the 
      Netherlands. Electronic address: t.schumacher@nki.nl.
FAU - Kesmir, Can
AU  - Kesmir C
AD  - Department of Theoretical Biology and Bioinformatics, Utrecht University, 3584 CH
      Utrecht, the Netherlands.
FAU - van Buuren, Marit M
AU  - van Buuren MM
AD  - Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Antibodies, Neoplasm/*therapeutic use
MH  - Biomarkers, Tumor/genetics/*immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Neoplasms/genetics/*immunology
MH  - T-Lymphocytes/immunology
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00513-3 [pii]
AID - 10.1016/j.ccell.2014.12.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):12-4. doi: 10.1016/j.ccell.2014.12.004.

PMID- 25584890
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20150114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - No need for constant help: human IgG2 antibodies have an autonomous agonistic
      activity for immunotherapy of cancer.
PG  - 10-1
LID - 10.1016/j.ccell.2014.12.010 [doi]
LID - S1535-6108(14)00519-4 [pii]
AB  - Agonistic antibodies specific for members of the tumor necrosis factor receptor
      protein family hold great promise for immunotherapy of cancer. In this issue of
      Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass
      may represent a superior backbone for the use of these antibodies in human
      therapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Lux, Anja
AU  - Lux A
AD  - Institute of Genetics, Department of Biology, University of Erlangen-Nurnberg,
      Erwin-Rommelstrasse 3, 91058 Erlangen, Germany.
FAU - Nimmerjahn, Falk
AU  - Nimmerjahn F
AD  - Institute of Genetics, Department of Biology, University of Erlangen-Nurnberg,
      Erwin-Rommelstrasse 3, 91058 Erlangen, Germany. Electronic address:
      falk.nimmerjahn@fau.de.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, IgG)
SB  - IM
CON - Cancer Cell. 2015 Jan 12;27(1):138-48. PMID: 25500122
MH  - Animals
MH  - Antibodies, Monoclonal/*chemistry/*therapeutic use
MH  - Humans
MH  - Immunoglobulin G/*chemistry/*therapeutic use
MH  - Receptors, IgG/*immunology
MH  - Thymoma/*prevention & control
MH  - Thymus Neoplasms/*prevention & control
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00519-4 [pii]
AID - 10.1016/j.ccell.2014.12.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):10-1. doi: 10.1016/j.ccell.2014.12.010.

PMID- 25584889
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20171110
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Vascular-promoting therapy reduced tumor growth and progression by improving
      chemotherapy efficacy.
PG  - 7-9
LID - 10.1016/j.ccell.2014.12.009 [doi]
LID - S1535-6108(14)00518-2 [pii]
AB  - In this issue of Cancer Cell, Wong and colleagues describe a novel approach of
      increasing the number of functional blood vessels in tumors using a low-dose
      therapy regimen of Cilengtide and Verapamil. This method enhanced gemcitabine
      delivery, uptake, and metabolism within tumor cells to reduce tumor growth and
      progression.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Bridges, Esther
AU  - Bridges E
AD  - Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall
      Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
FAU - Harris, Adrian L
AU  - Harris AL
AD  - Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall
      Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
      Electronic address: aharris.lab@oncology.ox.ac.uk.
LA  - eng
GR  - 11359/Cancer Research UK/United Kingdom
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Snake Venoms)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 4EDF46E4GI (Cilengitide)
RN  - B76N6SBZ8R (gemcitabine)
RN  - CJ0O37KU29 (Verapamil)
SB  - IM
CON - Cancer Cell. 2015 Jan 12;27(1):123-37. PMID: 25584895
MH  - Animals
MH  - Antimetabolites, Antineoplastic/*administration & dosage
MH  - Carcinoma, Lewis Lung/*drug therapy/*pathology
MH  - Deoxycytidine/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Pancreatic Neoplasms/*drug therapy
MH  - Snake Venoms/*administration & dosage
MH  - Verapamil/*administration & dosage
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00518-2 [pii]
AID - 10.1016/j.ccell.2014.12.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):7-9. doi: 10.1016/j.ccell.2014.12.009.

PMID- 25584888
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20150114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Breaking up is hard to do: PI3K isoforms on the rebound.
PG  - 5-7
LID - 10.1016/j.ccell.2014.12.003 [doi]
LID - S1535-6108(14)00512-1 [pii]
AB  - In this issue of Cancer Cell, Schwartz and colleagues and Costa and colleagues
      demonstrate that inhibition of PI3Kalpha or PI3Kbeta in cancer cells with
      hyperactivated PI3Kalpha or PI3Kbeta, respectively, activates the other isoform, 
      leading to a "rebound" of the PI3K activity through different compensation
      mechanisms.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Cescon, David W
AU  - Cescon DW
AD  - Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer
      Centre/University Health Network, Toronto, ON M5T 2M9, Canada; Medical Oncology
      and Hematology, Princess Margaret Cancer Centre/University Health Network and
      University of Toronto, ON M5T 2M9, Canada.
FAU - Gorrini, Chiara
AU  - Gorrini C
AD  - Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer
      Centre/University Health Network, Toronto, ON M5T 2M9, Canada.
FAU - Mak, Tak W
AU  - Mak TW
AD  - Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer
      Centre/University Health Network, Toronto, ON M5T 2M9, Canada. Electronic
      address: tmak@uhnresearch.ca.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (2-(1-(7-methyl-2-morpholin-4-yl-4-oxo-4H-pyrido(1,2-a)pyrimidin-9-yl)ethylamino)
      benzoic acid)
RN  - 0 (AZD8186)
RN  - 0 (Aniline Compounds)
RN  - 0 (Chromones)
RN  - 0 (NVP-BYL719)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidinones)
RN  - 0 (Thiazoles)
RN  - 0 (ortho-Aminobenzoates)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
CON - Cancer Cell. 2015 Jan 12;27(1):97-108. PMID: 25544637
CON - Cancer Cell. 2015 Jan 12;27(1):109-22. PMID: 25544636
MH  - Aniline Compounds/*pharmacology
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Breast Neoplasms/*drug therapy
MH  - Chromones/*pharmacology
MH  - Class I Phosphatidylinositol 3-Kinases/*metabolism
MH  - Female
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - PTEN Phosphohydrolase/*genetics
MH  - Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Pyrimidinones/*pharmacology
MH  - Thiazoles/*pharmacology
MH  - ortho-Aminobenzoates/*pharmacology
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00512-1 [pii]
AID - 10.1016/j.ccell.2014.12.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):5-7. doi: 10.1016/j.ccell.2014.12.003.

PMID- 25584887
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - mTOR signaling in melanoma: oncogene-induced pseudo-senescence?
PG  - 3-5
LID - 10.1016/j.ccell.2014.12.005 [doi]
LID - S1535-6108(14)00514-5 [pii]
AB  - Oncogene-induced senescence (OIS) is thought to be a barrier to malignant
      transformation resulting from the strong activation of oncogenes. In this issue
      of Cancer Cell, Damsky and colleagues suggest activation of mTORC1 and mTORC2 is 
      required for OIS evasion in human melanomas harboring oncogenic BRAF mutations.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Souroullas, George P
AU  - Souroullas GP
AD  - Department of Genetics, Lineberger Comprehensive Cancer Center, University of
      North Carolina, Chapel Hill, NC 27599, USA.
FAU - Sharpless, Norman E
AU  - Sharpless NE
AD  - Department of Genetics, Lineberger Comprehensive Cancer Center, University of
      North Carolina, Chapel Hill, NC 27599, USA; Department of Medicine, Lineberger
      Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599,
      USA. Electronic address: nes@med.unc.edu.
LA  - eng
GR  - R01 AG024379/AG/NIA NIH HHS/United States
GR  - R01 CA163896/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Multiprotein Complexes)
RN  - EC 2.7.1.- (Stk11 protein, mouse)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Braf protein, mouse)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CON - Cancer Cell. 2015 Jan 12;27(1):41-56. PMID: 25584893
MH  - Animals
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Melanoma, Experimental/*pathology
MH  - Multiprotein Complexes/*metabolism
MH  - Nevus/*metabolism
MH  - Protein-Serine-Threonine Kinases/*metabolism
MH  - Proto-Oncogene Proteins B-raf/*metabolism
MH  - Skin Neoplasms/*metabolism
MH  - TOR Serine-Threonine Kinases/*metabolism
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00514-5 [pii]
AID - 10.1016/j.ccell.2014.12.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):3-5. doi: 10.1016/j.ccell.2014.12.005.

PMID- 25584886
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20171129
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Common TLR5 mutations control cancer progression.
PG  - 1-3
LID - 10.1016/j.ccell.2014.12.008 [doi]
LID - S1535-6108(14)00517-0 [pii]
AB  - The mechanisms regulating tumor-associated inflammation are incompletely
      understood. In this issue of Cancer Cell, Rutkowski and colleagues indicate that 
      TLR5 signaling deficiency, which occurs in approximately 10% of the population,
      changes interactions with commensal microbiota and deregulates a cascade of
      inflammatory events that can suppress or accelerate extraintestinal cancers.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Pfirschke, Christina
AU  - Pfirschke C
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Garris, Christopher
AU  - Garris C
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA.
FAU - Pittet, Mikael J
AU  - Pittet MJ
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical
      School, Boston, MA 02114, USA. Electronic address: mpittet@mgh.harvard.edu.
LA  - eng
GR  - R01 CA206890/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-6)
RN  - 0 (Toll-Like Receptor 5)
SB  - IM
CON - Cancer Cell. 2015 Jan 12;27(1):27-40. PMID: 25533336
MH  - Animals
MH  - Humans
MH  - Interleukin-17/*metabolism
MH  - Interleukin-6/*metabolism
MH  - *Microbiota
MH  - Neoplasms/*immunology/*pathology
MH  - Toll-Like Receptor 5/*genetics/*metabolism
EDAT- 2015/01/15 06:00
MHDA- 2015/03/17 06:00
CRDT- 2015/01/14 06:00
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00517-0 [pii]
AID - 10.1016/j.ccell.2014.12.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):1-3. doi: 10.1016/j.ccell.2014.12.008.

PMID- 25544637
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Measurement of PIP3 levels reveals an unexpected role for p110beta in early
      adaptive responses to p110alpha-specific inhibitors in luminal breast cancer.
PG  - 97-108
LID - 10.1016/j.ccell.2014.11.007 [doi]
LID - S1535-6108(14)00458-9 [pii]
AB  - BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 
      3-kinase (PI3K) catalytic subunit (p110a), is currently in clinical trials for
      the treatment of solid tumors, especially luminal breast cancers with PIK3CA
      mutations and/or HER2 amplification. This study reveals that, even among these
      sensitive cancers, the initial efficacy of p110alpha inhibition is mitigated by
      rapid re-accumulation of the PI3K product PIP3 produced by the p110beta isoform. 
      Importantly, the reactivation of PI3K mediated by p110beta does not invariably
      restore AKT phosphorylation, demonstrating the limitations of using phospho-AKT
      as a surrogate to measure PI3K activation. Consistently, we show that the
      addition of the p110beta inhibitor to BYL719 prevents the PIP3 rebound and
      induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant cancers.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Costa, Carlotta
AU  - Costa C
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Ebi, Hiromichi
AU  - Ebi H
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Martini, Miriam
AU  - Martini M
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, 10126 Torino, Italy.
FAU - Beausoleil, Sean A
AU  - Beausoleil SA
AD  - Cell Signaling Technology, Inc., Danvers, MA 01923, USA.
FAU - Faber, Anthony C
AU  - Faber AC
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Jakubik, Charles T
AU  - Jakubik CT
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Huang, Alan
AU  - Huang A
AD  - Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
FAU - Wang, Youzhen
AU  - Wang Y
AD  - Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
FAU - Nishtala, Madhuri
AU  - Nishtala M
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Hall, Ben
AU  - Hall B
AD  - Cell Signaling Technology, Inc., Danvers, MA 01923, USA.
FAU - Rikova, Klarisa
AU  - Rikova K
AD  - Cell Signaling Technology, Inc., Danvers, MA 01923, USA.
FAU - Zhao, Jean
AU  - Zhao J
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of
      Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, 
      MA 02215, USA.
FAU - Hirsch, Emilio
AU  - Hirsch E
AD  - Molecular Biotechnology Center, Department of Molecular Biotechnology and Health 
      Sciences, University of Torino, 10126 Torino, Italy.
FAU - Benes, Cyril H
AU  - Benes CH
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Engelman, Jeffrey A
AU  - Engelman JA
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA. Electronic address: jengelman@partners.org.
LA  - eng
GR  - P50 CA168504/CA/NCI NIH HHS/United States
GR  - R01 CA137008/CA/NCI NIH HHS/United States
GR  - R01 CA172461/CA/NCI NIH HHS/United States
GR  - R01CA137008/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141224
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (2-(1-(7-methyl-2-morpholin-4-yl-4-oxo-4H-pyrido(1,2-a)pyrimidin-9-yl)ethylamino)
      benzoic acid)
RN  - 0 (NVP-BYL719)
RN  - 0 (Pyrimidinones)
RN  - 0 (Thiazoles)
RN  - 0 (ortho-Aminobenzoates)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Cancer Cell. 2015 Jan 12;27(1):5-7. PMID: 25584888
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors/*metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Pyrimidinones/*pharmacology
MH  - Receptor, ErbB-2/genetics
MH  - Signal Transduction/drug effects
MH  - Thiazoles/*pharmacology
MH  - ortho-Aminobenzoates/*pharmacology
PMC - PMC4745884
MID - NIHMS749263
EDAT- 2014/12/30 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/12/30 06:00
PHST- 2014/05/04 00:00 [received]
PHST- 2014/09/22 00:00 [revised]
PHST- 2014/11/08 00:00 [accepted]
PHST- 2014/12/30 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00458-9 [pii]
AID - 10.1016/j.ccell.2014.11.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):97-108. doi: 10.1016/j.ccell.2014.11.007. Epub
      2014 Dec 24.

PMID- 25544636
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20170220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by
      selective inhibition of PI3Kbeta.
PG  - 109-22
LID - 10.1016/j.ccell.2014.11.008 [doi]
LID - S1535-6108(14)00459-0 [pii]
AB  - In PTEN-mutated tumors, we show that PI3Kalpha activity is suppressed and PI3K
      signaling is driven by PI3Kbeta. A selective inhibitor of PI3Kbeta inhibits the
      Akt/mTOR pathway in these tumors but not in those driven by receptor tyrosine
      kinases. However, inhibition of PI3Kbeta only transiently inhibits Akt/mTOR
      signaling because it relieves feedback inhibition of IGF1R and other receptors
      and thus causes activation of PI3Kalpha and a rebound in downstream signaling.
      This rebound is suppressed and tumor growth inhibition enhanced with combined
      inhibition of PI3Kalpha and PI3Kbeta. In PTEN-deficient models of prostate
      cancer, this effective inhibition of PI3K causes marked activation of androgen
      receptor activity. Combined inhibition of both PI3K isoforms and androgen
      receptor results in major tumor regressions.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Schwartz, Sarit
AU  - Schwartz S
AD  - Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Wongvipat, John
AU  - Wongvipat J
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Trigwell, Cath B
AU  - Trigwell CB
AD  - AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
FAU - Hancox, Urs
AU  - Hancox U
AD  - AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
FAU - Carver, Brett S
AU  - Carver BS
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Rodrik-Outmezguine, Vanessa
AU  - Rodrik-Outmezguine V
AD  - Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Will, Marie
AU  - Will M
AD  - Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Yellen, Paige
AU  - Yellen P
AD  - Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - de Stanchina, Elisa
AU  - de Stanchina E
AD  - Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Baselga, Jose
AU  - Baselga J
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Scher, Howard I
AU  - Scher HI
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Barry, Simon T
AU  - Barry ST
AD  - AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
FAU - Sawyers, Charles L
AU  - Sawyers CL
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Chandarlapaty, Sarat
AU  - Chandarlapaty S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer 
      Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY
      10065, USA.
FAU - Rosen, Neal
AU  - Rosen N
AD  - Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY
      10065, USA. Electronic address: rosenn@mskcc.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA094060/CA/NCI NIH HHS/United States
GR  - R01 CA193837/CA/NCI NIH HHS/United States
GR  - P50-CA92629/CA/NCI NIH HHS/United States
GR  - P50 CA092629/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA155169/CA/NCI NIH HHS/United States
GR  - P01 CA094060/CA/NCI NIH HHS/United States
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
GR  - R01 CA182503/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141224
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (AZD8186)
RN  - 0 (Aniline Compounds)
RN  - 0 (Chromones)
RN  - 0 (NVP-BYL719)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Thiazoles)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
CIN - Cancer Cell. 2015 Jan 12;27(1):5-7. PMID: 25584888
MH  - Aniline Compounds/*pharmacology
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Chromones/*pharmacology
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Neoplasms/*drug therapy/genetics/pathology
MH  - PTEN Phosphohydrolase/*genetics
MH  - Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Signal Transduction/drug effects
MH  - Thiazoles/*pharmacology
PMC - PMC4293347
MID - NIHMS643301
EDAT- 2014/12/30 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/12/30 06:00
PHST- 2014/05/02 00:00 [received]
PHST- 2014/09/25 00:00 [revised]
PHST- 2014/11/08 00:00 [accepted]
PHST- 2014/12/30 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00459-0 [pii]
AID - 10.1016/j.ccell.2014.11.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub
      2014 Dec 24.

PMID- 25533336
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20161019
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Microbially driven TLR5-dependent signaling governs distal malignant progression 
      through tumor-promoting inflammation.
PG  - 27-40
LID - 10.1016/j.ccell.2014.11.009 [doi]
LID - S1535-6108(14)00460-7 [pii]
AB  - The dominant TLR5(R392X) polymorphism abrogates flagellin responses in >7% of
      humans. We report that TLR5-dependent commensal bacteria drive malignant
      progression at extramucosal locations by increasing systemic IL-6, which drives
      mobilization of myeloid-derived suppressor cells (MDSCs). Mechanistically,
      expanded granulocytic MDSCs cause gammadelta lymphocytes in TLR5-responsive
      tumors to secrete galectin-1, dampening antitumor immunity and accelerating
      malignant progression. In contrast, IL-17 is consistently upregulated in
      TLR5-unresponsive tumor-bearing mice but only accelerates malignant progression
      in IL-6-unresponsive tumors. Importantly, depletion of commensal bacteria
      abrogates TLR5-dependent differences in tumor growth. Contrasting differences in 
      inflammatory cytokines and malignant evolution are recapitulated in
      TLR5-responsive/unresponsive ovarian and breast cancer patients. Therefore,
      inflammation, antitumor immunity, and the clinical outcome of cancer patients are
      influenced by a common TLR5 polymorphism.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Rutkowski, Melanie R
AU  - Rutkowski MR
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Stephen, Tom L
AU  - Stephen TL
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Svoronos, Nikolaos
AU  - Svoronos N
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Allegrezza, Michael J
AU  - Allegrezza MJ
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Tesone, Amelia J
AU  - Tesone AJ
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Perales-Puchalt, Alfredo
AU  - Perales-Puchalt A
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Brencicova, Eva
AU  - Brencicova E
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Escovar-Fadul, Ximena
AU  - Escovar-Fadul X
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Nguyen, Jenny M
AU  - Nguyen JM
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Cadungog, Mark G
AU  - Cadungog MG
AD  - Helen F. Graham Cancer Center, Christiana Care Health System, 4701
      Ogletown-Stanton Road, Newark, DE 19713, USA.
FAU - Zhang, Rugang
AU  - Zhang R
AD  - Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA
      19104, USA.
FAU - Salatino, Mariana
AU  - Salatino M
AD  - Division of Endocrine and Oncologic Surgery, Department of Surgery, University of
      Pennsylvania, Philadelphia, PA 19104-1693, USA.
FAU - Tchou, Julia
AU  - Tchou J
AD  - Division of Endocrine and Oncologic Surgery, Department of Surgery, University of
      Pennsylvania, Philadelphia, PA 19104-1693, USA; Rena Rowan Breast Center,
      University of Pennsylvania, Philadelphia, PA 19104-1693, USA; Abramson Cancer
      Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
      19104-1693, USA.
FAU - Rabinovich, Gabriel A
AU  - Rabinovich GA
AD  - Laboratorio de Inmunopatologia, Instituto de Biologia y Medicina Experimental
      (IBYME-CONICET), Buenos Aires, Argentina.
FAU - Conejo-Garcia, Jose R
AU  - Conejo-Garcia JR
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA. Electronic address: jrconejo@wistar.org.
LA  - eng
SI  - SRA/SRP045910
GR  - P30CA10815/CA/NCI NIH HHS/United States
GR  - R01CA178687/CA/NCI NIH HHS/United States
GR  - U54 CA151662/CA/NCI NIH HHS/United States
GR  - T32CA009171/CA/NCI NIH HHS/United States
GR  - R01CA157664/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01CA124515/CA/NCI NIH HHS/United States
GR  - U54CA151662/CA/NCI NIH HHS/United States
GR  - R01 CA124515/CA/NCI NIH HHS/United States
GR  - CA010815/CA/NCI NIH HHS/United States
GR  - T32 CA009171/CA/NCI NIH HHS/United States
GR  - R01 CA163377/CA/NCI NIH HHS/United States
GR  - R01 CA157664/CA/NCI NIH HHS/United States
GR  - R01 CA178687/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20141218
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Galectin 1)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-6)
RN  - 0 (Toll-Like Receptor 5)
SB  - IM
CIN - Cancer Cell. 2015 Jan 12;27(1):1-3. PMID: 25584886
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Galectin 1/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Interleukin-17/*metabolism
MH  - Interleukin-6/*metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - *Microbiota
MH  - Molecular Sequence Data
MH  - Neoplasm Transplantation
MH  - Neoplasms/*immunology/*pathology
MH  - Polymorphism, Single Nucleotide
MH  - Signal Transduction
MH  - Toll-Like Receptor 5/*genetics/*metabolism
PMC - PMC4293269
MID - NIHMS642910
EDAT- 2014/12/24 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/12/24 06:00
PHST- 2014/04/25 00:00 [received]
PHST- 2014/08/29 00:00 [revised]
PHST- 2014/11/08 00:00 [accepted]
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00460-7 [pii]
AID - 10.1016/j.ccell.2014.11.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):27-40. doi: 10.1016/j.ccell.2014.11.009. Epub 2014
      Dec 18.

PMID- 25533335
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20170922
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly
      progressive, therapeutically targetable disease.
PG  - 72-84
LID - 10.1016/j.ccell.2014.11.002 [doi]
LID - S1535-6108(14)00453-X [pii]
AB  - We undertook a comprehensive clinical and biological investigation of serial
      medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family
      amplifications and P53 pathway defects commonly emerged at relapse, and all
      patients in this group died of rapidly progressive disease postrelapse. To study 
      this interaction, we investigated a transgenic model of MYCN-driven
      medulloblastoma and found spontaneous development of Trp53 inactivating
      mutations. Abrogation of p53 function in this model produced aggressive tumors
      that mimicked characteristics of relapsed human tumors with combined P53-MYC
      dysfunction. Restoration of p53 activity and genetic and therapeutic suppression 
      of MYCN all reduced tumor growth and prolonged survival. Our findings identify
      P53-MYC interactions at medulloblastoma relapse as biomarkers of clinically
      aggressive disease that may be targeted therapeutically.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Hill, Rebecca M
AU  - Hill RM
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Kuijper, Sanne
AU  - Kuijper S
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Lindsey, Janet C
AU  - Lindsey JC
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Petrie, Kevin
AU  - Petrie K
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Schwalbe, Ed C
AU  - Schwalbe EC
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Barker, Karen
AU  - Barker K
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Boult, Jessica K R
AU  - Boult JK
AD  - Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton
      SM2 5NG, UK.
FAU - Williamson, Daniel
AU  - Williamson D
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Ahmad, Zai
AU  - Ahmad Z
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Hallsworth, Albert
AU  - Hallsworth A
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Ryan, Sarra L
AU  - Ryan SL
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Poon, Evon
AU  - Poon E
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Robinson, Simon P
AU  - Robinson SP
AD  - Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton
      SM2 5NG, UK.
FAU - Ruddle, Ruth
AU  - Ruddle R
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Raynaud, Florence I
AU  - Raynaud FI
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Howell, Louise
AU  - Howell L
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Kwok, Colin
AU  - Kwok C
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK.
FAU - Joshi, Abhijit
AU  - Joshi A
AD  - Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Nicholson, Sarah Leigh
AU  - Nicholson SL
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Crosier, Stephen
AU  - Crosier S
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Ellison, David W
AU  - Ellison DW
AD  - St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
FAU - Wharton, Stephen B
AU  - Wharton SB
AD  - Sheffield Institute for Translational Neuroscience, University of Sheffield,
      Sheffield S10 2HQ, UK.
FAU - Robson, Keith
AU  - Robson K
AD  - Children's Brain Tumour Research Centre, Queen's Medical Centre, University of
      Nottingham, Nottingham NG7 2RD, UK.
FAU - Michalski, Antony
AU  - Michalski A
AD  - Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, 
      UK.
FAU - Hargrave, Darren
AU  - Hargrave D
AD  - Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, 
      UK.
FAU - Jacques, Thomas S
AU  - Jacques TS
AD  - Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, 
      UK; Neural Development Unit, UCL Institute of Child Health, London WC1N 1EH, UK.
FAU - Pizer, Barry
AU  - Pizer B
AD  - Oncology Unit, Alder Hey Children's Hospital, Liverpool L12 2AP, UK.
FAU - Bailey, Simon
AU  - Bailey S
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK.
FAU - Swartling, Fredrik J
AU  - Swartling FJ
AD  - Department of Immunology, Genetics and Pathology, Science for Life Laboratory,
      Rudbeck Laboratory, Uppsala University, Uppsala 751 85, Sweden.
FAU - Weiss, William A
AU  - Weiss WA
AD  - Department of Pediatrics, UCSF Benioff Children's Hospital, University of
      California, San Francisco, San Francisco, CA 94158, USA; Departments of Neurology
      and Neurological Surgery, University of California, San Francisco, San Francisco,
      CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of
      California, San Francisco, San Francisco, CA 94158, USA.
FAU - Chesler, Louis
AU  - Chesler L
AD  - Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG,
      UK. Electronic address: louis.chesler@icr.ac.uk.
FAU - Clifford, Steven C
AU  - Clifford SC
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne
      NE1 4LP, UK. Electronic address: steve.clifford@ncl.ac.uk.
LA  - eng
SI  - GEO/GSE62618
SI  - GEO/GSE62625
GR  - 11566/Cancer Research UK/United Kingdom
GR  - C1060/A10334/Cancer Research UK/United Kingdom
GR  - C34648/A12054/Cancer Research UK/United Kingdom
GR  - C8464/A13457/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141218
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MYC protein, human)
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Cerebellar Neoplasms/drug therapy/*genetics/pathology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Infant
MH  - Male
MH  - Medulloblastoma/drug therapy/*genetics/pathology
MH  - Mice
MH  - Molecular Sequence Data
MH  - Mutation
MH  - N-Myc Proto-Oncogene Protein
MH  - Neoplasm Recurrence, Local/drug therapy/*genetics
MH  - Neoplasms, Experimental
MH  - Nuclear Proteins/genetics/metabolism
MH  - Oncogene Proteins/genetics/metabolism
MH  - Proto-Oncogene Proteins c-myc/*genetics/metabolism
MH  - Signal Transduction
MH  - Tumor Suppressor Protein p53/*genetics/metabolism
MH  - Young Adult
PMC - PMC4297293
EDAT- 2014/12/24 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/12/24 06:00
PHST- 2014/04/25 00:00 [received]
PHST- 2014/09/02 00:00 [revised]
PHST- 2014/11/05 00:00 [accepted]
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00453-X [pii]
AID - 10.1016/j.ccell.2014.11.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):72-84. doi: 10.1016/j.ccell.2014.11.002. Epub 2014
      Dec 18.

PMID- 25500122
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20171116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Conformation of the human immunoglobulin G2 hinge imparts superagonistic
      properties to immunostimulatory anticancer antibodies.
PG  - 138-48
LID - 10.1016/j.ccell.2014.11.001 [doi]
LID - S1535-6108(14)00452-8 [pii]
AB  - Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are
      transforming cancer treatment but require optimization for maximum clinical
      impact. Here, we show that, unlike other immunoglobulin isotypes, human IgG2 (h2)
      imparts FcgammaR-independent agonistic activity to immune-stimulatory mAbs such
      as anti-CD40, -4-1BB, and -CD28. Activity is provided by a subfraction of h2,
      h2B, that is structurally constrained due its unique arrangement of hinge region 
      disulfide bonds. Agonistic activity can be transferred from h2 to h1 by swapping 
      their hinge and CH1 domains, and substitution of key hinge and CH1 cysteines
      generates homogenous h2 variants with distinct agonistic properties. This
      provides the exciting opportunity to engineer clinical reagents with defined
      therapeutic activity regardless of FcgammaR expression levels in the local
      microenvironment.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - White, Ann L
AU  - White AL
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK. Electronic address: a.l.white@soton.ac.uk.
FAU - Chan, H T Claude
AU  - Chan HT
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - French, Ruth R
AU  - French RR
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Willoughby, Jane
AU  - Willoughby J
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Mockridge, C Ian
AU  - Mockridge CI
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Roghanian, Ali
AU  - Roghanian A
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Penfold, Christine A
AU  - Penfold CA
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Booth, Steven G
AU  - Booth SG
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Dodhy, Ali
AU  - Dodhy A
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Polak, Marta E
AU  - Polak ME
AD  - Clinical and Experimental Sciences, Faculty of Medicine, University of
      Southampton, Tremona Road, Southampton SO16 6YD, UK.
FAU - Potter, Elizabeth A
AU  - Potter EA
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Ardern-Jones, Michael R
AU  - Ardern-Jones MR
AD  - Clinical and Experimental Sciences, Faculty of Medicine, University of
      Southampton, Tremona Road, Southampton SO16 6YD, UK.
FAU - Verbeek, J Sjef
AU  - Verbeek JS
AD  - Department of Human Genetics, Leiden University Medical Centre, Albinusdreef 2,
      2333 ZA Leiden, the Netherlands.
FAU - Johnson, Peter W M
AU  - Johnson PW
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Al-Shamkhani, Aymen
AU  - Al-Shamkhani A
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Cragg, Mark S
AU  - Cragg MS
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Beers, Stephen A
AU  - Beers SA
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
FAU - Glennie, Martin J
AU  - Glennie MJ
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona
      Road, Southampton SO16 6YD, UK.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141211
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD28 Antigens)
RN  - 0 (CD40 Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, IgG)
RN  - 0 (Tumor Necrosis Factor Receptor Superfamily, Member 9)
SB  - IM
CIN - Cancer Cell. 2015 Jan 12;27(1):10-1. PMID: 25584890
MH  - Animals
MH  - Antibodies, Monoclonal/*chemistry/immunology/*therapeutic use
MH  - CD28 Antigens/immunology
MH  - CD40 Antigens/immunology
MH  - Cells, Cultured
MH  - Humans
MH  - Immunoglobulin G/*chemistry/immunology/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Receptors, IgG/*immunology
MH  - Thymoma/drug therapy/immunology/*prevention & control
MH  - Thymus Neoplasms/drug therapy/immunology/*prevention & control
MH  - Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology
MH  - Vaccination/methods
PMC - PMC4297290
EDAT- 2014/12/17 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/08/06 00:00 [received]
PHST- 2014/10/03 00:00 [revised]
PHST- 2014/11/04 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00452-8 [pii]
AID - 10.1016/j.ccell.2014.11.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub
      2014 Dec 11.

PMID- 25500121
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20171027
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 27
IP  - 1
DP  - 2015 Jan 12
TI  - Paradox-breaking RAF inhibitors that also target SRC are effective in
      drug-resistant BRAF mutant melanoma.
PG  - 85-96
LID - 10.1016/j.ccell.2014.11.006 [doi]
LID - S1535-6108(14)00457-7 [pii]
AB  - BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients 
      eventually relapse with acquired resistance, and others present intrinsic
      resistance to these drugs. Resistance is often mediated by pathway reactivation
      through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or
      mutant NRAS, which drive paradoxical reactivation of the pathway. We describe
      pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds
      do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS 
      mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that 
      are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF
      inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and
      NRAS mutant melanomas and second-line treatment for patients who develop
      resistance.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Girotti, Maria Romina
AU  - Girotti MR
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20
      4BX, UK.
FAU - Lopes, Filipa
AU  - Lopes F
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Preece, Natasha
AU  - Preece N
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Niculescu-Duvaz, Dan
AU  - Niculescu-Duvaz D
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Zambon, Alfonso
AU  - Zambon A
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Davies, Lawrence
AU  - Davies L
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Whittaker, Steven
AU  - Whittaker S
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Saturno, Grazia
AU  - Saturno G
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20
      4BX, UK.
FAU - Viros, Amaya
AU  - Viros A
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20
      4BX, UK.
FAU - Pedersen, Malin
AU  - Pedersen M
AD  - Targeted Therapy Team, The Institute of Cancer Research, London SW3 6JB, UK.
FAU - Suijkerbuijk, Bart M J M
AU  - Suijkerbuijk BM
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Menard, Delphine
AU  - Menard D
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - McLeary, Robert
AU  - McLeary R
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Johnson, Louise
AU  - Johnson L
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Fish, Laura
AU  - Fish L
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK.
FAU - Ejiama, Sarah
AU  - Ejiama S
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20
      4BX, UK.
FAU - Sanchez-Laorden, Berta
AU  - Sanchez-Laorden B
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20
      4BX, UK.
FAU - Hohloch, Juliane
AU  - Hohloch J
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20
      4BX, UK.
FAU - Carragher, Neil
AU  - Carragher N
AD  - Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine,
      University of Edinburgh, Edinburgh EH4 2XR, UK.
FAU - Macleod, Kenneth
AU  - Macleod K
AD  - Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine,
      University of Edinburgh, Edinburgh EH4 2XR, UK.
FAU - Ashton, Garry
AU  - Ashton G
AD  - Histology Unit, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
FAU - Marusiak, Anna A
AU  - Marusiak AA
AD  - Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute,
      Manchester M20 4BX, UK.
FAU - Fusi, Alberto
AU  - Fusi A
AD  - University of Manchester, Christie NHS Foundation Trust, Manchester M20 4BX, UK.
FAU - Brognard, John
AU  - Brognard J
AD  - Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute,
      Manchester M20 4BX, UK.
FAU - Frame, Margaret
AU  - Frame M
AD  - Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine,
      University of Edinburgh, Edinburgh EH4 2XR, UK.
FAU - Lorigan, Paul
AU  - Lorigan P
AD  - University of Manchester, Christie NHS Foundation Trust, Manchester M20 4BX, UK.
FAU - Marais, Richard
AU  - Marais R
AD  - Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20
      4BX, UK. Electronic address: richard.marais@cruk.manchester.ac.uk.
FAU - Springer, Caroline
AU  - Springer C
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London SM2 5NG, UK. Electronic address: caroline.springer@icr.ac.uk.
LA  - eng
GR  - 096444/Wellcome Trust/United Kingdom
GR  - C15759/A12328/Cancer Research UK/United Kingdom
GR  - A17240/Cancer Research UK/United Kingdom
GR  - 100282/Wellcome Trust/United Kingdom
GR  - C157/A15703/Cancer Research UK/United Kingdom
GR  - Wellcome Trust/United Kingdom
GR  - WT1005X/Wellcome Trust/United Kingdom
GR  - 100282/Z/12/Z/Wellcome Trust/United Kingdom
GR  - 11566/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141211
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-(methylthio)-4-(3-oxo-3,4-dihydro
      pyrido(2,3-b)pyrazin-8-yloxy)phenyl)urea)
RN  - 0
      (1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido
      (3,2-b)pyrazin-8-yloxy)phenyl)urea)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazines)
RN  - EC 2.7.10.2 (src-Family Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
CIN - Pigment Cell Melanoma Res. 2015 May;28(3):242-3. PMID: 25677495
EIN - Cancer Cell. 2017 Mar 13;31(3):466. PMID: 28292443
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Melanoma/*drug therapy/pathology
MH  - Melanoma, Experimental
MH  - Mice
MH  - Mice, Nude
MH  - Phenylurea Compounds/*pharmacology
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
MH  - Pyrazines/*pharmacology
MH  - Xenograft Model Antitumor Assays
MH  - src-Family Kinases/*antagonists & inhibitors
PMC - PMC4297292
EDAT- 2014/12/17 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/05/17 00:00 [received]
PHST- 2014/08/11 00:00 [revised]
PHST- 2014/11/07 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S1535-6108(14)00457-7 [pii]
AID - 10.1016/j.ccell.2014.11.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014
      Dec 11.
